PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kagawa, R; Fujiki, R; Tsumura, M; Sakata, S; Nishimura, S; Itan, Y; Kong, XF; Kato, Z; Ohnishi, H; Hirata, O; Saito, S; Ikeda, M; El Baghdadi, J; Bousfiha, A; Fujiwara, K; Oleastro, M; Yancoski, J; Perez, L; Danielian, S; Ailal, F; Takada, H; Hara, T; Puel, A; Boisson-Dupuis, S; Bustamante, J; Casanova, JL; Ohara, O; Okada, S; Kobayashi, M				Kagawa, Reiko; Fujiki, Ryoji; Tsumura, Miyuki; Sakata, Sonoko; Nishimura, Shiho; Itan, Yuval; Kong, Xiao-Fei; Kato, Zenichiro; Ohnishi, Hidenori; Hirata, Osamu; Saito, Satoshi; Ikeda, Maiko; El Baghdadi, Jamila; Bousfiha, Aziz; Fujiwara, Kaori; Oleastro, Matias; Yancoski, Judith; Perez, Laura; Danielian, Silvia; Ailal, Fatima; Takada, Hidetoshi; Hara, Toshiro; Puel, Anne; Boisson-Dupuis, Stephanie; Bustamante, Jacinta; Casanova, Jean-Laurent; Ohara, Osamu; Okada, Satoshi; Kobayashi, Masao			Alanine-scanning mutagenesis of human signal transducer and activator of transcription 1 to estimate loss- or gain-of-function variants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Signal transduction and activator of transcription 1; alanine scanning; chronic mucocutaneous candidiasis; Mendelian susceptibility to mycobacterial disease; reference database	CHRONIC MUCOCUTANEOUS CANDIDIASIS; FUNCTION STAT1 MUTATIONS; IFN-GAMMA IMMUNITY; MYCOBACTERIAL DISEASE; COMBINED IMMUNODEFICIENCY; MULTIFOCAL OSTEOMYELITIS; MENDELIAN SUSCEPTIBILITY; CLINICAL PHENOTYPE; INBORN-ERRORS; EX-VIVO	Background: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis. LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD). Moreover, 6% of patients with chronic mucocutaneous candidiasis with a GOF STAT1 mutation have mycobacterial disease, obscuring the functional significance of the identified STAT1 mutations. Current computational approaches, such as combined annotation-dependent depletion, do not distinguish LOF and GOF variants. Objective: We estimated variations in the CCD/DBD of STAT1. Methods: We mutagenized 342 individual wild-type amino acids in the CCD/DBD (45.6% of full-length STAT1) to alanine and tested the mutants for STAT1 transcriptional activity. Results: Of these 342 mutants, 201 were neutral, 30 were LOF, and 111 were GOF mutations in a luciferase assay. This assay system correctly estimated all previously reported LOF mutations (100%) and slightly fewer GOF mutations (78.1%) in the CCD/DBD of STAT1. We found that GOF alanine mutants occurred at the interface of the antiparallel STAT1 dimer, suggesting that they destabilize this dimer. This assay also precisely predicted the effect of 2 hypomorphic and dominant negative mutations, E157K and G250E, in the CCD of STAT1 that we found in 2 unrelated patients with Mendelian susceptibility to mycobacterial diseases. Conclusion: The systematic alanine-scanning assay is a useful tool to estimate the GOF or LOF status and the effect of heterozygous missense mutations in STAT1 identified in patients with severe infectious diseases, including mycobacterial and fungal diseases.	[Kagawa, Reiko; Tsumura, Miyuki; Sakata, Sonoko; Nishimura, Shiho; Hirata, Osamu; Saito, Satoshi; Okada, Satoshi; Kobayashi, Masao] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan; [Fujiki, Ryoji; Ohara, Osamu] Kazusa DNA Res Inst, Dept Dev Technol, Chiba, Japan; [Itan, Yuval; Kong, Xiao-Fei; Puel, Anne; Boisson-Dupuis, Stephanie; Bustamante, Jacinta; Casanova, Jean-Laurent; Okada, Satoshi] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, 1230 York Ave, New York, NY 10021 USA; [Kato, Zenichiro; Ohnishi, Hidenori] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan; [Kato, Zenichiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Struct Med, Gifu, Japan; [Ikeda, Maiko] Okazaki City Hosp, Dept Pediat, Aichi, Japan; [El Baghdadi, Jamila] Mil Hosp Mohamed V Hay Riad, Genet Unit, Rabat, Morocco; [Bousfiha, Aziz; Ailal, Fatima] Hassan II Univ Casablanca, Fac Med & Pharm, Lab Clin Immunol Inflammat & Allergy, Casablanca, Morocco; [Bousfiha, Aziz; Ailal, Fatima] Averroes Univ Hosp, Dept Pediat Infect Dis, Clin Immunol Unit, Casablanca, Morocco; [Fujiwara, Kaori] Natl Hosp Org Fukuyama Med Ctr, Dept Pediat, Hiroshima, Japan; [Oleastro, Matias; Yancoski, Judith; Perez, Laura; Danielian, Silvia] Juan Pedro Garrahan Natl Hosp Pediat, Dept Immunol, Buenos Aires, DF, Argentina; [Takada, Hidetoshi; Hara, Toshiro] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka, Japan; [Puel, Anne; Boisson-Dupuis, Stephanie; Bustamante, Jacinta; Casanova, Jean-Laurent] INSERM U1163, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Puel, Anne; Boisson-Dupuis, Stephanie; Bustamante, Jacinta; Casanova, Jean-Laurent] Paris Descartes Univ, Imagine Inst, Sorbonne Paris Cite, Paris, France; [Bustamante, Jacinta] Necker Hosp Sick Children, AP HP, Ctr Study Primary Immunodeficiencies, Paris, France; [Casanova, Jean-Laurent] Necker Hosp Sick Children, AP HP, Pediat Hematol Immunol Unit, Paris, France; [Casanova, Jean-Laurent] Howard Hughes Med Inst, New York, NY USA; [Ohara, Osamu] RIKEN, Ctr Integrat Med Sci, Lab Integrat Gen, Yokohama, Kanagawa, Japan	Hiroshima University; Kazusa DNA Research Institute; Rockefeller University; Gifu University; Gifu University; Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat; Hassan II University of Casablanca; Mohammed First University of Oujda; Hassan II University of Casablanca; Ibn Rochd University Hospital Center of Casablanca; Hospital de Pediatria Doctor Juan Garrahan; Kyushu University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; RIKEN	Okada, S (corresponding author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	saok969@gmail.com	Ohara, Osamu/G-5448-2015; Puel, Anne/H-7305-2017; Bustamante, Jacinta/H-7877-2017; Boisson-Dupuis, Stéphanie/I-2040-2017; Okada, Satoshi/B-8901-2011; Boisson-Dupuis, Stephanie/AAF-5066-2021; Casanova, Jean-Laurent/I-3418-2017	Ohara, Osamu/0000-0002-3328-9571; Puel, Anne/0000-0003-2603-0323; Bustamante, Jacinta/0000-0002-3439-2482; Boisson-Dupuis, Stéphanie/0000-0002-7115-116X; Okada, Satoshi/0000-0002-4622-5657; Kong, Xiao-Fei/0000-0001-9983-2373; Casanova, Jean-Laurent/0000-0002-7782-4169	Japan Society for the Promotion of Science [22591161, 25713039, 16H05355, 16K15528]; Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and development (AMED); Research on Measures for Intractable Diseases funding from the Japanese Ministry of Health, Labour and Welfare [H22-Nanchi-ippan-078]; GSK Japan Research Grant; Kurozumi Medical Foundation; INSERM; University Paris Descartes; Rockefeller University; St Giles Foundation; US National Institute of Allergy and Infectious Diseases [R37AI095983, U01AI109697]; French National Research Agency (ANR) under the "Investments for the future'' program [ANR-10-IAHU-01]; Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI109697, R37AI095983] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [17K10112] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and development (AMED)(Japan Agency for Medical Research and Development (AMED)); Research on Measures for Intractable Diseases funding from the Japanese Ministry of Health, Labour and Welfare; GSK Japan Research Grant; Kurozumi Medical Foundation(Kurozumi Medical Foundation); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University Paris Descartes; Rockefeller University; St Giles Foundation; US National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); French National Research Agency (ANR) under the "Investments for the future'' program(French National Research Agency (ANR)); Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by Grants in Aid for Scientific Research from the Japan Society for the Promotion of Science (22591161 to M.K. and 25713039, 16H05355, and 16K15528 to S.O.) and was supported in part by the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and development (AMED). This study was also supported in part by Research on Measures for Intractable Diseases funding from the Japanese Ministry of Health, Labour and Welfare (H22-Nanchi-ippan-078 to M.K.), GSK Japan Research Grant 2014, and the Kurozumi Medical Foundation. The Laboratory of Human Genetics of Infectious Diseases is supported by institutional grants from INSERM, University Paris Descartes, the Rockefeller University, the St Giles Foundation, the US National Institute of Allergy and Infectious Diseases (grant no. R37AI095983 and U01AI109697), and grants from the French National Research Agency (ANR) under the "Investments for the future'' program (grant no. ANR-10-IAHU-01). The sequence analysis was supported by the Analysis Center of Life Science, Natural Science Center for Basic Research and Development, Hiroshima University.	Al Rushood M, 2013, J PEDIATR-US, V163, P277, DOI 10.1016/j.jpeds.2013.02.040; Baris S, 2016, J CLIN IMMUNOL, V36, P641, DOI 10.1007/s10875-016-0312-3; Boisson-Dupuis S, 2012, CURR OPIN IMMUNOL, V24, P364, DOI 10.1016/j.coi.2012.04.011; Bustamante J, 2014, SEMIN IMMUNOL, V26, P454, DOI 10.1016/j.smim.2014.09.008; Cann HM, 2002, SCIENCE, V296, P261; Aldave JC, 2013, J CLIN IMMUNOL, V33, P1273, DOI 10.1007/s10875-013-9947-5; Chapgier A, 2006, PLOS GENET, V2, P1193, DOI 10.1371/journal.pgen.0020131; Chapgier A, 2009, J CLIN INVEST, V119, P1502, DOI 10.1172/JCI37083; Depner M, 2016, J CLIN IMMUNOL, V36, P73, DOI 10.1007/s10875-015-0214-9; Dhalla F, 2016, CLIN EXP IMMUNOL, V184, P216, DOI 10.1111/cei.12746; Dotta L, 2016, CLIN IMMUNOL, V164, P1, DOI 10.1016/j.clim.2015.12.010; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Frans G, 2014, J ALLERGY CLIN IMMUN, V134, P1209, DOI 10.1016/j.jaci.2014.05.044; Giardino G, 2016, PEDIAT ALLERG IMM-UK, V27, P220, DOI 10.1111/pai.12496; Gussow AB, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0869-4; Higgins E, 2015, J ALLERGY CLIN IMMUN, V135, P551, DOI 10.1016/j.jaci.2014.12.1867; Hirata O, 2013, HAEMATOLOGICA, V98, P1641, DOI 10.3324/haematol.2013.083741; Hori T, 2012, J CLIN IMMUNOL, V32, P1213, DOI 10.1007/s10875-012-9744-6; Itan Y, 2016, NAT METHODS, V13, P109, DOI 10.1038/nmeth.3739; Itan Y, 2015, P NATL ACAD SCI USA, V112, P13615, DOI 10.1073/pnas.1518646112; Itan Y, 2015, P NATL ACAD SCI USA, V112, P11426, DOI 10.1073/pnas.1515057112; Jakobsson M, 2008, NATURE, V451, P998, DOI 10.1038/nature06742; Kataoka S, 2016, J ALLERGY CLIN IMMUN, V137, P619, DOI 10.1016/j.jaci.2015.06.028; Kilic SS, 2015, J CLIN IMMUNOL, V35, P80, DOI 10.1007/s10875-014-0111-7; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kong XF, 2010, BLOOD, V116, P5895, DOI 10.1182/blood-2010-04-280586; Kristensen IA, 2011, J CLIN IMMUNOL, V31, P265, DOI 10.1007/s10875-010-9480-8; Kumar N, 2014, J ALLERGY CLIN IMMUN, V134, P236, DOI 10.1016/j.jaci.2014.02.037; Lee PPW, 2014, J ALLERGY CLIN IMMUN, V133, P894, DOI 10.1016/j.jaci.2013.08.051; Lim CP, 2006, MOL BIOSYST, V2, P536, DOI 10.1039/b606246f; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Martinez-Martinez L, 2015, MOL IMMUNOL, V68, P597, DOI 10.1016/j.molimm.2015.09.014; Mekki N, 2014, J INVEST DERMATOL, V134, P1155, DOI 10.1038/jid.2013.480; Mertens C, 2006, GENE DEV, V20, P3372, DOI 10.1101/gad.1485406; Meyer T, 2004, J BIOL CHEM, V279, P18998, DOI 10.1074/jbc.M400766200; Miosge LA, 2015, P NATL ACAD SCI USA, V112, pE5189, DOI 10.1073/pnas.1511585112; Mizoguchi Y, 2014, J LEUKOCYTE BIOL, V95, P667, DOI 10.1189/jlb.0513250; Moreira IS, 2007, PROTEINS, V68, P803, DOI 10.1002/prot.21396; Nielsen Jakob, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-211372; Romberg N, 2013, J ALLERGY CLIN IMMUN, V131, P1691, DOI 10.1016/j.jaci.2013.01.004; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Sampaio EP, 2012, J CLIN IMMUNOL, V32, P681, DOI 10.1007/s10875-012-9659-2; Shamriz O, 2013, PEDIATR INFECT DIS J, V32, P1345, DOI 10.1097/01.inf.0000437067.43859.4c; Sharfe N, 2014, J ALLERGY CLIN IMMUN, V133, P807, DOI 10.1016/j.jaci.2013.09.032; Smeekens SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029248; Soltesz B, 2013, J MED GENET, V50, P567, DOI 10.1136/jmedgenet-2013-101570; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takezaki S, 2012, J IMMUNOL, V189, P1521, DOI 10.4049/jimmunol.1200926; Tanimura M, 2015, INT J CARDIOL, V196, P88, DOI 10.1016/j.ijcard.2015.05.183; Toth B, 2012, LANCET, V379, P2500, DOI 10.1016/S0140-6736(12)60365-1; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Tsumura M, 2012, HUM MUTAT, V33, P1377, DOI 10.1002/humu.22113; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Wang XW, 2013, J ALLERGY CLIN IMMUN, V131, P1242, DOI 10.1016/j.jaci.2012.11.005; Yamazaki Y, 2014, J IMMUNOL, V193, P4880, DOI 10.4049/jimmunol.1401467; Zerbe CS, 2016, CLIN INFECT DIS, V62, P986, DOI 10.1093/cid/civ1220; Zheng J, 2015, EUR J IMMUNOL, V45, P2834, DOI 10.1002/eji.201445344; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102	61	29	30	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					232	241		10.1016/j.jaci.2016.09.035	http://dx.doi.org/10.1016/j.jaci.2016.09.035			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	28011069	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000404542000023
J	Shoda, T; Matsuda, A; Nomura, I; Okada, N; Orihara, K; Mikami, H; Ishimura, N; Ishihara, S; Matsumoto, K; Kinoshita, Y				Shoda, Tetsuo; Matsuda, Akio; Nomura, Ichiro; Okada, Naoko; Orihara, Kanami; Mikami, Hironobu; Ishimura, Norihisa; Ishihara, Shunji; Matsumoto, Kenji; Kinoshita, Yoshikazu			Eosinophilic esophagitis versus proton pump inhibitor-responsive esophageal eosinophilia: Transcriptome analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EOE		[Shoda, Tetsuo; Matsuda, Akio; Nomura, Ichiro; Okada, Naoko; Orihara, Kanami; Matsumoto, Kenji] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Shoda, Tetsuo; Nomura, Ichiro] Natl Ctr Child Hlth & Dev, Div Allergy, Tokyo, Japan; [Orihara, Kanami] Waseda Univ, Waseda Inst Adv Study, Tokyo, Japan; [Mikami, Hironobu; Ishimura, Norihisa; Ishihara, Shunji; Kinoshita, Yoshikazu] Shimane Univ, Sch Med, Dept Gastroenterol & Hepatol, Matsue, Shimane, Japan	National Center for Child Health & Development - Japan; National Center for Child Health & Development - Japan; Waseda University; Shimane University	Shoda, T (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan.; Shoda, T (corresponding author), Natl Ctr Child Hlth & Dev, Div Allergy, Tokyo, Japan.	shoda-t@ncchd.go.jp; kinosita@med.shimane-u.ac.jp	Ishimura, Norihisa/AGX-5590-2022; 岡田, 直子/GRI-9555-2022	Ishimura, Norihisa/0000-0001-8039-3155; 岡田, 直子/0000-0002-3378-5778; Orihara, Kanami/0000-0002-2652-4529; Shoda, Tetsuo/0000-0001-8337-5438	Health and Labor Sciences Research grants; Research on Intractable Diseases from the Ministry of Health, Labour and Welfare [12103036]; Agency for Medical Research and Development, Japan [27280401, 27280301]	Health and Labor Sciences Research grants(Ministry of Health, Labour and Welfare, Japan); Research on Intractable Diseases from the Ministry of Health, Labour and Welfare; Agency for Medical Research and Development, Japan	This research was supported by Health and Labor Sciences Research grants, Research on Intractable Diseases from the Ministry of Health, Labour and Welfare (grant no. 12103036 to I.N.), and grants from the Agency for Medical Research and Development, Japan (grant no. 27280401 to I.N. and grant no. 27280301 to K.M.).	Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Jiao D, 2016, J GASTROENTEROL; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Molina-Infante J, 2016, GUT, V65, P524, DOI 10.1136/gutjnl-2015-310991; Molina-Infante J, 2015, AM J GASTROENTEROL, V110, P1567, DOI 10.1038/ajg.2015.314; Molina-Infante J, 2011, CLIN GASTROENTEROL H, V9, P110, DOI 10.1016/j.cgh.2010.09.019; Sayej WN, 2009, J PEDIATR GASTR NUTR, V49, P393, DOI 10.1097/MPG.0b013e31819c4b3e; Shoda T, 2016, J ALLERGY CLIN IMMUN, V138, P299, DOI 10.1016/j.jaci.2015.11.042; Shoda T, 2015, ALLERGOL INT, V64, P260, DOI 10.1016/j.alit.2015.03.002; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043	11	29	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					2010	+		10.1016/j.jaci.2016.11.028	http://dx.doi.org/10.1016/j.jaci.2016.11.028			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28063872	Bronze			2022-12-18	WOS:000402724600040
J	Levin, M; Levander, F; Palmason, R; Greiff, L; Ohlin, M				Levin, Mattias; Levander, Fredrik; Palmason, Robert; Greiff, Lennart; Ohlin, Mats			Antibody-encoding repertoires of bone marrow and peripheral blood-a focus on IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IGG4		[Levin, Mattias; Levander, Fredrik; Ohlin, Mats] Lund Univ, Dept Immunotechnol, Lund, Sweden; [Levander, Fredrik] Lund Univ, Dept Bioinformat Infrastruct Life Sci, Lund, Sweden; [Palmason, Robert] Skane Univ Hosp, Dept Hematol Oncol & Med Phys, Lund, Sweden; [Greiff, Lennart] Lund Univ, Dept Clin Sci, Lund, Sweden; [Greiff, Lennart] Skane Univ Hosp, Dept ORL Head & Neck Surg, Lund, Sweden; [Levin, Mattias] Alligator Biosci AB, Lund, Sweden	Lund University; Lund University; Lund University; Skane University Hospital; Lund University; Lund University; Skane University Hospital	Ohlin, M (corresponding author), Lund Univ, Dept Immunotechnol, Lund, Sweden.	mats.ohlin@immun.lth.se	Ohlin, Mats/A-7307-2010	Ohlin, Mats/0000-0002-5105-1938; Levander, Fredrik/0000-0002-0710-9792	Swedish Research Council [521-2011-3282]; Lund University (ALF [Avtal om Lakarutbildning och Forskning])	Swedish Research Council(Swedish Research CouncilEuropean Commission); Lund University (ALF [Avtal om Lakarutbildning och Forskning])	This study was supported by a grant from the Swedish Research Council (grant no. 521-2011-3282) and Lund University (ALF [Avtal om Lakarutbildning och Forskning]).	Briney BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100839; Dunand CJH, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0238; Eckl-Dorna J, 2012, CLIN EXP ALLERGY, V42, P1347, DOI 10.1111/j.1365-2222.2012.04030.x; Gadermaier E, 2014, INT ARCH ALLERGY IMM, V163, P77, DOI 10.1159/000355947; Georgiou G, 2014, NAT BIOTECHNOL, V32, P158, DOI 10.1038/nbt.2782; Nirula A, 2011, CURR OPIN RHEUMATOL, V23, P119, DOI 10.1097/BOR.0b013e3283412fd4; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Persson H, 2008, MOL IMMUNOL, V45, P2715, DOI 10.1016/j.molimm.2008.01.004; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	10	29	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1026	1030		10.1016/j.jaci.2016.06.040	http://dx.doi.org/10.1016/j.jaci.2016.06.040			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27521279	hybrid			2022-12-18	WOS:000397295800034
J	Notarangelo, LD; Fleisher, TA				Notarangelo, Luigi D.; Fleisher, Thomas A.			Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Personalized medicine; primary immunodeficiency disorders; immune dysregulation; autoimmunity; therapy mutation	OF-FUNCTION MUTATIONS; CHRONIC MUCOCUTANEOUS CANDIDIASIS; FUNCTION STAT1 MUTATIONS; CXCR4 ANTAGONIST PLERIXAFOR; FUNCTION SIGNAL TRANSDUCER; STEM-CELL TRANSPLANTATION; IMMUNE DYSREGULATION; WHIM-SYNDROME; GERMLINE MUTATIONS; LONG-TERM	Primary immunodeficiency disorders (PIDs) represent a range of genetically determined diseases that typically have increased susceptibility to infections and in many cases also have evidence of immune dysregulation that often presents as autoimmunity. Most recently, the concept of gain-of-function mutations associated with PIDs has become well recognized and adds a new dimension to the understanding of this group of disorders, moving beyond the more commonly seen loss-of-function mutations. The rapidly expanding genetic defects that have been identified in patients with previously uncharacterized PIDs has opened up the potential for targeted therapy directed at the specific disease-causing abnormality. This has been driven by linking PID-specific genetic defects to the associated unique abnormalities in cellular signaling pathways amenable to directed therapies. These include agents that either block overactive or enhance underresponsive cellular pathways. Selected primary immunodeficiencies were chosen, the genetic defects of which have been recently characterized and are amenable to targeted therapy, as a reflection of the power of precision medicine.	[Notarangelo, Luigi D.] NIAID, Clin Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA; [Fleisher, Thomas A.] NIH, Ctr Clin, Dept Lab Med, Serv Immunol, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Fleisher, TA (corresponding author), Dept Lab Med, CC, Ctr Dr,MSC 1508,Bldg 10,Room 2C306, Bethesda, MD 20892 USA.	tfleishe@mail.nih.gov			Intramural Research Program of the National Institutes of Allergy and Infectious Diseases; National Institutes of Health Clinical Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001222] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL010342] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Allergy and Infectious Diseases; National Institutes of Health Clinical Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by the Intramural Research Program of the National Institutes of Allergy and Infectious Diseases and the National Institutes of Health Clinical Center.	Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Bilgin YM, 2016, CURR OPIN HEMATOL, V23, P67, DOI 10.1097/MOH.0000000000000200; Camporeale A, 2012, FRONT BIOSCI-LANDMRK, V17, P2306, DOI 10.2741/4054; Aldave JC, 2013, J CLIN IMMUNOL, V33, P1273, DOI 10.1007/s10875-013-9947-5; Casanova JL, 2012, IMMUNITY, V36, P515, DOI 10.1016/j.immuni.2012.03.016; Chandrasekaran P, 2016, J ALLERGY CLIN IMMUN, V138, P1222, DOI 10.1016/j.jaci.2016.05.007; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Coulter T. I., 2016, J ALLERGY CLIN IMMUN; Dale DC, 2011, BLOOD, V118, P4963, DOI 10.1182/blood-2011-06-360586; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Depner M, 2016, J CLIN IMMUNOL, V36, P73, DOI 10.1007/s10875-015-0214-9; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Elgizouli M, 2016, CLIN EXP IMMUNOL, V183, P221, DOI 10.1111/cei.12706; Elkaim E, 2016, J ALLERGY CLIN IMMUN, V138, P210, DOI 10.1016/j.jaci.2016.03.022; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Freeman AF, 2010, DIS MARKERS, V29, P123, DOI [10.1155/2010/580197, 10.3233/DMA-2010-0734]; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Gulino AV, 2004, BLOOD, V104, P444, DOI 10.1182/blood-2003-10-3532; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Haddad E, 2015, BLOOD, V125, P583, DOI 10.1182/blood-2014-11-610592; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Herrero-Beaumont G, 2012, REUMATOL CLIN, V8, P78, DOI 10.1016/j.reuma.2011.08.002; Higgins E, 2015, J ALLERGY CLIN IMMUN, V135, P551, DOI 10.1016/j.jaci.2014.12.1867; Hirahara K, 2016, CURR OPIN IMMUNOL, V43, P89, DOI 10.1016/j.coi.2016.10.001; Kane A, 2014, CURR OPIN IMMUNOL, V28, P49, DOI 10.1016/j.coi.2014.01.015; Kawai T, 2009, CURR OPIN HEMATOL, V16, P20, DOI 10.1097/MOH.0b013e32831ac557; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Kumar N, 2014, J ALLERGY CLIN IMMUN, V134, P236, DOI 10.1016/j.jaci.2014.02.037; Lee S, 2016, J ALLERGY CLIN IMMUN, V137, P327, DOI 10.1016/j.jaci.2015.08.036; Levy E, 2016, CLIN IMMUNOL, V168, P88, DOI 10.1016/j.clim.2016.03.006; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; McCormick PJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008102; McDermott DH, 2015, CELL, V160, P686, DOI 10.1016/j.cell.2015.01.014; McDermott DH, 2014, BLOOD, V123, P2308, DOI 10.1182/blood-2013-09-527226; McDermott DH, 2011, BLOOD, V118, P4957, DOI 10.1182/blood-2011-07-368084; McDermott DH, 2011, J CELL MOL MED, V15, P2071, DOI 10.1111/j.1582-4934.2010.01210.x; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Nademi Z, 2016, J ALLERGY CLIN IMMUN; Navarini AA, 2016, J ALLERGY CLIN IMMUN; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Palmer DC, 2009, TRENDS IMMUNOL, V30, P592, DOI 10.1016/j.it.2009.09.009; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Rao VK, 2016, ESID 17 BIENN M BARC; Revel-Vilk S, 2015, CLIN IMMUNOL, V159, P84, DOI 10.1016/j.clim.2015.04.007; Romberg N, 2013, J ALLERGY CLIN IMMUN, V131, P1691, DOI 10.1016/j.jaci.2013.01.004; Roskoski R, 2016, PHARMACOL RES, V111, P784, DOI 10.1016/j.phrs.2016.07.038; Sampaio EP, 2013, J ALLERGY CLIN IMMUN, V131, P1624, DOI 10.1016/j.jaci.2013.01.052; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwartz DM, 2016, NAT REV RHEUMATOL, V12, P25, DOI 10.1038/nrrheum.2015.167; Seidel MG, 2015, J ALLERGY CLIN IMMUN, V135, P1384, DOI 10.1016/j.jaci.2014.10.048; Slatter MA, 2016, J ALLERGY CLIN IMMUN, V138, P615, DOI 10.1016/j.jaci.2016.01.045; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Weinacht KGC, 2017, J ALLERGY CLIN IMMUN; Zheng J, 2015, EUR J IMMUNOL, V45, P2834, DOI 10.1002/eji.201445344	67	29	31	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					715	725		10.1016/j.jaci.2017.01.004	http://dx.doi.org/10.1016/j.jaci.2017.01.004			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	28270363	Bronze, Green Accepted			2022-12-18	WOS:000397295800001
J	Johansson, MW; Evans, MD; Crisafi, GM; Holweg, CTJ; Matthews, JG; Jarjour, NN				Johansson, Mats W.; Evans, Michael D.; Crisafi, Gina M.; Holweg, Cecile T. J.; Matthews, John G.; Jarjour, Nizar N.			Serum periostin is associated with type 2 immunity in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LUNG; LEBRIKIZUMAB; ADULTS		[Johansson, Mats W.] Univ Wisconsin, Dept Biomol Chem, Madison, WI USA; [Evans, Michael D.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Crisafi, Gina M.; Jarjour, Nizar N.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Holweg, Cecile T. J.; Matthews, John G.] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Roche Holding; Genentech	Jarjour, NN (corresponding author), Univ Wisconsin, Dept Med, Madison, WI 53706 USA.	nnj@medicine.wisc.edu		Evans, Michael/0000-0001-7449-3993; Johansson, Mats/0000-0001-5699-978X	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069116, U10HL109168] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000427] Funding Source: Medline; NCRR NIH HHS [M01 RR003186, UL1 RR025011] Funding Source: Medline; NHLBI NIH HHS [U10 HL109168, R01 HL069116] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Geh EN, 2015, ENVIRON HEALTH PERSP, V123, P1159, DOI 10.1289/ehp.1409065; James A, 2014, AM J RESP CRIT CARE, pA4244; Jarjour NN, 2012, AM J RESP CRIT CARE, V185, P356, DOI 10.1164/rccm.201107-1317PP; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Johansson MW, 2013, AM J RESP CELL MOL, V48, P503, DOI 10.1165/rcmb.2012-0150OC; Nagasaki T, 2014, AM J RESP CRIT CARE, V190, P1449, DOI 10.1164/rccm.201407-1290LE; Scheerens H, 2014, CLIN EXP ALLERGY, V44, P38, DOI 10.1111/cea.12220; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104	11	29	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1904	+		10.1016/j.jaci.2015.12.1346	http://dx.doi.org/10.1016/j.jaci.2015.12.1346			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27061252	Bronze, Green Accepted			2022-12-18	WOS:000377527200039
J	Johansson, SGO				Johansson, S. G. O.			The discovery of IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; inflammation; mast cell; immunoglobulin; sensitization; reagin	PRAUSNITZ-KUSTNER REACTION; HUMAN MYELOMA PROTEIN; GAMMAE-ANTIBODIES; IMMUNOGLOBULIN; INHIBITION	In 1919, the search began for the factor, later called reagin, that could mediate an allergy, such as allergic asthma, in sera of allergic subjects. In 1967, the fifth class of immunoglobulins, IgE, was discovered and found to be able to carry reagin activity. This discovery has had immense importance for the understanding, diagnosis, and treatment of allergic diseases.	[Johansson, S. G. O.] Karolinska Inst, Dept Med, Immunol & Allergy Unit, Stockholm, Sweden; [Johansson, S. G. O.] Karolinska Univ Hosp, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Johansson, SGO (corresponding author), Karolinska Univ Hosp, Immunol & Allergy Unit, Solna L2 04, S-17176 Stockholm, Sweden.	s.g.o.johansson@ki.se						BENNICH HH, 1968, B WORLD HEALTH ORGAN, V38, P151; COOMBS RRA, 1954, BRIT J EXP PATHOL, V35, P472; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1964, IMMUNOCHEMISTRY, V1, P197, DOI 10.1016/0019-2791(64)90043-6; ISHIZAKA K, 1969, J IMMUNOL, V102, P69; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; Johansson SGO, 2005, J ALLERGY CLIN IMMUN, V115, P644, DOI 10.1016/j.jaci.2004.11.027; STANWORTH DR, 1968, LANCET, V2, P17; STANWORTH DR, 1967, LANCET, V2, P330; WIDE L, 1967, LANCET, V2, P1105	11	29	30	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1671	1673		10.1016/j.jaci.2016.04.004	http://dx.doi.org/10.1016/j.jaci.2016.04.004			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27264002	Bronze			2022-12-18	WOS:000377527200005
J	Gieras, A; Linhart, B; Roux, KH; Dutta, M; Khodoun, M; Zafred, D; Cabauatan, CR; Lupinek, C; Weber, M; Focke-Tejkl, M; Keller, W; Finkelman, FD; Valenta, R				Gieras, Anna; Linhart, Birgit; Roux, Kenneth H.; Dutta, Moumita; Khodoun, Marat; Zafred, Domen; Cabauatan, Clarissa R.; Lupinek, Christian; Weber, Milena; Focke-Tejkl, Margarete; Keller, Walter; Finkelman, Fred D.; Valenta, Rudolf			IgE epitope proximity determines immune complex shape and effector cell activation capacity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen; IgE epitope; immune complex; effector cells	GRASS-POLLEN ALLERGEN; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; BASOPHILIC LEUKEMIA; MAST-CELLS; RESPONSES; ASTHMA; IDENTIFICATION; DEGRANULATION; ANAPHYLAXIS	Background: IgE-allergen complexes induce mast cell and basophil activation and thus immediate allergic inflammation. They are also important for IgE-facilitated allergen presentation to T cells by antigen-presenting cells. Objective: To investigate whether the proximity of IgE binding sites on an allergen affects immune complex shape and subsequent effector cell activation in vitro and in vivo. Methods: We constructed artificial allergens by grafting IgE epitopes in different numbers and proximity onto a scaffold protein. The shape of immune complexes formed between artificial allergens and the corresponding IgE was studied by negative-stain electron microscopy. Allergenic activity was determined using basophil activation assays. Mice were primed with IgE, followed by injection of artificial allergens to evaluate their in vivo allergenic activity. Severity of systemic anaphylaxis was measured by changes in body temperature. Results: We could demonstrate simultaneous binding of 4 IgE antibodies in close vicinity to each other. The proximity of IgE binding sites on allergens influenced the shape of the resulting immune complexes and the magnitude of effector cell activation and in vivo inflammation. Conclusions: Our results demonstrate that the proximity of IgE epitopes on an allergen affects its allergenic activity. We thus identified a novel mechanism by which IgE-allergen complexes regulate allergic inflammation. This mechanism should be important for allergy and other immune complex-mediated diseases.	[Gieras, Anna; Linhart, Birgit; Cabauatan, Clarissa R.; Lupinek, Christian; Weber, Milena; Focke-Tejkl, Margarete; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, A-1090 Vienna, Austria; [Roux, Kenneth H.; Dutta, Moumita] Florida State Univ, Dept Biol Sci, B-157, Tallahassee, FL 32306 USA; [Roux, Kenneth H.; Dutta, Moumita] Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; [Khodoun, Marat; Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Khodoun, Marat; Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Div Rheumatol Allergy & Immunol, Cincinnati, OH USA; [Khodoun, Marat; Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Cellular & Immunobiol, Cincinnati, OH 45229 USA; [Zafred, Domen; Keller, Walter] Karl Franzens Univ Graz, Div Struct Biol, Inst Mol Biosci, Graz, Austria	Medical University of Vienna; State University System of Florida; Florida State University; State University System of Florida; Florida State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University of Graz	Valenta, R (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Lupinek, Christian/I-3311-2019; Zafred, Domen/Q-6244-2018; Dutta, Moumita/AAI-3002-2020; Gieras, Anna/S-8345-2019; Keller, Walter/AAW-1501-2021	Lupinek, Christian/0000-0002-8612-8245; Zafred, Domen/0000-0002-2029-4902; Keller, Walter/0000-0002-2261-958X; Cabauatan, Clarissa/0000-0001-8404-7065; Valenta, Rudolf/0000-0001-5944-3365; Gieras, Anna/0000-0002-5147-2281; Linhart, Birgit/0000-0001-6857-3049	Austrian Science Fund [F1815, F4605, P23350-B11]; Merit Award from the US Department of Veterans Affairs; Austrian Science Fund (FWF) [P 23350] Funding Source: researchfish	Austrian Science Fund(Austrian Science Fund (FWF)); Merit Award from the US Department of Veterans Affairs; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by the Austrian Science Fund (grant nos. F1815, F4605, and P23350-B11) and a Merit Award from the US Department of Veterans Affairs.	BALL T, 1994, J BIOL CHEM, V269, P28323; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Dombrowicz D, 2001, CURR OPIN IMMUNOL, V13, P716, DOI 10.1016/S0952-7915(01)00284-9; ECCLESTON E, 1973, NATURE-NEW BIOL, V244, P73, DOI 10.1038/newbio244073b0; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; EVANS SV, 1988, J BIOL CHEM, V263, P4263; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; FEWTRELL C, 1980, J IMMUNOL, V125, P701; Flicker S, 2006, J ALLERGY CLIN IMMUN, V117, P1336, DOI 10.1016/j.jaci.2006.02.012; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gieras A, 2007, J ALLERGY CLIN IMMUN, V119, P384, DOI 10.1016/j.jaci.2006.09.034; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; GREENE WK, 1992, MOL IMMUNOL, V29, P257, DOI 10.1016/0161-5890(92)90107-9; Hochwallner H, 2010, J ALLERGY CLIN IMMUN, V125, P1279, DOI 10.1016/j.jaci.2010.03.007; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; HOLOWKA D, 1990, BIOCHEMISTRY-US, V29, P4607, DOI 10.1021/bi00471a015; KAGEYSOBOTKA A, 1981, J IMMUNOL, V127, P2285; Khodoun MV, 2011, P NATL ACAD SCI USA, V108, P12413, DOI 10.1073/pnas.1105695108; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landsteiner K, 1924, J EXP MED, V39, P631, DOI 10.1084/jem.39.5.631; Levin M, 2013, J IMMUNOL, V191, P551, DOI 10.4049/jimmunol.1202051; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MARONE G, 1981, INT ARCH ALLER A IMM, V65, P339, DOI 10.1159/000232773; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; Nimmerjahn F, 2010, IMMUNOL REV, V236, P265, DOI 10.1111/j.1600-065X.2010.00910.x; Padavattan S, 2009, J IMMUNOL, V182, P2141, DOI 10.4049/jimmunol.0803018; Roux Kenneth H., 1996, Methods (Orlando), V10, P247, DOI 10.1006/meth.1996.0099; Roux KH, 1998, J IMMUNOL, V161, P4083; ROUX KH, 1987, P NATL ACAD SCI USA, V84, P4984, DOI 10.1073/pnas.84.14.4984; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; Wills-Karp M, 2004, NAT REV GENET, V5, P376, DOI 10.1038/nrg1326; Willumsen N, 2012, CLIN EXP ALLERGY, V42, P1227, DOI 10.1111/j.1365-2222.2012.04009.x; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	40	29	29	5	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1557	1565		10.1016/j.jaci.2015.08.055	http://dx.doi.org/10.1016/j.jaci.2015.08.055			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26684291	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000376180200032
J	Jelding-Dannemand, E; Schoos, AMM; Bisgaard, H				Jelding-Dannemand, Ea; Schoos, Ann-Marie Malby; Bisgaard, Hans			Breast-feeding does not protect against allergic sensitization in early childhood and allergy-associated disease at age 7 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Breast-feeding; sensitization; asthma; eczema; skin prick test; specific IgE; children	SKIN PRICK TEST; ATOPIC DISEASE; ASTHMA; CHILDREN; RISK; IGE; RHINITIS; WHEEZE; COHORT; PREVALENCE	Background: Extended breast-feeding is recommended for newborn children at risk of allergy-associated diseases, but the evidence of a protective effect on sensitization and these diseases remains elusive. Objective: The aim of this study was to investigate the effects of the duration of exclusive breast-feeding on the development of sensitization in preschool children. Methods: Information on breast-feeding was gathered by interviews involving 335 children aged 1, 6, and 12 months from the Copenhagen Prospective Study on Asthma in Childhood(2000) birth cohort born to mothers with a history of asthma. Skin prick test responses and specific IgE levels against 12 common inhalant and 10 food allergens were assessed longitudinally at ages 1/2 year, 1 1/2 years, 4 years, and 6 years. Eczema, wheeze/asthma, and allergic rhinitis were diagnosed at the Copenhagen Prospective Studies on Asthma in Childhood clinic at 7 years of age, strictly adhering to predefined algorithms. Associations between duration of exclusive breast-feeding and outcomes were analyzed by logistic regression. Results: We found no significant association between duration of exclusive breast-feeding and development of sensitization in the first 6 years of life (odds ratio [OR]: 1/2 year, 1.10 [95% CI, 0.90-1.36]; 1 1/2 years, 1.15 [95% CI, 0.97-1.36]; 4 years, 1.08 [95% CI, 0.93-1.25]; and 6 years, 0.96 [95% CI, 0.84-1.10]) or with current eczema, wheeze/asthma, and allergic rhinitis at age 7 years (OR, 1.07 [95% CI, 0.92-1.24]; OR, 0.97 [95% CI, 0.82-1.14]; and OR, 1.02 [95% CI, 0.84-1.23], respectively). Adjusting for reverse causation by excluding children with eczema, wheeze, or a positive skin prick test response before ending exclusive breast-feeding did not alter the results. Conclusion: Exclusive breast-feeding does not affect sensitization in early childhood or associated diseases at 7 years of age in at-risk children.	[Bisgaard, Hans] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen Prospect Studies Asthma Childhood, DK-2820 Gentofte, Denmark; [Bisgaard, Hans] Univ Copenhagen, Danish Pediat Asthma Ctr, Gentofte Hosp, DK-2820 Gentofte, Denmark	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Bisgaard, H (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen Prospect Studies Asthma Childhood, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016; Schoos, Ann-Marie Malby/AAO-7677-2020	Bisgaard, Hans/0000-0003-4131-7592; Schoos, Ann-Marie Malby/0000-0002-5827-0885	Ministry of Health [903516]; Danish Council for Strategic Research [0603-00280B]; Danish Council for Independent Research [10-082884, 271-08-0815]	Ministry of Health; Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Council for Independent Research(Det Frie Forskningsrad (DFF))	The Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) is funded by private and public research funds, all of which are listed at www.copsac.com. The Lundbeck Foundation (R16-A1694); the Ministry of Health (grant no. 903516); the Danish Council for Strategic Research (grant no. 0603-00280B); the Danish Council for Independent Research (grant no. 10-082884; 271-08-0815); and the Capital Region Research Foundation have provided core support for COPSAC. Thermo Fisher Scientific Inc sponsored the IgE analyses. No pharmaceutical company was involved in the study. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript.	Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V126, P567, DOI 10.1016/j.jaci.2010.06.026; Chulada PC, 2003, J ALLERGY CLIN IMMUN, V111, P328, DOI 10.1067/mai.2003.127; Ciprandi G, 2011, EUR J INTERN MED, V22, pE75, DOI 10.1016/j.ejim.2011.05.009; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; Duncan JM, 2008, CURR OPIN ALLERGY CL, V8, P398, DOI 10.1097/ACI.0b013e32830d82ed; Eidelman AI, 2012, PEDIATRICS, V129, pE827, DOI 10.1542/peds.2011-3552; Elliott L, 2008, J ALLERGY CLIN IMMUN, V122, P49, DOI 10.1016/j.jaci.2008.04.001; Giwercman C, 2010, J ALLERGY CLIN IMMUN, V125, P866, DOI 10.1016/j.jaci.2010.01.026; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; Halken S, 2004, PEDIAT ALLERG IMM-UK, V15, P9, DOI 10.1111/j.1399-3038.2004.0148b.x; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Kramer MS, 2007, BMJ-BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Kramer MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003517.pub2; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Lanting CI, 2005, ACTA PAEDIATR, V94, P935, DOI 10.1080/08035250510036723; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Paganelli R, 1998, ALLERGY, V53, P763; Peroni DG, 2003, CLIN EXP ALLERGY, V33, P1349, DOI 10.1046/j.1365-2222.2003.01766.x; Ro AD, 2012, EUR J PEDIATR, V171, P479, DOI 10.1007/s00431-011-1580-9; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Schoos AMM, 2015, ALLERGY, V70, P41, DOI 10.1111/all.12523; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Shakespeare J, 2004, MIDWIFERY, V20, P251, DOI 10.1016/j.midw.2003.12.011; Thygarajan A, 2008, CURR OPIN PEDIATR, V20, P698, DOI 10.1097/MOP.0b013e3283154f88; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	32	29	30	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1302	+		10.1016/j.jaci.2015.02.023	http://dx.doi.org/10.1016/j.jaci.2015.02.023			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	25843315				2022-12-18	WOS:000364787200020
J	Lundell, AC; Hesselmar, B; Nordstrom, I; Adlerberth, I; Wold, AE; Rudin, A				Lundell, Anna-Carin; Hesselmar, Bill; Nordstrom, Inger; Adlerberth, Ingegerd; Wold, Agnes E.; Rudin, Anna			Higher B-cell activating factor levels at birth are positively associated with maternal dairy farm exposure and negatively related to allergy development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prospective birth cohort; B-cell activating factor; dairy farm; pregnancy; immature/naive B cells; memory B cells; hygiene hypothesis; allergy; sex	TOLL-LIKE RECEPTORS; ANTIBODY DEFICIENCY; FACTOR BAFF; TNF FAMILY; HAY-FEVER; EXPRESSION; ASTHMA; BACTERIAL; ECZEMA; TRANSPLANTATION	Background: A high proportion of circulating immature/naive CD5(+) B cells during early infancy is a risk factor for allergy development. B-cell activating factor (BAFF) is an important cytokine for B-cell maturation. Objective: We sought to investigate whether BAFF levels are related to environmental exposures during pregnancy and early childhood and whether BAFF levels are associated with postnatal B-cell maturation and allergic disease. Methods: In the FARMFLORA study, including both farming and nonfarming families, we measured BAFF levels in plasma from mothers and their children at birth and at 1, 4, 18, and 36 months of age. Infants' blood samples were also analyzed for B-cell numbers and proportions of CD5(+) and CD27(+) B cells. Allergic disease was clinically evaluated at 18 and 36 months of age. Results: Circulating BAFF levels were maximal at birth, and farmers' children had higher BAFF levels than nonfarmers' children. Higher BAFF levels at birth were positively associated with proportions of CD27(+) memory B cells among farmers' children and inversely related to proportions of CD5(+) immature/naive B cells among nonfarmers' children. Children with allergic disease at 18 months of age had lower cord blood BAFF levels than nonallergic children. At birth, girls had higher BAFF levels and lower proportions of CD5(+) B cells than boys. Conclusions: Farm exposure during pregnancy appears to induce BAFF production in the newborn child, and high neonatal BAFF levels were associated with more accelerated postnatal B-cell maturation, which lend further strength to the role of B cells in the hygiene hypothesis.	[Lundell, Anna-Carin; Nordstrom, Inger; Rudin, Anna] Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, S-40530 Gothenburg, Sweden; [Adlerberth, Ingegerd; Wold, Agnes E.] Univ Gothenburg, Sahlgrenska Acad, Dept Infect Dis, S-40530 Gothenburg, Sweden; [Hesselmar, Bill] Univ Gothenburg, Sahlgrenska Acad, Dept Pediat, S-40530 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg	Lundell, AC (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Rheumatol & Inflammat Res, Box 480, S-40530 Gothenburg, Sweden.	anna-carin.lundell@rheuma.gu.se		Rudin, Anna/0000-0002-4137-1276				Aagaard K, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008599; Batten M, 2000, J EXP MED, V192, P1453, DOI 10.1084/jem.192.10.1453; Bemark M, 2012, CLIN EXP IMMUNOL, V167, P15, DOI 10.1111/j.1365-2249.2011.04469.x; Bienertova-Vasku J, 2015, J REPROD IMMUNOL, V109, P89, DOI 10.1016/j.jri.2014.12.003; Carsetti R, 2004, IMMUNOL REV, V197, P179, DOI 10.1111/j.0105-2896.2004.0109.x; Cuss AK, 2006, J IMMUNOL, V176, P1506, DOI 10.4049/jimmunol.176.3.1506; Duriez M, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00316; Frei R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091097; Granato A, 2014, J IMMUNOL, V192, P5761, DOI 10.4049/jimmunol.1300749; Guo WJ, 2008, CHINESE MED J-PEKING, V121, P309, DOI 10.1097/00029330-200802020-00006; Jin R, 2008, INT J MOL MED, V21, P233; Kato A, 2006, J IMMUNOL, V177, P7164, DOI 10.4049/jimmunol.177.10.7164; Kreuzaler M, 2012, J IMMUNOL, V188, P497, DOI 10.4049/jimmunol.1102321; Langat DL, 2008, AM J PATHOL, V172, P1303, DOI 10.2353/ajpath.2008.071139; Lundell AC, 2009, CLIN EXP ALLERGY, V39, P662, DOI 10.1111/j.1365-2222.2008.03176.x; Lundell AC, 2014, J IMMUNOL, V193, P510, DOI 10.4049/jimmunol.1302990; Lundell AC, 2012, J IMMUNOL, V188, P4315, DOI 10.4049/jimmunol.1103223; Marie-Cardine A, 2008, CLIN IMMUNOL, V127, P14, DOI 10.1016/j.clim.2007.11.013; Nardelli B, 2001, BLOOD, V97, P198, DOI 10.1182/blood.V97.1.198; Patni S, 2009, BIOL REPROD, V80, P243, DOI 10.1095/biolreprod.108.069252; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rolink AG, 2002, EUR J IMMUNOL, V32, P2004, DOI 10.1002/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5; Sandin A, 2011, PEDIAT ALLERG IMM-UK, V22, P477, DOI 10.1111/j.1399-3038.2010.01106.x; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Scapini P, 2003, J EXP MED, V197, P297, DOI 10.1084/jem.20021343; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Seydel LS, 2012, AM J TROP MED HYG, V86, P613, DOI 10.4269/ajtmh.2012.11-0463; Shamssain MH, 1999, ARCH DIS CHILD, V81, P313, DOI 10.1136/adc.81.4.313; Song N, 2014, J ASTHMA, V51, P232, DOI 10.3109/02770903.2013.867973; Stout MJ, 2013, AM J OBSTET GYNECOL, V208, P221; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tangeras LH, 2014, J REPROD IMMUNOL, V106, P89, DOI 10.1016/j.jri.2014.04.004; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; VANASPEREN PP, 1985, CLIN EXP IMMUNOL, V62, P753; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Williams HC, 1996, LANCET, V348, P1391, DOI 10.1016/S0140-6736(05)65466-9	39	29	29	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1074	+		10.1016/j.jaci.2015.03.022	http://dx.doi.org/10.1016/j.jaci.2015.03.022			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25936566				2022-12-18	WOS:000362976300026
J	Brown, SD; Brown, LA; Stephenson, S; Dodds, JC; Douglas, SL; Qu, HY; Fitzpatrick, AM				Brown, Sheena D.; Brown, Lou Ann; Stephenson, Susan; Dodds, Jennifer C.; Douglas, Shaneka L.; Qu, Hongyan; Fitzpatrick, Anne M.			Characterization of a high TNF-alpha phenotype in children with moderate-to-severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							BACTERIAL BIOFILMS; MIDDLE-EAR		[Brown, Sheena D.; Brown, Lou Ann; Stephenson, Susan; Dodds, Jennifer C.; Douglas, Shaneka L.; Qu, Hongyan; Fitzpatrick, Anne M.] Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA; [Brown, Lou Ann; Fitzpatrick, Anne M.] Cyst Fibrosis & Airways Dis Res, Childrens Healthcare Atlanta Ctr, Atlanta, GA USA	Emory University; Children's Healthcare of Atlanta (CHOA)	Brown, SD (corresponding author), Emory Univ, Dept Pediat, Sch Med, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu	Brown, Sheena/AGK-6465-2022	Fitzpatrick, Anne/0000-0002-2933-5926	NCATS NIH HHS [UL1 TR000454] Funding Source: Medline; NINR NIH HHS [R01 NR012021] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR012021] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P1604, DOI 10.1016/j.jaci.2011.03.031; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gagliardo R, 2011, J ALLERGY CLIN IMMUN, V128, P635, DOI 10.1016/j.jaci.2011.03.045; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P687, DOI 10.1016/j.jaci.2011.12.001; Hall-Stoodley L, 2006, JAMA-J AM MED ASSOC, V296, P202, DOI 10.1001/jama.296.2.202; Holgate ST, 2011, EUR RESPIR J, V37, P1352, DOI 10.1183/09031936.00063510; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nistico L, 2011, J CLIN MICROBIOL, V49, P1411, DOI 10.1128/JCM.00756-10; Nistico Laura, 2009, V493, P191, DOI 10.1007/978-1-59745-523-7_12; Parsek MR, 2003, ANNU REV MICROBIOL, V57, P677, DOI 10.1146/annurev.micro.57.030502.090720; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P3, DOI 10.1016/j.jaci.2013.10.018	17	29	31	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1651	1654		10.1016/j.jaci.2014.08.054	http://dx.doi.org/10.1016/j.jaci.2014.08.054			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25725987	Green Accepted			2022-12-18	WOS:000355933400033
J	Cetica, V; Hackmann, Y; Grieve, S; Sieni, E; Ciambotti, B; Coniglio, ML; Pende, D; Gilmour, K; Romagnoli, P; Griffiths, GM; Arico, M				Cetica, Valentina; Hackmann, Yvonne; Grieve, Samantha; Sieni, Elena; Ciambotti, Benedetta; Coniglio, Maria Luisa; Pende, Daniela; Gilmour, Kimberly; Romagnoli, Paolo; Griffiths, Gillian M.; Arico, Maurizio			Patients with Griscelli syndrome and normal pigmentation identify RAB27A mutations that selectively disrupt MUNC13-4 binding	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hemophagocytic lymphohistiocytosis; familial hemophagocytic lymphohistiocytosis; Griscelli syndrome type 2; melanophilin; cytotoxic T lymphocyte; natural killer cells	FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; STEM-CELL TRANSPLANTATION; MYOSIN VA; MELANOSOME TRANSPORT; GRANULE SECRETION; PLASMA-MEMBRANE; PERFORIN; LYMPHOCYTES; EXPRESSION; LYSOSOMES	Background: Familial hemophagocytic lymphohistiocytosis (FHL) is a rare and often fatal disorder characterized by defective cellular cytotoxicity and hyperinflammation, and the only cure known to date is hematopoietic stem cell transplantation. Mutations in RAB27A, LYST, and AP3B1 give rise to FHL associated with oculocutaneous albinism, and patients with FHL are usually only screened for mutations in these genes when albinism is observed. A number of patients with FHL and normal pigmentation remain without a genetic diagnosis. Objective: We asked whether patients with FHL with immunodeficiency but with normal pigmentation might sometimes have mutations that affected cellular cytotoxicity without affecting pigmentation. Methods: We carried out mutation analysis of RAB27A, LYST, and AP3B1 in patients with FHL with pigment dilution, as well as a cohort with no clinical evidence of pigment dilution but no mutations in the other known FHL-related genes (PRF1, STXBP2, and UNC13D). Results: We identify patients with Griscelli syndrome type 2 with biallelic mutations in RAB27A in the absence of albinism. All 6 patients carried mutations at amino acids R141, Y159, or S163 of Rab27a that disrupt the interaction of Rab27a with Munc13-4, without impairing the interaction between melanophilin and Rab27a. Conclusion: These studies highlight the need for RAB27A sequencing in patients with FHL with normal pigmentation and identify a critical binding site for Munc13-4 on Rab27a, revealing the molecular basis of this interaction.	[Cetica, Valentina; Sieni, Elena; Ciambotti, Benedetta; Coniglio, Maria Luisa] Azienda Osped Univ Meyer Childrens Hosp, Pediat Hematol Oncol, Florence, Italy; [Hackmann, Yvonne; Grieve, Samantha; Griffiths, Gillian M.] Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2QQ, England; [Pende, Daniela] Azienda Osped Univ San Martino, Ist Nazl Ric Cancro, Ist Ricovero & Cura Carattere Sci, Genoa, Italy; [Gilmour, Kimberly] Great Ormond St Hosp Sick Children, Immunol, London, England; [Romagnoli, Paolo] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Arico, Maurizio] Ist Toscano Tumori, Pediat Oncol Network, Florence, Italy	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Genoa; IRCCS AOU San Martino IST; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Florence; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica	Griffiths, GM (corresponding author), Cambridge Inst Med Res, Cambridge Biomed Campus, Cambridge CB2 0XY, England.	gg305@cam.ac.uk; maurizio.arico@asp.rg.it	Sieni, Elena/J-8729-2018; Romagnoli, Paolo/AAJ-9636-2020; Arico, Maurizio/S-3039-2019; Pende, Daniela/J-7429-2016; Cetica, Valentina/J-2885-2018	Sieni, Elena/0000-0002-6192-9812; Arico, Maurizio/0000-0002-1908-6671; Pende, Daniela/0000-0003-1565-451X; Cetica, Valentina/0000-0001-8549-4158; ROMAGNOLI, Paolo/0000-0002-9614-7247; Griffiths, Gillian/0000-0003-0434-5842	Associazione Italiana Ricerca Istiocitosi (AIRI); Associazione Ciemmeesse-Girotondo per il Meyer; Ministero della Salute [RF-TOS-2008-1219488, RF-2010-2316606]; European Commission [306124]; Wellcome Trust [075880, 100140]; NIHR-BRC	Associazione Italiana Ricerca Istiocitosi (AIRI); Associazione Ciemmeesse-Girotondo per il Meyer; Ministero della Salute(Ministry of Health, Italy); European Commission(European CommissionEuropean Commission Joint Research Centre); Wellcome Trust(Wellcome TrustEuropean Commission); NIHR-BRC	Supported in part by grants from Associazione Italiana Ricerca Istiocitosi (AIRI) O.N.L.U.S., Associazione Ciemmeesse-Girotondo per il Meyer O.N.L.U.S., Ministero della Salute (Bando Malattie Rare RF-TOS-2008-1219488), the Seventh Framework Programme (FP7) of the European Commission ("FIGHT-HLH'' Project number 306124; to M.A.), Ministero della Salute (RF-2010-2316606; to D.P.), and grants from the Wellcome Trust (075880 and 100140) and NIHR-BRC (to G.M.G.).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Al-Idrissi E, 2010, J PEDIAT HEMATOL ONC, V32, P494, DOI 10.1097/MPH.0b013e3181e34dc9; Arico M, 1996, LEUKEMIA, V10, P197; Arico M, 2001, BRIT J HAEMATOL, V114, P761, DOI 10.1046/j.1365-2141.2001.02936.x; Baker KS, 2008, BONE MARROW TRANSPL, V42, P175, DOI 10.1038/bmt.2008.133; Bryceson YT, 2012, BLOOD, V119, P2754, DOI 10.1182/blood-2011-08-374199; Cesaro S, 2008, HAEMATOL-HEMATOL J, V93, P1694, DOI 10.3324/haematol.13142; Chavas LMG, 2008, STRUCTURE, V16, P1468, DOI 10.1016/j.str.2008.07.015; Cooper N, 2008, BONE MARROW TRANSPL, V42, pS47, DOI 10.1038/bmt.2008.283; Elstak ED, 2011, BLOOD, V118, P1570, DOI 10.1182/blood-2011-02-339523; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; GRISCELLI C, 1978, AM J MED, V65, P691, DOI 10.1016/0002-9343(78)90858-6; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Henter JI, 1997, PED PEDIAT ONCOL, V28, P342, DOI DOI 10.1002/(SICI)1096-911; Holt O, 2008, TRAFFIC, V9, P446, DOI 10.1111/j.1600-0854.2008.00714.x; Horne A, 2005, BRIT J HAEMATOL, V129, P622, DOI 10.1111/j.1365-2141.2005.05501.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Jabado N, 1997, BLOOD, V90, P4743, DOI 10.1182/blood.V90.12.4743.4743_4743_4748; Kotting C, 2013, FEBS LETT, V587, P2025, DOI 10.1016/j.febslet.2013.05.021; Kogawa K, 2002, BLOOD, V99, P61, DOI 10.1182/blood.V99.1.61; Marcenaro S, 2006, BLOOD, V108, P2316, DOI 10.1182/blood-2006-04-015693; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, BLOOD, V101, P2736, DOI 10.1182/blood-2002-09-2789; Menasche G, 2008, BLOOD, V112, P5052, DOI 10.1182/blood-2008-02-141069; Neeft M, 2005, MOL BIOL CELL, V16, P731, DOI 10.1091/mbc.E04-10-0923; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Schmid JP, 2009, BLOOD, V114, P211, DOI 10.1182/blood-2009-02-207845; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; Sieni E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00167; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Trambas C, 2005, BLOOD, V106, P932, DOI 10.1182/blood-2004-09-3713; Trizzino A, 2008, J MED GENET, V45, P15, DOI 10.1136/jmg.2007.052670; Trottestam H, 2011, BLOOD, V118, P4577, DOI 10.1182/blood-2011-06-356261; Westbroek W, 2012, PIGM CELL MELANOMA R, V25, P47, DOI 10.1111/j.1755-148X.2011.00901.x; Wheeler RD, 2010, BRIT J HAEMATOL, V150, P727, DOI 10.1111/j.1365-2141.2010.08289.x; Wu XF, 2001, J CELL SCI, V114, P1091; zur Stadt U, 2005, HUM MOL GENET, V14, P827, DOI 10.1093/hmg/ddi076; zur Stadt U, 2009, AM J HUM GENET, V85, P482, DOI 10.1016/j.ajhg.2009.09.005	41	29	30	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1310	U738		10.1016/j.jaci.2014.08.039	http://dx.doi.org/10.1016/j.jaci.2014.08.039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25312756	Green Published, hybrid			2022-12-18	WOS:000353980700025
J	Hofmaier, S; Hatzler, L; Rohrbach, A; Panetta, V; Hakimeh, D; Bauer, CP; Hoffman, U; Forster, J; Zepp, F; Schuster, A; Stock, P; Wahn, U; Keil, T; Lau, S; Matricardi, PM				Hofmaier, Stephanie; Hatzler, Laura; Rohrbach, Alexander; Panetta, Valentina; Hakimeh, Dani; Bauer, Carl Peter; Hoffman, Ute; Forster, Johannes; Zepp, Fred; Schuster, Antje; Stock, Philippe; Wahn, Ulrich; Keil, Thomas; Lau, Susanne; Matricardi, Paolo Maria			"Default'' versus "pre-atopic'' IgG responses to foodborne and airborne pathogenesis-related group 10 protein molecules in birch-sensitized and nonatopic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; Bet v 1; birch pollen; birth cohort; childhood; IgE; IgG; pathogenesis-related group 10 protein	SUBCLASS ANTIBODIES; ALLERGY; FOOD; CAT; CHILDHOOD; EXPOSURE; AFFINITY; WHEAT; LIFE; DOG	Background: The route and dose of exposure are believed to be relevant factors in the sensitization process. Pathogenesis-related group 10 protein (PR-10) molecules are a family of allergenic proteins shared by many pollens (eg, birch and alder) and foods (eg, apple, peach, and soy). Children are exposed to both pollen-derived (inhaled) and food-derived (ingested) PR-10 molecules. Objective: We sought to investigate the role of route and dose of exposure in the evolution of IgG and IgE responses to recombinant PR-10 molecules. Methods: The German Multicentre Allergy Study examined a birth cohort born in 1990. Blood samples were collected at the ages of 1, 2, 3, 5, 6, 7, 10, and 13 years. Participants were included in the present analysis if they had (1) at least 1 serum sample at each of the 4 age periods or time points (1-3 years, 5-7 years, 10 years, and 13 years) and (2) IgE responses to birch (children with birch atopy) or no IgE response at all to 9 common aeroallergens and food allergens (nonatopic children). Therefore serum IgE antibodies to a panel of 4 airborne and 5 foodborne extracts, as well as to Bet v 1, were measured in singleplex assays, whereas IgG and IgE antibodies to a panel of 3 airborne PR-10 molecules (rBet v 1, rAln g 1, and rCor a 1.0101) and 7 foodborne PR-10 molecules (rCor a 1.0401, rMal d 1, rPru p 1, rGly m 4, rAra h 8, rApi g 1, and rDau c 1) were tested by using a multiplex microarray. Results: In the present analyses we included 28 children with birch atopy and randomly selected 28 nonatopic children from the 190 children fulfilling the inclusion criteria. Two different patterns of IgG responses to PR-10 molecules were identified. Among nonatopic subjects, a 'default'' IgG response was directed mostly against foodborne PR-10, started often before age 2 years, stayed weak, and was mostly transient. Among all atopic subjects, the default IgG response at age 1 year was overwhelmed after age 2 years by an 'pre-atopic'' IgG response, which started with or shortly before the IgE response and was intense and persistent. This atopic IgG response, as well as the IgE response, involved progressively more foodborne PR-10 proteins with frequencies and levels related to their homology with Bet v 1. Conclusions: The results suggest that children have a default antibody response to PR-10 molecules, which is early, weak, and transient; does not involve IgE; and is initiated by foodborne PR-10. By contrast, an atopic antibody response to PR-10 molecules is delayed, strong, and persistent; involves both IgG and IgE; and is initiated by airborne PR-10.	[Hofmaier, Stephanie; Hatzler, Laura; Rohrbach, Alexander; Hakimeh, Dani; Stock, Philippe; Wahn, Ulrich; Lau, Susanne; Matricardi, Paolo Maria] Charite, Dept Paediat Pneumol & Immunol, D-13353 Berlin, Germany; [Panetta, Valentina] Laltrastat Srl, Consultancy & Training, Biostat Off, Rome, Italy; [Bauer, Carl Peter; Hoffman, Ute] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Forster, Johannes] St Josefs Hosp, Dept Pediat St Hedwig, Freiburg, Germany; [Zepp, Fred] Johannes Gutenberg Univ Mainz, Ctr Med, Dept Pediat & Adolescent Med, D-55122 Mainz, Germany; [Schuster, Antje] Univ Dusseldorf, Dept Pediat Cardiol & Pneumol, Dusseldorf, Germany; [Keil, Thomas] Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; Johannes Gutenberg University of Mainz; Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg	Matricardi, PM (corresponding author), Charite, Dept Paediat Pneumol & Immunol, Augustenburger Pl, D-13353 Berlin, Germany.	paolo.matricardi@charite.de	Dramburg, Stephanie/AAM-8340-2020	Dramburg, Stephanie/0000-0002-9303-3260; Hatzler, Laura/0000-0001-8795-6205; Lau, Susanne/0000-0002-5189-4265	German Research Foundation (DFG) [MA-4740/1-1]; German Multicentre Allergy Study (MAS); German Federal Ministry of Education and Research [07015633, 07 ALE 27, 01EE9405/5, 01EE9406]; German Research Foundation [KE 1462/2-1]	German Research Foundation (DFG)(German Research Foundation (DFG)); German Multicentre Allergy Study (MAS); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG))	The present analysis was supported by the German Research Foundation (DFG), grant number MA-4740/1-1. The German Multicentre Allergy Study (MAS) birth cohort was funded further by grants from the German Federal Ministry of Education and Research (07015633, 07 ALE 27, 01EE9405/5, and 01EE9406) and the German Research Foundation (KE 1462/2-1).	Aalberse R, 2011, ALLERGY, V66, P28, DOI 10.1111/j.1398-9995.2011.02628.x; Aalberse RC, 2000, AM J RESP CRIT CARE, V162, pS124, DOI 10.1164/ajrccm.162.supplement_2.ras-14; Aalberse Rob C, 2007, Clin Mol Allergy, V5, P2, DOI 10.1186/1476-7961-5-2; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1690, DOI 10.1046/j.1365-2222.2002.01463.x; Curin M, 2014, J ALLERGY CLIN IMMUN, V133, P918, DOI 10.1016/j.jaci.2013.10.058; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P1480, DOI 10.1016/j.jaci.2011.03.014; Eysink PED, 2002, CLIN EXP ALLERGY, V32, P556, DOI 10.1046/j.0954-7894.2002.01335.x; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; Hochwallner H, 2011, ALLERGY, V66, P1201, DOI 10.1111/j.1398-9995.2011.02635.x; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P112, DOI 10.1034/j.1399-3038.1999.00015.x; Jin C, 2008, J ALLERGY CLIN IMMUN, V121, P185, DOI 10.1016/j.jaci.2007.07.047; Jonsson F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00016; KEMENY DM, 1989, CLIN EXP ALLERGY, V19, P545, DOI 10.1111/j.1365-2222.1989.tb02431.x; Krause S, 2009, J ALLERGY CLIN IMMUN, V124, P771, DOI 10.1016/j.jaci.2009.06.008; Lack G, 2008, NEW ENGL J MED, V359, P1252, DOI 10.1056/NEJMcp0800871; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Matricardi PM, 2008, CLIN EXP ALLERGY, V38, P493, DOI 10.1111/j.1365-2222.2007.02912.x; Melioli G, 2011, CLIN BIOCHEM, V44, P1005, DOI 10.1016/j.clinbiochem.2011.05.007; Niederberger V, 2002, EUR J IMMUNOL, V32, P576, DOI 10.1002/1521-4141(200202)32:2<576::AID-IMMU576>3.0.CO;2-U; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Poulsen LK, 2007, ANN MED, V39, P440, DOI 10.1080/07853890701449354; Richard C, 2012, EUR ANN ALLERGY CLIN, V44, P243; Roulias A, 2014, ALLERGY, V69, P208, DOI 10.1111/all.12306; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Scott-Taylor TH, 2010, PEDIAT ALLERG IMM-UK, V21, P935, DOI 10.1111/j.1399-3038.2010.01025.x; Sverremark-Ekstrom E, 2012, PEDIAT ALLERG IMM-UK, V23, P224, DOI 10.1111/j.1399-3038.2012.01290.x; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P147, DOI 10.1097/00130832-200204000-00011; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040	33	29	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1367	U435		10.1016/j.jaci.2014.09.048	http://dx.doi.org/10.1016/j.jaci.2014.09.048			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25458000	Green Submitted			2022-12-18	WOS:000353980700031
J	Thyssen, JP; Tang, L; Husemoen, LLN; Stender, S; Szecsi, PB; Menne, T; Johansen, JD; Linneberg, A				Thyssen, Jacob P.; Tang, Line; Husemoen, Lise Lotte N.; Stender, Steen; Szecsi, Pal B.; Menne, Torkil; Johansen, Jeanne D.; Linneberg, Allan			Filaggrin gene mutations are not associated with food and aeroallergen sensitization without concomitant atopic dermatitis in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OF-FUNCTION MUTATIONS; PEANUT ALLERGY; RISK; INFANTS		[Thyssen, Jacob P.; Menne, Torkil; Johansen, Jeanne D.] Copenhagen Univ Hosp Gentofte, Dept Dermatoallergol, Natl Allergy Res Ctr, Gentofte, Denmark; [Tang, Line; Husemoen, Lise Lotte N.; Linneberg, Allan] Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark; [Stender, Steen; Szecsi, Pal B.] Copenhagen Univ Hosp Gentofte, Dept Clin Biochem, Gentofte, Denmark; [Linneberg, Allan] Glostrup Univ Hosp, Dept Clin Expt Res, Glostrup, Denmark; [Linneberg, Allan] Univ Copenhagen, Dept Clin Med, Fac Hlth & Med Sci, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen	Thyssen, JP (corresponding author), Copenhagen Univ Hosp Gentofte, Dept Dermatoallergol, Natl Allergy Res Ctr, Gentofte, Denmark.	jacob.p.thyssen@regionh.dk	Johansen, Jeanne/AAM-6382-2021; Thyssen, Jacob/ABD-8517-2020; Møllehave, Line Tang/U-6360-2019	Johansen, Jeanne/0000-0002-3537-8463; Møllehave, Line Tang/0000-0001-7116-9346; Szecsi, Pal/0000-0003-3446-0411; Linneberg, Allan/0000-0002-0994-0184; Thyssen, Jacob Pontoppidan/0000-0003-3770-1743	Lundbeck Foundation [R139-2012-12679] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Meldgaard M, 2012, CLIN CHIM ACTA, V413, P1488, DOI 10.1016/j.cca.2012.06.014; Tan HTT, 2012, J ALLERGY CLIN IMMUN, V130, P1211, DOI 10.1016/j.jaci.2012.07.022; Thyssen JP, 2014, J ALLERGY CLIN IMMUN, V134, P792, DOI 10.1016/j.jaci.2014.06.014; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033	9	29	30	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1375	U440		10.1016/j.jaci.2015.01.001	http://dx.doi.org/10.1016/j.jaci.2015.01.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25678087				2022-12-18	WOS:000353980700032
J	Myers, JMB; Martin, LJ; Kovacic, MB; Mersha, TB; He, H; Pilipenko, V; Lindsey, MA; Ericksen, MB; Bernstein, DI; LeMasters, GK; Lockey, JE; Hershey, GKK				Myers, Jocelyn M. Biagini; Martin, Lisa J.; Kovacic, Melinda Butsch; Mersha, Tesfaye B.; He, Hua; Pilipenko, Valentina; Lindsey, Mark A.; Ericksen, Mark B.; Bernstein, David I.; LeMasters, Grace K.; Lockey, James E.; Hershey, Gurjit K. Khurana			Epistasis between serine protease inhibitor Kazal-type 5 (SPINK5) and thymic stromal lymphopoietin (TSLP) genes contributes to childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; genetic association; epistasis; skin-related genes	FILAGGRIN NULL MUTATIONS; ATOPIC-DERMATITIS; MISSING HERITABILITY; ALLERGIC DISEASE; HAY-FEVER; ASSOCIATION; POPULATION; NETHERTON; POLYMORPHISMS; GENETICS	Background: Epithelial genes have previously been associated with asthma but only explain a small fraction of heritability. In part, this might be due to epistasis, which is often not considered. Objective: We sought to determine independent and epistatic associations between filaggrin (FLG), serine protease inhibitor Kazal-type 5 (SPINK5), and thymic stromal lymphopoietin (TSLP) gene variants and childhood asthma. Methods: Using a candidate gene approach, we genotyped 29 variants in FLG, SPINK5, and TSLP in asthmatic, allergic, and nonallergic nonasthmatic white and black children participating in the well-phenotyped Greater Cincinnati Pediatric Clinic Repository. Associations with asthma were also assessed in 6 replication populations. Results: We observed independent associations of variants in SPINK5 (P = .003) and TSLP (P = .006) with childhood asthma; a SPINK5 single nucleotide polymorphism was replicated. In subjects with 1 or more SPINK5 risk alleles, the absence of the TSLP protective minor alleles was associated with a significant increase in asthma (67% vs 53%, P = .0017). In contrast, the presence or absence of TSLP minor alleles did not affect asthma risk in subjects without the SPINK5 risk alleles. The SPINK5 and TSLP epistasis was replicated in a black population (P = .036) who did not display independent association with variants in these genes. Conclusions: Our results support epistasis between SPINK5 and TSLP, which contributes to childhood asthma. These findings emphasize the importance of using biology to inform analyses to identify genetic susceptibility to complex diseases. The results from our study have clinical relevance and support that the therapeutic effects of anti-TSLP therapy in asthmatic patients might be dependent on SPINK5 genotype.	[Myers, Jocelyn M. Biagini; Martin, Lisa J.; Kovacic, Melinda Butsch; Mersha, Tesfaye B.; He, Hua; Pilipenko, Valentina; Lindsey, Mark A.; Ericksen, Mark B.; Hershey, Gurjit K. Khurana] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Bernstein, David I.] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA; [LeMasters, Grace K.; Lockey, James E.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, 3333 Burnet Ave,MLC 7037, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Khurana Hershey, Gurjit/0000-0001-6663-977X; Biagini, Jocelyn/0000-0002-4378-6133	National Institutes of Health [U19AI070235, R01ES011170, R21ES016830]; Cincinnati Children's Research Foundation; Cincinnati Genomic Control Cohort; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES016830, R01ES011170] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cincinnati Children's Research Foundation; Cincinnati Genomic Control Cohort; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants U19AI070235 (to G.K.K.H.), R01ES011170 (to G.K.L.), and R21ES016830 (to M.B.K.). Supported in part by the Cincinnati Children's Research Foundation and its Cincinnati Genomic Control Cohort.	Acevedo N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060111; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1999, Control Clin Trials, V20, P91; [Anonymous], RAND DOUBL BLIND PLA; Asmussen L, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e71; Baye TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016522; Birben E, 2012, RESP MED, V106, P349, DOI 10.1016/j.rmed.2011.11.007; Bloom B, 2012, VITAL HLTH STAT, V10, P10; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051268; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Enomoto H, 2008, J HUM GENET, V53, P615, DOI 10.1007/s10038-008-0293-z; Epstein TG, 2012, ANN ALLERG ASTHMA IM, V108, P145, DOI 10.1016/j.anai.2012.01.004; Ferreira MAR, 2009, ALLERGY, V64, P1623, DOI 10.1111/j.1398-9995.2009.02091.x; Genuneit J, 2009, CLIN EXP ALLERGY, V39, P1875, DOI 10.1111/j.1365-2222.2009.03364.x; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Han B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S12-S3; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; Harris JR, 1997, AM J RESP CRIT CARE, V156, P43, DOI 10.1164/ajrccm.156.1.9609094; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Hewett DR, 2005, HUM MOL GENET, V14, P335, DOI 10.1093/hmg/ddi030; Hovnanian A, 2013, CELL TISSUE RES, V351, P289, DOI 10.1007/s00441-013-1558-1; Kabesch M, 2004, CLIN EXP ALLERGY, V34, P340, DOI 10.1111/j.1365-2222.2004.01860.x; Koppelman GH, 1999, EUR RESPIR J, V13, P2, DOI 10.1183/09031936.99.13100299; Kosoy R, 2009, HUM MUTAT, V30, P69, DOI 10.1002/humu.20822; Kovacic MB, 2012, PEDIAT ALLER IMM PUL, V25, P104, DOI 10.1089/ped.2011.0116; Kovacic MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023714; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Liu QJ, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-59; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; March ME, 2011, DISCOV MED, V11, P35; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Martin LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033454; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; NARAYANASWAMY CR, 1991, J R STAT SOC C-APPL, V40, P309; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Orsmark-Pietras C, 2008, HUM MOL GENET, V17, P1673, DOI 10.1093/hmg/ddn058; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Poninska J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016933; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rogers AJ, 2007, J ALLERGY CLIN IMMUN, V120, P1332, DOI 10.1016/j.jaci.2007.09.037; Sakabe J, 2013, J BIOL CHEM, V288, P17179, DOI 10.1074/jbc.M113.476820; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Shi LY, 2008, CLIN IMMUNOL, V129, P202, DOI 10.1016/j.clim.2008.07.015; Spielman RS, 1996, AM J HUM GENET, V59, P983; Sullivan PF, 2007, BIOL PSYCHIAT, V61, P1121, DOI 10.1016/j.biopsych.2006.11.010; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Ungvari I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033573; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010; Zuk O, 2012, P NATL ACAD SCI USA, V109, P1193, DOI 10.1073/pnas.1119675109	61	29	30	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					891	U503		10.1016/j.jaci.2014.03.037	http://dx.doi.org/10.1016/j.jaci.2014.03.037			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	24831437	Green Accepted, Bronze			2022-12-18	WOS:000343155700016
J	Sakabe, J; Kamiya, K; Yamaguchi, H; Ikeya, S; Suzuki, T; Aoshima, M; Tatsuno, K; Fujiyama, T; Suzuki, M; Yatagai, T; Ito, T; Ojima, T; Tokura, Y				Sakabe, Jun-Ichi; Kamiya, Koji; Yamaguchi, Hayato; Ikeya, Shigeki; Suzuki, Takahiro; Aoshima, Masahiro; Tatsuno, Kazuki; Fujiyama, Toshiharu; Suzuki, Masako; Yatagai, Tsuyoshi; Ito, Taisuke; Ojima, Toshiyuki; Tokura, Yoshiki			Proteome analysis of stratum corneum from atopic dermatitis patients by hybrid quadrupole-orbitrap mass spectrometer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ECZEMA; GENE		[Sakabe, Jun-Ichi; Kamiya, Koji; Yamaguchi, Hayato; Ikeya, Shigeki; Suzuki, Takahiro; Aoshima, Masahiro; Tatsuno, Kazuki; Fujiyama, Toshiharu; Yatagai, Tsuyoshi; Ito, Taisuke; Tokura, Yoshiki] Hamamatsu Univ, Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 4312102, Japan; [Suzuki, Masako] Hamamatsu Univ, Equipment Ctr, Sch Med, Hamamatsu, Shizuoka 4312102, Japan; [Ojima, Toshiyuki] Hamamatsu Univ, Sch Med, Dept Community Hlth & Prevent Med, Hamamatsu, Shizuoka 4312102, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Sakabe, J (corresponding author), Hamamatsu Univ, Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 4312102, Japan.	jsakabe@hama-med.ac.jp		Sakabe, Jun-Ichi/0000-0002-8237-0472				Broccardo CJ, 2011, J ALLERGY CLIN IMMUN, V127, P186, DOI 10.1016/j.jaci.2010.10.033; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Komatsu N, 2007, EXP DERMATOL, V16, P513, DOI 10.1111/j.1600-0625.2007.00562.x; Mori T, 2010, BRIT J DERMATOL, V162, P83, DOI 10.1111/j.1365-2133.2009.09440.x; MYAL Y, 1991, MOL CELL ENDOCRINOL, V80, P165, DOI 10.1016/0303-7207(91)90153-J; Sakabe J, 2013, J BIOL CHEM, V288, P17179, DOI 10.1074/jbc.M113.476820; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Yamaguchi H, 2013, J DERMATOL SCI, V72, P240, DOI 10.1016/j.jdermsci.2013.07.009	9	29	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					957	960		10.1016/j.jaci.2014.07.054	http://dx.doi.org/10.1016/j.jaci.2014.07.054			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25282569	Bronze			2022-12-18	WOS:000343155700026
J	Beigelman, A; Zeiger, RS; Mauger, D; Strunk, RC; Jackson, DJ; Martinez, FD; Morgan, WJ; Covar, R; Szefler, SJ; Taussig, LM; Bacharier, LB				Beigelman, Avraham; Zeiger, Robert S.; Mauger, David; Strunk, Robert C.; Jackson, Daniel J.; Martinez, Fernando D.; Morgan, Wayne J.; Covar, Ronina; Szefler, Stanley J.; Taussig, Lynn M.; Bacharier, Leonard B.		NHLBI	The association between vitamin D status and the rate of exacerbations requiring oral corticosteroids in preschool children with recurrent wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SERUM 25-HYDROXYVITAMIN D; D DEFICIENCY; CHILDHOOD ASTHMA; RISK; PREVALENCE; PREGNANCY		[Beigelman, Avraham; Strunk, Robert C.; Bacharier, Leonard B.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Beigelman, Avraham; Strunk, Robert C.; Bacharier, Leonard B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Zeiger, Robert S.] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Zeiger, Robert S.] Univ Calif La Jolla, Dept Pediat, La Jolla, CA USA; [Mauger, David] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Jackson, Daniel J.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [Martinez, Fernando D.; Morgan, Wayne J.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Covar, Ronina] Natl Jewish Hlth, Dept Pediat, Div Pediat Clin Pharmacol, Denver, CO USA; [Covar, Ronina] Natl Jewish Hlth, Dept Pediat, Div Allergy & Immunol, Denver, CO USA; [Covar, Ronina] Univ Colorado, Sch Med, Denver, CO USA; [Szefler, Stanley J.; Taussig, Lynn M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Szefler, Stanley J.; Taussig, Lynn M.] Univ Denver, Denver, CO USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Pulm Med Sect, Breathing Inst, Dept Pediat, Denver, CO USA	Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Kaiser Permanente; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Wisconsin System; University of Wisconsin Madison; University of Arizona; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Denver; Children's Hospital Colorado	Beigelman, A (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.	beigelman_a@kids.wustl.edu		Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063; Szefler, Stanley/0000-0002-6911-3199	NCATS NIH HHS [UL1 TR000448, UL1 TR001082, KL2 TR000450, UL1 TR000427, KL2 TR000428] Funding Source: Medline; NCRR NIH HHS [M01 RR00036, M01 RR00051, 1 UL1RR025780, M01 RR00997] Funding Source: Medline; NHLBI NIH HHS [5U10HL064307, U10 HL064295, 5U10HL064295, U10 HL064307, 5U10HL064288, U10 HL064305, U10 HL064287, 5U10HL064287, 5U10HL064313, 5U10HL064305, U10 HL064288] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448, UL1TR001082, UL1TR000427, KL2TR000428, KL2TR000450] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, UL1RR025780, M01RR000997, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL064287, U10HL064288, U10HL064305, U10HL064307, U10HL064313, U10HL064295] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P287, DOI 10.1016/j.jaci.2012.04.025; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Brehm JM, 2012, AM J RESP CRIT CARE, V186, P140, DOI 10.1164/rccm.201203-0431OC; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Cameron AC, 1996, J BUS ECON STAT, V14, P209, DOI 10.2307/1392433; El Hayek J, 2013, J NUTR, V143, P154, DOI 10.3945/jn.112.169144; Ersfeld DL, 2004, CLIN BIOCHEM, V37, P867, DOI 10.1016/j.clinbiochem.2004.06.006; Gordon CM, 2008, ARCH PEDIAT ADOL MED, V162, P505, DOI 10.1001/archpedi.162.6.505; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hollams EM, 2012, CURR OPIN ALLERGY CL, V12, P228, DOI 10.1097/ACI.0b013e3283534a32; Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009-0051; Litonjua AA, 2012, CURR OPIN ALLERGY CL, V12, P179, DOI 10.1097/ACI.0b013e3283507927; Morales E, 2012, EPIDEMIOLOGY, V23, P64, DOI 10.1097/EDE.0b013e31823a44d3; Pike KC, 2012, THORAX, V67, P950, DOI 10.1136/thoraxjnl-2012-201888; Powe CE, 2013, NEW ENGL J MED, V369, P1991, DOI 10.1056/NEJMoa1306357; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Wagner D, 2009, CLIN BIOCHEM, V42, P1549, DOI 10.1016/j.clinbiochem.2009.07.013; Wu AC, 2012, AM J RESP CRIT CARE, V186, P508, DOI 10.1164/rccm.201202-0351OC; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647	23	29	31	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1489	+		10.1016/j.jaci.2014.02.024	http://dx.doi.org/10.1016/j.jaci.2014.02.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24698320	Green Accepted			2022-12-18	WOS:000335450700041
J	Larenas-Linnemann, D; Wahn, U; Kopp, M				Larenas-Linnemann, Desiree; Wahn, Ulrich; Kopp, Matthias			Use of omalizumab to improve desensitization safety in allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							BEE-VENOM IMMUNOTHERAPY; ANTI-IGE TREATMENT; COMBINATION TREATMENT; LEUKOTRIENE RELEASE; RUSH IMMUNOTHERAPY; RHINITIS; CHILDREN; PRETREATMENT; XOLAIR; RHINOCONJUNCTIVITIS		[Larenas-Linnemann, Desiree] Hosp Med Sur, Mexico City 14050, DF, Mexico; [Wahn, Ulrich] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Kopp, Matthias] Med Univ Lubeck, Airway Res Ctr North ARCN, Dept Pediat Allergy & Pulmonol, D-23538 Lubeck, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Lubeck	Larenas-Linnemann, D (corresponding author), Hosp Med Sur, Torre 2,Cons 602,Puente Piedra 150, Mexico City 14050, DF, Mexico.	Marlar1@prodigy.net.mx		Larenas Linnemann, Desiree/0000-0002-5713-5331				Bez C, 2004, CLIN EXP ALLERGY, V34, P1079, DOI 10.1111/j.1365-2222.2004.01998.x; Busse W, 2012, J ALLERGY CLIN IMMUN, V129, P983, DOI 10.1016/j.jaci.2012.01.033; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Galera C, 2009, J INVEST ALLERG CLIN, V19, P225; Gomis VS, 2008, J INVEST ALLERG CLIN, V18, P225; Kamin W, 2010, PEDIAT ALLERG IMM-UK, V21, pE160, DOI 10.1111/j.1399-3038.2009.00900.x; Klunker S, 2007, J ALLERGY CLIN IMMUN, V120, P688, DOI 10.1016/j.jaci.2007.05.034; Kopp MV, 2009, CLIN EXP ALLERGY, V39, P271, DOI 10.1111/j.1365-2222.2008.03121.x; Kopp MV, 2007, PEDIATR ALLERGY IMMU, V18, P523, DOI 10.1111/j.1399-3038.2007.00557.x; Kopp MV, 2013, PEDIAT ALLERG IMM-UK, V24, P427, DOI 10.1111/pai.12098; Kopp MV, 2003, PEDIAT ALLERG IMM-UK, V14, P401, DOI 10.1034/j.1399-3038.2003.00068.x; Kopp MV, 2002, J ALLERGY CLIN IMMUN, V110, P728, DOI 10.1067/mai.2002.128804; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lowe PJ, 2011, BRIT J CLIN PHARMACO, V72, P306, DOI 10.1111/j.1365-2125.2011.03962.x; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Nopp A, 2007, ALLERGY, V62, P1175, DOI 10.1111/j.1398-9995.2007.01476.x; Nopp A, 2010, ALLERGY, V65, P56, DOI 10.1111/j.1398-9995.2009.02144.x; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P973, DOI 10.1111/j.1398-9995.2004.00552.x	19	29	33	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					937	U588		10.1016/j.jaci.2013.12.1089	http://dx.doi.org/10.1016/j.jaci.2013.12.1089			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24581432				2022-12-18	WOS:000332397600059
J	Fabian, MP; Adamkiewicz, G; Stout, NK; Sandel, M; Levy, JI				Fabian, Maria Patricia; Adamkiewicz, Gary; Stout, Natasha Kay; Sandel, Megan; Levy, Jonathan Ian			A simulation model of building intervention impacts on indoor environmental quality, pediatric asthma, and costs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Air pollution; allergen; asthma; discrete event simulation; energy savings; green building; housing; intervention; indoor air; lung function; NO2; PM2.5	FORCED EXPIRATORY VOLUME; INNER-CITY CHILDREN; HOME; HEALTH; CLASSIFICATION; EXACERBATIONS; SEVERITY; EXPOSURE; TRIGGER; ADULTS	Background: Although indoor environmental conditions can affect pediatric asthmatic patients, few studies have characterized the effect of building interventions on asthma-related outcomes. Simulation models can evaluate such complex systems but have not been applied in this context. Objective: We sought to evaluate the impact of building interventions on indoor environmental quality and pediatric asthma health care use, and to conduct cost comparisons between intervention and health care costs and energy savings. Methods: We applied our previously developed discrete event simulation model (DEM) to simulate the effect of environmental factors, medication compliance, seasonality, and medical history on (1) pollutant concentrations indoors and (2) asthma outcomes in low-income multifamily housing. We estimated health care use and costs at baseline and subsequent to interventions, and then compared health care costs with energy savings and intervention costs. Results: Interventions, such as integrated pest management and repairing kitchen exhaust fans, led to 7% to 12% reductions in serious asthma events with 1- to 3-year payback periods. Weatherization efforts targeted solely toward tightening a building envelope led to 20% more serious asthma events, but bundling with repairing kitchen exhaust fans and eliminating indoor sources (eg, gas stoves or smokers) mitigated this effect. Conclusion: Our pediatric asthma model provides a tool to prioritize individual and bundled building interventions based on their effects on health and costs, highlighting the tradeoffs between weatherization, indoor air quality, and health. Our work bridges the gap between clinical and environmental health sciences by increasing physicians' understanding of the effect that home environmental changes can have on their patients' asthma.	[Fabian, Maria Patricia; Levy, Jonathan Ian] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA; [Fabian, Maria Patricia; Adamkiewicz, Gary; Levy, Jonathan Ian] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Cambridge, MA 02138 USA; [Stout, Natasha Kay] Harvard Univ, Sch Med, Dept Populat Med, Cambridge, MA 02138 USA; [Stout, Natasha Kay] Harvard Pilgrim Hlth Care Inst, Baltimore, MD USA; [Sandel, Megan] Boston Med Univ, Sch Med, Dept Gen Pediat, Boston, MA USA	Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Fabian, MP (corresponding author), 715 Albany St,Talbot 4W, Boston, MA 02118 USA.	pfabian@bu.edu	Levy, Jon/B-4542-2011	Levy, Jon/0000-0002-1116-4006; Fabian, M. Patricia/0000-0002-1658-3349	National Institute of Environmental Health Sciences [R21ES017522]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES017522] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by award number R21ES017522 from the National Institute of Environmental Health Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Environmental Health Sciences or the National Institutes of Health.	Adgate JL, 2008, J EXPO SCI ENV EPID, V18, P430, DOI 10.1038/sj.jes.7500638; American Academy of Pediatrics, 2008, 2007 08 AAP MED REIM; [Anonymous], 2010, RED BOOK PHARM FUND; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Brugge D, 2001, New Solut, V11, P149; Brugge Doug, 2007, Reviews on Environmental Health, V22, P245; Burke JM, 2001, J EXPO ANAL ENV EPID, V11, P470, DOI 10.1038/sj.jea.7500188; Centers for Disease Control and Prevention, 2010, NAT HOSP DISCH SURV; Centers for Disease Control and Prevention, 2011, AMB MED CAR UT EST 2; Centers for Disease Control and Prevention, 2010, SUMM HLTH STAT US CH; Community Access Partnership of Stafford County, WEATH; Crocker DD, 2011, AM J PREV MED, V41, pS5, DOI [10.1016/j.amepre.2011.04.011, 10.1016/j.amepre.2011.05.012]; Digenis-Bury EC, 2008, AM J PUBLIC HEALTH, V98, P85, DOI 10.2105/AJPH.2006.094912; Fabian MP, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-66; Fabian P, 2012, INDOOR AIR, V22, P12, DOI 10.1111/j.1600-0668.2011.00742.x; Frey U, 2007, CURR OPIN ALLERGY CL, V7, P223, DOI 10.1097/ACI.0b013e32810fd771; Fuhlbrigge AL, 2006, J ALLERGY CLIN IMMUN, V117, P359, DOI 10.1016/j.jaci.2005.10.036; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; Homewyse, COST KITCH EXH FANS; Howden-Chapman P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1411; Hynes H, 2000, PLANNING PRACTICE RE, V15, P21; Hynes HP, 2003, J PUBLIC HEALTH POL, V24, P401, DOI 10.2307/3343385; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; Johnston NW, 2006, THORAX, V61, P722, DOI 10.1136/thx.2005.045161; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Lanphear BP, 2011, PEDIATRICS, V127, P93, DOI 10.1542/peds.2009-2312; Law AM, 1991, SIMULATION MODELING; LBL, HOM EN SAV; Lee K, 1998, J AIR WASTE MANAGE, V48, P736, DOI 10.1080/10473289.1998.10463717; Levy JI, 1998, J AIR WASTE MANAGE, V48, P553, DOI 10.1080/10473289.1998.10463704; Levy JI, 2006, SOC SCI MED, V63, P2191, DOI 10.1016/j.socscimed.2006.05.006; Levy Jonathan I, 2004, Environ Health, V3, P13, DOI 10.1186/1476-069X-3-13; Long CM, 2001, ENVIRON SCI TECHNOL, V35, P2089, DOI 10.1021/es001477d; Merrill CT, 2005, HCUP FACT BOOK; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39, DOI 10.1067/mai.2001.116289; Peters JL, 2007, J ASTHMA, V44, P455, DOI 10.1080/02770900701421971; Sharma HP, 2007, PEDIATR CLIN N AM, V54, P103, DOI 10.1016/j.pcl.2006.11.007; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Stranges E, 2006, HOSP STAYS RELATED A; Takaro TK, 2011, AM J PUBLIC HEALTH, V101, P55, DOI 10.2105/AJPH.2010.300008; US Department of Labor, 2013, MED CAR CONS PRIC IN; US Environmental Protection Agency, 2006, 600R05004AF OFF RES; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Wu AC, 2007, J ALLERGY CLIN IMMUN, V120, P1146, DOI 10.1016/j.jaci.2007.07.055; ZHANG JF, 1994, INDOOR AIR, V4, P95, DOI 10.1111/j.1600-0668.1994.t01-2-00004.x	48	29	29	2	53	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					77	84		10.1016/j.jaci.2013.06.003	http://dx.doi.org/10.1016/j.jaci.2013.06.003			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	281MM	23910689	Green Accepted			2022-12-18	WOS:000329105700010
J	Dreyfus, DH				Dreyfus, David H.			Herpesviruses and the microbiome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hygiene hypothesis; genomics; microbiome; herpes; therapy; vaccines	HERPES-SIMPLEX-VIRUS; EPSTEIN-BARR-VIRUS; VARICELLA-ZOSTER-VIRUS; BUDESONIDE INHALATION SUSPENSION; HYPERSENSITIVITY SYNDROME; SMALLPOX VACCINATION; T-CELLS; ENDOTHELIAL-CELLS; INFECTIOUS BURDEN; GENETIC-VARIANTS	The focus of this article will be to examine the role of common herpesviruses as a component of the microbiome of atopic patients and to review clinical observations suggesting that atopic patients might be predisposed to more severe and atypical herpes-related illness because their immune response is biased toward a T(H)2 cytokine profile. Human populations are infected with 8 herpesviruses, including herpes simplex virus HSV1 and HSV2 (also termed HHV1 and HHV2), varicella zoster virus (VZV or HHV3), EBV (HHV4), cytomegalovirus (HHV5), HHV6, HHV7, and Kaposi sarcoma-associated herpesvirus (termed KSV or HHV8). Herpesviruses are highly adapted to lifelong infection of their human hosts and thus can be considered a component of the human "microbiome" in addition to their role in illness triggered by primary infection. HSV1 and HSV2 infection and reactivation can present with more severe cutaneous symptoms termed eczema herpeticum in the atopic population, similar to the more severe eczema vaccinatum, and drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) is associated with reactivation of HSV6 and possibly other herpesviruses in both atopic and nonatopic patients. In this review evidence is reviewed that primary infection with herpesviruses may have an atypical presentation in the atopic patient and conversely that childhood infection might alter the atopic phenotype. Reactivation of latent herpesviruses can directly alter host cytokine profiles through viral expression of cytokine-like proteins, such as IL-10 (EBV) or IL-6 (cytomegalovirus and HHV8), viral encoded and secreted siRNA and microRNAs, and modulation of expression of host transcription pathways, such as nuclear factor kappa B. Physicians caring for allergic and atopic populations should be aware of common and uncommon presentations of herpes-related disease in atopic patients to provide accurate diagnosis and avoid unnecessary laboratory testing or incorrect diagnosis of other conditions, such as drug allergy or autoimmune disease. Antiviral therapy and vaccines should be administered promptly when indicated clinically.	[Dreyfus, David H.] Yale Univ, Sch Med, Dept Pediat, Clin Fac, New Haven, CT 06510 USA; [Dreyfus, David H.] Ctr Allergy Asthma & Immunol, Waterbury, CT USA	Yale University	Dreyfus, DH (corresponding author), Yale Univ, Sch Med, Dept Pediat, Clin Fac Pediat, 1389 W Main St,Suite 205, Waterbury, CT 06708 USA.	dhdreyfusmd@gmail.com						Abdel-Haq Nahed M., 2004, Indian Journal of Pediatrics, V71, P89, DOI 10.1007/BF02725664; Abel L, 2010, J PEDIATR-US, V157, P623, DOI 10.1016/j.jpeds.2010.04.020; Alam R., 2011, IMMUNOL ALLERGY CLIN, V31, pix; Alcantara-Neves NM, 2012, J ALLERGY CLIN IMMUN, V129, P359, DOI 10.1016/j.jaci.2011.09.015; Alcantara- Neves NM, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Aouam K, 2008, EPILEPSIA, V49, P1630, DOI 10.1111/j.1528-1167.2008.01660.x; Arbuckle JH, 2010, P NATL ACAD SCI USA, V107, P5563, DOI 10.1073/pnas.0913586107; Aronson PL, 2013, PEDIATR DERMATOL, V30, P215, DOI 10.1111/j.1525-1470.2012.01859.x; Aronson PL, 2013, PEDIATR DERMATOL, V30, P207, DOI 10.1111/j.1525-1470.2012.01860.x; Audry M, 2011, J ALLERGY CLIN IMMUN, V128, P610, DOI 10.1016/j.jaci.2011.04.059; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P1227, DOI 10.1067/mai.2003.1483; Beatty PR, 1997, J IMMUNOL, V158, P4045; Bloch DB, 2012, J ALLERGY CLIN IMMUN, V129, P1678, DOI 10.1016/j.jaci.2012.01.046; Bonekamp D, 2011, RADIOGRAPHICS, V31, P1793, DOI 10.1148/rg.316115502; Botto S, 2011, BLOOD, V117, P352, DOI 10.1182/blood-2010-06-291245; Breithaupt AD, 2012, CUTIS, V90, P13; Brisson M, 2002, JAMA-J AM MED ASSOC, V287, P2211, DOI 10.1001/jama.287.17.2211; BRISSON M, 2003, J MED VIROL S1, V70, P31; Bryant KF, 2012, J VIROL, V86, P6825, DOI 10.1128/JVI.00374-12; Caselli E, 2008, EUR ARCH OTO-RHINO-L, V265, P377, DOI 10.1007/s00405-007-0453-3; Caselli E, 2007, NEW MICROBIOL, V30, P173; Caselli E, 2007, BLOOD, V109, P2718, DOI 10.1182/blood-2006-03-012500; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Chaves SS, 2008, J INFECT DIS, V197, pS170, DOI 10.1086/522161; CHOONG K, 1995, PEDIATR INFECT DIS J, V14, P809; Ciccocioppo R, 2011, INFLAMM BOWEL DIS, V17, pE113, DOI 10.1002/ibd.21790; Criado PR, 2012, AN BRAS DERMATOL, V87, P435, DOI 10.1590/S0365-05962012000300013; De Caterina R, 2004, NEW ENGL J MED, V350, P4, DOI 10.1056/NEJMp038190; Descamps V, 1997, BRIT J DERMATOL, V137, P605, DOI 10.1111/j.1365-2133.1997.tb03795.x; DOWELL SF, 1993, PEDIATRICS, V92, P223; Dreyfus DH, 2011, AUTOIMMUN REV, V11, P88, DOI 10.1016/j.autrev.2011.08.005; Dreyfus DH, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-422; Dreyfus DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005778; Dreyfus DH, 1996, IMMUNOL REV, V152, P89, DOI 10.1111/j.1600-065X.1996.tb00912.x; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Gao PS, 2012, J INVEST DERMATOL, V132, P650, DOI 10.1038/jid.2011.374; Getahun A, 2012, J IMMUNOL, V189, P2965, DOI 10.4049/jimmunol.1201407; Good CB, 2007, NEW ENGL J MED, V357, P89; Gourzones C, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-271; Guo YQ, 2011, J EXP MED, V208, P2083, DOI 10.1084/jem.20101568; Hamaguchi Y, 2010, INT J DERMATOL, V49, P700, DOI 10.1111/j.1365-4632.2009.04441.x; Hambleton S, 2008, FRONT BIOSCI-LANDMRK, V13, P2696, DOI 10.2741/2876; Hambleton S, 2008, J INFECT DIS, V197, pS196, DOI 10.1086/522131; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; Hussain I, 2003, CHEST, V124, P1968, DOI 10.1378/chest.124.5.1968; Igde M, 2009, IRAN J ALLERGY ASTHM, V8, P149, DOI 08.03/ijaai.7784; Irons RD, 2008, CHEM-BIOL INTERACT, V172, P81, DOI 10.1016/j.cbi.2007.11.005; James KM, 2012, J ALLERGY CLIN IMMUN, V130, P343, DOI 10.1016/j.jaci.2012.05.056; Janson C, 2007, J ALLERGY CLIN IMMUN, V120, P673, DOI 10.1016/j.jaci.2007.05.003; Jin CQ, 2012, INT J LAB HEMATOL, V34, P164, DOI 10.1111/j.1751-553X.2011.01375.x; Kanai K, 2007, VIRUS GENES, V35, P563, DOI 10.1007/s11262-007-0153-5; Kis LL, 2006, BLOOD, V107, P2928, DOI 10.1182/blood-2005-06-2569; Liu Y, 1997, J IMMUNOL, V158, P604; Luca NJC, 2012, J PEDIATR-US, V161, P671, DOI 10.1016/j.jpeds.2012.03.057; Macaladad N, 2007, VACCINE, V25, P2139, DOI 10.1016/j.vaccine.2006.11.011; MACNEIL IA, 1990, J IMMUNOL, V145, P4167; Malterer G, 2011, RNA BIOL, V8, P30, DOI 10.4161/rna.8.1.13745; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Merindol N, 2012, J IMMUNOL, V189, P5016, DOI 10.4049/jimmunol.1201759; Milgrom H, 2005, CURR OPIN ALLERGY CL, V5, P207, DOI 10.1097/01.all.0000168782.28841.71; Minnicelli C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046005; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; Morito H, 2012, J DERMATOL, V39, P669, DOI 10.1111/j.1346-8138.2011.01365.x; Morris VA, 2012, VIROLOGY, V428, P112, DOI 10.1016/j.virol.2012.03.013; Murphy K, 2006, INT J CLIN PRACT, V60, P1548, DOI 10.1111/j.1742-1241.2006.01189.x; Nilsson C, 2009, CLIN EXP ALLERGY, V39, P509, DOI 10.1111/j.1365-2222.2008.03147.x; Nishimura M, 2008, CELL IMMUNOL, V251, P31, DOI 10.1016/j.cellimm.2008.03.001; Patel MS, 2008, INFECT CONT HOSP EP, V29, P1157, DOI 10.1086/591975; Peng W, 2008, J NEUROVIROL, V14, P41, DOI 10.1080/13550280701793957; Picard D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001116; Ponsonby AL, 2006, CLIN EXP IMMUNOL, V146, P463, DOI 10.1111/j.1365-2249.2006.03235.x; Rezende RA, 2006, AM J OPHTHALMOL, V141, P1120, DOI 10.1016/j.ajo.2006.01.072; Rezende RA, 2007, AM J OPHTHALMOL, V143, P623, DOI 10.1016/j.ajo.2006.12.003; Rezende RA, 2006, AM J OPHTHALMOL, V142, P563, DOI 10.1016/j.ajo.2006.05.025; Sacre K, 2012, AIDS, V26, P805, DOI 10.1097/QAD.0b013e328351f780; Sancho-Shimizu V, 2007, CURR OPIN ALLERGY CL, V7, P495, DOI 10.1097/ACI.0b013e3282f151d2; Sancho-Shimizu V, 2011, J CLIN INVEST, V121, P4889, DOI 10.1172/JCI59259; Sartori AMC, 2004, INT J INFECT DIS, V8, P259, DOI 10.1016/j.ijid.2003.09.006; Silverberg JI, 2010, J ALLERGY CLIN IMMUN, V126, P300, DOI 10.1016/j.jaci.2010.05.041; Szefler SJ, 2004, ANN ALLERG ASTHMA IM, V93, P83, DOI 10.1016/S1081-1206(10)61451-2; Takahashi M, 2008, J INFECT DIS, V197, pS41, DOI 10.1086/522132; Tamburro KM, 2012, VIROLOGY, V433, P220, DOI 10.1016/j.virol.2012.08.014; Thomson KJ, 2005, BONE MARROW TRANSPL, V35, P1065, DOI 10.1038/sj.bmt.1704959; Tseng HF, 2009, PEDIATR INFECT DIS J, V28, P1069, DOI 10.1097/INF.0b013e3181acf84f; Uebe B, 2002, EUR J PEDIATR, V161, P442, DOI 10.1007/s00431-002-0981-1; Umetsu DT, 2004, ANN NY ACAD SCI, V1029, P88, DOI 10.1196/annals.1309.012; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; van Beek J, 2006, AM J SURG PATHOL, V30, P59, DOI 10.1097/01.pas.0000176428.06629.1e; Vazquez M, 2004, CURR OPIN PEDIATR, V16, P80; Veiga RV, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-24; Verstraeten T, 2003, PEDIATRICS, V112, pE98, DOI 10.1542/peds.112.2.e98; von Hertzen LC, 2007, EUR RESPIR J, V30, P809, DOI 10.1183/09031936.00069807; von Hertzen LC, 2006, INT ARCH ALLERGY IMM, V140, P89, DOI 10.1159/000092251; von Mutius E, 2012, J ALLERGY CLIN IMMUN, V129, P1202, DOI 10.1016/j.jaci.2011.12.994; Voo KS, 2005, CANCER RES, V65, P1577, DOI 10.1158/0008-5472.CAN-04-2552; Ward KN, 2005, CURR OPIN INFECT DIS, V18, P247, DOI 10.1097/01.qco.0000168386.16519.93; Ward KN, 2005, ARCH DIS CHILD, V90, P619, DOI 10.1136/adc.2004.062216; Ward KN, 2005, J CLIN VIROL, V32, P183, DOI 10.1016/j.jcv.2004.11.008; Weinberg A, 2009, J INFECT DIS, V200, P1068, DOI 10.1086/605611; Wollenberg A, 2012, CHEM IMMUNOL ALLERGY, V96, P89, DOI 10.1159/000331892; Wroblewski JM, 2002, J IMMUNOL METHODS, V264, P19, DOI 10.1016/S0022-1759(01)00565-8; Yang SY, 2011, J CHIN MED ASSOC, V74, P48, DOI 10.1016/j.jcma.2011.01.008; Zerr DM, 2012, CURR OPIN INFECT DIS, V25, P438, DOI 10.1097/QCO.0b013e3283553362; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	105	29	32	0	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1278	1286		10.1016/j.jaci.2013.02.039	http://dx.doi.org/10.1016/j.jaci.2013.02.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23611298				2022-12-18	WOS:000327538200006
J	Khodoun, MV; Kucuk, ZY; Strait, RT; Krishnamurthy, D; Janek, K; Clay, CD; Morris, SC; Finkelman, FD				Khodoun, Marat V.; Kucuk, Zeynep Yesim; Strait, Richard T.; Krishnamurthy, Durga; Janek, Kevin; Clay, Corey D.; Morris, Suzanne C.; Finkelman, Fred D.			Rapid desensitization of mice with anti-Fc gamma RIIb/Fc gamma RIII mAb safely prevents IgG-mediated anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; IgG; Fc gamma R; mouse; macrophage; basophil; neutrophil; rapid desensitization	PLATELET-ACTIVATING-FACTOR; MAST-CELL DEGRANULATION; IMMUNOGLOBULIN-G; SYSTEMIC-ANAPHYLAXIS; EPSILON-RI; IN-VIVO; RECEPTOR; MOUSE; ANTIBODIES; RELEASE	Background: Stimulatory IgG receptors (Fc gamma Rs) on bone marrow-derived cells contribute to the pathogenesis of several autoimmune and inflammatory disorders. Monoclonal antibodies that block Fc gamma Rs might suppress these diseases, but they can induce anaphylaxis. Objective: We wanted to determine whether a rapid desensitization approach can safely suppress IgG/Fc gamma R-mediated anaphylaxis. Methods: Mice were injected with serially increasing doses of 2.4G2, a rat mAb that blocks the inhibitory Fc gamma R, Fc gamma RIIb, and the stimulatory receptor, Fc gamma RIII. Rectal temperature was used to detect the development of anaphylaxis. Passive and active IgG-mediated anaphylaxis were evaluated in mice that had been rapidly desensitized with 2.4G2 or mock-desensitized in mice in which monocyte/macrophages, basophils, or neutrophils had been depleted or desensitized and in mice in which Fc gamma RI, Fc gamma RIII, and/or FcgRIV had been deleted or blocked. Results: Rapid desensitization with 2.4G2 prevented 2.4G2-induced shock and completely suppressed IgG-mediated anaphylaxis. Rapid desensitization of ovalbumin-sensitized mice with 2.4G2 was safer and more effective than rapid desensitization with ovalbumin. 2.4G2 treatment completely blocked FcgRIII and removed most Fc gamma RI and Fc gamma RIV from nucleated peripheral blood cells. Because IgG2a-mediated anaphylaxis was partially FcgRI and FcgRIV dependent, the effects of 2.4G2 on Fc gamma RI and Fc gamma RIV were probably crucial for its complete inhibition of IgG2a-mediated anaphylaxis. IgG2a-mediated anaphylaxis was partially inhibited by depletion or desensitization of monocyte/macrophages, basophils, or neutrophils. Conclusion: IgG-mediated anaphylaxis can be induced by ligation of Fc gamma RI, Fc gamma RIII, or Fc gamma RIV on monocycte/macrophages, basophils, or neutrophils and can be safely suppressed by rapid desensitization with anti-Fc gamma RII/RIII mAb. A similar approach may safely suppress other Fc gamma R-dependent immunopathology.	[Khodoun, Marat V.; Strait, Richard T.; Krishnamurthy, Durga; Morris, Suzanne C.] Cincinnati Vet Affairs Med Ctr, Dept Res, Cincinnati, OH USA; [Khodoun, Marat V.; Krishnamurthy, Durga; Clay, Corey D.; Morris, Suzanne C.; Finkelman, Fred D.] Univ Cincinnati, Sch Med, Div Immunol Allergy & Rheumatol, Dept Med, Cincinnati, OH 45267 USA; [Kucuk, Zeynep Yesim] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Strait, Richard T.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Janek, Kevin] Univ Cincinnati, Sch Med, Cincinnati, OH 45267 USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Cellular & Mol Immunol, Cincinnati, OH 45229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center	Finkelman, FD (corresponding author), Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Hlth Profess Bldg,3255 Eden Ave,Suite 350, Cincinnati, OH 45267 USA.	finkelfd@ucmail.uc.edu			US Department of Veterans Affairs Merit Award; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971] Funding Source: NIH RePORTER	US Department of Veterans Affairs Merit Award(US Department of Veterans Affairs); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the US Department of Veterans Affairs Merit Award (F.D.F.).	Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; ARAUJOJORGE T, 1993, INFECT IMMUN, V61, P4925, DOI 10.1128/IAI.61.11.4925-4928.1993; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; BERGAMASCHINI L, 1995, J LAB CLIN MED, V125, P348; Bergtold A, 2006, J IMMUNOL, V177, P7287, DOI 10.4049/jimmunol.177.10.7287; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; CAMUSSI G, 1983, INT ARCH ALLER A IMM, V70, P245, DOI 10.1159/000233331; CAMUSSI G, 1981, IMMUNOLOGY, V42, P191; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Chung KM, 2006, J VIROL, V80, P1340, DOI 10.1128/JVI.80.3.1340-1351.2006; da Silva FP, 2007, NAT MED, V13, P1368, DOI 10.1038/nm1665; DEHAAS M, 1995, BLOOD, V86, P2403, DOI 10.1182/blood.V86.6.2403.bloodjournal8662403; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Domingo P, 2002, AM J MED, V112, P19, DOI 10.1016/S0002-9343(01)01047-6; Endeman H, 2009, CLIN VACCINE IMMUNOL, V16, P1087, DOI 10.1128/CVI.00037-09; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; FINKELMAN FD, 1981, J IMMUNOL, V126, P680; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Hashimoto T, 2012, J PATHOL, V228, P1, DOI 10.1002/path.4062; Hedin H, 1980, Dev Biol Stand, V48, P179; Hirano M, 2007, NAT IMMUNOL, V8, P762, DOI 10.1038/ni1477; Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381; Ioan-Facsinay A, 2002, IMMUNITY, V16, P391, DOI 10.1016/S1074-7613(02)00294-7; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V131, P1555, DOI 10.1016/j.jaci.2013.02.043; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Meyer D, 1998, BLOOD, V92, P3997, DOI 10.1182/blood.V92.11.3997.423k52_3997_4002; Miele E, 2004, J PEDIATR GASTR NUTR, V38, P502, DOI 10.1097/00005176-200405000-00008; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; OKADA S, 1991, BLOOD, V78, P1706; Ouma C, 2012, HUM GENET, V131, P289, DOI 10.1007/s00439-011-1076-8; Radeke HH, 2002, J BIOL CHEM, V277, P27535, DOI 10.1074/jbc.M200419200; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; SANCHEZCRESPO M, 1980, IMMUNOLOGY, V40, P645; Schiller C, 2000, EUR J IMMUNOL, V30, P481; SCHMIDT AP, 1969, NEW ENGL J MED, V280, P188, DOI 10.1056/NEJM196901232800404; Sole-Violan J, 2011, CRIT CARE MED, V39, P1388, DOI 10.1097/CCM.0b013e31820eda74; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; Strait RT, 2011, J EXP MED, V208, P2525, DOI 10.1084/jem.20110159; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2003, J IMMUNOL, V170, P3835, DOI 10.4049/jimmunol.170.7.3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Teeling JL, 2001, BLOOD, V98, P1095, DOI 10.1182/blood.V98.4.1095; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Tuzun E, 2006, J NEUROIMMUNOL, V174, P157, DOI 10.1016/j.jneuroim.2006.01.015; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Umeda Y, 2007, Kyobu Geka, V60, P69; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; VANDEWINKEL JGJ, 1995, J IMMUNOL, V154, P2896; WALDMANN TA, 1969, PROG ALLERGY, V13, P1, DOI 10.1159/000287491; WILDE DB, 1983, J IMMUNOL, V131, P2178; Yee AMF, 2000, CLIN INFECT DIS, V30, P25, DOI 10.1086/313588; Yoshida H, 1996, AM J HEMATOL, V53, P158, DOI 10.1002/(SICI)1096-8652(199611)53:3<158::AID-AJH2>3.3.CO;2-8	60	29	31	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1375	1387		10.1016/j.jaci.2013.09.008	http://dx.doi.org/10.1016/j.jaci.2013.09.008			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	24139828	Green Accepted			2022-12-18	WOS:000327538200017
J	Lan, F; Zhang, N; Zhang, J; Krysko, O; Zhang, QB; Xian, JM; Derycke, L; Qi, YY; Li, K; Liu, SX; Lin, P; Bachert, C				Lan, Feng; Zhang, Nan; Zhang, Jie; Krysko, Olga; Zhang, Quanbo; Xian, Junming; Derycke, Lara; Qi, Yanyu; Li, Kai; Liu, Shixi; Lin, Ping; Bachert, Claus			Forkhead box protein 3 in human nasal polyp regulatory T cells is regulated by the protein suppressor of cytokine signaling 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Forkhead box protein 3; suppressor of cytokine signaling 3; signal transducer and activator of transcription 3; airway disease; nasal polyps	SOCS PROTEINS; FOXP3 EXPRESSION; INFLAMMATION; GENERATION; MECHANISM; EXPANSION; RESPONSES; DISEASE; STAT3	Background: In patients with persistent upper airway inflammation, the number of forkhead box protein 3 (Foxp3)(+) regulatory T (Treg) cells is reduced, but the regulation of Foxp3 expression in Treg cells is poorly understood. Objective: We investigated the interaction between suppressor of cytokine signaling 3 (SOCS3) and Foxp3 expression in the airway mucosa. Methods: Expression of SOCS3 and Foxp3 was measured in tissue from patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and control tissue. Coexpression of SOCS3 and Foxp3 was evaluated in PBMCs and in tissue from patients with CRSwNP. We also switched off and overexpressed SOCS3 in tissue from patients with CRSwNP and in pancreatic carcinoma epithelial-like cell line (PANC-1) cells and examined the effect on Foxp3 expression. Results: SOCS3 gene and protein expression was upregulated in inflammatory cells in airway mucosa, whereas Foxp3 gene and protein expression was downregulated. Mucosal Treg cells coexpressed both proteins. Switching off the expression of SOCS3 in human airway mucosa resulted in Foxp3 upregulation, whereas inducing it in PANC-1 cells led to Foxp3 downregulation. We also found that phosphorylation of signal transducer and activator of transcription (STAT) 3 was decreased in inflamed mucosa, and we hypothesized that SOCS3 was responsible. Phosphorylation of STAT3 increased on silencing SOCS3 expression in inflamed mucosa and decreased on SOCS3 plasmid transfection in PANC-1 cells. Conclusion: For the first time, we demonstrate that SOCS3 and Foxp3 are coexpressed in Treg cells in human nasal mucosa and that SOCS3 negatively regulates Foxp3 expression in human airway mucosa, possibly through phosphorylation of STAT3. Hence SOCS3 could be a potential target for restoring Foxp3 expression in Treg cells in patients with persistent mucosal inflammation.	[Lan, Feng; Zhang, Jie; Zhang, Quanbo; Qi, Yanyu; Li, Kai; Lin, Ping] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Div Geriatr,Ctr Med Stem Cell Biol, Chengdu 610041, Sichuan, Peoples R China; [Lan, Feng; Zhang, Nan; Krysko, Olga; Derycke, Lara; Bachert, Claus] Univ Ghent, ENT Dept, Upper Airways Res Lab, B-9000 Ghent, Belgium; [Xian, Junming; Liu, Shixi] Sichuan Univ, West China Hosp, Dept Otorhinolaryngol, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Ghent University; Sichuan University	Lin, P (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Div Geriatr,Ctr Med Stem Cell Biol, 1 Keyuan 4 Rd,Gaopeng Ave, Chengdu 610041, Sichuan, Peoples R China.	liusx999@163.com; linping9@yahoo.com.cn	Zhang, Nan/AAQ-3944-2020; Krysko, Olga/C-2481-2009; Bachert, Claus/J-8825-2012	Krysko, Olga/0000-0001-5019-0752; 	Start-up Foundation of the West China Hospital of Sichuan University [136050132]; European Commission [260895]; Flemish Scientific Research Board, FWO [A12/5-HB-KH3, G.0436.04, 3G.0489, G.0642.10N]; Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN); Interuniversity Attraction Poles Program-Belgian State Belgian Science Policy [IAP P7/30]	Start-up Foundation of the West China Hospital of Sichuan University; European Commission(European CommissionEuropean Commission Joint Research Centre); Flemish Scientific Research Board, FWO(FWO); Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN); Interuniversity Attraction Poles Program-Belgian State Belgian Science Policy(Belgian Federal Science Policy Office)	Supported by grant 136050132 from the Start-up Foundation of the West China Hospital of Sichuan University; by grants to C.B. from the European Commission's Seventh Framework programme under grant agreement no. 260895 (PREDICTA); from the Flemish Scientific Research Board, FWO, No. A12/5-HB-KH3, project G.0436.04, 3G.0489, G.0642.10N; by the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN); and by the Interuniversity Attraction Poles Program-Belgian State Belgian Science Policy, No. IAP P7/30.	Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Choi JM, 2010, P NATL ACAD SCI USA, V107, P18575, DOI 10.1073/pnas.1000400107; Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Hausding M, 2011, INT IMMUNOL, V23, P1, DOI 10.1093/intimm/dxq451; Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Kinjyo I, 2006, J EXP MED, V203, P1021, DOI 10.1084/jem.20052333; Krysko O, 2011, ALLERGY, V66, P396, DOI 10.1111/j.1398-9995.2010.02498.x; Laurence A, 2012, IMMUNITY, V37, P209, DOI 10.1016/j.immuni.2012.05.027; Li XY, 2010, J ALLERGY CLIN IMMUN, V125, P1061, DOI 10.1016/j.jaci.2010.02.023; Matsumura Y, 2007, J IMMUNOL, V179, P2170, DOI 10.4049/jimmunol.179.4.2170; Moriwaki A, 2011, AM J RESP CELL MOL, V44, P448, DOI 10.1165/rcmb.2009-0051OC; Muthukumarana P, 2007, TRANSPLANTATION, V84, pS6, DOI 10.1097/01.tp.0000269116.06510.db; Nguyen KD, 2011, BLOOD, V117, P3793, DOI 10.1182/blood-2010-11-318832; Pallandre JR, 2007, J IMMUNOL, V179, P7593, DOI 10.4049/jimmunol.179.11.7593; Palmer DC, 2009, TRENDS IMMUNOL, V30, P592, DOI 10.1016/j.it.2009.09.009; Passerini L, 2008, INT IMMUNOL, V20, P421, DOI 10.1093/intimm/dxn002; Pillemer BBL, 2007, EUR J IMMUNOL, V37, P2082, DOI 10.1002/eji.200737193; Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Sel S, 2008, J ALLERGY CLIN IMMUN, V121, P910, DOI 10.1016/j.jaci.2007.12.1175; Taleb S, 2009, J EXP MED, V206, P2067, DOI 10.1084/jem.20090545; Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464; Thomas Mike, 2008, Prim Care Respir J, V17, P79, DOI 10.3132/pcrj.2008.00029; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Crombruggen K, 2011, J ALLERGY CLIN IMMUN, V128, P728, DOI 10.1016/j.jaci.2011.07.049; van de Geijn GJM, 2004, J LEUKOCYTE BIOL, V76, P237, DOI 10.1189/jlb.0104041; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747	33	29	31	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1314	+		10.1016/j.jaci.2013.06.010	http://dx.doi.org/10.1016/j.jaci.2013.06.010			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23910692				2022-12-18	WOS:000327538200011
J	Ramirez, RM; Jacobs, RL				Ramirez, Robert M.; Jacobs, Robert L.			Eosinophilic esophagitis treated with immunotherapy to dust mites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Ramirez, Robert M.; Jacobs, Robert L.] Biogen Res Inst, San Antonio, TX USA		Ramirez, RM (corresponding author), Biogen Res Inst, San Antonio, TX USA.	rramirez@certifiedallergysa.com		Jacobs, Robert/0000-0002-2831-9086				De Swert L, 2013, J ALLERGY CLIN IMMUN, V131, P600, DOI 10.1016/j.jaci.2012.10.057; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Moawad FJ, 2010, ALIMENT PHARM THER, V31, P509, DOI 10.1111/j.1365-2036.2009.04199.x; PEREZ J, 2011, ANN ALLERG ASTHMA S1, V107, pA59; Rayapudi M, 2010, J LEUKOCYTE BIOL, V88, P337, DOI 10.1189/jlb.0110025	5	29	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					503	504		10.1016/j.jaci.2013.04.053	http://dx.doi.org/10.1016/j.jaci.2013.04.053			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23763975				2022-12-18	WOS:000322631700040
J	Kim, DK; Kim, HS; Kim, AR; Kim, JH; Kim, B; Noh, G; Kim, HS; Beaven, MA; Kim, YM; Choi, WS				Kim, Do Kyun; Kim, Hyuk Soon; Kim, A-Ram; Kim, Ji Hyung; Kim, Bokyung; Noh, Geunwoong; Kim, Hyung Sik; Beaven, Michael A.; Kim, Young Mi; Choi, Wahn Soo			DJ-1 regulates mast cell activation and IgE-mediated allergic responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						DJ-1; reactive oxygen species; mast cells; allergy; Fc epsilon RI-mediated signals	FC-EPSILON-RI; OXYGEN SPECIES GENERATION; NITRIC-OXIDE; FYN KINASE; PHOSPHORYLATION; OXIDANTS; STRESS; CA2+; SYK	Background: DJ-1 is an antioxidant protein known to reduce levels of reactive oxygen species (ROS), but its presence or function in mast cells and allergic diseases is unknown. Objectives: We sought to determine the role and mechanism of DJ-1 in allergic responses in vitro and in vivo. Methods: ROS and DJ-1 levels in serum or culture medium were measured with ELISA kits. The role of DJ-1 was evaluated in mast cell cultures and passive cutaneous anaphylaxis in normal or DJ-1 knockout (KO) mice. The mechanism of DJ-1 action was examined by using immunoblotting, immunoprecipitation, RT-PCR, and other molecular biological approaches. Results: Patients with atopic dermatitis had increased levels of ROS and diminished levels of DJ-1. DJ-1 KO mice exhibited enhanced passive cutaneous anaphylaxis and augmented ROS levels in sera and bone marrow-derived mast cells (BMMCs). Furthermore, antigen-induced degranulation and production of TNF-alpha and IL-4 were significantly amplified in DJ-1 KO and anti-DJ-1 small interfering RNA-transfected BMMCs compared with that seen in wild-type (WT) BMMCs. Studies with these cells and BMMCs transfected with small interfering RNAs against the phosphatases Src homology domain 2-containing protein tyrosine phosphatase (SHP) 1 and SHP-2 revealed that the DJ-1 KO phenotype could be attributed to suppression of SHP-1 activity and enhancement of SHP-2 activity, leading to strengthened signaling through linker for activation of T cells, phospholipase C gamma, and mitogen-activated protein kinases. Conclusions: A deficiency or constitutive activation of DJ-1 can have implications in mast cell-driven allergic diseases, such as asthma and anaphylaxis.	[Kim, Do Kyun; Kim, Hyuk Soon; Kim, A-Ram; Kim, Ji Hyung; Kim, Bokyung; Choi, Wahn Soo] Konkuk Univ, Coll Med, Funct Genom Inst, Dept Immunol & Physiol, Chungju 380701, South Korea; [Noh, Geunwoong] Chungnam Natl Univ Hosp, Dept Pediat, Subdiv Allergy & Clin Immunol, Taejon, South Korea; [Kim, Hyung Sik] Pusan Natl Univ, Coll Pharm, Pusan, South Korea; [Beaven, Michael A.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; [Kim, Young Mi] Duksung Womens Univ, Coll Pharm, Seoul, South Korea	Konkuk University; Konkuk University Medical Center; Chungnam National University; Chungnam National University Hospital; Pusan National University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Duksung Women's University	Choi, WS (corresponding author), Konkuk Univ, Coll Med, Dept Immunol, Chungju 380701, South Korea.	wahnchoi@kku.ac.kr		Kim, Hyuk Soon/0000-0002-0566-0142	National Research Foundation of Korea (NRF); Korean government (MEST) [2011-0028873]; Regional Innovation Center Program of the Ministry of Knowledge Economy at Konkuk University, Korea; Intramural Program of the National Heart, Lung, and Blood Institute, National Institutes of Health; National Research Foundation of Korea; Regional Innovation Center Program of the Ministry of Knowledge Economy, Korea	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korean government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Regional Innovation Center Program of the Ministry of Knowledge Economy at Konkuk University, Korea; Intramural Program of the National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Research Foundation of Korea(National Research Foundation of Korea); Regional Innovation Center Program of the Ministry of Knowledge Economy, Korea(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea)	Supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MEST, no. 2011-0028873) and in part by the Regional Innovation Center Program of the Ministry of Knowledge Economy at Konkuk University, Korea. M. A. B. was supported by the Intramural Program of the National Heart, Lung, and Blood Institute, National Institutes of Health.; D. K. Kim, H. S. Kim, A.-R. Kim, J. H. Kim, and W. S. Choi have received research support from the National Research Foundation of Korea and in part from the Regional Innovation Center Program of the Ministry of Knowledge Economy, Korea. The rest of the authors declare that they have no relevant conflicts of interest.	Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Barnes PJ, 2011, J BIOL CHEM, V286, P32899, DOI 10.1074/jbc.R110.206466; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Brooks AC, 1999, BRIT J PHARMACOL, V128, P585, DOI 10.1038/sj.bjp.0702838; Ekoff M, 2011, ADV EXP MED BIOL, V716, P47, DOI 10.1007/978-1-4419-9533-9_4; Gilfillan AM, 2011, CRIT REV IMMUNOL, V31, P475, DOI 10.1615/CritRevImmunol.v31.i6.30; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hong H, 2007, BLOOD, V110, P2511, DOI 10.1182/blood-2007-01-066092; Jensen Bettina M, 2006, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0323s74; Jin YJ, 1998, J IMMUNOL, V161, P1743; Kahle PJ, 2009, FREE RADICAL BIO MED, V47, P1354, DOI 10.1016/j.freeradbiomed.2009.08.003; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kim JW, 2009, BIOCHEM PHARMACOL, V77, P1506, DOI 10.1016/j.bcp.2009.01.019; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kinumi T, 2004, BIOCHEM BIOPH RES CO, V317, P722, DOI 10.1016/j.bbrc.2004.03.110; Kuehn HS, 2008, J IMMUNOL, V181, P7706, DOI 10.4049/jimmunol.181.11.7706; Lee JH, 2011, J IMMUNOL, V187, P1807, DOI 10.4049/jimmunol.1100296; Ma HT, 2009, CRIT REV IMMUNOL, V29, P155, DOI 10.1615/CritRevImmunol.v29.i2.40; Nakata K, 2008, J IMMUNOL, V181, P5414, DOI 10.4049/jimmunol.181.8.5414; Niu XF, 1996, CIRC RES, V79, P992, DOI 10.1161/01.RES.79.5.992; Oranje AP, 2007, BRIT J DERMATOL, V157, P645, DOI 10.1111/j.1365-2133.2007.08112.x; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pushparaj PN, 2009, J IMMUNOL, V183, P221, DOI 10.4049/jimmunol.0803430; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; RUDZKI E, 1994, DERMATOLOGY, V189, P41, DOI 10.1159/000246781; Sly LM, 2008, J IMMUNOL, V181, P3850, DOI 10.4049/jimmunol.181.6.3850; Suzuki Y, 2003, J IMMUNOL, V171, P6119, DOI 10.4049/jimmunol.171.11.6119; Suzuki Y, 2005, CHEM IMMUNOL ALLERGY, V87, P32, DOI 10.1159/000087569; Swindle EJ, 2004, J BIOL CHEM, V279, P48751, DOI 10.1074/jbc.M409738200; Swindle EJ, 2007, J IMMUNOL, V179, P7059, DOI 10.4049/jimmunol.179.10.7059; Taira T, 2004, EMBO REP, V5, P213, DOI 10.1038/sj.embor.7400074; Wilson MA, 2011, ANTIOXID REDOX SIGN, V15, P111, DOI 10.1089/ars.2010.3481; Wolfreys K, 1997, EUR J IMMUNOL, V27, P297, DOI 10.1002/eji.1830270143; Wu M, 2004, PLOS BIOL, V2, P327, DOI 10.1371/journal.pbio.0020069; Xu R, 2001, EUR J IMMUNOL, V31, P1571, DOI 10.1002/1521-4141(200105)31:5<1571::AID-IMMU1571>3.0.CO;2-U; Xu XM, 2010, PLANT SIGNAL BEHAV, V5, P1034, DOI 10.4161/psb.5.8.12298; Zhang J, 2002, MOL CELL BIOL, V22, P8144, DOI 10.1128/MCB.22.23.8144-8154.2002; Zhang L, 2010, J IMMUNOL, V184, P1180, DOI 10.4049/jimmunol.0901972	42	29	30	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1653	+		10.1016/j.jaci.2012.10.012	http://dx.doi.org/10.1016/j.jaci.2012.10.012			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23182168	Green Accepted			2022-12-18	WOS:000320532800026
J	King, PT; Lim, S; Pick, A; Ngui, J; Prodanovic, Z; Downey, W; Choong, C; Kelman, A; Baranyai, E; Francis, M; Moshinsky, R; Bardin, PG; Holmes, PW; Holdsworth, SR				King, Paul T.; Lim, Steven; Pick, Adrian; Ngui, James; Prodanovic, Zdenka; Downey, William; Choong, Cliff; Kelman, Anthony; Baranyai, Elizabeth; Francis, Michelle; Moshinsky, Randall; Bardin, Philip G.; Holmes, Peter W.; Holdsworth, Stephen R.			Lung T-cell responses to nontypeable Haemophilus influenzae in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cell; chronic obstructive pulmonary disease; bacteria; inflammation	COPD; INFLAMMATION; EXACERBATIONS; COLONIZATION; PREVENTION; CIGARETTE; ASTHMA; TISSUE; SMOKE	Background: Chronic obstructive pulmonary disease (COPD) is characterized by pulmonary inflammation that persists after the cessation of smoking. T cells have a major role in driving inflammation in patients with COPD and are activated by specific antigens to produce mediators, such as cytokines. The antigens that activate lung T cells have not been clearly defined. Nontypeable Haemophilus influenzae (NTHi) is the dominant bacterium isolated from the lungs of patients with COPD. Objective: We sought to measure the response of lung tissue T cells to stimulation with NTHi. Methods: We obtained lung tissue from 69 subjects having lobectomies for lung cancer. Of the group, 39 subjects had COPD, and 30 without COPD were classified as control subjects. The lung tissue was dispersed into single-cell suspensions and stimulated with live NTHi. Cells were labeled with antibodies for 5 important inflammatory mediators in patients with COPD and analyzed by using flow cytometry. Results: NTHi produced strong activation of both T-H cells and cytotoxic T cells in the COPD cohort. The COPD cohort had significantly higher levels of cells producing TNF-alpha, IL-13, and IL-17 in both T-cell subsets. When control subjects were divided into those with and without a significant smoking history and compared with patients with COPD, there was a progressive increase in the numbers of T cells producing cytokines from nonsmoking control subjects to smoking control subjects to patients with COPD. Conclusion: NTHi activates lung T cells in patients with COPD. This proinflammatory profibrotic response might be a key cause of inflammation in patients with COPD and has implications for treatment.	[King, Paul T.; Lim, Steven; Holdsworth, Stephen R.] Monash Univ, Dept Med, Melbourne, Vic 3168, Australia; [King, Paul T.; Pick, Adrian; Choong, Cliff; Moshinsky, Randall; Bardin, Philip G.; Holmes, Peter W.] Monash Univ, Dept Surg, Melbourne, Vic 3168, Australia; [Ngui, James] Monash Med Ctr, Melbourne, Vic, Australia; [Pick, Adrian; Downey, William; Baranyai, Elizabeth] Cabrini Hosp, Melbourne, Vic, Australia; [Prodanovic, Zdenka] MMC Southern Hlth, Tissue Bank Serv, Melbourne, Vic, Australia; [Kelman, Anthony] MMC Southern Hlth, Southern Hlth Pathol, Melbourne, Vic, Australia; [Francis, Michelle] MMC Southern Hlth, Microbiol, Melbourne, Vic, Australia	Monash University; Monash University; Monash University; Cabrini Health	King, PT (corresponding author), Monash Univ, Monash Med Ctr, Dept Med, 246 Clayton Rd, Melbourne, Vic 3168, Australia.	paul.king@monash.edu			Faculty of Medicine, Nursing and Health Sciences, Monash University	Faculty of Medicine, Nursing and Health Sciences, Monash University(Monash University)	Supported by a Strategic Grant, Faculty of Medicine, Nursing and Health Sciences, Monash University (to P.T.K.).	Ahren IL, 2001, J INFECT DIS, V184, P150, DOI 10.1086/322016; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; [Anonymous], 2008, TOP 10 CAUS DEATH; Bandi V, 2003, FEMS IMMUNOL MED MIC, V37, P69, DOI 10.1016/S0928-8244(03)00100-7; Bandi V, 2001, AM J RESP CRIT CARE, V164, P2114, DOI 10.1164/ajrccm.164.11.2104093; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Brusselle GG, 2009, EUR RESPIR J, V34, P219, DOI 10.1183/09031936.00150208; Cosio MG, 2009, NEW ENGL J MED, V360, P2445, DOI 10.1056/NEJMra0804752; Drannik AG, 2004, AM J RESP CRIT CARE, V170, P1164, DOI 10.1164/rccm.200311-1521OC; Dromann D, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-67; Elias Jack, 2004, Chest, V126, p111S, DOI 10.1378/chest.126.2_suppl_1.111S; Elias Jack A, 2006, Proc Am Thorac Soc, V3, P494, DOI 10.1513/pats.200603-068MS; FORSGREN J, 1994, INFECT IMMUN, V62, P673, DOI 10.1128/IAI.62.2.673-679.1994; Gadgil Aneal, 2008, Int J Chron Obstruct Pulmon Dis, V3, P531; Gaschler GJ, 2009, AM J RESP CRIT CARE, V179, P666, DOI 10.1164/rccm.200808-1306OC; Gosselink JV, 2010, AM J RESP CRIT CARE, V181, P1329, DOI 10.1164/rccm.200812-1902OC; Groenewegen KH, 2003, RESP MED, V97, P770, DOI 10.1016/S0954-6111(03)00026-X; Hill AT, 2000, AM J MED, V109, P288, DOI 10.1016/S0002-9343(00)00507-6; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hodge G, 2007, CLIN EXP IMMUNOL, V150, P22, DOI 10.1111/j.1365-2249.2007.03451.x; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Johnston J.W., 2010, CURRENT PROTOCOLS MI; King PT, 2008, CLIN EXP IMMUNOL, V152, P542, DOI 10.1111/j.1365-2249.2008.03667.x; King PT, 2003, AM J RESP CRIT CARE, V167, P587, DOI 10.1164/rccm.200207-728OC; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Marti-Lliteras P, 2009, INFECT IMMUN, V77, P4232, DOI 10.1128/IAI.00305-09; Moller LVM, 1998, AM J RESP CRIT CARE, V157, P950; Murphy K, 2008, JANEWAYS IMMUNOBIOLO, P323; Murphy TF, 2004, AM J RESP CRIT CARE, V170, P266, DOI 10.1164/rccm.200403-354OC; Murphy TF, 2001, HARRISONS PRINCIPLES, P939; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rosell A, 2005, ARCH INTERN MED, V165, P891, DOI 10.1001/archinte.165.8.891; Shapiro SD, 2001, AM J RESP CRIT CARE, V164, P339, DOI 10.1164/ajrccm.164.3.2105072c; Soriano Joan B, 2011, Proc Am Thorac Soc, V8, P363, DOI 10.1513/pats.201102-017RM; Staempfli MR, 2009, NAT REV IMMUNOL, V9, P377, DOI 10.1038/nri2530; Strober Warren, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.ima03bs111; Sullivan AK, 2005, AM J RESP CRIT CARE, V172, P590, DOI 10.1164/rccm.200410-1332OC; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	43	29	31	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1314	U104		10.1016/j.jaci.2012.09.030	http://dx.doi.org/10.1016/j.jaci.2012.09.030			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23142009				2022-12-18	WOS:000318912200006
J	Liu, Y; Yu, HJ; Wang, N; Zhang, YN; Huang, SK; Cui, YH; Liu, Z				Liu, Yang; Yu, Hai-Jing; Wang, Nan; Zhang, Ya-Na; Huang, Shau-Ku; Cui, Yong-Hua; Liu, Zheng			Clara cell 10-kDa protein inhibits T(H)17 responses through modulating dendritic cells in the setting of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; Clara cell 10-kDa protein; dendritic cell; inhibition; T(H)17 response	CHRONIC RHINOSINUSITIS; AIRWAY INFLAMMATION; OX40 LIGAND; EXPRESSION; INTERLEUKIN-17; INDUCTION; REGULATOR; IMMUNITY; MICE	Background: T(H)17 responses have recently been implicated to play a role in allergic airway diseases, but their local expression in the setting of allergic rhinitis (AR) and their regulation in allergic airway diseases remain unclear. Objective: We sought to investigate the regulatory role of Clara cell 10-kDa protein (CC10), an endogenous regulator of airway inflammation, on T(H)17 responses in the setting of AR. Methods: Wild-type and homozygous CC10-null mice were used to establish an ovalbumin (OVA)-induced AR model. Human recombinant CC10 was given during sensitization or challenge. T(H)17 responses in human subjects and mice were examined by using flow cytometry, quantitative RT-PCR assay, immunohistochemistry, and ELISA. The direct effect of CC10 on T(H)17 cells and CD11c(+) dendritic cells (DCs) was studied by means of cell culture. Adoptive transfer was used to examine the influence of CC10-conditioned DCs on airway inflammation. The regulatory effect of CC10 on the expression of the CCL20 gene was tested by using the BEAS-2B cell line. Results: Compared with those of control subjects, T(H)17 responses were enhanced in the nasal mucosa of patients with AR. CC10-null mice with AR showed enhanced T(H)17 responses, and CC10 treatment significantly decreased T(H)17 responses. CC10 had no direct effect on in vitro T(H)17 cell differentiation. CC10 could significantly decrease the expression of OX40 ligand, IL-23, and IL-6 but enhance CD86 and TGF-beta expression in DCs. Importantly, CC10 was able to inhibit T(H)17 cell polarization in the presence of OVA-pulsed DCs. CC10 pretreatment inhibited T(H)17 responses elicited by adoptive transfer of OVA-pulsed DCs. Furthermore, CC10 decreased the expression of CCL20 in BEAS-2B cells induced by inflammatory cytokines. Conclusion: T(H)17 responses are enhanced in patients with AR, and CC10 inhibits T(H)17 responses through modulation of the function of DCs. (J Allergy Clin Immunol 2013;131:387-94.)	[Liu, Yang; Wang, Nan; Zhang, Ya-Na; Cui, Yong-Hua; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan 430030, Peoples R China; [Yu, Hai-Jing] Zhongshan Hosp, Dept Liver Dis, Wuhan, Peoples R China; [Huang, Shau-Ku] Natl Hlth Res Inst, Taipei, Taiwan; [Huang, Shau-Ku] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA	Huazhong University of Science & Technology; National Health Research Institutes - Taiwan; Johns Hopkins University	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.	zhengliuent@hotmail.com	Huang, Shau-Ku/F-5509-2010		National Natural Science Foundation of China (NSFC) [81020108018, 30872847]; State Education Ministry [NCET-07-0326]; Ministry of Health of China [201202005]; National Institutes of Health [AI052468, AI073610]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI073610, R01AI052468] Funding Source: NIH RePORTER	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); State Education Ministry; Ministry of Health of China; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Natural Science Foundation of China (NSFC) grants 81020108018 and 30872847 and the program for New Century Excellent Talents in University from the State Education Ministry grant NCET-07-0326 (to Z.L.), a grant from Ministry of Health of China (201202005), and, in part, National Institutes of Health grants AI052468 and AI073610 (to S.-K.H).	Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Bae YS, 2004, J IMMUNOL, V173, P607, DOI 10.4049/jimmunol.173.1.607; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chen L, 2009, J ALLERGY CLIN IMMUN, V123, pS49, DOI 10.1016/j.jaci.2008.12.154; Chen LC, 2001, J IMMUNOL, V167, P3025, DOI 10.4049/jimmunol.167.6.3025; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Ciprandi G, 2009, ALLERGY, V64, P1375, DOI 10.1111/j.1398-9995.2009.02010.x; D'Arena G, 1998, HAEMATOLOGICA, V83, P197; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Gill MA, 2012, J ALLERGY CLIN IMMUN, V129, P889, DOI 10.1016/j.jaci.2012.02.028; Hung CH, 2004, J ALLERGY CLIN IMMUN, V114, P664, DOI 10.1016/j.jaci.2004.05.042; Jenkins SJ, 2007, J IMMUNOL, V179, P3515, DOI 10.4049/jimmunol.179.6.3515; Johansson S, 2007, J ALLERGY CLIN IMMUN, V120, P308, DOI 10.1016/j.jaci.2007.03.021; KleinJan A, 2006, J ALLERGY CLIN IMMUN, V118, P1117, DOI 10.1016/j.jaci.2006.05.030; Koya T, 2007, J ALLERGY CLIN IMMUN, V119, P1241, DOI 10.1016/j.jaci.2007.01.039; Laurence A, 2007, IMMUNITY, V26, P371, DOI 10.1016/j.immuni.2007.02.009; Lee HY, 2004, EXP MOL MED, V36, P135, DOI 10.1038/emm.2004.20; Liu Y, 2010, CLIN EXP ALLERGY, V40, P1632, DOI 10.1111/j.1365-2222.2010.03549.x; Liu Z, 2007, ALLERGY, V62, P999, DOI 10.1111/j.1398-9995.2007.01381.x; Liu Z, 2004, J ALLERGY CLIN IMMUN, V114, P783, DOI 10.1016/j.jaci.2004.04.052; Liu Z, 2009, ALLERGY, V64, P149, DOI 10.1111/j.1398-9995.2008.01847.x; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Miller Thomas L, 2005, Pediatr Crit Care Med, V6, P698, DOI 10.1097/01.PCC.0000165565.96773.08; Moser M, 2003, IMMUNITY, V19, P5, DOI 10.1016/S1074-7613(03)00182-1; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Quan SH, 2012, ANN ALLERG ASTHMA IM, V108, P342, DOI 10.1016/j.anai.2012.02.014; Rate A, 2009, J IMMUNOL, V182, P72, DOI 10.4049/jimmunol.182.1.72; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Shalev I, 2008, J IMMUNOL, V180, P249, DOI 10.4049/jimmunol.180.1.249; Singh TP, 2011, AM J PATHOL, V178, P699, DOI 10.1016/j.ajpath.2010.10.008; Song CW, 2008, J IMMUNOL, V181, P6117, DOI 10.4049/jimmunol.181.9.6117; Taleb S, 2009, J EXP MED, V206, P2067, DOI 10.1084/jem.20090545; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wang H, 2008, AM J RHINOL, V22, P343, DOI 10.2500/ajr.2008.22.3184; Wang H, 2010, AM J RESP CRIT CARE, V181, P908, DOI 10.1164/rccm.200904-0597OC; Willmann K, 2000, J LEUKOCYTE BIOL, V67, P536, DOI 10.1002/jlb.67.4.536; Zhang XH, 2012, AM J RESP CRIT CARE, V185, P140, DOI 10.1164/rccm.201103-0456OC	40	29	38	0	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					387	+		10.1016/j.jaci.2012.11.027	http://dx.doi.org/10.1016/j.jaci.2012.11.027			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23273949	Green Accepted			2022-12-18	WOS:000314661500016
J	Liu, Y; Sun, YT; Chang, LJ; Li, N; Li, HB; Yu, YN; Bryce, PJ; Grammer, LC; Schleimer, RP; Zhu, DC				Liu, Yu; Sun, Yongtao; Chang, Lee-Jah; Li, Newton; Li, Huabin; Yu, Yanni; Bryce, Paul J.; Grammer, Leslie C.; Schleimer, Robert P.; Zhu, Daocheng			Blockade of peanut allergy with a novel Ara h 2-Fc gamma fusion protein in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut; fusion protein; immunotherapy; anaphylaxis; mast cells; basophils	ORAL IMMUNOTHERAPY; FOOD ALLERGY; MECHANISMS; ANAPHYLAXIS	Background: Conventional immunotherapy for peanut allergy using crude peanut extracts is not recommended because of the unacceptably high risk of anaphylaxis. Allergen-specific immunotherapy is not currently undertaken for peanut allergy. Objectives: The objective of this study was to develop a novel peanut-human fusion protein to block peanut-induced anaphylaxis. Methods: We genetically designed and expressed a novel plant-human fusion protein composed of the major peanut allergen Ara h 2 and human IgG Fc gamma 1. We tested the Ara h 2-Fc gamma fusion protein (AHG2)'s function in purified human basophils. Transgenic mice expressing human Fc epsilon RI alpha and a murine peanut allergy model were used. Results: AHG2 inhibited histamine release induced by whole peanut extract (WPE) from basophils of patients with peanut allergy, whereas the fusion protein itself did not induce mediator release. AHG2 inhibited the WPE-induced, peanut-specific, IgE-mediated passive cutaneous anaphylaxis in hFc epsilon RI alpha transgenic mice. AHG2 also significantly inhibited acute anaphylactic reactivity, including the prototypical decrease in body temperature in WPE-sensitized mice challenged with crude peanut extract. Histologic evaluation of the airways showed that AHG2 decreased peanut-induced inflammation, whereas the fusion protein itself did not induce airway inflammation in peanut-sensitized mice. AHG2 did not exert an inhibitory effect in mice lacking Fc gamma RII. Conclusion: AHG2 inhibited peanut-specific IgE-mediated allergic reactions in vitro and in vivo. Linking specific peanut allergen to Fc gamma can provide a new approach for the allergen immunotherapy of peanut allergy. (J Allergy Clin Immunol 2013;131:213-21.)	[Liu, Yu; Chang, Lee-Jah; Li, Newton; Li, Huabin; Yu, Yanni; Bryce, Paul J.; Grammer, Leslie C.; Schleimer, Robert P.; Zhu, Daocheng] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA; [Sun, Yongtao; Zhu, Daocheng] Fourth Mil Med Univ, Tangdu Hosp, Dept Infect Dis, Xian 710032, Peoples R China	Northwestern University; Feinberg School of Medicine; Air Force Military Medical University	Zhu, DC (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, 240 E Huron, Chicago, IL 60611 USA.	yongtaos@hotmail.com; dczhu@northwestern.edu			National Institutes of Health grant [R21 AI088808]; Food Allergy and Anaphylaxis Network; American Academy of Allergy, Asthma Immunology; Northwestern Memorial Foundation; Food Allergy Initiative; National Institutes of Health (NIH); American Academy of Allergy, Asthma & Immunology (AAAAI); SC Electric Co; Lippincott; UpToDate; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI088808] Funding Source: NIH RePORTER	National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy and Anaphylaxis Network; American Academy of Allergy, Asthma Immunology; Northwestern Memorial Foundation; Food Allergy Initiative; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma & Immunology (AAAAI); SC Electric Co; Lippincott; UpToDate; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant R21 AI088808; the Food Allergy and Anaphylaxis Network; the American Academy of Allergy, Asthma & Immunology; the Northwestern Memorial Foundation; and the Food Allergy Initiative.; D. Zhu has received grants and travel support from the National Institutes of Health (NIH); the Food Allergy and Anaphylaxis Network; the American Academy of Allergy, Asthma & Immunology (AAAAI); the Northwestern Memorial Foundation; and the Food Allergy Initiative. L. C. Grammer has received grants and travel support from the NIH, the Food Allergy and Anaphylaxis Network, and S&C Electric Co; has consultant arrangements with Astellas Pharmaceuticals; is employed by Northwestern University and the Northwestern Medical Faculty Foundation; has received payment for lectures from the AAAAI; and has received royalties from Lippincott and UpToDate. R. P. Schleimer has received grants from the NIH and has consultant arrangements with Intersect ENT, GlaxoSmithKline, and Allakos. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Finkelman FD, 2010, CURR OPIN IMMUNOL, V22, P783, DOI 10.1016/j.coi.2010.10.005; Jackman J, 2010, J BIOL CHEM, V285, P20850, DOI 10.1074/jbc.M110.113910; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Maloney JM, 2006, J ALLERGY CLIN IMMUN, V118, P719, DOI 10.1016/j.jaci.2006.05.017; Masilamani M, 2011, J ALLERGY CLIN IMMUN, V128, P1242, DOI 10.1016/j.jaci.2011.05.009; McDermott RA, 2007, CLIN EXP ALLERGY, V37, P752, DOI 10.1111/j.1365-2222.2007.02701.x; Metcalfe DD, 2009, J ALLERGY CLIN IMMUN, V124, P639, DOI 10.1016/j.jaci.2009.08.035; Patil SP, 2011, J ALLERGY CLIN IMMUN, V128, P1259, DOI 10.1016/j.jaci.2011.06.015; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P326, DOI 10.1016/j.jaci.2010.11.024; Sun JF, 2007, J IMMUNOL, V179, P6696, DOI 10.4049/jimmunol.179.10.6696; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; Terada T, 2006, CLIN IMMUNOL, V120, P45, DOI 10.1016/j.clim.2005.12.010; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; Uermosi C, 2010, J ALLERGY CLIN IMMUN, V126, P375, DOI 10.1016/j.jaci.2010.05.040; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	30	29	34	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					213	U309		10.1016/j.jaci.2012.10.018	http://dx.doi.org/10.1016/j.jaci.2012.10.018			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	062YR	23199607	Green Accepted			2022-12-18	WOS:000312961200026
J	Lunardon, L; Payne, AS				Lunardon, Luisa; Payne, Aimee S.			Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							B-CELL DEPLETION		[Lunardon, Luisa; Payne, Aimee S.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA	University of Pennsylvania	Lunardon, L (corresponding author), Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057217, K08AR053505, R01AR057001] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR053505, AR057001, P30 AR057217, K08 AR053505, R01 AR057001] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmed AR, 2006, NEW ENGL J MED, V355, P1772, DOI 10.1056/NEJMoa062930; Albert D, 2008, ANN RHEUM DIS, V67, P1724, DOI 10.1136/ard.2007.083162; Goto S, 2009, INT J HEMATOL, V89, P305, DOI 10.1007/s12185-009-0269-6; Joly P, 2007, NEW ENGL J MED, V357, P545, DOI 10.1056/NEJMoa067752; Looney RJ, 2004, ARTHRITIS RHEUM, V50, P2580, DOI 10.1002/art.20430; Murrell DE, 2008, J AM ACAD DERMATOL, V58, P1043, DOI 10.1016/j.jaad.2008.01.012; Pijpe J, 2005, ARTHRITIS RHEUM-US, V52, P2740, DOI 10.1002/art.21260; Schmidt E, 2009, CLIN IMMUNOL, V132, P334, DOI 10.1016/j.clim.2009.05.007; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013	9	29	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					800	803		10.1016/j.jaci.2012.03.022	http://dx.doi.org/10.1016/j.jaci.2012.03.022			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22541247	Green Accepted			2022-12-18	WOS:000308463500031
J	Vadas, P; Perelman, B				Vadas, Peter; Perelman, Boris			Effect of epinephrine on platelet-activating factor-stimulated human vascular smooth muscle cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epinephrine; platelet-activating factor; platelet-activating factor receptor; human vascular smooth muscle cells; anaphylaxis	RECEPTOR GENE-EXPRESSION; GUINEA-PIG LUNG; ANAPHYLACTIC REACTIONS; SIGNAL-TRANSDUCTION; MAST-CELLS; MANAGEMENT; FOOD; PROSTAGLANDIN; MODULATION; MECHANISMS	Background: Animal and human data show that platelet-activating factor (PAF) mediates the life-threatening manifestations of anaphylaxis. Although administration of epinephrine is the mainstay of therapy of acute anaphylaxis, the interaction between epinephrine and PAF has not been studied. In particular, the effect of the timing of epinephrine administration on the action of PAF has not been examined. Objective: Using human vascular smooth muscle cells (HVSMCs), we examined the effect of timing of epinephrine addition on the action of PAF. Methods: The effect of epinephrine on PAF-mediated prostaglandin E-2 (PGE(2)) release from human aortic smooth muscle cells was examined. Epinephrine was added at various times before and after PAF stimulation. Results: HVSMCs stimulated with PAF released PGE(2) in a concentration-and time-dependent manner. Whereas preincubation of HVSMCs with epinephrine before the addition of PAF suppressed PGE(2) release, treatment with epinephrine after PAF stimulation was less effective with time after PAF stimulation. PGE(2) release was suppressed by means of preincubation with 8-bromo-cyclic AMP and forskolin. Conclusions: PAF induced PGE(2) release from HVSMCs in a concentration-and time-dependent manner, and early addition of epinephrine was essential for the control of PAF-induced PGE(2) release. Epinephrine was most effective when administered before stimulation with PAF but was progressively less effective with time after PAF stimulation. (J Allergy Clin Immunol 2012;129:1329-33.)	[Vadas, Peter; Perelman, Boris] Univ Toronto, St Michaels Hosp, Div Allergy & Clin Immunol, Dept Med, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Vadas, P (corresponding author), Univ Toronto, St Michaels Hosp, Div Allergy & Clin Immunol, Dept Med, 30 Bond St,Suite 8-161, Toronto, ON M5B 1W8, Canada.	vadasp@smh.ca			National Peanut Board	National Peanut Board	Supported by grants-in-aid from the National Peanut Board.	Ashikaga T, 1996, CLIN EXP PHARMACOL P, V23, P36; BAZAN NG, 1991, LIPIDS, V26, P1236, DOI 10.1007/BF02536539; Bellou A, 2003, SHOCK, V19, P71, DOI 10.1097/00024382-200301000-00014; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHAO W, 1990, J BIOL CHEM, V265, P17576; DOYLE VM, 1986, FEBS LETT, V197, P13, DOI 10.1016/0014-5793(86)80288-5; Estelle F, 2008, J ALLERGY CLIN IMMUN, V121, pS402, DOI 10.1016/j.jaci.2007.08.061; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Gaumond F, 1997, J CARDIOVASC PHARM, V30, P169, DOI 10.1097/00005344-199708000-00004; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252, DOI 10.1016/S1081-1206(10)60714-4; HARCZY M, 1986, PHARMACOL RES, V18, P111, DOI 10.1016/0031-6989(86)90043-3; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; JANCAR S, 1987, BRAZ J MED BIOL RES, V20, P487; KAWAGUCHI H, 1986, HYPERTENSION, V8, P192, DOI 10.1161/01.HYP.8.3.192; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; Marone G, 2005, TRENDS IMMUNOL, V26, P25, DOI 10.1016/j.it.2004.10.010; Marone Gianni, 2004, Novartis Found Symp, V257, P133; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669; Nakao A, 1997, AM J PHYSIOL-RENAL, V273, pF445, DOI 10.1152/ajprenal.1997.273.3.F445; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schwartz Lawrence B, 2004, Novartis Found Symp, V257, P65; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; Sicherer SH, 2007, PEDIATRICS, V119, P638, DOI 10.1542/peds.2006-3689; Simons KJ, 2010, CURR OPIN ALLERGY CL, V10, P354, DOI 10.1097/ACI.0b013e32833bc670; Sirois P, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P1033; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; Thivierge M, 1996, J IMMUNOL, V157, P4681; THIVIERGE M, 1993, J BIOL CHEM, V268, P17457; Ueno N, 2011, J BIOL CHEM, V286, P37249, DOI 10.1074/jbc.M111.290312; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; VALONE FH, 1982, J IMMUNOL, V129, P1637; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921	47	29	29	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1329	1333		10.1016/j.jaci.2012.02.027	http://dx.doi.org/10.1016/j.jaci.2012.02.027			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22460068				2022-12-18	WOS:000303418000023
J	Weigmann, B; Schughart, N; Wiebe, C; Sudowe, S; Lehr, HA; Jonuleit, H; Vogel, L; Becker, C; Neurath, MF; Grabbe, S; Saloga, J; Bellinghausen, I				Weigmann, Benno; Schughart, Nadja; Wiebe, Christian; Sudowe, Stephan; Lehr, Hans A.; Jonuleit, Helmut; Vogel, Lothar; Becker, Christoph; Neurath, Markus F.; Grabbe, Stephan; Saloga, Joachim; Bellinghausen, Iris			Allergen-induced IgE-dependent gut inflammation in a human PBMC-engrafted murine model of allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Humanized mice; IgE; allergen; colon; inflammation; basophils; histamine; platelet-activating factor	REGULATORY T-CELLS; SEVERE COMBINED IMMUNODEFICIENCY; BLOOD MONONUCLEAR-CELLS; SCID MICE; FOOD ALLERGY; EXPERIMENTAL COLITIS; IMMUNE-RESPONSES; DENDRITIC CELLS; MOUSE MODEL; ASTHMA	Background: Humanized murine models comprise a new tool to analyze novel therapeutic strategies for allergic diseases of the intestine. Objective: In this study we developed a human PBMC-engrafted murine model of allergen-driven gut inflammation and analyzed the underlying immunologic mechanisms. Methods: Nonobese diabetic (NOD)-scid-gamma c(-/-) mice were injected intraperitoneally with human PBMCs from allergic donors together with the respective allergen or not. Three weeks later, mice were challenged with the allergen orally or rectally, and gut inflammation was monitored with a high-resolution video miniendoscopic system, as well as histologically. Results: Using the aeroallergens birch or grass pollen as model allergens and, for some donors, also hazelnut allergen, we show that allergen-specific human IgE in murine sera and allergen-specific proliferation and cytokine production of human CD4(+) T cells recovered from spleens after 3 weeks could only be measured in mice treated with PBMCs plus allergen. Importantly, these mice had the highest endoscopic scores evaluating translucent structure, granularity, fibrin, vascularity, and stool after oral or rectal allergen challenge and a strong histologic inflammation of the colon. Analyzing the underlying mechanisms, we demonstrate that allergen-associated colitis was dependent on IgE, human IgE receptor-expressing effector cells, and the mediators histamine and platelet-activating factor. Conclusion: These results demonstrate that allergic gut inflammation can be induced in human PBMC-engrafted mice, allowing the investigation of pathophysiologic mechanisms of allergic diseases of the intestine and evaluation of therapeutic interventions. (J Allergy Clin Immunol 2012; 129:1126-35.)	[Schughart, Nadja; Wiebe, Christian; Sudowe, Stephan; Jonuleit, Helmut; Grabbe, Stephan; Saloga, Joachim; Bellinghausen, Iris] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, D-55131 Mainz, Germany; [Vogel, Lothar] Paul Ehrlich Inst, Div Allergol, D-6070 Langen, Germany; [Weigmann, Benno; Becker, Christoph; Neurath, Markus F.] Univ Erlangen Nurnberg, Med Clin 1, D-91054 Erlangen, Germany; [Lehr, Hans A.] CHU Vaudois, Inst Univ Pathol, CH-1011 Lausanne, Switzerland	Johannes Gutenberg University of Mainz; Paul Ehrlich Institute; University of Erlangen Nuremberg; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Bellinghausen, I (corresponding author), Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.	iris.bellinghausen@unimedizin-mainz.de	Becker, Christoph/L-2996-2016; Grabe, Stephan/AAJ-4578-2021; Jonuleit, Helmut/D-8059-2011; Becker, Christoph/A-6694-2008	Grabe, Stephan/0000-0002-6863-8719; Jonuleit, Helmut/0000-0002-5672-9365; Becker, Christoph/0000-0002-1388-1041	Deutsche Forschungsgemeinschaft (DFG) [BE 4504/2-1, WE 4656/1-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	Supported by Deutsche Forschungsgemeinschaft (DFG) BE 4504/2-1 and WE 4656/1-1 grants.	Akbari O, 2003, CURR OPIN IMMUNOL, V15, P627, DOI 10.1016/j.coi.2003.09.012; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Albert DH, 1998, J PHARMACOL EXP THER, V284, P83; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Arnett HA, 2007, ADV DRUG DELIVER REV, V59, P1084, DOI 10.1016/j.addr.2007.06.013; Axelsson LG, 1996, INFLAMM RES, V45, P181, DOI 10.1007/BF02285159; Bellinghausen I, 2006, CLIN EXP ALLERGY, V36, P1546, DOI 10.1111/j.1365-2222.2006.02601.x; Bonds RS, 2008, CURR OPIN ALLERGY CL, V8, P82, DOI 10.1097/ACI.0b013e3282f4177e; Cox L, 2008, ALLERGY ASTHMA PROC, V29, P580, DOI 10.2500/aap.2008.29.3162; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; Duez C, 1996, EUR J IMMUNOL, V26, P1088, DOI 10.1002/eji.1830260520; GAGNON R, 1995, J ALLERGY CLIN IMMUN, V95, P1268, DOI 10.1016/S0091-6749(95)70085-4; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Herz U, 2004, CLIN EXP ALLERGY, V34, P478, DOI 10.1111/j.1365-2222.2004.01887.x; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Kaul S, 2007, CLIN EXP ALLERGY, V37, P141, DOI 10.1111/j.1365-2222.2006.02618.x; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; King M, 2008, CLIN IMMUNOL, V126, P303, DOI 10.1016/j.clim.2007.11.001; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Ledford DK, 2009, EXPERT OPIN BIOL TH, V9, P933, DOI 10.1517/14712590903036060; Martin H, 2011, J ALLERGY CLIN IMMUN; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; PESTEL J, 1994, J IMMUNOL, V153, P3804; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Wang YH, 2008, CURR OPIN IMMUNOL, V20, P697, DOI 10.1016/j.coi.2008.09.004; Weigmann B, 2008, J EXP MED, V205, P2099, DOI 10.1084/jem.20072484; Xystrakis E, 2007, CURR OPIN ALLERGY CL, V7, P535, DOI 10.1097/ACI.0b013e3282f14d7c	33	29	30	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1126	1135		10.1016/j.jaci.2011.11.036	http://dx.doi.org/10.1016/j.jaci.2011.11.036			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22236728				2022-12-18	WOS:000302144600029
J	Li, XN; Ampleford, EJ; Howard, TD; Moore, WC; Li, HS; Busse, WW; Castro, M; Erzurum, SC; Fitzpatrick, AM; Gaston, B; Israel, E; Jarjour, NN; Teague, WG; Wenzel, SE; Hawkins, GA; Bleecker, ER; Meyers, DA				Li, Xingnan; Ampleford, Elizabeth J.; Howard, Timothy D.; Moore, Wendy C.; Li, Huashi; Busse, William W.; Castro, Mario; Erzurum, Serpil C.; Fitzpatrick, Anne M.; Gaston, Benjamin; Israel, Elliot; Jarjour, Nizar N.; Teague, W. Gerald; Wenzel, Sally E.; Hawkins, Gregory A.; Bleecker, Eugene R.; Meyers, Deborah A.			The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENOME-WIDE ASSOCIATION; CHROMOSOME 11Q13; VARIANT; ECZEMA		[Li, Xingnan; Ampleford, Elizabeth J.; Howard, Timothy D.; Moore, Wendy C.; Li, Huashi; Hawkins, Gregory A.; Bleecker, Eugene R.; Meyers, Deborah A.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27106 USA; [Busse, William W.] Univ Wisconsin, Dept Med, Madison, WI USA; [Castro, Mario] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Castro, Mario] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Erzurum, Serpil C.] Lerner Res Inst, Cleveland, OH USA; [Fitzpatrick, Anne M.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; [Gaston, Benjamin; Teague, W. Gerald] Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA USA; [Israel, Elliot] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA; [Jarjour, Nizar N.] Univ Wisconsin Hosp & Clin, Dept Med, Madison, WI 53792 USA; [Jarjour, Nizar N.] Univ Wisconsin Hosp & Clin, Dept Publ Hlth Sci, Madison, WI 53792 USA; [Wenzel, Sally E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA	Wake Forest University; Wake Forest Baptist Medical Center; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); Cleveland Clinic Foundation; Emory University; University of Virginia; Harvard University; Brigham & Women's Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Li, XN (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC 27106 USA.	xinli@wfubmc.edu		Wenzel, Sally/0000-0002-4242-0164; Fitzpatrick, Anne/0000-0002-2933-5926	NCATS NIH HHS [UL1 TR000005, UL1 TR000448] Funding Source: Medline; NCRR NIH HHS [M01RR018390, UL1 RR024992, M01RR03186, M01RR07122, UL1RR024992, M01 RR007122, M01 RR003186, M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [R01 HL076285, R01 HL069155, R01 HL069170, U10 HL109164, R01 HL069349, R01 HL091762, HL69174, HL087665, HL69149, R01 HL069149, HL69116, HL69130, R01 HL069167-10, R01 HL087665, HL69167, HL69170, R01 HL069130, R01 HL069174, HL69349, HL76285, R01 HL069167, HL69155, R01 HL069116, HL091762, HL87665] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005, UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122, UL1RR024992, M01RR003186, M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069349, R01HL069170, R01HL069149, R01HL069167, R01HL069116, R01HL069155, R01HL069130, R01HL069174, R01HL087665, R01HL091762, R01HL076285] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Li X, 2010, J ALLERGY CLIN IMMUN, V125, pe11; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Marenholz I, 2011, HUM MOL GENET, V20, P2443, DOI 10.1093/hmg/ddr117; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V125, P170, DOI 10.1016/j.jaci.2009.10.046; Tran DQ, 2009, P NATL ACAD SCI USA, V106, P13445, DOI 10.1073/pnas.0901944106; Weidinger S, 2010, CURR OPIN ALLERGY CL, V10, P408, DOI 10.1097/ACI.0b013e32833d7d2d	10	29	30	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					575	578		10.1016/j.jaci.2011.09.040	http://dx.doi.org/10.1016/j.jaci.2011.09.040			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22070912	Green Accepted			2022-12-18	WOS:000299951700047
J	Ohnishi, H; Miyata, R; Suzuki, T; Nose, T; Kubota, K; Kato, Z; Kaneko, H; Kondo, N				Ohnishi, Hidenori; Miyata, Rie; Suzuki, Tomonori; Nose, Touichiro; Kubota, Kazuo; Kato, Zenichiro; Kaneko, Hideo; Kondo, Naomi			A rapid screening method to detect autosomal-dominant ectodermal dysplasia with immune deficiency syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNODEFICIENCY		[Ohnishi, Hidenori; Kubota, Kazuo; Kato, Zenichiro; Kaneko, Hideo; Kondo, Naomi] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan; [Miyata, Rie; Suzuki, Tomonori; Nose, Touichiro] Tokyo Kita Social Insurance Hosp, Dept Pediat, Tokyo, Japan; [Kaneko, Hideo] Nagara Med Ctr, Dept Clin Res, Gifu, Japan	Gifu University	Ohnishi, H (corresponding author), Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan.	ohnishih@gifu-u.ac.jp						Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; Granados EL, 2008, HUM MUTAT, V29, P861, DOI 10.1002/humu.20740; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; McDonald DR, 2007, J ALLERGY CLIN IMMUN, V120, P900, DOI 10.1016/j.jaci.2007.08.035; Picard C, 2010, MEDICINE, V89, P403, DOI 10.1097/MD.0b013e3181fd8ec3; Takada H, 2006, J PEDIATR-US, V148, P546, DOI 10.1016/j.jpeds.2005.12.015	8	29	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					578	580		10.1016/j.jaci.2011.09.042	http://dx.doi.org/10.1016/j.jaci.2011.09.042			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22078572				2022-12-18	WOS:000299951700048
J	Nelsen, LM; Shields, KE; Cunningham, ML; Stoler, JM; Bamshad, MJ; Eng, PM; Smugar, SS; Gould, AL; Philip, G				Nelsen, Linda M.; Shields, Kristine E.; Cunningham, Michael L.; Stoler, Joan M.; Bamshad, Michael J.; Eng, P. Mona; Smugar, Steven S.; Gould, A. Lawrence; Philip, George			Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Nelsen, Linda M.] Merck Sharp & Dohme Corp, Dept Epidemiol, Whitehouse Stn, NJ USA; [Shields, Kristine E.] Merck Sharp & Dohme Corp, Dept Clin Risk Management & Safety Surveillance, Whitehouse Stn, NJ USA; [Smugar, Steven S.] Merck Sharp & Dohme Corp, Dept Global Sci & Med Publicat, Whitehouse Stn, NJ USA; [Gould, A. Lawrence] Merck Sharp & Dohme Corp, Dept Early Dev Stat, Whitehouse Stn, NJ USA; [Philip, George] Merck Sharp & Dohme Corp, Dept Clin Res, Whitehouse Stn, NJ USA; [Cunningham, Michael L.] Univ Washington, Dept Craniofacial Med, Seattle, WA 98195 USA; [Bamshad, Michael J.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Stoler, Joan M.] Childrens Hosp, Div Genet, Boston, MA 02115 USA; [Eng, P. Mona] i3 Drug Safety, Boston, MA USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Boston Children's Hospital	Nelsen, LM (corresponding author), Merck Sharp & Dohme Corp, Dept Epidemiol, Whitehouse Stn, NJ USA.	linda_nelsen@merck.com	Nelsen, Linda/GZL-1004-2022	Smugar, Steve/0000-0002-9379-9928; Shields, Kristine/0000-0001-5741-3824				[Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, P34, DOI 10.1016/j.jaci.2004.10.023; [Anonymous], 2010, SING MONT SOD PRESCR; [Anonymous], 2007, PREGN REG SINGULAIR; Bakhireva LN, 2007, J ALLERGY CLIN IMMUN, V119, P618, DOI 10.1016/j.jaci.2006.12.618; Blais L, 2010, BIRTH DEFECTS RES A, V88, P216, DOI 10.1002/bdra.20651; Dombrowski Mitchell P, 2008, Obstet Gynecol, V111, P457, DOI 10.1097/AOG.0b013e3181665ff4; Holmes LB, 2002, AM J MED GENET, V112, P297, DOI 10.1002/ajmg.10781; Rosano A, 2000, AM J MED GENET, V93, P110, DOI 10.1002/1096-8628(20000717)93:2<110::AID-AJMG6>3.0.CO;2-9; Sarkar M, 2009, EUR J CLIN PHARMACOL, V65, P1259, DOI 10.1007/s00228-009-0713-9; Schatz M, 2004, J ALLERGY CLIN IMMUN, V113, P1040, DOI 10.1016/j.jaci.2004.03.017	10	29	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					251	254		10.1016/j.jaci.2011.09.003	http://dx.doi.org/10.1016/j.jaci.2011.09.003			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22000568				2022-12-18	WOS:000298634000034
J	Thomas, A; Lemanske, RF; Jackson, DJ				Thomas, Alex; Lemanske, Robert F., Jr.; Jackson, Daniel J.			Approaches to stepping up and stepping down care in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; step-up; step-down; stepwise; guidelines; severity; control; step-up intermittent; step-up short-term; step-up long-term	ACTING BETA-AGONISTS; RANDOMIZED CONTROLLED-TRIAL; MILD PERSISTENT ASTHMA; EXHALED NITRIC-OXIDE; SINGLE INHALER; DOUBLE-BLIND; FLUTICASONE PROPIONATE/SALMETEROL; AIRWAY HYPERRESPONSIVENESS; UNCONTROLLED ASTHMA; UP THERAPY	The variability in symptom control is a challenging feature of asthma that necessitates careful monitoring and the need to step up and step down individualized therapeutic regimens over time. This stepwise concept in asthma therapy can be considered in at least 3 contexts. For lack of control that is persistent over long periods of time, an increase in the overall medication or a step-up long-term strategy is indicated. A second approach, the step-up short-term strategy, can be used during a temporary loss of acceptable control, such as at the onset of a viral respiratory tract illness. In these cases a step-up in therapy is usually terminated in 3 to 10 days once asthma control has been satisfactorily achieved. Finally, for treating symptoms related to the variability of asthma on a day-to-day basis, inhaled corticosteroids used concomitantly with a beta-agonist have been evaluated, although this treatment is not currently approved in the United States. We will term this particular intervention a step-up intermittent strategy. Here we summarize the existing data regarding these 3 approaches to step up care and step down management, as well as to identify areas where more comparative studies are necessary to provide further guidance to clinicians regarding proper step-up and step-down strategies in the care of asthma. (J Allergy Clin Immunol 2011;128:915-24.)	[Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Clin Sci Ctr H4 468, Sect Allergy Immunol & Rheumatol,Dept Pediat, Madison, WI 53792 USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, DJ (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Clin Sci Ctr H4 468, Sect Allergy Immunol & Rheumatol,Dept Pediat, 600 Highland Ave, Madison, WI 53792 USA.	djj@medicine.wisc.edu			National Institutes of Health from National Center for Research Resources (NCRR) [1UL1RR025011, U10HL098090, P01 HL70831]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, U10HL098090] Funding Source: NIH RePORTER	National Institutes of Health from National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grants 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources (NCRR), U10HL098090, and P01 HL70831.	Aalbers R, 2004, CURR MED RES OPIN, V20, P225, DOI 10.1185/030079903125002928; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Chowdhury BA, 2010, NEW ENGL J MED, V362, P1169, DOI 10.1056/NEJMp1002074; FitzGerald JM, 2005, CLIN THER, V27, P393, DOI 10.1016/j.clinthera.2005.03.006; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Fuhlbrigge AL, 2006, PEDIATRICS, V118, pE347, DOI 10.1542/peds.2005-2962; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; *GINA, 1998, NIH PUBL; Godard P, 2008, RESP MED, V102, P1124, DOI 10.1016/j.rmed.2008.03.014; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Ind PW, 2004, RESP MED, V98, P464, DOI 10.1016/j.rmed.2003.07.010; Jackson DJ, 2009, J ALLERGY CLIN IMMUN, V124, P949, DOI 10.1016/j.jaci.2009.07.024; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Koenig SM, 2008, J ASTHMA, V45, P681, DOI 10.1080/02770900802168695; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Sears MR, 2009, CHEST, V136, P604, DOI 10.1378/chest.09-1214; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Smith AD, 2009, J ALLERGY CLIN IMMUN, V124, P714, DOI 10.1016/j.jaci.2009.07.020; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Stallberg B, 2003, INT J CLIN PRACT, V57, P656; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; *US DEP HHS, 1991, NIH PUBL; US Department of Health and Human Services. National Asthma Education and Prevention Program, 2007, NIH PUBL; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	45	29	30	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					915	924		10.1016/j.jaci.2011.07.014	http://dx.doi.org/10.1016/j.jaci.2011.07.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21855125	Green Accepted			2022-12-18	WOS:000296578200001
J	Schatz, M; Zeiger, RS				Schatz, Michael; Zeiger, Robert S.			Improving asthma outcomes in large populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; population management; quality of care; administrative data; asthma control	COMPUTERIZED PHARMACY DATA; EMERGENCY HOSPITAL-CARE; QUALITY-OF-LIFE; ADMINISTRATIVE DATA; PERSISTENT ASTHMA; HEDIS ASTHMA; VALIDATION; RISK; EXACERBATIONS; ORGANIZATION	This article summarizes our experience using administrative, survey, and telephone information to define asthma severity, impairment, risk, and quality of care in our large Kaiser Permanente population. Our data suggest that the 2-year Healthcare Effectiveness Data and Information Set definition of persistent asthma is a good surrogate for survey-defined persistent asthma, and thus it would be reasonable to direct asthma population management and quality-of-care assessments at patients with Healthcare Effectiveness Data and Information Set-defined persistent asthma for 2 years in a row. For population management, the numbers of short-acting beta-agonist (SABA) canisters dispensed and validated tools on mail or telephone surveys have been used to assess asthma impairment. Algorithms based on pharmacy data (SABA canister and oral corticosteroid dispensings and prior emergency hospital care) have been used to assess the risk domain of asthma control. The asthma medication ratio (controllers divided by controllers plus SABAs) has been shown to be related to improved outcomes and is recommended as an asthma quality-of-care marker. It is hoped that outreach to patients and providers based on these indicators will improve asthma outcomes in patients cared for in individual practices, as well as in large health plans. (J Allergy Clin Immunol 2011;128:273-7.)	[Schatz, Michael; Zeiger, Robert S.] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA	Kaiser Permanente	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org		Zeiger, Robert/0000-0001-5788-5063	Aerocrine; Genentech; GlaxoSmithKline; Merck	Aerocrine; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company)	M. Schatz has consulted for Amgen, Merck, and GlaxoSmithKline and has received research support from Aerocrine, Genentech, GlaxoSmithKline, and Merck. R. S. Zeiger declares that he has no relevant conflict of interest.	AKINBAMI LJ, 2011, NATL HLTH STAT REPOR, V32, P1; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS93; Apter AJ, 2009, J ALLERGY CLIN IMMUN, V123, P1237, DOI 10.1016/j.jaci.2009.04.028; Berger WE, 2004, ANN ALLERG ASTHMA IM, V93, P538, DOI 10.1016/S1081-1206(10)61260-4; *CDCP, ASTHM; Davies Thomas J, 2006, Manag Care Interface, V19, P29; Fuhlbrigge A, 2004, MED CARE, V42, P465, DOI 10.1097/01.mlr.0000124249.84045.d7; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Fuhlbrigge A, 2009, ALLERGY ASTHMA PROC, V30, P529, DOI 10.2500/aap.2009.30.3276; Kamble S, 2009, J ASTHMA, V46, P73, DOI 10.1080/02770900802503107; Liu AH, 2010, J PEDIATR-US, V157, P276, DOI 10.1016/j.jpeds.2010.02.017; Mosen DM, 2010, AM J MANAG CARE, V16, P821; Mosen DM, 2005, AM J MANAG CARE, V11, P650; National Committee for Quality Assurance, 2008, HEDIS TECHN SPEC; Osborne ML, 2007, CHEST, V132, P1151, DOI 10.1378/chest.05-3084; Schatz M, 2005, CHEST, V128, P1968, DOI 10.1378/chest.128.4.1968; Schatz M, 2005, J ALLERGY CLIN IMMUN, V116, P1307, DOI 10.1016/j.jaci.2005.09.027; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; Schatz M, 2004, AM J MANAG CARE, V10, P25; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P564, DOI 10.1016/j.jaci.2004.12.005; SCHATZ M, 2011, AM THOR SOC INT C MA; Schatz M, 2008, ANN ALLERG ASTHMA IM, V101, P235, DOI 10.1016/S1081-1206(10)60487-5; Schatz M, 2008, AM J MANAG CARE, V14, P206; Schatz M, 2006, J ALLERGY CLIN IMMUN, V118, P1048, DOI 10.1016/j.jaci.2006.07.057; Schatz M, 2007, J ALLERGY CLIN IMMUN, V119, P336, DOI 10.1016/j.jaci.2006.08.042; Schatz M, 2006, AM J MANAG CARE, V12, P478; Schatz M, 2006, CHEST, V130, P43, DOI 10.1378/chest.130.1.43; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P995, DOI 10.1016/j.jaci.2006.01.053; Schatz M, 2010, AM J MANAG CARE, V16, pE281; Schatz M, 2010, AM J MANAG CARE, V16, P327; Talreja N, 2011, ANN ALLERG ASTHMA IM, V106, P24, DOI 10.1016/j.anai.2010.10.017; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Yong PL, 2009, J ALLERGY CLIN IMMUN, V124, P961, DOI 10.1016/j.jaci.2009.07.027; Zeiger RS, 2008, J ALLERGY CLIN IMMUN, V121, P885, DOI 10.1016/j.jaci.2007.12.1178; Zeiger RS, 2010, AM J MANAG CARE, V16, P897	35	29	33	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					273	277		10.1016/j.jaci.2011.03.027	http://dx.doi.org/10.1016/j.jaci.2011.03.027			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21497885				2022-12-18	WOS:000293280800003
J	van Hoffen, E; Peeters, KABM; van Neerven, RJJ; van der Tas, CWH; Zuidmeer, L; van Ieperen-van Dijk, AG; Bruijnzeel-Koomen, CAFM; Knol, EF; van Ree, R; Knulst, AC				van Hoffen, Els; Peeters, Kim A. B. M.; van Neerven, R. J. Joost; van der Tas, Corrien W. H.; Zuidmeer, Laurian; van Ieperen-van Dijk, Adrie G.; Bruijnzeel-Koomen, Carla A. F. M.; Knol, Edward F.; van Ree, Ronald; Knulst, Andre C.			Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							FOOD ALLERGY; APPLE ALLERGY; SIT		[van Hoffen, Els; Peeters, Kim A. B. M.; van Neerven, R. J. Joost; van der Tas, Corrien W. H.; van Ieperen-van Dijk, Adrie G.; Bruijnzeel-Koomen, Carla A. F. M.; Knol, Edward F.; Knulst, Andre C.] Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands; [Zuidmeer, Laurian; van Ree, Ronald] Amsterdam Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands; [Zuidmeer, Laurian; van Ree, Ronald] Amsterdam Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van Hoffen, E (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol Allergol, Utrecht, Netherlands.	A.C.Knulst@umcutrecht.nl	van Neerven, Joost/GWZ-3214-2022	Zuidmeer-Jongejan, Laurian/0000-0003-3245-5555; Knol, Edward/0000-0001-7368-9820; Knulst, Andre/0000-0002-1056-3179; van Neerven, R.J.Joost/0000-0002-3991-5297				Asero R, 2004, ALLERGY, V59, P1269, DOI 10.1111/j.1398-9995.2004.00561.x; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI 10.1111/j.1365-2222.2004.1939.x; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Flinterman AE, 2008, CURR OPIN ALLERGY CL, V8, P261, DOI 10.1097/ACI.0b013e3282ffb145; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0	10	29	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					100	U176		10.1016/j.jaci.2010.08.021	http://dx.doi.org/10.1016/j.jaci.2010.08.021			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	20933256				2022-12-18	WOS:000285917300015
J	Wijga, A; Tabak, C; Postma, DS; Kerkhof, M; Wieringa, MH; Hoekstra, MO; Brunekreef, B; de Jongste, JC; Smit, HA				Wijga, Alet; Tabak, Cora; Postma, Dirkje S.; Kerkhof, Marjan; Wieringa, Marjan H.; Hoekstra, Maarten O.; Brunekreef, Bert; de Jongste, Johan C.; Smit, Henriette A.			Sex differences in asthma during the first 8 years of life: The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENDER-DIFFERENCES; CHILDHOOD		[Wijga, Alet; Tabak, Cora] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 AB Groningen, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 AB Groningen, Netherlands; [Wieringa, Marjan H.] Erasmus Univ, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, NL-3000 DR Rotterdam, Netherlands; [de Jongste, Johan C.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Pediat Resp Med, Rotterdam, Netherlands; [Hoekstra, Maarten O.] Radboud Univ Nijmegen Med Ctr, Dept Pediat, Nijmegen, Netherlands; [Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; [Brunekreef, Bert; Smit, Henriette A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; University of Groningen; University of Groningen; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Radboud University Nijmegen; Utrecht University; Utrecht University; Utrecht University Medical Center	Wijga, A (corresponding author), Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands.	alet.wijga@rivm.nl		brunekreef, bert/0000-0001-9908-0060				Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; MARTINEZ F, 2003, WHEEZING DISORDERS P; Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4; Scholtens S, 2009, J ALLERGY CLIN IMMUN, V123, P1312, DOI 10.1016/j.jaci.2009.02.029	6	29	30	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					275	277		10.1016/j.jaci.2010.09.022	http://dx.doi.org/10.1016/j.jaci.2010.09.022			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21094994				2022-12-18	WOS:000285917300043
J	Puga, I; Cols, M; Cerutti, A				Puga, Irene; Cols, Montserrat; Cerutti, Andrea			Innate signals in mucosal immunoglobulin class switching	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Mucosal immunity; B cells; immunoglobulin; class switching	PROPRIA DENDRITIC CELLS; T-CELL; IMMUNE REGULATION; A GENERATION; IGA RESPONSE; B-CELLS; GUT; HOMEOSTASIS; BACTERIA; DISEASE	The intestinal mucosa contains large communities of commensal bacteria that process otherwise indigestible food components, synthesize essential vitamins, stimulate the maturation of the immune system, and form an ecologic niche that prevents the growth of pathogenic species. Conversely, the intestine provides the commensals with a stable habitat rich in energy derived from the ingested food. A delicate homeostatic balance maintains this mutualistic relationship without triggering a destructive inflammatory response. Commensals orchestrate intestinal homeostasis by entertaining an intimate dialogue with epithelial cells and immune cells lodged in the mucosa. Such a dialogue generates finely tuned signaling programs that ensure a state of hyporesponsiveness against noninvasive commensals and a state of active readiness against invasive pathogens. In this dialogue epithelial cells function as "interpreters" that continuously translate microbial messages to "instruct" immune cells as to the antigenic composition of the intestinal lumen. This education process initiates sophisticated defensive strategies that comprise massive production of IgA, a noninflammatory mucosal antibody class that generates immunity while preserving homeostasis. (J Allergy Clin Immunol 2010; 126:889-95.)	[Cerutti, Andrea] IMIM Hosp Mar, Catalan Inst Res & Adv Studies, Barcelona 08003, Spain; [Cols, Montserrat; Cerutti, Andrea] Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY USA	ICREA; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Icahn School of Medicine at Mount Sinai	Cerutti, A (corresponding author), IMIM Hosp Mar, Catalan Inst Res & Adv Studies, Barcelona Biomed Res Pk,Av Dr Aiguader 88, Barcelona 08003, Spain.	acerutti@imim.es	Cols, Montserrat/J-3387-2013	Cols, Montserrat/0000-0001-6578-8378; Cerutti, Andrea/0000-0003-3026-4704	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057653, R01AI074378] Funding Source: NIH RePORTER; ICREA Funding Source: Custom; NIAID NIH HHS [R01 AI074378, R01 AI057653-05, R01 AI057653] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ICREA(ICREA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 2010, INFLAMM BOWEL DIS, V16, P703, DOI 10.1002/ibd.21040; Cerutti A, 2008, NAT REV IMMUNOL, V8, P421, DOI 10.1038/nri2322; Cerutti A, 2008, IMMUNITY, V28, P740, DOI 10.1016/j.immuni.2008.05.001; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Cong YZ, 2009, P NATL ACAD SCI USA, V106, P19256, DOI 10.1073/pnas.0812681106; Coombes JL, 2008, NAT REV IMMUNOL, V8, P435, DOI 10.1038/nri2335; Cunningham-Rundies C, 2007, IMMUNOL RES, V38, P78, DOI 10.1007/s12026-007-0024-0; Cunningham-Rundles C, 2005, NAT REV IMMUNOL, V5, P880, DOI 10.1038/nri1713; Fagarasan S, 2010, ANNU REV IMMUNOL, V28, P243, DOI 10.1146/annurev-immunol-030409-101314; Groom JR, 2007, J EXP MED, V204, P1959, DOI 10.1084/jem.20062567; Hapfelmeier S, 2010, SCIENCE, V328, P1705, DOI 10.1126/science.1188454; He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6; Muramatsu Masamichi, 2007, Adv Immunol, V94, P1, DOI 10.1016/S0065-2776(06)94001-2; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Peterson DA, 2007, CELL HOST MICROBE, V2, P328, DOI 10.1016/j.chom.2007.09.013; Rescigno M, 2009, J CLIN INVEST, V119, P2441, DOI 10.1172/JCI39134; Suzuki K, 2010, IMMUNITY, V33, P71, DOI 10.1016/j.immuni.2010.07.003; Tezuka H, 2007, NATURE, V448, P929, DOI 10.1038/nature06033; Tsuji M, 2008, IMMUNITY, V29, P261, DOI 10.1016/j.immuni.2008.05.014; Tsuji M, 2009, SCIENCE, V323, P1488, DOI 10.1126/science.1169152; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; Uematsu S, 2009, J GASTROENTEROL, V44, P803, DOI 10.1007/s00535-009-0094-y; Xu W, 2008, J IMMUNOL, V181, P276, DOI 10.4049/jimmunol.181.1.276; Xu WF, 2007, NAT IMMUNOL, V8, P294, DOI 10.1038/ni1434	26	29	29	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					889	895		10.1016/j.jaci.2010.09.026	http://dx.doi.org/10.1016/j.jaci.2010.09.026			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	21050939	Green Accepted			2022-12-18	WOS:000283727100001
J	Pitt, TJ; Cisneros, N; Kalicinsky, C; Becker, AB				Pitt, Tracy J.; Cisneros, Nestor; Kalicinsky, Chrystyna; Becker, Allan B.			Successful treatment of idiopathic anaphylaxis in an adolescent	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OMALIZUMAB		[Pitt, Tracy J.; Cisneros, Nestor; Kalicinsky, Chrystyna; Becker, Allan B.] Childrens Hosp, Winnipeg, MB R3A 1S1, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba	Pitt, TJ (corresponding author), Childrens Hosp, 840 Sherbrook St, Winnipeg, MB R3A 1S1, Canada.	tracypitt@hotmail.com						Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603	3	29	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					415	416		10.1016/j.jaci.2010.05.043	http://dx.doi.org/10.1016/j.jaci.2010.05.043			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624653	Bronze			2022-12-18	WOS:000281203800043
J	Mooster, JL; Cancrini, C; Simonetti, A; Rossi, P; Di Matteo, G; Romiti, ML; Di Cesare, S; Notarangelo, L; Geha, RS; McDonald, DR				Mooster, Jana L.; Cancrini, Caterina; Simonetti, Alessandra; Rossi, Paolo; Di Matteo, Gigliola; Romiti, Maria Luisa; Di Cesare, Silvia; Notarangelo, Luigi; Geha, Raif S.; McDonald, Douglas R.			Immune deficiency caused by impaired expression of nuclear factor-kappa B essential modifier (NEMO) because of a mutation in the 5 ' untranslated region of the NEMO gene	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NEMO; immune deficiency; recurrent infections; 5 ' untranslated region mutation	ESSENTIAL MODULATOR MUTATION; ECTODERMAL DYSPLASIA; INHERITED DISORDERS; HUMAN-DISEASE; IMMUNODEFICIENCY; RESPONSES; SYSTEM	Background: Nuclear factor-kappa B (NF-kappa B) is a key transcription factor that regulates both innate and adaptive immunity as well as ectodermal development. Mutations in the coding region of the I kappa B kinase gamma/NF-kappa B essential modifier (NEMO) gene cause X-linked ectodermal dysplasia with immunodeficiency. Objective: To determine the genetic cause of recurrent sinopulmonary infections and dysganunaglobulinemia in a patient with a normal NEMO coding sequence and his affected brother. Methods: TNF-alpha and IFN-alpha production in response to Toll-like receptor (TLR) stimulation was analyzed by ELISA, NEMO mRNA levels were measured by quantitative PCR, and NEMO protein expression was measured by Western blotting. NF-kappa B activation was assessed by nuclear translocation of p65 and luciferase reporter gene assays. Results: TLR-induced TNF-alpha and IFN-alpha production by PBMCs was impaired in the patient and his brother. Sequencing of the patient's NEMO gene revealed a novel mutation in the 5' untranslated region, which was also present in the brother, resulting in abnormally spliced transcripts and a 4-fold reduction in mRNA levels. NEMO protein levels in EBV transformed B cells and fibroblasts from the index patient were 8-fold lower than normal controls. NF-kappa B p65 nuclear translocation in the patient's EBV B cells after TLR7 ligation was defective. NF-kappa B-dependent luciferase gene expression in IL-1-stimulated fibroblasts from the patient was impaired. Conclusion: This is the first description of immune deficiency resulting from low expression of a normal NEMO protein. (J Allergy Clin Immunol 2010;126:127-32.)	[Mooster, Jana L.; Notarangelo, Luigi; Geha, Raif S.; McDonald, Douglas R.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Cancrini, Caterina; Simonetti, Alessandra; Rossi, Paolo; Di Matteo, Gigliola; Romiti, Maria Luisa; Di Cesare, Silvia] Childrens Hosp Bambino Gesu, Dept Pediat, Rome, Italy; [Cancrini, Caterina; Simonetti, Alessandra; Rossi, Paolo; Di Matteo, Gigliola; Romiti, Maria Luisa; Di Cesare, Silvia] Univ Roma Tor Vergata, Sch Med, Rome, Italy	Harvard University; Boston Children's Hospital; IRCCS Bambino Gesu; University of Rome Tor Vergata	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu; Douglas.McDonald@childrens.harvard.edu	rossi, paolo/D-6504-2012; Simonetti, Alessandra/B-1938-2017; DI MATTEO, GIGLIOLA/AAB-5968-2020; Rossi, Paolo/K-5746-2016; DI CESARE, SILVIA/AAB-5754-2020; Notarangelo, Luigi D/F-9718-2016	Rossi, Paolo/0000-0003-2620-7918; DI CESARE, SILVIA/0000-0002-9912-7997; Notarangelo, Luigi D/0000-0002-8335-0262; DI MATTEO, GIGLIOLA/0000-0001-8344-5635; cancrini, caterina/0000-0001-8410-9617	National Institutes of Health [AI076210, AI076625]; Children's Hospital Boston; March of Dimes; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI076210, K08AI076625] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Hospital Boston; March of Dimes(March of Dimes); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI076210 (to R.S.G.) and AI076625 (to D.R.M.). J.L.M. is supported by the Stern Family Fund at Children's Hospital Boston.; R. S. Geha has received research support from the National Institutes of Health and the March of Dimes. The rest of the authors have declared that they have no conflict of interest.	Fusco F, 2006, GENE, V383, P99, DOI 10.1016/j.gene.2006.07.022; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Ku CL, 2005, IMMUNOL REV, V203, P10, DOI 10.1111/j.0105-2896.2005.00235.x; Kumar H, 2009, BIOCHEM J, V420, P1, DOI 10.1042/BJ20090272; McDonald DR, 2006, J ALLERGY CLIN IMMUN, V118, P1357, DOI 10.1016/j.jaci.2006.08.006; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Puel A, 2006, AM J HUM GENET, V78, P691, DOI 10.1086/501532; Puel A, 2004, CURR OPIN IMMUNOL, V16, P34, DOI 10.1016/j.coi.2003.11.013; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641	16	29	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					127	132		10.1016/j.jaci.2010.04.026	http://dx.doi.org/10.1016/j.jaci.2010.04.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20542322	Green Accepted			2022-12-18	WOS:000280061800023
J	Suzuki, M; Zheng, XF; Zhang, XS; Zhang, ZX; Ichim, TE; Sun, HT; Nakamura, Y; Inagaki, A; Beduhn, M; Shunnar, A; Garcia, B; Min, WP				Suzuki, Motohiko; Zheng, Xiufen; Zhang, Xusheng; Zhang, Zhu-Xu; Ichim, Thomas E.; Sun, Hongtao; Nakamura, Yoshihisa; Inagaki, Akira; Beduhn, Marianne; Shunnar, Aminah; Garcia, Bertha; Min, Wei-Ping			A novel allergen-specific therapy for allergy using CD40-silenced dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; CD40; small interfering RN; dendritic cells; regulatory T cells	REGULATORY T-CELLS; STEADY-STATE; IN-VIVO; CD40; ANTISENSE; INHIBITION; MODULATION; RESPONSES; SIRNAS; RNA	Background: Induction of RNA interference with small interfering RNA (siRNA) has demonstrated therapeutic potential through the knockdown of target genes. We have previously reported that systemic administration of CD40 siRNA is capable of attenuating allergic symptoms but in an allergen-nonspecific fashion. However, siRNA-based allergen-specific therapy for allergy has not been developed. Objective: We attempted to develop a new allergen-specific therapy for allergy using CD40-silenced and allergen-pulsed dendritic cells (DCs). Methods: Bone marrow derived DCs were silenced with CD40 siRNA and pulsed with ovalbumin (OVA). Mice had allergy after intraperitoneal sensitization with OVA and keyhole limpet hemocyanin, followed by intranasal challenge with the same allergens. The mice were treated with CD40-silenced and OVA-pulsed DCs (CD40-silenced OVA DCs) either before allergic sensitization or after establishing allergic rhinitis. Results: Mice receiving CD40-silenced OVA DCs either before or after the establishment of allergic rhinitis showed remarkable reductions in allergic symptoms caused by OVA challenge, as well as anti-OVA IgE levels in sera. Additionally, CD40-silenced OVA DCs suppressed eosinophil infiltration at the nasal septum, OVA-specific T-cell responses, T-cell production of IL-4 and IL-5 after stimulation with OVA, and CD4(+)CD25(-) effector T-cell responses. Furthermore, CD40-silenced OVA DCs facilitated the generation of CD4(+)CD25(+) forkhead box protein 3 positive OVA-specific regulatory T cells, which inhibit allergic responses in vivo. However, CD40-silenced OVA DCs suppressed only OVA-specific allergy but did not inhibit keyhole limpet hemocyanin induced allergy, suggesting that CD40-silenced OVA DCs induce allergen-specific tolerance. Conclusions: This study is the first to demonstrate a novel allergen-specific therapy for allergy through DC-mediated immune modulation after gene silencing of CD40. (J Allergy Clin Immunol 2010;125:737-43.)	[Suzuki, Motohiko; Zheng, Xiufen; Zhang, Xusheng; Zhang, Zhu-Xu; Sun, Hongtao; Nakamura, Yoshihisa; Inagaki, Akira; Beduhn, Marianne; Shunnar, Aminah; Garcia, Bertha; Min, Wei-Ping] Univ Western Ontario, Dept Surg, London, ON N6A 5A5, Canada; [Suzuki, Motohiko; Zheng, Xiufen; Zhang, Xusheng; Zhang, Zhu-Xu; Sun, Hongtao; Nakamura, Yoshihisa; Inagaki, Akira; Beduhn, Marianne; Shunnar, Aminah; Garcia, Bertha; Min, Wei-Ping] Univ Western Ontario, Dept Pathol, London, ON N6A 5A5, Canada; [Suzuki, Motohiko; Zheng, Xiufen; Zhang, Xusheng; Zhang, Zhu-Xu; Sun, Hongtao; Nakamura, Yoshihisa; Inagaki, Akira; Beduhn, Marianne; Shunnar, Aminah; Garcia, Bertha; Min, Wei-Ping] Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5A5, Canada; [Suzuki, Motohiko] Nagoya City Univ, Dept Otorhinolaryngol, Nagoya, Aichi, Japan; [Ichim, Thomas E.] Medistem Labs, San Diego, CA USA; [Min, Wei-Ping] London Hlth Sci Ctr, Multiorgan Transplant Program, London, England	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Nagoya City University	Min, WP (corresponding author), Univ Western Ontario, Dept Surg, 339 Windermere Rd,Univ Hosp C9-136, London, ON N6A 5A5, Canada.	suzu-mo@med.nagoya-cu.ac.jp; weiping.min@uwo.ca	Zhang, Zhu-Xu/G-3361-2011	Zhang, Zhu-Xu/0000-0002-8335-3738	Canadian Institute of Health Research (CIHR); London Health Sciences Centre; Japan Society for the Promotion of Science (JSPS)	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); London Health Sciences Centre; Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	W.-P.M. has received grant support from the Canadian Institute of Health Research (CIHR) and London Health Sciences Centre. M.S. has received a Grant-in-Aid from the Japan Society for the Promotion of Science (JSPS).	Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fechner H, 2007, GENE THER, V14, P211, DOI 10.1038/sj.gt.3302872; Fewell GD, 2006, DRUG DISCOV TODAY, V11, P975, DOI 10.1016/j.drudis.2006.09.008; Fire AZ, 2007, ANGEW CHEM INT EDIT, V46, P6967, DOI 10.1002/anie.200701979; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Hill JA, 2003, J IMMUNOL, V171, P691, DOI 10.4049/jimmunol.171.2.691; Kelland L, 2006, EXPERT OPIN INV DRUG, V15, P1309, DOI 10.1517/13543784.15.11.1309; Kuwana M, 2002, HUM IMMUNOL, V63, P1156, DOI 10.1016/S0198-8859(02)00754-1; Liao HT, 2005, OLIGONUCLEOTIDES, V15, P196, DOI 10.1089/oli.2005.15.196; Lu L, 1999, TRANSPLANTATION, V68, P747, DOI 10.1097/00007890-199909270-00006; Nouri-Shirazi M, 2002, TRANSPLANTATION, V74, P1035, DOI 10.1097/00007890-200210150-00024; Steinman RM, 2003, ANN NY ACAD SCI, V987, P15, DOI 10.1111/j.1749-6632.2003.tb06029.x; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Suzuki M, 2009, ALLERGY, V64, P387, DOI 10.1111/j.1398-9995.2008.01839.x; Suzuki M, 2008, J IMMUNOL, V180, P8461, DOI 10.4049/jimmunol.180.12.8461; Suzuki M, 2007, INT IMMUNOPHARMACOL, V7, P46, DOI 10.1016/j.intimp.2006.08.010; Tarhini Ahmad A, 2007, Future Oncol, V3, P263, DOI 10.2217/14796694.3.3.263; Thompson JD, 2002, DRUG DISCOV TODAY, V7, P912, DOI 10.1016/S1359-6446(02)02410-8; Tong AW, 2005, CURR OPIN MOL THER, V7, P114; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Yacyshyn B, 2007, CLIN GASTROENTEROL H, V5, P215, DOI 10.1016/j.cgh.2006.11.001; You S, 2007, P NATL ACAD SCI USA, V104, P6335, DOI 10.1073/pnas.0701171104; Zheng XF, 2009, BLOOD, V113, P2646, DOI 10.1182/blood-2008-04-151191; Zheng XX, 2003, IMMUNOL REV, V196, P75, DOI 10.1046/j.1600-065X.2003.00089.x	27	29	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					737	743		10.1016/j.jaci.2009.11.042	http://dx.doi.org/10.1016/j.jaci.2009.11.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226305				2022-12-18	WOS:000275883200033
J	Hulse, KE; Reefer, AJ; Engelhard, VH; Patrie, JT; Ziegler, SF; Chapman, MD; Woodfolk, JA				Hulse, Kathryn E.; Reefer, Amanda J.; Engelhard, Victor H.; Patrie, James T.; Ziegler, Steven F.; Chapman, Martin D.; Woodfolk, Judith A.			Targeting allergen to Fc gamma RI reveals a novel T(H)2 regulatory pathway linked to thymic stromal lymphopoietin receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H22-Fel d 1; thymic stromal lymphopoietin; thymic stromal lymphopoietin receptor; atopic dermatitis; blood dendritic cells; monocyte-derived dendritic cells; T(H)2 cells; Fc gamma RI	PROTEIN-TYROSINE KINASE; EUROPEAN TASK-FORCE; ATOPIC-DERMATITIS; DENDRITIC CELLS; EPITHELIAL-CELLS; CONSENSUS REPORT; SCORAD INDEX; OX40 LIGAND; INFLAMMATION; TSLP	Background: The molecule H22-Fel d 1, which targets cat allergen to Fc gamma RI on dendritic cells (DCs), has the potential to treat cat allergy because of its T-cell modulatory properties. Objective: We sought to investigate whether the T-cell response induced by H22-Fel d I is altered in the presence of the T(H)2-promoting cytokine thymic stromal lymphopoietin (TSLP). Methods: Studies were performed in subjects with cat allergy with and without atopic dermatitis. Monocyte-derived DCs were primed with H22-Fel d I in the presence or absence of TSLP, and the resulting T-cell cytokine repertoire was analyzed by flow cytometry. The capacity for H22-Fel d I to modulate TSLP receptor expression on DCs was examined by flow cytometry in the presence or absence of inhibitors of Fc receptor signaling molecules. Results: Surprisingly, TSLP alone was a weak inducer of T(H)2 responses irrespective of atopic status; however, DCs coprimed with TSLP and H22-Fel d I selectively and synergistically amplified T(H)2 responses in highly atopic subjects. This effect was OX40 ligand independent, pointing to an unconventional TSLP-mediated pathway. Expression of TSLP receptor was upregulated on atopic DCs primed with H22-Fel d 1 through a pathway regulated by Fc gamma RI-associated signaling components, including src-related tyrosine kinases and Syk, as well as the downstream molecule phosphoinositide 3-kinase. Inhibition of TSLP receptor upregulation triggered by H22-Fel d 1 blocked TSLP-mediated T(H)2 responses. Conclusion: Discovery of a novel T(H)2 regulatory pathway linking Fc gamma RI signaling to TSLP receptor upregulation and consequent TSLP-mediated effects questions the validity of receptor-targeted allergen vaccines. (J Allergy Clin Immunol 2010;125:247-56.)	[Woodfolk, Judith A.] Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; [Engelhard, Victor H.] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; [Patrie, James T.] Univ Virginia Hlth Syst, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA; [Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA USA; [Chapman, Martin D.] Indoor Biotechnol Inc, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia; Benaroya Research Institute; INDOOR Biotechnologies	Woodfolk, JA (corresponding author), Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu			National Institutes of Health [AI-052196, AI-070364]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052196, U19AI070364] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR055695, R01AR056113] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health R01 grant AI-052196 and U19 grant AI-070364. M.D.C. is a cofounder and co-owner of Indoor Biotechnologies, Inc, and receives income and research support from the company.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; DURDEN DL, 1995, J IMMUNOL, V154, P4039; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; ELENTNER A, 2009, J CELL MOL MED; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Guyre CA, 2001, J IMMUNOL, V167, P6303, DOI 10.4049/jimmunol.167.11.6303; HARRISON PT, 1994, J BIOL CHEM, V269, P24396; Headley MB, 2009, J IMMUNOL, V182, P1641, DOI 10.4049/jimmunol.182.3.1641; Huang ZY, 2006, J LEUKOCYTE BIOL, V80, P1553, DOI 10.1189/jlb.0106019; Hulse KE, 2008, J ALLERGY CLIN IMMUN, V121, P756, DOI 10.1016/j.jaci.2007.10.016; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kiefer F, 1998, MOL CELL BIOL, V18, P4209, DOI 10.1128/MCB.18.7.4209; Kim YK, 2007, J IMMUNOL, V178, P5375, DOI 10.4049/jimmunol.178.8.5375; Knight ZA, 2005, CHEM BIOL, V12, P621, DOI 10.1016/j.chembiol.2005.04.011; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lam D, 2008, J IMMUNOL, V181, P2925, DOI 10.4049/jimmunol.181.4.2925; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Ng N, 2006, J ALLERGY CLIN IMMUN, V117, P1074, DOI 10.1016/j.jaci.2006.03.025; Novak N, 2004, CURR ALLERGY ASTHM R, V4, P263, DOI 10.1007/s11882-004-0069-2; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; 1993, DERMATOLOGY, V186, P23	28	29	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					247	256		10.1016/j.jaci.2009.10.027	http://dx.doi.org/10.1016/j.jaci.2009.10.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG		Green Accepted, Bronze			2022-12-18	WOS:000273660500031
J	Calabria, CW; Coop, CA; Tankersley, MS				Calabria, Christopher W.; Coop, Christopher A.; Tankersley, Michael S.			The LOCAL Study: Local reactions do not predict local reactions in allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Local reaction; large local reaction; systemic reaction; subcutaneous immunotherapy; safety	PLACEBO-CONTROLLED TRIAL; SYSTEMIC REACTIONS; RUSH-IMMUNOTHERAPY; ADVERSE-REACTIONS; DOSE ADJUSTMENT; DOUBLE-BLIND; PREMEDICATION; PRETREATMENT; INJECTIONS; VENOM	Background: Although previous immunotherapy studies have demonstrated that a local reaction does not predict a systemic reaction, no study has investigated whether a local reaction predicts a local reaction. Objective: To determine whether a local reaction predicts a local reaction at the next immunotherapy injection. Methods: A retrospective analysis of an electronic immunotherapy database over a 12-month period was performed at a single site that did not dose-adjust for local reactions. Total injections, small local reactions (less than or equal to the size of patient's palm), large local reactions (LLRs; larger than the patient's palm), systemic reactions, and whether a local reaction was followed by a local reaction were recorded. Results: Between August 2005 and July 2006, 360 patients received a total of 9678 injections. Of all patients, 78.3% had at least I local reaction, and 7.5% had an LLR. The total local reaction rate was 16.3% (1574/9678), the small local reaction rate was 15.9% (1536/9678), and the LLR rate was 0.4% (38/9678). Of all local reactions followed by another injection, 27.2% were followed by a local reaction. The sensitivity and positive predictive value for a local reaction predicting a local reaction at the next injection were 26.2% and 27.2%, respectively. In contrast, the specificity for the absence of a local reaction predicting the absence of a subsequent local reaction was 85.5%. For LLRs, only 6.0% were followed by another LLR; the sensitivity, positive predictive value, and specificity were 5.2%, 6.0%, and 99.6%, respectively. Conclusion: In a clinic that does not dose-adjust for local reactions, local reactions do not predict local reactions at the next immunotherapy injection. (J Allergy Clin Immunol 2009;124:739-44.)	[Calabria, Christopher W.; Coop, Christopher A.; Tankersley, Michael S.] Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, San Antonio, TX 78236 USA	United States Department of Defense; United States Air Force	Calabria, CW (corresponding author), Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, 2200 Bergquist Dr,Suite 1, San Antonio, TX 78236 USA.	christopher.calabria@lackland.af.mil						BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458, DOI 10.1016/S0091-6749(97)70135-0; Calabria CW, 2008, J ALLERGY CLIN IMMUN, V121, P222, DOI 10.1016/j.jaci.2007.08.016; Coop CA, 2008, ANN ALLERG ASTHMA IM, V101, P96, DOI 10.1016/S1081-1206(10)60841-1; Coop CA, 2007, ANN ALLERG ASTHMA IM, V99, P77, DOI 10.1016/S1081-1206(10)60625-4; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; Kain ZN, 2007, PEDIATRICS, V119, P608, DOI 10.1542/peds.2006-3030; Kelso JM, 2004, ANN ALLERG ASTHMA IM, V92, P225, DOI 10.1016/S1081-1206(10)61551-7; More DR, 2002, ANN ALLERG ASTHMA IM, V88, P391, DOI 10.1016/S1081-1206(10)62370-8; NELSON BL, 1986, ANN ALLERGY, V56, P331; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; PORTNOY J, 1994, ANN ALLERGY, V73, P409; PRIGAL SJ, 1972, ANN ALLERGY, V30, P529; RAMIREZ DA, 1981, ANN ALLERGY, V47, P435; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; Roy SR, 2007, ANN ALLERG ASTHMA IM, V99, P82, DOI 10.1016/S1081-1206(10)60626-6; Tankersley MS, 2000, J ALLERGY CLIN IMMUN, V106, P840, DOI 10.1067/mai.2000.110468; Wohrl S, 2007, INT ARCH ALLERGY IMM, V144, P137, DOI 10.1159/000103225; Yoshihiro O, 2006, ANN ALLERG ASTHMA IM, V96, P600, DOI 10.1016/S1081-1206(10)63556-9; 2007, J ALLERGY CLIN IMMUN, V120, pS25	20	29	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					739	744		10.1016/j.jaci.2009.07.048	http://dx.doi.org/10.1016/j.jaci.2009.07.048			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767075				2022-12-18	WOS:000270802800018
J	Juntti, H; Osterlund, P; Kokkonen, J; Dunder, T; Renko, M; Pokka, T; Julkunen, I; Uhari, M				Juntti, Hanna; Osterlund, Pamela; Kokkonen, Jorma; Dunder, Teija; Renko, Marjo; Pokka, Tytti; Julkunen, Ilkka; Uhari, Matti			Cytokine responses in cord blood predict the severity of later respiratory syncytial virus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cord blood; cytokine; respiratory syncytial virus	CHILDHOOD ASTHMA; INTERFERON-GAMMA; IMMUNE-RESPONSES; VIRAL-INFECTIONS; DISEASE SEVERITY; EARLY-LIFE; IN-VITRO; AGE 13; BRONCHIOLITIS; INTERLEUKIN-8	Background: It has been claimed that an early respiratory syncytial virus (RSV) infection can induce asthma and recurrent wheezing. Objective: We addressed the question of whether infants contracting an early RSV infection differ from healthy children in their cytokine production at birth. Methods: In a prospective cohort study cord blood samples were collected from 1084 newborns during autumn 2001. Of 47 of these newborns with subsequent virologically confirmed RSV infection before 6 months of age, 24 had enough cells for stimulation in cord blood samples (14 of those were hospitalized). Twenty-eight children had other respiratory virus infections (16 with enough cells), and samples from 48 healthy children of the 1084 total served as control specimens. Stimulated cytokine production of mononuclear cells was measured. The responses in the groups were evaluated by means of factor analysis. Results: The infants hospitalized for RSV infection had higher LPS-stimulated combined IL-6 and IL-8 responses than the infants treated as outpatients (P = .005) or the healthy control subjects (P = .02). The hospitalized patients with RSV showed lower IL-10, IL-2, IL-4, IL-5, and IL-10 responses than those treated as outpatients (P = .02). High IL-6 and IL-8 responsiveness predicted a severe RSV infection (odds ratio, 2.20; 95% CI, 1.17-4.14; P = .01). The unstimulated cytokine responses at birth did not differ between the patients and healthy control subjects. Conclusion: The results suggest that natural differences in innate immunity predispose children to severe RSV infection rather than the infection modifying immune responses in childhood. (J Allergy Clin Immunol 2009;124:52-8.)	[Juntti, Hanna; Kokkonen, Jorma; Dunder, Teija; Renko, Marjo; Pokka, Tytti; Uhari, Matti] Univ Oulu, Dept Paediat, FI-90014 Oulu, Finland; [Osterlund, Pamela; Julkunen, Ilkka] Natl Publ Hlth Inst, Helsinki, Finland	University of Oulu; Finland National Institute for Health & Welfare	Juntti, H (corresponding author), Univ Oulu, Dept Paediat, POB 5000, FI-90014 Oulu, Finland.	hanna.juntti@oulu.fi	Renko, Marjo/F-7811-2014; Österlund, Pamela/L-2528-2015; Österlund, Pamela/AGH-9008-2022	Renko, Marjo/0000-0003-0507-4773; Österlund, Pamela/0000-0002-2229-6661; Österlund, Pamela/0000-0002-2229-6661; D, Teija/0000-0002-5159-1256	Medical Research Council of the Academy of Finland; Foundation for Pediatric Research; Research Foundation of the Orion Corporation; Alma and K.A. Snellman Foundation; Allergy Research Foundation, Finland	Medical Research Council of the Academy of Finland(Academy of Finland); Foundation for Pediatric Research; Research Foundation of the Orion Corporation; Alma and K.A. Snellman Foundation; Allergy Research Foundation, Finland	Supported in part by the Medical Research Council of the Academy of Finland and grants from the Foundation for Pediatric Research, the Research Foundation of the Orion Corporation, the Alma and K.A. Snellman Foundation, and the Allergy Research Foundation, Finland.	Angelone DF, 2006, PEDIATR RES, V60, P205, DOI 10.1203/01.pdr.0000228319.10481.ea; Bennett BL, 2007, J INFECT DIS, V195, P1532, DOI 10.1086/515575; BISWAS S, 1995, PEDIATR INFECT DIS J, V14, P919; Blanco-Quiros A, 1999, PEDIATR PULM, V28, P175, DOI 10.1002/(SICI)1099-0496(199909)28:3<175::AID-PPUL3>3.0.CO;2-U; Bont L, 1999, EUR RESPIR J, V14, P144, DOI 10.1034/j.1399-3003.1999.14a24.x; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; Brandenburg AH, 2000, J MED VIROL, V62, P267, DOI 10.1002/1096-9071(200010)62:2&lt;267::AID-JMV20&gt;3.0.CO;2-8; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Dunder T, 2007, PEDIATR ALLERGY IMMU, V18, P105, DOI 10.1111/j.1399-3038.2006.00499.x; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Goetghebuer T, 2004, CLIN EXP ALLERGY, V34, P801, DOI 10.1111/j.1365-2222.2004.1947.x; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; HIETALA J, 1988, SCAND J INFECT DIS, V20, P595, DOI 10.3109/00365548809035659; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261; Janssen R, 2007, J INFECT DIS, V196, P826, DOI 10.1086/520886; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; Juntti H, 2005, CLIN EXP ALLERGY, V35, P59, DOI 10.1111/j.1365-2222.2004.02125.x; Juntti H, 2003, ALLERGY, V58, P878, DOI 10.1034/j.1398-9995.2003.00233.x; JUNTTI H, 2008, 26 ANN M EUR SOC PAE; Kips JC, 2001, EUR RESPIR J, V18, p24S, DOI 10.1183/09031936.01.00229601; Kline R. B., 1994, EASY GUIDE FACTOR AN; Krishnan S, 2003, J INFECT DIS, V188, P433, DOI 10.1086/376530; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Laham FR, 2004, J INFECT DIS, V189, P2047, DOI 10.1086/383350; Langrish CL, 2002, CLIN EXP IMMUNOL, V128, P118, DOI 10.1046/j.1365-2249.2002.01817.x; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; McNamara PS, 2004, EUR RESPIR J, V23, P106, DOI 10.1183/09031936.03.00048103; Openshaw PJM, 2005, CLIN MICROBIOL REV, V18, P541, DOI 10.1128/CMR.18.3.541-555.2005; Perez-Yarza EG, 2007, PEDIATR INFECT DIS J, V26, P733, DOI 10.1097/INF.0b013e3180618c42; Phaybouth V, 2006, AM J PHYSIOL-LUNG C, V290, pL222, DOI 10.1152/ajplung.00148.2005; *PUBL HLTH I FINL, 2009, RESP SYNC VIR RSV PR; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Schauer U, 2004, CLIN EXP IMMUNOL, V138, P102, DOI 10.1111/j.1365-2249.2004.02582.x; Sheeran P, 1999, PEDIATR INFECT DIS J, V18, P115, DOI 10.1097/00006454-199902000-00007; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Simoes EAF, 2003, J PEDIATR-US, V143, pS118, DOI 10.1067/S0022-3476(03)00511-0; Smyth RL, 2002, PEDIATR PULM, V33, P339, DOI 10.1002/ppul.10080; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Tsutsumi H, 1996, CLIN EXP IMMUNOL, V106, P442, DOI 10.1046/j.1365-2249.1996.d01-874.x; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	42	29	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					52	58		10.1016/j.jaci.2009.04.014	http://dx.doi.org/10.1016/j.jaci.2009.04.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19482350				2022-12-18	WOS:000267909700005
J	Gupta, RS; Zhang, XY; Sharp, LK; Shannon, JJ; Weiss, KB				Gupta, Ruchi S.; Zhang, Xingyou; Sharp, Lisa K.; Shannon, John J.; Weiss, Kevin B.			The protective effect of community factors on childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; prevalence; community; neighborhood; childhood; environment; social capital; disparity	HOUSE-DUST MITE; SOCIOECONOMIC-STATUS; AIR-POLLUTION; ENVIRONMENTAL INTERVENTION; PSYCHOSOCIAL FACTORS; COCKROACH ALLERGEN; TOBACCO-SMOKE; EXPOSURE; PREVALENCE; CHILDREN	Background: Asthma burden in the US is not evenly distributed. Although asthma prevalence varies widely across urban neighborhoods, little attention has been paid to the community as a key contributor. Objective: To determine the effect of positive socio-environmental community factors on childhood asthma prevalence in Chicago. Methods: From 2003 to 2005, an asthma screening survey was conducted among children attending Chicago Public/Catholic schools from kindergarten through eighth grade. One hundred five schools participated, yielding a stratified representation of 4 race-income groups. Positive community factors, such as social capital, economic potential, and community amenities, were assessed by using the Metro Chicago Information Center's Community Vitality Index. Results: Of the surveys returned, 45,177 (92%) were geocoded into 287 neighborhoods. Neighborhoods were divided into quartile groups by asthma prevalence (mean, 8%, 12%, 17%, 25%). Community vitality (54% vs 44%; P < .0001) and economic potential (64% vs 38%; P < .0001) were significantly higher in neighborhoods with low asthma prevalence. Neighborhood interaction (36% vs 73%; P < .0001) and stability (40% vs 53%; P < .0001) were significantly higher in neighborhoods with high asthma prevalence. Overall, positive factors explained 21% of asthma variation. Childhood asthma increased as the black population increased in a community (P < .0001). Accordingly, race/ethnicity was controlled. In black neighborhoods, these factors remained significantly higher in neighborhoods with low asthma prevalence. When considered alongside socio-demographic/individual characteristics, overall community vitality as well as social capital continued to contribute significantly to asthma variation. Conclusion: Asthma prevalence in Chicago is strongly associated with socio-environmental factors thought to enrich a community. A deeper understanding of this impact may lend insight into interventions to reduce childhood asthma. (J Allergy Clin Immunol 2009;123:1297-304.)	[Gupta, Ruchi S.] Childrens Mem Hosp, Chicago, IL 60614 USA; [Gupta, Ruchi S.; Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; [Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Div Gen Internal Med, Chicago, IL 60611 USA; [Zhang, Xingyou] Amer Acad Family Physicians, Robert Graham Ctr Policy Studies Family Med & Pri, Washington, DC USA; [Sharp, Lisa K.] Univ Illinois, Dept Med, Sect Hlth Promot, Chicago, IL USA; [Shannon, John J.] Cook Cty Hosp, Dept Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA; [Weiss, Kevin B.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Gupta, RS (corresponding author), Childrens Mem Hosp, 2300 Childrens Plaza,Box 157, Chicago, IL 60614 USA.	rugupta@childrensmemorial.org		Sharp, Lisa/0000-0002-7809-9042	National Heart, Lung, and Blood Institute [5U01 HL072478-05]; National Institute of Child Health and Human Development [K 12 HD052902]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD052902] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072478] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Heart, Lung, and Blood Institute grant 5U01 HL072478-05 and National Institute of Child Health and Human Development grant K 12 HD052902.	Akinbami, 2006, STATE CHILDHOOD ASTH, V381; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Almqvist C, 2005, CLIN EXP ALLERGY, V35, P612, DOI 10.1111/j.1365-2222.2005.02243.x; Baxter LK, 2007, J EXPO SCI ENV EPID, V17, P433, DOI 10.1038/sj.jes.7500532; BENER A, 2005, ALLERG IMMUNOL PARIS, V37, P163; Berry CA, 2005, ANN ALLERG ASTHMA IM, V95, P53, DOI 10.1016/S1081-1206(10)61188-X; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Byrd RS, 2006, CURR OPIN PULM MED, V12, P68, DOI 10.1097/01.mcp.0000199001.68908.45; Cagney KA, 2004, J GEN INTERN MED, V19, P229, DOI 10.1111/j.1525-1497.2004.30359.x; Cesaroni G, 2003, EUR RESPIR J, V22, P619, DOI 10.1183/09031936.03.00091202; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939, DOI 10.1289/ehp.02110939; Crain EF, 1998, ARCH PEDIAT ADOL MED, V152, P333; DAVIDSON AE, 1994, ANN ALLERGY, V72, P469; Debley JS, 2004, PEDIATR PULM, V38, P443, DOI 10.1002/ppul.20108; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Fagan JK, 2001, ANN ALLERG ASTHMA IM, V86, P177, DOI 10.1016/S1081-1206(10)62688-9; Farcomeni A, 2008, STAT METHODS MED RES, V17, P347, DOI 10.1177/0962280206079046; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.0000181308.51440.75; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; Grant EN, 2005, ANN ALLERG ASTHMA IM, V95, P19, DOI 10.1016/S1081-1206(10)61183-0; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Gupta RS, 2008, J ALLERGY CLIN IMMUN, V121, P639, DOI 10.1016/j.jaci.2007.11.036; HALFON N, 1993, PEDIATRICS, V91, P56; *INT CONS POL SOC, 2007, PROJ HUM DEV CHIC NE; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6.426S; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Migilaretti G, 2004, PEDIATR PULM, V38, P198, DOI 10.1002/ppul.20057; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ottenbacher KJ, 1998, AM J EPIDEMIOL, V147, P615; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266, DOI 10.1016/S1081-1206(10)62824-4; Peters JL, 2007, J URBAN HEALTH, V84, P185, DOI 10.1007/s11524-006-9146-2; Peterson JW, 2006, HEALTH PROMOT PRACT, V7, pS56, DOI 10.1177/1524839906287067; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Schwartz J, 2004, PEDIATRICS, V113, P1037; Shalowitz MU, 2007, AMBUL PEDIATR, V7, P271, DOI 10.1016/j.ambp.2007.03.004; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Swahn MH, 2006, AM J PUBLIC HEALTH, V96, P802, DOI 10.2105/AJPH.2005.066514; Tatum AJ, 2005, IMMUNOL ALLERGY CLIN, V25, P15, DOI 10.1016/j.iac.2004.09.003; Thomas SD, 1999, CHEST, V116, p135S, DOI 10.1378/chest.116.suppl_2.135S; Wainwright NWJ, 2007, ALLERGY, V62, P554, DOI 10.1111/j.1398-9995.2007.01316.x; Weil CM, 1999, PEDIATRICS, V104, P1274, DOI 10.1542/peds.104.6.1274; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Wolf RL, 2003, ANN ALLERG ASTHMA IM, V90, P500, DOI 10.1016/S1081-1206(10)61843-1; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965	59	29	29	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1297	1304		10.1016/j.jaci.2009.03.039	http://dx.doi.org/10.1016/j.jaci.2009.03.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	455WO	19450873	Green Accepted			2022-12-18	WOS:000266799100020
J	Ueta, M; Uematsu, S; Akira, S; Kinoshita, S				Ueta, Mayumi; Uematsu, Satoshi; Akira, Shizuo; Kinoshita, Shigeru			Toll-like receptor 3 enhances late-phase reaction of experimental allergic conjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							INNATE IMMUNITY; TLR3		[Ueta, Mayumi; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; [Ueta, Mayumi] Doshisha Univ, Fac Life & Med Sci, Res Ctr Regenerat Med, Kyoto 602, Japan; [Uematsu, Satoshi; Akira, Shizuo] Osaka Univ, Microbial Dis Res Inst, Dept Hosp Def, Osaka, Japan	Kyoto Prefectural University of Medicine; Doshisha University; Osaka University	Ueta, M (corresponding author), Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan.	mueta@koto.kpu-m.ac.jp	Akira, Shizuo/C-3134-2009					Cavassani KA, 2008, J EXP MED, V205, P2609, DOI 10.1084/jem.20081370; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Negishi H, 2008, P NATL ACAD SCI USA, V105, P20446, DOI 10.1073/pnas.0810372105; Sel S, 2007, J IMMUNOL, V178, P7805, DOI 10.4049/jimmunol.178.12.7805; Ueta M, 2005, BIOCHEM BIOPH RES CO, V331, P285, DOI 10.1016/j.bbrc.2005.02.196; Ueta M, 2008, CORNEA, V27, pS31, DOI 10.1097/ICO.0b013e31817f2a7f; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P476, DOI 10.1016/j.jaci.2007.04.024; Ueta M, 2009, J ALLERGY CLIN IMMUN, V123, P466, DOI 10.1016/j.jaci.2008.09.044; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262	9	29	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1187	1189		10.1016/j.jaci.2009.03.008	http://dx.doi.org/10.1016/j.jaci.2009.03.008			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19362356				2022-12-18	WOS:000266309400035
J	Shearer, WT; Ochs, HD; Lee, BN; Cohen, EN; Reuben, JM; Cheng, I; Thompson, B; Butel, JS; Blancher, A; Abbal, M; Aviles, H; Sonnenfeld, G				Shearer, William T.; Ochs, Hans D.; Lee, Bang-Ning; Cohen, Evan N.; Reuben, James M.; Cheng, Irene; Thompson, Bruce; Butel, Janet S.; Blancher, Antoine; Abbal, Michel; Aviles, Hernan; Sonnenfeld, Gerald			Immune responses in adult female volunteers during the bed-rest model of spaceflight: Antibodies and cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Head-down tilt; bed rest; phi X-174 immunization; IgG class switching; spaceflight model; proinflammatory and anti-inflammatory cytokines; female study subjects	CELL-MEDIATED-IMMUNITY; HEAD-DOWN TILT; ANTARCTIC WINTER; SPACE-FLIGHT; EXHAUSTIVE EXERCISE; VIRUS; WOMEN; MEN	Background: It is unknown whether a prolonged period of bed rest will affect human immune responses, particularly in female subjects. Objective: We sought to measure immune responses in adult female subjects exposed to prolonged bed rest. Methods: Adult (25-40 years) female volunteers (n = 24) were maintained in a supine (6 degrees tilt) head-down bed-rest (HDBR) position for 60 days: 8 with HDBR only, 8 with HDBR and regular muscular exercise, and 8 with HDBR and dietary protein supplementation. Subjects were immunized with bacteriophage phi X-174. Antibody production and plasma cytokine levels were determined. Results: The rate of primary antibody production of the HDBR plus exercise group increased faster (P = .01) and to a higher level versus that of the HDBR-only group (P = .03) and that of the HDBR plus diet group (trend P = .08). The rates of secondary antibody production between the 3 groups were similar, but the level of antibody in the HDBR plus exercise group remained higher versus that in the HDBR-only group (P = .03). Both the HDBR (P = .001) and HDBR plus diet (P = .02) groups had time-related progressive increases in TNF-alpha receptor levels, but the HDBR plus exercise group remained at baseline. The HDBR plus exercise group experienced an acute increase in IL-1 receptor antagonist levels versus the HDBR (P = .02) and the HDBR plus diet (P = .02) groups, with similar increases in RANTES levels. Conclusions: The exercise countermeasure accelerated primary antibody production and increased antibody levels to bacteriophage phi X-174 and also opposed the potentially harmful effects of increased TNF-a levels caused by prolonged bed rest, possibly by activating the anti-inflammatory cytokine IL-1 receptor antagonist and the chemotactic factor RANTES. (J Allergy Clin Immunol 2009;123:900-5.)	[Shearer, William T.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat & Immunol, Houston, TX 77030 USA; [Ochs, Hans D.] Univ Washington, Childrens Hosp & Reg Med Ctr, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Lee, Bang-Ning; Cohen, Evan N.; Reuben, James M.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Cheng, Irene; Thompson, Bruce] Clin Trials & Surveys Corp, Baltimore, MD USA; [Butel, Janet S.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Blancher, Antoine; Abbal, Michel] Univ Toulouse 3, Fac Med Rangueil, Immunol Lab, F-31062 Toulouse, France; [Aviles, Hernan; Sonnenfeld, Gerald] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA	Baylor College of Medicine; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; State University of New York (SUNY) System; State University of New York (SUNY) Binghamton	Shearer, WT (corresponding author), Texas Childrens Hosp, Baylor Coll Med, Dept Pediat & Immunol, 6621 Fannin St,MC FC330-01, Houston, TX 77030 USA.	wtsheare@texaschildrenshospital.org	Cohen, Evan N/AFP-3323-2022	Cohen, Evan N/0000-0003-4192-9644; Shearer, William/0000-0002-2483-2130; Butel, Janet/0000-0002-6876-3245	National Aeronautics and Space Administration [NCC 9-58]	National Aeronautics and Space Administration(National Aeronautics & Space Administration (NASA))	Supported by the National Aeronautics and Space Administration through NASA Cooperative Agreement NCC 9-58 with the National Space Biomedical Research Institute.	Bruunsgaard H, 1997, MED SCI SPORT EXER, V29, P1176, DOI 10.1097/00005768-199709000-00009; COPE AP, 2008, CLIN IMMUNOLOGY PRIN, P767; Custaud MA, 2002, AUTON NEUROSCI-BASIC, V100, P66, DOI 10.1016/S1566-0702(02)00132-7; Edgell H, 2007, AM J PHYSIOL-REG I, V293, pR2343, DOI 10.1152/ajpregu.00187.2007; Lawler A, 2004, SCIENCE, V303, P610, DOI 10.1126/science.303.5658.610; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Meck JV, 2004, AM J PHYSIOL-HEART C, V286, pH1486, DOI 10.1152/ajpheart.00740.2003; Mehta SK, 2000, J MED VIROL, V61, P235, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;235::AID-JMV10&gt;3.0.CO;2-4; Nieman DC, 2007, SPORTS MED, V37, P412, DOI 10.2165/00007256-200737040-00036; Nieman DC, 1997, J APPL PHYSIOL, V82, P1385, DOI 10.1152/jappl.1997.82.5.1385; Pierson DL, 2005, BRAIN BEHAV IMMUN, V19, P235, DOI 10.1016/j.bbi.2004.08.001; PROUD D, 2003, ALLERGY PRINCIPLES P, P373; PYUN KH, 1989, CLIN IMMUNOL IMMUNOP, V51, P252, DOI 10.1016/0090-1229(89)90024-X; Schmitt DA, 2000, PFLUG ARCH EUR J PHY, V441, pR79, DOI 10.1007/s004240000349; Schmitt DA, 1996, J INTERF CYTOK RES, V16, P151, DOI 10.1089/jir.1996.16.151; Shearer WT, 2007, ACTA ASTRONAUT, V60, P247, DOI 10.1016/j.actaastro.2006.08.005; Shearer WT, 2005, J ALLERGY CLIN IMMUN, V115, P1297, DOI 10.1016/j.jaci.2005.03.003; Shearer WT, 2002, J ALLERGY CLIN IMMUN, V109, P854, DOI 10.1067/mai.2002.123873; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P160, DOI 10.1067/mai.2001.112269; SHEARER WT, 2003, ENCY SPACE SCI TECHN, P810; Shirai T, 2003, J ALLERGY CLIN IMMUN, V111, P1353, DOI 10.1067/mai.2003.1504; Smith TP, 2004, J APPL PHYSIOL, V97, P491, DOI 10.1152/japplphysiol.01404.2003; Sonnenfeld G, 2007, ACTA ASTRONAUT, V60, P234, DOI 10.1016/j.actaastro.2006.08.004; Sonnenfeld Gerald, 2003, Rev Environ Health, V18, P1; Suzuki K, 2003, EXERC IMMUNOL REV, V9, P48; Suzuki K, 2002, EXERC IMMUNOL REV, V8, P6; Watenpaugh DE, 2000, J APPL PHYSIOL, V89, P218, DOI 10.1152/jappl.2000.89.1.218	27	29	29	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					900	905		10.1016/j.jaci.2008.12.016	http://dx.doi.org/10.1016/j.jaci.2008.12.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19232702				2022-12-18	WOS:000265058600018
J	Boyce, JA; Broide, D; Matsumoto, K; Bochner, BS				Boyce, Joshua A.; Broide, David; Matsumoto, Kenji; Bochner, Bruce S.			Advances in mechanisms of asthma, allergy, and immunology in 2008	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN MAST-CELLS; AIRWAY INFLAMMATION; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; STAPHYLOCOCCUS-AUREUS; RHINOVIRUS ILLNESSES; EPITHELIAL-CELLS; HAY-FEVER; T-CELLS; EXPRESSION	This review summarizes selected articles appearing in 2008 in the Journal. Articles chosen include those improving our understanding of mechanisms of allergic diseases by focusing on human basophil, mast cell, and eosinophil biology; IgE and its high-affinity receptor on various cells; novel properties of omalizumab; airways remodeling; and genetics. Articles from other journals have been included to supplement the topics presented. (J Allergy Clin Immunol 2009;123:569-74.)	[Bochner, Bruce S.] Johns Hopkins Univ, Dept Med, Div Allergy & Clin Immunol, Sch Med,Johns Hopkins Asthma & Ctr, Baltimore, MD 21224 USA; [Boyce, Joshua A.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; [Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Broide, David] Univ Calif San Diego, Dept Med, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA; [Matsumoto, Kenji] Natl Res Inst Child Hlth & Dev, Dept Allergy & Immunol, Tokyo, Japan	Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Diego; National Center for Child Health & Development - Japan	Bochner, BS (corresponding author), Johns Hopkins Univ, Dept Med, Div Allergy & Clin Immunol, Sch Med,Johns Hopkins Asthma & Ctr, 5501 Hopkins Bayview Circle,Room 2B71, Baltimore, MD 21224 USA.	bbochner@jhmi.edu		Broide, David/0000-0001-8405-9090	National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072265, T32AI007056] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Disclosure of potential conflict of interest: J. A. Boyce is a speaker for Merck and has received research support from the National Institutes of Health. B. S. Bochner has consulted for Sanofi-Aventis. Amgen, and Therakos has received speaker honoraria from Merck and has received research support from Enobia anti the National Institutes of Health. D. Broide has received research support front the National Institutes Of Health. K. Matsumoto has declared that he has no conflicts of interest.	Adamko DJ, 2008, J ALLERGY CLIN IMMUN, V122, P383, DOI 10.1016/j.jaci.2008.03.020; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Cardona ID, 2006, AM J CLIN DERMATOL, V7, P273, DOI 10.2165/00128071-200607050-00001; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Corren J, 2008, J ALLERGY CLIN IMMUN, V121, P506, DOI 10.1016/j.jaci.2007.11.026; Dauvillier S, 2002, J IMMUNOL, V169, P2274, DOI 10.4049/jimmunol.169.5.2274; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Fujita S, 2008, J ALLERGY CLIN IMMUN, V121, P95, DOI 10.1016/j.jaci.2007.08.038; Hamilton RG, 2008, J ALLERGY CLIN IMMUN, V122, P305, DOI 10.1016/j.jaci.2008.05.009; Hua XY, 2008, J ALLERGY CLIN IMMUN, V122, P107, DOI 10.1016/j.jaci.2008.03.026; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Ju HR, 1996, BIOSCI BIOTECH BIOCH, V60, P1856, DOI 10.1271/bbb.60.1856; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kearley J, 2008, J ALLERGY CLIN IMMUN, V122, P617, DOI 10.1016/j.jaci.2008.05.048; Kelly JT, 2008, J ALLERGY CLIN IMMUN, V122, P671, DOI 10.1016/j.jaci.2008.08.013; Kormann MSD, 2008, J ALLERGY CLIN IMMUN, V122, P86, DOI 10.1016/j.jaci.2008.04.039; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee JH, 2008, J ALLERGY CLIN IMMUN, V121, P1225, DOI 10.1016/j.jaci.2007.12.1160; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.200409-1175OC; Legg JP, 2003, AM J RESP CRIT CARE, V168, P633, DOI 10.1164/rccm.200210-1148OC; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; MacGlashan D, 2008, J ALLERGY CLIN IMMUN, V121, P1500, DOI 10.1016/j.jaci.2008.04.019; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mazuc E, 2008, J ALLERGY CLIN IMMUN, V122, P188, DOI 10.1016/j.jaci.2008.04.026; Mrabet-Dahbi S, 2008, J ALLERGY CLIN IMMUN, V121, P1013, DOI 10.1016/j.jaci.2007.11.029; Nakashima K, 2006, J HUM GENET, V51, P284, DOI 10.1007/s10038-005-0358-1; Negri J, 2008, J ALLERGY CLIN IMMUN, V121, P1232, DOI 10.1016/j.jaci.2008.02.007; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Pacheco K, 2008, J ALLERGY CLIN IMMUN, V122, P896, DOI 10.1016/j.jaci.2008.08.025; Puxeddu I, 2008, J ALLERGY CLIN IMMUN, V121, P1400, DOI 10.1016/j.jaci.2008.03.003; Ringvall M, 2008, J ALLERGY CLIN IMMUN, V121, P1020, DOI 10.1016/j.jaci.2007.11.031; Ruppert AA, 2008, J ALLERGY CLIN IMMUN, V121, P253, DOI 10.1016/j.jaci.2007.10.040; Salamon P, 2008, J ALLERGY CLIN IMMUN, V121, P448, DOI 10.1016/j.jaci.2007.08.054; Semic-Jusufagic A, 2007, J ALLERGY CLIN IMMUN, V119, P930, DOI 10.1016/j.jaci.2006.12.639; Siddiqui S, 2008, J ALLERGY CLIN IMMUN, V122, P335, DOI 10.1016/j.jaci.2008.05.020; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P1054, DOI 10.1016/j.jaci.2007.11.027; Simon HU, 2007, IMMUNOL ALLERGY CLIN, V27, P519, DOI 10.1016/j.iac.2007.07.003; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Slats AM, 2008, J ALLERGY CLIN IMMUN, V121, P1196, DOI 10.1016/j.jaci.2008.02.017; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Trivedi NN, 2008, J ALLERGY CLIN IMMUN, V121, P1262, DOI 10.1016/j.jaci.2008.01.019; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Vonakis BM, 2008, CURR OPIN IMMUNOL, V20, P709, DOI 10.1016/j.coi.2008.09.005; Wang J, 2008, J ALLERGY CLIN IMMUN, V121, P1219, DOI 10.1016/j.jaci.2007.12.1150; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yang YW, 2008, J ALLERGY CLIN IMMUN, V121, P1393, DOI 10.1016/j.jaci.2008.02.031; Yokoi H, 2008, J ALLERGY CLIN IMMUN, V121, P499, DOI 10.1016/j.jaci.2007.10.004	59	29	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					569	574		10.1016/j.jaci.2009.01.041	http://dx.doi.org/10.1016/j.jaci.2009.01.041			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19281904	Green Accepted			2022-12-18	WOS:000264731200013
J	MacGlashan, D; Undem, BJ				MacGlashan, Donald, Jr.; Undem, Bradley J.			Inducing an anergic state in mast cells and basophils without secretion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						desensitization; spleen tyrosine kinase; phosphatidyl-inositol 3' kinase	FC-EPSILON-RI; IGE-MEDIATED STIMULATION; HISTAMINE-RELEASE; TYROSINE KINASE; NONSPECIFIC DESENSITIZATION; NEGATIVE REGULATION; SYK KINASE; ANTI-IGE; ACTIVATION; BINDING	Background: IgE-mediated secretion from mast cells or basophils depends on the activity of both spleen tyrosine kinase (syk) and phosphatidyl inositol 3' kinase (PI3K), but several specific downregulatory pathways (eg, loss of syk expression) do not. Objective: We tested whether stimulation with antigen in the presence of a syk inhibitor (NVP-QAB205) would ablate secretion while simultaneously allowing anergy. Methods: The anergic or desensitized state in human basophils, cultured-derived mast cells, and in situ stimulated airway mast cells (in organ baths) was assessed after stimulation with antigen in the presence of syk inhibitor. Results: Antigen caused 35 +/- 7% and 62 +/- 10% histamine release from basophils and mast cells, respectively, and it caused an 87 +/- 5% histamine/leukotriene D-4-dependent contraction of human isolated bronchi. All of these responses were blocked >95% by the syk inhibitor. Rechallenging the preparations with antigen, after first washing out the syk inhibitor and antigen, revealed that near complete anergy (92% to 100%) occurred in each case. A similar result was found when using a PI3K inhibitor, LY294002, in studies of basophils. Conclusion: Although the syk inhibitor nearly abolished the antigen-induced secretion from mast cells and basophils, it had little effect on the pathways involved in anergy. These results suggest that syk and PI3K are not involved in downregulation leading to anergy.	[MacGlashan, Donald, Jr.; Undem, Bradley J.] Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University	MacGlashan, D (corresponding author), Johns Hopkins Univ, Ctr Asthma & Allergy, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu			NIAID NIH HHS [AI20253] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020253] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DROBIS JD, 1976, J IMMUNOL, V117, P1049; ELLIS JL, 1994, AM J RESP CRIT CARE, V150, P717, DOI 10.1164/ajrccm.150.3.8087342; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Jiang K, 2002, J IMMUNOL, V168, P3155, DOI 10.4049/jimmunol.168.7.3155; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kepley CL, 2005, INT ARCH ALLERGY IMM, V138, P29, DOI 10.1159/000087355; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kitaura J, 2007, J IMMUNOL, V178, P455, DOI 10.4049/jimmunol.178.1.455; Komiya A, 2003, INT ARCH ALLERGY IMM, V130, P40, DOI 10.1159/000068374; Lavens-Phillips SE, 1999, FASEB J, V13, pA338; LICHTENSTEIN LM, 1971, INT ARCH ALLER A IMM, V41, P56, DOI 10.1159/000230488; MACGLASHAN D, 1983, J IMMUNOL, V130, P2337; MacGlashan D, 1998, J LEUKOCYTE BIOL, V63, P59, DOI 10.1002/jlb.63.1.59; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; MacGlashan D, 2003, J IMMUNOL, V170, P4914, DOI 10.4049/jimmunol.170.10.4914; MacGlashan D, 2006, J IMMUNOL, V177, P1040, DOI 10.4049/jimmunol.177.2.1040; MacGlashan DW, 2008, J IMMUNOL, V180, P4208, DOI 10.4049/jimmunol.180.6.4208; MacGlashan DW, 2007, J LEUKOCYTE BIOL, V82, P1003, DOI 10.1189/jlb.0207103; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; Malbec O, 2002, MOL IMMUNOL, V38, P1295, DOI 10.1016/S0161-5890(02)00078-0; MENDOZA GR, 1982, INT ARCH ALLER A IMM, V68, P101, DOI 10.1159/000233076; Miura K, 2000, BLOOD, V96, P2199, DOI 10.1182/blood.V96.6.2199.h8002199_2199_2205; Miura K, 2001, CLIN EXP ALLERGY, V31, P1732, DOI 10.1046/j.1365-2222.2001.01236.x; Miura K, 2001, J IMMUNOL, V167, P7027, DOI 10.4049/jimmunol.167.12.7027; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; Paolini R, 2002, J BIOL CHEM, V277, P36940, DOI 10.1074/jbc.M204948200; Paolini R, 2001, P NATL ACAD SCI USA, V98, P9611, DOI 10.1073/pnas.161298098; PRUZANSKY JJ, 1988, IMMUNOLOGY, V65, P443; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; STARK BJ, 1987, J ALLERGY CLIN IMMUN, V79, P523, DOI 10.1016/0091-6749(87)90371-X; Vilarino N, 2005, J IMMUNOL METHODS, V296, P11, DOI 10.1016/j.jim.2004.10.009; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; Yokoi H, 2008, J ALLERGY CLIN IMMUN, V121, P499, DOI 10.1016/j.jaci.2007.10.004; Yu M, 2006, J IMMUNOL, V176, P2421, DOI 10.4049/jimmunol.176.4.2421; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	42	29	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1500	1506		10.1016/j.jaci.2008.04.019	http://dx.doi.org/10.1016/j.jaci.2008.04.019			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18539198				2022-12-18	WOS:000256771700029
J	Van der Gugten, AC; Den Otter, M; Meijer, Y; Pasmans, SGAM; Knulst, AC; Hoekstra, MO				Van der Gugten, Anne C.; Den Otter, Martine; Meijer, Yolanda; Pasmans, Suzanne G. A. M.; Knulst, Andre C.; Hoekstra, Maarten O.			Usefulness of specific IgE levels in predicting cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ORAL FOOD CHALLENGES; CHILDREN; DIAGNOSIS		[Van der Gugten, Anne C.; Den Otter, Martine; Meijer, Yolanda; Hoekstra, Maarten O.] Wilhelmina Childrens Hosp, Ctr Pediat Allergol, Utrecht, Netherlands; [Pasmans, Suzanne G. A. M.; Knulst, Andre C.] Univ Med Ctr, Dept Dermatol Allergol, Utrecht, Netherlands	Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center	Hoekstra, MO (corresponding author), Wilhelmina Childrens Hosp, Ctr Pediat Allergol, Utrecht, Netherlands.	m.o.hoekstra@umcutrecht.nl	Pasmans, Suzanne/AAI-6016-2021	Pasmans, Suzanne/0000-0003-1018-4475; Knulst, Andre/0000-0002-1056-3179				Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Flinterman AE, 2006, ALLERGY, V61, P370, DOI 10.1111/j.1398-9995.2006.01018.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Niggemann B, 2005, ALLERGY, V60, P865, DOI 10.1111/j.1398-9995.2005.00828.x; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SAMPSON HA, 2001, J ALLERGY CLIN IMMUN, V107, P981	10	29	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					531	533		10.1016/j.jaci.2007.10.042	http://dx.doi.org/10.1016/j.jaci.2007.10.042			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18155280				2022-12-18	WOS:000253337800040
J	Phipatanakul, W; Litonjua, AA; Platts-Mills, TAE; Naccara, LM; Celedon, JC; Abdulkerim, H; Hoffman, EB; Gold, DR				Phipatanakul, Wanda; Litonjua, Augusto A.; Platts-Mills, Thomas A. E.; Naccara, Lisa M.; Celedon, Juan C.; Abdulkerim, Hassen; Hoffman, Elaine B.; Gold, Diane R.			Sensitization to mouse allergen and asthma and asthma morbidity among women in Boston	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SOCIOECONOMIC-FACTORS; EXPOSURE; PREVALENCE; PREDICTORS; CHILDREN; HOMES; IGE		Childrens Hosp, Dept Pediat, Div Allergy & Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Virginia, Ctr Asthma & Allergy, Charlottesville, VA USA; Harvard Univ, Sch Med, Dept Biostat, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Virginia; Harvard University; Harvard Medical School	Phipatanakul, W (corresponding author), Childrens Hosp, Dept Pediat, Div Allergy & Immunol, Boston, MA 02115 USA.	phipatanakul@childrens.harvard.edu		Platts-Mills, Thomas/0000-0002-1263-329X; Litonjua, Augusto/0000-0003-0422-5875	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI054972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES007036, R01ES007036] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/EHS 35785, K23 AI 054972, K23 AI054972-05, K23 AI054972] Funding Source: Medline; NIEHS NIH HHS [R56 ES007036, ES 07036, R01 ES007036] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/ajrccm.165.7.2103044; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615, DOI 10.1067/mai.2001.113523; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Matsui EC, 2006, ANN ALLERG ASTHMA IM, V97, P514, DOI 10.1016/S1081-1206(10)60943-X; Phipatanakul W, 2005, ALLERGY, V60, P697, DOI 10.1111/j.1398-9995.2005.00825.x; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795	10	29	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					954	956		10.1016/j.jaci.2007.05.010	http://dx.doi.org/10.1016/j.jaci.2007.05.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17590423	Green Accepted			2022-12-18	WOS:000250157700035
J	Matsui, EC; Eggleston, PA; Breysse, PN; Rand, CS; Diette, GB				Matsui, Elizabeth C.; Eggleston, Peyton A.; Breysse, Patrick N.; Rand, Cynthia S.; Diette, Gregory B.			Mouse allergen-specific antibody responses in inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; inner-city asthma; mouse sensitization; IgG; IgG(4)	SKIN-TEST SENSITIVITY; CD4(+) T-CELLS; EXPOSURE; SENSITIZATION; HOMES; PREVALENCE; MORBIDITY; TOLERANCE; ANTIGEN; IGG	Background: Although mouse allergen exposure is common in inner-city homes, little is known about the relationships between exposure and humoral immune responses to mouse allergen in this population. Objective: To examine relationships between mouse allergen exposure and allergen-specific IgE and IgG responses in inner-city children with asthma. Methods: Inner-city children with asthma underwent skin testing and venipuncture for determination of mouse allergen-specific IgE and IgG levels. Settled dust samples were collected from their homes for allergen analysis. Results: The study population (n = 112) was predominantly African American (92%) with a mean age of 4.4 years. The prevalence rate of mouse sensitization was 25% and did not consistently increase with increasing Mus m I levels. Instead, the prevalence rate was lowest among those exposed to <2 mu g/g, increased among those exposed to 2-7.9 mu g/g and 8-29.9 mu g/g, and then decreased among participants exposed to 29.9 mu g/g (14%, 20%, 40%, and 28%, respectively). Similarly, the prevalence rates of mouse allergen-specific IgG and IgG(4) did not increase across increasing exposure categories. Mouse 4 were strongly associated with allergen-specific IgG and IgG IgE sensitization (odds ratios [95% CI], 82.8 [20.5-334.4] and 50.4 [14.0-181.7], respectively). Conclusion: High-level exposure to mouse allergen in children may be associated with attenuated humoral responses of all isotypes rather than selective attenuation of IgE. Clinical implications: Protection against allergic sensitization by high-dose allergen exposure may not be mediated by preferential production of IgG over IgE.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Matsui, EC (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	ematsui@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL067850, K23HL004266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI060955, R03AI062974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, P01ES009606] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL04266, HL67850] Funding Source: Medline; NIAID NIH HHS [AI62974, AI060955] Funding Source: Medline; NIEHS NIH HHS [P30 ES03819, ES09606] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barbey C, 2004, CLIN EXP ALLERGY, V34, P654, DOI 10.1111/j.1365-2222.2004.1929.x; Bush R K, 2001, ILAR J, V42, P4; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Holt PG, 2000, AM J RESP CRIT CARE, V161, pS172, DOI 10.1164/ajrccm.161.supplement_2.a1q4-5; Ise W, 2002, J IMMUNOL, V168, P3242, DOI 10.4049/jimmunol.168.7.3242; Matsui EC, 2006, CLIN EXP ALLERGY, V36, P1097, DOI 10.1111/j.1365-2222.2006.02534.x; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2004, ANN ALLERG ASTHMA IM, V93, P171, DOI 10.1016/S1081-1206(10)61471-8; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Portengen L, 2004, CLIN EXP ALLERGY, V34, P1243, DOI 10.1111/j.1365-2222.2004.02025.x; PRICE JA, 1989, J ALLERGY CLIN IMMUN, V84, P520, DOI 10.1016/0091-6749(89)90366-7; Rennels M, 2002, PEDIATR INFECT DIS J, V21, P978, DOI 10.1097/00006454-200210000-00019; Schram-Bijkerk D, 2006, ALLERGY, V61, P640, DOI 10.1111/j.1398-9995.2006.01079.x; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60, DOI 10.1016/S1081-1206(10)62324-1; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x	25	29	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					910	915		10.1016/j.jaci.2006.12.663	http://dx.doi.org/10.1016/j.jaci.2006.12.663			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17337296				2022-12-18	WOS:000245729500020
J	Kondo, Y; Komatsubara, R; Nakajima, Y; Yasuda, T; Kakami, M; Tsuge, I; Urisu, A				Kondo, Yasuto; Komatsubara, Ryo; Nakajima, Yoichi; Yasuda, Toshitaka; Kakami, Michiko; Tsuge, Iktrya; Urisu, Atsuo			Parvalbumin is not responsible for cross-reactivity between tuna and marlin: A case report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY; ADULTS		Fujita Hlth Univ, Dept Pediat, Toyoake, Aichi, Japan; Toyo Suisan Kaisha Ltd, Tokyo, Japan	Fujita Health University	Kondo, Y (corresponding author), Fujita Hlth Univ, Dept Pediat, Toyoake, Aichi, Japan.	ykondo@fujita-hu.ac.jp						Asero R, 1999, ALLERGY, V54, P1228, DOI 10.1034/j.1398-9995.1999.00359.x; Caballero ML, 2004, PARASITOL RES, V93, P248, DOI 10.1007/s00436-004-1099-3; Hansen TK, 1997, ANN ALLERG ASTHMA IM, V78, P187, DOI 10.1016/S1081-1206(10)63386-8; Helbling A, 1999, ANN ALLERG ASTHMA IM, V83, P517, DOI 10.1016/S1081-1206(10)62862-1; Kelso JM, 1996, ANN ALLERG ASTHMA IM, V77, P227, DOI 10.1016/S1081-1206(10)63260-7; Kondo Y, 2002, CLIN EXP ALLERGY, V32, P590, DOI 10.1046/j.0954-7894.2002.01337.x; Kondo Y, 2005, ALLERGOL INT, V54, P317, DOI DOI 10.2332/ALLERG0LINT.54.317; Lim DLC, 2005, J ALLERGY CLIN IMMUN, V115, P874, DOI 10.1016/j.jaci.2004.12.1117; Sampson HA, 2003, PEDIATRICS, V111, P1601	9	29	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1382	1383		10.1016/j.jaci.2006.07.047	http://dx.doi.org/10.1016/j.jaci.2006.07.047			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	117NP	17137869				2022-12-18	WOS:000242880300028
J	Gabler, M; Scheiblhofer, S; Kern, K; Leitner, WW; Stoecklinger, A; Hauser-Kronberger, C; Alinger, B; Lechner, B; Prinz, M; Vrtala, S; Valenta, R; Thalhamer, J; Weiss, R				Gabler, Maximilian; Scheiblhofer, Sandra; Kern, Kerstin; Leitner, Wolfgang W.; Stoecklinger, Angelika; Hauser-Kronberger, Cornelia; Alinger, Beate; Lechner, Berta; Prinz, Monika; Vrtala, Susanne; Valenta, Rudolf; Thalhamer, Josef; Weiss, Richard			Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						type I allergy; DNA vaccine; genetic immunization; replicase; alphavirus; Phl p 5; IgE; bronchoalveolar lavage; eosinophils; lung pathology	IMMUNOGLOBULIN-E SYNTHESIS; IGE ANTIBODY-FORMATION; BIRCH-POLLEN ALLERGEN; IMMUNE-RESPONSES; DENDRITIC CELLS; TH1 RESPONSES; IN-VIVO; GENETIC IMMUNIZATION; AIRWAY INFLAMMATION; MAJOR ALLERGEN	Background: Replicase-based DNA vaccines stimulate T(H)1-biased immune responses at ultralow doses and induce self-removal of transfected cells through apoptosis. Both aspects are important requirements for efficient and safe DNA-based immunotherapy of type I allergies. Objective: A Sindbis virus replicon-based DNA vaccine encoding the major timothy grass pollen allergen Phi p 5 was evaluated for its antiallergic potential compared with a conventional DNA vaccine in a BALB/c mouse model of allergy. Methods: Mice were intradermally prevaccinated with plasmid DNA, followed by sensitization and intranasal allergen provocation with recombinant Phi p 5. In vitro proliferation and cytokine secretion was measured in splenocyte cultures. Distribution of IgG1, IgG2a, and IgE antibody subclasses was determined by means of ELISA. IgE-mediated degranulation was measured with the basophil release assay. Bronchoalveolar lavage fluid was analyzed for eosinophils, IL-4, IL-5, IL-13, and IFN-gamma. Mucus production, inflammatory infiltrates, and epithelial damage were determined in lung sections. Results: Both vaccines induced T(H)1-biased immune responses, resulting in suppression of functional IgE, reduction of eosinophilia in bronchoalveolar lavage fluid, and alleviation of lung pathology. However, immunization with the replicon DNA vaccine elicited these effects at a 100-fold lower dose compared with the conventional DNA vaccine. Conclusions: The increased immunogenicity of replicon-based DNA vaccines allows for application of extremely low doses, thereby eliminating the concerns associated with conventional DNA vaccines, which have to be administered at milligram amounts to induce immune reactions in human subjects. Clinical implications: Their high safety profile makes replicon-based DNA vaccines promising candidates for treatment of type I allergies in the clinic.	Salzburg Univ, Dept Mol Biol, Div Allergy & Immunol, Christian Doppler Lab Allergy Diagnost & Therapy, A-5020 Salzburg, Austria; Natl Canc Inst, Dermatol Branch, NIH, Bethesda, MD USA; Gen Hosp & Paracelsus Univ Salzburg, Dept Pathol, Salzburg, Austria; Med Univ Vienna, Dept Pathophysiol, Ctr Physiol & Pathophysiol, Vienna, Austria	Salzburg University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Medical University of Vienna	Thalhamer, J (corresponding author), Salzburg Univ, Dept Mol Biol, Div Allergy & Immunol, Christian Doppler Lab Allergy Diagnost & Therapy, Hellbrunnerstasse 34, A-5020 Salzburg, Austria.	Josef.Thalhamer@sbg.ac.at	Weiss, Richard/N-7279-2013; Thalhamer, Josef/E-5787-2011; Gabler, Maximilian/ABG-3105-2020; Leitner, Wolfgang W/F-5741-2011	Weiss, Richard/0000-0003-3185-7253; Thalhamer, Josef/0000-0003-2285-6400; Leitner, Wolfgang W/0000-0003-3125-5922; Scheiblhofer, Sandra/0000-0003-2867-9054; Valenta, Rudolf/0000-0001-5944-3365; Gabler, Maximilian/0000-0002-8860-9675; Vrtala, Susanne/0000-0003-4250-8243	Austrian Science Fund FWF [L 181] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Adel-Patient K, 2001, INT ARCH ALLERGY IMM, V126, P59, DOI 10.1159/000049495; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Berglund P, 1998, NAT BIOTECHNOL, V16, P562, DOI 10.1038/nbt0698-562; CONRY RM, 1995, GENE THER, V2, P59; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hariharan MJ, 1998, J VIROL, V72, P950, DOI 10.1128/JVI.72.2.950-958.1998; Hartl A, 2004, METHODS, V32, P328, DOI 10.1016/j.ymeth.2003.08.014; Hartl A, 1999, J ALLERGY CLIN IMMUN, V103, P107, DOI 10.1016/S0091-6749(99)70533-6; Hartl A, 2004, ALLERGY, V59, P65, DOI 10.1046/j.1398-9995.2003.00335.x; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hochreiter R, 2003, J ALLERGY CLIN IMMUN, V112, P579, DOI 10.1067/mai.2003.1652; Hochreiter R, 2003, EUR J IMMUNOL, V33, P1667, DOI 10.1002/eji.200323377; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Jacquet A, 2003, CLIN EXP ALLERGY, V33, P218, DOI 10.1046/j.1365-2222.2003.01584.x; KAHN P, 2003, IAVI REPORT, V7, P3; Kwon SS, 2001, ALLERGY, V56, P741, DOI 10.1034/j.1398-9995.2001.056008741.x; Laaksonen K, 2003, J ALLERGY CLIN IMMUN, V112, P1171, DOI 10.1016/j.jaci.2003.08.043; Leitner WW, 2004, VACCINE, V22, P1537, DOI 10.1016/j.vaccine.2003.10.013; Leitner WW, 2003, NAT MED, V9, P33, DOI 10.1038/nm813; Leitner WW, 2000, CANCER RES, V60, P51; Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6; Li L, 1998, J IMMUNOL, V161, P3128; LOWRIE DB, 1994, VACCINE, V12, P1537, DOI 10.1016/0264-410X(94)90080-9; MacGregor RB, 2002, AIDS, V16, P2137, DOI 10.1097/00002030-200211080-00005; Peng HJ, 2002, VACCINE, V20, P1761, DOI 10.1016/S0264-410X(02)00029-4; Randolph DA, 1999, J IMMUNOL, V162, P2375; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Restifo NP, 2000, CURR OPIN IMMUNOL, V12, P597, DOI 10.1016/S0952-7915(00)00148-5; Restifo NP, 2001, NAT BIOTECHNOL, V19, P527, DOI 10.1038/89255; Rottinghaus ST, 2003, VACCINE, V21, P4604, DOI 10.1016/S0264-410X(03)00447-X; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Scheiblhofer S, 2003, MICROBES INFECT, V5, P939, DOI 10.1016/S1286-4579(03)00182-5; Scheiblhofer S, 2001, EUR J IMMUNOL, V31, P692, DOI 10.1002/1521-4141(200103)31:3&lt;692::AID-IMMU692&gt;3.0.CO;2-Y; SCHEIBLHOFER S, 2006, METHODS MOL MED DNA; Spies B, 2003, J IMMUNOL, V171, P5908, DOI 10.4049/jimmunol.171.11.5908; ULMEER JB, 1993, SCIENCE, V259, P1748; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; VRTALA S, 1993, J IMMUNOL, V151, P4773; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; Weiss Richard, 2005, Current Drug Targets - Inflammation and Allergy, V4, P585, DOI 10.2174/156801005774322171; Wolfowicz CB, 2003, VACCINE, V21, P1195, DOI 10.1016/S0264-410X(02)00485-1; XU D, 1995, IMMUNOLOGY, V84, P173; Yasumi T, 2005, J IMMUNOL, V174, P1325, DOI 10.4049/jimmunol.174.3.1325; Ying H, 1999, NAT MED, V5, P823, DOI 10.1038/10548	48	29	34	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					734	741		10.1016/j.jaci.2006.04.048	http://dx.doi.org/10.1016/j.jaci.2006.04.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950295				2022-12-18	WOS:000240649000031
J	Bonilla, FA; Geha, RS				Bonilla, FA; Geha, RS			Update on primary immunodeficiency diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetic diseases; human; immunodeficiency; immunology; infection	COMMON VARIABLE IMMUNODEFICIENCY; ANHIDROTIC ECTODERMAL DYSPLASIA; SEVERE CONGENITAL NEUTROPENIA; URACIL-DNA GLYCOSYLASE; LIVE VIRAL VACCINES; B-CELL DEVELOPMENT; DIGEORGE-SYNDROME; GENE-THERAPY; THYMUS TRANSPLANTATION; IGA DEFICIENCY	The pace of discoveryin primary immunodeficiency continues to accelerate. In particular, lymphocyte defects have been the source of the most impressive expansion in recent years. Novel forms of agammaglobulinemia, class-switch defects, and T-B+ severe combined immunodeficiency have been described. Little by little, the genetic heterogeneity of the common variable immumodeficiency and IgA deficiency phenotypes continues to be unraveled as new molecular defects have been reported in these patients as well. The phenotypic spectrum of DiGeorge syndrome has been further developed, along with promising advances in therapy. Defects of nuclear factor kappa B regulation and Toll-like receptor signaling have been described, along with defects of chemokine receptors and cytoplasmic proteases. Clinically defined immunodeficiencies, such as hyper-IgE syndrome and idiopathic CD4 lymphocytopenia, are also discussed. Finally significant adverse effects in some patients have tempered initial enthusiasm for gene therapy.	Childrens Hosp Boston, Div Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Bonilla, FA (corresponding author), Childrens Hosp Boston, Div Immunol, Fegan Bldg,6th Floor,300 Longwood Ave, Boston, MA 02215 USA.	francisco.bonilla@childrens.harvard.edu						Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Binstadt BA, 2003, J ALLERGY CLIN IMMUN, V111, P697, DOI 10.1067/mai.2003.1380; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Check E, 2005, NATURE, V434, P127, DOI 10.1038/434127b; Chinen J, 2003, J ALLERGY CLIN IMMUN, V111, P573, DOI 10.1067/mai.2003.165; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Conley ME, 2005, IMMUNOL REV, V203, P216, DOI 10.1111/j.0105-2896.2005.00233.x; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; De Ravel TJL, 2001, GENET COUNSEL, V12, P379; Devriendt K, 2001, NAT GENET, V27, P313, DOI 10.1038/85886; Diaz GA, 2005, IMMUNOL REV, V203, P235, DOI 10.1111/j.0105-2896.2005.00226.x; Durandy A, 2005, IMMUNOL REV, V203, P67, DOI 10.1111/j.0105-2896.2005.00222.x; Edwards E, 2004, CLIN IMMUNOL, V111, P93, DOI 10.1016/j.clim.2003.12.005; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Ehrlich M, 2003, CLIN IMMUNOL, V109, P17, DOI 10.1016/S1521-6616(03)00201-8; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Grimbacher B, 2005, IMMUNOL REV, V203, P244, DOI 10.1111/j.0105-2896.2005.00228.x; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Imai K, 2003, NAT IMMUNOL, V4, P1023, DOI 10.1038/ni974; Kanegane H, 2000, CLIN EXP IMMUNOL, V120, P512, DOI 10.1046/j.1365-2249.2000.01244.x; Ku CL, 2005, IMMUNOL REV, V203, P10, DOI 10.1111/j.0105-2896.2005.00235.x; Kubota K, 2004, FEBS LETT, V564, P147, DOI 10.1016/S0014-5793(04)00332-1; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Longerich S, 2005, TRENDS GENET, V21, P253, DOI 10.1016/j.tig.2005.02.013; Lougaris V, 2005, IMMUNOL REV, V203, P48, DOI 10.1111/j.0105-2896.2005.00229.x; Markert ML, 2004, BLOOD, V104, P2574, DOI 10.1182/blood-2003-08-2984; Markert ML, 2003, BLOOD, V102, P1121, DOI 10.1182/blood-2002-08-2545; Morra M, 2001, BLOOD, V98, P1321, DOI 10.1182/blood.V98.5.1321; Moylett EH, 2004, CLIN IMMUNOL, V112, P106, DOI 10.1016/j.clim.2004.02.008; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Orange JS, 2002, MICROBES INFECT, V4, P1545, DOI 10.1016/S1286-4579(02)00038-2; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Perez EE, 2003, PEDIATRICS, V112, pE325, DOI 10.1542/peds.112.4.e325; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Renner ED, 2004, J PEDIATR-US, V144, P93, DOI 10.1016/S0022-3476(03)00449-9; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; Sawada A, 2003, J CLIN INVEST, V112, P1707, DOI 10.1172/JCI18937; Scheimberg I, 2001, PEDIATR DEVEL PATHOL, V4, P237, DOI 10.1007/s100240010171; Stewart DM, 2001, CLIN IMMUNOL, V99, P94, DOI 10.1006/clim.2001.5024; Tanaka S, 2004, EUR J PEDIATR, V163, P122, DOI 10.1007/s00431-003-1375-8; Vitale M, 2002, BLOOD, V99, P1723, DOI 10.1182/blood.V99.5.1723; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Yabe T, 2002, BLOOD, V100, P1496, DOI 10.1182/blood-2001-12-0252; Yagi H, 2003, LANCET, V362, P1366, DOI 10.1016/S0140-6736(03)14632-6; Zeidler C, 2002, SEMIN HEMATOL, V39, P82, DOI 10.1053/shem.2002.31913	51	29	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S435	S441		10.1016/j.jaci.2005.09.051	http://dx.doi.org/10.1016/j.jaci.2005.09.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VS	16455342				2022-12-18	WOS:000235865400003
J	Baldassarre, S; Schandene, L; Choufani, G; Michils, A				Baldassarre, S; Schandene, L; Choufani, G; Michils, A			Asthma attacks induced by low doses of celecoxib, aspirin, and acetaminophen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COX-2 INHIBITORS; SAFETY; ROFECOXIB		Erasme Univ Hosp, Chest Dept, B-1070 Brussels, Belgium; Erasme Univ Hosp, Immunol Dept, B-1070 Brussels, Belgium; Erasme Univ Hosp, Ear Nose & Throat Dept, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles	Baldassarre, S (corresponding author), Erasme Univ Hosp, Chest Dept, 808 Route Lennik, B-1070 Brussels, Belgium.							Bavbek S, 2004, J ASTHMA, V41, P67, DOI 10.1081/JAS-120026063; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Kelkar PS, 2001, J RHEUMATOL, V28, P2553; Levy MB, 2001, ANN ALLERG ASTHMA IM, V87, P72, DOI 10.1016/S1081-1206(10)62327-7; Murr D, 2003, ANN DERMATOL VENER, V130, P519; Passero M, 2003, CHEST, V123, P2155, DOI 10.1378/chest.123.6.2155; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Woessner KM, 2004, ANN ALLERG ASTHMA IM, V93, P339, DOI 10.1016/S1081-1206(10)61392-0	9	29	32	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					215	217		10.1016/j.jaci.2005.10.021	http://dx.doi.org/10.1016/j.jaci.2005.10.021			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387610	Bronze			2022-12-18	WOS:000235687100036
J	Goleva, E; Cardona, ID; Ou, LS; Leung, DYM				Goleva, E; Cardona, ID; Ou, LS; Leung, DYM			Factors that regulate naturally occurring T regulatory cell-mediated suppression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T regulatory cells; immune suppression; superantigens; atopic dermatitis	INDUCED TNF RECEPTOR; IMMUNOLOGICAL SELF-TOLERANCE; TRANSCRIPTION FACTOR FOXP3; DENDRITIC CELLS; CUTTING EDGE; AUTOIMMUNE-DISEASE; ATOPIC-DERMATITIS; TRYPTOPHAN CATABOLISM; IMMUNE DYSREGULATION; CLINICAL IMMUNOLOGY	T regulatory (Treg) cells play a key role in the modulation of allergic and autoimmune responses. This review will discuss the factors that regulate naturally occurring Treg (nTreg) cell-mediated suppression. The involvement of cytokines, costimulatory molecules, and ligands; on antigen-presenting cells in the inhibition of nTreg cell-mediated suppression in vitro is summarized. Understanding the events that control suppressive function of nTreg cells will allow manipulation of these cells to inhibit or enhance their functions in the development of novel therapies for autoimmune and allergic diseases.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Chang Gung Childrens Hosp, Dept Pediat, Taoyuan, Taiwan; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; Chang Gung Memorial Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,Room K926i, Denver, CO 80206 USA.	leungd@njc.org			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI052453, R01AI052453, N01AI040029, T32AI007365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676, R01AR041256, R21AR051634] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00051] Funding Source: Medline; NIAID NIH HHS [N01 AI40030, T32 AI 07365, N01 AI40029, AI052453] Funding Source: Medline; NIAMS NIH HHS [AR45676, 5R21AR051634, AR41256] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Balandina A, 2005, BLOOD, V105, P735, DOI 10.1182/blood-2003-11-3900; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bensinger SJ, 2004, J IMMUNOL, V172, P5287, DOI 10.4049/jimmunol.172.9.5287; Bettelli E, 2005, P NATL ACAD SCI USA, V102, P5138, DOI 10.1073/pnas.0501675102; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; CARDONA ID, 2005, J ALLERGY CLIN IMM S, V115, pS271; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chinen J, 2004, J ALLERGY CLIN IMMUN, V114, P398, DOI 10.1016/j.jaci.2004.05.036; Choi BK, 2004, J LEUKOCYTE BIOL, V75, P785, DOI 10.1189/jlb.1003491; Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488; de la Rosa M, 2004, EUR J IMMUNOL, V34, P2480, DOI 10.1002/eji.200425274; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fehervari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495; Fehervari Z, 2004, INT IMMUNOL, V16, P1769, DOI 10.1093/intimm/dxh178; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010; Gondek DC, 2005, J IMMUNOL, V174, P1783, DOI 10.4049/jimmunol.174.4.1783; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823; Kanamaru F, 2004, J IMMUNOL, V172, P7306, DOI 10.4049/jimmunol.172.12.7306; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111/j.1365-2141.2004.04999.x; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158; Kwon B, 2003, EXP MOL MED, V35, P8, DOI 10.1038/emm.2003.2; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Lundgren A, 2005, INFECT IMMUN, V73, P523, DOI 10.1128/IAI.73.1.523-531.2005; Manzotti CN, 2002, EUR J IMMUNOL, V32, P2888, DOI 10.1002/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Mills KHG, 2004, NAT REV IMMUNOL, V4, P841, DOI 10.1038/nri1485; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P635, DOI 10.1016/j.jaci.2004.01.741; Nguyen XD, 2004, J ALLERGY CLIN IMMUN, V114, P296, DOI 10.1016/j.jaci.2004.04.048; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Ochs HD, 2005, IMMUNOL REV, V203, P156, DOI 10.1111/j.0105-2896.2005.00231.x; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pasare C, 2004, IMMUNITY, V21, P733, DOI 10.1016/j.immuni.2004.10.006; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Paust S, 2005, IMMUNOL REV, V204, P195, DOI 10.1111/j.0105-2896.2005.00247.x; Paust S, 2004, P NATL ACAD SCI USA, V101, P10398, DOI 10.1073/pnas.0403342101; Pop SM, 2005, J EXP MED, V201, P1333, DOI 10.1084/jem.20042398; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Scheffold A, 2005, EUR J IMMUNOL, V35, P1336, DOI 10.1002/eji.200425887; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shevach EM, 2001, IMMUNOL REV, V182, P58, DOI 10.1034/j.1600-065X.2001.1820104.x; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Su L, 2004, J IMMUNOL, V173, P4994, DOI 10.4049/jimmunol.173.8.4994; Sugimoto K, 2003, HEPATOLOGY, V38, P1437, DOI 10.1016/j.hep.2003.09.026; Tang QZ, 2003, J IMMUNOL, V171, P3348, DOI 10.4049/jimmunol.171.7.3348; Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519; Thornton AM, 2004, EUR J IMMUNOL, V34, P366, DOI 10.1002/eji.200324455; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Valzasina B, 2005, BLOOD, V105, P2845, DOI 10.1182/blood-2004-07-2959; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Yamano Y, 2005, J CLIN INVEST, V115, P1361, DOI [10.1172/JCI200523913, 10.1172/JCI23913]; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422; Zheng Y, 2004, J IMMUNOL, V172, P2778, DOI 10.4049/jimmunol.172.5.2778	76	29	33	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1094	1100		10.1016/j.jaci.2005.08.051	http://dx.doi.org/10.1016/j.jaci.2005.08.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275382	Bronze			2022-12-18	WOS:000235686700023
J	Santamaria, F; Montella, S; De Stefano, S; Sperli, F; Barbarano, F; Valerio, G				Santamaria, F; Montella, S; De Stefano, S; Sperli, F; Barbarano, F; Valerio, G			Relationship between exhaled nitric oxide and body mass index in children and adolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OBESITY		Univ Naples Federico II, Dept Pediat, I-80131 Naples, Italy; Parthenope Univ, Sch Movement Sci DiSIST, Naples, Italy	University of Naples Federico II; Parthenope University Naples	Santamaria, F (corresponding author), Univ Naples Federico II, Dept Pediat, Via Pansini,5, I-80131 Naples, Italy.		Santamaria, Francesca/AAC-3503-2022	Valerio, Giuliana/0000-0001-5063-4333; Montella, Silvia/0000-0002-3133-1166				Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; de Winter-de Groot KM, 2005, J ALLERGY CLIN IMMUN, V115, P419, DOI 10.1016/j.jaci.2004.11.025; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; Leung TF, 2004, PEDIAT ALLERG IMM-UK, V15, P344, DOI 10.1111/j.1399-3038.2004.00164.x; Lobstein T, 2003, Obes Rev, V4, P195, DOI 10.1046/j.1467-789X.2003.00116.x; Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45	7	29	30	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1163	1164		10.1016/j.jaci.2005.07.018	http://dx.doi.org/10.1016/j.jaci.2005.07.018			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275394				2022-12-18	WOS:000235686700035
J	Shibuya, H; Hirohata, S				Shibuya, H; Hirohata, S			Differential effects of IFN-alpha on the expression of various T(H)2 cytokines in human CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; T(H)1; T(H)2; IL-4; IL-5; IL-13; c-Maf; GATA-3; T-bet; Fox-P3	TRANSCRIPTION FACTOR GATA-3; INTERFERON-ALPHA; GENE-EXPRESSION; FUNCTIONAL DIVERSITY; INTERLEUKIN-5 GENE; TH1 RESPONSES; C-MAF; INDUCTION; IL-4; PROLIFERATION	Background: In both human subjects and mice, T helper cells are classified into 2 subsets, T(H)1 and T(H)2 cells, on the basis of the cytokines they produce. Although IFN-alpha has been shown to enhance human T(H)1 responses, its influences on human T(H)2 responses have not yet been fully characterized. In addition, the mechanism for induction of T(H)1 responses by IFN-alpha has not been fully delineated. Objective: The present study was undertaken to explore the direct effects of IFN-alpha on the expression of various cytokines in human CD4(+) T cells with a system using immobilized anti-CD3, which permits activation of CD4(+) T cells in the complete absence of accessory cells. Methods: Highly purified CD4(+) T cells obtained from healthy donors were stimulated with immobilized anti-CD3 with or without IFN-alpha and IL-12 in the complete absence of accessory cells. The production of cytokines was estimated by means of ELISA. The expression of mRNA for various cytokines, as well as transcription factors, was evaluated by using quantitative PCR. Results: IFN-alpha enhanced IL-4 protein and mRNA expression in immobilized anti-CD3-stimulated CD4(+) T cells, irrespective of the presence of IL-12, whereas IFN-alpha suppressed the expression of IL-5 and IL-13. Of note, IFN-alpha enhanced the expression of mRNA for c-Maf, T-bet, and Fox-P3, irrespective of the presence of IL-12, but not that for GATA-3, in anti-CD3-stimulated CD4(+) T cells. Conclusion: These results indicate that IFN-alpha enhances the induction of T(H)1 responses through upregulation of T-bet mRNA expression, as well as the induction of T(H)2 responses through upregulation of c-Maf mRNA expression, followed by IL-4 expression. Moreover, the data also suggest that IFN-alpha might suppress the expression of IL-5 and IL-13 in differentiated T(H)2 cells.	Teikyo Univ, Sch Med, Dept Internal Med, Itabashi Ku, Tokyo 1738605, Japan	Teikyo University	Hirohata, S (corresponding author), Teikyo Univ, Sch Med, Dept Internal Med, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.	shunsei@med.teikyo-u.ac.jp						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Andreone P, 2004, CYTOKINE, V26, P95, DOI 10.1016/j.cyto.2003.08.014; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; DEMEURE CE, 1994, J IMMUNOL, V152, P4775; Farrar JD, 2002, J CLIN INVEST, V109, P431, DOI 10.1172/JCI200215093; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; GEPPERT TD, 1987, J IMMUNOL, V138, P1660; Hibbert L, 2003, J INTERF CYTOK RES, V23, P513, DOI 10.1089/10799900360708632; Hirohata S, 1999, CLIN EXP IMMUNOL, V115, P78; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; JUNG T, 1995, EUR J IMMUNOL, V25, P2413, DOI 10.1002/eji.1830250843; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; Kelly BL, 2000, J IMMUNOL, V165, P2982, DOI 10.4049/jimmunol.165.6.2982; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Lavenu-Bombled C, 2002, J BIOL CHEM, V277, P18313, DOI 10.1074/jbc.M110013200; Lichtman AH, 1997, CURR BIOL, V7, P242; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Parronchi P, 1996, EUR J IMMUNOL, V26, P697, DOI 10.1002/eji.1830260328; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Rogge L, 1998, J IMMUNOL, V161, P6567; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Schandene L, 1996, J CLIN INVEST, V97, P309, DOI 10.1172/JCI118417; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Shibuya H, 2003, CLIN EXP IMMUNOL, V132, P216, DOI 10.1046/j.1365-2249.2003.02128.x; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; TENDLER CL, 1994, CANCER RES, V54, P4430; Terabe M, 2004, CANCER IMMUNOL IMMUN, V53, P79, DOI 10.1007/s00262-003-0445-0; Wu CY, 2000, EUR J IMMUNOL, V30, P1364, DOI 10.1002/(SICI)1521-4141(200005)30:5<1364::AID-IMMU1364>3.0.CO;2-U; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	39	29	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					205	212		10.1016/j.jaci.2005.03.016	http://dx.doi.org/10.1016/j.jaci.2005.03.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990796				2022-12-18	WOS:000235686300031
J	Cabana, MD; Le, TT				Cabana, MD; Le, TT			Challenges in asthma patient education	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						counseling; chronic disease management; health care providers; Internet; educational technology	SELF-MANAGEMENT; HEALTH; PHYSICIAN; CARE; INTERNET; IMPACT		Univ Michigan, Hlth Syst, Div Gen Pediat, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; Johns Hopkins Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD USA	University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins Medicine	Cabana, MD (corresponding author), Univ Michigan, Hlth Syst, Div Gen Pediat, Dept Pediat & Communicable Dis, 6-D-19 NIB,Box 0456,300 N Ingalls St, Ann Arbor, MI 48109 USA.	mcabana@med.umich.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007056] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 70771] Funding Source: Medline; NIAID NIH HHS [T32 AI 07056] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams William G, 2003, AMIA Annu Symp Proc, P1; Brach C, 2000, MED CARE RES REV, V57, P181, DOI 10.1177/107755800773743655; Bruzzese JM, 2004, PATIENT EDUC COUNS, V55, P396, DOI 10.1016/j.pec.2003.04.009; Cabana MD, 2004, CLIN PEDIATR, V43, P269, DOI 10.1177/000992280404300308; Cabana MD, 2003, J PEDIATR-US, V143, P413, DOI 10.1067/S0022-3476(03)00438-4; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; Clark Noreen M, 2003, Paediatr Respir Rev, V4, P325, DOI 10.1016/S1526-0542(03)00091-5; Couturaud F, 2002, J ASTHMA, V39, P493, DOI 10.1081/JAS-120004913; Croft DR, 2002, CHEST, V121, P1301, DOI 10.1378/chest.121.4.1301; Druss BG, 2003, NEW ENGL J MED, V348, P130, DOI 10.1056/NEJMsa020993; George M, 2001, HEART LUNG, V30, P392, DOI 10.1067/mhl.2001.118364; Hoskins G, 2001, J Am Acad Nurse Pract, V13, P376; Katon W, 2001, GEN HOSP PSYCHIAT, V23, P138, DOI 10.1016/S0163-8343(01)00136-0; Krishna S, 2003, PEDIATRICS, V111, P503, DOI 10.1542/peds.111.3.503; Murray E, 2003, ARCH INTERN MED, V163, P1727, DOI 10.1001/archinte.163.14.1727; *NATL HEART LUNG B, 1997, 974051 NIH; Oermann Marilyn H, 2003, J Pediatr Nurs, V18, P389, DOI 10.1016/S0882-5963(03)00161-1; Perneger TV, 2002, AM J MED, V113, P7, DOI 10.1016/S0002-9343(02)01136-1; Robertson R, 1997, FAM PRACT, V14, P227, DOI 10.1093/fampra/14.3.227; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Schreurs KMG, 2003, PATIENT EDUC COUNS, V51, P133, DOI 10.1016/S0738-3991(02)00197-0; Sockrider MM, 2004, PEDIATR PULM, P183, DOI 10.1002/ppul.70100; Toelle BG, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002171.PUB2; Walters JAE, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001288.pub3; Wolf FM, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000326; Yawn BP, 2000, J SCHOOL HEALTH, V70, P153, DOI 10.1111/j.1746-1561.2000.tb06462.x	26	29	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1225	1227		10.1016/j.jaci.2005.03.004	http://dx.doi.org/10.1016/j.jaci.2005.03.004			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940138				2022-12-18	WOS:000229815400018
J	Bossuyt, X; Marien, G; Meyts, I; Proesmans, M; De Boeck, K				Bossuyt, X; Marien, G; Meyts, I; Proesmans, M; De Boeck, K			Determination of IgG subclasses: A need for standardization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Hosp Leuven, Lab Med, Louvain, Belgium; Univ Hosp Leuven, Dept Pediat, Louvain, Belgium	KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven	Bossuyt, X (corresponding author), Univ Hosp Leuven, Lab Med, Louvain, Belgium.		Bossuyt, Xavier/B-2085-2019; Meyts, Isabelle/Z-3295-2019	Bossuyt, Xavier/0000-0001-6856-8485; 				Clinical and Laboratory Standards Institute, 2004, EP5A2 CLSI; KLEIN F, 1985, CLIN CHIM ACTA, V150, P119, DOI 10.1016/0009-8981(85)90262-1; Schauer U, 2003, CLIN CHEM, V49, P1924, DOI 10.1373/clinchem.2003.022350; VLUG A, 1994, ANN BIOL CLIN-PARIS, V52, P561	4	29	30	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					872	874		10.1016/j.jaci.2005.01.039	http://dx.doi.org/10.1016/j.jaci.2005.01.039			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806013				2022-12-18	WOS:000228373400032
J	Galli, SJ				Galli, SJ			Pathogenesis and management of anaphylaxis: Current status and future challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							FC-EPSILON-RI; MAST-CELL; HIGH-AFFINITY; IGE; EXPRESSION; ANTIBODY; RECEPTOR; MOUSE		Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University	Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu						BOCK G, 2004, ANAPHYLAXIS; DUPLAY D, 2004, PHYS DESK REF; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; GRUPE SL, 2005, J ALLERGY CLIN IMMUN, V115, pS483; Hamilton RG, 2005, J ALLERGY CLIN IMMUN, V115, P648, DOI 10.1016/j.jaci.2004.12.007; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; Johansson SGO, 2005, J ALLERGY CLIN IMMUN, V115, P644, DOI 10.1016/j.jaci.2004.11.027; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kirkpatrick CH, 2005, J ALLERGY CLIN IMMUN, V115, P642, DOI 10.1016/j.jaci.2004.12.010; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI 10.1016/j.jaci.2005.01.009; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAMPSON HA, 2004, ANAPHYLAXIS, P161; SCHWARTZ LB, 2004, ANAPHYLAXIS, P65; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Simons FER., 1994, ANCESTORS ALLERGY; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663	25	29	30	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					571	574		10.1016/j.jaci.2004.12.1133	http://dx.doi.org/10.1016/j.jaci.2004.12.1133			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753906				2022-12-18	WOS:000227687000021
J	Upham, JW; Holt, PG; Taylor, A; Thornton, CA; Prescott, SL				Upham, JW; Holt, PG; Taylor, A; Thornton, CA; Prescott, SL			HLA-DR expression on neonatal monocytes is associated with allergen-specific immune responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						neonatal immune junction; allergy; monocytes; B cells; antigen-presenting cells	CORD-BLOOD; T-CELL; DENDRITIC CELLS; INTERFERON-GAMMA; INHALANT ALLERGENS; VACCINE ANTIGENS; EARLY-CHILDHOOD; EARLY-LIFE; IFN-GAMMA; MICE	Background: The specific mechanisms regulating priming of T-cell immunity to common allergens during early childhood remain to be elucidated, though increasing evidence indicates that antigen-presenting cell function is impaired in childhood. Objective: Examine the relationship between HLA-DR expression on monocytes and B cells, allergen-specific T-cell responses at birth, and clinical outcomes at 2 years of age. Methods: Blood mononuclear cells were obtained from 36 healthy neonates who were followed up clinically to the age of 2 years. Expression of HLA-DR by monocytes and B cells was determined at baseline and after in vitro exposure to IFN-gamma, a cytokine that is known to upregulate the expression of HLA-DR. Mononuclear cells were stimulated with endotoxin or a panel of inhalant and food allergens, and cytokine responses and lymphoproliferation were determined after 1 and 5 days, respectively. Results: The magnitude of HLA-DR upregulation on IFN-gamma-stimulated cord blood CD14(+) monocytes was consistently correlated with allergen-induced, but not mitogen-induced, lymphoproliferation at birth. HLA-DR upregulation on monocytes was also positively associated with endotoxin-induced IL-12 p70 synthesis (tau = 0.46; P < .001) but inversely related to mite- and ovalbumin-induced IL-13 synthesis (P = .0006 and P < .003, respectively). HLA-DR expression on unstimulated cord blood monocytes was inversely associated with symptoms of atopic disease at the 2-year follow-up (P = .015). In contrast, HLA-DR expression on B cells was not associated with these parameters of immune function. Conclusions: These findings suggest that the maturity of neonatal monocytes and their responsiveness to external stimuli are linked to differing patterns of immune reactivity at birth and to the risk of allergic symptoms in early childhood.	Univ Western Australia, Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA 6872, Australia; Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6872, Australia; Univ Coll Swansea, Sch Med, Swansea, W Glam, Wales	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia; Swansea University	Upham, JW (corresponding author), Univ Western Australia, Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	johnu@ichr.uwa.edu.au	Upham, John/F-4420-2010; Prescott, Susan/H-5665-2014; Holt, Patrick/H-1548-2011	Upham, John/0000-0002-0017-3433; Holt, Patrick/0000-0003-1193-0935				Adkins B, 1998, J IMMUNOL, V160, P4217; Adkins P, 2001, J IMMUNOL, V166, P918, DOI 10.4049/jimmunol.166.2.918; Ausiello CM, 1999, INFECT IMMUN, V67, P4064, DOI 10.1128/IAI.67.8.4064-4071.1999; Barrios C, 1996, EUR J IMMUNOL, V26, P2666, DOI 10.1002/eji.1830261118; Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Delespesse G, 1998, VACCINE, V16, P1415, DOI 10.1016/S0264-410X(98)00101-7; Devereux G, 2001, CLIN EXP ALLERGY, V31, P1686, DOI 10.1046/j.1365-2222.2001.01215.x; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Guo TL, 1996, CELL IMMUNOL, V171, P1, DOI 10.1006/cimm.1996.0166; Hammad H, 2002, J IMMUNOL, V169, P1524, DOI 10.4049/jimmunol.169.3.1524; Hassan J, 2001, J IMMUNOL, V167, P1970, DOI 10.4049/jimmunol.167.4.1970; Holt PG, 2000, AM J RESP CRIT CARE, V162, pS91, DOI 10.1164/ajrccm.162.supplement_2.ras-7; Hornell TMC, 2003, J IMMUNOL, V171, P2374, DOI 10.4049/jimmunol.171.5.2374; HUNT DWC, 1994, BLOOD, V84, P4333, DOI 10.1182/blood.V84.12.4333.bloodjournal84124333; Koppelman B, 1997, IMMUNITY, V7, P861, DOI 10.1016/S1074-7613(00)80404-5; LITTMAN BH, 1989, J IMMUNOL, V142, P520; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MARODI L, 1994, J IMMUNOL, V153, P5643; Martinez X, 1997, P NATL ACAD SCI USA, V94, P8726, DOI 10.1073/pnas.94.16.8726; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; Matthews NC, 2000, J IMMUNOL, V164, P6206, DOI 10.4049/jimmunol.164.12.6206; Min BK, 2000, CELL IMMUNOL, V200, P45, DOI 10.1006/cimm.2000.1618; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Smillie FI, 2001, CLIN EXP ALLERGY, V31, P1194, DOI 10.1046/j.1365-2222.2001.01173.x; Snijders A, 1998, CLIN EXP IMMUNOL, V111, P472; TAYLOR S, 1985, J IMMUNOL, V134, P1493; Trivedi HN, 1997, HUM IMMUNOL, V57, P69, DOI 10.1016/S0198-8859(97)00202-4; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; Varis I, 2001, EUR J HAEMATOL, V66, P107, DOI 10.1034/j.1600-0609.2001.00281.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WILSON CB, 1986, J CLIN INVEST, V77, P860, DOI 10.1172/JCI112383; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x; ZOLA H, 1995, PEDIATR RES, V38, P397, DOI 10.1203/00006450-199509000-00021	38	29	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1202	1208		10.1016/j.jaci.2004.06.051	http://dx.doi.org/10.1016/j.jaci.2004.06.051			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536432				2022-12-18	WOS:000225047800031
J	Wolff, N; Yannai, S; Karin, N; Levy, Y; Reifen, R; Dalai, I; Cogan, U				Wolff, N; Yannai, S; Karin, N; Levy, Y; Reifen, R; Dalai, I; Cogan, U			Identification and characterization of linear B-cell epitopes of beta-globulin, a major allergen of sesame seeds	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergenicity; sesame seeds; major allergen; IgE; amino acid sequence; peptide synthesis; epitopes	IGE-BINDING EPITOPES; STORAGE PROTEINS; 2S ALBUMIN; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; FOOD ALLERGENS; HYPERSENSITIVITY; ANAPHYLAXIS	Background: The increased consumption of foods containing sesame seeds is paralleled by an increase in reported sesame-induced allergic reactions. Objective: This study aimed at identifying and characterizing the linear B-cell epitopes of the 14-kd beta-globulin, the major allergen of sesame seed. Methods: A peptide containing 71 amino acids (peptide B) was previously identified by us as the IgE-binding region on beta-globulin. To determine the amino acid sequence of the IgE-binding sites on peptide B, we synthesized overlapping peptides 20 and 10 amino acid residues long that span the entire length of peptide B, which were offset from each other by 10 and 2 amino acid residues, respectively. Sera from 20 subjects given diagnoses of allergy to sesame beta-globulin served to identify the epitopes by using the dot-blot test. Results: At least 9 different IgE-recognition sites were identified on peptide B. Three of them, numbers 2, 3, and 13 (corresponding to amino acids 46-55, 48-57, and 76-86, respectively, in the beta-globulin sequence), appeared to be immunodominant IgE-binding epitopes. Also, these peptides were best recognized in terms of intensity of response. There was no obvious sequence motif shared by the 9 different IgE-binding epitopes of beta-globulin. However, approximately 60% of the amino acids represented in the epitopes are hydrophobic residues. Conclusion: Identification of the IgE-binding epitopes might provide a better understanding of the functional role the allergens play in the disease and might have implications for immunodiagnosis and probably immunotherapy.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Fac Med, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Immunol, Fac Med, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel; Schneider Children Med Ctr, Kipper Inst Immunol, Petah Tiqwa, Israel; E Wolfson Med Ctr, Pediat Allergy & Clin Immunol Unit, Dept Pediat, Holon, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Tel Aviv University; Sackler Faculty of Medicine	Cogan, U (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Fac Med, IL-32000 Haifa, Israel.	cogan@tx.technion.ac.il						Alday E, 1996, ALLERGY, V51, P69, DOI 10.1111/j.1398-9995.1996.tb00019.x; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; Banerjee B, 1999, INFECT IMMUN, V67, P2284, DOI 10.1128/IAI.67.5.2284-2291.1999; Bashir MEH, 1998, INT ARCH ALLERGY IMM, V115, P73, DOI 10.1159/000023833; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOKE SK, 1997, J IMMUNOL, V100, P171; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; ELSAYED S, 1989, INT ARCH ALLER A IMM, V89, P410, DOI 10.1159/000234984; Fuchs RL, 1996, FOOD TECHNOL-CHICAGO, V50, P83; Hamelmann E, 2002, ALLERGY, V57, P983, DOI 10.1034/j.1398-9995.2002.02165.x; HARAHISHIMURA I, 1993, PLANT J, V4, P793, DOI 10.1046/j.1365-313X.1993.04050793.x; Hefle SL, 1996, FOOD TECHNOL-CHICAGO, V50, P86; HERIAN A, 1990, INT ARCH ALLER A IMM, V92, P192; KAGI MK, 1993, ANN ALLERGY, V71, P127; Kanny G, 1996, ALLERGY, V51, P952; KoloppSarda MN, 1997, CLIN EXP ALLERGY, V27, P1285, DOI [10.1046/j.1365-2222.1997.1490951.x, 10.1111/j.1365-2222.1997.tb01173.x]; Lehrer SB, 1996, CRIT REV FOOD SCI, V36, P553, DOI 10.1080/10408399609527739; LEIMGRUBER A, 1991, CLIN EXP ALLERGY, V21, P127, DOI 10.1111/j.1365-2222.1991.tb00814.x; MALISH D, 1981, J ALLERGY CLIN IMMUN, V67, P35, DOI 10.1016/0091-6749(81)90042-7; PADLAN EA, 1992, STRUCTURE ANTIGENS, V1, P29; Pajno GB, 2000, ALLERGY, V55, P199, DOI 10.1034/j.1398-9995.2000.00494.x; Pastorello EA, 2001, J CHROMATOGR B, V756, P85, DOI 10.1016/S0378-4347(01)00073-1; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Reese G, 2001, J CHROMATOGR B, V756, P157, DOI 10.1016/S0378-4347(01)00104-9; Selo I, 1999, CLIN EXP ALLERGY, V29, P1055, DOI 10.1046/j.1365-2222.1999.00612.x; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Stickler M, 2003, ENVIRON HEALTH PERSP, V111, P251, DOI 10.1289/ehp.5707; Tai SSK, 1999, J AGR FOOD CHEM, V47, P4932, DOI 10.1021/jf990366z; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Wigotzki M, 2000, FOOD AGR IMMUNOL, V12, P217, DOI 10.1080/09540100050140759; Wolff N, 2003, FOOD CHEM TOXICOL, V41, P1165, DOI 10.1016/S0278-6915(03)00107-8	37	29	34	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1151	1158		10.1016/j.jaci.2004.07.038	http://dx.doi.org/10.1016/j.jaci.2004.07.038			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536424				2022-12-18	WOS:000225047800024
J	Alam, R; Busse, WW				Alam, R; Busse, WW			The eosinophil - Quo vadis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							PULMONARY FIBROSIS; AIRWAY EOSINOPHILS; T-CELLS; INFLAMMATION; ASTHMA; EXPRESSION; IL-5; HYPERRESPONSIVENESS; MEMBRANE; PROTEIN		Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Natl Jewish Med & Res Ctr, Div Allergy & Immunol, Denver, CO USA; Univ Wisconsin, Sch Med, Dept Med, Allergy & Clin Immunol Sect, Madison, WI USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin Hosp, Dept Med, Clin Sci Ctr K4 912, 600 Highland Ave, Madison, WI 53792 USA.							Amin K, 2000, AM J RESP CRIT CARE, V162, P2295, DOI 10.1164/ajrccm.162.6.9912001; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P3, DOI 10.1016/j.jaci.2003.09.046; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Dombrowicz D, 2001, CURR OPIN IMMUNOL, V13, P716, DOI 10.1016/S0952-7915(01)00284-9; DUNNILL MS, 1990, HISTOPATHOLOGY, V16, P321, DOI 10.1111/j.1365-2559.1990.tb01135.x; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foster PS, 2001, IMMUNOL REV, V179, P173, DOI 10.1034/j.1600-065X.2001.790117.x; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leiferman KM, 2004, J ALLERGY CLIN IMMUN, V113, P50, DOI 10.1016/j.jaci.2003.10.051; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; O'Byrne PM, 2001, J ALLERGY CLIN IMMUN, V108, P503, DOI 10.1067/mai.2001.119149; Phipps S, 2002, J IMMUNOL, V169, P4604, DOI 10.4049/jimmunol.169.8.4604; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shinkai K, 2002, NATURE, V420, P825, DOI 10.1038/nature01202; THRALL RS, 1990, AM REV RESPIR DIS, V126, P488; van Rijt LS, 2003, J IMMUNOL, V171, P3372, DOI 10.4049/jimmunol.171.7.3372; Wang SH, 2001, J IMMUNOL, V166, P2741, DOI 10.4049/jimmunol.166.4.2741; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9; Woodruff PG, 2001, J ALLERGY CLIN IMMUN, V108, P753, DOI 10.1067/mai.2001.119411; Yang D, 2003, BLOOD, V102, P3396, DOI 10.1182/blood-2003-01-0151; Ying S, 1999, J IMMUNOL, V163, P6321	30	29	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					38	42		10.1016/j.jaci.2003.10.054	http://dx.doi.org/10.1016/j.jaci.2003.10.054			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713905				2022-12-18	WOS:000187837900004
J	Rafatpanah, H; Bennett, E; Pravica, V; McCoy, MJ; David, TJ; Hutchinson, IV; Arkwright, PD				Rafatpanah, H; Bennett, E; Pravica, V; McCoy, MJ; David, TJ; Hutchinson, IV; Arkwright, PD			Association between novel GM-CSF gene polymorphisms and the frequency and severity of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; skin; atopic dermatitis; cytokines; GM-CSF; IL-I beta; TNF-alpha; gene polymorphisms	TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; DENDRITIC CELLS; CHILDHOOD ASTHMA; LANGERHANS CELLS; TNF-ALPHA; ACTIVATION; TNF-ALPHA-308; KERATINOCYTES; MATURATION	Background: Genetic factors are known to be important in determining an individual's predisposition to atopic dermatitis. The specific genes that are clinically important in this process are still largely unknown. Objective: Because dendritic cells initiate immune responses and thus are critical to the priming of an individual to potential allergens, we hypothesized that genetic factors controlling the activity of these cells determine an individual's propensity to atopic dermatitis. Methods: We studied known functional polymorphisms of the IL-1beta and TNF-alpha genes and describe novel polymorphisms of the GM-CSF gene in 113 children with atopic dermatitis and 114 controls. All 3 factors are known to be important modulators of the function of skin Langerhans' (dendritic) cells. Results: The inheritance of a homozygous GM-CSF -677*C/C genotype was associated with complete absence of severe atopic dermatitis within this cohort of children (P < .001). Furthermore, the odds ratio of having atopic dermatitis in children who were not of this genotype was 7.5 (2.2-25). Conclusion: The GM-CSF genotype is an important genetic marker predicting an individual's predisposition to atopic dermatitis.	Univ Manchester, Acad Unit Child Hlth, Manchester, Lancs, England; Univ Manchester, Sch Biol Sci, Immunol Res Grp, Manchester, Lancs, England	University of Manchester; University of Manchester	Arkwright, PD (corresponding author), Univ Manchester, Booth Hall Childrens Hosp, Acad Unit Child Hlth, Charleston Rd, Manchester M9 7AA, Lancs, England.		Arkwright, Peter/C-5149-2012; Rafatpanah, Houshang/O-7391-2018	Rafatpanah, Houshang/0000-0002-1061-5864; Arkwright, Peter/0000-0002-7411-5375				Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; Anderson GG, 1998, ARCH DIS CHILD, V78, P488, DOI 10.1136/adc.78.5.488; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V108, P281, DOI 10.1067/mai.2001.117259; Crossley M, 1996, MOL CELL BIOL, V16, P1695; EMERY AEH, 1986, METHODOLOGY MED GENE, P3; FIORENTINI P, 1995, BIOCHEM BIOPH RES CO, V214, P1015, DOI 10.1006/bbrc.1995.2387; Forrest S, 1999, J ALLERGY CLIN IMMUN, V104, P1066, DOI 10.1016/S0091-6749(99)70090-4; Geissmann F, 1999, J IMMUNOL, V162, P4567; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; He JQ, 2003, CHEST, V123, p438S, DOI 10.1378/chest.123.3_suppl.438S; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; Lee HJ, 2000, ANN ALLERG ASTHMA IM, V84, P553, DOI 10.1016/S1081-1206(10)62522-7; Lin YC, 2002, ALLERGY, V57, P831, DOI 10.1034/j.1398-9995.2002.23719.x; Louis R, 2000, EUR RESPIR J, V16, P604, DOI 10.1034/j.1399-3003.2000.16d06.x; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Pastore S, 2000, J INVEST DERMATOL, V115, P1134, DOI 10.1046/j.1523-1747.2000.00149.x; Perrey C, 1999, TRANSPL IMMUNOL, V7, P127, DOI 10.1016/S0966-3274(99)80030-6; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; Strobl H, 1999, MICROBES INFECT, V1, P1283, DOI 10.1016/S1286-4579(99)00256-7; Strobl H, 1996, J IMMUNOL, V157, P1499; SUMIMOTO S, 1992, ARCH DIS CHILD, V67, P277, DOI 10.1136/adc.67.3.277; Sumiyoshi K, 2002, CLIN EXP ALLERGY, V32, P309, DOI 10.1046/j.1365-2222.2002.01221.x; TAGIEV AF, 1995, GENETIKA+, V31, P1370; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Winchester EC, 2000, HUM GENET, V107, P591, DOI 10.1007/s004390000410; Witte JS, 2002, EUR J HUM GENET, V10, P82, DOI 10.1038/sj.ejhg.5200746	33	29	30	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					593	598		10.1067/mai.2003.1699	http://dx.doi.org/10.1067/mai.2003.1699			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679820				2022-12-18	WOS:000185231200020
J	Liu, YH; Kao, MC; Lai, YL; Tsai, JJ				Liu, YH; Kao, MC; Lai, YL; Tsai, JJ			Efficacy of local nasal immunotherapy for Dp2-induced airway inflammation in mice: Using Dp2 peptide and fungal immunomodulatory peptide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						local nasal immunotherapy; group 2 allergen of Dermatophagoides; pteronyssinus; Dp2 epitope peptides; fungal immunomodulatory peptide	RAGWEED-ALLERGIC RHINITIS; BEE VENOM IMMUNOTHERAPY; DUST MITE ALLERGEN; CPG OLIGODEOXYNUCLEOTIDES; INTRANASAL IMMUNOTHERAPY; MURINE MODEL; IFN-GAMMA; RESPONSES; IGE; DNA	Background: Local nasal immunotherapy (LNIT) is an effective immunotherapy. Peptides derived from the group 2 allergen of Dermatophagoides pteronyssinus, Dp2 28-40 and Dp2 28-40A, and fungal immunomodulatory peptide (FIP) have been shown to act as T(H)1 potential and response-inducing adjuvant. LNIT by the use of Dp2 peptides in conjunction with FIP were investigated. Objective: We sought to determine whether Dp2-induced airway inflammation in mice could be downregulated by Dp2 peptides or a mixture of Dp2 peptides with FIP. Method: Mice were sensitized with rDp2 followed by LNIT with Dp2 peptides, FIP, or FIP and a mixture of Dp2 peptides. After intratracheal challenge with rDp2, the airway inflammation and hyperresponsiveness were determined by bronchoalveolar lavage fluid (BALF) analysis and methacholine challenge. Results: Both Dp2 peptides and FIP were able to inhibit rDp2-induced airway inflammation and airway hyperresponsiveness. An increase in IFN-gamma and a decrease in IL-5 in BALF and sera were found after LNIT with Dp2 peptides, FIP, and mixtures of both. Serum levels of TGF-beta were reduced after LNIT with FIP and Dp2 28-40. Penh values were significantly decreased after methacholine challenge in both the early and late phase. Conclusions: LNIT with allergen-derived peptides and FIP can produce an anti-inflammatory effect on allergen-induced airway inflammation. LNIT with selected peptides and FIP might be a good alternative therapy for allergic airway disease.	Cathay Gen Hosp, Sect Allergy & Immunol, Taipei 112, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Physiol, Taipei 10764, Taiwan	Cathay General Hospital; National Taiwan University	Tsai, JJ (corresponding author), Cathay Gen Hosp, Sect Allergy & Immunol, No 280 Sect 4,Jen Ai Rd, Taipei 112, Taiwan.							ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Bertoni M, 1999, ANN ALLERG ASTHMA IM, V82, P47, DOI 10.1016/S1081-1206(10)62659-2; BJORKSTEN B, 1994, ALLERGY, V49, P299, DOI 10.1111/j.1398-9995.1994.tb02271.x; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Broide D, 1998, J IMMUNOL, V161, P7054; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; FOX PC, 1981, IMMUNOLOGY, V43, P227; GEORGITIS JW, 1984, J ALLERGY CLIN IMMUN, V74, P694, DOI 10.1016/0091-6749(84)90232-X; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V75, P496, DOI 10.1016/S0091-6749(85)80023-3; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Jahn-Schmid B, 1999, J ALLERGY CLIN IMMUN, V104, P1015, DOI 10.1016/S0091-6749(99)70083-7; Jarnicki AG, 2002, J ALLERGY CLIN IMMUN, V110, P610, DOI 10.1067/mai.2002.128485; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kline JN, 1998, J IMMUNOL, V160, P2555; KO JL, 1995, EUR J BIOCHEM, V228, P244, DOI 10.1111/j.1432-1033.1995.tb20256.x; Leong KP, 2001, ANN ALLERG ASTHMA IM, V87, P96, DOI 10.1016/S1081-1206(10)62201-6; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1983, CLIN ALLERGY, V13, P509, DOI 10.1111/j.1365-2222.1983.tb02632.x; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Smith AM, 1999, LUNG BIOL HEALTH DIS, V136, P99; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; Sun SQ, 1998, J EXP MED, V187, P1145, DOI 10.1084/jem.187.7.1145; Sur S, 1999, J IMMUNOL, V162, P6284; Tsai JJ, 2000, INT ARCH ALLERGY IMM, V121, P205, DOI 10.1159/000024318; Tsitoura DC, 1996, J IMMUNOL, V157, P2160; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Verhoef A, 2000, J IMMUNOL, V164, P6034, DOI 10.4049/jimmunol.164.11.6034; WELSH PW, 1983, J ALLERGY CLIN IMMUN, V71, P454, DOI 10.1016/0091-6749(83)90461-X; Wiedermann U, 1999, INT IMMUNOL, V11, P1715, DOI 10.1093/oxfordjournals.intimm.a019877	42	29	36	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					301	310		10.1067/mai.2003.1619	http://dx.doi.org/10.1067/mai.2003.1619			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897735	Bronze			2022-12-18	WOS:000184650600013
J	Lindqvist, A; Karjalainen, EM; Laitinen, LA; Kava, T; Altraja, A; Pulkkinen, M; Halme, M; Laitinen, A				Lindqvist, A; Karjalainen, EM; Laitinen, LA; Kava, T; Altraja, A; Pulkkinen, M; Halme, M; Laitinen, A			Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: A randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; salmeterol; fluticasone; cromoglycate; inflammation; tenascin; bronchial biopsy	BRONCHOALVEOLAR LAVAGE; INHALED FORMOTEROL; INFLAMMATION; BUDESONIDE; APOPTOSIS; ALBUTEROL; TENASCIN; SYMPTOMS; AGONIST; INDEXES	Background: Salmeterol (SLM) is a long-acting beta(2)-receptor agonist that produces bronchodilatation for 12 hours in asthmatic subjects. The effects of the regular use of long-acting beta(2)-agonists on airway inflammation are largely unknown. Objectives: We examined the effects of 16 weeks of treatment with 50 mug SLM bid, 250 mug fluticasone propionate (FP) bid, 5 mg disodium cromoglycate (DSCG) qid, or placebo on airway inflammation in bronchial mucosa. Methods: Airway inflammation was assessed in bronchial biopsy specimens before and after treatments and bronchial hyperresponsiveness (BHR) in 80 patients with newly diagnosed asthma. Inflammatory cells and tenascin in the basement membrane were studied with immunohistochemical methods. Peak expiratory flow rate (PEF), symptoms, and need for rescue medication were recorded. Results: SLM, FP, and DSCG reduced symptoms and need for rescue medication (P < .04). Both SLM and FP improved PEF and increased PD15FEV(1) to histamine by 2.8 and 5.2 doubling dose units, respectively. Both compounds reduced BHR more than placebo (P < .05). Both SLM and placebo had no effect on any inflammatory cell type. In both FP-treated and DSCG-treated patients, the number of EG2-positive eosinophils in the airway mucosa decreased (P = .002 and P < .05, respectively). Conclusions: SLM showed no anti-eosinophil properties in this study, but it provided good symptom control. FP provided the best anti-eosinophil properties and symptom relief of the studied compounds.	Univ Helsinki, Cent Hosp, Dept Med, Clin Res Unit Pulm Med, Helsinki, Finland; N Carelia Cent Hosp, Dept Pulm Med, Joensuu, Finland; Univ Helsinki, Inst Biomed, Dept Anat, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Laitinen, A (corresponding author), Hosp Dist Helsinki & Uusimaa, POB 100, Helsinki 00029, Finland.							Altraja A, 1999, RESP MED, V93, P445, DOI 10.1016/S0954-6111(99)90086-0; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Boulet LP, 2001, CLIN EXP ALLERGY, V31, P430, DOI 10.1046/j.1365-2222.2001.01014.x; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Jeffery PK, 2000, RESP MED, V94, pS9, DOI 10.1016/S0954-6111(00)90127-6; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Kraft M, 1997, CHEST, V111, P1249, DOI 10.1378/chest.111.5.1249; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; *NAT HEART BLOOD L, 1997, NIH PUBL; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Siegel S., 1988, NONPARAMETRIC STAT B, V2nd; SOLER M, 1994, EUR RESPIR J, V7, P1973; SOVIJARVI ARA, 1993, CHEST, V104, P164, DOI 10.1378/chest.104.1.164; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; Viljanen AA, 1982, SCAND J CLIN INVES S, V42, P1; Wallin A, 1999, AM J RESP CRIT CARE, V159, P79, DOI 10.1164/ajrccm.159.1.9801007; Zhang XZ, 2000, EUR J PHARMACOL, V406, P325, DOI 10.1016/S0014-2999(00)00690-7	27	29	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					23	28		10.1067/mai.2003.1500	http://dx.doi.org/10.1067/mai.2003.1500			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847475	Bronze			2022-12-18	WOS:000184010600005
J	Dorscheid, DR; Low, E; Conforti, A; Shifrin, S; Sperling, AI; White, SR				Dorscheid, DR; Low, E; Conforti, A; Shifrin, S; Sperling, AI; White, SR			Corticosteroid-induced apoptosis in mouse airway epithelium: Effect in normal airways and after allergen-induced airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway epithelium; apoptosis; corticosteroids	PROGRAMMED CELL-DEATH; IN-VITRO; ASTHMA; GLUCOCORTICOIDS; PROLIFERATION; INJURY	Background: Damage to the airway epithelium is one prominent feature of the damage seen in chronic asthma. Corticosteroids induce apoptosis in inflammatory cells, which in part explains their ability to suppress airway inflammation. However, corticosteroid therapy does not necessarily reverse the epithelial damage seen in asthmatic airways. Objective: We hypothesized that corticosteroids might induce airway epithelial cell apoptosis as one potential explanation for this persistent damage. Methods: BALB/c mice were treated with 1 mg/kg dexamethasone by means of intraperitoneal injection for 3 days to 4 weeks. Additional mice were sensitized and challenged with ovalbumin and then followed for 14 days with or without dexamethasone treatment starting on day 4 after challenge. Apoptosis was measured by using terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling and immunohistochemistry for the p85 cleavage product of poly (adenosine diphosphate-ribose) polymerase. Shed epithelial cells were counted in bronchoalveolar lavage fluid. Results: In a time-dependent manner dexamethasone treatment increased epithelial cell apoptosis and shedding into the airway lumen. This was not associated with any change in the abundance of the apoptotic regulator Bcl-x(L). In animals sensitized and challenged with ovalbumin, treatment with 1 mg/kg dexamethasone starting 4 days after challenge reversed the inflammatory changes but did not reverse either epithelial cell shedding or apoptosis seen after allergen challenge. Conclusion: Corticosteroids might induce apoptotic cell death of airway epithelium in vivo and fail to mitigate epithelial cell shedding and apoptosis elicited by means of allergen challenge. This raises the possibility that at least one of the major components of chronic airway damage in asthma, epithelial shedding, might in part result from a major therapy used for disease control.	Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Univ British Columbia, McDonald Res Labs, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, ICAPTURE Ctr, Vancouver, BC V5Z 1M9, Canada	University of Chicago; University of British Columbia; University of British Columbia	White, SR (corresponding author), Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, 5841 S Maryland Ave,MC 6076, Chicago, IL 60637 USA.		Sperling, Anne/ACZ-2351-2022	Sperling, Anne I./0000-0002-4265-9212	NHLBI NIH HHS [HL 60531, HL 63300, HL 64068] Funding Source: Medline; NIAID NIH HHS [AI 46549] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060531, R01HL064068, R01HL063300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046549] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMSON IYR, 1990, AM J PATHOL, V137, P385; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V101, pS427, DOI 10.1016/S0091-6749(98)70154-X; BARNES PJ, 1993, AM REV RESPIR DIS, V148, P1; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Bourcier T, 1999, INVEST OPHTH VIS SCI, V40, P1061; COMPTON MM, 1986, ENDOCRINOLOGY, V118, P38, DOI 10.1210/endo-118-1-38; Djukanovic R, 1997, AM J RESP CRIT CARE, V155, P826, DOI 10.1164/ajrccm.155.3.9117012; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; Dye JA, 1997, AM J RESP CELL MOL, V17, P625, DOI 10.1165/ajrcmb.17.5.2749; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; FORESI A, 1990, CHEST, V98, P528, DOI 10.1378/chest.98.3.528; FRIGAS E, 1980, LAB INVEST, V42, P35; Gama P, 2000, ANAT RECORD, V260, P213; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Godfrey RWA, 1997, MICROSC RES TECHNIQ, V38, P488, DOI 10.1002/(SICI)1097-0029(19970901)38:5<488::AID-JEMT5>3.0.CO;2-E; HARRIS RA, 1995, BRIT J CANCER, V72, P386, DOI 10.1038/bjc.1995.343; Kimura K, 1997, J PATHOL, V181, P235; Kockx MM, 1998, AM J PATHOL, V152, P885; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V97, P153, DOI 10.1016/S0091-6749(96)80215-6; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; Meagher LC, 1996, J IMMUNOL, V156, P4422; Padrid PA, 1998, AM J RESP CELL MOL, V18, P453, DOI 10.1165/ajrcmb.18.4.3055; Quaroni A, 1999, AM J PHYSIOL-GASTR L, V277, pG1027, DOI 10.1152/ajpgi.1999.277.5.G1027; SINGER KL, 1994, J BIOL CHEM, V269, P16108; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Vignola AM, 2001, J ALLERGY CLIN IMMUN, V108, P738, DOI 10.1067/mai.2001.119160; Wan H, 2000, EUR RESPIR J, V15, P1058, DOI 10.1034/j.1399-3003.2000.01514.x; WEN LP, 1997, AM J PHYSIOL, V273, P921; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; YUKAWA T, 1990, AM J RESP CELL MOL, V2, P341, DOI 10.1165/ajrcmb/2.4.341	33	29	30	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					360	366		10.1067/mai.2003.117	http://dx.doi.org/10.1067/mai.2003.117			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	644WF	12589357				2022-12-18	WOS:000180942700021
J	Limaye, S; Steele, RH; Quin, J; Cleland, B				Limaye, S; Steele, RH; Quin, J; Cleland, B			An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECOMBINANT-HUMAN-ERYTHROPOIETIN		Liverpool Hosp, Dept Immunol, Sydney, NSW, Australia; Liverpool Hosp, Dept Renal Med, Sydney, NSW, Australia	Liverpool Hospital; Liverpool Hospital	Limaye, S (corresponding author), Liverpool Hosp, Dept Immunol, Sydney, NSW, Australia.							Cheung WK, 2000, BIOPHARM DRUG DISPOS, V21, P211, DOI 10.1002/bdd.231; GARCIA JE, 1993, NEPHRON, V65, P636, DOI 10.1159/000187578; HARDWICK N, 1993, CONTACT DERMATITIS, V28, P123; SHELLEY WB, 1995, LANCET, V345, P1312, DOI 10.1016/S0140-6736(95)90963-X	4	29	30	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					530	530		10.1067/mai.2002.126460	http://dx.doi.org/10.1067/mai.2002.126460			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209107				2022-12-18	WOS:000177936900030
J	Niggemann, B; Ziegert, M; Reibel, S				Niggemann, B; Ziegert, M; Reibel, S			Importance of chamber size for the outcome of atopy patch testing in children with atopic dermatitis and food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopy patch test; children; DBPCFC; food challenge	DOUBLE-BLIND; CHALLENGES; INFANTS; SKIN	Because the small backs of young children offer little space for atopy patch testing, it would be helpful to use smaller chambers. We therefore compared 6-mm chambers with the 12-mm chambers used in previous studies. We performed 55 double-blind, placebo-controlled food challenges in 30 children (17 boys, 13 girls) aged 3 to 58 months (median, 13 months). Sensitivity, specificity, positive predictive value, negative predictive value, and efficiency results show that the 12-mm chamber size yields much better results than the 6-mm chamber size. Therefore, 1,2-mm cups should be used for atopy patch tests with food, even in infants and small children.	Humboldt Univ, Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Niggemann, B (corresponding author), Humboldt Univ, Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.							BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91, DOI 10.1046/j.1365-2222.1999.00454.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x	11	29	30	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					515	516		10.1067/mai.2002.126659	http://dx.doi.org/10.1067/mai.2002.126659			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209104				2022-12-18	WOS:000177936900027
J	Shearer, WT; Lee, BN; Cron, SG; Rosenblatt, HM; Smith, EO; Lugg, DJ; Nickolls, PM; Sharp, RM; Rollings, K; Reuben, JM				Shearer, WT; Lee, BN; Cron, SG; Rosenblatt, HM; Smith, EO; Lugg, DJ; Nickolls, PM; Sharp, RM; Rollings, K; Reuben, JM			Suppression of human anti-inflammatory plasma cytokines IL-10 and IL-1RA with elevation of proinflammatory cytokine IFN-gamma during the isolation of the Antarctic winter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antarctic winter-over; model of isolation; effect of space flight; proinflammatory vs anti-inflammatory cytokine balance; latent virus infection; T-cell activation	CELL-MEDIATED-IMMUNITY; SPACEFLIGHT; SLEEP; MODEL	Cellular immune function has been shown to be decreased and latent virus shedding to be increased in human beings isolated during the Antarctic winter, a model used for assessing some effects of space flight. However, the balance of proinflammatory (IFN-gamma) and anti-inflammatory (IL-10 and IL-1RA) cytokines has not previously been evaluated. We therefore sought to determine whether isolation during the Antarctic winter would alter the proinflammatory and anti-inflammatory cytokine balance. Cytokine levels were measured with ELISA in monthly plasma samples from January through September 1999 in 21 study subjects in the Antarctic and 7 control subjects on Macquarie Island. There was a significant time-dependent increase in plasma IFN-gamma (P = .039) as well as decreases in IL-10 (P = .042) and IL-1RA (P = .053) in the study subjects compared with the control subjects. The study subjects also had significantly increased plasma IFN-gamma levels (P less than or equal to .045) but decreased IL-10 and IL-1RA levels (P less than or equal to .036) at individual time points of isolation. Isolation of human beings in the Antarctic appears to shift the plasma cytokine balance toward a proinflammatory profile. These observations are consistent with T-cell activation that might be due to activation of latent viruses, and they could hold importance for determining the risks of space flight.	Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Australian Antarctic Div, Kingston, Tas, Australia	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Australian Antarctic Division	Shearer, WT (corresponding author), Texas Childrens Hosp, 6621 Fannin St MC 1-3291, Houston, TX 77030 USA.			Shearer, William/0000-0002-2483-2130				Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Mehta SK, 2000, J MED VIROL, V61, P235, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;235::AID-JMV10&gt;3.0.CO;2-4; Moldofsky H, 1999, SLEEP MED REV, V3, P325, DOI 10.1053/smrv.1999.0068; MULLER HK, 1995, IMMUNOL CELL BIOL, V73, P316, DOI 10.1038/icb.1995.48; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P165, DOI 10.1067/mai.2001.112270; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P160, DOI 10.1067/mai.2001.112269; Sonnenfeld G, 1996, J INTERF CYTOK RES, V16, P409, DOI 10.1089/jir.1996.16.409; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Tingate TR, 1997, IMMUNOL CELL BIOL, V75, P275, DOI 10.1038/icb.1997.42	10	29	30	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					854	857		10.1067/mai.2002.123873	http://dx.doi.org/10.1067/mai.2002.123873			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994711				2022-12-18	WOS:000175687800017
J	Suzuki, M; Maghni, K; Molet, S; Shimbara, A; Hamid, QA; Martin, JG				Suzuki, M; Maghni, K; Molet, S; Shimbara, A; Hamid, QA; Martin, JG			IFN-gamma secretion by CD8(+) T cells inhibits allergen-induced airway eosinophilia but not late airway responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; T(H)1/T(H)2; antisense oligodeoxynucleotides; eosinophils; late responses	MESSENGER-RNA EXPRESSION; SOLUBLE-PROTEIN ANTIGENS; BROWN-NORWAY RATS; INTERFERON-GAMMA; BRONCHIAL BIOPSIES; IMMUNE-RESPONSES; IGE PRODUCTION; MURINE MODEL; LYMPHOCYTES; ASTHMA	Background: CD8(+) T cells can suppress allergen-induced late airway responses (LARs) and airway inflammation. Objective: To test the hypothesis that the suppression of LARs and airway eosinophilia by CD8(+) T cells is IFN-gamma mediated, we tested the effects of adoptively transferred CD8(+) T cells, in which IFN-gamma synthesis was inhibited by an antisense (AS) oligodeoxynucleotide (ODN), on the airway responses of a rat model of allergic asthma. Methods: CD8(+) T cells were harvested from the cervical lymph nodes of ovalbumin (OVA)-sensitized Brown Norway rats for administration to other actively sensitized syngeneic rats. CD8(+) T cells (2 x 10(6)) were incubated for 6 hours with 2 mumol/L AS ODN or sense ODN and were injected intraperitoneally into recipients; inhibition of IFN-gamma expression in vitro by AS ODN was shown by means of flow cytometry. Two days later, rats were challenged with aerosolized OVA. Results: OVA-induced LAR and bronchoalveolar lavage (BAL) fluid eosinophilia were suppressed by sense ODN-treated CD8(+) T cells. IFN-gamma expression in BAL cells was elevated in these animals. IFNgamma expression in BAL cells was at control levels in recipients of AS ODN-treated CD8(+) cells, confirming the success of the AS treatment in vivo. BAL eosinophilia was also largely restored in the AS ODN treatment group. In contrast, the CD8(+) T cell-induced suppression of the LAR was not significantly affected by AS ODN pretreatment. Conclusions: These results indicate that CD8(+) T cells inhibit airway eosinophilia through secretion of IFN-gamma but may suppress the LAR by means of other mechanisms.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	McGill University	Martin, JG (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.			Martin, James/0000-0001-7574-5363				Allakhverdi Z, 2000, AM J RESP CRIT CARE, V162, P1123, DOI 10.1164/ajrccm.162.3.9910001; BATES JHT, 1989, RESP PHYSIOL, V78, P369, DOI 10.1016/0034-5687(89)90111-4; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Coyle AJ, 1996, J IMMUNOL, V156, P2680; DEL PG, 1988, J IMMUNOL, V140, P4193; GAJEWSKI TF, 1989, J IMMUNOL, V143, P15; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Hofstra CL, 1998, AM J RESP CELL MOL, V19, P826, DOI 10.1165/ajrcmb.19.5.3027; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; Holmes BJ, 1997, EUR J IMMUNOL, V27, P2657, DOI 10.1002/eji.1830271027; Huang TJ, 1999, IMMUNOLOGY, V98, P280; Isogai S, 2000, EUR RESPIR J, V16, P22, DOI 10.1034/j.1399-3003.2000.16a05.x; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Kaminuma O, 1997, AM J RESP CELL MOL, V16, P448, DOI 10.1165/ajrcmb.16.4.9115756; KELSO A, 1991, IMMUNOL REV, V123, P85, DOI 10.1111/j.1600-065X.1991.tb00607.x; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MacAry PA, 1998, J IMMUNOL, V160, P580; MCMENAMIN C, 1995, J IMMUNOL, V154, P4390; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Mishima H, 1998, AM J RESP CRIT CARE, V158, P1863, DOI 10.1164/ajrccm.158.6.9709123; Molet S, 1999, J ALLERGY CLIN IMMUN, V104, P205, DOI 10.1016/S0091-6749(99)70137-5; Mueller R, 1996, RESP MED, V90, P79, DOI 10.1016/S0954-6111(96)90202-4; Nakamura T, 1997, J IMMUNOL, V158, P2648; Noble A, 1998, J IMMUNOL, V160, P559; Noble A, 1998, J IMMUNOL, V160, P566; OLIVENSTEIN R, 1993, J CLIN INVEST, V92, P1477, DOI 10.1172/JCI116725; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RENZ H, 1994, J IMMUNOL, V152, P351; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; Schroeder RA, 1998, HEPATOLOGY, V27, P711, DOI 10.1002/hep.510270312; Suzuki M, 1999, J IMMUNOL, V163, P5574; SWAIN SL, 1990, J IMMUNOL, V145, P3796; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WATANABE A, 1995, AM J RESP CRIT CARE, V152, P64, DOI 10.1164/ajrccm.152.1.7599864; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	42	29	29	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					803	809		10.1067/mai.2002.123233	http://dx.doi.org/10.1067/mai.2002.123233			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994704				2022-12-18	WOS:000175687800010
J	Borish, L				Borish, L			Sinusitis and asthma: Entering the realm of evidence-based medicine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							EXPRESSION; EOSINOPHIL		Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Borish, L (corresponding author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Box 801355, Charlottesville, VA 22908 USA.							Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; BRUGMAN SM, 1993, AM REV RESPIR DIS, V147, P314, DOI 10.1164/ajrccm/147.2.314; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Jarjour NN, 2000, J ALLERGY CLIN IMMUN, V105, P1169, DOI 10.1067/mai.2000.106376; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382, DOI 10.1164/ajrccm.152.4.7551399; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; PFISTER R, 1994, J ALLERGY CLIN IMMUN, V94, P804, DOI 10.1016/0091-6749(94)90146-5; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Zinreich SJ, 1998, AM J MED SCI, V316, P2, DOI 10.1016/S0002-9629(15)40365-9	20	29	29	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					606	608		10.1067/mai.2002.123024	http://dx.doi.org/10.1067/mai.2002.123024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941306	Bronze			2022-12-18	WOS:000175132600004
J	Mascia, F; Mariani, V; Giannetti, A; Girolomoni, G; Pastore, S				Mascia, F; Mariani, V; Giannetti, A; Girolomoni, G; Pastore, S			House dust mite allergen exerts no direct proinflammatory effects on human keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epithelial cells; dermatophagoides pteronyssinus; cytokines; chemokines; atopic dermatitis	ATOPY PATCH TEST; BRONCHIAL EPITHELIAL-CELLS; COLONY-STIMULATING FACTOR; DERMATITIS; ECZEMA; SENSITIZATION; ACTIVATION; ANTIGEN; SKIN	Background: Dermatophagoides pteronyssinus is a trigger of atopic dermatitis. Many D pteronyssinus allergens are proteases that can elicit airway inflammation by stimulating the release of cytokines and chemokines by bronchial epithelial cells. Objective: We sought to investigate whether D pteronyssinus allergens can exert a similar activity on skin keratinocytes. Methods: Primary cultures of keratinocytes from healthy subjects or patients with atopic dermatitis and normal human bronchial epithelial cells were compared for cytokine production in response to D pteronyssinus extract. Results: Keratinocytes, but not bronchial epithelial cells, displayed a modest dose-dependent release of IL-1alpha and IL-1 receptor antagonist but no induction of their mRNA after exposure to D pteronyssinus. However, D pteronyssinus also degraded these cytokines. On the other hand, D pteronyssinus extract induced bronchial epithelial cells, but not keratinocytes, to increased expression of IL-8/CXCL8 and GNICSF mRNA and protein. These effects were efficiently abrogated by a mixture of cysteine and serine protease inhibitors. Both IL-8 and GM-CSF were fully resistant to D pteronyssinus proteolytic attack. No induction of monocyte chemoattractant protein 1/CCL2, RANTES/CCL5, or IFN-gamma-induced protein of 10 kd/CXCL10 was detected in either cell type. Only bronchial epithelial cells expressed protease-activated receptor (PAR) 4 mRNA, whereas PAR-1, PAR-2, and PAR-3 mRNA was found in both cell types. D pteronyssinus did not affect PAR mRNA signals. Conclusions: Although D pteronyssinus can cause proteolysis-dependent release of cytokines from keratinocytes, it appears incapable of activating de novo expression of cytokines and chemokines, arguing against a direct proinflammatory activity of house dust mite on the skin.	Ist Dermopatico Immacolata, Immunol Lab, IRCCS, I-00167 Rome, Italy; Univ Modena, Dept Dermatol, I-41100 Modena, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); Universita di Modena e Reggio Emilia	Pastore, S (corresponding author), Ist Dermopatico Immacolata, Immunol Lab, IRCCS, Via Monti Creta 104, I-00167 Rome, Italy.		GIROLOMONI, Giampiero/AAC-3405-2022					BUROKERKILGORE M, 1993, ANAL BIOCHEM, V208, P387, DOI 10.1006/abio.1993.1066; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Charman C, 1999, BMJ-BRIT MED J, V318, P1600, DOI 10.1136/bmj.318.7198.1600; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; Friedmann PS, 1999, CLIN EXP ALLERGY, V29, P869, DOI 10.1046/j.1365-2222.1999.00647.x; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; GONDO A, 1986, BRIT J DERMATOL, V115, P485, DOI 10.1111/j.1365-2133.1986.tb06243.x; King C, 1998, J IMMUNOL, V161, P3645; Langeveld-Wildschut EG, 2000, J ALLERGY CLIN IMMUN, V105, P1008, DOI 10.1067/mai.2000.106544; MAEDA K, 1992, Journal of Dermatological Science, V3, P73, DOI 10.1016/0923-1811(92)90038-D; Murphy JE, 2000, J INVEST DERMATOL, V114, P602, DOI 10.1046/j.1523-1747.2000.00917.x; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; Pastore S, 2000, J INVEST DERMATOL, V115, P1134, DOI 10.1046/j.1523-1747.2000.00149.x; Reibman J, 2000, J IMMUNOL, V165, P1618, DOI 10.4049/jimmunol.165.3.1618; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P379, DOI 10.1159/000237609; Ring J, 2001, J AM ACAD DERMATOL, V45, pS49, DOI 10.1067/mjd.2001.117015.24; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SEIDENARI S, 1992, ANN ALLERGY, V69, P201; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TANAKA Y, 1990, Journal of Dermatological Science, V1, P361, DOI 10.1016/0923-1811(90)90593-3; Thompson P. J., 2001, Clinical and Experimental Allergy Reviews, V1, P107, DOI 10.1046/j.1472-9725.2001.00018.x; Tupker RA, 1998, ALLERGY, V53, P92, DOI 10.1111/j.1398-9995.1998.tb05006.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Winton HL, 1998, BRIT J PHARMACOL, V124, P1048, DOI 10.1038/sj.bjp.0701905; Wistokat-Wulfing A, 1999, CLIN EXP ALLERGY, V29, P513	34	29	30	2	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					532	538		10.1067/mai.2002.121830	http://dx.doi.org/10.1067/mai.2002.121830			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11898003				2022-12-18	WOS:000174586400023
J	Zanconato, S; Scollo, M; Zaramella, C; Landi, L; Zacchello, F; Baraldi, E				Zanconato, S; Scollo, M; Zaramella, C; Landi, L; Zacchello, F; Baraldi, E			Exhaled carbon monoxide levels after a course of oral prednisone in children with asthma exacerbation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exhaled carbon monoxide; exhaled nitric oxide; children; glucocorticoids	NITRIC-OXIDE LEVELS; HEME OXYGENASE; CHILDHOOD ASTHMA; EXPRESSION; CORTICOSTEROIDS; INFLAMMATION; MACROPHAGES; AIRWAYS; MARKERS; STRESS	Background: Fractional exhaled nitric oxide (FENO) and exhaled carbon monoxide (ECO) have been proposed as markers of airway inflammation and oxidative stress. Objective: The aim of this study was to assess the effect of oral prednisone treatment on FENO and ECO levels in a group of 30 asthmatic children with asthma exacerbation. Methods: Thirty asthmatic children with asthma exacerbation were treated with oral prednisone for 5 days (1 mg/kg/day). Before and after prednisone therapy, ECO was measured by means of a chemical analyzer and FENO was measured by means of a chemiluminescence analyzer. ECO and FENO were also measured in a group of healthy nonatopic children. Results: Before therapy, both ECO values and FENO Values were higher in asthmatic children (ECO, 3.2 +/- 0.2 ppm; FENO online, 74.9 +/- 6.2 ppb; FENO offline, 20.2 +/- 1.4 ppb) than in healthy controls (ECO, 2.0 +/- 0.2 ppm [P < .01]; FENO online, 10.1 +/- 0.8 [P < .0001]; FENO offline, 5.9 +/- 0.4 ppb [P < .0001]). An overlap in ECO values was found between healthy controls and asthmatic children. After prednisone therapy, there was a significant reduction in FENO values (FENO online, 40.6 +/- 4.6 ppb [P < .0001]; FENO offline, 11.1 +/- 0.8 ppb [P < 0.0001]) and a slight but nonsignificant decrease in ECO values (2.7 +/- 0.2 ppm [P = not significant]) in the asthmatic group. No significant correlation between ECO values and FENO values was found in either the asthmatic children or the controls. Conclusions: After a course of prednisone therapy, in children with asthma exacerbation there is a significant decrease in FENO but no significant change in ECO levels. This possibly suggests that ECO is less sensitive than FENO to inhibition by corticosteroids.	Univ Padua, Dept Pediat, Unit Resp Med & Allergy, I-35128 Padua, Italy	University of Padua	Baraldi, E (corresponding author), Univ Padua, Dept Pediat, Unit Resp Med & Allergy, Via Giustiniani 3, I-35128 Padua, Italy.		baraldi, eugenio/AAC-5233-2022	BARALDI, EUGENIO/0000-0002-1829-3652				APPLEGATE LA, 1991, CANCER RES, V51, P974; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262, DOI 10.1164/ajrccm.159.1.9804063; Baraldi E, 1997, J PEDIATR-US, V131, P381, DOI 10.1016/S0022-3476(97)80062-5; Baraldi E, 2000, AM J RESP CRIT CARE, V162, P1828, DOI 10.1164/ajrccm.162.5.2002014; CANTONI L, 1991, BIOCHEM J, V279, P891, DOI 10.1042/bj2790891; FUKUSHIMA T, 1995, EUR J PHARM-MOLEC PH, V289, P103, DOI 10.1016/0922-4106(95)90174-4; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; Horvath I, 1998, THORAX, V53, P668, DOI 10.1136/thx.53.8.668; Hunt J, 2000, J PEDIATR-US, V137, P14, DOI 10.1067/mpd.2000.107526; Jobsis Q, 2001, THORAX, V56, P285, DOI 10.1136/thorax.56.4.285; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Lim S, 2000, AM J RESP CRIT CARE, V162, P1912, DOI 10.1164/ajrccm.162.5.9909081; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Paredi P, 1999, EUR RESPIR J, V13, P48, DOI 10.1183/09031936.99.13104899; Piacentini GL, 1999, EUR RESPIR J, V13, P1386, DOI 10.1034/j.1399-3003.1999.13f25.x; POLGAR G, 1974, PULMONARY FUNCTION T; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; Scollo M, 2000, AM J RESP CRIT CARE, V161, P1047, DOI 10.1164/ajrccm.161.3.9905043; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45, DOI 10.1164/ajrccm.160.1.9809091; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Uasuf CG, 1999, J PEDIATR-US, V135, P569, DOI 10.1016/S0022-3476(99)70054-5; Yamara M, 1999, EUR RESPIR J, V13, P757, DOI 10.1034/j.1399-3003.1999.13d10.x; Yamaya M, 2001, CLIN EXP ALLERGY, V31, P417, DOI 10.1046/j.1365-2222.2001.01013.x; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140, DOI 10.1164/ajrccm.156.4.96-08056; [No title captured]	30	29	33	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					440	445		10.1067/mai.2002.121954	http://dx.doi.org/10.1067/mai.2002.121954			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897988				2022-12-18	WOS:000174586400009
J	Cain, WT; Cable, G; Oppenheimer, JJ				Cain, WT; Cable, G; Oppenheimer, JJ			The ability of the community pharmacist to learn the proper actuation techniques of inhaler devices	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						community pharmacist; education; inhaler device; asthma; Turbuhaler; Diskus; metered-dose inhaler; actuation technique; change score	INHALATION; KNOWLEDGE; AEROSOL	Today, greater responsibility is placed on community pharmacists for the education of patients than ever before. Thus community pharmacists were recruited for this study and asked to demonstrate the proper steps in the actuation sequences of 3 inhaler devices. Baseline measurements were followed by an instructional session on the proper actuation technique, and then a posttest was conducted 4 to 6 weeks later. The mean changes between baseline and postinstruction percentage scores for the metered-dose inhaler device, the Turbuhaler, and the Diskus were (mean +/- SD) 17.1% +/- 15.4%, 22.6% +/- 18.7%, and 38.4% +/- 19.6%, respectively. This study demonstrates that a single instructional session can dramatically improve a community pharmacist's ability to demonstrate the correct method of actuation.	Atlantic Hlth Syst, Springfield, NJ USA; Pulm & Allergy Associates, Springfield, NJ USA; Overlook Hosp, Summit, NJ USA	Atlantic Health System; Atlantic Health System	Oppenheimer, JJ (corresponding author), 101 Madison Ave, Morristown, NJ 07960 USA.							ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; COCKCROFT DW, 1993, ANN ALLERGY, V71, P83; HANANIA NA, 1994, CHEST, V105, P111, DOI 10.1378/chest.105.1.111; KESTEN S, 1993, CHEST, V104, P1737, DOI 10.1378/chest.104.6.1737; MICKLE TR, 1990, DICP ANN PHARMAC, V24, P927, DOI 10.1177/106002809002401003; *NAT ASTHM ED PROG, 1991, DHHS PUBL; NEWMAN SP, 1985, CHEST, V88, pS152, DOI 10.1378/chest.88.2.152S; SELF TH, 1998, CAN MED ASSOC J, V128, P129; SHIM C, 1980, AM J MED, V69, P891, DOI 10.1016/S0002-9343(80)80016-7	9	29	30	3	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					918	920		10.1067/mai.2001.119153	http://dx.doi.org/10.1067/mai.2001.119153			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742268				2022-12-18	WOS:000172938400006
J	Park, Y; Chang, YS; Lee, SW; Cho, SY; Kim, YK; Min, KU; Kim, YY; Cho, SH; Sung, YC				Park, Y; Chang, YS; Lee, SW; Cho, SY; Kim, YK; Min, KU; Kim, YY; Cho, SH; Sung, YC			The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; CpG oligodeoxynucleotides; 3 ' dG(6)-run; phosphodiester; T(H)1; immune modulation	IMMUNOSTIMULATORY DNA-SEQUENCES; CD8 T-CELLS; BACTERIAL-DNA; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; AIRWAY HYPERRESPONSIVENESS; INFLAMMATION; MOTIFS; MURINE; MICE; EOSINOPHILIA	Background: Oligodeoxynucleotides containing a CpG motif (CpG ODNs), as potent inducers of T(H)1 immunity, are considered promising candidates for immune modulation in asthma. We have previously demonstrated that conjugation of a hexameric deoxyriboguanosine run to the 3' terminus (3' dG(6)-run) of phosphodiester (PE) CpG ODNs enhanced their immunostimulatory activities in vitro. Objective: This study aimed to evaluate the effect of a 3' dG(6)-run conjugation to PE or phosphorothioate (PS) CpG ODNs on protection against murine allergic asthma in vivo. Methods: Balb/c mice were sensitized to ovalbumin by intraperitoneal injection with or without CpG ODNs (PS CpG ODNs, PE CpG ODNs, and those with 3'dG(6)-run) and subsequently challenged with ovalbumin. We evaluated airway hyperresponsiveness, eosinophil proportion in bronchoalveolar lavage fluid, airway inflammation, and ovalbumin-specific antibody responses. Results: The conjugation of a 3' dG(6)-run to PE CpG ODNs enhanced the production of IFN-gamma from ovalbumin-specific T-H cells and prevented the development of asthma in terms of airway hyperresponsiveness, airway eosinophilia, and ovalbumin-specific IgE responses; these effects were comparable to those of PS CpG ODNs. Enhanced effects of the 3' dG(6)-run were also observed in PS CpG ODNs, though they were lower than those in PE CpG ODNs. Conclusion: This study suggests that conjugation of a 3' dG(6)-run to CpG ODNs might provide an effective method for immune modulation of allergic asthma.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Natl Lab DNA Med, Pohang, South Korea; Seoul Natl Univ, Med Res Ctr, Inst Allergy & Clin Immunol, Seoul, South Korea	Seoul National University (SNU); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU)	Cho, SH (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.		Min, Kyung-Up/J-5468-2012; Chang, Yoon-Seok/J-5628-2012; Cho, Sang Heon/J-2793-2012	Chang, Yoon-Seok/0000-0003-3157-0447; Park, Yunji/0000-0003-0042-202X				Ballas ZK, 1996, J IMMUNOL, V157, P1840; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; Bishop JS, 1996, J BIOL CHEM, V271, P5698, DOI 10.1074/jbc.271.10.5698; Broide D, 1998, J IMMUNOL, V161, P7054; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Holt PG, 1999, NATURE, V402, pB12; KEMENY DM, 1991, INT ARCH ALLER A IMM, V94, P99, DOI 10.1159/000235337; KIMURA Y, 1994, J BIOCHEM-TOKYO, V116, P991, DOI 10.1093/oxfordjournals.jbchem.a124658; Kline JN, 1998, J IMMUNOL, V160, P2555; Krieg AM, 2000, IMMUNOL TODAY, V21, P521, DOI 10.1016/S0167-5699(00)01719-9; Lee SW, 2000, J IMMUNOL, V165, P3631, DOI 10.4049/jimmunol.165.7.3631; Lipford GB, 2000, IMMUNOLOGY, V101, P46, DOI 10.1046/j.1365-2567.2000.00077.x; Monteith DK, 1997, ANTI-CANCER DRUG DES, V12, P421; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; SARMIENTO UM, 1994, ANTISENSE RES DEV, V4, P99, DOI 10.1089/ard.1994.4.99; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Shirota H, 2000, J IMMUNOL, V164, P5575, DOI 10.4049/jimmunol.164.11.5575; STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79	23	29	35	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					570	576						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590383				2022-12-18	WOS:000171760300016
J	Paul, ME; Shearer, WT; Kozinetz, CA; Lewis, DE				Paul, ME; Shearer, WT; Kozinetz, CA; Lewis, DE			Comparison of CD8(+) T-cell subsets in HIV-infected rapid progressor children versus non-rapid progressor children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pediatric HIV-1 infection; CD4(+) T cells; CD8(+) T cells; CD8(+) T-cell subsets; HIV disease progression	VIRUS TYPE-1 INFECTION; LYMPHOCYTE-ACTIVATION; DISEASE PROGRESSION; CD4(+) LYMPHOCYTES; VIRAL LOAD; EXPRESSION; CD28; CD38; MARKERS; MEMORY	Background: CD8(+) T-cell subsets have not been adequately described in HIV-infected (HIV+) children classified with respect to disease progression as rapid-progressors (RPs) and non-rapid progressors (non-RPs). Objective: The purpose of this investigation was to determine the distribution of CD8(+) T-cell subsets in HIV+ children and correlate the findings with degree of immunosuppression and HIV viral burden. Methods: By means of 3-color flow cytometry, percentages of CD38(+)DR(+), CD28(+), and CD57(+) CD8(+) T-cell subsets were examined in RP (n=15) and non-RP (n=36) HIV+ children and in HIV- exposed but uninfected (n=11) and HIV-unexposed (n=8) children. The CD8(+) T-cell subsets were correlated with mean CD4(+) T-cell percentages and HIV RNA levels. Analysis of covariance was used for group comparisons for the control of the covariate of age. Results: The HIV-exposed and HIV-unexposed controls were not different from each other in CD8(+) T-cell subset percentages, except that the DR(-)CD38(+)CD8(+) T-cell percentages were higher in the exposed controls than in the unexposed controls. RPs had a higher mean percentage of DR(+)CD38(+)CD8(+) T cells than non-RPs and both control groups, and RPs had higher viremia than non-RPs. CD38(+)CD8(+) T-cell percentages did not correlate with viral burden as it has been seen to do in HIV+ adults. Percentages of CD28(+)CD8(+) T cells were lower in HIV-infected children than in controls. There was a positive correlation of percentage of CD28(+)CD57(-)CD8(+) T cells with CD4(+) T-cell percentages in each HIV-infected group. Conclusion: CD8(+) T cells become activated (dual expression of DR and CD38) and lose CD28, some acquiring CD57, in relation to rapidity of disease progression in pediatric HIV infection.	Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Paul, ME (corresponding author), Texas Childrens Hosp, Baylor Coll Med, 6621 Fannin St,MC 1-3291, Houston, TX 77030 USA.		Paul, Mary/AAA-2722-2021	Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [RR-00188] Funding Source: Medline; NIAID NIH HHS [AI36211, AI37131] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bariou C, 1997, AIDS RES HUM RETROV, V13, P1301, DOI 10.1089/aid.1997.13.1301; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; BORTHWICK NJ, 1994, AIDS, V8, P431, DOI 10.1097/00002030-199404000-00004; Bouscarat F, 1996, AIDS RES HUM RETROV, V12, P17, DOI 10.1089/aid.1996.12.17; Bouscarat F, 1999, AIDS RES HUM RETROV, V15, P1419, DOI 10.1089/088922299309928; BRINCHMANN JE, 1994, J INFECT DIS, V169, P730, DOI 10.1093/infdis/169.4.730; Brugnoni D, 1997, CLIN EXP IMMUNOL, V109, P412, DOI 10.1046/j.1365-2249.1997.4871386.x; Burgisser P, 1999, CLIN EXP IMMUNOL, V115, P458; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; Chamberlain WD, 2000, CLIN IMMUNOL, V94, P160, DOI 10.1006/clim.1999.4832; Clerici M, 2000, BLOOD, V96, P3866, DOI 10.1182/blood.V96.12.3866.h8003866_3866_3871; De Martino M, 1998, PEDIATR RES, V43, P752, DOI 10.1203/00006450-199806000-00007; DEMARTINO M, 1994, LANCET, V343, P191; GIORGI JV, 1994, J INFECT DIS, V170, P775, DOI 10.1093/infdis/170.4.775; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Greenough TC, 1997, J INFECT DIS, V176, P118, DOI 10.1086/514013; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kline MW, 1995, PEDIATR AIDS HIV INF, V6, P350; Legrand E, 1997, AIDS RES HUM RETROV, V13, P1383, DOI 10.1089/aid.1997.13.1383; LEVACHER M, 1992, CLIN EXP IMMUNOL, V90, P376; Lewis DE, 1999, AIDS, V13, P1029, DOI 10.1097/00002030-199906180-00005; Lewis DE, 1999, CLIN IMMUNOL, V90, P302, DOI 10.1006/clim.1998.4663; LEWIS DE, 1994, J IMMUNOL, V153, P412; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; Liu Z, 1998, J ACQ IMMUN DEF SYND, V18, P332, DOI 10.1097/00042560-199808010-00004; Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003; Lloyd TE, 1997, J IMMUNOL, V158, P1551; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; McCloskey TW, 1998, BLOOD, V92, P4230, DOI 10.1182/blood.V92.11.4230.423k22_4230_4237; McCloskey TW, 1997, CLIN IMMUNOL IMMUNOP, V84, P46, DOI 10.1006/clin.1997.4370; Mocroft A, 1997, J ACQ IMMUN DEF SYND, V14, P158, DOI 10.1097/00042560-199702010-00009; Niehues T, 1998, PEDIATR RES, V44, P265, DOI 10.1203/00006450-199808000-00021; PLAEGERMARSHALL S, 1994, CLIN IMMUNOL IMMUNOP, V71, P19, DOI 10.1006/clin.1994.1046; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; Rich KC, 1997, CLIN DIAGN LAB IMMUN, V4, P358, DOI 10.1128/CDLI.4.3.358-361.1997; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; Roos MTL, 1998, AIDS, V12, P1745, DOI 10.1097/00002030-199814000-00005; SCHLESINGER M, 1995, PEDIATR RES, V38, P390, DOI 10.1203/00006450-199509000-00020; Than S, 1999, J IMMUNOL, V162, P3680; Vigano A, 1998, LANCET, V352, P1905, DOI 10.1016/S0140-6736(05)60396-0; Weekes MP, 1999, IMMUNOLOGY, V98, P443, DOI 10.1046/j.1365-2567.1999.00901.x	44	29	35	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					258	264		10.1067/mai.2001.117179	http://dx.doi.org/10.1067/mai.2001.117179			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496243	Bronze			2022-12-18	WOS:000170584600015
J	Anliker, MD; Reindl, J; Vieths, S; Wuthrich, B				Anliker, MD; Reindl, J; Vieths, S; Wuthrich, B			Allergy caused by ingestion of persimmon (Diospyros kaki): Detection of specific IgE and cross-reactivity to profilin and carbohydrate determinants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						carbohydrate determinants; cross-reactivity; double -blind; placebo-controlled; food-challenge; allergy; Diospyros kaki; persimmon; profilin; IgE	ADVERSE-REACTIONS; POLLEN; APPLE; FRUIT	Background: Allergy to persimmon (Diospyros kaki) is very rare and not yet confirmed by means of double-blind, placebo-controlled, food-challenge (DBPCFC), Thus far, specific IgE to this fruit and cross-reactivity to pollen and other foods has not been determined. Objective: The objective was to confirm allergy to persimmon in 3 patients with an according personal history and to characterize allergens and cross-reactivity of specific IgE antibodies to pollen and food allergens, One patient reacted with pruritus, penis edema, urticaria, and asthma; the second reacted with nausea and vomitus; and the third reacted with rhinoconjunctivitis, asthma, and stomachache after ingestion of persimmon. Methods: Patients underwent skin prick testing with routine allergens, latex, persimmon, and other foods. Allergy to persimmon was confirmed by means of a DBPCFC, Specific serum IgE levels were measured with CAP-FEIA and the enzyme allergosorbent test (EAST) method, EAST and immunoblot inhibitions were carried out with persimmon; birch, grass, and ragweed pollen; latex; and N-glycans as inhibitors. Results: All patients had positive skin test responses, DBPCFC and specific IgE assays to persimmon, Blot and EAST inhibition assays revealed IgE to cross-reactive profilin in one patient and IgE to cross-reacting carbohydrate determinants in all patients. Conclusions: This is the first report on 3 cases of allergy to persimmon verified by means of DBPCFC and detection of specific IgE, The sensitization is due to cross-reactive profilin and carbohydrate determinants.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Paul Ehrlich Inst, Dept Allergol, D-6070 Langen, Germany	University of Zurich; University Zurich Hospital; Paul Ehrlich Institute	Anliker, MD (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.							Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; FAH J, 1995, CLIN EXP ALLERGY, V25, P1018, DOI 10.1111/j.1365-2222.1995.tb00405.x; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Prandini M, 1999, ALLERGY, V54, P897, DOI 10.1034/j.1398-9995.1999.00268.x; Reindl J, 2000, J ALLERGY CLIN IMMUN, V106, P379, DOI 10.1067/mai.2000.107602; RUDESCHKO O, 1995, ALLERGY, V50, P262, DOI 10.1111/j.1398-9995.1995.tb01144.x; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VIETHS S, 1992, DEUT LEBENSM-RUNDSCH, V88, P239; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x; Wuthrich B, 1997, ALLERGY, V52, P428, DOI 10.1111/j.1398-9995.1997.tb01023.x	20	29	30	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					718	723		10.1067/mai.2001.113568	http://dx.doi.org/10.1067/mai.2001.113568			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	423RG	11295664				2022-12-18	WOS:000168190100027
J	Fujikura, T; Shimosawa, T; Yakuo, I				Fujikura, T; Shimosawa, T; Yakuo, I			Regulatory effect of histamine H1 receptor antagonist on the expression of messenger RNA encoding CC chemokines in the human nasal mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal allergy; CC chemokine; monocyte chemotactic protein 1; monocyte chemotactic protein 3; RANTES; eotaxin; histamine; carebastine	BRONCHIAL EPITHELIAL-CELLS; SEASONAL ALLERGIC RHINITIS; ACTIVATING FACTOR; INFLAMMATORY MEDIATORS; ENDOTHELIAL-CELLS; IN-VITRO; MONOCYTE; RELEASE; EOSINOPHILS; CHEMOATTRACTANT	Background: Allergic rhinitis is characterized by tissue accumulati on of inflammatory cells. CC chemokines, including monocyte chemotactic protein (MCP) 1, MCP-3, RANTES, and eotaxin, are thought to play an important role in inducing selective recruitment of these cells to the allergic inflammatory site. Furthermore, MCPs have been indicated as histamine-releasing factors. Histamine is an important mediator in the pathogenesis of nasal allergy. The regulation of histamine may have a role In the management of allergic inflammation. Objective: The objectives of this study were to investigate the expression of MCP-1, MCP3, RANTES, and eotaxin In the nasal mucosa of patients with allergic rhinitis and to clarify the effect of histamine and antihistamine on the regulation of the expression of these CC chemokines. Methods: By using a semiquantitative reverse transcriptase PCR technique, the numbers of copies of messenger RNA encoding MCP-1, MCP-3 RANTES, and eotaxin were measured in explant cultures of human nasal mucosa. In culture medium specific antigen or histamine was added. Furthermore, the effect of preincubation with the antihistamine carebastine was estimated. Results: Mite antigen (1:2 x 10(4) dilution) and histamine (10(-4) to 10(-3) mol/L) upregulated the messenger RNA expression of these CC chemokines at 3- to 10-fold increases. Carebastine (10(-7) to 10(-6) mol/L,) inhibited this upregulation. Conclusion: Our results suggest that histamine may induce CC chemokine production in the nasal mucosa of patients with allergic rhinitis. This Indicates that there may be a prolonged inflammatory cycle in the histamine-MCP axis In allergic rhinitis, The regulation of histamine-CC chemokine interaction could lead to new therapeutic approaches in the treatment of nasal allergy.	Nippon Med Sch, Dept Otorhinolaryngol, Tokyo 113, Japan; Univ Tokyo, Dept Endocrinol & Nephrol, Tokyo, Japan; Dainippon Pharmaceut Co Ltd, Dept Safety Pharmacol Dev, Res Labs, Osaka, Japan	Nippon Medical School; University of Tokyo; Dainippon Sumitomo Pharmaceutical Company	Fujikura, T (corresponding author), Yatsu Hoken Hosp, Dept Otorhinolaryngol, 4-6-16 Yatsu, Narashino, Chiba 2750026, Japan.		Shimosawa, Tatsuo/A-2920-2015	Shimosawa, Tatsuo/0000-0002-8742-5129				ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; Bayram H, 1999, J ALLERGY CLIN IMMUN, V104, P93, DOI 10.1016/S0091-6749(99)70119-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; Fujikura T, 1998, ARCH OTOLARYNGOL, V124, P1331, DOI 10.1001/archotol.124.12.1331; GRANT JA, 1991, J ALLERGY CLIN IMMUN, V88, P683, DOI 10.1016/0091-6749(91)90170-S; JEANNIN P, 1994, BLOOD, V84, P2229; JOHNSON CL, 1990, AM J PHYSIOL, V258, pC533, DOI 10.1152/ajpcell.1990.258.3.C533; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; KUNA P, 1993, J IMMUNOL, V150, P1932; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; NOAH TL, 1991, AM J RESP CELL MOL, V5, P484, DOI 10.1165/ajrcmb/5.5.484; OHTSUKA H, 1981, ARCH OTO-RHINO-LARYN, V233, P227, DOI 10.1007/BF00454387; OKADA C, 1994, INT ARCH ALLERGY IMM, V103, P384, DOI 10.1159/000236658; OKAYAMA M, 1992, J ALLERGY CLIN IMMUN, V89, P1144, DOI 10.1016/0091-6749(92)90298-G; OTSUKA H, 1995, J ALLERGY CLIN IMMUN, V96, P528, DOI 10.1016/S0091-6749(95)70297-0; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Rajakulasingam K, 1997, AM J RESP CRIT CARE, V155, P696, DOI 10.1164/ajrccm.155.2.9032215; Sprenger H, 1996, J EXP MED, V184, P1191, DOI 10.1084/jem.184.3.1191; TAKIZAWA H, 1995, INT ARCH ALLERGY IMM, V108, P260, DOI 10.1159/000237162; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; Teran LM, 1996, CLIN EXP ALLERGY, V26, P1005, DOI 10.1111/j.1365-2222.1996.tb00640.x; UGUNCCIONI M, 1997, J CLIN INVEST, V100, P1137; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; YAMAGUCHI T, 1994, ARZNEIMITTEL-FORSCH, V44-1, P59	33	29	38	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					123	128		10.1067/mai.2001.111236	http://dx.doi.org/10.1067/mai.2001.111236			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11150001				2022-12-18	WOS:000166533300021
J	Colavita, AM; Hastie, AT; Musani, AI; Pascual, RM; Reinach, AJ; Lustine, HT; Galati, SA; Zangrilli, JG; Fish, JE; Peters, SP				Colavita, AM; Hastie, AT; Musani, AI; Pascual, RM; Reinach, AJ; Lustine, HT; Galati, SA; Zangrilli, JG; Fish, JE; Peters, SP			Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin-10; allergic asthma; cytokines; macrophages; eosinophils; glucocorticoids; segmental antigen challenge; bronchoalveolar lavage; immunocytochemistry	T-CELL CLONE; CYTOKINE PRODUCTION; HUMAN EOSINOPHILS; INTERLEUKIN-10; INFLAMMATION; EXPRESSION; PROLIFERATION; MACROPHAGES; MONOCYTES; INCREASE	Background: IL-10 is an anti-inflammatory cytokine made by lymphocytes, monocytes-macrophages, and eosinophils, and it may have an important role in regulating the asthmatic inflammatory response. IL-10 levels have been reported to be reduced in asthmatic airways, potentially contributing to more intense inflammation. Objective: We sought to determine whether IL-10 levels were deficient in patients with mild asthma compared with controls and to determine whether IL-10 levels were associated with the resolution of eosinophilic inflammation. Methods: We quantified IL-10 levels in the bronchoalveolar lavage (BAL) fluid (ELISA), BAL cells (quantitative immuno-cytochemistry), purified alveolar macrophages-monocytes studied ex vivo (ELISA), before (day 1) and after (24 hours [day 2], 1 week [day 9], and 2 weeks [day 16]) segmental antigen challenge (SAC), and investigated the effect of glucocorticoid treatment on ex vivo macrophage-monocyte IL-10 production. Results: IL-10 levels were significantly higher in the BAL fluid of mild asthmatic subjects who demonstrated a dual reaction (both early and late) after whole lung ragweed inhalation challenge compared with nonallergic, nonasthmatic control subjects before and 24 hours and 1 week after SAG. Macrophages-monocytes obtained before and after SAC from asthmatic patients also secreted increased amounts of IL-10 ex vivo than those from 0controls. Dexamethasone did not significantly change spontaneous IL-10 secretion from macrophages-monocytes in vitro. Quantitative immunocytochemical analysis of BAL cells demonstrated increased IL-10 in macrophages 24 hours after SAC and a similar trend in eosinophils. Conclusion: IL-10 is not deficient in mild asthma. Furthermore, BAL IL-20 levels are significantly higher in asthmatic subjects with a dual response than in control subjects before and after SAG. The increase in IL-10 was coincident with the initial increase in BAL eosinophils, although BAL eosinophilia persisted after IL-10 levels had returned to baseline, suggesting that the increased IL-10 levels could not promptly terminate this localized eosinophilic response.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Crit Care Pulm Allerg & Immunol Dis, Philadelphia, PA 19107 USA	Jefferson University	Peters, SP (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Crit Care Pulm Allerg & Immunol Dis, 1025 Walnut St,805 Coll Bldg, Philadelphia, PA 19107 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024509] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03663] Funding Source: Medline; NIAID NIH HHS [AI24509] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Colavita AM, 2000, CLIN CHEST MED, V21, P263, DOI 10.1016/S0272-5231(05)70265-3; COLLINS DS, 1993, AM REV RESPIR DIS, V147, P677, DOI 10.1164/ajrccm/147.3.677; DELPRETE G, 1993, J IMMUNOL, V150, P353; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Hastie AT, 1997, AM J PHYSIOL-LUNG C, V273, pL401, DOI 10.1152/ajplung.1997.273.2.L401; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Lamkhioued B, 1996, ANN NY ACAD SCI, V796, P203, DOI 10.1111/j.1749-6632.1996.tb32582.x; Magnan A, 1998, ALLERGY, V53, P1092, DOI 10.1111/j.1398-9995.1998.tb03821.x; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURPHY S, 1997, NIH PUBLICATION; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SHAVER JR, 1995, AM J RESP CRIT CARE, V152, P1189, DOI 10.1164/ajrccm.152.4.7551369; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TOMITA K, 2000, AM J RESP CRIT CARE, V161, pA923; VIERA P, 1991, P NATL ACAD SCI USA, V88, P1172	24	29	32	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					880	886		10.1067/mai.2000.110475	http://dx.doi.org/10.1067/mai.2000.110475			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080710				2022-12-18	WOS:000167865200012
J	Busse, WW				Busse, WW			Mechanisms and advances in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB   11, 1999	WASHINGTON, D.C.			allergy; asthma; atopy; cytokines; hay fever; measles; T lymphocytes	EAST-GERMANY; RESPIRATORY-TRACT; VIRAL-INFECTIONS; ATOPY; ASTHMA; PREVALENCE; CHILDREN; WEST; IGE	There have been many attempts to explain the increases in the incidence of allergic diseases, including hay fever and allergic asthma, that have been documented worldwide in recent decades. Epidemiologic studies offer rich opportunities to uncover sometimes unexpected correlations between lifestyle, environmental exposures, temporal development of the immune system, and genetics, Examples include the differing prevalence of atopy, bronchial hyperresponsiveness, and asthma in East and West Germany around the time of reunification, which suggests that a "western" lifestyle presents a greater risk for the development of allergic responses than the more traditionally suspected factor of outdoor air pollutant levels. Other epidemiologic studies suggest how infections may interface with an atopic patterning: Evidence from natural measles exposure and nonwheeze-inducing lower respiratory tract infections in young children implicate early childhood viral infections as protective against the development of atopy and airway allergic sensitivity, although in later life viral airway infections exacerbate asthma symptoms, These studies and others involving the scrutiny of lymphocyte subtypes in atopic individuals, notably T-H1 and T-H2 cells, are helping to formulate a theory of interdependence between the early development of the immune system, allergen exposure, and the diverse community of airway cells whose secretory products generate the final physiologic response pattern.	Univ Wisconsin Hosp, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin Hosp, 600 Highland Ave,Room H6-360, Madison, WI 53792 USA.							BURKHOLTER D, 1995, ACI NEWS, V7, P113; Busse WW, 1997, CIBA F SYMP, V206, P208; CALHOUN WJ, 1991, AM REV RESPIR DIS, V144, P1267, DOI 10.1164/ajrccm/144.6.1267; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; HOLT PG, 1997, CIBA FDN S, V206, P36; IMADA M, 1995, IMMUNOLOGY, V85, P373; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644, DOI 10.1164/ajrccm.151.5.7735627; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; NELSON DJ, 1995, J IMMUNOL, V155, P3517; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; *PHARM INF NETW, 1999, ASTHM INC MORT STILL; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shi HZ, 1999, J ALLERGY CLIN IMMUN, V103, P388, DOI 10.1016/S0091-6749(99)70461-6; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483	21	29	30	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S593	S598						6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	328QU	10856163				2022-12-18	WOS:000087862200001
J	Ratner, PH; Lim, JC; Georges, GC				Ratner, PH; Lim, JC; Georges, GC		Ebastine Study Grp	Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antihistamine; ebastine; loratadine; seasonal allergic rhinitis	DOUBLE-BLIND; EFFICACY; TOLERABILITY; CETIRIZINE; PATTERN	Background: Ebastine and Ioratadine are 2 nonsedating second-generation H-1 antihistamines with once-daily dosing. Objective: We compared the efficacy and safety of ebastine 20 mg and 10 mg, loratadine 10 mg, and placebo administered once daily for 4 weeks in controlling the symptoms of seasonal allergic rhinitis (SAR). Methods: In a double-blind, placebo-controlled, randomized, parallel-group study, 565 patients with ragweed SAR, ages 12 to 70 years, received either ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, or placebo once daily for 4 weeks. Patients recorded morning and evening reflective scores (past 12 hours) as well as snapshot scores (at time of recording) for nasal discharge, congestion, sneezing, itching, and total eye symptoms. Total symptom score (TSS) is the sum of these 5 scores. Results: Ebastine 20 mg produced significantly greater (P < .05) reductions from baseline compared with loratadine 10 mg over the entire treatment period in the mean daily reflective (42.5% vs 36.3%) and mean morning snapshot (40.3% vs 31.3%) TSS. The overall improvement in daily reflective and morning snapshot TSS was comparable between ebastine 10 mg and loratadine 10 mg and significantly better than placebo (P < .05). The total percent of patients with adverse events was similar among all 4 treatment groups (P = .78). Conclusion: Ebastine 20 mg given once daily was significantly superior to loratadine 10 mg given once daily at improving the rhinitis total symptom score throughout the day and at awakening over a 4-week period, Ebastine 20 mg and 10 mg doses were both efficacious and well tolerated in the treatment of SAR.	Rhone Poulenc Pharmaceut Inc, Collegeville, PA 19426 USA; Sylvana Res, San Antonio, TX USA		Georges, GC (corresponding author), Rhone Poulenc Pharmaceut Inc, 500 Arcola Rd,Mailstop 4C30, Collegeville, PA 19426 USA.							BLAISS MS, 1998, DRUG BENEFITS TRENDS, V10, P32; Bousquet J, 1999, ALLERGY, V54, P562, DOI 10.1034/j.1398-9995.1999.00984.x; Davies RJ, 1998, CLIN DRUG INVEST, V16, P413, DOI 10.2165/00044011-199816060-00001; DEMOLINA M, 1989, DRUG INVEST, V1, P40; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; Gehanno P, 1996, ANN ALLERG ASTHMA IM, V76, P507, DOI 10.1016/S1081-1206(10)63269-3; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; LURIA X, 1995, ALLERGY, V50, P199; Molnar J, 1996, J AM COLL CARDIOL, V27, P76, DOI 10.1016/0735-1097(95)00426-2; MORGANROTH J, 1991, AM J CARDIOL, V67, P774, DOI 10.1016/0002-9149(91)90541-R; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; ROSS RN, 1996, AM J MANAG CARE, V2, P285; SMOLENSKY MH, 1995, J ALLERGY CLIN IMMUN, V95, P1084, DOI 10.1016/S0091-6749(95)70212-1; STEMPEL DA, 1996, DRUG BENEFIT TRENDS, V8, P15; STEMPEL DA, 1996, DRUG BENEFIT TRENDS, V8, P51; Storms WW, 1996, DRUGS, V52, P20, DOI 10.2165/00003495-199600521-00006; VINCENT J, 1988, BRIT J CLIN PHARMACO, V26, P503, DOI 10.1111/j.1365-2125.1988.tb05289.x; Wiseman LR, 1996, DRUGS, V51, P260, DOI 10.2165/00003495-199651020-00006; 1999, PHYSICIANS DESK REFE, P2825; 1999, PHYSICIANS DESK REFE, P1705	20	29	34	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1101	1107		10.1067/mai.2000.105525	http://dx.doi.org/10.1067/mai.2000.105525			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856142				2022-12-18	WOS:000087781800009
J	Wolfe, J; Rooklin, A; Grady, J; Munk, ZM; Stevens, A; Prillaman, B; Duke, S; Harding, S				Wolfe, J; Rooklin, A; Grady, J; Munk, ZM; Stevens, A; Prillaman, B; Duke, S; Harding, S			Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by Diskus device in patients with asthma treated with or without inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Thoracic-Society	MAY 16-22, 1997	SAN FRANCISCO, CA	Amer Thorac Soc		fluticasone propionate; asthma; administration; inhaled corticosteroid; Diskus; efficacy	TO-MODERATE ASTHMA; QUALITY-OF-LIFE; BECLOMETHASONE DIPROPIONATE; PERSISTENT ASTHMA; POWDER INHALERS; DRUG EFFICACY; DRY POWDER; BUDESONIDE; AEROSOL; CHRONOTHERAPY	Background: There are limited published data regarding the efficacy of once- versus twice-daily administration of fluticasone propionate. Objective: Our purpose was to evaluate the effectiveness of fluticasone propionate powder 200 mu g/d administered as a once- or twice-daily dosage regimen in patients who were currently being treated with bronchodilators only (BD patients) and in patients who required inhaled corticosteroids for maintenance treatment of asthma (ICS patients). Methods: Five hundred seventy patients were randomly assigned to receive one of the following inhaled treatments through the Diskus device (Glaxo Wellcome, Research Triangle Park, NC) for 12 weeks: fluticasone propionate 100 mu g twice daily (FP100BID) or 200 mu g once daily (FP200QD) or placebo. Results: ED patients treated with FP100BID, FP200QD, and placebo had mean increases in FEV1 from baseline to end point of 0.49 L, 0.37 L, and 0.21 L, respectively (P < .001, FP100BID vs placebo; P = .05, FP200QD vs placebo). ICS patients treated with FP100BID and FP200QD had mean increases in FEV1 of 0.27 L and 0.11 L, respectively, compared with a decrease in FEV1 of -0.08 L with placebo (P < .001, PP100BID vs placebo; P = .023, FP200QD vs placebo). ED patients treated with FP100BID and FP200QD had mean increases in morning peak expiratory flow from baseline to end point of 31 L/min and 27 L/min, respectively, compared with a 1 L/min increase in patients treated with placebo. ICS patients treated with FP100BID had a mean increase in morning peak expiratory flow (from baseline to end point) of IS L/min compared with mean decreases of -3 L/min and -12 L/min in the FP200QD and placebo groups, respectively. More patients were withdrawn from placebo (26% and 48%, in ED and ICS patients, respectively) than from fluticasone propionate (7%-9% [BID-QD] and 18%-32% [BID-QD], in ED and ICS patients, respectively) because of failure to meet predetermined asthma stability criteria. Conclusion: The efficacies of FP100BID and FP200QD were comparable with regard to improvement in pulmonary function and asthma stability in ED patients. In ICS patients, asthma control was maintained with FP200QD, whereas FP100BID provided greater improvements in pulmonary function and asthma stability.	Allergy & Asthma Associates Santa Clara Valley, San Jose, CA 95117 USA; Allergy Res Associates, Chester, PA USA; Boulder Med Clin, Boulder, CO USA; Breco Res Ctr, Houston, TX USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Wolfe, J (corresponding author), Allergy & Asthma Associates Santa Clara Valley, 4155 Moorpk Ave,Suite 3, San Jose, CA 95117 USA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BARNES NC, 1993, EUR RESPIR J, V6, P877; Bisgaard H, 1997, PEDIATR PULM, P27; Boushey HA, 1998, J ALLERGY CLIN IMMUN, V102, pS5, DOI 10.1016/S0091-6749(98)70001-6; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; Galant SP, 1996, ANN ALLERG ASTHMA IM, V77, P112, DOI 10.1016/S1081-1206(10)63496-5; Galant SP, 1999, ANN ALLERG ASTHMA IM, V82, P273, DOI 10.1016/S1081-1206(10)62608-7; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; JONES AH, 1994, RESP MED, V88, P293, DOI 10.1016/0954-6111(94)90059-0; Lawrence M, 1997, AM J RESP CRIT CARE, V156, P744, DOI 10.1164/ajrccm.156.3.9608058; LEBLANC P, 1994, ALLERGY, V49, P380, DOI 10.1111/j.1398-9995.1994.tb02286.x; Lee E, 1980, STAT METHODS SURVIVA; Lorentzen KA, 1996, RESP MED, V90, P609, DOI 10.1016/S0954-6111(96)90019-0; LUNDBACK B, 1993, RESP MED, V87, P609, DOI 10.1016/S0954-6111(05)80264-1; McFadden ER, 1999, J ALLERGY CLIN IMMUN, V104, P46, DOI 10.1016/S0091-6749(99)70112-0; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V103, P267, DOI 10.1016/S0091-6749(99)70501-4; *NIH, 1997, NIH PUBL; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Pearlman DS, 1997, ANN ALLERG ASTHMA IM, V78, P356, DOI 10.1016/S1081-1206(10)63196-1; Peden DB, 1998, J ALLERGY CLIN IMMUN, V102, P32, DOI 10.1016/S0091-6749(98)70052-1; Pincus DJ, 1997, J ALLERGY CLIN IMMUN, V100, P771, DOI 10.1016/S0091-6749(97)70272-0; PINCUS DJ, 1995, J ALLERGY CLIN IMMUN, V95, P1172, DOI 10.1016/S0091-6749(95)70073-0; Polgar G, 1971, PULMONARY FUNCTION T; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Venables T., 1996, BRIT J CLIN PHARMACO, V7, P15; Wasserman SI, 1996, J ASTHMA, V33, P265, DOI 10.3109/02770909609055367; WEINER P, 1995, THORAX, V50, P1270, DOI 10.1136/thx.50.12.1270; Wolfe JD, 1996, CLIN THER, V18, P635, DOI 10.1016/S0149-2918(96)80214-1	38	29	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1153	1161		10.1067/mai.2000.107037	http://dx.doi.org/10.1067/mai.2000.107037			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	327EX	10856150				2022-12-18	WOS:000087781800017
J	Holgate, ST; Arshad, H; Stryszak, P; Harrison, JE				Holgate, ST; Arshad, H; Stryszak, P; Harrison, JE			Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; mometasone furoate; bronchoconstriction; adenosine challenge; placebo	AIRWAY INFLAMMATION; INHALED CORTICOSTEROIDS; ALLERGIC RHINITIS; GLUCOCORTICOIDS; BUDESONIDE; EFFICACY; NASONEX; SAFETY	Background: Mometasone furoate (MF) is a new potent corticosteroid for use in treating asthma. Objective: To test the lower range of the dose-response curve, effects of MF delivered by dry ponder inhaler (DPI) AMP-induced bronchoconstriction were compared with those of placebo. Methods: In a placebo-controlled, 3-phase cross-over, single-center, double-blind study, 15 patients with mild asthma were randomized to three 2-week treatment phases (separated by 4-week washout phases) with MF DPI 50 mu g twice daily, MF DPI 100 mu g twice daily, or placebo. AMP challenge was performed before and at the end of each treatment phase. Results: Thirteen patients completed all 3 phases and were included in the primary efficacy analysis. Treatment with MF DPI 50 mu g twice daily or with MF DPI 100 mu g twice daily significantly reduced the bronchoconstrictor response to AMP, displacing the dose-response curve to the right by 2.81 and 3.11 doubling dilutions, respectively, compared with placebo (P < .0001). The improvement in FEV1 over the 2-week treatment phase was significantly (P less than or equal to .033) greater during treatment with MF DPI 50 mu g or 100 mu g twice daily then with placebo. Peak expiratory flow rate, wheezing scores, difficulty breathing scores. nocturnal awakenings requiring salbutamol, and puffs of salbutamol per day also indicated a greater improvement in respiratory function and symptoms of asthma with MF DPI 50 or 100 mu g twice daily than with placebo. Both doses of MF DPL were well tolerated. Conclusions: Treatment Kith low doses of MF DPI decreased airway responsiveness to AMP challenge and improved secondary measures of pulmonary function and asthma symptoms.	Univ Southampton, Southampton Gen Hosp, Southampton S016 6YD, Hants, England; Schering Plough Res Inst, Kenilworth, NJ 07033 USA	University of Southampton; Merck & Company; Schering-Plough Research Institute	Holgate, ST (corresponding author), Univ Southampton, Southampton Gen Hosp, Med 1,Level D, Southampton S016 6YD, Hants, England.							Aziz I, 1998, EUR RESPIR J, V12, P580, DOI 10.1183/09031936.98.12030580; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BARTON BE, 1991, IMMUNOPHARM IMMUNOT, V13, P251, DOI 10.3109/08923979109019704; Bernstein DI, 1999, RESP MED, V93, P603, DOI 10.1016/S0954-6111(99)90099-9; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51, DOI 10.1016/S1081-1206(10)63084-0; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; Crocker IC, 1998, ANN ALLERG ASTHMA IM, V80, P509, DOI 10.1016/S1081-1206(10)63075-X; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Holgate ST, 1997, CIBA F SYMP, V206, P5; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Medansky R S, 1988, Cutis, V42, P480; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1016/S0194-5998(98)70235-9; NAYAK AS, 1999, IN PRESS ANN ALLERGY; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560, DOI 10.1164/ajrccm/146.3.560; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; POLOSA R, 1993, J ALLERGY CLIN IMMUN, V92, P288, DOI 10.1016/0091-6749(93)90172-C; Prakash A, 1998, DRUGS, V55, P145, DOI 10.2165/00003495-199855010-00009; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1	22	29	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					906	911		10.1067/mai.2000.105709	http://dx.doi.org/10.1067/mai.2000.105709			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808170				2022-12-18	WOS:000087185000008
J	Olsson, N; Rak, S; Nilsson, G				Olsson, N; Rak, S; Nilsson, G			Demonstration of mast cell chemotactic activity in bronchoalveolar lavage fluid collected from asthmatic patients before and during pollen season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inflammation; mast cells; migration; stem cell factor; transforming growth factor-beta	SIGNAL-TRANSDUCTION PATHWAY; ALLERGIC NASAL EPITHELIUM; METACHROMATIC CELLS; AIRWAY INFLAMMATION; MUCOSAL RESPONSE; LAMINA PROPRIA; C3A; PATHOGENESIS; PROVOCATION; CHALLENGE	Background: Mast cells are versatile effector cells of primary importance in asthma and airway inflammation. During inflammation mast cells accumulate in the bronchial epithelium, The mechanism for this increase in mast cell number has not been defined. Objectives: The aim of this study was to examine the presence of mast cell chemotactic activity in bronchoalveolar lavage (BAL) fluid taken before and at the end of 2 pollen seasons from patients with allergic asthma, Methods: To measure mast cell chemotactic activity, we used a modified Boyden chamber and the human mast cell line HMC-1 or in vitro-developed mast cells as responder cells. Results: A total of 27 patients were investigated, of which 8 exhibited mast cell chemotactic activity in their BAL fluid collected before season, A significant increase in the activity was found in 18 of 27 BAL fluids sampled at the end of the pollen season, No difference was found between patients treated with immunotherapy or placebo. The presence of stem cell factor could be detected in all BAL fluids analyzed. Blocking antibodies against stem cell factor or transforming growth factor-beta partially blocked the activity in some of the BAL fluids. Treatment of the responder cells with pertussis toxin reduced the migratory activity in 13 of 14 BAL fluids collected during pollen season. Conclusion: This study demonstrates the presence of mast cell chemotactic activity in BAL fluids from patients with allergic asthma, with a significant increase In activity during pollen season. The major part of this activity consisted of factors mediating their effect through G(i)-protein coupled receptors, This activity may be responsible fur the mast cell accumulation in the intraepithelial layer seen in allergic asthmatic patients.	Univ Uppsala, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Sahlgrenska Univ Hosp, Allergy Ctr, S-41345 Gothenburg, Sweden	Uppsala University; Sahlgrenska University Hospital	Nilsson, G (corresponding author), Univ Uppsala, Dept Genet & Pathol, S-75185 Uppsala, Sweden.			Nilsson, Gunnar/0000-0001-6795-5512				BORRES MP, 1990, ALLERGY, V45, P98, DOI 10.1111/j.1398-9995.1990.tb00465.x; Busse W. W., 1998, ALLERGY PRINCIPLES P; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Cheney R, 1996, PUBLIC HEALTH REP, V111, P83; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; Galli SJ, 1997, J EXP MED, V186, P343, DOI 10.1084/jem.186.3.343; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80, DOI 10.1164/ajrccm/148.1.80; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; KAWABORI S, 1985, CLIN ALLERGY, V15, P509, DOI 10.1111/j.1365-2222.1985.tb02303.x; KAWABORI S, 1983, CLIN ALLERGY, V13, P181, DOI 10.1111/j.1365-2222.1983.tb02586.x; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lippert U, 1998, J IMMUNOL, V161, P2600; Liu FT, 1997, J CLIN INVEST, V99, P1465, DOI 10.1172/JCI119306; Nilsson G, 1996, J IMMUNOL, V157, P1693; NILSSON G, 1994, J IMMUNOL, V153, P3717; Nilsson G, 1999, BLOOD, V93, P2791; NILSSON G, 1994, SCAND J IMMUNOL, V39, P489, DOI 10.1111/j.1365-3083.1994.tb03404.x; Nilsson G, 1996, ALLERGY ASTHMA PROC, V17, P59, DOI 10.2500/108854196778645074; Nilsson G., 1995, ASTHMA RHINITIS, P195; OKUDA M, 1983, EUR J RESPIR DIS, V64, P7; Olsson N, 1999, BIOCHEM BIOPH RES CO, V254, P143, DOI 10.1006/bbrc.1998.9911; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; PESCI A, 1993, AM REV RESPIR DIS, V147, P684, DOI 10.1164/ajrccm/147.3.684; PIPKORN U, 1989, AM REV RESPIR DIS, V140, P729, DOI 10.1164/ajrccm/140.3.729; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Saito H, 1996, J IMMUNOL, V157, P343; Teran LM, 1997, CLIN EXP ALLERGY, V27, P396; VANDEGRAAF EA, 1992, J IMMUNOL METHODS, V147, P241, DOI 10.1016/S0022-1759(12)80014-7; VIEGAS M, 1987, INT ARCH ALLER A IMM, V82, P275, DOI 10.1159/000234205; WASSERMAN SI, 1994, AM J RESP CRIT CARE, V150, pS39, DOI 10.1164/ajrccm/150.5_Pt_2.S39	35	29	34	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					455	461		10.1067/mai.2000.104380	http://dx.doi.org/10.1067/mai.2000.104380			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719293				2022-12-18	WOS:000088946700009
J	Kulig, M; Bergmann, R; Edenharter, G; Wahn, U				Kulig, M; Bergmann, R; Edenharter, G; Wahn, U		Multicenter Allergy Study Grp	Does allergy in parents depend on allergy in their children? Recall bias in parental questioning of atopic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic diseases; atopic family history; questioning of parents; children; recall bias	ENVIRONMENTAL-FACTORS; MEDICAL RECORDS; FAMILY HISTORY; RISK-FACTORS; CHILDHOOD; EPIDEMIOLOGY; PREDICTORS; AGREEMENT; SYMPTOMS; NEWBORN	Background: A positive atopic family history has proved to be one important risk factor for the development of atopic dis eases in offspring. However, many epidemiologists are concerned about the accuracy and reliability of data because responses to questionnaires can be biased for many reasons. Objective: The study investigated whether responses of parents questioned about their atopic diseases change depending on the development of atopic symptoms in their children. Methods: During a prospective birth cohort study on atopy in children (the Multicenter Allergy Study) parents filled out questionnaires twice within 2 years about their atopic diseases. Differences between the 2 responses were examined by log-linear and logistic regression models depending on the diagnosed atopy status of the study children. Results: Mothers tended to report more atopic diseases in the second questioning than in the first, indicating a nondifferential misclassification Fathers were influenced by the development of atopic diseases in their children: they reported significantly more atopic diseases if the child developed atopic illness with atopic dermatitis. Conclusion: In parental questioning about atopic diseases, a recall bias must be considered for the association of atopic family history and atopy In children. Especially in case-control and cross-sectional studies, such misclassifications can result in biased estimates of prognosis and risk factors.	Humboldt Univ, Klinikum Charite, Inst Arbeitzmed Sozialmed & Epidemiol, D-10098 Berlin, Germany; Humboldt Univ, Dept Pediat Pneumol & Immunol, Berlin, Germany; Robert Koch Inst, D-1000 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Robert Koch Institute	Kulig, M (corresponding author), Humboldt Univ, Klinikum Charite, Inst Arbeitzmed Sozialmed & Epidemiol, D-10098 Berlin, Germany.							ABDULRAZZAQ YM, 1994, ALLERGY, V49, P737, DOI 10.1111/j.1398-9995.1994.tb02096.x; ABERG N, 1993, CLIN EXP ALLERGY, V23, P829, DOI 10.1111/j.1365-2222.1993.tb00260.x; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; BERGMANN KE, 1990, CLIN EXP ALLERGY, V20, P21, DOI 10.1111/j.1365-2222.1990.tb02466.x; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann R L, 1993, Pediatr Allergy Immunol, V4, P130, DOI 10.1111/j.1399-3038.1993.tb00081.x; BOUSQUET J, 1995, NESTLE NUTR WORKS SE, V34, P93; CRONER S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI DOI 10.1111/J.1399-3038.1990.TB00003.X; Diepgen TL, 1996, J INVEST DERMATOL, V106, P977, DOI 10.1111/1523-1747.ep12338475; Francis B., 1993, GLIM SYSTEM RELEASE; HAPPLE R, 1982, INT ARCH ALLER A IMM, V68, P90, DOI 10.1159/000233072; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834, DOI 10.1093/oxfordjournals.aje.a116745; Johnson CC, 1996, CLIN EXP ALLERGY, V26, P624, DOI 10.1111/j.1365-2222.1996.tb00588.x; KHOURY MJ, 1995, EPIDEMIOLOGY, V6, P511, DOI 10.1097/00001648-199509000-00009; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LINDSEY J. K., 1995, MODELLING FREQUENCY; LINET MS, 1989, J CLIN EPIDEMIOL, V42, P1207, DOI 10.1016/0895-4356(89)90119-4; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MAY SM, 1994, J CLIN EPIDEMIOL, V47, P1315, DOI 10.1016/0895-4356(94)90137-6; MERTENS TE, 1993, LANCET, V342, P418, DOI 10.1016/0140-6736(93)92820-J; ODELRAM H, 1995, ALLERGY, V50, P585, DOI 10.1111/j.1398-9995.1995.tb01204.x; PHILLIPS PH, 1991, AM J EPIDEMIOL, V133, P757, DOI 10.1093/oxfordjournals.aje.a115954; RUIZ RGG, 1992, CLIN EXP ALLERGY, V22, P762, DOI 10.1111/j.1365-2222.1992.tb02816.x; VERVLOET D, 1991, CLIN EXP ALLERGY, V21, P733, DOI 10.1111/j.1365-2222.1991.tb03203.x; WRIGHT AL, 1994, PEDIATRICS, V94, P895	28	29	30	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				274	278		10.1016/S0091-6749(00)90076-9	http://dx.doi.org/10.1016/S0091-6749(00)90076-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669847				2022-12-18	WOS:000085402200011
J	Creticos, PS; Eiden, JJ; Balcer, SL; Van Nest, G; Kagey-Sobotka, A; Tuck, SF; Norman, PS; Lichtenstein, LM				Creticos, PS; Eiden, JJ; Balcer, SL; Van Nest, G; Kagey-Sobotka, A; Tuck, SF; Norman, PS; Lichtenstein, LM			Immunostimulatory oligonucleotides conjugated to Amb a 1: Safety, skin test reactivity, and basophil histamine release	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Johns Hopkins Univ, Baltimore, MD 21218 USA	Johns Hopkins University									0	29	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	2	S		215	S70	S70		10.1016/S0091-6749(00)90645-6	http://dx.doi.org/10.1016/S0091-6749(00)90645-6			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	287WR					2022-12-18	WOS:000085530100213
J	Peterson, EL; Ownby, DR; Kallenbach, L; Johnson, CC				Peterson, EL; Ownby, DR; Kallenbach, L; Johnson, CC			Evaluation of air and dust sampling schemes for Fel d 1, Der f 1, and Der p 1 allergens in homes in the Detroit area	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Der f 1; Der p 1; Fel d 1; correlation; sampling	IN-HOUSE DUST; MITE ALLERGENS; ASTHMATIC-CHILDREN; INDOOR ALLERGENS; AIRBORNE DUST; DER-II	Background: Studies often use a point estimate of allergen exposure without fully justifying the accuracy of this single measure as an estimate of total exposure. Many studies have reported relationships between indoor allergen concentrations and manifestations of allergic disease on the basis of single samples. Objectives: The purposes of this study were to (1) characterize the variability in dust and air concentrations of allergens, (2) assess the relationships between dust and air concentrations of allergens, and (3) determine the minimum number and timing of samples to characterize annual indoor allergen exposure. Methods: As part of a prospective cohort study of asthma in children, air and dust samples were repeatedly obtained from the homes of children residing in suburban Detroit, Michigan. Concentrations of Fel d 1, Der f 1, and Der p 1 were measured in the samples. The results of various patterns of sampling were compared with yearly averages. Results: The concentrations of all 3 allergens in both air and dust varied widely both within and between homes. The allergen concentrations had peak concentrations in the fall. There was little correlation between air and dust concentrations. Our results indicate that as few as 2 or 3 samples taken late in the year provide good estimates of the annual average concentrations. Conclusions: Two or 3 samples, obtained 1 month apart and taken late in the year, represent the best balance between sampling effort and accuracy of the yearly exposure estimates of Fel d 1, Der f 1, and Der p 1 in temperate climates similar to those of Detroit, Michigan.	Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Med Coll Georgia, Dept Pediat, Sect Allergy Immunol, Augusta, GA 30912 USA; Wayne State Univ, Sch Med, Dept Community Med, Detroit, MI 48201 USA	Henry Ford Health System; Henry Ford Hospital; University System of Georgia; Augusta University; Wayne State University	Peterson, EL (corresponding author), Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, 1 Ford Pl,3E, Detroit, MI 48202 USA.			Johnson, Christine Cole/0000-0002-6864-6604	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024156] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24156] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; CHAPMAN MD, 1995, PEDIAT ALLERG IMM-UK, V6, P8, DOI 10.1111/j.1399-3038.1995.tb00378.x; COCHRAN WG, 1997, SAMPLING TECHNIQUES, P150; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DYBENDAL T, 1994, ALLERGY, V49, P210, DOI 10.1111/j.1398-9995.1994.tb02651.x; KUEHR J, 1994, CLIN EXP ALLERGY, V24, P229, DOI 10.1111/j.1365-2222.1994.tb00224.x; LEDFORD DK, 1994, J ALLERGY CLIN IMMUN, V94, P327, DOI 10.1053/ai.1994.v94.a56012; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MUNIR AKM, 1994, ALLERGY, V49, P508, DOI 10.1111/j.1398-9995.1994.tb01121.x; MUNIR AKM, 1995, ALLERGY, V50, P55, DOI 10.1111/j.1398-9995.1995.tb02483.x; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x	16	29	30	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				348	355		10.1016/S0091-6749(99)70378-7	http://dx.doi.org/10.1016/S0091-6749(99)70378-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452756				2022-12-18	WOS:000082364800027
J	White, MV; Sander, N				White, MV; Sander, N			Asthma from the perspective of the patient	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; side effects; medications; beta-agonists; nebulizer; patient satisfaction		Background: The published literature is lacking in data on the frequency and severity of medication side effects in the general asthma population. Methods: Questionnaires regarding asthma severity, treatment, and medication side effects were answered by 1230 and 604 pediatric and adult asthmatics, respectively, 70% to 75% of whom were consulting a specialist. Results: Most respondents (58%-79%) reported unwanted side effects from their bronchodilators, most of which had been racemic albuterol prescribed in either generic or name brand form. Side effects were most common in nebulizer users of all ages and in pediatric patients using oral medications. The most common troublesome side effects were jitteriness (58%), restlessness (57%), tachycardia (56%) and cough (56%) in the pediatric patients and tachycardia (64%), jitteriness (60%), shaky hands (43%), and restlessness (42%) in the adult respondents. Most patients had spoken to their physicians about their side effects, and the most common response was to change brands within the same class of medication, adjust the dose, or advise the patients to tolerate the side effects because the medications were necessary and side effects were to be expected. Fewer than 4% of all respondents viewed their physicians as "caring/sympathetic/willing to listen/discuss their bronchodilator side effects." Twenty-five to thirty percent of patients had reduced their bronchodilator dose on their own, and 14% to 24% had skipped doses to avoid unwanted side effects. Hospitalizations mere infrequent and were most commonly seen in the nebulizer users, who were also rated by their physicians as more likely to have severe asthma. Other markers of asthma control (such as emergency room visits, unscheduled doctor visits, and being sent home from school/work for asthma symptoms) were not only common in the nebulizer user group but also in children who used oral medications. This group was more likely to have been classified by their physicians as having mild asthma, suggesting perhaps a need for more intensive asthma education in this group. Conclusion: Medication side effects are common in individuals with asthma and are most often ascribed by the patients to their bronchodilators. There is a need for new, rapid-acting bronchodilators with fewer side effects.	Inst Asthma & Allergy, Washington, DC 20010 USA; Allergy & Asthma Network Mothers Asthmat, Fairfax, VA USA		White, MV (corresponding author), Inst Asthma & Allergy, 106 Irving St NW,Suite 108, Washington, DC 20010 USA.							Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; Garbe E, 1998, JAMA-J AM MED ASSOC, V280, P539, DOI 10.1001/jama.280.6.539; *NIH NAT HEART LUN, 1997, PUBL NIH NAT HEART L; *NIH NAT HEART LUN, 1995, PUBL NIH NAT HEART L; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; Saha MT, 1997, ACTA PAEDIATR, V86, P138, DOI 10.1111/j.1651-2227.1997.tb08854.x; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455	8	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S47	S52		10.1016/S0091-6749(99)70273-3	http://dx.doi.org/10.1016/S0091-6749(99)70273-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452788	Bronze			2022-12-18	WOS:000082419400006
J	Aden, E; Weber, B; Bossert, J; Teppke, M; Frank, E; Wahl, R; Fiebig, H; Cromwell, O				Aden, E; Weber, B; Bossert, J; Teppke, M; Frank, E; Wahl, R; Fiebig, H; Cromwell, O			Standardization of Alternaria alternata: Extraction and quantification of Alt a 1 by using an mAb-based 2-site binding assay	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternaria alternata; monoclonal antibody; Alt a 1; ELISA; skin prick test; allergens; fungi	MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; MAJOR ALLERGENS; IGE ANTIBODIES; DERMATOPHAGOIDES; PROTEINS; ELISA	Background: Alternaria alternata is recognized as an important cause of allergic disease. As with other molds, the extracts of A alternata used for diagnosis and therapy are highly heterogeneous, and there is a need for improved standardization. The major allergen Alt a 1 is well characterized and has been produced as a recombinant protein, but very few data are available on the Alt a 1 content in extracts. Objective: An assay for the quantification of Alt a 1 was developed and used for monitoring batch-to-batch consistency of A alternata extracts, and the correlation between skin prick test responses and Alt a 1 concentrations was studied. Methods: A 2-site binding assay based on an Alt a 1-specific mAb was developed and used for the quantification of Alt a 1 in allergen extracts. Quantitative skin prick tests were performed on 16 A alternata-sensitive patients and correlated with the Alt a 1 concentration. Results: The Alt a 1-specific mAb was found to be suitable for affinity purification, as well as for a 2-site binding quantification assay. In allergen extracts the Alt a 1 content was estimated as 2% to 4.7% of total protein. Quantitative skin prick tests showed an Alt a 1 concentration-dependent response. Conclusion: Quantification of Alt a 1 in A alternata extracts reflects their batch-to-batch consistency Skin prick test responses to a standardized A alternata extract correlate with the Alt a 1 contents. An extract containing 3.7 mu g/mL Alt a 1 caused a response equal to that of a 1% histamine dihydrochloride solution.	Allergopharma Joachim Ganzer KG, D-21465 Reinbek, Germany; Univ Hamburg, Dept Biochem & Mol Biol, Hamburg, Germany	Allergopharma; University of Hamburg	Weber, B (corresponding author), Allergopharma Joachim Ganzer KG, Hermann Korner Str 52, D-21465 Reinbek, Germany.							ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; ARRUDA LK, 1992, J ALLERGY CLIN IMMUN, V89, P1166, DOI 10.1016/0091-6749(92)90301-H; Bush RK, 1997, ANN ALLERG ASTHMA IM, V78, P287, DOI 10.1016/S1081-1206(10)63183-3; CHAPMAN MD, 1988, ALLERGY S5, V42, P7; Crameri R, 1998, MYCOSES, V41, P56, DOI 10.1111/j.1439-0507.1998.tb00585.x; CURRAN IHA, 1993, INT ARCH ALLERGY IMM, V102, P267, DOI 10.1159/000236535; De Vouge MW, 1998, INT ARCH ALLERGY IMM, V116, P261, DOI 10.1159/000023954; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; FAHLBUSCH B, 1994, CLIN EXP ALLERGY, V24, P752, DOI 10.1111/j.1365-2222.1994.tb00986.x; HARLOW E, 1988, ANTIBODIES LABORATOR, P524; HELM RM, 1988, J ALLERGY CLIN IMMUN, V81, P651, DOI 10.1016/0091-6749(88)91035-4; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEYER CH, 1994, CLIN EXP ALLERGY, V24, P1041, DOI 10.1111/j.1365-2222.1994.tb02741.x; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PARIS S, 1991, J ALLERGY CLIN IMMUN, V88, P902, DOI 10.1016/0091-6749(91)90247-L; PARIS S, 1990, J ALLERGY CLIN IMMUN, V85, P941, DOI 10.1016/0091-6749(90)90081-E; Portnoy J, 1998, ANN ALLERG ASTHMA IM, V81, P59; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Weber B, 1998, ALLERGOLOGIE, V21, P116; YASUEDA H, 1994, CLIN EXP ALLERGY, V24, P1030, DOI 10.1111/j.1365-2222.1994.tb02739.x	23	29	30	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					128	135		10.1016/S0091-6749(99)70124-7	http://dx.doi.org/10.1016/S0091-6749(99)70124-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400850				2022-12-18	WOS:000081738900019
J	Janezic, A; Chapman, CJ; Snow, RE; Hourihane, JO; Warner, JO; Stevenson, FK				Janezic, A; Chapman, CJ; Snow, RE; Hourihane, JO; Warner, JO; Stevenson, FK			Immunogenetic analysis of the heavy chain variable regions of IgE from patients allergic to peanuts	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; allergy; peanut; variable region genes; V-H; B cells	ARA-H-I; ATOPIC-DERMATITIS; ANTIBODY DIVERSITY; B-LYMPHOCYTES; GENE; HYPERSENSITIVITY; IDENTIFICATION; REPERTOIRE; EXPRESSION; SEQUENCES	Peanuts are one of the most allergenic of the foods, and hypersensitivity responses to peanut allergens can be fatal. Although the nature of the antigenic components of peanuts is being defined at the molecular level, there is little information on the induced IgE antibodies, which are central to the allergic reaction. Recognition sites of IgE antibody molecules arise from the variable regions of heavy and light chains (V-H and V-L). By using nested polymerase chain reactions with specific primers for the available repertoire of V-H genes, together with primers in the constant epsilon region, we have amplified V-H sequences of IgE from blood lymphocytes of two patients with peanut allergy. After cloning and sequencing the products, we found a predominance of V(H)1 family use in both patients, which was not found in control IgM-specific primers. The IgE V-H sequences were highly somatically mutated, but in only six of 17 cases was there clear evidence for clustering of amino acids indicative of antigen selection. Previous results from patients with allergy to house dust mites have indicated predominance of V(H)5 use and little evidence for antigen selection. Although results from two patients allergic to peanuts must be regarded as preliminary, they do suggest that the IgE response to peanuts may have a different V-H bias, with a similar mutational pattern.	Southampton Univ Hosp, Mol Immunol Grp, Tenovus Lab, Southampton SO16 6YD, Hants, England; Southampton Univ Hosp, Dept Child Hlth, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Stevenson, FK (corresponding author), Southampton Univ Hosp, Mol Immunol Grp, Tenovus Lab, Southampton SO16 6YD, Hants, England.		Warner, John/AAF-9587-2020; Chapman, Caroline/B-7503-2012	Stevenson, Freda/0000-0002-0933-5021				BEREK C, 1993, IMMUNOL TODAY, V14, P400, DOI 10.1016/0167-5699(93)90143-9; BEREK C, 1992, IMMUNOL REV, V126, P5, DOI 10.1111/j.1600-065X.1992.tb00628.x; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BURKS AW, 1995, INT ARCH ALLERGY IMM, V107, P248, DOI 10.1159/000236993; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; CAMPBELL MJ, 1992, MOL IMMUNOL, V29, P193, DOI 10.1016/0161-5890(92)90100-C; CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; CHAPMAN CJ, 1993, J IMMUNOL, V151, P1051; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; Ewan PW, 1996, BRIT MED J, V312, P1074; HAWKINS RE, 1994, BLOOD, V83, P3279; KASAIAN MT, 1995, CLIN EXP ALLERGY, V25, P794; KIM S, 1981, CELL, V27, P573, DOI 10.1016/0092-8674(81)90399-8; MATTILA PS, 1995, EUR J IMMUNOL, V25, P2578, DOI 10.1002/eji.1830250926; Mockridge CI, 1996, J IMMUNOL, V157, P2449; SAHOTA S, 1994, LEUKEMIA, V8, P1285; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SASSO EH, 1989, J IMMUNOL, V142, P2778; SILVERMAN GJ, 1992, INT REV IMMUNOL, V9, P55; Snow Rachel E., 1996, Human Antibodies and Hybridomas, V7, P157; SNOW RE, 1995, J IMMUNOL, V154, P5576; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	27	29	30	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					391	396		10.1016/S0091-6749(98)70253-2	http://dx.doi.org/10.1016/S0091-6749(98)70253-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525457				2022-12-18	WOS:000072593900018
J	Lemanske, RF				Lemanske, RF			A review of the current guidelines for allergic rhinitis and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	21st Century Management of Upper Respiratory Allergic Diseases - a Focus on Allergy and Asthma	JAN 13-14, 1997	CHICAGO, ILLINOIS				CHILDREN; IMMUNOTHERAPY		Univ Wisconsin Hosp, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Lemanske, RF (corresponding author), Univ Wisconsin Hosp, 600 Highland Ave,H4-432, Madison, WI 53792 USA.							ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; BURNEY PGJ, 1993, ASTHMA, P3; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR ML, 1987, J EPIDEMIOL COMMUN H, V41, P185, DOI 10.1136/jech.41.3.185; CRETICOS PS, 1992, JAMA-J AM MED ASSOC, V268, P2831; GREENBERGER PA, 1992, IMMUNOL ALLERGY CLIN, V12, P1; *INT RHIN MAN WORK, 1994, EUR J ALLERGY CLIN S, V19, P6; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MURRAY AB, 1990, J ALLERGY CLIN IMMUN, V86, P732, DOI 10.1016/S0091-6749(05)80177-0; National Heart Lung and Blood Institute National Asthma Education Program, 1991, J ALLERGY CLIN IMMUN, V88, P425, DOI DOI 10.1016/0091-6749(91)92135-N; *NIH, 1995, NHBLI PUBL; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194	14	29	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	2	S			S392	S396		10.1016/S0091-6749(98)70228-3	http://dx.doi.org/10.1016/S0091-6749(98)70228-3			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZA245	9500736				2022-12-18	WOS:000072343900012
J	Douglas, RG; Weiner, JM; Abramson, MJ; O'Hehir, RE				Douglas, RG; Weiner, JM; Abramson, MJ; O'Hehir, RE			Prevalence of severe ant-venom allergy in southeastern Australia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MYRMECIA		Monash Univ, Alfred Hosp, Dept Allergy & Clin Immunol, Melbourne, Vic 3181, Australia; Monash Univ, Sch Med, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Monash University	Weiner, JM (corresponding author), Monash Univ, Alfred Hosp, Dept Allergy & Clin Immunol, Melbourne, Vic 3181, Australia.		Abramson, Michael/AAQ-2671-2020; O'Hehir, Robyn E/H-3627-2011	Abramson, Michael/0000-0002-9954-0538; O'Hehir, Robyn E/0000-0002-3489-7595; Weiner, John/0000-0001-5895-8973				DONOVAN GR, 1993, BIOCHIM BIOPHYS ACTA, V1171, P272, DOI 10.1016/0167-4781(93)90065-L; STREET MD, 1994, CLIN EXP ALLERGY, V24, P590, DOI 10.1111/j.1365-2222.1994.tb00957.x; STUCKEY M, 1982, LANCET, V2, P41; Weiner JM, 1995, ANN ALLERG ASTHMA IM, V74, P60	4	29	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				129	131		10.1016/S0091-6749(98)70206-4	http://dx.doi.org/10.1016/S0091-6749(98)70206-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449514	Bronze			2022-12-18	WOS:000071539800022
J	Robinson, PJ; Hegele, RG; Schellenberg, RR				Robinson, PJ; Hegele, RG; Schellenberg, RR			Allergic sensitization increases airway reactivity in guinea pigs with respiratory syncytial virus bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute bronchiolitis; allergic sensitization; animal model	SUBSTANCE-P; SMOOTH-MUSCLE; ASTHMA; INFECTION; HYPERRESPONSIVENESS; ENDOPEPTIDASE	Background: Respiratory syncytial virus (RSFT) causes acute bronchiolitis in children and has been implicated in the pathogenesis of recurrent wheezing and asthma, However, few, children exposed to RSV experience acute bronchiolitis or its sequelae, suggesting a subgroup of susceptible children, An allergic diathesis may predispose children to subsequent airway disease. Objective: This study was carried out to determine whether a preexisting allergic state, induced by repeated inhalational exposures to ovalbumin, potentiates nonspecific airway responsiveness to acetylcholine and increases airway inflammation during acute RSV bronchiolitis in guinea pigs. Methods: Forty guinea pigs were randomized into four groups: nonsensitized, noninfected (ovalbumin-, RSV-); sensitized, noninfected (ovalbumin+, RSV-): nonsensitized, infected (ovalbumin-, RSV+); sensitized, infected (ovalbumin+, RSV+), Depending on grouping, animals were exposed to either repeated aerosols of ovalbumin or saline solution and were subsequently inoculated with either human RSV or uninfected culture medium. Six days after inoculation, animals underwent acetylcholine challenge, and lung specimens were prepared for histologic scoring of airway inflammation. Results: Maximal increases in pulmonary resistance (centimeters of water per milliliter per second) to acetylcholine were greater for RSV alone (12.4 +/- 3.9) and ovalbumin alone (13.7 +/- 3.9) compared with controls (4.3 +/- 1.1), but significantly greater increases occurred in ovalbumin+, RSV+ animals (34.0 +/- 11.0), These ovalbumin+, RSV+ animals demonstrated the combined histologic changes noted with RSV alone and ovalbumin alone including airway epithelial necrosis, mononuclear and granulocyte infiltrates, airway wall edema, hyperplasia of bronchus-associated lymphoid tissue, and goblet cell metaplasia, Conclusion: Prior allergic sensitization potentiates the physiologic and structural changes induced by acute RSV bronchiolitis. These results suggest that an allergic diathesis may increase the severity of RSV infections in children.	UNIV BRITISH COLUMBIA,PULM RES LAB,ST PAULS HOSP,VANCOUVER,BC V6Z 1Y6,CANADA	St. Paul's Hospital; University of British Columbia; University of Saskatchewan				Hegele, Richard/0000-0003-1073-8044				BARNETT K, 1988, AM REV RESPIR DIS, V138, P780, DOI 10.1164/ajrccm/138.4.780; DRURY RAB, 1967, CARLETONS HISTOLOGIC, P48; FRYER AD, 1991, BRIT J PHARMACOL, V102, P267, DOI 10.1111/j.1476-5381.1991.tb12164.x; GODFREY K, 1986, MED USES STATISTICS, P205; HEGELE RG, 1993, EUR RESPIR J, V6, P1324; HULBERT WC, 1985, J APPL PHYSIOL, V58, P625, DOI 10.1152/jappl.1985.58.2.625; ISHIDA K, 1989, J APPL PHYSIOL, V67, P1133, DOI 10.1152/jappl.1989.67.3.1133; LADENIUS ARC, 1995, BRIT J PHARMACOL, V115, P1048, DOI 10.1111/j.1476-5381.1995.tb15917.x; LANDAU LI, 1994, THORAX, V49, P293, DOI 10.1136/thx.49.4.293; LUNDBERG JM, 1983, P NATL ACAD SCI-BIOL, V80, P1120, DOI 10.1073/pnas.80.4.1120; MATSAS R, 1985, BIOCHEM J, V228, P487, DOI 10.1042/bj2280487; MATSAS R, 1983, P NATL ACAD SCI-BIOL, V80, P3111, DOI 10.1073/pnas.80.10.3111; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; Robinson PJ, 1996, PEDIATR PULM, V22, P248, DOI 10.1002/(SICI)1099-0496(199610)22:4<248::AID-PPUL4>3.0.CO;2-I; SHEPPARD D, 1988, J CLIN INVEST, V81, P1111, DOI 10.1172/JCI113424; SIGURS N, 1995, PEDIATRICS, V95, P500; VONNEERGAARD K, 1927, Z KLIN MED, V105, P51; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8	19	29	33	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					492	498		10.1016/S0091-6749(97)70141-6	http://dx.doi.org/10.1016/S0091-6749(97)70141-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338543				2022-12-18	WOS:A1997YA52900011
J	Klouche, M; Klinger, MHF; Kuhnel, W; Wilhelm, D				Klouche, M; Klinger, MHF; Kuhnel, W; Wilhelm, D			Endocytosis, storage, and release of IgE by human platelets: Differences in patients with type I allergy and nonatopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; platelets; alpha-granule; allergy; PAF; RANTES	HUMAN BLOOD-PLATELETS; CYTO-TOXIC FUNCTIONS; ADHESIVE PROTEINS; HUMAN EOSINOPHILS; ACTIVATING FACTOR; ALPHA-GRANULES; RANTES; LOCALIZATION; RECEPTOR; INTERNALIZATION	Platelets of atopic individuals differ in alpha-granular contents and in the amount of biologically active mediators released compared with platelets of nonatopic subjects, Because platelets carry the low-affinity IgE receptor (CD23), they may contribute to long-lasting IgE sensitivity by serving as a storage pool for IgE. We compared 45 atopic individuals with immediate-type allergies and 25 nonatopic control subjects with respect to storage and release of IgE by their platelets, Platelets of atopic individuals were characterized by a 10-fold higher median IgE content compared with those of nonatopic control subjects, The platelet IgE content correlated with the serum IgE level in the four atopic individuals with seasonal allergies who were followed up monthly over I year, Platelet stimulation with platelet activating factor, but not with thrombin or adenosine diphosphate, resulted in a release of 65% of the stored IgE. Conversely, platelet stimulation with monoclonal IgE/kappa resulted in the release of the chemokine RANTES. Platelet alpha-granules were identified as the main storage compartment for IgE by postembedding immunocytochemistry, Although more than half of the alpha-granules showed gold labeling for IgE, additional labeling was found on the external face of the plasma membrane and within the open canalicular system, indicating endocytosis and exocytosis of IgE, Moreover, the detection of CD23 not only on the plasma membrane but also on membranes of the alpha-granules further supports the existence of an exchange of IgE between the blood plasma and an internal storage compartment. Endocytosis could be confirmed by the uptake of an IgE myeloma protein coupled to colloidal gold. We conclude that platelets of atopic individuals may contribute to allergic inflammation by serving as a storage pool for IgE and by their increased capacity to liberate further mediators of allergy in response to IgE stimulation.	UNIV LUBECK,SCH MED,INST IMMUNOL & TRANSFUS MED,D-2400 LUBECK,GERMANY; UNIV LUBECK,SCH MED,INST ANAT,D-2400 LUBECK,GERMANY; PRODERM,INST APPL DERMATOL RES,SCHENEFELD,GERMANY	University of Lubeck; University of Lubeck								ALAM R, 1993, J IMMUNOL, V150, P3442; AMEISEN JC, 1986, BRIT J HAEMATOL, V64, P21, DOI 10.1111/j.1365-2141.1986.tb07570.x; AVERILL FJ, 1992, AM REV RESPIR DIS, V145, P571, DOI 10.1164/ajrccm/145.3.571; BEHNKE O, 1992, J SUBMICR CYTOL PATH, V24, P169; BEHNKE O, 1989, THROMB HAEMOSTASIS, V62, P718; CAPRON A, 1985, INT ARCH ALLER A IMM, V77, P107, DOI 10.1159/000233762; CAPRON M, 1986, J EXP MED, V164, P72, DOI 10.1084/jem.164.1.72; FOREMEN JC, 1994, TXB IMMUNOPHARMACOLO, P53; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268-960X(93)90024-X; HERD CM, 1994, EUR RESPIR J, V7, P1145; Holmsen H, 1969, Scand J Haematol Suppl, V8, P3; HOLMSEN H, 1970, J LAB CLIN MED, V75, P840; JOSEPH M, 1986, EUR J IMMUNOL, V16, P306, DOI 10.1002/eji.1830160318; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KLINGER MHF, 1995, CELL TISSUE RES, V279, P453, DOI 10.1007/BF00318157; KLINGER MHF, 1995, INT ARCH ALLERGY IMM, V107, P541, DOI 10.1159/000237097; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; KUNA P, 1992, J IMMUNOL, V149, P636; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; Mannaioni P F, 1995, Inflamm Res, V44 Suppl 1, pS16, DOI 10.1007/BF01674374; MENTLEIN R, 1989, CELL TISSUE RES, V258, P309; MORLEY J, 1984, NEW ENGL J MED, V17, P1142; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PAGE C P, 1989, European Respiratory Journal, V2, p483S; POULSEN LK, 1992, ALLERGY, V47, P560, DOI 10.1111/j.1398-9995.1992.tb00682.x; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SPIEGELBERG HL, 1984, ADV IMMUNOL, V35, P61, DOI 10.1016/S0065-2776(08)60574-X; SUZUKI H, 1990, HISTOCHEMISTRY, V94, P337; TSICOPOULOS A, 1989, J IMMUNOL, V142, P2683; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WENCELDRAKE JD, 1990, AM J PATHOL, V136, P61; WENCELDRAKE JD, 1993, BLOOD, V81, P62; WILHELM D, 1993, LANCET, V342, P64	36	29	30	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1997	100	2					235	241		10.1016/S0091-6749(97)70230-6	http://dx.doi.org/10.1016/S0091-6749(97)70230-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XR351	9275146				2022-12-18	WOS:A1997XR35100015
J	LeducBrodard, V; Inacio, F; Jaquinod, M; Forest, E; David, B; Peltre, G				LeducBrodard, V; Inacio, F; Jaquinod, M; Forest, E; David, B; Peltre, G			Characterization of Dac g 4, a major basic allergen from Dactylis glomerata pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen; allergen; monoclonal antibody; biosensor; immunoaffinity; purification; mass spectrometry; cross-reaction	DER-P-I; GRASS-POLLEN; IGE ANTIBODIES; MONOCLONAL-ANTIBODIES; KENTUCKY BLUEGRASS; CROSS-REACTIVITY; F-I; DERMATOPHAGOIDES; ELECTROPHORESIS; SPECIFICITY	Monoclonal antibodies were produced against Dac g 4, a purified major basic allergen from Dactylis glomerata pollen. Their ability to be used for immunopurification of Dac g 4 was studied on a BIAcore apparatus (Pharmacia). The allergen was purified by affinity chromatography with one monoclonal antibody. Its precise molecular mass, 59,185 +/- 30 d, was determined by mass spectrometry. Its isoelectric point is 10.4. Sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblotting showed that Dac g 4-related proteins of similar molecular mass were detected in the majority of allergenic grass pollen species. By double-site ELISAs, we have estimated that Dac g 4 represents about 6% of the total proteins from a water-soluble extract. One monoclonal antibody (mAb H) recognized a 60 kd cross-reactive protein in other grass pollens, though none in any of the tree or weed pollens tested. Inhibition studies of IgE antibody binding to Dac g 4 with pollen extracts confirmed the presence of cross-reactive allergens in Secale cereale, Lolium perenne, Festuca elatior, Holcus lanatus, Bromus arvensis, Poa pratense, Hordeum sativum, and Phleum pratense.	INST PASTEUR, UNITE IMMUNOALLERGIE, F-75724 PARIS 15, FRANCE; INST BIOL STRUCT, LAB SPECTROMETRIE MASSE PROT, GRENOBLE, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)			Forest, Eric/E-9042-2012					BALDO BA, 1982, PROG ALLERGY, V30, P1; BATARD T, 1993, INT ARCH ALLERGY IMM, V100, P68, DOI 10.1159/000236390; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRODARD V, 1993, INT ARCH ALLERGY IMM, V102, P72, DOI 10.1159/000236553; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; EKRAMODDOULLAH AKM, 1983, MOL IMMUNOL, V20, P465, DOI 10.1016/0161-5890(83)90027-5; EKRAMODDOULLAH AKM, 1982, MOL IMMUNOL, V19, P1527, DOI 10.1016/0161-5890(82)90263-2; ESCH RE, 1987, J ALLERGY CLIN IMMUN, V79, P489, DOI 10.1016/0091-6749(87)90367-8; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; GORG A, 1980, J BIOCHEM BIOPH METH, V3, P273, DOI 10.1016/0165-022X(80)90008-1; HAAVIK S, 1985, INT ARCH ALLER A IMM, V78, P260, DOI 10.1159/000233896; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HNATOWICH DJ, 1987, J NUCL MED, V28, P1294; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEDUCBRODARD V, 1994, CELL MOL BIOL, V40, P1; LEDUCBRODARD V, 1995, THESIS U DI DIDEROT; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOURAD W, 1988, J IMMUNOL, V139, P4034; OLSEN E, 1991, J IMMUNOL, V147, P205; PELTRE G, 1987, GRANA, V26, P158, DOI 10.1080/00173138709429945; PELTRE G, 1982, IMMUNOL LETT, V5, P127, DOI 10.1016/0165-2478(82)90096-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SU SN, 1991, CLIN EXP ALLERGY, V21, P449, DOI 10.1111/j.1365-2222.1991.tb01685.x; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611	27	29	32	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1065	1072		10.1016/S0091-6749(96)80193-X	http://dx.doi.org/10.1016/S0091-6749(96)80193-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977507				2022-12-18	WOS:A1996WB37800011
J	RaulfHeimsoth, M; Chen, ZP; Liebers, V; Allmers, H; Baur, X				RaulfHeimsoth, M; Chen, ZP; Liebers, V; Allmers, H; Baur, X			Lymphocyte proliferation response to extracts from different latex materials and to the purified latex allergen Hev b 1 (rubber elongation factor)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; rubber elongation factor; Hev b 1; lymphocyte stimulation	MITE DERMATOPHAGOIDES-PTERONYSSINUS; T-CELL RESPONSES; MAJOR ALLERGEN; BRASILIENSIS; IDENTIFICATION; DIAGNOSIS; PROTEINS; ASTHMA	Background: Type I allergy to latex is a growing problem, especially among health care workers. A detailed study of the peripheral blood cell responses to latex allergens has not been reported. Methods: Peripheral blood mononuclear cells of patients and healthy subjects were isolated and stimulated with protein extracts from latex sap and latex gloves and the purified latex allergen Hev b 1 (rubber elongation factor) at different concentrations to determine the antigen-specific proliferation response. The examined patients were sensitized to latex by occupational exposure (n = 23) and had rhinitis, conjunctivitis, contact urticaria, and/or asthma. Two control groups of nonsensitized subjects were studied: one occupationally exposed to latex (n = 8), and the second, not exposed to latex (n = 8). Results: In general, only latex-exposed subjects responded to the different latex antigen preparations. Lymphocyte proliferation responses to latex sap were found in 65% of latex-sensitized subjects and in 37.5% of the latex-exposed healthy subjects. Latex glove extract induced a significant proliferative response in 47.8% of latex-sensitized patients and in 25% of the latex-sensitized individuals. Hev b 1 induced lymphocyte proliferation responses in 52% of the latex-sensitized patients and in 25% of the latex-exposed subjects, indicating that Hev b 1 is relevant antigen in these latex-sensitized and latex-exposed groups. Peripheral blood mononuclear cells of 39.1% of the latex-sensitized subjects responded to all three allergen preparations (latex sap and latex glove extract, as well as Hev b 1). We could find no correlation between latex-specific IgE level and latex-induced lymphocyte proliferation response. Conclusion: Our data indicate that the 14 kd protein Hev b 1 is a relevant allergen in health care workers. It can be detected by specific IgE antibodies to Hev b 1, as well as in lymphocyte proliferation assay. In addition, our study suggests that antigen-specific proliferation response to latex is associated with exposure to latex, but not with the level of specific latex IgE. This may be useful for the evaluation and prediction of latex hypersensitivity development.	RUHR UNIV BOCHUM, PROFESS ASSOC RES INST OCCUPAT MED, D-44789 BOCHUM, GERMANY	Ruhr University Bochum								ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; BAUR X, 1993, LANCET, V342, P1148, DOI 10.1016/0140-6736(93)92127-F; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; CHEN Z, 1995, J ALLERGY CLIN IMMUN, V95, P154; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DENNIS MS, 1989, J BIOL CHEM, V264, P18608; FINK JN, 1994, ALLERGY CLIN IMMUNOL, V6, P4; Hamann CP, 1993, AM J CONTACT DERMATI, V4, P4, DOI DOI 10.1097/01634989-199303000-00003; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; KURUP VP, 1995, IMMUNOL ALLERGY CLIN, V15, P45; LIEBERS V, 1991, INT ARCH ALLER A IMM, V95, P163, DOI 10.1159/000235423; LIGHT DR, 1989, J BIOL CHEM, V264, P18589; MURALI PS, 1994, J LAB CLIN MED, V124, P638; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OWNBY DR, 1995, IMMUNOL ALLERGY CLIN, V15, P31; RAWLE FC, 1984, J IMMUNOL, V133, P195; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; TURJANMAA K, 1989, ALLERGY, V44, P181, DOI 10.1111/j.1398-9995.1989.tb02259.x; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; WILLIAMS PB, 1995, J ALLERGY CLIN IMMUN, V95, P88, DOI 10.1016/S0091-6749(95)70156-7	28	29	30	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					640	651		10.1016/S0091-6749(96)70098-2	http://dx.doi.org/10.1016/S0091-6749(96)70098-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828542	Bronze			2022-12-18	WOS:A1996VJ42800021
J	JalilColome, J; deAndrade, AD; Birnbaum, J; Casanova, D; Mege, JL; Lanteaume, A; Charpin, D; Vervloet, D				JalilColome, J; deAndrade, AD; Birnbaum, J; Casanova, D; Mege, JL; Lanteaume, A; Charpin, D; Vervloet, D			Sex difference in Fel d 1 allergen production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; allergy; pets; cat	CAT	Background: Previous experiments have shown that in vivo Fel d 1 production is under hormonal control. It strongly decreased 1 month after castration of male cats and increased after testosterone injection. Objective: These results led us to put forward the hypothesis that Fel d 1 production could be more important in male than in female cats. Five adult male and five adult female cats were studied Methods: On day 0 three separate sites of each cat's trunk were shaved, and a 5.72 cm(2) area in each site was washed twice (D0a and D0b) with 5 ml of distilled water: Then a collar was attached to the neck to prevent contamination from saliva. Twenty-four hours Inter on day 1, all areas were washed again once (D1a). Skin washes and fur extracts from the shaved areas were evaluated for Fel d 1 content. The same procedures (apart from collection of fur) were repeated 5 months later: Results: The Fel d 1 level was higher in the first skin wash of male cats compared with that of female cats on each separate sire of the trunk in both experiments, initially and 5 months Inter: Results were significant in the first experiment (median Fel d I per milliliter: 69.4 and 28.9 mU, respectively, for the combined three sites; p < 0.05). Fel d 1 production over a 24-hour period was higher in male cats, but the difference did not reach statistical significance. Furthermore, correlation between Fel d 1 levels in washes D0a and in fur was highly significant (p < 0.01). Conclusion: These, results confirm that Fel d 1 originates from skin. Furthermore, they suggest that Fel d 1 production is higher in male than in female cats.	HOP ST MARGUERITE,DEPT MALAD RESP,SERV PNEUMOALLERGOL,MARSEILLE,FRANCE; CNRS,SERV ANIM,MARSEILLE,FRANCE; HOP ST MARGUERITE,IMMUNOL LAB,F-13277 MARSEILLE 9,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Dornelas de Andrade, Armele/AAO-7337-2021; MEGE, JEAN-LOUIS/O-6063-2016	Dornelas de Andrade, Armele/0000-0001-9430-4395; 				BROWN PR, 1984, INT ARCH ALLER A IMM, V74, P67, DOI 10.1159/000233518; CHARPIN C, 1994, CLIN EXP ALLERGY, V12, P1174; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V36, P462; DeAndrade AD, 1996, CLIN EXP ALLERGY, V26, P178, DOI 10.1111/j.1365-2222.1996.tb00077.x; MATA P, 1992, ANN ALLERGY, V69, P321; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; WENTZ PE, 1990, J ALLERGY CLIN IMMUN, V85, P94, DOI 10.1016/0091-6749(90)90228-V; WOODFOLK JA, 1992, ANN ALLERGY, V69, P273; ZIELONKA TM, 1994, CLIN EXP ALLERGY, V12, P1169	9	29	30	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					165	168		10.1016/S0091-6749(96)70238-5	http://dx.doi.org/10.1016/S0091-6749(96)70238-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765830				2022-12-18	WOS:A1996VA69200019
J	Gall, H; Kalveram, CM; Sick, H; Sterry, W				Gall, H; Kalveram, CM; Sick, H; Sterry, W			Allergy to the heat-labile proteins alpha-lactalbumin and beta-lactoglobulin in mare's milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						heat-labile allergy proteins; alpha-lactalbumin; beta-lactoglobulin; mare's milk; whey		Background: Allergy to mare's milk is rare. Recently however, mare's milk has been recommended for treatment of various ailments by practitioners of ''alternative medicine,'' and it is available in health food stores. Objective: We report a case of allergic reaction to mare's milk in a 51-year-old woman wile was able to tolerate cow's milk. Methods: The protein composition of mare's milk was determined by methods based on measurement of nitrogen content. The patient underwent prick and intracutaneous tests with commercially available bovine milk proteins and several mare's milk preparations, including mare's milk granulate and boiled mare's milk. RAST and immunoblotting were also performed. Results: Results of skin testing and RAST with cow's milk were negative but demonstrated an IgE-mediated allergy to mare's milk. Immunoblotting revealed two allergen bands with molecular weights of 16 and 18 kd, most likely representing the whey proteins alpha-lactalbumin and beta-lactoglobulin. The bands disappeared after the mare's milk was boiled indicating that the proteins are heat-labile. Conclusion: The results of this study demonstrate the existence of an IgE-mediated mar e's milk allergy caused by low molecular weight hear-labile proteins, most likely alpha-lactalbumin and beta-lactoglobulin, which do not cross-react with the corresponding whey proteins in cow's milk.	LAB KALVERAM,MUNSTER,GERMANY; BUNDESANSTALT MILCHFORSCH,D-2300 KIEL,GERMANY		Gall, H (corresponding author), UNIV ULM,DERMATOL ABT,DEPT DERMATOL,OBERER ESELSBERG 40,D-89081 ULM,GERMANY.							BARMAN TE, 1970, BIOCHIM BIOPHYS ACTA, V214, P242, DOI 10.1016/0005-2795(70)90094-2; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CONTI A, 1984, H-S Z PHYSIOL CHEM, V365, P1393, DOI 10.1515/bchm2.1984.365.2.1393; DEAN TP, 1993, CLIN EXP ALLERGY, V23, P205, DOI 10.1111/j.1365-2222.1993.tb00883.x; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249	5	29	30	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1304	1307		10.1016/S0091-6749(96)70199-9	http://dx.doi.org/10.1016/S0091-6749(96)70199-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648027	Bronze			2022-12-18	WOS:A1996VD60700019
J	Hadjiliadis, D; Banks, DE; Tarlo, SM				Hadjiliadis, D; Banks, DE; Tarlo, SM			The relationship between latex skin prick test responses and clinical allergic responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; allergy; skin tests	NATURAL-RUBBER LATEX; CONTACT URTICARIA; SYSTEMIC REACTIONS; GLOVE CONTACT; SPINA-BIFIDA; HYPERSENSITIVITY; ANAPHYLAXIS; BANANA; IGE; PREVALENCE	Background: Allergic responses to latex have been reported more frequently in the past 5 years. Although commercial skin prick test solutions are available and can be used in the diagnosis of latex allergy in some countries, the characteristics of patients sensitized to later relative to their skin test responses have not been reported. Objective: The purpose of this study is to relate the clinical characteristics of patients with later sensitivity to the size of their latex skirt prick test response. Methods: A retrospective review of patients who were attending a hospital-based allergy and asthma clinic and who had positive skin test responses to a commercial latex skin test solution was undertaken. Results: Of 47 patients who had skin test responses to latex, 36 had a mean wheal diameter at least 3 mm greater than the negative control (diluent). Sixty-eight per cent were health care workers. There was a positive association between the size of skin test response and severity of latex-induced symptoms (p < 0.001). A history of banana sensitivity was also associated with larger skin test responses (p < 0.05). Conclusion: The size of the skin prick test response to latex solution that is commercially available in Canada reflects the severity of latex-induced clinical allergic responses.	TORONTO HOSP,ASTHMA CTR,WESTERN DIV,TORONTO,ON M5T 2S8,CANADA; GAGE RES INST,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto				Tarlo, Susan/0000-0002-4746-5310				ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; DOLEN WK, 1992, J ALLERGY CLIN IMMUN, V89, P224; FRANSWAY A, 1992, INT LAT C SENS LAT M, P43; HADJILIADIS D, 1995, J ALLERGY CLIN IMMUN, V96, P431, DOI 10.1016/S0091-6749(95)70067-6; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; Leger R R, 1992, J Pediatr Nurs, V7, P371; LEVY D, 1993, ALLERGY, V43, pS1; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; MEEROPOL E, 1990, NEW ENGL J MED, V323, P1072; MONERETVAUTRIN DA, 1990, LANCET, V335, P865, DOI 10.1016/0140-6736(90)90989-I; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; PECQUET C, 1990, J AM ACAD DERMATOL, V22, P631, DOI 10.1016/0190-9622(90)70086-W; PECQUET C, 1992, 15 EUR C ALL CLIN IM; SANDBERG ET, 1992, J ALLERGY CLIN IMMUN, V89, P224; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; SLATER JE, 1992, ANN ALLERGY, V68, P203; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1994, J ALLERGY CLIN IMMUN, V93, P820; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; YASSIN MS, 1994, ANN ALLERGY, V72, P245; YOUNG MC, 1992, J ALLERGY CLIN IMMUN, V89, P226; 1992, CONN MED, V56, P149	37	29	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1202	1206		10.1016/S0091-6749(96)70185-9	http://dx.doi.org/10.1016/S0091-6749(96)70185-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648013				2022-12-18	WOS:A1996VD60700005
J	Krasnick, J; Meuwissen, HJ; Nakao, MA; Yeldandi, A; Patterson, R				Krasnick, J; Meuwissen, HJ; Nakao, MA; Yeldandi, A; Patterson, R			Hypersensitivity pneumonitis: Problems in diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PIGEON-BREEDERS		NORTHWESTERN UNIV,SCH MED,DIV ALLERGY IMMUNOL,CHICAGO,IL 60611; NORTHWESTERN MEM HOSP,DEPT MED,DIV ALLERGY IMMUNOL,CHICAGO,IL; NORTHWESTERN MEM HOSP,DEPT MED,ERNEST S BAZLEY ASTHMA & ALLERG DIS CTR,CHICAGO,IL	Northwestern University; Northwestern Memorial Hospital; Northwestern Memorial Hospital								BARBORIAK JJ, 1973, J LAB CLIN MED, V82, P372; COLEMAN A, 1988, AM J SURG PATHOL, V2, P514; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; KRAUSEHOOYMAN L, 1983, INT ARCH ALLER A IMM, V71, P245, DOI 10.1159/000233398; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347	5	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					1027	1030		10.1016/S0091-6749(96)80080-7	http://dx.doi.org/10.1016/S0091-6749(96)80080-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655880				2022-12-18	WOS:A1996UG08600020
J	VIRTANEN, T; MAGGI, E; MANETTI, R; PICCINNI, MP; SAMPOGNARO, S; PARRONCHI, P; DECARLI, M; ZUCCATI, G; ROMAGNANI, S				VIRTANEN, T; MAGGI, E; MANETTI, R; PICCINNI, MP; SAMPOGNARO, S; PARRONCHI, P; DECARLI, M; ZUCCATI, G; ROMAGNANI, S			NO RELATIONSHIP BETWEEN SKIN-INFILTRATING T-H2-LIKE CELLS AND ALLERGEN-SPECIFIC IGE RESPONSE IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; CYTOKINE; DERMATOPHAGOIDES PTERONYSSINUS; IGE; LOLIUM PERENNE; SKIN; T-CELL SUBSET	HELPER T-CELLS; CYTOKINE PRODUCTION; CD4+ LYMPHOCYTES; EXPRESSION; PROFILE; SUBSETS; FREQUENCY	More than 500 CD4(+) T-cell clones (TCCs) derived from the skin of eight patients with atopic dermatitis (AD), two patients with nonatopic dermatologic disorders, two patients with allergic rhinitis, and one healthy nonatopic donor were analyzed for both their pattern of cytokine production and their antigen specificity. The proportions of TCCs from patients with AD producing interleukin-4 in response to stimulation with phorbol 12-myristate 13-acetate pins anti-CD3 antibody were higher, whereas the proportions of interferon-gamma-producing TCCs were lower than those of control subjects. In two patients with AD, the majority of TCCs had a T-H2/T-H0-like phenotype, whereas in six patients with AD a T-H1/T-H0-like phenotype was prevalent. TCCs with a T-H2/T-H0-like phenotype wets also isolated from the healthy skin of two patients with allergic rhinitis and one nonatopic donor: In contrast, no T-H2-like TCCs were derived from the skin of the two patients with dermatologic disorders of nonallergic origin. No unambiguous correlation was found between the proportions of TCCs producing interleukin-4 or interferon-gamma (or of TCCs with T-H2- or T-H1-like profile) and the level of total serum IgE, suggesting that CD4(+) T cells infiltrating the atopic skin do not play a major role in the production of serum IgE antibodies. When TCCs from five patients with AD were examined for their specificity, the proportions of allergen-specific (Dermatophagoides pteronyssinus and Lol p 1) clones were consistently 6% or lower even in patients with high titers of ryegrass- or D. pteronyssinus-specific IgE antibodies. Because similar percentages of allergen-specific TCCs were found in skin from two healthy control subjects, the role of aeroallergens in favoring and maintaining skin lesions in patients with AD remains unclear.	UNIV FLORENCE, DEPT ALLERGOL & CLIN IMMUNOL, FLORENCE, ITALY; UNIV FLORENCE, DEPT DERMATOL, FLORENCE, ITALY	University of Florence; University of Florence	VIRTANEN, T (corresponding author), UNIV KUOPIO, DEPT CLIN MICROBIOL, POB 1627, SF-70211 KUOPIO, FINLAND.		Maggi, Enrico/AAA-8045-2019; Parronchi, Paola/AAE-5422-2022	Maggi, Enrico/0000-0002-1824-3583; Parronchi, Paola/0000-0002-9184-5089				BARKER JNWN, 1990, BRIT J DERMATOL, V122, P451, DOI 10.1111/j.1365-2133.1990.tb14721.x; BIERBER T, 1992, ACTA DERM-VENEREOL, V176, P54; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; FREW AJ, 1992, J ALLERGY CLIN IMMUN, V89, P783, DOI 10.1016/0091-6749(92)90431-Z; FREW AJ, 1988, J IMMUNOL, V141, P4158; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P256, DOI 10.1016/0091-6749(75)90145-1; JONES HE, 1975, BRIT J DERMATOL, V92, P17; KAGI MK, 1994, INT ARCH ALLERGY IMM, V103, P332, DOI 10.1159/000236651; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KING CL, 1992, CHEM IMMUNOL, V54, P136; LEUNG DYM, 1991, ALLERGY PROC, V12, P339, DOI 10.2500/108854191778879106; MAGGI E, 1991, J IMMUNOL, V146, P1169; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROMAGNANI S, 1994, IMMUNOL REV, V140, P73, DOI 10.1111/j.1600-065X.1994.tb00865.x; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; STONE SP, 1973, ARCH DERMATOL, V108, P806, DOI 10.1001/archderm.108.6.806; TERR AI, 1986, CLIN REV ALLERG, V4, P267, DOI 10.1007/BF02993161; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	29	29	29	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1995	96	3					411	420		10.1016/S0091-6749(95)70061-7	http://dx.doi.org/10.1016/S0091-6749(95)70061-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RU660	7560644				2022-12-18	WOS:A1995RU66000014
J	FORSTER, E; DUDLER, T; GMACHL, M; ABERER, W; URBANEK, R; SUTER, M				FORSTER, E; DUDLER, T; GMACHL, M; ABERER, W; URBANEK, R; SUTER, M			NATURAL AND RECOMBINANT ENZYMATICALLY ACTIVE OR INACTIVE BEE VENOM PHOSPHOLIPASE A(2) HAS THE SAME POTENCY TO RELEASE HISTAMINE FROM BASOPHILS IN PATIENTS WITH HYMENOPTERA ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HISTAMINE RELEASE; RECOMBINANT ALLERGEN; GLYCOSYLATION; BEE VENOM PHOSPHOLIPASE A2	IGE ANTIBODIES; PURIFICATION; EPITOPE	Background: A complementary DNA encoding the major bee venom allergen phospholipase A(2) (PLA) has been characterized recently. Recombinant PLA was produced in Escherichia coli and purified to apparent homogeneity. Natural PLA was compared with recombinant PLA in its ability to release histamine from blood basophils. Methods: A synthetic gene encoding the mature form of PLA was expressed in E. coli, and the polypeptide was purified to homogeneity by affinity chromatography and refolded, yielding fully enzymatically active PLA. In addition, we have produced a genetically engineered enzymatically inactive variant by substitution of a single amino acid residue in the catalytic center. A standard histamine release assay was used to compare the potency of natural PLA with correctly folded enzymatically active and inactive recombinant PLA to release histamine from blood basophils of nine patients with bee venom allergy. Results: Recombinant enzymatically active PLA and purified natural protein were equally effective in releasing histamine from sensitized basophils. By comparing the histamine-releasing capacity of enzymatically active and inactive recombinant allergen, we further demonstrate that catalytic activity is not a requirement for allergenicity in the effector phase. Denaturation of natural PLA or incorrect folding of recombinant protein resulted in a total loss of allergenic potency. Conclusion: We demonstrate the feasibility of producing native-like recombinant allergens with or without enzymatic activity. We also provide evidence for the requirement of correct three-dimensional structure of PLA to induce histamine release from basophils and thus evidence for its recognition by IgE.	SWISS INST ALLERGY & ASTHMA RES,CH-7270 DAVOS,SWITZERLAND; AUSTRIAN ACAD SCI,INST MOLEC BIOL,A-5020 SALZBURG,AUSTRIA; UNIV VIENNA,DEPT PEDIAT,VIENNA,AUSTRIA; UNIV VIENNA,DEPT DERMATOL 1,VIENNA,AUSTRIA	Swiss Institute of Allergy & Asthma Research; Austrian Academy of Sciences; University of Vienna; University of Vienna				Forster-Waldl, Elisabeth/0000-0002-8484-9890				BJORKSTEN F, 1987, 4TH INT P EHRLICH S, P279; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; DUDLER T, 1994, J IMMUNOL, V152, P5514; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; FORD SA, 1991, INT ARCH ALLER A IMM, V95, P178, DOI 10.1159/000235426; Goding JW, 1983, MONOCLONAL ANTIBODIE; GUMOWISKI PI, 1991, HDB APPLIED MYCOLOGY, P53; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; Kraft D., 1993, MOL BIOL IMMUNOLOGY; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; MULLER U, IN PRESS J ALLERGY C; Muller UR., 1990, INSECT STING ALLERGY; SCHNEIDER T, 1994, J ALLERGY CLIN IMMUN, V94, P61, DOI 10.1016/0091-6749(94)90072-8; SIRAGANIAN RP, 1983, TRENDS PHARMACOL SCI, V4, P432, DOI 10.1016/0165-6147(83)90478-9; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; SUTER M, 1994, ALLERGOLOGIE, V9, P414; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x	21	29	32	1	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1229	1235		10.1016/S0091-6749(95)70080-3	http://dx.doi.org/10.1016/S0091-6749(95)70080-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7541059				2022-12-18	WOS:A1995RD30900011
J	SPECTOR, SL				SPECTOR, SL			THE COMMON COLD - CURRENT THERAPY AND NATURAL-HISTORY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COMMON COLD; UPPER RESPIRATORY INFECTION; EPIDEMIOLOGY; ETIOLOGY; PATHOPHYSIOLOGY; TREATMENT	EXPERIMENTAL RHINOVIRUS COLDS; DOUBLE-BLIND; NASAL SECRETIONS; INTERFERON-GAMMA; HUMAN VOLUNTEERS; CONTROLLED TRIAL; CLINICAL-TRIAL; ZINC GLUCONATE; INFECTION; PROPHYLAXIS	Despite its prevalence, the common cold is complicated and can be difficult To asat, even symptomatically. There is still no cure for the myriad of viruses that cause the common cold. Many of the most popular remedies are either ineffective or counter productive. This paper reviews the causes and course of upper respiratory infections, and discusses treatment options, including a new anticholinergic aqueous formulation for controlling rhinorrhea.			SPECTOR, SL (corresponding author), ALLERGY RES FDN,11620 WILSHIRE BLVD,SUITE 201,LOS ANGELES,CA 90025, USA.							ANSARI SA, 1991, J CLIN MICROBIOL, V29, P2115, DOI 10.1128/JCM.29.10.2115-2119.1991; BARDIN PG, 1993, CLIN EXP ALLERGY, V24, P457; BARROW GI, 1990, CLIN EXP ALLERGY, V20, P45, DOI 10.1111/j.1365-2222.1990.tb02774.x; BERKOWITZ RB, 1991, ANN ALLERGY, V67, P593; BRYAN WTK, 1964, 85TH ANN M AM LAR AS, P145; CATE TR, 1964, J CLIN INVEST, V43, P56, DOI 10.1172/JCI104894; COHEN S, 1993, AM J PUBLIC HEALTH, V83, P1277, DOI 10.2105/AJPH.83.9.1277; DOCKHORN R, 1992, J ALLERGY CLIN IMMUN, V90, P1076, DOI 10.1016/0091-6749(92)90126-M; DOYLE WJ, 1993, ANN OTO RHINOL LARYN, V102, P521, DOI 10.1177/000348949310200706; DOYLE WJ, 1994, J ALLERGY CLIN IMMUN, V93, P534, DOI 10.1016/0091-6749(94)90364-6; ECCLES R, 1990, CLIN OTOLARYNGOL, V15, P39, DOI 10.1111/j.1365-2273.1990.tb00430.x; ELKHATIEB A, 1993, J INFECT DIS, V168, P618, DOI 10.1093/infdis/168.3.618; ERNST E, 1990, ANN MED, V22, P225, DOI 10.3109/07853899009148930; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; FIREMAN P, 1993, PHARMACOTHERAPY, V13, pS101; FORSTALL GJ, 1994, JAMA-J AM MED ASSOC, V271, P1109, DOI 10.1001/jama.271.14.1109; GODFREY JC, 1992, J INT MED RES, V20, P234, DOI 10.1177/030006059202000305; GRAHAM NMH, 1990, J INFECT DIS, V162, P1277, DOI 10.1093/infdis/162.6.1277; GREIFF L, 1994, THORAX, V49, P121, DOI 10.1136/thx.49.2.121; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; HAYDEN FG, 1988, ANTIVIR RES, V9, P233, DOI 10.1016/0166-3542(88)90055-1; HEMILA H, 1994, SCAND J INFECT DIS, V26, P1, DOI 10.3109/00365549409008582; HEMILA H, 1992, BRIT J NUTR, V67, P3, DOI 10.1079/BJN19920004; HIGGINS PG, 1990, ANTIVIR RES, V14, P339, DOI 10.1016/0166-3542(90)90052-9; HIGGINS PG, 1988, J INTERFERON RES, V8, P591, DOI 10.1089/jir.1988.8.591; HSIA J, 1990, J INFECT DIS, V162, P591, DOI 10.1093/infdis/162.3.591; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; MACKNIN ML, 1990, JAMA-J AM MED ASSOC, V264, P989; MONTO AS, 1989, ANTIMICROB AGENTS CH, V33, P387, DOI 10.1128/AAC.33.3.387; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; SAKETKHOO K, 1978, CHEST, V74, P408, DOI 10.1378/chest.74.4.408; SATTAR SA, 1993, APPL ENVIRON MICROB, V59, P1579, DOI 10.1128/AEM.59.5.1579-1585.1993; SEDERBERG-OLSEN J F, 1989, Rhinology (Utrecht), V27, P251; SKONER DP, 1993, J ALLERGY CLIN IMMUN, V92, P732, DOI 10.1016/0091-6749(93)90017-A; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; SPERBER SJ, 1992, ANN INTERN MED, V117, P37, DOI 10.7326/0003-4819-117-1-37; SPERBER SJ, 1989, J INFECT DIS, V160, P700, DOI 10.1093/infdis/160.4.700; SPERBER SJ, 1989, B NEW YORK ACAD MED, V65, P145; SPERBER SJ, 1988, ANTIMICROB AGENTS CH, V32, P409, DOI 10.1128/AAC.32.4.409; STONE AA, 1992, BEHAV MED, V18, P115, DOI 10.1080/08964289.1992.9936961; TRIGG CJ, 1994, EUR RESPIR J, V7, P703, DOI 10.1183/09031936.94.07040703; TURNER BW, 1992, J ALLERGY CLIN IMMUN, V90, P474, DOI 10.1016/0091-6749(92)90172-X; TYRRELL D, 1989, BRIT MED J, V298, P1280, DOI 10.1136/bmj.298.6683.1280; TYRRELL DAJ, 1993, EPIDEMIOL INFECT, V111, P143, DOI 10.1017/S0950268800056764; WEISMANN K, 1990, DAN MED BULL, V37, P279; WINTHER B, 1986, JAMA-J AM MED ASSOC, V256, P1763, DOI 10.1001/jama.256.13.1763; Winther B, 1992, Rhinol Suppl, V14, P228	50	29	33	1	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1133	1138		10.1016/S0091-6749(95)70218-0	http://dx.doi.org/10.1016/S0091-6749(95)70218-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7751530	Green Published, Bronze			2022-12-18	WOS:A1995QY91800010
J	HENDELES, L; HARMAN, E; HUANG, D; OBRIEN, R; BLAKE, K; DELAFUENTE, J				HENDELES, L; HARMAN, E; HUANG, D; OBRIEN, R; BLAKE, K; DELAFUENTE, J			THEOPHYLLINE ATTENUATION OF AIRWAY RESPONSES TO ALLERGEN - COMPARISON WITH CROMOLYN METERED-DOSE INHALER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						THEOPHYLLINE; CROMOLYN; ALLERGIC ASTHMA ANTIINFLAMMATORY	EXERCISE-INDUCED ASTHMA; SODIUM CROMOGLYCATE; BRONCHIAL HYPERRESPONSIVENESS; RESPONSIVENESS; AEROSOL; HISTAMINE; BRONCHODILATORS; INHIBITION; INCREASE; RHINITIS	Background: The purpose of this study was to compare the protection afforded by individualized doses of theophylline and a cromolyn meter ed-dose inhaler (MDI) during allergen challenge. Methods: The study design was randomized, double-blind, and crossover: Responses to inhaled allergen were measured in 16 subjects with allergic asthma (age range, 18 to 35 years) after. 7 days of treatment with either placebo, once daily slow-release theophylline producing a mean +/- SD serum concentration of 16 +/- 5 mu g/ml during the late phase, or 2 mg of cromolyn administered by MDI four times daily. Forced expiratory volume in 1 second was measured at frequent intervals, and airway responsiveness to histamine was measured before and 3 hours after allergen challenge. Results: The mean +/- SD maximum decrease in forced expiratory volume in 1 second during the late phase was 30% +/- 14% during placebo treatment, 16% +/- 13% during theophylline treatment, and 13% +/- 14% during cromolyn treatment (placebo vs theophylline and cromolyn, p = 0.0001; theophylline vs cromolyn, p = 0.1). The geometric mean fold increase in airway responsiveness was 3.0 +/- 1.7 during placebo treatment, 1.7 +/- 1.7 during theophylline treatment, and 1.5 +/- 1.6 during cromolyn treatment (placebo vs theophylline and cromolyn, p = 0.0001; theophylline vs cromolyn, p = 0.1). Conclusions: Theophylline, when administered once daily as a slow-release formulation, was as effective as cromolyn, administered four times daily through an MDI, in attenuating airway responses to inhaled allergen. The protection afforded by both treatments, however; was modest when compared with the results of similar studies with inhaled corticosteroids or other cromolyn formulations that deliver more drug to the lungs than the MDI available in the United States.	UNIV FLORIDA,DIV PEDIAT PULM,GAINESVILLE,FL; UNIV FLORIDA,DEPT MED,DIV PULM,GAINESVILLE,FL; UNIV FLORIDA,DEPT STAT,DIV BIOSTAT,GAINESVILLE,FL 32611	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	HENDELES, L (corresponding author), UNIV FLORIDA,HLTH SCI CTR,COLL PHARM,POB 100486,GAINESVILLE,FL 32610, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000082] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00082] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABRAMOWITZ PW, 1980, J ALLERGY CLIN IMMUN, V66, P123, DOI 10.1016/0091-6749(80)90059-7; ANDERSSON P, 1985, ANTIASTHMA XANTHINES, P187; AUBIER M, 1991, AM REV RESPIR DIS, V143, P346, DOI 10.1164/ajrccm/143.2.346; BONER AL, 1990, ANN ALLERGY, V64, P530; BRENNER M, 1988, CLIN ALLERGY, V18, P143, DOI 10.1111/j.1365-2222.1988.tb02853.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1989, J ALLERGY CLIN IMMUN, V83, P913, DOI 10.1016/0091-6749(89)90105-X; CRESCIOLI S, 1991, ANN ALLERGY, V66, P245; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; EGGLESTON PA, 1981, CLIN PHARMACOL THER, V29, P505, DOI 10.1038/clpt.1981.70; ERJEFALT I, 1986, ACTA PHYSIOL SCAND, V128, P653, DOI 10.1111/j.1748-1716.1986.tb08027.x; FINK G, 1987, CLIN ALLERGY, V17, P313, DOI 10.1111/j.1365-2222.1987.tb02020.x; GUSTAFSSON B, 1991, THORAX, V46, P360, DOI 10.1136/thx.46.5.360; HOAG JE, 1991, ANN ALLERGY, V66, P53; HOWELL RE, 1990, J PHARMACOL EXP THER, V255, P1008; LAI CKW, 1989, AM REV RESPIR DIS, V140, P917, DOI 10.1164/ajrccm/140.4.917; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403, DOI 10.1164/ajrccm/136.6.1403; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NACLERIO RM, 1986, J ALLERGY CLIN IMMUN, V78, P874, DOI 10.1016/0091-6749(86)90233-2; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; NIELSON CP, 1988, AM REV RESPIR DIS, V137, P25, DOI 10.1164/ajrccm/137.1.25; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; PATEL KR, 1982, THORAX, V37, P663, DOI 10.1136/thx.37.9.663; PATEL KR, 1986, EUR J RESPIR DIS, V69, P256; PATEL KR, 1986, BRIT J CLIN PHARMACO, V21, P231, DOI 10.1111/j.1365-2125.1986.tb05181.x; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; ROBSON RA, 1981, BRIT J CLIN PHARMACO, V11, P383, DOI 10.1111/j.1365-2125.1981.tb01136.x; SALMON B, 1990, ARCH DIS CHILD, V65, P401, DOI 10.1136/adc.65.4.401; SHORE A, 1978, NATURE, V274, P586, DOI 10.1038/274586a0; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; TULLETT WM, 1985, THORAX, V40, P41, DOI 10.1136/thx.40.1.41; WALKER SR, 1972, J PHARM PHARMACOL, V24, P525, DOI 10.1111/j.2042-7158.1972.tb09051.x; WARD AJM, 1993, AM REV RESPIR DIS, V147, P518, DOI 10.1164/ajrccm/147.3.518; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1989, ANN ALLERGY, V63, P1; YAHAV Y, 1988, ARCH DIS CHILD, V63, P592, DOI 10.1136/adc.63.6.592	37	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1995	95	2					505	514		10.1016/S0091-6749(95)70312-8	http://dx.doi.org/10.1016/S0091-6749(95)70312-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH697	7852666				2022-12-18	WOS:A1995QH69700002
J	WASSERFALLEN, JB; SPAETH, P; GUILLOU, L; PECOUD, AR				WASSERFALLEN, JB; SPAETH, P; GUILLOU, L; PECOUD, AR			ACQUIRED DEFICIENCY IN C1-INHIBITOR ASSOCIATED WITH SIGNET-RING CELL GASTRIC ADENOCARCINOMA - A PROBABLE CONNECTION OF ANTITUMOR-ASSOCIATED ANTIBODIES, HEMOLYTIC-ANEMIA, AND COMPLEMENT TURNOVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						C1-INH DEFICIENCY; ACQUIRED; ADENOCARCINOMA; GASTRIC; ANEMIA; HEMOLYTIC	C1 INHIBITOR DEFICIENCY; ESTERASE INHIBITOR; MULTIPLE-MYELOMA; ANGIOEDEMA; ANTIGENS; PARAPROTEINEMIA; EXPRESSION; PEROXIDASE; CARCINOMA; LYMPHOMA	Background: Acquired deficiency in C1-inhibitor (C1-INH) associated with malignancy is often asymptomatic because clinical manifestations are nor dependent on a critical complement threshold (in contrast to hereditary C1-INH deficiency). Increased complement consumption involving different kinds of antibodies is the postulated mechanism for this disease, but other factors must play an important role. Case report: A 76-year-old woman with unremarkable medical history experienced three episodes of angioedema over 6 months. Investigations revealed a complement profile characteristic of acquired deficiency in C1-INH, a hemolytic anemia, and a signet ring cell adenocarcinoma (linitis plastica). A gastrectomy and a splenectomy were performed. The postoperative course was characterized by a complete disappearance of the symptoms of angioedema and hemolytic anemia. A local recurrence of the tumor 5 months later could not be resected. The patient died 17 months after the initial surgery was performed. Results: Quantitative and functional analyses of the complement factors showed persistent excessive complement consumption. Markers of hemolytic anemia disappeared after tumor removal but recurred in the second part of the disease evolution. Immunohistochemical findings in tumor tissue showed loss of normal blood group antigens but expression of Le(a) antigen as well as C1q deposition. Conclusion: To explain the whole clinical and laboratory picture, we hypothesize a connection between tumor immunohistochemical profile, complement consumption, and hemolytic anemia. Tumor cell surface antigens might lead to a permanent but asymptomatic complement consumption that is worsened and becomes clinically manifest by superimposed hemolytic anemia caused by cross-reactive antibodies to newly expressed blood group antigens on tumor cells. This hypothesis should be confirmed by other observations.	CHU VAUDOIS,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,LAUSANNE,SWITZERLAND; SWISS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,ZLB,CH-3000 BERN,SWITZERLAND; CHU VAUDOIS,INST PATHOL,LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)								ALPER CA, 1974, NEW ENGL J MED, V291, P287, DOI 10.1056/NEJM197408082910606; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; BALI JP, 1976, CANCER RES, V36, P2124; BERETTA KR, 1991, SCHWEIZ MED WSCHR, V121, P943; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CASALI P, 1978, ACTA HAEMATOL-BASEL, V59, P277, DOI 10.1159/000207773; CICARDI M, 1985, Complement, V2, P133; CICARDI M, 1993, AM J MED, V95, P169, DOI 10.1016/0002-9343(93)90257-P; COHEN SH, 1978, J ALLERGY CLIN IMMUN, V62, P217, DOI 10.1016/0091-6749(78)90210-5; DABELSTEEN E, 1983, CANCER RES, V43, P1451; DAVIDSOHN I, 1966, ARCH PATHOL, V81, P381; DAY NK, 1976, CLIN EXP IMMUNOL, V26, P189; ERNST C, 1984, AM J PATHOL, V11, P451; FIECHTNER JJ, 1980, CLIN IMMUNOL IMMUNOP, V15, P642; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GOLD JM, 1972, NATURE-NEW BIOL, V239, P60, DOI 10.1038/newbio239060a0; GORDON EH, 1983, ANN ALLERGY, V51, P378; GORDON EH, 1983, ANN ALLERGY, V51, P349; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAUPTMANN G, 1979, CLIN EXP IMMUNOL, V37, P523; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JOINER KA, 1983, AM J CLIN PATHOL, V79, P65, DOI 10.1093/ajcp/79.1.65; JOISEL F, 1983, J IMMUNOL METHODS, V59, P229, DOI 10.1016/0022-1759(83)90035-2; JONES RR, 1979, BRIT J DERMATOL, V101, P711; KAPLAN AP, 1989, ALLERGY PRINCIPLES P, P1377; MALBRAN A, 1988, J ALLERGY CLIN IMMUN, V81, P1199, DOI 10.1016/0091-6749(88)90891-3; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MASAMUNE H, 1952, Tohoku J Exp Med, V56, P37; MASSA MC, 1982, J AM ACAD DERMATOL, V7, P255, DOI 10.1016/S0190-9622(82)70115-X; MAYER MM, 1972, EXPT IMMUNOCHEMISTRY, P133; MELAMED J, 1986, J ALLERGY CLIN IMMUN, V77, P322; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; MURATA K, 1992, AM J CLIN PATHOL, V98, P67, DOI 10.1093/ajcp/98.1.67; ORNTOFT TF, 1989, INT J CANCER, V43, P774, DOI 10.1002/ijc.2910430505; PASCUAL M, 1987, AM J MED, V83, P959, DOI 10.1016/0002-9343(87)90659-0; PASQUALI JL, 1984, INT ARCH ALLER A IMM, V74, P284, DOI 10.1159/000233560; PLATTSMILLS TAE, 1974, J IMMUNOL, V110, P348; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSENFELD SI, 1975, J ALLERGY CLIN IMMUN, V55, P104; SCHIFFERLI JA, 1987, CLIN EXP IMMUNOL, V69, P188; SCHREIBER AD, 1976, BLOOD, V48, P567; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V765, P640; SOKOL RJ, 1981, BRIT MED J, V282, P2023, DOI 10.1136/bmj.282.6281.2023; SPAETH PJ, 1984, COMPLEMENT, V1, P147; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315	46	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				124	131		10.1016/S0091-6749(95)70160-5	http://dx.doi.org/10.1016/S0091-6749(95)70160-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822653				2022-12-18	WOS:A1995QC31200016
J	REISMAN, RE				REISMAN, RE			VENOM HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INSECT-STING ANAPHYLAXIS; HYMENOPTERA VENOM; ALLERGIC PATIENTS; NATURAL-HISTORY; IMMUNOTHERAPY; CHALLENGE; SEVERITY; ALLERGENICITY; ANTIGENICITY; SENSITIVITY		SUNY BUFFALO,SCH MED,BUFFALO,NY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P944, DOI 10.1016/0091-6749(89)90393-X; BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; CHAFEE FH, 1970, ACTA ALLERGOL, V25, P292, DOI 10.1111/j.1398-9995.1970.tb01265.x; CONFINOCOHEN R, 1993, J ALLERGY CLIN IMMUN, V91, P189; FRAZIER CLAUDE A., 1964, SOUTHERN MED J, V57, P1028, DOI 10.1097/00007611-196409000-00006; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V76, P803, DOI 10.1016/0091-6749(85)90752-3; GOLDBERG A, 1988, ANN ALLERGY, V61, P177; GOLDEN D B K, 1991, Journal of Allergy and Clinical Immunology, V87, P237, DOI 10.1016/0091-6749(91)91675-J; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; GOLDEN DBK, 1988, J ALLERGY CLIN IMMUN, V81, P202; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; LANTNER R, 1989, J ALLERGY CLIN IMMUN, V84, P900, DOI 10.1016/0091-6749(89)90387-4; LOCKEY R, 1983, J ALLERGY CLIN IMMUN, V71, P141, DOI 10.1016/0091-6749(83)90334-2; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; Mueller H.L., 1990, INSECT STING ALLERGY; MUELLER HL, 1959, NEW ENGL J MED, V261, P374, DOI 10.1056/NEJM195908202610803; MUELLER U, 1981, J ALLERGY CLIN IMMUN, V67, P290, DOI 10.1016/0091-6749(81)90024-5; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1984, J ALLERGY CLIN IMMUN, V73, P246, DOI 10.1016/S0091-6749(84)80015-9; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P282, DOI 10.1016/S0091-6749(05)80004-1; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; REISMAN RE, 1988, ANN ALLERGY, V61, P383; REISMAN RE, 1989, J ALLERGY CLIN IMMUN, V83, P1049, DOI 10.1016/0091-6749(89)90446-6; SCHUBERTH KC, 1981, J ALLERGY CLIN IMMUN, V81, P200; SCHWARTZ HJ, 1990, J ALLERGY CLIN IMMUN, V85, P709, DOI 10.1016/0091-6749(90)90188-A; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; VALENTINE MD, 1991, NEW ENGL J MED, V23, P1601; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5	41	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					651	658		10.1016/0091-6749(94)90167-8	http://dx.doi.org/10.1016/0091-6749(94)90167-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930296				2022-12-18	WOS:A1994PM27300001
J	IGEA, JM; FERNANDEZ, M; QUIRCE, S; DELAHOZ, B; GOMEZ, MLD				IGEA, JM; FERNANDEZ, M; QUIRCE, S; DELAHOZ, B; GOMEZ, MLD			GREEN BEAN HYPERSENSITIVITY - AN OCCUPATIONAL ALLERGY IN A HOMEMAKER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						GREEN BEAN; OCCUPATIONAL ASTHMA; CONTACT URTICARIA; INHALATION	LEGUME BOTANICAL FAMILY; FOOD HYPERSENSITIVITY; CROSS-ALLERGENICITY; CHILDREN; ASTHMA	As a member of the legume family, the green bean is frequently associated with food allergy. However, allergic reactions caused by skin contact or by inhalation of vapors from boiling legumes are rare. This article presents a case of occupational asthma in a homemaker symptoms occurred during preparation and cooking of raw green beans. Skin pride, rub, and bronchial provocation tests were performed on the patient In vitro tests were done with the serum samples of the patient and 10 control subjects (5 atopic and 5 nonatopic). Test results indicate that the patient has type I hypersensitivity to raw green bean antigen(s). This case is of interest because it demonstrates that a food allergen, when inhaled, can induce respiratory symptoms in sensitized patients and may even be the source of primary sensitization.	HOSP RAMON Y CAJAL,SERV ALERGIA,E-28034 MADRID,SPAIN	Hospital Universitario Ramon y Cajal			de la Hoz, Belen/AAA-8067-2019; s, q/AAD-7171-2020	de la Hoz, Belen/0000-0002-5127-8702; 				BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BUSH RK, 1977, CLIN ALLERGY, V7, P369, DOI 10.1111/j.1365-2222.1977.tb01465.x; KEMP AS, 1985, CLIN ALLERGY, V15, P73, DOI 10.1111/j.1365-2222.1985.tb02258.x; MONEO I, 1980, ALLERGOL IMMUNOPAT S, V7, P311; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; VALDIVIESO R, 1988, ALLERGY, V43, P536, DOI 10.1111/j.1398-9995.1988.tb01633.x	7	29	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					33	35		10.1016/0091-6749(94)90068-X	http://dx.doi.org/10.1016/0091-6749(94)90068-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027496				2022-12-18	WOS:A1994NX39300005
J	OKAYAMA, Y; ELLATI, SG; LEIFERMAN, KM; CHURCH, MK				OKAYAMA, Y; ELLATI, SG; LEIFERMAN, KM; CHURCH, MK			EOSINOPHIL GRANULE PROTEINS INHIBIT SUBSTANCE-P-INDUCED HISTAMINE-RELEASE FROM HUMAN SKIN MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHIL GRANULE PROTEINS; MAJOR BASIC PROTEIN (MBP); EOSINOPHIL PEROXIDASE (EPO); EOSINOPHIL-DERIVED NEUROTOXIN (EDN); EOSINOPHIL CATIONIC PROTEIN (ECP); HUMAN SKIN MAST CELLS; SUBSTANCE P; HISTAMINE RELEASE	MAJOR BASIC-PROTEIN; CATIONIC PROTEIN; COLD URTICARIA; HEAT URTICARIA; SECRETION; BASOPHIL; ACTIVATION; ASTHMA; PROSTAGLANDIN-D2; RIBONUCLEASE	We have investigated the activity of the four principal cationic proteins of the eosinophil granules, major basic protein (MBP), eosinophil peroxidase (EPO), eosinophil-derived neurotoxin, and eosinophil cationic protein on histamine release from human skin mast cells. These four cationic proteins, over the concentration range of to to 200 mu g/ml, did not induce significant histamine release, nor did they prime anti-IgE-induced histamine release from human skin mast cells significantly. However; a brief incubation (15 minutes) of two of the four principal eosinophil granule proteins, MBP and EPO, at concentrations of 50 to 200 mu g/ml, caused a significant concentration-related inhibition of histamine release induced by 30 mu mol/L substance P. The concentrations producing 50% inhibition for MBP and EPO on substance P-induced histamine release were 30 mu g/ml and 100 mu g/ml, respectively. This inhibitory effect appears to be a direct effect of these proteins on skin mast cells because purified (78% to 85%) skin mast cells displayed a similar response to MBP and EPO (n = 4). Also when skin mast cells were incubated with 100 mu g/ml MBP and EPO for is minutes and washed twice before activation by substance P, the inhibitory effect was not altered. These two proteins also inhibited histamine release induced by 10 mu g/ml compound 48/80. These results suggest that MBP and EPO affect the same binding site(s) on skin mast cells as those of substance P.	MAYO CLIN & MAYO FDN, DEPT DERMATOL, ROCHESTER, MN 55905 USA	Mayo Clinic	OKAYAMA, Y (corresponding author), SOUTHAMPTON GEN HOSP, IMMUNOPHARMACOL GRP, CTR BLOCK, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015231, R01AI015231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036008, R23AR036008] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15231] Funding Source: Medline; NIAMS NIH HHS [AR 36008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ANAND P, 1983, BRIT J PHARMACOL, V78, P665, DOI 10.1111/j.1476-5381.1983.tb09418.x; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; BARKER RL, 1989, J IMMUNOL, V143, P952; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENYON RC, 1987, J IMMUNOL, V138, P861; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; FOREMAN JC, 1980, BIOCHIM BIOPHYS ACTA, V629, P587, DOI 10.1016/0304-4165(80)90164-6; FOREMAN JC, 1983, J PHYSIOL-LONDON, V335, P449, DOI 10.1113/jphysiol.1983.sp014543; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; FUKUDA T, 1985, J IMMUNOL, V135, P1349; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; GOETZL EJ, 1984, J IMMUNOL, V133, P3255; HEAVEY DJ, 1986, J ALLERGY CLIN IMMUN, V78, P458, DOI 10.1016/0091-6749(86)90033-3; HENDERSON WR, 1980, J EXP MED, V152, P265, DOI 10.1084/jem.152.2.265; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KEPHART GM, 1984, LAB INVEST, V50, P51; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KORO O, 1986, BRIT J DERMATOL, V115, P721, DOI 10.1111/j.1365-2133.1986.tb06654.x; LEIFERMAN KM, 1986, CLIN RES, V34, pA762; LEIFERMAN KM, 1984, CLIN RES, V32, pA598; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWMAN MA, 1988, J ALLERGY CLIN IMMUN, V81, P574, DOI 10.1016/0091-6749(88)90199-6; LOWMAN MA, 1988, BRIT J PHARMACOL, V95, P121, DOI 10.1111/j.1476-5381.1988.tb16555.x; MOUSLI M, 1990, IMMUNOL LETT, V25, P355, DOI 10.1016/0165-2478(90)90207-7; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PENNER R, 1988, P NATL ACAD SCI USA, V85, P9856, DOI 10.1073/pnas.85.24.9856; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; PIOTROWSKI W, 1984, AGENTS ACTIONS, V14, P420, DOI 10.1007/BF01973842; ROHRBACH MS, 1990, J EXP MED, V172, P1271, DOI 10.1084/jem.172.4.1271; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; TAI PC, 1986, CLIN EXP IMMUNOL, V63, P728; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; THOMAS LL, 1989, IMMUNOLOGY, V66, P611; TOBIN MC, 1986, MOL IMMUNOL, V23, P245, DOI 10.1016/0161-5890(86)90050-7; TOTHKASA I, 1983, J INVEST DERMATOL, V80, P34, DOI 10.1111/1523-1747.ep12530993; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180	45	29	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1994	93	5					900	909		10.1016/0091-6749(94)90384-0	http://dx.doi.org/10.1016/0091-6749(94)90384-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL919	7514197				2022-12-18	WOS:A1994NL91900015
J	TILLIELEBLOND, I; GOSSET, P; JANIN, A; DALENNE, R; JOSEPH, M; WALLAERT, B; TONNEL, AB				TILLIELEBLOND, I; GOSSET, P; JANIN, A; DALENNE, R; JOSEPH, M; WALLAERT, B; TONNEL, AB			TUMOR-NECROSIS-FACTOR-ALPHA RELEASE DURING SYSTEMIC REACTION IN COLD URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PRIMARY COLD URTICARIA; TUMOR NECROSIS FACTOR-ALPHA; MAST CELL; SHOCK-LIKE REACTION	FC-EPSILON-RI; MAST-CELLS; HISTAMINE-RELEASE; TNF-ALPHA; CACHECTIN; PROSTAGLANDIN-D2; PREVENTION	Primary cold urticaria (PCU) characterized by the association of urticaria, angioedema, and sometimes a shock-like reaction after cold exposure, is usually considered to be linked with histamine and prostaglandin D-2 release by mast cells. To determine the involvement of cytokines, we studied the release of armor necrosis factor-alpha (TNF-alpha) in the blood of the efferent vein after immersion of the hand in chilled water. Five patients with PCU were compared with a control population (three patients with nonphysical urticaria and three healthy subjects). Among patients with PCU who underwent the cold immersion test, two exhibited a shock-like reaction with a large urticarial plaque (patients 1 and 2), one had only a mild cutaneous reaction, and two had no reaction. Patient 1 was reevaluated after 6 months of treatment with H-1 and H-2 antihistamines: he did not respond to this challenge. All controls were strictly negative. Histamine was released within the first minute after the challenge in the three patients with PCU but at a higher level for the two patients who had a systemic reaction. TNF-alpha was undetectable in the blood of the patient with only a mild cutaneous reaction, whereas TNF-alpha release was observed for the two patients with a systemic reaction, 2 and 6 minutes after the end of the cold immersion test. The two other patients and the control subjects released neither histamine nor TNF-alpha. In parallel, pathologic and immunohistochemical (with a rabbit anti-TNF-alpha antibody) studies were performed on skin biopsy specimens collected 10 minutes after ice-cube test. Four patients with PCU who had positive ice-cube test results were studied, as well as patient 1 after treatment, who did not respond to the ice-cube rest. The pathologic study revealed that mast cells were the only cells infiltrating the dermis in PCU and that most of mast cells were degranulated but only in the four patients with positive ice-cube test results. Immunohistochemical study revealed that only mast cells were stained by anti-TNF antibody (90% +/- 2.5%). In conclusion, besides histamine release, cold exposure in PCU induces a concomittent TNF-alpha release by mast cells. Its detection in blood suggests that in addition to histamine, TNF-alpha may be implicated in the shock-like reaction in cold urticaria.	INST PASTEUR,INSERM,CJF 9006,F-59019 LILLE,FRANCE; CTR HOSP REG UNIV LILLE,SERV PNEUMOIMMUNOALLERGOL,LILLE,FRANCE; CHRU,SERV ANAT & CYTOL PATHOL C,LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille			Gosset, Philippe/C-6174-2018	Gosset, Philippe/0000-0002-4043-6429				BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HEAVEY DJ, 1986, J ALLERGY CLIN IMMUN, V78, P458, DOI 10.1016/0091-6749(86)90033-3; Horton BT, 1936, J AMER MED ASSOC, V107, P1263, DOI 10.1001/jama.1936.02770420001001; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; HUSTON DP, 1986, ANN INTERN MED, V104, P507, DOI 10.7326/0003-4819-104-4-507; INOUE S, 1980, J ALLERGY CLIN IMMUN, V66, P299, DOI 10.1016/0091-6749(80)90025-1; JUHLIN L, 1961, JAMA-J AM MED ASSOC, V177, P371, DOI 10.1001/jama.1961.73040320001004; KAPLAN AP, 1977, J ALLERGY CLIN IMMUN, V60, P324, DOI 10.1016/0091-6749(77)90113-0; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KEATHEY TM, 1988, J ALLERGY CLIN IMMUN, V82, P256; ORMEROD AD, 1988, J ALLERGY CLIN IMMUN, V82, P586, DOI 10.1016/0091-6749(88)90968-2; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RADERMECKER M, 1980, ALLERGOL IMMUNOPATH, V8, P384; ROSE B, 1947, AM J MED, V3, P545, DOI 10.1016/0002-9343(47)90200-3; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SHERMAN WB, 1950, J ALLERGY, V21, P414, DOI 10.1016/0021-8707(50)90017-7; STEFFEN M, 1989, IMMUNOLOGY, V66, P445; Tomioka H, 1979, Monogr Allergy, V14, P313; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WANDERER AA, 1986, J ALLERGY CLIN IMMUN, V78, P417, DOI 10.1016/0091-6749(86)90027-8; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WANDERER AA, 1990, J ALLERGY CLIN IMMUN, V85, P955	28	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					501	509		10.1016/0091-6749(94)90360-3	http://dx.doi.org/10.1016/0091-6749(94)90360-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	7509821				2022-12-18	WOS:A1994MY58100012
J	PORTNOY, J; PACHECO, F; BARNES, C; UPADRASHTA, B; CRENSHAW, R; ESCH, R				PORTNOY, J; PACHECO, F; BARNES, C; UPADRASHTA, B; CRENSHAW, R; ESCH, R			SELECTION OF REPRESENTATIVE ALTERNARIA STRAIN GROUPS ON THE BASIS OF MORPHOLOGY, ENZYME PROFILE, AND ALLERGEN CONTENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALTERNARIA; STRAINS; ENZYMES; IMMUNOBLOT; IMMUNOASSAY	POLYACRYLAMIDE GELS; TENUIS; PROTEINS; EXTRACTS; MEDIA	In an attempt to identify representative strains, 12 strains of Alternaria alternata were contributed by four different research groups. Each was grown on two types of solid media and characterized with descriptions of pigmentation and morphology. Enzyme profiles were determined on both the cellular antigen and the culture filtrate material with use of a commercial kit. Concentrations of a previously described Alt a 1 and a 70 kd allergen, GP70, were measured by a two-antibody ''sandwich'' ELISA. Allergenic proteins were visualized by IgE immunoblots. With use of these criteria, four separate strains were identified that might serve as representative of Alternaria for further research.	GREER LABS,LENOIR,NC		PORTNOY, J (corresponding author), CHILDRENS MERCY HOSP,ALLERGY IMMUNOL SECT,KANSAS CITY,MO 64108, USA.				NIAID NIH HHS [AI27476-01A1] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P432, DOI 10.1016/0091-6749(82)90005-7; BARRON GL, 1968, GENERA HYPHOMYCETES, P88; HELM RM, 1987, INT ARCH ALLER A IMM, V82, P178, DOI 10.1159/000234184; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHIESEN F, 1992, J ALLERGY CLIN IMMUN, V89, P386; MCGINNIS MR, 1982, PICTORIAL HDB MED IM; PARIS S, 1990, J ALLERGY CLIN IMMUN, V85, P941, DOI 10.1016/0091-6749(90)90081-E; PORTNOY J, 1990, ANN ALLERGY, V65, P109; PRIS S, 1991, J ALLERGY CLIN IMMUN, V88, P902; SCHAFFER NATHAN, 1959, ANN ALLERGY, V17, P380; STERINGER I, 1987, INT ARCH ALLER A IMM, V84, P190, DOI 10.1159/000234422; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIJAY HM, 1985, INT ARCH ALLER A IMM, V78, P37, DOI 10.1159/000233860; VIJAY HM, 1989, GRANA, V28, P53, DOI 10.1080/00173138909431012; VIJAY HM, 1984, INT ARCH ALLER A IMM, V74, P256, DOI 10.1159/000233554; VIJAY HM, 1989, J ALLERGY CLIN IMMUN, V83, P216; WAHL R, 1989, ANN ALLERGY, V63, P527; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	19	29	29	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					773	782		10.1016/0091-6749(93)90197-N	http://dx.doi.org/10.1016/0091-6749(93)90197-N			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454800				2022-12-18	WOS:A1993KU20300010
J	CARMONA, MJ; BLANCA, M; GARCIA, A; FERNANDEZ, S; BURGOS, F; MIRANDA, A; VEGA, JM; GARCIA, J				CARMONA, MJ; BLANCA, M; GARCIA, A; FERNANDEZ, S; BURGOS, F; MIRANDA, A; VEGA, JM; GARCIA, J			INTOLERANCE TO PIROXICAM IN PATIENTS WITH ADVERSE REACTIONS TO NONSTEROIDAL ANTIINFLAMMATORY DRUGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PIROXICAM; NSAID; INTOLERANCE; ADVERSE REACTIONS	ANTI-INFLAMMATORY DRUGS; ASPIRIN; INHIBITION; MODE	To evaluate the tolerance to piroxicam in patients with urticaria induced by analgesic and/or nonsteroidal antiinflammatory drugs (NSAIDs), we carried out a 2-year study in an outpatient clinic. All the patients referred to the clinic for study entered a protocol for evaluation of intolerance to one or more drugs. If patients were allergic to at least two different NSAIDs they were allocated to group A, but if patients were allergic to only one they were considered as having selective intolerance (group B). Either piroxicam or placebo was administered under controlled conditions to both groups. In group A, five out of 18 patients had a positive response to piroxicam. In group B, in all the 25 cases studied a good tolerance to piroxicam was shown. These results indicate that in the group with intolerance to NSAIDs piroxicam induced a positive reaction in 27% of the cases, and that this drug should be administered with caution and with a previous controlled challenge in this type of patient. Piroxicam was well tolerated in the group with selective intolerance, indicating that mechanisms other than interference with the prostaglandin synthesis and release of inflammatory mediators participate in allergic reactions to NSAIDs.	CARLOS HAYA HOSP,ALLERGY UNIT,MALAGA,SPAIN	Hospital Carlos Haya			Carmona, María José/AAM-4340-2020	Carmona, María José/0000-0002-4835-6933				BLANCA M, 1989, ANN ALLERGY, V62, P295; BORNICHAK EA, 1989, AM J MED, V28, P44; BURCH RM, 1983, J PHARMACOL EXP THER, V227, P84; CARTY TJ, 1980, PROSTAGLANDINS, V19, P51, DOI 10.1016/0090-6980(80)90153-7; CARTY TJ, 1980, PROSTAGLANDINS, V19, P671, DOI 10.1016/0090-6980(80)90166-5; Coscojuela C, 1985, Med Cutan Ibero Lat Am, V13, P291; DEWECK AL, 1971, INT ARCH ALLER A IMM, V41, P393, DOI 10.1159/000230534; FIGEREIDO A, 1987, CONTACT DERMATITIS, V17, P73; FLOWER RJ, 1980, PHARMACOL BASIS THER, P682; FRENCH JK, 1987, J RHEUMATOL, V14, P1018; GARCIA A, 1991, Journal of Allergy and Clinical Immunology, V87, P229, DOI 10.1016/0091-6749(91)91640-F; GOETZL EJ, 1986, J ALLERGY CLIN IMMUN, V77, P693, DOI 10.1016/0091-6749(86)90412-4; Heynen G, 1987, Eur J Rheumatol Inflamm, V8, P86; HONEIN K, 1988, GASTROEN CLIN BIOL, V12, P79; KOCHEVAR IE, 1986, ARCH DERMATOL, V122, P1283, DOI 10.1001/archderm.122.11.1283; KOENING BW, 1987, ARNEIM FORSCH DRU RE, V37, P296; LOMBARDINO JG, 1982, MED RES REV, V2, P127, DOI 10.1002/med.2610020202; MCKERROW KJ, 1986, J AM ACAD DERMATOL, V15, P1237, DOI 10.1016/S0190-9622(86)70296-X; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; STEVENSON DD, 1988, ALLERGY PRINCIPLES P, V2; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; VANE JR, 1976, J ALLERGY CLIN IMMUN, V58, P691, DOI 10.1016/0091-6749(76)90181-0	23	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				873	879		10.1016/0091-6749(92)90459-F	http://dx.doi.org/10.1016/0091-6749(92)90459-F			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1460195				2022-12-18	WOS:A1992KD19000003
J	VITTORI, E; SCIACCA, F; COLOTTA, F; MANTOVANI, A; MATTOLI, S				VITTORI, E; SCIACCA, F; COLOTTA, F; MANTOVANI, A; MATTOLI, S			PROTECTIVE EFFECT OF NEDOCROMIL SODIUM ON THE INTERLEUKIN-1 INDUCED PRODUCTION OF INTERLEUKIN-8 IN HUMAN BRONCHIAL EPITHELIAL-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INTERLEUKIN-8; AIRWAY EPITHELIUM; INFLAMMATION	NEUTROPHIL CHEMOTACTIC FACTOR; ATTRACTANT ACTIVATION PROTEIN-1; BRONCHOALVEOLAR LAVAGE FLUID; HUMAN MONONUCLEAR PHAGOCYTES; GENE-EXPRESSION; TOLUENE DIISOCYANATE; RELEASE; ASTHMA; HISTAMINE; INVITRO	Cellular constituents of the bronchial mucosa may participate in the recruitment of polymorphonuclear leukocytes to the inflammed airways through the generation of the neutrophil chemotactic peptide, interleukin-8 (IL-8). One important aspect of this interaction could be represented by the ability of pulmonary monokines, particularly IL-1, to induce gene expression of IL-8 in bronchial epithelial cells. In this study, we have evaluated the constitutive and IL-1-induced production of IL-8 by cultured human bronchial epithelial cells and examined the ability of the anti-inflammatory drug, nedocromil sodium, to inhibit the cytokine synthesis and release. Northern blot analysis demonstrated that IL-1-beta-treated human bronchial epithelial cells expressed appreciable levels of IL-8 mRNA during a period of 8 hours. This finding was associated with an increased release of immunoreactive IL-8 to the culture media, as assessed by specific ELISA. The bronchial epithelial cell-derived IL-8 demonstrated specific biologic activity, since the supernatants of stimulated bronchial epithelial cells possessed neutrophil chemotactic activity that could be inhibited by an antibody against human IL-8. Nedocromil sodium reduced the IL-1-induced release of IL-8 in a dose-dependent manner, but concentrations of the compounds, up to 10(-5) mol/L, did not affect the constitutive production of this cytokine.	DIAGNOST CTR RESP & ALLERG DIS, VIA ALESSANDRIA 4, I-20144 MILAN, ITALY; INST PHARMACOL RES MARIO NEGRI, MILAN, ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Mantovani, Alberto/HCI-7449-2022; Sciacca, Francesca/AAL-8917-2021; Mattoli, Sabrina/H-8211-2014	Mantovani, Alberto/0000-0001-5578-236X; Sciacca, Francesca/0000-0002-7411-4567; Mattoli, Sabrina/0000-0002-6866-604X; Colotta, Francesco/0000-0001-8601-2309				Allegra L, 1989, Eur Respir J Suppl, V6, p460s; BACON KB, 1989, BIOCHEM BIOPH RES CO, V165, P349, DOI 10.1016/0006-291X(89)91076-0; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BURKE LA, 1991, EUR RESPIR J, V4, pS85; CASALE TB, 1991, J ALLERGY CLIN IMMUN, V87, P565, DOI 10.1016/0091-6749(91)90016-H; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DISTEFANO A, 1988, EUR RESPIR J, V1, pS182; DUNNILL MJ, 1967, THORAX, V24, P176; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FRIGAS E, 1991, EUR RESPIR J, V4, pS123; GIBSON PG, 1989, THORAX, V44, P693, DOI 10.1136/thx.44.9.693; GODARD P, 1987, AM REV RESPIR DIS, V135, P318; HAYES AA, 1988, CHEST, V94, P521, DOI 10.1378/chest.94.3.521; HUNNINGHAKE GW, 1984, AM REV RESPIR DIS, V130, P476; HUNNINGHAKE GW, 1980, J CLIN INVEST, V66, P473, DOI 10.1172/JCI109878; KELLY C, 1988, THORAX, V43, P684, DOI 10.1136/thx.43.9.684; KOYAMA S, 1989, AM J PHYSIOL, V257, pL130, DOI 10.1152/ajplung.1989.257.2.L130; LAL S, 1984, THORAX, V39, P809, DOI 10.1136/thx.39.11.809; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEBEL B, 1988, CLIN ALLERGY, V18, P605, DOI 10.1111/j.1365-2222.1988.tb02912.x; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; LEUNG KBP, 1986, EUR J RESPIR DIS, V69, P223; MARINI M, 1992, PULM PHARMACOL, V5, P61, DOI 10.1016/0952-0600(92)90019-D; MARINI M, 1991, AM J RESP CELL MOL, V4, P519, DOI 10.1165/ajrcmb/4.6.519; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P211; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; MATTOLI S, 1990, J CELL PHYSIOL, V142, P379, DOI 10.1002/jcp.1041420222; MATTOLI S, 1990, AM J PHYSIOL, V259, pL320, DOI 10.1152/ajplung.1990.259.4.L320; MATTOLI S, 1990, INT ARCH ALLER A IMM, V92, P16, DOI 10.1159/000235218; MATTOLI S, 1992, CHEST, V101, pS27, DOI 10.1378/chest.101.3.27S; MERRILL WW, 1980, J CLIN INVEST, V65, P268, DOI 10.1172/JCI109668; MEZZETTI M, 1991, J ALLERGY CLIN IMMUN, V87, P930, DOI 10.1016/0091-6749(91)90414-J; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; NADEL JA, 1984, J ALLERGY CLIN IMMUN, V73, P651, DOI 10.1016/0091-6749(84)90299-9; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; PARSONS PE, 1985, AM REV RESPIR DIS, V132, P490; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RANKIN JA, 1990, J CLIN INVEST, V86, P1556, DOI 10.1172/JCI114875; SCHRODER JM, 1989, J EXP MED, V170, P847, DOI 10.1084/jem.170.3.847; SICA A, 1990, IMMUNOLOGY, V69, P548; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SUZUKI K, 1989, J EXP MED, V169, P1895, DOI 10.1084/jem.169.6.1895; SYLVESTER I, 1990, AM REV RESPIR DIS, V141, P683, DOI 10.1164/ajrccm/141.3.683; THOREL T, 1988, INT ARCH ALLER A IMM, V85, P232, DOI 10.1159/000234508; WATSON ML, 1988, IMMUNOLOGY, V65, P567; WHITE MV, 1989, IMMUNOL LETT, V22, P151, DOI 10.1016/0165-2478(89)90182-X; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844; YOSHIMURA T, 1987, J IMMUNOL, V139, P788	56	29	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					76	84		10.1016/S0091-6749(06)80013-8	http://dx.doi.org/10.1016/S0091-6749(06)80013-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1321178	Bronze			2022-12-18	WOS:A1992JE25500009
J	MENON, PK; STANKUS, RP; RANDO, RJ; SALVAGGIO, JE; LEHRER, SB				MENON, PK; STANKUS, RP; RANDO, RJ; SALVAGGIO, JE; LEHRER, SB			ASTHMATIC RESPONSES TO PASSIVE CIGARETTE-SMOKE - PERSISTENCE OF REACTIVITY AND EFFECT OF MEDICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; TOBACCO SMOKE; BRONCHIAL REACTIVITY	DISODIUM-CROMOGLYCATE; BRONCHOALVEOLAR LAVAGE; SODIUM CROMOGLYCATE; LUNG	The present study assessed the persistence of cigarette-smoke reactivity and the effects of drug pretreatment on bronchial responsiveness to environmental tobacco smoke (ETS). Two groups of subjects were chosen for the study. Group I consisted of 15 atopic smoke-sensitive subjects with asthma, six of whom were defined "reactors" and nine "nonreactors" to ETS challenge. Group II consisted of 15 atopic subjects without asthma and with documented upper respiratory tract symptoms on exposure to ETS. All subjects were challenged for 2 to 6 hours with mechanically generated ETS in a static inhalation chamber. Five/six subjects in group I, who were previously demonstrated as reactors 24 months earlier, remained reactive within 1 to 2 hours of continuous ETS exposure. Pretreatment with albuterol, cromolyn, and a combination of albuterol and cromolyn 30 minutes before ETS exposure significantly diminished airway reactivity to ETS. All nine previous nonreactors in group I remained nonreactive despite rechallenge with ETS for up to 6 hours. Group II subjects challenged under identical conditions did not reveal a significant decline in FEV1 on challenge with ETS. These studies demonstrate the persistence of ETS reactivity during a 2-year period. Although cromolyn sodium and/or albuterol can protect against reactivity, mechanisms of ETS-induced airway reactivity remain unknown.	TULANE UNIV,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112; TULANE UNIV,DEPT MED,PULM DIS SECT,NEW ORLEANS,LA 70112	Tulane University; Tulane University			Rando, Roy/AAN-6118-2020					CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; DAHMS TE, 1981, CHEST, V80, P530, DOI 10.1378/chest.80.5.530; DIAZ P, 1984, J ALLERGY CLIN IMMUN, V74, P41, DOI 10.1016/0091-6749(84)90085-X; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; FLINT KC, 1985, CLIN SCI, V68, P427, DOI 10.1042/cs0680427; GAYRARD P, 1975, POSTGRAD MED J, V51, P102; HARRIES MG, 1981, ANN ALLERGY, V46, P156; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; MENON P, 1990, Journal of Allergy and Clinical Immunology, V85, P287; MENON P, 1989, J ALLERGY CLIN IMMUN, V82, P245; SHEPHARD RJ, 1979, ENVIRON RES, V20, P392, DOI 10.1016/0013-9351(79)90015-X; SHEPPARD D, 1988, J CLIN INVEST, V81, P1111, DOI 10.1172/JCI113424; SKEDINGER MC, 1987, J ALLERGY CLIN IMMUN, V80, P573, DOI 10.1016/0091-6749(87)90009-1; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V82, P331, DOI 10.1016/0091-6749(88)90003-6; STERLING TD, 1982, JAPCA J AIR WASTE MA, V32, P250, DOI 10.1080/00022470.1982.10465397; WIEDEMANN HP, 1986, CHEST, V89, P180, DOI 10.1378/chest.89.2.180; DHHS77157C PUBL	19	29	29	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					861	869		10.1016/0091-6749(91)90242-G	http://dx.doi.org/10.1016/0091-6749(91)90242-G			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1744356				2022-12-18	WOS:A1991GW26200006
J	MARQUARDT, DL; WALKER, LL				MARQUARDT, DL; WALKER, LL			LYSOPHOSPHATIDYLCHOLINE INDUCES MAST-CELL SECRETION AND PROTEIN-KINASE-C ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MAST CELLS; PROTEIN KINASE-C; STAUROSPORINE; PERTUSSIS TOXIN; CALCIUM; LYSOPHOSPHATIDYLCHOLINE	SULFATE-E-PROTEOGLYCAN; MEDIATOR RELEASE; PHORBOL ESTERS; ADENOSINE RESPONSIVENESS; BETA-HEXOSAMINIDASE; PHOSPHOLIPASE-C; RBL-2H3 CELLS; METABOLISM; 1,2-DIACYLGLYCEROL; AMINOPHYLLINE	Lysophosphatidylcholine (lyso-PC), a natural product of phospholipase A2 activity, induced the secretion of both granule-associated beta-hexosaminidase and newly generated leukotriene C4 from mouse bone marrow-derived mast cells. Micromolar concentrations of lyso-PC potentiated the release of beta-hexosaminidase induced by specific antigen but not the calcium ionophore, A23187. Exogenous adenosine was relatively ineffective in enhancing beta-hexosaminidase release from cells challenged with lyso PC. Lyso-PC caused a marked increase in intracellular free-calcium levels and induced the activation of protein kinase C (PKC). These effects could not be abrogated by a prolonged preincubation with pertussis toxin. Staurosporine, an inhibitor of PKC, partially inhibited the abilities of antigen and A23187 to induce beta-hexosaminidase release but was ineffective when lyso-PC was the secretagogue. Lyso-PC appears to activate mast cell PKC, but its ability to stimulate mast cell mediator release appears to be related to its ability to elevate intracellular free calcium concentrations.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI025507, R01AI017268, R01AI025507] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17268, AI-25507] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; ALI H, 1990, J BIOL CHEM, V265, P745; GILFILLAN AM, 1990, AGENTS ACTIONS, V30, P418, DOI 10.1007/BF01966307; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIMAN AS, 1985, J IMMUNOL, V134, P548; KENNERLY DA, 1979, J IMMUNOL, V122, P152; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; MAJERUS PW, 1990, CELL, V63, P459, DOI 10.1016/0092-8674(90)90442-H; MARQUARDT DL, 1988, BIOCHEM PHARMACOL, V37, P4019, DOI 10.1016/0006-2952(88)90088-3; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MARQUARDT DL, 1989, J IMMUNOL, V142, P1268; MARQUARDT DL, 1986, J ALLERGY CLIN IMMUN, V78, P462, DOI 10.1016/0091-6749(86)90034-5; MARQUARDT DL, 1990, BIOCHEM PHARMACOL, V39, P1929, DOI 10.1016/0006-2952(90)90611-N; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; NISHIJIMA J, 1989, BIOCHEMISTRY-US, V28, P2902, DOI 10.1021/bi00433a023; OISHI K, 1988, J BIOL CHEM, V263, P6865; OISHI K, 1990, J BIOL CHEM, V265, P70; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RAZIN E, 1984, J IMMUNOL, V132, P1479; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445	21	29	30	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					721	730		10.1016/0091-6749(91)90178-Q	http://dx.doi.org/10.1016/0091-6749(91)90178-Q			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1835466				2022-12-18	WOS:A1991GQ45200006
J	ZWEIMAN, B; ATKINS, PC; VONALLMEN, C; GLEICH, GJ				ZWEIMAN, B; ATKINS, PC; VONALLMEN, C; GLEICH, GJ			RELEASE OF EOSINOPHIL GRANULE PROTEINS DURING IGE-MEDIATED ALLERGIC SKIN REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MAJOR BASIC-PROTEIN; CELLULAR INFLAMMATORY RESPONSES; LATE-PHASE REACTION; BRONCHIAL-ASTHMA; HISTAMINE; EPITHELIUM; DEPOSITION; CHALLENGE; SPUTUM	To determine whether the eosinophil (EOS), a prominent component of human allergic skin reactions, releases its potentially pathogenic components in vivo, we appended collection chambers to the bases of unroofed skin blisters and challenged the sites for varying time periods with either pollen antigen (Ag) or buffer (B)-control solutions. In seven sensitive subjects, continuous challenge with pollen Ag consistently induced release of more major basic protein (MBP) and eosinophil-derived neutrophil (EDN) than did B solution. Low levels of both MBP and EDN were observed during the first hour with increased accumulation during the second to fifth hour. Comparison of Ag- versus B-challenged site responses in individual subjects demonstrated significantly higher levels of both MBP and EDN at Ag than at B sites during the second to fifth hour. Levels of both MBP and EDN in the second to fifth hour correlated significantly with histamine release in the same sites in the first hour (r = 0.66 and 0.83, respectively). Imprints of the skin bases of the chambers after 5 hours demonstrated variable numbers of EOS at the Ag-challenged sites and only occasional EOS at the B-challenged sites; most cells on the skin bases were neutrophils. However, immunofluorescence localization of MBP in biopsy specimens of the blister bases revealed striking extra cellular MBP deposition. These findings indicate that EOS components accumulate in vivo in IgE-mediated human skin reactions, even when prominent EOS accumulation is not visualized, possibly because the EOS are degranulated in the allergic-reaction site. Release of EOS components in these reactions may be linked to earlier mast cell activation. Because cationic EOS granule proteins are toxic for tissues, they could play a pathogenic role in late-phase allergic reactions.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	ZWEIMAN, B (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,512 JOHNSON PAVIL,PHILADELPHIA,PA 19104, USA.				NIAID NIH HHS [AI 15231] Funding Source: Medline; PHS HHS [R0114332] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015231, R01AI015231] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BEDARD PM, 1983, J ALLERGY CLIN IMMUN, V71, P394, DOI 10.1016/0091-6749(83)90068-4; BROFMAN JD, 1989, J APPL PHYSIOL, V66, P1867, DOI 10.1152/jappl.1989.66.4.1867; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; FLEEKOP PD, 1987, J ALLERGY CLIN IMMUN, V80, P140, DOI 10.1016/0091-6749(87)90122-9; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HASTIE AT, 1987, AM REV RESPIR DIS, V135, P848, DOI 10.1164/arrd.1987.135.4.848; HUBSCHER T, 1985, J IMMUNOL, V114, P1379; JACOBY DB, 1988, AM REV RESPIR DIS, V137, P13, DOI 10.1164/ajrccm/137.1.13; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SHALIT M, 1988, J IMMUNOL, V141, P821; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; VENGE P, 1988, AM REV RESPIR DIS, V138, P554; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WHITE SR, IN PRESS AM J PHYSL; ZWEIMAN B, 1990, J IMMUNOL, V144, P3953	27	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					984	992		10.1016/0091-6749(91)90421-J	http://dx.doi.org/10.1016/0091-6749(91)90421-J			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	1709185				2022-12-18	WOS:A1991FM09500011
J	SHEFFER, AL; SAMUELS, LL				SHEFFER, AL; SAMUELS, LL			CETIRIZINE - ANTIALLERGIC THERAPY BEYOND TRADITIONAL H1 ANTIHISTAMINES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB			PHASE ASTHMATIC REACTIONS; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE; HISTAMINE; EOSINOPHILS; PHARMACOKINETICS; MODULATION; RELEASE; HUMANS; CELLS	For three decades, traditional H1 antihistamines have been used in the treatment of allergic diseases. They are effective in reducing histamine-related symptoms, but the use of such agents has been limited by sedation and anticholinergic side effects. These adverse effects are fewer with the recently introduced H1 antihistamines. One of these, citirizine, a human metabolite of hydroxyzine, is characterized by its high selectivity for H1 receptor site and its reliable and consistent inhibition of histamine-induced allergic reactions. It also blocks eosinophil infiltration to the site of allergen-induced cutaneous reactions. Cetirizine has proved effective in the treatment of seasonal and perennial allergic rhinitis and urticaria. It is excreted primarily by renal mechanisms. It is well tolerated by elderly patients. Cetirizine has a low rate of penetration of the blood-brain barrier, and it has minimal central nervous system impairment. Furthermore, it can be given once a day. Cetirizine's low incidence of sedation and anticholinergic side effects contribute to its high profile of safety. In this article the characteristics, pharmacology, pharmacokinetics, and mode of action of cetirizine are reviewed.	PFIZER INC,NEW DRUG DEV,NEW YORK,NY; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,ALLERGY CLIN,BOSTON,MA 02115; DEACONESS HOSP,ALLERGY SECT,BOSTON,MA	Pfizer; Harvard University; Brigham & Women's Hospital; Harvard Medical School								ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; COULIE P, 1989, DRUG DEVELOP RES, V17, P199, DOI 10.1002/ddr.430170303; DIAZ P, 1986, J ALLERGY CLIN IMMUN, V77, P244; Douglas W.W., 1985, PHARMACOL BASIS THER, P605; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FADEL R, 1988, J ALLERGY CLIN IMMUN, V81, P178, DOI 10.1016/0091-6749(88)90277-1; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; GENGO FM, 1987, CLIN PHARMACOL THER, V42, P265, DOI 10.1038/clpt.1987.145; GENGO FM, 1987, ANN ALLERGY, V59, P53; GENGO FM, 1990, ANN ALLERGY, V64, P522; GHYS L, 1989, J INT MED RES, V17, P24, DOI 10.1177/030006058901700103; KAY AB, 1985, CLIN EXP IMMUNOL, V62, P1; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; MATZKE GR, 1987, ANN ALLERGY, V59, P25; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; NICHOLSON AN, 1986, EUR J CLIN PHARMACOL, V30, P27, DOI 10.1007/BF00614191; NICHOLSON AN, 1983, LANCET, V2, P211; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SIMONS FE, 1987, ANN ALLERGY, V59, P20; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; SNYDER SH, 1987, ANN ALLERGY, V59, P4; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WASSERMAN SI, 1989, ALLERGY ASTHMA NEW T, P189; WOOD SG, 1987, ANN ALLERGY, V59, P31	26	29	32	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1040	1046		10.1016/S0091-6749(05)80251-9	http://dx.doi.org/10.1016/S0091-6749(05)80251-9			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	1979800				2022-12-18	WOS:A1990ER13100010
J	PARKER, SL; LEZNOFF, A; SUSSMAN, GL; TARLO, SM; KRONDL, M				PARKER, SL; LEZNOFF, A; SUSSMAN, GL; TARLO, SM; KRONDL, M			CHARACTERISTICS OF PATIENTS WITH FOOD-RELATED COMPLAINTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST MICHAELS HOSP,DEPT IMMUNOL,TORONTO M5B 1W8,ONTARIO,CANADA; UNIV TORONTO,DEPT MED,TORONTO M5S 1A8,ONTARIO,CANADA; WELLESLEY COLL HOSP,DIV CLIN IMMUNOL,ALLERGY SECT,TORONTO M4Y 1J3,ONTARIO,CANADA; TORONTO GEN HOSP,TORONTO M5G 1L7,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	PARKER, SL (corresponding author), UNIV TORONTO,FAC MED,DEPT NUTR SCI,TORONTO M5S 1A8,ONTARIO,CANADA.			Tarlo, Susan/0000-0002-4746-5310				ATKINS FM, 1986, J ALLERGY CLIN IMMUN, V78, P174, DOI 10.1016/0091-6749(86)90010-2; ATKINS FM, 1988, J ALLERGY CLIN IMMUN, V81, P185, DOI 10.1016/0091-6749(88)90304-1; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BELL IR, 1982, CLIN ECOLOGY NEW MED; BERGER SM, 1985, BERGERS IMMUNE POWER; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; CROOK WG, 1984, YEAST CONNECTION MED; EGGER J, 1983, LANCET, V1, P1866; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; HANSON LA, 1984, NUTR REV, V42, P137; HEINER DC, 1981, N ENGL SOC ALLERGY P, V2, P192; KING DS, 1981, BIOL PSYCHIAT, V16, P3; LIPOWSKI ZJ, 1986, CAN MED ASSOC J, V135, P609; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P329, DOI 10.1016/0091-6749(85)90067-3; MONRO J, 1984, LANCET, V2, P719; PARKER SL, IN PRESS INT J EAT D; PEARSON DJ, 1983, LANCET, V1, P1259; PEARSON DJ, 1985, J ROY COLL PHYS LOND, V19, P154; PODELL RN, 1984, POSTGRAD MED, V75, P221, DOI 10.1080/00325481.1984.11697967; RIX KJB, 1984, BRIT J PSYCHIAT, V145, P121, DOI 10.1192/bjp.145.2.121; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P16; STEWART DE, 1985, CAN MED ASSOC J, V133, P1001; TAYLOR S L, 1985, Food Technology, V39, P65; ZIMMERMAN B, 1985, CAN MED ASSOC J, V133, P965; 1985, SAS USERS GUIDE STAT	28	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				503	511		10.1016/S0091-6749(05)80206-4	http://dx.doi.org/10.1016/S0091-6749(05)80206-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229812				2022-12-18	WOS:A1990EG45400010
J	PHILLIPS, GD; FINNERTY, JP; HOLGATE, ST				PHILLIPS, GD; FINNERTY, JP; HOLGATE, ST			COMPARATIVE PROTECTIVE EFFECT OF THE INHALED BETA-2-AGONIST SALBUTAMOL (ALBUTEROL) ON BRONCHOCONSTRICTION PROVOKED BY HISTAMINE, METHACHOLINE, AND ADENOSINE 5'-MONOPHOSPHATE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PHILLIPS, GD (corresponding author), SOUTHAMPTON GEN HOSP,DEPT IMMUNOPHARMACOL,LEVEL D,CTR BLOCK,TREMONA RD,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							AHRENS RC, 1987, J ALLERGY CLIN IMMUN, V79, P876, DOI 10.1016/0091-6749(87)90235-1; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1976, AM REV RESPIR DIS, V114, P493; BANDOUVAKIS J, 1981, BRIT J DIS CHEST, V75, P295, DOI 10.1016/0007-0971(81)90009-7; BARNES PJ, 1981, THORAX, V36, P726, DOI 10.1136/thx.36.10.726; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; BUTCHERS PR, 1979, BRIT J PHARMACOL, V67, P23; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAN W, 1986, CLIN SCI, V70, pP65; CHUNG KF, 1984, CLIN SCI, V66, P665, DOI 10.1042/cs0660665; CHUNG KF, 1982, AM REV RESPIR DIS, V126, P849; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; FERRIS L, 1978, BRIT MED J, V1, P1697, DOI 10.1136/bmj.1.6128.1697; FLINT KC, 1987, BRONCHOALVEOLAR MAST, P39; GUSTAFSSON LE, 1986, EUR J PHARMACOL, V120, P179, DOI 10.1016/0014-2999(86)90538-8; HETZEL MR, 1977, BRIT J DIS CHEST, V71, P109, DOI 10.1016/0007-0971(77)90091-2; HOLGATE ST, 1986, ARCH INT PHARMACOD T, V280, P240; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEWIS RA, 1984, DRUGS LUNG, P63; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; OKAYAMA M, 1986, AM REV RESPIR DIS, V133, pA93; PAUWELS R, 1988, American Review of Respiratory Disease, V137, P212; PAUWELS RA, 1987, AM REV RESPIR DIS, V136, P374, DOI 10.1164/ajrccm/136.2.374; PHILLIPS G D, 1988, American Review of Respiratory Disease, V137, P29; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS GD, IN PRESS AM REV RESP; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SALOME CM, 1983, THORAX, V38, P854, DOI 10.1136/thx.38.11.854; SCHILD H., 1936, QUART JOUR EXP PHYSIOL, V26, P165; SCHUMACHER MJ, 1980, J ALLERGY CLIN IMMUN, V66, P33, DOI 10.1016/0091-6749(80)90135-9; SKIDMORE IF, 1986, ASTHMA CLIN PHARM TH, P171; VATHENEN AS, 1988, LANCET, V1, P554	39	29	29	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					755	762		10.1016/0091-6749(90)90195-A	http://dx.doi.org/10.1016/0091-6749(90)90195-A			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2182697	Bronze			2022-12-18	WOS:A1990DA43700012
J	BUSSE, WW; SWENSON, CA				BUSSE, WW; SWENSON, CA			THE RELATIONSHIP BETWEEN PLASMA HISTAMINE CONCENTRATIONS AND BRONCHIAL OBSTRUCTION TO ANTIGEN CHALLENGE IN ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN, SCH MED, ALLERGY & CLIN IMMUNOL SECT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010404, R01AI015685, R01AI023181] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 23181, AI 15685, AI 10404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMED T, 1981, J ALLERGY CLIN IMMUN, V67, P135, DOI 10.1016/0091-6749(81)90009-9; ALLEN DH, 1979, CHEST, V75, P235; ASSEM ESK, 1973, INT ARCH ALLER A IMM, V45, P708, DOI 10.1159/000231070; ASSEM ESK, 1970, INT ARCH ALLER A IMM, V38, P68, DOI 10.1159/000230260; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1980, J ALLERGY CLIN IMMUN, V66, P478, DOI 10.1016/0091-6749(80)90009-3; ATKINS PC, 1984, J ALLERGY CLIN IMMUN, V73, P341, DOI 10.1016/0091-6749(84)90406-8; BEHRENS BL, 1987, LAB INVEST, V56, P101; BOWSHER RR, 1983, J BIOL CHEM, V258, P2215; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHURCH MK, 1982, CLIN ALLERGY, V12, P223, DOI 10.1111/j.1365-2222.1982.tb02522.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; FICK RB, 1987, AM REV RESPIR DIS, V135, P1204; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; FROLUND L, 1986, ALLERGY, V41, P30, DOI 10.1111/j.1398-9995.1986.tb00271.x; HOLGATE ST, 1985, CLIN ALLERGY, V15, P221, DOI 10.1111/j.1365-2222.1985.tb02279.x; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; HOWARTH PH, 1984, J ALLERGY CLIN IMMUN, V73, P391, DOI 10.1016/0091-6749(84)90414-7; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V80, P703, DOI 10.1016/0091-6749(87)90291-0; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; IND PW, 1983, CLIN ALLERGY, V13, P61, DOI 10.1111/j.1365-2222.1983.tb02568.x; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KOPFERSCHMITTKUBLER MC, 1987, J ALLERGY CLIN IMMUN, V80, P730, DOI 10.1016/0091-6749(87)90295-8; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEMANSKE RF, 1987, ALLERGY PRINCIPLES P, P247; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; NAGY L, 1981, Allergie und Immunologie (Leipzig), V27, P48; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; PEPYS J, 1968, LANCET, V2, P134; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; SPECTOR S, 1979, J ALLERGY CLIN IMMUN, V64, P580, DOI 10.1016/0091-6749(79)90016-2; SPECTOR SL, 1983, PROVOCATIVE CHALLENG, V2, P97; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	40	29	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				658	666		10.1016/0091-6749(89)90293-5	http://dx.doi.org/10.1016/0091-6749(89)90293-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2681330	Bronze			2022-12-18	WOS:A1989CA31400002
J	VANMETRE, TE; MARSH, DG; ADKINSON, NF; KAGEYSOBOTKA, A; KHATTIGNAVONG, A; NORMAN, PS; ROSENBERG, GL				VANMETRE, TE; MARSH, DG; ADKINSON, NF; KAGEYSOBOTKA, A; KHATTIGNAVONG, A; NORMAN, PS; ROSENBERG, GL			IMMUNOTHERAPY DECREASES SKIN SENSITIVITY TO CAT EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,ALLERGY CLIN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine					NCRR NIH HHS [RR 00722] Funding Source: Medline; NIAID NIH HHS [AI 08270, R01-AI 18374] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018374, R37AI008270, R01AI008270] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON MC, 1981, J IMMUNOL, V127, P972; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; LINDGREN BW, 1968, STATISTICAL THEORY, P437; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; Siegel S., 1956, NONPARAMETRIC STAT B; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TURKELTAUB PC, 1982, J ALLERGY CLIN IMMUN, V70, P343, DOI 10.1016/0091-6749(82)90023-9; VANMETRE TE, 1986, J ALLERGY CLIN IMMUN, V78, P62, DOI 10.1016/0091-6749(86)90116-8; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P202; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3	20	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					888	899		10.1016/0091-6749(89)90102-4	http://dx.doi.org/10.1016/0091-6749(89)90102-4			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2654256				2022-12-18	WOS:A1989U716100008
J	ORMEROD, AD; BLACK, AK; DAWES, J; MURDOCH, RD; KORO, O; BARR, RM; GREAVES, MW				ORMEROD, AD; BLACK, AK; DAWES, J; MURDOCH, RD; KORO, O; BARR, RM; GREAVES, MW			PROSTAGLANDIN-D2 AND HISTAMINE-RELEASE IN COLD URTICARIA UNACCOMPANIED BY EVIDENCE OF PLATELET ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST THOMAS HOSP,INST DERMATOL,LONDON SE1 7EH,ENGLAND; MRC,SNBTS BLOOD COMPONENT ASSAY GRP,EDINBURGH,SCOTLAND; GUYS HOSP,DIV MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								BENTLEYPHILLIPS CB, 1976, LANCET, V2, P63; BOLTON AE, 1976, BRIT J HAEMATOL, V33, P233, DOI 10.1111/j.1365-2141.1976.tb03534.x; CHURCH MK, 1982, J IMMUNOL, V129, P2116; DAWES J, 1978, THROMB RES, V12, P851, DOI 10.1016/0049-3848(78)90279-7; DURHAM SR, 1985, LANCET, V2, P36; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; GUILLOUX L, 1981, CLIN CHIM ACTA, V116, P269, DOI 10.1016/0009-8981(81)90046-2; HEAVEY DJ, 1986, J ALLERGY CLIN IMMUN, V78, P458, DOI 10.1016/0091-6749(86)90033-3; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN KL, 1981, BLOOD, V57, P199; KEAHEY TM, 1980, ARCH DERMATOL, V116, P174, DOI 10.1001/archderm.116.2.174; Kobza Black A, 1981, BR J CLIN PHARM, V12, P327; KORO O, 1986, BRIT J DERMATOL, V115, P721, DOI 10.1111/j.1365-2133.1986.tb06654.x; LUDLAM CA, 1976, BRIT J HAEMATOL, V33, P239, DOI 10.1111/j.1365-2141.1976.tb03535.x; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WASSERMAN SI, 1984, J ALLERGY CLIN IMMUN, V74, P275, DOI 10.1016/0091-6749(84)90258-6; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756; WEINSTOCK G, 1986, J ALLERGY CLIN IMMUN, V77, P188	19	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					586	589		10.1016/0091-6749(88)90968-2	http://dx.doi.org/10.1016/0091-6749(88)90968-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	2459177				2022-12-18	WOS:A1988Q639900008
J	BUSSE, WW				BUSSE, WW			RESPIRATORY-INFECTIONS AND BRONCHIAL HYPERREACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BUSSE, WW (corresponding author), UNIV WISCONSIN,SCH MED,600 HIGHLAND AVE,MADISON,WI 53792, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015685, P50AI010404] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 10404, AI 15685] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERMAN SZ, 1975, J ALLERGY CLIN IMMUN, V56, P206, DOI 10.1016/0091-6749(75)90091-3; BUCKNER CK, 1981, J CLIN INVEST, V67, P376, DOI 10.1172/JCI110045; BUCKNER CK, 1985, AM REV RESPIR DIS, V132, P305; BUSSE WW, 1983, J ALLERGY CLIN IMMUN, V71, P382, DOI 10.1016/0091-6749(83)90066-0; CONROY MC, 1977, J IMMUNOL, V118, P1317; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GADDY JN, 1986, AM REV RESPIR DIS, V134, P969, DOI 10.1164/arrd.1986.134.5.969; GURWITZ D, 1981, J PEDIATR-US, V98, P551, DOI 10.1016/S0022-3476(81)80758-5; HALL WJ, 1976, AM REV RESPIR DIS, V113, P141; HALPERIN SA, 1983, AM REV RESPIR DIS, V128, P806; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P967; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; PICKEN JJ, 1972, AM J MED, V52, P738, DOI 10.1016/0002-9343(72)90079-4; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; WALSH JJ, 1961, ARCH INTERN MED, V108, P376, DOI 10.1001/archinte.1961.03620090048006; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WELLIVER RC, 1983, PEDIATR CLIN N AM, V30, P819; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; ZWEIMAN B, 1971, J ALLERGY CLIN IMMUN, V48, P283, DOI 10.1016/0091-6749(71)90029-7	28	29	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1988	81	5	1				770	775		10.1016/0091-6749(88)90930-X	http://dx.doi.org/10.1016/0091-6749(88)90930-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N7036	3286716				2022-12-18	WOS:A1988N703600002
J	BADIER, M; BEAUMONT, D; OREHEK, J				BADIER, M; BEAUMONT, D; OREHEK, J			ATTENUATION OF HYPERVENTILATION-INDUCED BRONCHOSPASM BY TERFENADINE - A NEW ANTIHISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MERRELL DOW RES INST,MARSEILLE,FRANCE; INSERM UNITE,MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)								ANDERSON SD, 1985, J ALLERGY CLIN IMMUN, V76, P763, DOI 10.1016/0091-6749(85)90745-6; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BRANDON ML, 1980, ANN ALLERGY, V44, P71; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; GILLIOZ F, 1983, B EUR PHYSIOPATH RES, V19, P563; GRANERUS G, 1971, SCAND J RESPIR DIS, V52, P131; HARTLEY JPR, 1980, THORAX, V35, P675, DOI 10.1136/thx.35.9.675; HUTHER KJ, 1977, EUR J CLIN PHARMACOL, V12, P195, DOI 10.1007/BF00609860; KULSHRESTHA VK, 1978, BRIT J CLIN PHARMACO, V6, P25, DOI 10.1111/j.1365-2125.1978.tb01677.x; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; NIEMEGEERS CJE, 1982, DRUG DEVELOP RES, V2, P559, DOI 10.1002/ddr.430020607; OBYRNE PM, 1983, AM REV RESPIR DIS, V128, P611; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PHIPPS RJ, 1985, BRONCHIAL ASTHMA MEC, P741; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; SORKIN EM, 1985, DRUGS, V29, P34, DOI 10.2165/00003495-198529010-00002; TATTERSFIELD AE, 1981, THORAX, V36, P561, DOI 10.1136/thx.36.8.561; TINKELMAN DG, 1976, AM REV RESPIR DIS, V114, P87; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	21	29	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					437	440		10.1016/0091-6749(88)90913-X	http://dx.doi.org/10.1016/0091-6749(88)90913-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0993	2448358				2022-12-18	WOS:A1988M099300011
J	KEAHEY, TM; INDRISANO, J; LAVKER, RM; KALINER, MA				KEAHEY, TM; INDRISANO, J; LAVKER, RM; KALINER, MA			DELAYED VIBRATORY ANGIOEDEMA - INSIGHTS INTO PATHOPHYSIOLOGIC MECHANISMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205; UNIV PENN,SCH MED,DEPT DERMATOL,DUHRING LABS,PHILADELPHIA,PA 19104	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Pennsylvania								ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; CASALE TB, 1984, J ALLERGY CLIN IMMUN, V73, P775, DOI 10.1016/0091-6749(84)90447-0; DAVIS KC, 1986, J ALLERGY CLIN IMMUN, V77, P566, DOI 10.1016/0091-6749(86)90346-5; DAVIS KC, 1984, J ALLERGY CLIN IMMUN, V73, P810, DOI 10.1016/0091-6749(84)90451-2; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; DYER J, 1982, J ALLERGY CLIN IMMUN, V70, P82, DOI 10.1016/0091-6749(82)90233-0; KALINER M, 1980, J ALLERGY CLIN IMMUN, V68, P365; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; LAVKER RM, 1979, J INVEST DERMATOL, V73, P59, DOI 10.1111/1523-1747.ep12532763; LEMANSKE R, 1982, CRC CRIT REV IMMUNOL, V1, P547; LETTBROWN MA, 1984, CELL IMMUNOL, V87, P445, DOI 10.1016/0008-8749(84)90013-3; METZGER WJ, 1976, J ALLERGY CLIN IMMUN, V57, P605, DOI 10.1016/0091-6749(76)90012-9; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; PATTERSON R, 1972, J ALLERGY CLIN IMMUN, V50, P174, DOI 10.1016/0091-6749(72)90048-6; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TING S, 1983, J ALLERGY CLIN IMMUN, V71, P546, DOI 10.1016/0091-6749(83)90435-9; WENER MH, 1983, ANN INTERN MED, V98, P44, DOI 10.7326/0003-4819-98-1-44; WHITE MV, 1985, J ALLERGY CLIN IMMUN, V75, P175, DOI 10.1016/0091-6749(85)90419-1	22	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					831	838		10.1016/S0091-6749(87)80273-7	http://dx.doi.org/10.1016/S0091-6749(87)80273-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	2447143				2022-12-18	WOS:A1987L502000010
J	VENGE, P; DAHL, R; HAKANSSON, L				VENGE, P; DAHL, R; HAKANSSON, L			HEAT-LABILE NEUTROPHIL CHEMOTACTIC ACTIVITY IN SUBJECTS WITH ASTHMA AFTER ALLERGEN INHALATION - RELATION TO THE LATE ASTHMATIC REACTION AND EFFECTS OF ASTHMA MEDICATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									AARHUS UNIV HOSP,DEPT RESP MED,DK-8000 AARHUS C,DENMARK	Aarhus University	VENGE, P (corresponding author), UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN.		Dahl, Ronahl/F-8170-2013					ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; CHURCH MK, 1985, CLIN ALLERGY, V15, P311, DOI 10.1111/j.1365-2222.1985.tb02998.x; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; HAKANSSON L, 1980, SCAND J IMMUNOL, V11, P271, DOI 10.1111/j.1365-3083.1980.tb00235.x; HAKANSSON L, 1985, J LEUKOCYTE BIOL, V38, P521, DOI 10.1002/jlb.38.4.521; HARGREAVE FE, 1979, SMALL AIRWAYS HLTH D, P143; HEGARDT B, 1981, ALLERGY, V36, P115, DOI 10.1111/j.1398-9995.1981.tb04105.x; KAY AB, 1985, INFLAMMATION BASIC M; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; MACHADO L, 1984, THESIS ACTA U UPSALI, P504; MARTIN GL, 1980, J ALLERGY CLIN IMMUN, V66, P204, DOI 10.1016/0091-6749(80)90040-8; MORLEY J, 1984, LANCET, V2, P1142; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; VENGE P, 1982, ALLERGY, V37, P55, DOI 10.1111/j.1398-9995.1982.tb04117.x; VENGE P, 1985, GLUCOCORTICO STEROID, P21; 1975, CHEST, V67, P583	19	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					679	688		10.1016/0091-6749(87)90287-9	http://dx.doi.org/10.1016/0091-6749(87)90287-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	3119689				2022-12-18	WOS:A1987K993000007
J	BOSCO, LA; KNAPP, DE; GERSTMAN, B; GRAHAM, CF				BOSCO, LA; KNAPP, DE; GERSTMAN, B; GRAHAM, CF			ASTHMA DRUG-THERAPY TRENDS IN THE UNITED-STATES, 1972 TO 1985	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BOSCO, LA (corresponding author), US FDA,EPIDEMIOL DEV BRANCH,HFN-730,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							CAMPBELL AH, 1976, MED J AUSTRALIA, V1, P386, DOI 10.5694/j.1326-5377.1976.tb140697.x; KEATING G, 1984, BRIT MED J, V289, P348, DOI 10.1136/bmj.289.6441.348; 1972, IMS AM NATIONAL PRES; 1977, IMS AM NATIONAL PRES; 1985, IMS AM NATIONAL DISE; 1981, IMS AM NATIONAL PRES	6	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			398	402		10.1016/0091-6749(87)90058-3	http://dx.doi.org/10.1016/0091-6749(87)90058-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624691				2022-12-18	WOS:A1987K103700010
J	GRAFT, DF; SCHUBERTH, KC; KAGEYSOBOTKA, A; KWITEROVICH, KA; NIV, Y; LICHTENSTEIN, LM; VALENTINE, MD				GRAFT, DF; SCHUBERTH, KC; KAGEYSOBOTKA, A; KWITEROVICH, KA; NIV, Y; LICHTENSTEIN, LM; VALENTINE, MD			ASSESSMENT OF PROLONGED VENOM IMMUNOTHERAPY IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI-15443] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015443] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; CLAYTON WF, 1983, CLIN ALLERGY, V13, P301, DOI 10.1111/j.1365-2222.1983.tb02604.x; CONROY MC, 1977, FED PROC, V36, P1216; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1983, J ALLERGY CLIN IMMUN, V71, P140, DOI 10.1016/0091-6749(83)90330-5; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; RANDOLPH CC, 1985, J ALLERGY CLIN IMMUN, V75, P151, DOI 10.1016/0091-6749(85)90320-3; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P3, DOI 10.1016/0091-6749(79)90074-5; Richman P. G., 1986, Monograph on insect allergy, P13; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; YUNGINGER JW, 1978, J ALLERGY CLIN IMMUN, V61, P93, DOI 10.1016/0091-6749(78)90231-2; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V64, P1, DOI 10.1016/0091-6749(79)90073-3	21	29	29	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					162	169		10.1016/0091-6749(87)90125-4	http://dx.doi.org/10.1016/0091-6749(87)90125-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3611537				2022-12-18	WOS:A1987J657500007
J	PROSS, HF; DAY, JH; CLARK, RH; LEES, REM				PROSS, HF; DAY, JH; CLARK, RH; LEES, REM			IMMUNOLOGICAL STUDIES OF SUBJECTS WITH ASTHMA EXPOSED TO FORMALDEHYDE AND UREA-FORMALDEHYDE FOAM INSULATION (UFFI) OFF PRODUCTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									QUEENS UNIV,DEPT RADIAT ONCOL,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT MED,DIV ALLERGY & IMMUNOL,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT CHEM ENGN,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT COMMUNITY HLTH & EPIDEMIOL,KINGSTON K7L 3N6,ONTARIO,CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada	PROSS, HF (corresponding author), QUEENS UNIV,DEPT MICROBIOL & IMMUNOL,KINGSTON K7L 3N6,ONTARIO,CANADA.							AMMANN AJ, 1977, J IMMUNOL METHODS, V17, P365, DOI 10.1016/0022-1759(77)90119-3; BANCROFT GJ, 1981, J IMMUNOL, V126, P988; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRODER S, 1984, NEW ENGL J MED, V311, P1292, DOI 10.1056/NEJM198411153112006; CUNNINGHAMRUNDLES S, 1981, JNCI-J NATL CANCER I, V67, P585; DAY JH, 1984, CAN MED ASSOC J, V131, P1061; DEAN JH, 1984, TOXICOL APPL PHARM, V72, P519, DOI 10.1016/0041-008X(84)90129-7; DIAMOND RD, 1977, P SOC EXP BIOL MED, V154, P259; DROLLER MJ, 1979, CELL IMMUNOL, V47, P248, DOI 10.1016/0008-8749(79)90335-6; DUMAS T, 1980, J CHROMATOGR, V200, P206, DOI 10.1016/S0021-9673(00)84934-1; ELLIOTT BE, 1984, METHOD ENZYMOL, V108, P49; ENNIS FA, 1981, LANCET, V1, P891; EPSTEIN E, 1966, ARCH DERMATOL, V94, P186, DOI 10.1001/archderm.94.2.186; FLEISCHMANN WR, 1984, TRANSPLANT P, V16, P516; Friedenreich V., 1930, THOMSEN HEMAGGLUTINA; FRIGAS E, 1984, MAYO CLIN PROC, V59, P295, DOI 10.1016/S0025-6196(12)61423-2; GALLINGER LA, 1980, INT J CANCER, V26, P139, DOI 10.1002/ijc.2910260204; GLASS W I, 1961, N Z Med J, V60, P423; HANNA N, 1981, J IMMUNOL, V127, P1754; HARRIS JC, 1981, JAMA-J AM MED ASSOC, V245, P243, DOI 10.1001/jama.245.3.243; HARRISON JR, 1984, CAN MED ASSOC J, V130, P351; HENDRICK DJ, 1982, J OCCUP ENVIRON MED, V24, P893; HENDRICK DJ, 1977, BRIT J IND MED, V34, P11; HERBERMAN RR, 1979, NATURE, V277, P221, DOI 10.1038/277221a0; HOKLAND P, 1981, LEUKEMIA RES, V5, P349, DOI 10.1016/0145-2126(81)90007-2; HOWELL DN, 1982, HUM IMMUNOL, V5, P233, DOI 10.1016/0198-8859(82)90136-7; JONDAL M, 1972, J EXP MED, V136, P207, DOI 10.1084/jem.136.2.207; JONDAL M, 1975, INT J CANCER, V15, P596, DOI 10.1002/ijc.2910150409; KADISH AS, 1981, J IMMUNOL, V127, P1817; KIESSLING R, 1976, INT J CANCER, V17, P275, DOI 10.1002/ijc.2910170217; LABBE KA, 1984, ENVIRON RES, V35, P246, DOI 10.1016/0013-9351(84)90133-6; Maibach H., 1983, FORMALDEHYDE TOXICIT, P166; MALUISH AE, 1983, J IMMUNOL, V131, P503; MOORE M, 1980, BRIT J CANCER, V41, P378, DOI 10.1038/bjc.1980.61; OLDHAM RK, 1976, INT J CANCER, V18, P145, DOI 10.1002/ijc.2910180203; PERUSSIA B, 1983, J IMMUNOL, V130, P2133; PIRILA V, 1949, Ann Med Intern Fenn, V38, P38; POPA V, 1969, DIS CHEST, V56, P395, DOI 10.1378/chest.56.5.395; PROSS H, 1985, IMMUNOBIOLOGY NATURA, P11; PROSS HF, 1984, J IMMUNOL METHODS, V68, P235; PROSS HF, 1982, INT J CANCER, V29, P383, DOI 10.1002/ijc.2910290404; PROSS HF, 1981, J CLIN IMMUNOL, V1, P51, DOI 10.1007/BF00915477; PROSS HF, 1976, INT J CANCER, V18, P593, DOI 10.1002/ijc.2910180508; PROSS HF, 1981, INT ARCH ALLER A IMM, V66, P365, DOI 10.1159/000232845; PROSS HF, 1980, NATURAL CELL MEDIATE, P1063; PROSS HT, 1978, CELL IMMUNOL, V43, P160; RIESENFELD I, 1980, INT J CANCER, V25, P399, DOI 10.1002/ijc.2910250315; RUSH PJ, 1986, J RHEUMATOL, V13, P475; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; SAKSELA E, 1979, SCAND J IMMUNOL, V10, P257, DOI 10.1111/j.1365-3083.1979.tb01348.x; SANDLER SG, 1978, ISRAEL J MED SCI, V14, P1177; SANTOLI D, 1978, J IMMUNOL, V121, P532; SELIGMANN M, 1984, NEW ENGL J MED, V311, P1286, DOI 10.1056/NEJM198411153112005; SHEPPARD D, 1984, ENVIRON RES, V35, P133, DOI 10.1016/0013-9351(84)90120-8; SPRINGER GF, 1976, CANCER, V37, P169, DOI 10.1002/1097-0142(197601)37:1<169::AID-CNCR2820370124>3.0.CO;2-#; Stewart W E, 1981, INTERFERON SYSTEM; STITES DP, 1984, BASIC CLIN IMMUNOL, P353; TAKASUGI M, 1977, CANCER RES, V37, P413; TARGAN S, 1980, J IMMUNOL, V124, P2157; THOMAS Y, 1983, IMMUNOL REV, V74, P113, DOI 10.1111/j.1600-065X.1983.tb01086.x; TIMONEN T, 1980, J IMMUNOL METHODS, V36, P285, DOI 10.1016/0022-1759(80)90133-7; TRINCHIERI G, 1978, J IMMUNOL, V120, P1845; ULLBERG M, 1981, SCAND J IMMUNOL, V14, P285, DOI 10.1111/j.1365-3083.1981.tb00566.x; WELSH RM, 1984, MICROBIOLOGY 1984, P320; WIBERG GS, 1981, CAN J PUBLIC HEALTH, V72, P335	65	29	30	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					797	810		10.1016/0091-6749(87)90213-2	http://dx.doi.org/10.1016/0091-6749(87)90213-2			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	2437172				2022-12-18	WOS:A1987H434900016
J	WARRINGTON, RJ; MARTENS, CJ; RUBIN, M; RUTHERFORD, WJ; AOKI, FY				WARRINGTON, RJ; MARTENS, CJ; RUBIN, M; RUTHERFORD, WJ; AOKI, FY			IMMUNOLOGICAL STUDIES IN SUBJECTS WITH A SERUM SICKNESS-LIKE ILLNESS AFTER IMMUNIZATION WITH HUMAN-DIPLOID CELL RABIES VACCINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,HLTH SCI CTR,DEPT MED,WINNIPEG R3E 0Z3,MANITOBA,CANADA; UNIV MANITOBA,DEPT IMMUNOL,WINNIPEG R3E 0Z3,MANITOBA,CANADA; UNIV MANITOBA,HLTH SCI CTR,DEPT MED MICROBIOL,WINNIPEG R3E 0Z3,MANITOBA,CANADA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	WARRINGTON, RJ (corresponding author), UNIV MANITOBA,HLTH SCI CTR,ALLERGY & CLIN IMMUNOL SECT,C319,700 WILLIAM AVE,WINNIPEG R3E 0Z3,MANITOBA,CANADA.							ANDERSON LJ, 1980, JAMA-J AM MED ASSOC, V244, P781; BAER H, 1985, J ALLERGY CLIN IMMUN, V75, P137, DOI 10.1016/0091-6749(85)90265-9; BERNARD KW, 1982, JAMA-J AM MED ASSOC, V247, P1138, DOI 10.1001/jama.247.8.1138; COX JH, 1976, J CLIN MICROBIOL, V3, P96; DEUTSCH AJ, 1985, J ALLERGY CLIN IMMUN, V75, P108, DOI 10.1016/0091-6749(85)90151-4; NICHOLSON KG, 1978, J INFECT DIS, V137, P783, DOI 10.1093/infdis/137.6.783; POHL DA, 1980, J IMMUNOL METHODS, V36, P13, DOI 10.1016/0022-1759(80)90090-3; SCHURRENGERGER P, 1984, MMWR, V33, P185; SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535	9	29	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					605	610		10.1016/S0091-6749(87)80156-2	http://dx.doi.org/10.1016/S0091-6749(87)80156-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3558997				2022-12-18	WOS:A1987G972000009
J	ANDERSSON, M; PIPKORN, U				ANDERSSON, M; PIPKORN, U			INHIBITION OF THE DERMAL IMMEDIATE ALLERGIC REACTION THROUGH PROLONGED TREATMENT WITH TOPICAL GLUCOCORTICOSTEROIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LUND HOSP,DEPT EAR NOSE & THROAT,S-22185 LUND,SWEDEN	Lund University; Skane University Hospital								BURGE PS, 1982, EUR J RESP DIS S, V122, P163; DAHL R, 1982, EUR J RESPIR DIS, V63, P167; DREBORG S, 1986, J ALLERGY CLIN IMMUN, V77, P223; EASTON JG, 1981, J ALLERGY CLIN IMMUN, V67, P388, DOI 10.1016/0091-6749(81)90084-1; EIDINGER D, 1962, NATURE, V196, P693; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GRONNEBERG R, 1985, ALLERGY, V40, P223; GRONNEBERG R, 1981, ALLERGY, V36, P201, DOI 10.1111/j.1398-9995.1981.tb01835.x; HORAK F, 1982, ANN ALLERGY, V48, P305; KJELLMAN NIM, IN PRESS ALLERGY; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LAVKER RM, 1985, J IMMUNOL, V135, P2368; MCKENZIE AW, 1962, ARCH DERMATOL, V86, P611, DOI 10.1001/archderm.1962.01590110047006; OKUDA M, 1980, CLIN OTOLARYNGOL, V53, P15; PELIKAN Z, 1982, ANN ALLERGY, V49, P200; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1968, EXCERPTA MED INT C S, V162, P221; PIPKORN U, 1982, ALLERGY, V37, P29; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1985, ANNU REV PHARMACOL, V25, P381, DOI 10.1146/annurev.pharmtox.25.1.381; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; STAHLE M, 1984, ACTA DERM-VENEREOL, V64, P239; SVENSJO E, 1985, GLUCOCORTICOSTEROIDS, P136; VILSVIK J S, 1975, Clinical Allergy, V5, P291, DOI 10.1111/j.1365-2222.1975.tb01865.x; ZWEIMAN B, 1976, J ALLERGY CLIN IMMUN, V58, P657, DOI 10.1016/0091-6749(76)90177-9	29	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					345	349		10.1016/0091-6749(87)90153-9	http://dx.doi.org/10.1016/0091-6749(87)90153-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	2434546				2022-12-18	WOS:A1987G179100008
J	VANTOORENENBERGEN, AW; DIEGES, PH				VANTOORENENBERGEN, AW; DIEGES, PH			DEMONSTRATION OF SPICE-SPECIFIC IGE IN PATIENTS WITH SUSPECTED FOOD ALLERGIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ERASMUS UNIV,HOSP DIJKZIGT,DEPT ALLERGOL,3015 GD ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	VANTOORENENBERGEN, AW (corresponding author), ERASMUS UNIV,HOSP DIJKZIGT,DEPT CHEM,ALLERGOL DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; FORSBECK M, 1979, CONTACT DERMATITIS, V5, P191, DOI 10.1111/j.1600-0536.1979.tb04839.x; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; KAUPPINEN K, 1980, CONTACT DERMATITIS, V6, P251, DOI 10.1111/j.1600-0536.1980.tb04924.x; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; PELTRE P, 1983, FOLIA ALLERGOL IM S4, V30, P84; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; STOBART T, 1977, HERBS SPICES FLAVOUR, P98; THIEL CL, 1981, RAST S BERLIN, V3, P161; THIEL CL, 1984, KOLNER RAST S, P118; VANTOORENENBERGEN AW, 1985, J ALLERGY CLIN IMMUN, V76, P477, DOI 10.1016/0091-6749(85)90730-4; WUTHRICH B, 1984, DEUT MED WOCHENSCHR, V109, P981, DOI 10.1055/s-2008-1069310	15	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1987	79	1					108	113		10.1016/S0091-6749(87)80024-6	http://dx.doi.org/10.1016/S0091-6749(87)80024-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F8810	2433321				2022-12-18	WOS:A1987F881000020
J	MASSICOT, JG; COHEN, SG				MASSICOT, JG; COHEN, SG			EPIDEMIOLOGIC AND SOCIOECONOMIC ASPECTS OF ALLERGIC DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MASSICOT, JG (corresponding author), NIAID,ALLERGY & CLIN IMMUNOL BRANCH,IMMUNOL ALLERG & IMMUNOL DIS PROGRAM,BETHESDA,MD 20205, USA.							ADO AD, 1975, EPIDEMIOLOGY ALLERGI; BESSOT JC, 1983, REV FR ALLERGOL, V23, P1, DOI 10.1016/S0335-7457(83)80049-5; BOGOVA AV, 1976, SOV MEDITISINA, V7, P127; BOGOVA AV, 1983, IMMUNOLOGIYA, V6, P83; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; DENIS J, 1984, INT S PREVENTION ALL; EASTON KK, 1982, CLIN ALLERGY, V18, P107; PONCE DP, ANN ALLERGY; SHU JL, 1981, CHIN J TUBERCULOSIS, V46, P32; VARONIER HS, 1984, HELV PAEDIATR ACTA, V39, P129; 1982, ANN REPORT MINISTRY; 1981, DHHS NIH822019 PUBL; 1983, ESTUDIO COABORATIVO; 1979, DHEW NIH79387 PUBL; 1979, ALERGIA, V25, P73	15	29	29	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1986	78	5	2	S			954	958		10.1016/0091-6749(86)90284-8	http://dx.doi.org/10.1016/0091-6749(86)90284-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E9719	3782672				2022-12-18	WOS:A1986E971900005
J	SAMPSON, HA				SAMPSON, HA			DIFFERENTIAL-DIAGNOSIS IN ADVERSE REACTIONS TO FOODS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SAMPSON, HA (corresponding author), DUKE UNIV,MED CTR,DEPT PEDIAT,DIV ALLERGY IMMUNOL,BOX 3266,DURHAM,NC 27710, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019116] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19116] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN DH, 1981, NEW ENGL J MED, V305, P1154; ANDERSON JA, 1984, NUTR REV, V42, P109, DOI 10.1111/j.1753-4887.1984.tb02299.x; ANDERSON JA, 1984, NIH842442 PUBL; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; BARNETSON RS, 1983, CLIN REACTIONS FOOD, P15; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BETHUNE HC, 1964, AM J PSYCHIAT, V121, P245, DOI 10.1176/ajp.121.3.245; BOAT TF, 1975, J PEDIATR-US, V87, P23, DOI 10.1016/S0022-3476(75)80062-X; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1983, J ALLERGY CLIN IMMUN, V71, P98, DOI 10.1016/0091-6749(83)90162-8; BRODSKY CM, 1983, PSYCHOSOMATICS, V24, P731, DOI 10.1016/S0033-3182(83)73168-3; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; CROOK WG, 1983, YEAST CONNECTION; EGGER J, 1983, LANCET, V2, P866; ELSAS LJ, 1973, J PEDIATR-US, V83, P226, DOI 10.1016/S0022-3476(73)80480-9; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; FINN R, 1978, LANCET, V1, P426; FRY L, 1973, LANCET, V1, P288; GRANERUS G, 1968, SCAND J CLIN LAB INV, VS 22, P49; GRAY GM, 1980, NUTRITION GASTROENTE, P50; GRYBOSKI JD, 1966, PEDIATRICS, V38, P299; HEINER DC, 1962, AM J DIS CHILD, V103, P634, DOI 10.1001/archpedi.1962.02080020649003; HILL DJ, 1984, CLIN REV ALLERG, V2, P125; HORWITZ D, 1964, JAMA-J AM MED ASSOC, V188, P1108; JAKOBSSON I, 1978, LANCET, V2, P437; JUHLIN L, 1981, BRIT J DERMATOL, V104, P369, DOI 10.1111/j.1365-2133.1981.tb15306.x; JUHLIN L, 1980, INT J DERMATOL, V19, P548, DOI 10.1111/j.1365-4362.1980.tb00802.x; KATZ SI, 1978, J INVEST DERMATOL, V70, P63, DOI 10.1111/1523-1747.ep12541202; KAYOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; KWOK RHM, 1968, NEW ENGL J MED, V278, P796; Liener I. E., 1980, TOXIC CONSTITUENTS P; LIFSHITZ F, 1977, CLIN GASTROENTEROL, V6, P415; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MAY CD, 1980, NEW ENGL J MED, V302, P1142, DOI 10.1056/NEJM198005153022009; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1984, NUTR REV, V42, P72, DOI 10.1111/j.1753-4887.1984.tb02293.x; MERSON MH, 1974, JAMA-J AM MED ASSOC, V228, P1268; Moneret-Vautrin D. A., 1983, Clinical reactions to food, P135; NOSE O, 1979, ARCH DIS CHILD, V54, P436, DOI 10.1136/adc.54.6.436; PATTON WDM, 1954, J PHYSL, V123, pP58; PAULLEY JW, 1954, BRIT MED J, V2, P1318, DOI 10.1136/bmj.2.4900.1318; PEARSON DJ, 1983, LANCET, V1, P1259; RAPPORT JL, 1984, ARCH GEN PSYCHIATRY, V41, P1073; RIX KJB, 1984, BRIT J PSYCHIAT, V145, P121, DOI 10.1192/bjp.145.2.121; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAPEIKA N, 1969, FOOD PHARM; SCHACHTER M, 1952, J PHYSIOL-LONDON, V118, P258, DOI 10.1113/jphysiol.1952.sp004790; SCHWACHMAN H, 1978, CURR PROBL PEDIA AUG; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SCUDAMORE HH, 1982, J ALLERGY CLIN IMMUN, V70, P129, DOI 10.1016/0091-6749(82)90241-X; SMITH CK, 1978, ANN INTERN MED, V88, P520, DOI 10.7326/0003-4819-88-4-520; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; TAYLOR SL, 1982, J FOOD PROTECT, V45, P455, DOI 10.4315/0362-028X-45.5.455; TAYLOR SL, 1979, APPL ENVIRON MICROB, V37, P274, DOI 10.1128/AEM.37.2.274-278.1979; TAYLOR SL, 1984, SEAFOOD TOXINS, P417; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; WALDMANN TA, 1967, NEW ENGL J MED, V276, P762; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0; WILSON JF, 1964, JAMA-J AM MED ASSOC, V189, P568; [No title captured]	65	29	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			212	219		10.1016/0091-6749(86)90014-X	http://dx.doi.org/10.1016/0091-6749(86)90014-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3722648				2022-12-18	WOS:A1986D299700014
J	PICHURKO, BM; SULLIVAN, B; PORCELLI, RJ; MCFADDEN, ER				PICHURKO, BM; SULLIVAN, B; PORCELLI, RJ; MCFADDEN, ER			ENDOGENOUS ADRENERGIC MODIFICATION OF EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CASE WESTERN RESERVE UNIV HOSP,SCH MED,CTR ASTHMA & ALLERG DIS,2074 ABINGTON RD,CLEVELAND,OH 44106; VET ADM MED CTR,NORTHPORT,NY 11768; CASE WESTERN RESERVE UNIV HOSP,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106; BRIGHAM & WOMENS HOSP,SHIPLEY INST MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Case Western Reserve University; Case Western Reserve University Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Case Western Reserve University Hospital; Case Western Reserve University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [HL17873, HL19170] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019170] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON SD, 1976, SCAND J RESPIR DIS, V57, P41; BARNES PJ, 1981, THORAX, V36, P435, DOI 10.1136/thx.36.6.435; BEIL M, 1977, KLIN WOCHENSCHR, V55, P577, DOI 10.1007/BF01490511; BENDOV I, 1982, AM REV RESPIR DIS, V125, P530, DOI 10.1164/arrd.1982.125.5.530; BERKIN KE, 1985, Q J EXP PHYSIOL CMS, V70, P203, DOI 10.1113/expphysiol.1985.sp002903; CHANYEUNG MM, 1971, AM REV RESPIR DIS, V104, P915; CHRYSSANTHOPOULOS C, 1978, J ALLERGY CLIN IMMUN, V61, P17, DOI 10.1016/0091-6749(78)90468-2; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; ESLER M, 1982, CLIN SCI, V62, P247, DOI 10.1042/cs0620247; GODFREY S, 1973, J ALLERGY CLIN IMMUN, V52, P199, DOI 10.1016/0091-6749(73)90058-4; GRIFFITHS J, 1972, Chest, V62, P527; HALLMAN H, 1978, LIFE SCI, V23, P1049, DOI 10.1016/0024-3205(78)90665-3; HARTLEY LH, 1972, J APPL PHYSIOL, V33, P602; IND PW, 1983, BR J CLIN PHARM, V15, P145; JAMES L, 1976, J ALLERGY CLIN IMMUN, V57, P408, DOI 10.1016/0091-6749(76)90055-5; LARSSON K, 1982, CHEST, V82, P560, DOI 10.1378/chest.82.5.560; LEE TH, 1983, LANCET, V1, P520; MCFADDEN ER, UNPUB J CLIN INVEST; MCNEILL RS, 1966, Q J MED, V35, P55; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; ROBERTSON D, 1979, CIRCULATION, V59, P637, DOI 10.1161/01.CIR.59.4.637; SCHNALL RP, 1980, THORAX, V35, P828, DOI 10.1136/thx.35.11.828; SILVERBERG AB, 1978, AM J PHYSIOL, V234, P252; STIRLING DR, 1983, J APPL PHYSIOL, V54, P934, DOI 10.1152/jappl.1983.54.4.934; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; WARREN JB, 1982, BRIT J DIS CHEST, V76, P147, DOI 10.1016/S0007-0971(82)80050-8; WATSON RDS, 1980, CLIN SCI, V58, P37, DOI 10.1042/cs0580037; WEAST RC, 1978, HDB CHEM PHYSICS, P41; WEILERRAVELL D, 1981, J ALLERGY CLIN IMMUN, V67, P391, DOI 10.1016/0091-6749(81)90085-3; ZEILINSKI J, 1980, THORAX, V35, P823; 1962, AM REV RESPIR DIS, V85, P762	33	29	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					796	801		10.1016/0091-6749(86)90376-3	http://dx.doi.org/10.1016/0091-6749(86)90376-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711547				2022-12-18	WOS:A1986C869400003
J	GRAVER, LM; ROBERTSON, DA; LEVI, R; BECKER, CG; WEKSLER, BB; GAY, WA				GRAVER, LM; ROBERTSON, DA; LEVI, R; BECKER, CG; WEKSLER, BB; GAY, WA			IGE-MEDIATED HYPERSENSITIVITY IN HUMAN-HEART TISSUE - HISTAMINE-RELEASE AND FUNCTIONAL-CHANGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CORNELL UNIV, MED CTR, COLL MED, DEPT PHARMACOL, 1300 YORK AVE, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT SURG, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Cornell University; Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018828, R01HL034215] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 18828, HL 34215] Funding Source: Medline; NIGMS NIH HHS [GM 20091] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEHRINGHAUS U, 1983, BRIT J PHARMACOL, V80, P73, DOI 10.1111/j.1476-5381.1983.tb11051.x; ALLAN G, 1981, J PHARMACOL EXP THER, V217, P157; ALLAN G, 1980, PROSTAGLANDINS CARDI, P223; AUSTIN SM, 1984, AM J MED, V77, P729, DOI 10.1016/0002-9343(84)90374-7; BARAKA A, 1980, JAMA-J AM MED ASSOC, V243, P1745, DOI 10.1001/jama.243.17.1745; BEAVEN MA, 1982, KLIN WOCHENSCHR, V60, P873, DOI 10.1007/BF01716943; BERNREITER M, 1959, JAMA-J AM MED ASSOC, V170, P1628, DOI 10.1001/jama.1959.03010140008003; BOOTH BH, 1970, J AMER MED ASSOC, V211, P627, DOI 10.1001/jama.211.4.627; BRATER DC, 1982, CLIN PHARMACOL THER, V32, P484, DOI 10.1038/clpt.1982.192; BURKE JA, 1982, J PHARMACOL EXP THER, V221, P235; CAPURRO N, 1975, CIRC RES, V36, P520, DOI 10.1161/01.RES.36.4.520; CAPURRO N, 1973, BRIT J PHARMACOL, V48, P620, DOI 10.1111/j.1476-5381.1973.tb08249.x; CRIEP LH, 1971, ANN ALLERGY, V29, P399; FEIGEN GA, 1969, AM J CARDIOL, V24, P474, DOI 10.1016/0002-9149(69)90490-1; FUCHS S, 1978, HDB EXPT IMMUNOLOGY; GUO ZG, 1983, J PHARMACOL METHOD, V9, P127; GUO ZG, 1984, J CARDIOVASC PHARM, V6, P1210; ISHIZAKA K, 1983, ALLERGY PRINCIPLES P, P43; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; KALSNER S, 1984, SCIENCE, V223, P1435, DOI 10.1126/science.6701530; LEVI R, 1975, J PHARMACOL EXP THER, V192, P113; LEVI R, 1982, KLIN WOCHENSCHR, V60, P965, DOI 10.1007/BF01716956; LEVI R, 1980, EUR J PHARMACOL, V62, P41, DOI 10.1016/0014-2999(80)90479-3; LEVI R, 1984, CIRC RES, V54, P117, DOI 10.1161/01.RES.54.2.117; LEVI R, 1981, CIRC RES, V49, P545, DOI 10.1161/01.RES.49.2.545; Levi R, 1980, DRUG INDUCED HEART D, P377; LEVI R, 1979, HISTAMINE RECEPTORS, P99; LEVI R, 1985, PROSTAGLANDINS LEUKO, P275; LEVI R, 1982, PHARM HISTAMINE RECE, P236; LEVI R, 1982, LEUKOTRIENES OTHER L, P215; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEHTA J, 1985, AM HEART J, V109, P1, DOI 10.1016/0002-8703(85)90407-7; PETSAS AA, 1973, CHEST, V64, P66, DOI 10.1378/chest.64.1.66; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; STEIN I, 1970, J ALLERGY, V45, P48, DOI 10.1016/0021-8707(70)90016-X; SULLIVAN TJ, 1982, JAMA-J AM MED ASSOC, V248, P2161, DOI 10.1001/jama.248.17.2161; WEKSLER BB, 1983, NEW ENGL J MED, V308, P800, DOI 10.1056/NEJM198304073081402; WOLFF AA, 1986, CIRC RES, V58, P1; ZAVECZ JH, 1977, CIRC RES, V40, P15, DOI 10.1161/01.RES.40.1.15	40	29	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					709	714		10.1016/0091-6749(86)90415-X	http://dx.doi.org/10.1016/0091-6749(86)90415-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	2422240				2022-12-18	WOS:A1986C390300013
J	STEWART, GA; BUTCHER, A; LEES, K; ACKLAND, J				STEWART, GA; BUTCHER, A; LEES, K; ACKLAND, J			IMMUNOCHEMICAL AND ENZYMATIC ANALYSES OF EXTRACTS OF THE HOUSE DUST MITE DERMATOPHAGOIDES-PTERONYSSINUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									COMMONWEALTH SERUM LABS,PARKVILLE,VIC 3052,AUSTRALIA		STEWART, GA (corresponding author), PRINCESS MARGARET HOSP,CHILDRENS MED RES FDN,CLIN IMMUNOL RES UNIT,PERTH,WA 6008,AUSTRALIA.							ACKLAND J, 1984, J ALLERGY CLIN IMMUN, V74, P848, DOI 10.1016/0091-6749(84)90189-1; ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P53, DOI 10.1016/0019-2791(69)90178-5; BOUSQUET J, 1978, ANN ALLERGY, V41, P164; BOUSQUET J, 1980, ANN ALLERGY, V45, P316; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAPMAN MD, 1982, 11 P INT C ALL CLIN, P531; COTTRELL JM, 1984, 15 P NORD C ALL TURK; CROWLE AJ, 1977, J IMMUNOL METHODS, V17, P379, DOI 10.1016/0022-1759(77)90122-3; Harris, 1976, HDB ENZYME ELECTROPH; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P142, DOI 10.1016/0091-6749(84)90277-X; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1980, ALLERGY, V35, P227, DOI 10.1111/j.1398-9995.1980.tb01756.x; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; LOJDA Z, 1979, ENZYME HISTOCHEMISTR; LOWENSTEIN H, 1977, INT ARCH ALLER A IMM, V55, P1, DOI 10.1159/000231900; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; RODBARD D, 1974, P S RADIOIMMUNOASSAY, P165; STEWART GA, 1980, AUST J EXP BIOL MED, V58, P259, DOI 10.1038/icb.1980.26; STEWART GA, 1983, INT ARCH ALLER A IMM, V71, P340, DOI 10.1159/000233417; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; URIEL J, 1971, METHODS IMMUNOLOGY I, V3, P294; WEEKE B, 1974, ACTA ALLERGOL, V29, P402, DOI 10.1111/j.1398-9995.1974.tb01661.x; WESTERGAARD JL, 1980, J IMMUNOL METHODS, V34, P164; WIDE L, 1967, LANCET, V2, P1105; WOLDEN B, 1982, INT ARCH ALLER A IMM, V68, P144, DOI 10.1159/000233084; APIZYM INSTRUCTION M	29	29	31	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				14	24		10.1016/0091-6749(86)90316-7	http://dx.doi.org/10.1016/0091-6749(86)90316-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3944371				2022-12-18	WOS:A1986AZD3600004
J	ERFFMEYER, JE; SIEGLE, RL; LIEBERMAN, P				ERFFMEYER, JE; SIEGLE, RL; LIEBERMAN, P			ANAPHYLACTOID REACTIONS TO RADIOCONTRAST MATERIAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									VET ADM HOSP,SAN ANTONIO,TX; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; PRESBYTERIAN HOSP DALLAS,SAN ANTONIO,TX; UNIV TENNESSEE,CTR HLTH SCI,MEMPHIS,TN 38163	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of Tennessee System; University of Tennessee Health Science Center								ALMEN T, 1973, Acta Radiologica Supplementum, V335, P233; ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; Ansell G, 1968, Clin Radiol, V19, P175, DOI 10.1016/S0009-9260(68)80059-5; ANSELL G, 1980, INVESTIGATIVE RADI S, V15, P32; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; ARROYAVE CM, 1979, J ALLERGY CLIN IMMUN, V63, P277; ARROYAVE CM, 1977, CLIN EXP IMMUNOL, V29, P87; ARROYAVE CM, 1980, INVEST RADIOL, V15, P21; ASPELIN P, 1979, ACTA RADIOL DIAGN, V20, P1; BRASCH RC, 1976, INVEST RADIOL, V11, P1, DOI 10.1097/00004424-197601000-00001; BRASCH RC, 1976, INVEST RADIOL, V11, P347, DOI 10.1097/00004424-197609000-00002; BRASCH RC, 1970, INVEST RADIOL, V5, P510, DOI 10.1097/00004424-197011000-00017; CHO KJ, 1978, AM J ROENTGENOL, V131, P509, DOI 10.2214/ajr.131.3.509; COGAN FC, 1979, J ALLERGY CLIN IMMUN, V64, P299; COLEMAN WP, 1964, SOUTHERN MED J, V57, P1401, DOI 10.1097/00007611-196412000-00004; DUNN CR, 1975, INVEST RADIOL, V10, P317, DOI 10.1097/00004424-197507000-00006; ELIAS J, 1979, J ALLERGY CLIN IMMUN, V66, P242; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; FREYRIA AM, 1982, J ALLERGY CLIN IMMUN, V69, P397, DOI 10.1016/0091-6749(82)90152-X; GATES DF, 1972, J UROLOGY, V108, P627, DOI 10.1016/S0022-5347(17)60821-8; Gonsette R E, 1977, Acta Radiol Suppl, V355, P247; GONSETTE RE, 1980, INVEST RADIOL, V15, P26; GOREVIC P, 1979, J ALLERGY CLIN IMMUN, V63, P225, DOI 10.1016/0091-6749(79)90105-2; GRAINGER RG, 1980, BRIT J RADIOL, V53, P739, DOI 10.1259/0007-1285-53-632-739; GRAMMER LC, 1983, HOSP PRACT, V18, P89; GREENBERGER P, 1980, J ALLERGY CLIN IMMUN, V65, P220; GREENBERGER P, 1980, INVEST RADIOL, V15, P40; GREENBERGER P A, 1984, Journal of Allergy and Clinical Immunology, V73, P164; GREENBERGER PA, 1981, J ALLERGY CLIN IMMUN, V67, P185, DOI 10.1016/0091-6749(81)90059-2; GROPPE G, 1974, AGENTS ACTIONS, V3, P143; HALPERN B, 1967, J ALLERGY, V40, P168, DOI 10.1016/0021-8707(67)90006-8; HASSELBACHER P, 1980, J ALLERGY CLIN IMMUN, V66, P217, DOI 10.1016/0091-6749(80)90042-1; HIGGINS CB, 1977, RADIOLOGY, V124, P599, DOI 10.1148/124.3.599; HILDRETH EA, 1960, RADIOLOGY, V74, P246, DOI 10.1148/74.2.246; HOOK WA, 1981, IMMUNOLOGY, V43, P723; KALIMO K, 1980, ANN ALLERGY, V45, P253; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; KAPLAN AP, 1978, ALLERGY PRINCIPLES P, P1080; KELLY JF, 1978, J ALLERGY CLIN IMMUN, V62, P181, DOI 10.1016/0091-6749(78)90104-5; KLEINKNECHT D, 1974, CLIN NEPHROL, V2, P116; KOLB WP, 1978, J IMMUNOL, V121, P1232; LANG J, 1975, INVEST RADIOL, V10, P314, DOI 10.1097/00004424-197507000-00005; Lang J H, 1967, Invest Radiol, V2, P396, DOI 10.1097/00004424-196711000-00017; LANG JH, 1976, INVEST RADIOL, V11, P303, DOI 10.1097/00004424-197607000-00007; LASSER EC, 1979, J ALLERGY CLIN IMMUN, V64, P105, DOI 10.1016/0091-6749(79)90043-5; LASSER EC, 1974, RADIOLOGY, V110, P49, DOI 10.1148/110.1.49; LASSER EC, 1970, INVEST RADIOL, V5, P446; LASSER EC, 1981, INVEST RADIOL, V16, P20, DOI 10.1097/00004424-198101000-00004; LASSER EC, 1971, AMER J ROENTGENOL RA, V113, P415; LASSER EC, 1979, AM J ROENTGENOL, V132, P171, DOI 10.2214/ajr.132.2.171; LASSER EC, 1981, RADIOLOGY, V140, P11, DOI 10.1148/radiology.140.1.6166025; LASSER EC, 1981, ALLERGY, V36, P369, DOI 10.1111/j.1398-9995.1981.tb01840.x; LASSER EC, 1980, INVEST RADIOL, V15, P6; LASSER EC, 1980, INVEST RADIOL, V15, P2; LIEBERMAN P, 1978, J ALLERGY CLIN IMMUN, V62, P174, DOI 10.1016/0091-6749(78)90103-3; LIEBERMAN P, 1979, J ALLERGY CLIN IMMUN, V64, P13, DOI 10.1016/0091-6749(79)90076-9; LITTNER MR, 1977, RADIOLOGY, V124, P17, DOI 10.1148/124.1.17; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MCCLENNAN BL, 1976, INVEST RADIOL, V11, P240, DOI 10.1097/00004424-197605000-00013; MILLER WL, 1975, J ALLERGY CLIN IMMUN, V56, P291, DOI 10.1016/0091-6749(75)90103-7; NEOH SH, 1982, INVEST RADIOL, V16, P152; PETERS GA, 1966, J ALLERGY, V38, P74, DOI 10.1016/0021-8707(66)90046-3; RAININKO R, 1979, ACTA RADIOL DIAGN, V20, P410, DOI 10.1177/028418517902000302; RAPOPORT S, 1982, RADIOLOGY, V143, P321, DOI 10.1148/radiology.143.2.7071332; READ RC, 1959, J THORAC CARDIOV SUR, V38, P685, DOI 10.1016/S0022-5223(19)32431-6; RICE M, 1981, J ALLERGY CLIN IMM S, V67, P71; RING J, 1984, Journal of Allergy and Clinical Immunology, V73, P165; RING J, 1978, CLIN EXP IMMUNOL, V34, P302; RING J, 1978, CLIN EXP IMMUNOL, V32, P105; RING J, 1978, J LAB CLIN MED, V92, P584; ROCKOFF SD, 1971, INVEST RADIOL, V6, P110, DOI 10.1097/00004424-197103000-00004; ROCKOFF SD, 1972, INVEST RADIOL, V7, P177; ROCKOFF SD, 1971, INVEST RADIOL, V6, P186; ROCKOFF SD, 1970, INVEST RADIOL, V6, P503; ROSENFIELD AT, 1977, INVEST RADIOL, V12, P295, DOI 10.1097/00004424-197705000-00016; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SCHONING B, 1982, KLIN WOCHENSCHR, V60, P1048, DOI 10.1007/BF01716970; SCHULZE B, 1980, INVEST RADIOL      S, V15, P18; SHAPIRO GA, 1977, RADIOLOGY, V124, P641, DOI 10.1148/124.3.641; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SHEHADI WH, 1980, RADIOLOGY, V137, P299, DOI 10.1148/radiology.137.2.7433658; SHEHADI WH, 1974, RADIOLOGY, V113, P219, DOI 10.1148/113.1.219; SHEHADI WH, 1966, AMER J ROENTGENOL RA, V97, P762, DOI 10.2214/ajr.97.3.762; SHEHADI WH, 1982, RADIOLOGY, V143, P13; SIEGLE RL, 1978, J UROLOGY, V119, P581, DOI 10.1016/S0022-5347(17)57557-6; SIEGLE RL, 1976, INVEST RADIOL, V11, P98, DOI 10.1097/00004424-197603000-00004; SIEGLE RL, 1980, INVEST RADIOL, V15, P13; SIMON RA, 1979, J ALLERGY CLIN IMMUN, V63, P281, DOI 10.1016/0091-6749(79)90114-3; SIMON SW, 1954, J ALLERGY, V25, P395, DOI 10.1016/0021-8707(54)90002-7; SMALL P, 1982, CLIN ALLERGY, V12, P289, DOI 10.1111/j.1365-2222.1982.tb02530.x; SWEENEY MJ, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90360-3; TILL G, 1978, INT ARCH ALLER A IMM, V56, P543, DOI 10.1159/000232070; TURNER E, 1982, RADIOLOGY, V143, P327, DOI 10.1148/radiology.143.2.7071333; WAKKERSGARRITSEN BG, 1976, ANN ALLERGY, V36, P122; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; YOCUM MW, 1978, J ALLERGY CLIN IMMUN, V62, P309, DOI 10.1016/0091-6749(78)90163-X; ZEMAN RK, 1977, INVEST RADIOL, V12, P203, DOI 10.1097/00004424-197703000-00022; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159; 1980, MED LETT DRUGS THER, V23, P56	101	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					401	410		10.1016/0091-6749(85)90079-X	http://dx.doi.org/10.1016/0091-6749(85)90079-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	3973314				2022-12-18	WOS:A1985AEB4600013
J	REED, CE				REED, CE			ADRENERGIC BRONCHODILATORS - PHARMACOLOGY AND TOXICOLOGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO MED SCH,DEPT INTERNAL MED,DIV ALLERG DIS,ROCHESTER,MN 55901	Mayo Clinic	REED, CE (corresponding author), MAYO CLIN & MAYO FDN,DIV ALLERG DIS,ROCHESTER,MN 55905, USA.				NIAID NIH HHS [AI-21255] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021255] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Joseph X, 1981, Fundam Appl Toxicol, V1, P443, DOI 10.1016/S0272-0590(81)80025-5; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; STILES GL, 1983, LIFE SCI, V33, P467, DOI 10.1016/0024-3205(83)90796-8; SZENTIVANYI A, 1983, ALLERGY PRINCIPLES P, P303; VENTER JC, 1983, ALLERGY, P503; WEINER N, 1980, PHARMACOL BASIS THER, P138	7	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					335	341		10.1016/0091-6749(85)90650-5	http://dx.doi.org/10.1016/0091-6749(85)90650-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2862174				2022-12-18	WOS:A1985APE8900014
J	TING, S; RAULS, DO; REIMAN, BEF				TING, S; RAULS, DO; REIMAN, BEF			INHIBITORY EFFECT OF HYDROXYZINE ON ANTIGEN-INDUCED HISTAMINE-RELEASE INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WILLIAM BEAUMONT ARMY MED CTR,DEPT PATHOL,ELECTRON MICROSCOPY SECT,EL PASO,TX 79920; WILLIAM BEAUMONT ARMY MED CTR,DEPT CLIN INVEST,EL PASO,TX 79920	William Beaumont Army Medical Center; William Beaumont Army Medical Center	TING, S (corresponding author), WILLIAM BEAUMONT ARMY MED CTR,DEPT MED,ALLERGY IMMUNOL SERV,EL PASO,TX 79920, USA.							BEAVEN MA, 1979, MONOGR ALLERGY, V13, P1; EPPINGER H, 1913, WIEN MED WOCHENSCHR, V43, P141; GRANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11; LEWIS SJ, 1981, AGENTS ACTIONS, V11, P228, DOI 10.1007/BF01967619; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; MATTHEWS CN, 1973, BRIT J DERMATOL, V88, P279; MONROE EW, 1981, INT J DERMATOL, V20, P32, DOI 10.1111/j.1365-4362.1981.tb05282.x; MOTA I, 1960, BRIT J PHARM CHEMOTH, V15, P396, DOI 10.1111/j.1476-5381.1960.tb01262.x; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; PEPYS J, 1979, MAST CELL ITS ROLE H, P61; RHODES RB, 1975, J ALLERGY CLIN IMMUN, V55, P180; TING S, 1980, J ALLERGY CLIN IMMUN, V66, P417, DOI 10.1016/0091-6749(80)90122-0; TING S, 1983, ALLERGY, V38, P11, DOI 10.1111/j.1398-9995.1983.tb00850.x; TING S, 1983, J ALLERGY CLIN IMMUN, V71, P12, DOI 10.1016/0091-6749(83)90540-7; TING S, 1983, J ALLERGY CLIN IMMUN, V71, P437, DOI 10.1016/0091-6749(83)90458-X; TING S, 1983, J ALLERGY CLIN IMMUN, V71, P546, DOI 10.1016/0091-6749(83)90435-9; TING S, 1982, CLIN RES, V30, P166; YAMAMOTO S, 1973, IMMUNOLOGY, V24, P77	18	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					63	66		10.1016/0091-6749(85)90013-2	http://dx.doi.org/10.1016/0091-6749(85)90013-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	2578493	Bronze			2022-12-18	WOS:A1985ABF2600009
J	DERER, MM; MIESCHER, S; JOHANSSON, B; FROST, H; GORDON, J				DERER, MM; MIESCHER, S; JOHANSSON, B; FROST, H; GORDON, J			APPLICATION OF THE DOT IMMUNOBINDING ASSAY TO ALLERGY DIAGNOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; CIBA GEIGY AG,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; Novartis								ADKINSON NF, 1980, J ALLERGY CLIN IMMUN, V65, P1, DOI 10.1016/0091-6749(80)90169-4; ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8; BLANCHARD GC, 1982, J IMMUNOL METHODS, V52, P81, DOI 10.1016/0022-1759(82)90352-0; BRUYNZEEL PLB, 1979, CLIN CHIM ACTA, V91, P67, DOI 10.1016/0009-8981(79)90472-8; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; GORDON J, UNPUB DIAGNOSTIC POT; GORDON J, 1983, IMMUNOENZYMATIC TECH, P303; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HERBERT FA, 1982, ANN ALLERGY, V49, P311; ISERSKY C, 1974, J IMMUNOL, V112, P1909; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; JOHANSSON SGO, 1982, CLIN IMMUNOLOGY UPDA, P124; JOHANSSON SGO, 1967, NOBEL S, V3, P1973; KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2; KING WP, 1982, ARCH OTOLARYNGOL, V108, P781; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LYNCH NR, 1975, CLIN EXP IMMUNOL, V22, P35; MAGNUSSON CGM, 1982, J ALLERGY CLIN IMMUN, V70, P326, DOI 10.1016/0091-6749(82)90021-5; METZGER WJ, 1981, CLIN ALLERGY, V11, P523, DOI 10.1111/j.1365-2222.1981.tb02170.x; NYE L, 1975, Clinical Allergy, V5, P13, DOI 10.1111/j.1365-2222.1975.tb01832.x; RAO PVS, 1983, J IMMUNOL METHODS, V57, P71, DOI 10.1016/0022-1759(83)90066-2; RORDORF C, 1983, J IMMUNOL METHODS, V59, P105, DOI 10.1016/0022-1759(83)90150-3; SCOTT ML, 1981, INT ARCH ALLER A IMM, V64, P222, DOI 10.1159/000232696; THOMPSON RA, 1983, LANCET, V1, P169; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIDE L, 1967, LANCET, V2; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	29	29	32	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	1					85	92		10.1016/0091-6749(84)90093-9	http://dx.doi.org/10.1016/0091-6749(84)90093-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SZ648	6376599				2022-12-18	WOS:A1984SZ64800014
J	YAMAUCHI, N; SUKO, M; MORITA, Y; SUZUKI, S; ITO, K; MIYAMOTO, T				YAMAUCHI, N; SUKO, M; MORITA, Y; SUZUKI, S; ITO, K; MIYAMOTO, T			DECREASED AIRWAY RESPONSIVENESS TO HISTAMINE IN GOLD SALT TREATED GUINEA-PIGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											YAMAUCHI, N (corresponding author), UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN.							ARAKI H, 1969, JAP J ALLERG, V18, P106; BARTHOLOMEW LE, 1965, ARTHRITIS RHEUM-US, V8, P376, DOI 10.1002/art.1780080306; BRINK C, 1980, J PHARMACOL EXP THER, V215, P426; CAILLA HL, 1976, ANAL BIOCHEM, V70, P195, DOI 10.1016/S0378-5173(83)90100-X; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DANIELE RP, 1979, PULMONARY DISEASES D, P576; FREYBERG RH, 1972, ARTHRITIS ALLIED CON, P455; HONMA M, 1977, BIOCHEM MED METAB B, V18, P257, DOI 10.1016/0006-2944(77)90060-6; ISHIZAKI T, 1965, DIAGNOSIS TREATMENT, V53, P750; Janoff A, 1970, Biochem Pharmacol, V19, P626, DOI 10.1016/0006-2952(70)90222-4; JOSSOP JD, 1973, ANN RHEUM DIS, V32, P294; KURAKANE K, 1957, JAP J CLIN MED, V16, P1477; LIPSKY PE, 1976, ARTHRITIS RHEUM, V19, P808; LORBER A, 1968, ARTHRITIS RHEUM, V11, P170, DOI 10.1002/art.1780110207; MEAD J, 1960, J APPL PHYSIOL, V15, P325, DOI 10.1152/jappl.1960.15.3.325; MIYAMOTO T, 1974, J JAP SOC INTERN MED, V63, P90; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; NAKAGAWA T, 1978, ANN ALLERGY, V40, P272; NATHAN RA, 1979, J ALLERGY CLIN IMMUN, V64, P491, DOI 10.1016/0091-6749(79)90058-7; NOMURA T, 1974, JAP J THORAC DIS, V12, P522; Okatani Y, 1970, JPN MED J, V2432, P17; PANUSH RS, 1976, ARTHRITIS RHEUM, V19, P907, DOI 10.1002/art.1780190512; PERSELLIN RH, 1966, ARTHRITIS RHEUM-US, V9, P57, DOI 10.1002/art.1780090107; SATO T, 1981, CLIN CHIM ACTA, V110, P215; SATO T, 1982, ANAL BIOCHEM, V121, P409, DOI 10.1016/0003-2697(82)90500-0; SHIDA T, 1973, INT C SERIES, V300, P19; SUGIHARA H, 1953, J JPN MED ASS, V29, P436; SUZUKI S, 1983, J ALLERGY CLIN IMMUN, V72, P469, DOI 10.1016/0091-6749(83)90583-3; TAZAWA M, 1975, JAP J ALLERGY, V24, P42; VERNONROBERTS B, 1978, ANN RHEUM DIS, V37, P1; WALZ DT, 1971, ANN RHEUM DIS, V30, P303, DOI 10.1136/ard.30.3.303; WELLS HG, 1932, GOLD CHEM TUBERCULOS, P426	33	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	6					802	807		10.1016/0091-6749(84)90182-9	http://dx.doi.org/10.1016/0091-6749(84)90182-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW418	6094640				2022-12-18	WOS:A1984TW41800007
J	DORSCH, W; RING, J; MELZER, H				DORSCH, W; RING, J; MELZER, H			A SELECTIVE INHIBITOR OF THROMBOXANE BIOSYNTHESIS ENHANCES IMMEDIATE AND INHIBITS LATE CUTANEOUS ALLERGIC REACTIONS IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MUNICH,DEPT PEDIAT,D-8000 MUNICH 2,FED REP GER; UNIV MUNICH,DEPT DERMATOL,D-8000 MUNICH 2,FED REP GER; PFIZER CLIN RES,MUNICH,FED REP GER	University of Munich; University of Munich; Pfizer			Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				ADCOCK JJ, 1980, BRIT J PHARMACOL, V69, P167, DOI 10.1111/j.1476-5381.1980.tb07886.x; ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; BERTI F, 1979, BRIT J PHARMACOL, V65, P629, DOI 10.1111/j.1476-5381.1979.tb07874.x; DALY MJ, 1974, BRIT J PHARMACOL, V51, P599, DOI 10.1111/j.1476-5381.1974.tb09679.x; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DORSCH W, 1981, J ALLERGY CLIN IMMUN, V67, P117, DOI 10.1016/0091-6749(81)90006-3; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; DORSCH W, 1983, ALLERGOLOGIE, V6, P94; DORSCH W, 1981, N-S ARCH PHARMACOL, V317, P351, DOI 10.1007/BF00501318; ENGINEER DM, 1978, BRIT J PHARMACOL, V64, P211, DOI 10.1111/j.1476-5381.1978.tb17291.x; FAIRFAX AJ, 1982, PROSTA LEUKOTR MED, V8, P239, DOI 10.1016/0262-1746(82)90046-4; FEINMARK SJ, 1982, J BIOL CHEM, V257, P2816; FOLCO G, 1982, EUR J PHARMACOL, V78, P159, DOI 10.1016/0014-2999(82)90232-1; Harris D N, 1980, Adv Prostaglandin Thromboxane Res, V6, P437; HIGGS EA, 1978, PROSTAGLANDINS, V16, P153, DOI 10.1016/0090-6980(78)90018-7; LEFER AM, 1981, THROMB RES, V23, P265, DOI 10.1016/0049-3848(81)90016-5; MARONE G, 1981, INT ARCH ALLER A IMM, V66, P144, DOI 10.1159/000232888; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PARRY MJ, 1982, LANCET, V2, P164; PECK MJ, 1978, BRIT J PHARMACOL, V62, P464; PIPER PJ, 1982, ALLERGOLOGIE, V5, P138; RANDALL MJ, 1981, THROMB RES, V23, P145, DOI 10.1016/0049-3848(81)90247-4; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Stalenheim G, 1979, Monogr Allergy, V14, P264; STEEL LK, 1981, J BIOL CHEM, V256; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; TYLER HM, 1981, LANCET, V1, P629; UENO A, 1982, INT S PROSTAGLANDINS; VARGAFTIG BB, 1981, CLIN RES PROC, V17, P723; VERMYLEN J, 1981, LANCET, V1, P1073; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; WILLIAMS TJ, 1977, NATURE, V270, P530, DOI 10.1038/270530a0	33	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					168	174		10.1016/0091-6749(83)90525-0	http://dx.doi.org/10.1016/0091-6749(83)90525-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6604081				2022-12-18	WOS:A1983RD95900010
J	PAULL, BR; COGHLAN, TH; VINSON, SB				PAULL, BR; COGHLAN, TH; VINSON, SB			FIRE ANT VENOM HYPERSENSITIVITY .1. COMPARISON OF FIRE ANT VENOM AND WHOLE-BODY EXTRACT IN THE DIAGNOSIS OF FIRE ANT ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TEXAS A&M UNIV,DEPT FAMILY MED,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT ENTOMOL,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	PAULL, BR (corresponding author), TEXAS A&M UNIV,DEPT MED MICROBIOL & IMMUNOL,COLLEGE STN,TX 77843, USA.				NIAID NIH HHS [AI 17903] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAER H, 1979, TOXICON, V17, P397, DOI 10.1016/0041-0101(79)90267-8; BLUM MS, 1958, SCIENCE, V128, P306, DOI 10.1126/science.128.3319.306-a; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; JAMES FK, 1976, J ALLERGY CLIN IMMUN, V58, P110, DOI 10.1016/0091-6749(76)90112-3; JAMES FK, 1976, J ASTHMA RES, V13, P179, DOI 10.3109/02770907609104174; JAMES JK, 1982, MAR P IMP FIR ANT C; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LOCKEY RF, 1974, J ALLERGY CLIN IMMUN, V54, P132, DOI 10.1016/0091-6749(74)90050-5; RHODES RB, 1975, J ALLERGY CLIN IMMUN, V56, P84; RHODES RB, 1977, J FLA MED ASS, V64, P247; STROM GB, 1980, J ALLERGY CLIN IMMUN, V65, P202; TRIPLETT RF, 1976, SOUTHERN MED J, V69, P258, DOI 10.1097/00007611-197603000-00002; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477, DOI 10.1097/00007611-197304000-00019; WIDE L, 1967, LANCET, V2, P1105; Yeager W, 1978, J Med Assoc Ga, V67, P101; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4	18	29	29	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					448	453		10.1016/0091-6749(83)90460-8	http://dx.doi.org/10.1016/0091-6749(83)90460-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6601669				2022-12-18	WOS:A1983QQ74200003
J	PELIKAN, Z				PELIKAN, Z			THE CHANGES IN THE NASAL SECRETIONS OF EOSINOPHILS DURING THE IMMEDIATE NASAL RESPONSE TO ALLERGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PELIKAN, Z (corresponding author), INST MED SCI DE KLOKKENBERG,DEPT ALLERGOL & IMMUNOL,GALDERSEWEG 81,4800 RA BREDA,NETHERLANDS.							ANDERSEN HC, 1943, THESIS COPENHAGEN; BACKMAN A, 1979, MAST CELL ITS ROLE H, P468; BEESON PB, 1980, EOSINOPHIL HLTH DISE, P313; BHANDARI CM, 1976, ANN ALLERGY, V37, P280; BICKMORE JT, 1976, LARYNGOSCOPE, V86, P516, DOI 10.1288/00005537-197604000-00007; BOOTH BH, 1972, ALLERGIC DISEASES DI, P63; BRYAN WTK, 1958, T AM ACAD OPHTHALMOL, V63, P597; CONNELL JT, 1976, BRONCHIAL ASTHMA MEC, P481; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P73, DOI 10.1016/0091-6749(77)90086-0; GLEICH GJ, 1980, EOSINOPHIL HLTH DISE, P79; GOETZL EJ, 1975, ARCH PATHOL, V99, P1; GOETZL EJ, 1975, NEW DIRECTIONS ASTHM, P173; HANSEL FK, 1953, CLIN ALLERGY, P408; HANSEL FK, 1975, ALLERGY IMMUNITY OTO, P52; HANSEL FRENCH K., 1934, JOUR ALLERGY, V5, P357, DOI 10.1016/S0021-8707(34)90159-3; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; HUBSCHER TT, 1977, ANN ALLERGY, V38, P83; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; KAJOSAARI M, 1981, ALLERGY, V36, P329, DOI 10.1111/j.1398-9995.1981.tb01584.x; MALMBERG H, 1979, ALLERGY, V34, P331; MALMBERG H, 1979, ALLERGY, V34, P389, DOI 10.1111/j.1398-9995.1979.tb02008.x; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MURRAY AB, 1969, J ALLERGY, V43, P1, DOI 10.1016/0021-8707(69)90014-8; MURRAY AB, 1970, ANN ALLERGY, V28, P142; MURRAY AB, 1971, CAN MED ASSOC J, V104, P599; MYGIND N, 1973, ARCH KLIN EXP OHR, V204, P123, DOI 10.1007/BF00302160; MYGIND N, 1979, ALLERGY, V34, P195, DOI 10.1111/j.1398-9995.1979.tb01699.x; Mygind N, 1979, NASAL ALLERGY, P170; OCONNELL JM, 1978, RESPIRATION, V35, P65, DOI 10.1159/000193861; OLSSON I, 1979, ALLERGY, V34, P353, DOI 10.1111/j.1398-9995.1979.tb02005.x; OTTESEN EA, 1978, ALLERGY PRINCIPLES P, P584; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PELIKAN Z, 1977, ANN ALLERGY, V38, P263; PELIKAN Z, 1981, 12TH P ANN M EUR AC, P634; PELIKAN Z, 1979, MAST CELL ITS ROLE H, P772; PELIKAN Z, 1982, 38TH ANN M AM AC ALL; SASAKI Y, 1977, ANN ALLERGY, V39, P106; SLAVIN RG, 1964, J ALLERGY, V35, P499, DOI 10.1016/0021-8707(64)90081-4; SMITH JA, 1980, CELL BIOL INFLAMMATI, P189; SMITH RE, 1968, ANN ALLERGY, V26, P80; SPECTOR SL, 1980, J ALLERGY CLIN IMMUN, V66, P129, DOI 10.1016/0091-6749(80)90060-3; VAHERI EINO, 1956, ACTA ALLERGOL, V10, P203, DOI 10.1111/j.1398-9995.1956.tb02997.x; WILLIAMS RB, 1972, ANN ALLERGY, V30, P189; Zucker-Franklin D, 1974, Adv Intern Med, V19, P1	44	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	6					657	662		10.1016/0091-6749(83)90625-5	http://dx.doi.org/10.1016/0091-6749(83)90625-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RW048	6643872				2022-12-18	WOS:A1983RW04800004
J	RUZICKA, T; WASSERMAN, SI; SOTER, NA; PRINTZ, MP				RUZICKA, T; WASSERMAN, SI; SOTER, NA; PRINTZ, MP			INHIBITION OF RAT MAST-CELL ARACHIDONIC-ACID CYCLOOXYGENASE BY DAPSONE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN DIEGO, SCH MED, DEPT MED, DIV PHARMACOL & RHEUMATOL ALLERGY, LA JOLLA, CA 92093 USA; HARVARD UNIV, SCH MED, DEPT DERMATOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, IMMUNODERMATOL SECT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV DERMATOL, BOSTON, MA 02115 USA	University of California System; University of California San Diego; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital				Soter, Nicholas/0000-0003-3518-3209	NHLBI NIH HHS [HL-25457] Funding Source: Medline; NIAID NIH HHS [AI-17268, AI-18139] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL025457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017268] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRANCO VP, 1974, ARCH DERMATOL, V110, P563, DOI 10.1001/archderm.110.4.563; BEIGUELMAN B, 1974, B WORLD HEALTH ORGAN, V51, P467; BRAVERMAN IM, 1975, J INVEST DERMATOL, V64, P105, DOI 10.1111/1523-1747.ep12510321; FLOWER RJ, 1976, BRIT J PHARMACOL, V56, P229, DOI 10.1111/j.1476-5381.1976.tb07446.x; GAUDET RJ, 1980, J NEUROCHEM, V35, P653, DOI 10.1111/j.1471-4159.1980.tb03704.x; GOWER RG, 1977, J INVEST DERMATOL, V69, P477, DOI 10.1111/1523-1747.ep12511631; Jakschik B A, 1980, Adv Prostaglandin Thromboxane Res, V6, P163; KATZ SI, 1977, MEDICINE, V56, P443, DOI 10.1097/00005792-197709000-00005; LANG PG, 1979, J AM ACAD DERMATOL, V1, P479, DOI 10.1016/S0190-9622(79)80088-2; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LEWIS RA, 1981, BIOCH ACUTE ALLERGIC, P239; MATTHEWS CNA, 1978, BRIT J DERMATOL, V99, P455, DOI 10.1111/j.1365-2133.1978.tb06188.x; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; RUZICKA T, 1982, BIOCHIM BIOPHYS ACTA, V711, P391, DOI 10.1016/0005-2760(82)90052-2; RUZICKA T, 1981, BRIT J DERMATOL, V104, P53, DOI 10.1111/j.1365-2133.1981.tb01711.x; RUZICKA T, 1981, ARCH DERMATOL RES, V270, P347, DOI 10.1007/BF00403939; SKIDGEL RA, 1978, PROSTAGLANDINS, V16, P1, DOI 10.1016/0090-6980(78)90196-X; SOTER NA, 1976, J INVEST DERMATOL, V66, P344, DOI 10.1111/1523-1747.ep12482901; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SOTER NA, 1978, CLIN EXP IMMUNOL, V32, P46; STECHSCHULTE DJ, 1967, J EXP MED, V125, P127, DOI 10.1084/jem.125.1.127; STENDAHL O, 1978, J CLIN INVEST, V62, P214, DOI 10.1172/JCI109109; THOMPSON DM, 1976, P ROY SOC MED, V69, P389, DOI 10.1177/003591577606900603; THOMPSON DM, 1975, P ROY SOC MED, V68, P273, DOI 10.1177/003591577506800501; WASSERMAN SI, 1980, INT J DERMATOL, V19, P7, DOI 10.1111/j.1365-4362.1980.tb01984.x; WELLS GC, 1969, P ROY SOC MED, V62, P665, DOI 10.1177/003591576906200712; WINTROUB BU, 1978, NEW ENGL J MED, V298, P417, DOI 10.1056/NEJM197802232980803	27	29	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					365	370		10.1016/0091-6749(83)90501-8	http://dx.doi.org/10.1016/0091-6749(83)90501-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6413566				2022-12-18	WOS:A1983RN33000006
J	MAY, CD				MAY, CD			FOOD ALLERGY - LESSONS FROM THE PAST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																		ALVAREZ WC, 1929, MED CLIN N AM, V12, P1589; ANDRESEN AFR, 1925, MED J REC, V122, P271; BARNATHAN L, 1911, THESIS FM PARIS; BERNSTEIN M, 1981, 37TH P ANN M AM AC A; Blackley CH., 1873, EXPT RES CAUSES NATU; BOCK SA, 1980, AM J DIS CHILD, V134, P973, DOI 10.1001/archpedi.1980.02130220049015; COCA AF, 1931, ASTHMA HAY FEVER; COOKE RA, 1921, P NEW YORK PATH SOC, V21, P8; Cooke RA, 1947, ALLERGY THEORY PRACT; Duke WW, 1923, ARCH INTERN MED, V32, P298, DOI 10.1001/archinte.1923.00110200144010; DUKE WW, 1922, ANN CLIN MED, V1, P178; EYERMAN CH, 1931, J ALLERGY, V11, P106; Hoobler BR, 1916, AM J DIS CHILD, V12, P129; HUTINEL, 1908, CLINIQUE, V3; LAROCHE CT, 1911, CR SOC BIOL, V70, P169; LAROCHE G, 1919, ANAPHYLAXIE ALIMENTA; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; RACKEMANN FM, 1931, CLIN ALLERGY; Richet C, 1911, CR SOC BIOL, V70, P44; ROSENAU MJ, 1906, HYGIENIC LABORATORY, V29; ROWE AH, 1930, J MED FRANC, V19, P170; ROWE AH, 1932, FOOD ALLERGY; Schloss OM, 1920, AM J DIS CHILD, V19, P433; Schloss OM, 1912, AM J DIS CHILD, V3, P341; Turnbull JA, 1924, BOSTON MED SURG J, V191, P438, DOI 10.1056/NEJM192409041911003; VAUGHAN WT, 1939, PRACTICE ALLERGY; WARD JF, 1922, NEW YORK STATE J MED, V115, P592; WOLF S, 1959, P ASS RESEARCH NERVO, V37, P147	29	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	3					255	259		10.1016/S0091-6749(82)80001-8	http://dx.doi.org/10.1016/S0091-6749(82)80001-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NF697	7037911	Bronze			2022-12-18	WOS:A1982NF69700001
J	MUELLER, U; ELLIOTT, W; REISMAN, R; ISHAY, J; WALSH, S; STEGER, R; WYPYCH, J; ARBESMAN, C				MUELLER, U; ELLIOTT, W; REISMAN, R; ISHAY, J; WALSH, S; STEGER, R; WYPYCH, J; ARBESMAN, C			COMPARISON OF BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF VENOMS FROM 4 HORNET SPECIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT MED,BUFFALO,NY 14214; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14214; SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214; BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center								BEQUAERT J., 1931, ENTOMOLOGICA AMERICANA, V12, P71; FLETCHER JE, 1979, TOXICON, V17, P591, DOI 10.1016/0041-0101(79)90233-2; KERN F, 1976, J ALLERGY CLIN IMMUN, V57, P554, DOI 10.1016/0091-6749(76)90006-3; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KRYSPIN J, 1977, RES B, V207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; LIGHT WC, 1976, POSTGRAD MED, V58, P153; LOEWENSTEIN H, 1980, J ALLERGY CLIN IMMUN, V65, P201; NAIR BC, 1976, J ALLERGY CLIN IMMUN, V58, P101, DOI 10.1016/0091-6749(76)90111-1; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P281, DOI 10.1016/0091-6749(79)90145-3; TOLKSDORF S, 1968, WOORTHINGTON MANUAL, P35; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; WYPYCH JI, 1979, J ALLERGY CLIN IMMUN, V63, P267, DOI 10.1016/0091-6749(79)90111-8	14	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	4					290	298		10.1016/0091-6749(81)90024-5	http://dx.doi.org/10.1016/0091-6749(81)90024-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LL697	7204785				2022-12-18	WOS:A1981LL69700007
J	ROSE, JQ; NICKELSEN, JA; MIDDLETON, E; YURCHAK, AM; PARK, BH; JUSKO, WJ				ROSE, JQ; NICKELSEN, JA; MIDDLETON, E; YURCHAK, AM; PARK, BH; JUSKO, WJ			PREDNISOLONE DISPOSITION IN STEROID-DEPENDENT ASTHMATICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,SCH PHARM,DEPT PHARMACEUT,BUFFALO,NY 14214; SUNY BUFFALO,SCH MED,DEPT MED,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Jusko, William J/G-4885-2015		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024211, R37GM024211] Funding Source: NIH RePORTER; NCI NIH HHS [CA-24215] Funding Source: Medline; NHLBI NIH HHS [HL-10628] Funding Source: Medline; NIGMS NIH HHS [GM-24211] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI Y, 1964, STEROID DYNAMICS; BALLARD PL, 1975, MONOGR ENDOCRINOL, V12, P25; BENET LZ, 1979, J PHARM SCI, V68, P1071, DOI 10.1002/jps.2600680845; CAMPAGNA FA, 1963, J PHARM SCI, V52, P605, DOI 10.1002/jps.2600520626; COLLINS JV, 1975, Q J MED, V44, P259; COLLINS JV, 1970, LANCET, V2, P1047; DOLEN JG, 1978, IMMUNOL COMMUN, V7, P677, DOI 10.3109/08820137809068728; DWYER J, 1967, AUSTRALAS ANN MED, V16, P297; Gibaldi M, 1975, TRAPEZOID RULE PHARM, P293; JUSKO WJ, 1979, J PHARM SCI, V68, P1358, DOI 10.1002/jps.2600681106; KAPLOW LS, 1974, 1ST P INT S PULS CYT, P262; LOWELL FC, 1970, J ALLERGY, V45, P131; MAY CS, 1980, BRIT J DIS CHEST, V74, P91; NATIELLE MG, 1963, NBS91 HDB, pT16; ROCCI JL, 1980, J PHARM SCI, V69, P977; ROSE JQ, 1979, J CHROMATOGR, V162, P273, DOI 10.1016/S0378-4347(00)81514-5; ROSE JQ, J PHARMACOKINET BIOP; SCHWARTZ HJ, 1968, ANN INTERN MED, V69, P493, DOI 10.7326/0003-4819-69-3-493; WEST KM, 1958, METABOLISM, V7, P441; WILSON CG, 1975, BRIT J CLIN PHARMACO, V2, P321, DOI 10.1111/j.1365-2125.1975.tb02778.x	20	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					366	373		10.1016/0091-6749(80)90115-3	http://dx.doi.org/10.1016/0091-6749(80)90115-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	7440853				2022-12-18	WOS:A1980KQ96500004
J	HUTCHCROFT, BJ; MOORE, EG; ORANGE, RP				HUTCHCROFT, BJ; MOORE, EG; ORANGE, RP			EFFECTS OF H-1 AND H-2-RECEPTOR ANTAGONISM ON THE RESPONSE OF MONKEY SKIN TO INTRADERMAL HISTAMINE, REVERSE-TYPE ANAPHYLAXIS, AND PASSIVE CUTANEOUS ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DEPT IMMUNOL,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427, DOI 10.1111/j.1476-5381.1966.tb01674.x; BLACK JW, 1972, NATURE, V236, P358; BRIMBLECOMBE RW, 1975, J INT MED RES, V3, P86, DOI 10.1177/030006057500300205; CHARKIN LW, 1974, AGENTS ACTIONS, V4, P297; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; DOUGLAS WW, 1970, PHARMACOL BASIS, P639; DRAZEN JM, 1978, AM REV RESPIR DIS, V117, P479; HOGBERG B, 1960, ACTA PHYSIOL SCAND, V48, P133, DOI 10.1111/j.1748-1716.1960.tb01853.x; KRAVIS TC, 1974, J IMMUNOL, V113, P244; LICHTENSTEIN L M, 1973, P91; LICHTENSTEIN LM, 1973, INT S HISTAMINE H2 R, P187; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; PATTERSON R, IN PRESS; PERPER RJ, 1972, INT ARCH ALLER A IMM, V43, P837, DOI 10.1159/000230901; PHANUPHAK P, 1978, CLIN ALLERGY, V8, P429, DOI 10.1111/j.1365-2222.1978.tb01493.x; POWELL JR, 1976, AM J PHYSIOL, V231, P1002, DOI 10.1152/ajplegacy.1976.231.4.1002	16	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					376	382		10.1016/0091-6749(79)90209-4	http://dx.doi.org/10.1016/0091-6749(79)90209-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	36420				2022-12-18	WOS:A1979GY51400002
J	LEVINE, MI				LEVINE, MI			SYSTEMIC REACTIONS TO IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	3					209	209						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GN274					2022-12-18	WOS:A1979GN27400257
J	DUNSKY, EH; ZWEIMAN, B				DUNSKY, EH; ZWEIMAN, B			DIRECT DEMONSTRATION OF HISTAMINE-RELEASE IN ALLERGIC REACTIONS IN SKIN USING A SKIN CHAMBER TECHNIQUE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV PENN,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19174; VET ADM HOSP,PHILADELPHIA,PA 19104	University of Pennsylvania								EIDINGER D, 1964, J ALLERGY, V35, P77, DOI 10.1016/0021-8707(64)90052-8; FELARCA AB, 1971, J ALLERGY CLIN IMMUN, V48, P125, DOI 10.1016/0091-6749(71)90007-8; GREAVES MW, 1972, IMMUNOLOGY, V23, P239; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KAPLAN AP, 1977, MAR AM C ALL IMM NEW; KAY AB, 1971, J IMMUNOL, V107, P899; LEVY DA, 1973, J LAB CLIN MED, V81, P291; METZGER WJ, 1976, J ALLERGY CLIN IMMUN, V57, P605, DOI 10.1016/0091-6749(76)90012-9; ORANGE RP, 1971, J EXP MED          S, V134, P136; Osler A G, 1968, Adv Immunol, V8, P183, DOI 10.1016/S0065-2776(08)60467-8; SENN H, 1969, J LAB CLIN MED, V74, P742; SOTER NA, 1976, J INVEST DERMATOL, V67, P313, DOI 10.1111/1523-1747.ep12514349; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; WINKELMANN RK, 1966, J INVEST DERMATOL, V46, P220, DOI 10.1038/jid.1966.33	15	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	2					127	130		10.1016/0091-6749(78)90091-X	http://dx.doi.org/10.1016/0091-6749(78)90091-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FL835	78937				2022-12-18	WOS:A1978FL83500011
J	NORMAN, PS; LICHTENSTEIN, LM				NORMAN, PS; LICHTENSTEIN, LM			COMPARISONS OF ALUM-PRECIPITATED AND UNPRECIPITATED AQUEOUS RAGWEED POLLEN EXTRACTS IN TREATMENT OF HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NORMAN, PS (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239, USA.							LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P94, DOI 10.1016/0091-6749(73)90081-X; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1	8	29	29	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	6					384	389		10.1016/0091-6749(78)90118-5	http://dx.doi.org/10.1016/0091-6749(78)90118-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC593	659729				2022-12-18	WOS:A1978FC59300007
J	CHERVINSKY, P				CHERVINSKY, P			DOUBLE-BLIND-STUDY OF IPRATROPIUM BROMIDE, A NEW ANTICHOLINERGIC BRONCHODILATOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGY ASSOC INC,NEW BEDFORD,MA 02740									CHERVINSKY P, 1975, CURR THER RES CLIN E, V17, P507; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; DUNNETT CW, 1964, BIOMETRICS, V20, P482, DOI 10.2307/2528490; GOLDBERG R, 1975, POSTGRAD MED J, V51, P53, DOI 10.1136/pgmj.51.592.53; GRIECO MH, 1971, J ALLERGY CLIN IMMUN, V48, P143, DOI 10.1016/0091-6749(71)90009-1; KLOCK LE, 1975, AM REV RESPIR DIS, V112, P371; REED CE, 1974, J ALLERGY CLIN IMMUN, V53, P34, DOI 10.1016/0091-6749(74)90097-9; Ulmer W T, 1971, Med Klin, V66, P326; WALLENSTEIN S, 1973, DEC AM STAT ASS ANN; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	10	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	1					22	30		10.1016/0091-6749(77)90172-5	http://dx.doi.org/10.1016/0091-6749(77)90172-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	CS828	137921	Bronze			2022-12-18	WOS:A1977CS82800004
J	PINGLETON, WW; BONE, RC; KERBY, GR; RUTH, WE				PINGLETON, WW; BONE, RC; KERBY, GR; RUTH, WE			OROPHARYNGEAL CANDIDIASIS IN PATIENTS TREATED WITH TRIAMCINOLONE ACETONIDE AEROSOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV KANSAS,MED CTR,DEPT INTERNAL MED,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center								BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; BULOW KD, 1974, CURR THER RES, V16, P110; DENNIS M, 1964, J ALLERGY, V35, P70, DOI 10.1016/0021-8707(64)90051-6; FALLIERS CJ, 1976, J ALLERGY CLIN IMMUN, V57, P1, DOI 10.1016/0091-6749(76)90073-7; FLETCHER CM, 1975, POSTGRAD MED J    S4, V51, P90; HODSON ME, 1974, AM REV RESPIR DIS, V110, P403; KRIZ RJ, 1976, CHEST, V69, P455, DOI 10.1378/chest.69.4.455; MCALLEN MK, 1974, BMJ-BRIT MED J, V1, P171, DOI 10.1136/bmj.1.5900.171; SMITH A P, 1973, British Journal of Diseases of the Chest, V67, P208, DOI 10.1016/0007-0971(73)90055-7; WILLEY RF, 1976, BRIT J DIS CHEST, V70, P32, DOI 10.1016/0007-0971(76)90004-8; WILLIAMS MH, 1974, AM REV RESPIR DIS, V109, P538; 1974, LANCET, V2, P303	12	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	4					254	258		10.1016/0091-6749(77)90140-3	http://dx.doi.org/10.1016/0091-6749(77)90140-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DX458	908795				2022-12-18	WOS:A1977DX45800010
J	FRANKLIN, R; BAER, H				FRANKLIN, R; BAER, H			COMPARISON OF HONEYBEE VENOMS AND THEIR COMPONENTS FROM VARIOUS SOURCES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FOOD & DRUG ADM,BUR BIOL,8800 ROCKVILLE PIKE,BETHESDA,MD 20014	US Food & Drug Administration (FDA)								BACHMAYER H, 1972, J INSECT PHYSIOL, V18, P1515, DOI 10.1016/0022-1910(72)90230-2; BARR SE, 1971, ANN ALLERGY, V29, P49; BENTON AW, 1963, SCIENCE, V142, P228, DOI 10.1126/science.142.3589.228; BENTON AW, 1963, NATURE, V198, P295, DOI 10.1038/198295b0; CONDREA ELEANOR, 1965, TOXICON, V2, P261, DOI 10.1016/0041-0101(65)90024-3; FRANKLIN RM, 1974, P SOC EXP BIOL MED, V147, P585, DOI 10.3181/00379727-147-38393; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; Habermann E, 1968, Ergeb Physiol, V60, P220; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; KABAT EA, 1961, EXPERIMENTAL IMMUNOC, P149; Miller LC, 1944, P SOC EXP BIOL MED, V57, P261; MUNJAL D, 1972, TOXICON, V10, P367, DOI 10.1016/0041-0101(72)90060-8; NATELSON S, 1961, MICROTECHNIQUES CLIN, P306; PARRISH HM, 1963, AM J MED SCI, V245, P35; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SHIPOLINI RA, 1971, FEBS LETT, V17, P39, DOI 10.1016/0014-5793(71)80558-6; SHULMAN S, 1966, J IMMUNOL, V96, P29; SOBOTKA A, 1973, J ALLERGY CLIN IMMUN, V51, P97, DOI 10.1016/S0091-6749(73)80043-0; STEIGERW.F, 1966, IND MED SURG, V35, P1045; TOLKSDORF S, 1949, J LAB CLIN MED, V34, P74	20	29	30	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	5					285	298		10.1016/0091-6749(75)90001-9	http://dx.doi.org/10.1016/0091-6749(75)90001-9			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AB754	804500				2022-12-18	WOS:A1975AB75400001
J	KONTOUKARAKITSOS, K; SALVAGGIO, JE; MATHEWS, KP				KONTOUKARAKITSOS, K; SALVAGGIO, JE; MATHEWS, KP			COMPARATIVE NASAL ABSORPTION OF ALLERGENS IN ATOPIC AND NONATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,MED SCH,DEPT INTERN MED,ANN ARBOR,MI; LOUISIANA STATE UNIV,SCH MED,DEPT MED,NEW ORLEANS,LA; LOUISIANA STATE UNIV,SCH MED,DEPT MICROBIOL,NEW ORLEANS,LA	University of Michigan System; University of Michigan; Louisiana State University System; Louisiana State University System								CHAIT RA, 1950, J ALLERGY, V21, P153, DOI 10.1016/0021-8707(50)90119-5; Cohen MB, 1930, J IMMUNOL, V18, P419; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; LESKOWITZ S, 1961, J ALLERGY, V32, P152, DOI 10.1016/0021-8707(61)90068-5; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MCDEVITT HO, 1971, PROGR IMMUNOL, V1, P495; NEWCOMB RW, 1969, J IMMUNOL, V103, P215; SALVAGGIO J, 1969, J ALLERGY, V44, P344, DOI 10.1016/0021-8707(69)90026-4; SALVAGGIO J, 1966, J ALLERGY, V38, P31, DOI 10.1016/0021-8707(66)90070-0; SALVAGGIO J E, 1973, Clinical Allergy, V3, P43, DOI 10.1111/j.1365-2222.1973.tb01308.x; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SALVAGGIO JE, 1965, INT ARCH ALLER A IMM, V26, P264, DOI 10.1159/000229578; SCHWARTZ HJ, 1968, J ALLERGY, V42, P169, DOI 10.1016/0021-8707(68)90090-7; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P509; SULZBERGER MB, 1934, J ALLERGY, V5, P554; TADA T, 1970, Journal of Immunology, V104, P377; TAYLOR, 1973, LANCET, V2, P111; Walzer M, 1931, P SOC EXP BIOL MED, V28, P0425; Walzer Matthew, 1942, JOUR ALLERGY, V13, P554, DOI 10.1016/S0021-8707(42)90068-6	19	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	4					241	248		10.1016/0091-6749(75)90143-8	http://dx.doi.org/10.1016/0091-6749(75)90143-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	W1385	1168213				2022-12-18	WOS:A1975W138500005
J	SLOTT, RI; ZWEIMAN, B				SLOTT, RI; ZWEIMAN, B			HISTOLOGIC STUDIES OF HUMAN SKIN-TEST RESPONSES TO RAGWEED AND COMPOUND 48-80 .2. EFFECTS OF CORTICOSTEROID-THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA	University of Pennsylvania								ANDERSEN V, 1969, CELL TISSUE KINET, V2, P139, DOI 10.1111/j.1365-2184.1969.tb01000.x; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BOSEILA AWA, 1963, ANN NY ACAD SCI, V103, P394, DOI 10.1111/j.1749-6632.1963.tb53711.x; COHEN SG, 1974, NEW ENGL J MED, V290, P457, DOI 10.1056/NEJM197402212900810; COHEN SG, 1964, J ALLERGY, V35, P346, DOI 10.1016/0021-8707(64)90098-X; COHEN SG, 1963, P SOC EXP BIOL MED, V113, P29, DOI 10.3181/00379727-113-28266; CSABA G, 1971, ACTA MORPHOL HUNG, V19, P131; EDINGER D, 1962, NATURE, V196, P683; EDINGER D, 1964, J ALLERGY, V35, P77; ESSELLIER AF, 1954, BLOOD, V9, P531, DOI 10.1182/blood.V9.5.531.531; FEINBERG AR, 1967, J ALLERGY, V40, P73, DOI 10.1016/0021-8707(67)90100-1; FELARCA AB, 1971, J ALLERGY CLIN IMMUN, V48, P125, DOI 10.1016/0091-6749(71)90007-8; FELARCA AB, 1969, J ALLERGY, V43, P114, DOI 10.1016/0021-8707(69)90131-2; FOWLER JW, 1966, J ALLERGY, V37, P19, DOI 10.1016/0021-8707(66)90106-7; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LITT M, 1960, BLOOD, V16, P1330, DOI 10.1182/blood.V16.3.1330.1330; LITT M, 1963, AM J PATHOL, V42, P529; LITT M, 1964, ANN NY ACAD SCI, V116, P964, DOI 10.1111/j.1749-6632.1964.tb52562.x; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; SPEIRS RS, 1958, ANN NY ACAD SCI, V73, P283, DOI 10.1111/j.1749-6632.1959.tb40804.x	20	29	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	4					232	240		10.1016/0091-6749(75)90142-6	http://dx.doi.org/10.1016/0091-6749(75)90142-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	W1385	1091685				2022-12-18	WOS:A1975W138500004
J	STARR, JC; BRASHER, GW				STARR, JC; BRASHER, GW			ERYTHEMA MARGINATUM PRECEDING HEREDITARY ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									SCOTT & WHITE CLIN,DEPT ALLERGY & IMMUNOL,TEMPLE,TX 76501	Scott & White Medical Center								AUSTEN KF, 1965, NEW ENGL J MED, V272, P649, DOI 10.1056/NEJM196504012721301; BLOHME G, 1972, ACTA MED SCAND, V191, P209; COHEN JD, 1961, ANN INTERN MED, V54, P331, DOI 10.7326/0003-4819-54-2-331; DENNEHY JJ, 1970, ANN INTERN MED, V73, P55, DOI 10.7326/0003-4819-73-1-55; DONALDSON VH, 1966, PEDIATRICS, V37, P1017; HYMAN C, 1967, J INVEST DERMATOL, V49, P533, DOI 10.1038/jid.1967.175; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; Osler W, 1888, AM J MED SCI, V95, P362; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SPAULDING W B, 1955, Can Med Assoc J, V73, P181	11	29	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	6					352	355		10.1016/0091-6749(74)90119-5	http://dx.doi.org/10.1016/0091-6749(74)90119-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T2239	4208069				2022-12-18	WOS:A1974T223900005
J	FOUCARD, T; AAS, K; JOHANSSO.SG				FOUCARD, T; AAS, K; JOHANSSO.SG			CONCENTRATION OF IGE ANTIBODIES, PK TITERS, AND CHOPPED LUNG TITERS IN SERA FROM CHILDREN WITH HYPERSENSITIVITY TO COD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP UPPSALA,RIKS HOSP,PEDIAT RES INST,ALLERGY UNIT,UPPSALA,SWEDEN; UNIV HOSP UPPSALA,BLOOD CTR,UPPSALA 75014,SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; AAS K, 1966, INT ARCH ALLER A IMM, V29, P346, DOI 10.1159/000229716; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; EVANS R, 1972, J ALLERGY CLIN IMMUN, V49, P285, DOI 10.1016/0091-6749(72)90096-6; FEINBERG AR, 1968, J ALLERGY, V42, P157, DOI 10.1016/0021-8707(68)90088-9; FOUCARD T, 1972, INT ARCH ALLER A IMM, V42, P711, DOI 10.1159/000230651; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; JOHANSSON SGO, UNPUBLISHED RESULTS; LEVY DA, 1967, J IMMUNOL, V99, P1068; PERLMAN F, 1967, J ALLERGY, V39, P205, DOI 10.1016/0021-8707(67)90012-3; SHEARD P, 1967, NATURE, V216, P283, DOI 10.1038/216283a0; STANWORT.DR, 1965, IMMUNOLOGY, V8, P323; STANWORTH DR, 1967, LANCET, V2, P330; STENIUS B, 1971, Clinical Allergy, V1, P37, DOI 10.1111/j.1365-2222.1971.tb02446.x; WIDE L, 1967, LANCET, V2, P1105	17	29	29	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	1					39	44		10.1016/0091-6749(73)90007-9	http://dx.doi.org/10.1016/0091-6749(73)90007-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O5651	4118410				2022-12-18	WOS:A1973O565100006
J	BARDANA, EJ; MCCLATCHY, JK; MINDEN, P; FARR, RS				BARDANA, EJ; MCCLATCHY, JK; MINDEN, P; FARR, RS			PRIMARY INTERACTION OF ANTIBODY TO COMPONENTS OF ASPERGILLI .1. IMMUNOLOGICAL AND CHEMICAL CHARACTERISTICS OF A NONPRECIPITATING ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AMOS W M G, 1970, Journal of Medical Laboratory Technology, V27, P18; BARDANA EJ, 1972, J ALLERGY CLIN IMMUN, V50, P222, DOI 10.1016/0091-6749(72)90016-4; BARKER SA, 1962, IMMUNOLOGY, V5, P627; BIGUET J, 1966, REV IMMUNOL THER ANT, V30, P165; BIGUET J, 1962, CR HEBD ACAD SCI, V254, P3768; BRONNEST.R, 1965, ACTA MED SCAND, V177, P385; BURKE BJ, 1970, THORAX, V25, P702, DOI 10.1136/thx.25.6.702; DROUHET E, 1970, 10 INT C MICR MEX CI; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; FEINBERG JG, 1963, INT ARCH ALLER A IMM, V22, P274, DOI 10.1159/000229371; FERRARI A, 1960, ANN NY ACAD SCI, V87, P792, DOI 10.1111/j.1749-6632.1960.tb23236.x; FORSGREN A, 1967, J IMMUNOL, V99, P19; FURLONG NB, 1967, METHOD CANCER RES, V3, P27; GERNEZRIEUX C, 1963, PRESSE MED, V71, P1541; GOLDSTEIN GB, 1970, J ALLERGY, V46, P340, DOI 10.1016/0021-8707(70)90085-7; GOREN MB, 1967, J BACTERIOL, V94, P1258, DOI 10.1128/JB.94.4.1258-1259.1967; GURWITH MJ, 1971, ARCH INTERN MED, V128, P541, DOI 10.1001/archinte.128.4.541; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; HENDERSON AH, 1969, HYPERSENSITIVITY DIS, P20; IRANI FA, 1971, AM REV RESPIR DIS, V103, P552; KONG YCM, 1967, BACTERIOL REV, V31, P35, DOI 10.1128/MMBR.31.1.35-53.1967; KRONVALL G, 1970, IMMUNOCHEMISTRY, V7, P124, DOI 10.1016/0019-2791(70)90036-4; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MINDEN P, 1969, J EXP MED, V130, P931, DOI 10.1084/jem.130.5.931; MINDEN P, 1967, J IMMUNOL, V99, P304; MINDEN P, 1971, INFECT IMMUN, V3, P524, DOI 10.1128/IAI.3.4.524-529.1971; MINDEN P, 1969, J IMMUNOL, V102, P832; MINDEN P, 1967, HDB EXPERIMENTAL IMM, pCH13; MIYAMOTO T, 1969, J ALLERGY, V44, P228, DOI 10.1016/0021-8707(69)90089-6; MONOD O, 1957, J Fr Med Chir Thorac, V11, P257; NISONOFF A, 1964, Methods Med Res, V10, P134; NYGAARD AP, 1963, BIOCHEM BIOPH RES CO, V12, P98, DOI 10.1016/0006-291X(63)90242-0; PARKER JD, 1970, AM REV RESPIR DIS, V101, P551; PEPYS J, 1959, AM REV RESPIR DIS, V80, P167; PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119; REDDY PA, 1970, AM REV RESPIR DIS, V101, P928; SJOQUIST J, 1967, S QUANT BIOL, V32, P577; SLAVIN RG, 1969, AM J MED, V47, P306, DOI 10.1016/0002-9343(69)90156-9; SLAVIN RG, 1970, J ALLERGY, V46, P150, DOI 10.1016/0021-8707(70)90093-6; STEVENS EAM, 1970, THORAX, V25, P11, DOI 10.1136/thx.25.1.11; SUZUKI S, 1967, JPN J MICROBIOL, V11, P269, DOI 10.1111/j.1348-0421.1967.tb00345.x; SVENNERHOLM L, 1956, J NEUROCHEM, V1, P42, DOI 10.1111/j.1471-4159.1956.tb12053.x; Tran Van Ky P, 1968, Rev Immunol Ther Antimicrob, V32, P37; Tran Van Ky P, 1966, Rev Immunol Ther Antimicrob, V30, P13; WALTER JE, 1968, DIS CHEST, V53, P729; WRIGHT GL, 1971, CLIN CHIM ACTA, V32, P285, DOI 10.1016/0009-8981(71)90345-7; YOUNG RC, 1971, AM REV RESPIR DIS, V104, P710; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002; ZIMMERMAN SB, 1965, ANAL BIOCHEM, V10, P444, DOI 10.1016/0003-2697(65)90313-1	50	29	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	4					208	+		10.1016/0091-6749(72)90015-2	http://dx.doi.org/10.1016/0091-6749(72)90015-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N6855	4342188	Bronze			2022-12-18	WOS:A1972N685500003
J	Liu, J; Chang, HW; Huang, ZM; Nakamura, M; Sekhon, S; Ahn, R; Munoz-Sandoval, P; Bhattarai, S; Beck, KM; Sanchez, IM; Yang, E; Pauli, M; Arron, ST; Fung-Leung, WP; Munoz, E; Liu, XJ; Bhutani, T; North, J; Fourie, AM; Rosenblum, MD; Liao, W				Liu, Jared; Chang, Hsin-Wen; Huang, Zhi-Ming; Nakamura, Mio; Sekhon, Sahil; Ahn, Richard; Munoz-Sandoval, Priscila; Bhattarai, Shrishti; Beck, Kristen M.; Sanchez, Isabelle M.; Yang, Eric; Pauli, Mariela; Arron, Sarah T.; Fung-Leung, Wai-Ping; Munoz, Ernesto; Liu, Xuejun; Bhutani, Tina; North, Jeffrey; Fourie, Anne M.; Rosenblum, Michael D.; Liao, Wilson			Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8(+) T cells in autoimmunity and cancer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Single-cell RNA sequencing; Smart-seq2; psoriasis; CD8(+) T cell; T-cell exhaustion; melanoma	MONOCLONAL-ANTIBODY; ATOPIC-DERMATITIS; LESIONAL SKIN; SEQ DATA; EXPRESSION; RESIDENT; TRANSCRIPTOME; NORMALIZATION; PLAQUES; PLACEBO	Background: Psoriasis is an inflammatory, IL-17-driven skin disease in which autoantigen-induced CD8(+) T cells have been identified as pathogenic drivers. Objective: Our study focused on comprehensively characterizing the phenotypic variation of CD8(+) T cells in psoriatic lesions. Methods: We used single-cell RNA sequencing to compare CD8(+) T-cell transcriptomic heterogeneity between psoriatic and healthy skin. Results: We identified 11 transcriptionally diverse CD8(+) T-cell subsets in psoriatic and healthy skin. Among several inflammatory subsets enriched in psoriatic skin, we observed 2 Tc17 cell subsets that were metabolically divergent, were developmentally related, and expressed CXCL13, which we found to be a biomarker of psoriasis severity and which achieved comparable or greater accuracy than IL17A in a support vector machine classifier of psoriasis and healthy transcriptomes. Despite high coinhibitory receptor expression in the Tc17 cell clusters, a comparison of these cells with melanoma-infiltrating CD8(+) T cells revealed upregulated cytokine, cytolytic, and metabolic transcriptional activity in the psoriatic cells that differed from an exhaustion program. Conclusion: Using high-resolution single-cell profiling in tissue, we have uncovered the diverse landscape of CD8(+) T cells in psoriatic and healthy skin, including 2 nonexhausted Tc17 cell subsets associated with disease severity.	[Liu, Jared; Chang, Hsin-Wen; Huang, Zhi-Ming; Munoz-Sandoval, Priscila; Bhattarai, Shrishti; Yang, Eric; Pauli, Mariela; Arron, Sarah T.; Bhutani, Tina; North, Jeffrey; Rosenblum, Michael D.; Liao, Wilson] Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,N431, San Francisco, CA 94115 USA; [Nakamura, Mio] Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; [Sekhon, Sahil] Howard Univ, Dept Dermatol, Washington, DC 20059 USA; [Ahn, Richard] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA; [Beck, Kristen M.] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA; [Sanchez, Isabelle M.] Univ Illinois, Dept Dermatol, Chicago, IL USA; [Fung-Leung, Wai-Ping; Munoz, Ernesto; Liu, Xuejun; Fourie, Anne M.] Janssen Res & Dev LLC, La Jolla, CA USA	University of California System; University of California San Francisco; University of Michigan System; University of Michigan; Howard University; University of California System; University of California Los Angeles; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Liao, W (corresponding author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St,N431, San Francisco, CA 94115 USA.	wilson.liao@ucsf.edu		Sekhon, Sahil/0000-0003-0035-1110	Janssen Biotech, Inc; National Institutes of Health [5U01AI119125]; AbbVie; Amgen; Janssen; Novartis; Regeneron; Sanofi; TRex Bio; LEO Pharma	Janssen Biotech, Inc(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AbbVie(AbbVie); Amgen(Amgen); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Novartis(Novartis); Regeneron(Regeneron); Sanofi; TRex Bio; LEO Pharma(LEO Pharma)	Supported by a grant from Janssen Biotech, Inc, to the University of California San Francisco. W.L. is funded in part by grants from the National Institutes of Health (5U01AI119125) and AbbVie, Amgen, Janssen, Novartis, Regeneron, Sanofi, and TRex Bio. T.B. is currently an investigator for Celgene, Janssen, Merck, and Regeneron; she has served as an advisor for AbbVie, Lilly, and Pfizer. M.D.R is a founder and consultant for TRex Bio; in addition, he is a founder of Sitryx Bio, and he receives funding from AbbVie, LEO Pharma, and TRex Bio.	Albanesi C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01549; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Arakawa A, 2015, J EXP MED, V212, P2203, DOI 10.1084/jem.20151093; Arra A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1273300; Bengsch B, 2016, IMMUNITY, V45, P358, DOI 10.1016/j.immuni.2016.07.008; Blauvelt A, 2017, J AM ACAD DERMATOL, V76, P405, DOI 10.1016/j.jaad.2016.11.041; Boddupalli CS, 2016, J CLIN INVEST, V126, P3905, DOI 10.1172/JCI85329; Brembilla NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01682; Canete JD, 2007, ANN RHEUM DIS, V66, P720, DOI 10.1136/ard.2006.062042; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Cheuk S, 2014, J IMMUNOL, V192, P3111, DOI 10.4049/jimmunol.1302313; Clark RA, 2006, J IMMUNOL, V176, P4431, DOI 10.4049/jimmunol.176.7.4431; DEBOER OJ, 1994, ARCH DERMATOL RES, V286, P87, DOI 10.1007/BF00370733; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fuller MJ, 2003, J IMMUNOL, V170, P477, DOI 10.4049/jimmunol.170.1.477; Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004; Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1829, DOI 10.1038/jid.2010.36; Haugh IM, 2018, DRUG DES DEV THER, V12, P3879, DOI 10.2147/DDDT.S167149; Hijnen D, 2013, J INVEST DERMATOL, V133, P973, DOI 10.1038/jid.2012.456; Hueber W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001107; Kim TG, 2014, J INVEST DERMATOL, V134, P1462, DOI 10.1038/jid.2013.534; Klimatcheva E, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0068-1; Kunkel EJ, 2002, AM J PATHOL, V160, P347, DOI 10.1016/S0002-9440(10)64378-7; Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621; Leonardi C, 2012, NEW ENGL J MED, V366, P1190, DOI 10.1056/NEJMoa1109997; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Li HJ, 2019, CELL, V176, P775, DOI 10.1016/j.cell.2018.11.043; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Lu J, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165374; Martin E, 2009, PLOS BIOL, V7, P525, DOI 10.1371/journal.pbio.1000054; Matos TR, 2017, J CLIN INVEST, V127, P4031, DOI 10.1172/JCI93396; McCarthy DJ, 2017, BIOINFORMATICS, V33, P1179, DOI 10.1093/bioinformatics/btw777; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Milner JJ, 2017, NATURE, V552, P253, DOI 10.1038/nature24993; Narayan A, 2020, DENSITY PRESERVING D, V2020; Ortega C, 2009, J LEUKOCYTE BIOL, V86, P435, DOI [10.1189/jlb.0109046, 10.1189/JLB.0109046]; Papp KA, 2012, NEW ENGL J MED, V366, P1181, DOI 10.1056/NEJMoa1109017; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Petrelli A, 2018, J CLIN INVEST, V128, P4669, DOI 10.1172/JCI96107; R Development Core Team, 2011, R LANG ENV STAT COMP; Reich K, 2017, J AM ACAD DERMATOL, V76, P418, DOI 10.1016/j.jaad.2016.11.042; Reich K, 2017, LANCET, V390, P276, DOI 10.1016/S0140-6736(17)31279-5; Res PCM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014108; Risso D, 2014, NAT BIOTECHNOL, V32, P896, DOI 10.1038/nbt.2931; Sathaliyawala T, 2013, IMMUNITY, V38, P187, DOI 10.1016/j.immuni.2012.09.020; Soneson C, 2018, NAT METHODS, V15, P255, DOI [10.1038/NMETH.4612, 10.1038/nmeth.4612]; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2898, DOI 10.1038/jid.2014.261; Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Valentine KM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01322; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Workel HH, 2019, CANCER IMMUNOL RES, V7, P784, DOI 10.1158/2326-6066.CIR-18-0517; WroneSmith T, 1997, AM J PATHOL, V151, P1321; Yawalkar N, 2001, BRIT J DERMATOL, V144, P1133, DOI 10.1046/j.1365-2133.2001.04222.x; Yen HR, 2009, J IMMUNOL, V183, P7161, DOI 10.4049/jimmunol.0900368	60	28	29	5	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2021	147	6					2370	2380		10.1016/j.jaci.2020.11.028	http://dx.doi.org/10.1016/j.jaci.2020.11.028		JUN 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM7ID	33309739	Green Accepted			2022-12-18	WOS:000657773400003
J	Eljaszewicz, A; Ruchti, F; Radzikowska, U; Globinska, A; Boonpiyathad, T; Gschwend, A; Morita, H; Helbling, A; Arasi, S; Kahlert, H; Berek, N; Nandy, A; Akdis, M; Willers, C; Moniuszko, M; Akdis, CA; Sokolowska, M				Eljaszewicz, Andrzej; Ruchti, Fiorella; Radzikowska, Urszula; Globinska, Anna; Boonpiyathad, Tadech; Gschwend, Anna; Morita, Hideaki; Helbling, Arthur; Arasi, Stefania; Kahlert, Helga; Berek, Nadine; Nandy, Andreas; Akdis, Mubeccel; Willers, Christoph; Moniuszko, Marcin; Akdis, Cezmi A.; Sokolowska, Milena			Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen immunotherapy; innate immune cells; antigen-presenting cells; monocytes; DCs; ILC; NK cells	INTERFERON-PRODUCING CELLS; NATURAL-KILLER-CELLS; MECHANISMS; RHINITIS; RECRUITMENT; MAINTENANCE; MACROPHAGES; EXPRESSION; INDUCTION; INFECTION	Background: Despite the efficacy of allergen-specific immunotherapy (AIT), the role of trained immunity and tolerance in this process has not been elucidated. Objective: Here, we have performed a comprehensive longitudinal analysis of the systemic innate immune cell repertoire during the course of AIT. Methods: Patients with allergy received standard preseasonal subcutaneous AIT with allergoids to birch and/or grass. Healthy controls were monitored without any intervention. Flow cytometry of innate lymphoid cell (ILC), natural killer cell, monocyte cell, and dendritic cell (DC) subsets was performed at baseline, 3 months (birch season), 6 months (grass seasons), and 12 months after the therapy in patients or at similar seasonal time points in controls. Additional analyses were performed in the third-year birch and grass season. Results: We observed a durable decrease in group 2 ILCs and an increase of group 1 ILCs after AIT, with dynamic changes in their composition. We found that an expansion of CD127(+)CD25(++) clusters caused observed shifts in the heterogeneity of group 1 ILCs. In addition, we observed development of CD127(+)CD25(++)c-Kit(+) group 3 ILC clusters. Moreover, we found an increase in the number of intermediate monocytes in parallel with a reduction in nonclassical monocytes during the first year after AIT. Classical and intermediate monocytes presented significant heterogeneity in patients with allergy, but AIT reduced the HLA-DR++ clusters. Finally, an increase in plasmacytoid DCs and CD141(+) myeloid DCs was observed in individuals with allergy, whereas the number of CD1c(+) myeloid DCs was reduced during the first year of AIT. Conclusion: AIT induces changes in the composition and heterogeneity of circulating innate immune cells and brings them to the level observed in healthy individuals. Monitoring of ILCs, monocytes, and DCs during AIT might serve as a novel biomarker strategy.	[Eljaszewicz, Andrzej; Ruchti, Fiorella; Radzikowska, Urszula; Globinska, Anna; Boonpiyathad, Tadech; Morita, Hideaki; Arasi, Stefania; Akdis, Mubeccel; Akdis, Cezmi A.; Sokolowska, Milena] Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; [Eljaszewicz, Andrzej; Ruchti, Fiorella; Radzikowska, Urszula; Globinska, Anna; Boonpiyathad, Tadech; Morita, Hideaki; Akdis, Cezmi A.; Sokolowska, Milena] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Eljaszewicz, Andrzej; Radzikowska, Urszula; Moniuszko, Marcin] Med Univ Bialystok, Dept Regenerat Med & Immune Regulat, Bialystok, Poland; [Moniuszko, Marcin] Med Univ Bialystok, Dept Allergol & Internal Med, Bialystok, Poland; [Boonpiyathad, Tadech] Phramongkutklao Hosp, Dept Med, Bangkok, Thailand; [Boonpiyathad, Tadech] Chulalongkorn Univ, Fac Med, Bangkok, Thailand; [Morita, Hideaki] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Gschwend, Anna; Helbling, Arthur] Univ Hosp Bern, Univ Clin Rheumatol Immunol & Allergol, Insel Hosp, Bern, Switzerland; [Arasi, Stefania] Bambino Gesu Childrens Res Hosp IRCCS, Dept Pediat Med, Pediat Allergol Unit, Rome, Italy; [Kahlert, Helga; Berek, Nadine; Nandy, Andreas; Willers, Christoph] Allergopharma GmbH & Co KG, Reinbek, Germany	Swiss Institute of Allergy & Asthma Research; University of Zurich; Medical University of Bialystok; Medical University of Bialystok; Phramongkutklao Hospital; Chulalongkorn University; National Center for Child Health & Development - Japan; University of Bern; University Hospital of Bern; IRCCS Bambino Gesu; Allergopharma	Sokolowska, M (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Immune Metab, Herman Burchard Str 9, CH-7265 Davos, Switzerland.	milena.sokolowska@siaf.uzh.ch	Morita, Hideaki/ADL-2008-2022; Morita, Hideaki/S-2214-2016	Morita, Hideaki/0000-0003-0928-8322; Boonpiyathad, Tadech/0000-0001-8690-7647; Eljaszewicz, Andrzej/0000-0002-8980-1474; Ruchti, Fiorella/0000-0002-4993-1127; Moniuszko, Marcin/0000-0001-7183-3120	Allergopharma KG, Germany; Swiss National Science Foundation, Switzerland [310030_189334/1]	Allergopharma KG, Germany; Swiss National Science Foundation, Switzerland(Swiss National Science Foundation (SNSF))	Supported by a collaborative grant from Allergopharma KG, Germany, as well as by the Swiss National Science Foundation, Switzerland (grant 310030_189334/1 [to M.S.] ) .	Akdis CA, 2015, WORLD ALLERGY ORGAN, V8, DOI 10.1186/s40413-015-0063-2; Akdis CA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7390; Bacher P, 2018, J ALLERGY CLIN IMMUN, V142, P1697, DOI 10.1016/j.jaci.2018.10.016; Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536; Bernink JH, 2019, NAT IMMUNOL, V20, P992, DOI 10.1038/s41590-019-0423-0; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Boonpiyathad T, 2019, J ALLERGY CLIN IMMUN, V143, P1077, DOI 10.1016/j.jaci.2018.10.061; Boonpiyathad T, 2019, ALLERGY, V74, P976, DOI 10.1111/all.13684; Castellanos JG, 2019, J CLIN INVEST, V129, P2640, DOI 10.1172/JCI124617; Chinthrajah RS, 2016, J ALLERGY CLIN IMMUN, V137, P984, DOI 10.1016/j.jaci.2016.02.004; Dalton HJ, 2014, CANCER RES, V74, P1287, DOI 10.1158/0008-5472.CAN-13-2825; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Deniz G, 2013, J ALLERGY CLIN IMMUN, V132, P527, DOI 10.1016/j.jaci.2013.07.030; Doherty TA, 2014, J ALLERGY CLIN IMMUN, V133, P1203, DOI 10.1016/j.jaci.2013.12.1086; Dominguez-Andres J, 2019, CURR OPIN IMMUNOL, V56, P10, DOI 10.1016/j.coi.2018.09.001; Eguiluz-Gracia I, 2018, CLIN EXP ALLERGY, V48, P1631, DOI 10.1111/cea.13265; Eguiluz-Gracia I, 2016, J ALLERGY CLIN IMMUN, V137, P1872, DOI 10.1016/j.jaci.2015.11.025; Eljaszewicz A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/831387; Global Initiative for Asthma, 2022, GLOB STRAT ASTHM MAN; Globinska A, 2017, EXPERT REV CLIN IMMU, V13, P991, DOI 10.1080/1744666X.2017.1366314; Gomez-Olarte S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01671; Gorska MM, 2017, CURR OPIN ALLERGY CL, V17, P50, DOI 10.1097/ACI.0000000000000327; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Hasegawa H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00350; Hayashi Y, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-29; Helfrich S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00930; Hochdorfer T, 2019, EUR J IMMUNOL, V49, P884, DOI 10.1002/eji.201848006; Hrusch CL, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-014-0494-9; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kanakoudi-Tsakalidou F, 2001, CLIN EXP IMMUNOL, V123, P402, DOI 10.1046/j.1365-2249.2001.01471.x; Kelly A, 2018, J EXP MED, V215, P2725, DOI 10.1084/jem.20171491; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Kouser Lubna, 2017, Curr Treat Options Allergy, V4, P43, DOI 10.1007/s40521-017-0117-5; Krohn IK, 2018, ALLERGY, V73, P837, DOI 10.1111/all.13340; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lambrecht Bart N, 2009, Handb Exp Pharmacol, P99, DOI 10.1007/978-3-540-71029-5_5; Lao-Araya M, 2014, J ALLERGY CLIN IMMUN, V134, P1193, DOI 10.1016/j.jaci.2014.07.029; Li N, 2018, J EXP MED, V215, P1383, DOI 10.1084/jem.20171934; Li S, 2019, J ALLERGY CLIN IMMUN, V143, P2321, DOI 10.1016/j.jaci.2019.01.047; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lombardi V, 2016, J ALLERGY CLIN IMMUN, V138, P305, DOI 10.1016/j.jaci.2015.12.1325; Lundberg K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148838; Maeda K, 2019, ALLERGY, V74, P1660, DOI 10.1111/all.13788; Martinez-Gonzalez I, 2016, IMMUNITY, V45, P198, DOI 10.1016/j.immuni.2016.06.017; Mitthamsiri W, 2018, ALLERGY ASTHMA IMMUN, V10, P662, DOI 10.4168/aair.2018.10.6.662; Morita H, 2019, J ALLERGY CLIN IMMUN, V143, P2190, DOI 10.1016/j.jaci.2018.12.1018; Morita H, 2016, J ALLERGY CLIN IMMUN, V138, P1253, DOI 10.1016/j.jaci.2016.09.011; Mulder WJM, 2019, NAT REV DRUG DISCOV, V18, P553, DOI 10.1038/s41573-019-0025-4; Nagasawa M, 2019, J EXP MED, V216, P1762, DOI 10.1084/jem.20190490; Narasimhan PB, 2019, ANNU REV IMMUNOL, V37, P439, DOI 10.1146/annurev-immunol-042617-053119; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Netea MG, 2017, CELL HOST MICROBE, V21, P297, DOI 10.1016/j.chom.2017.02.003; Ogle ME, 2016, EXP BIOL MED, V241, P1084, DOI 10.1177/1535370216650293; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Pfaar O, 2017, ALLERGY, V72, P713, DOI 10.1111/all.13092; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Raker VK, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00569; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Sato K, 2017, CURR TOP MICROBIOL, V410, P47, DOI 10.1007/82_2017_60; Sciume G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01579; Shamji MH, 2017, J ALLERGY CLIN IMMUN, V140, P1485, DOI 10.1016/j.jaci.2017.10.010; Shen C, 2014, CLIN EXP ALLERGY, V44, P831, DOI 10.1111/cea.12308; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Stehle C, 2018, IMMUNOL REV, V286, P102, DOI 10.1111/imr.12712; Tang-Huau TL, 2019, SEMIN CELL DEV BIOL, V86, P44, DOI 10.1016/j.semcdb.2018.02.018; Verma M, 2020, J ALLERGY CLIN IMMUN, V145, pAB1; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Winkler C, 2019, J ALLERGY CLIN IMMUN, V144, P61, DOI 10.1016/j.jaci.2019.01.027; Young LJ, 2008, NAT IMMUNOL, V9, P1244, DOI 10.1038/ni.1665; Zaslona Z, 2014, J IMMUNOL, V193, P4245, DOI 10.4049/jimmunol.1400580; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558	72	28	28	4	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2021	147	5					1865	1877		10.1016/j.jaci.2020.08.042	http://dx.doi.org/10.1016/j.jaci.2020.08.042		MAY 2021	13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SD7ZH	33039478	Green Published, hybrid, Green Accepted			2022-12-18	WOS:000651594300007
J	Rama, TA; Moreira, A; Castells, M				Rama, Tiago Azenha; Moreira, Andre; Castells, Mariana			mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Rama, Tiago Azenha; Moreira, Andre] Ctr Hosp Univ Sao Joao, Serv Imunoalergol, Porto, Portugal; [Rama, Tiago Azenha; Moreira, Andre] Univ Porto, Fac Med, Dept Patol, Serv Imunol Basica & Clin, Porto, Portugal; [Moreira, Andre] Univ Porto, EPIUnit, Inst Saude Publ, Porto, Portugal; [Moreira, Andre] Univ Porto, Fac Med, Porto, Portugal; [Castells, Mariana] Harvard Med Sch, Brigham & Womens Hosp, Div Allergy & Clin Immunol, Boston, MA 02115 USA	Universidade do Porto; Universidade do Porto; Universidade do Porto; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Rama, TA (corresponding author), Ctr Hosp Univ Sao Joao, Serv Imunoalergol, Porto, Portugal.; Rama, TA (corresponding author), Univ Porto, Fac Med, Dept Patol, Serv Imunol Basica & Clin, Porto, Portugal.	tarama@med.up.pt	Moreira, André/AAH-9683-2020; Rama, Tiago Azenha/AAN-7604-2020	Moreira, André/0000-0002-7294-9296; Rama, Tiago Azenha/0000-0003-0134-617X				Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Parente R, 2017, PEDIAT ALLERG IMM-UK, V28, P93, DOI 10.1111/pai.12647; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760	5	28	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					877	878		10.1016/j.jaci.2021.01.004	http://dx.doi.org/10.1016/j.jaci.2021.01.004		MAR 2021	2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RA9TV	33485650	Bronze, Green Published			2022-12-18	WOS:000631762400010
J	Bakker, DS; Nierkens, S; Knol, EF; Giovannone, B; Delemarre, EM; van der Schaft, J; van Wijk, F; De Bruin-Weller, MS; Drylewicz, J; Thijs, JL				Bakker, Daphne S.; Nierkens, Stefan; Knol, Edward F.; Giovannone, Barbara; Delemarre, Eveline M.; van der Schaft, Jorien; van Wijk, Femke; De Bruin-Weller, Marjolein S.; Drylewicz, Julia; Thijs, Judith L.			Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; endotypes; clusters; biomarkers; prediction; personalized medicine; principal components analysis		Background: Atopic dermatitis (AD) is a highly heterogeneous disease, both clinically and biologically, whereas patients are still being treated according to a "one-size-fits-all"approach. Stratification of patients into biomarker-based endotypes is important for future development of personalized therapies. Objective: Our aim was to confirm previously defined serum biomarker-based patient clusters in a new cohort of patients with AD. Methods: A panel of 143 biomarkers was measured by using Luminex technology in serum samples from 146 patients with severe AD (median Eczema Area and Severity Index = 28.3; interquartile range = 25.2-35.3). Principal components analysis followed by unsupervised k-means cluster analysis of the biomarker data was used to identify patient clusters. A prediction model was built on the basis of a previous cohort to predict the 1 of the 4 previously identified clusters to which the patients of our new cohort would belong. Results: Cluster analysis identified 4 serum biomarker-based clusters, 3 of which (clusters B, C, and D) were comparable to the previously identified clusters. Cluster A (33.6%) could be distinguished from the other clusters as being a "skin-homing chemokines/IL-1R1-dominant"cluster, whereas cluster B (18.5%) was a "T(H)1/T(H)2/T(H)17-dominant"cluster, cluster C (18.5%) was a "T(H)2/T(H)22/PARC-dominant"cluster, and cluster D (29.5%) was a "T(H)2/eosinophil-inferior"cluster. Additionally, by using a prediction model based on our previous cohort we accurately assigned the new cohort to the 4 previously identified clusters by including only 10 selected serum biomarkers. Conclusion: We confirmed that AD is heterogeneous at the immunopathologic level and identified 4 distinct biomarker-based clusters, 3 of which were comparable with previously identified clusters. Cluster membership could be predicted with a model including 10 serum biomarkers.	[Bakker, Daphne S.; Knol, Edward F.; van der Schaft, Jorien; De Bruin-Weller, Marjolein S.; Thijs, Judith L.] Univ Med Ctr Utrecht, Natl Expertise Ctr Atop Dermatitis, Dept Dermatol & Allergol, Utrecht, Netherlands; [Bakker, Daphne S.; Nierkens, Stefan; Knol, Edward F.; Giovannone, Barbara; Delemarre, Eveline M.; van Wijk, Femke; Drylewicz, Julia] Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Bakker, DS (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	d.s.bakker-4@umcutrecht.nl	Drylewicz, Julia/I-4703-2019	Drylewicz, Julia/0000-0002-9434-8459; Knol, Edward/0000-0001-7368-9820; Giovannone, Barbara/0000-0003-3143-1922	Regeneron; Sanofi Genzyme Pharmaceuticals, Inc.	Regeneron(Regeneron); Sanofi Genzyme Pharmaceuticals, Inc.	Research was funded by Regeneron and Sanofi Genzyme Pharmaceuticals, Inc.	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Baines KJ, 2017, INT J CHRONIC OBSTR, V12, P541, DOI 10.2147/COPD.S119443; Bakker DS, 2019, CLIN EXP ALLERGY, V49, P1641, DOI 10.1111/cea.13495; Baumgrass R, 2010, J ALLERGY CLIN IMMUN, V126, P183, DOI 10.1016/j.jaci.2010.04.032; Bieber T, 2017, J ALLERGY CLIN IMMUN, V139, pS58, DOI 10.1016/j.jaci.2017.01.008; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; BUCKLAND ST, 1993, J APPL ECOL, V30, P478, DOI 10.2307/2404188; de Bruin-Weller M, 2018, BRIT J DERMATOL, V178, P1083, DOI 10.1111/bjd.16156; de Jager W, 2005, J IMMUNOL METHODS, V300, P124, DOI 10.1016/j.jim.2005.03.009; Eyerich K, 2013, ALLERGY, V68, P974, DOI 10.1111/all.12184; Farrell AM, 2001, BRIT J DERMATOL, V144, P24, DOI 10.1046/j.1365-2133.2001.03948.x; Ferraccioli GF, 2005, ANN NY ACAD SCI, V1051, P658, DOI 10.1196/annals.1361.110; Garmhausen D, 2013, ALLERGY, V68, P498, DOI 10.1111/all.12112; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Kato Y, 2006, INT ARCH ALLERGY IMM, V139, P245, DOI 10.1159/000091170; Leek JT, 2019, SVA SURROGATE VARIAB; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Novak N, 2011, ALLERGY, V66, P830, DOI 10.1111/j.1398-9995.2011.02571.x; R Core Team, 2020, R LANG ENV STAT COMP; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; Schmitt J, 2014, J ALLERGY CLIN IMMUN, V134, P800, DOI 10.1016/j.jaci.2014.07.043; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Thijs J, 2015, CURR OPIN ALLERGY CL, V15, P453, DOI 10.1097/ACI.0000000000000198; Thijs JL, 2018, J ALLERGY CLIN IMMUN, V141, P1523, DOI 10.1016/j.jaci.2017.12.991; Thijs JL, 2017, J ALLERGY CLIN IMMUN, V140, P730, DOI 10.1016/j.jaci.2017.03.023; Wen HC, 2018, J ALLERGY CLIN IMMUN, V142, P324, DOI 10.1016/j.jaci.2018.02.047; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Wollenberg A, 2017, J AM ACAD DERMATOL, V76, pAB20; Zhou LS, 2019, J ALLERGY CLIN IMMUN, V144, P144, DOI 10.1016/j.jaci.2019.01.015	36	28	28	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					189	198		10.1016/j.jaci.2020.04.062	http://dx.doi.org/10.1016/j.jaci.2020.04.062		JAN 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32526312	hybrid			2022-12-18	WOS:000613645900023
J	Perugino, CA; Kaneko, N; Maehara, T; Mattoo, H; Kers, J; Allard-Chamard, H; Mahajan, VS; Liu, H; Della-Torre, E; Murphy, SJH; Ghebremichael, M; Wallace, ZS; Bolster, MB; Harvey, LM; Mylvaganam, G; Tuncay, Y; Liang, L; Montesi, SB; Zhang, XW; Tinju, A; Mochizuki, K; Munemura, R; Sakamoto, M; Moriyama, M; Nakamura, S; Yosef, N; Stone, JH; Pillai, S				Perugino, Cory A.; Kaneko, Naoki; Maehara, Takashi; Mattoo, Hamid; Kers, Jesper; Allard-Chamard, Hugues; Mahajan, Vinay S.; Liu, Hang; Della-Torre, Emanuel; Murphy, Samuel J. H.; Ghebremichael, Musie; Wallace, Zachary S.; Bolster, Marcy B.; Harvey, Liam M.; Mylvaganam, Geetha; Tuncay, Yesim; Liang, Lloyd; Montesi, Sydney B.; Zhang, Xiuwei; Tinju, Akira; Mochizuki, Keita; Munemura, Ryusuke; Sakamoto, Mizuki; Moriyama, Masafumi; Nakamura, Seiji; Yosef, Nir; Stone, John H.; Pillai, Shiv			CD4(+) and CD8(+) cytotoxic Tlymphocytes may induce mesenchymal cell apoptosis in IgG(4)-related disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgG4-RD; CD4(+)CTL; CD8(+)CTL; apoptosis; CD28(lo); CD28(null)	T-CELLS; IGG4-RELATED DACRYOADENITIS; CLASSIFICATION CRITERIA; LYMPHOCYTES; CD28(-); ACTIVATION; EXPRESSION; SUBSETS	Background: IgG(4)-related disease (IgG(4)-RD) is an immune-mediated fibrotic disorder that has been linked to CD4(+) cytotoxic T lymphocytes (CD4(+)CTLs). The effector phenotype of CD4(+)CTLs and the relevance of both CD8(+) cytotoxic T lymphocytes (CD8(+)CTLs) and apoptotic cell death remain undefined in IgG(4)-RD. Objective: We sought to define CD4(+)CTL heterogeneity, characterize the CD8(+)CTL response in the blood and in lesions, and determine whether enhanced apoptosis may contribute to the pathogenesis of IgG(4)-RD. Methods: Blood analyses were undertaken using flow cytometry, cell sorting, transcriptomic analyses at the population and single-cell levels, and next-generation sequencing for the TCR repertoire. Tissues were interrogated using multicolor immunofluorescence. Results were correlated with clinical data. Results: We establish that among circulating CD4(+)CTLs in IgG(4)-RD, CD27(lo)CD28(lo)CD57(hi) cells are the dominant effector subset, exhibit marked clonal expansion, and differentially express genes relevant to cytotoxicity, activation, and enhanced metabolism. We also observed prominent infiltration of granzyme A-expressing CD8(+)CTLs in disease tissues and clonal expansion in the blood of effector/memory CD8(+) T cells with an activated and cytotoxic phenotype. Tissue studies revealed an abundance of cells undergoing apoptotic cell death disproportionately involving nonimmune, nonendothelial cells of mesenchymal origin. Apoptotic cells showed significant upregulation of HLA-DR. Conclusions: CD4(+)CTLs and CD8(+)CTLs may induce apoptotic cell death in tissues of patients with IgG(4)-RD with preferential targeting of nonendothelial, nonimmune cells of mesenchymal origin.	[Perugino, Cory A.; Kaneko, Naoki; Maehara, Takashi; Mattoo, Hamid; Kers, Jesper; Allard-Chamard, Hugues; Mahajan, Vinay S.; Liu, Hang; Della-Torre, Emanuel; Murphy, Samuel J. H.; Ghebremichael, Musie; Mylvaganam, Geetha; Tuncay, Yesim; Pillai, Shiv] Ragon Inst MGH MIT & Harvard, 400 Technol Sq, Cambridge, MA 02139 USA; [Perugino, Cory A.; Wallace, Zachary S.; Bolster, Marcy B.; Harvey, Liam M.; Stone, John H.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Kaneko, Naoki; Maehara, Takashi; Tinju, Akira; Mochizuki, Keita; Munemura, Ryusuke; Sakamoto, Mizuki; Moriyama, Masafumi; Nakamura, Seiji] Kyushu Univ, Sect Oral & Maxillofacial Oncol, Div Maxillofacial Diagnost & Surg Sci, Fac Dent Sci, Fukuoka, Japan; [Mattoo, Hamid] Sanofi, Immunol & Inflammat Therapeut Area, Cambridge, MA USA; [Kers, Jesper] Univ Amsterdam, Amsterdam UMC, Amsterdam Infect & Immun Inst AI&II, Amsterdam Cardiovasc Sci ACS, Amsterdam, Netherlands; [Kers, Jesper] Univ Amsterdam, Van t Hoff Inst Mol Sci HIMS, Amsterdam, Netherlands; [Allard-Chamard, Hugues] Univ Sherbrooke, Div Rheumatol, Fac Med & Sci Sante, Sherbrooke, PQ, Canada; [Allard-Chamard, Hugues] Ctr Rech Clin Etienne Le Bel, Sherbrooke, PQ, Canada; [Mahajan, Vinay S.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Liu, Hang] China Med Univ, Dept Rheumatol & Immunol, First Hosp, Shenyang, Peoples R China; [Della-Torre, Emanuel] IRCCS San Raffaele Sci Inst, Unit Immunol Rheumatol Allergy & Rare Dis UnIRAR, Milan, Italy; [Liang, Lloyd; Montesi, Sydney B.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA; [Zhang, Xiuwei; Yosef, Nir] Univ Calif Berkeley, Berkeley, CA 94720 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Massachusetts General Hospital; Kyushu University; Sanofi-Aventis; University of Amsterdam; University of Amsterdam; University of Sherbrooke; Harvard University; Brigham & Women's Hospital; China Medical University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Harvard University; Massachusetts General Hospital; University of California System; University of California Berkeley	Pillai, S (corresponding author), Ragon Inst MGH MIT & Harvard, 400 Technol Sq, Cambridge, MA 02139 USA.	pillai@helix.mgh.harvard.edu	Della Torre, Emanuel/AAB-5024-2022; Allard-Chamard, H/J-2827-2019; Mahajan, Vinay S/AAF-3303-2019	Allard-Chamard, H/0000-0001-7850-2658; Bolster, Marcy/0000-0002-5413-9345; Murphy, Samuel/0000-0002-5694-3572	National Institutes of Health (NIH) Autoimmune Centers of Excellence [U19 AI 110495]; Rheumatology Research Foundation Scientist Development Award; Scleroderma Foundation New Investigator Grant; UCB; Japan Society for the Promotioin of Science [JP18KK0260]; Takeda Science Foundation; WorkVisitGrant of theAmsterdamInfection and Immunity Institute; NIH [AI113163]; National Institute of Allergy and Infectious Diseases [P30AI060354]; Cariplo Foundation; Parker B. Francis Fellowship; NIH Autoimmune Centers of Excellence [UM1 AI1144295]	National Institutes of Health (NIH) Autoimmune Centers of Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rheumatology Research Foundation Scientist Development Award; Scleroderma Foundation New Investigator Grant; UCB(UCB Pharma SA); Japan Society for the Promotioin of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF)); WorkVisitGrant of theAmsterdamInfection and Immunity Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Cariplo Foundation(Fondazione Cariplo); Parker B. Francis Fellowship; NIH Autoimmune Centers of Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health (NIH) Autoimmune Centers of Excellence (grant no. U19 AI 110495 to S.P.). C.A.P. was supported by a Rheumatology Research Foundation Scientist Development Award, a Scleroderma Foundation New Investigator Grant and a Sponsored Research Agreement with UCB. T.M. was supported by Japan Society for the Promotioin of Science (grant no. JP18KK0260) and the Takeda Science Foundation. J.K. was supported by aWorkVisitGrant of theAmsterdamInfection and Immunity Institute. V.S.M. was supported by theNIH (grant no. AI113163). M.G. was supported by the National Institute of Allergy and Infectious Diseases (grant no. P30AI060354). E.D.-T. was supported by the Giovani Ricercatori Research Grant from the Cariplo Foundation. S.B.M. was supported by a Parker B. Francis Fellowship and a Scleroderma Foundation New Investigator Grant, and J.H.S. was supported by the NIH Autoimmune Centers of Excellence (grant no. UM1 AI1144295).	Caielli S, 2019, NAT MED, V25, P75, DOI 10.1038/s41591-018-0254-9; Carrasco J, 2006, BLOOD, V108, P2897, DOI 10.1182/blood-2005-11-007237; Carruthers MN, 2015, ANN RHEUM DIS, V74, P1171, DOI 10.1136/annrheumdis-2014-206605; Chattopadhyay PK, 2009, J LEUKOCYTE BIOL, V85, P88, DOI 10.1189/jlb.0208107; Della-Torre E, 2020, J ALLERGY CLIN IMMUN, V145, P968, DOI 10.1016/j.jaci.2019.07.004; Della-Torre E, 2018, ARTHRITIS RHEUMATOL, V70, P1133, DOI 10.1002/art.40469; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Eckert RC, 2004, CYTOM PART A, V59A, P182, DOI 10.1002/cyto.a.20052; Elliott MR, 2017, J IMMUNOL, V198, P1387, DOI 10.4049/jimmunol.1601520; Fasth AER, 2009, J IMMUNOL, V183, P4792, DOI 10.4049/jimmunol.0803688; Fonseka CY, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq0305; Gilani SR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008959; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Heinle R, 2014, AUTOIMMUN REV, V13, P383, DOI 10.1016/j.autrev.2014.01.035; Jun JB, 2003, CURR OPIN RHEUMATOL, V15, P756, DOI 10.1097/00002281-200311000-00012; Kamisawa T, 2015, LANCET, V385, P1460, DOI 10.1016/S0140-6736(14)60720-0; Maehara T, 2020, J CLIN INVEST, V130, P2451, DOI 10.1172/JCI131700; Maehara T, 2017, ANN RHEUM DIS, V76, P377, DOI 10.1136/annrheumdis-2016-209139; Mahajan VS, 2014, ANNU REV PATHOL-MECH, V9, P315, DOI 10.1146/annurev-pathol-012513-104708; Mamedov IZ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00456; Masago R, 2001, ARTHRITIS RHEUM, V44, P693, DOI 10.1002/1529-0131(200103)44:3<693::AID-ANR119>3.0.CO;2-7; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Nakamura H, 2018, INT J MOL SCI, V19; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Parekh S, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy059; Patil VS, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan8664; Perugino CA, 2019, J ALLERGY CLIN IMMUN, V143, P736, DOI 10.1016/j.jaci.2018.05.011; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sasaki T, 2020, INT IMMUNOL, V32, P163, DOI 10.1093/intimm/dxz073; Schmidt D, 1996, J CLIN INVEST, V97, P2027, DOI 10.1172/JCI118638; Sgonc R, 1996, J CLIN INVEST, V98, P785, DOI 10.1172/JCI118851; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Strioga M, 2011, IMMUNOLOGY, V134, P17, DOI 10.1111/j.1365-2567.2011.03470.x; Sun ZP, 2008, J CLIN IMMUNOL, V28, P464, DOI 10.1007/s10875-008-9213-4; Tabeya T, 2014, MOD RHEUMATOL, V24, P953, DOI 10.3109/14397595.2014.882045; Thewissen M, 2007, J IMMUNOL, V179, P6514, DOI 10.4049/jimmunol.179.10.6514; Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01157-4; Trombetta John J, 2014, Curr Protoc Mol Biol, V107, DOI 10.1002/0471142727.mb0422s107; Uhal BD, 2002, CHEST, V122, p293S, DOI 10.1378/chest.122.6_suppl.293S; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Wallace ZS, 2020, ARTHRITIS RHEUMATOL, V72, P7, DOI [10.1002/art.41120, 10.1136/annrheumdis-2019-216561]; Wallace ZS, 2018, ARTHRIT CARE RES, V70, P1671, DOI 10.1002/acr.23543; Weiskopf D, 2015, P NATL ACAD SCI USA, V112, pE4256, DOI 10.1073/pnas.1505956112; Winer DA, 2011, NAT MED, V17, P610, DOI 10.1038/nm.2353	44	28	29	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					368	382		10.1016/j.jaci.2020.05.022	http://dx.doi.org/10.1016/j.jaci.2020.05.022		JAN 2021	15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PS2UA	32485263	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000607781700010
J	Ungar, B; Pavel, AB; Li, R; Kimmel, G; Nia, J; Hashim, P; Kim, HJ; Chima, M; Vekaria, AS; Estrada, Y; Xu, H; Peng, XY; Singer, GK; Baum, D; Mansouri, Y; Taliercio, M; Guttman-Yassky, E				Ungar, Benjamin; Pavel, Ana B.; Li, Randall; Kimmel, Grace; Nia, John; Hashim, Peter; Kim, Hee Jin; Chima, Margot; Vekaria, Anjali S.; Estrada, Yeriel; Xu, Hui; Peng, Xiangyu; Singer, Giselle K.; Baum, Danielle; Mansouri, Yasaman; Taliercio, Mark; Guttman-Yassky, Emma			Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PSORIASIS; FEATURES		[Ungar, Benjamin; Pavel, Ana B.; Li, Randall; Kimmel, Grace; Nia, John; Hashim, Peter; Kim, Hee Jin; Chima, Margot; Vekaria, Anjali S.; Estrada, Yeriel; Xu, Hui; Peng, Xiangyu; Singer, Giselle K.; Baum, Danielle; Mansouri, Yasaman; Taliercio, Mark; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA; [Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Rockefeller University	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA.	Emma.Guttman@mountsinai.org		Ungar, Benjamin/0000-0003-0882-8163; , Ana Brandusa/0000-0002-8155-8553	Novartis Pharmaceuticals Company	Novartis Pharmaceuticals Company	This study was funded by Novartis Pharmaceuticals Company.	Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P1, DOI 10.1016/j.jaci.2018.10.032; Eyerich K, 2017, EUR J IMMUNOL, V47, P607, DOI 10.1002/eji.201646723; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Hawkes JE, 2017, J ALLERGY CLIN IMMUN, V140, P645, DOI 10.1016/j.jaci.2017.07.004; Levy R, 2016, P NATL ACAD SCI USA, V113, pE8277, DOI 10.1073/pnas.1618300114; Noda S, 2016, J INVEST DERMATOL, V136, pS40, DOI 10.1016/j.jid.2016.02.253; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Sacotte R, 2018, CLIN DERMATOL, V36, P595, DOI 10.1016/j.clindermatol.2018.05.007; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046	9	28	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					394	+		10.1016/j.jaci.2020.04.055	http://dx.doi.org/10.1016/j.jaci.2020.04.055		JAN 2021	4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PS2UA	32428528	Bronze			2022-12-18	WOS:000607781700015
J	Rodriguez-Dominguez, A; Berings, M; Rohrbach, A; Huang, HJ; Curin, M; Gevaert, P; Matricardi, PM; Valenta, R; Vrtala, S				Rodriguez-Dominguez, Azahara; Berings, Margot; Rohrbach, Alexander; Huang, Huey-Jy; Curin, Mirela; Gevaert, Philippe; Matricardi, Paolo M.; Valenta, Rudolf; Vrtala, Susanne			Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						House dust mite; immunotherapy; recombinant allergens; basophil activation; IgE; IgG; IgG(1); IgG(2); IgG(3); IgG(4); IgG subclass; allergen microarray	HOUSE-DUST MITE; FC-GAMMA-RIIB; IGE REACTIVITY PROFILES; GRASS-POLLEN ALLERGEN; SUBCUTANEOUS IMMUNOTHERAPY; IMMUNOLOGICAL MECHANISMS; CLINICAL-EFFICACY; DOUBLE-BLIND; P 23; RECOMBINANT	Background: House dust mites (HDMs) are among the most important allergen sources containing many different allergenic molecules. Analysis of patients from a double-blind, placebo-controlled allergen-specific immunotherapy (AIT) study indicated that patients may benefit from AIT to different extents depending on their molecular sensitization profiles. Objective: Our aim was to investigate in a real-life setting whether stratification of patients with HDM allergy according to molecular analysis may enhance AIT success. Methods: Serum and nasal secretion samples from patients with HDM allergy (n = 24) (at baseline, 7, 15, 33, and 52 weeks) who had received 1 year of treatment with a well-defined subcutaneous AIT form (Alutard SQ 510) were tested for IgE and IgG reactivity to 15 microarrayed HDM allergen molecules with ImmunoCAP Immuno-solid-phase Allergen Chip technology. IgG subclass levels to allergens and peptides were determined by ELISA, and IgG blocking was assessed by basophil activation. In vitro parameters were related to reduction of symptoms determined by combined symptom medication score and visual analog scale score. Results: Alutard SQ 510 induced protective IgG mainly against Dermatophagoides pteronyssinus (Der p) 1 and Der p 2 and to a lesser extent to Der p 23, but not to the other important allergens such as Der p 5, Der p 7, and Der p 21, showing better clinical efficacy in patients sensitized only to Der p 1 and/or Der p 2 as compared with patients having additional IgE specificities. Conclusion: Stratification of patients with HDM allergy according to molecular sensitization profiles and molecular monitoring of AIT-induced IgG responses may enhance the success of AIT.	[Rodriguez-Dominguez, Azahara; Huang, Huey-Jy; Curin, Mirela; Valenta, Rudolf; Vrtala, Susanne] Med Univ Vienna, Ctr Pathophysiol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria; [Berings, Margot; Gevaert, Philippe] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Rohrbach, Alexander; Matricardi, Paolo M.] Charite Univ Med Berlin, Dept Pediat Pulmonol Immunol & Intens Care Med, Berlin, Germany; [Valenta, Rudolf] Fed Biomed Agcy Russia, NRC Inst Immunol, Moscow, Russia; [Valenta, Rudolf] Sechenov First State Med Univ, Dept Clin Immunol & Allergy, Moscow, Russia; [Valenta, Rudolf] Karl Landsteiner Univ Hlth Sci, Krems, Austria	Medical University of Vienna; Ghent University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; NRC Institute of Immunology FMBA of Russia; Sechenov First Moscow State Medical University	Vrtala, S (corresponding author), Med Univ Vienna, Ctr Pathophysiol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	susanne.vrtala@meduniwien.ac.at	Gevaert, Philippe/AAP-1892-2020; Gevaert, Philippe/ABA-4588-2021	Gevaert, Philippe/0000-0002-1629-8468; Huang, Huey-Jy/0000-0001-5464-0132; Valenta, Rudolf/0000-0001-5944-3365; Curin, Mirela/0000-0003-2575-4127	Austrian Science Fund [DK W 1248-B13, F4602, F4605]; Medical University of Vienna; Flemish Scientific Research Foundation (Flanders, Belgium); Flemish Scientific Research Foundation [FWO.3F0.2013.0004.01, FWO.3F0.2013.0004.02]; Government of the Russian Federation [14.W03.31.0024]; Flemish Scientific Research Foundation	Austrian Science Fund(Austrian Science Fund (FWF)); Medical University of Vienna; Flemish Scientific Research Foundation (Flanders, Belgium)(FWO); Flemish Scientific Research Foundation; Government of the Russian Federation; Flemish Scientific Research Foundation	Funded by the Austrian Science Fund (grants DK W 1248-B13, F4602, and F4605), the Medical University of Vienna, and the Flemish Scientific Research Foundation (Flanders, Belgium). M. Berings receives funds from the Flemish Scientific Research Foundation (grants FWO.3F0.2013.0004.01 and FWO.3F0.2013.0004.02). R. Valenta is the recipient of a megagrant of the Government of the Russian Federation (grant 14.W03.31.0024). P. Gevaert receives a grant as a senior clinical investigator from the Flemish Scientific Research Foundation. The opinions, results, and conclusions reported in this article are those of the authors and are independent of the funding sources.	Acevedo N, 2019, ALLERGY ASTHMA IMMUN, V11, P450, DOI 10.4168/aair.2019.11.4.450; Banerjee S, 2014, J IMMUNOL, V192, P4867, DOI 10.4049/jimmunol.1400064; Berings M, 2018, CLIN EXP ALLERGY, V48, P970, DOI 10.1111/cea.13157; Berings M, 2017, J ALLERGY CLIN IMMUN, V140, P301, DOI 10.1016/j.jaci.2016.11.047; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Burton OT, 2018, J ALLERGY CLIN IMMUN, V141, P189, DOI 10.1016/j.jaci.2017.03.045; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Casset A, 2012, INT ARCH ALLERGY IMM, V159, P253, DOI 10.1159/000337654; Chen KW, 2012, ALLERGY, V67, P609, DOI 10.1111/j.1398-9995.2012.02794.x; Chen KW, 2019, J ALLERGY CLIN IMMUN, V143, P1248, DOI 10.1016/j.jaci.2018.10.048; Chevigne A, 2018, J ALLERGY CLIN IMMUN, V142, P398, DOI 10.1016/j.jaci.2018.05.027; Cox L, 2015, CURR OPIN OTOLARYNGO, V23, P247, DOI 10.1097/MOO.0000000000000150; Eckl-Dorna J, 2019, EBIOMEDICINE, P1; Eifan AO, 2013, EXPERT OPIN BIOL TH, V13, P1543, DOI 10.1517/14712598.2013.844226; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Fernandez-Caldas E, 2014, CHEM IMMUNOL ALLERGY, V100, P234, DOI 10.1159/000358860; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Gieras A, 2007, J ALLERGY CLIN IMMUN, V119, P384, DOI 10.1016/j.jaci.2006.09.034; Gieras A, 2016, J ALLERGY CLIN IMMUN, V137, P1557, DOI 10.1016/j.jaci.2015.08.055; Huang HJ, 2019, ALLERGY, V74, P2461, DOI 10.1111/all.13956; Huang HJ, 2018, J ALLERGY CLIN IMMUN, V142, P1656, DOI 10.1016/j.jaci.2018.07.010; Incorvaia C, 2018, J MED ECON, V21, P553, DOI 10.1080/13696998.2018.1423567; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jarnicki AG, 2002, CLIN EXP ALLERGY, V32, P942, DOI 10.1046/j.1365-2745.2002.01407.x; Kiel MA, 2013, J ALLERGY CLIN IMMUN, V132, P353, DOI 10.1016/j.jaci.2013.03.013; Lai XX, 2013, INT ARCH ALLERGY IMM, V160, P37, DOI 10.1159/000339239; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Lupinek C, 2012, J ALLERGY CLIN IMMUN, V130, P1418, DOI 10.1016/j.jaci.2012.06.028; Madritsch C, 2011, CLIN EXP ALLERGY, V41, P270, DOI 10.1111/j.1365-2222.2010.03666.x; Nakamura R, 2010, ALLERGY, V65, P1266, DOI 10.1111/j.1398-9995.2010.02363.x; Orengo JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03636-8; Park KH, 2016, YONSEI MED J, V57, P1427, DOI 10.3349/ymj.2016.57.6.1427; Pfaar O, 2016, ALLERGY, V71, P967, DOI 10.1111/all.12860; Posa D, 2017, J ALLERGY CLIN IMMUN, V139, P541, DOI 10.1016/j.jaci.2016.08.014; Pree I, 2007, J IMMUNOL, V179, P5309, DOI 10.4049/jimmunol.179.8.5309; Rauber MM, 2020, ALLERGY, V75, P450, DOI 10.1111/all.13996; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Resch Y, 2015, J ALLERGY CLIN IMMUN, V136, P1083, DOI 10.1016/j.jaci.2015.03.024; Rondon C, 2016, ALLERGY, V71, P1057, DOI 10.1111/all.12889; Schmid JM, 2016, J ALLERGY CLIN IMMUN, V137, P562, DOI 10.1016/j.jaci.2015.05.023; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Shamji MH, 2019, J ALLERGY CLIN IMMUN, V143, P1067, DOI 10.1016/j.jaci.2018.09.039; Shamji MH, 2017, J ALLERGY CLIN IMMUN, V140, P1485, DOI 10.1016/j.jaci.2017.10.010; Siroux V, 2016, J ALLERGY CLIN IMMUN; Thomas WR, 2018, MOL IMMUNOL, V100, P120, DOI 10.1016/j.molimm.2018.03.016; Thomas WR, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0649-y; Valenta R, 2018, J ALLER CL IMM-PRACT, V6, P1845, DOI 10.1016/j.jaip.2018.08.032; Valenta R, 2018, ADV IMMUNOL, V138, P195, DOI 10.1016/bs.ai.2018.03.002; Valenta R, 2016, J ALLERGY CLIN IMMUN, V137, P351, DOI 10.1016/j.jaci.2015.12.1299; Varney VA, 2003, CLIN EXP ALLERGY, V33, P1076, DOI 10.1046/j.1365-2222.2003.01735.x; Weghofer M, 2008, EUR J CLIN INVEST, V38, P959, DOI 10.1111/j.1365-2362.2008.02048.x; Weghofer M, 2008, ALLERGY, V63, P758, DOI 10.1111/j.1398-9995.2008.01647.x; Weghofer M, 2008, INT ARCH ALLERGY IMM, V147, P101, DOI 10.1159/000135696; Weghofer M, 2013, J IMMUNOL, V190, P3059, DOI 10.4049/jimmunol.1202288; Wollmann E, 2015, J ALLERGY CLIN IMMUN, V136, P806, DOI 10.1016/j.jaci.2015.02.034; Zha LS, 2018, J ALLERGY CLIN IMMUN, V142, P1529, DOI 10.1016/j.jaci.2017.09.054; Zhao DY, 2016, INT ARCH ALLERGY IMM, V169, P113, DOI 10.1159/000444391	61	28	29	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					1097	1108		10.1016/j.jaci.2020.03.029	http://dx.doi.org/10.1016/j.jaci.2020.03.029			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32298697	hybrid, Green Published			2022-12-18	WOS:000588153700014
J	Altrichter, S; Frischbutter, S; Fok, JS; Kolkhir, P; Jiao, QQ; Skov, PS; Metz, M; Church, MK; Maurer, M				Altrichter, Sabine; Frischbutter, Stefan; Fok, Jie Shen; Kolkhir, Pavel; Jiao, Qingqing; Skov, Per Stahl; Metz, Martin; Church, Martin K.; Maurer, Marcus			The role of eosinophils in chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Urticaria chronic spontaneous urticaria; mast cell; eosinophil	CHRONIC IDIOPATHIC URTICARIA; MAJOR BASIC-PROTEIN; ENDOTHELIAL GROWTH-FACTOR; MAST-CELLS; HELMINTH INFECTION; AUTOLOGOUS SERUM; GRANULE PROTEINS; HEAT URTICARIA; LESIONAL SKIN; TOTAL ABSENCE	Chronic spontaneous urticaria (CSU) is considered to be primarily a mast cell driven disease. However, recent evidence suggests that eosinophils may also have an axial role in symptomology. Histologic studies have demonstrated the presence of both eosinophils and eosinophil granules, indicative of activation, in CSU lesions. Although many allergic and inflammatory conditions are associated with a peripheral blood eosinophilia, the converse appears to be the case in CSU, with a peripheral blood eosinopenia being observed in many patients. Possible mechanisms include the depletion of blood eosinophils by recruitment into the skin during active disease and immunologic destruction in the blood. We also address in some detail the interactions between eosinophils and mast cells, particularly the cytokine cross-talk of these cells and mediator release possibly leading to clinical symptoms. Also, activation by eosinophil proteins of the coagulation pathway leads to the generation of thrombin and increased mast cell degranulation. Finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms. Clearly, a new picture of an important role of eosinophils in the pathogenesis of CSU is emerging.	[Altrichter, Sabine; Frischbutter, Stefan; Fok, Jie Shen; Kolkhir, Pavel; Jiao, Qingqing; Metz, Martin; Church, Martin K.; Maurer, Marcus] Charite Univ Med Berlin, Dermatol Allergol, Dept Dermatol & Allergy, Allergie Ctr Charite, Berlin, Germany; [Altrichter, Sabine; Frischbutter, Stefan; Fok, Jie Shen; Kolkhir, Pavel; Jiao, Qingqing; Metz, Martin; Church, Martin K.; Maurer, Marcus] Free Univ Berlin, Berlin, Germany; [Altrichter, Sabine; Frischbutter, Stefan; Fok, Jie Shen; Kolkhir, Pavel; Jiao, Qingqing; Metz, Martin; Church, Martin K.; Maurer, Marcus] Humboldt Univ, Berlin, Germany; [Altrichter, Sabine; Frischbutter, Stefan; Fok, Jie Shen; Kolkhir, Pavel; Jiao, Qingqing; Metz, Martin; Church, Martin K.; Maurer, Marcus] Berlin Inst Hlth, Berlin, Germany; [Fok, Jie Shen] Box Hill Hosp, Dept Resp Med, Melbourne, Vic, Australia; [Fok, Jie Shen] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia; [Kolkhir, Pavel] IM Sechenov First Moscow State Med Univ, Div Immune Mediated Skin Dis, Sechenov Univ, Moscow, Russia; [Jiao, Qingqing] Soochow Univ, Dept Dermatol, Affiliated Hosp 1, Suzhou, Peoples R China; [Skov, Per Stahl] Univ Hosp Southern Denmark, Dermatol Dept, Odense, Denmark; [Skov, Per Stahl] RefLab ApS, Copenhagen, Denmark; [Skov, Per Stahl] Natl Univ Copenhagen, Inst Immunol, Copenhagen, Denmark	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Box Hill Hospital; Monash University; Sechenov First Moscow State Medical University; Soochow University - China; University of Southern Denmark; Odense University Hospital; University of Copenhagen	Maurer, M (corresponding author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020; Frischbutter, Stefan/AAM-9487-2021; Metz, Martin/B-8799-2009	Maurer, Marcus/0000-0002-4121-481X; Frischbutter, Stefan/0000-0003-3971-7343; Metz, Martin/0000-0002-4070-9976; Altrichter, Sabine/0000-0001-9955-385X; Kolkhir, Pavel/0000-0001-5380-8132	GA2LEN fellowship; GA2LEN network of Urticaria Centers of Reference and Excellence; Russian Academic Excellence Project 5-100	GA2LEN fellowship; GA2LEN network of Urticaria Centers of Reference and Excellence; Russian Academic Excellence Project 5-100(Ministry of Education and Science, Russian FederationProject 5-100, Ministry of Education and Science, Russian Federation)	P. Kolkhir was supported by a GA2LEN fellowship. This project benefitted from the support of the GA2LEN network of Urticaria Centers of Reference and Excellence (www.ga2len-ucare.com) and the Russian Academic Excellence Project 5-100.	Acharya KR, 2014, J BIOL CHEM, V289, P17406, DOI 10.1074/jbc.R113.546218; ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Asero R, 2009, WORLD ALLERGY ORGAN, V2, P213, DOI 10.1097/WOX.0b013e3181bb965f; Blanchard C, 2009, ADV IMMUNOL, V101, P81, DOI 10.1016/S0065-2776(08)01003-1; Caproni M, 2003, EXP DERMATOL, V12, P621, DOI 10.1034/j.1600-0625.2003.00010.x; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; Cheng LE, 2015, J EXP MED, V212, P513, DOI 10.1084/jem.20141671; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Criado PR, 2013, AN BRAS DERMATOL, V88, P355, DOI 10.1590/abd1806-4841.20131532; Cugno M, 2018, ALLERGY, V73, P2408, DOI 10.1111/all.13587; Cugno M, 2009, INT ARCH ALLERGY IMM, V148, P170, DOI 10.1159/000155748; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; Davis MDP, 2003, J ALLERGY CLIN IMMUN, V112, P988, DOI 10.1016/j.jaci.2003.08.028; Deeks ED, 2017, DRUGS, V77, P777, DOI 10.1007/s40265-017-0740-2; Diny NL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00484; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Fitzsimmons CM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00061; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Folci M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5615109; FRANKLIN W, 1981, ANN INTERN MED, V94, P352, DOI 10.7326/0003-4819-94-3-352; Freeman GL, 1998, ALLERGY, V53, P331, DOI 10.1111/j.1398-9995.1998.tb03901.x; Fujisawa D, 2014, J ALLERGY CLIN IMMUN, V134, P622, DOI 10.1016/j.jaci.2014.05.004; Galdiero MR, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00103; Gangwar RS, 2017, PHARMACOL THERAPEUT, V170, P37, DOI 10.1016/j.pharmthera.2016.10.010; Gleich GJ, 2013, ALLERGY, V68, P829, DOI 10.1111/all.12169; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; Grattan CEH, 1997, BRIT J DERMATOL, V136, P141, DOI 10.1111/j.1365-2133.1997.tb08774.x; HAAS N, 1995, ARCH DERMATOL RES, V287, P180, DOI 10.1007/BF01262329; Hartman ML, 2001, BLOOD, V97, P1086, DOI 10.1182/blood.V97.4.1086; Hepworth MR, 2012, P NATL ACAD SCI USA, V109, P6644, DOI 10.1073/pnas.1112268109; Huang L, 2016, TRENDS PARASITOL, V32, P798, DOI 10.1016/j.pt.2016.05.004; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; IRWIN RB, 1985, J ALLERGY CLIN IMMUN, V76, P35, DOI 10.1016/0091-6749(85)90801-2; Ishizuka T, 1999, INFLAMMATION, V23, P25, DOI 10.1023/A:1020235400073; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; JUHLIN L, 1977, LANCET, V1, P1233; JUHLIN L, 1992, ACTA DERM-VENEREOL, V72, P197; JUHLIN L, 1988, EUR J HAEMATOL, V40, P368; Karakonstantis S, 2018, INFECT DIS-NOR, V50, P163, DOI 10.1080/23744235.2017.1388537; Kay AB, 2015, BRIT J DERMATOL, V172, P1294, DOI 10.1111/bjd.13621; Kay AB, 2014, BRIT J DERMATOL, V171, P505, DOI 10.1111/bjd.12991; Kay AB, 2014, CLIN EXP ALLERGY, V44, P1053, DOI 10.1111/cea.12348; Kim S, 2010, J IMMUNOL, V184, P1143, DOI 10.4049/jimmunol.0902447; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; Koh YI, 2002, J ALLERGY CLIN IMMUN, V109, P714, DOI 10.1067/mai.2002.122462; Kolkhir P, 2020, J ALLER CL IMM-PRACT, V8, P318, DOI 10.1016/j.jaip.2019.08.025; Kolkhir P, 2017, J ALLERGY CLIN IMMUN, V139, P1772, DOI 10.1016/j.jaci.2016.08.050; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Kovalszki A, 2016, PRIMARY CARE, V43, P607, DOI 10.1016/j.pop.2016.07.010; Krisinger MJ, 2012, BLOOD, V120, P1717, DOI 10.1182/blood-2012-02-412080; Lakin E, 2019, THERANOSTICS, V9, P829, DOI 10.7150/thno.29902; Lee JK, 2019, J ALLER CL IMM-PRACT, V7, P1659, DOI 10.1016/j.jaip.2018.11.018; LEIFERMAN KM, 1989, J AM ACAD DERMATOL, V21, P75, DOI 10.1016/S0190-9622(89)70151-1; Magerl M, 2018, J DTSCH DERMATOL GES, V16, P477, DOI 10.1111/ddg.13481; Magerl M, 2010, J ALLERGY CLIN IMMUN, V126, P665, DOI 10.1016/j.jaci.2010.05.047; Martins CF, 2018, ALLERGOL INT, V67, P114, DOI 10.1016/j.alit.2017.06.012; Maurer M, 2015, J EUR ACAD DERMATOL, V29, P16, DOI 10.1111/jdv.13198; MAYOU SC, 1986, BRIT J DERMATOL, V115, P371, DOI 10.1111/j.1365-2133.1986.tb05754.x; MEKORI YA, 1988, ARCH DERMATOL, V124, P230, DOI 10.1001/archderm.124.2.230; Minai-Fleminger Y, 2009, INFLAMM RES, V58, P631, DOI 10.1007/s00011-009-0042-6; Miyamasu M, 1999, CYTOKINE, V11, P751, DOI 10.1006/cyto.1999.0487; Munitz A, 2006, BLOOD, V107, P1996, DOI 10.1182/blood-2005-07-2926; MURPHY GF, 1987, J ALLERGY CLIN IMMUN, V80, P603, DOI 10.1016/0091-6749(87)90015-7; Naclerio RM, 2010, INT J GEN MED, V3, P47; Neves JS, 2010, J ALLERGY CLIN IMMUN, V125, P477, DOI 10.1016/j.jaci.2009.11.029; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Okayama Y, 1998, INT ARCH ALLERGY IMM, V117, P48, DOI 10.1159/000053571; Oliveira S. H. P., 2003, Current Drug Targets - Inflammation and Allergy, V2, P313, DOI 10.2174/1568010033483990; Oliver ET, 2019, INT ARCH ALLERGY IMM, V179, P21, DOI 10.1159/000496162; Pawankar R, 2011, ASIA PAC ALLERGY, V1, P157, DOI 10.5415/apallergy.2011.1.3.157; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Puccetti A, 2005, CLIN EXP ALLERGY, V35, P1599, DOI 10.1111/j.1365-2222.2005.02380.x; Ramirez GA, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9095275; RAZIN E, 1984, J IMMUNOL, V133, P3282; Robida PA, 2018, IMMUNOL REV, V282, P151, DOI 10.1111/imr.12638; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; Saini SS, 2014, IMMUNOL ALLERGY CLIN, V34, P33, DOI 10.1016/j.iac.2013.09.012; Sakurai Y, 2015, ALLERGOL INT, V64, P96, DOI 10.1016/j.alit.2014.07.006; Schmetzer O, 2018, J ALLERGY CLIN IMMUN, V142, P876, DOI 10.1016/j.jaci.2017.10.035; Schoepke N, 2019, ALLERGY, V74, P2427, DOI 10.1111/all.13949; Shah AD, 2016, OPEN HEART, V3, DOI 10.1136/openhrt-2016-000477; SPRY CJF, 1985, INT ARCH ALLER A IMM, V77, P252, DOI 10.1159/000233803; Staumont-Salle D, 2006, CLIN REV ALLERG IMMU, V30, P13, DOI 10.1385/CRIAI:30:1:013; Tedeschi A, 2009, ALLERGY, V64, P1616, DOI 10.1111/j.1398-9995.2009.02069.x; Toyoda M, 1996, AM J DERMATOPATH, V18, P49, DOI 10.1097/00000372-199602000-00008; Uhm TG, 2012, ALLERGY ASTHMA IMMUN, V4, P68, DOI 10.4168/aair.2012.4.2.68; Walsh GM, 2015, CURR OPIN ALLERGY CL, V15, P392, DOI 10.1097/ACI.0000000000000183; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236; Zellweger F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0526-9; Zhang HY, 2011, CYTOKINE, V53, P231, DOI 10.1016/j.cyto.2010.10.005; Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397	95	28	28	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1510	1516		10.1016/j.jaci.2020.03.005	http://dx.doi.org/10.1016/j.jaci.2020.03.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32224275				2022-12-18	WOS:000539157800003
J	Louvrier, C; Assrawi, E; El Khouri, E; Melki, I; Copin, B; Bourrat, E; Lachaume, N; Cador-Rousseau, B; Duquesnoy, P; Piterboth, W; Awad, F; Jumeau, C; Legendre, M; Grateau, G; Georgin-Lavialle, S; Karabina, SA; Amselem, S; Giurgea, I				Louvrier, Camille; Assrawi, Eman; El Khouri, Elma; Melki, Isabelle; Copin, Bruno; Bourrat, Emmanuelle; Lachaume, Noemie; Cador-Rousseau, Berengere; Duquesnoy, Philippe; Piterboth, William; Awad, Fawaz; Jumeau, Claire; Legendre, Marie; Grateau, Gilles; Georgin-Lavialle, Sophie; Karabina, Sonia A.; Amselem, Serge; Giurgea, Irina			NLRP3-associated autoinflammatory diseases: Phenotypic and molecular characteristics of germline versus somatic mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NLRP3-associated autoinflammatory diseases; NLRP3; somatic mosaic mutations; NLRP3-inflammasome activation; mutational hot spot	CIAS1 MUTATIONS; ARTICULAR SYNDROME; PERIODIC SYNDROME; GENE; MOSAICISM; GENOTYPE	Background: NLRP3-associated autoinflammatory diseases (NLRP3-AIDs) include conditions of various severities, due to germline or somatic mosaic NLRP3 mutations. Objective: To identify mosaic-versus germline-specific NLRP3 mutations' characteristics, we reinterpreted all the mutations reported in NLRP3-AIDs and performed an in-depth study of 3 novel patients. Methods: The pathogenicity of all reported mosaic/germline mutations was reassessed according to international recommendations and their location on the NLRP3 3-dimensional structure. Deep-targeted sequencing and NLRP3-inflammasome-activation assays were used to identify the disease-causing mutation in 3 patients. Results: We identified, in 3 patients, mosaic mutations affecting the same NLRP3 amino acid (Glu569). This residue belongs to 1 of the 2 mosaic mutational hot spots that face each other in the core of the NLRP3 ATPase domain. The review of the 90 NLRP3 mutations identified in 277 patients revealed that those hot spots account for 68.5% of patients (37 of 54) with mosaic mutations. Glu569 is affected in 22% of the patients (12 of 54) with mosaic mutations and in 0.4% of patients (1 of 223) with germline mutations. Only 8 of 90 mutations were found in mosaic and germinal states. All of the germline mutations were associated with a severe phenotype. These data suggest that mutations found only in mosaic state could be incompatible with life if present in germinal state. None of the 5 most frequent germline mutations was identified in mosaic state. Mutations found only in germinal state could, therefore, be asymptomatic in mosaic state. Conclusions: The phenotypic spectrum of NLRP3-AIDs appears to be related to the germinal/mosaic status and localization of the underlying mutations.	[Louvrier, Camille; Assrawi, Eman; El Khouri, Elma; Duquesnoy, Philippe; Awad, Fawaz; Jumeau, Claire; Legendre, Marie; Grateau, Gilles; Georgin-Lavialle, Sophie; Karabina, Sonia A.; Amselem, Serge; Giurgea, Irina] Sorbonne Univ, INSERM, Childhood Genet Disorders, Paris, France; [Louvrier, Camille; Copin, Bruno; Piterboth, William; Legendre, Marie; Amselem, Serge; Giurgea, Irina] Hop Armand Trousseau, AP HP, Dept Genet Med, Paris, France; [Melki, Isabelle; Bourrat, Emmanuelle; Lachaume, Noemie] Hop Robert Debre, AP HP, Ctr Reference Rhumatismes & Autoimmun Syst Enfant, Serv Pediat Gen Malad Infect & Med Interne Pediat, Paris, France; [Cador-Rousseau, Berengere] Ctr Hosp Univ Pontchaillou, Serv Med Interne, Rennes, France; [Grateau, Gilles; Georgin-Lavialle, Sophie] Hop Tenon, AP HP, Serv Med Interne, Paris, France; [Grateau, Gilles; Georgin-Lavialle, Sophie] Hop Tenon, AP HP, Ctr Reference Malad Autoinflammatoires & Amyloses, Paris, France; [Awad, Fawaz] Al Quds Univ, Biochem & Mol Biol Dept, Fac Med, Jerusalem, Israel	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Amselem, S; Giurgea, I (corresponding author), Hop Armand Trousseau, INSERM, UMR S933, 26 Ave Dr Arnold Netter, F-75012 Paris, France.	serge.amselem@inserm.fr; irina.giurgea@inserm.fr	El Khouri, Elma/GRN-8601-2022; Legendre, Marie/AAD-7018-2021; Giurgea, Irina/AGX-6879-2022	Legendre, Marie/0000-0003-2178-0846; Giurgea, Irina/0000-0002-5035-2958; Awad, Fawaz/0000-0002-8214-394X	Agence Nationale de la Recherche, France [ANR-17-CE17-0021-01]; European Union [779295]; Institut National de la Sante et de la Recherche Medicale (INSERM), France [00552404]	Agence Nationale de la Recherche, France(French National Research Agency (ANR)); European Union(European Commission); Institut National de la Sante et de la Recherche Medicale (INSERM), France(Institut National de la Sante et de la Recherche Medicale (Inserm))	This study was funded by the Agence Nationale de la Recherche, France (ANR-17-CE17-0021-01), and a European Union Grant Agreement (H2020, 779295). C. Louvrier was supported by Institut National de la Sant~e et de la Recherche Medicale (INSERM), France (Poste d'Accueil, 00552404).	Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 2007, ARTHRITIS RHEUM-US, V56, P1273, DOI 10.1002/art.22491; Assrawi E., 2019, J INVEST DERMATOL; Awad F, 2018, PHARMACOL THERAPEUT, V187, P133, DOI 10.1016/j.pharmthera.2018.02.011; Broderick L, 2015, ANNU REV PATHOL-MECH, V10, P395, DOI 10.1146/annurev-pathol-012414-040431; Cooper DN, 2011, HUM MUTAT, V32, P1075, DOI 10.1002/humu.21557; Fan WM, 2018, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01117; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Haverkamp MH, 2014, CLIN EXP IMMUNOL, V177, P720, DOI 10.1111/cei.12361; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Izawa K, 2012, DNA RES, V19, P143, DOI 10.1093/dnares/dsr047; Jeanson L, 2016, HUM MUTAT, V37, P776, DOI 10.1002/humu.23005; Jesus AA, 2008, J CLIN IMMUNOL, V28, P134, DOI 10.1007/s10875-007-9150-7; Jesus AA, 2012, J CLIN IMMUNOL, V32, P922, DOI 10.1007/s10875-012-9688-x; Jimenez-Trevino S, 2013, ANN RHEUM DIS, V72, P1109, DOI 10.1136/annrheumdis-2012-202913; Labrousse M, 2018, CRIT REV CL LAB SCI, V55, P432, DOI 10.1080/10408363.2018.1488805; Leslie KS, 2006, ARCH DERMATOL, V142, P1591, DOI 10.1001/archderm.142.12.1591; Man SM, 2015, IMMUNOL REV, V265, P6, DOI 10.1111/imr.12296; Matsubara T, 2006, ARTHRITIS RHEUM-US, V54, P2314, DOI 10.1002/art.21965; Mensa-Vilaro A, 2016, ARTHRITIS RHEUMATOL, V68, P3035, DOI 10.1002/art.39770; Nakagawa K, 2015, ANN RHEUM DIS, V74, P603, DOI 10.1136/annrheumdis-2013-204361; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; Nishikomori R, 2019, INT IMMUNOL, V31, P649, DOI 10.1093/intimm/dxz047; Paccaud Y, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-52; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rosen-Wolff A, 2003, EUR J HAEMATOL, V71, P215, DOI 10.1034/j.1600-0609.2003.00109.x; Rowczenio DM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01410; Saito M, 2008, BLOOD, V111, P2132, DOI 10.1182/blood-2007-06-094201; Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; Tran TA, 2012, SEMIN ARTHRITIS RHEU, V42, P327, DOI 10.1016/j.semarthrit.2012.03.005; Walenta L, 2018, REPRODUCTION, V156, P231, DOI 10.1530/REP-18-0111; Zhou Q, 2015, ARTHRITIS RHEUMATOL, V67, P2482, DOI 10.1002/art.39190	33	28	31	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1254	1261		10.1016/j.jaci.2019.11.035	http://dx.doi.org/10.1016/j.jaci.2019.11.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31816408	Bronze			2022-12-18	WOS:000523633400021
J	Greuter, T; Hirano, I; Dellon, ES				Greuter, Thomas; Hirano, Ikuo; Dellon, Evan S.			Emerging therapies for eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Eosinophilic esophagitis; treatment; steroids; diet; biologics	THYMIC STROMAL LYMPHOPOIETIN; ADULT PATIENTS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; STEROID-THERAPY; EFFICACY; PLACEBO; BUDESONIDE; CHILDREN; INFLAMMATION	Despite advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single agent has been approved by the US Food and Drug Administration to treat EoE. Off-label, EoE is currently treated by using the 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic dilation. In the recent past, considerable progress in terms of EoE treatment has been made: (1) new EoE-specific steroid formulations optimizing mucosal deposition have been developed, which has culminated in recent approval of a budesonide effervescent tablet in Europe; (2) biologics used for other T(H)2-mediated diseases, such as allergic asthma and atopic eczema, as well as purpose developed biologics, have been studied in phase II trials in patients with EoE; and (3) novel dietary restriction strategies have evolved. Finally, further insights into the pathogenesis of EoE have revealed several novel disease mediators that might be targeted in the future. In the following article we will discuss recent advances in EoE treatment with regard to swallowed topical steroids, biological agents, dietary approaches, and novel molecular targets.	[Greuter, Thomas] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland; [Hirano, Ikuo] Northwestern Univ, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA; [Dellon, Evan S.] UNC Hosp, Div Gastroenterol & Hepatol, CB 7080,Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27516 USA	University of Zurich; University Zurich Hospital; Northwestern University; University North Carolina Hospital; University of North Carolina; University of North Carolina Chapel Hill	Dellon, ES (corresponding author), UNC Hosp, Div Gastroenterol & Hepatol, CB 7080,Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27516 USA.	edellon@med.unc.edu			Swiss National Science Foundation [P2ZHP3_168561]; Swiss Society of Gastroenterology; Novartis Foundation for medical-biological research; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR); CEGIR [U54 AI117804]; National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NCATS; APFED; CURED; EFC	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Society of Gastroenterology; Novartis Foundation for medical-biological research(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR); CEGIR; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); APFED; CURED; EFC	This work was supported by a grant from the Swiss National Science Foundation (grant no. P2ZHP3_168561; to T.G.), a young investigator award from the Swiss Society of Gastroenterology (to T.G.), a research grant from the Novartis Foundation for medical-biological research (to T.G.), and a training grant from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR; to T.G.). CEGIR (U54 AI117804) is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translation Sciences (NCATS), and is funded through collaboration between the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NCATS. CEGIR is also supported by patient advocacy groups including APFED, CURED, and EFC.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P1205, DOI 10.1016/j.jaci.2010.10.031; Alexander JA, 2017, CLIN GASTROENTEROL H, V15, P214, DOI 10.1016/j.cgh.2016.09.013; [Anonymous], 2019, CLIN GASTROENTEROL H; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Butz BK, 2014, GASTROENTEROLOGY, V147, P324, DOI 10.1053/j.gastro.2014.04.019; Cheng Katherine, 2017, Transl Sci Rare Dis, V2, P141, DOI 10.3233/TRD-170016; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Cotton CC, 2019, DIGEST DIS SCI, V64, P1401, DOI 10.1007/s10620-019-05602-w; de Rooij WE, 2019, DRUGS, V79, P1419, DOI 10.1007/s40265-019-01173-2; Dellon E, 2019, AM J GASTROENTEROL, V114; Dellon ES, 2019, GASTROENTEROLOGY, V157, P65, DOI 10.1053/j.gastro.2019.03.014; Dellon ES, 2019, J ALLERGY CLIN IMMUN, V143, pAB208, DOI 10.1016/j.jaci.2018.12.635; Dellon ES, 2018, GASTROENTEROLOGY, V154, pS260; Dellon ES, 2019, CLIN GASTROENTEROL H, V17, P666, DOI 10.1016/j.cgh.2018.05.051; Dellon ES, 2017, GASTROENTEROLOGY, V152, P776, DOI 10.1053/j.gastro.2016.11.021; Dellon ES, 2012, GASTROENTEROLOGY, V143, P321, DOI 10.1053/j.gastro.2012.04.049; Forbes EE, 2008, J EXP MED, V205, P897, DOI 10.1084/jem.20071046; Gauvreau GM, 2018, CLIN EXP ALLERGY, V48, P445, DOI 10.1111/cea.13114; Greuter T, 2018, CLIN TRANSL GASTROEN, V9, DOI 10.1038/s41424-018-0074-8; Greuter T, 2019, CLIN GASTROENTEROL H, V17, P419, DOI 10.1016/j.cgh.2018.05.045; Greuter T, 2017, AM J GASTROENTEROL, V112, P1527, DOI 10.1038/ajg.2017.202; Hardenberg JHB, 2018, J INVEST DERMATOL, V138, P23, DOI 10.1016/j.jid.2017.05.026; Hirano I., 2019, GASTROENTEROLOGY; Hirano I, 2019, AM J GASTROENTEROL, V114, pS230; Hirano I, 2019, GASTROENTEROLOGY, V156, P592, DOI 10.1053/j.gastro.2018.10.051; Hirano I, 2017, GASTROENTEROLOGY, V152, pS195, DOI 10.1016/S0016-5085(17)30960-5; Katzka DA, 2014, CLIN GASTROENTEROL H, V12, P1824, DOI 10.1016/j.cgh.2014.02.039; Kliewer K, 2019, GASTROENTEROLOGY, V156, pS172; Kuang FL, 2019, NEW ENGL J MED, V380, P1336, DOI 10.1056/NEJMoa1812185; Legrand F, 2019, J ALLERGY CLIN IMMUN, V143, P2227, DOI 10.1016/j.jaci.2018.10.066; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lieberman JA, 2018, ANN ALLERG ASTHMA IM, V120, P527, DOI 10.1016/j.anai.2018.03.006; Loizou D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0113483; Lucendo A, 2019, GASTROENTEROLOGY, V156, pS1509; Lucendo AJ, 2019, GASTROENTEROLOGY, V157, P74, DOI 10.1053/j.gastro.2019.03.025; Markowitz JE, 2018, J PEDIATR GASTR NUTR, V66, P893, DOI 10.1097/MPG.0000000000001840; Miehlke S, 2016, GUT, V65, P390, DOI 10.1136/gutjnl-2014-308815; Molina-Infante J, 2018, J ALLERGY CLIN IMMUN, V141, P1365, DOI 10.1016/j.jaci.2017.08.038; Nhu QM, 2018, AM J GASTROENTEROL, V113, P1261, DOI 10.1038/s41395-018-0145-1; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Odiase E, 2019, GASTROENTEROLOGY, V156, pS39; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shoda T, 2018, LANCET GASTROENTEROL, V3, P477, DOI 10.1016/S2468-1253(18)30096-7; Song DJ, 2017, ALLERGY ASTHMA IMMUN, V9, P360, DOI 10.4168/aair.2017.9.4.360; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V129, P456, DOI 10.1016/j.jaci.2011.11.044; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Straumann A, 2013, ALLERGY, V68, P375, DOI 10.1111/all.12096; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Straumann A, 2008, J ALLERGY CLIN IMMUN, V122, P425, DOI 10.1016/j.jaci.2008.06.012; Straumann A, 2010, GASTROENTEROLOGY, V139, P1526, DOI 10.1053/j.gastro.2010.07.048; Taft TH, 2018, CLIN GASTROENTEROL H, V16, P1840, DOI 10.1016/j.cgh.2018.06.022; Travers J, 2016, J ALLERGY CLIN IMMUN, V138, P1381, DOI 10.1016/j.jaci.2016.09.001; Warners MJ, 2018, GASTROENTEROLOGY, V154, P57, DOI 10.1053/j.gastro.2017.08.062; Wen T, 2019, J CLIN INVEST, V129, P2014, DOI 10.1172/JCI125917; Youngblood BA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126219; Zhan TN, 2018, CLIN GASTROENTEROL H, V16, P1730, DOI 10.1016/j.cgh.2018.04.013; Zhu X, 2010, GASTROENTEROLOGY, V139, P182, DOI 10.1053/j.gastro.2010.03.057	62	28	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					38	45		10.1016/j.jaci.2019.10.027	http://dx.doi.org/10.1016/j.jaci.2019.10.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31705907	Green Accepted, Bronze			2022-12-18	WOS:000505590800005
J	Levy, BD; Abdulnour, REE; Tavares, A; Bruggemann, TR; Norris, PC; Bai, Y; Ai, XB; Serhan, CN				Levy, Bruce D.; Abdulnour, Raja-Elie E.; Tavares, Alexander; Bruggemann, Thayse R.; Norris, Paul C.; Bai, Yan; Ai, Xingbin; Serhan, Charles N.			Cysteinyl maresins regulate the prophlogistic lung actions of cysteinyl leukotrienes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Resolution; inflammation; lung; asthma	TISSUE-REGENERATIVE RESOLVIN; 1ST TOTAL-SYNTHESIS; RESOLUTION; IDENTIFICATION; BIOSYNTHESIS; ASTHMA; MEDIATORS; RECEPTOR; ENZYMES; PROMOTE	Background: Cysteinyl leukotrienes (CysLTs) are potent prophlogistic mediators in asthmatic patients; however, inhibition of CysLT receptor 1 is not a consistently effective treatment, suggesting additional regulatory mechanisms. Other cysteinyl-containing lipid mediators (LMs) derived from docosahexaenoic acid, namely maresin conjugates in tissue regeneration (MCTRs), were recently discovered. Therefore their production and actions in the lung are of considerable interest. Objective: We sought to determine MCTR production, bioactions, and mechanisms in the human lung and in patients with experimental allergic airway inflammation. Methods: LM metabololipidomic profiling of the lung was performed by using liquid chromatography with tandem mass spectrometry. Donor-derived human precision-cut lung slices were exposed to leukotriene (LT) D-4, MCTRs, or both before determination of airway contraction. The actions of exogenous MCTRs on murine allergic host responses were determined in the setting of ovalbumin- and house dust mite-induced lung inflammation. Results: Lipidomic profiling showed that the most abundant cysteinyl LMs in healthy human lungs were MCTRs, whereas CysLTs were most prevalent in patients with disease. MCTRs blocked LTD4-initiated airway contraction in human precision-cut lung slices. In mouse allergic lung inflammation MCTRs were present with temporally regulated production. With ovalbumin-induced inflammation, MCTR1 was most potent for promoting resolution of eosinophils, and MCTR3 potently decreased airway hyperreactivity to methacholine, bronchoalveolar lavage fluid albumin, and serum IgE levels. MCTR1 and MCTR3 inhibited lung eosinophilia after house dust mite-induced inflammation. Conclusion: These results identified lung MCTRs that blocked human LTD4-induced airway contraction and promoted resolution of murine allergic airway responses when added exogenously. Together, these findings uncover proresolving mechanisms for lung responses that can be disrupted in patients with disease.	[Levy, Bruce D.; Abdulnour, Raja-Elie E.; Tavares, Alexander; Bruggemann, Thayse R.; Bai, Yan; Ai, Xingbin] Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Med Div, 75 Francis St, Boston, MA 02115 USA; [Norris, Paul C.; Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesia Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA; [Norris, Paul C.; Serhan, Charles N.] Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Serhan, CN (corresponding author), Hale Bldg Transformat Med, 60 Fenwood Rd, Boston, MA 02115 USA.	blevy@bwh.harvard.edu; cserhan@bwh.harvard.edu		Levy, Bruce David/0000-0001-9515-5731	National Institutes of Health [P01GM095467, R01HL122531, K08HL130540]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health P01GM095467 (to C.N.S. and B.D.L.), R01HL122531 (to B.D.L.), and K08HL130540 (to R.E.A.).	Austen KF, 1973, EXC MED INT C; Bai Y, 2016, AM J RESP CELL MOL, V54, P656, DOI 10.1165/rcmb.2015-0290MA; Bankova LG, 2016, P NATL ACAD SCI USA, V113, P6242, DOI 10.1073/pnas.1605957113; Bisgaard H, 2016, NEW ENGL J MED, V375, P2530, DOI 10.1056/NEJMoa1503734; Chiang N, 2018, FASEB J, V32, P4043, DOI 10.1096/fj.201701493R; Dalli J, 2016, P NATL ACAD SCI USA, V113, P12232, DOI 10.1073/pnas.1607003113; Dalli J, 2015, FASEB J, V29, P2120, DOI 10.1096/fj.14-268441; Dalli J, 2014, P NATL ACAD SCI USA, V111, pE4753, DOI 10.1073/pnas.1415006111; de la Rosa X, 2018, AM J PATHOL, V188, P950, DOI 10.1016/j.ajpath.2018.01.004; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Haeggstrom JZ, 2018, J CLIN INVEST, V128, P2680, DOI 10.1172/JCI97945; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Holgate ST, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.25; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Khatri SB, 2019, CLIN CHEST MED, V40, pXIII, DOI 10.1016/j.ccm.2018.12.001; Krishnamoorthy N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao4747; KUMLIN M, 1990, BIOCHIM BIOPHYS ACTA, V1044, P201, DOI 10.1016/0005-2760(90)90304-G; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Peebles RS, 2019, PHARMACOL THERAPEUT, V193, P1, DOI 10.1016/j.pharmthera.2018.08.001; Perretti M, 2015, TRENDS PHARMACOL SCI, V36, P737, DOI 10.1016/j.tips.2015.07.007; Piper PJ., 1980, P I BASIC MED SCI RO; Rackemann FM, 1918, BOSTON MED SURG J, V178, P770, DOI 10.1056/NEJM191806061782302; Rodriguez AR, 2017, TETRAHEDRON LETT, V58, P1662, DOI 10.1016/j.tetlet.2017.03.041; Rodriguez AR, 2015, TETRAHEDRON LETT, V56, P5811, DOI 10.1016/j.tetlet.2015.09.020; Rodriguez AR, 2015, TETRAHEDRON LETT, V56, P3936, DOI 10.1016/j.tetlet.2015.04.131; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; WASSERMAN SI, 1994, AM J RESP CRIT CARE, V150, pS39, DOI 10.1164/ajrccm/150.5_Pt_2.S39; Wasserman SI, 2006, J ALLERGY CLIN IMMUN, V118, P978, DOI 10.1016/j.jaci.2006.08.007; Yokomizo T, 2018, J CLIN INVEST, V128, P2691, DOI 10.1172/JCI97946	34	28	28	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					335	344		10.1016/j.jaci.2019.09.028	http://dx.doi.org/10.1016/j.jaci.2019.09.028			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31622689	Green Accepted, Bronze			2022-12-18	WOS:000505590800037
J	James, B; Milstien, S; Spiegel, S				James, Briana; Milstien, Sheldon; Spiegel, Sarah			ORMDL3 and allergic asthma: From physiology to pathology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; ORM1 (yeast)-like protein 3; unfolded protein response; endoplasmic reticulum stress; ceramide; sphingolipids	UNFOLDED PROTEIN RESPONSE; NOVO CERAMIDE SYNTHESIS; AIRWAY RESPONSIVENESS; EXPRESSION; PALMITOYLTRANSFERASE; STRESS; MODEL	There is a strong genetic component to asthma, and numerous genome-wide association studies have identified ORM1 (yeast)-like protein 3 (ORMDL3) as a gene associated with asthma susceptibility. However, how ORMDL3 contributes to asthma pathogenesis and its physiologic functions is not well understood and a matter of great debate. This rostrum describes recent advances and new insights in understanding of the multifaceted functions of ORMDL3 in patients with allergic asthma. We also suggest a potential unifying paradigm and discuss molecular mechanisms for the pathologic functions of ORMDL3 in asthma related to its evolutionarily conserved role in regulation of sphingolipid homeostasis. Finally, we briefly survey the utility of sphingolipid metabolites as potential biomarkers for allergic asthma.	[James, Briana; Milstien, Sheldon; Spiegel, Sarah] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, POB 980614, Richmond, VA 23298 USA; [James, Briana; Milstien, Sheldon; Spiegel, Sarah] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, POB 980614, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, POB 980614, Richmond, VA 23298 USA.; Spiegel, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, POB 980614, Richmond, VA 23298 USA.	sarah.spiegel@vcuhealth.org			National Institutes of Health [R01AI125433]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI125433] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health Grant R01AI125433 (to S.S.).	Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Cai L, 2016, J LIPID RES, V57, P1412, DOI 10.1194/jlr.M065920; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Carreras-Sureda A, 2013, HUM MOL GENET, V22, P519, DOI 10.1093/hmg/dds450; Chen J, 2018, J ALLERGY CLIN IMMUN, V142, P207, DOI 10.1016/j.jaci.2017.08.015; Choi S, 2018, FASEB J, V32, P5724, DOI 10.1096/fj.201800141R; Dang J, 2017, J IMMUNOL, V199, P1647, DOI 10.4049/jimmunol.1602124; Davis DL, 2019, J BIOL CHEM, V294, P5146, DOI 10.1074/jbc.RA118.007291; Epstein S, 2012, J LIPID RES, V53, P412, DOI 10.1194/jlr.M022186; Goldfinger M, 2009, J IMMUNOL, V182, P7038, DOI 10.4049/jimmunol.0802990; Gupta SD, 2015, J BIOL CHEM, V290, P90, DOI 10.1074/jbc.M114.588236; Ha SG, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3479; Kiefer K, 2015, J BIOL CHEM, V290, P2822, DOI 10.1074/jbc.M114.595116; Kothari PH, 2018, J ALLERGY CLIN IMMUN, V141, P2282, DOI 10.1016/j.jaci.2017.11.057; Liu M, 2012, J CELL SCI, V125, P2428, DOI 10.1242/jcs.100578; Liu YP, 2017, CLIN EXP ALLERGY, V47, P371, DOI 10.1111/cea.12903; Loser S, 2017, J ALLERGY CLIN IMMUN, V139, P1496, DOI 10.1016/j.jaci.2016.07.033; Maekawa M, 2016, SCI REP-UK, V6, DOI 10.1038/srep35762; Masini E, 2008, J PHARMACOL EXP THER, V324, P548, DOI 10.1124/jpet.107.131565; Miller M, 2017, J IMMUNOL, V198, P3017, DOI 10.4049/jimmunol.1601848; Miller M, 2017, J ALLERGY CLIN IMMUN, V139, P1373, DOI 10.1016/j.jaci.2016.08.053; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Mousley CJ, 2008, MOL BIOL CELL, V19, P4785, DOI 10.1091/mbc.E08-04-0426; Oyeniran C, 2015, J ALLERGY CLIN IMMUN, V136, P1035, DOI 10.1016/j.jaci.2015.02.031; Perzanowski MS, 2017, AM J RESP CRIT CARE, V195, P1068, DOI 10.1164/rccm.201609-1884LE; Petrache I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062968; Price MM, 2013, J ALLERGY CLIN IMMUN, V131, P501, DOI 10.1016/j.jaci.2012.07.014; Reinke SN, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01740-2016; Schedel M, 2015, J ALLERGY CLIN IMMUN, V136, P893, DOI 10.1016/j.jaci.2015.03.014; Schmiedel BJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13426; Senkal CE, 2011, J BIOL CHEM, V286, P42446, DOI 10.1074/jbc.M111.287383; Shimobayashi M, 2013, MOL BIOL CELL, V24, P870, DOI 10.1091/mbc.E12-10-0753; Siow D, 2015, J LIPID RES, V56, P898, DOI 10.1194/jlr.M057539; Spassieva SD, 2009, BIOCHEM J, V424, P273, DOI 10.1042/BJ20090699; Stein MM, 2018, J ALLERGY CLIN IMMUN, V142, P749, DOI 10.1016/j.jaci.2017.12.974; Toncheva AA, 2015, ALLERGY, V70, P1288, DOI 10.1111/all.12652; Trinh HKT, 2016, SCI REP-UK, V6, DOI 10.1038/srep36599; Wang S, 2015, P NATL ACAD SCI USA, V112, P3728, DOI 10.1073/pnas.1422455112; Worgall TS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005765; Zhakupova A, 2016, FASEB J, V30, P4289, DOI 10.1096/fj.201600639R; Zhang YM, 2019, AM J RESP CRIT CARE, V199, P478, DOI 10.1164/rccm.201803-0438OC	43	28	28	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					634	640		10.1016/j.jaci.2019.07.023	http://dx.doi.org/10.1016/j.jaci.2019.07.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	31376405	Green Accepted, Bronze			2022-12-18	WOS:000485222300002
J	Biagini Myers, JM; Schauberger, E; He, H; Martin, LJ; Kroner, J; Hill, GM; Ryan, PH; LeMasters, GK; Bernstein, DI; Lockey, JE; Arshad, SH; Kurukulaaratchy, R; Hershey, GKK				Biagini Myers, Jocelyn M.; Schauberger, Eric; He, Hua; Martin, Lisa J.; Kroner, John; Hill, Gregory M.; Ryan, Patrick H.; LeMasters, Grace K.; Bernstein, David I.; Lockey, James E.; Arshad, S. Hasan; Kurukulaaratchy, Ramesh; Hershey, Gurjit K. Khurana			A Pediatric Asthma Risk Score to better predict asthma development in young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma prediction score; persistent wheezing; sensitization; childhood asthma	EXHALED NITRIC-OXIDE; PRESCHOOL AGE; INDEX; BIOMARKERS; EXPOSURE; INFANTS; DISEASE; WHEEZE; LIFE	Background: Asthma phenotypes are currently not amenable to primary prevention or early intervention because their natural history cannot be reliably predicted. Clinicians remain reliant on poorly predictive asthma outcome tools because of a lack of better alternatives. Objective: We sought to develop a quantitative personalized tool to predict asthma development in young children. Methods: Data from the Cincinnati Childhood Allergy and Air Pollution Study (n = 762) birth cohort were used to identify factors that predicted asthma development. The Pediatric Asthma Risk Score (PARS) was constructed by integrating demographic and clinical data. The sensitivity and specificity of PARS were compared with those of the Asthma Predictive Index (API) and replicated in the Isle of Wight birth cohort. Results: PARS reliably predicted asthma development in the Cincinnati Childhood Allergy and Air Pollution Study (sensitivity = 0.68, specificity = 0.77). Although both the PARS and API predicted asthma in high-risk children, the PARS had improved ability to predict asthma in children with mild-tomoderate asthma risk. In addition to parental asthma, eczema, and wheezing apart from colds, variables that predicted asthma in the PARS included early wheezing (odds ratio [OR], 2.88; 95% CI, 1.52-5.37), sensitization to 2 or more food allergens and/or aeroallergens (OR, 2.44; 95% CI, 1.49-4.05), and African American race (OR, 2.04; 95% CI, 1.19-3.47). The PARS was replicated in the Isle of Wight birth cohort (sensitivity = 0.67, specificity = 0.79), demonstrating that it is a robust, valid, and generalizable asthma predictive tool. Conclusions: The PARS performed better than the API in children with mild-to-moderate asthma. This is significant because these children are the most common and most difficult to predict and might be the most amenable to prevention strategies.	[Biagini Myers, Jocelyn M.; Schauberger, Eric; Kroner, John; Hill, Gregory M.; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA; [Schauberger, Eric] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [He, Hua; Martin, Lisa J.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA; [Ryan, Patrick H.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Biagini Myers, Jocelyn M.; Martin, Lisa J.; Ryan, Patrick H.; Hershey, Gurjit K. Khurana] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA; [LeMasters, Grace K.; Bernstein, David I.; Lockey, James E.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA; [Bernstein, David I.] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA; [Arshad, S. Hasan; Kurukulaaratchy, Ramesh] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org	Martin, Lisa/E-2425-2016; Hill, Greg/AAM-2738-2020; Schauberger, Eric/A-9213-2008; Ryan, Patrick/HDO-1133-2022	Martin, Lisa/0000-0001-8702-9946; Hill, Greg/0000-0002-3238-7057; Schauberger, Eric/0000-0001-5069-7190; Kurukulaaratchy, Ramesh/0000-0002-1588-2400	National Institutes of Health [2U19AI70235, R01ES011170, R01HL082925, T32ES010957, R01ES019890]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060515, U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES019890, R01ES011170, T32ES010957] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants 2U19AI70235 (to G.K.K.H., J.M.B.M., and L.J.M.), R01ES011170 (to G.K.L., G.K.K.H., D.I.B., and J.E.L.), R01HL082925 (to S.H.A. and R.K.), T32ES010957 (to E.S.), and R01ES019890 (to P.H.R.).	Akinbami Lara J, 2012, NCHS Data Brief, P1; Amin P, 2014, J ALLER CL IMM-PRACT, V2, P709, DOI 10.1016/j.jaip.2014.08.009; Arshad SH, 2018, INT J EPIDEMIOL, V47, P1043, DOI 10.1093/ije/dyy023; Ater D, 2014, PEDIATR PULM, V49, P952, DOI 10.1002/ppul.22926; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894, DOI 10.1164/ajrccm.154.4.8887582; Bloemen K, 2010, BIOMARKERS, V15, P583, DOI 10.3109/1354750X.2010.504307; Burbach GJ, 2009, ALLERGY, V64, P1507, DOI 10.1111/j.1398-9995.2009.02089.x; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Chang TS, 2013, J ALLER CL IMM-PRACT, V1, P152, DOI 10.1016/j.jaip.2012.10.008; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Balinotti JE, 2013, ARCH ARGENT PEDIATR, V111, P191, DOI [10.5546/aap.2013.191, 10.5546/aap.2013.eng.191]; Epstein TG, 2012, ANN ALLERG ASTHMA IM, V108, P145, DOI 10.1016/j.anai.2012.01.004; Flores C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026807; Guilbert TW, 2010, J ALLERGY CLIN IMMUN, V126, P417, DOI 10.1016/j.jaci.2010.06.024; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Iossifova YY, 2009, ANN ALLERG ASTHMA IM, V102, P131, DOI 10.1016/S1081-1206(10)60243-8; Kim KW, 2006, J KOREAN MED SCI, V21, P1012, DOI 10.3346/jkms.2006.21.6.1012; Klaassen EMM, 2015, AM J RESP CRIT CARE, V191, P201, DOI 10.1164/rccm.201408-1537OC; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Luo G, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0224-9; Mikati I, 2018, AM J PUBLIC HEALTH, V108, P480, DOI [10.2105/AJPH.2017.304297, 10.2105/ajph.2017.304297]; National Asthma Education and Prevention Program (NAEPP) NHLBI, 2007, NATL HEART LUNG BLOO, P213; Newman NC, 2013, ENVIRON HEALTH PERSP, V121, P731, DOI 10.1289/ehp.1205555; Palmer LJ, 2000, GENOME RES, V10, P1280, DOI 10.1101/gr.143400; R Development Core Team, 2007, R LANG ENV STAT COMP; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007; Semega JL, 2017, US CENSUS BUREAU CUR; Singer F, 2013, ALLERGY, V68, P531, DOI 10.1111/all.12127; Thakur N, 2017, CHEST, V151, P804, DOI 10.1016/j.chest.2016.11.027; Urban League of Greater Southwestern Ohio, 2015, STAT BLACK CINC 2015; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2; Wi CI, 2018, ALLERGY, V73, P1276, DOI 10.1111/all.13403; 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI DOI 10.1016/J.JACI.2009.06.045	40	28	28	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1803	+		10.1016/j.jaci.2018.09.037	http://dx.doi.org/10.1016/j.jaci.2018.09.037			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30554722	Green Accepted			2022-12-18	WOS:000466784600016
J	Scott, O; Roifman, CM				Scott, Ori; Roifman, Chaim M.			NF-kappa B pathway and the Goldilocks principle: Lessons from human disorders of immunity and inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NF-kappa B; canonical; noncanonical; signaling; immune regulation	ANHIDROTIC ECTODERMAL DYSPLASIA; STEM-CELL TRANSPLANTATION; OF-FUNCTION MUTATIONS; PYOGENIC BACTERIAL-INFECTIONS; INCONTINENTIA PIGMENTI; COMBINED IMMUNODEFICIENCY; NONSENSE MUTATION; SIGNALING PATHWAY; INNATE IMMUNITY; ALPHA MUTATION	Nuclear factor k-light-chain-enhancer of activated B cells (NF-kappa B) signaling pathways play a key role in various cell processes related to host immunity. The last few years have seen an explosion of disorders associated with NF-kappa B components from core members of the canonical and noncanonical cascades to adaptor protein and ubiquitination-related enzymes. Disease phenotypes have extended beyond susceptibility to infections and include autoimmunity, lymphoproliferation, atopy, and inflammation. Concurrently, studies are unveiling a tightly regulated system marked by extensive cross-talk between the canonical and noncanonical pathways, as well as among the NF-kappa B and other signaling pathways. As the rate of discovery in the realm of NF-kappa B defects accelerates, this review presents a timely summary of major known defects causing human disease, as well as diagnostic, therapeutic, and research challenges and opportunities.	[Scott, Ori; Roifman, Chaim M.] Hosp Sick Children, Dept Pediat, Div Immunol & Allergy, Toronto, ON, Canada; [Scott, Ori; Roifman, Chaim M.] Univ Toronto, Toronto, ON, Canada; [Roifman, Chaim M.] Hosp Sick Children, Canadian Ctr Primary Immunodeficiency, Toronto, ON, Canada; [Roifman, Chaim M.] Hosp Sick Children, Jeffrey Modell Res Lab Diag Primary Immunodeficie, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Roifman, CM (corresponding author), Hosp Sick Children, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca		Scott, Ori/0000-0002-3470-5725				Altin JA, 2011, J ALLERGY CLIN IMMUN, V127, P1277, DOI 10.1016/j.jaci.2010.12.1081; Arjunaraja S, 2015, CURR OPIN ALLERGY CL, V15, P533, DOI 10.1097/ACI.0000000000000217; Badran YR, 2017, J EXP MED, V214, P1937, DOI 10.1084/jem.20160724; Berlin AL, 2002, J AM ACAD DERMATOL, V47, P169, DOI 10.1067/mjd.2002.125949; Boisson B, 2015, J EXP MED, V212, P939, DOI 10.1084/jem.20141130; Boztug H, 2016, J CLIN IMMUNOL, V36, P533, DOI 10.1007/s10875-016-0306-1; Brohl AS, 2015, J CLIN IMMUNOL, V35, P32, DOI 10.1007/s10875-014-0106-4; Brue T, 2014, BMC MED GENET, V15, DOI 10.1186/s12881-014-0139-9; Cepika AM, 2018, J ALLERGY CLIN IMMUN, V142, P1679, DOI 10.1016/j.jaci.2018.10.026; Charbit-Henrion F, 2017, J PEDIATR GASTR NUTR, V64, P378, DOI 10.1097/MPG.0000000000001262; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Courtois G, 2005, CELL MOL LIFE SCI, V62, P1682, DOI 10.1007/s00018-005-5031-5; Cunningham-Rundles C, 2010, BLOOD, V116, P7, DOI 10.1182/blood-2010-01-254417; Dadi H, 2018, J ALLERGY CLIN IMMUN, V141, P1818, DOI 10.1016/j.jaci.2017.06.047; Damgaard RB, 2016, CELL, V166, P1215, DOI 10.1016/j.cell.2016.07.019; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dogbevia GK, 2017, ANN NEUROL, V82, P93, DOI 10.1002/ana.24981; Dubois SM, 2014, BLOOD, V123, P2199, DOI 10.1182/blood-2013-05-504019; Duncan CJA, 2018, ANN RHEUM DIS, V77, P783, DOI 10.1136/annrheumdis-2016-210944; Dupuis-Girod S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e97; Dupuis-Girod S, 2006, PEDIATRICS, V118, pE205, DOI 10.1542/peds.2005-2661; Fish JD, 2009, BONE MARROW TRANSPL, V43, P217, DOI 10.1038/bmt.2008.308; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; Fusco F, 2008, HUM MUTAT, V29, P595, DOI 10.1002/humu.20739; Fusco F, 2015, INT REV IMMUNOL, V34, P445, DOI 10.3109/08830185.2015.1055331; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Granados EL, 2008, HUM MUTAT, V29, P861, DOI 10.1002/humu.20740; Greil J, 2013, J ALLERGY CLIN IMMUN, V131, P1376, DOI 10.1016/j.jaci.2013.02.012; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Jabara HH, 2013, J ALLERGY CLIN IMMUN, V132, P151, DOI 10.1016/j.jaci.2013.04.047; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Janssen R, 2004, J EXP MED, V200, P559, DOI 10.1084/jem.20040773; Kajiura F, 2004, J IMMUNOL, V172, P2067, DOI 10.4049/jimmunol.172.4.2067; Kaustio M, 2017, J ALLERGY CLIN IMMUN, V140, P782, DOI 10.1016/j.jaci.2016.10.054; Kinoshita D, 2006, J IMMUNOL, V176, P3995, DOI 10.4049/jimmunol.176.7.3995; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Ku CL, 2007, J MED GENET, V44, P16, DOI 10.1136/jmg.2006.044446; Kuehn HS, 2017, BLOOD, V130, P1553, DOI 10.1182/blood-2017-05-782177; Lal RA, 2017, J CLIN ENDOCR METAB, V102, P2127, DOI 10.1210/jc.2017-00341; Lee CE, 2014, BLOOD, V124, P2964, DOI 10.1182/blood-2014-06-578542; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Legarda-Addison D, 2007, J IMMUNOL, V178, P7767, DOI 10.4049/jimmunol.178.12.7767; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Lindsley AW, 2014, J CLIN IMMUNOL, V34, P910, DOI 10.1007/s10875-014-0095-3; Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022; Lupino E, 2012, J IMMUNOL, V188, P2545, DOI 10.4049/jimmunol.1102938; Ma CA, 2017, NAT GENET, V49, P1192, DOI 10.1038/ng.3898; Ma CA, 2011, HUM MUTAT, V32, P318, DOI 10.1002/humu.21439; Manthiram K, 2017, NAT IMMUNOL, V18, P832, DOI 10.1038/ni.3777; Torres JM, 2014, J CLIN INVEST, V124, P5239, DOI 10.1172/JCI77493; McDonald DR, 2007, J ALLERGY CLIN IMMUN, V120, P900, DOI 10.1016/j.jaci.2007.08.035; Merico D, 2015, LYMPHOSIGN J, V2, P147, DOI DOI 10.14785/LPSN-2015-0005; Miot C, 2017, BLOOD, V130, P1456, DOI 10.1182/blood-2017-03-771600; Miraghazadeh B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00613; Mousallem T, 2014, BLOOD, V124, P2046, DOI 10.1182/blood-2014-04-571265; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Nielsen C, 2014, J CLIN IMMUNOL, V34, P916, DOI 10.1007/s10875-014-0097-1; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Onder L, 2015, EUR J IMMUNOL, V45, P2218, DOI 10.1002/eji.201545677; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Ovadia A, 2017, J ALLERGY CLIN IMMUN, V140, P1199, DOI 10.1016/j.jaci.2017.05.007; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11; Punwani D, 2015, J CLIN IMMUNOL, V35, P135, DOI 10.1007/s10875-014-0125-1; Rivkin E, 2013, NATURE, V498, P318, DOI 10.1038/nature12296; Rozmus J, 2016, CLIN IMMUNOL, V168, P1, DOI 10.1016/j.clim.2016.04.011; Scarselli A, 2015, J CLIN IMMUNOL, V35, P373, DOI 10.1007/s10875-015-0154-4; Schimke LF, 2013, J CLIN IMMUNOL, V33, P1088, DOI 10.1007/s10875-013-9906-1; Schipp C, 2016, HAEMATOLOGICA, V101, pE392, DOI 10.3324/haematol.2016.145136; Schlechter N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01624; Scott O, 2017, LYMPHOSIGN J, V4, P45, DOI 10.14785/lymphosign-2016-0016; Sharfe N, 2015, J AUTOIMMUN, V65, P90, DOI 10.1016/j.jaut.2015.09.001; Shim WH, 2017, ADV EDUC TECHNOL INS, V209, P1, DOI [DOI 10.4018/978-1-5225-2000-9.CH001, DOI 10.4018/978-1-5225-2000-9.ch001]; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Snow AL, 2012, J EXP MED, V209, P2247, DOI 10.1084/jem.20120831; Stepensky P, 2013, J ALLERGY CLIN IMMUN, V131, P477, DOI 10.1016/j.jaci.2012.11.050; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Turvey SE, 2014, J ALLERGY CLIN IMMUN, V134, P276, DOI 10.1016/j.jaci.2014.06.015; Vasanthakumar A, 2017, CELL REP, V20, P2906, DOI 10.1016/j.celrep.2017.08.068; Vincent Feng-Sheng Shih, 2011, Cell Research, V21, P86; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Willmann KL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6360; Yoshioka T, 2013, J CLIN IMMUNOL, V33, P1165, DOI 10.1007/s10875-013-9924-z; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459; Zhu MZ, 2006, J CLIN INVEST, V116, P2964, DOI 10.1172/JCI28326; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914; 2012, NAT IMMUNOL, V13, P1178, DOI DOI 10.1038/NI.2457	91	28	27	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1688	1701		10.1016/j.jaci.2019.03.016	http://dx.doi.org/10.1016/j.jaci.2019.03.016			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30940520	Bronze			2022-12-18	WOS:000466784600003
J	Morgan, BW; Grigsby, MR; Siddharthan, T; Chowdhury, M; Rubinstein, A; Gutierrez, L; Irazola, V; Miranda, JJ; Bernabe-Ortiz, A; Alam, D; Wise, RA; Checkley, W				Morgan, Brooks W.; Grigsby, Matthew R.; Siddharthan, Trishul; Chowdhury, Muhammad; Rubinstein, Adolfo; Gutierrez, Laura; Irazola, Vilma; Miranda, J. Jaime; Bernabe-Ortiz, Antonio; Alam, Dewan; Wise, Robert A.; Checkley, William			Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic obstructive pulmonary disease; COPD; overlap; asthma-COPD overlap; ACO; epidemiology; risk factors; health outcomes; spirometry; population-based	COPD OVERLAP; CLINICAL-FEATURES; REFERENCE VALUES; BIOMASS SMOKE; GLOBAL BURDEN; LUNG; INFLAMMATION; PREVALENCE; HEALTH; PATHOGENESIS	Background: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) represents the confluence of bronchial airway hyperreactivity and chronic airflow limitation and has been described as leading to worse lung function and quality of life than found with either singular disease process. Objective: We aimed to describe the prevalence and risk factors for ACO among adults across 6 low-and middle-income countries (LMICs). Methods: We compiled cross-sectional data for 11,923 participants aged 35 to 92 years from 4 population-based studies in 12 settings. We defined COPD as postbronchodilator FEV1/forced vital capacity ratio below the lower limit of normal, asthma as wheeze or medication use in 12 months or selfreported physician diagnosis, and ACO as having both. Results: The prevalence of ACO was 3.8% (0% in rural Puno, Peru, to 7.8% in Matlab, Bangladesh). The odds of having ACO were higher with household exposure to biomass fuel smoke (odds ratio [OR], 1.48; 95% CI, 0.98-2.23), smoking tobacco (OR, 1.28 per 10 pack-years; 95% CI, 1.22-1.34), and having primary or less education (OR, 1.35; 95% CI, 1.07-1.70) as compared to nonobstructed nonasthma individuals. ACO was associated with severe obstruction (FEV1 %, < 50; 31.6% of ACO vs 10.9% of COPD alone) and severe spirometric deficits compared with participants with asthma (21.61 z scores FEV1; 95% CI, 21.48 to 21.75) or COPD alone (20.94 z scores; 95% CI, 20.78 to 21.10). Conclusions: ACO may be as prevalent and more severe in LMICs than has been reported in high-income settings.Exposure to biomass fuel smoke may be an overlooked risk factor, and we favor diagnostic criteria for ACO that include environmental exposures common to LMICs.	[Morgan, Brooks W.; Grigsby, Matthew R.; Siddharthan, Trishul; Wise, Robert A.; Checkley, William] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1830 East Monument St,Rm 555, Baltimore, MD 21287 USA; [Morgan, Brooks W.; Grigsby, Matthew R.; Siddharthan, Trishul; Wise, Robert A.; Checkley, William] Johns Hopkins Univ, Sch Med, Ctr Global Noncommunicable Dis, Baltimore, MD USA; [Chowdhury, Muhammad] Icddr B, Noncommunicable Dis Hlth Syst & Populat Studies D, Dhaka, Bangladesh; [Rubinstein, Adolfo; Gutierrez, Laura; Irazola, Vilma] Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, Argentina; [Miranda, J. Jaime; Bernabe-Ortiz, Antonio] Univ Peruana Cayetano Heredia, Sch Med, CRONICAS Ctr Excellence Chron Dis, Lima, Peru; [Miranda, J. Jaime] Univ Peruana Cayetano Heredia, Sch Med, Dept Med, Lima, Peru; [Alam, Dewan] York Univ, Fac Hlth, Sch Kinesiol & Hlth Sci, Toronto, ON, Canada	Johns Hopkins University; Johns Hopkins University; International Centre for Diarrhoeal Disease Research (ICDDR); Universidad Peruana Cayetano Heredia; Universidad Peruana Cayetano Heredia; York University - Canada	Checkley, W (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1830 East Monument St,Rm 555, Baltimore, MD 21287 USA.	wcheckl1@jhmi.edu	Siddharthan, Trishul/ABI-7593-2020	Siddharthan, Trishul/0000-0001-9914-1839; Wise, Robert/0000-0002-8353-2349; Checkley, William/0000-0003-1106-8812; Bernabe-Ortiz, Antonio/0000-0002-6834-1376	National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) in the United States [268200900029C]; NHLBI [HHSN268200900033C]; Fogarty International Center [5R25TW009340]; COPD Discovery Award from Johns Hopkins University; NIH [UM1HL134590]; National Research Service Award through the National Institute of Environmental Health Sciences of the NIH [1F32ES028577]; NIH Office of the Director, Fogarty International Center; NHLBI through the International Clinical Research Fellows Program at Vanderbilt University [R24 TW007988]; American Relief and Recovery Act; FOGARTY INTERNATIONAL CENTER [D43TW009340, R25TW009340, D43TW011401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [UM1HL134590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES028577] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) in the United States; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); COPD Discovery Award from Johns Hopkins University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Research Service Award through the National Institute of Environmental Health Sciences of the NIH; NIH Office of the Director, Fogarty International Center; NHLBI through the International Clinical Research Fellows Program at Vanderbilt University; American Relief and Recovery Act; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The Pulmonary Risk in South America Study was sponsored and funded by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH) in the United States (contract no. 268200900029C). The CRONICAS study was supported by the NHLBI (contract no. HHSN268200900033C). The Lung Function in Nakaseke and Kampala study was supported in part by the Fogarty International Center (grant no. 5R25TW009340) and by a COPD Discovery Award from Johns Hopkins University. W.C. is supported in part by the NIH (grant no. UM1HL134590). T.S. was supported by a National Research Service Award through the National Institute of Environmental Health Sciences of the NIH (grant no. 1F32ES028577). A.R. was supported by the NIH Office of the Director, Fogarty International Center, and the NHLBI through the International Clinical Research Fellows Program at Vanderbilt University (grant no. R24 TW007988) and the American Relief and Recovery Act.	Abramson MJ, 2014, INT J CHRONIC OBSTR, V9, P945, DOI 10.2147/COPD.S46761; Alam DS, 2015, COPD, V12, P658, DOI 10.3109/15412555.2015.1041101; Barrecheguren M, 2015, INT J CHRONIC OBSTR, V10, P1745, DOI 10.2147/COPD.S87025; Baumann LM, 2011, J ALLERGY CLIN IMMUN, V127, P875, DOI 10.1016/j.jaci.2010.11.031; Bonten TN, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02008-2016; Bostoen K, 2006, INT J EPIDEMIOL, V35, P751, DOI 10.1093/ije/dyl019; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Brzostek D, 2014, POSTEP DERM ALERGOL, V31, P372, DOI 10.5114/pdia.2014.47120; Burney P, 1996, EUR RESPIR J, V9, P687; CAREY V, 1993, BIOMETRIKA, V80, P517, DOI 10.1093/biomet/80.3.517; Cataldo D, 2017, INT J CHRONIC OBSTR, V12, DOI 10.2147/COPD.S124459; Chan-Yeung M, 2004, INT J TUBERC LUNG D, V8, P2; Chao LW, 2012, J DEV ECON, V98, P94, DOI 10.1016/j.jdeveco.2011.08.007; Chung JW, 2014, INT J CHRONIC OBSTR, V9, P795, DOI 10.2147/COPD.S61093; Chung WS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000755; de Marco R, 2015, EUR RESPIR J, V46, P671, DOI 10.1183/09031936.00008615; de Marco R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062985; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; GINA/GOLD, 2015, DIAGN DIS CHRON AIRF; Global Asthma Network, 2014, GLOB ASTHM REP; Global Initiative for Chronic Obstructive Lung Disease Inc., 2017, POCK GUID COPD DIAGN; Global Strategy for Asthma Management and Prevention, 2017, GLOB IN ASTHM; Golpe R, 2017, INT J CHRONIC OBSTR, V12, P2639, DOI 10.2147/COPD.S141068; Guarnieri MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088455; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hardin M, 2014, EUR RESPIR J, V44, P341, DOI 10.1183/09031936.00216013; Hardin M, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-127; Henriksen AH, 2018, COPD, V15, P27, DOI 10.1080/15412555.2017.1408580; HOGG JC, 1993, J ALLERGY CLIN IMMUN, V92, P1, DOI 10.1016/0091-6749(93)90029-F; Hu GP, 2010, CHEST, V138, P20, DOI 10.1378/chest.08-2114; Kauppi P, 2011, J ASTHMA, V48, P279, DOI 10.3109/02770903.2011.555576; Leung JM, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3772; MacNee W, 2006, BRIT MED J, V332, P1202, DOI 10.1136/bmj.332.7551.1202; Menezes AMB, 2014, CHEST, V145, P297, DOI 10.1378/chest.13-0622; Milanese M, 2014, RESP MED, V108, P1091, DOI 10.1016/j.rmed.2014.05.016; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Viladrich IM, 2016, ARCH BRONCONEUMOL, V52, P36, DOI 10.1016/j.arbres.2015.04.016; Miranda JJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000610; Miravitlles M, 2013, RESP MED, V107, P1053, DOI 10.1016/j.rmed.2013.03.007; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Orie NGM, 1961, BRONCHITIS INT S; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Postma DS, 2015, EUR RESPIR J, V46, P587, DOI 10.1183/13993003.00810-2015; Putcha N, 2016, IMMUNOL ALLERGY CLIN, V36, P515, DOI 10.1016/j.iac.2016.03.003; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Robinson CL, 2011, THORAX, V66, P1051, DOI 10.1136/thx.2011.158956; Rubinstein AL, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-34; Shaya FT, 2008, CHEST, V134, P14, DOI 10.1378/chest.07-2317; SIDDHARTHAN T, 2017, AM J RESP CRIT CARE, V195; Siddharthan T, 2018, AM J RESP CRIT CARE, V197, P611, DOI 10.1164/rccm.201709-1861OC; Slats A, 2016, THER ADV RESPIR DIS, V10, P57, DOI 10.1177/1753465815617082; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Sussan TE, 2014, AM J RESP CELL MOL, V50, P538, DOI 10.1165/rcmb.2013-0201OC; Tamada T, 2015, INT J CHRONIC OBSTR, V10, P2169, DOI 10.2147/COPD.S88274; Travers J, 2007, RESP MED, V101, P1313, DOI 10.1016/j.rmed.2006.10.011; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Wjst M, 2007, PLOS MED, V4, P203, DOI 10.1371/journal.pmed.0040072; Woodruff PG, 2017, AM J RESP CRIT CARE, V196, P375, DOI 10.1164/rccm.201705-0973WS; Zeki Amir A, 2011, J Allergy (Cairo), V2011, P861926, DOI 10.1155/2011/861926	62	28	28	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1598	1606		10.1016/j.jaci.2018.06.052	http://dx.doi.org/10.1016/j.jaci.2018.06.052			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30291842	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000463348900033
J	Ferreira, MAR; Vonk, JM; Baurecht, H; Marenholz, I; Tian, C; Hoffman, JD; Helmer, Q; Tillander, A; Ullemar, V; Lu, Y; Ruschendorf, F; Hinds, DA; Hubner, N; Weidinger, S; Magnusson, PKE; Jorgenson, E; Lee, YA; Boomsma, DI; Karlsson, R; Almqvist, C; Koppelman, GH; Paternoster, L				Ferreira, Manuel A. R.; Vonk, Judith M.; Baurecht, Hansjorg; Marenholz, Ingo; Tian, Chao; Hoffman, Joshua D.; Helmer, Quinta; Tillander, Annika; Ullemar, Vilhelmina; Lu, Yi; Ruschendorf, Franz; Hinds, David A.; Hubner, Norbert; Weidinger, Stephan; Magnusson, Patrik K. E.; Jorgenson, Eric; Lee, Young-Ae; Boomsma, Dorret I.; Karlsson, Robert; Almqvist, Catarina; Koppelman, Gerard H.; Paternoster, Lavinia		23 Me Res Team; Collaborators SHARE Study	Eleven loci with new reproducible genetic associations with allergic disease risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; atopic dermatitis; atopy; genome-wide association study; transcriptome	B-CELL DEVELOPMENT; HAY-FEVER; ASTHMA; IL-27; TRANSCRIPTOME; EXPRESSION; RECEPTOR; VARIANTS; LAT; HERITABILITY	Background: A recent genome-wide association study (GWAS) identified 99 loci that contain genetic risk variants shared between asthma, hay fever, and eczema. Many more risk loci shared between these common allergic diseases remain to be discovered, which could point to new therapeutic opportunities. Objective: We sought to identify novel risk loci shared between asthma, hay fever, and eczema by applying a gene-based test of association to results from a published GWAS that included data from 360,838 subjects. Methods: We used approximate conditional analysis to adjust the results from the published GWAS for the effects of the top risk variants identified in that study. We then analyzed the adjusted GWAS results with the EUGENE gene-based approach, which combines evidence for association with disease risk across regulatory variants identified in different tissues. Novel gene-based associations were followed up in an independent sample of 233,898 subjects from the UK Biobank study. Results: Of the 19,432 genes tested, 30 had a significant gene-based association at a Bonferroni-corrected P value of 2.5 x 10(-6). Of these, 20 were also significantly associated (P < .05/30 = .0016) with disease risk in the replication sample, including 19 that were located in 11 loci not reported to contain allergy risk variants in previous GWASs. Among these were 9 genes with a known function that is directly relevant to allergic disease: FOSL2, VPRBP, IPCEF1, PRR5L, NCF4, APOBR, IL27, ATXN2L, and LAT. For 4 genes (eg, ATXN2L), a genetically determined decrease in gene expression was associated with decreased allergy risk, and therefore drugs that inhibit gene expression or function are predicted to ameliorate disease symptoms. The opposite directional effect was observed for 14 genes, including IL27, a cytokine known to suppress T(H)2 responses. Conclusion: Using a gene-based approach, we identified 11 risk loci for allergic disease that were not reported in previous GWASs. Functional studies that investigate the contribution of the 19 associated genes to the pathophysiology of allergic disease and assess their therapeutic potential are warranted.	[Ferreira, Manuel A. R.] QIMR Berghofer Med Res Inst, Genet & Computat Biol, Brisbane, Qld, Australia; [Vonk, Judith M.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Epidemiol, Groningen, Netherlands; [Baurecht, Hansjorg; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Allergol & Venereol, Campus Kiel, Amsterdam, Netherlands; [Marenholz, Ingo; Ruschendorf, Franz; Hubner, Norbert; Lee, Young-Ae] Max Delbruck Ctr MDC Mol Med, Berlin, Germany; [Marenholz, Ingo; Lee, Young-Ae] Univ Med Berlin, Expt & Clin Res Ctr Charite, Clin Pediat Allergy, Berlin, Germany; [Tian, Chao; Hinds, David A.; 23 Me Res Team] 23andMe Inc, Mountain View, CA USA; [Hoffman, Joshua D.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Helmer, Quinta; Boomsma, Dorret I.] Vrije Univ, Netherlands Twin Register, Dept Biol Psychol, Amsterdam, Netherlands; [Tillander, Annika; Ullemar, Vilhelmina; Lu, Yi; Magnusson, Patrik K. E.; Karlsson, Robert; Almqvist, Catarina] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Tillander, Annika; Ullemar, Vilhelmina; Lu, Yi; Magnusson, Patrik K. E.; Karlsson, Robert; Almqvist, Catarina] Karolinska Inst, Swedish Twin Registry, Stockholm, Sweden; [Jorgenson, Eric] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA; [Almqvist, Catarina] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Pediat Allergy & Pulmonol Unit, Stockholm, Sweden; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands; [Paternoster, Lavinia] Univ Bristol, Sch Social & Community Med, MRC Integrat Epidemiol Unit, Bristol, Avon, England	QIMR Berghofer Medical Research Institute; University of Groningen; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of California System; University of California San Francisco; Vrije Universiteit Amsterdam; Karolinska Institutet; Karolinska Institutet; Kaiser Permanente; Karolinska Institutet; Karolinska University Hospital; University of Groningen; University of Groningen; University of Bristol	Ferreira, MAR (corresponding author), Royal Brisbane Hosp, QIMR Berghofer Med Res Inst, Locked Bag 2000, Herston, Qld 4029, Australia.	manuel.ferreira@qimrberghofer.edu.au	Magnusson, Patrik KE/C-4458-2017; Koppelman, Gerard/AAG-9187-2020; tian, chao/GYD-3462-2022; Boomsma, Dorret I/AAX-4470-2020; Lu, Yi/G-9292-2018	Magnusson, Patrik KE/0000-0002-7315-7899; Koppelman, Gerard/0000-0001-8567-3252; Lu, Yi/0000-0001-9933-3654	UK Biobank Resource [10074]; National Health and Medical Research Council (NHMRC) of Australia [APP1124501]; National Institutes of Health (NIH) [CA112355]; UK MRC [MR/J012165/1, MC_UU_12013]; MRC [MR/J012165/1, MC_UU_12013/1, MC_PC_19009] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R25CA112355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK116738] Funding Source: NIH RePORTER	UK Biobank Resource; National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UK MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research has been conducted using the UK Biobank Resource under Application no. 10074. M.A.R.F. was supported by a Senior Research Fellowship (APP1124501) from the National Health and Medical Research Council (NHMRC) of Australia. J.D.H. was supported by National Institutes of Health (NIH) postdoctoral training grant CA112355. L.P. was funded by a UK MRC fellowship award (MR/J012165/1) and works in a unit funded by the UK MRC (MC_UU_12013). Detailed acknowledgments are provided in the Online Repository in this article's Online Repository at www.jacionline.org.	Aguado E, 2002, SCIENCE, V296, P2036, DOI 10.1126/science.1069057; Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Alves BN, 2014, J IMMUNOL, V192, P3121, DOI 10.4049/jimmunol.1302351; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Bacchelli C, 2017, J ALLERGY CLIN IMMUN, V139, P634, DOI 10.1016/j.jaci.2016.05.036; Bakshi A, 2016, SCI REP-UK, V6, DOI 10.1038/srep32894; Barbeira A, 2016, BIORXIV, DOI [10.1101/045260, DOI 10.1101/045260]; Brown ML, 2000, P NATL ACAD SCI USA, V97, P7488, DOI 10.1073/pnas.120184097; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Bycroft C., 2017, GENOME WIDE GENETIC; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; Crotzer VL, 2012, J IMMUNOL, V189, P3800, DOI 10.4049/jimmunol.1103080; Davis JR, 2016, AM J HUM GENET, V98, P216, DOI 10.1016/j.ajhg.2015.11.021; de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219; Do JS, 2017, P NATL ACAD SCI USA, V114, P10190, DOI 10.1073/pnas.1703100114; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Ellson CD, 2006, J EXP MED, V203, P1927, DOI 10.1084/jem.20052069; Fadista J, 2016, EUR J HUM GENET, V24, P1202, DOI 10.1038/ejhg.2015.269; Fagnani C, 2008, TWIN RES HUM GENET, V11, P121, DOI 10.1375/twin.11.2.121; Ferreira MA, 2017, NAT GENET, V49, P1752, DOI 10.1038/ng.3985; Ferreira MAR, 2017, J ALLERGY CLIN IMMUN, V139, P1148, DOI 10.1016/j.jaci.2016.07.017; Ferreira MAR, 2014, TWIN RES HUM GENET, V17, P505, DOI 10.1017/thg.2014.59; Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367; Gonzalez JR, 2014, AM J HUM GENET, V94, P361, DOI 10.1016/j.ajhg.2014.01.015; Graham GJ, 2012, IMMUNOL LETT, V145, P30, DOI 10.1016/j.imlet.2012.04.004; Guo ZL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10307; Hu RZ, 2014, IMMUNITY, V41, P605, DOI 10.1016/j.immuni.2014.09.015; Jirmo AC, 2016, J IMMUNOL, V197, P4219, DOI 10.4049/jimmunol.1601094; Kassmeier MD, 2012, EMBO J, V31, P945, DOI 10.1038/emboj.2011.455; Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531; Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009; Meunier C, 2002, J BIOL CHEM, V277, P9139, DOI 10.1074/jbc.M105970200; Mifsud B, 2015, NAT GENET, V47, P598, DOI 10.1038/ng.3286; Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903; Muallem G, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006173; Nelson MR, 2015, NAT GENET, V47, P856, DOI 10.1038/ng.3314; Ng SL, 2011, P NATL ACAD SCI USA, V108, P21170, DOI 10.1073/pnas.1119137109; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; Odhams CA, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007071; Oh SJ, 2010, J BIOL CHEM, V285, P14610, DOI 10.1074/jbc.M109.043935; Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570; Pierce BL, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004818; Sadewasser A, 2017, MOL CELL PROTEOMICS, V16, P728, DOI 10.1074/mcp.M116.065904; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Thomsen SF, 2006, INT J TUBERC LUNG D, V10, P1268; Tong T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10379-x; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Ubieta K, 2017, J EXP MED, V214, P2059, DOI 10.1084/jem.20160514; Ullemar V, 2016, ALLERGY, V71, P230, DOI 10.1111/all.12783; van Beijsterveldt CEM, 2007, EUR RESPIR J, V29, P516, DOI 10.1183/09031936.00065706; Venkateswarlu K, 2003, J BIOL CHEM, V278, P43460, DOI 10.1074/jbc.M304078200; Wrann CD, 2012, J CLIN INVEST, V122, P1010, DOI 10.1172/JCI58431; Wurm S, 2015, GENE DEV, V29, P144, DOI 10.1101/gad.249748.114; Xu ZY, 2017, GENETICS, V207, P893, DOI 10.1534/genetics.117.300270; Yang B, 2017, J INVEST DERMATOL, V137, P1166, DOI 10.1016/j.jid.2017.01.010; Yang J, 2012, NAT GENET, V44, P369, DOI 10.1038/ng.2213; Yoshimoto T, 2007, J IMMUNOL, V179, P4415, DOI 10.4049/jimmunol.179.7.4415; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu WQ, 2012, NATURE, V492, P252, DOI 10.1038/nature11603	60	28	28	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					691	699		10.1016/j.jaci.2018.03.012	http://dx.doi.org/10.1016/j.jaci.2018.03.012			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HK2DJ	29679657	Green Published, Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000457718700028
J	Peled, A; Sarig, O; Sun, GP; Samuelov, L; Ma, CA; Zhang, Y; Dimaggio, T; Nelson, CG; Stone, KD; Freeman, AF; Malki, L; Vidal, LS; Chamarthy, LM; Briskin, V; Mohamad, J; Pavlovsky, M; Walter, JE; Milner, JD; Sprecher, E				Peled, Alon; Sarig, Ofer; Sun, Guangping; Samuelov, Liat; Ma, Chi A.; Zhang, Yuan; Dimaggio, Tom; Nelson, Celeste G.; Stone, Kelly D.; Freeman, Alexandra F.; Malki, Liron; Vidal, Lucia Seminario; Chamarthy, Latha M.; Briskin, Valeria; Mohamad, Janan; Pavlovsky, Mor; Walter, Jolan E.; Milner, Joshua D.; Sprecher, Eli			Loss-of-function mutations in caspase recruitment domain-containing protein 14 (CARD14) are associated with a severe variant of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; psoriasis; CARD14; nuclear factor kappa B	NF-KAPPA-B; PITYRIASIS-RUBRA-PILARIS; GENOME-WIDE ASSOCIATION; INNATE IMMUNE-RESPONSE; ANTIMICROBIAL PEPTIDES; SUSCEPTIBILITY LOCI; SKIN; PSORIASIS; DEFICIENCY; EXPRESSION	Background: Atopic dermatitis (AD) is a highly prevalent chronic inflammatory skin disease that is known to be, at least in part, genetically determined. Mutations in caspase recruitment domain-containing protein 14 (CARD14) have been shown to result in various forms of psoriasis and related disorders. Objective: We aimed to identify rare DNA variants conferring a significant risk for AD through genetic and functional studies in a cohort of patients affected with severe AD. Methods: Whole-exome and direct gene sequencing, immunohistochemistry, real-time PCR, ELISA, and functional assays in human keratinocytes were used. Results: In a cohort of patients referred with severe AD, DNA sequencing revealed in 4 patients 2 rare heterozygous missense mutations in the gene encoding CARD14, a major regulator of nuclear factor kappa B (NF-kappa B). A dual luciferase reporter assay demonstrated that both mutations exert a dominant loss-of-function effect and result in decreased NF-kappa B signaling. Accordingly, immunohistochemistry staining showed decreased expression of CARD14 in patients' skin, as well as decreased levels of activated p65, a surrogate marker for NF-kappa B activity. CARD14-deficient or mutant-expressing keratinocytes displayed abnormal secretion of key mediators of innate immunity. Conclusions: Although dominant gain-of-function mutations in CARD14 are associated with psoriasis and related diseases, loss-of-function mutations in the same gene are associated with a severe variant of AD.	[Peled, Alon; Sarig, Ofer; Samuelov, Liat; Malki, Liron; Briskin, Valeria; Mohamad, Janan; Pavlovsky, Mor; Sprecher, Eli] Tel Aviv Med Ctr & Sch Med, Dept Dermatol, Tel Aviv, Israel; [Peled, Alon; Samuelov, Liat; Mohamad, Janan; Sprecher, Eli] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Tel Aviv, Israel; [Sun, Guangping; Ma, Chi A.; Zhang, Yuan; Dimaggio, Tom; Nelson, Celeste G.; Stone, Kelly D.; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, 10 Ctr Dr,Room 11N240A, Bethesda, MD 20892 USA; [Freeman, Alexandra F.] NIAID, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Vidal, Lucia Seminario] Univ S Florida, Dept Dermatol, Tampa Bay, FL USA; [Chamarthy, Latha M.] Johns Hopkins All Childrens Hosp, Univ South Florida, Div Pediat Allergy Immunol, St Petersburg, FL USA; [Chamarthy, Latha M.] Adv Allergy & Asthma Care, Pinellas Pk, FL USA; [Walter, Jolan E.] Massachusetts Gen Hosp Children, Boston, MA USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine	Milner, JD (corresponding author), NIAID, Lab Allerg Dis, NIH, 10 Ctr Dr,Room 11N240A, Bethesda, MD 20892 USA.; Sprecher, E (corresponding author), Tel Aviv Sourasky Med Ctr, Dept Dermatol, 6 Weizmann St, IL-64239 Tel Aviv, Israel.	joshua.milner@nih.gov; elisp@tlvmc.gov.il	Zhang, Yuan/C-7777-2018; Seminario-Vidal, Lucia/AAR-3314-2020	Zhang, Yuan/0000-0001-9932-917X; 	Intramural Research Program of the NIAID, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001098] Funding Source: NIH RePORTER	Intramural Research Program of the NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank our patients and their families for their participation in our studies. Hematoxylin and eosin-stained slides were provided by Dr Ignacio Gonzalez Gomez, Johns Hopkins All Children's Hospital, St Petersburg, Florida. We are thankful to Dr Yinon Ben-Neriah, Hebrew University, Jerusalem, Israel, for the gift of the NF-kappa B reporter and Dr Anne Bowcock, Imperial College London, London, United Kingdom, for the gift of the CARD14 cDNA construct. This work was supported in part by the Intramural Research Program of the NIAID, NIH.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Akiyama M, 2017, J ALLERGY CLIN IMMUN, V140, P1545, DOI 10.1016/j.jaci.2017.05.019; Ashkenazy H, 2010, NUCLEIC ACIDS RES, V38, pW529, DOI 10.1093/nar/gkq399; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; Berki DM, 2015, J INVEST DERMATOL, V135, P2964, DOI 10.1038/jid.2015.288; Biedermann T, 2004, J INVEST DERM SYMP P, V9, P5, DOI 10.1111/j.1087-0024.2004.00829.x; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2017, J ALLERGY CLIN IMMUN, V139, pS65, DOI 10.1016/j.jaci.2017.01.011; Chieosilapatham P, 2017, CLIN EXP IMMUNOL, V190, P155, DOI 10.1111/cei.13013; Clausen ML, 2016, CURR PROBL DERMATOL, V49, P38, DOI 10.1159/000441543; de Jongh GJ, 2005, J INVEST DERMATOL, V125, P1163, DOI 10.1111/j.0022-202X.2005.23935.x; Dhonncha EN, 2017, BRIT J DERMATOL, V177, P1752, DOI 10.1111/bjd.15262; Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Ferreira MA, 2018, J ALLERGY CLIN IMMUN; Fuchs-Telem D, 2012, AM J HUM GENET, V91, P163, DOI 10.1016/j.ajhg.2012.05.010; Girolomoni G, 2017, J EUR ACAD DERMATOL, V31, P1616, DOI 10.1111/jdv.14433; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Harder J, 2010, J INVEST DERMATOL, V130, P1355, DOI 10.1038/jid.2009.432; Hecht M, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S8-S1; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Howes A, 2016, BIOCHEM J, V473, P1759, DOI 10.1042/BCJ20160270; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jiang CY, 2012, IMMUNOL REV, V246, P141, DOI 10.1111/j.1600-065X.2012.01110.x; Jordan CT, 2012, AM J HUM GENET, V90, P784, DOI 10.1016/j.ajhg.2012.03.012; Jordan CT, 2012, AM J HUM GENET, V90, P796, DOI 10.1016/j.ajhg.2012.03.013; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Kiatsurayanon C, 2018, CURR PHARM DESIGN, V24, P1092, DOI 10.2174/1381612824666180327164445; Kim BE, 2007, J ALLERGY CLIN IMMUN, V119, P457, DOI 10.1016/j.jaci.2006.10.005; Kim BE, 2018, ALLERGY ASTHMA IMMUN, V10, P207, DOI 10.4168/aair.2018.10.3.207; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li QL, 2015, J INVEST DERMATOL, V135, P1905, DOI 10.1038/jid.2015.65; Liu YG, 2017, J INVEST DERMATOL, V137, P359, DOI 10.1016/j.jid.2016.09.020; Lyons JJ, 2018, J EXP MED, V215, P1009, DOI 10.1084/jem.20172306; Ma CA, 2017, NAT GENET, V49, P1192, DOI 10.1038/ng.3898; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mellett M, 2018, J INVEST DERMATOL, V138, P2010, DOI 10.1016/j.jid.2018.03.1525; Myles IA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120608; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; Nomura T, 2018, INT IMMUNOL, V30, P419, DOI 10.1093/intimm/dxy015; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Otsuka A, 2017, IMMUNOL REV, V278, P246, DOI 10.1111/imr.12545; Patel S, 2018, BIOMED PHARMACOTHER, V105, P526, DOI 10.1016/j.biopha.2018.05.148; Paternoster L, 2015, NAT GENET, V47, P1449, DOI 10.1038/ng.3424; Peltonen L, 2006, HUM MOL GENET, V15, pR67, DOI 10.1093/hmg/ddl060; Saeki H, 2017, BRIT J DERMATOL, V177, P419, DOI 10.1111/bjd.15493; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Schmitt A, 2016, J INVEST DERMATOL, V136, P788, DOI 10.1016/j.jid.2015.12.027; Schmuth M, 2002, EXP DERMATOL, V11, P135, DOI 10.1034/j.1600-0625.2002.110205.x; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Sidler D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15395; Takahashi T, 2017, DERMATOL CLIN, V35, P39, DOI 10.1016/j.det.2016.07.006; Tanner MJ, 2007, J BIOL CHEM, V282, P17141, DOI 10.1074/jbc.M700169200; Nguyen TT, 2012, J DERMATOL SCI, V68, P63, DOI 10.1016/j.jdermsci.2012.07.010; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang MC, 2018, IMMUNITY, V49, P66, DOI 10.1016/j.immuni.2018.05.012; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X; Weiss D, 2017, J AM ACAD DERMATOL, V76, P91, DOI 10.1016/j.jaad.2016.07.047	64	28	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					173	+		10.1016/j.jaci.2018.09.002	http://dx.doi.org/10.1016/j.jaci.2018.09.002			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30248356	Bronze			2022-12-18	WOS:000454918300023
J	Bacher, P; Scheffold, A				Bacher, Petra; Scheffold, Alexander			The effect of regulatory T cells on tolerance to airborne allergens and allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Aeroantigen; forkhead box P3; regulatory T cell; tolerance; allergy; ignorance	GRASS-POLLEN IMMUNOTHERAPY; TERM CLINICAL-EFFICACY; II PEPTIDE TETRAMERS; X-LINKED SYNDROME; AIRWAY INFLAMMATION; MEMORY-PHENOTYPE; TREG CELLS; INDUCED RHINOCONJUNCTIVITIS; SUBLINGUAL IMMUNOTHERAPY; IMMUNE DYSREGULATION	Forkhead box P3-positive regulatory T (Treg) cells are essential mediators of tolerance against self-antigens and harmless exogenous antigens. Treg cell deficiencies result in multiple autoimmune and allergic syndromes in neonates. How Treg cells affect conventional allergies against aeroantigens, which are restricted to a few specific proteins released from inhaled particles, remains controversial. The hallmarks of antigen-Specific loss of tolerance are allergen-specific T(H)2 cells and IgE. However, difficulties in identifying the rare allergen-specific Treg cells have obscured the cellular basis of tolerance to aeroallergens, which is also a major obstacle for the rational design of novel and more efficient allergen-specific immunotherapies. Recent technological progress allowing characterization of allergen-specific effectors and Treg cells with minimal in vitro manipulation revealed their detailed contribution to tolerance. The data identified inhaled particles as immunodominant Treg cell targets in healthy and allergic subjects. Conversely, the supposed immunodominant major allergens being rapidly released from inhaled particles apparently do not actively induce tolerance but are ignored by the immune system. Here, the partially contradictory data on various allergen-specific T-cell types in healthy subjects, allergic patients, and patients undergoing allergen-specific immunotherapy are discussed and integrated into one model, postulating Treg cell-dependent and Treg cell-independent checkpoints of tolerance and allergy development.	[Bacher, Petra; Scheffold, Alexander] Christian Albrechts Univ Kiel, Inst Immunol, Arnold Heller Str 3, D-24105 Kiel, Germany; [Bacher, Petra] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Bacher, Petra] Univ Klin Schleswig Holstein, Kiel, Germany	University of Kiel; University of Kiel; University of Kiel; Schleswig Holstein University Hospital	Scheffold, A (corresponding author), Christian Albrechts Univ Kiel, Inst Immunol, Arnold Heller Str 3, D-24105 Kiel, Germany.	alexander.scheffold@uksh.de	Bacher, Petra/AAF-1565-2021; Scheffold, Alexander/S-2090-2016	Bacher, Petra/0000-0003-4264-6451; Scheffold, Alexander/0000-0002-0626-343X	Cystic Fibrosis Foundation (USA) [SCHEFF15G0]; German Federal Ministry of Education and Science (BMBF) [ART4Fun Fkz 03ZZ0813A, DIAT Fkz 03ZZ0827A]; German Research Foundation (DFG) [Fkz Sche 670/2-1, Fkz TRR 241/1]; Christiane Herzog Stiftung, Stuttgart, Germany; Mukoviszidose e.V., Bonn; German Cystic Fibrosis Association	Cystic Fibrosis Foundation (USA); German Federal Ministry of Education and Science (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Foundation (DFG)(German Research Foundation (DFG)); Christiane Herzog Stiftung, Stuttgart, Germany; Mukoviszidose e.V., Bonn; German Cystic Fibrosis Association	Supported by grants from the Cystic Fibrosis Foundation (USA; SCHEFF15G0), the German Federal Ministry of Education and Science (BMBF)-Project InfectControl 2020 (ART4Fun Fkz 03ZZ0813A and DIAT Fkz 03ZZ0827A), and the German Research Foundation (DFG, Fkz Sche 670/2-1 and Fkz TRR 241/1 project B07; to A.S.) and by a grant from the Christiane Herzog Stiftung, Stuttgart, Germany, and the Mukoviszidose e.V., Bonn, and the German Cystic Fibrosis Association (to P.B.).	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; Anderson AE, 2009, CLIN EXP ALLERGY, V39, P1693, DOI 10.1111/j.1365-2222.2009.03320.x; Archila LD, 2016, CLIN EXP ALLERGY, V46, P871, DOI 10.1111/cea.12746; Archila LD, 2014, CLIN EXP ALLERGY, V44, P986, DOI 10.1111/cea.12324; Asam C, 2015, ALLERGY, V70, P1201, DOI 10.1111/all.12696; Aslam A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011028; Bacher P, 2014, MUCOSAL IMMUNOL, V7, P916, DOI 10.1038/mi.2013.107; Bacher P, 2018, MUCOSAL IMMUNOL; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Bacher P, 2015, CURR OPIN PHARMACOL, V23, P17, DOI 10.1016/j.coph.2015.04.005; Bacher P, 2013, CYTOM PART A, V83A, P692, DOI [10.1002/cyto.a.22317, 10.1002/cyto.22317]; Bacher P, 2013, J IMMUNOL, V190, P3967, DOI 10.4049/jimmunol.1202221; Barzaghi F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00211; Bateman EAL, 2006, J ALLERGY CLIN IMMUN, V118, P1350, DOI 10.1016/j.jaci.2006.07.040; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bonvalet M, 2012, CLIN EXP ALLERGY, V42, P1745, DOI 10.1111/cea.12015; Bonvalet M, 2011, CLIN EXP ALLERGY, V41, P821, DOI 10.1111/j.1365-2222.2011.03708.x; Campion SL, 2014, J EXP MED, V211, P1273, DOI 10.1084/jem.20130555; Cebula A, 2013, NATURE, V497, P258, DOI 10.1038/nature12079; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cosmi L, 2004, BLOOD, V103, P3117, DOI 10.1182/blood-2003-09-3302; Crack LR, 2011, CLIN EXP ALLERGY, V41, P1555, DOI 10.1111/j.1365-2222.2011.03819.x; Davis MM, 2011, NAT REV IMMUNOL, V11, P551, DOI 10.1038/nri3020; Dehzad N, 2011, J IMMUNOL, V186, P2238, DOI 10.4049/jimmunol.1002027; Archila LD, 2015, J ALLERGY CLIN IMMUN, V136, P983, DOI 10.1016/j.jaci.2015.01.029; Dong J, 2007, J IMMUNOL, V179, P2389, DOI 10.4049/jimmunol.179.4.2389; Dullaers M, 2017, J ALLERGY CLIN IMMUN, V140, P76, DOI 10.1016/j.jaci.2016.09.020; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Engelhardt KR, 2014, CURR TOP MICROBIOL, V380, P1, DOI 10.1007/978-3-662-43492-5_1; Erekosima N, 2014, LARYNGOSCOPE, V124, P616, DOI 10.1002/lary.24295; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gabrysova L, 2010, EUR J IMMUNOL, V40, P1386, DOI 10.1002/eji.200940151; Gardner LM, 2004, INT ARCH ALLERGY IMM, V133, P1, DOI 10.1159/000075248; Geginat J, 2013, SEMIN IMMUNOL, V25, P252, DOI 10.1016/j.smim.2013.10.012; Girtsman T, 2010, J LEUKOCYTE BIOL, V88, P537, DOI 10.1189/jlb.0110044; Grindebacke H, 2009, J CLIN IMMUNOL, V29, P752, DOI 10.1007/s10875-009-9312-x; Hadeiba H, 2003, J IMMUNOL, V170, P5502, DOI 10.4049/jimmunol.170.11.5502; Haringer B, 2009, J EXP MED, V206, P1009, DOI 10.1084/jem.20082238; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P349, DOI 10.1067/mai.2001.117461; Hinz D, 2016, CLIN EXP ALLERGY, V46, P705, DOI 10.1111/cea.12692; Huang H, 2013, J IMMUNOL, V191, P1136, DOI 10.4049/jimmunol.1201899; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jaffar Z, 2004, J IMMUNOL, V172, P3842, DOI 10.4049/jimmunol.172.6.3842; Jia YM, 2015, EXPERT OPIN DRUG DEL, V12, P993, DOI 10.1517/17425247.2015.1044435; Jin HS, 2013, J CLIN INVEST, V123, P4923, DOI 10.1172/JCI69355; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kailaanmaki A, 2014, IMMUNOLOGY, V141, P52, DOI 10.1111/imm.12166; Kailaanmaki A, 2016, CLIN EXP ALLERGY, V46, P720, DOI 10.1111/cea.12694; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kearley J, 2008, J ALLERGY CLIN IMMUN, V122, P617, DOI 10.1016/j.jaci.2008.05.048; Keles S, 2011, J ALLERGY CLIN IMMUN, V128, P808, DOI 10.1016/j.jaci.2011.04.033; Kerstan A, 2012, J ALLERGY CLIN IMMUN, V130, P994, DOI 10.1016/j.jaci.2012.05.010; Kinnunen T, 2010, EUR J IMMUNOL, V40, P2460, DOI 10.1002/eji.201040328; Klimek L, 2016, EXPERT REV CLIN IMMU, V12, P1123, DOI 10.1080/1744666X.2016.1189825; Kreiner E, 2017, J ALLERGY CLIN IMMUN, V140, P771, DOI 10.1016/j.jaci.2016.10.055; Kwok WW, 2012, J IMMUNOL, V188, P2537, DOI 10.4049/jimmunol.1102190; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; Lambrecht BN, 2017, NAT IMMUNOL, V18, P1076, DOI 10.1038/ni.3829; Lee HM, 2012, IMMUNITY, V37, P475, DOI 10.1016/j.immuni.2012.07.009; Leech MD, 2007, J IMMUNOL, V179, P7050, DOI 10.4049/jimmunol.179.10.7050; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lou W, 2012, PEDIAT ALLERG IMM-UK, V23, P141, DOI 10.1111/j.1399-3038.2011.01249.x; Macaubas C, 2006, J IMMUNOL, V176, P5069, DOI 10.4049/jimmunol.176.8.5069; Maggi L, 2007, J ALLERGY CLIN IMMUN, V120, P429, DOI 10.1016/j.jaci.2007.05.002; Marsh D.G., 1975, THE ANTIGENS, V3, P271; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moon JJ, 2011, P NATL ACAD SCI USA, V108, P14602, DOI 10.1073/pnas.1109806108; Nakayama T, 2017, ANNU REV IMMUNOL, V35, P53, DOI 10.1146/annurev-immunol-051116-052350; Ng THS, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00129; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Parviainen S, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.06.005; Pereira-Santos MC, 2008, CLIN EXP ALLERGY, V38, P291, DOI 10.1111/j.1365-2222.2007.02887.x; Platts-Mills T. A., 2012, IMMUNOLOGY, P371; Platts-Mills TAE, 2011, IMMUNOL REV, V242, P51, DOI 10.1111/j.1600-065X.2011.01021.x; Rabin RL, 2008, CLIN EXP IMMUNOL, V153, P19, DOI 10.1111/j.1365-2249.2008.03679.x; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Renand A, 2018, J ALLERGY CLIN IMMUN, V141, P1750, DOI 10.1016/j.jaci.2017.09.041; Renand A, 2015, J ALLERGY CLIN IMMUN, V136, P1627, DOI 10.1016/j.jaci.2015.07.031; Russler-Germain EV, 2017, MUCOSAL IMMUNOL, V10, P1375, DOI 10.1038/mi.2017.65; Rutz S, 2011, CURR OPIN IMMUNOL, V23, P605, DOI 10.1016/j.coi.2011.07.018; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Saito K, 2008, J IMMUNOL, V181, P6889, DOI 10.4049/jimmunol.181.10.6889; Santegoets SJAM, 2015, CANCER IMMUNOL IMMUN, V64, P1271, DOI 10.1007/s00262-015-1729-x; Saraiva M, 2009, IMMUNITY, V31, P209, DOI 10.1016/j.immuni.2009.05.012; Schoenbrunn A, 2012, J IMMUNOL, V189, P5985, DOI 10.4049/jimmunol.1201090; Schulten V, 2016, CLIN EXP ALLERGY, V46, P439, DOI 10.1111/cea.12653; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Senti G, 2012, J ALLERGY CLIN IMMUN, V129, P128, DOI 10.1016/j.jaci.2011.08.036; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Shafiani S, 2013, IMMUNITY, V38, P1261, DOI 10.1016/j.immuni.2013.06.003; Shah N, 2012, CURR ALLERGY ASTHM R, V12, P373, DOI 10.1007/s11882-012-0286-z; Shamji MH, 2017, J ALLERGY CLIN IMMUN, V140, P1485, DOI 10.1016/j.jaci.2017.10.010; Skrindo I, 2011, CLIN EXP ALLERGY, V41, P954, DOI 10.1111/j.1365-2222.2011.03710.x; Sou T, 2011, TRENDS BIOTECHNOL, V29, P191, DOI 10.1016/j.tibtech.2010.12.009; Stassen M, 2004, J IMMUNOL, V173, P267, DOI 10.4049/jimmunol.173.1.267; Su LF, 2013, IMMUNOL REV, V255, P95, DOI 10.1111/imr.12095; Su LF, 2013, IMMUNITY, V38, P373, DOI 10.1016/j.immuni.2012.10.021; Suffia IJ, 2006, J EXP MED, V203, P777, DOI 10.1084/jem.20052056; Swamy RS, 2012, J ALLERGY CLIN IMMUN, V130, P215, DOI 10.1016/j.jaci.2012.04.021; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Thunberg S, 2007, CLIN EXP ALLERGY, V37, P1127, DOI 10.1111/j.1365-2222.2007.02739.x; Traidl-Hoffmann C, 2009, J ALLERGY CLIN IMMUN, V123, P558, DOI 10.1016/j.jaci.2008.12.003; Ulges A, 2015, NAT IMMUNOL, V16, P267, DOI 10.1038/ni.3083; Valenta R, 2018, ADV IMMUNOL, V138, P195, DOI 10.1016/bs.ai.2018.03.002; Valenta R, 2016, J ALLERGY CLIN IMMUN, V137, P351, DOI 10.1016/j.jaci.2015.12.1299; Van Hemelen D, 2015, ALLERGY, V70, P49, DOI 10.1111/all.12524; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Walker JA, 2018, NAT REV IMMUNOL, V18, P121, DOI 10.1038/nri.2017.118; Wambre E, 2008, INT ARCH ALLERGY IMM, V146, P99, DOI 10.1159/000113513; Wambre E, 2018, IMMUNOL ALLERGY CLIN, V38, P27, DOI 10.1016/j.iac.2017.09.003; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wambre E, 2015, CURR OPIN ALLERGY CL, V15, P581, DOI 10.1097/ACI.0000000000000216; Wambre E, 2014, J ALLERGY CLIN IMMUN, V133, P872, DOI 10.1016/j.jaci.2013.10.054; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Wan YSY, 2007, NATURE, V445, P766, DOI 10.1038/nature05479; Wang YQ, 2010, J IMMUNOL, V185, P5983, DOI 10.4049/jimmunol.1001255; Weissler KA, 2018, J ALLERGY CLIN IMMUN, V141, P1699, DOI 10.1016/j.jaci.2018.01.035; Yamanaka K, 2009, J ALLERGY CLIN IMMUN, V124, P842, DOI 10.1016/j.jaci.2009.06.020; Yao Y, 2018, J ALLERGY CLIN IMMUN, V142, P321, DOI 10.1016/j.jaci.2018.03.008	142	28	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1697	1709		10.1016/j.jaci.2018.10.016	http://dx.doi.org/10.1016/j.jaci.2018.10.016			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	30527063				2022-12-18	WOS:000452315800002
J	Suto, H; Nambu, A; Morita, H; Yamaguchi, S; Numata, T; Yoshizaki, T; Shimura, E; Arae, K; Asada, Y; Motomura, K; Kaneko, M; Abe, T; Matsuda, A; Iwakura, Y; Okumura, K; Saito, H; Matsumoto, K; Sudo, K; Nakae, S				Suto, Hajime; Nambu, Aya; Morita, Hideaki; Yamaguchi, Sachiko; Numata, Takafumi; Yoshizaki, Takamichi; Shimura, Eri; Arae, Ken; Asada, Yousuke; Motomura, Kenichiro; Kaneko, Mari; Abe, Takaya; Matsuda, Akira; Iwakura, Yoichiro; Okumura, Ko; Saito, Hirohisa; Matsumoto, Kenji; Sudo, Katsuko; Nakae, Susumu			IL-25 enhances T(H)17 cell-mediated contact dermatitis by promoting IL-1 beta production by dermal dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-25; IL-33; thymic stromal lymphopoietin; contact hypersensitivity; gene-deficient mice; T(H)2; T(H)17	INNATE LYMPHOID-CELLS; IMMUNE-RESPONSES; MAST-CELLS; INFLAMMATION; INTERLEUKIN-25; EXPRESSION; PHASE; CYTOKINES; RECEPTOR; ROLES	Background: In addition to thymic stromal lymphopoietin and IL-33, IL-25 is known to induce T(H)2 cytokine production by various cell types, including T(H)2 cells, T(H)9 cells, invariant natural killer T cells, and group 2 innate lymphoid cells, involved in T(H)2-type immune responses. Because both T(H)2-type and T(H)17-type cells/cytokines are crucial for contact hypersensitivity (CHS), IL-25 can contribute to this by enhancing T(H)2-type immune responses. However, the precise role of IL-25 in the pathogenesis of fluorescein isothiocyanate-induced CHS is poorly understood. Objective: We investigated the contribution of IL-25 to CHS using Il25(-/-) mice. Methods: CHS was evaluated by means of measurement of ear skin thickness in mice after fluorescein isothiocyanate painting. Skin dendritic cell (DC) migration, hapten-specific T-H cell differentiation, and detection of IL-1 beta-producing cells were determined by using flow cytometry, ELISA, and immunohistochemistry, respectively. Results: In contrast to thymic stromal lymphopoietin, we found that IL-25 was not essential for skin DC migration or hapten-specific T-H cell differentiation in the sensitization phase of CHS. Unexpectedly, mast cell-and non-immune cell-derived IL-25 was important for hapten-specific T(H)17 cell-mediated rather than T(H)2 cell-mediated inflammation in the elicitation phase of CHS by enhancing T(H)17-related, but not T(H)2-related, cytokines in the skin. In particular, IL-1 beta produced by dermal DCs in response to IL-25 was crucial for hapten-specific T(H)17 cell activation, contributing to induction of local inflammation in the elicitation phase of CHS. Conclusion: Our results identify a novel IL-25 inflammatory pathway involved in induction of T(H)17 cell-mediated, but not T(H)2 cell-mediated, CHS. IL-25 neutralization can be a potential approach for treatment of CHS.	[Suto, Hajime; Shimura, Eri; Okumura, Ko] Juntendo Univ, Atopy Res Ctr, Tokyo, Japan; [Asada, Yousuke; Matsuda, Akira] Juntendo Univ, Dept Ophthalmol, Tokyo, Japan; [Nambu, Aya; Yamaguchi, Sachiko; Numata, Takafumi; Yoshizaki, Takamichi; Shimura, Eri; Nakae, Susumu] Univ Tokyo, Ctr Expt Med & Syst Biol, Inst Med Sci, Lab Syst Biol, Tokyo, Japan; [Morita, Hideaki; Arae, Ken; Motomura, Kenichiro; Saito, Hirohisa; Matsumoto, Kenji] Natl Res Inst Child Hlth & Dev, Dept Allergy & Clin Immunol, Tokyo, Japan; [Arae, Ken] Kyorin Univ, Fac Hlth Sci, Dept Immunol, Tokyo, Japan; [Kaneko, Mari] RIKEN, Anim Resource Dev Unit, Ctr Life Sci Technol, Kobe, Hyogo, Japan; [Kaneko, Mari; Abe, Takaya] RIKEN, Genet Engn Team, Ctr Life Sci Technol, Kobe, Hyogo, Japan; [Iwakura, Yoichiro] Tokyo Univ Sci, Ctr Expt Anim Models, Inst Biomed Sci, Chiba, Japan; [Sudo, Katsuko] Tokyo Med Univ, Anim Res Ctr, Tokyo, Japan; [Nakae, Susumu] Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Saitama, Japan	Juntendo University; Juntendo University; University of Tokyo; National Center for Child Health & Development - Japan; Kyorin University; RIKEN; RIKEN; Tokyo University of Science; Tokyo Medical University; Japan Science & Technology Agency (JST)	Nakae, S (corresponding author), Univ Tokyo, Ctr Expt Med & Syst Biol, Inst Med Sci, Lab Syst Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	snakae@ims.u-tokyo.ac.jp	Morita, Hideaki/ADL-2008-2022; Morita, Hideaki/S-2214-2016; Matsuda, Akira/A-9981-2010	Morita, Hideaki/0000-0003-0928-8322; Matsuda, Akira/0000-0002-0792-3663; Saito, Hirohisa/0000-0002-6630-8337; Numata, Takafumi/0000-0002-6109-0156; Nambu, Aya/0000-0002-2797-6420	Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency; Health Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan; Japan Chemical Industry Association Long-range Research Initiative; Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [16K20333, 15H04866] Funding Source: KAKEN	Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency(Japan Science & Technology Agency (JST)); Health Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Japan Chemical Industry Association Long-range Research Initiative; Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by Grants-in-Aid for Young Scientists (A and B; to S.N.); the Program for Improvement of Research Environment for Young Researchers, Special Coordination Funds for Promoting Science and Technology (to S.N.), from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency (to S.N.); a Health Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan (to H.S., S.N., and K.M.); and a grant from the Japan Chemical Industry Association Long-range Research Initiative (to S.N.).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P639, DOI 10.1038/ni1467; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Angkasekwinai P, 2013, INFECT IMMUN, V81, P3731, DOI 10.1128/IAI.00646-13; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Corrigan CJ, 2011, J ALLERGY CLIN IMMUN, V128, P116, DOI 10.1016/j.jaci.2011.03.043; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Han HW, 2017, IMMUNOL REV, V278, P116, DOI 10.1111/imr.12546; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Ikeda K, 2003, BLOOD, V101, P3594, DOI 10.1182/blood-2002-09-2817; Ishii Akina, 2010, Allergology International, V59, P399, DOI 10.2332/allergolint.10-OA-0218; Iwakura Y, 2008, IMMUNOL REV, V226, P57, DOI 10.1111/j.1600-065X.2008.00699.x; Kim MR, 2002, BLOOD, V100, P2330, DOI 10.1182/blood-2002-01-0012; Kiyonari H, 2010, GENESIS, V48, P317, DOI 10.1002/dvg.20614; Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Mattii M, 2013, EXP DERMATOL, V22, P813, DOI 10.1111/exd.12272; Nakae S, 2001, INT IMMUNOL, V13, P1471, DOI 10.1093/intimm/13.12.1471; Nakae S, 2007, J LEUKOCYTE BIOL, V81, P1258, DOI 10.1189/jlb.1006610; Nambu Aya, 2010, Allergology International, V59, P125, DOI 10.2332/allergolint.10-RAI-0190; Oboki Keisuke, 2008, Allergol Int, V57, P121, DOI 10.2332/allergolint.R-07-160; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Ohno T, 2009, J IMMUNOL, V183, P7890, DOI 10.4049/jimmunol.0802449; Owyang AM, 2006, J EXP MED, V203, P843, DOI 10.1084/jem.20051496; Pan GH, 2001, J IMMUNOL, V167, P6559, DOI 10.4049/jimmunol.167.11.6559; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Reynolds JM, 2010, CYTOKINE GROWTH F R, V21, P413, DOI 10.1016/j.cytogfr.2010.10.002; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Senra L, 2016, J INVEST DERMATOL, V136, P1970, DOI 10.1016/j.jid.2016.06.009; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Suzukawa M, 2012, J IMMUNOL, V189, P3641, DOI 10.4049/jimmunol.1200461; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Yao XJ, 2016, RESPIROLOGY, V21, P638, DOI 10.1111/resp.12707; Zaph C, 2008, J EXP MED, V205, P2191, DOI 10.1084/jem.20080720; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	41	28	29	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1500	+		10.1016/j.jaci.2017.12.1007	http://dx.doi.org/10.1016/j.jaci.2017.12.1007			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29522843	Bronze			2022-12-18	WOS:000449429800013
J	Lazarinis, N; Bood, J; Gomez, C; Kolmert, J; Lantz, AS; Gyllfors, P; Davis, A; Wheelock, CE; Dahlen, SE; Dahlen, B				Lazarinis, Nikolaos; Bood, Johan; Gomez, Cristina; Kolmert, Johan; Lantz, Ann-Sofie; Gyllfors, Par; Davis, Andy; Wheelock, Craig E.; Dahlen, Sven-Erik; Dahlen, Barbro			Leukotriene E-4 induces airflow obstruction and mast cell activation through the cysteinyl leukotriene type 1 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; cysteinyl leukotrienes; receptors; bronchoconstriction; mast cells; sputum cells; leukotrienes; mass spectrometry; lipid mediators in urine	ASTHMATIC SUBJECTS; ARACHIDONIC-ACID; CONTROLLED-TRIAL; SMALL AIRWAYS; IN-VIVO; MONTELUKAST; ANTAGONIST; RESPONSIVENESS; INFLAMMATION; METHACHOLINE	Background: Leukotriene (LT) E-4 is the final active metabolite among the cysteinyl leukotrienes (CysLTs). Animal studies have identified a distinct LTE4 receptor, suggesting that current cysteinyl leukotriene type 1 (CysLT(1)) receptor antagonists can provide incomplete inhibition of CysLT responses. Objective: We tested this hypothesis by assessing the influence of the CysLT(1) antagonist montelukast on responses induced by means of inhalation of LTE4 in asthmatic patients. Methods: Fourteen patients with mild intermittent asthma and 2 patients with aspirin-exacerbated respiratory disease received 20 mg of montelukast twice daily and placebo for 5 to 7 days in a randomized, double-blind, crossover study (NCT01841164). The PD20 value was determined at the end of each treatment period based on an increasing dose challenge. Measurements included lipid mediators in urine and sputum cells 4 hours after LTE4 challenge. Results: Montelukast completely blocked LTE4-induced bronchoconstriction. Despite tolerating an at least 10 times higher dose of LTE4 after montelukast, there was no difference in the percentage of eosinophils in sputum. Urinary excretion of all major lipid mediators increased after LTE4 inhalation. Montelukast blocked release of the mast cell product prostaglandin (PG) D-2, as well as release of PGF(2 alpha) and thromboxane (Tx) A(2), but not increased excretion of PGE(2) and its metabolites or isoprostanes. Conclusion: LTE4 induces airflow obstruction and mast cell activation through the CysLT(1) receptor.	[Lazarinis, Nikolaos; Bood, Johan; Lantz, Ann-Sofie; Dahlen, Barbro] Karolinska Univ Hosp Huddinge, Dept Med, Div Resp Med & Allergy, Stockholm, Sweden; [Bood, Johan; Gomez, Cristina; Kolmert, Johan; Dahlen, Sven-Erik] Natl Inst Environm Med, Unit Expt Asthma & Allergy Res, Stockholm, Sweden; [Gomez, Cristina; Kolmert, Johan; Wheelock, Craig E.] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden; [Gyllfors, Par] Stockholm Asthma & Allergy Clin, Molndal, Sweden; [Davis, Andy] AstraZeneca, Molndal, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; AstraZeneca	Lazarinis, N (corresponding author), Karolinska Univ Hosp, Dept Med, Div Resp Med & Allergy, Huddinge C2-88, SE-14186 Stockholm, Sweden.	nikolaos.lazarinis@ki.se	Gómez Castellà, Cristina/B-2726-2017	Gómez Castellà, Cristina/0000-0001-8518-0095; Wheelock, Craig/0000-0002-8113-0653; Lazarinis, Nikolaos/0000-0003-2078-0705	Swedish Heart-Lung Foundation; MRC; Stockholm County Council Research Funds (ALF); Asthma and Allergy Research Foundation; Swedish Foundation for Strategic Research; Karolinska Institutet; AstraZeneca; Vardal Foundation; U-BIOPRED (IMI initiative for severe asthma); Swedish Heart-Lung Foundation [HLF 20150640]; Science for Life Laboratory	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Stockholm County Council Research Funds (ALF); Asthma and Allergy Research Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Karolinska Institutet(Karolinska Institutet); AstraZeneca(AstraZeneca); Vardal Foundation; U-BIOPRED (IMI initiative for severe asthma); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Science for Life Laboratory	Supported by the Swedish Heart-Lung Foundation, MRC, Stockholm County Council Research Funds (ALF), and the Asthma and Allergy Research Foundation. The ChAMP (Centre for Allergy Research Highlights Asthma Markers of Phenotype) consortium is funded by the Swedish Foundation for Strategic Research, the Karolinska Institutet, AstraZeneca & Science for Life Laboratory Joint Research Collaboration, and the Vardal Foundation. C.G. and J.K. were supported by U-BIOPRED (IMI initiative for severe asthma). C.E.W. was supported by the Swedish Heart-Lung Foundation (HLF 20150640).	ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; [Anonymous], 2015, GLOB STRAT ASTHM MAN; ARM JP, 1990, AM REV RESPIR DIS, V142, P1112, DOI 10.1164/ajrccm/142.5.1112; Back M, 2011, PHARMACOL REV, V63, P539, DOI 10.1124/pr.110.004184; Balgoma D, 2013, ANAL CHEM, V85, P7866, DOI 10.1021/ac401461b; Bankova LG, 2016, P NATL ACAD SCI USA, V113, P6242, DOI 10.1073/pnas.1605957113; Bood JR, 2015, J APPL PHYSIOL, V119, P272, DOI 10.1152/japplphysiol.00301.2015; BUCKNER CK, 1986, J PHARMACOL EXP THER, V237, P558; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1506, DOI 10.1164/ajrccm/146.6.1506; CHRISTIE PE, 1991, J ALLERGY CLIN IMMUN, V88, P193, DOI 10.1016/0091-6749(91)90328-L; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DAHLEN SE, 1983, ACTA PHYSIOL SCAND, V118, P393, DOI 10.1111/j.1748-1716.1983.tb07289.x; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DeLepeleire I, 1997, CLIN PHARMACOL THER, V61, P83, DOI 10.1016/S0009-9236(97)90184-3; Foster HR, 2016, SCI REP-UK, V6, DOI 10.1038/srep20461; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Gyllfors P, 2005, THORAX, V60, P902, DOI 10.1136/thx.2005.041913; Harrington LS, 2008, FASEB J, V22, P4005, DOI 10.1096/fj.08-107979; HUA XY, 1985, N-S ARCH PHARMACOL, V330, P136, DOI 10.1007/BF00499906; Idborg H, 2014, PROSTAG LEUKOTR ESS, V91, P269, DOI 10.1016/j.plefa.2014.09.006; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Laitinen A, 2005, J ALLERGY CLIN IMMUN, V115, P259, DOI 10.1016/j.jaci.2004.10.021; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Liu T, 2015, J IMMUNOL, V194, P5061, DOI 10.4049/jimmunol.1402959; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Maric J, 2018, J ALLERGY CLIN IMMUN, V141, P1761, DOI 10.1016/j.jaci.2017.09.050; Mechiche H, 2003, CLIN EXP ALLERGY, V33, P887, DOI 10.1046/j.1365-2222.2003.01696.x; Naji N, 2013, RESP MED, V107, P503, DOI 10.1016/j.rmed.2012.12.022; Nieto A, 2006, RESP MED, V100, P1180, DOI 10.1016/j.rmed.2005.10.025; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; O'Sullivan S, 1999, PROSTAG OTH LIPID M, V57, P149, DOI 10.1016/S0090-6980(98)00076-8; OHICKEY SP, 1988, EUR RESPIR J, V1, P913; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V127, P95, DOI 10.1111/j.1748-1716.1986.tb07880.x; PIPER PJ, 1982, BRIT J PHARMACOL, V77, P267, DOI 10.1111/j.1476-5381.1982.tb09295.x; RAUD J, 1988, P NATL ACAD SCI USA, V85, P2315, DOI 10.1073/pnas.85.7.2315; Reiss TF, 1996, J ALLERGY CLIN IMMUN, V98, P528, DOI 10.1016/S0091-6749(96)70086-6; Safholm J, 2015, J ALLERGY CLIN IMMUN, V136, P1232, DOI 10.1016/j.jaci.2015.04.002; Williamson PA, 2011, LUNG, V189, P121, DOI 10.1007/s00408-010-9275-y; Zaslona Z, 2014, J ALLERGY CLIN IMMUN, V133, P379, DOI 10.1016/j.jaci.2013.07.037; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605	45	28	29	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2018	142	4					1080	1089		10.1016/j.jaci.2018.02.024	http://dx.doi.org/10.1016/j.jaci.2018.02.024			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GV7RG	29518425	Bronze			2022-12-18	WOS:000446327300009
J	Mao, HW; Yang, WL; Latour, S; Yang, J; Winter, S; Zheng, J; Ni, K; Lv, MM; Liu, CJ; Huang, HM; Chan, KW; Lee, PPW; Tu, WW; Fischer, A; Lau, YL				Mao, Huawei; Yang, Wanling; Latour, Sylvain; Yang, Jing; Winter, Sarah; Zheng, Jian; Ni, Ke; Lv, Minmin; Liu, Chenjing; Huang, Hongmei; Chan, Koon-Wing; Lee, Pamela Pui-Wah; Tu, Wenwei; Fischer, Alain; Lau, Yu-Lung			RASGRP1 mutation in autoimmune lymphoproliferative syndrome-like disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALPS-like disease; RasGRP1; immunodeficiency; immune dysregulation; T-cell receptor signaling; genetic defect	T-CELL DEVELOPMENT; B-CELL; LYMPHOCYTE; ACTIVATION; IMMUNODEFICIENCY; GENERATION; IMMUNITY; PROTEIN; CD4	Background: Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of lymphocyte homeostasis due to impaired apoptosis. It was initially regarded as a very rare disease, but recent studies show that it may be more common than previously thought. Defects in a couple of genes have been identified in a proportion of patients with ALPS, but around one-third of such patients remain undefined genetically. Objective: We describe 2 siblings presenting with ALPS-like disease. This study aimed to identify the genetic cause responsible for this phenotype. Methods: Whole-exome sequencing and molecular and functional analyses were used to identify and characterize the genetic defect. Clinical and immunological analysis was also performed and reported. Results: The 2 patients presented with chronic lymphadenopathy, hepatosplenomegaly, autoimmune hemolytic anemia, immune thrombocytopenia, and the presence of antinuclear autoantibody and other autoantibodies, but normal double-negative T cells. They also suffered from recurrent infections. Novel compound heterozygous mutations of RASGRP1 encoding Ras guanyl nucleotide releasing protein 1 were identified in the 2 siblings. The mutations impaired T-cell receptor signaling, leading to defective T-cell activation and proliferation, as well as impaired activation-induced cell death of T cells. Conclusions: This study shows for the first time that RASGRP1 mutation should be considered in patients with ALPS-like disease. We also propose to investigate the intracellular proteins involved in the T-cell receptor signaling pathway in similar patients but with unknown genetic cause.	[Mao, Huawei; Liu, Chenjing; Huang, Hongmei; Lau, Yu-Lung] Univ Hong Kong, Shenzhen Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; [Mao, Huawei; Yang, Wanling; Yang, Jing; Zheng, Jian; Ni, Ke; Chan, Koon-Wing; Lee, Pamela Pui-Wah; Tu, Wenwei; Lau, Yu-Lung] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China; [Mao, Huawei; Yang, Wanling; Yang, Jing; Lv, Minmin; Lee, Pamela Pui-Wah; Tu, Wenwei; Lau, Yu-Lung] Shenzhen Engn Lab Primary Immunodeficiency Diag &, Shenzhen, Peoples R China; [Latour, Sylvain; Winter, Sarah] Necker Childrens Hosp, AP HP, Lab Lymphocyte Activat & Susceptibil EBV Infect, Inserm,UMR 1163, Paris, France; [Fischer, Alain] Necker Childrens Hosp, AP HP, Immunol & Pediat Hematol Dept, Paris, France	University of Hong Kong; University of Hong Kong; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Mao, HW (corresponding author), Univ Hong Kong, Shenzhen Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.; Lau, YL (corresponding author), Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.	maohw@hku-zch.org; lauylung@hku.hk	Latour, Sylvain/H-3652-2017; Lau, Yu Lung/C-4322-2009	Latour, Sylvain/0000-0001-8238-4391; Lau, Yu Lung/0000-0002-4780-0289	National Natural Science Foundation of China [81671626]; Shenzhen Science, Technology and Innovation Commission [JCYJ20140411175241066]; Shenzhen Development and Reform Commission [[2015]164]; Hong Kong Health and Medical Research Fund [01120846]; Society for the Relief of Disabled Children	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Science, Technology and Innovation Commission; Shenzhen Development and Reform Commission; Hong Kong Health and Medical Research Fund; Society for the Relief of Disabled Children	This study was supported partly by grants from the National Natural Science Foundation of China (grant no. 81671626 to H.M.), Shenzhen Science, Technology and Innovation Commission (grant no. JCYJ20140411175241066 to H.M.), the Shenzhen Development and Reform Commission (grant no. [2015]164 to Y.-L.L. and H.M.), Hong Kong Health and Medical Research Fund (grant no. 01120846 to W.Y., Y.-L.L., and P.P.-W.L.), and the Society for the Relief of Disabled Children (to Y.-L.L.).	Aguado E, 2002, SCIENCE, V296, P2036, DOI 10.1126/science.1069057; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen XX, 2008, J IMMUNOL, V180, P5973, DOI 10.4049/jimmunol.180.9.5973; Chen Y, 2012, J IMMUNOL, V189, P61, DOI 10.4049/jimmunol.1103272; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Coughlin JJ, 2006, IMMUNOL LETT, V105, P77, DOI 10.1016/j.imlet.2006.01.005; Coughlin JJ, 2005, J IMMUNOL, V175, P7179, DOI 10.4049/jimmunol.175.11.7179; Daley SR, 2013, ELIFE, V2, DOI 10.7554/eLife.01020; Del-Rey M, 2006, BLOOD, V108, P1306, DOI 10.1182/blood-2006-04-015776; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Fuller DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038796; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Kortum RL, 2012, MOL CELL BIOL, V32, P2748, DOI 10.1128/MCB.00317-12; Ksionda Olga, 2013, Front Biol (Beijing), V8, P508; Lee PPW, 2014, J ALLERGY CLIN IMMUN, V133, P894, DOI 10.1016/j.jaci.2013.08.051; Lee SH, 2009, J IMMUNOL, V183, P7931, DOI 10.4049/jimmunol.0902012; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Oliveira JB, 2007, P NATL ACAD SCI USA, V104, P8953, DOI 10.1073/pnas.0702975104; Oliveira JB, 2010, BLOOD, V116, pE35, DOI 10.1182/blood-2010-04-280347; Plagnol V, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002216; Priatel JJ, 2002, IMMUNITY, V17, P617, DOI 10.1016/S1074-7613(02)00451-X; Priatel JJ, 2007, J IMMUNOL, V179, P2143, DOI 10.4049/jimmunol.179.4.2143; Priatel JJ, 2010, J IMMUNOL, V184, P666, DOI 10.4049/jimmunol.0803521; Qu HQ, 2009, J MED GENET, V46, P553, DOI 10.1136/jmg.2009.067140; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Salzer E, 2016, NAT IMMUNOL, V17, P1352, DOI 10.1038/ni.3575; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Sommers CL, 2002, SCIENCE, V296, P2040, DOI 10.1126/science.1069066; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Stone James C, 2011, Genes Cancer, V2, P320, DOI 10.1177/1947601911408082; Strasser A, 2008, IMMUNOL CELL BIOL, V86, P57, DOI 10.1038/sj.icb.7100141; Takagi M, 2011, BLOOD, V117, P2887, DOI 10.1182/blood-2010-08-301515; Tu WW, 2008, BLOOD, V112, P2554, DOI 10.1182/blood-2008-04-152041; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Yasuda S, 2007, J IMMUNOL, V179, P4890, DOI 10.4049/jimmunol.179.7.4890	42	28	29	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					595	+		10.1016/j.jaci.2017.10.026	http://dx.doi.org/10.1016/j.jaci.2017.10.026			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29155103	hybrid			2022-12-18	WOS:000440664400026
J	Van Dyken, SJ; Locksley, RM				Van Dyken, Steven J.; Locksley, Richard M.			Chitins and chitinase activity in airway diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Acidic mammalian chitinase; age-related disease; chitotriosidase; chitin; chitinase; fibrosis; epithelium; innate lymphoid cell; interleukins; interstitial lung disease; polysaccharide; pulmonary fibrosis	ACIDIC MAMMALIAN CHITINASE; INNATE LYMPHOID-CELLS; HUMAN CHITOTRIOSIDASE; TUFT CELLS; TYPE-2; IMMUNITY; TISSUE; INFLAMMATION; RESPONSES; IDENTIFICATION	Chitin, one of the most abundant biopolymers on Earth, is bound and degraded by chitinases, specialized enzymes that are similarly widespread in nature. Chitin catabolism affects global carbon and nitrogen cycles through a host of diverse biological processes, but recent work has focused attention on systems of chitin recognition and degradation conserved in mammals, connecting an ancient pathway of polysaccharide processing to human diseases influenced by persistent immune triggering. Here we review current advances in our understanding of how chitin-chitinase interactions affect mucosal immune feedback mechanisms essential to maintaining homeostasis and organ health.	[Van Dyken, Steven J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Locksley, Richard M.] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, 513 Parnassus Ave,51032, San Francisco, CA 94143 USA; [Locksley, Richard M.] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol Immunol, 513 Parnassus Ave,51032, San Francisco, CA 94143 USA	Washington University (WUSTL); Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Locksley, RM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, 513 Parnassus Ave,51032, San Francisco, CA 94143 USA.; Locksley, RM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol Immunol, 513 Parnassus Ave,51032, San Francisco, CA 94143 USA.	locksley@medicine.ucsf.edu		Van Dyken, Steven/0000-0002-9787-0883	HHMI; National Institutes of Health NIH; SABRE Center at UCSF; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107202, R01HL128903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026918] Funding Source: NIH RePORTER	HHMI(Howard Hughes Medical Institute); National Institutes of Health NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SABRE Center at UCSF; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by HHMI (to R.M.L.), the National Institutes of Health NIH; (to R.M.L. and S.V.D.) and funds from the SABRE Center at UCSF.	Artzi L, 2017, NAT REV MICROBIOL, V15, P83, DOI 10.1038/nrmicro.2016.164; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Bussink AP, 2006, INT REV CYTOL, V252, P71, DOI 10.1016/S0074-7696(06)52001-7; Chen F, 2012, NAT MED, V18, P260, DOI 10.1038/nm.2628; Chou YT, 2006, BIOCHEMISTRY-US, V45, P4444, DOI 10.1021/bi0525977; de Jonge R, 2010, SCIENCE, V329, P953, DOI 10.1126/science.1190859; Deguchi S, 2015, SCI REP-UK, V5, DOI 10.1038/srep11907; Deytieux C, 2007, J EXP BOT, V58, P1851, DOI 10.1093/jxb/erm049; Ehrlich H, 2013, SCI REP-UK, V3, DOI 10.1038/srep03497; Fadel F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154190; Fernandez JG, 2013, ADV FUNCT MATER, V23, P4454, DOI 10.1002/adfm.201300053; Fitz LJ, 2012, AM J RESP CELL MOL, V46, P71, DOI 10.1165/rcmb.2011-0095OC; Flint HJ, 2012, GUT MICROBES, V3, P289, DOI 10.4161/gmic.19897; Funkhouser JD, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-96; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; Gerbe F, 2016, NATURE, V529, P226, DOI 10.1038/nature16527; Goedken ER, 2011, PROTEIN EXPRES PURIF, V75, P55, DOI 10.1016/j.pep.2010.08.013; Goncalves IR, 2016, BMC EVOL BIOL, V16, DOI 10.1186/s12862-016-0815-9; Gooday GW, 1990, BIODEGRADATION, V1, P177, DOI 10.1007/BF00058835; Goto M, 2003, ARCH ORAL BIOL, V48, P701, DOI 10.1016/S0003-9969(03)00150-X; Hegedus D, 2009, ANNU REV ENTOMOL, V54, P285, DOI 10.1146/annurev.ento.54.110807.090559; Howitt MR, 2016, SCIENCE, V351, P1329, DOI 10.1126/science.aaf1648; Huang QS, 2012, GLYCOBIOLOGY, V22, P23, DOI 10.1093/glycob/cwr092; Hussain M, 2013, J MOL EVOL, V76, P240, DOI 10.1007/s00239-013-9553-4; Igarashi K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4975; Janiak MC, 2017, MOL BIOL EVOL; Karo-Atar D, 2016, MUCOSAL IMMUNOL, V9, P240, DOI 10.1038/mi.2015.56; Kashimura A, 2015, INT J MOL SCI, V16, P4028, DOI 10.3390/ijms16024028; Keyhani NO, 1999, BBA-GEN SUBJECTS, V1473, P108, DOI 10.1016/S0304-4165(99)00172-5; Kim LK, 2015, P NATL ACAD SCI USA, V112, pE2891, DOI 10.1073/pnas.1507393112; Kimura M, 2016, PLOS ONE, V11; Krykbaev R, 2010, GENE, V452, P63, DOI 10.1016/j.gene.2009.12.005; Larsbrink J, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0674-z; Latge JP, 2014, CURR OPIN MICROBIOL, V20, P111, DOI 10.1016/j.mib.2014.05.009; Lechner AJ, 2018, CELL STEM CELL, V21, P120; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Manno N, 2014, CARBOHYD POLYM, V113, P607, DOI 10.1016/j.carbpol.2014.07.011; McFall-Ngai MJ, 2014, ANNU REV MICROBIOL, V68, P177, DOI 10.1146/annurev-micro-091313-103654; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Morgan JLW, 2013, NATURE, V493, P181, DOI 10.1038/nature11744; Nakamura A, 2018, PHYS CHEM CHEM PHYS, V20, P3010, DOI 10.1039/c7cp04606e; Nikolov S, 2010, ADV MATER, V22, P519, DOI 10.1002/adma.200902019; Ohno M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37756; Okawa K, 2016, MOL BIOL EVOL, V33, P3183, DOI 10.1093/molbev/msw198; Oldroyd GED, 2013, NAT REV MICROBIOL, V11, P252, DOI 10.1038/nrmicro2990; Olland AM, 2009, PROTEIN SCI, V18, P569, DOI 10.1002/pro.63; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Schimpl M, 2012, BIOCHEM J, V446, P149, DOI 10.1042/BJ20120377; Seibold MA, 2009, J BIOL CHEM, V284, P19650, DOI 10.1074/jbc.M109.012443; Soragni A, 2015, MOL CELL, V57, P1011, DOI 10.1016/j.molcel.2015.01.026; Stankiewicz BA, 1997, SCIENCE, V276, P1541, DOI 10.1126/science.276.5318.1541; Sutherland TE, 2011, CHEM BIOL, V18, P569, DOI 10.1016/j.chembiol.2011.02.017; Tabata E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19940-8; Tan YP, 2015, NAT CHEM BIOL, V11, P488, DOI [10.1038/nchembio.1833, 10.1038/NCHEMBIO.1833]; Tolonen AC, 2015, ENVIRON MICROBIOL, V17, P2618, DOI 10.1111/1462-2920.12495; Vaaje-Kolstad G, 2013, FEBS J, V280, P3028, DOI 10.1111/febs.12181; Van Dyken SJ, 2017, CELL, V169, P497, DOI 10.1016/j.cell.2017.03.044; Van Dyken SJ, 2016, NAT IMMUNOL, V17, P1381, DOI 10.1038/ni.3582; Van Dyken SJ, 2014, IMMUNITY, V40, P414, DOI 10.1016/j.immuni.2014.02.003; Van Dyken SJ, 2011, J IMMUNOL, V187, P2261, DOI 10.4049/jimmunol.1100972; van Eijk M, 2005, INT IMMUNOL, V17, P1505, DOI 10.1093/intimm/dxh328; Vannella KM, 2016, NAT IMMUNOL, V17, P538, DOI 10.1038/ni.3417; von Moltke J, 2017, J EXP MED, V214, P27, DOI 10.1084/jem.20161274; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Wolters PJ, 2018, LANCET RESP MED, V6, P154, DOI 10.1016/S2213-2600(18)30007-9; Wysokowski M, 2014, PALEOBIOLOGY, V40, P529, DOI 10.1666/13083; Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	70	28	28	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					364	369		10.1016/j.jaci.2018.06.017	http://dx.doi.org/10.1016/j.jaci.2018.06.017			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29959948	Bronze, Green Accepted			2022-12-18	WOS:000440664400003
J	Van Nieuwenhove, E; Garcia-Perez, JE; Helsen, C; Rodriguez, PD; van Schouwenburg, PA; Dooley, J; Schlenner, S; van der Burg, M; Verhoeyen, E; Gijsbers, R; Frietze, S; Schjerven, H; Meyts, I; Claessens, F; Humblet-Baron, S; Wouters, C; Liston, A				Van Nieuwenhove, Erika; Garcia-Perez, Josselyn E.; Helsen, Christine; Rodriguez, Princess D.; van Schouwenburg, Pauline A.; Dooley, James; Schlenner, Susan; van der Burg, Mirjam; Verhoeyen, Els; Gijsbers, Rik; Frietze, Seth; Schjerven, Hilde; Meyts, Isabelle; Claessens, Frank; Humblet-Baron, Stephanie; Wouters, Carine; Liston, Adrian			A kindred with mutant IKAROS and autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							B-CELLS; EXPRESSION		[Van Nieuwenhove, Erika; Garcia-Perez, Josselyn E.; Dooley, James; Schlenner, Susan; Meyts, Isabelle; Humblet-Baron, Stephanie; Wouters, Carine; Liston, Adrian] KUL Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium; [Van Nieuwenhove, Erika; Garcia-Perez, Josselyn E.; Dooley, James; Schlenner, Susan; Humblet-Baron, Stephanie; Liston, Adrian] VLB Ctr Brain & Dis Res, Leuven, Belgium; [Van Nieuwenhove, Erika; Meyts, Isabelle; Wouters, Carine] Univ Hosp Leuven, Leuven, Belgium; [Helsen, Christine; Claessens, Frank] KUL Univ Leuven, Dept Cellular & Mol Med, Leuven, Belgium; [Rodriguez, Princess D.; Frietze, Seth] Univ Vermont, Dept Med Lab & Radiat Sci, Burlington, VT USA; [van Schouwenburg, Pauline A.; van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Verhoeyen, Els] Univ Claude Bernard Lyon 1, Univ Lyon, Ecole Normale Super Lyon, Team EVIR,Inserm,CIRI, Lyon, France; [Verhoeyen, Els] Univ Cate dAzur, INSERM, C3M, Nice, France; [Gijsbers, Rik] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Lab Viral Vector Technol & Gene Therapy, Leuven, Belgium; [Gijsbers, Rik] Leuven Viral Vector Core, Leuven, Belgium; [Schjerven, Hilde] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	KU Leuven; University Hospital Leuven; University of Vermont; Erasmus University Rotterdam; Erasmus MC; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; KU Leuven; University of California System; University of California San Francisco	Wouters, C (corresponding author), KUL Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium.; Wouters, C (corresponding author), Univ Hosp Leuven, Leuven, Belgium.	carine.wouters@uzleuven.be; adrian.liston@vib.be	Verhoeyen, Els/AAW-4853-2021; Verhoeyen, Els/H-6360-2016; Meyts, Isabelle/Z-3295-2019; Van Nieuwenhove, Erika/H-7445-2018; Schlenner, Susan/P-7905-2017; Claessens, Frank/M-8565-2016	Verhoeyen, Els/0000-0001-9224-5491; Van Nieuwenhove, Erika/0000-0001-9584-3198; Humblet-Baron, Stephanie/0000-0003-4684-069X; Schlenner, Susan/0000-0002-8553-3388; Claessens, Frank/0000-0002-8676-7709; Wouters, Carine/0000-0002-6426-8845; Helsen, Christine/0000-0003-1048-2798	European Research Council grant IMMUNO; KU Leuven (GOA); Fonds voor Wetenschappelijk Onderzoek (FWO) [1S22716N, 1272517N]; Dutch Organisation for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek/Zorgonderzoek en Medische wetenschappen VIDI grant) [91712323]; Dutch Organisation for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek/Zorgonderzoek en Medische wetenschappen VENI grant) [91616058]; American Cancer Society [14-196-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI127709] Funding Source: NIH RePORTER	European Research Council grant IMMUNO; KU Leuven (GOA)(KU Leuven); Fonds voor Wetenschappelijk Onderzoek (FWO)(FWO); Dutch Organisation for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek/Zorgonderzoek en Medische wetenschappen VIDI grant); Dutch Organisation for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek/Zorgonderzoek en Medische wetenschappen VENI grant); American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the European Research Council grant IMMUNO and the KU Leuven (GOA). E.V.N. (1S22716N) and S.H.-B. (1272517N) are Fonds voor Wetenschappelijk Onderzoek (FWO) fellows. Part of this work was supported by the Dutch Organisation for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek/Zorgonderzoek en Medische wetenschappen VIDI grant no. 91712323 to M.B., VENI grant no. 91616058 to P.A.S.) and by an Institutional Research Grant from the American Cancer Society (grant no. 14-196-01 to S.F.).	Bogaert DJ, 2018, J ALLERGY CLIN IMMUN, V141, P432, DOI 10.1016/j.jaci.2017.08.019; DORKEN B, 1986, J IMMUNOL, V136, P4470; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; Heizmann B, 2016, BIOCHEM BIOPH RES CO, V470, P714, DOI 10.1016/j.bbrc.2016.01.060; Hoshino A, 2017, J ALLERGY CLIN IMMUN, V140, P223, DOI 10.1016/j.jaci.2016.09.029; Kirstetter P, 2002, EUR J IMMUNOL, V32, P720, DOI 10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Wojcik H, 2007, EUR J IMMUNOL, V37, P1022, DOI 10.1002/eji.200637026	9	28	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					699	702		10.1016/j.jaci.2018.04.008	http://dx.doi.org/10.1016/j.jaci.2018.04.008			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29705243	Green Accepted, Bronze			2022-12-18	WOS:000440664400043
J	Gul, E; Sayar, EH; Gungor, B; Eroglu, FK; Surucu, N; Keles, S; Guner, SN; Findik, S; Alpdundar, E; Ayanoglu, IC; Kayaoglu, B; Geckin, BN; Sanli, HA; Kahraman, T; Yakicier, C; Muftuoglu, M; Oguz, B; Ayvaz, DNC; Gursel, I; Ozen, S; Reisli, I; Gursel, M				Gul, Ersin; Sayar, Esra Hazar; Gungor, Bilgi; Eroglu, Fehime Kara; Surucu, Naz; Keles, Sevgi; Guner, Sukru Nail; Findik, Siddika; Alpdundar, Esin; Ayanoglu, Ihsan Cihan; Kayaoglu, Basak; Geckin, Busra Nur; Sanli, Hatice Asena; Kahraman, Tamer; Yakicier, Cengiz; Muftuoglu, Meltem; Oguz, Berna; Ayvaz, Deniz Nazire Cagdas; Gursel, Ihsan; Ozen, Seza; Reisli, Ismail; Gursel, Mayda			Type I IFN-related NETosis in ataxia telangiectasia and Artemis deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiencies; autoinflammation; ataxia telangiectasia; Artemis deficiency; type I IFN; interferonopathy; neutrophil extracellular traps; NETosis	NEUTROPHIL EXTRACELLULAR TRAPS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACUTE MYOCARDIAL-INFARCTION; COMBINED IMMUNODEFICIENCY; CUTANEOUS GRANULOMAS; MITOCHONDRIAL-DNA; DCLRE1C MUTATIONS; DISEASE; DAMAGE; INTERFERONOPATHIES	Background: Pathological inflammatory syndromes of unknown etiology are commonly observed in ataxia telangiectasia (AT) and Artemis deficiency. Similar inflammatory manifestations also exist in patients with STING-associated vasculopathy in infancy (SAVI). Objective: We sought to test the hypothesis that the inflammation-associated manifestations observed in patients with AT and Artemis deficiency stem from increased type I IFN signature leading to neutrophil-mediated pathological damage. Methods: Cytokine/protein signatures were determined by ELISA, cytometric bead array, or quantitative PCR. Stat1 phosphorylation levels were determined by flow cytometry. DNA species accumulating in the cytosol of patients' cells were quantified microscopically and flow cytometrically. Propensity of isolated polymorhonuclear granulocytes to form neutrophil extracellular traps (NETs) was determined using fluorescence microscopy and picogreen assay. Neutrophil reactive oxygen species levels and mitochondrial stress were assayed using fluorogenic probes, microscopy, and flow cytometry. Results: Type I and III IFNsignatures were elevated in plasma and peripheral blood cells of patients with AT, Artemis deficiency, and SAVI. Chronic IFN production stemmed fromthe accumulation of DNA in the cytoplasm of ATand Artemis-deficient cells. Neutrophils isolated from patients spontaneously produced NETs and displayed indicators of oxidative and mitochondrial stress, supportive of theirNETotic tendencies. Asimilar phenomenonwas also observed in neutrophils from healthy controls exposed to patient plasma samples or exogeneous IFN-alpha. Conclusions: Type I IFN-mediated neutrophil activation and NET formation may contribute to inflammatory manifestations observed in patients with AT, Artemis deficiency, and SAVI. Thus, neutrophils represent a promising target to manage inflammatory syndromes in diseases with active type I IFN signature.	[Gul, Ersin; Gungor, Bilgi; Surucu, Naz; Alpdundar, Esin; Ayanoglu, Ihsan Cihan; Kayaoglu, Basak; Geckin, Busra Nur; Sanli, Hatice Asena; Gursel, Mayda] Middle East Tech Univ, Dept Biol Sci, TR-06800 Ankara, Turkey; [Sayar, Esra Hazar; Keles, Sevgi; Guner, Sukru Nail; Reisli, Ismail] Necmettin Erbakan Univ, Meram Med Fac, Dept Immunol & Allergy, Konya, Turkey; [Eroglu, Fehime Kara; Kahraman, Tamer; Gursel, Ihsan] Ihsan Dogramaci Bilkent Univ, Dept Mol Biol & Genet, Therapeut Oligodeoxynucleotide Res Lab, Thorlab, Ankara, Turkey; [Findik, Siddika] Necmettin Erbakan Univ, Meram Med Fac, Dept Pathol, Konya, Turkey; [Yakicier, Cengiz; Muftuoglu, Meltem] Acibadem Mehmet Ali Aydinlar Univ, Dept Mol Biol & Genet, Istanbul, Turkey; [Oguz, Berna] Hacettepe Univ, Fac Med, Dept Radiol, Ankara, Turkey; [Ayvaz, Deniz Nazire Cagdas] Hacettepe Univ, Fac Med, Dept Pediat Immunol, Ankara, Turkey; [Ozen, Seza] Hacettepe Univ, Fac Med, Dept Pediat Rheumatol, Ankara, Turkey	Middle East Technical University; Necmettin Erbakan University; Selcuk University; Ihsan Dogramaci Bilkent University; Necmettin Erbakan University; Selcuk University; Acibadem University; Hacettepe University; Hacettepe University; Hacettepe University	Gursel, M (corresponding author), Middle East Tech Univ, Dept Biol Sci, TR-06800 Ankara, Turkey.	mgursel@metu.edu.tr	Kayaoglu, Basak/GLU-5712-2022; Guner, Sukru Nail/A-9841-2018; Kayaoglu, Basak/ABA-1261-2020; Gursel, M/H-1812-2012; Cagdas, Deniz/I-9104-2013; OZEN, SEZA/I-9096-2013; Hazar, Esra/ADV-6389-2022; Hazar, Esra/AAF-6902-2022; Ayanoğlu, İhsan Cihan/AAZ-5565-2020; Geckin, Büsranur/ABE-6013-2020; Gursel, Ihsan/AAT-7168-2021; Muftuoglu, Meltem/AAG-5004-2019	Kayaoglu, Basak/0000-0002-5752-3086; Guner, Sukru Nail/0000-0002-8860-6132; Kayaoglu, Basak/0000-0002-5752-3086; Gursel, M/0000-0003-0044-9054; Cagdas, Deniz/0000-0003-2213-4627; Hazar, Esra/0000-0003-0338-1040; Hazar, Esra/0000-0003-0338-1040; Geckin, Büsranur/0000-0002-4751-4960; Muftuoglu, Meltem/0000-0001-5372-4780; Ayanoglu, Ihsan Cihan/0000-0003-4300-1401; Gursel, Ihsan/0000-0003-3761-1166; Sanli, Hatice Asena/0000-0003-2337-6003; Kahraman, Tamer/0000-0002-5527-7336; Gul, Ersin/0000-0003-2873-8034	Scientific and Technological Research Council of Turkey (TUBITAK) [315S125, 115S430]	Scientific and Technological Research Council of Turkey (TUBITAK)(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK))	This project was partially supported by the Scientific and Technological Research Council of Turkey (TUBITAK) (grant nos. 315S125 and 115S430).	Aamann MD, 2010, FASEB J, V24, P2334, DOI 10.1096/fj.09-147991; AMMANN AJ, 1971, J PEDIATR-US, V78, P821, DOI 10.1016/S0022-3476(71)80353-0; Apostolidou E, 2016, ANN RHEUM DIS, V75, P269, DOI 10.1136/annrheumdis-2014-205958; Belot A, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-44; Bennike TB, 2015, INFLAMM BOWEL DIS, V21, P2052, DOI 10.1097/MIB.0000000000000460; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brzostek-Racine S, 2011, J IMMUNOL, V187, P5336, DOI 10.4049/jimmunol.1100040; Carmona-Rivera C, 2015, ANN RHEUM DIS, V74, P1417, DOI 10.1136/annrheumdis-2013-204837; Carmona-Rivera C, 2013, SEMIN IMMUNOPATHOL, V35, P455, DOI 10.1007/s00281-013-0375-7; Cheng OZ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00001; Chiam LYT, 2011, DERMATOLOGY, V223, P13, DOI 10.1159/000330335; Chrysanthopoulou A, 2014, J PATHOL, V233, P294, DOI 10.1002/path.4359; Couser WG, 2015, KIDNEY INT, V88, P938, DOI 10.1038/ki.2015.259; Crow MK, 2014, CURR OPIN RHEUMATOL, V26, P467, DOI 10.1097/BOR.0000000000000087; Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850; de Boer OJ, 2013, THROMB HAEMOSTASIS, V109, P290, DOI 10.1160/TH12-06-0425; de Jesus AA, 2015, ANNU REV IMMUNOL, V33, P823, DOI 10.1146/annurev-immunol-032414-112227; Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109; Denny MR, 2010, J IMMUNOL, V184, P3284, DOI 10.4049/jimmunol.0902199; Drolet BA, 1997, DERMATOLOGY, V194, P273, DOI 10.1159/000246117; Dwyer M, 2014, J INNATE IMMUN, V6, P765, DOI 10.1159/000363242; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Felgentreff K, 2015, J ALLERGY CLIN IMMUN, V136, P140, DOI 10.1016/j.jaci.2015.03.005; Furumoto Y, 2017, ARTHRITIS RHEUMATOL, V69, P148, DOI 10.1002/art.39818; Garcia-Romo GS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001201; Grabcanovic-Musija F, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0221-7; Hakkim A, 2010, P NATL ACAD SCI USA, V107, P9813, DOI 10.1073/pnas.0909927107; Harbort CJ, 2015, BLOOD, V126, P2842, DOI 10.1182/blood-2015-05-645424; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; He ZX, 2016, THROMB HAEMOSTASIS, V115, P738, DOI 10.1160/TH15-09-0710; IJspeert H, 2011, GENES IMMUN, V12, P434, DOI 10.1038/gene.2011.16; Kahlenberg JM, 2013, J IMMUNOL, V191, P4895, DOI 10.4049/jimmunol.1302005; Kambas K, 2014, ANN RHEUM DIS, V73, P1854, DOI 10.1136/annrheumdis-2013-203430; Kambas K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00385; Kambas K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045427; Kutukculer N, 2000, AUTOIMMUNITY, V32, P145, DOI 10.3109/08916930008994084; Lam AR, 2014, CANCER RES, V74, P2193, DOI 10.1158/0008-5472.CAN-13-1703; Lande R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001180; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Le Deist F, 2004, IMMUNOL REV, V200, P142, DOI 10.1111/j.0105-2896.2004.00169.x; Lee PP, 2013, CLIN IMMUNOL, V149, P464, DOI 10.1016/j.clim.2013.08.006; Lee-Kirsch MA, 2015, SEMIN IMMUNOPATHOL, V37, P349, DOI 10.1007/s00281-015-0500-x; Leffler J, 2012, J IMMUNOL, V188, P3522, DOI 10.4049/jimmunol.1102404; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027; Maciejczyk M, 2017, REDOX BIOL, V11, P375, DOI 10.1016/j.redox.2016.12.030; Marcos V, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/408935; McGrath-Morrow SA, 2010, J PEDIATR-US, V156, P682, DOI 10.1016/j.jpeds.2009.12.007; Menegazzo L, 2015, ACTA DIABETOL, V52, P497, DOI 10.1007/s00592-014-0676-x; Mitroulis I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029318; Moschella F, 2013, CLIN CANCER RES, V19, P4249, DOI 10.1158/1078-0432.CCR-12-3666; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Nowak-Wegrzyn A, 2004, J PEDIATR-US, V144, P505, DOI 10.1016/j.jpeds.2003.12.046; Rodero MP, 2016, J EXP MED, V213, P2527, DOI 10.1084/jem.20161596; Schroeder SA, 2014, PEDIATR PULM, V49, P389, DOI 10.1002/ppul.22817; Shen YJ, 2015, CELL REP, V11, P460, DOI 10.1016/j.celrep.2015.03.041; Smith CK, 2015, CURR OPIN RHEUMATOL, V27, P448, DOI 10.1097/BOR.0000000000000197; Soderberg D, 2015, RHEUMATOLOGY, V54, P2085, DOI 10.1093/rheumatology/kev217; Stakos DA, 2015, EUR HEART J, V36, P1405, DOI 10.1093/eurheartj/ehv007; Villanueva E, 2011, J IMMUNOL, V187, P538, DOI 10.4049/jimmunol.1100450; Volk T, 2015, HUM MOL GENET, V24, P7361, DOI 10.1093/hmg/ddv437; Wang YD, 2014, DIABETES, V63, P4239, DOI 10.2337/db14-0480; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Woodbine L, 2011, NUCLEIC ACIDS RES, V39, P6986, DOI 10.1093/nar/gkr331; Yu QJ, 2015, CELL REP, V11, P785, DOI 10.1016/j.celrep.2015.03.069	65	28	29	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					246	257		10.1016/j.jaci.2017.10.030	http://dx.doi.org/10.1016/j.jaci.2017.10.030			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29155101	Bronze, Green Published			2022-12-18	WOS:000437837500027
J	Segal, LN; Martinez, FJ				Segal, Leopoldo N.; Martinez, Fernando J.			Chronic obstructive pulmonary disease subpopulations and phenotyping	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Chronic bronchitis; emphysema; asthma; chronic obstructive pulmonary disease; inflammation; exacerbation; computed tomographic scan; microbiome	TRADE-CENTER DUST; SMALL-AIRWAY-OBSTRUCTION; BLOOD EOSINOPHIL COUNT; CORTICOSTEROID TREATMENT; INHALED CORTICOSTEROIDS; COMPUTED-TOMOGRAPHY; ACUTE EXACERBATIONS; PRECISION MEDICINE; CIGARETTE-SMOKING; NORMAL SPIROMETRY	The diagnosis and treatment of chronic obstructive pulmonary disease (COPD) has been based largely on a one-size-fits-all approach. Diagnosis of COPD is based on meeting the physiologic criteria of fixed obstruction in forced expiratory flows and treatment focus on symptomatic relief, with limited effect on overall prognosis. However, patients with COPD have distinct features that determine very different evolutions of the disease. In this review we highlight distinct subgroups of COPD characterized by unique pathophysiologic derangements, response to treatment, and disease progression. It is likely that identification of subgroups of COPD will lead to discovery of much needed disease-modifying therapeutic approaches. We argue that a precision approach that integrates multiple dimensions (clinical, physiologic, imaging, and endotyping) is needed to move the field forward in the treatment of this disease.	[Segal, Leopoldo N.] NYU, Sch Med, Div Pulm & Crit Care Med, New York, NY 10003 USA; [Martinez, Fernando J.] Cornell Univ, Joan & Sanford Weill Med Coll 1, Div Pulm & Crit Care Med, Ithaca, NY 14853 USA	New York University; Cornell University	Segal, LN (corresponding author), NYU, Sch Med, 462 First Ave 7W54, New York, NY 10016 USA.	Leopoldo.Segal@nyumc.org		Segal, Leopoldo/0000-0003-3559-9431	 [K23 AI102970]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI102970] Funding Source: NIH RePORTER	; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant K23 AI102970.	Aarli BB, 2017, INT J CHRONIC OBSTR, V12, P2179, DOI 10.2147/COPD.S138720; Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Amer Thoracic Soc European Respir, 2003, AM J RESP CRIT CARE, V168, P818, DOI 10.1164/rccm.168.7.818; Azarpazhooh A, 2006, J PERIODONTOL, V77, P1465, DOI 10.1902/jop.2006.060010; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Banauch GI, 2010, CHEST, V138, P1116, DOI 10.1378/chest.10-0187; Barnes NC, 2016, EUR RESPIR J, V47, P1374, DOI 10.1183/13993003.01370-2015; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P240, DOI 10.1164/rccm.2604008; Barnes PJ, 2015, J ALLERGY CLIN IMMUN, V136, P531, DOI 10.1016/j.jaci.2015.05.052; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bathoorn Erik, 2008, Int J Chron Obstruct Pulmon Dis, V3, P217; Bel EH, 2017, CHEST, V152, P1276, DOI 10.1016/j.chest.2017.05.019; Berger Kenneth I, 2015, ERJ Open Res, V1; Berger KI, 2016, AM J IND MED, V59, P767, DOI 10.1002/ajim.22639; Berger KI, 2016, ERJ OPEN RES, V2; Bhatt SP, 2016, AM J RESP CRIT CARE, V194, P178, DOI 10.1164/rccm.201511-2219OC; Bhatt SP, 2016, JAMA-J AM MED ASSOC, V315, P498, DOI 10.1001/jama.2015.19431; Blasi F, 2012, CURR OPIN PHARMACOL, V12, P293, DOI 10.1016/j.coph.2012.01.006; Bourbeau J, 2014, COPD, V11, P125, DOI 10.3109/15412555.2012.665520; Broekema M, 2009, AM J RESP CRIT CARE, V180, P1170, DOI 10.1164/rccm.200906-0828OC; Bush A, 2015, LANCET, V385, P1273, DOI 10.1016/S0140-6736(15)60654-7; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1; Caplan-Shaw CE, 2011, J OCCUP ENVIRON MED, V53, P981, DOI 10.1097/JOM.0b013e31822fff60; Cazzola M, 2017, MOL DIAGN THER, V21, P345, DOI 10.1007/s40291-017-0266-z; Cazzola M, 2016, J ALLERGY CLIN IMMUN, V138, P977, DOI 10.1016/j.jaci.2016.04.028; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Cerveri I, 2008, THORAX, V63, P1040, DOI 10.1136/thx.2008.095554; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chapman KR, 2015, LANCET, V386, P360, DOI 10.1016/S0140-6736(15)60860-1; Christenson SA, 2015, AM J RESP CRIT CARE, V191, P758, DOI 10.1164/rccm.201408-1458OC; Ciba Guest Symposium, 1959, THORAX, V14, P286, DOI 10.1136/thx.14.4.286; Cosio M G, 2000, Monaldi Arch Chest Dis, V55, P124; Couper D, 2014, THORAX, V69, P491, DOI 10.1136/thoraxjnl-2013-203897; CRAWFORD ABH, 1985, J APPL PHYSIOL, V59, P838, DOI 10.1152/jappl.1985.59.3.838; Crisafulli E, 2008, THORAX, V63, P487, DOI 10.1136/thx.2007.086371; Cvejic L, 2011, RESPIROLOGY, V16, P269, DOI 10.1111/j.1440-1843.2010.01875.x; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277, DOI 10.1164/ajrccm.158.4.9802078; Divo M, 2012, AM J RESP CRIT CARE, V186, P155, DOI 10.1164/rccm.201201-0034OC; Divo MJ, 2015, EUR RESPIR J, V46, P640, DOI 10.1183/09031936.00171614; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; DUBOIS AB, 1956, J APPL PHYSIOL, V8, P587, DOI 10.1152/jappl.1956.8.6.587; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Fishman A, 2003, NEW ENGL J MED, V348, P2059; Friedman SM, 2011, AM J RESP CRIT CARE, V184, P582, DOI 10.1164/rccm.201011-1909OC; Galban CJ, 2012, NAT MED, V18, P1711, DOI 10.1038/nm.2971; Han MK, 2017, LANCET RESP MED, V5, P619, DOI 10.1016/S2213-2600(17)30207-2; Han MK, 2010, AM J RESP CRIT CARE, V182, P598, DOI 10.1164/rccm.200912-1843CC; Harvey BG, 2015, EUR RESPIR J, V46, P1589, DOI 10.1183/13993003.02377-2014; Hayes C, 1998, Ann Periodontol, V3, P257, DOI 10.1902/annals.1998.3.1.257; Hill AT, 2000, AM J MED, V109, P288, DOI 10.1016/S0002-9343(00)00507-6; Hizawa N, 2007, CHEST, V132, P1485, DOI 10.1378/chest.07-1103; Hogg JC, 2017, PHYSIOL REV, V97, P529, DOI 10.1152/physrev.00025.2015; Hogg JC, 2009, ANNU REV PATHOL-MECH, V4, P435, DOI 10.1146/annurev.pathol.4.110807.092145; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Imai K, 2005, EUR RESPIR J, V25, P250, DOI 10.1183/09031936.05.00023704; Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Jones RC, 2009, AM J RESP CRIT CARE, V180, P1189, DOI 10.1164/rccm.200902-0271OC; Kanoh S, 2010, CLIN MICROBIOL REV, V23, P590, DOI 10.1128/CMR.00078-09; Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117; Kazeros A, 2015, J OCCUP ENVIRON MED, V57, P610, DOI 10.1097/JOM.0000000000000458; Keene JD, 2017, AM J RESP CRIT CARE, V195, P473, DOI 10.1164/rccm.201607-1330OC; KESTEN S, 1994, CHEST, V105, P1042, DOI 10.1378/chest.105.4.1042; Kim V, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-52; Kim V, 2011, CHEST, V140, P626, DOI 10.1378/chest.10-2948; Kirby M, 2018, AM J RESP CRIT CARE, V197, P56, DOI 10.1164/rccm.201704-0692OC; Kleinert S, 2018, LANCET, V391, P292, DOI 10.1016/S0140-6736(17)32205-5; Kraft M, 2006, AM J RESP CRIT CARE, V174, P238, DOI 10.1164/rccm.2604007; Kraft M, 2006, AM J RESP CRIT CARE, V174, P243, DOI 10.1164/rccm.2604009; Kurashima K, 2016, INT J CHRONIC OBSTR, V11, P479, DOI 10.2147/COPD.S97343; Labaki WW, 2017, AM J RESP CRIT CARE, V196, P1372, DOI 10.1164/rccm.201703-0451PP; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Le Rouzic O, 2017, CHEST; Izquierdo-Alonso JL, 2013, RESP MED, V107, P724, DOI 10.1016/j.rmed.2013.01.001; MACKLEM PT, 1967, J APPL PHYSIOL, V22, P395, DOI 10.1152/jappl.1967.22.3.395; Maestrelli P, 2001, AM J RESP CRIT CARE, V164, pS76, DOI 10.1164/ajrccm.164.supplement_2.2106067; McDonough JE, 2011, NEW ENGL J MED, V365, P1567, DOI 10.1056/NEJMoa1106955; Mohan A, 2010, RESPIROLOGY, V15, P536, DOI 10.1111/j.1440-1843.2010.01722.x; Mokhlesi B, 2002, CHEST, V121, P361, DOI 10.1378/chest.121.2.361; MONSO E, 1995, AM J RESP CRIT CARE, V152, P1316, DOI 10.1164/ajrccm.152.4.7551388; Murgu S, 2013, CLIN CHEST MED, V34, P527, DOI 10.1016/j.ccm.2013.05.003; Murphy TF, 2008, AM J RESP CRIT CARE, V177, P853, DOI 10.1164/rccm.200709-1413OC; Ochs RA, 2009, ACAD RADIOL, V16, P46, DOI 10.1016/j.acra.2008.05.020; Oppenheimer BW, 2007, CHEST, V132, P1275, DOI 10.1378/chest.07-0913; Oshagbemi Olorunfemi A, 2017, Am J Respir Crit Care Med, V195, P1402, DOI 10.1164/rccm.201701-0009LE; Papaioannou AI, 2017, COPD, V14, P635, DOI 10.1080/15412555.2017.1386644; Papi A, 2006, AM J RESP CRIT CARE, V173, P1114, DOI 10.1164/rccm.200506-859OC; Parker CM, 2005, EUR RESPIR J, V26, P420, DOI 10.1183/09031936.05.00136304; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 2017, NEW ENGL J MED, V377, P1613, DOI 10.1056/NEJMoa1708208; Pavord ID, 2018, LANCET, V391, P350, DOI 10.1016/S0140-6736(17)30879-6; Pavord ID, 2016, LANCET RESP MED, V4, P731, DOI 10.1016/S2213-2600(16)30148-5; PIIPER J, 1966, RESP PHYSIOL, V1, P75, DOI 10.1016/0034-5687(66)90030-2; Pillai SG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000421; Pomares X, 2011, INT J CHRONIC OBSTR, V6, P449, DOI 10.2147/COPD.S23655; Puhan MA, 2009, LANCET, V374, P704, DOI 10.1016/S0140-6736(09)61301-5; Rascon-Aguilar IE, 2006, CHEST, V130, P1096, DOI 10.1378/chest.130.4.1096; Ravensberg AJ, 2013, RESP MED, V107, P959, DOI 10.1016/j.rmed.2013.03.018; Regan EA, 2015, JAMA INTERN MED, V175, P1539, DOI 10.1001/jamainternmed.2015.2735; Rennard SI, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-18; Roche N, 2017, AM J RESP CRIT CARE, V195, P1189, DOI 10.1164/rccm.201701-0193OC; Russell REK, 2002, AM J RESP CELL MOL, V26, P602, DOI 10.1165/ajrcmb.26.5.4685; Russell S L, 1999, Spec Care Dentist, V19, P128, DOI 10.1111/j.1754-4505.1999.tb01413.x; Saha Shironjit, 2006, Int J Chron Obstruct Pulmon Dis, V1, P39, DOI 10.2147/copd.2006.1.1.39; Scannapieco F A, 1998, Ann Periodontol, V3, P251, DOI 10.1902/annals.1998.3.1.251; Scannapieco FA, 2001, J PERIODONTOL, V72, P50, DOI 10.1902/jop.2001.72.1.50; Schnell K, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-26; Sciurba FC, 2010, NEW ENGL J MED, V363, P1233, DOI 10.1056/NEJMoa0900928; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC; Segal LN, 2017, THORAX, V72, P13, DOI 10.1136/thoraxjnl-2016-208599; Segal LN, 2011, COPD, V8, P145, DOI 10.3109/15412555.2011.560127; Sethi S, 2006, AM J RESP CRIT CARE, V173, P991, DOI 10.1164/rccm.200509-1525OC; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi S, 2007, AM J RESP CRIT CARE, V176, P356, DOI 10.1164/rccm.200703-417OC; Sethi S, 2011, CLIN INFECT DIS, V52, pS290, DOI 10.1093/cid/cir044; Shrimanker R, 2017, CLIN SCI, V131, P1027, DOI 10.1042/CS20160028; Siddiqui SH, 2015, AM J RESP CRIT CARE, V192, P523, DOI 10.1164/rccm.201502-0235LE; Sin DD, 2016, EUR RESPIR J, V48, P664, DOI 10.1183/13993003.00436-2016; Singh D, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-43; Smith BM, 2014, AM J MED, V127, DOI 10.1016/j.amjmed.2013.09.020; Suzuki T, 2001, CHEST, V120, P730, DOI 10.1378/chest.120.3.730; Tashkin DP, 2008, EUR RESPIR J, V31, P742, DOI 10.1183/09031936.00129607; Thomson NC, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02061-2016; Thomson NC, 2013, RESP MED, V107, P1501, DOI 10.1016/j.rmed.2013.07.017; Turato G, 2017, AM J RESP CRIT CARE; TURINO GM, 1969, SCIENCE, V165, P709, DOI 10.1126/science.165.3894.709; van der Lee I, 2009, RESP MED, V103, P1892, DOI 10.1016/j.rmed.2009.06.005; Verbanck S, 2004, AM J RESP CRIT CARE, V170, P414, DOI 10.1164/rccm.200401-037OC; Verbanck S, 1998, AM J RESP CRIT CARE, V157, P1573, DOI 10.1164/ajrccm.157.5.9710042; VERBANCK S, 1990, J APPL PHYSIOL, V69, P2269, DOI 10.1152/jappl.1990.69.6.2269; Vogelmeier CF, 2017, EUR RESPIR J, V49, DOI [10.1164/rccm.201701-0218PP, 10.1183/13993003.00214-2017, 10.1111/resp.13012, 10.1016/j.arbres.2017.02.001]; Watz H, 2016, LANCET RESP MED, V4, P390, DOI 10.1016/S2213-2600(16)00100-4; Wedzicha JA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-181; Wedzicha JA, 2013, CHEST, V143, P1302, DOI 10.1378/chest.12-1489; Wilkinson TMA, 2006, CHEST, V129, P317, DOI 10.1378/chest.129.2.317; Woodruff PG, 2017, AM J RESP CRIT CARE, V196, P375, DOI 10.1164/rccm.201705-0973WS; Woodruff PG, 2016, NEW ENGL J MED, V374, P1811, DOI 10.1056/NEJMoa1505971; Woodruff PG, 2015, LANCET, V385, P1789, DOI 10.1016/S0140-6736(15)60693-6; Xavier RF, 2013, RESPIRATION, V86, P479, DOI 10.1159/000348398; Xu WN, 2008, AM J RESP CRIT CARE, V178, P913, DOI 10.1164/rccm.200804-619OC; YANAI M, 1992, J APPL PHYSIOL, V72, P1016, DOI 10.1152/jappl.1992.72.3.1016; Zysman M, 2017, INT J CHRONIC OBSTR, V12, P1819, DOI 10.2147/COPD.S129787	149	28	31	5	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					1961	1971		10.1016/j.jaci.2018.02.035	http://dx.doi.org/10.1016/j.jaci.2018.02.035			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29884286	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000434701600001
J	Dispenza, MC; Pongracic, JA; Singh, AM; Bochner, BS				Dispenza, Melanie C.; Pongracic, Jacqueline A.; Singh, Anne M.; Bochner, Bruce S.			Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Dispenza, Melanie C.; Pongracic, Jacqueline A.; Singh, Anne M.; Bochner, Bruce S.] Northwestern Univ, Dept Med, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Pongracic, Jacqueline A.; Singh, Anne M.] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp Chicago, Div Allergy Immunol, Dept Pediat,Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Bochner, BS (corresponding author), Northwestern Univ, Dept Med, Div Allergy & Immunol, Feinberg Sch Med, Chicago, IL 60611 USA.	bruce.bochner@northwestern.edu	Dispenza, Melanie/L-9123-2019		Dixon Translational Innovation Award through the Northwestern University Clinical and Translational Sciences Institute; Dixon Translational Innovation Award through Northwestern Memorial Foundation; Northwestern University Allergy Immunology Research Program; T32 grant from the National Institute of Allergy and Infectious Diseases [AI083216]; K23 grant from the National Institute of Allergy and Infectious Diseases [AI100995]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI100995, T32AI083216] Funding Source: NIH RePORTER	Dixon Translational Innovation Award through the Northwestern University Clinical and Translational Sciences Institute; Dixon Translational Innovation Award through Northwestern Memorial Foundation; Northwestern University Allergy Immunology Research Program; T32 grant from the National Institute of Allergy and Infectious Diseases; K23 grant from the National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded in part by a 2016 Dixon Translational Innovation Award to B.S.B. through the Northwestern University Clinical and Translational Sciences Institute and Northwestern Memorial Foundation, and the Northwestern University Allergy Immunology Research Program as well as T32 grant AI083216 to M.C.D. and K23 grant AI100995 to A.M.S. from the National Institute of Allergy and Infectious Diseases.	Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Dispenza MC, 2017, EXPERT REV CLIN IMMU, V13, P921, DOI 10.1080/1744666X.2017.1370374; Iyer AS, 2011, J BIOL CHEM, V286, P9503, DOI 10.1074/jbc.M110.165613; Korosec P, 2017, J ALLERGY CLIN IMMUN, V140, P750, DOI 10.1016/j.jaci.2016.12.989; Kuehn HS, 2008, J IMMUNOL, V181, P7706, DOI 10.4049/jimmunol.181.11.7706; Lin C, 2017, PEDIAT ALLERG IMM-UK, V28, P619, DOI 10.1111/pai.12767; MacGlashan D, 2011, INT IMMUNOPHARMACOL, V11, P475, DOI 10.1016/j.intimp.2010.12.018; Regan JA, 2017, J ALLERGY CLIN IMMUN, V140, P875, DOI 10.1016/j.jaci.2017.03.013; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540	9	28	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1914	+		10.1016/j.jaci.2017.12.987	http://dx.doi.org/10.1016/j.jaci.2017.12.987			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29360526	Bronze, Green Accepted			2022-12-18	WOS:000432148200043
J	Weissler, KA; Rasooly, M; DiMaggio, T; Bolan, H; Cantave, D; Martino, D; Neeland, MR; Tang, MLK; Dang, TD; Allen, KJ; Frischmeyer-Guerrerio, PA				Weissler, Katherine A.; Rasooly, Marjohn; DiMaggio, Tom; Bolan, Hyejeong; Cantave, Daly; Martino, David; Neeland, Melanie R.; Tang, Mimi L. K.; Dang, Thanh D.; Allen, Katrina J.; Frischmeyer-Guerrerio, Pamela A.			Identification and analysis of peanut-specific effector T and regulatory T cells in children allergic and tolerant to peanut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; regulatory T; antigen specificity; CD154; CD137; cutaneous lymphocyte antigen; alpha 4 beta 7; route of sensitization; food allergy	FOOD ALLERGY; ATOPIC-DERMATITIS; IMMUNE-RESPONSES; HOMING RECEPTOR; RISK-FACTOR; FOXP3 GENE; ANTIGEN; PREVALENCE; MILK; EXPRESSION	Background: Peanut allergy (PA) is potentially life-threatening and generally persists for life. Recent data suggest the skin might be an important route of initial sensitization to peanut, whereas early oral exposure to peanut is protective. In mice regulatory T (Treg) cells are central to the development of food tolerance, but their contribution to the pathogenesis of food allergy in human subjects is less clear. Objective: We sought to quantify and phenotype CD4(+) peanut-specific effector T (ps-Teff) cells and peanut-specific regulatory T (ps-Treg) cells in children with and without PA or PS. Methods: ps-Teff and ps-Treg cells were identified from peripheral blood of children with PA, children with PS, and nonsensitized/nonallergic (NA) school-aged children and 1-year-old infants based on upregulation of CD154 or CD137, respectively, after stimulation with peanut extract. Expression of cytokines and homing receptors was evaluated by using flow cytometry. Methylation at the forkhead box protein 3 (FOXP3) locus was measured as a marker of Treg cell stability. Results: Differential upregulation of CD154 and CD137 efficiently distinguished ps-Teff and ps-Treg cells. A greater percentage of ps-Teff cells from infants with PA and infants with PS expressed the skin-homing molecule cutaneous lymphocyte antigen, suggesting activation after exposure through the skin, compared with NA infants. Although ps-Teff cells in both school-aged and infant children with PA produced primarily T(H)2 cytokines, a T(H)1-skewed antipeanut response was seen only in NA school-aged children. The frequency, homing receptor expression, and stability of ps-Treg cells in infants and school-aged children were similar, regardless of allergic status. Conclusions: Exposure to peanut through the skin can prime the development of T(H)2 ps-Teff cells, which promote sensitization to peanut, despite the presence of normal numbers of ps-Treg cells.	[Weissler, Katherine A.; Rasooly, Marjohn; DiMaggio, Tom; Bolan, Hyejeong; Cantave, Daly; Frischmeyer-Guerrerio, Pamela A.] NIAID, Lab Allerg Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Martino, David; Neeland, Melanie R.; Tang, Mimi L. K.; Dang, Thanh D.; Allen, Katrina J.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Tang, Mimi L. K.; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia; [Martino, David; Tang, Mimi L. K.; Dang, Thanh D.; Allen, Katrina J.] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Frischmeyer-Guerrerio, PA (corresponding author), BG 10 RM 11N240B MSC 1889,10 Ctr Dr, Bethesda, MD 20892 USA.	pamela.guerrerio@nih.gov	Neeland, Melanie/AAA-7402-2019; Guerrerio, Pamela/S-9360-2019; Tang, Mimi/ABD-8350-2020; Allen, Katrina/I-4361-2018; Dang, Thanh/AAK-1608-2021; Martino, DJ/X-1753-2019	Tang, Mimi/0000-0002-3839-5293; Allen, Katrina/0000-0002-1921-4493; Dang, Thanh/0000-0003-2010-5582; Martino, DJ/0000-0001-6823-4696; Neeland, Melanie/0000-0001-7301-9982	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001202] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.	Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; Ashley SE, 2017, ALLERGY, V72, P1356, DOI 10.1111/all.13143; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Bacher P, 2014, MUCOSAL IMMUNOL, V7, P916, DOI 10.1038/mi.2013.107; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Bacher P, 2014, J IMMUNOL, V193, P3332, DOI 10.4049/jimmunol.1400776; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Begin P, 2015, J ALLERGY CLIN IMMUN, V135, P1636, DOI 10.1016/j.jaci.2015.03.010; Bernard H, 2014, ALLERGY, V69, P888, DOI 10.1111/all.12411; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2013, J ALLERGY CLIN IMMUN, V132, P630, DOI 10.1016/j.jaci.2013.02.034; Chan SMH, 2012, ALLERGY, V67, P336, DOI 10.1111/j.1398-9995.2011.02765.x; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Frischmeyer-Guerrerio PA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006448; Ganeshan K, 2012, J IMMUNOL, V188, P594, DOI 10.4049/jimmunol.1102389; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Grindebacke H, 2009, J IMMUNOL, V183, P4360, DOI 10.4049/jimmunol.0901091; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hill DA, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0673-z; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Kantele A, 1999, J IMMUNOL, V162, P5173; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Koplin JJ, 2015, INT J EPIDEMIOL, V44, P1161, DOI 10.1093/ije/dyu261; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lexmond WS, 2016, J CLIN INVEST, V126, P4030, DOI 10.1172/JCI85129; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Martin PE, 2015, CLIN EXP ALLERGY, V45, P255, DOI 10.1111/cea.12406; Morikawa H, 2014, IMMUNOL REV, V259, P192, DOI 10.1111/imr.12174; Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Prescott SL, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-21; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Qamar N, 2015, CLIN EXP ALLERGY, V45, P1663, DOI 10.1111/cea.12570; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; Rott LS, 1997, J CLIN INVEST, V100, P1204, DOI 10.1172/JCI119633; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Schoenbrunn A, 2012, J IMMUNOL, V189, P5985, DOI 10.4049/jimmunol.1201090; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Smith KA, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-49; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tiemessen MM, 2004, J ALLERGY CLIN IMMUN, V113, P932, DOI 10.1016/j.jaci.2003.12.016; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Trendelenburg V, 2013, ALLERGY, V68, P1460, DOI 10.1111/all.12226; Tuano KS, 2015, J ALLERGY CLIN IMMUN, V135, P273, DOI 10.1016/j.jaci.2014.09.024; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Verbsky JW, 2013, CURR OPIN PEDIATR, V25, P708, DOI 10.1097/MOP.0000000000000029; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Zhang YX, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad4322; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750	58	28	28	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1699	U289		10.1016/j.jaci.2018.01.035	http://dx.doi.org/10.1016/j.jaci.2018.01.035			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29454004	Green Accepted, Bronze			2022-12-18	WOS:000432148200017
J	Wang, P; Zhao, W; Sun, J; Tao, T; Chen, X; Zheng, YY; Zhang, CH; Chen, Z; Gao, YQ; She, F; Li, YQ; Wei, LS; Lu, P; Chen, CP; Zhou, J; Wang, DQ; Chen, L; Shi, XH; Deng, LH; Zhuge, RH; Chen, HQ; Zhu, MS				Wang, Pei; Zhao, Wei; Sun, Jie; Tao, Tao; Chen, Xin; Zheng, Yan-Yan; Zhang, Cheng-Hai; Chen, Zhong; Gao, Yun-Qian; She, Fan; Li, Ye-Qiong; Wei, Li-Sha; Lu, Ping; Chen, Cai-Ping; Zhou, Ji; Wang, Da-Quan; Chen, Liang; Shi, Xiao-Hao; Deng, Linhong; Zhuge, Ronghua; Chen, Hua-Qun; Zhu, Min-Sheng			Inflammatory mediators mediate airway smooth muscle contraction through a G protein-coupled receptor-transmembrane protein 16A-voltage-dependent Ca2+ channel axis and contribute to bronchial hyperresponsiveness in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway smooth muscle; asthma; hypersensitivity; inflammatory mediator; TMEM16A	ACTIVATED CHLORIDE CHANNEL; PIG TRACHEAL MYOCYTES; LEUKOTRIENE D-4; IN-VIVO; CALCIUM; EXPRESSION; HISTAMINE; RESPONSIVENESS; METHACHOLINE; ANTAGONISTS	Background: Allergic inflammation has long been implicated in asthmatic hyperresponsiveness of airway smooth muscle (ASM), but its underlying mechanism remains incompletely understood. Serving as G protein-coupled receptor agonists, several inflammatory mediators can induce membrane depolarization, contract ASM, and augment cholinergic contractile response. We hypothesized that the signal cascade integrating on membrane depolarization by the mediators might involve asthmatic hyperresponsiveness. Objective: We sought to investigate the signaling transduction of inflammatory mediators in ASM contraction and assess its contribution in the genesis of hyperresponsiveness. Methods: We assessed the capacity of inflammatory mediators to induce depolarization currents by electrophysiological analysis. We analyzed the phenotypes of transmembrane protein 16A (TMEM16A) knockout mice, applied pharmacological reagents, and measured the Ca2+ signal during ASM contraction. To study the role of the depolarization signaling in asthmatic hyperresponsiveness, we measured the synergistic contraction by methacholine and inflammatory mediators both ex vivo and in an ovalbumin-induced mouse model. Results: Inflammatory mediators, such as 5-hydroxytryptamin, histamine, U46619, and leukotriene D-4, are capable of inducing Ca2+-activated Cl-currents in ASM cells, and these currents are mediated by TMEM16A. A combination of multiple analysis revealed that a G protein-coupled receptor-TMEM16-Avoltage-dependent Ca2+ channel signaling axis was required for ASM contraction induced by inflammatory mediators. Block of TMEM16A activity may significantly inhibit the synergistic contraction of acetylcholine and the mediators and hence reduces hypersensitivity. Conclusions: A G protein-coupled receptor-TMEM16-Avoltage-dependent Ca2+ channel axis contributes to inflammatory mediator-induced ASM contraction and synergistically activated TMEM16A by allergic inflammatory mediators with cholinergic stimuli.	[Wang, Pei; Zhao, Wei; Sun, Jie; Tao, Tao; Chen, Xin; Zheng, Yan-Yan; Zhang, Cheng-Hai; Chen, Zhong; Gao, Yun-Qian; She, Fan; Li, Ye-Qiong; Wei, Li-Sha; Chen, Cai-Ping; Zhu, Min-Sheng] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Model Anim Res Ctr, Minist Educ MOE,Key Lab Model Anim Dis Study, Nanjing, Jiangsu, Peoples R China; [Wang, Pei; Zhao, Wei; Sun, Jie; Tao, Tao; Chen, Xin; Zheng, Yan-Yan; Zhang, Cheng-Hai; Chen, Zhong; Gao, Yun-Qian; She, Fan; Li, Ye-Qiong; Wei, Li-Sha; Chen, Cai-Ping; Zhu, Min-Sheng] Nanjing Univ, Med Sch, Nanjing, Jiangsu, Peoples R China; [Zheng, Yan-Yan; Chen, Hua-Qun] Nanjing Normal Univ, Coll Life Sci, Nanjing 210023, Jiangsu, Peoples R China; [Lu, Ping; Zhuge, Ronghua] China Pharmaceut Univ, Jiangsu Key Lab Drug Discovery Metab Dis, Ctr Drug Discovery, Nanjing, Jiangsu, Peoples R China; [Chen, Cai-Ping] Jiangsu Prov Hosp, Dept Resp, Nanjing, Jiangsu, Peoples R China; [Zhou, Ji] Jiangsu Prov Hosp, Dept Thorac & Cardiovasc Surg, Nanjing, Jiangsu, Peoples R China; [Wang, Da-Quan; Chen, Liang] Univ Massachusetts, Med Sch, Dept Microbiol & Physiol Syst, Worcester, MA USA; [Shi, Xiao-Hao; Deng, Linhong] Changzhou Univ, Inst Biomed Engn & Hlth Sci, Changzhou, Peoples R China; [Zhu, Min-Sheng] Innovat Ctr Cardiovasc Disorders, Beijing, Peoples R China	Nanjing University; Nanjing University; Nanjing Normal University; China Pharmaceutical University; Nanjing Medical University; Nanjing Medical University; University of Massachusetts System; University of Massachusetts Worcester; Changzhou University	Chen, HQ (corresponding author), Nanjing Normal Univ, Coll Life Sci, Nanjing 210023, Jiangsu, Peoples R China.; Zhu, MS (corresponding author), Nanjing Univ, Model Anim Res Ctr, Nanjing 210061, Jiangsu, Peoples R China.	chenhuaqun@njnu.edu.cn; zhums@nju.edu.cn	Deng, Linhong/O-3218-2019; Deng, Linhong/C-1485-2009	Deng, Linhong/0000-0003-1970-8239; Chen, Xin/0000-0003-3304-8943; Lu, Ping/0000-0002-8953-1494	National Natural Science Foundation of China [31330034, 31371356/30971540, 31501182, 11532003]; Jiangsu Major Nature Science Foundation of High Education [13KJA180004]; National Key Scientific Research Program of China (973 program) [2014CB964701]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Major Nature Science Foundation of High Education; National Key Scientific Research Program of China (973 program)	This work was supported by the National Natural Science Foundation of China (31330034 to M.-S.Z., 31371356/30971540 to H.-Q.C., 31501182 to C.-P.C., and 11532003 to L.D.), Jiangsu Major Nature Science Foundation of High Education (13KJA180004), and National Key Scientific Research Program of China (973 program; grant 2014CB964701).	ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ARMOUR CL, 1989, EUR J PHARMACOL, V165, P215, DOI 10.1016/0014-2999(89)90715-2; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 2001, PULM PHARMACOL THER, V14, P329, DOI 10.1006/pupt.2000.0318; Billington CK, 2003, RESP RES, V4; Borchers MT, 2003, AM J PHYSIOL-LUNG C, V285, pL114, DOI 10.1152/ajplung.00322.2002; Brightling CE, 2002, NEW ENGL J MED, V346, P827; Canning BJ, 2001, RESP PHYSIOL, V125, P113, DOI 10.1016/S0034-5687(00)00208-5; Catalli A, 2004, AM J PHYSIOL-LUNG C, V287, pL1035, DOI 10.1152/ajplung.00138.2004; Chipperfield AR, 2000, PROG BIOPHYS MOL BIO, V74, P175, DOI 10.1016/S0079-6107(00)00024-9; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; COLEMAN RA, 1989, BRIT J PHARMACOL, V96, P688, DOI 10.1111/j.1476-5381.1989.tb11869.x; COLEMAN RA, 1981, BRIT J PHARMACOL, V73, P773, DOI 10.1111/j.1476-5381.1981.tb16814.x; Danielsson J, 2015, ANESTHESIOLOGY, V123, P569, DOI 10.1097/ALN.0000000000000769; Davis AJ, 2010, AM J PHYSIOL-CELL PH, V299, pC948, DOI 10.1152/ajpcell.00018.2010; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; Fernandes DJ, 2003, J APPL PHYSIOL, V95, P844, DOI 10.1152/japplphysiol.00192.2003; Ferrera L, 2009, J BIOL CHEM, V284, P33360, DOI 10.1074/jbc.M109.046607; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gallos G, 2013, AM J PHYSIOL-LUNG C, V305, pL625, DOI 10.1152/ajplung.00068.2013; Gerthoffer WT, 1996, J PHARMACOL EXP THER, V278, P800; Gorenne I, 1998, J PHARMACOL EXP THER, V284, P549; Heinze C, 2014, J CLIN INVEST, V124, P675, DOI 10.1172/JCI70025; Hirota S, 2007, EUR RESPIR J, V30, P114, DOI 10.1183/09031936.00147706; Huang F, 2009, P NATL ACAD SCI USA, V106, P21413, DOI 10.1073/pnas.0911935106; JANSSEN LJ, 1993, J PHYSIOL-LONDON, V465, P661, DOI 10.1113/jphysiol.1993.sp019699; JANSSEN LJ, 1992, J PHYSIOL-LONDON, V453, P197, DOI 10.1113/jphysiol.1992.sp019224; Jin X, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004184; LANGLANDS JM, 1989, BRIT J PHARMACOL, V98, P336, DOI 10.1111/j.1476-5381.1989.tb12600.x; Manoury B, 2010, J PHYSIOL-LONDON, V588, P2305, DOI 10.1113/jphysiol.2010.189506; Moore BD, 2012, RESPIRATION, V83, P529, DOI 10.1159/000336835; Namkung W, 2011, J BIOL CHEM, V286, P2365, DOI 10.1074/jbc.M110.175109; Penn Raymond B, 2008, Proc Am Thorac Soc, V5, P47, DOI 10.1513/pats.200705-054VS; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Shiraki A, 2009, CLIN EXP ALLERGY, V39, P236, DOI 10.1111/j.1365-2222.2008.03164.x; STORK AP, 1994, BRIT J PHARMACOL, V113, P1093, DOI 10.1111/j.1476-5381.1994.tb17108.x; Takami M, 1998, PHARMACOL RES, V38, P133, DOI 10.1006/phrs.1998.0345; VANAMSTERDAM RGM, 1989, EUR J PHARM-MOLEC PH, V172, P175, DOI 10.1016/0922-4106(89)90008-4; WEICHMAN BM, 1983, J PHARMACOL EXP THER, V225, P310; Yang GC, 2004, AM J PHYSIOL-LUNG C, V286, pL992, DOI 10.1152/ajplung.00367.2003; Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313; Zariwala HA, 2012, J NEUROSCI, V32, P3131, DOI 10.1523/JNEUROSCI.4469-11.2012; Zhang CH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11358; Zhang CH, 2013, AM J RESP CRIT CARE, V187, P374, DOI 10.1164/rccm.201207-1303OC; Zhang WC, 2010, J BIOL CHEM, V285, P5522, DOI 10.1074/jbc.M109.062836; Zhuge R, 2010, J BIOL CHEM, V285, P2203, DOI 10.1074/jbc.M109.067546	46	28	30	0	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1259	+		10.1016/j.jaci.2017.05.053	http://dx.doi.org/10.1016/j.jaci.2017.05.053			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28754608	Bronze			2022-12-18	WOS:000429197800012
J	Vrtis, R; Vang, F; Kang, T; Salazar, L; Anderson, E; Pappas, T; Gangnon, R; Evans, MD; Jackson, DJ; Lemanske, RF; Bochkov, YA; Gern, JE				Vrtis, Rose; Vang, Fue; Kang, Teresa; Salazar, Lisa; Anderson, Elizabeth; Pappas, Tressa; Gangnon, Ronald; Evans, Michael D.; Jackson, Daniel J.; Lemanske, Robert F., Jr.; Bochkov, Yury A.; Gern, James E.			Association of rhinovirus species with common cold and asthma symptoms and bacterial pathogens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INFECTION; AZITHROMYCIN; SEVERITY; CHILDREN		[Vrtis, Rose; Vang, Fue; Kang, Teresa; Salazar, Lisa; Anderson, Elizabeth; Pappas, Tressa; Jackson, Daniel J.; Lemanske, Robert F., Jr.; Bochkov, Yury A.; Gern, James E.] Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA; [Gangnon, Ronald; Evans, Michael D.] Univ Wisconsin, Dept Biostat, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gern, JE (corresponding author), Univ Wisconsin, Dept Pediat, Madison, WI 53792 USA.	gern@medicine.wisc.edu		Gern, James/0000-0002-6667-4708; Gangnon, Ronald/0000-0003-2587-6714; Evans, Michael/0000-0001-7449-3993	National Institutes of Health (NIH) [T32 AI007635, U19 AI070503-01, U19 AI104317, P01 HL070831]; Clinical and Translational Science Award program, through the NIH National Center for Advancing Translational Sciences [UL1TR000427]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI104317, T32AI007635, U19AI070503] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical and Translational Science Award program, through the NIH National Center for Advancing Translational Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by the National Institutes of Health (NIH) (grant nos. T32 AI007635, U19 AI070503-01, U19 AI104317, and P01 HL070831), and the project was supported by the Clinical and Translational Science Award program, through the NIH National Center for Advancing Translational Sciences (grant no. UL1TR000427).	Bacharier LB, 2015, JAMA-J AM MED ASSOC, V314, P2034, DOI 10.1001/jama.2015.13896; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Bochkov YA, 2014, J CLIN MICROBIOL, V52, P2461, DOI 10.1128/JCM.00075-14; Gouveia EL, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-323; Greiner O, 2003, J CLIN MICROBIOL, V41, P1386, DOI 10.1128/JCM.41.4.1386-1390.2003; Kloepfer KM, 2014, J ALLERGY CLIN IMMUN, V133, P1301, DOI 10.1016/j.jaci.2014.02.030; Lee WM, 2012, AM J RESP CRIT CARE, V186, P886, DOI 10.1164/rccm.201202-0330OC; National Asthma Education and Prevention Program, 2007, EXP PAN REP 3 GUID D; Parker D, 2011, AM J RESP CELL MOL, V45, P189, DOI 10.1165/rcmb.2011-0011RT; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Stokholm J, 2016, LANCET RESP MED, V4, P19, DOI [10.1016/S2213-2600(15)00500-7, 10.1016/S2213-2600(16)00050-3]; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Wang X, 2011, INT J MED MICROBIOL, V301, P303, DOI 10.1016/j.ijmm.2010.11.004	14	28	30	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					822	+		10.1016/j.jaci.2017.09.027	http://dx.doi.org/10.1016/j.jaci.2017.09.027			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29111214	Bronze, Green Accepted			2022-12-18	WOS:000424410800052
J	Wong, XFCC; Denil, SLIJ; Foo, JN; Chen, HJ; Tay, ASL; Haines, RL; Tang, MBY; McLean, WHI; Sandilands, A; Smith, FJD; Lane, EB; Liu, JJ; Common, JEA				Wong, X. F. Colin C.; Denil, Simon L. I. J.; Foo, Jia Nee; Chen, Huijia; Tay, Angeline Su Ling; Haines, Rebecca L.; Tang, Mark B. Y.; McLean, W. H. Irwin; Sandilands, Aileen; Smith, Frances J. D.; Lane, E. Birgitte; Liu, Jianjun; Common, John E. A.			Array-based sequencing of filaggrin gene for comprehensive detection of disease-associated variants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ATOPIC-DERMATITIS; MUTATIONS		[Wong, X. F. Colin C.; Denil, Simon L. I. J.; Chen, Huijia; Tay, Angeline Su Ling; Haines, Rebecca L.; Lane, E. Birgitte; Common, John E. A.] ASTAR, Inst Med Biol, Singapore, Singapore; [Foo, Jia Nee; Liu, Jianjun] ASTAR, Genome Inst Singapore, Singapore, Singapore; [Foo, Jia Nee] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Tang, Mark B. Y.] Natl Skin Ctr, Singapore, Singapore; [McLean, W. H. Irwin; Sandilands, Aileen; Smith, Frances J. D.] Univ Dundee, Dermatol & Genet Med, Div Biol Chem & Drug Discovery, Sch Life Sci, Dundee, Scotland	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National Skin Centre; University of Dundee	Common, JEA (corresponding author), ASTAR, Inst Med Biol, Singapore, Singapore.	john.common@imb.a-star.edu.sg	Liu, Jianjun/AAK-4989-2020; Foo, Jia Nee/D-6069-2014; Common, John/Q-6412-2018	Liu, Jianjun/0000-0002-3255-3019; Foo, Jia Nee/0000-0001-9899-2308; Common, John/0000-0002-3280-7365	A*STAR Strategic Positioning Fund (SPF) grants for basic and translational skin research [IAF SPF 2013/004, IAF SPF 2013/005]; A*STAR SPF grant for genetic orphan diseases [IAF SPF 2012/005]; Wellcome Trust Strategic Award [098439]; MRC [MR/P012248/1] Funding Source: UKRI	A*STAR Strategic Positioning Fund (SPF) grants for basic and translational skin research; A*STAR SPF grant for genetic orphan diseases; Wellcome Trust Strategic Award(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded by A*STAR Strategic Positioning Fund (SPF) grants for basic and translational skin research (grant nos. IAF SPF 2013/004 and IAF SPF 2013/005 to J.E.A.C., E.B.L., J.N.F., S.L.I.J.D., and J.L.), and A*STAR SPF grant for genetic orphan diseases (grant no. IAF SPF 2012/005 to X.F.C.C.W.). A.S and F.J.D.S. were supported by a Wellcome Trust Strategic Award (grant no. 098439) to W.H.I.M.	Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Chen H, 2011, BRIT J DERMATOL, V165, P106, DOI 10.1111/j.1365-2133.2011.10331.x; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433	8	28	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					814	U1107		10.1016/j.jaci.2017.10.001	http://dx.doi.org/10.1016/j.jaci.2017.10.001			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29056476	Green Published, Green Submitted, hybrid			2022-12-18	WOS:000424410800049
J	Leung, ASY; Wong, GWK; Tang, MLK				Leung, Agnes S. Y.; Wong, Gary W. K.; Tang, Mimi L. K.			Food allergy in the developing world	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Food allergy; prevalence; developing country; ethnicity	SOUTH-AFRICAN CHILDREN; PEANUT ALLERGY; ATOPIC-DERMATITIS; SENSITIZATION; ANAPHYLAXIS; PREVALENCE; INFANTS		[Leung, Agnes S. Y.; Wong, Gary W. K.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, Shatin, Hong Kong, Peoples R China; [Tang, Mimi L. K.] Murdoch Childrens Res Inst, Allergy & Immune Disorders, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Melbourne, Vic, Australia	Chinese University of Hong Kong; Prince of Wales Hospital; Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne	Tang, MLK (corresponding author), 50 Flemington Rd, Parkville, Vic 3052, Australia.	mimi.tang@rch.org.au	Leung, Agnes/ABD-6851-2020; Wong, Gary WK/AAY-9207-2020; Tang, Mimi/ABD-8350-2020	Leung, Agnes/0000-0001-8249-4478; Wong, Gary WK/0000-0001-5939-812X; Tang, Mimi/0000-0002-3839-5293	Hong Kong Institute of Allergy; Innovation and Technology Fund (HKSAR); Hong Kong Research Grant Council [CUHK4512/M, CUHK 477110]; TS Lo Foundation; National Health and Medical Research Council; Danone Nutricia; Nestle Health Sciences; MD Linx	Hong Kong Institute of Allergy; Innovation and Technology Fund (HKSAR); Hong Kong Research Grant Council(Hong Kong Research Grants Council); TS Lo Foundation; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Danone Nutricia(Danone Nutricia); Nestle Health Sciences(Nestle SA); MD Linx	A.S.Y. Leung has received grants from the Hong Kong Institute of Allergy and the Innovation and Technology Fund (HKSAR). G.W.K. Wong has received grants from the Hong Kong Research Grant Council (grant nos. CUHK4512/M and CUHK 477110) and the TS Lo Foundation. M.L.K. Tang has board memberships with Nestle Nutrition Institute and Danone Nutricia; has consultant arrangements with Deerfield Consulting, GLG Consulting, and Bayer; is employed by ProTA Therapeutics; has received grants from the National Health and Medical Research Council; has received payment for lectures from Danone Nutricia and Nestle Health Sciences; is an inventor on a patent owned by Murdoch Children's Research Institute; has received royalties from Wilkinson Publishing; has received payment for the development of educational presentations from MD Linx; and has stock/stock options from ProTA Therapeutics.	[Anonymous], 2017, NATL ACAD SCI ENG ME; Basera W, 2015, ANN ALLERG ASTHMA IM, V115, P113, DOI 10.1016/j.anai.2015.06.003; Du Toit G, 2007, J ALLERGY CLIN IMMUN, V119, pS196, DOI 10.1016/j.jaci.2006.12.136; Gray CL, 2015, PEDIAT ALLERG IMM-UK, V26, P721, DOI 10.1111/pai.12459; Gray CL, 2014, PEDIAT ALLERG IMM-UK, V25, P572, DOI 10.1111/pai.12270; Hu Y, 2010, PEDIATR INT, V52, P820, DOI 10.1111/j.1442-200X.2010.03166.x; Keet CA, 2014, ANN ALLERG ASTHMA IM, V112, P222, DOI 10.1016/j.anai.2013.12.007; Kool B, 2016, POSTGRAD MED J, V92, P640, DOI 10.1136/postgradmedj-2015-133530; Koplin JJ, 2014, ALLERGY, V69, P1639, DOI 10.1111/all.12487; Levy MB, 2012, ISR MED ASSOC J, V14, P29; Mahesh PA, 2016, ALLERGY, V71, P1010, DOI 10.1111/all.12868; Obeng BB, 2011, INT ARCH ALLERGY IMM, V155, P63, DOI 10.1159/000318704; Panjari M, 2016, CLIN EXP ALLERGY, V46, P602, DOI 10.1111/cea.12699; Prescott SL, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-21; Sole D, 2011, CLINICS, V66, P943, DOI 10.1590/S1807-59322011000600004; Tanno LK, 2012, ALLERGY, V67, P783, DOI 10.1111/j.1398-9995.2012.02829.x; Umasunthar T, 2013, CLIN EXP ALLERGY, V43, P1333, DOI 10.1111/cea.12211	17	28	35	3	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					76	+		10.1016/j.jaci.2017.11.008	http://dx.doi.org/10.1016/j.jaci.2017.11.008			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	29174528	Bronze			2022-12-18	WOS:000419312200008
J	Sorensen, M; Kuehn, A; Mills, ENC; Costello, CA; Ollert, M; Smabrekke, L; Primicerio, R; Wickman, M; Klingenberg, C				Sorensen, Martin; Kuehn, Annette; Mills, E. N. Clare; Costello, Carol Ann; Ollert, Markus; Smabrekke, Lars; Primicerio, Raul; Wickman, Magnus; Klingenberg, Claus			Cross-reactivity in fish allergy: A double-blind, placebo-controlled food-challenge trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PARVALBUMIN; COD		[Sorensen, Martin; Klingenberg, Claus] Univ Hosp North Norway, Dept Paediat & Adolescent Med, Tromso, Norway; [Sorensen, Martin; Klingenberg, Claus] Arctic Univ Norway, Univ Tromso, Inst Clin Med, Paediat Res Grp, Tromso, Norway; [Kuehn, Annette; Ollert, Markus] Luxembourg Inst Hlth, Dept Infect & Immun, Esch Sur Alzette, Luxembourg; [Mills, E. N. Clare; Costello, Carol Ann] Univ Manchester, Div Infect Immun & Resp Med, Sch Biol Sci, Manchester, Lancs, England; [Mills, E. N. Clare; Costello, Carol Ann] Univ Manchester, Manchester Inst Biotechnol, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Ollert, Markus] Univ Southern Denmark, Dept Dermatol, Odense Res Ctr Anaphylaxis, Odense, Denmark; [Ollert, Markus] Univ Southern Denmark, Allergy Ctr, Odense Res Ctr Anaphylaxis, Odense, Denmark; [Smabrekke, Lars; Primicerio, Raul] Arctic Univ Norway, Univ Tromso, Dept Pharm, Tromso, Norway; [Wickman, Magnus] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Wickman, Magnus] Soder Sjukhuset, Sachs Childrens Hosp, Stockholm, Sweden	UiT The Arctic University of Tromso; University Hospital of North Norway; UiT The Arctic University of Tromso; Luxembourg Institute of Health; University of Manchester; University of Manchester; University of Southern Denmark; University of Southern Denmark; UiT The Arctic University of Tromso; Karolinska Institutet; Sodersjukhuset Hospital	Sorensen, M (corresponding author), Univ Hosp North Norway, Dept Paediat & Adolescent Med, Tromso, Norway.; Sorensen, M (corresponding author), Arctic Univ Norway, Univ Tromso, Inst Clin Med, Paediat Res Grp, Tromso, Norway.	martin.sorensen@unn.no	Klingenberg, Claus/AAH-4467-2019	Klingenberg, Claus/0000-0001-6950-1573; Ollert, Markus W./0000-0002-8055-0103; Kuehn, Annette/0000-0003-0474-2135	Northern Norway Regional Health Authority; University of Tromso; University Hospital of North Norway; Norwegian Asthma and Allergy Association, Research fund; Odd Berg Group, Medical Research fund; Norwegian Allergology and Immunopathology Association, Research fund; Klosterstiftelsen, Research fund for asthma and allergy in children; Ministry of Higher Education and Research (MESR), Luxembourg; Thermo Fischer Scientific A/B	Northern Norway Regional Health Authority; University of Tromso; University Hospital of North Norway; Norwegian Asthma and Allergy Association, Research fund; Odd Berg Group, Medical Research fund; Norwegian Allergology and Immunopathology Association, Research fund; Klosterstiftelsen, Research fund for asthma and allergy in children; Ministry of Higher Education and Research (MESR), Luxembourg; Thermo Fischer Scientific A/B	Northern Norway Regional Health Authority; University of Tromso; University Hospital of North Norway; the Norwegian Asthma and Allergy Association, Research fund; Odd Berg Group, Medical Research fund; the Norwegian Allergology and Immunopathology Association, Research fund; Klosterstiftelsen, Research fund for asthma and allergy in children; the Ministry of Higher Education and Research (MESR), Luxembourg; and Thermo Fischer Scientific A/B (supplied ImmunoCAP tests free of charge). None of the funding sources was involved in study design, collection, analysis, or interpretation of data, in writing the report, or the decision to submit the article for publication.	AAS K, 1969, J ALLERGY, V44, P333, DOI 10.1016/0021-8707(69)90025-2; Ballmer-Weber BK, 2015, J ALLERGY CLIN IMMUN, V135, P964, DOI 10.1016/j.jaci.2014.10.047; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Helbling A, 1999, ANN ALLERG ASTHMA IM, V83, P517, DOI 10.1016/S1081-1206(10)62862-1; Kuehn A, 2013, CLIN EXP ALLERGY, V43, P811, DOI 10.1111/cea.12117; Kuehn A, 2010, INT ARCH ALLERGY IMM, V153, P359, DOI 10.1159/000316346; Mourad AA, 2015, EXPERT REV CLIN IMMU, V11, P419, DOI 10.1586/1744666X.2015.1009896; Sharp MF, 2014, CLIN REV ALLERG IMMU, V46, P258, DOI 10.1007/s12016-013-8363-1; Van Do T, 2005, J ALLERGY CLIN IMMUN, V116, P1314, DOI 10.1016/j.jaci.2005.07.033	9	28	28	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1170	+		10.1016/j.jaci.2017.03.043	http://dx.doi.org/10.1016/j.jaci.2017.03.043			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL	28479332	Bronze			2022-12-18	WOS:000412172900035
J	Miller, M; Rosenthal, P; Beppu, A; Gordillo, R; Broide, DH				Miller, Marina; Rosenthal, Peter; Beppu, Andrew; Gordillo, Ruth; Broide, David H.			Oroscomucoid like protein 3 (ORMDL3) transgenic mice have reduced levels of sphingolipids including sphingosine-1-phosphate and ceramide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYPERRESPONSIVENESS		[Miller, Marina; Rosenthal, Peter; Beppu, Andrew; Broide, David H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Gordillo, Ruth] Univ Texas Southwestern Med Ctr Dallas, Touchstone Diabet Ctr, Internal Med, Dallas, TX 75390 USA	University of California System; University of California San Diego; University of Texas System; University of Texas Southwestern Medical Center Dallas	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	dbroide@ucsd.edu		Gordillo, Ruth/0000-0001-6533-2493; Broide, David/0000-0001-8405-9090	National Institutes of Health [AI 107779, AI 38425, AI 70535, AI 72115, AI242236]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072115, R37AI038425, R01AI107779, R01AI038425, U19AI070535, R01AI124236] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Health (grant nos. AI 107779, AI 38425, AI 70535, AI 72115, and AI242236 to D.H.B.).	Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787; Cantero D, 2013, INT FORUM ALLERGY RH, V3, P877, DOI 10.1002/alr.21213; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Hothorn T, 2008, J STAT SOFTW, V28, P1; Lin SY, 2015, AM J RHINOL ALLERGY, V29, P82, DOI 10.2500/ajra.2015.29.4142; Matz MV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071448; Miller M, 2014, J IMMUNOL, V192, P3475, DOI 10.4049/jimmunol.1303047; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Price MM, 2013, J ALLERGY CLIN IMMUN, V131, P501, DOI 10.1016/j.jaci.2012.07.014; Ramezanpour M, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9798206; Roviezzo F, 2010, AM J RESP CELL MOL, V42, P572, DOI 10.1165/rcmb.2009-0108OC; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Warshauer JT, 2015, DIABETES-METAB RES, V31, P734, DOI 10.1002/dmrr.2662; Worgall TS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006730; Worgall TS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005765; Zamar D, 2007, J STAT SOFTW, V21, P1	19	28	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1373	1376		10.1016/j.jaci.2016.08.053	http://dx.doi.org/10.1016/j.jaci.2016.08.053			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27826095	Green Accepted, Bronze			2022-12-18	WOS:000398771800033
J	Frans, G; Moens, L; Schaballie, H; Wuyts, G; Liston, A; Poesen, K; Janssens, A; Rice, GI; Crow, YJ; Meyts, I; Bossuyt, X				Frans, Glynis; Moens, Leen; Schaballie, Heidi; Wuyts, Greet; Liston, Adrian; Poesen, Koen; Janssens, Ann; Rice, Gillian I.; Crow, Yanick J.; Meyts, Isabelle; Bossuyt, Xavier			Homozygous N-terminal missense mutation in TRNT1 leads to progressive B-cell immunodeficiency in adulthood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CONGENITAL SIDEROBLASTIC ANEMIA; DEVELOPMENTAL DELAY SIFD; REFERENCE VALUES; SUBPOPULATIONS; DEFICIENCY; FEVERS; CCA		[Frans, Glynis; Moens, Leen; Wuyts, Greet; Bossuyt, Xavier] Katholieke Univ Leuven, Expt Immunol Lab, Dept Microbiol & Immunol, Leuven, Belgium; [Schaballie, Heidi; Meyts, Isabelle] Katholieke Univ Leuven, Dept Microbiol & Immunol, Childhood Immunol, Leuven, Belgium; [Schaballie, Heidi; Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Liston, Adrian] Katholieke Univ Leuven, Autoimmune Genet, Dept Microbiol & Immunol, Leuven, Belgium; [Liston, Adrian] VIB, Leuven, Belgium; [Poesen, Koen; Bossuyt, Xavier] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium; [Janssens, Ann] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium; [Rice, Gillian I.; Crow, Yanick J.] Manchester Acad Hlth Ctr, Fac Med & Human Sci, Inst Human Dev, Manchester Ctr Genom Med, Manchester, Lancs, England; [Crow, Yanick J.] INSERM, UMR 1163, Lab Neurogenet & Neuroinflammat, Paris, France; [Crow, Yanick J.] Sorbonne Paris Cite Univ, Paris Descartes, Inst Imagine, Paris, France	KU Leuven; KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; University of Manchester; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Bossuyt, X (corresponding author), Katholieke Univ Leuven, Expt Immunol Lab, Dept Microbiol & Immunol, Leuven, Belgium.; Bossuyt, X (corresponding author), Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium.	xavier.bossuyt@uzleuven.be	Bossuyt, Xavier/B-2085-2019; Meyts, Isabelle/Z-3295-2019; Rice, Gillian I/G-3128-2015; Crow, Yanick J/N-6120-2014	Bossuyt, Xavier/0000-0001-6856-8485; Rice, Gillian I/0000-0002-4223-0571; Crow, Yanick J/0000-0001-7211-7564	Research Council of the Catholic University of Leuven, Belgium; Klinisch Onderzoeksfonds mandate of the KU Leuven, Belgium	Research Council of the Catholic University of Leuven, Belgium; Klinisch Onderzoeksfonds mandate of the KU Leuven, Belgium	This work was supported by a Geconcerteerde Onderzoeksactie grant from the Research Council of the Catholic University of Leuven, Belgium. I.M. is supported by a Klinisch Onderzoeksfonds mandate of the KU Leuven, Belgium.	Angelo LS, 2015, IMMUNOL RES, V62, P341, DOI 10.1007/s12026-015-8664-y; Chakraborty PK, 2014, BLOOD, V124, P2867, DOI 10.1182/blood-2014-08-591370; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; Crow YJ, 2015, NAT REV IMMUNOL, V15, P429, DOI 10.1038/nri3850; DeLuca AP, 2016, HUM MOL GENET, V25, P44, DOI 10.1093/hmg/ddv446; Giannelou AA, 2015, ANN RHEUM DIS, V74, pA30, DOI 10.1136/annrheumdis-2015-207259.70; Gineau L, 2012, J CLIN INVEST, V122, P821, DOI 10.1172/JCI61014; Goring ME, 2013, BBA-PROTEINS PROTEOM, V1834, P2097, DOI 10.1016/j.bbapap.2013.07.003; Hou YM, 2010, IUBMB LIFE, V62, P251, DOI 10.1002/iub.301; Ma CS, 2014, IMMUNOL CELL BIOL, V92, P64, DOI 10.1038/icb.2013.55; Morbach H, 2010, CLIN EXP IMMUNOL, V162, P271, DOI 10.1111/j.1365-2249.2010.04206.x; Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Sasarman F, 2015, HUM MOL GENET, V24, P2841, DOI 10.1093/hmg/ddv044; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wiseman DH, 2013, BLOOD, V122, P112, DOI 10.1182/blood-2012-08-439083; Woellner C, 2010, J ALLERGY CLIN IMMUN, V125, P424, DOI 10.1016/j.jaci.2009.10.059	18	28	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					360	+		10.1016/j.jaci.2016.06.050	http://dx.doi.org/10.1016/j.jaci.2016.06.050			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27531075	Bronze			2022-12-18	WOS:000393996800040
J	Shelef, DQ; Rand, C; Streisand, R; Horn, IB; Yadav, K; Stewart, L; Foushee, N; Waters, D; Teach, SJ				Shelef, Deborah Q.; Rand, Cynthia; Streisand, Randi; Horn, Ivor B.; Yadav, Kabir; Stewart, Lisa; Foushee, Naja; Waters, Damian; Teach, Stephen J.			Using stakeholder engagement to develop a patient-centered pediatric asthma intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; stress; intervention; patient engagement; stakeholder engagement; protocol development	OUTCOMES RESEARCH-INSTITUTE; RACIAL DISPARITIES; ENGAGING PATIENTS; CHILDREN; STRESS; TRIAL	Stakeholder engagement has the potential to develop research interventions that are responsive to patient and provider preferences. This approach contrasts with traditional models of clinical research in which researchers determine the study's design. This article describes the effect of stakeholder engagement on the design of a randomized trial of an intervention designed to improve child asthma outcomes by reducing parental stress. The study team developed and implemented a stakeholder engagement process that provided iterative feedback regarding the study design, patient-centered outcomes, and intervention. Stakeholder engagement incorporated the perspectives of parents of children with asthma; local providers of community-based medical, legal, and social services; and national experts in asthma research methodology and implementation. Through a year-long process of multidimensional stakeholder engagement, the research team successfully refined and implemented a patient-centered study protocol. Key stakeholder contributions included selection of patient-centered outcome measures, refinement of intervention content and format, and language framing the study in a culturally appropriate manner. Stakeholder engagement was a useful framework for developing an intervention that was acceptable and relevant to our target population. This approach might have unique benefits in underserved populations, leading to sustainable improvement in health outcomes and reduced disparities.	[Shelef, Deborah Q.; Streisand, Randi; Foushee, Naja; Waters, Damian] Childrens Natl Hlth Syst, Ctr Translat Sci, Washington, DC USA; [Teach, Stephen J.] Childrens Natl Hlth Syst, Dept Pediat, Washington, DC USA; [Rand, Cynthia] Johns Hopkins Med Ctr, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD USA; [Horn, Ivor B.] Univ Washington, Seattle Childrens Hosp, Sch Med, Seattle, WA 98195 USA; [Yadav, Kabir] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA; [Stewart, Lisa] Patient Centered Outcomes Res Inst, Engagement Div, Washington, DC USA	Children's National Health System; Children's National Health System; Johns Hopkins University; Johns Hopkins Medicine; Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Shelef, DQ (corresponding author), Childrens Natl Hlth Syst, 111 Michigan Ave NW, Washington, DC 20010 USA.	dquint@childrensnational.org		Yadav, Kabir/0000-0002-1092-9935	Patient-Centered Outcomes Research Institute (PCORI) Award [AS-1307-05284]	Patient-Centered Outcomes Research Institute (PCORI) Award(Patient-Centered Outcomes Research Institute - PCORI)	Research reported in this article was funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (AS-1307-05284). The funder played an important role in the community engagement process reported herein but played no role in the preparation of this manuscript. One of the authors (L.S.) was an independent paid consultant to the research team during the engagement process but is now employed by the PCORI in Washington, DC. The views, statements and opinions in this article, report are solely the responsibility of the authors and do not necessarily represent the views of the PCORI, its Board of Governors or Methodology Committee.	Akinbami LJ, 2014, J ALLERGY CLIN IMMUN, V134, P547, DOI 10.1016/j.jaci.2014.05.037; Beck AF, 2016, JAMA PEDIATR, V170, P695, DOI 10.1001/jamapediatrics.2016.0269; Clougherty JE, 2009, J URBAN HEALTH, V86, P214, DOI 10.1007/s11524-008-9341-4; Erwin K, 2016, J COMP EFFECT RES, V5, P17, DOI 10.2217/cer.15.52; Exley D, 2015, EUR RESPIR REV, V24, P299, DOI 10.1183/16000617.00004114; Fleurence R, 2013, HEALTH AFFAIR, V32, P393, DOI 10.1377/hlthaff.2012.1176; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Forsythe LP, 2016, J GEN INTERN MED, V31, P13, DOI 10.1007/s11606-015-3450-z; Frank L, 2015, QUAL LIFE RES, V24, P1033, DOI 10.1007/s11136-014-0893-3; Halterman JS, 2011, ARCH PEDIAT ADOL MED, V165, P262, DOI 10.1001/archpediatrics.2011.1; Hasnain-Wynia R, 2014, CLIN THER, V36, P619, DOI 10.1016/j.clinthera.2014.04.005; Horner CC, 2016, J ALLERGY CLIN IMMUN, V138, P1196, DOI 10.1016/j.jaci.2016.01.054; Kauffman KS, 2013, J COMP EFFECT RES, V2, P313, DOI [10.2217/cer.13.11, 10.2217/CER.13.11]; Laster N, 2009, J ASTHMA, V46, P731, DOI 10.1080/02770900903082571; Lee A, 2016, J ALLERGY CLIN IMMUN, V138, P740, DOI 10.1016/j.jaci.2016.01.014; McDaniel M, 2014, MAKING SENSE CHILDHO; National Heart Lung and Blood Institute/ National Asthma Education and Prevention Program, 2007, NIH PUBLICATION, V07-4051; Rand CS, 2012, J ALLERGY CLIN IMMUN, V129, pS136, DOI 10.1016/j.jaci.2011.12.987; Rosenberg SL, 2014, J ALLERGY CLIN IMMUN, V134, P1009, DOI 10.1016/j.jaci.2014.07.005; Selby JV, 2015, JAMA-J AM MED ASSOC, V314, P2235, DOI 10.1001/jama.2015.15139; Teach SJ, 2006, ARCH PEDIAT ADOL MED, V160, P535, DOI 10.1001/archpedi.160.5.535; Woolf SH, 2016, HEALTH AFFAIR, V35, P590, DOI 10.1377/hlthaff.2015.1512; Yonas MA, 2012, CURR OPIN ALLERGY CL, V12, P202, DOI 10.1097/ACI.0b013e32835090c9	23	28	28	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1512	1517		10.1016/j.jaci.2016.10.001	http://dx.doi.org/10.1016/j.jaci.2016.10.001			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	EF0MK	27744029	Bronze			2022-12-18	WOS:000390019300002
J	Ishizaka, K; Ishizaka, T				Ishizaka, Kimishige; Ishizaka, Teruko			Identification of IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; reagin	REAGINIC ANTIBODY; GAMMAE-GLOBULIN; HUMAN LEUKOCYTES; PHYSICOCHEMICAL PROPERTIES; PASSIVE SENSITIZATION; HISTAMINE RELEASE; MECHANISMS; MYELOMA; IMMUNOGLOBULIN; ANTIGEN	Progress in protein chemistry in the 1950s revealed that the biologic activities of proteins, such as hemoglobin and enzymes, are based on partial structures in the protein molecules. This principle suggested to us the possibility that the human antibodies responsible for induction of reaginic hypersensitivity reactions might have unique structures that are lacking in the antibody molecules involved in immunity and that the differences in the structures of human antibody molecules can be recognized by the immune systems of experimental animals. Our studies were based on the hypothesis that reaginic antibody activity is associated with a unique immunoglobulin isotype, which is now called IgE. As expected, identification of IgE facilitated the analysis of immunologic mechanisms of reaginic hypersensitivity. Subsequent studies revealed that IgE specifically bound to basophilic granulocytes and mast cells through the Fc portion of the molecules and that cross-linking of the cell-bound IgE antibody molecules by allergen induced the release of bioactive mediators, such as histamine and leukotrienes, which initiate allergic reactions. (J Allergy Clin Immunol 2016;137:1646-50.)	[Ishizaka, Kimishige; Ishizaka, Teruko] La Jolla Inst Allergy & Immunol, La Jolla, CA USA	La Jolla Institute for Immunology	Ishizaka, K (corresponding author), 1695-15 Zao Hango, Yamagata, Yamagata 9902305, Japan.	kishizak@agate.plala.or.jp						BENNICH H, 1969, J IMMUNOL, V102, P826; HEREMANS JF, 1962, NATURE, V193, P1091, DOI 10.1038/1931091b0; ISHIZAKA K, 1965, J IMMUNOL, V95, P197; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1966, J ALLERGY, V38, P108, DOI 10.1016/0021-8707(66)90050-5; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; ISHIZAKA K, 1967, J IMMUNOL, V99, P849; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; ISHIZAKA K, 1968, J IMMUNOL, V100, P554; ISHIZAKA K, 1969, J IMMUNOL, V103, P588; ISHIZAKA K, 1962, J IMMUNOL, V88, P690; ISHIZAKA K, 1968, J ALLERGY, V42, P330, DOI 10.1016/0021-8707(68)90095-6; ISHIZAKA K, 1968, J IMMUNOL, V101, P68; ISHIZAKA K, 1967, J IMMUNOL, V98, P490; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; ISHIZAKA T, 1969, J IMMUNOL, V102, P884; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; OGAWA M, 1969, NEW ENGL J MED, V281, P1217, DOI 10.1056/NEJM196911272812204; TOMIOKA H, 1971, J IMMUNOL, V107, P971	22	28	29	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1646	1650		10.1016/j.jaci.2015.12.1343	http://dx.doi.org/10.1016/j.jaci.2015.12.1343			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27090936	hybrid			2022-12-18	WOS:000377527200002
J	Wawrzyniak, P; Akdis, CA; Finkelman, FD; Rothenberg, ME				Wawrzyniak, Paulina; Akdis, Cezmi A.; Finkelman, Fred D.; Rothenberg, Marc E.			Advances and highlights in mechanisms of allergic disease in 2015	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; atopic dermatitis; asthma; eosinophilia; allergen immunotherapy	THYMIC STROMAL LYMPHOPOIETIN; PLATELET-ACTIVATING-FACTOR; REGULATORY T-CELLS; ATOPIC-DERMATITIS; MAST-CELL; IGE ANTIBODIES; AIRWAY HYPERRESPONSIVENESS; HYPERSENSITIVITY REACTIONS; IMMUNE DYSREGULATION; TRANSCRIPTION FACTOR	This review highlights some of the advances in mechanisms of allergic disease, particularly anaphylaxis, including food allergy, drug hypersensitivity, atopic dermatitis (AD), allergic conjunctivitis, and airway diseases. During the last year, a mechanistic advance in food allergy was achieved by focusing on mechanisms of allergen sensitization. Novel biomarkers and treatment for mastocytosis were presented in several studies. Novel therapeutic approaches in the treatment of atopic dermatitis and psoriasis showed that promising supplementation of the infant's diet in the first year of life with immunoactive prebiotics might have a preventive role against early development of AD and that therapeutic approaches to treat AD in children might be best directed to the correction of a T(H)2/T(H)1 imbalance. Several studies were published emphasizing the role of the epithelial barrier in patients with allergic diseases. An impaired skin barrier as a cause for sensitization to food allergens in children and its relationship to filaggrin mutations has been an important development. Numerous studies presented new approaches for improvement of epithelial barrier function and novel biologicals used in the treatment of inflammatory skin and eosinophilic diseases. In addition, novel transcription factors and signaling molecules that can develop as new possible therapeutic targets have been reported.	[Wawrzyniak, Paulina; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Wawrzyniak, Paulina; Akdis, Cezmi A.] CK CARE, Davos, Switzerland; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Allergy Immunol & Rheumatol, Cincinnati, OH USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA	Swiss Institute of Allergy & Asthma Research; University of Zurich; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Dept Immunol, Obere Str 22,Davos Pl, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020; Wawrzyniak, Paulina/AAD-7265-2020; Wawrzyniak, Paulina/HCG-8924-2022; Wawrzyniak, Paulina/AAG-3548-2019	Akdis, Cezmi/0000-0001-8020-019X; Wawrzyniak, Paulina/0000-0001-9641-2103; 				Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Akhabir L, 2014, J ALLERGY CLIN IMMUN, V134, P729, DOI 10.1016/j.jaci.2014.02.039; Altman AM, 2015, J ALLERGY CLIN IMMUN, V135, P830, DOI 10.1016/j.jaci.2014.10.049; Amano W, 2015, J ALLERGY CLIN IMMUN, V136, P667, DOI 10.1016/j.jaci.2015.03.051; Amison RT, 2015, J ALLERGY CLIN IMMUN, V135, P528, DOI 10.1016/j.jaci.2014.09.032; [Anonymous], 2015, J ALLERGY CLIN IMMUN, V136, P484, DOI 10.1016/j.jaci.2014.12.1941; Anzilotti C, 2015, J ALLERGY CLIN IMMUN, V136, P487, DOI 10.1016/j.jaci.2014.12.1943; dos Santos-Pinto JRA, 2015, J ALLERGY CLIN IMMUN, V135, P264, DOI 10.1016/j.jaci.2014.07.006; Ashino S, 2014, J ALLERGY CLIN IMMUN, V133, P1162, DOI 10.1016/j.jaci.2013.10.036; Balenga NA, 2014, J ALLERGY CLIN IMMUN, V134, P451, DOI 10.1016/j.jaci.2014.01.019; Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Bentley JK, 2014, J ALLERGY CLIN IMMUN, V134, P1433, DOI 10.1016/j.jaci.2014.05.029; Bhakta NR, 2014, J ALLERGY CLIN IMMUN, V134, P1187, DOI 10.1016/j.jaci.2014.07.034; Bin LH, 2014, J ALLERGY CLIN IMMUN, V134, P848, DOI 10.1016/j.jaci.2014.07.018; Bochner BS, 2015, J ALLERGY CLIN IMMUN, V135, P598, DOI 10.1016/j.jaci.2014.11.031; Broesby-Olsen S, 2015, J ALLERGY CLIN IMMUN, V135, P262, DOI 10.1016/j.jaci.2014.06.031; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Bublin M, 2014, J ALLERGY CLIN IMMUN, V134, P521, DOI 10.1016/j.jaci.2014.04.015; Bunyavanich S, 2015, J ALLERGY CLIN IMMUN, V135, P31, DOI 10.1016/j.jaci.2014.10.015; Cagnoni EF, 2015, J ALLERGY CLIN IMMUN, V135, P1352, DOI 10.1016/j.jaci.2014.08.021; Campbell BC, 2015, J ALLERGY CLIN IMMUN, V135, P133, DOI 10.1016/j.jaci.2014.06.034; Chan TF, 2015, J ALLERGY CLIN IMMUN, V135, P539, DOI 10.1016/j.jaci.2014.09.031; Chan YC, 2014, J ALLERGY CLIN IMMUN, V134, P1394, DOI 10.1016/j.jaci.2014.06.029; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Chou J, 2015, J ALLERGY CLIN IMMUN, V136, P479; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P941; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091; Czarnowicki T, 2015, J ALLERGY CLIN IMMUN, V136, P208, DOI 10.1016/j.jaci.2015.03.032; da Rosa JC, 2015, J ALLERGY CLIN IMMUN, V135, P712, DOI 10.1016/j.jaci.2014.11.017; de Groot JC, 2015, J ALLERGY CLIN IMMUN, V135, P670, DOI 10.1016/j.jaci.2014.11.033; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Eschborn M, 2015, J ALLERGY CLIN IMMUN, V136, P159, DOI 10.1016/j.jaci.2015.04.020; Ferstl R, 2014, J ALLERGY CLIN IMMUN, V134, P744, DOI 10.1016/j.jaci.2014.04.034; Fornasa G, 2015, J ALLERGY CLIN IMMUN, V136, P413, DOI 10.1016/j.jaci.2015.04.011; Fowler SJ, 2015, J ALLERGY CLIN IMMUN, V135, P822, DOI 10.1016/j.jaci.2014.09.034; Furuta GT, 2015, NEW ENGL J MED, V373, P1640, DOI 10.1056/NEJMra1502863; Gambineri E, 2015, J ALLERGY CLIN IMMUN, V135, P260, DOI 10.1016/j.jaci.2014.09.009; Gao L, 2015, J ALLERGY CLIN IMMUN, V136, P1591, DOI 10.1016/j.jaci.2015.06.047; Ghonim MA, 2015, J ALLERGY CLIN IMMUN, V135, P425, DOI 10.1016/j.jaci.2014.09.005; Gielen V, 2015, J ALLERGY CLIN IMMUN, V136, P177, DOI 10.1016/j.jaci.2014.11.039; Gill P, 2015, J ALLERGY CLIN IMMUN, V135, P1424, DOI 10.1016/j.jaci.2015.04.019; Goldblum RM, 2014, J ALLERGY CLIN IMMUN, V134, P967, DOI 10.1016/j.jaci.2014.05.009; Goldenberg A, 2015, J ALLER CL IMM-PRACT, V3, P661, DOI 10.1016/j.jaip.2015.02.007; Gruber C, 2015, J ALLERGY CLIN IMMUN, V136, P1696, DOI 10.1016/j.jaci.2015.07.049; Hansen S, 2015, J ALLERGY CLIN IMMUN, V136, P169, DOI 10.1016/j.jaci.2014.12.1924; Harb H, 2015, J ALLERGY CLIN IMMUN, V135, P15, DOI 10.1016/j.jaci.2014.11.009; Harvima IT, 2014, J ALLERGY CLIN IMMUN, V134, P530, DOI 10.1016/j.jaci.2014.03.007; Hatchwell L, 2014, J ALLERGY CLIN IMMUN, V133, P1720, DOI 10.1016/j.jaci.2013.11.014; Havstad S, 2014, J ALLERGY CLIN IMMUN, V134, P722, DOI 10.1016/j.jaci.2014.01.022; Hofmaier S, 2015, J ALLERGY CLIN IMMUN, V135, P1367, DOI 10.1016/j.jaci.2014.09.048; Hradetzky S, 2015, J ALLERGY CLIN IMMUN, V135, P1378, DOI 10.1016/j.jaci.2014.10.038; Ilmarinen P, 2015, J ALLERGY CLIN IMMUN, V136, P482, DOI 10.1016/j.jaci.2014.12.1922; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jia Y, 2015, J ALLERGY CLIN IMMUN, V135, P799, DOI 10.1016/j.jaci.2015.01.004; Jutel M, 2015, J ALLERGY CLIN IMMUN, V136, P556, DOI 10.1016/j.jaci.2015.04.047; Kaplan MH, 2015, NAT REV IMMUNOL, V15, P295, DOI 10.1038/nri3824; Kharya G, 2014, J ALLERGY CLIN IMMUN, V134, P1199, DOI 10.1016/j.jaci.2014.04.041; Kim JH, 2015, J ALLERGY CLIN IMMUN, V136, P205, DOI 10.1016/j.jaci.2015.04.026; Kiwamoto T, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Kiwamoto T, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Kiwamoto T, 2015, J ALLERGY CLIN IMMUN, V135, P1329, DOI 10.1016/j.jaci.2014.10.027; Kiwamoto T, 2014, J ALLERGY CLIN IMMUN, V133, P240, DOI 10.1016/j.jaci.2013.05.018; Knight JM, 2014, J ALLERGY CLIN IMMUN, V133, P189, DOI 10.1016/j.jaci.2013.03.049; Krueger JG, 2015, J ALLERGY CLIN IMMUN, V136, P116, DOI 10.1016/j.jaci.2015.01.018; Kubo T, 2015, J ALLERGY CLIN IMMUN, V136, P1413, DOI 10.1016/j.jaci.2015.05.006; Kuo NW, 2014, J ALLERGY CLIN IMMUN, V134, P731, DOI 10.1016/j.jaci.2014.03.018; Lee JJ, 2015, J ALLERGY CLIN IMMUN, V135, P477, DOI 10.1016/j.jaci.2014.07.003; Leiferman KM, 2015, J ALLERGY CLIN IMMUN, V135, P488, DOI 10.1016/j.jaci.2014.11.036; Leung DYM, 2014, J ALLERGY CLIN IMMUN, V134, P769, DOI 10.1016/j.jaci.2014.08.008; Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011; Li H, 2016, J ALLERGY CLIN IMMUN, V137, P613; Li JJ, 2015, J ALLERGY CLIN IMMUN, V136, P462, DOI 10.1016/j.jaci.2014.11.044; Lin CH, 2015, J ALLERGY CLIN IMMUN, V135, P1063, DOI 10.1016/j.jaci.2014.09.041; Lu L, 2015, EUR J CLIN NUTR, V69, P717, DOI 10.1038/ejcn.2015.67; MacDonald KG, 2015, J ALLERGY CLIN IMMUN, V135, P946, DOI 10.1016/j.jaci.2014.12.1932; Madritsch C, 2015, J ALLERGY CLIN IMMUN, V136, P490, DOI 10.1016/j.jaci.2015.01.006; Martino D, 2015, J ALLERGY CLIN IMMUN, V135, P1319, DOI 10.1016/j.jaci.2014.12.1933; Mashiko S, 2015, J ALLERGY CLIN IMMUN, V136, P351, DOI 10.1016/j.jaci.2015.01.033; Mazzeo C, 2015, J ALLERGY CLIN IMMUN, V135, P1603, DOI 10.1016/j.jaci.2014.11.026; McAleer MA, 2015, J ALLERGY CLIN IMMUN, V136, P1268, DOI 10.1016/j.jaci.2015.05.002; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Meazza R, 2014, J ALLERGY CLIN IMMUN, V134, P1381, DOI 10.1016/j.jaci.2014.04.043; Michels AW, 2015, J ALLERGY CLIN IMMUN, V136, P252, DOI 10.1016/j.jaci.2015.06.024; Mullins RJ, 2015, J ALLERGY CLIN IMMUN, V136, P367, DOI 10.1016/j.jaci.2015.05.009; Munoz-Cano R, 2016, J ALLERGY CLIN IMMUN, V137, P137, DOI 10.1016/j.jaci.2015.05.042; Nagao M, 2016, J ALLERGY CLIN IMMUN, V137, P861, DOI 10.1016/j.jaci.2015.08.001; Nagarkar DR, 2015, J ALLERGY CLIN IMMUN, V136, P202, DOI 10.1016/j.jaci.2015.01.036; Nakagomi D, 2015, J ALLERGY CLIN IMMUN, V135, P1397, DOI 10.1016/j.jaci.2014.10.055; Nakamura Y, 2014, J ALLERGY CLIN IMMUN, V133, P568, DOI 10.1016/j.jaci.2013.07.040; Nassiri M, 2016, J ALLERGY CLIN IMMUN, V137, P312, DOI 10.1016/j.jaci.2015.07.001; Nassiri M, 2015, J ALLERGY CLIN IMMUN, V135, P491, DOI 10.1016/j.jaci.2014.09.004; Nocerino R, 2015, J ALLERGY CLIN IMMUN, V135, P833, DOI 10.1016/j.jaci.2014.12.1912; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Noda S, 2015, J ALLERGY CLIN IMMUN, V135, P324, DOI 10.1016/j.jaci.2014.11.015; Oskeritzian CA, 2015, J ALLERGY CLIN IMMUN, V135, P1008, DOI 10.1016/j.jaci.2014.10.044; Pascual M, 2014, J ALLERGY CLIN IMMUN, V134, P972, DOI 10.1016/j.jaci.2014.05.015; Patel DA, 2014, J ALLERGY CLIN IMMUN, V134, P1402, DOI 10.1016/j.jaci.2014.07.013; Pellerin L, 2014, J ALLERGY CLIN IMMUN, V134, P1459, DOI 10.1016/j.jaci.2014.07.056; Pfeffer PE, 2015, J ALLERGY CLIN IMMUN, V135, P824, DOI 10.1016/j.jaci.2014.09.044; Pham D, 2014, J ALLERGY CLIN IMMUN, V134, P204, DOI 10.1016/j.jaci.2013.12.021; Pravettoni V, 2014, J ALLERGY CLIN IMMUN, V133, P1218, DOI 10.1016/j.jaci.2013.10.033; Reeves SR, 2014, J ALLERGY CLIN IMMUN, V134, P663, DOI 10.1016/j.jaci.2014.04.007; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Sala-Cunill A, 2015, J ALLERGY CLIN IMMUN, V135, P1031, DOI 10.1016/j.jaci.2014.07.057; Schnaar RL, 2015, J ALLERGY CLIN IMMUN, V135, P609, DOI 10.1016/j.jaci.2014.10.057; Sehra S, 2015, J ALLERGY CLIN IMMUN, V136, P433, DOI 10.1016/j.jaci.2015.01.021; Seltmann J, 2015, J ALLERGY CLIN IMMUN, V135, P1659, DOI 10.1016/j.jaci.2015.01.048; Shamji MH, 2015, J ALLERGY CLIN IMMUN, V135, P913, DOI 10.1016/j.jaci.2014.09.049; Sharma S, 2014, J ALLERGY CLIN IMMUN, V134, P1153, DOI 10.1016/j.jaci.2014.04.011; Shi MH, 2014, J ALLERGY CLIN IMMUN, V134, P1163, DOI 10.1016/j.jaci.2014.04.035; Shin HW, 2015, J ALLERGY CLIN IMMUN, V135; Sicherer SH, 2015, J ALLERGY CLIN IMMUN, V135, P357, DOI 10.1016/j.jaci.2014.12.1906; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P324, DOI 10.1016/j.jaci.2013.11.013; Silverberg JI, 2015, J ALLERGY CLIN IMMUN, V135, P721; Silverberg JI, 2016, J ALLERGY CLIN IMMUN, V137, P492; Smith SG, 2015, J ALLERGY CLIN IMMUN, V135, P1594, DOI 10.1016/j.jaci.2014.12.1918; Stanic B, 2015, J ALLERGY CLIN IMMUN, V135, P771, DOI 10.1016/j.jaci.2014.07.041; Starkl P, 2016, J ALLERGY CLIN IMMUN, V137, P246, DOI 10.1016/j.jaci.2015.08.005; Stehle C, 2016, NAT IMMUNOL, V17, P43, DOI 10.1038/ni.3353; Stephenson ST, 2015, J ALLERGY CLIN IMMUN, V136, P454, DOI 10.1016/j.jaci.2015.01.023; Stinson SE, 2015, J ALLERGY CLIN IMMUN, V135, P395, DOI 10.1016/j.jaci.2014.08.027; Su WR, 2015, J ALLERGY CLIN IMMUN, V136, P423, DOI 10.1016/j.jaci.2014.12.1926; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Sumpter TL, 2015, J ALLERGY CLIN IMMUN, V135, P1019, DOI 10.1016/j.jaci.2014.07.036; Taylan F, 2015, J ALLERGY CLIN IMMUN, V136, P507, DOI 10.1016/j.jaci.2015.02.010; Theoharides TC, 2015, NEW ENGL J MED, V373, P163, DOI 10.1056/NEJMra1409760; Theoharides TC, 2014, J ALLERGY CLIN IMMUN, V134, P1197, DOI 10.1016/j.jaci.2014.05.023; Thyssen JP, 2015, J ALLERGY CLIN IMMUN, V135, P1375, DOI 10.1016/j.jaci.2015.01.001; Touzot F, 2014, J ALLERGY CLIN IMMUN, V134, P1203, DOI 10.1016/j.jaci.2014.05.039; Tsai YG, 2014, J ALLERGY CLIN IMMUN, V134, P1206, DOI 10.1016/j.jaci.2014.06.005; Tsoumakidou M, 2014, J ALLERGY CLIN IMMUN, V134, P944, DOI 10.1016/j.jaci.2014.05.045; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Ubel C, 2014, J ALLERGY CLIN IMMUN, V133, P198, DOI 10.1016/j.jaci.2013.09.049; Ullah MA, 2014, J ALLERGY CLIN IMMUN, V134, P440, DOI 10.1016/j.jaci.2013.12.1035; van der Veer E, 2014, J ALLERGY CLIN IMMUN, V134, P1413, DOI 10.1016/j.jaci.2014.05.003; Vasanthakumar A, 2015, NAT IMMUNOL, V16, P276, DOI 10.1038/ni.3085; Vos BJPR, 2015, J ALLERGY CLIN IMMUN, V135, P792, DOI 10.1016/j.jaci.2014.05.047; Wang Q, 2015, J ALLERGY CLIN IMMUN, V135, P781, DOI 10.1016/j.jaci.2014.09.015; Wawrzyniak M, 2015, J ALLERGY CLIN IMMUN, V135, P1625, DOI 10.1016/j.jaci.2014.11.006; Wegrzyn AS, 2015, J ALLERGY CLIN IMMUN, V136, P194; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Weng Z, 2015, J ALLERGY CLIN IMMUN, V135, P1044, DOI 10.1016/j.jaci.2014.10.032; White KD, 2015, J ALLERGY CLIN IMMUN, V136, P219, DOI 10.1016/j.jaci.2015.05.050; Xia MC, 2015, J ALLERGY CLIN IMMUN, V136, P441, DOI 10.1016/j.jaci.2015.02.014; Xie M, 2015, J ALLERGY CLIN IMMUN, V135, P386, DOI 10.1016/j.jaci.2014.08.023; Xue L, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Xue LZ, 2015, J ALLERGY CLIN IMMUN, V135, P1358, DOI 10.1016/j.jaci.2014.09.006; Yip KH, 2014, J ALLERGY CLIN IMMUN, V133, P1356, DOI 10.1016/j.jaci.2013.11.030; Yokouchi M, 2015, J DERMATOL SCI, V77, P28, DOI 10.1016/j.jdermsci.2014.11.007; Yu HS, 2015, J ALLERGY CLIN IMMUN, V135, P827, DOI 10.1016/j.jaci.2014.10.040; Zanotti R, 2015, J ALLERGY CLIN IMMUN, V136, P135, DOI 10.1016/j.jaci.2014.11.035; Zaslona Z, 2014, J ALLERGY CLIN IMMUN, V133, P379, DOI 10.1016/j.jaci.2013.07.037	156	28	32	0	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1681	1696		10.1016/j.jaci.2016.02.010	http://dx.doi.org/10.1016/j.jaci.2016.02.010			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27090934				2022-12-18	WOS:000377527200007
J	Levin, M; King, JJ; Glanville, J; Jackson, KJL; Looney, TJ; Hoh, RA; Mari, A; Andersson, M; Greiff, L; Fire, AZ; Boyd, SD; Ohlin, M				Levin, Mattias; King, Jasmine J.; Glanville, Jacob; Jackson, Katherine J. L.; Looney, Timothy J.; Hoh, Ramona A.; Mari, Adriano; Andersson, Morgan; Greiff, Lennart; Fire, Andrew Z.; Boyd, Scott D.; Ohlin, Mats			Persistence and evolution of allergen-specific IgE repertoires during subcutaneous specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aeroallergens; allergen-specific antibodies; clonotype evolution; IgE; immunoglobulin class-switch; local immunity; repertoire; specific immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; CLASS SWITCH RECOMBINATION; NASAL-MUCOSA; ANTIGEN SELECTION; PERIPHERAL-BLOOD; IMMUNOGLOBULIN-E; B-CELLS; CHRONIC RHINOSINUSITIS; ANTIBODY REPERTOIRES; RHINITIS PATIENTS	Background: Specific immunotherapy ( SIT) is the only treatment with proved long-term curative potential in patients with allergic disease. Allergen-specific IgE is the causative agent of allergic disease, and antibodies contribute to SIT, but the effects of SIT on aeroallergen-specificB-cell repertoires are not well understood. Objective: We sought to characterize the IgE sequences expressed by allergen-specific B cells and track the fate of these B-cell clones during SIT. Methods: We used high-throughput antibody gene sequencing and identification of allergen-specific IgE with combinatorial antibody fragment library technology to analyze immunoglobulin repertoires of blood and the nasal mucosa from aeroallergen-sensitized subjects before and during the first year of subcutaneous SIT. Results: Of 52 distinct allergen-specific IgE heavy chains from 8 allergic donors, 37 were also detected by using high-throughput antibody gene sequencing of blood samples, nasal mucosal samples, or both. The allergen-specific clones had increased persistence, higher likelihood of belonging to clones expressing other switched isotypes, and possibly larger clone size than the rest of the IgE repertoire. Clone members in nasal tissue showed close mutational relationships. Conclusion: In the future, combining functional binding studies, deep antibody repertoire sequencing, and information on clinical outcomes in larger studies might aid assessment of SIT mechanisms and efficacy.	[Levin, Mattias; Ohlin, Mats] Lund Univ, Dept Immunotechnol, Medicon Village Bldg 406, SE-22381 Lund, Sweden; [King, Jasmine J.] Stanford Univ, Dept Biol, Stanford, CA 94305 USA; [King, Jasmine J.; Jackson, Katherine J. L.; Looney, Timothy J.; Hoh, Ramona A.; Fire, Andrew Z.; Boyd, Scott D.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Fire, Andrew Z.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Glanville, Jacob] Stanford Univ, Dept Immunol, Stanford, CA 94305 USA; [Mari, Adriano] IDI IRCCS, Ctr Mol Allergol, Rome, Italy; [Mari, Adriano] Associated Ctr Mol Allergol, Rome, Italy; [Andersson, Morgan; Greiff, Lennart] Skane Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Lund, Sweden	Lund University; Stanford University; Stanford University; Stanford University; Stanford University; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Lund University; Skane University Hospital	Ohlin, M (corresponding author), Lund Univ, Dept Immunotechnol, Medicon Village Bldg 406, SE-22381 Lund, Sweden.	mats.ohlin@immun.lth.se	Ohlin, Mats/A-7307-2010; Jackson, Katherine/AAE-4326-2019	Ohlin, Mats/0000-0002-5105-1938; Fire, Andrew/0000-0001-6217-8312; Jackson, Katherine/0000-0002-9952-7069	Swedish Research Council [521-2011-3282]; Alfred Osterlunds stiftelse; University Regional Grant (ALF); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI065359, U19AI104209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007276] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); Alfred Osterlunds stiftelse; University Regional Grant (ALF); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the Swedish Research Council (grant no. 521-2011-3282), Alfred Osterlunds stiftelse, University Regional Grant (ALF).	Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Andreasson U, 2006, J MOL BIOL, V362, P212, DOI 10.1016/j.jmb.2006.06.062; Berkowska MA, 2014, J ALLERGY CLIN IMMUN, V134, P688, DOI 10.1016/j.jaci.2014.03.036; Boyd SD, 2010, J IMMUNOL, V184, P6986, DOI 10.4049/jimmunol.1000445; Boyd SD, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000540; Cameron L, 2003, J IMMUNOL, V171, P3816, DOI 10.4049/jimmunol.171.7.3816; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Coker HA, 2003, J IMMUNOL, V171, P5602, DOI 10.4049/jimmunol.171.10.5602; Dahlke I, 2006, J ALLERGY CLIN IMMUN, V117, P1477, DOI 10.1016/j.jaci.2005.12.1359; Davies JM, 2004, CLIN EXP ALLERGY, V34, P429, DOI 10.1111/j.1365-2222.2004.01900.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EFREMOV DG, 1993, J IMMUNOL, V151, P2195; Floistrup H, 2006, J ALLERGY CLIN IMMUN, V117, P59, DOI 10.1016/j.jaci.2005.09.039; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gadermaier E, 2011, ALLERGY, V66, P1174, DOI 10.1111/j.1398-9995.2011.02592.x; Gadermaier E, 2014, INT ARCH ALLERGY IMM, V163, P77, DOI 10.1159/000355947; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Hankin CS, 2011, IMMUNOL ALLERGY CLIN, V31, P325, DOI 10.1016/j.iac.2011.03.007; Hellgren J, 2010, ALLERGY, V65, P776, DOI 10.1111/j.1398-9995.2009.02269.x; Hoh RA, 2016, J ALLERGY CLIN IMMUN, V137, P157, DOI 10.1016/j.jaci.2015.05.029; Horst A, 2002, CLIN EXP IMMUNOL, V130, P370, DOI 10.1046/j.1365-2249.2002.02025.x; Jackson KJL, 2014, CELL HOST MICROBE, V16, P105, DOI 10.1016/j.chom.2014.05.013; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; Jiang N, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006834; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kerzel S, 2010, J IMMUNOL, V185, P2253, DOI 10.4049/jimmunol.0902942; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Levin M, 2013, INT ARCH ALLERGY IMM, V161, P122, DOI 10.1159/000345421; Lund G, 2012, J IMMUNOL METHODS, V383, P4, DOI 10.1016/j.jim.2012.05.021; Marth K, 2010, MOL IMMUNOL, V47, P2323, DOI 10.1016/j.molimm.2010.05.285; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Meijer PJ, 2006, J MOL BIOL, V358, P764, DOI 10.1016/j.jmb.2006.02.040; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; Noon L, 1911, LANCET, V1, P1572; Parameswaran P, 2013, CELL HOST MICROBE, V13, P691, DOI 10.1016/j.chom.2013.05.008; Pomes A, 2010, INT ARCH ALLERGY IMM, V152, P1, DOI 10.1159/000260078; Pomponi D, 2013, BRIT J DERMATOL, V168, P1205, DOI 10.1111/bjd.12161; Pratt E, 2010, AM J RHINOL ALLERGY, V24, P416, DOI 10.2500/ajra.2010.24.3538; Saggy I, 2012, PROTEIN ENG DES SEL, V25, P539, DOI 10.1093/protein/gzs060; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Soyer OU, 2013, ALLERGY, V68, P161, DOI 10.1111/all.12085; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; Wang C, 2014, J IMMUNOL, V192, P603, DOI 10.4049/jimmunol.1301384; Wang Y., 2014, INT J DISTRIB SENS N, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0110024; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532; Wu YCB, 2014, J ALLERGY CLIN IMMUN, V134, P604, DOI 10.1016/j.jaci.2014.07.010	51	28	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1535	1544		10.1016/j.jaci.2015.09.027	http://dx.doi.org/10.1016/j.jaci.2015.09.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26559321	hybrid, Green Accepted			2022-12-18	WOS:000376180200030
J	Thysen, AH; Rasmussen, MA; Kreiner-Moller, E; Larsen, JM; Folsgaard, NV; Bonnelykke, K; Stokholm, J; Bisgaard, H; Brix, S				Thysen, Anna Hammerich; Rasmussen, Morten Arendt; Kreiner-Moller, Eskil; Larsen, Jeppe Madura; Folsgaard, Nilofar Vahman; Bonnelykke, Klaus; Stokholm, Jakob; Bisgaard, Hans; Brix, Susanne			Season of birth shapes neonatal immune function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birth season; cord blood immune cells; airway mucosa; neonatal immunity	REGULATORY T-CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; MULTIPLE-SCLEROSIS; CORD BLOOD; RHEUMATOID-ARTHRITIS; CYTOKINE RESPONSES; ATOPIC DISEASE; LINING FLUID; VITAMIN-D; ASTHMA	Background: Birth season has been reported to be a risk factor for several immune-mediated diseases. We hypothesized that this association is mediated by differential changes in neonatal immune phenotype and function with birth season. Objective: We sought to investigate the influence of season of birth on cord blood immune cell subsets and inflammatory mediators in neonatal airways. Methods: Cord blood was phenotyped for 26 different immune cell subsets, and at 1 month of age, 20 cytokines and chemokines were quantified in airway mucosal lining fluid. Multivariate partial least squares discriminant analyses were applied to determine whether certain immune profiles dominate by birth season, and correlations between individual cord blood immune cells and early airway immune mediators were defined. Results: We found a birth season-related fluctuation in neonatal immune cell subsets and in early-life airway mucosal immune function. The seasonal airway immune pattern was associated with the number of activated and regulatory T cells in cord blood whereas it was independent of concomitant presence of pathogenic airway microbes. Specifically, summer newborns presented with the lowest levels of all cell types and mediators; fall newborns displayed high levels of activated T cells and mucosal IL-12p70, TNF-alpha, IL-13, IL-10, and IL-2; and winter newborns had the highest levels of innate immune cells, IL-5, type 17-related immune mediators, and activated T cells. Conclusion: Birth season fluctuations seem to affect neonatal immune development and result in differential potentiation of cord blood immune cells and early airway mucosal immune function.	[Thysen, Anna Hammerich; Rasmussen, Morten Arendt; Kreiner-Moller, Eskil; Larsen, Jeppe Madura; Folsgaard, Nilofar Vahman; Bonnelykke, Klaus; Stokholm, Jakob; Bisgaard, Hans] Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark; [Thysen, Anna Hammerich; Larsen, Jeppe Madura; Brix, Susanne] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, Copenhagen, Denmark; [Rasmussen, Morten Arendt] Univ Copenhagen, Dept Food Sci, Spect & Chemometr, Copenhagen, Denmark	University of Copenhagen; Technical University of Denmark; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Copenhagen Prospect Studies Asthma Childhood, Ledreborg Alle 34, DK-2820 Gentofte, Denmark.	bisgaard@copsac.com	Rasmussen, Morten/AAE-9517-2020; Pedersen, Susanne Brix/B-3484-2009; Bisgaard, Hans/N-4761-2016; Larsen, Jeppe Madura/K-6518-2019; Arendt, Morten/S-8843-2017	Rasmussen, Morten/0000-0001-7431-5206; Pedersen, Susanne Brix/0000-0001-8951-6705; Bisgaard, Hans/0000-0003-4131-7592; Larsen, Jeppe Madura/0000-0003-1492-0708; Arendt, Morten/0000-0001-7431-5206; Bonnelykke, Klaus/0000-0003-2003-1018; Thysen, Anna Hammerich/0000-0002-2914-1099; Stokholm, Jakob/0000-0003-4989-9769				AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Barker M, 2003, J CHEMOMETR, V17, P166, DOI 10.1002/cem.785; Baschat A A, 2003, J Matern Fetal Neonatal Med, V13, P381, DOI 10.1080/jmf.13.6.381.384; Behrens F, 2007, ANN RHEUM DIS, V66, P1151, DOI 10.1136/ard.2006.068320; Bisgaard H, 2013, CLIN EXP ALLERGY, V43, P1384, DOI 10.1111/cea.12213; Burchill MA, 2008, IMMUNITY, V28, P112, DOI 10.1016/j.immuni.2007.11.022; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V125, P1387, DOI 10.1016/j.jaci.2010.01.039; Coneus K, 2012, J HEALTH ECON, V31, P180, DOI 10.1016/j.jhealeco.2011.09.006; Currie J, 2009, J HEALTH ECON, V28, P688, DOI 10.1016/j.jhealeco.2009.02.001; Dillie KTS, 2008, CLIN EXP ALLERGY, V38, P298, DOI 10.1111/j.1365-2222.2007.02891.x; Disanto G, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-69; Dobson R, 2013, J NEUROL NEUROSUR PS, V84, P427, DOI 10.1136/jnnp-2012-303934; Dong HL, 2012, BRIT J NUTR, V108, P459, DOI 10.1017/S0007114511005824; Dopico XC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8000; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Folsgaard NV, 2013, AM J RESP CRIT CARE, V187, P589, DOI 10.1164/rccm.201207-1297OC; Folsgaard NV, 2012, AM J RESP CRIT CARE, V185, P275, DOI 10.1164/rccm.201108-1471OC; Gold DR, 2009, J ALLERGY CLIN IMMUN, V124, P1078, DOI 10.1016/j.jaci.2009.08.021; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; Hirota K, 2007, J EXP MED, V204, P2803, DOI 10.1084/jem.20071397; Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107; Kahn HS, 2009, DIABETES CARE, V32, P2010, DOI 10.2337/dc09-0891; Keet CA, 2012, ALLERGY, V67, P775, DOI 10.1111/j.1398-9995.2012.02823.x; Keski-Nisula L, 2010, CLIN EXP ALLERGY, V40, P1658, DOI 10.1111/j.1365-2222.2010.03601.x; Kihlstrom A, 2003, ALLERGY, V58, P871, DOI 10.1034/j.1398-9995.2003.00232.x; Knudsen TB, 2007, J ASTHMA, V44, P257, DOI 10.1080/02770900701246832; Kobayashi T, 2008, GUT, V57, P1682, DOI 10.1136/gut.2007.135053; Kuan WP, 2010, J RHEUMATOL, V37, P257, DOI 10.3899/jrheum.090769; Kuzume K, 2007, PEDIATR ALLERGY IMMU, V18, P281, DOI 10.1111/j.1399-3038.2006.00526.x; Lee JW, 2008, J IMMUNOL, V181, P6536, DOI 10.4049/jimmunol.181.9.6536; Lendor C, 2008, ANN ALLERG ASTHMA IM, V101, P193, DOI 10.1016/S1081-1206(10)60209-8; Liang HE, 2012, NAT IMMUNOL, V13, P58, DOI 10.1038/ni.2182; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470; McGuirk P, 2010, CURR ALLERGY ASTHM R, V10, P21, DOI 10.1007/s11882-009-0078-2; Mullins RJ, 2011, PEDIAT ALLERG IMM-UK, V22, P583, DOI 10.1111/j.1399-3038.2011.01151.x; Narumi S, 2000, CYTOKINE, V12, P1561, DOI 10.1006/cyto.2000.0757; Nicholson GC, 2011, J ALLERGY CLIN IMMUN, V128, P800, DOI 10.1016/j.jaci.2011.05.013; Nilsson L, 1997, ARCH DIS CHILD, V76, P341, DOI 10.1136/adc.76.4.341; Norval M, 2008, PHOTOCHEM PHOTOBIOL, V84, P19, DOI 10.1111/j.1751-1097.2007.00239.x; PAYNE CM, 1986, DIAGN MICR INFEC DIS, V5, P39, DOI 10.1016/0732-8893(86)90090-8; Prasad M, 2010, PUBLIC HEALTH NUTR, V13, P939, DOI 10.1017/S1368980010001138; Santner-Nanan B, 2013, J IMMUNOL, V191, P145, DOI 10.4049/jimmunol.1203165; Staples KJ, 2012, J ALLERGY CLIN IMMUN, V130, P1404, DOI 10.1016/j.jaci.2012.07.023; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Stensballe LG, 2009, J PEDIATR-US, V154, P296, DOI 10.1016/j.jpeds.2008.07.053; SUR S, 1995, J ALLERGY CLIN IMMUN, V96, P661, DOI 10.1016/S0091-6749(95)70265-2; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693, DOI 10.1289/ehp.021100693; VanDurenSchmidt K, 1997, PEDIATR RES, V41, P128, DOI 10.1203/00006450-199701000-00020; Watchmaker PB, 2014, NAT IMMUNOL, V15, P98, DOI 10.1038/ni.2768; Watson PE, 2007, EUR J CLIN NUTR, V61, P1271, DOI 10.1038/sj.ejcn.1602644; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Willer CJ, 2005, BMJ-BRIT MED J, V330, P120, DOI 10.1136/bmj.38301.686030.63; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yang J, 2009, ARTHRITIS RHEUM-US, V60, P1472, DOI 10.1002/art.24499; Yost CC, 2009, BLOOD, V113, P6419, DOI 10.1182/blood-2008-07-171629	61	28	31	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1238	+		10.1016/j.jaci.2015.08.041	http://dx.doi.org/10.1016/j.jaci.2015.08.041			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26581916	Bronze			2022-12-18	WOS:000373351200032
J	Harb, H; Raedler, D; Ballenberger, N; Bock, A; Kesper, DA; Renz, H; Schaub, B				Harb, Hani; Raedler, Diana; Ballenberger, Nikolaus; Boeck, Andreas; Kesper, Doerthe A.; Renz, Harald; Schaub, Bianca			Childhood allergic asthma is associated with increased IL-13 and FOXP3 histone acetylation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POLYMORPHISMS		[Harb, Hani; Kesper, Doerthe A.; Renz, Harald] Univ Marburg, Inst Lab Med Pathobiochem & Mol Diagnost, Marburg, Germany; [Raedler, Diana; Ballenberger, Nikolaus; Boeck, Andreas; Schaub, Bianca] LMU, Univ Childrens Hosp Munich, Dept Pulm & Allergy, Munich, Germany; [Schaub, Bianca] German Ctr Lung Res DZL, Munich, Germany	Philipps University Marburg; University of Munich	Harb, H (corresponding author), Univ Marburg, Inst Lab Med Pathobiochem & Mol Diagnost, Marburg, Germany.	Bianca.Schaub@med.uni-muenchen.de	Harb, Hani/HGB-7333-2022; Harb, Hani/J-6517-2019; Schaub, Bianca/B-9935-2019	Harb, Hani/0000-0001-8218-2538; Harb, Hani/0000-0001-8218-2538; Schaub, Bianca/0000-0003-1652-8873				Beghe B, 2010, ALLERGY, V65, P474, DOI 10.1111/j.1398-9995.2009.02167.x; Chen KW, 2008, MOL IMMUNOL, V45, P2486, DOI 10.1016/j.molimm.2008.01.006; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Kabesch M, 2012, BIOCHIMIE, V94, P2231, DOI 10.1016/j.biochi.2012.07.017; Raedler D, 2015, J ALLERGY CLIN IMMUN, V135, P81, DOI 10.1016/j.jaci.2014.07.046; Shazia M, 2013, IRAN J ALLERGY ASTHM, V12, P391; Stefanowicz D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044213; Strickland DH, 2011, TRENDS IMMUNOL, V32, P420, DOI 10.1016/j.it.2011.06.010; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Xiao Y, 2010, CURR OPIN IMMUNOL, V22, P583, DOI 10.1016/j.coi.2010.08.013	11	28	28	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					200	202		10.1016/j.jaci.2015.01.027	http://dx.doi.org/10.1016/j.jaci.2015.01.027			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25769912				2022-12-18	WOS:000357542200026
J	Hayes, SM; Howlin, R; Johnston, DA; Webb, JS; Clarke, SC; Stoodley, P; Harries, PG; Wilson, SJ; Pender, SLE; Faust, SN; Hall-Stoodley, L; Salib, RJ				Hayes, Stephen M.; Howlin, Robert; Johnston, David A.; Webb, Jeremy S.; Clarke, Stuart C.; Stoodley, Paul; Harries, Philip G.; Wilson, Susan J.; Pender, Sylvia L. E.; Faust, Saul N.; Hall-Stoodley, Luanne; Salib, Rami J.			Intracellular residency of Staphylococcus aureus within mast cells in nasal polyps: A novel observation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC RHINOSINUSITIS; BIOFILMS		[Hayes, Stephen M.; Howlin, Robert; Webb, Jeremy S.; Clarke, Stuart C.; Stoodley, Paul; Wilson, Susan J.; Pender, Sylvia L. E.; Faust, Saul N.; Hall-Stoodley, Luanne; Salib, Rami J.] Univ Southampton, Southampton NIHR Resp Biomed Res Unit, Southampton SO9 5NH, Hants, England; [Hayes, Stephen M.; Howlin, Robert; Webb, Jeremy S.; Clarke, Stuart C.; Stoodley, Paul; Wilson, Susan J.; Pender, Sylvia L. E.; Faust, Saul N.; Hall-Stoodley, Luanne; Salib, Rami J.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England; [Hayes, Stephen M.; Howlin, Robert; Webb, Jeremy S.; Clarke, Stuart C.; Stoodley, Paul; Wilson, Susan J.; Pender, Sylvia L. E.; Faust, Saul N.; Hall-Stoodley, Luanne; Salib, Rami J.] Acad Unit Clin & Expt Sci, Fac Med, Southampton, Hants, England; [Hayes, Stephen M.; Webb, Jeremy S.; Clarke, Stuart C.; Stoodley, Paul; Wilson, Susan J.; Pender, Sylvia L. E.; Faust, Saul N.; Hall-Stoodley, Luanne; Salib, Rami J.] Univ Southampton, Southampton, Hants, England; [Howlin, Robert; Webb, Jeremy S.] Fac Nat & Environm Sci, Ctr Biol Sci, Southampton, Hants, England; [Johnston, David A.] Biomed Imaging Unit, Southampton, Hants, England; [Webb, Jeremy S.; Clarke, Stuart C.; Stoodley, Paul; Faust, Saul N.; Hall-Stoodley, Luanne; Salib, Rami J.] Inst Life Sci, Southampton, Hants, England; [Clarke, Stuart C.] Publ Hlth England, Southampton, Hants, England; [Stoodley, Paul] Natl Ctr Adv Tribol, Fac Engn, Southampton, Hants, England; [Stoodley, Paul; Hall-Stoodley, Luanne] Ohio State Univ, Ctr Microbial Interface Biol, Columbus, OH 43210 USA; [Wilson, Susan J.] Histochem Res Unit, Southampton, Hants, England; [Faust, Saul N.; Hall-Stoodley, Luanne; Salib, Rami J.] Southampton NIHR Wellcome Trust Clin Res Facil, Southampton, Hants, England	University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; Public Health England; University System of Ohio; Ohio State University	Hayes, SM (corresponding author), Univ Southampton, Southampton NIHR Resp Biomed Res Unit, Southampton SO9 5NH, Hants, England.	R.J.Salib@soton.ac.uk	Hall-Stoodley, Luanne/AAF-1925-2020; Stoodley, Paul/E-5079-2013; Faust, Saul/J-9779-2014	Stoodley, Paul/0000-0001-6069-273X; Johnston, David/0000-0001-6703-6014; Webb, Jeremy/0000-0003-2068-8589; Faust, Saul/0000-0003-3410-7642; Salib, Rami/0000-0002-6753-7844; Clarke, Stuart/0000-0002-7009-1548				Abel J, 2011, J INNATE IMMUN, V3, P495, DOI 10.1159/000327714; Bachert C, 2003, CURR ALLERGY ASTHM R, V3, P523, DOI 10.1007/s11882-003-0065-y; Beezhold DH, 2003, ANN ALLERG ASTHMA IM, V90, P439, DOI 10.1016/S1081-1206(10)61830-3; Cohen M, 2009, AM J RHINOL ALLERGY, V23, P255, DOI 10.2500/ajra.2009.23.3319; Ebo DG, 2013, INT ARCH ALLERGY IMM, V161, P220, DOI 10.1159/000346721; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Pomponi D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035697; Sachse F, 2010, ALLERGY, V65, P1430, DOI 10.1111/j.1398-9995.2010.02381.x; Singhal D, 2010, AM J RHINOL ALLERGY, V24, P169, DOI 10.2500/ajra.2010.24.3462; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Stelekati E, 2009, IMMUNITY, V31, P665, DOI 10.1016/j.immuni.2009.08.022; Tan NCW, 2012, LARYNGOSCOPE, V122, P1655, DOI 10.1002/lary.23317	12	28	29	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1648	1651		10.1016/j.jaci.2014.12.1929	http://dx.doi.org/10.1016/j.jaci.2014.12.1929			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25680455	Bronze			2022-12-18	WOS:000355933400032
J	Altman, AM; Camargo, CA; Simons, FER; Lieberman, P; Sampson, HA; Schwartz, LB; Zitt, FM; Collins, C; Tringale, M; Wilkinson, M; Wood, RA				Altman, Ashley M.; Camargo, Carlos A., Jr.; Simons, F. Estelle R.; Lieberman, Philip; Sampson, Hugh A.; Schwartz, Lawrence B.; Zitt, F. Myron; Collins, Charlotte; Tringale, Michael; Wilkinson, Marilyn; Wood, Robert A.			Anaphylaxis in America: A national physician survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD-INDUCED ANAPHYLAXIS; KOREAN CHILDREN; ENVIRONMENT; MANAGEMENT; ALLERGY; ASTHMA; CARE		[Altman, Ashley M.; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA; [Simons, F. Estelle R.] Univ Manitoba, Dept Pediat & Child Hlth, Sect Allergy & Clin Immunol, Winnipeg, MB R3T 2N2, Canada; [Lieberman, Philip] Univ Tennessee, Coll Med, Dept Internal Med, Germantown, TN USA; [Lieberman, Philip] Univ Tennessee, Coll Med, Dept Pediat, Germantown, TN USA; [Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Div Allergy & Immunol, Dept Pediat, New York, NY 10029 USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23298 USA; [Zitt, F. Myron] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Collins, Charlotte; Tringale, Michael] Asthma & Allergy Fdn Amer, Landover, MD USA; [Wilkinson, Marilyn] Abt SRBI Inc, Silver Spring, MD USA	Johns Hopkins University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Manitoba; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Altman, AM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA.	rwood@jhmi.edu	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Tringale, Mike/0000-0003-3139-6637	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007007] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI007007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aun MV, 2014, J ALLER CL IMM-PRACT, V2, P414, DOI [10.1016/j.jaip.2014.03.014, 10.1016/j.jaip.2014.08.015]; Fineman S, 2013, ANN ALLERG ASTHMA IM, V111, P529, DOI 10.1016/j.anai.2013.09.026; Grossman SL, 2013, J PEDIATR-US, V163, P841, DOI 10.1016/j.jpeds.2013.02.050; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Kang SH, 2013, ANN ALLERG ASTHMA IM, V110, P364, DOI 10.1016/j.anai.2013.03.008; Kim HJ, 2012, EXP DERMATOL, V21, P672, DOI 10.1111/j.1600-0625.2012.01539.x; Krugman SD, 2006, PEDIATRICS, V118, pE554, DOI 10.1542/peds.2005-2906; Lee JY, 2012, INT ARCH ALLERGY IMM, V157, P363, DOI 10.1159/000328778; Lee SY, 2012, INT ARCH ALLERGY IMM, V158, P168, DOI 10.1159/000330820; Rudders SA, 2010, PEDIATRICS, V125, pE711, DOI 10.1542/peds.2009-2832; Russell WS, 2013, WORLD J EMERG MED, V4, P98, DOI [10.5847/wjem.j.issn.1920-8642.2013.02.003, 10.5847/wjem.j.1920-8642.2013.02.003]; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461, DOI 10.1016/S1081-1206(10)62258-2; Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Wang J, 2004, J ALLERGY CLIN IMMUN, V114, P689, DOI 10.1016/j.jaci.2004.05.024; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P461, DOI 10.1016/j.jaci.2013.08.016; Yu HS, 2013, ALLERGY ASTHMA IMMUN, V5, P211, DOI 10.4168/aair.2013.5.4.211	17	28	30	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					830	833		10.1016/j.jaci.2014.10.049	http://dx.doi.org/10.1016/j.jaci.2014.10.049			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25577592	Green Accepted, Bronze			2022-12-18	WOS:000351065000037
J	Westerhof, GA; Vollema, EM; Weersink, EJ; Reinartz, SM; de Nijs, SB; Bel, EH				Westerhof, Guus A.; Vollema, Elise M.; Weersink, Els J.; Reinartz, Susanne M.; de Nijs, Selma B.; Bel, Elisabeth H.			Predictors for the development of progressive severity in new-onset adult asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adult-onset asthma; new-onset asthma; asthma severity; prospective follow-up study; predictors; smoking	LUNG-FUNCTION DECLINE; AIR-FLOW LIMITATION; TO-TREAT ASTHMA; INHALED CORTICOSTEROIDS; FOLLOW-UP; SMOKING; OUTCOMES; PHENOTYPES; SMOKERS; RISK	Background: A proportion of patients with adult-onset asthma have severe disease. Risk factors for an increase in asthma severity are poorly known. Objective: We sought to identify predictors for the development of severe asthma in adults. Methods: A cohort of 200 adults with new-onset asthma was prospectively followed for 2 years. At baseline, patients underwent a comprehensive assessment of clinical, functional, and inflammatory parameters. After 2 years, change in asthma severity was assessed by using the Global Initiative for Asthma score (range, 1-4), which is based on asthma control (Asthma Control Questionnaire), lung function (FEV1), and inhaled corticosteroid requirement. ANOVA and multiple regression equations were used in the analysis. Results: One hundred twenty-eight patients completed 2 years of follow-up. Seventeen (13.3%) patients had an increase in asthma severity, whereas 53 (41.4%) patients had a decrease. A lower postbronchodilator FEV1/forced vital capacity ratio and a higher number of cigarette pack years smoked at baseline were significantly associated with an increase in asthma severity at follow-up. Multiple regression equations showed that only the number of cigarette pack years smoked was independently associated with an increase in asthma severity, with an odds ratio of 1.4 (95% CI, 1.02-1.91) for every 10 pack years smoked. Conclusion: A history of cigarette smoking in patients with new-onset adult asthma predicts an increase in asthma severity during the first 2 years of the disease in a dose-dependent manner.	[Westerhof, Guus A.; Vollema, Elise M.; Weersink, Els J.; de Nijs, Selma B.; Bel, Elisabeth H.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1100 DE Amsterdam, Netherlands; [Reinartz, Susanne M.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1100 DE Amsterdam, Netherlands; [Reinartz, Susanne M.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Westerhof, GA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Resp Med, F5-260,POB 22700, NL-1100 DE Amsterdam, Netherlands.	G.A.Westerhof@amc.uva.nl			GlaxoSmithKline; Regeneron; Cipla	GlaxoSmithKline(GlaxoSmithKline); Regeneron(Regeneron); Cipla	E. J. Weersink has received consultancies fees from Boehringer. S. M. Reinartz's institution has received funding from GlaxoSmithKline, as has that of S. B. de Nijs, G. A. Westerhof, E. M. Vollema, E. J. Weersink, and E. H. Bel. E. H. Bel has also received or has grants pending from Chiesi; has received compensation from Novartis for board membership; has received consultancy fees from GlaxoSmithKline, Regeneron, and Cipla; and has received payment for delivering lectures from GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	Amelink M, 2013, ALLERGY, V68, P674, DOI 10.1111/all.12136; Amelink M, 2012, CLIN EXP ALLERGY, V42, P769, DOI 10.1111/j.1365-2222.2012.03977.x; Amelink M, 2013, J ALLERGY CLIN IMMUN, V132, P336, DOI 10.1016/j.jaci.2013.04.052; Broekema M, 2009, AM J RESP CRIT CARE, V180, P1170, DOI 10.1164/rccm.200906-0828OC; Chipps BE, 2012, J ALLERGY CLIN IMMUN, V130, P332, DOI 10.1016/j.jaci.2012.04.014; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Eisner MD, 2007, NICOTINE TOB RES, V9, P53, DOI 10.1080/14622200601078293; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Haahtela T, 2009, J ALLERGY CLIN IMMUN, V124, P1180, DOI 10.1016/j.jaci.2009.09.036; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; O'Byrne PM, 2009, CHEST, V136, P1514, DOI 10.1378/chest.09-1049; Paggiaro PL, 2002, EUR RESPIR J, V20, p3S, DOI 10.1183/09031936.02.00000302; Pietinalho A, 2009, ALLERGY, V64, P1722, DOI 10.1111/j.1398-9995.2009.02208.x; Polosa R, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-16; Ronmark E, 2007, RESP MED, V101, P2370, DOI 10.1016/j.rmed.2007.06.011; Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; Thomson NC, 2013, J ALLERGY CLIN IMMUN, V131, P1008, DOI 10.1016/j.jaci.2012.12.1574; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907	34	28	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1051	+		10.1016/j.jaci.2014.05.005	http://dx.doi.org/10.1016/j.jaci.2014.05.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24954263	Bronze			2022-12-18	WOS:000344938900008
J	Burns, SO; Plagnol, V; Gutierrez, BM; Al Zahrani, D; Curtis, J; Gaspar, M; Hassan, A; Jones, AM; Malone, M; Rampling, D; McLatchie, A; Doffinger, R; Gilmour, KC; Henriquez, F; Thrasher, AJ; Gaspar, HB; Nejentsev, S				Burns, Siobhan O.; Plagnol, Vincent; Gutierrez, Beatriz Morillo; Al Zahrani, Daifulah; Curtis, James; Gaspar, Miguel; Hassan, Amel; Jones, Alison M.; Malone, Marian; Rampling, Dyanne; McLatchie, Alex; Doffinger, Rainer; Gilmour, Kimberly C.; Henriquez, Frances; Thrasher, Adrian J.; Gaspar, H. Bobby; Nejentsev, Sergey			Immunodeficiency and disseminated mycobacterial infection associated with homozygous nonsense mutation of IKK beta	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NF-KAPPA-B; ANHIDROTIC ECTODERMAL DYSPLASIA; LIVER DEGENERATION; ACTIVATION; ALPHA; MICE; NEMO		[Burns, Siobhan O.; McLatchie, Alex] UCL, Inst Immun & Transplantat, London, England; [Burns, Siobhan O.; McLatchie, Alex] Royal Free London NHS Fdn Trust, Dept Immunol, London, England; [Burns, Siobhan O.; Gutierrez, Beatriz Morillo; Hassan, Amel; Jones, Alison M.; Malone, Marian; Rampling, Dyanne; Gilmour, Kimberly C.; Henriquez, Frances; Thrasher, Adrian J.; Gaspar, H. Bobby] Great Ormond St Hosp Children NHS Fdn Trust, London, England; [Plagnol, Vincent] UCL, UCL Genet Inst, London, England; [Al Zahrani, Daifulah] King Abdul Aziz Med City, Dept Pediat, Jeddah, Saudi Arabia; [Curtis, James; Doffinger, Rainer; Nejentsev, Sergey] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England; [Henriquez, Frances; Thrasher, Adrian J.; Gaspar, H. Bobby] UCL, Mol Immunol Unit, Inst Child Hlth, London, England	University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Jeddah; University of Cambridge; University of London; University College London	Burns, SO (corresponding author), UCL, Inst Immun & Transplantat, London, England.	siobhan.burns@ucl.ac.uk; sn262@cam.ac.uk	Jones, Alison/AAF-5530-2020	Doffinger, R/0000-0002-9841-3617; Morillo Gutierrez, Beatriz/0000-0001-5160-3627; Thrasher, Adrian/0000-0002-6097-6115; Burns, Siobhan/0000-0002-3356-9506; Plagnol, Vincent/0000-0002-5597-9215	Wellcome Trust [095198, 090233/Z/09/Z, 095198/Z/10/Z] Funding Source: Medline; Great Ormond Street Hospital Childrens Charity [V1242] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Great Ormond Street Hospital Childrens Charity		Alangari AA, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/691956; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; Lahtela J, 2010, NEW ENGL J MED, V363, P1631, DOI 10.1056/NEJMoa0911698; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Pannicke U, 2012, J CLIN IMMUNOL, V32, P381; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Pasparakis M, 2012, IMMUNOL REV, V246, P346, DOI 10.1111/j.1600-065X.2012.01109.x; Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11; Samaniego S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054124; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866	15	28	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					215	218		10.1016/j.jaci.2013.12.1093	http://dx.doi.org/10.1016/j.jaci.2013.12.1093			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24679846	Green Published, hybrid			2022-12-18	WOS:000338930300027
J	Chan, EC; Bai, Y; Kirshenbaum, AS; Fischer, ER; Simakova, O; Bandara, G; Scott, LM; Wisch, LB; Cantave, D; Carter, MC; Lewis, JC; Noel, P; Maric, I; Gilfillan, AM; Metcalfe, DD; Wilson, TM				Chan, Eunice Ching; Bai, Yun; Kirshenbaum, Arnold S.; Fischer, Elizabeth R.; Simakova, Olga; Bandara, Geethani; Scott, Linda M.; Wisch, Laura B.; Cantave, Daly; Carter, Melody C.; Lewis, John C.; Noel, Pierre; Maric, Irina; Gilfillan, Alasdair M.; Metcalfe, Dean D.; Wilson, Todd M.			Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						KIT; K509I; mastocytosis; germline; mast cells; well differentiated	FC-EPSILON-RI; GASTROINTESTINAL STROMAL TUMORS; C-KIT; SYSTEMIC MASTOCYTOSIS; ACTIVATION; EXPRESSION; ISOFORMS; PATIENT; CLASSIFICATION; POPULATION	Background: Mastocytosis associated with germline KIT activating mutations is exceedingly rare. We report the unique clinicopathologic features of a patient with systemic mastocytosis caused by a de novo germline KIT K509I mutation. Objectives: We sought to investigate the effect of the germline KIT K509I mutation on human mast cell development and function. Methods: Primary human mast cells derived from CD34(+) peripheral blood progenitors were examined for growth, development, survival, and IgE-mediated activation. In addition, a mast cell transduction system that stably expressed the KIT K509I mutation was established. Results: KIT K509I biopsied mast cells were round, CD25(-), and well differentiated. KIT K509I progenitors cultured in stem cell factor (SCF) demonstrated a 10-fold expansion compared with progenitors from healthy subjects and developed into mature hypergranular mast cells with enhanced antigen-mediated degranulation. KIT K509I progenitors cultured in the absence of SCF survived but lacked expansion and developed into hypogranular mast cells. A KIT K509I mast cell transduction system revealed SCF-independent survival to be reliant on the preferential splicing of KIT at the adjacent exonic junction. Conclusion: Germline KIT mutations associated with mastocytosis drive a well-differentiated mast cell phenotype distinct to that of somatic KIT D816V disease, the oncogenic potential of which might be influenced by SCF and selective KIT splicing.	[Chan, Eunice Ching; Bai, Yun; Kirshenbaum, Arnold S.; Bandara, Geethani; Scott, Linda M.; Wisch, Laura B.; Cantave, Daly; Carter, Melody C.; Gilfillan, Alasdair M.; Metcalfe, Dean D.; Wilson, Todd M.] NIAID, Mast Cell Biol Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Fischer, Elizabeth R.] NIAID, Res Technol Sect, Rocky Mt Labs, NIH, Hamilton, MT USA; [Simakova, Olga; Maric, Irina] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Lewis, John C.] Mayo Clin, Div Allergy Asthma & Clin Immunol, Scottsdale, AZ USA; [Noel, Pierre] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Wilson, TM (corresponding author), NIH, 6701 Democracy Blvd,Rm 914, Bethesda, MD 20892 USA.	twilson@mail.nih.gov			Division of Intramural Research of the National Institute of Allergy and Infectious Diseases/National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249, ZICAI001052] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL080005] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases/National Institutes of Health.	Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Akin C., 2004, Journal of Allergy and Clinical Immunology, V113, pS327, DOI 10.1016/j.jaci.2004.01.683; Alvarez-Twose I, 2012, J CLIN ONCOL, V30, pE126, DOI 10.1200/JCO.2011.38.9973; Bachelet I, 2006, J BIOL CHEM, V281, P27190, DOI 10.1074/jbc.M602359200; Bai Y, 2013, LEUKEMIA, V27, P278, DOI 10.1038/leu.2012.218; Beghini A, 2001, CANCER, V92, P657, DOI 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Chan EC, 2013, EXP HEMATOL, V41, P870, DOI 10.1016/j.exphem.2013.05.005; CROSIER PS, 1993, BLOOD, V82, P1151; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; Hartmann K, 2005, GASTROENTEROLOGY, V129, P1042, DOI 10.1053/j.gastro.2005.06.060; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; Horny HP, 2008, WHO CLASSIFICATION T, P54; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; Jensen BM, 2008, J PHARMACOL EXP THER, V324, P128, DOI 10.1124/jpet.107.125237; Jensen Bettina M., 2007, Inflammation & Allergy Drug Targets, V6, P57, DOI 10.2174/187152807780077255; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Lewis A, 2013, CLIN EXP ALLERGY, V43, P50, DOI 10.1111/cea.12045; Lunderius C, 2000, EUR J IMMUNOL, V30, P3396, DOI 10.1002/1521-4141(2000012)30:12<3396::AID-IMMU3396>3.0.CO;2-O; Maric I, 2007, J ALLERGY CLIN IMMUN, V120, P680, DOI 10.1016/j.jaci.2007.05.024; Metcalfe DD, 2008, BLOOD, V112, P946, DOI 10.1182/blood-2007-11-078097; Nagata H, 1997, INT ARCH ALLERGY IMM, V113, P184, DOI 10.1159/000237541; Pal S, 2012, PHARMACOL THERAPEUT, V136, P283, DOI 10.1016/j.pharmthera.2012.08.005; Pedersen M, 2009, CELL SIGNAL, V21, P413, DOI 10.1016/j.cellsig.2008.11.008; PIAO XH, 1994, BLOOD, V83, P476; Radinger M, 2010, CURR PROTOC IMMUNOL; Sanchez-Munoz L, 2011, MODERN PATHOL, V24, P1157, DOI 10.1038/modpathol.2011.84; Speight RA, 2013, J CLIN ONCOL, V31, pE245, DOI 10.1200/JCO.2012.42.0133; Tang X, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015156; Teodosio C, 2010, J ALLERGY CLIN IMMUN, V125, P719, DOI 10.1016/j.jaci.2009.10.020; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Wasag B, 2011, EXP HEMATOL, V39, P859, DOI 10.1016/j.exphem.2011.05.009; Wilson TM, 2011, HAEMATOL-HEMATOL J, V96, P459, DOI 10.3324/haematol.2010.031690; Woolhiser MR, 2001, EUR J IMMUNOL, V31, P3298, DOI 10.1002/1521-4141(200111)31:11<3298::AID-IMMU3298>3.0.CO;2-U; Xu ZW, 2010, CELL MOL IMMUNOL, V7, P11, DOI 10.1038/cmi.2009.108; Zhang LY, 2006, LEUKEMIA RES, V30, P373, DOI 10.1016/j.leukres.2005.08.015; Zhang S, 1998, J PATHOL, V186, P59, DOI 10.1002/(SICI)1096-9896(199809)186:1<59::AID-PATH140>3.0.CO;2-J	40	28	30	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					178	+		10.1016/j.jaci.2013.12.1090	http://dx.doi.org/10.1016/j.jaci.2013.12.1090			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24582309	Green Accepted			2022-12-18	WOS:000338930300023
J	Wechsler, JB; Hsu, CL; Bryce, PJ				Wechsler, Joshua B.; Hsu, Chia-Lin; Bryce, Paul J.			IgE-mediated mast cell responses are inhibited by thymol-mediated, activation-induced cell death in skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; thymol; calcium; passive cutaneous anaphylaxis	NITRIC-OXIDE SYNTHASE; ESSENTIAL PLANT OILS; ATOPIC-DERMATITIS; THERAPEUTIC TARGETS; ALLERGIC DISEASES; CA2+ HOMEOSTASIS; TYROSINE KINASE; IN-VITRO; 2 PARTS; APOPTOSIS	Background: Mast cells play a critical role in inflammatory skin diseases through releasing proinflammatory mediators; however, few therapies directly target these cells. In 1878, the use of topical thymol, a now recognized potent agonist for transient receptor potential channels, was first described to treat eczema and psoriasis. Objective: We sought to determine the mechanisms through which thymol can alter skin inflammation. Methods: We examined the effect of topical thymol on IgE-dependent responses using a mast cell-dependent passive cutaneous anaphylaxis (PCA) model, as well as in vitro-cultured mast cells. Results: Thymol dose-dependently inhibited PCA when administered topically 24 hours before antigen challenge but provoked an ear-swelling response directly on application. This direct effect was associated with local mast cell degranulation and was absent in histamine-deficient mice. However, unlike with PCA responses, there was no late-phase swelling. In vitro thymol directly triggered calcium flux in mast cells through transient receptor potential channel activation, along with degranulation and cytokine transcription. However, no cytokine protein was produced. Instead, thymol induced a significant increase in apoptotic cell death that was seen both in vitro and in vivo. Conclusions: We propose that the efficacy of thymol in reducing IgE-dependent responses is through promotion of activation-induced apoptotic cell death of mast cells and that this likely explains the clinical benefits observed in early clinical reports.	[Wechsler, Joshua B.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Pediat Gastroenterol Hepatol & Nutr, Chicago, IL USA; [Hsu, Chia-Lin; Bryce, Paul J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Bryce, PJ (corresponding author), Northwestern Univ, Dept Med, Div Allergy Immunol, 240 E Huron Ave, Chicago, IL 60611 USA.	p-bryce@northwestern.edu		Wechsler, Joshua/0000-0002-1275-3275	National Institutes of Health/National Institute of Allergy and Infectious Diseases [R01 AI072570]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076456, R01AI105839] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases R01 AI072570 (to P.J.B.).	Alenius H, 2002, J ALLERGY CLIN IMMUN, V109, P106, DOI 10.1067/mai.2002.120553; Andres C, 2008, CURR ALLERGY ASTHM R, V8, P179, DOI 10.1007/s11882-008-0029-3; Archana PR, 2009, MUTAT RES-GEN TOX EN, V680, P70, DOI 10.1016/j.mrgentox.2009.09.010; Bachelet I, 2005, J IMMUNOL, V175, P7989, DOI 10.4049/jimmunol.175.12.7989; Basch Ethan, 2004, Journal of Herbal Pharmacotherapy, V4, P49, DOI 10.1080/J157v04n01_07; Baser KHC, 2008, CURR PHARM DESIGN, V14, P3106, DOI 10.2174/138161208786404227; BENSLEY SH, 1952, STAIN TECHNOL, V27, P269, DOI 10.3109/10520295209105090; Berent-Maoz B, 2006, J IMMUNOL, V176, P2272, DOI 10.4049/jimmunol.176.4.2272; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Brenner D, 2008, CRIT REV ONCOL HEMAT, V66, P52, DOI 10.1016/j.critrevonc.2008.01.002; Burt S, 2004, INT J FOOD MICROBIOL, V94, P223, DOI 10.1016/j.ijfoodmicro.2004.03.022; Chang HT, 2011, PHARMACOLOGY, V88, P201, DOI 10.1159/000331864; Crocker H R, 1878, Br Med J, V1, P225; Darsow U, 2005, J EUR ACAD DERMATOL, V19, P286, DOI 10.1111/j.1468-3083.2005.01249.x; Deb DD, 2011, CHEM-BIOL INTERACT, V193, P97, DOI 10.1016/j.cbi.2011.05.009; del Camino D, 2010, J NEUROSCI, V30, P15165, DOI 10.1523/JNEUROSCI.2580-10.2010; Dong Z, 2006, ANNU REV PATHOL-MECH, V1, P405, DOI 10.1146/annurev.pathol.1.110304.100218; Ekoff M, 2011, ADV EXP MED BIOL, V716, P47, DOI 10.1007/978-1-4419-9533-9_4; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gombert M, 2005, J IMMUNOL, V174, P5082, DOI 10.4049/jimmunol.174.8.5082; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Guo N, 2009, J MED MICROBIOL, V58, P1074, DOI 10.1099/jmm.0.008052-0; Hartmann K, 1997, J IMMUNOL, V159, P4006; HORSMANHEIMO L, 1994, BRIT J DERMATOL, V131, P348, DOI 10.1111/j.1365-2133.1994.tb08522.x; Horvathova E, 2007, NEOPLASMA, V54, P478; Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944; Hsu SS, 2011, EUR J PHARMACOL, V670, P85, DOI 10.1016/j.ejphar.2011.08.017; Inoue T, 2008, J LEUKOCYTE BIOL, V83, P1218, DOI 10.1189/jlb.1007667; Inoue T, 2009, MOL IMMUNOL, V47, P222, DOI 10.1016/j.molimm.2009.09.033; IRANI AMA, 1989, ALLERGY, V44, P31; Juurikivi A, 2005, ANN RHEUM DIS, V64, P1126, DOI 10.1136/ard.2004.029835; Karlberg M, 2010, J IMMUNOL, V185, P2555, DOI 10.4049/jimmunol.0903656; Karra L, 2009, CURR OPIN IMMUNOL, V21, P708, DOI 10.1016/j.coi.2009.09.010; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kim DO, 2004, CRIT REV FOOD SCI, V44, P253, DOI 10.1080/10408690490464960; Kovarova M, 2004, CURR MED CHEM, V11, P2083, DOI 10.2174/0929867043364801; Lee SP, 2008, BRIT J PHARMACOL, V153, P1739, DOI 10.1038/bjp.2008.85; Liu FT, 2011, CLIN REV ALLERG IMMU, V41, P298, DOI 10.1007/s12016-011-8252-4; Luskova P, 2004, CURR PHARM DESIGN, V10, P1727, DOI 10.2174/1381612043384538; Ma HT, 2011, ADV EXP MED BIOL, V716, P62, DOI 10.1007/978-1-4419-9533-9_5; Ma ZC, 2010, INT ARCH ALLERGY IMM, V153, P413, DOI 10.1159/000316353; Mahmud H, 2009, CELL PHYSIOL BIOCHEM, V24, P407, DOI 10.1159/000257433; Malaviya R, 2002, J IMMUNOL, V168, P421, DOI 10.4049/jimmunol.168.1.421; Moran MM, 2011, NAT REV DRUG DISCOV, V10, P601, DOI 10.1038/nrd3456; Navi D, 2007, CLIN REV ALLERG IMMU, V33, P144, DOI 10.1007/s12016-007-0029-4; Nguyen TX, 2010, MOL NUTR FOOD RES, V54, P1833, DOI 10.1002/mnfr.200900577; Ohtsu H, 2001, FEBS LETT, V502, P53, DOI 10.1016/S0014-5793(01)02663-1; Paller AS, 2012, SEMIN CUTAN MED SURG, V31, pS10, DOI 10.1016/j.sder.2012.07.004; Prasad P, 2008, J IMMUNOL, V181, P5024, DOI 10.4049/jimmunol.181.7.5024; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; Satooka H, 2012, J AGR FOOD CHEM, V60, P2746, DOI 10.1021/jf204525b; SHAPIRO S, 1995, ORAL MICROBIOL IMMUN, V10, P241, DOI 10.1111/j.1399-302X.1995.tb00149.x; Shen AY, 2009, NAT PROD COMMUN, V4, P749; Slamenova D, 2007, NEOPLASMA, V54, P108; Soboloff J, 2002, J BIOL CHEM, V277, P13812, DOI 10.1074/jbc.M112129200; SOTER NA, 1989, ALLERGY, V44, P16, DOI 10.1111/j.1398-9995.1989.tb02449.x; Stammati A, 1999, FOOD CHEM TOXICOL, V37, P813, DOI 10.1016/S0278-6915(99)00075-7; Suzuki Y, 2010, BBA-MOL CELL RES, V1803, P372, DOI 10.1016/j.bbamcr.2009.11.003; Tanei R, 2013, J EUR ACAD DERMATOL, V27, P952, DOI 10.1111/j.1468-3083.2012.04612.x; Theoharides TC, 2007, IMMUNOL REV, V217, P65, DOI 10.1111/j.1600-065X.2007.00519.x; Tsai M, 2011, ADV EXP MED BIOL, V716, P186, DOI 10.1007/978-1-4419-9533-9_11; Vigo PG, 2006, J AM ACAD DERMATOL, V55, P168, DOI 10.1016/j.jaad.2005.12.045; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; Zhou JS, 2007, J EXP MED, V204, P2797, DOI 10.1084/jem.20071391	65	28	29	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1735	1743		10.1016/j.jaci.2013.12.024	http://dx.doi.org/10.1016/j.jaci.2013.12.024			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24486068	Green Accepted			2022-12-18	WOS:000336672500028
J	Larose, MC; Turcotte, C; Chouinard, F; Ferland, C; Martin, C; Provost, V; Laviolette, M; Flamand, N				Larose, Marie-Chantal; Turcotte, Caroline; Chouinard, Francois; Ferland, Claudine; Martin, Cyril; Provost, Veronique; Laviolette, Michel; Flamand, Nicolas			Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALTERNATIVELY ACTIVATED MACROPHAGES; CELLS; 15-LIPOXYGENASE-1		[Larose, Marie-Chantal; Turcotte, Caroline; Chouinard, Francois; Ferland, Claudine; Martin, Cyril; Provost, Veronique; Laviolette, Michel; Flamand, Nicolas] Univ Laval, Fac Med, Inst Univ Cardiol & Pneumol Quebec, Ctr Rech,Dept Med, Quebec City, PQ G1V 4G5, Canada	Laval University	Larose, MC (corresponding author), Univ Laval, Fac Med, Inst Univ Cardiol & Pneumol Quebec, Ctr Rech,Dept Med, Quebec City, PQ G1V 4G5, Canada.	Nicolas.Flamand@criucpq.ulaval.ca	Flamand, Nicolas/H-5823-2019	Flamand, Nicolas/0000-0001-5944-7200	Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Brunnstrom A, 2011, LIPIDS, V46, P69, DOI 10.1007/s11745-010-3485-1; Chouinard F, 2011, J IMMUNOL, V186, P3188, DOI 10.4049/jimmunol.1002853; Feltenmark S, 2008, P NATL ACAD SCI USA, V105, P680, DOI 10.1073/pnas.0710127105; Forsell PKA, 2012, LIPIDS, V47, P781, DOI 10.1007/s11745-012-3684-z; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Oka S, 2004, J LEUKOCYTE BIOL, V76, P1002, DOI 10.1189/jlb.0404252; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; Zhu YM, 2011, J IMMUNOL, V186, P516, DOI 10.4049/jimmunol.1000955	9	28	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2014	133	5					1480	+		10.1016/j.jaci.2013.12.1081	http://dx.doi.org/10.1016/j.jaci.2013.12.1081			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG5HS	24530098	Bronze			2022-12-18	WOS:000335450700037
J	Cagigi, A; Rinaldi, S; Di Martino, A; Manno, EC; Zangari, P; Aquilani, A; Cotugno, N; Nicolosi, L; Villani, A; Bernardi, S; Donatelli, I; Pahwa, S; Rossi, P; Palma, P				Cagigi, Alberto; Rinaldi, Stefano; Di Martino, Angela; Manno, Emma Concetta; Zangari, Paola; Aquilani, Angela; Cotugno, Nicola; Nicolosi, Luciana; Villani, Alberto; Bernardi, Stefania; Donatelli, Isabella; Pahwa, Savita; Rossi, Paolo; Palma, Paolo			Premature immune senescence during HIV-1 vertical infection relates with response to influenza vaccination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTIRETROVIRAL THERAPY; H1N1/09 VACCINE; B-CELLS; NONRESPONDERS		[Cagigi, Alberto; Manno, Emma Concetta; Zangari, Paola; Aquilani, Angela; Cotugno, Nicola; Bernardi, Stefania; Rossi, Paolo; Palma, Paolo] Univ Rome, Unit Immune & Infect Dis, Univ Dept Pediat, DPUO,Bambino Gesu Childrens Hosp, Tor Vergata, Italy; [Rinaldi, Stefano] Univ Rome, Dept Publ Hlth, Tor Vergata, Italy; [Di Martino, Angela; Donatelli, Isabella] Bambino Gesu Pediat Hosp, Dept Infect Parasit & Immunomediated Dis, WHO Natl Influenza Ctr, ISS, Rome, Italy; [Nicolosi, Luciana; Villani, Alberto] Bambino Gesu Pediat Hosp, Dept Pediat Med, Rome, Italy; [Pahwa, Savita] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA	IRCCS Bambino Gesu; University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Bambino Gesu; Istituto Superiore di Sanita (ISS); IRCCS Bambino Gesu; University of Miami	Cagigi, A (corresponding author), Univ Rome, Unit Immune & Infect Dis, Univ Dept Pediat, DPUO,Bambino Gesu Childrens Hosp, Tor Vergata, Italy.	alberto.cagigi@gmail.com	Palma, Paolo/K-3379-2016; Nicolosi, Luciana/AAA-7329-2020; Aquilani, Angela/AAB-3465-2019; Rossi, Paolo/K-5746-2016; Pahwa, Savita/AAA-4900-2019; Cagigi, Alberto/K-4824-2016; Manno, Emma Concetta/AAA-5952-2020; Palma, Paolo/AAK-9275-2020; Bernardi, stefania/AAA-2803-2020; Cotugno, Nicola/AAB-9462-2019; Zangari, Paola/AAA-6406-2020; Villani, Alberto/K-9844-2018	Rossi, Paolo/0000-0003-2620-7918; Pahwa, Savita/0000-0002-4470-4216; Cagigi, Alberto/0000-0002-3567-9514; Palma, Paolo/0000-0002-3066-4719; Cotugno, Nicola/0000-0002-7748-1581; Bernardi, Stefania/0000-0001-5672-0881; Di Martino, Angela/0000-0003-3571-2211; Aquilani, Angela/0000-0002-6679-8911				Cagigi A, 2013, VACCINE, V31, P2231, DOI 10.1016/j.vaccine.2013.03.002; Cagigi A, 2012, HUM VACC IMMUNOTHER, V8, P1784, DOI 10.4161/hv.21827; Cagigi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005427; Colonna-Romano G, 2009, MECH AGEING DEV, V130, P681, DOI 10.1016/j.mad.2009.08.003; Khurana S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002920; Moir S, 2008, J INFECT DIS, V197, P572, DOI 10.1086/526789; Pallikkuth S, 2012, BLOOD, V120, P985, DOI 10.1182/blood-2011-12-396648; Pallikkuth S, 2011, J ALLERGY CLIN IMMUN, V128, P1279, DOI 10.1016/j.jaci.2011.05.033; Pallikkuth S, 2011, J IMMUNOL, V186, P6173, DOI 10.4049/jimmunol.1100264	9	28	28	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					592	594		10.1016/j.jaci.2013.10.003	http://dx.doi.org/10.1016/j.jaci.2013.10.003			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24290278				2022-12-18	WOS:000332397100043
J	Bonner, K; Pease, JE; Corrigan, CJ; Clark, P; Kay, AB				Bonner, Kandace; Pease, James E.; Corrigan, Christopher J.; Clark, Peter; Kay, A. Barry			CCL17/thymus and activation-regulated chemokine induces calcitonin gene-related peptide in human airway epithelial cells through CCR4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CGRP; CCL17; CCR4; epithelial cells; airways; asthma; allergy; vasculature; inflammation	LATE ASTHMATIC REACTIONS; MACROPHAGE-DERIVED CHEMOKINE; ENDOTHELIAL GROWTH-FACTOR; POTENT VASODILATOR; ALLERGEN CHALLENGE; ATOPIC SUBJECTS; RECEPTOR 4; EXPRESSION; HYPERRESPONSIVENESS; INFLAMMATION	Background: Calcitonin gene-related peptide (CGRP) is a potent arterial and venous vasodilator. Increased airway epithelial cell expression of CGRP, together with increased CCL17 expression, was previously observed in a model of provoked asthma in atopic human subjects. Objective: We sought to determine whether CCL17 induces CCR4-dependent CGRP synthesis and secretion by human airway epithelial cells. Methods: Human airway epithelial cell lines (BEAS-2B and A549) and human primary airway cells were cultured with CCL17 or various other cytokines, and CGRP expression was measured by using RT-PCR, quantitative immunofluorescence, and enzyme immunoassay. CCR4 expression was determined in cultured cells by using flow cytometry and in bronchial biopsy specimens by using immunohistochemistry. Results: CCL17 induced a several thousand-fold increase in CGRP mRNA expression and released peptide product from BEAS-2B and A549 cells in a time-and concentration-dependent fashion. Concentration-dependent CCL17-induced release of CGRP by primary human airway epithelial cells was also observed. Under comparable conditions, CCL17 induced greater CGRP release from BEAS-2B cells than either IL-13, a cytokine mixture (TNF-alpha, GM-CSF, and IL-1), or CCL22. CCR4 was expressed by BEAS-2B and A549 cells and internalized after ligation with CCL17. CCL17-induced CGRP release was inhibited by a specific anti-CCR4 blocking antibody. Bronchial biopsy specimens obtained from healthy volunteers and asthmatic patients before and after provoked asthma all exhibited CCR4 staining of equivalent intensity, indicating that the receptor is constitutively expressed. Conclusions: CCL17-induced, CCR4-dependent release of CGRP by human airway epithelial cells represents a novel inflammatory pathway and a possible target in patients with asthma and allergic disease.	[Bonner, Kandace; Pease, James E.; Clark, Peter; Kay, A. Barry] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, London SW7 2AZ, England; [Corrigan, Christopher J.] Kings Coll London, Sch Med, MRC Asthma UK Ctr Allerg Mech Asthma, London, England	Imperial College London; University of London; King's College London	Kay, AB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Sir Alexander Fleming Bldg,South Kensington Campu, London SW7 2AZ, England.	p.clark@imperial.ac.uk; a.b.kay@imperial.ac.uk	; Pease, James/X-4521-2018	Corrigan, Chris/0000-0002-0706-6534; Pease, James/0000-0003-3749-0341	Asthma UK; Imperial College London; National Institutes of Health; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	Asthma UK; Imperial College London(General Electric); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by Asthma UK and Imperial College London.; Disclosure of potential conflict of interest: J. E. Pease has consultant arrangements with GlaxoSmithKline and receives royalties from the National Institutes of Health. C. J. Corrigan has consultant arrangements with Novartis and Chiesi and has received payment for lectures from Allergy Therapeutics. A. B. Kay has received grants from Asthma UK. The rest of the authors declare that they have no relevant conflicts of interest.	Ali FR, 2007, THORAX, V62, P750, DOI 10.1136/thx.2006.072041; Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; Aoki-Nagase T, 2002, AM J PHYSIOL-LUNG C, V283, pL963, DOI 10.1152/ajplung.00130.2002; Bailey SR, 2009, PULM PHARMACOL THER, V22, P417, DOI 10.1016/j.pupt.2009.04.007; Bonner K, 2010, J ALLERGY CLIN IMMUN, V126, P1277, DOI 10.1016/j.jaci.2010.08.013; Booth BW, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-51; Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003; BRAIN SD, 1985, BRIT J PHARMACOL, V86, P855, DOI 10.1111/j.1476-5381.1985.tb11107.x; BRAIN SD, 1986, J INVEST DERMATOL, V87, P533, DOI 10.1111/1523-1747.ep12455620; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Dakhama A, 2002, AM J RESP CRIT CARE, V165, P1137, DOI 10.1164/ajrccm.165.8.2109058; Ding WH, 2008, J IMMUNOL, V181, P6020, DOI 10.4049/jimmunol.181.9.6020; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Faffe DS, 2003, AM J PHYSIOL-LUNG C, V285, pL907, DOI 10.1152/ajplung.00120.2003; Fukuda K, 2003, J ALLERGY CLIN IMMUN, V111, P520, DOI 10.1067/mai.2003.59; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; HENKE H, 1987, BRAIN RES, V410, P404, DOI 10.1016/0006-8993(87)90348-9; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Jopling LA, 2002, J BIOL CHEM, V277, P6864, DOI 10.1074/jbc.M109974200; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Kay AB, 2007, ALLERGY, V62, P495, DOI 10.1111/j.1398-9995.2007.01342.x; Kay AB, 2011, J ALLERGY CLIN IMMUN, V127, P232, DOI 10.1016/j.jaci.2010.10.028; Leung TF, 2003, EUR RESPIR J, V21, P616, DOI 10.1183/09031936.03.00083303; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Penna G, 2002, J IMMUNOL, V169, P6673, DOI 10.4049/jimmunol.169.12.6673; Ritter M, 2005, BIOCHEM BIOPH RES CO, V334, P254, DOI 10.1016/j.bbrc.2005.06.084; Rochlitzer S, 2011, CLIN EXP ALLERGY, V41, P1609, DOI 10.1111/j.1365-2222.2011.03822.x; Sacchetti M, 2011, MOL VIS, V17, P47; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; Tanaka H, 2003, AM J RESP CRIT CARE, V168, P1495, DOI 10.1164/rccm.200306-727OC; Wang HC, 2002, J NEUROIMMUNOL, V130, P155, DOI 10.1016/S0165-5728(02)00221-7; Wang Zhao, 2011, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V25, P1371	37	28	29	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					942	+		10.1016/j.jaci.2013.04.015	http://dx.doi.org/10.1016/j.jaci.2013.04.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23731651				2022-12-18	WOS:000325096500022
J	Pavord, ID; Bafadhel, M				Pavord, Ian D.; Bafadhel, Mona			Exhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; SPUTUM CELL COUNTS; AIRWAY INFLAMMATION; DOUBLE-BLIND; ASTHMA; EXACERBATIONS; IDENTIFICATION; MEPOLIZUMAB		[Pavord, Ian D.; Bafadhel, Mona] Univ Oxford, Nuffield Dept Med, Dept Resp Med, Oxford OX3 7FZ, England	University of Oxford	Pavord, ID (corresponding author), Univ Oxford, Nuffield Dept Med, Dept Resp Med, Old Rd Campus, Oxford OX3 7FZ, England.	ian.pavord@ndm.ox.ac.uk	Bafadhel, Mona/ABB-1170-2021	Pavord, Ian/0000-0002-4288-5973; Bafadhel, Mona/0000-0002-9993-2478	National Institute for Health Research [NF-SI-0510-10157] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Gibson PG, 2002, THORAX, V57, P178, DOI 10.1136/thorax.57.2.178; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hospers JJ, 1999, AM J RESP CRIT CARE, V160, P1869, DOI 10.1164/ajrccm.160.6.9811041; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007; Parameswaran K, 2000, EUR RESPIR J, V15, P486, DOI 10.1034/j.1399-3003.2000.15.10.x; Pavord ID, 2013, LANCET RESP MED, V1, P84, DOI 10.1016/S2213-2600(12)70049-8; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Powell H, 2011, LANCET, V378, P983, DOI 10.1016/S0140-6736(11)60971-9; Saha S, 2006, EUR RESPIR J, V27, P863, DOI 10.1183/09031936.06.00146705; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048	19	28	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					828	829		10.1016/j.jaci.2013.07.045	http://dx.doi.org/10.1016/j.jaci.2013.07.045			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	24001802				2022-12-18	WOS:000325096500007
J	Okelo, SO; Eakin, MN; Patino, CM; Teodoro, AP; Bilderback, AL; Thompson, DA; Loiaza-Martinez, A; Rand, CS; Thyne, S; Diette, GB; Riekert, KA				Okelo, Sande O.; Eakin, Michelle N.; Patino, Cecilia M.; Teodoro, Alvin P.; Bilderback, Andrew L.; Thompson, Darcy A.; Loiaza-Martinez, Antonio; Rand, Cynthia S.; Thyne, Shannon; Diette, Gregory B.; Riekert, Kristin A.			The Pediatric Asthma Control and Communication Instrument asthma questionnaire: For use in diverse children of all ages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Impairment; control; children; assessment; accuracy; survey; validation; Pediatric Asthma Control and Communication Instrument; Spanish	QUALITY-OF-LIFE; CHILDHOOD ASTHMA; LATINO CHILDREN; CARE UTILIZATION; SEVERITY; VALIDATION; RELIABILITY; SYMPTOMS; VALIDITY; DISPARITIES	Background: National Institutes of Health asthma guidelines recommend questionnaires to assess asthma control, but these questionnaires are not useable across the entire pediatric age spectrum and have not been validated among significant numbers of minority or Spanish-speaking children. Objective: We sought to evaluate a questionnaire designed to assess asthma control across a broad age range of minority and Spanish-speaking children cared for in an outpatient setting. Methods: Between July 1, 2007, and September 30, 2010, we collected information using the Pediatric Asthma Control and Communication Instrument (PACCI), the Asthma Control Test (ACT; or the childhood ACT for children 4-11 years old), the Pediatric Asthma Caregiver Quality of Life Questionnaire, and lung function and clinicians' ratings of asthma status among a population of children presenting for routine asthma specialist care. The PACCI measure of asthma control was validated by evaluating accuracy, internal reliability, and concurrent, discriminative, and known-groups validity. Results: We collected information on 265 English-and 52 Spanish-speaking children (mean age, 8.2 years; 58% male; 44% African American). Across all age groups and in both languages, PACCI control showed good internal reliability and strong concurrent, discriminative, and known-groups validity with ACT and Pediatric Asthma Caregiver Quality of Life Questionnaire scores and clinicians' ratings of asthma control. The accuracy of the PACCI in classifying children with uncontrolled asthma was good (area under the curve, 0.83; 95% CI, 0.79-0.88). Conclusions: The PACCI accurately measures asthma control in English-and Spanish-speaking children. The PACCI should be useful to clinicians to assess and classify asthma according to National Institutes of Health asthma guidelines.	[Okelo, Sande O.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Eakin, Michelle N.; Bilderback, Andrew L.; Rand, Cynthia S.; Diette, Gregory B.; Riekert, Kristin A.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA; [Thompson, Darcy A.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; [Patino, Cecilia M.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; [Teodoro, Alvin P.] Cornell Univ, New York Presbyterian Weill Med Coll, Dept Pediat, New York, NY 10021 USA; [Loiaza-Martinez, Antonio] Hosp Infantil Las Calif, Tijuana, Mexico; [Thyne, Shannon] UC San Francisco, Dept Pediat, San Francisco, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Southern California; Cornell University; University of California System; University of California San Francisco	Okelo, SO (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, 10833 Le Conte Ave,MDCC 287B, Los Angeles, CA 90095 USA.	sandeokelo@jhmi.edu	Thompson, Darcy/AAP-5055-2020	Patino, Cecilia M./0000-0001-5742-2157	National Heart, Lung, and Blood Institute [HL089410]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K23HD060666] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL089410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K24ES021098] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Heart, Lung, and Blood Institute grant HL089410.	Altman DG, 1990, PRACTICAL STAT MED R; [Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Asmussen L, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e71; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Berg J, 2004, J ASTHMA, V41, P147, DOI 10.1081/JAS-120026072; Cabana MD, 2005, CLIN PEDIATR, V44, P319, DOI 10.1177/000992280504400406; Cabana MD, 2003, CLIN PEDIATR, V42, P121, DOI 10.1177/000992280304200204; Canino G, 2006, SOC SCI MED, V63, P2926, DOI 10.1016/j.socscimed.2006.07.017; Canino G, 2012, ANN ALLERG ASTHMA IM, V108, P266, DOI 10.1016/j.anai.2012.02.002; Chan KS, 2005, MED CARE, V43, P256, DOI 10.1097/00005650-200503000-00008; Cohen RT, 2006, CHEST, V130, P463, DOI 10.1016/S0012-3692(15)51862-X; Demissie S, 2012, PEDIAT ALLER IMM PUL, V25, P17, DOI 10.1089/ped.2011.0107; Ducharme Francine M, 2004, Can Respir J, V11, P541; Fagnano M, 2011, ACAD PEDIATR, V11, P493, DOI 10.1016/j.acap.2011.05.006; Goodyear-Smith F, 2008, ANN FAM MED, V6, P213, DOI 10.1370/afm.795; Gupta RS, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-45; Halterman JS, 2006, ARCH DIS CHILD, V91, P766, DOI 10.1136/adc.2006.096123; Halterman JS, 2000, PEDIATRICS, V105, P272; Halterman JS, 2005, ARCH PEDIAT ADOL MED, V159, P422, DOI 10.1001/archpedi.159.5.422; Halterman JS, 2003, AMBUL PEDIATR, V3, P102, DOI 10.1367/1539-4409(2003)003<0102:APPIPA>2.0.CO;2; Halterman JS, 2002, ARCH PEDIAT ADOL MED, V156, P141, DOI 10.1001/archpedi.156.2.141; HANLEY JA, 1989, CRIT REV DIAGN IMAG, V29, P307; Hosmer DW, 2005, APPL LOGISTIC REGRES, P143, DOI DOI 10.1002/0471722146; Ibero M, 2007, J ALLERGY CLIN IMMUN, V119, pS73, DOI 10.1016/j.jaci.2006.11.309; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Kachru R, 2006, ANN ALLERG ASTHMA IM, V97, P775, DOI 10.1016/S1081-1206(10)60969-6; Kleinbaum DG, 2008, ONE WAY ANAL VARIENC, P420; Koolen BB, 2011, EUR RESPIR J, V38, P561, DOI 10.1183/09031936.00173710; Lang TA, 2006, REPORT STAT MED ANNO; Lara M, 2000, MED CARE, V38, P342, DOI 10.1097/00005650-200003000-00011; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Murphy KR, 2009, J ALLERGY CLIN IMMUN, V123, P833, DOI 10.1016/j.jaci.2009.01.058; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Newman TB, 2009, EVIDENCE-BASED DIAGNOSIS, P1, DOI 10.1017/CBO9780511759512; Okelo SO, 2008, PEDIATRICS, V122, pE195, DOI 10.1542/peds.2007-2271; Okelo SO, 2009, PEDIAT; Patino CM, 2008, J ALLERGY CLIN IMMUN, V122, P936, DOI 10.1016/j.jaci.2008.08.027; Patino CM, 2005, AM J RESP CRIT CARE, V2, pA254; Perry TT, 2012, ANN ALLERG ASTHMA IM, V108, P254, DOI 10.1016/j.anai.2012.01.017; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schroeder Stephan D, 2008, S D Med, V61, P27; Sharek PJ, 2002, PEDIATRICS, V110, P797, DOI 10.1542/peds.110.4.797; Skinner Elizabeth A, 2004, Dis Manag, V7, P305, DOI 10.1089/dis.2004.7.305; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Stewart KA, 2010, ARCH PEDIAT ADOL MED, V164, P720, DOI 10.1001/archpediatrics.2010.100; Verini M, 2001, ALLERGY ASTHMA PROC, V22, P297; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Wells S, 2010, HEART, V96, P708, DOI 10.1136/hrt.2009.191320; Wolfenden LL, 2003, ARCH INTERN MED, V163, P231, DOI 10.1001/archinte.163.2.231; Zorc JJ, 2006, J ASTHMA, V43, P753, DOI 10.1080/02770900601031615	51	28	28	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					55	U120		10.1016/j.jaci.2013.01.007	http://dx.doi.org/10.1016/j.jaci.2013.01.007			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23434285	Green Accepted			2022-12-18	WOS:000321052300006
J	Teodosio, C; Garcia-Montero, AC; Jara-Acevedo, M; Sanchez-Munoz, L; Pedreira, CE; Alvarez-Twose, I; Matarraz, S; Morgado, JM; Barcena, P; Matito, A; Mayado, A; Sanchez, ML; Diez-Campelo, M; Escribano, L; Orfao, A				Teodosio, Cristina; Garcia-Montero, Andres C.; Jara-Acevedo, Maria; Sanchez-Munoz, Laura; Pedreira, Carlos E.; Alvarez-Twose, Ivan; Matarraz, Sergio; Morgado, Jose M.; Barcena, Paloma; Matito, Almudena; Mayado, Andrea; Luz Sanchez, Maria; Diez-Campelo, Maria; Escribano, Luis; Orfao, Alberto			Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Systemic mastocytosis; D816V KIT mutation; gene expression profile; mast cells; cDNA microarrays	CYCLIN B1; KIT MUTATION; SPANISH NETWORK; OVEREXPRESSION; CANCER; CLASSIFICATION; MICROARRAYS; PATHWAYS; PROTEINS; CRITERIA	Background: Despite the fact that a great majority (>90%) of patients with systemic mastocytosis (SM) carry a common genetic lesion, the D816V KIT mutation, little is known regarding the molecular and biological pathways underlying the clinical heterogeneity of the disease. Objective: We sought to analyze the gene expression profile (GEP) of bone marrow mast cells (BMMCs) in patients with SM and its association with distinct clinical variants of the disease. Methods: GEP analyses were performed by using DNA-oligonucleotide microarrays in highly purified BMMCs from patients with SM carrying the D816V KIT mutation (n = 26) classified according to the diagnostic subtype of SM versus normal/reactive BMMCs (n = 7). Validation of GEP results was performed with flow cytometry in the same set of samples and in an independent cohort of 176 subjects. Results: Overall, 758 transcripts were significantly deregulated in patients with SM, with a common GEP (n = 398 genes) for all subvariants of SM analyzed. These were characterized by upregulation of genes involved in the innate and inflammatory immune response, including interferon-induced genes and genes involved in cellular responses to viral antigens, together with complement inhibitory molecules and genes involved in lipid metabolism and protein processing. Interestingly, aggressive SM additionally showed deregulation of apoptosis and cell cyclerelated genes, whereas patients with indolent SM displayed increased expression of adhesion-related molecules. Conclusion: BMMCs from patients with different clinical subtypes of SM display distinct GEPs, which might reflect new targetable pathways involved in the pathogenesis of the disease. (J Allergy Clin Immunol 2013;131:1213-24.)	[Teodosio, Cristina; Garcia-Montero, Andres C.; Jara-Acevedo, Maria; Matarraz, Sergio; Barcena, Paloma; Mayado, Andrea; Luz Sanchez, Maria; Escribano, Luis; Orfao, Alberto] USAL, CSIC, IBMCC, Serv Gen Citometria,Ctr Invest Canc, Madrid, Spain; [Teodosio, Cristina; Garcia-Montero, Andres C.; Jara-Acevedo, Maria; Matarraz, Sergio; Barcena, Paloma; Mayado, Andrea; Luz Sanchez, Maria; Diez-Campelo, Maria; Escribano, Luis; Orfao, Alberto] IBSAL, Salamanca, Spain; [Teodosio, Cristina; Garcia-Montero, Andres C.; Jara-Acevedo, Maria; Matarraz, Sergio; Barcena, Paloma; Mayado, Andrea; Luz Sanchez, Maria; Escribano, Luis; Orfao, Alberto] Univ Salamanca, Dept Med, E-37008 Salamanca, Spain; [Sanchez-Munoz, Laura; Alvarez-Twose, Ivan; Morgado, Jose M.; Matito, Almudena] Hosp Virgen del Valle, Ctr Estudios Mastocitosis Castilla La Mancha, Toledo, Spain; [Pedreira, Carlos E.] Univ Fed Rio de Janeiro, COPPE, Engn Grad Program, BR-21945 Rio De Janeiro, Brazil; [Pedreira, Carlos E.] Fac Med, Rio De Janeiro, Brazil; [Diez-Campelo, Maria] Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; Complejo Hospitalario de Toledo; Universidade Federal do Rio de Janeiro; University of Salamanca	Orfao, A (corresponding author), Ctr Invest Canc, Campus Miguel de Unamuno, Salamanca 37007, Spain.	orfao@usal.es	Matarraz, Sergio/AAE-8249-2019; Garcia-Montero, Andres C/B-6558-2017; Pedreira, Carlos/I-5629-2013; Montero, Andres/HGA-9093-2022; Orfao, Alberto/B-5801-2017	Garcia-Montero, Andres C/0000-0003-4360-1386; Pedreira, Carlos/0000-0002-9312-4023; Alvarez-Twose, Ivan/0000-0002-1190-4473; Matito, Almudena/0000-0002-9547-4844; Diez Campelo, Maria/0000-0002-1467-6779; Jara-Acevedo, Maria/0000-0001-7965-7512; Teodosio, Cristina/0000-0002-2097-7199; Diez Campelo, Maria/0000-0003-0386-4835; MATARRAZ, SERGIO/0000-0003-4634-8005; Sanchez-Munoz, Laura/0000-0003-1757-7255	Fondo de Investigaciones Sanitarias (FIS) [PI11/02399]; Instituto de Salud Carlos III, Ministerio de Economia y Competitividad (Madrid, Spain) [PS09/00032, RTICC RD06/0020/0035]; Programa Nacional de Internacionalizacion de la I1D; Ministerio de Economia y Competitividad (Madrid, Spain) [PIB2010BZ-00565]; Junta de Castilla y Leon [SAN/103/2011]; Fundacion Sociosanitaria de Castilla-La Mancha [2010/008, G-2010/C-002]; Fundacion Espanola de Mastocitosis (FEM); Brazilian National Research Council (CNPq); Rio de Janeiro Research Foundation (FAPERJ), Rio de Janeiro, Brazil; Fundacao para a Ciencia e Tecnologia (FCT) of Portugal [SFRH/BD/17545/2004]; Programa personal tecnico de apoyo a la investigacion; Fundacao para a Ciencia e Tecnologia-Portugal; ISCIII; JCyL; FAPERJ; CNPq; CAPES; Spanish Ministry of Health; Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain	Fondo de Investigaciones Sanitarias (FIS)(Instituto de Salud Carlos III); Instituto de Salud Carlos III, Ministerio de Economia y Competitividad (Madrid, Spain); Programa Nacional de Internacionalizacion de la I1D; Ministerio de Economia y Competitividad (Madrid, Spain); Junta de Castilla y Leon(Junta de Castilla y Leon); Fundacion Sociosanitaria de Castilla-La Mancha; Fundacion Espanola de Mastocitosis (FEM); Brazilian National Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Rio de Janeiro Research Foundation (FAPERJ), Rio de Janeiro, Brazil(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); Fundacao para a Ciencia e Tecnologia (FCT) of Portugal(Portuguese Foundation for Science and Technology); Programa personal tecnico de apoyo a la investigacion; Fundacao para a Ciencia e Tecnologia-Portugal(Portuguese Foundation for Science and Technology); ISCIII(Instituto de Salud Carlos III); JCyL(Junta de Castilla y Leon); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain	Supported by grants from Fondo de Investigaciones Sanitarias (FIS); PI11/02399; PS09/00032 and RTICC RD06/0020/0035 (FEDER) from Instituto de Salud Carlos III, Ministerio de Economia y Competitividad (Madrid, Spain); Programa Nacional de Internacionalizacion de la I1D; PIB2010BZ-00565 from Ministerio de Economia y Competitividad (Madrid, Spain); Junta de Castilla y Leon (Grant SAN/103/2011); Fundacion Sociosanitaria de Castilla-La Mancha (2010/008 y G-2010/C-002); Fundacion Espanola de Mastocitosis (FEM 2010); Brazilian National Research Council (CNPq), and Rio de Janeiro Research Foundation (FAPERJ), Rio de Janeiro, Brazil. C. T. was supported by a grant from Fundacao para a Ciencia e Tecnologia (FCT) of Portugal (SFRH/BD/17545/2004). M.J.-A. was supported by a grant from Programa personal tecnico de apoyo a la investigacion. Ministerio de Ciencia e Innovacion-Universidad de Salamanca, Spain.; C. Teodosio has been supported by one or more grants from Fundacao para a Ciencia e Tecnologia-Portugal. A. C. Garcia-Montero has been supported by one or more grants from ISCIII and JCyL. C. E. Pedreira has been supported by one or more grants from FAPERJ and CNPq, is employed by the Federal University of Rio de Janeiro, and has received one or more grants from or has one or more grants pending with CNPq, CAPES, FAPERJ. L. Escribano has been supported by one or more grants from the Spanish Ministry of Health. A. Orfao has been supported by one or more grants from Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid, Spain. The rest of the authors declare that they have no relevant conflicts of interest.	Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Akin C, 2007, BLOOD, V110, P2331, DOI 10.1182/blood-2006-06-028100; Allan K, 2000, ARCH PATHOL LAB MED, V124, P216; Alvarez-Twose I, 2012, J CLIN ONCOL, V30, pE126, DOI 10.1200/JCO.2011.38.9973; Alvarez-Twose I, 2010, J ALLERGY CLIN IMMUN, V125, P1269, DOI 10.1016/j.jaci.2010.02.019; Androic I, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-391; Baumgartner C, 2009, AM J PATHOL, V175, P2416, DOI 10.2353/ajpath.2009.080953; Bohm A, 2010, EXP HEMATOL, V38, P744, DOI 10.1016/j.exphem.2010.05.006; Boyce JA, 2007, IMMUNOL REV, V217, P168, DOI 10.1111/j.1600-065X.2007.00512.x; Brown MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034055; Campbell JD, 2011, RESPIROLOGY, V16, P407, DOI 10.1111/j.1440-1843.2011.01942.x; Carmona-Saez P, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r3; Cooper CS, 2007, NAT CLIN PRACT UROL, V4, P677, DOI 10.1038/ncpuro0946; D'ambrosio C, 2003, J ALLERGY CLIN IMMUN, V112, P1162, DOI 10.1016/j.jaci.2003.07.008; Dietrich N, 2010, P NATL ACAD SCI USA, V107, P8748, DOI 10.1073/pnas.0912551107; Douglas JL, 2009, VIROLOGY, V390, P174, DOI 10.1016/j.virol.2009.05.011; Escribano L, 2004, CYTOM PART B-CLIN CY, V58B, P1, DOI 10.1002/cyto.b.10072; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Fishelson Z, 2003, MOL IMMUNOL, V40, P109, DOI 10.1016/S0161-5890(03)00112-3; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Hastie T., 2009, ELEMENTS STAT LEARNI, V2, P241; Horny HP, 2008, WHO CLASSIFICATION T, P54; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Matarraz S, 2011, CYTOM PART B-CLIN CY, V80B, P354, DOI 10.1002/cyto.b.20605; Moses AV, 2002, J VIROL, V76, P8383, DOI 10.1128/JVI.76.16.8383-8399.2002; Niedoszytko M, 2011, ALLERGY, V66, P648, DOI 10.1111/j.1398-9995.2010.02521.x; Niedoszytko M, 2011, ALLERGY, V66, P229, DOI 10.1111/j.1398-9995.2010.02477.x; Nunez-Lopez R, 2003, BRIT J HAEMATOL, V120, P257, DOI 10.1046/j.1365-2141.2003.04055.x; Okaty BW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016493; Pomerantz RG, 2010, BRIT J DERMATOL, V163, P1090, DOI 10.1111/j.1365-2133.2010.09973.x; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sanchez-Munoz L, 2011, MODERN PATHOL, V24, P1157, DOI 10.1038/modpathol.2011.84; Song YM, 2008, CARCINOGENESIS, V29, P307, DOI 10.1093/carcin/bgm269; Soria JC, 2000, CANCER RES, V60, P4000; Sotlar K, 2003, AM J PATHOL, V162, P737, DOI 10.1016/S0002-9440(10)63870-9; Tefferi A, 2009, LEUKEMIA, V23, P900, DOI 10.1038/leu.2009.37; Teodosio C, 2012, LEUKEMIA, V26, P951, DOI 10.1038/leu.2011.293; Teodosio C, 2010, J ALLERGY CLIN IMMUN, V125, P719, DOI 10.1016/j.jaci.2009.10.020; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; VALENT P, 1992, BLOOD, V80, P2237; Wilson TM, 2011, HAEMATOL-HEMATOL J, V96, P459, DOI 10.3324/haematol.2010.031690	46	28	28	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1213	+		10.1016/j.jaci.2012.12.674	http://dx.doi.org/10.1016/j.jaci.2012.12.674			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23403045				2022-12-18	WOS:000317187200032
J	Bensaid, B; Rozieres, A; Nosbaum, A; Nicolas, JF; Berard, F				Bensaid, Benoit; Rozieres, Aurore; Nosbaum, Audrey; Nicolas, Jean-Francois; Berard, Frederic			Amikacin-induced drug reaction with eosinophilia and systemic symptoms syndrome: Delayed skin test and ELISPOT assay results allow the identification of the culprit drug	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Bensaid, Benoit; Nosbaum, Audrey; Nicolas, Jean-Francois; Berard, Frederic] CHU Lyon Sud, Drug Allergy Unit CCR2A, Dept Allergy & Clin Immunol, Pierre Benite, France; [Bensaid, Benoit; Rozieres, Aurore; Nosbaum, Audrey; Nicolas, Jean-Francois; Berard, Frederic] INSERM, U851, F-69008 Lyon, France; [Nosbaum, Audrey; Nicolas, Jean-Francois; Berard, Frederic] Univ Lyon 1, F-69365 Lyon, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Bensaid, B (corresponding author), CHU Lyon Sud, Drug Allergy Unit CCR2A, Dept Allergy & Clin Immunol, Pierre Benite, France.	benoit.ben-said@chu-lyon.fr	Nosbaum, Audrey/AAC-9329-2020; ROZIERES, Aurore/M-4447-2014; Bérard, Frédéric/F-8099-2013; Nicolas, Jean-François/AAW-9289-2020	Nosbaum, Audrey/0000-0003-2281-9052; ROZIERES, Aurore/0000-0003-0293-4002; BERARD, frederic/0000-0003-0094-6122; NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X				Devos SA, 2002, EUR J DERMATOL, V12, P506; Eshki M, 2009, ARCH DERMATOL, V145, P67, DOI 10.1001/archderm.145.1.67; Frouin E, 2005, ANN DERMATOL VENER, V132, P1000, DOI 10.1016/S0151-9638(05)79566-1; Hmouda H, 2005, ANN PHARMACOTHER, V39, P165, DOI 10.1345/aph.1E430; Kardaun SH, 2007, BRIT J DERMATOL, V156, P609, DOI 10.1111/j.1365-2133.2006.07704.x; Liippo J, 2008, CONTACT DERMATITIS, V59, P268, DOI 10.1111/j.1600-0536.2008.01419.x; Rozieres A, 2009, ALLERGY, V64, P534, DOI 10.1111/j.1398-9995.2008.01674.x	7	28	28	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1413	1414		10.1016/j.jaci.2012.05.042	http://dx.doi.org/10.1016/j.jaci.2012.05.042			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	22840850				2022-12-18	WOS:000311641100023
J	Speckmann, C; Neumann, C; Borte, S; la Marca, G; Sass, JO; Wiech, E; Fisch, P; Schwarz, K; Buchholz, B; Schlesier, M; Felgentreff, K; Grimbacher, B; Santisteban, I; Bali, P; Hershfield, MS; Ehl, S				Speckmann, Carsten; Neumann, Carla; Borte, Stephan; la Marca, Giancarlo; Sass, Joern Oliver; Wiech, Elisabeth; Fisch, Paul; Schwarz, Klaus; Buchholz, Bernd; Schlesier, Michael; Felgentreff, Kerstin; Grimbacher, Bodo; Santisteban, Ines; Bali, Pawan; Hershfield, Michael S.; Ehl, Stephan			Delayed-onset adenosine deaminase deficiency: Strategies for an early diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SEVERE COMBINED IMMUNODEFICIENCY		[Speckmann, Carsten; Sass, Joern Oliver; Felgentreff, Kerstin; Ehl, Stephan] Univ Freiburg, Med Ctr, Ctr Pediat & Aldolescent Med, Freiburg, Germany; [Speckmann, Carsten; Schwarz, Klaus; Schlesier, Michael; Felgentreff, Kerstin; Grimbacher, Bodo; Ehl, Stephan] Univ Freiburg, Med Ctr, Ctr Chron Immunodeficiency, Freiburg, Germany; [Neumann, Carla] Univ Munich, Med Poliklin, Klinikum Univ Munchen, D-8000 Munich, Germany; [Borte, Stephan] Hosp St Georg gGmbH Leipzig, Immuno Deficiency Ctr Leipzig, Jeffrey Modell Diagnost & Res Ctr Primary Immunod, Leipzig, Germany; [Borte, Stephan] Univ Leipzig, Translat Ctr Regenerat Med, Leipzig, Germany; [la Marca, Giancarlo] Univ Florence, Dept Pharmacol, Florence, Italy; [la Marca, Giancarlo] Meyer Childrens Univ Hosp, Mass Spectrometry Lab, Florence, Italy; [Wiech, Elisabeth; Fisch, Paul] Univ Freiburg, Inst Pathol, Med Ctr, Freiburg, Germany; [Schwarz, Klaus] Univ Hosp Ulm, Inst Transfus Med, Ulm, Germany; [Schwarz, Klaus] Inst Clin Transfus Med & Immunogenet, Ulm, Germany; [Buchholz, Bernd] Univ Heidelberg, Univ Childrens Hosp, Med Fac Mannheim, Heidelberg, Germany; [Schlesier, Michael; Grimbacher, Bodo] Univ Freiburg, Med Ctr, Dept Rheumatol & Immunol, Freiburg, Germany; [Santisteban, Ines; Bali, Pawan; Hershfield, Michael S.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	University of Freiburg; University of Freiburg; University of Munich; Leipzig University; University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Freiburg; Ulm University; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Freiburg; Duke University	Speckmann, C (corresponding author), Univ Freiburg, Med Ctr, Ctr Pediat & Aldolescent Med, Freiburg, Germany.	carsten.speckmann@uniklinik-freiburg.de	la Marca, Giancarlo/A-2853-2013; Ehl, Stephan/AAM-6006-2020	la marca, giancarlo/0000-0003-3319-7260; Speckmann, Carsten/0000-0002-6217-1556; Ehl, Stephan/0000-0002-9265-2721				Arredondo Vega FX, 2002, BLOOD, V99, P1005; Arredondo-Vega FX, 1998, AM J HUM GENET, V63, P1049, DOI 10.1086/302054; Azzari C, 2011, J ALLERGY CLIN IMMUN, V127, P1394, DOI 10.1016/j.jaci.2011.03.040; Borte S, 2012, BLOOD, V119, P2552, DOI 10.1182/blood-2011-08-371021; CHAFFEE S, 1992, J CLIN INVEST, V89, P1643, DOI 10.1172/JCI115761; Felgentreff K, 2011, CLIN IMMUNOL, V141, P73, DOI 10.1016/j.clim.2011.05.007; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; Lainka E, 2005, CLIN DIAGN LAB IMMUN, V12, P861, DOI 10.1128/CDLI.12.7.861-866.2005; Lipstein EA, 2010, PEDIATRICS, V125, pE1226, DOI 10.1542/peds.2009-1567; Ozsahin H, 1997, BLOOD, V89, P2849, DOI 10.1182/blood.V89.8.2849; SHOVLIN CL, 1994, J IMMUNOL, V153, P2331; Somech R, 2009, J ALLERGY CLIN IMMUN, V124, P848, DOI 10.1016/j.jaci.2009.07.003	12	28	30	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					991	994		10.1016/j.jaci.2012.04.004	http://dx.doi.org/10.1016/j.jaci.2012.04.004			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22578972				2022-12-18	WOS:000309594800024
J	Berg, ND; Husemoen, LLN; Thuesen, BH; Hersoug, LG; Elberling, J; Thyssen, JP; Carlsen, BC; Johansen, JD; Menne, T; Bonnelykke, K; Stender, S; Meldgaard, M; Szecsi, PB; Linneberg, A				Berg, Nikolaj Drimer; Husemoen, Lise Lotte N.; Thuesen, Betina Heinsbaek; Hersoug, Lars-Georg; Elberling, Jesper; Thyssen, Jacob Pontoppidan; Carlsen, Berit Christina; Johansen, Jeanne Duus; Menne, Torkil; Bonnelykke, Klaus; Stender, Steen; Meldgaard, Michael; Szecsi, Pal Bela; Linneberg, Allan			Interaction between filaggrin null mutations and tobacco smoking in relation to asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; filaggrin; R501X; 2282del4; tobacco smoking; gene-environment interaction; genotype; population based; health examination; Health2006	PARTY DIAGNOSTIC-CRITERIA; OF-FUNCTION MUTATIONS; SKIN BARRIER FUNCTION; ALLERGIC SENSITIZATION; STRUCTURAL PROTEINS; ATOPIC-DERMATITIS; CIGARETTE-SMOKE; GENE; SYMPTOMS; EXPOSURE	Background: The mechanisms underlying the association between filaggrin (FLG) deficiency and asthma are not known. It has been hypothesized that FLG deficiency leads to enhanced percutaneous exposure to environmental substances that might trigger immune responses. We hypothesized that interactions between FLG deficiency and environmental exposures play a role in asthma development. Objective: We sought to investigate possible interactions between FLG null mutations and tobacco smoking in relation to asthma. Methods: A total of 3471 adults from a general population sample participated in a health examination. Lung function and serum specific IgE levels to inhalant allergens were measured, and information on asthma and smoking was obtained by means of questionnaire. Participants were genotyped for the 2 most common FLG null mutations in white subjects: R501X and 2282del4. Another Danish population was used for replication. Results: The FLG null mutation genotype was significantly associated with a higher prevalence of asthma and decreased FEV1/forced vital capacity ratio. In logistic regression analyses with asthma as the outcome, a significant interaction was found between FLG null mutations and smoking status (P = .02). This interaction was confirmed, although it was not statistically significant, in another Danish population study. Interactions between FLG genotype and cumulated smoking exposure were found in relation to asthma (P = .03) and decreased FEV1/forced vital capacity ratio (P = .03). A 3-way interaction was found among FLG genotype, smoking, and asthma, suggesting that the FLG-smoking interaction mainly played a role in nonatopic subjects. Conclusion: FLG null mutations modified the effects of smoking on the risk of asthma. This finding might have implications for risk stratification of the population. (J Allergy Clin Immunol 2012;129:374-80.)	[Berg, Nikolaj Drimer; Husemoen, Lise Lotte N.; Thuesen, Betina Heinsbaek; Hersoug, Lars-Georg; Linneberg, Allan] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, DK-2600 Glostrup, Denmark; [Elberling, Jesper] Danish Res Ctr Chem Sens, Copenhagen, Denmark; [Thyssen, Jacob Pontoppidan; Carlsen, Berit Christina; Johansen, Jeanne Duus; Menne, Torkil] Natl Allergy Res Ctr, Dept Dermatoallergol, Copenhagen, Denmark; [Bonnelykke, Klaus] Danish Paediat Asthma Ctr, COPSAC, Dept Pediat, Skejby, Denmark; [Stender, Steen; Meldgaard, Michael; Szecsi, Pal Bela] Univ Copenhagen, Dept Clin Biochem, Gentofte Univ Hosp, DK-1168 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Linneberg, A (corresponding author), Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Nordre Ringvej 57,Bldg 84-85, DK-2600 Glostrup, Denmark.	alllin01@regionh.dk	Thyssen, Jacob/ABD-8517-2020; Johansen, Jeanne/AAM-6382-2021	Johansen, Jeanne/0000-0002-3537-8463; Linneberg, Allan/0000-0002-0994-0184; Bonnelykke, Klaus/0000-0003-2003-1018; Thyssen, Jacob Pontoppidan/0000-0003-3770-1743; Elberling, Jesper/0000-0002-8925-4722; Szecsi, Pal/0000-0003-3446-0411; Thuesen, Betina/0000-0001-9772-4344; Hersoug, lars-Georg/0000-0002-2391-5284	Health Insurance Foundation; philanthropic foundation TrygFonden; Danish Board of Health; Danish Environmental Protection Agency; Copenhagen County Research Foundation; Aase and Einar Danielsens Foundation; Velux Foundation, ALK-Abello A/S, Denmark; Danish Scientific Research Council	Health Insurance Foundation; philanthropic foundation TrygFonden; Danish Board of Health; Danish Environmental Protection Agency; Copenhagen County Research Foundation; Aase and Einar Danielsens Foundation; Velux Foundation, ALK-Abello A/S, Denmark; Danish Scientific Research Council	Supported by the Health Insurance Foundation and the philanthropic foundation TrygFonden.; Supported by the Danish Board of Health; the Danish Environmental Protection Agency; the Copenhagen County Research Foundation; the Aase and Einar Danielsens Foundation; the Velux Foundation, ALK-Abello A/S, Denmark; and the Danish Scientific Research Council.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Berg ND, 2008, INT ARCH OCC ENV HEA, V81, P881, DOI 10.1007/s00420-007-0282-0; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bonnelykke K, 2010, PEDIAT ALLERG IMM-UK, V21, P954, DOI 10.1111/j.1399-3038.2010.01073.x; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Eugen-Olsen J, 2010, J INTERN MED, V268, P296, DOI 10.1111/j.1365-2796.2010.02252.x; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Hersoug LG, 2010, RESPIROLOGY, V15, P993, DOI 10.1111/j.1440-1843.2010.01758.x; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Karrasch S, 2011, RESP MED, V105, P713, DOI 10.1016/j.rmed.2010.11.002; Kimber I, 1996, TOXICOL LETT, V86, P89, DOI 10.1016/0378-4274(96)03678-8; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P980, DOI 10.1067/mai.2003.1394; Linneberg A, 2001, ALLERGY, V56, P328, DOI 10.1034/j.1398-9995.2000.00509.x-i1; McGrath J., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004722.PUB2; Mcleish AC, 2010, J ASTHMA, V47, P345, DOI 10.3109/02770900903556413; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; PEDERSEN OF, 1983, B EUR PHYSIOPATH RES, V19, P515; Pekkanen J, 2005, EUR RESPIR J, V26, P28, DOI 10.1183/09031936.05.00120104; Petersen AB, 2004, CLIN BIOCHEM, V37, P882, DOI 10.1016/j.clinbiochem.2004.06.010; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101; Proksch E, 2008, EXP DERMATOL, V17, P1063, DOI 10.1111/j.1600-0625.2008.00786.x; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; Redlich Carrie A, 2010, Proc Am Thorac Soc, V7, P134, DOI 10.1513/pats.201002-025RM; Reno F, 2011, ORAL ONCOL, V47, P827, DOI 10.1016/j.oraloncology.2011.06.006; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rousset F, 2008, MOL ECOL RESOUR, V8, P103, DOI 10.1111/j.1471-8286.2007.01931.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Shahzad K, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-292; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wu ZH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005227	44	28	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					374	U154		10.1016/j.jaci.2011.08.045	http://dx.doi.org/10.1016/j.jaci.2011.08.045			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22088612				2022-12-18	WOS:000299951700011
J	Rizzi, M; Neumann, C; Fielding, AK; Marks, R; Goldacker, S; Thaventhiran, J; Tarzi, MD; Schlesier, M; Salzer, U; Eibel, H; Warnatz, K; Finke, J; Grimbacher, B; Peter, HH				Rizzi, Marta; Neumann, Carla; Fielding, Adele K.; Marks, Reinhard; Goldacker, Sigune; Thaventhiran, James; Tarzi, Michael D.; Schlesier, Michael; Salzer, Ulrich; Eibel, Hermann; Warnatz, Klaus; Finke, Juergen; Grimbacher, Bodo; Peter, Hans-Hartmut			Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Rizzi, Marta; Marks, Reinhard; Goldacker, Sigune; Schlesier, Michael; Salzer, Ulrich; Eibel, Hermann; Warnatz, Klaus; Finke, Juergen; Peter, Hans-Hartmut] Univ Med Ctr Freiburg, CCI, Freiburg, Germany; [Rizzi, Marta; Neumann, Carla; Goldacker, Sigune; Schlesier, Michael; Peter, Hans-Hartmut] Univ Med Ctr Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany; [Marks, Reinhard; Finke, Juergen] Univ Med Ctr Freiburg, Dept Hematol, Freiburg, Germany; [Fielding, Adele K.] UCL, Dept Hematol, London, England; [Thaventhiran, James; Tarzi, Michael D.; Grimbacher, Bodo] Royal Free Hosp, Div Clin Immunol, London NW3 2QG, England	University of Freiburg; University of Freiburg; University of Freiburg; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Rizzi, M (corresponding author), Univ Med Ctr Freiburg, CCI, Freiburg, Germany.	hans-hartmut.peter@uniklinik-freiburg.de	Rizzi, Marta/ABE-7264-2020; Warnatz, Klaus/AAD-3464-2022; Fielding, Adele/AFM-9369-2022	Thaventhiran, James/0000-0001-8616-074X; Rizzi, Marta/0000-0002-5153-6089				Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Eibel H, 2010, CURR OPIN ALLERGY CL, V10, P526, DOI 10.1097/ACI.0b013e32833fea1c; Ochtrop MLG, 2011, BLOOD, V118, P309, DOI 10.1182/blood-2010-11-321695; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Sorror ML, 2005, BLOOD, V106, P2912, DOI 10.1182/blood-2005-05-2004; Storek J, 2008, SEMIN IMMUNOPATHOL, V30, P425, DOI 10.1007/s00281-008-0132-5; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744	7	28	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1371	U783		10.1016/j.jaci.2011.07.055	http://dx.doi.org/10.1016/j.jaci.2011.07.055			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21930294				2022-12-18	WOS:000298342700038
J	Peng, RD; Paigen, B; Eggleston, PA; Hagberg, KA; Krevans, M; Curtin-Brosnan, J; Benson, C; Shreffler, WG; Matsui, EC				Peng, Roger D.; Paigen, Beverly; Eggleston, Peyton A.; Hagberg, Karol A.; Krevans, Mary; Curtin-Brosnan, Jean; Benson, Cristy; Shreffler, Wayne G.; Matsui, Elizabeth C.			Both the variability and level of mouse allergen exposure influence the phenotype of the immune response in workers at a mouse facility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mouse allergen; IgE; IgG(4); laboratory animal allergy	LABORATORY-ANIMAL WORKERS; RAT URINARY ALLERGENS; UNITED-STATES; CAT ALLERGEN; SENSITIZATION; ASTHMA; ANTIBODIES; CHILDREN; IGE; PREVALENCE	Background: The role of natural aeroallergen exposure in modulating allergen-specific immune responses is not well understood. Objective: We sought to examine relationships between mouse allergen exposure and mouse-specific immune responses. Methods: New employees (n = 179) at a mouse facility underwent repeated assessment of mouse allergen exposure, skin prick tests (SPTs), and measurement of mouse-specific IgG levels. Relationships between the mean level of exposure, variability of exposure (calculated as log deviation), and time to development of immunologic outcomes were examined by using Cox proportional hazards models. Results: By 24 months, 32 (23%) participants had experienced a positive SPT response, and 10 (8%) had mouse-specific IgG(4). The incidence of a positive SPT response increased as levels of exposure increased from low to moderate, peaking at 1.2 ng/m(3), and decreased beyond this point (P = .04). The more variable the exposure was across visits, the lower the incidence of a positive SPT response (hazard ratio [HR], 0.17; 95% CI, 0.07-0.41). Variability of exposure was an independent predictor of a positive SPT response in a model that included both exposure metrics. In contrast, the incidence of mouse-specific IgG(4) increased with increasing levels of mouse allergen exposure (HR, 2.9; 95% CI, 1.4-6.0), and there was evidence of a higher risk of mouse-specific IgG(4) with greater variability of exposure (HR, 6.3; 95% CI, 0.4-95.2). Conclusion: Both the level and variability of mouse allergen exposure influence the humoral immune response, with specific patterns of exposure associated with specific immunophenotypes. Exposure variability might be a more important predictor of a positive SPT response, whereas the average exposure level might be a more important predictor of mouse-specific IgG(4). (J Allergy Clin Immunol 2011;128:390-6.)	[Peng, Roger D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Paigen, Beverly; Hagberg, Karol A.; Krevans, Mary; Benson, Cristy] Jackson Lab, Bar Harbor, ME 04609 USA; [Eggleston, Peyton A.; Curtin-Brosnan, Jean; Matsui, Elizabeth C.] Johns Hopkins Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD USA; [Shreffler, Wayne G.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Jackson Laboratory; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; Massachusetts General Hospital	Matsui, EC (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	ematsui@jhmi.edu			National Institute of Allergy and Infectious Disease [R01AI070630, R01AI0818451, R03AI0629745, K23AI060955]; National Institutes of Health; Environmental Protection Agency; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI081845, R01AI070630, K23AI060955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606, P50ES015903] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Environmental Protection Agency(United States Environmental Protection Agency); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institute of Allergy and Infectious Disease (R01AI070630, R01AI0818451, R03AI0629745, and K23AI060955).; R. D. Peng receives research support from the National Institutes of Health and the Environmental Protection Agency. E. C. Matsui receives research support from the National Institutes of Health and the Environmental Protection Agency. The rest of the authors have declared that they have no conflict of interest.	Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; AALBERSE RC, 1983, J IMMUNOL, V130, P722; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Cory Stella, 2010, Morbidity and Mortality Weekly Report, V59, P1; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Hollander A, 1999, ALLERGY, V54, P142, DOI 10.1034/j.1398-9995.1999.00630.x; Jeal H, 2006, AM J RESP CRIT CARE, V174, P21, DOI 10.1164/rccm.200506-964OC; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P112, DOI 10.1034/j.1399-3038.1999.00015.x; KROP EJ, 2009, J ALLERGY CLIN IMMUN, V123, pE1; KROP EJ, 2010, ALLERGY; Krop EJM, 2009, J ALLERGY CLIN IMMUN, V123, P694, DOI 10.1016/j.jaci.2008.12.021; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Matsui EC, 2004, ANN ALLERG ASTHMA IM, V93, P171, DOI 10.1016/S1081-1206(10)61471-8; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Matsui EC, 2007, J ALLERGY CLIN IMMUN, V119, P910, DOI 10.1016/j.jaci.2006.12.663; McHugh MK, 2009, J ASTHMA, V46, P759, DOI 10.3109/02770900903067895; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nieuwenhuijsen MJ, 2003, OCCUP ENVIRON MED, V60, P104, DOI 10.1136/oem.60.2.104; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Portengen L, 2004, CLIN EXP ALLERGY, V34, P1243, DOI 10.1111/j.1365-2222.2004.02025.x; Wegienka G, 2010, J ALLERGY CLIN IMMUN, V126, P274, DOI 10.1016/j.jaci.2010.05.001; Witteman AM, 1996, INT ARCH ALLERGY IMM, V109, P369, DOI 10.1159/000237265; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358	34	28	28	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					390	U414		10.1016/j.jaci.2011.04.050	http://dx.doi.org/10.1016/j.jaci.2011.04.050			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ		Green Accepted			2022-12-18	WOS:000293280800021
J	Marashi, SM; Raeiszadeh, M; Workman, S; Rahbar, A; Soderberg-Naucler, C; Klenerman, P; Chee, R; Webster, AD; Milne, RSB; Emery, VC				Marashi, Sayed Mahdi; Raeiszadeh, Mohammad; Workman, Sarita; Rahbar, Afsar; Soderberg-Naucler, Cecilia; Klenerman, Paul; Chee, Ronnie; Webster, A. David; Milne, Richard S. B.; Emery, Vincent C.			Inflammation in common variable immunodeficiency is associated with a distinct CD8(+) response to cytomegalovirus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cytomegalovirus; common variable immunodeficiency; inflammation; CD8(+) T cells	T-CELLS; CD8+T CELLS; ANTIGEN; DISEASES; UPDATE; IDENTIFICATION; APOPTOSIS; SUBSET; ASSAY; CTL	Background: Common variable immunodeficiency is the most common primary immunodeficiency. A subset of patients has debilitating inflammatory complications. Objectives: We investigated the role of cytomegalovirus (CMV), and the T-cell response targeted at this virus, in this inflammatory disease. Methods: Phenotypic and functional assays were used to profile CMV-specific T cells in patients with common variable immunodeficiency with and without inflammatory complications. Highly sensitive immunohistochemistry was used to detect CMV antigens at sites of inflammation. Results: Cytomegalovirus was significantly associated with inflammatory disease, which occurred in 31 of 43 (72%) virus-exposed patients and 8 of 31 (26%) naive patients (P = .0001). CMV pp65-NLVPMVATV epitope-specific CD8(+) T-cell frequencies were significantly elevated in inflammatory patients, but these cells did not show evidence of exhaustion, with low levels of programmed death-1 and high T-cell receptor avidity. Rather, they showed features consistent with high in vivo functionality and proliferative activity including reduced levels of the anti-inflammatory marker CD73 (1.67% of NLV+ cells were CD73(+) vs 42.01% in noninflammatory patients; P = .004) and increased Ki-67 expression (37% vs 2% in noninflammatory patients; P < .0001). In vitro, the CMV-specific T cells showed high antigen-specific proliferative potential compared with cells from noninflammatory patients. By using sensitive immunohistochemistry, we detected for the first time viral antigen at the sites of inflammation, indicative of active viral replication. Conclusion: Our data strongly support a direct role for CMV and a hyperreactive CMV-specific immune response in the debilitating chronic inflammatory complications of common variable immunodeficiency. (J Allergy Clin Immunol 2011;127:1385-93.)	[Emery, Vincent C.] UCL, Sch Med, Med Res Council Ctr Med Mol Virol, Div Infect & Immun, London NW3 2QG, England; [Raeiszadeh, Mohammad; Workman, Sarita] UCL, Sch Med, Dept Immunol, Div Infect & Immun, London NW3 2QG, England; [Chee, Ronnie; Webster, A. David] Royal Free Hosp NHS Trust, Dept Clin Immunol, London, England; [Rahbar, Afsar; Soderberg-Naucler, Cecilia] Karolinska Inst, Dept Med, Ctr Mol Med, Stockholm, Sweden; [Klenerman, Paul] Univ Oxford, Oxford, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; Karolinska Institutet; University of Oxford	Emery, VC (corresponding author), UCL, Sch Med, Med Res Council Ctr Med Mol Virol, Div Infect & Immun, Royal Free Campus,Rowland Hill St, London NW3 2QG, England.	vemery@medsch.ucl.ac.uk	; Emery, Vincent/G-8928-2013	klenerman, paul/0000-0003-4307-9161; Rahbar, Afsar/0000-0003-1158-2512; Emery, Vincent/0000-0001-5893-9756	Medical Research Council; Wellcome Trust; Primary Immunodeficiency Association; Swedish Medical Research Foundation; James Martin 21st Century School; NIHR Biomedical Research Centre; Tehran University of Medical Sciences; Iranian Ministry of Health; Roche; RATOS; Oxypharma; Swedish Medical Research Council	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Primary Immunodeficiency Association; Swedish Medical Research Foundation(Swedish Medical Research Council (SMRC)); James Martin 21st Century School; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Tehran University of Medical Sciences(Tehran University of Medical Sciences); Iranian Ministry of Health; Roche(Roche Holding); RATOS; Oxypharma; Swedish Medical Research Council(Swedish Medical Research Council (SMRC))	The UCL MRC Centre for Medical Molecular Virology is supported by a Centre Grant from the Medical Research Council. Part of this work was supported by a Wellcome Trust Grant to V.C.E. and colleagues and a grant from the Primary Immunodeficiency Association to A.D.W. Work in C.S.-N.'s laboratory is supported by the Swedish Medical Research Foundation. Research in P.K.'s laboratory is funded by the Medical Research Council, the Wellcome Trust, the James Martin 21st Century School, and the NIHR Biomedical Research Centre Programme. S.M.M. received a scholarship from the Tehran University of Medical Sciences and was supported by a PhD studentship from the Iranian Ministry of Health.; Disclosure of potential conflict of interest: S. Workman has received honoraria from Octopharma. C. Soderberg-Naucler and V. C. Emery have received research support from Roche, RATOS, Oxypharma, and the Swedish Medical Research Council. The rest of the authors have declared that they have no conflict of interest.	AlexanderMiller MA, 1996, J EXP MED, V184, P485, DOI 10.1084/jem.184.2.485; Anderton SM, 2001, IMMUNOLOGY, V104, P367, DOI 10.1046/j.1365-2567.2001.01324.x; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; Carbone J, 2006, Allergol Immunopathol (Madr), V34, P131, DOI 10.1157/13091037; Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1084/jem.20052246; Chapel H, 2003, CLIN EXP IMMUNOL, V132, P9, DOI 10.1046/j.1365-2249.2003.02110.x; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Chua I, 2007, CLIN EXP IMMUNOL, V150, P306, DOI 10.1111/j.1365-2249.2007.03481.x; Colgan Sean P, 2006, Purinergic Signal, V2, P351, DOI 10.1007/s11302-005-5302-5; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Derby MA, 2001, EUR J IMMUNOL, V31, P2951, DOI 10.1002/1521-4141(2001010)31:10<2951::AID-IMMU2951>3.0.CO;2-Q; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; Geha RS, 2007, J ALLERGY CLIN IMMUN, V120, P776, DOI 10.1016/j.jaci.2007.08.053; Grunewald JKG, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-10; Halliday E, 2003, J INFECTION, V46, P1, DOI 10.1053/jinf.2002.1066; Harkins L, 2002, LANCET, V360, P1557, DOI 10.1016/S0140-6736(02)11524-8; Holm AM, 2004, CLIN EXP IMMUNOL, V138, P278, DOI 10.1111/j.1365-2249.2004.02630.x; Hutchinson SL, 2003, J BIOL CHEM, V278, P24285, DOI 10.1074/jbc.M300633200; JAFFE JS, 1993, BLOOD, V82, P192, DOI 10.1182/blood.V82.1.192.bloodjournal821192; Jang EY, 2009, CLIN INFECT DIS, V48, pE121, DOI 10.1086/599116; Kannanganat S, 2007, J VIROL, V81, P8468, DOI 10.1128/JVI.00228-07; Klenerman P, 2004, EUR J IMMUNOL, V34, P313, DOI 10.1002/eji.200324844; Lilley BN, 2005, IMMUNOL REV, V207, P126, DOI 10.1111/j.0105-2896.2005.00318.x; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Malamut G, 2008, J HEPATOL, V48, P74, DOI 10.1016/j.jhep.2007.08.011; Mocarski ES, 2002, TRENDS MICROBIOL, V10, P332, DOI 10.1016/S0966-842X(02)02393-4; Nebbia G, 2008, AM J TRANSPLANT, V8, P2590, DOI 10.1111/j.1600-6143.2008.02425.x; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Raeiszadeh M, 2006, CLIN EXP IMMUNOL, V146, P234, DOI 10.1111/j.1365-2249.2006.03209.x; Samanta M, 2003, J UROLOGY, V170, P998, DOI 10.1097/01.ju.0000080263.46164.97; Serrano D, 2000, CLIN IMMUNOL, V97, P248, DOI 10.1006/clim.2000.4941; Soderberg-Naucler C, 2008, J CLIN VIROL, V41, P218, DOI 10.1016/j.jcv.2007.11.009; Thatayatikom A, 2005, ANN ALLERG ASTHMA IM, V95, P293, DOI 10.1016/S1081-1206(10)61228-8; Walker LJ, 2010, CLIN EXP IMMUNOL, V159, P245, DOI 10.1111/j.1365-2249.2009.04047.x; Webster ADB, 2001, IMMUNOL ALLERGY CLIN, V21, P1, DOI 10.1016/S0889-8561(05)70190-9; WEBSTER ADB, 1999, GRANULOMATOUS DISORD, P387; Wooldridge L, 2007, EUR J IMMUNOL, V37, P1323, DOI 10.1002/eji.200636765; WRIGHT JJ, 1990, BLOOD, V76, P2046; YAP PL, 1994, J HEPATOL, V21, P455, DOI 10.1016/S0168-8278(05)80328-9; Yegutkin GG, 2010, J IMMUNOL, V184, P5112, DOI 10.4049/jimmunol.0902760; Yong PFK, 2008, IMMUNOL ALLERGY CLIN, V28, P367, DOI 10.1016/j.iac.2008.01.001	41	28	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1385	U122		10.1016/j.jaci.2011.04.001	http://dx.doi.org/10.1016/j.jaci.2011.04.001			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21536322	Green Accepted			2022-12-18	WOS:000291048500009
J	Arbes, SJ; Matsui, EC				Arbes, Samuel J., Jr.; Matsui, Elizabeth C.			Can oral pathogens influence allergic disease?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Oral microflora; oral pathogens; gingivitis; periodontitis; periodontal diseases; allergy; asthma; hay fever; allergic rhinitis; hygiene hypothesis	DESTRUCTIVE PERIODONTAL-DISEASE; RESPIRATORY ALLERGIES; INVERSE ASSOCIATION; HYGIENE HYPOTHESIS; SERUM ANTIBODIES; CHILDREN; HEALTH; ADULTS; RISK; ACQUISITION	The hygiene hypothesis contends that fewer opportunities for infections and microbial exposures have resulted in more widespread asthma and atopic disease. Consistent with that hypothesis, decreases in infectious oral diseases over the past half century have coincided with increases in the prevalence of asthma and other allergic diseases. This observation has led some researchers to speculate that exposures to oral bacteria, including pathogens associated with periodontal diseases, such as gingivitis and periodontitis, might play a protective role in the development of asthma and allergy. Colonization of the oral cavity with bacteria, including some species of periodontal pathogens, begins shortly after birth, and the detection of serum antibodies to oral pathogens in early childhood provides evidence of an early immune response to these bacteria. Current knowledge of the immune response to oral bacteria and the immunologic pathogenesis of periodontal diseases suggests biologically plausible mechanisms by which oral pathogens could influence the risk of allergic disease. However, studies investigating the association between oral pathogen exposures and allergic disease are few in number and limited by cross-sectional or case-control design, exclusion of young children, and use of surrogate measures of oral bacterial colonization. Additional studies, particularly well-designed case-control studies among very young children and prospective birth cohort studies, are needed. (J Allergy Clin Immunol 2011;127:1119-27.)	[Arbes, Samuel J., Jr.] Rho Inc, Chapel Hill, NC 27517 USA; [Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Rho; Johns Hopkins University	Arbes, SJ (corresponding author), Rho Inc, 6330 Quadrangle Dr,Rho Bldg, Chapel Hill, NC 27517 USA.	sam_arbes@rhoworld.com		Matsui, Elizabeth/0000-0001-8134-5593	National Institutes of Health	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Disclosure of potential conflict of interest: S. J. Arbes is employed by Rho, Inc. E. C. Matsui receives research support from the National Institutes of Health.	Albandar JM, 1999, J PERIODONTOL, V70, P13, DOI 10.1902/jop.1999.70.1.13; Arbes SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1169, DOI 10.1016/j.jaci.2006.07.029; BECK JD, 2002, CARRANZAS CLIN PERIO, P74; Boggess KA, 2005, AM J OBSTET GYNECOL, V193, P1121, DOI 10.1016/j.ajog.2005.05.050; Borrell LN, 2005, J DENT RES, V84, P924, DOI 10.1177/154405910508401010; BURT BA, 2005, DENTISTRY DENTAL PRA; Card JW, 2010, INFECT IMMUN, V78, P2488, DOI 10.1128/IAI.01270-09; Carletto-Korber FPM, 2010, PEDIATR DENT, V32, P205; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Darby I, 2001, PERIODONTOL 2000, V26, P33, DOI 10.1034/j.1600-0757.2001.2260103.x; Dewhirst FE, 2010, J BACTERIOL, V192, P5002, DOI 10.1128/JB.00542-10; Domejean S, 2010, J DENT RES, V89, P51, DOI 10.1177/0022034509353400; Dye B.A., 2007, VITAL HLTH STAT, V11, P1; Dye BA, 2005, J CLIN PERIODONTOL, V32, P1189, DOI 10.1111/j.1600-051X.2005.00856.x; Eloot A K, 2004, Eur J Paediatr Dent, V5, P210; Friedrich N, 2006, CLIN EXP ALLERGY, V36, P495, DOI 10.1111/j.1365-2222.2006.02455.x; Friedrich N, 2008, J CLIN PERIODONTOL, V35, P305, DOI 10.1111/j.1600-051X.2008.01200.x; GROSSI SG, 1994, J PERIODONTOL, V65, P260, DOI 10.1902/jop.1994.65.3.260; Gu Y., 2010, PERIODONTAL DIS OVER, P5; Haake S.K., 2002, CARRANZAS CLIN PERIO, V6, P96; Haake SK, 2002, CLIN PERIODONTOLOGY, P153; Haake SK, 2002, CARRANZAS CLIN PERIO, P132; Haffajee AD, 2005, J CLIN PERIODONTOL, V32, P33, DOI 10.1111/j.1600-051X.2004.00624.x; Hujoel PP, 2008, J PERIODONTOL, V79, P1330, DOI [10.1902/jop.2008.070648, 10.1902/jop.2008.070648 ]; Kanasi E, 2010, J DENT RES, V89, P378, DOI 10.1177/0022034509360010; Lamell CW, 2000, J CLIN MICROBIOL, V38, P1196, DOI 10.1128/JCM.38.3.1196-1199.2000; Laurikainen K, 1998, ALLERGY, V53, P316, DOI 10.1111/j.1398-9995.1998.tb03894.x; Madianos PN, 2010, PERIODONTAL DIS OVER, P24; Maupome G, 2010, J AM DENT ASSOC, V141, P1061, DOI 10.14219/jada.archive.2010.0335; McDerra Esther J. C., 1998, Pediatric Dentistry, V20, P281; Mehta Abhishek, 2009, N Y State Dent J, V75, P44; MOUTON C, 1981, INFECT IMMUN, V31, P182, DOI 10.1128/IAI.31.1.182-192.1981; Nakajima T, 2005, J DENT RES, V84, P639, DOI 10.1177/154405910508400711; Petersen PE, 2004, INT DENT J, V54, P329; Romagnani S, 2007, J ALLERGY CLIN IMMUN, V119, P1511, DOI 10.1016/j.jaci.2007.04.005; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Shulman Jay D, 2003, Pediatr Dent, V25, P279; Soncini JA, 2010, ANAEROBE, V16, P278, DOI 10.1016/j.anaerobe.2009.10.007; Stensson M, 2010, INT J PAEDIATR DENT, V20, P165, DOI 10.1111/j.1365-263X.2010.01037.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tanner ACR, 2002, J DENT RES, V81, P53, DOI 10.1177/154405910208100112; van Winkelhoff AJ, 2005, J CLIN PERIODONTOL, V32, P16, DOI 10.1111/j.1600-051X.2005.00805.x; von Hertzen LC, 2006, INT ARCH ALLERGY IMM, V140, P89, DOI 10.1159/000092251	43	28	31	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1119	1127		10.1016/j.jaci.2011.03.023	http://dx.doi.org/10.1016/j.jaci.2011.03.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21531254	Bronze			2022-12-18	WOS:000290018600004
J	Vanbervliet, B; Akdis, M; Vocanson, M; Rozieres, A; Benetiere, J; Rouzaire, P; Akdis, CA; Nicolas, JF; Hennino, A				Vanbervliet, Beatrice; Akdis, Muebeccel; Vocanson, Marc; Rozieres, Aurore; Benetiere, Josette; Rouzaire, Paul; Akdis, Cezmi A.; Nicolas, Jean-Francois; Hennino, Ana			Histamine receptor H1 signaling on dendritic cells plays a key role in the IFN-gamma/IL-17 balance in T cell-mediated skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; CD8(+) T cell; histamine; H1R; dendritic cell	PROINFLAMMATORY CYTOKINE PRODUCTION; INDUCED AIRWAY INFLAMMATION; ATOPIC-DERMATITIS; CONTACT HYPERSENSITIVITY; INTESTINAL INFLAMMATION; CUTTING EDGE; MURINE MODEL; RESPONSES; ASTHMA; IL-23	Background: The diverse effects of histamine on immune regulation are a result of the differential expression and regulation of 4 histamine receptors. Many of the immediate allergic and inflammatory actions of histamine are mediated via the type 1 receptor (H1R). Objectives: We hypothesized that H1R was involved in the fine-tuning of the initiation of T cell-mediated skin pathology-that is, dermatitis. Methods: The impact of the H1R invalidation on the development of skin inflammation was analyzed in a mouse model of atopic dermatitis. Results: We show that H1r(-/-) mice developed reduced allergen-specific skin lesions. Lack of H1R expression on dendritic cells (DCs) led to diminished IL-12, upregulated IL-23, and IL-6 production upon allergen stimulation. H1R engagement on dendritic cells was necessary for DC activation and subsequent priming of effector IFN-gamma(+)CD8(+) T cells. We demonstrate here that H1R blockade on DCs promotes generation of noneffector IL-17(+)CD8(+) T cells that are unable to initiate the skin inflammation. Conclusion: Our data identify that histamine signaling through the H1R on DCs is an important early event conditioning the quality of the skin effector immune response. (J Allergy Clin Immunol 2011;127:943-53.)	[Vanbervliet, Beatrice; Vocanson, Marc; Rozieres, Aurore; Benetiere, Josette; Nicolas, Jean-Francois; Hennino, Ana] INSERM, U851, F-69007 Lyon, France; [Vanbervliet, Beatrice; Vocanson, Marc; Rozieres, Aurore; Benetiere, Josette; Rouzaire, Paul; Nicolas, Jean-Francois; Hennino, Ana] Univ Lyon, IFR128, Lyon, France; [Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; [Rouzaire, Paul; Nicolas, Jean-Francois] CH Lyon Sud, Pierre Benite, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Swiss Institute of Allergy & Asthma Research; University of Zurich; CHU Lyon	Hennino, A (corresponding author), INSERM, U851, 21 Ave Tony Garnier, F-69007 Lyon, France.	ana.hennino@inserm.fr	Rouzaire, Paul/L-5723-2015; ROZIERES, Aurore/M-4447-2014; Akdis, Cezmi/AAV-4844-2020; Vocanson, Marc/G-5431-2017; Nicolas, Jean-François/AAW-9289-2020; Hennino, Ana/I-5837-2014	ROZIERES, Aurore/0000-0003-0293-4002; Akdis, Cezmi/0000-0001-8020-019X; Vocanson, Marc/0000-0002-0181-8862; ROUZAIRE, Paul/0000-0002-0595-4378; NICOLAS, JEAN FRANCOIS/0000-0003-4204-803X; Hennino, Ana/0000-0002-2619-8559	Societe Francaise d'Immunologie; Swiss National Science Foundation [32-125249, 32-118226]; Novartis; Stallargenes; Swiss National Science Foundation; Global Allergy; Christine Kuhne Center for Allergy Research; Imvision GmbH; European Union; Asthma European Network	Societe Francaise d'Immunologie; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis(Novartis); Stallargenes; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Global Allergy; Christine Kuhne Center for Allergy Research; Imvision GmbH; European Union(European Commission); Asthma European Network	A.H. was supported by Societe Francaise d'Immunologie. C.A.A. and M. A. were supported by Swiss National Science Foundation (nos. 32-125249 and 32-118226) grants.; Disclosure of potential conflict of interest: C. A. Akdis receives research support from Novartis, Stallargenes, the Swiss National Science Foundation, the Global Allergy and Asthma European Network, and the Christine Kuhne Center for Allergy Research; is a fellow and interest group member of the American Academy of Allergy, Asthma & Immunology; is vice president of the European Academy of Allergy and Clinical Immunology; and is an ex-committee member and WP leader for GA2LEN. M. Akdis receives research support from the Swiss National Science Foundation, Imvision GmbH, and the European Union. The rest of the authors have declared that they have no conflict of interest.	Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; Akiba H, 2002, J IMMUNOL, V168, P3079, DOI 10.4049/jimmunol.168.6.3079; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; Bryce PJ, 2006, J CLIN INVEST, V116, P1624, DOI 10.1172/JCI26150; Bryce PJ, 2003, J ALLERGY CLIN IMMUN, V112, P149, DOI 10.1067/mai.2003.1616; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; Ciric B, 2009, J IMMUNOL, V182, P5296, DOI 10.4049/jimmunol.0900036; Curtis MM, 2009, J IMMUNOL, V183, P381, DOI 10.4049/jimmunol.0900939; Dy M, 2004, CYTOKINE GROWTH F R, V15, P393, DOI 10.1016/j.cytogfr.2004.06.003; FALUS A, 1992, IMMUNOL TODAY, V13, P154; Gelfand EW, 2002, J ALLERGY CLIN IMMUN, V110, P85, DOI 10.1067/mai.2002.124770a; He DG, 2006, J IMMUNOL, V177, P6852, DOI 10.4049/jimmunol.177.10.6852; Hennino A, 2007, J IMMUNOL, V178, P5571, DOI 10.4049/jimmunol.178.9.5571; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Kish DD, 2009, J IMMUNOL, V182, P5949, DOI 10.4049/jimmunol.0802830; Kryczek I, 2007, J IMMUNOL, V179, P1423, DOI 10.4049/jimmunol.179.3.1423; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Liu SJ, 2007, J LEUKOCYTE BIOL, V82, P354, DOI 10.1189/jlb.0207111; Machida I, 2004, J IMMUNOL, V172, P1833, DOI 10.4049/jimmunol.172.3.1833; Matsubara M, 2005, BIOCHEM PHARMACOL, V69, P433, DOI 10.1016/j.bcp.2004.10.006; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI200113930; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Morgan RK, 2007, J IMMUNOL, V178, P8081, DOI 10.4049/jimmunol.178.12.8081; Noubade R, 2007, J CLIN INVEST, V117, P3507, DOI 10.1172/JCI32792; O'Connor W, 2009, NAT IMMUNOL, V10, P603, DOI 10.1038/ni.1736; Ortega C, 2009, J LEUKOCYTE BIOL, V86, P435, DOI [10.1189/jlb.0109046, 10.1189/JLB.0109046]; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Parsons ME, 2006, BRIT J PHARMACOL, V147, pS127, DOI 10.1038/sj.bjp.0706440; Smit MJ, 1999, CLIN EXP ALLERGY, V29, P19, DOI 10.1046/j.1365-2222.1999.00008.x; Szeberenyi JB, 2001, IMMUNOL LETT, V76, P175, DOI 10.1016/S0165-2478(01)00184-5; Tajima M, 2008, J EXP MED, V205, P1019, DOI 10.1084/jem.20071133; Takai T, 2005, INT ARCH ALLERGY IMM, V137, P1, DOI 10.1159/000084607; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Yawalkar N, 2001, BRIT J DERMATOL, V144, P1133, DOI 10.1046/j.1365-2133.2001.04222.x; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404	44	28	30	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					943	U181		10.1016/j.jaci.2010.12.002	http://dx.doi.org/10.1016/j.jaci.2010.12.002			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21269673				2022-12-18	WOS:000289055800016
J	Diaz-Guzman, E; Mannino, DM				Diaz-Guzman, Enrique; Mannino, David M.			Airway obstructive diseases in older adults: From detection to treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; COPD; elderly; obstructive lung disease	PULMONARY-DISEASE; INHALED CORTICOSTEROIDS; LUNG-FUNCTION; RESPIRATORY SYMPTOMS; SMOKING-CESSATION; VITAMIN-D; FLUTICASONE PROPIONATE; HOSPITAL ADMISSIONS; NATIONAL-HEALTH; FLOW LIMITATION	Asthma and chronic obstructive pulmonary disease occur commonly and may overlap among older adults. Smoking, air pollution, and bronchial hyperresponsiveness are the main risk factors. The treatment of these diseases in older adults does not differ from the available guidelines but may be complicated by the presence of comorbidities. Smoking cessation is essential for smokers, and pulmonary rehabilitation must be considered regardless of the age of the patient. (J Allergy Clin Immunol 2010;126:702-9.)	[Mannino, David M.] Univ Kentucky, Dept Prevent Med & Environm Hlth, Coll Publ Hlth, Div Pulm Sleep & Crit Care Med, Lexington, KY 40536 USA	University of Kentucky	Mannino, DM (corresponding author), Univ Kentucky, Dept Prevent Med & Environm Hlth, Coll Publ Hlth, Div Pulm Sleep & Crit Care Med, 121 Washington Ave, Lexington, KY 40536 USA.	dmannino@uky.edu		Diaz, Enrique/0000-0002-0190-6686; Mannino, David/0000-0003-3646-7828	GlaxoSmithKline; Novartis; AstraZeneca	GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); AstraZeneca(AstraZeneca)	Disclosure of potential conflict of interest: D.M. Mannino receives research support from GlaxoSmithKline, Novartis, and AstraZeneca; has provided legal consultation/expert witness testimony in cases related to cigarette smoking and COPD; and is a board member of the COPD Foundation. E. Diaz-Guzman has declared that he has no conflict of interest.	Alsaeedi A, 2002, AM J MED, V113, P59, DOI 10.1016/S0002-9343(02)01143-9; Altose MD, 2000, NEW ENGL J MED, V343, P1902; [Anonymous], 1980, Ann Intern Med, V93, P391; Baltzan Marcel A, 2004, Can Respir J, V11, P407; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; Battaglia S, 2005, AGING CLIN EXP RES, V17, P287; Bellia V, 2000, AM J RESP CRIT CARE, V161, P1094, DOI 10.1164/ajrccm.161.4.9810093; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Bousquet J, 2007, GLOBAL SURVEILLANCE; Braman SS, 2007, CLIN CHEST MED, V28, P685, DOI 10.1016/j.ccm.2007.08.007; BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336, DOI 10.1164/ajrccm/143.2.336; Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Celli B, 2010, CHEST, V137, P20, DOI 10.1378/chest.09-0011; Celli B, 2009, AM J RESP CRIT CARE, V180, P948, DOI 10.1164/rccm.200906-0876OC; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Celli BR, 2008, CHEST, V133, P1451, DOI 10.1378/chest.07-2061; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Chaouat A, 1999, EUR RESPIR J, V14, P1002, DOI 10.1183/09031936.99.14510029; Choy DKL, 2002, CLIN EXP ALLERGY, V32, P702, DOI 10.1046/j.1365-2222.2002.01395.x; CONNOLLY MJ, 1992, THORAX, V47, P410, DOI 10.1136/thx.47.6.410; CONNOLLY MJ, 1995, CHEST, V108, P401, DOI 10.1378/chest.108.2.401; De Filippi F, 2003, ARCH GERONTOL GERIAT, V37, P33, DOI 10.1016/S0167-4943(03)00005-0; de Luise C, 2007, EUR J EPIDEMIOL, V22, P267, DOI 10.1007/s10654-007-9106-5; Diette GB, 2002, ARCH INTERN MED, V162, P1123, DOI 10.1001/archinte.162.10.1123; Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47; Drummond MB, 2008, JAMA-J AM MED ASSOC, V300, P2407, DOI 10.1001/jama.2008.717; ENRIGHT PL, 1994, CHEST, V106, P827, DOI 10.1378/chest.106.3.827; ENRIGHT PL, 1995, CHEST, V108, P663, DOI 10.1378/chest.108.3.663; Gartlehner G, 2006, ANN FAM MED, V4, P253, DOI 10.1370/afm.517; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; *GOLD, 2006, GLOB STRAT DIAGN MAN; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; Hardie JA, 2005, RESP MED, V99, P186, DOI 10.1016/j.rmed.2004.06.006; Hays JT, 2008, NEW ENGL J MED, V359, P2018, DOI 10.1056/NEJMct0800146; HIGGINS MW, 1993, JAMA-J AM MED ASSOC, V269, P2741, DOI 10.1001/jama.269.21.2741; Hospers JJ, 2000, LANCET, V356, P1313, DOI 10.1016/S0140-6736(00)02815-4; Ito K, 2009, CHEST, V135, P173, DOI 10.1378/chest.08-1419; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Janssens W, 2010, THORAX, V65, P215, DOI 10.1136/thx.2009.120659; Janssens W, 2009, AM J RESP CRIT CARE, V179, P630, DOI 10.1164/rccm.200810-1576PP; Johannessen A, 2005, INT J TUBERC LUNG D, V9, P926; Kalache A, 1999, Promot Educ, V6, P20, DOI 10.1177/102538239900600406; KALACHE A, 1999, PROMOT ED, V6, P44; KALACHE A, 1999, PROMOT ED, V6, P54; Katsura H, 2004, RESPIROLOGY, V9, P230, DOI 10.1111/j.1440-1843.2004.00561.x; Ko FWS, 2006, RESP MED, V100, P1598, DOI 10.1016/j.rmed.2005.12.007; Lebowitz MD, 1996, EUR RESPIR J, V9, P1029, DOI 10.1183/09031936.96.09051029; Lindberg A, 2006, RESP MED, V100, P264, DOI 10.1016/j.rmed.2005.04.029; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; Murtagh E, 2005, EUR J EPIDEMIOL, V20, P443, DOI 10.1007/s10654-005-1248-8; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Orozco-Levi M, 2006, EUR RESPIR J, V27, P542, DOI 10.1183/09031936.06.00052705; Pelkonen M, 2000, THORAX, V55, P746, DOI 10.1136/thorax.55.9.746; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Pezzoli L, 2003, AGE AGEING, V32, P43, DOI 10.1093/ageing/32.1.43; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434; Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418; RIJCKEN B, 1987, B EUR PHYSIOPATH RES, V23, P391; Rodrigo GJ, 2008, CHEST, V133, P1079, DOI 10.1378/chest.07-1167; Schirnhofer L, 2007, CHEST, V131, P29, DOI 10.1378/chest.06-0365; Shaya FT, 2008, CHEST, V134, P14, DOI 10.1378/chest.07-2317; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Simoni M, 2003, EUR RESPIR J, V21, p15S, DOI 10.1183/09031936.03.00403603; Sin BA, 2006, J INVEST ALLERG CLIN, V16, P44; Sin DD, 2005, THORAX, V60, P992, DOI 10.1136/thx.2005.045385; Singh S, 2009, ARCH INTERN MED, V169, P219, DOI 10.1001/archinternmed.2008.550; Singh S, 2008, JAMA-J AM MED ASSOC, V300, P1439, DOI 10.1001/jama.300.12.1439; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Sundararajan L, 2010, J CARDIOPULM REHABIL, V30, P121, DOI 10.1097/HCR.0b013e3181be7c56; Sutherland ER, 2003, THORAX, V58, P937, DOI 10.1136/thorax.58.11.937; Tait RJ, 2007, ADDICTION, V102, P148, DOI 10.1111/j.1360-0443.2006.01647.x; Taylor DH, 2002, AM J PUBLIC HEALTH, V92, P990, DOI 10.2105/AJPH.92.6.990; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; van Noord JA, 2000, THORAX, V55, P289, DOI 10.1136/thorax.55.4.289; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; Weiss ST, 1999, ENVIRON HEALTH PERSP, V107, P891, DOI 10.2307/3434571; Yang IA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002991.pub2; Yetley EA, 2008, AM J CLIN NUTR, V88, p558S, DOI 10.1093/ajcn/88.2.558S	82	28	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					702	709		10.1016/j.jaci.2010.08.022	http://dx.doi.org/10.1016/j.jaci.2010.08.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920760				2022-12-18	WOS:000282510000003
J	Perrin, K; Williams, M; Wijesinghe, M; James, K; Weatherall, M; Beasley, R				Perrin, Kyle; Williams, Mathew; Wijesinghe, Meme; James, Kate; Weatherall, Mark; Beasley, Richard			Randomized controlled trial of adherence with single or combination inhaled corticosteroid/long-acting beta-agonist inhaler therapy in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; adherence; compliance; inhaled corticosteroids; long-acting beta-agonists	MEDICATION ADHERENCE; HOSPITAL DISCHARGE; CLINICAL-TRIALS; MORTALITY; RISK; METAANALYSIS; MANAGEMENT; CHILDREN; SAFETY; PERSISTENCE	Background: The inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) combination inhaler has the potential to improve adherence with ICS therapy in asthma. Objective: To determine whether ICS/LABA combination inhaler therapy improves adherence compared with separate inhaler use. Methods: In a 24-week randomized controlled parallel group study, 111 subjects were prescribed 125 mu g fluticasone dipropionate (FP) and 25 mu g salmeterol, 2 actuations twice daily through either a combination inhaler or separate inhalers concurrently. Medication use was recorded by covert electronic monitors. The primary outcome variable was adherence during the final 6-week period, defined as the number of doses taken as a percentage of those prescribed. Results: Complete adherence data from the final 6-week period were available for 49 and 54 subjects in the separate and combination groups, respectively. The mean (SD) adherence was 73.7% (36.0) for FP, 76.7% (30.5) for salmeterol, and 82.4% (24.5) for FP/salmeterol. There were no significant differences in adherence between FP/salmeterol and FP (-8.7%; 95% CI, -10.6 to 3.3) and salmeterol (-5.6%; 95% CI, -16.4 to 5.1). There was no significant difference in overuse among the FP, salmeterol, or FP/salmeterol groups. In 2 (4%) of 49 subjects, salmeterol was effectively taken as monotherapy during a 6-week period. Conclusion: In the setting of a randomized controlled trial, use of a combination ICS/LABA inhaler does not markedly increase adherence above that observed with separate inhaler use. LABA monotherapy was observed in a small proportion of patients prescribed ICS and LABA therapy via separate inhalers. (J Allergy Clin Immunol 2010;126:505-10.)	[Perrin, Kyle; Williams, Mathew; Wijesinghe, Meme; James, Kate; Beasley, Richard] Med Res Inst New Zealand, Wellington 6242, New Zealand; [Perrin, Kyle; Wijesinghe, Meme; James, Kate; Weatherall, Mark; Beasley, Richard] Wellington Hosp, Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Weatherall, Mark; Beasley, Richard] Univ Otago, Wellington, New Zealand	Medical Research Institute Of New Zealand; University of Otago	Beasley, R (corresponding author), Med Res Inst New Zealand, Private Bag 7902, Wellington 6242, New Zealand.	Richard.Beasley@mrinz.ac.nz	Beasley, Richard/AAH-3908-2019; Weatherall, Mark/Y-6824-2019	Beasley, Richard/0000-0003-0337-406X; Weatherall, Mark/0000-0002-0051-9107	GlaxoSmithKline (GSK) [SAM106689]	GlaxoSmithKline (GSK)(GlaxoSmithKline)	Supported by a research grant from GlaxoSmithKline (GSK study no. SAM106689).	Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Beasley R, 2009, EUR RESPIR J, V33, P3, DOI 10.1183/09031936.00163408; Burgess SW, 2008, RESPIROLOGY, V13, P559, DOI 10.1111/j.1440-1843.2008.01292.x; Burgess SW, 2006, RESP MED, V100, P841, DOI 10.1016/j.rmed.2005.09.004; Chapman KR, 2000, RESP MED, V94, P2, DOI 10.1053/rmed.1999.0667; Charles T, 2007, J ALLERGY CLIN IMMUN, V119, P811, DOI 10.1016/j.jaci.2006.11.700; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; Ernst P, 2006, ANN INTERN MED, V145, P692, DOI 10.7326/0003-4819-145-9-200611070-00012; GIBSON NA, 1995, THORAX, V50, P1274, DOI 10.1136/thx.50.12.1274; Glassroth J, 2006, ANN INTERN MED, V144, P936, DOI 10.7326/0003-4819-144-12-200606200-00127; Hasford J, 2006, EUR RESPIR J, V28, P900, DOI 10.1183/09031936.00085606; Janson SL, 2003, AM J MED, V115, P620, DOI 10.1016/j.amjmed.2003.07.008; Janson SL, 2009, J ALLERGY CLIN IMMUN, V123, P840, DOI 10.1016/j.jaci.2009.01.053; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Marceau C, 2006, J ALLERGY CLIN IMMUN, V118, P574, DOI 10.1016/j.jaci.2006.06.034; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Randler C, 2007, WILSON J ORNITHOL, V119, P23, DOI 10.1676/04-014.1; Riekert KA, 2002, J CLIN PSYCHOL MED S, V9, P25, DOI 10.1023/A:1014131928789; Schatz M, 2003, J ALLERGY CLIN IMMUN, V111, P503, DOI 10.1067/mai.2003.178; Sears MR, 2009, EUR RESPIR J, V33, P21, DOI 10.1183/09031936.00145006; Simmons MS, 2000, CHEST, V118, P290, DOI 10.1378/chest.118.2.290; Smith A, 2006, CHEST, V130, P1034, DOI 10.1378/chest.130.4.1034; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; Stempel DA, 2005, RESP MED, V99, P1263, DOI 10.1016/j.rmed.2005.03.002; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608; Wijesinghe M, 2008, POSTGRAD MED J, V84, P467, DOI 10.1136/pgmj.2007.067165; Wijesinghe M, 2009, EUR RESPIR J, V34, P803, DOI 10.1183/09031936.00159708; [No title captured]	33	28	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					505	510		10.1016/j.jaci.2010.06.033	http://dx.doi.org/10.1016/j.jaci.2010.06.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20816187				2022-12-18	WOS:000281512500015
J	Konya, V; Sturm, EM; Schratl, P; Beubler, E; Marsche, G; Schuligoi, R; Lippe, IT; Peskar, BA; Heinemann, A				Konya, Viktoria; Sturm, Eva M.; Schratl, Petra; Beubler, Eckhard; Marsche, Gunther; Schuligoi, Rufina; Lippe, Irmgard Th.; Peskar, Bernhard A.; Heinemann, Akos			Endothelium-derived prostaglandin I-2 controls the migration of eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Endothelial cells; eosinophils; COX; prostaglandins; migration; adhesion; allergy	CELL-ADHESION MOLECULE-1; ALLERGIC INFLAMMATION; HUMAN MONOCYTES; DEFICIENT MICE; ASTHMA; NEUTROPHILS; EXPRESSION; RECEPTORS; ANALOG; TRANSMIGRATION	Background: Enhanced eosinophil migration from the blood into the tissue is a hallmark of allergic diseases. Prostaglandin (PG) I-2 is the major prostanoid released by endothelial cells. Mice deficient in PGI(2) receptors (IPs) show exaggerated eosinophilic inflammation in response to allergen. Objective: We set out to determine the role of PGI(2) in eosinophil trafficking. Methods: Human lung microvascular endothelial cells and purified human eosinophils were used to study adhesion and transendothelial migration. Morphologic studies were performed with fluorescence microscopy. Results: PGI(2) markedly attenuated the migration of eosinophils through cell-free filters but had no effect on neutrophil migration. The inhibitory effect of PGI(2) on eosinophils was prevented by the IP antagonist Cay10441 and the adenylyl cyclase inhibitor SQ22536. Similarly, PGI(2) prevented the adhesion of eosinophils to fibronectin and the rapid upregulation and activation of the adhesion molecule CD11b. IP expression on eosinophils was confirmed by means of flow cytometry and Western blotting. Furthermore, when endothelial cells were treated with the COX inhibitor diclofenac to abolish PGI(2) production, adhesion of eosinophils to endothelial monolayers and subsequent transendothelial migration were markedly enhanced. Similarly, the IP antagonist enhanced eosinophil adhesion to endothelial cells. Inhibition of PGI(2) biosynthesis decreased the electrical resistance of endothelial monolayers and compromised the texture of adherent junctions, as visualized by means of VE-cadherin and F-actin staining. Conclusion: We propose that endothelium-derived PGI(2) might be fundamental for the maintenance of the endothelial barrier function against infiltrating cells. These results suggest that selective IP agonists might have beneficial effects in allergic inflammation. (J Allergy Clin Immunol 2010;125:1105-13.)	[Konya, Viktoria; Sturm, Eva M.; Schratl, Petra; Beubler, Eckhard; Marsche, Gunther; Schuligoi, Rufina; Lippe, Irmgard Th.; Peskar, Bernhard A.; Heinemann, Akos] Med Univ Graz, Inst Expt & Clin Pharmacol, A-8010 Graz, Austria	Medical University of Graz	Heinemann, A (corresponding author), Med Univ Graz, Inst Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@medunigraz.at		Heinemann, Akos/0000-0002-8554-2372; Marsche, Gunther/0000-0002-2422-5381; Konya, Viktoria/0000-0002-7999-9093; Sturm, Eva/0000-0003-4898-884X	Austrian National Bank [11967, 13487]; Austrian Science Fund FWF [P19424-B05, P21004-B02]; Franz Lanyar Foundation [315, 316]; Medical University of Graz; AstraZeneca; Austrian Science Fund (FWF) [P 21004, P 22521] Funding Source: researchfish	Austrian National Bank; Austrian Science Fund FWF(Austrian Science Fund (FWF)); Franz Lanyar Foundation; Medical University of Graz; AstraZeneca(AstraZeneca); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by the Jubilaumsfonds of the Austrian National Bank (Grants 11967 and 13487), the Austrian Science Fund FWF (Grants P19424-B05 and P21004-B02), and the Franz Lanyar Foundation (Grants 315 and 316). V.K. has been funded by the PhD Program Molecular Medicine of the Medical University of Graz. A.H. has received research support and consultancy fees from AstraZeneca.; Disclosure of potential conflict of interest: G. Marsche has received research support front the Austrian Science Fund (FM.). A. Heinemann is an advisor for AstraZeneca and has received research support from the Austrian Science Fund (FWF) and the Austrian National Bank (OeNB). The rest of the authors have declared that they have no conflict of interest.	Aceves SS, 2008, CURR MOL MED, V8, P350, DOI 10.2174/156652408785161023; Aronoff DM, 2007, J IMMUNOL, V178, P1628, DOI 10.4049/jimmunol.178.3.1628; Barthel SR, 2006, AM J RESP CELL MOL, V35, P378, DOI 10.1165/rcmb.2006-0027OC; Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036; COUTURIER C, 1990, EUR J IMMUNOL, V20, P999, DOI 10.1002/eji.1830200508; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Giagoudakis G, 2005, PHARMACOTHERAPY, V25, P18, DOI 10.1592/phco.25.1.18.55618; Goya K, 2003, METABOLISM, V52, P192, DOI 10.1053/meta.2003.50025; GRAHAM IL, 1989, J IMMUNOL, V142, P2352; Hartnell A, 2004, J IMMUNOL, V173, P6448, DOI 10.4049/jimmunol.173.10.6448; Hashimoto K, 2004, J VIROL, V78, P10303, DOI 10.1128/JVI.78.19.10303-10309.2004; Heinemann A, 2005, J ALLERGY CLIN IMMUN, V116, P820, DOI 10.1016/j.jaci.2005.06.008; Heinemann A, 2003, J IMMUNOL, V170, P4752, DOI 10.4049/jimmunol.170.9.4752; Jaffar Z, 2007, J IMMUNOL, V179, P6193, DOI 10.4049/jimmunol.179.9.6193; Johansson MW, 2004, AM J RESP CELL MOL, V31, P413, DOI 10.1165/rcmb.2004-0099OC; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; Kamio K, 2008, AM J PHYSIOL-LUNG C, V294, pL1226, DOI 10.1152/ajplung.00129.2007; LEFER AM, 1994, METHOD FIND EXP CLIN, V16, P623; Lindemann S, 2003, BASIC RES CARDIOL, V98, P8, DOI 10.1007/s00395-003-0383-1; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Lintomen Leticia, 2008, BMC Pulm Med, V8, P13, DOI 10.1186/1471-2466-8-13; Matsumoto K, 1997, J ALLERGY CLIN IMMUN, V99, P648, DOI 10.1016/S0091-6749(97)70027-7; Nagao K, 2003, AM J RESP CELL MOL, V29, P314, DOI 10.1165/rcmb.2003-0035OC; Nakata J, 2005, RESPIROLOGY, V10, P149, DOI 10.1111/j.1440-1843.2005.00687.x; OKUYAMA M, 1995, LIFE SCI, V57, P1051, DOI 10.1016/0024-3205(95)02050-S; Peebles RS, 2002, AM J RESP CRIT CARE, V165, P1154, DOI 10.1164/rccm.2106025; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; REID DM, 1993, NEUROSCIENCE, V56, P529, DOI 10.1016/0306-4522(93)90353-H; Schratl P, 2006, EUR J IMMUNOL, V36, P2401, DOI 10.1002/eji.200535672; Schuligoi R, 2009, J LEUKOCYTE BIOL, V85, P136, DOI 10.1189/jlb.0608387; Sedgwick JB, 2002, J ALLERGY CLIN IMMUN, V110, P752, DOI 10.1067/mai.2002.128581; SHEPHARD EG, 1985, BRIT J CLIN PHARMACO, V19, P459, DOI 10.1111/j.1365-2125.1985.tb02671.x; Stafford JB, 2008, BIOCHEM BIOPH RES CO, V366, P104, DOI 10.1016/j.bbrc.2007.11.091; Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273; Takahashi HK, 2005, EUR J PHARMACOL, V517, P252, DOI 10.1016/j.ejphar.2005.05.020; Takahashi Y, 2002, BRIT J PHARMACOL, V137, P315, DOI 10.1038/sj.bjp.0704872; Turner EC, 2009, J MOL BIOL, V386, P579, DOI 10.1016/j.jmb.2008.12.030; UDEN AM, 1983, INT ARCH ALLER A IMM, V72, P91, DOI 10.1159/000234847; Ulcar R, 2004, EUR J PHARMACOL, V501, P9, DOI 10.1016/j.ejphar.2004.08.003; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; Wen Z G, 1990, Zhonghua Jie He He Hu Xi Za Zhi, V13, P224; Woerly G, 1999, INT ARCH ALLERGY IMM, V118, P95, DOI 10.1159/000024038; Yamada T, 1999, AFR STUDY MONOGR, V20, P1; Yamamoto H, 2005, ANN ALLERG ASTHMA IM, V94, P292, DOI 10.1016/S1081-1206(10)61311-7; Yildiz P, 2004, J ASTHMA, V41, P159, DOI 10.1081/JAS-120026073; Zhou WS, 2007, J IMMUNOL, V178, P702, DOI 10.4049/jimmunol.178.2.702	48	28	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1105	1113		10.1016/j.jaci.2009.12.002	http://dx.doi.org/10.1016/j.jaci.2009.12.002			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20153037				2022-12-18	WOS:000277686700021
J	Lee, S; Ballow, M				Lee, Susan; Ballow, Mark			Monoclonal antibodies and fusion proteins and their complications: Targeting B cells in autoimmune diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B-cell therapy; rheumatoid arthritis; systemic lupus erythematosus; monoclonal antibody; fusion protein	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKINS-LYMPHOMA; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; RECEPTOR INHIBITION; INADEQUATE RESPONSE; STIMULATOR BLYS; SERUM SICKNESS; PHASE-I	The immune system consists of a complex array of immunocompetent cells and inflammatory mediators that exist in complex networks. These components interact through cascades and feedback circuits, maintaining physiologic inflammation and immunosurveillance. In various autoimmune conditions, a foreign or auto-antigen may upset this fine balance, leading to dysregulated immunity, persistent inflammation, and ultimately pathologic sequelae. In recent years, there has been tremendous progress delineating the specific components of the immune system that contribute to normal immunity and specific disease states. With this greater understanding of pathogenesis coupled with advances in biotechnology, many immunomodulatory agents, commonly called biologic agents, have been introduced. The 2 most common classes of biologic agents are monoclonal antibodies and fusion proteins. These agents can inhibit targets with exquisite specificity to optimize outcomes and minimize toxicity. B cells contribute significantly to the initiation and perpetuation of the immune responses. B cells not only can produce potentially pathologic autoantibodies and proinflammatory cytokines but also can present antigens to T cells and provide costimulatory signals essential for T-cell activation, clonal expansion, and effector function. This review focuses on biologic agents targeting B cells in the treatment of rheumatoid arthritis and systemic lupus erythematosus. (J Allergy Clin Immunol 2010;125:814-20.)	[Lee, Susan] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92037 USA; [Lee, Susan] Univ Calif San Diego, VA San Diego Healthcare Syst, La Jolla, CA 92037 USA; [Ballow, Mark] SUNY Buffalo, Div Allergy & Immunol, Dept Pediat, Womens & Childrens Hosp Buffalo, Buffalo, NY 14260 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Women & Children's Hospital of Buffalo	Lee, S (corresponding author), Univ Calif San Diego, Div Rheumatol Allergy & Immunol, 9320 Campus Point Dr,Suite 225, La Jolla, CA 92037 USA.	s2lee@ucsd.edu			Grifols	Grifols	M. Ballow is on the Advisory Councils for Baxter Healthcare, Talecris Biotherapeutics, and CSL Baring; has received research support from Grifols; and has served as an expert witness on the topic of immunodeficiency disease. S. Lee has declared that she has no conflict of interest.	Aksoy S, 2007, LEUKEMIA LYMPHOMA, V48, P1307, DOI 10.1080/10428190701411441; Aksoy S, 2009, LEUKEMIA LYMPHOMA, V50, P357, DOI 10.1080/10428190902730219; Baker KP, 2003, ARTHRITIS RHEUM-US, V48, P3253, DOI 10.1002/art.11299; Benson MJ, 2008, J IMMUNOL, V180, P3655, DOI 10.4049/jimmunol.180.6.3655; Bosello S, 2008, J RHEUMATOL, V35, P1256; Boumpas DT, 2003, ARTHRITIS RHEUM-US, V48, P719, DOI 10.1002/art.10856; Burge DJ, 2008, CLIN THER, V30, P1806, DOI 10.1016/j.clinthera.2008.10.017; Calabrese LH, 2008, ANN RHEUM DIS, V67, P64, DOI 10.1136/ard.2008.097972; Castillo J, 2009, EXPERT OPIN INV DRUG, V18, P491, DOI [10.1517/13543780902832679 , 10.1517/13543780902832679]; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; Dall'Era M, 2007, ARTHRITIS RHEUM, V56, P4142, DOI 10.1002/art.23047; Ding CH, 2006, CURR OPIN INVEST DR, V7, P464; Ding C, 2008, EXPERT OPIN BIOL TH, V8, P1805, DOI 10.1517/14712598.8.11.1805 ; Ding C, 2008, BIODRUGS, V22, P239, DOI 10.2165/00063030-200822040-00003; Dorner T, 2008, CURR OPIN RHEUMATOL, V20, P263, DOI 10.1097/BOR.0b013e3282f5e08d; Dorner T, 2009, NAT REV RHEUMATOL, V5, P433, DOI 10.1038/nrrheum.2009.141; Emery P, 2008, ANN RHEUM DIS, V67, P1516, DOI 10.1136/ard.2008.092932; Emery P, 2006, ARTHRITIS RHEUM, V54, P1390, DOI 10.1002/art.21778; Furie R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2506; Garcia-Carrasco M, 2009, AUTOIMMUN REV, V8, P343, DOI 10.1016/j.autrev.2008.11.006; Garnero P, 2010, ARTHRITIS RHEUM-US, V62, P33, DOI 10.1002/art.25053; Genovese MC, 2008, ARTHRITIS RHEUM-US, V58, P2968, DOI 10.1002/art.23940; Goto S, 2009, INT J HEMATOL, V89, P305, DOI 10.1007/s12185-009-0269-6; Hellerstedt B, 2003, ANN ONCOL, V14, P1792, DOI 10.1093/annonc/mdg488; Hutas G, 2008, CURR OPIN INVEST DR, V9, P1206; Keystone E, 2007, ARTHRITIS RHEUM-US, V56, P3896, DOI 10.1002/art.23059; Lee SJ, 2005, J ALLERGY CLIN IMMUN, V116, P900, DOI 10.1016/j.jaci.2005.03.028; Leroux G, 2009, ARTHRIT RHEUM-ARTHR, V61, P577, DOI 10.1002/art.24366; Liossis SNC, 2005, J ALLERGY CLIN IMMUN, V116, P721, DOI 10.1016/j.jaci.2005.06.035; Mandik-Nayak L, 2008, CURR OPIN IMMUNOL, V20, P639, DOI 10.1016/j.coi.2008.08.003; Mariette X, 2003, ANN RHEUM DIS, V62, P168, DOI 10.1136/ard.62.2.168; Milani C, 2009, CURR OPIN MOL THER, V11, P200; Mohrbacher A, 2005, ARTHRITIS RES THER, V7, pS19, DOI 10.1186/ar1739; NAVARRA S, 2009, ARTHRITIS RHEUM S10, V60; Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303; Oldfield V, 2009, DRUGS, V69, P609, DOI 10.2165/00003495-200969050-00007; OSTERGAARD M, 2007, ARTHRITIS RHEUM S9, V56, pS793; Paul-Pletzer K, 2006, DRUG TODAY, V42, P559, DOI 10.1358/dot.2006.42.9.1025692; Pers JO, 2005, ANN NY ACAD SCI, V1050, P34, DOI 10.1196/annals.1313.004; Petri M, 2009, ARTHRITIS RHEUM S10, V60, pS774; Quartuccio L, 2009, RHEUMATOLOGY, V48, P1557, DOI 10.1093/rheumatology/kep314; Reynolds JA, 2009, LUPUS, V18, P67, DOI 10.1177/0961203308094653; Robak E, 2009, CURR DRUG TARGETS, V10, P26, DOI 10.2174/138945009787122833; Roschke V, 2002, J IMMUNOL, V169, P4314, DOI 10.4049/jimmunol.169.8.4314; Stohl W, 2005, ARTHRITIS RHEUM-US, V52, pS444; STROMATT S, 2009, ARTHRITIS RHEUM S10, V60, pS148; Tak PP, 2008, ARTHRITIS RHEUM-US, V58, P61, DOI 10.1002/art.23178; Taylor SRJ, 2009, ARTHRITIS RHEUM-US, V60, P1540, DOI 10.1002/art.24454; Teng YKO, 2009, ANN RHEUM DIS, V68, P1075, DOI 10.1136/ard.2008.100438; Thurlings RM, 2008, ARTHRITIS RHEUM-US, V58, P3657, DOI 10.1002/art.24035; VANVOLLENHOVEN RF, 2009, ARTHRITIS RHEUM S10, V60, pS730; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; Vugmeyster Y, 2006, AM J PATHOL, V168, P476, DOI 10.2353/ajpath.2006.050600; Wallace DJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P1168, DOI 10.1002/art.24699; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224; Yokota S, 2008, LANCET, V371, P998, DOI 10.1016/S0140-6736(08)60454-7; Zhang X, 2005, INT IMMUNOL, V17, P779, DOI 10.1093/intimm/dxh259	57	28	31	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					814	820		10.1016/j.jaci.2010.02.025	http://dx.doi.org/10.1016/j.jaci.2010.02.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20371395				2022-12-18	WOS:000276787900005
J	Nograles, KE; Suarez-Farinas, M; Shemer, A; Fuentes-Duculan, J; Chiricozzi, A; Cardinale, I; Zaba, LC; Kikuchi, T; Ramon, M; Bergman, R; Krueger, JG; Guttman-Yassky, E				Nograles, Kristine E.; Suarez-Farinas, Mayte; Shemer, Avner; Fuentes-Duculan, Judilyn; Chiricozzi, Andrea; Cardinale, Irma; Zaba, Lisa C.; Kikuchi, Toyoko; Ramon, Michal; Bergman, Reuven; Krueger, James G.; Guttman-Yassky, Emma			Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPRESSION; PSORIASIS; DISEASE; IL-22		[Nograles, Kristine E.; Suarez-Farinas, Mayte; Fuentes-Duculan, Judilyn; Chiricozzi, Andrea; Cardinale, Irma; Zaba, Lisa C.; Kikuchi, Toyoko; Krueger, James G.; Guttman-Yassky, Emma] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10021 USA; [Shemer, Avner] Tel Hashomer Med Ctr, Dept Dermatol, Ramat Gan, Israel; [Chiricozzi, Andrea] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy; [Ramon, Michal; Bergman, Reuven] Rambam Med Ctr & Tech, Dept Dermatol, Haifa, Israel; [Guttman-Yassky, Emma] Cornell Univ, Dept Dermatol, Weill Cornell Med Coll, New York, NY 10021 USA	Rockefeller University; University of Rome Tor Vergata; Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Cornell University	Guttman-Yassky, E (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10021 USA.	eguttman@rockefeller.edu	Nograles, Kristine/V-3648-2019; Zaba, Lisa/Q-9681-2019; Suarez-Farinas, Mayte/I-3558-2012	Suarez-Farinas, Mayte/0000-0001-8712-3553; Zaba, Lisa/0000-0001-9036-5465	NCRR NIH HHS [5UL1RR024143-03, UL1 RR024143] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI 10.1016/j.jaci.2008.10.031; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; HENSELER T, 1995, J AM ACAD DERMATOL, V32, P982, DOI 10.1016/0190-9622(95)91336-X; Iwakura Y, 2008, IMMUNOL REV, V226, P57, DOI 10.1111/j.1600-065X.2008.00699.x; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414	12	28	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					744	746		10.1016/j.jaci.2009.12.934	http://dx.doi.org/10.1016/j.jaci.2009.12.934			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20226306	Green Accepted			2022-12-18	WOS:000275883200035
J	Haberberger, RV; Tabeling, C; Runciman, S; Gutbier, B; Konig, P; Andratsch, M; Schutte, H; Suttorp, N; Gibbins, I; Witzenrath, M				Haberberger, Rainer V.; Tabeling, Christoph; Runciman, Sue; Gutbier, Birgitt; Koenig, Peter; Andratsch, Manfred; Schuette, Hartwig; Suttorp, Norbert; Gibbins, Ian; Witzenrath, Martin			Role of sphingosine kinase 1 in allergen-induced pulmonary vascular remodeling and hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pulmonary arterial hypertension; allergen-induced lung inflammation; vascular remodeling; perfused mouse lung; sphingosine kinase; sphingosine 1-phosphate	AIRWAY HYPERRESPONSIVENESS; ARTERIAL-HYPERTENSION; 1-PHOSPHATE; LUNG; INFLAMMATION; ASTHMA; MODEL; HYPERREACTIVITY; PATHOGENESIS; PATHWAY	Background: Immunologic processes might contribute to the pathogenesis of pulmonary arterial hypertension (PAH), a fatal condition characterized by progressive pulmonary arterial remodeling, increased pulmonary vascular resistance, and right ventricular failure. Experimental allergen-driven lung inflammation evoked morphologic and functional vascular changes that resembled those observed in patients with PAH. Sphingosine kinase 1 (SphK1) is the main pulmonary contributor to sphingosine-1-phosphate (SIP) synthesis, a modulator of immune and vascular functions. Objective: We sought to investigate the role of SphK1 in allergen-induced lung inflammation. Methods: SphK1-deficient mice and C57BI/6 littermates (wild-type [WT]animals) were subjected to acute or chronic allergen exposure. Results: After 4 weeks of systemic ovalbumin sensitization and local airway challenge, airway responsiveness increased less in SphK1(-/-) compared with WT mice, whereas pulmonary vascular responsiveness was greatly increased and did not differ between strains. Acute lung inflammation led to an increase in eosinophils and mRNA expression for SIP phosphatase 2 and SIP lyase in lungs of WT but not SphK1(-/-) mice. After repetitive allergen exposure for 8 weeks, airway responsiveness was not augmented in SphK1(-/-) or WT mice, but pulmonary vascular responsiveness was increased in both strains, with significantly higher vascular responsiveness in SphK1(-/-) mice compared with that seen in WT mice. Increased vascular responsiveness was accompanied by remodeling of the small and intra-acinar arteries. Conclusion: The data support a role for SphK1 and SIP in allergen-induced airway inflammation. However, SphK1 deficiency increased pulmonary vascular hyperresponsiveness, which is a component of PAH pathobiology. Moreover, we show for the first time the dissociation between inflammation-induced remodeling of the airways and pulmonary vasculature. (J Allergy Clin Immunol 2009;124:933-41.)	[Tabeling, Christoph; Gutbier, Birgitt; Schuette, Hartwig; Suttorp, Norbert; Witzenrath, Martin] Charite, Dept Infect & Resp Dis, D-10117 Berlin, Germany; [Haberberger, Rainer V.; Runciman, Sue; Gibbins, Ian] Flinders Univ S Australia, Dept Anat & Histol, Adelaide, SA 5001, Australia; [Koenig, Peter] Med Univ Lubeck, Dept Anat, Ctr Struct & Cell Biol Med, Lubeck, Germany; [Andratsch, Manfred] Innsbruck Med Univ, Dept & Med Phys, Innsbruck, Austria	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Flinders University South Australia; University of Lubeck; Medical University of Innsbruck	Witzenrath, M (corresponding author), Charite, Dept Infect & Resp Dis, Charitepl 1, D-10117 Berlin, Germany.	martin.witzenrath@charite.de	König, Peter/AAK-2021-2020	Haberberger, Rainer Viktor/0000-0001-8043-3786; Suttorp, Norbert/0000-0002-3958-1151; Tabeling, Christoph/0000-0001-9189-4318	German Research Foundation [OP 86/7-1]; German Federal Ministry of Education and Research; Flinders Medical Centre Foundation; Flinders University Facility of Health Sciences	German Research Foundation(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Flinders Medical Centre Foundation; Flinders University Facility of Health Sciences	Supported in part by grants from the German Research Foundation to M. W. (OP 86/7-1), the German Federal Ministry of Education and Research to N. S. (PROGRESS), and Flinders Medical Centre Foundation grant 2007-08 and Flinders University Facility of Health Sciences grant 2006-07 to R. H.	Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Barbera JA, 2003, EUR RESPIR J, V21, P892, DOI 10.1183/09031936.03.00115402; Brinkmann V, 2006, CURR OPIN PHARMACOL, V6, P244, DOI 10.1016/j.coph.2005.12.004; Chin KM, 2008, J AM COLL CARDIOL, V51, P1527, DOI 10.1016/j.jacc.2008.01.024; Daley E, 2008, J EXP MED, V205, P361, DOI 10.1084/jem.20071008; Edmunds NJ, 1998, BRIT J PHARMACOL, V124, P493, DOI 10.1038/sj.bjp.0701863; Fajardo I, 2004, AM J RESP CRIT CARE, V170, P477, DOI 10.1164/rccm.200402-178OC; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; Humbert M, 2004, J AM COLL CARDIOL, V43, p13S, DOI 10.1016/j.jacc.2004.02.029; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Kume H, 2007, J PHARMACOL EXP THER, V320, P766, DOI 10.1124/jpet.106.110718; Kurashima Y, 2007, J IMMUNOL, V179, P1577, DOI 10.4049/jimmunol.179.3.1577; Lai WQ, 2008, J IMMUNOL, V180, P4323, DOI 10.4049/jimmunol.180.6.4323; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006; Mechtcheriakova D, 2007, CELL SIGNAL, V19, P748, DOI 10.1016/j.cellsig.2006.09.004; Nishiuma T, 2008, AM J PHYSIOL-LUNG C, V294, pL1085, DOI 10.1152/ajplung.00445.2007; Pabst R, 2002, J ALLERGY CLIN IMMUN, V110, P209, DOI 10.1067/mai.2002.126836; Pfaff M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-48; Rabinovitch M, 2008, J CLIN INVEST, V118, P2372, DOI 10.1172/JCI33452; Rabinovitch M, 2007, ANNU REV PATHOL-MECH, V2, P369, DOI 10.1146/annurev.pathol.2.010506.092033; Rivera J, 2008, NAT REV IMMUNOL, V8, P753, DOI 10.1038/nri2400; Roviezzo F, 2007, AM J RESP CELL MOL, V36, P757, DOI 10.1165/rcmb.2006-0383OC; Simonneau G, 2004, J AM COLL CARDIOL, V43, p5S, DOI 10.1016/j.jacc.2004.02.037; Skeritzian CA, 2007, PHARMACOL THERAPEUT, V115, P390, DOI 10.1016/j.pharmthera.2007.05.011; Tormanen KR, 2005, AM J RESP CRIT CARE, V171, P19, DOI 10.1164/rccm.200406-498OC; Urata Yoshiko, 2005, Kobe Journal of Medical Sciences, V51, P17; Witzenrath M, 2006, EUR RESPIR J, V28, P370, DOI 10.1183/09031936.06.00080105; Witzenrath M, 2006, AM J PHYSIOL-LUNG C, V291, pL466, DOI 10.1152/ajplung.00011.2005; Zaiman A, 2005, AM J RESP CELL MOL, V33, P425, DOI 10.1165/rcmb.F307	31	28	29	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					933	941		10.1016/j.jaci.2009.06.034	http://dx.doi.org/10.1016/j.jaci.2009.06.034			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19665772				2022-12-18	WOS:000272108000009
J	Plaut, M; Sawyer, RT; Fenton, MJ				Plaut, Marshall; Sawyer, Richard T.; Fenton, Matthew J.			Summary of the 2008 National Institute of Allergy and Infectious Diseases-US Food and Drug Administration Workshop on Food Allergy Clinical Trial Design	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; clinical trials; clinical trial design; oral food challenge; precautions; prevention; treatment; tolerance; desensitization	COWS MILK ALLERGY; ORAL TOLERANCE INDUCTION; 1ST 3 YEARS; PEANUT ALLERGY; EGG ALLERGY; SUBLINGUAL IMMUNOTHERAPY; NATURAL-HISTORY; DOUBLE-BLIND; CHILDREN; SENSITIZATION	This article summarizes the proceedings of a 2008 Workshop on Food Allergy Clinical Trials Design co-organized by the National Institute of Allergy and Infectious Diseases and the US Food and Drug Administration. The use of food allergens both as therapy and for oral food challenges is associated with a risk of anaphylaxis. Investigators are strongly encouraged to address regulatory considerations by discussing proposed studies with the US Food and Drug Administration. Food allergen administration through the oral or sublingual routes might be less risky than through the subcutaneous route, but this hypothesis has not been proved, and subjects with food allergy might still be at high risk of allergic reactions to such allergen administration. Two distinct mechanisms might lead to beneficial clinical outcomes: desensitization (reversible when food allergen therapy is stopped) and tolerance (persistent benefit even after allergen therapy is stopped). There are important clinical distinctions between desensitization and tolerance. The efficacy of a therapy for food allergy can be evaluated by assessing changes in the dose response to double-blind, placebo-controlled oral food challenges before and after therapy and also by assessing changes in the number of allergic episodes during a longitudinal natural history/exposure study; both approaches have strengths and limitations. (,J Allergy Clin Immunol 2009;124:671-78.)	[Plaut, Marshall; Sawyer, Richard T.; Fenton, Matthew J.] NIAID, DAIT, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Plaut, M (corresponding author), NIAID, DAIT, NIH, 6610 Rockledge Dr,Room 3069, Bethesda, MD 20892 USA.	mplaut@niaid.nih.gov						Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Bahna SL, 2007, ALLERGY ASTHMA PROC, V28, P640, DOI 10.2500/aap.2007.28.3068; BOCK SA, 1987, PEDIATRICS, V79, P683; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Branum Amy M, 2008, NCHS Data Brief, P1; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Busse W, 2006, J ALLERGY CLIN IMMUN, V117, pS88, DOI 10.1016/j.jaci.2005.12.354; CLARK AT, ALLERGY IN PRESS; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; de Benedictis FM, 2009, ALLERGY, V64, P295, DOI 10.1111/j.1398-9995.2008.01779.x; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Frew AJ, 2008, NEW ENGL J MED, V358, P2259, DOI 10.1056/NEJMct0708337; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Hill DJ, 2007, J PEDIATR-US, V151, P359, DOI 10.1016/j.jpeds.2007.04.070; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Nelson HS, 2007, J ALLERGY CLIN IMMUN, V119, P769, DOI 10.1016/j.jaci.2007.01.036; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Plaut Marshall, 2004, Clin Allergy Immunol, V18, P681; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sicherer SH, 2008, J ALLERGY CLIN IMMUN, V121, pS96, DOI 10.1016/j.jaci.2007.12.384; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Skripak JM, 2008, PEDIAT ALLERG IMM-UK, V19, P368, DOI 10.1111/j.1399-3038.2008.00723.x; Skripak JM, 2007, J ALLERGY CLIN IMMUN, V120, P1172, DOI 10.1016/j.jaci.2007.08.023; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x	45	28	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					671	678		10.1016/j.jaci.2009.05.027	http://dx.doi.org/10.1016/j.jaci.2009.05.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19560803				2022-12-18	WOS:000270802800007
J	Esteba, CA; Klein, RB; McQuaid, EL; Fritz, GK; Seifer, R; Kopel, SJ; Santana, JR; Colon, A; Alvarez, M; Koinis-Mitchell, D; Ortega, AN; Martinez-Nieves, B; Canino, G				Esteba, Cynthia A.; Klein, Robert B.; McQuaid, Elizabeth L.; Fritz, Gregory K.; Seifer, Ronald; Kopel, Sheryl J.; Santana, Jose Rodriguez; Colon, Angel; Alvarez, Maria; Koinis-Mitchell, Daphne; Ortega, Alexander N.; Martinez-Nieves, Brenda; Canino, Glorisa			Conundrums in childhood asthma severity, control, and health care use: Puerto Rico versus Rhode Island	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; severity; control; clinical guidelines; Global Initiative for Asthma; Latino; Puerto Rican; Dominican; Rhode Island; health care use	CLASSIFYING ASTHMA; MEDICATION USE; PREVALENCE; SYMPTOMS; CHILDREN; VARIABILITY	Background: The lifetime prevalence of self-reported asthma among Puerto Ricans is very high, with increased asthma hospitalizations, emergency department visits, and mortality rates. Differences in asthma severity between the mainland and island, however, remain largely unknown. Objective: We sought to characterize differences in asthma severity and control among 4 groups: (1) Island Puerto Ricans, (2) Rhode Island (RI) Puerto Ricans, (3) RI Dominicans, and (4) RI whites. Methods: Eight hundred five children aged 7 to 15 years completed a diagnostic clinic session, including a formal interview, physical examination, spirometry, and allergy testing. Using a visual grid adapted from the Global Initiative for Asthma, asthma specialists practicing in each site determined an asthma severity rating. A corresponding level of asthma control was determined by using a computer algorithm. Results: Island Puerto Ricans had significantly milder asthma severity compared with RI Puerto Ricans, Dominicans, and whites (P < .001). Island Puerto Ricans were not significantly different from RI whites in asthma control. RI Puerto Ricans showed a trend toward less control compared with island Puerto Ricans (P = .061). RI Dominicans had the lowest rate of controlled asthma. Paradoxically, island Puerto Ricans had more emergency department visits in the past 12 months (P < .001) compared with the 3 RI groups. Conclusions: Potential explanations for the paradoxic finding of milder asthma in island Puerto Ricans in the face of high health care use are discussed. Difficulties in determining guideline-based composite ratings for severity versus control are explored in the context of disparate groups. (J Allergy Clin Immunol 2009;124:238-44.)	[Esteba, Cynthia A.; Klein, Robert B.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Allergy & Immunol,Dept Pediat, Providence, RI 02903 USA; [McQuaid, Elizabeth L.; Fritz, Gregory K.; Kopel, Sheryl J.; Koinis-Mitchell, Daphne] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Child Psychiat,Dept Psychiat, Providence, RI 02903 USA; [Martinez-Nieves, Brenda; Canino, Glorisa] Univ Puerto Rico, Sch Med, Dept Behav Med, San Juan, PR 00936 USA; [Ortega, Alexander N.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA; [Seifer, Ronald] Brown Univ, EP Bradley Hosp, Warren Alpert Med Sch, Dept Psychiat,Div Child Psychiat, Providence, RI 02912 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of California System; University of California Los Angeles; Brown University	Esteba, CA (corresponding author), Ctr Asthma & Allergy, 1 Hoppin St,Suite 304A, Providence, RI 02903 USA.	Cesteban@Lifespan.org	Alvarez, Maria/GZH-1345-2022; Ortega, Alexander/AAF-4175-2019	Ortega, Alexander/0000-0001-6861-6993; Seifer, Ronald/0000-0003-4879-2839	National Heart, Lung, and Blood Institute [U01-H1072438]; National Center of Minority Health and Health Disparities [5P60 MD002261-02]; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P60MD002261] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center of Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	Supported by U01-H1072438 (G. C. and G. F, P.I.s) from the National Heart, Lung, and Blood Institute. G. C.'s time is also supported by 5P60 MD002261-02 from the National Center of Minority Health and Health Disparities.	Alegria M, 2001, AM J PUBLIC HEALTH, V91, P1431, DOI 10.2105/AJPH.91.9.1431; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Baker KM, 2003, CHEST, V124, P2156, DOI 10.1378/chest.124.6.2156; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; BURCHARD EG, LOWER BRONCHODILATOR; Calhoun WJ, 2003, J ALLERGY CLIN IMMUN, V112, P1088, DOI 10.1016/j.jaci.2003.09.044; Canino G, 2006, SOC SCI MED, V63, P2926, DOI 10.1016/j.socscimed.2006.07.017; Chipps BE, 2006, J PEDIATR-US, V148, P517, DOI 10.1016/j.jpeds.2005.11.014; Choudhry Shweta, 2007, Proc Am Thorac Soc, V4, P226, DOI 10.1513/pats.200701-029AW; Coelho VLD, 1998, J NERV MENT DIS, V186, P477, DOI 10.1097/00005053-199808000-00005; Cohen RT, 2007, CHEST, V131, P1331, DOI 10.1378/chest.06-1917; Cohen RT, 2006, CLIN CHEST MED, V27, P401, DOI 10.1016/j.ccm.2006.04.004; Duncan G., 1997, CONSEQUENCES GROWING; Federico MJ, 2007, J ALLERGY CLIN IMMUN, V119, P50, DOI 10.1016/j.jaci.2006.10.019; Fuhlbrigge AL, 2004, CURR OPIN PULM MED, V10, P1, DOI 10.1097/00063198-200401000-00002; Global Initiative for Asthma, 2002, OR WORKSH REP GLOB S; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Kwok MY, 2006, PEDIATRICS, V117, pS71, DOI 10.1542/peds.2005-2000D; Lara M, 2006, PEDIATRICS, V117, P43, DOI 10.1542/peds.2004-1714; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; Lee S, 2003, ANN ALLERG ASTHMA IM, V91, P449, DOI 10.1016/S1081-1206(10)61512-8; Loyo-Berrios NI, 2006, J ASTHMA, V43, P619, DOI 10.1080/02770900600878693; Matias-Carrelo LE, 2003, CULT MED PSYCHIAT, V27, P291, DOI 10.1023/A:1025399115023; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; MITCHELL DK, 2008, ANN M AM THOR SOC MA; National Asthma Education and Prevention Program, 2007, HYPERLIPIDAEMIA; National Asthma Education Prevention Program (National Heart Lung and Blood Institute), 1997, 2 NAT ASTHM ED PREV; Ortega AN, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e1; Ortega AN, 2001, ANN ALLERG ASTHMA IM, V86, P405, DOI 10.1016/S1081-1206(10)62486-6; Polgar G, 1971, PULMONARY FUNCTION T; ROSIER MJ, 1994, AM J RESP CRIT CARE, V149, P1434, DOI 10.1164/ajrccm.149.6.8004295; Shingo S, 2001, EUR RESPIR J, V17, P220, DOI 10.1183/09031936.01.17202200; Stout JW, 2006, ARCH PEDIAT ADOL MED, V160, P844, DOI 10.1001/archpedi.160.8.844; The Global Initiative for Asthma, 2006, REV GINA REP GLOB ST; *US BUR CENS, CENS 2000 DEM PROF H; US Department of Health and Human Services, 2005, 2005 HHS POV GUID	38	28	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					238	244		10.1016/j.jaci.2009.05.014	http://dx.doi.org/10.1016/j.jaci.2009.05.014			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	482CD	19615729	Green Accepted			2022-12-18	WOS:000268860400009
J	Roumana, A; Pitsios, C; Vartholomaios, S; Kompoti, E; Kontou-Fili, K				Roumana, Areti; Pitsios, Constantinos; Vartholomaios, Stamatios; Kompoti, Evangelia; Kontou-Fili, Kalliopi			The safety of initiating Hymenoptera immunotherapy at 1 mu g of venom extract	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MASTOCYTOSIS		[Roumana, Areti; Pitsios, Constantinos; Vartholomaios, Stamatios; Kompoti, Evangelia; Kontou-Fili, Kalliopi] Laikon Gen Hosp, Dept Allergol & Clin Immunol, Athens, Greece	Laiko General Hospital	Roumana, A (corresponding author), Laikon Gen Hosp, Dept Allergol & Clin Immunol, Athens, Greece.	kontoufk@otenet.gr	Constantinos, Pitsios/AFQ-0259-2022	Vartholomaios, Stamatios/0000-0003-1667-5603; Pitsios, Constantinos/0000-0001-8935-278X				Birnbaum J, 2003, CLIN EXP ALLERGY, V33, P58, DOI 10.1046/j.1365-2222.2003.01564.x; Kontou-Fili K, 2008, ALLERGY, V63, P376, DOI 10.1111/j.1398-9995.2007.01604.x; KONTOUFILI K, 1991, SCHWEIZ MED S, V121, pS63; LOCKEY RF, 1990, J ALLERGY CLIN IMMUN, V86, P775, DOI 10.1016/S0091-6749(05)80182-4; MAIA LCS, 1974, INT ARCH ALLER A IMM, V46, P339; MOSBECH H, 2000, ALLERGY, V55, P775; Muller UR, 2009, CURR ALLERGY ASTHM R, V9, P64, DOI 10.1007/s11882-009-0010-9; Muller Ulrich, 2008, Clin Allergy Immunol, V21, P377; Schiavino D, 2004, ANN ALLERG ASTHMA IM, V92, P409, DOI 10.1016/S1081-1206(10)61775-9	9	28	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					379	381		10.1016/j.jaci.2009.05.026	http://dx.doi.org/10.1016/j.jaci.2009.05.026			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19560804	Bronze			2022-12-18	WOS:000268860400030
J	Keski-Nisula, L; Katila, ML; Remes, S; Heinonen, S; Pekkanen, J				Keski-Nisula, Leea; Katila, Marja-Leena; Remes, Sami; Heinonen, Seppo; Pekkanen, Juha			Intrauterine bacterial growth at birth and risk of asthma and allergic sensitization among offspring at the age of 15 to 17 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Amniotic fluid; asthma; allergic sensitization; bacteria; cesarean delivery; intrauterine; ureaplasma; skin prick test	AMNIOTIC-FLUID; CHILDHOOD ASTHMA; INTRAAMNIOTIC INFECTION; CESAREAN DELIVERY; NULLIPAROUS WOMEN; PREGNANCY; TERM; COLONIZATION; COHORT; CHILDREN	Background: Microbial colonization of the airways and intestine during birth might have an effect on the risk of asthma and allergic diseases later in life. Objective: We sought to evaluate the association between intrauterine microbial growth at the time of delivery and the development of asthma and allergic sensitization among offspring. Methods: Intrauterine bacterial culture results were recorded at the time of cesarean delivery of 460 children who were born at Kuopio University Hospital during 1990-1992. When the children reached the age of 15 to 17 years, self-administered questionnaires were sent to the mothers, and 382 of the children were also examined by using skin prick tests. Results: Intrauterine growth of potential pathogenic anaerobic bacteria and Streptococcus species at birth was associated with an increased risk of doctor-diagnosed asthma ever (odds ratio [OR], 4.51 [95% CI, 1.56-13.01]; OR, 2.53 [95% CI, 1.19-5.38]) and doctor-diagnosed current asthma (OR, 7.34 [95% CI, 2.44-22.03]; OR, 3.37 [95% CI, 1.46-7.76]) at the age of 15 to 17 years compared with the risk seen in subjects with negative microbial cultures. These findings remained significant also after applying the Bonferroni correction. No significant association after the Bonferroni correction was detected between intrauterine microbial growth and allergic sensitization among offspring. Conclusion: The results of this study indicated that specific intrauterine microbial growth at the time of birth might increase the risk of asthma among offspring through inflammatory mechanisms. These results indicate new potential targets for future studies on the effects of maternal vaginal microflora and intrauterine infection in the development of asthma among children (J Allergy Clin Immunol 2009;123:1305-11.)	[Keski-Nisula, Leea; Heinonen, Seppo] Kuopio Univ Hosp, Dept Obstet & Gynecol, Kuopio 70211, Finland; [Katila, Marja-Leena] Kuopio Univ Hosp, Dept Clin Microbiol, Kuopio 70211, Finland; [Remes, Sami] Kuopio Univ Hosp, Dept Pediat, Kuopio 70211, Finland; [Pekkanen, Juha] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	Keski-Nisula, L (corresponding author), Kuopio Univ Hosp, Dept Obstet & Gynecol, PL 1777, Kuopio 70211, Finland.	leea.keski-nisula@kuh.fi			Finnish Medical Association; Jalmari and Rauha Ahokas Foundation; Kerttu and Kalle Viik Foundation; National Public Health Institute	Finnish Medical Association; Jalmari and Rauha Ahokas Foundation; Kerttu and Kalle Viik Foundation; National Public Health Institute	Supported by the Finnish Medical Association. the Jalmari and Rauha Ahokas Foundation, the Kerttu and Kalle Viik Foundation, and the National Public Health Institute.	Adlerberth I, 2006, PEDIATR RES, V59, P96, DOI 10.1203/01.pdr.0000191137.12774.b2; Benn CS, 2002, J ALLERGY CLIN IMMUN, V110, P72, DOI 10.1067/mai.2002.125833; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Blackwell SC, 2008, AM J PERINAT, V25, P205, DOI 10.1055/s-2008-1064933; Calvani M, 2004, ALLERGY, V59, P99, DOI 10.1046/j.1398-9995.2003.00338.x; Daoud GA, 2006, FETAL DIAGN THER, V21, P77, DOI 10.1159/000089053; ESCHENBACH DA, 1993, CLIN INFECT DIS, V16, pS282, DOI 10.1093/clinids/16.Supplement_4.S282; GIBBS RS, 1982, J INFECT DIS, V145, P1, DOI 10.1093/infdis/145.1.1; Goncalves LF, 2002, MENT RETARD DEV D R, V8, P3, DOI 10.1002/mrdd.10008; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Hsu CD, 1998, AM J OBSTET GYNECOL, V179, P1267, DOI 10.1016/S0002-9378(98)70144-9; KESKINISULA L, 1995, ACTA OBSTET GYN SCAN, V74, P33, DOI 10.3109/00016349509009940; KeskiNisula L, 1997, AM J PERINAT, V14, P151, DOI 10.1055/s-2007-994117; KeskiNisula L, 1997, J REPROD MED, V42, P91; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Kumar R, 2008, J ALLERGY CLIN IMMUN, V121, P878, DOI 10.1016/j.jaci.2008.01.030; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Pekkanen J, 1997, EUR RESPIR J, V10, P1787, DOI 10.1183/09031936.97.10081787; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Romero Roberto, 2002, Semin Neonatol, V7, P259, DOI 10.1053/siny.2002.0121; Rusconi F, 2007, AM J RESP CRIT CARE, V175, P16, DOI 10.1164/rccm.200512-1978OC; Russell ARB, 2006, BJOG-INT J OBSTET GY, V113, P758, DOI 10.1111/j.1471-0528.2006.00952.x; SILVER RK, 1986, OBSTET GYNECOL, V68, P587; SOPER DE, 1989, AM J OBSTET GYNECOL, V161, P562, DOI 10.1016/0002-9378(89)90356-6; Tollanes MC, 2008, J PEDIATR-US, V153, P112, DOI 10.1016/j.jpeds.2008.01.029; von Hertzen L, 2007, ALLERGY, V62, P288, DOI 10.1111/j.1398-9995.2006.01281.x; von Mutius E, 2007, NEW ENGL J MED, V357, P1545, DOI 10.1056/NEJMe078119; Winn HN, 2007, CLIN PERINATOL, V34, P387, DOI 10.1016/j.clp.2007.03.012; Xu BZ, 1999, INT J EPIDEMIOL, V28, P723, DOI 10.1093/ije/28.4.723	31	28	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1305	1311		10.1016/j.jaci.2009.03.021	http://dx.doi.org/10.1016/j.jaci.2009.03.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19423155				2022-12-18	WOS:000266799100021
J	Pali-Scholl, I; Renz, H; Jensen-Jarolim, E				Pali-Schoell, Isabella; Renz, Harald; Jensen-Jarolim, Erika			Update on allergies in pregnancy, lactation, and early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; pregnancy; lactation; atopy; newborn; acid-suppression; prevention	INFANT NUTRITIONAL INTERVENTION; ENVIRONMENTAL TOBACCO-SMOKE; CONJUGATED LINOLEIC-ACID; FISH-OIL SUPPLEMENTATION; PLACEBO-CONTROLLED TRIAL; ORAL TOLERANCE INDUCTION; IMMUNOGLOBULIN-E IGE; FOOD ALLERGY; BREAST-MILK; AIRWAY INFLAMMATION	The factors responsible for the induction of allergic disease at an early age have not been completely identified. Therefore a major research focus is their identification to elaborate recommendations for prevention of sensitization in high-risk or atopic children. This review analyzes known or suspected reasons for sensitization in pregnant women and infants from both clinical and experimental animal studies. Recent studies and meta-analyses could not confirm the protective effect of an allergen-poor diet on the part of the mother during pregnancy and lactation. Likewise, the type of bottle feeding or the introduction of solid food into the child's diet might not significantly influence the development of atopy, allergy, or asthma in the child's life. Disappointingly, the few preventive measures remaining to reduce the risk of allergic sensitization and atopic diseases in mother and child are the avoidance of smoking and alcohol consumption during pregnancy and lactation and the avoidance of the impairment of gastric function. Further studies are urgently needed to address the influence of certain foods and nutrients, as well as environmental factors, for prevention of allergic diseases in the low- or high-risk infant. (J Allergy Clin Immunol 2009;123:1012-21.)	[Pali-Schoell, Isabella] Med Univ Vienna, Dept Pathophysiol, Ctr Physiol Pathophysiol & Immunol, A-1090 Vienna, Austria; [Renz, Harald] Hosp Philipps Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany	Medical University of Vienna; Philipps University Marburg	Pali-Scholl, I (corresponding author), Med Univ Vienna, Dept Pathophysiol, Ctr Physiol Pathophysiol & Immunol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	isabella.pali@meduniwien.ac.at	Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765	Hertha Firnberg stipends [T283-B13]; Austrian Science Fund [SFB F1808-B13]	Hertha Firnberg stipends(Austrian Science Fund (FWF)); Austrian Science Fund(Austrian Science Fund (FWF))	Supported by Hertha Firnberg stipends T283-B13 and SFB F1808-B13 of the Austrian Science Fund (FWF).	Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Alm B, 2008, PEDIATRICS, V121, P697, DOI 10.1542/peds.2007-1232; Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407; [Anonymous], 2007, J PEDIAT-BRAZIL, V83, P7, DOI [10.2223/JPED.1587, 10.1590/S0021-75572007000100004]; Assing K, 2007, ANN ALLERG ASTHMA IM, V98, P70, DOI 10.1016/S1081-1206(10)60862-9; Bakos N, 2006, IMMUNOL LETT, V107, P15, DOI 10.1016/j.imlet.2006.06.003; Bauer M, 2002, AM J OBSTET GYNECOL, V186, P117, DOI 10.1067/mob.2002.118306; Bjorksten B, 2008, NESTLE NUTR WORKS SE, V61, P243, DOI 10.1159/0000113498; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Boehm G, 2007, J NUTR, V137, p847S, DOI 10.1093/jn/137.3.847S; Bousquet J, 2004, ALLERGY, V59, P138, DOI 10.1046/j.1398-9995.2003.00359.x; Brand PLP, 2007, PEDIAT ALLERG IMM-UK, V18, P475, DOI 10.1111/j.1399-3038.2007.00541.x; Buhrer C, 1999, LANCET, V353, P1674, DOI 10.1016/S0140-6736(98)03975-0; Calder PC, 2006, BRIT J NUTR, V96, P774, DOI [10.1079/BJN20061917, 10.1079/BJN20061881]; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Cleary TG, 2004, ADV EXP MED BIOL, V554, P145; Dean T, 2007, J HUM NUTR DIET, V20, P95, DOI 10.1111/j.1365-277X.2007.00751.x; Dehlink E, 2009, CLIN EXP ALLERGY, V39, P246, DOI 10.1111/j.1365-2222.2008.03125.x; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.1139; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Devereux G, 2006, NAT REV IMMUNOL, V6, P869, DOI 10.1038/nri1958; Dotterud LK, 2007, CONTACT DERMATITIS, V56, P10, DOI 10.1111/j.1600-0536.2007.00980.x; Duchen K, 1991, Adv Exp Med Biol, V310, P427; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Dunstan JA, 2007, PEDIATR RES, V62, P689, DOI 10.1203/PDR.0b013e318159a93a; ElNawawy A, 1996, J TROP PEDIATRICS, V42, P166, DOI 10.1093/tropej/42.3.166; Feleszko W, 2007, CLIN EXP ALLERGY, V37, P498, DOI 10.1111/j.1365-2222.2006.02629.x; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Fiocchi A, 2006, ANN ALLERG ASTHMA IM, V97, P10, DOI 10.1016/S1081-1206(10)61364-6; Fitzsimon N, 2007, Ir Med J, V100, P27; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; Gerhold K, 2006, J ALLERGY CLIN IMMUN, V118, P666, DOI 10.1016/j.jaci.2006.05.022; GERRARD JW, 1986, ANN ALLERGY, V56, P351; Gonzalez-Quintela A, 2002, FRONT BIOSCI-LANDMRK, V7, pE234, DOI 10.2741/quintela; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Haahtela T, 2008, ALLERGY, V63, P634, DOI 10.1111/j.1398-9995.2008.01712.x; Halvorsen T, 2004, ACTA PAEDIATR, V93, P1294, DOI 10.1080/08035250410028101; Hersoug LG, 2006, MED HYPOTHESES, V67, P717, DOI 10.1016/j.mehy.2006.03.026; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Horak E, 2007, SWISS MED WKLY, V137, P608; Host A, 2008, PEDIAT ALLERG IMM-UK, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; Jaudszus A, 2008, J NUTR, V138, P1336, DOI 10.1093/jn/138.7.1336; Johnson CC, 2005, J ALLERGY CLIN IMMUN, V115, P1218, DOI 10.1016/j.jaci.2005.04.020; Jolly CA, 1997, J NUTR, V127, P37, DOI 10.1093/jn/127.1.37; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kelleher SL, 2001, ADV NUTR RES, V10, P39; Kemp AS, 2009, CLIN EXP ALLERGY, V39, P176, DOI 10.1111/j.1365-2222.2008.03141.x; Khakoo GA, 2004, ARCH DIS CHILD, V89, P295, DOI 10.1136/adc.2003.039016; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kirjavainen PV, 1999, ANN MED, V31, P288, DOI 10.3109/07853899908995892; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Korotkova M, 2004, CLIN EXP IMMUNOL, V137, P237, DOI 10.1111/j.1365-2249.2004.02527.x; Kramer MS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000133.pub2; Krauss-Etschmann S, 2008, J ALLERGY CLIN IMMUN, V121, P464, DOI 10.1016/j.jaci.2007.09.018; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kulig M, 1999, HUM EXP TOXICOL, V18, P241, DOI 10.1191/096032799678839987; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lack G, 2007, NESTLE NUTR WORKS SE, V59, P63, DOI 10.1159/000098513; Laiho K, 2003, PEDIATR RES, V53, P642, DOI 10.1203/01.PDR.0000055778.58807.C8; Lannero E, 2008, THORAX, V63, P172, DOI 10.1136/thx.2007.079053; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Levy J, 2000, AM J GASTROENTEROL, V95, pS8, DOI 10.1016/S0002-9270(99)00808-4; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Liem JJ, 2007, J ALLERGY CLIN IMMUN, V119, P1203, DOI 10.1016/j.jaci.2006.12.671; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755, DOI 10.1016/S0091-6749(99)70284-8; Linneberg A, 2006, CLIN EXP ALLERGY, V36, P714, DOI 10.1111/j.1365-2222.2006.02507.x; Linneberg A, 2004, CLIN EXP ALLERGY, V34, P1678, DOI 10.1111/j.1365-2222.2004.02101.x; Linneberg A, 2008, ALCOHOL CLIN EXP RES, V32, P553, DOI 10.1111/j.1530-0277.2008.00644.x; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903, DOI 10.1093/ajcn/84.4.903; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Loibichler C., 2002, Clinical and Experimental Allergy, V32, P1546, DOI 10.1046/j.1365-2222.2002.01479.x; MARRERO JM, 1992, BRIT J OBSTET GYNAEC, V99, P731, DOI 10.1111/j.1471-0528.1992.tb13873.x; McGlade JP, 2007, CLIN EXP ALLERGY, V37, P1267, DOI 10.1111/j.1365-2222.2007.02750.x; Michie CA, 1998, EUR CYTOKINE NETW, V9, P123; Miller RL, 2008, J CLIN INVEST, V118, P3265, DOI 10.1172/JCI37171; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Miyake Y, 2006, ANN EPIDEMIOL, V16, P614, DOI 10.1016/j.annepidem.2005.11.010; Moore Daniella Campelo Batalha Cox, 2006, Sao Paulo Med. J., V124, P298; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; Moya-Camarena SY, 1999, J LIPID RES, V40, P1426; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Negele K, 2004, PEDIAT ALLERG IMM-UK, V15, P48, DOI 10.1046/j.0905-6157.2003.00101.x; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Norris JM, 2005, JAMA-J AM MED ASSOC, V293, P2343, DOI 10.1001/jama.293.19.2343; O'Shea M, 2004, AM J CLIN NUTR, V79, p1199S, DOI 10.1093/ajcn/79.6.1199S; Oddy W H, 2000, Breastfeed Rev, V8, P5; Palvo F, 2008, J TROP PEDIATRICS, V54, P253, DOI 10.1093/tropej/fmn007; Penn AL, 2007, ENVIRON HEALTH PERSP, V115, P548, DOI 10.1289/ehp.9780; Pesonen M, 2006, CLIN EXP ALLERGY, V36, P1011, DOI 10.1111/j.1365-2222.2006.02526.x; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P200, DOI 10.1016/j.jaci.2007.03.045; Raherison C, 2008, ANN ALLERG ASTHMA IM, V100, P351, DOI 10.1016/S1081-1206(10)60598-4; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; Renz H, 2006, CHEM IMMUNOL ALLERGY, V91, P30; RONCHETTI R, 1990, J ALLERGY CLIN IMMUN, V86, P400, DOI 10.1016/S0091-6749(05)80104-6; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Salvatore S, 2005, PEDIAT ALLERG IMM-UK, V16, P558, DOI 10.1111/j.1399-3038.2005.00315.x; Samuelsen M, 2008, TOXICOLOGY, V246, P124, DOI 10.1016/j.tox.2008.01.001; Sausenthaler S, 2007, AM J CLIN NUTR, V85, P530; Schaefer MK, 2008, PEDIATRICS, V121, P783, DOI 10.1542/peds.2007-3638; Schauber J, 2008, J ALLERGY CLIN IMMUN, V121, P782, DOI 10.1016/j.jaci.2007.12.1170; Schernhammer ES, 2008, PEDIAT ALLERG IMM-UK, V19, P125, DOI 10.1111/j.1399-3038.2007.00597.x; Scholl I, 2007, FASEB J, V21, P1264, DOI 10.1096/fj.06-7223com; Scholl L, 2005, AM J CLIN NUTR, V81, P154; Sharma SK, 2007, ALLERGY ASTHMA PROC, V28, P647, DOI 10.2500/aap.2007.28.3059; Shin HJ, 2005, J IMMUNOL, V175, P7143, DOI 10.4049/jimmunol.175.11.7143; Sicherer SH, 2008, J ALLERGY CLIN IMMUN, V122, P29, DOI 10.1016/j.jaci.2008.05.019; Sole Dirceu, 2006, J Pediatr (Rio J), V82, P341, DOI [10.1590/S0021-75572006000600006, 10.2223/JPED.1521]; Sudo N, 1997, J IMMUNOL, V159, P1739; Szepfalusi Z, 2000, PEDIATR RES, V48, P404, DOI 10.1203/00006450-200009000-00024; Szepfalusi Z, 2006, CLIN EXP ALLERGY, V36, P1130, DOI 10.1111/j.1365-2222.2006.02559.x; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Ushiyama Y, 2002, J NUTR SCI VITAMINOL, V48, P345, DOI 10.3177/jnsv.48.345; Uthoff H, 2003, J IMMUNOL, V171, P3485, DOI 10.4049/jimmunol.171.7.3485; van Panhuys N, 2008, TISSUE ANTIGENS, V72, P91, DOI 10.1111/j.1399-0039.2008.01068.x; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; Venter C, 2006, J ALLERGY CLIN IMMUN, V117, P1118, DOI 10.1016/j.jaci.2005.12.1352; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Victor JR, 2003, J ALLERGY CLIN IMMUN, V111, P269, DOI 10.1067/mai.2003.39; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Vos AP, 2007, INT IMMUNOPHARMACOL, V7, P1582, DOI 10.1016/j.intimp.2007.07.024; Vos AP, 2006, INT IMMUNOPHARMACOL, V6, P1277, DOI 10.1016/j.intimp.2006.03.010; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x; Willers SM, 2007, THORAX, V62, P773, DOI 10.1136/thx.2006.074187; Wjst M, 2007, ALLERGY, V62, P1085, DOI 10.1111/j.1398-9995.2007.01437.x; Wjst M, 1999, ALLERGY, V54, P757, DOI 10.1034/j.1398-9995.1999.00193.x; Yu Y, 2002, BBA-MOL CELL BIOL L, V1581, P89, DOI 10.1016/S1388-1981(02)00126-9; Zeiger RS, 2003, PEDIATRICS, V111, P1662; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; Zizka J, 2007, PEDIATR ALLERGY IMMU, V18, P486, DOI 10.1111/j.1399-3038.2007.00563.x; Zutavern A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-81	143	28	32	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1012	1021		10.1016/j.jaci.2009.01.045	http://dx.doi.org/10.1016/j.jaci.2009.01.045			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19249083	Green Accepted			2022-12-18	WOS:000266309400005
J	Temprano, J; Mannino, DM				Temprano, James; Mannino, David M.			The effect of sex on asthma control from the National Asthma Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; control; cross-sectional; epidemiology; sex; national; severity; survey; symptoms	QUALITY-OF-LIFE; HEALTH-CARE UTILIZATION; REAL-WORLD EVALUATION; GENDER-DIFFERENCES; EMERGENCY-DEPARTMENT; NATURAL-HISTORY; SEVERITY; WOMEN; AGE; HOSPITALIZATION	Background: Previous studies have demonstrated conflicting results with regard to differences in asthma control between the sexes. Objective: We sought to identify sex differences in short-term and long-term measures of asthma control in adults from the National Asthma Survey. Methods: This study analyzed data from the National Asthma Survey (Four-State sample) sponsored by the National Center for Environmental Health, Centers for Disease Control and Prevention. Asthma control was compared between the sexes based on short-term (recent symptoms, asthma attacks, and albuterol use) and long-term (asthma attacks, work days lost, and urgent-care visits and hospitalizations in the prior year) measures. Composite scores for short-term and long-term control were calculated based on any single measure of poor asthma control and based on a sum of poor asthma control measures. Results: Women were more likely to have poor short-term asthma control based on any measure (adjusted odds ratio [OR], 1.20; CI, 1.01-1.44) or sum of measures (adjusted OR, 1.24; CI, 1.08-1.53) compared with men. Women also demonstrated worse asthma control based on any uncontrolled long-term measure (adjusted OR, 1.52; CI, 1.29-1.79) or sum of measures (adjusted OR, 1.68; CI, 1.45-1.93). These findings were present despite higher reported inhaled corticosteroid use and scheduled health care visits for asthma among women. Conclusions: Women demonstrated worse asthma control compared with men with regard to several short-term and long-term measures, despite reporting higher rates of inhaled corticosteroid use and routine asthma care visits. Further studies are needed to elucidate whether these findings are due to differences in health reporting or to pathophysiologic differences in asthma between the sexes. (J Allergy Clin Immunol 2009;123:854-60.)	[Temprano, James] Univ Kentucky, Dept Internal Med, Div Allergy & Immunol, Lexington, KY 40508 USA; [Mannino, David M.] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY 40508 USA	University of Kentucky; University of Kentucky	Temprano, J (corresponding author), Univ Kentucky, Dept Internal Med, Div Allergy & Immunol, 135 E Maxwell St,Suite 250, Lexington, KY 40508 USA.	jtemp1@email.uky.edu		Mannino, David/0000-0003-3646-7828	Building Interdisciplinary Research Careers in Women's Health (BIRCWH) NIH [2 K12 DA 14040-06]; NATIONAL INSTITUTE ON DRUG ABUSE [K12DA014040] Funding Source: NIH RePORTER	Building Interdisciplinary Research Careers in Women's Health (BIRCWH) NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported by Building Interdisciplinary Research Careers in Women's Health (BIRCWH) NIH 2 K12 DA 14040-06 (J.T.).	Agarwal AK, 1997, J ASTHMA, V34, P539, DOI 10.3109/02770909709055398; ALONSO J, 1990, AM J PUBLIC HEALTH, V80, P704, DOI 10.2105/AJPH.80.6.704; Arber S, 1999, SOC SCI MED, V48, P61, DOI 10.1016/S0277-9536(98)00289-5; Arbes SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1139, DOI 10.1016/j.jaci.2007.07.056; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Baibergenova A, 2005, EUR J EPIDEMIOL, V20, P947, DOI 10.1007/s10654-005-3635-6; Barnes NC, 2005, INT J CLIN PRACT, V59, P1017, DOI 10.1111/j.1742-1241.2005.00615.x; Belloch A, 2003, J ASTHMA, V40, P945, DOI 10.1081/JAS-120024595; Cazzoletti L, 2007, J ALLERGY CLIN IMMUN, V120, P1360, DOI 10.1016/j.jaci.2007.09.019; *CDCP, 2003, DAT SOURC; Chen Y, 2003, J CLIN EPIDEMIOL, V56, P180, DOI 10.1016/S0895-4356(02)00593-0; DAVIS MA, 1981, J HEALTH SOC BEHAV, V22, P298, DOI 10.2307/2136523; Day A, 2006, J ASTHMA, V43, P169, DOI 10.1080/02770900500499061; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; Dunlop DD, 2002, J GERONTOL B-PSYCHOL, V57, pS221, DOI 10.1093/geronb/57.4.S221; Eagan TML, 2002, EUR RESPIR J, V19, P599, DOI 10.1183/09031936.02.00247302; Eisner MD, 2002, ANN ALLERG ASTHMA IM, V89, P46, DOI 10.1016/S1081-1206(10)61910-2; ELIASSON O, 1986, J ALLERGY CLIN IMMUN, V77, P87, DOI 10.1016/0091-6749(86)90328-3; Emery CF, 2004, PSYCHOSOM MED, V66, P190, DOI 10.1097/01.psy.0000116775.98593.f4; Feinglass J, 1994, Ann Vasc Surg, V8, P343, DOI 10.1007/BF02132995; FREID VM, 2003, US 2003 CHART BOOK T; Giacomini MK, 1996, ARCH INTERN MED, V156, P1217, DOI 10.1001/archinte.156.11.1217; GIBBS CJ, 1984, THORAX, V39, P833, DOI 10.1136/thx.39.11.833; HANLEY SP, 1981, BRIT J DIS CHEST, V75, P306, DOI 10.1016/0007-0971(81)90010-3; Hopman WM, 2000, CAN MED ASSOC J, V163, P265; Humbert M, 2007, ALLERGY, V62, P95, DOI 10.1111/j.1398-9995.2006.01308.x; Johnston NW, 2006, THORAX, V61, P722, DOI 10.1136/thx.2005.045161; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; Kjellman B, 2000, RESP MED, V94, P454, DOI 10.1053/rmed.1999.0764; Laforest L, 2005, ANN ALLERG ASTHMA IM, V94, P473, DOI 10.1016/S1081-1206(10)61118-0; Laforest L, 2006, J ALLERGY CLIN IMMUN, V117, P1404, DOI 10.1016/j.jaci.2006.03.007; Larsson U, 2007, RESP MED, V101, P1291, DOI 10.1016/j.rmed.2006.10.014; Lee JH, 2006, J ASTHMA, V43, P179, DOI 10.1080/02770900600566405; Li JJ, 2005, POLYM ADVAN TECHNOL, V16, P11, DOI 10.1002/pat.547; MACINTYRE S, 1989, SOC SCI MED, V29, P1243, DOI 10.1016/0277-9536(89)90063-4; MacIntyre S, 1996, SOC SCI MED, V42, P617, DOI 10.1016/0277-9536(95)00335-5; MARSHALL JR, 1986, WOMEN HEALTH, V11, P67; *NAT HEART LUNG BL, 2007, 3 EXP PAN NAT HEART; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; OCONNOR KS, 2008, VITAL HLTH STAT, V46, P1; Orfila F, 2006, SOC SCI MED, V63, P2367, DOI 10.1016/j.socscimed.2006.06.017; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Owens GM, 2008, J MANAGE CARE PHARM, V14, pS2; Panettieri RA, 2008, J ALLERGY CLIN IMMUN, V121, P607, DOI 10.1016/j.jaci.2008.01.006; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Rhodes L, 2005, J ASTHMA, V42, P777, DOI 10.1080/02770900500308387; Schatz M, 2006, CHEST, V129, P50, DOI 10.1378/chest.129.1.50; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553, DOI 10.1016/S1081-1206(10)61533-5; Schatz M, 2007, J ASTHMA, V44, P391, DOI 10.1080/02770900701364296; Schatz M, 2006, J ALLERGY CLIN IMMUN, V118, P1048, DOI 10.1016/j.jaci.2006.07.057; Sexton M, 1998, BMJ-BRIT MED J, V317, P1434, DOI 10.1136/bmj.317.7170.1434; Shames RS, 1998, ANN ALLERG ASTHMA IM, V81, P65, DOI 10.1016/S1081-1206(10)63111-0; Sinclair AH, 2006, J ASTHMA, V43, P363, DOI 10.1080/02770900600705334; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; Song J, 2006, J WOMENS HEALTH, V15, P1205, DOI 10.1089/jwh.2006.15.1205; Spahn JD, 2008, J ALLERGY CLIN IMMUN, V121, P548, DOI 10.1016/j.jaci.2008.01.012; Stoloff SW, 2006, J ALLERGY CLIN IMMUN, V117, P544, DOI 10.1016/j.jaci.2006.01.005; Trawick DR, 2001, CHEST, V119, P115, DOI 10.1378/chest.119.1.115; VERBRUGGE LM, 1989, J HEALTH SOC BEHAV, V30, P282, DOI 10.2307/2136961; Weiner P, 2002, CHEST, V122, P197, DOI 10.1378/chest.122.1.197; Wenzel S, 2006, J ALLERGY CLIN IMMUN, V117, P508, DOI 10.1016/j.jaci.2005.12.1316; Wijnhoven HAH, 2003, J ASTHMA, V40, P189, DOI 10.1081/JAS-120017990; Woods SE, 2003, J WOMEN HEALTH GEN-B, V12, P481, DOI 10.1089/154099903766651603	64	28	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					854	860		10.1016/j.jaci.2008.12.009	http://dx.doi.org/10.1016/j.jaci.2008.12.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	431JW	19181370	Green Submitted			2022-12-18	WOS:000265058600011
J	Wang, F; Tang, H; Xu, JH; Kang, KF				Wang, Fang; Tang, Hui; Xu, Jin-hua; Kang, Ke-fei			Activation of the blood coagulation cascade is involved in patients with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MAST-CELLS; RECEPTORS		[Wang, Fang; Tang, Hui; Xu, Jin-hua; Kang, Ke-fei] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200433, Peoples R China	Fudan University	Wang, F (corresponding author), Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai 200433, Peoples R China.	huihuicandy@hotmail.com		Wang, Fang/0000-0002-3327-4177				Asero R, 2007, J ALLERGY CLIN IMMUN, V119, P705, DOI 10.1016/j.jaci.2006.08.043; Dugina TN, 2003, EUR J PHARMACOL, V471, P141, DOI 10.1016/S0014-2999(03)01752-7; Moormann C, 2006, J INVEST DERMATOL, V126, P746, DOI 10.1038/sj.jid.5700169; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003	4	28	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					972	973		10.1016/j.jaci.2009.01.039	http://dx.doi.org/10.1016/j.jaci.2009.01.039			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19251312				2022-12-18	WOS:000265058600036
J	Sicherer, SH; Leung, DYM				Sicherer, Scott H.; Leung, Donald Y. M.			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2008	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dermatology; skin disease; urticaria; atopic dermatitis; anaphylaxis; allergy; hypersensitivity; disorders; food; drug; insect venom	ATOPIC-DERMATITIS; DOUBLE-BLIND; COWS MILK; FECAL MICROBIOTA; ORAL TOLERANCE; RISK-FACTOR; IGE LEVELS; TREE NUT; FILAGGRIN; CHILDREN	This review highlights some of the research advances in anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects and in allergic skin disease that were reported in the Journal in 2008. Key epidemiologic observations include a rise in anaphylaxis in a population-based study and lower rates of peanut allergy in Israel, where infants consume peanut early compared with the United Kingdom, where dietary introduction is generally delayed. Advances in food allergy diagnosis include IgE epitope mapping that discloses the likelihood and severity of allergy; studies correlating likelihood of clinical reactivity on the basis of food-specific IgE to sesame, peanut, milk, and tree nuts; and an observation that a low baseline angiotensin-converting enzyme level may he associated with having pharyngeal edema during a reaction. Molecular, immunologic, and genetic studies are discerning pathways that are key in development of food allergy, identifying new modalities to interrupt mast cell degranulation, and elucidating risks associated with penicillin allergy. Regarding treatment, clinical studies show a majority of children with milk and egg allergy tolerate these proteins in modest amounts when they are extensively heated in baked goods, and studies show promise for oral immunotherapy to treat milk allergy and sublingual immunotherapy for honey bee venom hypersensitivity. The importance of skin barrier dysfunction has continued to be highlighted in the pathophysiology of atopic dermatitis (AD). Research has also continued to identify immunologic defects that contribute to the propensity of patients with AD to develop viral anti bacterial infection. New therapeutic approaches to AD, urticaria, and angioedema have been reported including use of probiotics, biologics, vitamin D, and skin barrier creams. (J Allergy Clin Immunol 2009;123:319-27.)	[Sicherer, Scott H.] Mt Sinai Hosp, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Mt Sinai Sch Med,Dept Pediat, New York, NY 10029 USA; [Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Denver, CO USA	Icahn School of Medicine at Mount Sinai; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sicherer, SH (corresponding author), Mt Sinai Hosp, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Mt Sinai Sch Med,Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			National Institutes of Health/National Institute of Allergy and Infectious Disease; Novartis and Genentech	National Institutes of Health/National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Novartis and Genentech	Sicherer has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Disease,. D. Y. M. Leung ha, received research support from Novartis and Genentech.	Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016; Apter AJ, 2008, J ALLERGY CLIN IMMUN, V122, P152, DOI 10.1016/j.jaci.2008.03.037; Ayuso R, 2008, J ALLERGY CLIN IMMUN, V122, P795, DOI 10.1016/j.jaci.2008.07.023; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; BERIN MC, 2008, J ALLERGY CLIN IMMUN, V121, P21; Beyer K, 2008, J ALLERGY CLIN IMMUN, V122, P419, DOI 10.1016/j.jaci.2008.06.006; Blok BMJF, 2008, J ALLERGY CLIN IMMUN, V122, P139, DOI 10.1016/j.jaci.2008.05.008; Brown SJ, 2008, J ALLERGY CLIN IMMUN, V121, P940, DOI 10.1016/j.jaci.2008.01.013; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P1344, DOI 10.1016/j.jaci.2008.02.037; Campana R, 2008, J ALLERGY CLIN IMMUN, V121, P528, DOI 10.1016/j.jaci.2007.09.014; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Clark AT, 2008, J ALLERGY CLIN IMMUN, V122, P286, DOI 10.1016/j.jaci.2008.05.015; Conner E, 2008, J ALLERGY CLIN IMMUN, V121, P258, DOI 10.1016/j.jaci.2007.10.044; Cresswell KM, 2008, J ALLERGY CLIN IMMUN, V121, P1112, DOI 10.1016/j.jaci.2007.12.1180; DAVIS CM, 2008, J ALLERGY CLIN IMMUN, V121; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Feng BS, 2008, J ALLERGY CLIN IMMUN, V122, P55, DOI 10.1016/j.jaci.2008.04.036; FLINTERMAN AE, 2008, J ALLERGY CLIN IMMUN, V121; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Flohr C, 2008, J ALLERGY CLIN IMMUN, V121, P141, DOI 10.1016/j.jaci.2007.08.066; GANESHAN K, 2008, J ALLERGY CLIN  1118; Gonzalez-Mancebo E, 2008, J ALLERGY CLIN IMMUN, V121, P1507, DOI 10.1016/j.jaci.2008.01.029; Gore C, 2008, J ALLERGY CLIN IMMUN, V121, P135, DOI 10.1016/j.jaci.2007.07.061; GUPTA G, 2008, J ALLERGY CLIN IMMUN, V121; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Hol J, 2008, J ALLERGY CLIN IMMUN, V121, P1448, DOI 10.1016/j.jaci.2008.03.018; Holzhauser T, 2009, J ALLERGY CLIN IMMUN, V123, P452, DOI 10.1016/j.jaci.2008.09.034; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Jung T, 2008, J ALLERGY CLIN IMMUN, V122, P1074, DOI 10.1016/j.jaci.2008.09.042; Kaplan AP, 2008, J ALLERGY CLIN IMMUN, V122, P569, DOI 10.1016/j.jaci.2008.07.006; Kirino M, 2008, J ALLERGY CLIN IMMUN, V122, P290, DOI 10.1016/j.jaci.2008.05.031; Konstantinou GN, 2008, J ALLERGY CLIN IMMUN, V122, P414, DOI 10.1016/j.jaci.2008.05.032; Koplin J, 2008, J ALLERGY CLIN IMMUN, V121, P1455, DOI 10.1016/j.jaci.2008.03.017; Kwiek B, 2008, J ALLERGY CLIN IMMUN, V122, P126, DOI 10.1016/j.jaci.2008.05.005; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lebre MC, 2008, J ALLERGY CLIN IMMUN, V122, P969, DOI 10.1016/j.jaci.2008.08.028; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Maloney JM, 2008, J ALLERGY CLIN IMMUN, V122, P145, DOI 10.1016/j.jaci.2008.04.014; Mandelin J, 2008, J ALLERGY CLIN IMMUN, V121, P777, DOI 10.1016/j.jaci.2007.12.1179; Mazuc E, 2008, J ALLERGY CLIN IMMUN, V122, P188, DOI 10.1016/j.jaci.2008.04.026; Mertes PM, 2008, J ALLERGY CLIN IMMUN, V122, P348, DOI 10.1016/j.jaci.2008.04.040; Muller UR, 2008, J ALLERGY CLIN IMMUN, V122, P1001, DOI 10.1016/j.jaci.2008.08.007; Norton L, 2008, J ALLERGY CLIN IMMUN, V122, P209, DOI 10.1016/j.jaci.2008.04.020; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nurmatov U, 2008, J ALLERGY CLIN IMMUN, V122, P353, DOI 10.1016/j.jaci.2008.05.028; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Park HW, 2008, J ALLERGY CLIN IMMUN, V121, P1059, DOI 10.1016/j.jaci.2007.12.1162; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Reefer AJ, 2008, J ALLERGY CLIN IMMUN, V121, P415, DOI 10.1016/j.jaci.2007.11.003; Rice NE, 2008, J ALLERGY CLIN IMMUN, V122, P834, DOI 10.1016/j.jaci.2008.07.027; Rogers AJ, 2007, J ALLERGY CLIN IMMUN, V120, P1332, DOI 10.1016/j.jaci.2007.09.037; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Severino MG, 2008, J ALLERGY CLIN IMMUN, V122, P44, DOI 10.1016/j.jaci.2008.03.031; Sicherer SH, 2008, J ALLERGY CLIN IMMUN, V121, P1351, DOI 10.1016/j.jaci.2008.01.032; SICHERER SH, 2008, J ALLERGY CLIN IMMUN, V122; Siebenhaar F, 2008, J ALLERGY CLIN IMMUN, V121, P955, DOI 10.1016/j.jaci.2007.11.013; Simon D, 2008, J ALLERGY CLIN IMMUN, V122, P423, DOI 10.1016/j.jaci.2008.06.010; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; SMITH M, 2008, J ALLERGY CLIN  1118, V121; Staumont-Salle D, 2008, J ALLERGY CLIN IMMUN, V121, P962, DOI 10.1016/j.jaci.2007.12.1165; Steckelbroeck S, 2008, J ALLERGY CLIN IMMUN, V121, P1323, DOI 10.1016/j.jaci.2008.04.008; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Untersmayr E, 2008, J ALLERGY CLIN IMMUN, V121, P1301, DOI 10.1016/j.jaci.2008.04.025; Van der Gugten AC, 2008, J ALLERGY CLIN IMMUN, V121, P531, DOI 10.1016/j.jaci.2007.10.042; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; Vonakis BM, 2008, J ALLERGY CLIN IMMUN, V121, P262, DOI 10.1016/j.jaci.2007.10.010; Wagner AH, 2008, J ALLERGY CLIN IMMUN, V121, P158, DOI 10.1016/j.jaci.2007.09.015; Wang J, 2008, J ALLERGY CLIN IMMUN, V121, P1219, DOI 10.1016/j.jaci.2007.12.1150; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; WEIDINGER S, 2008, J ALLERGY CLIN IMMUN, V122; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; YAMANAKA K, 2008, J ALLERGY CLIN IMMUN, V121; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030; Zavalkoff S, 2008, J ALLERGY CLIN IMMUN, V121, P1508, DOI 10.1016/j.jaci.2008.04.012; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	88	28	31	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					319	327		10.1016/j.jaci.2008.12.025	http://dx.doi.org/10.1016/j.jaci.2008.12.025			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19203656				2022-12-18	WOS:000263495000005
J	Waibler, Z; Sender, LY; Kamp, C; Muller-Berghaus, J; Liedert, B; Schneider, CK; Lower, J; Kalinke, U				Waibler, Zoe; Sender, Linda Y.; Kamp, Christel; Mueller-Berghaus, Jan; Liedert, Bernd; Schneider, Christian K.; Loewer, Johannes; Kalinke, Ulrich			Toward experimental assessment of receptor occupancy: TGN1412 revisited	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Superagonistic anti-CD28 mAb; first-in-human dosage calculation; phase I clinical trial design; TGN1412; receptor occupancy calculation		In March 2006, 6 healthy volunteers experienced serious adverse reactions during a first-in-human clinical trial of the superagonistic anti-CD28 mAb TGN1412. A first investigation excluded contaminations of the drug product or protocol irregularities as the root cause. Later, an expert scientific group convened in the United Kingdom to develop recommendations pertinent to minimizing risks of first-in-human clinical trials. The expert scientific group concluded from in silico calculations that at the initial dose of 0.1 mg/kg, which was adjusted on the basis of the no observed adverse effect level, approximately 86.2% to 90.9% CD28 receptor occupancy was obtained. Here we developed a flow cytometric method that revealed receptor occupancy of approximately 45% to 80% under the above conditions. Thus we present a method to experimentally determine receptor occupancy that can be taken as one parameter to define the minimal anticipated biological effect level as the basis for calculating safer starting doses for first-inhuman clinical trials for products in which a potential risk has been identified. Additional measures are being discussed that will help to significantly improve safety of first-in-human clinical trials. (J Allergy Clin Immunol 2008;122:890-2.)	[Waibler, Zoe; Sender, Linda Y.; Mueller-Berghaus, Jan; Liedert, Bernd; Loewer, Johannes; Kalinke, Ulrich] Paul Ehrlich Inst, Div Immunol, D-63225 Langen, Germany; [Kamp, Christel; Schneider, Christian K.] Paul Ehrlich Inst, Div EU Cooperat Microbiol, D-63225 Langen, Germany; [Kalinke, Ulrich] Ctr Expt & Clin Infect Res, TWINCORE, Hannover, Germany	Paul Ehrlich Institute; Paul Ehrlich Institute	Kalinke, U (corresponding author), Paul Ehrlich Inst, Div Immunol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	kalul@pei.de		Kamp, Christel/0000-0001-9997-6772; Kalinke, Ulrich/0000-0003-0503-9564	Paul-Ehrlich-Institut	Paul-Ehrlich-Institut	Supported by the Paul-Ehrlich-Institut.	*DEP HLTH, 2006, EXP GROUP PHAS ON CL; *EUR MED AG, CHMP POS PAP NONC SA; European Medicines Agency, GUID STRAT ID MIT RI; Schiehlen W, 2007, MULTIBODY SYST DYN, V18, P3, DOI 10.1007/s11044-007-9064-4; Schneider CK, 2006, NAT BIOTECHNOL, V24, P493, DOI 10.1038/nbt0506-493; Tang L, 2004, J PHARM SCI-US, V93, P2184, DOI 10.1002/jps.20125; *US FDA, GUID IND REV EST SAF	7	28	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					890	892		10.1016/j.jaci.2008.07.049	http://dx.doi.org/10.1016/j.jaci.2008.07.049			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18805577	Bronze			2022-12-18	WOS:000260940100004
J	Zavalkoff, S; Kagan, R; Joseph, L; St-Pierre, Y; Clarke, A				Zavalkoff, Samara; Kagan, Rhoda; Joseph, Lawrence; St-Pierre, Yvan; Clarke, Ann			The value of sesame-specific IgE levels in predicting sesame allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY; CHILDREN		[Zavalkoff, Samara] McGill Univ, Div Pediat, Montreal, PQ, Canada; [Kagan, Rhoda] McGill Univ, Div Pediat Allergy & Clin Immunol, Montreal, PQ, Canada; [St-Pierre, Yvan; Clarke, Ann] McGill Univ, Div Clin Epidemiol, Montreal, PQ, Canada; [Clarke, Ann] McGill Univ, McGill Univ Hlth Ctr, Div Clin Immunol & Allergy, Montreal, PQ, Canada; [Joseph, Lawrence] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Zavalkoff, S (corresponding author), McGill Univ, Div Pediat, Montreal, PQ, Canada.	ann.clarke@mcgill.ca						Cohen A, 2007, PEDIAT ALLERG IMM-UK, V18, P217, DOI 10.1111/j.1399-3038.2006.00506.x; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Gangur V, 2005, ANN ALLERG ASTHMA IM, V95, P4, DOI 10.1016/S1081-1206(10)61181-7; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Ho MHK, 2006, J ALLERGY CLIN IMMUN, V117, P1506, DOI 10.1016/j.jaci.2006.03.029; Leduc V, 2006, ALLERGY, V61, P349, DOI 10.1111/j.1398-9995.2006.01013.x; Pucar F, 2001, CLIN EXP ALLERGY, V31, P40, DOI 10.1046/j.1365-2222.2001.00962.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708	9	28	28	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1508	1510		10.1016/j.jaci.2008.04.012	http://dx.doi.org/10.1016/j.jaci.2008.04.012			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18539199				2022-12-18	WOS:000256771700031
J	Leb, VM; Jahn-Schmid, B; Schmetterer, KG; Kueng, HJ; Haiderer, D; Neunkirchner, A; Fischer, GF; Nissler, K; Harti, A; Thalhamer, J; Bohle, B; Seed, B; Pickl, WF				Leb, Victoria M.; Jahn-Schmid, Beatrice; Schmetterer, Klaus G.; Kueng, Hans J.; Haiderer, Daniela; Neunkirchner, Alina; Fischer, Gottfried F.; Nissler, Karl; Harti, Arnulf; Thalhamer, Josef; Bohle, Barbara; Seed, Brian; Pickl, Winfried F.			Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type I allergy; mugwort pollinosis; Art v 1; human T-cell receptor T-cell receptor transgenic T cells; artificial antigen-presenting cell	MUGWORT POLLEN ALLERGEN; ALTERED PEPTIDE LIGAND; CELL RECOGNITION; TRANSGENIC MICE; EPITOPE; INDUCTION; ART-V-1; BETA; SPECIFICITY; MECHANISMS	Background: Ninety-five percent of patients with mugwort allergy are sensitized to Art v 1, the sole major allergen in mugwort (Artemisia vulgaris) pollen. Sixty-nine percent of patients recognizing the single inummodominant T-cell epitope Art v 1(25-36) have an HLA-DRB1*01 phenotype. Objective: We studied cloning and functional expression of a human alpha beta T-cell receptor (TCR) specific for Art v 1(25-36). Methods: TCR chains were RT-PCR amplified from an Art v 1(25-36)-Specific T-cell clone, retrovirally transferred, and functionally tested in Jurkat T cells or alternatively in peripheral blood T lymphocytes of nonallergic individuals. Results: The et-chain of the TCR is composed of TRAV17 and TRAJ45 segments, and the beta-chain uses TRBV18, TRBD1, and TRBJ2-7. Analyses of 23 other Art v 1-specific T-cell clones did not reveal preferential usage of the TRAV17, TRBV18, or other TCR gene families. Efficient TCR transfer into Jurkat T cells was shown by binding of TCR V beta 18-specific mAb and DRB1*0101/Art v 1 tetramers. Transgenic Jurkat T cells specifically recognized syngeneic EBV B cells pulsed with Art v 1(25-36) peptide and artificial antigen-presenting cells expressing invariant chain::Art v 1 fusion proteins. Moreover, transfer of the TCR into peripheral blood lymphocytes generated T cells that were Art v 1 reactive. Activation of transgenic T cells by artificial antigen-presenting cells was strictly dependent on costimulation. Conclusion: For the first time, a detailed molecular and functional analysis of a human allergen-specific TCR is presented.	[Leb, Victoria M.; Jahn-Schmid, Beatrice; Schmetterer, Klaus G.; Kueng, Hans J.; Haiderer, Daniela; Neunkirchner, Alina; Bohle, Barbara; Pickl, Winfried F.] Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Inst Immunol, A-1090 Vienna, Austria	Medical University of Vienna	Pickl, WF (corresponding author), Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Inst Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.	winfried.pickl@meduniwien.ac.at	Pickl, Winfried F/E-5682-2011; Thalhamer, Josef/E-5787-2011	Thalhamer, Josef/0000-0003-2285-6400; Reichl, Victoria/0000-0001-7546-3438; Hartl, Arnulf/0000-0001-9626-6425; Pickl, Winfried F./0000-0003-0430-4952; Schmetterer, Klaus/0000-0001-9328-4871; Bohle, Barbara/0000-0002-5105-7985	Austrian Science Fund FWF [P 20011] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Baniyash M, 2004, NAT REV IMMUNOL, V4, P675, DOI 10.1038/nri1434; Bauer R, 2003, ALLERGY, V58, P1003, DOI 10.1034/j.1398-9995.2003.00170.x; Beyer K, 1999, J IMMUNOL, V162, P1186; Bohle B, 2006, CLIN REV ALLERG IMMU, V30, P97, DOI 10.1385/CRIAI:30:2:97; Bohle B, 2004, J IMMUNOL, V172, P6642, DOI 10.4049/jimmunol.172.11.6642; BREITENEDER H, 1995, IMMUNOGENETICS, V42, P53, DOI 10.1007/BF00164987; Clay TM, 1999, J IMMUNOL, V163, P507; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; Derdak SV, 2006, P NATL ACAD SCI USA, V103, P13144, DOI 10.1073/pnas.0602283103; Gafvelin G, 2007, J BIOL CHEM, V282, P3778, DOI 10.1074/jbc.M607938200; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; Han BY, 2005, NAT MED, V11, P645, DOI 10.1038/nm1250; Hayes SM, 2003, IMMUNOL REV, V191, P28, DOI 10.1034/j.1600-065X.2003.00011.x; Heemskerk MHM, 2004, J EXP MED, V199, P885, DOI 10.1084/jem.20031110; Himly M, 2002, FASEB J, V16, P106, DOI 10.1096/fj.02-0472fje; HSU BL, 1995, J EXP MED, V181, P805, DOI 10.1084/jem.181.2.805; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; Kinnunen T, 2007, J ALLERGY CLIN IMMUN, V119, P965, DOI 10.1016/j.jaci.2007.01.011; Kircher MF, 2002, J ALLERGY CLIN IMMUN, V109, P517, DOI 10.1067/mai.2002.121945; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lefranc MP, 2005, NUCLEIC ACIDS RES, V33, pD593, DOI 10.1093/nar/gki065; Metz-Favre C, 2007, J ALLERGY CLIN IMMUN, V120, P315, DOI 10.1016/j.jaci.2007.03.046; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Nissler K, 1998, BIOL CHEM, V379, P219, DOI 10.1515/bchm.1998.379.2.219; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; vanBergen J, 1997, P NATL ACAD SCI USA, V94, P7499, DOI 10.1073/pnas.94.14.7499; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; Wang JH, 2002, MOL IMMUNOL, V38, P1039, DOI 10.1016/S0161-5890(02)00033-0; WEDDERBURN LR, 1993, P NATL ACAD SCI USA, V90, P8214, DOI 10.1073/pnas.90.17.8214; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	43	28	29	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					64	71		10.1016/j.jaci.2007.10.006	http://dx.doi.org/10.1016/j.jaci.2007.10.006			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18037161				2022-12-18	WOS:000252372000010
J	Jarjour, NN; Wilson, SJ; Koenig, SM; Laviolette, M; Moore, WC; Davis, WB; Doherty, DE; Hamid, Q; Israel, E; Kavuru, MS; Ramsdell, JW; Tashkin, DP; Reilly, DS; Yancey, SW; Edwards, LD; Stauffer, JL; Dorinsky, PM; Djukanovic, R				Jarjour, Nizar N.; Wilson, Susan J.; Koenig, Steven M.; Laviolette, Michel; Moore, Wendy C.; Davis, W. Bruce; Doherty, Dennis E.; Hamid, Qutayba; Israel, Elliott; Kavuru, Mani S.; Ramsdell, Joe W.; Tashkin, Donald P.; Reilly, Donna S.; Yancey, Steven W.; Edwards, Lisa D.; Stauffer, John L.; Dorinsky, Paul M.; Djukanovic, Ratko			Control of airway inflammation maintained at a lower steroid dose with 100/50 mu g of fluticasone propionate/saimeterol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	100th International Conference of the American-Thoracic-Society	MAY 21-26, 2004	Orlando, FL	Amer Thorac Soc		fluticasone propionate; salmeterol; biopsy; bronchoalveolar lavage; eosinophils	INHALED CORTICOSTEROIDS; PERSISTENT ASTHMA; SALMETEROL; GLUCOCORTICOIDS; HYPERRESPONSIVENESS; EOSINOPHILS; BUDESONIDE; PROPIONATE; RECEPTOR; AGONISTS	Background: Inhaled corticosteroids (ICSs) have been shown to reverse epithelial damage and decrease lamina reticularis thickness in patients with asthma. Objective: This study investigated whether clinical asthma control and airway inflammation could be maintained after switching therapy from medium-dose fluticasone propionate (FP) to low-dose FP administered with the long-acting beta(2)-agonist (LABA) salmeterol. Methods: Eighty-eight subjects (age, >= 18 years) who, during open-label screening, demonstrated improved asthma control after an increase from 100 mu g of FP twice daily to 250 mu g of FP twice daily were randomized to receive 100150 mu g of FP/salmeterol through.a Diskus inhaler (GlaxoSmithKline, Research Triangle Park, NC) twice daily or continue 250 mu g of FP twice daily through a Diskus inhaler for 24 weeks. Clinical outcomes were monitored, and bronchial biopsy specimens and bronchoalveolar lavage fluid were obtained before and after 24 weeks of treatment. Results: There were no significant differences between treatments with respect to eosinophils in the bronchial mucosa and bronchoalveolar lavage fluid; mucosal mast cells, neutrophils, or CD3(+), CD4(+), CD8(+), or CD25(+) T lymphocytes; or concentration of mediators (GM-CSF, IL-8, and eosinophil cationic protein). The 2 treatments were not different with respect to lamina reticularis thickness. Consistent with the airway inflammatory measures, clinical and physiologic measures of asthma control were also similar. Conclusion: This study demonstrates that control of asthma and airway inflammation is maintained over the 24-week treatment period when patients requiring a medium-dose ICS are switched to a lower-dose ICS with a LABA. Clinical implications: A lower-dose ICS with a LABA is effective in controlling inflammation and providing clinical asthma control, confirming current guideline recommendations.	Univ Wisconsin, Sch Med, Pulm & Crit Care Med Sect, Madison, WI 53706 USA; Univ Southampton, Southampton SO9 5NH, Hants, England; Univ Virginia, Div Pulm Med & Crit Care, Charlottesville, VA 22903 USA; Laval Hosp & Univ, Montreal, PQ, Canada; Wake Forest Univ, Sch Med, Div Pulm & Crit Care Med, Winston Salem, NC 27109 USA; Med Coll Georgia, Augusta, GA 30912 USA; Univ Kentucky, Lexington, KY 40506 USA; McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 2T5, Canada; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Calif San Diego, Clin Trials Ctr, San Diego, CA 92103 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; GlaxoSmithKline, Resp Med Dev Ctr, Res Triangle Pk, NC USA	University of Wisconsin System; University of Wisconsin Madison; University of Southampton; University of Virginia; Wake Forest University; University System of Georgia; Augusta University; University of Kentucky; McGill University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cleveland Clinic Foundation; University of California System; University of California San Diego; University of California System; University of California Los Angeles; GlaxoSmithKline	Djukanovic, R (corresponding author), Southampton Gen Hosp, Tremona Rd, Southampton SO16 6YD, Hants, England.	r.djuka-novic@soton.ac.uk		Djukanovic, Ratko/0000-0001-6039-5612; Edwards, Lisa/0000-0002-4867-2151				Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Baraniuk JN, 1997, AM J RESP CRIT CARE, V155, P704, DOI 10.1164/ajrccm.155.2.9032216; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Busse W, 2003, J ALLERGY CLIN IMMUN, V111, P57, DOI 10.1067/mai.2003.38; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Efron B., 1994, MONOGR STAT APPL PRO, DOI DOI 10.1007/978-1-4899-4541-9; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; Johnson M., 2002, CURR ALLERGY CLIN IM, V15, P16; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Kraft M, 2003, CHEST, V124, P42, DOI 10.1378/chest.124.1.42; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Louis R, 2000, AM J RESP CRIT CARE, V161, P9, DOI 10.1164/ajrccm.161.1.9802048; MANTEL N, 1959, J NATL CANCER I, V22, P719; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Nelson HS, 2003, J ALLERGY CLIN IMMUN, V112, P29, DOI 10.1067/mai.2003.1558; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; THOMPSON AB, 1998, AM REV RESPIR DIS, V140, P1524; Umland SP, 2002, PULM PHARMACOL THER, V15, P35, DOI 10.1006/pupt.2001.0312; Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; 1990, AM REV RESP DIS S, V141, pS169	34	28	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					44	52		10.1016/j.jaci.2006.03.043	http://dx.doi.org/10.1016/j.jaci.2006.03.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	065UH	16815137				2022-12-18	WOS:000239184800005
J	Faith, A; McDonald, J; Peek, E; Richards, D; Caulfield, J; Chevretton, E; Roberts, D; Lee, T; Corrigan, C; Hawrylowicz, C				Faith, A; McDonald, J; Peek, E; Richards, D; Caulfield, J; Chevretton, E; Roberts, D; Lee, T; Corrigan, C; Hawrylowicz, C			Functional plasticity of human respiratory tract dendritic cells: GM-CSF enhances T(H)2 development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human respiratory tract; dendritic cells; GM-CSF; T(H)1/T(H)2	T-HELPER-CELL; ANTIGEN; IMMUNE; RECRUITMENT; HOMEOSTASIS; INDUCTION; RESPONSES; CAPACITY; SUBSETS; MUCOSA	Background: Dendritic cells within the human respiratory mucosa (RTDCs) are proposed to initiate immune responses to foreign antigens. Their capacity to polarize T-cell responses, however, has not been investigated. Objective: To compare RTDCs with peripheral blood dendritic cells (PBDCs) with regard to phenotype, cytokine production, capacity to polarize T-cell responses, and effects of exposure to the pleiotropic cytokine, GM-CSE. Methods: CD1a(+) RTDCs and CD1c(+) PBDCs were purified from nasal turbinates of patients with nonatopic rhinitis and peripheral blood of healthy individuals, respectively. In some experiments, matched CD1c(+) RTDCs and PBDCs from patients with rhinitis were compared. The phenotype of DC was examined by flow cytometry and cytokine production by cytometric bead array. DCs were cocultured with allogeneic naive CD4(+) T cells, and cytokine production was determined by immunophenotyping, cytometric bead array, and ELISA. Results: Both RTDCs and PBDCs exhibited an immature phenotype, but RTDCs expressed lower levels of MHC class II antigen. Cross-linking of CD40 on PBDCs, but not RTDCs, induced production of IL-12p70. In mixed lymphocyte cultures, RTDCs induced a T(H)1/T(H)2 profile, whereas PBDCs induced a T(H)1 profile. Exposure of RTDCs to GM-CSF induced a T(H)2 pattern of response in the mixed lymphocyte cultures. In contrast, exposure of PBDCs to GM-CSF promoted a T(H)1 response. Conclusion: This report emphasizes the importance of studying tissue-derived primary DCs, demonstrates functional plasticity of RTDCs, and implicates GM-CSF in amplifying the potential of RTDCs to initiate T(H)2 responses in the airways.	Guys Kings & St Thomas Sch Med, Dept Asthma Allergy & Resp Sci, London, England; Guys Kings & St Thomas Sch Med, Dept Ear Nose & Throat, London, England	University of London; King's College London; University of London; King's College London	Faith, A (corresponding author), Guys Hosp, Dept Asthma Allergy & Resp Sci, 5th Floor Thomas Guy House, London SE1 9RT, England.	alex.faith@kcl.ac.uk	Lee, Tak/AAA-9526-2020; Hawrylowicz, Catherine/Q-8483-2017	Lee, Tak/0000-0002-7554-4059; Hawrylowicz, Catherine/0000-0002-2337-7463; Corrigan, Chris/0000-0002-0706-6534				Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Carballido JM, 1997, EUR J IMMUNOL, V27, P515, DOI 10.1002/eji.1830270224; Cates EC, 2003, J ALLERGY CLIN IMMUN, V111, P1076, DOI 10.1067/mai.2003.1460; CELLA M, 2001, NAT IMMUNOL, V5, P919; Chevretton EB, 2003, J LARYNGOL OTOL, V117, P866, DOI 10.1258/002221503322542863; Cochand L, 1999, AM J RESP CELL MOL, V21, P547, DOI 10.1165/ajrcmb.21.5.3785; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JCI200216109; FOKKENS WJ, 1989, ALLERGY, V44, P167, DOI 10.1111/j.1398-9995.1989.tb02257.x; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Goddard S, 2004, AM J PATHOL, V164, P511, DOI 10.1016/S0002-9440(10)63141-0; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Ito T, 1999, J IMMUNOL, V163, P1409; Jahnsen FL, 2000, J IMMUNOL, V165, P4062, DOI 10.4049/jimmunol.165.7.4062; Jahnsen FL, 2004, AM J RESP CELL MOL, V30, P31, DOI 10.1165/rcmb.2002-0230OC; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kohrgruber N, 1999, J IMMUNOL, V163, P3250; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557, DOI 10.1164/ajrccm/147.6_Pt_1.1557; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Tada Y, 2001, EUR J IMMUNOL, V31, P294; Till SJ, 2001, ALLERGY, V56, P126, DOI 10.1034/j.1398-9995.2001.056002126.x; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; vanHaarst JMW, 1996, AM J RESP CELL MOL, V15, P752, DOI 10.1165/ajrcmb.15.6.8969270; VANHAARST JMW, 1994, AM J RESP CELL MOL, V10, P487, DOI 10.1165/ajrcmb.10.5.8179911; Vasu C, 2003, J IMMUNOL, V170, P5511, DOI 10.4049/jimmunol.170.11.5511; Vieira PL, 2000, J IMMUNOL, V164, P4507, DOI 10.4049/jimmunol.164.9.4507	31	28	32	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1136	1143		10.1016/j.jaci.2005.08.002	http://dx.doi.org/10.1016/j.jaci.2005.08.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275388				2022-12-18	WOS:000235686700029
J	Koopmans, JG; Lutter, R; Jansen, HM; van der Zee, JS				Koopmans, JG; Lutter, R; Jansen, HM; van der Zee, JS			Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inflammation; sputum; bronchodilator agents; anti-inflammatory agents	LATE ASTHMATIC RESPONSE; MEDIATOR RELEASE; BRONCHOALVEOLAR LAVAGE; AIRWAY INFLAMMATION; IN-VITRO; IGE; INTERLEUKIN-5; FLUTICASONE; INHIBITION; ACTIVATION	Background: Adding a long-acting beta(2)-agonist to inhaled corticosteroids results in better symptomatic asthma control than increasing the dose of inhaled corticosteroids. Objective: Investigating whether adding the long-acting beta(2)-agonist salmeterol to the inhaled corticosteroid fluticasone propionate has an effect on allergen-induced allergic inflammation in asthma. Methods: Bronchial allergen challenges were performed in 26 patients with allergic asthma, pretreating them with a single dose of either fluticasone/salmeterol (100/50 mu g) or fluticasone alone (100 mu g), in a double-blind, randomized, cross-over design. Sputum and serum markers of bronchial inflammation were measured after allergen challenge, as well as lung function parameters. Primary outcomes were sputum eosinophil numbers and eosinophil cationic protein. Results: Asthmatic responses after allergen challenge were significantly reduced after pretreatment with fluticasone/salmeterol relative to fluticasone alone. Sputum inflammatory markers after allergen challenge were not significantly affected by fluticasone/salmeterol pretreatment. By contrast, serum IL-5 was significantly reduced (geometric mean serum IL-5 [SEM]: 0.5 [0.3] vs 1.1 [0.3.1 pg/mL 1 hour and 0.6 [0.31 vs 1.1 [0.3] pg/mL 6 hours after challenge with fluticasone/salmeterol vs fluticasone alone pretreatment, respectively; P values <.05). Also, peripheral blood eosinophils were significantly reduced (geometric mean number X 10(6)/L [SEM]: 172 [0.1] vs 237 [0.1] at 6 hours and 271 [0.1] vs 351 [0.1] at 24 hours with fluticasone/salmeterol vs fluticasone alone pretreatment, respectively; P <.05). Conclusion: Adding salmeterol to fluticasone reduces allergen-induced serum IL-5 and peripheral blood eosinophils. This phenomenon may contribute to the improved clinical outcomes that result from adding a long-acting beta(2)-agonist to inhaled corticosteroids.	Univ Amsterdam, Dept Pulmonol, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Expt Immunol Lab, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van der Zee, JS (corresponding author), Univ Amsterdam, Dept Pulmonol, Acad Med Ctr, F4-208,POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.s.vanderzee@amc.uva.nl	van der Zee, Jaring S/M-8462-2013; van der Zee, Jaring/AAQ-6669-2021; van der Zee, Jaring/HGU-9235-2022	van der Zee, Jaring S/0000-0002-8698-6039; 				Babu K Suresh, 2003, Paediatr Respir Rev, V4, P40; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bissonnette EY, 1997, J ALLERGY CLIN IMMUN, V100, P825, DOI 10.1016/S0091-6749(97)70280-X; BRADDING P, 1995, J IMMUNOL, V155, P297; Bresser P, 2000, AM J RESP CRIT CARE, V162, P947, DOI 10.1164/ajrccm.162.3.9908103; BUTCHERS PR, 1991, BRIT J PHARMACOL, V104, P672, DOI 10.1111/j.1476-5381.1991.tb12487.x; Currie GP, 2003, ALLERGY, V58, P602, DOI 10.1034/j.1398-9995.2003.00188.x; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470, DOI 10.1164/ajrccm.163.6.9901105; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; *GINA, 2002, NIH PUBL; GRONNEBERG R, 1986, ALLERGY, V41, P71, DOI 10.1111/j.1398-9995.1986.tb00278.x; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V120, P8, DOI 10.1159/000024215; Hamelmann E, 1997, AM J RESP CELL MOL, V16, P674, DOI 10.1165/ajrcmb.16.6.9191469; Jarjour NN, 1997, AM J RESP CRIT CARE, V155, P1515, DOI 10.1164/ajrccm.155.5.9154851; Krouwels FH, 1997, J IMMUNOL METHODS, V203, P89, DOI 10.1016/S0022-1759(97)00016-1; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; MCNAMEE LA, 1991, J IMMUNOL METHODS, V141, P81, DOI 10.1016/0022-1759(91)90212-X; Nocker RET, 1999, AM J RESP CRIT CARE, V159, P1499, DOI 10.1164/ajrccm.159.5.9806116; Nocker RET, 2000, J LAB CLIN MED, V136, P39, DOI 10.1067/mlc.2000.107305; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; OKAYAMA Y, 1995, J IMMUNOL, V155, P1796; Pace E, 2004, J ALLERGY CLIN IMMUN, V114, P1216, DOI 10.1016/j.jaci.2004.07.052; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; REIMERT CM, 1991, J IMMUNOL METHODS, V138, P285, DOI 10.1016/0022-1759(91)90177-H; Roumestan C, 2002, J ALLERGY CLIN IMMUN, V109, pS240, DOI 10.1016/S0091-6749(02)81866-8; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Taylor DR, 2000, THORAX, V55, P595, DOI 10.1136/thorax.55.7.595; Van der Veen MJ, 1999, CLIN EXP ALLERGY, V29, P217; Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518; WEERSINK EJM, 1994, AM J RESP CRIT CARE, V150, P1262, DOI 10.1164/ajrccm.150.5.7952550; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6	37	28	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1007	1013		10.1016/j.jaci.2005.08.016	http://dx.doi.org/10.1016/j.jaci.2005.08.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275368				2022-12-18	WOS:000235686700009
J	Martyny, JW; Harbeck, RJ; Barker, EA; Sills, M; Silveira, L; Arbuckle, S; Newman, L				Martyny, JW; Harbeck, RJ; Barker, EA; Sills, M; Silveira, L; Arbuckle, S; Newman, L			Aerosolized sodium hypochlorite inhibits viability and allergenicity of mold on building materials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mold; bleach; Tilex; Aspergillus fumigatus; allergy; skin testing; building materials	DISINFECTANTS; FACILITIES; PROTEINS; BLEACH	Background: Commercial and residential buildings can become contaminated with molds, which may trigger allergic disorders. Mold remediation efforts may require costly replacement of mold-contaminated building materials. Disinfectants that contain dilute sodium hypochlorite can kill mold and are practical to use. Whether they also inhibit mold allergy symptoms is unknown. Objective: We tested the hypothesis that sodium hypochlorite-containing spray products kill Aspergillus fumigatus and inhibit A fumigatus allergens. Methods: A fumigatus was grown on 3 common building construction materials, as well as in solution by conventional laboratory methods. Two sodium hypochlorite-containing household products (diluted bleach and Tilex) were sprayed on the mold-contaminated materials or added to mold in solution and compared with untreated controls. Surface mold and associated debris were mechanically removed from treated and untreated boards. Conidia in the extracted board materials were quantified by light microscopy, examined for morphologic changes by scanning electron microscopy, and cultured for viable mold. Extracts were tested for A fumigatus antigen by ELISA, and for A fumigatus allergen by skin prick testing using extracts prepared from both the boards and the cultured solutions. Results: Both sodium hypochlorite disinfectants killed A fumigatus in solution and on mold-contaminated building materials. Light microscopy and scanning electron microscopy demonstrated changes to the conidial surface. Both dilute bleach and Tilex inhibited A fumigatus recognition by ELISA. Skin testing supported the results of the ELISAs and demonstrated loss of skin test reactivity to the sodium hypochlorite-treated mold solutions in most of the subjects. Of the 4 individuals who had a positive skin test result to mold grown on oriented strand board building material, 3 no longer reacted to extracts from bleach-treated boards. Conclusion: Spray application of sodium hypochlorite-containing disinfectants onto mold-contaminated building material kills A fumigatus, modifies the surface characteristics of A fumigatus conidia, reduces recognition of A fumigatus mold by ELISA, and results in loss of skin test reactivity to the treated mold in individuals allergic to A fumigatus.	Natl Jewish Ctr Immunol & Resp Med, Denver, CO 80206 USA	National Jewish Health	Martyny, JW (corresponding author), Natl Jewish Ctr Immunol & Resp Med, 1400 Jackson St, Denver, CO 80206 USA.	martynyj@njc.org						Allen MJ, 1999, INFECT IMMUN, V67, P4563, DOI 10.1128/IAI.67.9.4563-4569.1999; BEST M, 1990, APPL ENVIRON MICROB, V56, P377, DOI 10.1128/AEM.56.2.377-380.1990; BEST M, 1990, J CLIN MICROBIOL, V28, P2234, DOI 10.1128/JCM.28.10.2234-2239.1990; BLOOMFIELD SF, 1985, J HOSP INFECT, V6, P20, DOI 10.1016/S0195-6701(85)80014-1; BLOOMFIELD SF, 1989, J HOSP INFECT, V13, P231, DOI 10.1016/0195-6701(89)90003-0; *BUR ENV OCC DIS, 2003, EP GUID ASS REM FUNG; *CAL DEF HLTH SERV, 2004, IND AIR QUAL INF SHE; Chen P, 2001, CLIN EXP ALLERGY, V31, P1086, DOI 10.1046/j.1365-2222.2001.01127.x; DWYER RM, 1995, REV SCI TECH OIE, V14, P403, DOI 10.20506/rst.14.2.846; Federal-Provincial Committee on Environmental and Occupational Health (Canada), 1995, FUNG CONT PUBL BUILD; Matsui E, 2003, J ALLERGY CLIN IMMUN, V111, P396, DOI 10.1067/mai.2003.11; *MINN DEP HLTH IND, 2003, MOLD HOM; *OFF RAD IND ENV, 2001, PUBL EPA, P48; PERIERA WE, 1973, BIOCHIM BIOPHYS ACTA, V313, P170; Rutala WA, 1997, CLIN MICROBIOL REV, V10, P597, DOI 10.1128/CMR.10.4.597; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Willeke K., 1999, BIOAER ASS CONTR	17	28	31	1	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					630	635		10.1016/j.jaci.2005.05.008	http://dx.doi.org/10.1016/j.jaci.2005.05.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159635	Bronze			2022-12-18	WOS:000235686500025
J	Silkoff, PE; Zhang, LN; Dutton, S; Langmack, EL; Vedal, S; Murphy, J; Make, B				Silkoff, PE; Zhang, LN; Dutton, S; Langmack, EL; Vedal, S; Murphy, J; Make, B			Winter air pollution and disease parameters in advanced chronic obstructive pulmonary disease panels residing in Denver, Colorado	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						air pollution; chronic obstructive pulmonary disease; monitoring; spirometry	HOSPITAL ADMISSIONS; MORTALITY; INFLAMMATION; EMPHYSEMA	Background: Ambient pollution might worsen chronic obstructive pulmonary disease (COPD). Objective: We explored the associations of pollution to pulmonary function, rescue medication, and symptoms over 2 winters in 2 panels of subjects with advanced COPD in Denver, Colorado. Methods: Subjects measured lung function and recorded symptoms and rescue medications. Daily ambient pollution concentrations for particulate matter (PM10 and PM2.5), carbon monoxide (CO), and nitrogen dioxide (NO2) were obtained for Denver. Estimated effects of pollution on outcomes were derived for the same day and I and 2 days after pollution measurements (lags 0, 1, and 2, respectively). Results: Sixteen (mean age, 65.8 years; mean FEV1, 42.3% of predicted value) and 18 (mean age, 67.4 years; mean FEV1, 39.4% of predicted value) subjects participated in the first and second winters, respectively. There were no differences in demographic or disease characteristics between the 2 panels. In the first winter no detrimental associations were found. In the second winter, however, there were significant detrimental associations of CO in the morning and PM10, CO, and NO2 in the evening, increasing medication use at lag 0. Total symptom score increased at lag 0 with NO2. The concentrations of particulates were increased in the second winter compared with in the first winter, and this winter was colder and more humid. Conclusions: In the second winter, subjects with severe COPD had worse lung function at lags 0 and I and increased rescue medication at lag 0 with increases in ambient air pollution. The effects of pollution varied between the 2 winters, perhaps related to levels of pollution and weather patterns. Significant effects were seen despite ambient pollution levels that conformed to US Environmental Protection Agency standards.	Natl Jewish Ctr Immunol & Resp Med, Dept Med, Denver, CO 80206 USA; Univ Colorado, Ctr Hlth Sci, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Silkoff, PE (corresponding author), 224 Spruce Tree Rd, Radnor, PA 19087 USA.	philsilkoff@hotmail.com	Dutton, Steven J/C-5912-2011; silkoff, philip/S-9037-2016	silkoff, philip/0000-0001-6018-5199; Langmack, Esther/0000-0003-4991-7808				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; ANDERSON HR, 1995, THORAX, V50, P1188, DOI 10.1136/thx.50.11.1188; Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477, DOI 10.1164/ajrccm.153.2.8564086; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; Brauer M, 2001, J EXPO ANAL ENV EPID, V11, P490, DOI 10.1038/sj.jea.7500195; Brown JS, 2002, AM J RESP CRIT CARE, V166, P1240, DOI 10.1164/rccm.200205-399OC; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588; GHIO AJ, 1990, CHEST, V97, P400, DOI 10.1378/chest.97.2.400; Harre ESM, 1997, THORAX, V52, P1040, DOI 10.1136/thx.52.12.1040; Harrison DJ, 1997, HUM EXP TOXICOL, V16, P356, DOI 10.1177/096032719701600703; Jones PW, 2003, EUR RESPIR J, V21, p13S, DOI 10.1183/09031936.03.00077803; Koskela HO, 1996, CHEST, V110, P632, DOI 10.1378/chest.110.3.632; LENFANT C, 2001, GLOBAL INITIATIVE CH; Martin RJ, 1999, J ALLERGY CLIN IMMUN, V103, P535, DOI 10.1016/S0091-6749(99)70484-7; MOORE LG, 1982, AM REV RESPIR DIS, V126, P225; Pope CA, 1996, TOXICOLOGY, V111, P149, DOI 10.1016/0300-483X(96)03372-0; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; Sin DD, 2004, AM J RESP CRIT CARE, V170, P760, DOI 10.1164/rccm.200404-543OC; Sunyer J, 2002, THORAX, V57, P687, DOI 10.1136/thorax.57.8.687; Sunyer J, 2001, EUR RESPIR J, V17, P1024, DOI 10.1183/09031936.01.17510240; Tellez-Rojo MM, 2000, EUR RESPIR J, V16, P391, DOI 10.1034/j.1399-3003.2000.016003391.x; WINCHESTER JW, 1989, ARCH ENVIRON CON TOX, V18, P291, DOI 10.1007/BF01056216; Wong TW, 2002, OCCUP ENVIRON MED, V59, P30, DOI 10.1136/oem.59.1.30; Wordley J, 1997, OCCUP ENVIRON MED, V54, P108, DOI 10.1136/oem.54.2.108	27	28	28	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					337	344		10.1016/j.jaci.2004.11.035	http://dx.doi.org/10.1016/j.jaci.2004.11.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696092	Bronze			2022-12-18	WOS:000227043600021
J	Blanco, C; Sanchez-Garcia, F; Torres-Galvan, MJ; Dumpierrez, AG; Almeida, L; Figueroa, J; Ortega, N; Castillo, R; Gallego, MD; Carrillo, T				Blanco, C; Sanchez-Garcia, F; Torres-Galvan, MJ; Dumpierrez, AG; Almeida, L; Figueroa, J; Ortega, N; Castillo, R; Gallego, MD; Carrillo, T			Genetic basis of the latex-fruit syndrome: Association with HLA class II alleles in a Spanish population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; latex-fruit syndrome; hevein; HLA; microsatellite	HUMAN IMMUNE-RESPONSE; MAJOR ALLERGEN; HEVEA LATEX; ANTIGENS; LINKAGE; ASTHMA; ATOPY; CHITINASES; HAPLOTYPE; HLA-DRB1	Background: The latex-fruit syndrome is a well-defined disorder whose genetic background has not been elucidated. Objective: To study the genetic basis of the latex-fruit syndrome. Methods: In a case-control study, we have investigated a carefully selected group of patients allergic to latex, searching for association between latex-fruit allergy and HLA class I and 11 genes, HLA-DR functional groups, and markers IL4-R1 and FcepsilonRI-betaca. Results: Seventy-eight patients allergic to latex without spina bifida, 33% of them also allergic to fruits, were included in our protocol. Skin prick test results with both a commercial latex extract and purified hevein were significantly greater in patients allergic to latex and fruit than in patients allergic to latex and not fruit. A cutoff point of >7 turn for commercial latex skin prick test diagnosed latex-fruit allergy with a sensitivity of 66.7% (95% CI, 41.0-86.6) and a specificity of 83.3% (95% CI, 68.6-93.0) in our series of patients. No significant differences were found regarding HLA class 1, IL4-R1, or FcepsilonRI-betaca allele distributions. However, comparison of HLA class 11 allelic frequencies between patients allergic to latex and fruit and patients allergic to latex and not fruit showed significant associations of latex-fruit allergy with DQB1*0201 (corrected P value,.001; odds ratio, 7.3; 95% C1, 2.6-20.0), as well as with HLA-DR functional group E (corrected P value,.028; odds ratio, 16.0; 95% Cl, 1.9-134.1). When comparing allelic distribution among different subgroups of patients allergic to latex, additional significant associations of latex-fruit allergy with DRB1*0301 and *0901, and of latex and not fruit allergy with DQB1*0202, DRB1*0701 and *1101, were demonstrated. Conclusions: Latex-fruit allergy is associated with HLA-DQB1*0201, DRB1*0301, and *0901, as well as with HLA-DR functional group E, whereas latex-not-fruit allergy is associated with DQB1*0202, and with both DRB1*0701 and *1101 alleles.	Hosp Gran Canaria Dr Negrin, Serv Alergia, Las Palmas Gran Canaria 35012, Spain; Hosp Gran Canaria Dr Negrin, Serv Inmunol, Las Palmas Gran Canaria 35012, Spain; Hosp Gran Canaria Dr Negrin, Unidad Invest, Las Palmas Gran Canaria 35012, Spain		Castillo, R (corresponding author), Hosp Gran Canaria Dr Negrin, Serv Alergia, C Bco Ballena S-N, Las Palmas Gran Canaria 35012, Spain.	cblague@gobiemodecanarias.org	Blanco, Carlos/B-3895-2012	Blanco, Carlos/0000-0002-2893-6594; Sanchez-Garcia, Florentino/0000-0003-0304-6023				Beezhold DH, 1997, CLIN EXP IMMUNOL, V108, P114, DOI 10.1046/j.1365-2249.1997.d01-983.x; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; Blanco C, 1999, J ALLERGY CLIN IMMUN, V103, P507, DOI 10.1016/S0091-6749(99)70478-1; Blanco C, 2003, CURR ALLERGY ASTHM R, V3, P47, DOI 10.1007/s11882-003-0012-y; BLANCO C, 1994, ANN ALLERGY, V73, P309; BLANCO C, 1994, ALLERGY, V49, P454, DOI 10.1111/j.1398-9995.1994.tb00839.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Borish L, 1999, ANN ALLERG ASTHMA IM, V82, P413, DOI 10.1016/S1081-1206(10)62715-9; BUYSE I, 1993, TISSUE ANTIGENS, V41, P1, DOI 10.1111/j.1399-0039.1993.tb01970.x; Candore Giuseppina, 2002, Autoimmunity Reviews, V1, P29, DOI 10.1016/S1568-9972(01)00004-0; Cardaba B, 2000, J ALLERGY CLIN IMMUN, V105, P292, DOI 10.1016/S0091-6749(00)90079-4; Charous BL, 2002, J ALLERGY CLIN IMMUN, V109, P31, DOI 10.1067/mai.2002.120953; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V99, P402, DOI 10.1016/S0091-6749(97)70059-9; D'Amato M, 1999, HUM IMMUNOL, V60, P1250, DOI 10.1016/S0198-8859(99)00112-3; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V112, P1002, DOI 10.1016/j.jaci.2003.07.006; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P448, DOI 10.1046/j.1365-2222.2002.01306.x; Drouet M, 1998, EUR J DERMATOL, V8, P330; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; Fleva A, 2001, EXP CLIN IMMUNOGENET, V18, P13, DOI 10.1159/000049083; Folster-Holst R, 1998, HUM GENET, V102, P236, DOI 10.1007/s004390050685; FREIDHOFF LR, 1988, TISSUE ANTIGENS, V31, P211, DOI 10.1111/j.1399-0039.1988.tb02083.x; Lara-Marquez ML, 1999, CLIN EXP ALLERGY, V29, P60, DOI 10.1046/j.1365-2222.1999.00461.x; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Marsh Steven G. E., 2002, Tissue Antigens, V59, P172; McDermott AB, 1997, TISSUE ANTIGENS, V50, P8, DOI 10.1111/j.1399-0039.1997.tb02827.x; Molnar-Gabor E, 2000, LARYNGOSCOPE, V110, P422, DOI 10.1097/00005537-200003000-00017; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; Ou DW, 1998, HUM IMMUNOL, V59, P665, DOI 10.1016/S0198-8859(98)00067-6; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; Rihs HP, 1997, TISSUE ANTIGENS, V49, P92, DOI 10.1111/j.1399-0039.1997.tb02719.x; Rihs HP, 1998, CLIN EXP ALLERGY, V28, P175; Rihs HP, 2002, J ALLERGY CLIN IMMUN, V110, P507, DOI 10.1067/mai.2002.127282; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; Torres-Galvan MJ, 2000, ALLERGY, V55, P398, DOI 10.1034/j.1398-9995.2000.00524.x	36	28	30	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1070	1076		10.1016/j.jaci.2004.06.022	http://dx.doi.org/10.1016/j.jaci.2004.06.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536412				2022-12-18	WOS:000225047800012
J	Wang, J; Sicherer, SH; Nowak-Wegrzyn, A				Wang, J; Sicherer, SH; Nowak-Wegrzyn, A			Primary care physicians' approach to food-induced anaphylaxis: A survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EPINEPHRINE ABSORPTION		Mt Sinai Sch Med, New York, NY USA	Icahn School of Medicine at Mount Sinai	Wang, J (corresponding author), Mt Sinai Sch Med, New York, NY USA.	anna.nowak-wegrzyn@mssm.edu		Nowak-Wegrzyn, Anna/0000-0002-0960-9854				[Anonymous], 1998, J ALLERGY CLIN IMMUN, V101, pS465; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Gompels LL, 2002, POSTGRAD MED J, V78, P416, DOI 10.1136/pmj.78.921.416; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sicherer Scott H., 2003, Journal of Allergy and Clinical Immunology, V111, pS829, DOI 10.1067/mai.2003.152; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3	9	28	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					689	691		10.1016/j.jaci.2004.05.024	http://dx.doi.org/10.1016/j.jaci.2004.05.024			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15446292				2022-12-18	WOS:000223799600034
J	Leung, TF; Tang, NLS; Li, CY; Lam, CWK; Wong, GWK; Fok, TF				Leung, TF; Tang, NLS; Li, CY; Lam, CWK; Wong, GWK; Fok, TF			Association between TARC C-431T and atopy and asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ACTIVATION-REGULATED CHEMOKINE; THYMUS; GENE		Prince Wales Hosp, Dept Pediat, Shatin, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital	Leung, TF (corresponding author), Prince Wales Hosp, Dept Pediat, 6-F Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.	leung2142@cuhk.edu.hk	LEUNG, Ting Fan/E-7728-2013; Wong, Gary WK/AAY-9207-2020; Tang, Nelson L/P-5018-2017	LEUNG, Ting Fan/0000-0002-6469-1926; Wong, Gary WK/0000-0001-5939-812X; Tang, Nelson L/0000-0002-3607-5819				Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Leung TF, 2003, EUR RESPIR J, V21, P616, DOI 10.1183/09031936.03.00083303; Leung TF, 2002, J ALLERGY CLIN IMMUN, V110, P404, DOI 10.1067/mai.2002.126378; Leung TF, 2001, CLIN EXP ALLERGY, V31, P1515, DOI 10.1046/j.1365-2222.2001.01212.x; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Sekiya T, 2003, IMMUNOGENETICS, V54, P742, DOI 10.1007/s00251-002-0520-2; Wong GWK, 2001, CLIN EXP ALLERGY, V31, P1225, DOI 10.1046/j.1365-2222.2001.01140.x	10	28	29	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					199	202		10.1016/j.jaci.2004.03.048	http://dx.doi.org/10.1016/j.jaci.2004.03.048			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15282939				2022-12-18	WOS:000222534300032
J	Kurz, T; Strauch, K; Dietrich, H; Braun, S; Hierl, S; Jerkic, SP; Wienker, TF; Deichmann, KA; Heinzmann, A				Kurz, T; Strauch, K; Dietrich, H; Braun, S; Hierl, S; Jerkic, SP; Wienker, TF; Deichmann, KA; Heinzmann, A			Multilocus haplotype analyses reveal association between 5 novel IL-15 polymorphisms and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; association; haplotype analysis; case control analysis; inflammatiom; T-H(1)/T-H(2)	CELL PROLIFERATION; INTERFERON-GAMMA; INTERLEUKIN 15; BETA-CHAIN; CYTOKINE; EXPRESSION; GENE; INDUCTION; SAMPLE	Background: IL-15 is a T(H)1-related cytokine that is involved in the inflammatory response in various infectious and autoimmune diseases. IL-15 has recently been shown to be upregulated in T-cell-mediated inflammatory disorders. The observations suggest a potential role for this cytokine in a variety of pathologic conditions, including T(H)1-mediated and T(H)2-mediated inflammatory diseases. Objective: In this study, we searched for single nucleotide polymorphisms in the whole IL-15 gene and investigated their association with inflammatory and/or atopic phenotypes. Methods: The screening for single nucleotide polymorphisms was performed by single-strand conformation polymorphism analysis. Genotyping of the identified polymorphisms was performed by restriction fragment length polymorphism. Genotypic association analysis used the Armitage trend test. Haplotype frequency estimation and subsequent testing for differences between cases and controls were performed by using the programs FASTEHPLUS and FAMHAP. Results: We identified 5 novel noncoding nucleotide sequence variants, all of which were typed in our asthmatic, our atopic, and our control population. According to the Armitage trend test, none of the 5 polymorphisms is associated with the phenotype bronchial asthma or atopy. However, multilocus haplotype analysis based on simulations to find out whether the haplotype frequencies differed between cases and controls by using the program FAMHAP yielded a P value of 6.1 x 10(-5) in the asthmatic versus the control population, which is highly significant. Furthermore, we obtained a nominally significant result of P = .0232 for the atopic versus the control population by using FAMHAP. Conclusion: These results strongly underscore previous findings that suggest a potential role of this cytokine in allergic diseases.	Univ Freiburg, Childrens Hosp, D-79106 Freiburg, Germany; Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-5300 Bonn, Germany	University of Freiburg; University of Bonn	Heinzmann, A (corresponding author), Univ Freiburg, Childrens Hosp, Mathildenstr 1, D-79106 Freiburg, Germany.	heinzmann@kikli.ukl.uni-freiburg.de						ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; Borger P, 1999, IMMUNOLOGY, V96, P207; Carson WE, 1997, J CLIN INVEST, V99, P937, DOI 10.1172/JCI119258; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; CLARK AG, 1990, MOL BIOL EVOL, V7, P111; Clark VJ, 2001, HUM GENET, V108, P484, DOI 10.1007/s004390100512; Corry DB, 1999, NATURE, V402, pB18; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; GALLI SJ, 1995, ALLERGY, V50, P851, DOI 10.1111/j.1398-9995.1995.tb02490.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HIORT O, 1994, HUM MOL GENET, V3, P1163, DOI 10.1093/hmg/3.7.1163; Hoontrakoon R, 2002, AM J RESP CELL MOL, V26, P404, DOI 10.1165/ajrcmb.26.4.4517; Kirman I, 1996, AM J GASTROENTEROL, V91, P1789; KLEINETEBBE J, 1992, CLIN EXP ALLERGY, V22, P475, DOI 10.1111/j.1365-2222.1992.tb00150.x; Kruse S, 1999, IMMUNOLOGY, V96, P365; Masuda A, 2000, J BIOL CHEM, V275, P29331, DOI 10.1074/jbc.M910290199; McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297-189; McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296-175; Mori A, 1996, J IMMUNOL, V156, P2400; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Sakai T, 1998, GASTROENTEROLOGY, V114, P1237, DOI 10.1016/S0016-5085(98)70430-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; Schork NJ, 1998, TRENDS GENET, V14, P266, DOI 10.1016/S0168-9525(98)01497-8; Schwab SG, 2003, AM J HUM GENET, V72, P185, DOI 10.1086/345463; Seder RA, 1996, J IMMUNOL, V156, P2413; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Tishkoff SA, 2000, AM J HUM GENET, V67, P518, DOI 10.1086/303000; Waldmann T, 1998, Int Rev Immunol, V16, P205, DOI 10.3109/08830189809042995; Zhao JH, 2002, HUM HERED, V53, P36, DOI 10.1159/000048602; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	37	28	31	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					896	901		10.1016/j.jaci.2004.03.004	http://dx.doi.org/10.1016/j.jaci.2004.03.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131572	Bronze			2022-12-18	WOS:000221269000012
J	Buckley, RH				Buckley, RH			A historical review of bone marrow transplantation for immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							STEM-CELL TRANSPLANTATION; CHRONIC GRANULOMATOUS-DISEASE; NUCLEOSIDE PHOSPHORYLASE-DEFICIENCY; CORD BLOOD TRANSPLANTATION; IN-UTERO TRANSPLANTATION; WISKOTT-ALDRICH-SYNDROME; CLASS-II DEFICIENCY; HYPER-IGM SYNDROME; IMMUNOLOGICAL RECONSTITUTION; EUROPEAN EXPERIENCE		Duke Univ, Sch Med, Dept Pediat, Durham, NC 27706 USA; Duke Univ, Sch Med, Dept Immunol, Durham, NC USA	Duke University; Duke University	Buckley, RH (corresponding author), Duke Univ, Sch Med, Dept Pediat, Durham, NC 27706 USA.		Buckley, Rebecca/AAB-1578-2019					AMOS DB, 1968, J EXP MED, V128, P623, DOI 10.1084/jem.128.4.623; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; BACH FH, 1968, LANCET, V2, P1364; Benkerrou M, 1997, EUR J IMMUNOL, V27, P2043, DOI 10.1002/eji.1830270831; BERTHET F, 1994, PEDIATRICS, V93, P265; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Bertrand Y, 2002, BONE MARROW TRANSPL, V29, P759, DOI 10.1038/sj.bmt.1703531; Bonduel M, 1999, BONE MARROW TRANSPL, V24, P437, DOI 10.1038/sj.bmt.1701915; BORTIN MM, 1977, JAMA-J AM MED ASSOC, V238, P591, DOI 10.1001/jama.238.7.591; Broome CB, 1996, J PEDIATR-US, V128, P373, DOI 10.1016/S0022-3476(96)70285-8; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; Canioni D, 1997, PEDIATR PATHOL LAB M, V17, P645, DOI 10.1080/107710497174633; Carpenter PA, 1996, BONE MARROW TRANSPL, V17, P121; CASPER JT, 1990, J PEDIATR-US, V116, P262, DOI 10.1016/S0022-3476(05)82885-9; DeSantes KB, 1996, BONE MARROW TRANSPL, V17, P1171; DIBARTOLOMEO P, 1989, BONE MARROW TRANSPL, V4, P695; DROR Y, 1993, BLOOD, V81, P2021; Duplantier JE, 2001, CLIN IMMUNOL, V98, P313, DOI 10.1006/clim.2000.4994; Fasth A, 1993, Immunodeficiency, V4, P323; Filipovich AH, 2001, BLOOD, V97, P1598, DOI 10.1182/blood.V97.6.1598; FISCHER A, 1986, BLOOD, V67, P444; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; FISCHER A, 1994, BLOOD, V83, P1149; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; GATTI RA, 1968, LANCET, V2, P1366; GIRI N, 1994, AUST NZ J MED, V24, P26, DOI 10.1111/j.1445-5994.1994.tb04421.x; GOLDSOBEL AB, 1987, J PEDIATR-US, V111, P40, DOI 10.1016/S0022-3476(87)80339-6; GOMEZ L, 1995, J PEDIATR-US, V127, P76, DOI 10.1016/S0022-3476(95)70260-1; Gross TG, 1996, BONE MARROW TRANSPL, V17, P741; Haddad E, 1998, BLOOD, V91, P3646; HADDAD E, 1995, BLOOD, V85, P3328, DOI 10.1182/blood.V85.11.3328.bloodjournal85113328; HOBBS JR, 1992, EUR J PEDIATR, V151, P806, DOI 10.1007/BF01957929; Horwitz ME, 2001, NEW ENGL J MED, V344, P881, DOI 10.1056/NEJM200103223441203; KAMANI N, 1988, J PEDIATR-US, V113, P697, DOI 10.1016/S0022-3476(88)80382-2; Kane L, 2001, ARCH DIS CHILD-FETAL, V85, pF110, DOI 10.1136/fn.85.2.F110; Khawaja K, 2001, ARCH DIS CHILD, V84, P508, DOI 10.1136/adc.84.6.508; KLEIN C, 1995, BLOOD, V85, P580; Knutsen AP, 1999, J ALLERGY CLIN IMMUN, V103, P823, DOI 10.1016/S0091-6749(99)70426-4; Lanfranchi A., 2000, Haematologica, V85, P41; LEDEIST F, 1989, BLOOD, V74, P512; Liang JS, 2000, J FORMOS MED ASSOC, V99, P499; LOECHELT BJ, 1995, BONE MARROW TRANSPL, V16, P381; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; Markert ML, 2003, BLOOD, V102, P1121, DOI 10.1182/blood-2002-08-2545; Miano M, 1998, BONE MARROW TRANSPL, V21, pS37; MOEN RC, 1987, BLOOD, V70, P664; MULLERRUCHHOLTZ W, 1976, TRANSPLANT P, V8, P537; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Nagler A, 1999, BONE MARROW TRANSPL, V24, P339, DOI 10.1038/sj.bmt.1701903; O'Marcaigh AS, 2001, BONE MARROW TRANSPL, V27, P703, DOI 10.1038/sj.bmt.1702831; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; Ozsahin H, 1996, J PEDIATR-US, V129, P238, DOI 10.1016/S0022-3476(96)70248-2; Ozsahin H, 1998, BLOOD, V92, P2719, DOI 10.1182/blood.V92.8.2719.420k02_2719_2724; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; PRACHER E, 1994, BONE MARROW TRANSPL, V13, P655; RAPPEPORT JM, 1982, J PEDIATR-US, V101, P952, DOI 10.1016/S0022-3476(82)80017-6; REISNER Y, 1983, BLOOD, V61, P341; REISNER Y, 1978, P NATL ACAD SCI USA, V75, P2933, DOI 10.1073/pnas.75.6.2933; ROBERTS JL, 1989, J IMMUNOL, V143, P1575; SCHIFF SE, 1987, J IMMUNOL, V138, P2088; SCHNEIDER LC, 1990, J CLIN IMMUNOL, V10, P146, DOI 10.1007/BF00917914; Scholl PR, 1998, BONE MARROW TRANSPL, V22, P1215, DOI 10.1038/sj.bmt.1701512; Seger R A, 1994, Immunodeficiency, V5, P113; Seger RA, 2002, BLOOD, V100, P4344, DOI 10.1182/blood-2002-02-0583; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; THOMAS C, 1995, NEW ENGL J MED, V333, P426, DOI 10.1056/NEJM199508173330705; THOMAS C, 1995, BLOOD, V86, P1629, DOI 10.1182/blood.V86.4.1629.bloodjournal8641629; Wengler GS, 1996, LANCET, V348, P1484, DOI 10.1016/S0140-6736(96)09392-0; WIJNAENDTS L, 1989, BLOOD, V74, P2212; WILLIAMS LL, 1993, LANCET, V342, P587, DOI 10.1016/0140-6736(93)91413-G; Ziegner UHM, 2001, J PEDIATR-US, V138, P570, DOI 10.1067/mpd.2001.112511	73	28	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					793	800		10.1016/j.jaci.2004.01.764	http://dx.doi.org/10.1016/j.jaci.2004.01.764			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100688	Bronze			2022-12-18	WOS:000220956600038
J	Srivastava, K; Teper, AA; Zhang, TF; Li, S; Walsh, MJ; Huang, CK; Kattan, M; Schofield, BH; Sampson, HA; Li, XM				Srivastava, K; Teper, AA; Zhang, TF; Li, S; Walsh, MJ; Huang, CK; Kattan, M; Schofield, BH; Sampson, HA; Li, XM			Immunomodulatory effect of the antiasthma Chinese herbal formula MSSM-002 onT(H)2 cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; Chinese herbal medicine; T(H)1-T(H)2 responses; immunomodulation	GROWTH-FACTOR-BETA; CD4+ T-CELLS; ALTERNATIVE MEDICINE; MURINE MODEL; TH2 CELLS; TRANSCRIPTION FACTOR; AIRWAY INFLAMMATION; GATA-3 EXPRESSION; ALLERGIC DISEASE; IMMUNE-RESPONSES	Background: T(H)2 cytokines play a central role in the pathogenesis of allergic asthma. We previously showed that the "antiasthma" Chinese herbal formula MSSM-002 exhibited therapeutic effects on established allergic airway responses in a murine model of allergic asthma. However, the mechanisms underlying these effects are largely unknown. Objective: The objective of this study was to determine whether and how MSSM-002 modulates an established T(H)2 response and whether the actions of MSSM-002 on T(H)2 cell differs from corticosteroids. Methods: T(H)2 polarized splenocytes (T(H)2-SPCs) from mice with antigen-induced airway hyperresponsiveness and T(H)2 cloned cells, D10 G4.1 (D10), were cultured in the presence or absence of antigen with or without MSSM-002 and dexamethasone, and the proliferative responses and cytokine profiles were determined. Apoptosis and T(H)2 transcription factor GATA-3 expression and binding to IL-4 gene promoter and V-A enhancer in MSSM-002-treated D10 cells were also determined. Results: MSSM-002 significantly decreased antigen-induced proliferation and IL-4 and IL-5 production but increased IFN-gamma production by T(H)2-SPCs, whereas dexamethasone suppressed IFN-gamma as well as IL-4 and IL-5. Anti-IL-12 antibody, although abrogating MSSM-002 induction of IFN-gamma, had no significant effect on MSSM-002 suppression of IL-4 and IL-5 secretion. MSSM-002 also suppressed T(H)2 cytokine secretion by D10 cells, and in contrast to dexamethasone, MSSM-002 did not induce apoptosis of D10 cells. MSSM-002 markedly suppressed GATA-3 mRNA and protein expression and the binding to IL-4 gene promoter and V-A enhancer in D10 cells. Conclusion: MSSM-002, in contrast to the overall suppression of T cells by dexamethasone, exhibits immunomodulatory actions on T(H)2 cells caused, at least partially, by downregulation of GATA-3.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Li, XM (corresponding author), Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl, New York, NY 10029 USA.							Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Barnes PJ, 2001, CLIN EXP ALLERGY, V31, P667, DOI 10.1046/j.1365-2222.2001.01118.x; Bielory L, 1999, J ASTHMA, V36, P1, DOI 10.3109/02770909909065150; Claman HN, 2002, J ALLERGY CLIN IMMUN, V109, P1038, DOI 10.1067/mai.2002.125261; Donnet-Hughes A, 2000, IMMUNOL CELL BIOL, V78, P74, DOI 10.1046/j.1440-1711.2000.00882.x; Fallon PG, 2002, IMMUNITY, V17, P7, DOI 10.1016/S1074-7613(02)00332-1; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011; Krzesicki RF, 1997, AM J RESP CELL MOL, V16, P693, DOI 10.1165/ajrcmb.16.6.9191471; Kurup VP, 1999, CLIN IMMUNOL, V90, P404, DOI 10.1006/clim.1998.4656; LAKSHMI B, 2003, TERATOG CARCINOG M S, V1, P85, DOI DOI 10.1002/TCM.10065; Lee JM, 2001, PHYTOTHER RES, V15, P245, DOI 10.1002/ptr.830; Li BY, 2000, SCIENCE, V288, P2219, DOI 10.1126/science.288.5474.2219; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P660, DOI 10.1067/mai.2000.110102; Li XM, 1998, J IMMUNOL, V160, P1378; Li XM, 2002, J ALLERGY CLIN IMMUN, V109, P1038, DOI 10.1067/mai.2002.125262; Li XM, 2001, J ALLERGY CLIN IMMUN, V107, P693, DOI 10.1067/mai.2001.114110; Lohning M, 2002, ADV IMMUNOL, V80, P115, DOI 10.1016/S0065-2776(02)80014-1; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Marchetti MC, 2003, TOXICOL LETT, V139, P175, DOI 10.1016/S0378-4274(02)00431-9; MIGLIORATI G, 1994, PHARMACOL RES, V30, P43, DOI 10.1016/1043-6618(94)80086-3; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; *NIH, 2002, GLOB IN ASTHM GLOB S; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ranganath S, 1998, J IMMUNOL, V161, P3822; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SEREBRISKY D, 2000, AM J RESP CRIT CARE, V161, pA591; Smits HH, 2001, EUR J IMMUNOL, V31, P1055, DOI 10.1002/1521-4141(200104)31:4<1055::AID-IMMU1055>3.0.CO;2-7; Steurer-Stey C, 2002, SWISS MED WKLY, V132, P338; Strobel S, 2002, ANN NY ACAD SCI, V958, P47; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Yeung VP, 1998, J IMMUNOL, V161, P4146; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Ziment I, 2000, J ALLERGY CLIN IMMUN, V106, P603, DOI 10.1067/mai.2000.109432; Zou ZM, 2002, J ALLERGY CLIN IMMUN, V109, pS247, DOI 10.1016/S0091-6749(02)81886-3; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	48	28	29	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					268	276		10.1016/j.jaci.2003.10.062	http://dx.doi.org/10.1016/j.jaci.2003.10.062			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767441				2022-12-18	WOS:000188885700014
J	Ibanez, MD; Sastre, J; San Ireneo, MM; Laso, MT; Barber, D; Lombardero, M				Ibanez, MD; Sastre, J; San Ireneo, MM; Laso, MT; Barber, D; Lombardero, M			Different patterns of allergen recognition in children allergic to orange	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LIPID-TRANSFER PROTEINS; CROSS-REACTIVITY; PROFILIN; POLLEN		Hosp Univ Nino Jesus, Serv Alergia, Madrid 28009, Spain; Fdn Jimenez Diaz, Serv Alergia, E-28040 Madrid, Spain; ALK Abello SA, Dept I&D, Madrid, Spain	ALK-Abello AS	Ibanez, MD (corresponding author), Hosp Univ Nino Jesus, Serv Alergia, Avda Menendez Pelayo 65, Madrid 28009, Spain.		Barber, Domingo/Y-9516-2019	Barber, Domingo/0000-0002-5488-5700				Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; Asturias JA, 1998, MOL IMMUNOL, V35, P469, DOI 10.1016/S0161-5890(98)00036-4; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Duffort OA, 2002, J AGR FOOD CHEM, V50, P7738, DOI 10.1021/jf0258398; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1	7	28	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					175	177		10.1016/j.jaci.2003.10.059	http://dx.doi.org/10.1016/j.jaci.2003.10.059			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713927	Bronze			2022-12-18	WOS:000187837900026
J	Suda, T; Chida, K; Matsuda, H; Hashizume, H; Ide, K; Yokomura, K; Suzuki, K; Kuwata, H; Miwa, S; Nakano, H; Fujisawa, T; Enomoto, N; Matsushita, A; Nakamura, H				Suda, T; Chida, K; Matsuda, H; Hashizume, H; Ide, K; Yokomura, K; Suzuki, K; Kuwata, H; Miwa, S; Nakano, H; Fujisawa, T; Enomoto, N; Matsushita, A; Nakamura, H			High-dose intravenous glucocorticoid therapy abrogates circulating dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PERIPHERAL-BLOOD; GENERATION		Hamamatsu Univ Sch Med, Div 2, Dept Internal Med, Hamamatsu, Shizuoka 43131, Japan; Hamamatsu Univ Sch Med, Dept Dermatol, Hamamatsu, Shizuoka 43131, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Suda, T (corresponding author), Hamamatsu Univ Sch Med, Div 2, Dept Internal Med, Hamamatsu, Shizuoka 43131, Japan.		Kuwata, Hiro/N-2023-2019; Hashizume, Hideo/AAL-9490-2020	Kuwata, Hiro/0000-0002-5023-1777; Hashizume, Hideo/0000-0002-5809-0040				Canning MO, 2000, EUR J ENDOCRINOL, V143, P687, DOI 10.1530/eje.0.1430687; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Matsuda H, 2002, AM J RESP CRIT CARE, V166, P1050, DOI 10.1164/rccm.2110066; Ozaki Y, 2001, ARTHRITIS RHEUM-US, V44, P419, DOI 10.1002/1529-0131(200102)44:2<419::AID-ANR61>3.0.CO;2-U; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Robinson SP, 1999, EUR J IMMUNOL, V29, P2769, DOI 10.1002/(SICI)1521-4141(199909)29:09<2769::AID-IMMU2769>3.0.CO;2-2; Shodell M, 2001, J ALLERGY CLIN IMMUN, V108, P446, DOI 10.1067/mai.2001.117928; Suda T, 1996, J LEUKOCYTE BIOL, V60, P519, DOI 10.1002/jlb.60.4.519; Toker E, 2002, BRIT J OPHTHALMOL, V86, P521, DOI 10.1136/bjo.86.5.521; Woltman AM, 2002, J IMMUNOL, V168, P6181, DOI 10.4049/jimmunol.168.12.6181	10	28	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1237	1239		10.1016/j.jaci.2003.09.028	http://dx.doi.org/10.1016/j.jaci.2003.09.028			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657889				2022-12-18	WOS:000187154200032
J	Wisnewski, AV; Herrick, CA; Liu, Q; Chen, L; Bottomly, K; Redlich, CA				Wisnewski, AV; Herrick, CA; Liu, Q; Chen, L; Bottomly, K; Redlich, CA			Human gamma/delta T-cell proliferation and IFN-gamma production induced by hexamethylene diisocyanate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hexamethylene diisocyanate; gamma/delta T cell; interferon-gamma; T-cell receptor; occupational asthma; CD8; albumin; airway epithelial cell	MONOCYTE CHEMOATTRACTANT PROTEIN-1; TOLUENE DIISOCYANATE; OCCUPATIONAL ASTHMA; ANTIBODIES; WORKERS; SERUM; IGE; INFLAMMATION; ISOCYANATES; EXPRESSION	Background: The human immune response to isocyanate, a leading cause of occupational asthma, remains incompletely characterized, including the cell types involved and the form of the chemical that acts as an antigen. Objective: The purpose of this investigation was to characterize human T cells that respond to hexamethylene diisocyanate (HDI), an aliphatic isocyanate routinely used in the automobile body industry. Methods: Human T-cell lines were generated and characterized from peripheral blood of HDI-exposed and HDI-unexposed subjects, using two different HDI antigens, HDI-conjugated albumin and HDI-exposed human airway epithelial cells (NCI-H292). Flow cytometry was used to characterize the phenotype of HDI-responsive T cells. ELISA and intracellular staining techniques were used to evaluate HDI-induced cytokine production. DNA sequence analysis of T-cell receptors was used to further define clonal populations of HDI-responsive T cells. Results: HDI antigen preparations but not "mock exposed" control antigens lead to increased proliferation of specific cell types, CD3(+)CD4(-)CD8(dim) and/or CD3(+)CD4(-)CD8(-) cells, from HDI-exposed but not from HDI-unexposed subjects. These HDI-responsive T cells expressed unique oligoclonal gamma/delta rather than alpha/beta T-cell receptors, with characteristics suggestive of antigen-mediated selection and specificity. The HDI-stimulated gamma/delta T cells were associated with T(H)1-like cytokines and produce IFN-gamma but not IL-5 or IL-13. Conclusions: These data are the first to demonstrate that HDI can selectively stimulate gamma/delta T cells with the potential to modulate the human immune response to exposure.	Yale Sch Med, Dept Internal Med Immunobiol & Dermatol, New Haven, CT 06520 USA	Yale University	Wisnewski, AV (corresponding author), Yale Sch Med, Dept Internal Med Immunobiol & Dermatol, 333 Cedar St,LCI 105, New Haven, CT 06520 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069495, R01HL062622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH003457] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00125] Funding Source: Medline; NHLBI NIH HHS [HL 62622, R01 HL069495-01, R01 HL062622-02, HL 69495, R01 HL069495, R01 HL062622, R01 HL062622-01, R01 HL062622-03, R01 HL069495-03, R01 HL069495-02] Funding Source: Medline; NIEHS NIH HHS [ES 00355] Funding Source: Medline; NIOSH CDC HHS [OH 3457] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS		Bernstein DI, 2002, AM J RESP CRIT CARE, V166, P445, DOI 10.1164/rccm.2109018; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; Carlton G N, 2000, Appl Occup Environ Hyg, V15, P705; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; Cullinan P, 1998, CLIN EXP ALLERGY, V28, P668; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FINOTTO S, 1991, BRIT J IND MED, V48, P116; Herrick CA, 2002, J ALLERGY CLIN IMMUN, V109, P873, DOI 10.1067/mai.2002.123533; Lee Millina, 1998, Journal of Korean Medical Science, V13, P459; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; MAPP CE, 1999, ASTHMA WORKPLACE, V1, P457; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847, DOI 10.1016/S0091-6749(99)70297-6; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Redlich CA, 2002, INT IMMUNOPHARMACOL, V2, P213, DOI 10.1016/S1567-5769(01)00174-6; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160; SASTRE J, 1990, J ALLERGY CLIN IMMUN, V85, P567, DOI 10.1016/0091-6749(90)90094-K; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wisnewski AV, 2001, CURR OPIN ALLERGY CL, V1, P169, DOI 10.1097/01.all.0000011003.36723.d8; Wisnewski AV, 1999, J ALLERGY CLIN IMMUN, V104, P341, DOI 10.1016/S0091-6749(99)70377-5	25	28	29	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					538	546		10.1067/mai.2003.1713	http://dx.doi.org/10.1067/mai.2003.1713			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	719XW	13679813				2022-12-18	WOS:000185231200013
J	Suzuki, M; Kato, M; Hanaka, H; Izumi, T; Morikawa, A				Suzuki, M; Kato, M; Hanaka, H; Izumi, T; Morikawa, A			Actin assembly is a crucial factor for superoxide anion generation from adherent human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; activation; cytochalasin B; platelet-activating factor; complement component 5a; actin cytoskeleton; superoxide anion; protein kinase C; nicotinamide adenine dinucleotide phosphate oxidase	PLATELET-ACTIVATING-FACTOR; NADPH OXIDASE ACTIVATION; HUMAN NEUTROPHILS; DEGRANULATION; PROTEIN; MECHANISMS; CYTOSKELETON; INTEGRIN; RELEASE; CYTOCHALASINS	Background: Cellular adhesion is crucial for eosinophil effector functions. Objective: We sought to elucidate the role of the actin cytoskeleton in cellular adhesion and superoxide anion generation by human eosinophils. Methods: Eosinophils were stimulated with platelet-activating factor (PAF) or complement component 5a on human serum albumin-coated plates with or without an actin-polymerization inhibitor, cytochalasin B (CB), or cytochalasin D (CD). Superoxide anion generation was measured on the basis of reduction of absorbance associated with cytochrome c. Eosinophil adhesion was assessed on the basis of eosinophil protein X content in adherent cells. Transient stimulus-induced increase of intracellular calcium and translocation of protein kinase C (PKC) betaII, PKC delta, PKC zeta, and p47 phagocyte oxidase (a component of nicotinamide adenine dinucleotide phosphate oxidase) were also investigated. Results: CB, CD, or antibodies against CD18 (the beta2 chain of integrin, alphaMbeta2) inhibited stimulus-induced eosinophil superoxide anion generation. Stimulus-induced eosinophil adhesion was unaltered by CB, whereas it was significantly suppressed by CD or anti-CD18 antibodies. Transient PAF-induced intracellular calcium increase was also unaffected by CB or CD, but stimulus-induced eosinophil shape changes and translocation of PKCs and p47 phagocyte oxidase to the cell membrane region were completely inhibited by CB. PAF-induced eosinophil degranulation was inhibited by CB, CD, or anti-CD18 antibodies, whereas complement component 5-induced degranulation was not suppressed by CB. Conclusion: By itself, beta2 integrin-dependent cellular adhesion is not sufficient for promoting eosinophil effector function. Adequate actin assembly is required for eosinophil adhesion and also for full superoxide anion generation in eosinophils.	Gunma Univ, Sch Med, Dept Pediat, Gunma 3718511, Japan; Gunma Univ, Sch Med, Dept Biochem, Gunma 3718511, Japan	Gunma University; Gunma University	Kato, M (corresponding author), Gunma Univ, Sch Med, Dept Pediat, 3-39-22 Showa Machi, Gunma 3718511, Japan.							Bankers-Fulbright JL, 2001, J CELL PHYSIOL, V189, P306, DOI 10.1002/jcp.10022; BENGTSSON T, 1991, J LEUKOCYTE BIOL, V49, P236, DOI 10.1002/jlb.49.3.236; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Dekker LV, 2000, BIOCHEM J, V347, P285, DOI 10.1042/0264-6021:3470285; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; EBISAWA M, 1990, INT ARCH ALLER A IMM, V93, P93, DOI 10.1159/000235286; El-Shazly A, 1998, INT ARCH ALLERGY IMM, V117, P55, DOI 10.1159/000053573; Evans DJ, 1999, AM J PHYSIOL-LUNG C, V277, pL233, DOI 10.1152/ajplung.1999.277.2.L233; Ezeamuzie CI, 1999, BRIT J PHARMACOL, V127, P188, DOI 10.1038/sj.bjp.0702476; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Granfeldt D, 2001, INFLAMMATION, V25, P165, DOI 10.1023/A:1011084330283; HORIE S, 1994, J IMMUNOL, V152, P5457; Howard T H, 1994, Curr Opin Hematol, V1, P61; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; KANEKO M, 1995, J IMMUNOL, V155, P2631; KAPP A, 1994, J INVEST DERMATOL, V102, P906, DOI 10.1111/1523-1747.ep12383399; Kato M, 1998, AM J RESP CELL MOL, V18, P675, DOI 10.1165/ajrcmb.18.5.2885; KITA H, 1995, J IMMUNOL, V154, P4749; Kurtzhals JAL, 1998, CLIN EXP IMMUNOL, V112, P303; Leiferman KM, 2001, J AM ACAD DERMATOL, V45, pS21, DOI 10.1067/mjd.2001.117022; Lynch OT, 1999, BRIT J PHARMACOL, V128, P1149, DOI 10.1038/sj.bjp.0702892; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; MIYAMASU M, 1995, J IMMUNOL, V154, P1339; MUKHERJEE G, 1994, J LEUKOCYTE BIOL, V55, P685, DOI 10.1002/jlb.55.6.685; Nixon JB, 1999, J IMMUNOL, V163, P4574; Patel KD, 1998, BLOOD, V92, P3904, DOI 10.1182/blood.V92.10.3904.422k41_3904_3911; Pendleton A, 2001, CELL MOTIL CYTOSKEL, V48, P37; Powell WS, 1999, AM J RESP CELL MOL, V20, P163, DOI 10.1165/ajrcmb.20.1.3141; Sano A, 2001, AM J PHYSIOL-LUNG C, V281, pL844, DOI 10.1152/ajplung.2001.281.4.L844; Someya A, 1997, ARCH BIOCHEM BIOPHYS, V345, P207, DOI 10.1006/abbi.1997.0252; TAKAFUJI S, 1994, INT ARCH ALLERGY IMM, V104, P27, DOI 10.1159/000236743; Tamura M, 2000, BIOCHEM J, V349, P369, DOI 10.1042/0264-6021:3490369; Torres M, 1999, J IMMUNOL METHODS, V232, P89, DOI 10.1016/S0022-1759(99)00168-4; WALLING EA, 1988, ARCH BIOCHEM BIOPHYS, V264, P321, DOI 10.1016/0003-9861(88)90600-5; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WINQVIST I, 1984, IMMUNOLOGY, V51, P1; ZECKKAPP G, 1995, ALLERGY, V50, P34, DOI 10.1111/j.1398-9995.1995.tb02481.x	38	28	31	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					126	133		10.1067/mai.2003.1515	http://dx.doi.org/10.1067/mai.2003.1515			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847489				2022-12-18	WOS:000184010600020
J	Moylett, EH; Chinen, J; Shearer, WT				Moylett, EH; Chinen, J; Shearer, WT			Trichosporon pullulans infection in 2 patients with chronic granulomatous disease: An emerging pathogen and review of the literature	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						chronic granulomatous disease; Trichosporon pullulans; emerging pathogen	BREAKTHROUGH FUNGEMIA; CANCER-PATIENTS; BEIGELII; PROPHYLAXIS	Background: Chronic granulomatous disease is a genetically determined primary immunodeficiency disease in which phagocytic cells are unable to kill certain bacteria and fungi after ingestion. Manifestations include recurrent pyogenic infections caused by catalase-positive microbes. Trichosporoa species are emerging as opportunistic agents that cause systemic disease in immunocompromised patients. Typically disease has been described in association with T beigelli in patients with secondary immunodeficiency, such as underlying malignancy. Objective: The objective was to report the first 2 cases of T pullulans infection in 2 male children with chronic granulomatous disease. Methods: The records of the 2 patients were reviewed. In addition, all cases of T pullulans infection reported in the English language literature are presented. Results: This report brings to 7 the total number of cases of T pullulans reported and the first in patients with chronic granulomatous disease, one with invasive pneumonia and the other with an infected paronychium and localized cellulitis. In the 5 additional cases malignancy was the principal risk factor. Conclusion: T pullulans has rarely been reported as a fungal pathogen. The most prominent risk factor for the development of trichosporonosis is immunocompromise most notably with neutropenia. Abnormally functioning neutrophils, such as with chronic granulomatous disease, may also predispose individuals to this opportunistic pathogen. (J Allergy Clin Immunol 2003;111:1370-4.).	Texas Childrens Hosp, Sect Allergy & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Sect Allergol & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Moylett, EH (corresponding author), Texas Childrens Hosp, Sect Allergy & Immunol, 6621 Fannin St,MC FC330-01, Houston, TX 77030 USA.			Shearer, William/0000-0002-2483-2130				ANAISSIE EJ, 1989, EUR J CLIN MICROBIOL, V8, P323, DOI 10.1007/BF01963467; Erer B, 2000, BONE MARROW TRANSPL, V25, P745, DOI 10.1038/sj.bmt.1702231; Freydiere AM, 2001, MED MYCOL, V39, P9, DOI 10.1080/714030980; Goodman D, 2002, CLIN INFECT DIS, V35, pE35, DOI 10.1086/341305; Han MH, 2000, INT J DERMATOL, V39, P266, DOI 10.1046/j.1365-4362.2000.00910.x; HUGHES CE, 1988, ANN INTERN MED, V108, P772, DOI 10.7326/0003-4819-108-5-772_3; Krcmery V, 1999, SUPPORT CARE CANCER, V7, P39, DOI 10.1007/s005200050221; KREMERY V, 2002, J MED MICROBIOL, V51, P110; KUNOVA A, 1995, EUR J CLIN MICROBIOL, V14, P729, DOI 10.1007/BF01690888; Kunova A, 1996, INFECTION, V24, P273, DOI 10.1007/BF01781117; LOWENTHAL RM, 1987, BONE MARROW TRANSPL, V2, P321; LYMAN CA, 1994, J INFECT DIS, V170, P1557, DOI 10.1093/infdis/170.6.1557; Muranaka H, 1997, INFECT IMMUN, V65, P3422, DOI 10.1128/IAI.65.8.3422-3429.1997; Paphitou NI, 2002, ANTIMICROB AGENTS CH, V46, P1144, DOI 10.1128/AAC.46.4.1144-1146.2002; PONTES ZB, 2002, BRAZIL REV ARGENT MI, V34, P95; Roilides E, 1999, J CLIN MICROBIOL, V37, P18, DOI 10.1128/JCM.37.1.18-25.1999; Salazar GE, 2002, PEDIATR INFECT DIS J, V21, P161, DOI 10.1097/00006454-200202000-00016; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SHIGEHARA K, 1991, JPN J MED, V30, P135; Walsh T J, 1989, Infect Dis Clin North Am, V3, P43; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	21	28	36	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1370	1374		10.1067/mai.2003.1522	http://dx.doi.org/10.1067/mai.2003.1522			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12618748				2022-12-18	WOS:000183424700029
J	Sano, Y; Suzuki, N; Yamada, H; To, Y; Ogawa, C; Ohta, K; Adachi, M				Sano, Y; Suzuki, N; Yamada, H; To, Y; Ogawa, C; Ohta, K; Adachi, M			Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway hyperresponsiveness; airway inflammation; airway remodeling; bronchial asthma; EG2(+) cells; eosinophils; induced sputum; suplatast tosilate; T(H)2-type cytokines	AGENT	Background. Bronchial asthma is a chronic inflammatory disease characterized mainly by infiltration of the airway mucosa by various inflammatory cells, notably eosinophils. T(H)2-type cytokines are suggested to he deeply involved in the pathogenesis of asthma. Objective: We sought to determine the suppressive effects of suplatast tosilate, an inhibitor of T(H)2-type cytokines, on eosinophilic inflammation of the bronchial mucosa in patients with mild asthma. Methods: Airway hyperresponsiveness tests, pulmonary function tests, eosinophil measurements in induced sputum, and bronchial mucosa biopsies were performed before and after treatment with suplatast tosilate for 6 weeks in 15 patients with mild asthma and in 13 control patients with mild asthma not receiving suplatast tosilate. This study was performed as a case-controlled open study. Results: In the treatment group a significant improvement in the provocation concentration of histamine was observed (P < .05). improvements in peak expiratory flow (P < .01) and in symptom score (P < .05) were also noted in the suplatast tosilate-treated group. Moreover, the average number of infiltrating eosinophils and EG2(+) cells significantly decreased (both P < .05), as did the ratios of eosinophils and EG2(+) cells in sputum (both P < .01). The average number of CD4(+) and CD25(+) T lymphocytes also decreased (both P < .05). Conclusion: Suplatast tosilate appears to inhibit allergic airway inflammation mediated by T(H)2-type cytokine and to improve clinical symptoms in patients with mild asthma.	Doai Mem Hosp, Dept Allergy & Resp Med, Sumida Ku, Tokyo 1308587, Japan; Teikyo Univ, Sch Med, Dept Med, Tokyo 173, Japan; Showa Univ, Sch Med, Dept Internal Med 1, Tokyo 142, Japan	Teikyo University; Showa University	Sano, Y (corresponding author), Doai Mem Hosp, Dept Allergy & Resp Med, Sumida Ku, 2-1-11 Yokoami, Tokyo 1308587, Japan.							BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUSSE WW, 1992, ANN ALLERGY, V68, P286; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; CHUNG KF, 1992, BRIT MED BULL, V48, P179, DOI 10.1093/oxfordjournals.bmb.a072533; Corrigan CJ, 1996, EUR RESPIR J, V9, pS72; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84, DOI 10.1165/ajrcmb.14.1.8534490; HAMADA H, 1999, NIHON KYOHU SHIKKAN, V35, P692; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HOLGATE ST, 1993, EUR RESPIR J, V6, P1507; Iijima H, 1999, AM J RESP CRIT CARE, V160, P331, DOI 10.1164/ajrccm.160.1.9809059; Kobayashi Y, 2000, Arerugi, V49, P600; Kusumoto H, 1997, Nihon Kyobu Shikkan Gakkai Zasshi, V35, P550; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LAITINEN LA, 1995, ALLERGY PROC, V16, P63, DOI 10.2500/108854195778771435; MAKINO S, 1982, JPN J ALLERGOL, V31, P1074; MAKINO S, 1998, GUIDELINE PREVENTION; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; *NAT ASTHM ED PREV, 1997, NIH PUBL; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sano Y, 1997, CHEST, V112, P862, DOI 10.1378/chest.112.3.862-a; Tamaoki J, 2000, LANCET, V356, P273, DOI 10.1016/S0140-6736(00)02501-0; Taniguchi H, 1996, EUR J PHARMACOL, V318, P447, DOI 10.1016/S0014-2999(96)00810-2; WATANABE A, 1995, J CLIN INVEST, V96, P1303, DOI 10.1172/JCI118165; YAMAYA H, 1995, LIFE SCI, V56, P1647, DOI 10.1016/0024-3205(95)00132-P; YANAGIHARA Y, 1993, JPN J PHARMACOL, V61, P31, DOI 10.1254/jjp.61.31	26	28	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					958	966		10.1067/mai.2003.1415	http://dx.doi.org/10.1067/mai.2003.1415			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743558				2022-12-18	WOS:000182904500008
J	Gore, RB; Durrell, B; Bishop, S; Curbishley, L; Woodcock, A; Custovic, A				Gore, RB; Durrell, B; Bishop, S; Curbishley, L; Woodcock, A; Custovic, A			High-efficiency particulate arrest-filter vacuum cleaners increase personal cat allergen exposure in homes with cats	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal sampling; vacuum cleaning; Fel d 1; cat allergen; environmental control	HOUSE-DUST MITE; AERODYNAMIC CHARACTERISTICS; ANTIGEN; FEL-D-1; DOG	Background: On the basis of experimental chamber studies, vacuum cleaners with double-thickness bags and integral high-efficiency particulate arrest (HEPA) air filters are claimed to reduce airborne allergen levels and are currently recommended to allergic patients. Objectives: The objective of this study was to investigate the effect of vacuum cleaning on personal inhaled cat allergen exposure in homes with cats. Methods: Five unused new vacuum cleaners were compared with an old non-HEPA filter vacuum cleaner. Each vacuum cleaner was tested in an experimental chamber and in 5 homes with cats. Inhaled cat allergen was measured by nasal air sampling. Results: New vacuum cleaners failed to leak any allergen in the experimental chamber. There was a significant increase in inhaled cat allergen during vacuum cleaning in homes (F = 48.39, df = 1.4, P = .002) with no difference between the old vacuum cleaner and the unused new vacuum cleaners (5-fold and 3-fold increase compared to baseline, respectively; F 0.005, df = 1.4, P = .95). Conclusions: The use of new HEPA-filter vacuum cleaners increases inhaled cat allergen in homes with cats. The use of HEPA-filter modern vacuum cleaners to reduce pet allergen exposure in the homes of pet owners should not be justified merely on the basis of experimental chamber data.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Gore, RB (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578				Altman DG, 1991, PRACTICAL STAT MED R, P122; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; DAmato G, 1997, J ALLERGY CLIN IMMUN, V99, P577, DOI 10.1016/S0091-6749(97)70088-5; de Blay F, 1998, ALLERGY, V53, P411, DOI 10.1111/j.1398-9995.1998.tb03914.x; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; Green R, 1999, ALLERGY, V54, P403, DOI 10.1034/j.1398-9995.1999.00154.x; KALRA S, 1990, LANCET, V336, P449, DOI 10.1016/0140-6736(90)92004-2; O'Meara TJ, 1998, LANCET, V351, P1488, DOI 10.1016/S0140-6736(05)78870-X; Poulos LM, 1999, CLIN EXP ALLERGY, V29, P1232, DOI 10.1046/j.1365-2222.1999.00613.x; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V104, P1079, DOI 10.1016/S0091-6749(99)70092-8; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x; WOODFOLK JA, 1993, J ALLERGY CLIN IMMUN, V91, P829, DOI 10.1016/0091-6749(93)90339-H	17	28	28	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					784	787		10.1067/mai.2003.1378	http://dx.doi.org/10.1067/mai.2003.1378			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704358				2022-12-18	WOS:000182258500018
J	Lemanske, RF				Lemanske, RF			Issues in understanding pediatric asthma: Epidemiology and genetics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; environment; pediatric asthma; genetics; pathogenesis	TOTAL SERUM IGE; ATOPIC DISEASE; CHILDREN; RISK; CHILDHOOD; SENSITIZATION; ASSOCIATION; SYMPTOMS; HYPERRESPONSIVENESS; ALLERGEN	Asthma is a heterogeneous disease characterized by varying phenotypes. Ongoing research is focused on identifying which children who have wheezing early will progress to childhood asthma. Genetic factors, predominantly atopy and a parental history of asthma as well as environmental stimuli, are key components in the development of asthma. Investigation into immunologic processes indicates that atopic children may have a cytokine imbalance or dysregulation in which the transition from T helper 2 (T(H)2)-type to T(H)1-type immunity is delayed. Several risk factors have been identified in the pathophysiology of asthma, including sensitization and exposure to cockroaches, house dust mites, and the mold Allernaria alternata, among other aeroallergens. Viral respiratory infections, primarily those caused by respiratory syncytial virus, are a significant risk factor for the development of childhood wheezing in the first decade of life. A number of prospective epidemiologic studies are investigating, among other issues, the relations among cytokine dysregulation, respiratory tract infections, and allergen exposure and sensitization in the development of asthma. Identifying the pathogenic mechanisms should enable clinicians to identify children at high risk and thereby to treat childhood asthma more effectively.	Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Lemanske, RF (corresponding author), Univ Wisconsin Hosp & Clin, 600 Highland Ave,Room K4-916, Madison, WI 53792 USA.				NHLBI NIH HHS [HL-56396, HL-61979] Funding Source: Medline; NIAID NIH HHS [AI-34691] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BARBEE RA, 1985, CHEST, V87, pS21, DOI 10.1378/chest.87.1.21S; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497, DOI 10.1164/ajrccm.152.5.7582283; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Castro-Rodriguez JA, 1999, AM J RESP CRIT CARE, V159, P1891, DOI 10.1164/ajrccm.159.6.9811035; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Halonen M, 1999, AM J RESP CRIT CARE, V160, P564, DOI 10.1164/ajrccm.160.2.9809038; Holt PG, 2000, AM J RESP CRIT CARE, V161, pS172, DOI 10.1164/ajrccm.161.supplement_2.a1q4-5; Laan MP, 2000, CLIN EXP ALLERGY, V30, P944, DOI 10.1046/j.1365-2222.2000.00856.x; LARSEN GL, 1992, NEW ENGL J MED, V326, P1540; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Sarpong SB, 1998, J ALLERGY CLIN IMMUN, V101, P566, DOI 10.1016/S0091-6749(98)70369-0; Sears MR, 1996, ARCH DIS CHILD, V75, P392, DOI 10.1136/adc.75.5.392; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Singh BP, 1997, ALLERGY, V52, P232, DOI 10.1111/j.1398-9995.1997.tb00984.x; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	22	28	29	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6		S			S521	S524		10.1067/mai.2002.124564	http://dx.doi.org/10.1067/mai.2002.124564			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	568JU	12063507				2022-12-18	WOS:000176539300002
J	Beyer, K; Castro, R; Feidel, C; Sampson, HA				Beyer, K; Castro, R; Feidel, C; Sampson, HA			Milk-induced urticaria is associated with the expansion of T cells expressing cutaneous lymphocyte antigen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute urticaria; cutaneous lymphocyte antigen; lymphocyte; allergen; cow's milk; homing receptor; skin	ADHESION MOLECULE EXPRESSION; 1ST 3 YEARS; TNF-ALPHA; ATOPIC-DERMATITIS; CHILDREN; ALLERGY; INFANTS; INTOLERANCE; SITES; LIFE	Background: Two forms of IgE-mediated skin reactions, atopic dermatitis (AD) and urticaria, have been associated with milk allergy. The reason for these distinct reactions is poorly understood. T cells expressing cutaneous lymphocyte antigen (CLA), a unique skin-homing receptor, are known to play an important role in AD. In contrast, the role of lymphocytes in patients with milk-induced urticaria is unclear. Objective: The expression of the skin-specific homing receptor CLA after in vitro milk protein-specific stimulation was investigated to determine whether T-lymphocyte homing to the skin plays a role in food-induced urticaria. Methods: Fourteen patients with milk-induced urticaria but no evidence of AD w ere included in the study and compared with 6 children with milk-induced AD, 6 children with milk-induced gastrointestinal diseases, and 6 nonatopic and 6 atopic individuals without milk allergy. PBMCs were cultured in the presence or absence of caseins or tetanus toxoid. T-cell proliferation was determined, and T-cell phenotyping was performed by means of flow cytometry with anti-CD4, anti-CD8, and anti-CLA mAbs. Results: After in vitro stimulation with caseins, PBMCs from patients with milk-induced urticaria and AD had a significantly greater percentage of CD4(+) T cells expressing CLA than patients with milk-induced gastrointestinal symptoms and atopic or nonatopic control subjects. After tetanus stimulation in vitro, no significant difference between the groups was observed. T cells from both patients with milk-induced urticaria and control subjects proliferated well in response to caseins and tetanus. Conclusion: Lymphocytes expressing CLA are selectively activated in patients with milk-induced urticaria and may play an important role in the pathogenesis of this disease. Expression of CLA is not unique to milk-induced inflammation in the skin of patients with AD and milk allergy.	CUNY Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Jaffe Inst Food Allergy, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Beyer, K (corresponding author), CUNY Mt Sinai Sch Med, Div Pediat Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.				NCRR NIH HHS [MO1 RR-00071] Funding Source: Medline; NIAID NIH HHS [AI44236] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Benlounes N, 1999, J ALLERGY CLIN IMMUN, V104, P863, DOI 10.1016/S0091-6749(99)70300-3; BOCK SA, 1987, PEDIATRICS, V79, P683; Campbell DE, 1999, PEDIAT ALLERG IMM-UK, V10, P253, DOI 10.1034/j.1399-3038.1999.00042.x; de Vries IJM, 1998, J ALLERGY CLIN IMMUN, V102, P461, DOI 10.1016/S0091-6749(98)70136-8; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; Eppihimer MJ, 1996, CIRC RES, V79, P560, DOI 10.1161/01.RES.79.3.560; Haas N, 1998, ARCH DERMATOL, V134, P41, DOI 10.1001/archderm.134.1.41; Haas N, 1998, INT ARCH ALLERGY IMM, V115, P210, DOI 10.1159/000023902; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Henz BM, 2000, HAUTARZT, V51, P302, DOI 10.1007/s001050051039; Hermes B, 1999, J ALLERGY CLIN IMMUN, V103, P307, DOI 10.1016/S0091-6749(99)70506-3; HIDE DW, 1983, BRIT J CLIN PRACT, V37, P285; HILL DJ, 1988, CLIN ALLERGY, V18, P469, DOI 10.1111/j.1365-2222.1988.tb02897.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; LEUNG DYM, 1996, ATOPIC DERMATITIS PA, P113; Miki I, 1996, CELL IMMUNOL, V171, P285; PICKER LJ, 1994, CURR OPIN IMMUNOL, V6, P394, DOI 10.1016/0952-7915(94)90118-X; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1997, J ROY SOC MED, V90, P3; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238	24	28	29	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					688	693		10.1067/mai.2002.123235	http://dx.doi.org/10.1067/mai.2002.123235			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941320				2022-12-18	WOS:000175132600019
J	Aizawa, H; Plitt, J; Bochner, BS				Aizawa, H; Plitt, J; Bochner, BS			Human eosinophils express two Siglec-8 splice variants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Johns Hopkins Univ, Sch Med, Div Clin Immunol, Dept Med, Baltimore, MD 21224 USA	Johns Hopkins University	Aizawa, H (corresponding author), Johns Hopkins Univ, Sch Med, Div Clin Immunol, Dept Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Foussias G, 2000, BIOCHEM BIOPH RES CO, V278, P775, DOI 10.1006/bbrc.2000.3866; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Munday J, 2001, BIOCHEM J, V355, P489, DOI 10.1042/0264-6021:3550489	5	28	29	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					176	176		10.1067/mai.2002.120550	http://dx.doi.org/10.1067/mai.2002.120550			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799386	Bronze			2022-12-18	WOS:000173739300029
J	Quirce, S; Fernandez-Nieto, M; Polo, F; Sastre, J				Quirce, S; Fernandez-Nieto, M; Polo, F; Sastre, J			Soybean trypsin inhibitor is an occupational inhalant allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; EPIDEMIC; BAKERS; FLOUR		Fdn Jimenez Diaz, Dept Allergy, E-28040 Madrid, Spain; ALK Abello, E-28040 Madrid, Spain	ALK-Abello AS	Quirce, S (corresponding author), Fdn Jimenez Diaz, Dept Allergy, Av Reyes Catolicos 2, E-28040 Madrid, Spain.		s, q/AAD-7171-2020					BAUR X, 1988, RESPIRATION, V54, P70, DOI 10.1159/000195503; Baur X, 1996, ALLERGY, V51, P326, DOI 10.1111/j.1398-9995.1996.tb00093.x; BUSH RK, 1988, J ALLERGY CLIN IMMUN, V82, P251, DOI 10.1016/0091-6749(88)91007-X; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; Quirce S, 2000, CLIN EXP ALLERGY, V30, P839; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2	7	28	29	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					178	178		10.1067/mai.2002.120952	http://dx.doi.org/10.1067/mai.2002.120952			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799388				2022-12-18	WOS:000173739300031
J	Yamada, K; Elliott, WM; Brattsand, R; Valeur, A; Hogg, JC; Hayashi, S				Yamada, K; Elliott, WM; Brattsand, R; Valeur, A; Hogg, JC; Hayashi, S			Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						transcription factor activator protein 1; chemokines; eosinophils; epithelial cells; nuclear factor kappa B	MONOCYTE CHEMOATTRACTANT PROTEIN-1; MESSENGER-RNA EXPRESSION; FACTOR-KAPPA-B; GUINEA-PIG; INHALED GLUCOCORTICOIDS; BRONCHIAL BIOPSIES; CHEMOKINE EOTAXIN; ASTHMATICS; ACTIVATION; RANTES	Background: We recently reported that allergic lung inflammation in guinea pigs became steroid resistant in the presence of latent adenoviral infection. Objective: We sought to investigate the molecular mechanisms that underlie steroid resistance in adenoviral infection. Methods: Guinea pigs with a latent adenoviral infection were sensitized and challenged with ovalbumin (OVA) and given daily injections of budesonide (20 mg/kg administered intraperitoneally). Sham-infected animals received either saline challenge without budesonide injection or OVA challenge with or without budesonide. The inflammatory response in the lung was measured by means of quantitative histology. Eotaxin, monocyte chemoattractant protein 1 (MCP-1), and RANTES expression in the lung were analyzed by means of Northern blotting, and the binding activity of activator protein 1 (AP-1) and nuclear factor kappaB in nuclear extracts from the lung was analyzed with electrophoretic mobility shift assays. Results: OVA challenge increased eosinophil infiltration and eotaxin and MCP-1 mRNA expression in the lungs, and glucocorticoids reduced these increases in the sham-infected, but not the adenovirus-infected, animals. Changes in binding activity of AP-1, but not nuclear factor kappaB, paralleled changes in eotaxin and MCP-1 mRNA. Conclusion: We conclude that latent adenoviral infection inhibits the anti-inflammatory effects of glucocorticoids on allergen-induced eotaxin and MCP-1 expression through AP-1, leading to steroid-resistant allergic lung inflammation.	Univ British Columbia, St Pauls Hosp, McDonald Res Labs, iCAPTURE, Vancouver, BC V6Z 1Y6, Canada; Osaka Med Coll, Dept Internal Med 1, Osaka, Japan; Astra Zeneca R&D, Lund, Sweden	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; Osaka Medical College; AstraZeneca	Hayashi, S (corresponding author), Univ British Columbia, St Pauls Hosp, McDonald Res Labs, iCAPTURE, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.							ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Braciak TA, 1996, J IMMUNOL, V157, P5076; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Campbell EM, 1997, J IMMUNOL, V159, P1482; Chensue SW, 1999, J IMMUNOL, V163, P165; DEMOLY P, 1992, AM J RESP CELL MOL, V7, P128, DOI 10.1165/ajrcmb/7.2.128; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIOTT WM, 1995, AM J RESP CELL MOL, V12, P642, DOI 10.1165/ajrcmb.12.6.7766428; GarciaZepeda EA, 1997, GENOMICS, V41, P471, DOI 10.1006/geno.1997.4656; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Jahnsen FL, 1999, J IMMUNOL, V163, P1545; JAMIL S, 2000, AM J RESP CRIT CARE, V161, pA46; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Keicho N, 1999, AM J PHYSIOL-LUNG C, V277, pL523, DOI 10.1152/ajplung.1999.277.3.L523; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; MACEK V, 1994, AM J RESP CRIT CARE, V150, P7, DOI 10.1164/ajrccm.150.1.8025775; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; Matsukawa A, 2000, J IMMUNOL, V164, P1699, DOI 10.4049/jimmunol.164.4.1699; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723, DOI 10.1016/S0091-6749(99)70281-2; Pagano M., 2018, PRINCIPLES BIOSTATIS; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; SHYY YJ, 1990, BIOCHEM BIOPH RES CO, V169, P346, DOI 10.1016/0006-291X(90)90338-N; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; Vianna EO, 1998, J ALLERGY CLIN IMMUN, V102, P592, DOI 10.1016/S0091-6749(98)70274-X; Vitalis TZ, 1996, AM J RESP CELL MOL, V14, P225, DOI 10.1165/ajrcmb.14.3.8845172; Vitalis TZ, 1998, EUR RESPIR J, V11, P664; Wang JH, 1996, AM J RESP CELL MOL, V14, P27, DOI 10.1165/ajrcmb.14.1.8534483; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yamada K, 2000, J ALLERGY CLIN IMMUN, V106, P844, DOI 10.1067/mai.2000.110473; Yang Y, 1998, BLOOD, V92, P3912, DOI 10.1182/blood.V92.10.3912.422k23_3912_3923; Ying S, 1999, J IMMUNOL, V163, P6321; YOSHIMURA T, 1993, J IMMUNOL, V150, P5025	43	28	33	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					35	42		10.1067/mai.2002.120525	http://dx.doi.org/10.1067/mai.2002.120525			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799363				2022-12-18	WOS:000173739300006
J	Ahluwalia, P; Anderson, DF; Wilson, SJ; McGill, JI; Church, MK				Ahluwalia, P; Anderson, DF; Wilson, SJ; McGill, JI; Church, MK			Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nedocromil sodium; levocabastine; conjunctival challenge; seasonal allergic conjunctivitis; mast cells; histamine; prostaglandin D-2; intercellular adhesion molecule 1	MAST-CELL NUMBERS; IN-VIVO; PHARMACOLOGICAL PROPERTIES; LEUKOCYTE INFILTRATION; ADHESION MOLECULES; MEDIATOR RELEASE; EYE DISEASE; EXPRESSION; HISTAMINE; EFFICACY	Background: Nedocromil sodium and levocabastine are widely used for the treatment of ocular allergy, but their mechanisms of action are unclear. Objective: We sought to compare the efficacy and mechanisms of action of nedocromil sodium and levocabastine in reducing conjunctival symptoms after ocular allergen challenge. Methods: We performed a double-blind, placebo-controlled study in which 48 subjects were randomized to 3 groups to receive nedocromil sodium (2%), levocabastine (0.05%), or placebo eye drops twice daily for 2 weeks before ocular challenge with 10 muL of ryegrass extract. Symptom and tear histamine and PGD(2) concentrations were determined before challenge and at 10, 20, 30, 60, 180, and 360 minutes after challenge. Bulbar biopsy specimens were taken at 6 and 24 hours after challenge to assess conjunctival inflammatory cell numbers, adhesion molecule expression, and mast cell-associated IL-4, IL-5, IL-6, IL- 13, and TNF-alpha levels. Results: Both drugs significantly reduced total symptom scores (P < .05) at all times after challenge compared with placebo. Itching, hyperemia, and lacrimation were most affected. Nedocromil sodium treatment reduced tear concentrations of histamine (by 77%) and PGD(2) (by 70%) at 30 minutes after challenge (both P < .05). In biopsy specimens nedocromil sodium reduced the number of 3H4-positive mast cells (purportedly the secreted form of IL-4) by 49% at 6 hours and 59% at 24 hours (both P < .05). Levocabastine reduced intercellular adhesion molecule 1 expression by 52% at 6 hours and 45% at 24 hours (both P < .05). Conclusion: Nedocromil sodium and levocabastine both reduced the conjunctival symptoms after ocular allergen challenge but appeared to work by different mechanisms. Nedocromil sodium reduced mast cell function, whereas levocabastine appeared to have primarily antihistaminic actions, although it also reduced the expression of intercellular adhesion molecule 1.	Univ Southampton, Sch Med, Resp Cell & Mol Biol Res Div, Southampton, Hants, England	University of Southampton	Church, MK (corresponding author), Southampton Gen Hosp, Dermatopharmacol Unit, South Block 825, Southampton SO16 6YD, Hants, England.							ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; AMON U, 1995, HAUTARZT, V46, P234, DOI 10.1007/s001050050246; Anderson DF, 1997, CLIN EXP ALLERGY, V27, P1060, DOI 10.1111/j.1365-2222.1997.tb01258.x; AOKI Y, 1998, AM J PHYSIOL, V274, P1030; Bacon AS, 1998, INVEST OPHTH VIS SCI, V39, P322; Bacon AS, 2000, J ALLERGY CLIN IMMUN, V106, P948, DOI 10.1067/mai.2000.110930; BADDELEY SM, 1995, CLIN EXP ALLERGY, V25, P41, DOI 10.1111/j.1365-2222.1995.tb01001.x; BAKKER RA, 2000, P INT SEND HIST S SE; Bleecker ER, 1996, J ALLERGY CLIN IMMUN, V98, pS118, DOI 10.1016/S0091-6749(96)80139-4; BLUMENTHAL M, 1992, AM J OPHTHALMOL, V113, P56, DOI 10.1016/S0002-9394(14)75754-X; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; BROGDEN RN, 1993, DRUGS, V45, P693, DOI 10.2165/00003495-199345050-00007; Buscaglia S, 1996, CLIN EXP ALLERGY, V26, P1188, DOI 10.1046/j.1365-2222.1996.d01-267.x; Butrus S, 2000, CLIN THER, V22, P1462, DOI 10.1016/S0149-2918(00)83044-1; Chung KF, 1996, J ALLERGY CLIN IMMUN, V98, pS112, DOI 10.1016/S0091-6749(96)70026-X; Church M. RC. B. PH. R. MA. L., 1989, MAST CELL BASOPHIL D, P161; CHURCH MK, 1994, CELLS CYTOKINES LUNG, P13; CIPRANDI G, 1995, J ALLERGY CLIN IMMUN, V95, P612, DOI 10.1016/S0091-6749(95)70324-1; CIPRANDI G, 1990, ANN ALLERGY, V65, P156; Ciprandi G, 1998, ALLERGY, V53, P545, DOI 10.1111/j.1398-9995.1998.tb04099.x; DECHANT KL, 1991, DRUGS, V41, P202, DOI 10.2165/00003495-199141020-00006; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FRIES JWU, 1993, AM J PATHOL, V143, P725; Garrelds IM, 1996, ANN ALLERG ASTHMA IM, V76, P327, DOI 10.1016/S1081-1206(10)60033-6; Geiger E, 2000, J ALLERGY CLIN IMMUN, V105, P150, DOI 10.1016/S0091-6749(00)90190-8; HELLEBOID L, 1991, INVEST OPHTH VIS SCI, V32, P2281; Hickey MJ, 1999, J IMMUNOL, V163, P3441; JACKSON DM, 1992, EUR J PHARMACOL, V221, P175, DOI 10.1016/0014-2999(92)90790-B; JANSSENS M, 1992, DOC OPHTHALMOL, V82, P341, DOI 10.1007/BF00161022; Kremer B, 1998, ARZNEIMITTEL-FORSCH, V48, P924; MacLeod JDA, 1997, CLIN EXP ALLERGY, V27, P1328; McGill JI, 1998, BRIT J OPHTHALMOL, V82, P1203, DOI 10.1136/bjo.82.10.1203; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MORGAN SJ, 1991, J ALLERGY CLIN IMMUN, V87, P111, DOI 10.1016/0091-6749(91)90221-9; NOBLE S, 1995, DRUGS, V50, P1032, DOI 10.2165/00003495-199550060-00009; OKAYAMA Y, 1992, CLIN EXP ALLERGY, V22, P401, DOI 10.1111/j.1365-2222.1992.tb03102.x; PAZDRAK K, 1993, ALLERGY, V48, P598, DOI 10.1111/j.1398-9995.1993.tb00755.x; PROUD D, 1990, J ALLERGY CLIN IMMUN, V85, P896, DOI 10.1016/0091-6749(90)90075-F; Rihoux JP, 1999, INT ARCH ALLERGY IMM, V118, P380, DOI 10.1159/000024142; ROBINSON C, 1989, J INVEST DERMATOL, V93, P397, DOI 10.1111/1523-1747.ep12280290; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; Toru H, 1996, INT IMMUNOL, V8, P1367; WALLS AF, 1990, CLIN EXP ALLERGY, V20, P581, DOI 10.1111/j.1365-2222.1990.tb03153.x; WEEKE ER, 1987, MONOGR ALLERGY, V21, P1; Yoneda K, 1997, JPN J PHARMACOL, V73, P145, DOI 10.1254/jjp.73.145	46	28	31	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					449	454						6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544467				2022-12-18	WOS:000171215400019
J	Shirai, T; Hashimoto, D; Suzuki, K; Osawa, S; Aonahata, M; Chida, K; Nakamura, H				Shirai, T; Hashimoto, D; Suzuki, K; Osawa, S; Aonahata, M; Chida, K; Nakamura, H			Successful treatment of eosinophilic gastroenteritis with suplatast tosilate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA		Fujinomiya City Gen Hosp, Dept Internal Med, Fujinomiya, Japan; Fujinomiya City Gen Hosp, Dept Pathol, Fujinomiya, Japan; Hamamatsu Univ Sch Med, Dept Internal Med 2, Hamamatsu, Shizuoka, Japan	Hamamatsu University School of Medicine	Shirai, T (corresponding author), Fujinomiya City Gen Hosp, Dept Internal Med, 3-1 Nishiki Cho, Fujinomiya, Japan.		Osawa, Satoshi/AAS-3283-2020	Osawa, Satoshi/0000-0003-3414-1808				BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; Neustrom MR, 1999, J ALLERGY CLIN IMMUN, V104, P506, DOI 10.1016/S0091-6749(99)70404-5; Shim JJ, 2000, J ALLERGY CLIN IMMUN, V105, P739, DOI 10.1067/mai.2000.105221; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Tamaoki J, 2000, LANCET, V356, P273, DOI 10.1016/S0140-6736(00)02501-0; YAMAYA H, 1995, LIFE SCI, V56, P1647, DOI 10.1016/0024-3205(95)00132-P; Zhao GD, 2000, INT ARCH ALLERGY IMM, V121, P116, DOI 10.1159/000024306	7	28	31	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					924	925		10.1067/mai.2001.114705	http://dx.doi.org/10.1067/mai.2001.114705			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344364				2022-12-18	WOS:000168812300025
J	Ruohola, A; Heikkinen, T; Waris, M; Puhakka, T; Ruuskanen, O				Ruohola, A; Heikkinen, T; Waris, M; Puhakka, T; Ruuskanen, O			Intranasal fluticasone propionate does not prevent acute otitis media during viral upper respiratory infection in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	7th International Symposium on Recent Advances Otitis Media	JUN 01-05, 1999	FT LAUDERDALE, FLORIDA			acute otitis media; fluticasone propionate; respiratory infection; rhinovirus; virus	TIME-RESOLVED FLUOROIMMUNOASSAY; RHINOVIRUS INFECTIONS; TRACT INFECTION; CLINICAL SPECIMENS; SYNCYTIAL VIRUS; INFLUENZA-A; COMMON COLD; MIDDLE-EAR; NASAL; PCR	Background: Acute otitis media (AOM) is the most common complication of a viral upper respiratory infection (URI) in children, The virus-induced host inflammatory response in the nasopharynx plays a key role in the pathogenesis of AOM. Suppression of this inflammatory process might prevent the development of AOM as a complication. Objective: We sought to assess the effect of intranasally administered fluticasone propionate on prevention of AOM during a viral respiratory infection. Methods: A total of 210 children (mean age, 2.1 years; range, 0.7-3.9 years) with normal middle ear status and URI of 48 hours' duration or less were randomly allocated to receive either fluticasone (100 mu g twice daily) or placebo for 7 days. The specific viral cause of the infection was determined from nasopharyngeal aspirates obtained at the first visit, The children were re-examined at the end of the 7-day medication period. Results: In the fluticasone group AOM developed in 40 (38.1%) of 105 children compared with 29 (28.2%) of 103 children receiving placebo (P = .13). The viral cause of the respiratory infection was determined in 167 (86.1%) of 194 children from whom a nasopharyngeal aspirate was obtained. In children with rhinovirus infection, AOM developed significantly more often in the fluticasone group (45.7%) than in the placebo group (14.7%, P = .005). Conclusion: Intranasally administered fluticasone does not prevent the development of AOM during URI but may increase the incidence of AOM during rhinovirus infection.	Turku Univ Hosp, Dept Pediat, FIN-20521 Turku, Finland; Univ Turku, Dept Virol, SF-20500 Turku, Finland; Univ Turku, Biophys Lab, SF-20500 Turku, Finland	University of Turku; University of Turku; University of Turku	Ruohola, A (corresponding author), Turku Univ Hosp, Dept Pediat, PL 52, FIN-20521 Turku, Finland.		Waris, Matti E/A-6418-2008	Heikkinen, Terho/0000-0001-6504-0116; Waris, Matti/0000-0002-6747-0889	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bluestone CD, 1996, PEDIATR INFECT DIS J, V15, P281, DOI 10.1097/00006454-199604000-00002; Bluestone ChD, 1995, OTITIS MEDIA INFANTS, V2nd, P1; Chonmaitree T, 1997, ANN NY ACAD SCI, V830, P143, DOI 10.1111/j.1749-6632.1997.tb51886.x; Dagan R, 1996, PEDIATR INFECT DIS J, V15, P980, DOI 10.1097/00006454-199611000-00010; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; DOYLE WJ, 1994, ANN OTO RHINOL LARYN, V103, P59, DOI 10.1177/000348949410300111; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7; HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201; HALONEN P, 1995, J CLIN MICROBIOL, V33, P648, DOI 10.1128/JCM.33.3.648-653.1995; Heikkinen T, 1996, ANN MED, V28, P23, DOI 10.3109/07853899608999070; HEIKKINEN T, 1995, J PEDIATR-US, V126, P313, DOI 10.1016/S0022-3476(95)70569-4; HEIKKINEN T, 1994, PEDIATR INFECT DIS J, V13, P659, DOI 10.1097/00006454-199407000-00016; Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402; HENDERSON FW, 1982, NEW ENGL J MED, V306, P1377, DOI 10.1056/NEJM198206103062301; HIERHOLZER JC, 1987, J CLIN MICROBIOL, V25, P1662, DOI 10.1128/JCM.25.9.1662-1667.1987; Ho MT, 1999, NEW ENGL J MED, V341, P929, DOI 10.1056/NEJM199909233411301; KAMAHORA T, 1989, VIRUS RES, V12, P1; Koivunen P, 1999, PEDIATR INFECT DIS J, V18, P303, DOI 10.1097/00006454-199903000-00023; Lonnrot M, 1999, J MED VIROL, V59, P378, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;378::AID-JMV19&gt;3.0.CO;2-I; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052; Niemela M, 1999, ACTA PAEDIATR, V88, P553, DOI 10.1080/08035259950169585; NIKKARI S, 1989, J VIROL METHODS, V23, P29, DOI 10.1016/0166-0934(89)90086-4; NOAH TL, 1995, J INFECT DIS, V171, P584, DOI 10.1093/infdis/171.3.584; Papi A, 2000, J ALLERGY CLIN IMMUN, V105, P318, DOI 10.1016/S0091-6749(00)90082-4; Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791; Prince GA, 1996, J INFECT DIS, V173, P598, DOI 10.1093/infdis/173.3.598; PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120; Puhakka T, 1998, J ALLERGY CLIN IMMUN, V101, P726, DOI 10.1016/S0091-6749(98)70301-X; Puhakka T, 1998, J ALLERGY CLIN IMMUN, V102, P403, DOI 10.1016/S0091-6749(98)70127-7; RUUSKANEN O, 1989, PEDIATR INFECT DIS J, V8, P94; Santti J, 1997, J VIROL METHODS, V66, P139, DOI 10.1016/S0166-0934(97)00049-9; Sawyer MH, 1999, PEDIATR INFECT DIS J, V18, P1033, DOI 10.1097/00006454-199912000-00002; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TEELE DW, 1990, J INFECT DIS, V162, P685, DOI 10.1093/infdis/162.3.685; VOLOVITZ B, 1988, J PEDIATR-US, V112, P218, DOI 10.1016/S0022-3476(88)80058-1; WARIS M, 1988, J CLIN MICROBIOL, V26, P2581, DOI 10.1128/JCM.26.12.2581-2585.1988; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; Wiseman LR, 1997, DRUGS, V53, P885, DOI 10.2165/00003495-199753050-00014; WOODRUFF JF, 1979, J IMMUNOL, V123, P31	41	28	29	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					467	471						5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	356YN	10984365	Green Published, Bronze			2022-12-18	WOS:000089471900008
J	Hogan, MB; Piktel, D; Landreth, KS				Hogan, MB; Piktel, D; Landreth, KS			IL-5 production by bone marrow stromal cells: Implications for eosinophilia associated with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-5; bone marrow stromal cell; eosinophilopoiesis; asthma	ALLERGEN-INDUCED INCREASES; INTERLEUKIN-1 RECEPTOR ANTAGONIST; IN-VITRO; B-LYMPHOPOIESIS; MAST-CELL; EXPRESSION; PROGENITORS; CYTOKINES; INVITRO; DIFFERENTIATION	Background: Eosinophil infiltration of bronchial tissue is a hallmark of asthma, Recruitment of eosinophils into pulmonary tissue is dependent on the presence of IL-5, In addition, IL-5 plays a significant role in the differentiation, proliferation, and maturation of eosinophil progenitor cells in the bone marrow before recruitment into the lung. The contribution of bone marrow eosinophil production to eosinophilia associated with asthma is poorly understood. Objective: The aims of this study were to determine whether bone marrow stromal cells produce IL-5 and to determine whether IL-5 production by stromal cells is upregulated by IL-1, an inflammatory cytokine associated with asthma, Methods: IL-5 messenger (m)RNA from bone marrow stromal cells was amplified by RT-PCR and sequenced. Stromal cells were lysed, and IL-5 protein production was measured by ELISA, Upregulation of stromal cell IL-5 transcription, translation, and functional effect on eosinophil differentiation was evaluated after stimulation with recombinant IL-1 alpha and IL-1 beta and compared with untreated cells. Results: Bone marrow stromal cells transcribe and translate IL-5. The nucleotide sequence of IL-5 mRNA from stromal cells was identical to that previously reported for murine T cells. IL-5 mRNA. abundance in stromal cells increased with increasing cell confluence in culture, IL-5 mRNA and protein levels were upregulated by exposure of stromal cells to the inflammatory cytokines IL-1 alpha and IL-1 beta, Exposure of stromal cells to IL-1 resulted in increased eosinophil differentiation in coculture experiments with nonadherent bone marrow cells. Conclusion: The production of IL-5 mRNA and protein by bone marrow stromal cells is a novel finding that has implications for both normal eosinophilopoiesis and development of the accelerated eosinophil production associated with asthma.	W Virginia Univ, Sch Med, Dept Pediat, Morgantown, WV 26506 USA; W Virginia Univ, Sch Med, Dept Microbiol & Immunol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Hogan, MB (corresponding author), W Virginia Univ, Sch Med, Dept Pediat, POB 9214, Morgantown, WV 26506 USA.							AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; BILLIPS LG, 1990, BLOOD, V75, P611; BORISH L, 1992, J IMMUNOL, V149, P3078; BOURKE PF, 1995, BLOOD, V85, P2069, DOI 10.1182/blood.V85.8.2069.bloodjournal8582069; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; COLLINS LS, 1987, J IMMUNOL, V138, P1082; Crocker IC, 1998, J ASTHMA, V35, P187, DOI 10.3109/02770909809068207; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Denburg JA, 1999, INT ARCH ALLERGY IMM, V118, P101, DOI 10.1159/000024040; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; DUBUCQUOI S, 1994, J EXP MED, V179, P703, DOI 10.1084/jem.179.2.703; Gordon MY, 1997, BRIT J HAEMATOL, V96, P647, DOI 10.1111/bjh.1997.96.3.647; Guerriero A, 1997, BLOOD, V90, P3444, DOI 10.1182/blood.V90.9.3444; Hanifin JM, 1999, J AM ACAD DERMATOL, V41, P72, DOI 10.1016/S0190-9622(99)70410-X; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; Iguchi A, 1997, CELL STRUCT FUNCT, V22, P357, DOI 10.1247/csf.22.357; Inman MD, 1999, AM J RESP CELL MOL, V21, P473, DOI 10.1165/ajrcmb.21.4.3622; Inman MD, 1997, AM J RESP CELL MOL, V17, P634, DOI 10.1165/ajrcmb.17.5.2746; Kincade P W, 1991, Semin Immunol, V3, P379; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360, DOI 10.1165/ajrcmb.13.3.7654390; Linden M, 1999, ALLERGY, V54, P212, DOI 10.1034/j.1398-9995.1999.00756.x; MANETTI R, 1994, RES IMMUNOL, V145, P93, DOI 10.1016/S0923-2494(94)80019-7; Minshall EM, 1998, AM J RESP CRIT CARE, V158, P951, DOI 10.1164/ajrccm.158.3.9709114; Mohle R, 1997, BRIT J HAEMATOL, V99, P732, DOI 10.1046/j.1365-2141.1997.4713279.x; Moller A, 1998, IMMUNOLOGY, V93, P289; OHNISHI M, 1988, AM REV RESPIR DIS, V138, P560, DOI 10.1164/ajrccm/138.3.560; OKADA S, 1995, J ALLERGY CLIN IMMUN, V95, P1236, DOI 10.1016/S0091-6749(95)70081-1; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Sousa AR, 1996, AM J RESP CRIT CARE, V154, P1061, DOI 10.1164/ajrccm.154.4.8887608; STERN M, 1992, J IMMUNOL, V148, P3543; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125; Wood LJ, 1999, AM J RESP CRIT CARE, V159, P1457, DOI 10.1164/ajrccm.159.5.9808123; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737; Zeibecoglou K, 1999, J ALLERGY CLIN IMMUN, V103, P99, DOI 10.1016/S0091-6749(99)70532-4	42	28	32	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					329	336		10.1067/mai.2000.108309	http://dx.doi.org/10.1067/mai.2000.108309			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932078				2022-12-18	WOS:000088708100017
J	Shen, HD; Wang, CW; Chou, H; Lin, WL; Tam, MF; Huang, MH; Kuo, ML; Wang, SR; Han, SH				Shen, HD; Wang, CW; Chou, H; Lin, WL; Tam, MF; Huang, MH; Kuo, ML; Wang, SR; Han, SH			Complementary DNA cloning and immunologic characterization of a new Penicillium citrinum allergen (Pen c 3)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Penicillium citrinum; allergen; peroxisomal membrane protein; cDNA cloning; mAbs	ALKALINE SERINE PROTEINASE; ASPERGILLUS-FUMIGATUS; MAJOR ALLERGEN; MOLECULAR-CLONING; CANDIDA-BOIDINII; CROSS-REACTIVITY; SEQUENCE; ASTHMA; ANTIBODY	Background: Penicillium citrinum has been identified as the most prevalent airborne Penicillium species in the Taipei area. It is important to understand the allergenic composition of this ubiquitous fungal species. Objective: The complementary DNA (cDNA) clone of an allergen from P citrinum was isolated and expressed in Escherichia coli as a fusion protein. mAbs were prepared with the recombinant protein as antigen. The corresponding natural allergen in the fungal extracts was identified with the mAbs. Methods: A Uni-Zap XR P citrinum cDNA library was screened with sera from asthmatic patients. An IgE-binding cDNA clone was isolated and expressed as a glutathione-S-transferase fusion protein. The frequency of IgE binding to the expressed protein was analyzed by immunoblotting. Spleen cells from BALB/c mice immunized with the recombinant protein were fused with NS-1 cells for mAb generation. Results: A P citrinum cDNA library was screened with a mixture of serum samples from 4 asthmatic patients. An IgE-binding cDNA clone was obtained and designated as PCE2. PCE2 has a 694-bp insert that contains a 167 amino acids open reading frame. The deduced amino acid sequence of the encoded protein has 82.6% (138 amino acids) identity with an Aspergillus fumigatus peroxisomal membrane protein allergen (Asp f 3), PCES was expressed in E coli as a fusion protein and designated as Pen c 3. Sera from 13 (46%) of the 28 Penicillium-sensitized asthmatic patients demonstrated IgE binding to Pen c 3. In addition, 11 of the 13 Pen c 3-positive serum samples have IgE immunoblot reactivity to recombinant Asp f 3. The presence of IgE cross-reactivity between Pen c 3 and Asp f 3 was also detected by immunoblot inhibition. Four of the 6 mAbs generated against Pen c 3 cross-react with Asp f 3. The presence of the corresponding 18-k natural allergens in the crude extracts of P citrinum and A fumigatus were detected by immunoblot with use of the mAbs and sera from asthmatic patients. Conclusion: Results obtained suggest that the peroxisomal membrane protein (Pen c 3) is an important allergen of P citrinum. PCE2 is a full-length cDNA clone encoding this allergen. In addition, the mAbs generated may be useful in standardizing the diagnostic allergenic extracts.	Vet Gen Hosp, Dept Med Res, Taipei 112, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Chang Gung Childrens Hosp, Hlth Res Div, Taipei, Taiwan; Natl Yang Ming Univ, Dept Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Yang Ming Univ, Ctr Immunol, Taipei 112, Taiwan	Academia Sinica - Taiwan; Chang Gung Memorial Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Shen, HD (corresponding author), Vet Gen Hosp, Dept Med Res, Taipei 112, Taiwan.		Kuo, Min-Liang/C-4872-2009					Banerjee B, 1998, IMMUNOL ALLERGY CLIN, V18, P601, DOI 10.1016/S0889-8561(05)70024-2; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURR ML, 1988, J ROY SOC HEALTH, V108, P99, DOI 10.1177/146642408810800311; Chou H, 1999, INT ARCH ALLERGY IMM, V119, P282, DOI 10.1159/000024205; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; DANTZKER DR, 1987, AM REV RESPIR DIS, V136, P225; EBINA K, 1994, BBA-GENE STRUCT EXPR, V1219, P148, DOI 10.1016/0167-4781(94)90258-5; GARRARD LJ, 1989, J BIOL CHEM, V264, P13929; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; Hemmann S, 1998, CLIN EXP ALLERGY, V28, P860, DOI 10.1046/j.1365-2222.1998.00329.x; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; MUILENBERG M, 1990, Journal of Allergy and Clinical Immunology, V85, P247; Pitt JI, 1988, LAB GUIDE COMMON PEN; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; Shen HD, 1997, CLIN EXP ALLERGY, V27, P79; Shen HD, 1998, INT ARCH ALLERGY IMM, V116, P29, DOI 10.1159/000023921; Shen HD, 1999, CLIN EXP ALLERGY, V29, P642, DOI 10.1046/j.1365-2222.1999.00509.x; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; Shen HD, 1997, CLIN EXP ALLERGY, V27, P682, DOI 10.1111/j.1365-2222.1997.tb01197.x; Shen HD, 1999, INT ARCH ALLERGY IMM, V119, P259, DOI 10.1159/000024202; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEI DL, 1993, CURR MICROBIOL, V26, P137, DOI 10.1007/BF01577367; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; Yasueda H, 1998, BIOCHEM BIOPH RES CO, V248, P240, DOI 10.1006/bbrc.1998.8944	25	28	31	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					827	833		10.1067/mai.2000.105220	http://dx.doi.org/10.1067/mai.2000.105220			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756236	Bronze			2022-12-18	WOS:000086604100024
J	Asmus, MJ; Sherman, J; Hendeles, L				Asmus, MJ; Sherman, J; Hendeles, L			Bronchoconstrictor additives in bronchodilator solutions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						preservatives; sulfites; benzalkonium; bronchodilators; albuterol	CANINE LUNG PERIPHERY; BENZALKONIUM CHLORIDE; AIRWAY CONSTRICTION; NEBULIZER SOLUTIONS; ASTHMATIC SUBJECTS; PARADOXICAL BRONCHOCONSTRICTION; MICROBIAL-CONTAMINATION; HYPERREACTIVE AIRWAYS; INHALED PRESERVATIVES; IPRATROPIUM BROMIDE	Nebulized bronchodilator solutions are available in the United States as both nonsterile and sterile-filled products. Sulfites, benzalkonium chloride (BAG), or chlorobutanol are added to nonsterile products to prevent bacterial growth, but there have been reports of contaminated solutions containing preservatives. Ethylenediamine tetraacetic acid (EDTA) is added to some products to prevent discoloration of the solution. With the exception of chlorobutanol, ail of these additives are capable of inducing bronchospasm in a concentration-dependent manner. However, it is rarely apparent to the patient or health care provider that the additive diminishes the bronchodilator effects. Older products (eg, isoproterenol and isoetharine) contain enough sulfites to produce bronchospasm in most patients with asthma, even in those without a prior history of sulfite sensitivity. Bronchoconstriction from inhaled BAG is cumulative, prolonged, and correlates directly with basal airway responsiveness. The multidose dropper bottle of albuterol contains 50 mu g BAC/dose, which is below the threshold for bronchoconstriction whereas the screwcap unit-dose vial contains 300 mu g/dose, which is above the threshold for many patients. If the screwcap product is used in the emergency department, a patient could receive as much as 1800 mu g of BAC in the first hour. Three sterile-filled unit dose albuterol products contain no additives, whereas a fourth, (manufactured by Dey Laboratories) contains 300 mu g of EDTA, which is also below the threshold dose for bronchoconstriction, Only additive-free sterile solutions should be used for hourly or continuous nebulization of albuterol, The multidose dropper bottle or the Dey product can he used when the interval between doses is longer, whereas the screwcap product should not be used for acute therapy. Ipratropium is available only as a sterile, additive-free unit-dose vial, as is levalbuterol.	Univ Florida, Hlth Sci Ctr, Coll Pharm, Dept Pharm Practice, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Pediat Pulm Div, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Hendeles, L (corresponding author), Univ Florida, Hlth Sci Ctr, Coll Pharm, Dept Pharm Practice, Box 100486, Gainesville, FL 32610 USA.		Asmus, Michael J/U-8654-2019; Asmus, Michael/N-4016-2018	Asmus, Michael J/0000-0002-5939-7802; Asmus, Michael/0000-0002-5939-7802				BARNES KL, 1987, BRIT MED J, V295, P812, DOI 10.1136/bmj.295.6602.812; BEASLEY CRW, 1987, BRIT MED J, V294, P1197, DOI 10.1136/bmj.294.6581.1197-a; BEASLEY R, 1989, NEW ZEAL MED J, V102, P357; BEASLEY R, 1988, BRIT J CLIN PHARMACO, V25, P283, DOI 10.1111/j.1365-2125.1988.tb03305.x; Beasley R, 1998, PHARMACOTHERAPY, V18, P130; Berlin CM, 1997, PEDIATRICS, V99, P268; BOUCHER M, 1992, ANN PHARMACOTHER, V26, P772, DOI 10.1177/106002809202600604; COCCHETTO DM, 1991, J ASTHMA, V28, P49, DOI 10.3109/02770909109073370; DOWNES H, 1983, J APPL PHYSIOL, V55, P1496, DOI 10.1152/jappl.1983.55.5.1496; DOWNES H, 1985, J APPL PHYSIOL, V59, P92, DOI 10.1152/jappl.1985.59.1.92; ECKERT B, 1993, MED J AUSTRALIA, V159, P566, DOI 10.5694/j.1326-5377.1993.tb138031.x; ELLWOOD RK, 1982, AM REV RESPIR DIS S, V125, P61; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FINE JM, 1987, AM REV RESPIR DIS, V135, P826, DOI 10.1164/arrd.1987.135.4.826; FINNERTY JP, 1993, AM REV RESPIR DIS, V148, P512, DOI 10.1164/ajrccm/148.2.512; HIRSHMAN CA, 1983, J APPL PHYSIOL, V54, P1101, DOI 10.1152/jappl.1983.54.4.1101; HIRSHMAN CA, 1983, J APPL PHYSIOL, V54, P1108, DOI 10.1152/jappl.1983.54.4.1108; JONES PD, 1985, AUST NZ J MED, V15, P585; KOEPKE JW, 1984, JAMA-J AM MED ASSOC, V251, P2982, DOI 10.1001/jama.251.22.2982; KOEPKE JW, 1985, ANN ALLERGY, V54, P213; KWONG T, 1990, NEW ZEAL MED J, V103, P457; LILKER ES, 1981, NEW ENGL J MED, V305, P702; LINDEMAN KS, 1990, J APPL PHYSIOL, V68, P1114, DOI 10.1152/jappl.1990.68.3.1114; LINDEMAN KS, 1991, J APPL PHYSIOL, V71, P1848, DOI 10.1152/jappl.1991.71.5.1848; MERTZ JJ, 1967, AM REV RESPIR DIS, V95, P454; MISZKIEL KA, 1988, BRIT J CLIN PHARMACO, V25, P157, DOI 10.1111/j.1365-2125.1988.tb03286.x; MISZKIEL KAS, 1988, BR J CLIN PHARM, V20, P295; MORRIS AH, 1973, AM REV RESPIR DIS, V107, P802; *NAT ASTHM ED PREV, 1997, NIH PUBL; NICKLAS RA, 1990, J ALLERGY CLIN IMMUN, V85, P959, DOI 10.1016/0091-6749(90)90084-H; OCALLAGHAN C, 1989, BRIT MED J, V299, P1433, DOI 10.1136/bmj.299.6713.1433-a; Oie S, 1998, AM J HEALTH-SYST PH, V55, P2534, DOI 10.1093/ajhp/55.23.2534; READ GW, 1979, J PHARMACOL EXP THER, V211, P711; REISMAN RE, 1970, J ALLERGY, V46, P162, DOI 10.1016/0021-8707(70)90095-X; SANDERS CV, 1970, ANN INTERN MED, V73, P15, DOI 10.7326/0003-4819-73-1-15; SCHWARTZ HJ, 1984, J ALLERGY CLIN IMMUN, V74, P511, DOI 10.1016/0091-6749(84)90387-7; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P469, DOI 10.1016/0091-6749(84)90380-4; SUMMERS QA, 1991, BRIT J CLIN PHARMACO, V31, P204, DOI 10.1111/j.1365-2125.1991.tb05517.x; TRAUTLEIN J, 1976, CHEST, V70, P711, DOI 10.1378/chest.70.6.711; UTELL MJ, 1983, AM REV RESPIR DIS, V128, P444, DOI 10.1164/arrd.1983.128.3.444; WEXLER MR, 1991, ANN ALLERGY, V66, P267; WINDOM H, 1990, EUR RESPIR J, V3, P725; WORTHINGTON I, 1989, Canadian Journal of Hospital Pharmacy, V42, P165; WRIGHT W, 1990, AM REV RESPIR DIS, V141, P1400, DOI 10.1164/ajrccm/141.6.1400; ZHANG YG, 1990, AM REV RESPIR DIS, V141, P1405, DOI 10.1164/ajrccm/141.6.1405; 1997, FED REG, V62, P49639; 1988, LANCET, V8604, P202	48	28	31	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	2	S			S53	S60		10.1016/S0091-6749(99)70274-5	http://dx.doi.org/10.1016/S0091-6749(99)70274-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	233GX	10452789				2022-12-18	WOS:000082419400007
J	Assanasen, P; Baroody, FM; Naureckas, E; Naclerio, RM				Assanasen, P; Baroody, FM; Naureckas, E; Naclerio, RM			Warming of feet elevates nasal mucosal surface temperature and reduces the early response to nasal challenge with allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						warming of feet; nasal mucosal surface temperature; nasal provocation; allergic rhinitis	SUBSTANCE-P; AIR; HOT	Background: We have previously shown that hot, humid air partially reduces the early allergic response, Mechanisms for this effect have been suggested, but none has gained universal acceptance. The most likely explanations are a modification of mucosal temperature or a reduction in nasal secretion osmolality, Objective: We sought to investigate whether increasing the nasal mucosal surface temperature by immersing feet in warm water (WW) could decrease the immediate nasal response to challenge with allergen. Methods: We performed a randomized, 2-way crossover study on 14 subjects with seasonal allergic rhinitis outside of their allergy season. They immersed their feet in either WW (42 degrees C) or room-temperature water (RW; 30 degrees C) for 5 minutes before and during nasal challenge with diluent for the allergen extract, followed by 2 increasing doses of allergen. Results: There was a statistically significant increase in nasal mucosal:temperature from baseline after warming of feet (WW, 1.9 +/- 0.1 degrees C, vs RW: 0.2 +/- 0.1 degrees C; P = .001), but there were no significant differences in body temperature (WW, 0.1 +/- 0.1 degrees C, vs RW, 0.4 +/- 0.1 degrees C; P = .1), Net changes from diluent challenge for all parameters were compared between immersion of feet in WW and RW, Immersion of feet in WW significantly: inhibited allergen-induced sneezes (WW, 5.7 +/- 1.1, vs RW, 11.6 +/- 3.2; P < .01), human serum albumin levels (WW, 941.7 +/- 172.2 mu g/mL vs RW, 1524.8 +/- 220.6 mu g/mL; P < .01), and secretion weights (WW, 30.5 +/- 7.2 mg, vs RW, 41.8 +/- 6.8 mg; P < .01). Conclusion: Our data show that warming of feet decreases the early response to nasal challenge with antigen. This inhibitory effect is probably related to the increase in the nasal mucosal temperature.	Univ Chicago, Pritzker Sch Med, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Naclerio, RM (corresponding author), Univ Chicago, Pritzker Sch Med, Sect Otolaryngol Head & Neck Surg, 5841 S Maryland Ave,MC 1035, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001236] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01236] Funding Source: Medline; NIDCD NIH HHS [DC02742] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANGGARD A, 1981, EUR J RESP DIS S128, V64, P143; BAROODY FM, 1998, J ALLERGY CLIN IMMUN, P101; BINAGHI RA, 1983, J IMMUNOL METHODS, V65, P225, DOI 10.1016/0022-1759(83)90319-8; CAUNA N, 1970, ANAT REC, V168, P9, DOI 10.1002/ar.1091680102; Chung JH, 1997, ANN ALLERG ASTHMA IM, V78, P307, DOI 10.1016/S1081-1206(10)63187-0; COLE P, 1954, J Laryngol Otol, V68, P613, DOI 10.1017/S0022215100050040; COLE P, 1982, NOSE, P366; Desrosiers M, 1997, J ALLERGY CLIN IMMUN, V99, P77; DINARELLO CA, 1986, CANCER RES, V46, P6236; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; Drettner B., 1961, ACTA OTOLARYNGOL S S, V166, P1; DUSSER DJ, 1989, J CLIN INVEST, V84, P900, DOI 10.1172/JCI114251; ECCLES R, 1981, ACTA OTO-LARYNGOL, V91, P127, DOI 10.3109/00016488109138490; FOLKOW B, 1971, CIRCULATION, P448; GRAYSON K, 1990, THERMOREGULATION PHY, P221; Hastie AT, 1997, AM J PHYSIOL-LUNG C, V273, pL401, DOI 10.1152/ajplung.1997.273.2.L401; JANKOWSKI R, 1995, AM J RHINOL, V9, P241, DOI 10.2500/105065895781808865; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; LUNDQVIST GR, 1993, ACTA OTO-LARYNGOL, V113, P783, DOI 10.3109/00016489309135901; MALM L, 1975, RHINOLOGY, V13, P84; MIDDLETON E, 1960, J ALLERGY, V31, P448, DOI 10.1016/0021-8707(60)90008-3; MONGAR JL, 1957, J PHYSIOL-LONDON, V135, P320, DOI 10.1113/jphysiol.1957.sp005713; OBLAS B, 1990, BIOCHEM BIOPH RES CO, V166, P978, DOI 10.1016/0006-291X(90)90907-5; OLSSON P, 1985, ANN OTO RHINOL LARYN, V94, P153, DOI 10.1177/000348948509400211; OPHIR D, 1988, ANN ALLERGY, V60, P239; OPHIR D, 1988, ANN OTO RHINOL LARYN, V97, P257; RALSTON HJ, 1945, AM J PHYSIOL, V144, P305, DOI 10.1152/ajplegacy.1945.144.2.305; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SIMON H, 1980, LARYNG RHINOL OTOL V, V59, P808, DOI 10.1055/s-2007-1008933; Spiesman IG, 1936, AM J PHYSIOL, V115, P181; WHITE MD, 1995, EUR J APPL PHYSIOL O, V70, P207, DOI 10.1007/BF00238565; Willatt D. J., 1993, Rhinology (Utrecht), V31, P63; YAMAGIWA M, 1990, AM REV RESPIR DIS, V141, P1050, DOI 10.1164/ajrccm/141.4_Pt_1.1050; YERUSHALMI A, 1982, P NATL ACAD SCI-BIOL, V79, P4766, DOI 10.1073/pnas.79.15.4766	34	28	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				285	293		10.1016/S0091-6749(99)70368-4	http://dx.doi.org/10.1016/S0091-6749(99)70368-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452746				2022-12-18	WOS:000082364800017
J	Aziz, I; Lipworth, BJ				Aziz, I; Lipworth, BJ			In vivo effect of albuterol on methacholine-contracted bronchi in conjunction with salmeterol and formoterol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchoprotection; antagonism; airways; methacholine; albuterol; salmeterol; formoterol; polymorphism	TWICE-DAILY TREATMENT; BETA(2)-ADRENOCEPTOR POLYMORPHISM; INDUCED BRONCHOCONSTRICTION; ASTHMA; BRONCHODILATOR; TOLERANCE; AGONIST; RESPONSIVENESS; SUBSENSITIVITY; ASSOCIATION	Background: It has been shown in vitro that prior treatment with salmeterol and formoterol antagonizes the relaxant effect of albuterol in carbachol-contracted human bronchi. Objectives: The primary aim of this study was to evaluate whether there is a potential in vivo interaction between long- and short-acting beta(2)-agonists in the presence of increased airway tone induced by methacholine, In addition,a post hoc analysis was made, to evaluate the effects of beta(2)-adrenoceptor polymorphisms. Methods: Sixteen asthmatic subjects (mean age [+/-SD], 39 [13] years; FEV1, 81% [17%] of predicted value), all taking inhaled corticosteroids and having methacholine PD20 values of less than 500 mu g, were randomized in double-blind, double-dummy, cross-over fashion to receive single doses of inhaled placebo, inhaled formoterol 12 mu g, or inhaled salmeterol 50 mu g followed 12 hours later by a single dose of inhaled albuterol 400 mu g (low dose) or 1600 mu g (high dose). Methacholine challenges were performed on each of 6 separate occasions 1 hour after albuterol, Results: There was a greater numerical difference in geometric mean PD20 values between low- and high-dose albuterol after placebo dosing (671 mu g vs 1080 mu g, a 1.61-fold difference; P < .05) compared with low- and high-dose albuterol after formoterol dosing (660 mu g vs 799 mu g, a 1.21-fold difference; P = .4). or after salmeterol dosing (568 mu g vs 847 mu g, a 1.49-fold difference; P = .055). PD20 values with high-dose albuterol in combination with formoterol or salmeterol were numerically Lower than those found with high-dose albuterol in combination with placebo, but they were not significantly different, There was a significant difference between PD20 values with low-dose albuterol after dosing with formoterol (PD20 = 660 mu g, a 1.6-fold difference; P < .05) or with salmeterol (PD20 = 568 mu g, a 19-fold difference; P < .05) compared with PD20 with high-dose albuterol after placebo dosing (PD20 = 1080 mu g). Post hoc polymorphism analysis for pooled pretreatment with formoterol and salmeterol (excluding placebo pretreatment) showed significantly (P < .05) lower PD20 values with homozygous glycine-16 compared with heterozygous glycine/arginine-16 and significantly (P < .05) lower PD20 values with homozygous glutamate-27 compared with either heterozygous glutamate/glutamine-27 or homozygous glutamine-27, Conclusion: Compared with placebo, both salmeterol and formoterol caused a significant degree of antagonism of albuterol-induced bronchorelaxation in methacholine-contracted bronchi in vivo. This interaction could be caused by prolonged occupancy of airway beta(2)-adrenoceptors by long-acting beta(2)-agonists or by early tachyphylaxis 12 hours after a single-dose exposure. The degree of albuterol protection was also related to beta(2)-adrenoceptor polymorphism.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Resp Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Lipworth, BJ (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BEACH JR, 1993, THORAX, V48, P239, DOI 10.1136/thx.48.3.239; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Drotar DE, 1998, ANN ALLERG ASTHMA IM, V80, P31, DOI 10.1016/S1081-1206(10)62935-3; Egbagbe E, 1997, THORAX, V52, P239, DOI 10.1136/thx.52.3.239; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Grove A, 1996, THORAX, V51, P54, DOI 10.1136/thx.51.1.54; Hall IP, 1996, THORAX, V51, P351, DOI 10.1136/thx.51.4.351; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Lipworth B, 1998, AM J MED, V104, P431, DOI 10.1016/S0002-9343(98)00086-2; Lipworth BJ, 1997, BRIT J CLIN PHARMACO, V43, P9, DOI 10.1111/j.1365-2125.1997.tb00025.x; Lipworth BJ, 1999, J ALLERGY CLIN IMMUN, V103, P88, DOI 10.1016/S0091-6749(99)70530-0; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Molimard M, 1998, EUR RESPIR J, V11, P583; *NAT ASTHM ED PREV, 1997, EXP PAN REP 2 GUID D; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pearson MG, 1997, THORAX, V52, pS1; RABE KF, 1993, AM REV RESPIR DIS, V147, P1436, DOI 10.1164/ajrccm/147.6_Pt_1.1436; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603, DOI 10.1164/ajrccm.154.6.8970342	27	28	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				816	822		10.1016/S0091-6749(99)70425-2	http://dx.doi.org/10.1016/S0091-6749(99)70425-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329815				2022-12-18	WOS:000080470200016
J	Waldeck, B				Waldeck, B			Enantiomers of bronchodilating beta(2)-adrenoceptor agonists: Is there a cause for concern?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchodilator; beta-adrenoceptor agonist; asthma; airway smooth muscle; hyperreactivity; enantiomer; racemate	AIRWAY SMOOTH-MUSCLE; BETA-ADRENOCEPTOR AGONISTS; STERIC ASPECTS; GUINEA-PIGS; SALBUTAMOL ENANTIOMERS; RACEMIC SALBUTAMOL; S-SALBUTAMOL; TERBUTALINE; ALBUTEROL; ASTHMA	All bronchodilating beta(2)-adrenoceptor agonists in current clinical use are derivatives of adrenaline and are available as racemates. Whereas the vast majority of the pharmacologic and clinical documentation has been made with the racemates, there are a few studies with the individual enantiomers, It thus appears that all established pharmacologic effects of racemic beta(2)-agonists reside in the (R)-enantiomer, with the (S)-enantiomer being virtually inactive. In recent years the suspicion has been raised that the (S)-enantiomer:of the beta(2)-agonists is responsible for induction of airway hyperreactivity,This suspicion is based primarily on results obtained in guinea pigs exposed to (S)-enantiomers of beta(2)-agonists, A number of experiments in vitro have been undertaken to find a mechanism of action for these observations in vivo. Most of the results obtained are equivocal. However, the observation that (S)-salbutamol may cause mobilization of intracellular Ca2+, apparently by means of a cholinergic mechanism, deserves further investigation. The clinical studies are focused on the enantiomers of salbutamol. They confirm the preclinical findings that the pulmonary, as well as the extrapulmonary, effects of salbutamol reside in the (R)-enantiomer. The studies available so far do not convincingly show clinically significant airway hyperreactivity after exposure to the (S)-enantiomer. Further studies are needed to settle this issue.	AB Draco, Preclin R&D, S-22100 Lund, Sweden		Waldeck, B (corresponding author), AB Draco, Preclin R&D, POB 34, S-22100 Lund, Sweden.							AKERS IA, 1995, AM J RESP CRIT CARE, V151, pA274; ARIENS EJ, 1984, EUR J CLIN PHARMACOL, V26, P663, DOI 10.1007/BF00541922; BLUM P, 1995, AM J RESP CRIT CAR S, V151, pA273; BORGSTROM L, 1989, BRIT J CLIN PHARMACO, V27, P49, DOI 10.1111/j.1365-2125.1989.tb05334.x; BORGSTROM L, 1989, CHIRALITY, V1, P174, DOI 10.1002/chir.530010213; Boulton DW, 1996, BRIT J CLIN PHARMACO, V41, P35, DOI 10.1111/j.1365-2125.1996.tb00156.x; BOWMAN WC, 1980, HDB EXPT PHARMACOLOG, V54, P47; BRITTAIN RT, 1973, BRIT J PHARMACOL, V48, P144, DOI 10.1111/j.1476-5381.1973.tb08232.x; BUCKNER CK, 1974, J PHARMACOL EXP THER, V189, P616; CAHN RS, 1956, EXPERIENTIA, V12, P81, DOI 10.1007/BF02157171; CHAPMAN ID, 1992, TRENDS PHARMACOL SCI, V13, P231, DOI 10.1016/0165-6147(92)90071-D; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; Cockcroft DW, 1997, THORAX, V52, P845, DOI 10.1136/thx.52.10.845; DOBBINS DE, 1990, MICROCIRC ENDOTH LYM, V6, P3; GALLAND BC, 1993, BRIT J PHARMACOL, V108, P1016, DOI 10.1111/j.1476-5381.1993.tb13499.x; HADJOKAS NE, 1995, J ALLERGY CLIN IMMUN, V95, P735, DOI 10.1016/S0091-6749(95)70179-6; Handley DA, 1998, CHIRALITY, V10, P262, DOI 10.1002/(SICI)1520-636X(1998)10:3<262::AID-CHIR9>3.0.CO;2-B; HANSEL TT, 1993, AGENT ACTION SUPPL, V43, P281; HARTLEY D, 1971, J MED CHEM, V14, P895, DOI 10.1021/jm00291a036; Ind PW, 1997, THORAX, V52, P839, DOI 10.1136/thx.52.10.839; Jenne JW, 1998, J ALLERGY CLIN IMMUN, V102, P893, DOI 10.1016/S0091-6749(98)70324-0; JEPPSSON AB, 1984, ACTA PHARMACOL TOX, V54, P285; Johansson F, 1996, CLIN REV ALLERG IMMU, V14, P57, DOI 10.1007/BF02772203; JOHNSON M, 1993, LIFE SCI, V52, P2131, DOI 10.1016/0024-3205(93)90728-L; Kallstrom BL, 1996, CHIRALITY, V8, P567; KIKKAWA H, 1991, JPN J PHARMACOL, V57, P175, DOI 10.1254/jjp.57.175; Leff AR, 1997, PULM PHARMACOL THER, V10, P97, DOI 10.1006/pupt.1997.0082; LINDBERG S, 1995, EUR J PHARMACOL, V285, P275, DOI 10.1016/0014-2999(95)00416-I; Lipworth BJ, 1997, THORAX, V52, P849, DOI 10.1136/thx.52.10.849; MAZZONI L, 1994, PULM PHARMACOL, V7, P367, DOI 10.1006/pulp.1994.1043; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; NIALS AT, 1993, EUR RESP J S17, V6, pS589; Nielson CP, 1998, AM J RESP CRIT CARE, V157, P184, DOI 10.1164/ajrccm.157.1.9704070; NYBERG L, 1997, LUNG BIOL HEALTH DIS, V106, P87; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; PerrinFayolle M, 1996, CLIN REV ALLERG IMMU, V14, P139, DOI 10.1007/BF02772208; PERRINFAYOLLE M, 1995, LANCET, V346, P1101, DOI 10.1016/S0140-6736(95)91775-6; PRIOR C, 1998, BRIT J PHARMACOL, V123, P590; Ramsay C. M., 1998, European Respiratory Journal, V12, p324S; RUFFOLO RR, 1983, STEREOCHEMISTRY BIOL, P103; SANJAR S, 1988, LANCET, V2, P160; SANJAR S, 1990, J PHYSIOL-LONDON, V425, P43, DOI 10.1113/jphysiol.1990.sp018091; SCHMIDT D, 1999, IN PRESS AM J RESPIR; SVENSJO E, 1985, MICROVASC RES, V29, P253; TAKUWA Y, 1988, J BIOL CHEM, V263, P762; TAN YK, 1987, J CHROMATOGR-BIOMED, V422, P187, DOI 10.1016/0378-4347(87)80451-6; Templeton AGB, 1998, PULM PHARMACOL THER, V11, P1, DOI 10.1006/pupt.1998.0110; Teschemacher A, 1998, PULM PHARMACOL THER, V11, P253, DOI 10.1006/pupt.1998.0121; TESTA B, 1990, CHIRALITY, V2, P129, DOI 10.1002/chir.530020302; TROFAST J, 1991, CHIRALITY, V3, P443, DOI 10.1002/chir.530030606; VATHENEN AS, 1988, LANCET, V1, P554; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; VOSS HP, 1992, EUR J PHARM-MOLEC PH, V227, P403, DOI 10.1016/0922-4106(92)90158-R; VOSS HP, 1994, THESIS VRIJE U; WALDECK B, 1993, CHIRALITY, V5, P350, DOI 10.1002/chir.530050514; WALDECK B, 1985, ACTA PHARMACOL TOX, V56, P221; WALLE UK, 1993, BRIT J CLIN PHARMACO, V35, P413, DOI 10.1111/j.1365-2125.1993.tb04159.x; WALLE UK, 1989, CHIRALITY, V1, P121, DOI 10.1002/chir.530010205; WANG ZL, 1994, AM J RESP CRIT CARE, V149, P960, DOI 10.1164/ajrccm.149.4.8143062; Weersink EJM, 1997, BRIT J CLIN PHARMACO, V43, P169, DOI 10.1046/j.1365-2125.1997.05226.x; WETTERLIN K, 1972, J MED CHEM, V15, P1182, DOI 10.1021/jm00281a025; WILLIAMS JC, 1983, EUR J PHARMACOL, V88, P347, DOI 10.1016/0014-2999(83)90585-X; WITTENDERBY PA, 1993, EUR J PHARMACOL, V241, P121, DOI 10.1016/0014-2999(93)90942-B; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yamaguchi H, 1996, CLIN REV ALLERG IMMU, V14, P47, DOI 10.1007/BF02772202; Zhang XY, 1998, AM J PHYSIOL-LUNG C, V274, pL32, DOI 10.1152/ajplung.1998.274.1.L32; ZHANG XY, 1998, AM J RESP CRIT CARE, V157, pA721	69	28	28	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				742	748		10.1016/S0091-6749(99)70414-8	http://dx.doi.org/10.1016/S0091-6749(99)70414-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329804	Bronze			2022-12-18	WOS:000080470200004
J	Hemmer, W; Focke, M; Vieluf, D; Berg-Drewniok, B; Gotz, M; Jarisch, R				Hemmer, W; Focke, M; Vieluf, D; Berg-Drewniok, B; Gotz, M; Jarisch, R			Anaphylaxis induced by horsefly bites: Identification of a 69 kd IgE-binding salivary gland protein from Chrysops spp (Diptera Tabanidae) by western blot analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Dermatol & Pediat Allergy Clin, Vienna, Austria; Univ Hamburg Hosp, Dept Dermatol, D-2000 Hamburg, Germany; Wilhelminen Hosp, Dept Pediat, Vienna, Austria	University of Hamburg; University Medical Center Hamburg-Eppendorf; Wilhelminenspital	Hemmer, W (corresponding author), Dermatol & Pediat Allergy Clin, Franz Jonas Platz 8-6, Vienna, Austria.							ARGENTINE JA, 1995, INSECT BIOCHEM MOLEC, V25, P621, DOI 10.1016/0965-1748(94)00103-O; FRAZIER CA, 1973, ARCH DERMATOL, V107, P400, DOI 10.1001/archderm.107.3.400; Freye HB, 1996, ANN ALLERG ASTHMA IM, V76, P270, DOI 10.1016/S1081-1206(10)63440-0; HOFFMAN DR, 1995, MONOGRAPH INSECT ALL, P99; Maat-Bleeker F, 1995, ALLERGY S26, V50, P388; Marinotti O, 1996, COMP BIOCHEM PHYS B, V113, P675, DOI 10.1016/0305-0491(95)02035-7; WILBUR RD, 1975, J ALLERGY CLIN IMMUN, V55, P72; XU W, 1997, J ALLERGY CLIN IMMUN, V99, P152	8	28	32	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				134	136		10.1016/S0091-6749(98)70208-8	http://dx.doi.org/10.1016/S0091-6749(98)70208-8			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449516	Bronze			2022-12-18	WOS:000071539800024
J	Hiraguri, M; Miike, S; Sano, H; Kurasawa, K; Saito, Y; Iwamoto, I				Hiraguri, M; Miike, S; Sano, H; Kurasawa, K; Saito, Y; Iwamoto, I			Granulocyte-macrophage colony-stimulating factor and IL-5 activate mitogen-activated protein kinase through Jak2 kinase and phosphatidylinositol 3-kinase in human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology	JUL   06, 1996	TOKYO, JAPAN	Novartis Pharma KK, Tokyo, Japan		granulocyte-macrophage colony-stimulating factor; IL-5; mitogen-activated protein kinase; Jak2 kinase; phosphatidylinositol 3-kinase; eosinophils	EPIDERMAL GROWTH-FACTOR; MAP KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASE; HEMATOPOIETIC-CELLS; INTERLEUKIN (IL)-3; FACTOR-RECEPTOR; BETA(C) CHAIN; C-FOS; PHOSPHORYLATION	Mitogen-activated protein (MAP) kinases are activated by the sequential activation of Ras, Raf and MEK (MAP kinase kinase) and regulate a wide variety of cell functions. To determine the kinase cascade for granulocyte-macrophage colony-stimulating factor (GM-CSF)- and IL-5-induced MAP kinase activation in eosinophils, we studied the effect of inhibitors of Jak2 kinase, tyrosine kinases, phosphatidylinositol 3-kinase, and protein kinase C on GM-CSF-and IL-5-induced MAP kinase activation in human eosinophils. GMCSF and IL-5 activated 40, 42, and 44 kilodalton MAP kinase isoforms in eosinophils. This was indicated by the electrophoretic mobility shift of the three isoforms of MAP kinase in immunoblotting with anti-MAP kinase antibody and also by in-gel MAP kinase assay. MAP kinase activation was time-and dose-dependent, becoming maximal 3 to 15 minutes after stimulation. A Jak2 kinase inhibitor AG-490, a tyrosine kinase inhibitor genistein, and a phosphatidylinositol 3-kinase inhibitor wortmannin inhibited GM-CSF- and IL-5-induced MAP kinase activation in eosinophils, whereas a protein kinase C inhibitor staurosporine had a weak inhibitory effect. Furthermore, AG-490 and genistein prevented GM-CSF-induced tyrosine phosphorylation of Jak2 kinase in eosinophils. Taken together, these results indicate that GMCSF and IL-5 activate MAP kinases through the signaling pathway of Jak2 kinase-tyrosine phosphorylated beta chain-phosphatidylinositol 3-kinase-Ras in eosinophils.	Chiba Univ, Sch Med, Dept Internal Med, Chiba 260, Japan	Chiba University	Iwamoto, I (corresponding author), Chiba Univ, Sch Med, Dept Internal Med, 1-8-1 Inohana, Chiba 260, Japan.							Bates ME, 1996, J IMMUNOL, V156, P711; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAREY GB, 1995, ARCH BIOCHEM BIOPHYS, V316, P179, DOI 10.1006/abbi.1995.1026; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA SK, 1992, J BIOL CHEM, V267, P2987; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JUCKER M, 1995, J BIOL CHEM, V270, P27817; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIMURA M, 1992, BLOOD, V80, P1045; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKADA T, 1994, J BIOL CHEM, V269, P3563; PAZDRAK K, 1995, J IMMUNOL, V155, P397; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; PREVARSKAYA NB, 1995, J BIOL CHEM, V270, P24292, DOI 10.1074/jbc.270.41.24292; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SEHMI R, 1992, BLOOD, V79, P2952; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V189, P1503, DOI 10.1016/0006-291X(92)90245-G; SONODA Y, 1988, P NATL ACAD SCI USA, V85, P4360, DOI 10.1073/pnas.85.12.4360; STERN M, 1992, J IMMUNOL, V148, P3543; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORRES M, 1993, J IMMUNOL, V150, P1563; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WARRINGA RAJ, 1991, BLOOD, V77, P2694; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YANAGISAWA K, 1994, BLOOD, V84, P84; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	58	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	2	S			S45	S51						7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR026	9440544				2022-12-18	WOS:000071449600004
J	Crimi, E; Gaffi, D; Frittoli, E; Borgonovo, B; Burastero, SE				Crimi, E; Gaffi, D; Frittoli, E; Borgonovo, B; Burastero, SE			Depletion of circulating allergen-specific T-H2 T lymphocytes after allergen exposure in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; bronchial provocation tests; asthma; T-H2 lymphocytes	BRONCHOALVEOLAR LAVAGE; CELLS; ANTIGEN; INTERLEUKIN-4; INDIVIDUALS; RECEPTOR; BLOOD; RAT	Background: In allergic asthma, CD4(+) T lymphocytes are a fundamental component of local chronic inflammation. Their cytokine profile is oriented toward a T-H2 phenotype, characterized bg production of IL-4, IL-5, IL-10, and IL-13, Egress of T cells from blood to airways after allergen challenge has been described. Objective: We have studied a cohort of six patients with asthma who had multiple allergies to investigate how exposure to allergen afferts the proliferation of peripheral CD4(+) T lymphocytes with different allergen specificities and lymphokine profiles. Methods: For each patient, CD4(+) T cell lines were generated by in vitro stimulation with sensitizing and with nonsensitizing allergens, and IL-4 and interferon-gamma production by these lines was assessed. Proliferation of peripheral blood CD4(+) T lymphocytes in response to the same allergens was measured before and 24 hours after inhalation challenge with a sensitizing allergen. Results: We found that each single sensitizing allergen can deplete peripheral blood of T-H2-type CD4+ T lymphocytes specific for all sensitizing allergens, but not of T-H1-type CD4(+) T lymphocytes. Conclusions: Our results suggest the existence of mechanisms capable of sorting disease-associated antigen specificities together with defined lymphokine patterns into T lymphocytes that can migrate to target organs, in allergic asthma.	SAN RAFFAELE SCI INST,DEPT BIOTECHNOL,I-20132 MILAN,ITALY; UNIV GENOA,FAC MED & CHIRURG,DIPARTIMENTO SCI MOTORIE & RIABILITAT,GENOA,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Genoa			, Burastero/AAN-2425-2020	, Burastero/0000-0001-7302-6381				BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; BABI LFS, 1995, J IMMUNOL, V154, P1543; BABI LFS, 1995, INT ARCH ALLERGY IMM, V107, P359; BURASTERO SE, 1993, J ALLERGY CLIN IMMUN, V91, P1075, DOI 10.1016/0091-6749(93)90222-2; BURASTERO SE, 1995, J IMMUNOL, V155, P5836; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; EBNER C, 1995, J IMMUNOL, V154, P1932; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; Goebeler M, 1993, Behring Inst Mitt, P191; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; HALVORSEN R, 1986, INT ARCH ALLER A IMM, V80, P62, DOI 10.1159/000234027; HOLT PG, 1988, J EXP MED, V167, P262, DOI 10.1084/jem.167.2.262; LASALLE JM, 1992, J EXP MED, V176, P177, DOI 10.1084/jem.176.1.177; MOHAPATRA SS, 1994, IMMUNOLOGY, V81, P15; PALUMBO S, 1994, ALLERGY, V49, P222, DOI 10.1111/j.1398-9995.1994.tb02653.x; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; WASERMAN S, 1995, AM J RESP CRIT CARE, V151, P470, DOI 10.1164/ajrccm.151.2.7842208; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275; YSSEL H, 1994, CURR OPIN IMMUNOL, V6, P847, DOI 10.1016/0952-7915(94)90003-5	25	28	30	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				788	797		10.1016/S0091-6749(97)80013-9	http://dx.doi.org/10.1016/S0091-6749(97)80013-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215247	Bronze			2022-12-18	WOS:A1997XH19300012
J	Schramm, G; Bufe, A; Petersen, A; Haas, H; Schlaak, M; Becker, WM				Schramm, G; Bufe, A; Petersen, A; Haas, H; Schlaak, M; Becker, WM			Mapping of IgE-binding epitopes on the recombinant major group I allergen of velvet grass pollen, rHol I 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						group I allergens; velvet grass pollen; recombinant allergens; B-cell epitope mapping	LOL-P-I; V ALLERGENS; RYE GRASS; EXPRESSION; PROTEINS; CLONING; NITROCELLULOSE; GENE; DNA	Background: New and more successful approaches to diagnosis and therapy of allergic diseases require a more subtle understanding of the structure and the epitopes on the allergen molecule. Objective: This study was done to obtain more information on the structure and the IgE-binding epitopes of a major allergen of velvet grass pollen, Hol I 1. Methods: We cloned Hot I 1 from a complementary DNA library and performed B-cell epitope mapping with 21 recombinant fragments expressed as fusion proteins in Escherichia coli. The fragments were analyzed by Western blotting with sera from 50 different patients. Results: The patients' sera individually recognized at least four different IgE-binding regions (amino acids 1 to 27, 61 to 76, 84 to 105, and 158 to 240). According to their binding patterns with these epitopes, they were divided into five groups. Most sera (92%) bound to the C-terminal peptide (158 to 240), which consists of more than 80 amino acids, whereas there was virtually no binding to smaller fragments covering this region. In contrast to the C-terminal peptide, the IgE-binding peptides on the N terminus and on the middle region of the molecule were of a smaller size (15 to 30 amino acids). Conclusions: The major group I allergen of velvet grass bears at least four different IgE-binding epitopes, which were individually recognized by sera from different patients. The C terminus represents the major IgE-binding region and contains at least one discontinuous IgE-binding epitope, whereas the N terminus and middle region of Hol I 1 seem to contain continuous IgE-binding epitopes.			Schramm, G (corresponding author), FORSCHUNGSZENTRUM BORSTEL,DIV ALLERGOL,PK ALLEE 22,D-23845 BORSTEL,GERMANY.			Bufe, Albrecht/0000-0001-7335-9362				AAS K, 1975, INT ARCH ALLER A IMM, V49, P44, DOI 10.1159/000231375; BALL T, 1994, J BIOL CHEM, V269, P28323; BROADWATER AH, 1993, GENE, V131, P227, DOI 10.1016/0378-1119(93)90297-G; BUFE A, 1994, J ALLERGY CLIN IMMUN, V94, P173, DOI 10.1016/0091-6749(94)90037-X; ESCH RE, 1989, MOL IMMUNOL, V26, P557, DOI 10.1016/0161-5890(89)90007-2; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; ONG EK, 1995, MOL IMMUNOL, V32, P295, DOI 10.1016/0161-5890(94)00127-M; PAULI G, 1996, J ALLERGY CLIN IMMUN, V97, P1; PEREZ M, 1990, J BIOL CHEM, V265, P16210; PETERSEN A, 1995, J ALLERGY CLIN IMMUN, V95, P987, DOI 10.1016/S0091-6749(95)70099-4; RAFNAR T, 1992, J BIOL CHEM, V267, P21119; Sambrook J, 1989, MOL CLONING LAB MANU; SCHEINER O, 1992, INT ARCH ALLERGY IMM, V98, P93, DOI 10.1159/000236170; Schramm G, 1996, INT ARCH ALLERGY IMM, V110, P354, DOI 10.1159/000237328; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; SUPHIOGLU C, 1995, CLIN EXP ALLERGY, V25, P853, DOI 10.1111/j.1365-2222.1995.tb00028.x; SUPHIOGLU C, 1993, INT ARCH ALLERGY IMM, V102, P144, DOI 10.1159/000236565; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1994, ALLERGO J, V3, P90; VANREE R, 1994, ALLERGY, V49, P254; WALSH DJ, 1989, INT ARCH ALLER A IMM, V90, P78, DOI 10.1159/000235004; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3, DOI 10.1159/000235067	28	28	30	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	1				781	787		10.1016/S0091-6749(97)80012-7	http://dx.doi.org/10.1016/S0091-6749(97)80012-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XH193	9215246				2022-12-18	WOS:A1997XH19300011
J	Cicardi, M; Berti, E; Caputo, V; Radice, F; Gardinali, M; Agostoni, A				Cicardi, M; Berti, E; Caputo, V; Radice, F; Gardinali, M; Agostoni, A			Idiopathic capillary leak syndrome: Evidence of CD8-positive lymphocytes surrounding damaged endothelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERLEUKIN-2	Idiopathic capillary leak syndrome (ICLS) is a lethal disease characterized by recurrent fluid extravasation leading to hypovolemic shock underlaid by marked hemoconcentration (hematocrit as high as 80%).(1) Only 30 patients with ICLS have been reported in the literature, and the pathogenesis remains unknown. Extravasation of intravascular fluid, with similar clinical symptoms, is also a well-known complication of systemic administration of recombinant (r)IL-2.(2) In this last condition, direct in vivo interaction between IL-2-activated cells (probably LAK cells) and endothelium results in cytotoxicity to endothelial cells.(3) We previously provided evidence that cytokines participate in the pathogenesis of ICLS by demonstrating the appearance of IL-2 receptor-positive cells during attacks in a patient with this disease.(4) Now we have studied the pathology of the same patient, who died during an attack, and have found that in the skin there were perivascular infiltrates of CD8 lymphocytes surrounding damaged endothelial cells, a picture similar to that of rIL2-dependent capillary leak syndrome (CLS).	UNIV MILAN,INST INTERNAL MED,I-20122 MILAN,ITALY; UNIV MILAN,INST DERMATOL SCI,MILAN,ITALY; UNIV MILAN,INST PATHOL ANAT,MILAN,ITALY; OSPED MAGGIORE,IST RIC & CURA CARATTERE SCI,MILAN,ITALY	University of Milan; University of Milan; University of Milan			cicardi, marco/K-9219-2016; Berti, Emilio/F-5256-2012	cicardi, marco/0000-0003-1251-225X; Berti, Emilio/0000-0001-6753-4910				ATKINSON JP, 1977, MEDICINE, V56, P225, DOI 10.1097/00005792-197705000-00004; CAIN JR, 1986, KIDNEY INT, V29, P181; CICARDI M, 1990, ANN INTERN MED, V113, P475, DOI 10.7326/0003-4819-113-6-475; CLARKSON B, 1960, AM J MED, V29, P193, DOI 10.1016/0002-9343(60)90018-8; FUJITA S, 1991, CANCER, V68, P2169, DOI 10.1002/1097-0142(19911115)68:10<2169::AID-CNCR2820681014>3.0.CO;2-F; GONZALEZ NC, 1994, J APPL PHYSIOL, V77, P1341, DOI 10.1152/jappl.1994.77.3.1341; JOHANSSON BR, 1979, ACTA MED SCAND, V206, P413; MASON DY, 1992, J CLIN PATHOL, V45, P1084, DOI 10.1136/jcp.45.12.1084; ROSENSTEIN M, 1986, J IMMUNOL, V137, P1735; TEELUCKSINGH S, 1990, Q J MED, V75, P515	10	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					417	419		10.1016/S0091-6749(97)70061-7	http://dx.doi.org/10.1016/S0091-6749(97)70061-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058699				2022-12-18	WOS:A1997WM42200020
J	Yamashita, N; Kaneko, S; Kouro, O; Furue, M; Yamamoto, S; Sakane, T				Yamashita, N; Kaneko, S; Kouro, O; Furue, M; Yamamoto, S; Sakane, T			Soluble E-selectin as a marker of disease activity in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; soluble adhesion molecule; sE-selectin; sICAM-1; sVCAM-1; IgE	LEUKOCYTE ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; LANGERHANS CELLS; EXPRESSION; SUPERNATANTS; LYMPHOCYTES; INFILTRATE; ICAM-1; VCAM-1; SERUM	Background: Augmentation in the expression of adhesion molecules on endothelial cells can regulate leukocyte migration. These molecules are also shed into the circulation. The level of soluble adhesion molecules in the serum is known to reflect the degree of systemic inflammation, and this level can therefore be used as a marker of inflammation. Objective: To elucidate whether soluble adhesion molecules can be used as the marker of disease severity in atopic dermatitis, we examined the levels of soluble E-selectin, soluble intercellular adhesion molecule-1, and soluble vascular cell adhesion molecule-1 and compared these levels with the patients' symptom scores and their total serum IgE levels. Methods: Fifty-three patients with atopic dermatitis were studied. Soluble adhesion molecules were measured by ELISA. Results: The level of soluble E-selectin was higher in patients with atopic dermatitis than in healthy control subjects (p < 0.01), Moreover, soluble E-selectin is correlated with disease severity (p < 0.01). Soluble E-selectin also reflected the changes in symptom scores. In contrast, there were no differences in soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 between the patients and control subjects. Conclusion: Soluble E-selectin is a good marker of disease severity and of its activity in atopic dermatitis.	ST MARIANNA UNIV, SCH MED, DEPT MED, KAWASAKI, KANAGAWA, JAPAN; HIROSHIMA UNIV, SCH MED, DEPT DERMATOL, KAWASAKI, KANAGAWA, JAPAN; UNIV TOKYO, BRANCH HOSP, DEPT DERMATOL, KAWASAKI, KANAGAWA, JAPAN	Saint Marianna University; Hiroshima University; University of Tokyo	Yamashita, N (corresponding author), ST MARIANNA UNIV, SCH MED, DEPT IMMUNOL, MIYAMAE KU, 2-16-1 SUGAO, KAWASAKI, KANAGAWA 216, JAPAN.							BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; CHU W, 1994, J IMMUNOL, V153, P4179; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; CZECH W, 1996, SOLUBLE E SELECTIN S, V134, P17; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Hirai S, 1996, BRIT J DERMATOL, V134, P657, DOI 10.1111/j.1365-2133.1996.tb06965.x; IMOKAWA G, 1991, J INVEST DERMATOL, V15, P261; JAMES JM, 1993, J ALLERGY CLIN IMMUN, V91, P1155, DOI 10.1016/0091-6749(93)90318-A; KOBAYASHI T, 1994, CLIN EXP IMMUNOL, V96, P110; Koide Masayo, 1994, Journal of Dermatological Science, V8, P151, DOI 10.1016/0923-1811(94)90010-8; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LOBB RR, 1991, J IMMUNOL, V147, P124; NAKAJIMA T, 1995, BRIT J HAEMATOL, V89, P258, DOI 10.1111/j.1365-2141.1995.tb03298.x; NEWMAN W, 1993, J IMMUNOL, V150, P644; PETZELBAUER P, 1993, J IMMUNOL, V151, P5062; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SPRONK PE, 1994, CLIN EXP IMMUNOL, V97, P439; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; STONE SP, 1973, ARCH DERMATOL, V108, P806, DOI 10.1001/archderm.108.6.806; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VENGE P, 1993, CLIN EXP ALLERGY, V8, P149; WAKITA H, 1994, J CUTAN PATHOL, V21, P33, DOI 10.1111/j.1600-0560.1994.tb00688.x; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P149, DOI 10.1111/j.1365-2133.1985.tb00078.x	28	28	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					410	416		10.1016/S0091-6749(97)70060-5	http://dx.doi.org/10.1016/S0091-6749(97)70060-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058698	Bronze			2022-12-18	WOS:A1997WM42200019
J	Ismail, A; Bousaffara, R; Kaziz, J; Zili, J; ElKamel, A; Sfar, MT; Remadi, S; Chouchane, L				Ismail, A; Bousaffara, R; Kaziz, J; Zili, J; ElKamel, A; Sfar, MT; Remadi, S; Chouchane, L			Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TAP1 polymorphism; amplification refractory mutation system polymerase chain reaction; atopy; allergic asthma	CLASS-II REGION; BRONCHIAL HYPERRESPONSIVENESS; LINKAGE; ASTHMA; CHROMOSOME-11Q; DERMATITIS; MARKERS; ALLELES	Background: Transporter antigen peptide 1 (TAP1) and TAP2 gene products form a transporter molecule involved in antigen presentation. Polymorphic residues have been described in both genes and could have functional consequences in the immune response. Objective: We designed a case-control study to investigate the potential association of polymorphism of the TAP1 gene with atopy. Methods: We used the amplification refractory mutation system polymerase chain reaction to characterize TAP1 gene polymorphism in 84 unrelated Tunisian patients with atopy and 81 healthy control subjects. Results: Analysis of TAP1 polymorphism in Tunisian patients with atopy and in unaffected control subjects demonstrates a high relative risk (RR) of atopy in carriers of a codon (d) corresponding to a glycine at position 637 of the TAP1-B and TAP1-D alleles. The relative risk of allergic asthma is markedly higher in homozygotes (d/d) (RR = 22; p less than or equal to 0.0001). The TAP1-D allele, not observed in European populations, has a frequency of 5% in the Tunisian control subject group. A major increase of the frequency (f) of the D allele is observed in patients with allergic asthma (f = 35%) and in those with allergic rhinitis (f = 22%), indicating a high relative risk of allergic asthma (RR = 10.2; p less than or equal to 0.0001) and of allergic rhinitis (RR = 5.4; p less than or equal to 0.005) in individuals carrying this allele. DD homozygotes were found only among patients with allergic asthma (23% of patients with asthma). Further evidence of the strong association between TAP1 polymorphism and atopy was provided by the finding that atopy is transmitted by inheritance of the glycine-637 marker. Conclusions: Tunisian persons carrying the glycine-637 of the TAP1 protein may have an increased risk of atopy. Specific association was found between the homozygous TAP1 D/D genotype and allergic asthma.	FAC MED MONASTIR, IMMUNOL LAB, MONASTIR 5019, TUNISIA; FATTOUMA BOURGUIBA HOSP, DEPT DERMATOL, MONASTIR, TUNISIA; FATTOUMA BOURGUIBA HOSP, DEPT PNEUMOL, MONASTIR, TUNISIA; CNSS SOUSSE, DEPT DERMATOL, MONASTIR, TUNISIA; TAHAR SFAR HOSP MAHDIA, DEPT PEDIATRY, MONASTIR, TUNISIA	Universite de Monastir; Universite de Monastir; Hopital Fattouma Bourguiba; Universite de Monastir; Hopital Fattouma Bourguiba; Universite de Monastir; Hopital Universitaire Tahar Sfar			Chouchane, Lotfi/ABF-1360-2020					AMELUNG PJ, 1992, CLIN EXP ALLERGY, V22, P1077, DOI 10.1111/j.1365-2222.1992.tb00133.x; AYED K, 1987, TISSUE ANTIGENS, V29, P225; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; BRERETON HM, 1994, CLIN EXP ALLERGY, V24, P868, DOI 10.1111/j.1365-2222.1994.tb01809.x; CARABALLO LR, 1990, TISSUE ANTIGENS, V35, P182, DOI 10.1111/j.1399-0039.1990.tb01777.x; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; DYER P, 1994, HLA DIS, P93; HERRICK AL, 1989, LANCET, V1, P1295; HIZAWA N, 1992, CLIN EXP ALLERGY, V22, P1065, DOI 10.1111/j.1365-2222.1992.tb00131.x; HOPKIN JM, 1991, ANN NY ACAD SCI, V629, P26; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LARSEN FS, 1987, TISSUE ANTIGENS, V29, P1; LEUNG DYM, 1983, J IMMUNOL, V130, P1678; LEUNG DYM, 1981, J ALLERGY CLIN IMMUN, V67, P450, DOI 10.1016/0091-6749(81)90098-1; LYMPANY P, 1992, CLIN EXP ALLERGY, V22, P1085, DOI 10.1111/j.1365-2222.1992.tb00134.x; LYMPANY P, 1992, J ALLERGY CLIN IMMUN, V89, P619, DOI 10.1016/0091-6749(92)90330-5; MAPP CE, 1994, EUR RESPIR J, V7, P15559; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSH DG, 1990, GENETIC ENV FACTORS, P97; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; OZOWA A, 1981, J AM DERMATOL, V4, P205; PANHUYSEN CIM, 1995, ALLERGY, V50, P863, DOI 10.1111/j.1398-9995.1995.tb02491.x; POWIS SH, 1993, IMMUNOGENETICS, V38, P345; POWIS SH, 1993, IMMUNOGENETICS, V37, P373, DOI 10.1007/BF00216802; RATNER B, 1951, AMA AM J DIS CHILD, V82, P666, DOI 10.1001/archpedi.1951.02040040687002; RICH SS, 1992, CLIN EXP ALLERGY, V22, P1070, DOI 10.1111/j.1365-2222.1992.tb00132.x; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANENDERT PM, 1992, P NATL ACAD SCI USA, V89, P11594, DOI 10.1073/pnas.89.23.11594; YOUNG RP, 1993, AM REV RESPIR DIS, V147, pA113	35	28	30	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					216	223		10.1016/S0091-6749(97)70099-X	http://dx.doi.org/10.1016/S0091-6749(97)70099-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042048				2022-12-18	WOS:A1997WH83100011
J	Terada, N; Maesako, KI; Hamano, N; Ikeda, T; Sai, M; Yamashita, T; Fukuda, S; Konno, A				Terada, N; Maesako, KI; Hamano, N; Ikeda, T; Sai, M; Yamashita, T; Fukuda, S; Konno, A			RANTES production in nasal epithelial cells and endothelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RANTES; nasal epithelial cells; endothelial cells; RT-PCR; nasal allergy	PERIPHERAL-BLOOD EOSINOPHILS; COLONY-STIMULATING FACTOR; CHEMOKINE RANTES; CYTOKINE RANTES; ACTIVATING FACTOR; MESSENGER-RNA; FACTOR-ALPHA; TNF-ALPHA; EXPRESSION; INTERLEUKIN-5	Background: It is well documented that the chemokine that is regulated upon activation, normal T expressed and presumably secreted, RANTES, is produced by macrophages, platelets, fibroblasts, and renal tubular epithelial cells. Recently, however, production of RANTES by vascular endothelium and airway epithelial cells was demonstrated in human umbilical vein endothelial cells (HUVECs) and epithelial cell lines. Objective: This investigation was aimed at determining whether human nasal epithelial cells (HNECs) and human mucosal microvascular endothelial cells (HMMECs) produce RANTES when they are stimulated by several cytokines. Methods: HNECs nd HMMECs were isolated from nasal mucosa and subsequent continuous subcultures and were stimulated either by IL-1 beta or by the combination of tumor necrosis factor alpha (TNF-alpha) and interferon gamma (IFN-gamma). Results: After the combined stimulation by TNF-alpha and IFN-gamma, HNECs and HMMECs dramatically produced RANTES, as previously observed in HUVECs and bronchial epithelial cell line BEAS-2B. IL-1 beta also increased RANTES production to a lesser extent. We also demonstrated that the amount of RANTES induced by TNF-alpha and IFN-gamma was higher in HNECs and HMMECs obtained from patients with nasal allergy than in those from patients without allergy. Conclusion: RANTES from HNECs and HMMECs likely plays a critical role in eosinophil infiltration of the nasal mucosa in subjects with nasal allergy.	MORINAGA BIOSCI LABS INC,KANAGAWA,JAPAN; MITSUBIHISI KAGAKU BIOCLIN LABS INC,DIV RES & DEV,TOKYO,JAPAN; MITSUBIHISI KAGAKU BIOCLIN LABS INC,DEPT GENE ANAL,TOKYO,JAPAN		Terada, N (corresponding author), CHIBA UNIV,SCH MED,DEPT OTORHINOLARYNGOL,1-8-1 INOHANA,CHIBA 260,JAPAN.							ALAM R, 1993, J IMMUNOL, V150, P3442; ALTMAN LC, 1993, J ALLERGY CLIN IMMUN, V92, P527, DOI 10.1016/0091-6749(93)90077-S; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BRAUN RK, 1993, EUR J IMMUNOL, V23, P956, DOI 10.1002/eji.1830230429; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; DESREUMAUX P, 1992, J EXP MED, V175, P293, DOI 10.1084/jem.175.1.293; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; EBISAWA M, 1994, J IMMUNOL, V153, P2153; FINOTTO S, 1994, J IMMUNOL, V153, P2278; FUKUDA K, 1989, AM J OTOLARYNG, V10, P85, DOI 10.1016/0196-0709(89)90131-2; HAMID Q, 1992, BLOOD, V80, P1496; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; KAKAZU T, 1995, INT ARCH ALLERGY IMM, V108, P43, DOI 10.1159/000237200; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; KONNO A, 1988, ORL TOKYO S7, V31, P241; KUNA P, 1992, J IMMUNOL, V149, P636; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; MINNICOZZI M, 1994, J IMMUNOL, V153, P2664; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; NAGY L, 1982, CLIN EXP IMMUNOL, V47, P541; NELSON PJ, 1993, J IMMUNOL, V151, P2601; OKUDA M, 1974, OTOLOGIA FUKUOKA, V20, P297; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PATTISON J, 1994, LANCET, V343, P209, DOI 10.1016/S0140-6736(94)90992-X; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING NEW YORK; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SHERRY B, 1991, CURR OPIN IMMUNOL, V3, P56, DOI 10.1016/0952-7915(91)90077-E; STELLATO C, 1995, J IMMUNOL, V155, P410; TERADA N, 1994, J ALLERGY CLIN IMMUN, V94, P629, DOI 10.1016/0091-6749(94)90140-6; TERADA N, 1992, J ALLERGY CLIN IMMUN, V90, P160, DOI 10.1016/0091-6749(92)90067-C; TERADA N, 1993, ACTA OTOLARYNGOL S S, V506, P57; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	43	28	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	2	S			S230	S237		10.1016/S0091-6749(96)70071-4	http://dx.doi.org/10.1016/S0091-6749(96)70071-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC447	8977532				2022-12-18	WOS:A1996WC44700009
J	Schmidt, M; McConnell, TJ; Hoffman, DR				Schmidt, M; McConnell, TJ; Hoffman, DR			Production of a recombinant imported fire ant venom allergen, Sol i 2, in native and immunoreactive form	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; fire ants; insect venom; baculovirus expression system Sol i 2; recombinant allergen	HYMENOPTERA VENOM; PHOSPHOLIPASE A(2); POLYCLONAL ANTIBODIES; EXPRESSION; COMPONENTS; FRAGMENTS; ANTIGEN-5; PROTEINS; VECTOR; VIRUS	Background: The complementary DNA encoding for the important imported fire ant venom allergen, Sol i 2, has previously been cloned. The binding of human IgE antibodies to Sol i 2 has been demonstrated to be conformation-dependent. Methods: A complete cDNA clone encoding the Sol i 2 protein sequence and its natural signal sequence has been produced by polymerase chain reaction. The clone was ligated into a pBluebac III transfer vector (Invitrogen Corp., San Diego, Calif), and the recombinant baculovirus was isolated by plaque purification. The recombinant baculovirus was grown in Sf9 and High-Five cells (Invitrogen Corp.) in serum-free media. The recombinant Sol i 2 was isolated and characterized. Results: Recombinant (r) Sol i 2 was produced in microgram/per milliliter amounts in Sf9 cells and at 30 mu g/ml in High-Five cells. It was isolated by ultrafiltration and reverse-phase chromatography. The rSol i 2 demonstrated similar binding to natural-Sol i 2 in both a conformation-dependent ELISA assay and in RAST with sera from patients allergic to Sol i 2. The N-terminal sequence of the rSol i 2 was identical to that of the natural molecule. No significant increase in binding activity was found after treatment of rSol i 2 with protein disulfide isomerase. The binding of rSol i 2 to a conformation-dependent monoclonal antibody was lost by heating in sodium dodecylsulfate and reduction. Conclusions: A recombinant Sol i 2 protein was produced at high yield in a baculovirus expression system by using serum-free medium with a sequence identical to that of the natural molecule. Conformation-dependent immunologic assays indicate that the recombinant protein is produced with the native conformation.	E CAROLINA UNIV,SCH MED,DEPT PATHOL & LAB MED,GREENVILLE,NC 27858; KAROLINSKA HOSP,DEPT LAB MED,DIV CLIN IMMUNOL,S-10401 STOCKHOLM,SWEDEN; E CAROLINA UNIV,DEPT BIOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University; Karolinska Institutet; Karolinska University Hospital; University of North Carolina; East Carolina University				McConnell, Thomas/0000-0003-3176-4938	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017162] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17162] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAND JM, 1972, TOXICON, V10, P259, DOI 10.1016/0041-0101(72)90011-6; CARO MR, 1957, ARCH DERMATOL, V75, P475, DOI 10.1001/archderm.1957.01550160001001; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FORSTER E, 1995, J ALLERGY CLIN IMMUN, V95, P1229, DOI 10.1016/S0091-6749(95)70080-3; GOLDBERGER RF, 1964, J BIOL CHEM, V239, P1406; HOFFMAN DR, 1995, ALLERGY, V50, P535, DOI 10.1111/j.1398-9995.1995.tb01196.x; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P307, DOI 10.1016/0091-6749(87)90036-4; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1987, J ALLERGY CLIN IMMUN, V80, P300, DOI 10.1016/0091-6749(87)90035-2; HOFFMAN DR, 1991, ANN ALLERGY, V66, P29; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; JUNG RC, 1963, DERMATOL TROPICA, P241; KING TP, 1995, J ALLERGY CLIN IMMUN, V95, P306; KING TP, 1995, J IMMUNOL, V154, P577; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT M, 1993, FEBS LETT, V319, P138, DOI 10.1016/0014-5793(93)80053-W; SCHNEIDER T, 1994, INT ARCH ALLERGY IMM, V104, P262, DOI 10.1159/000236675; SCHNEIDER T, 1994, J ALLERGY CLIN IMMUN, V94, P61, DOI 10.1016/0091-6749(94)90072-8; SMITH AM, 1992, J ALLERGY CLIN IMMUN, V89, P293; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1985, P NATL ACAD SCI USA, V82, P8404, DOI 10.1073/pnas.82.24.8404; SOLDATOVA LN, 1995, ALLERGY S2L, V50, P135; STAFFORD CT, 1992, J ALLERGY CLIN IMMUN, V90, P653, DOI 10.1016/0091-6749(92)90139-S; SUTER M, 1994, ALLERGOLOGIE, V17, P414; TOMALSKI MD, 1993, ARCH INSECT BIOCHEM, V22, P303, DOI 10.1002/arch.940220302; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990	29	28	32	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					82	88		10.1016/S0091-6749(96)70229-4	http://dx.doi.org/10.1016/S0091-6749(96)70229-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765821				2022-12-18	WOS:A1996VA69200010
J	Sakaguchi, M; Inouye, S; Sasaki, R; Hashimoto, M; Kobayashi, C; Yasueda, H				Sakaguchi, M; Inouye, S; Sasaki, R; Hashimoto, M; Kobayashi, C; Yasueda, H			Measurement of airborne mite allergen exposure in individual subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airborne; allergen bending; Der 1; mite	DER-II; ASTHMA; HOMES; CAT	To evaluate the extent of personal exposure to airborne mite allergens, subjects were asked to carry a personal ail sampler when in their houses. The level of Der I allergen trapped by the sampler was measured with a highly sensitive immunoassay. There were great variations in airborne Del I exposure in each subject. When used bedding was replaced with new allergen-free bedding, we detected a decrease in the allergen level. The use of new bedding seems to be an effective measure for reducing airborne mite allergen exposure.	NIPPON VET & ANIM SCI UNIV,DIV WILD ANIM MED,MUSASHINO,TOKYO,JAPAN; NATL SAGAMIHARA HOSP,CLIN RES CTR ALLERGY & RHEUMATOL,SAGAMIHARA,KANAGAWA,JAPAN	Nippon Veterinary & Life Science University	Sakaguchi, M (corresponding author), NATL INST HLTH & NUTR,DEPT EPIDEMIOL,SHINJUKU KU,TOYAMA 1-23-1,TOKYO 162,JAPAN.		Inouye, Sharon/R-7216-2019					COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; Platts-Mills TA, 1993, ALLERGY PRINCIPLES P, P469; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; SAKAGUCHI M, 1993, J ALLERGY CLIN IMMUN, V92, P797, DOI 10.1016/0091-6749(93)90056-L; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SAKAGUCHI M, 1992, ALLERGY, V47, P55, DOI 10.1111/j.1398-9995.1992.tb02250.x; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TOVEY ER, 1992, EXP APPL ACAROL, V16, P181, DOI 10.1007/BF01201500; YASEUDA H, 1994, CLIN EXP ALLERGY, V19, P1030; YASUEDA H, 1989, INT ARCH ALLER A IMM, V90, P182, DOI 10.1159/000235021	12	28	30	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1040	1044		10.1016/S0091-6749(96)70255-5	http://dx.doi.org/10.1016/S0091-6749(96)70255-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626979	Bronze			2022-12-18	WOS:A1996UL26100002
J	Hakansson, L; Bjornsson, E; Janson, C; Schmekel, B				Hakansson, L; Bjornsson, E; Janson, C; Schmekel, B			Increased adhesion to vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 of eosinophils from patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; neutrophil; adhesion; E-selectin; VCAM-1; ICAM-1; CD11b CD18; VLA-4; asthma	LEUKOCYTE ADHESION; BRONCHOALVEOLAR LAVAGE; NEUTROPHIL ADHERENCE; ENDOTHELIAL-CELLS; CD11B/CD18 MAC-1; QUESTIONNAIRE; INFLAMMATION; VARIABILITY; FIBRONECTIN; EPITHELIUM	Adhesion of peripheral blood eosinophil and neutrophil granulocytes to the endothelial cell adherence receptors E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 has been measured. The study included patients with allergic rhinitis, patients with mild allergic and nonallergic asthma, and healthy individuals; 10 persons were in each group. In addition, assay of eosinophil and neutrophil cell surface expression of the receptor complex CD11b/CD18 was performed. Increased eosinophil adhesion to vascular cell adhesion molecule-1 (p<0.05) and intercellular adhesion molecule-1 (p<0.05) was demonstrated in the patients with a more labile asthma, that is, a peak expiratory flow rate variability of more than 10%, suggesting a relationship to the degree of ongoing inflammation in the airways of the patients. The increased eosinophil adhesion was most probably due to a functional upregulation of the CD11b/CD18 and very late activation antigen-4 receptors, because the number of receptors measured as cell surface expression was unaltered. The increased eosinophil adhesion in the patients with high peak expiratory flow rate variability appeared independent of atopy. The increased adhesion was not entirely specific to the eosinophils, because neutrophils from patients with a peak expiratory flow rate variability of more than 10% also demonstrated increased adhesion to intercellular adhesion molecule-1 (p<0.05) when compared with neutrophils from the patients with low peak expiratory flow rate variability. In conclusion, the demonstrated priming of eosinophil adhesion to vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 might be one contributing mechanism behind the selective accumulation of eosinophils in the lung tissue of patients with asthma.	UNIV UPPSALA HOSP, DEPT LUNG MED, S-75185 UPPSALA, SWEDEN; UNIV UPPSALA HOSP, ASTHMA RES CTR, S-75185 UPPSALA, SWEDEN; LINKOPING UNIV HOSP, DEPT CLIN PHYSIOL, S-58185 LINKOPING, SWEDEN	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Linkoping University	Hakansson, L (corresponding author), UNIV UPPSALA HOSP, DEPT CLIN CHEM, INFLAMMAT RES LAB, S-75185 UPPSALA, SWEDEN.			Bjornsson, Eythor/0000-0003-1186-8473				AALBERS R, 1993, AM REV RESPIR DIS, V147, P76, DOI 10.1164/ajrccm/147.1.76; ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; BALZANO G, 1989, CHEST, V95, P1239, DOI 10.1378/chest.95.6.1239; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BJORNSSON E, 1994, ALLERGY, V49, P730, DOI 10.1111/j.1398-9995.1994.tb02095.x; BLOM M, 1994, BLOOD, V83, P2978, DOI 10.1182/blood.V83.10.2978.2978; BOCHNER BS, 1994, J IMMUNOL, V152, P774; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; CALDERON E, 1992, J ALLERGY CLIN IMMUN, V90, P852, DOI 10.1016/0091-6749(92)90112-F; CALHOUN WJ, 1991, ANN NY ACAD SCI, V629, P62; CARLOS TM, 1994, BLOOD, V84, P2068; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; COCKCROFT DW, 1991, ASTHMA ITS PATHOLOGY, P51; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DRANSFIELD I, 1991, CHEM IMMUNOL, V50, P13; DREBORG S, 1989, ALLERGY, V44, pS52; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GUNDEL RH, 1992, CLIN EXP ALLERGY, V22, P569, DOI 10.1111/j.1365-2222.1992.tb00167.x; HAKANSSON L, 1994, J IMMUNOL METHODS, V176, P53, DOI 10.1016/0022-1759(94)90350-6; HAKANSSON L, 1990, J ALLERGY CLIN IMMUN, V85, P743, DOI 10.1016/0091-6749(90)90193-8; HAMID Q, 1991, INT ARCH ALLER A IMM, V94, P169, DOI 10.1159/000235353; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HIGGINS BG, 1992, AM REV RESPIR DIS, V145, P588, DOI 10.1164/ajrccm/145.3.588; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KYANAUNG U, 1990, ALLERGY CLIN IMMUNOL, V2, P163; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SAITO H, 1986, BLOOD, V67, P50; SAMOSZUK MK, 1988, AM J PATHOL, V132, P455; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; VENGE P, 1988, AM REV RESPIR DIS, V138, pS54, DOI 10.1164/ajrccm/138.6_Pt_2.S54; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WHITE SR, 1990, AM J PHYSIOL, V259, pL294, DOI 10.1152/ajplung.1990.259.4.L294; ZIMMERMAN B, 1993, CLIN EXP ALLERGY, V23, P564, DOI 10.1111/j.1365-2222.1993.tb00895.x; 1983, CLIN RESP PHYS, V19, pS22	51	28	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				941	950		10.1016/S0091-6749(95)70232-6	http://dx.doi.org/10.1016/S0091-6749(95)70232-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543753				2022-12-18	WOS:A1995TN12400012
J	EBERLEINKONIG, B; RUEFF, F; PRZYBILLA, B				EBERLEINKONIG, B; RUEFF, F; PRZYBILLA, B			GENERALIZED URTICARIA CAUSED BY SESAME SEEDS WITH NEGATIVE PRICK TEST-RESULTS AND WITHOUT DEMONSTRABLE SPECIFIC IGE ANTIBODIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							ANAPHYLAXIS				EBERLEINKONIG, B (corresponding author), UNIV MUNICH,DERMATOL KLIN & POLIKLIN,FRAUENLOBSTR 9-11,D-80337 MUNICH,GERMANY.							JAMES C, 1991, NEW YORK STATE J MED, V91, P457; KAGI MK, 1993, ANN ALLERGY, V71, P127; SAMPSON H, 1988, ANN ALLERGY, V60, P263; VOCKS E, 1993, ALLERGY, V48, P168, DOI 10.1111/j.1398-9995.1993.tb00708.x	4	28	28	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1995	96	4					560	561		10.1016/S0091-6749(95)70302-0	http://dx.doi.org/10.1016/S0091-6749(95)70302-0			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TA095	7560670				2022-12-18	WOS:A1995TA09500019
J	WERFEL, S; MASSEY, W; LICHTENSTEIN, LM; BOCHNER, BS				WERFEL, S; MASSEY, W; LICHTENSTEIN, LM; BOCHNER, BS			PREFERENTIAL RECRUITMENT OF ACTIVATED, MEMORY T-LYMPHOCYTES INTO SKIN CHAMBER FLUIDS DURING HUMAN CUTANEOUS LATE-PHASE ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LYMPHOCYTE HOMING; MEMORY T LYMPHOCYTE; SKIN CHAMBER; LATE-PHASE RESPONSE; CUTANEOUS ALLERGIC INFLAMMATION; CD25; HLA-DR; CD45RO	COLONY-STIMULATING FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; MICROVASCULAR ENDOTHELIAL-CELLS; BRONCHOALVEOLAR LAVAGE FLUID; MESSENGER-RNA EXPRESSION; MONOCLONAL-ANTIBODY; ANTIGEN CHALLENGE; ATOPIC SUBJECTS; L-SELECTIN; SUBSETS	To determine whether activated memory T lymphocytes (CD3(+)CD4(+)CD45RO(+)CD25(+)HLA-DR(+)) preferentially accumulate during the cutaneous IgE-dependent fate-phase response, we challenged 10 atopic patients with allergen and monitored the cellular influx for 12 hours with a skin blister chamber model. Four patients with allergy were also challenged with irrelevant allergen in control experiments. Histamine release and the size of the cutaneous fate-phase response were measured. Light microscopic analysis and phenotyping of recruited and blood lymphocytes were performed with immunofluorescence and flow cytometry. Antigen challenge induced significant histamine release, a macroscopic late-phase response, and significant cellular influx in the appropriately challenged patients with allergy but not in control subjects. In the control group, only limited phenotypic analyses could be performed, which demonstrated an equivalent percentage of CD3(+)CD4(+) cells in the chamber fluids compared with blood. In contrast, a higher proportion of CD4(+) T lymphocytes and a lower proportion of CD8(+) T lymphocytes accumulated in chamber fluids during the late-phase response compared with that present in blood. The vast majority of the recruited T lymphocytes expressed a memory phenotype (CD45RO(+)) with enhanced percentages of CD25(+) and HLA-DR(+) cells. Also, these cells had increased levels of very late antigen-4 (CD49d/CD29) and reduced levels of L-selectin compared with the same cells in blood. These results demonstrate that allergen challenge of the skin in patients with allergy leads to the preferential accumulation of activated memory T lymphocytes. The mechanism by which these cells are selectively recruited during cutaneous allergic inflammation remains to be determined.	JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ASTHMA & ALLERGY CTR,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49545] Funding Source: Medline; NIAID NIH HHS [AI27429, AI-07290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BOIS RMD, 1992, AM REV RESPIR DIS, V145, P1205; BOS JD, 1993, IMMUNOL TODAY, V15, P75; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; CHARLESWORTH EN, 1989, INT ARCH ALLER A IMM, V88, P50, DOI 10.1159/000234747; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHIN LH, 1990, J INVEST DERMATOL, V95, P29; CHIN YH, 1990, J INVEST DERMATOL, V94, P413, DOI 10.1111/1523-1747.ep12874486; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; CORRIGAN CJ, 1988, LANCET, V1, P1129; DETMAR M, 1992, J INVEST DERMATOL, V98, P147, DOI 10.1111/1523-1747.ep12555746; DOMINIQUE S, 1990, THORAX, V45, P391, DOI 10.1136/thx.45.5.391; DURHAM SR, 1984, NEW ENGL J MED, V311, P1398, DOI 10.1056/NEJM198411293112202; DURHAM SR, 1992, J IMMUNOL, V148, P2390; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FREW AJ, 1988, J IMMUNOL, V141, P4158; FREW AJ, 1991, CLIN EXP IMMUNOL, V84, P270; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; HORGAN KJ, 1992, J IMMUNOL, V149, P4082; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; KANOF ME, 1988, J IMMUNOL, V140, P3701; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KYANAUNG U, 1991, J IMMUNOL, V146, P521; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MACKAY CR, 1991, IMMUNOL TODAY, V12, P189, DOI 10.1016/0167-5699(91)90051-T; MACKAY CR, 1991, NATURE, V349, P737, DOI 10.1038/349737a0; MASSEY W, 1993, J IMMUNOL, V150, P1084; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PICKER LJ, 1992, CURR OPIN IMMUNOL, V4, P277, DOI 10.1016/0952-7915(92)90077-R; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PICKER LJ, 1990, AM J PATHOL, V136, P153; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SCHWARTING R, 1989, LEUCOCYTE TYPING 4 W, P399; SCHWARTZ BR, 1990, J CLIN INVEST, V85, P2019, DOI 10.1172/JCI114668; SMITT JHS, 1986, CLIN EXP DERMATOL, V11, P159, DOI 10.1111/j.1365-2230.1986.tb00441.x; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; SWERLICK RA, 1992, J IMMUNOL, V149, P698; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; ZACHARY CB, 1983, BRIT J DERMATOL, V108, P411, DOI 10.1111/j.1365-2133.1983.tb04593.x; ZWEIMAN B, 1988, CLIN ALLERGY, V18, P419, DOI 10.1111/j.1365-2222.1988.tb02892.x	51	28	28	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					57	65		10.1016/S0091-6749(95)70033-1	http://dx.doi.org/10.1016/S0091-6749(95)70033-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622764	Bronze			2022-12-18	WOS:A1995RK38300008
J	PASCUAL, C; CRESPO, JF; QUIRALTE, J; LOPEZ, C; WHEELER, G; MARTINESTEBAN, M				PASCUAL, C; CRESPO, JF; QUIRALTE, J; LOPEZ, C; WHEELER, G; MARTINESTEBAN, M			IN-VITRO DETECTION OF SPECIFIC IGE ANTIBODIES TO ERYTHROMYCIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; ANTIBODIES; ERYTHROMYCIN; RADIOIMMUNOASSAY		Background: In vitro tests for detecting drug-specific IgE would be useful in identifying patients at risk for immediate hypersensitivity reactions to therapeutic doses of a drug. Objective: We attempted to verify that IgE-mediated reactions to erythromycin occur and to identify IgE antibodies specific for erythromycin in serum from a patient who had urticaria immediately after administration of the drug. Methods: Skin prick testing was performed on the patient and five control subjects. Serum from the patient, pooled sera from nonatopic subjects allergic to common aeroallergens, and cord blood controls were analyzed for erythromycin-specific IgE by radioimmunoassay. Sepharose (Pharmacia, Uppsala, Sweden) was used as solid phase covalently linked to erythromycin Results: We were able to detect erythromycin-specific IgE antibodies in serum from the patient who had an allergic reaction to this antibiotic, but specific IgE could not be detected in control sera. Conclusion: immunologic IgE-mediated reactions to erythromycin do occur, and in vitro diagnosis of such reactions can be made by using Sepharose as a solid phase covalently linked to this drug.	ARKANSAS CHILDRENS HOSP, LITTLE ROCK, AR USA	Arkansas Children's Hospital	PASCUAL, C (corresponding author), HOSP INFANTIL LA PAZ, SERV ALERGIA, INMUNOALERGIA LAB, CASTELLANA 261, E-28046 MADRID, SPAIN.		IBIS, ALERGICAS/C-1733-2016					BALDO BA, 1990, MONOGR ALLERGY, V28, P11; DAVIES RJ, 1975, CLIN ALLERGY, V1, P99; Florido Lopez J F, 1991, Allergy, V46, P77, DOI 10.1111/j.1398-9995.1991.tb00546.x; HARLE DG, 1990, INT ARCH ALLER A IMM, V92, P439, DOI 10.1159/000235177; HARLE DG, 1990, MOL IMMUNOL, V27, P853, DOI 10.1016/0161-5890(90)90151-O; IGEA JM, 1991, ANN ALLERGY, V66, P216; Malet A, 1992, Allergol Immunopathol (Madr), V20, P127; SLATER JE, 1991, ANN ALLERGY, V66, P193	8	28	29	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					668	671		10.1016/S0091-6749(95)70170-2	http://dx.doi.org/10.1016/S0091-6749(95)70170-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897148				2022-12-18	WOS:A1995QM01700005
J	WENZEL, SE; TRUDEAU, JB; WESTCOTT, JY; BEAM, WR; MARTIN, RJ				WENZEL, SE; TRUDEAU, JB; WESTCOTT, JY; BEAM, WR; MARTIN, RJ			SINGLE ORAL DOSE OF PREDNISONE DECREASES LEUKOTRIENE B-4 PRODUCTION BY ALVEOLAR MACROPHAGES FROM PATIENTS WITH NOCTURNAL ASTHMA BUT NOT CONTROL SUBJECTS - RELATIONSHIP TO CHANGES IN CELLULAR INFLUX AND FEV(1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MACROPHAGE; LEUKOTRIENES; LAVAGE; INFLAMMATION; NEUTROPHILS; THROMBOXANE	ARACHIDONIC-ACID METABOLISM; BRONCHOALVEOLAR LAVAGE; ALLERGEN CHALLENGE; 5-LIPOXYGENASE INHIBITOR; ATOPIC ASTHMATICS; BRONCHIAL-ASTHMA; INFLAMMATION; GENERATION; MEDIATORS; LUNG	Background: Nocturnal worsening of asthma is associated,vith an increase bl numbers of airway inflammatory cells during the early morning. However, cell function during the night, with and without administration of steroids, has not been investigated Objective: This study was designed to determine the effect of prednisone on pulmonary alveolar macrophage production of leukotriene B-2 and thromborane B-2 at night and how it relates to changes in pulmonary function and cellular influx. Methods: Alveolar macrophages were obtained from patients with nocturnal asthma, patients with nonnocturnal asthma, and normal control subjects at 4:00 AM by bronchoalveolar lavage after administration of placebo and prednisone. Cells were placed in limited cell culture and eicosanoids were measured from baseline and stimulated cells. Results: Patients with nocturnal asthma had both a significantly greater fall in forced expiratory volume in 1 second (FEV(1)) and a greater influx of neutrophils and eosinophils at 4:00 AM than normal subjects after placebo treatment, whereas patients with nonnocturnal asthma had intermediary responses. There was no difference in baseline or stimulated LTB(4) production during placebo administration in the three groups. After prednisone treatment there was an improvement in the nocturnal fall in FEV(1) and a significant decrease in the neutrophil influx in patients with nocturnal asthma compared with the other groups. These changes were accompanied by a significant decrease in the stimulated LTB(4) production in patients with nocturnal asthma compared with a small increase in both patients with nonnocturnal asthma and normal subjects. Thromboxane B-2 production did not change. The decrease in LTB(4) production was correlated with the fall in granulocytic cells and improvement in the nocturnal FEV(1). However the two variables with the greatest combined influence on the improvement in FEV(1) were the decrease in stimulated LTB(4) production and die fall in neutrophil influx Conclusions: We demonstrate for the first time that a single oral dose of prednisone decreases LTB(4) production from alveolar macrophages, obtained at night from patients with nocturnal asthma, during a time of known inflammation. Further, this decrease in stimulated production is associated with decreases in cellular influx and improvement in pulmonary function.	UNIV COLORADO,HLTH SCI CTR,DENVER,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WENZEL, SE (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206, USA.				NHLBI NIH HHS [HL02254, HL36577, HL34303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, P01HL036577] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGG LR, 1980, EUR J RESPIR DIS, V61, P298; BALTER MS, 1988, AM REV RESPIR DIS, V138, P1134, DOI 10.1164/ajrccm/138.5.1134; BEAM W R, 1991, American Review of Respiratory Disease, V143, pA626; BERNSTEIN L, 1985, AM REV RESPIR DIS, V132, P180; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CALHOUN W, 1992, AM REV RESPIR DIS, V145, P37; CHANEZ P, 1991, AM REV RESPIR DIS, V144, P923, DOI 10.1164/ajrccm/144.4.923; DAMON M, 1987, PROSTAG OTH LIPID M, V34, P291, DOI 10.1016/0090-6980(87)90251-6; DAMON M, 1989, EUR RESPIR J, V2, P202; Daniel W. W., 1990, APPL NONPARAMETRIC S, P240; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; FABI LM, 1987, AM REV RESPIR DIS, V136, P36; FICK RB, 1987, AM REV RESPIR DIS, V135, P1204; FUJIMURA M, 1990, CHEST, V98, P656, DOI 10.1378/chest.98.3.656; HENDERSON WR, 1987, AM REV RESPIR DIS, V135, P1176; HUI KP, 1991, THORAX, V46, P184, DOI 10.1136/thx.46.3.184; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; LUI M, 1990, AM REV RESPIR DIS, V142, P126; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MARTIN TR, 1984, AM REV RESPIR DIS, V129, P106; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; Snedecor G. W, 1989, STAT METHODS, V8th; STANDIFORD TJ, 1992, AM J RESP CELL MOL, V6, P75, DOI 10.1165/ajrcmb/6.1.75; TRUDEAU J, 1994, AM J RESPIR CRIT CAR, pA941; WARWICK A, 1988, AM J MED, V85, P6; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; ZOCCA E, 1990, J APPL PHYSIOL, V68, P1576, DOI 10.1152/jappl.1990.68.4.1576; 1975, CHEST, V76, P583	34	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					870	881		10.1016/0091-6749(94)90155-4	http://dx.doi.org/10.1016/0091-6749(94)90155-4			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963156	Bronze			2022-12-18	WOS:A1994PR24000012
J	LEE, HJ; MATSUDA, I; NAITO, Y; YOKOTA, T; ARAI, N; ARAI, K				LEE, HJ; MATSUDA, I; NAITO, Y; YOKOTA, T; ARAI, N; ARAI, K			SIGNALS AND NUCLEAR FACTORS THAT REGULATE THE EXPRESSION OF INTERLEUKIN-4 AND INTERLEUKIN-5 GENES IN HELPER T-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1993 Conference	JUL   17, 1993	TOKYO, JAPAN			NUCLEAR FACTORS; IL-4 GENE; IL-5 GENE; HELPER T CELLS; SIGNAL TRANSDUCTION	NF-KAPPA-B; PROTEIN KINASE-A; GM-CSF GENE; TRANSCRIPTION FACTOR; ACTIVATION SIGNALS; LYMPHOKINE GENES; P40X PROTEIN; HUMAN IL-3; CAMP; IDENTIFICATION	Mouse thymoma line EL-4 cells produce cytokines such as interleukin (IL)-2, IL-3, IL-4, IL-10, and granulocyte-macrophage colony-stimulating factor in response to phorbol 12-myristate 13-acetate (PMA). EL-4 cells also produce low levels of IL-5 when stimulated by PMA alone; however cAMP greatly augments PMA-dependent IL-5 production. A transient transfection assay revealed that two signals PMA and cAMP, are required for optimal activation of the IL-5 promoter. In contrast, cAMP almost completely inhibited the PMA-dependent activation of the endogenous IL-2 gene, as well as the transfected IL-2 promoter. These results indicate that the IL-5 gene is positively regulated by cAMP in a manner opposite to that for the IL-2 gene. One of the nuclear factors (NFs) that regulates the response of the IL-5 promoter to cAMP and PMA has properties similar to NF for activated t cell. The P sequence of the IL-4 gene, defined as a responsive element for PMA and calcium ionophore (A23187), shares sequence similarity with the NF kappa B and the NF-activated T cell binding sites. We attempted to determine whether NF(P), a nuclear factor specific for the P sequence, is assays both NF-kappa B (P65 or P65/P50 heterodimer) and NF-AT bound to the P sequence. However, sequence specificity of NF-AT was more similar to that of NF(P), and only a small amount of P65 was detected in NF(P). These results indicate that a component or components of NF-AT have the potential to reconstitute NF(P), whereas NF-kappa B alone does not account for NF(P) in Jurkat crude extract. Taken together, these results suggest that NF-AT-like factors are involved in the reegulation of IL-4 and IL-5 genes.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Yokota, Takashi/J-8483-2015					ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; BETZ M, 1991, J IMMUNOL, V146, P108; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; CAMPBELL HD, 1988, EUR J BIOCHEM, V174, P345, DOI 10.1111/j.1432-1033.1988.tb14104.x; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; HOFMANN B, 1993, P NATL ACAD SCI USA, V90, P6676, DOI 10.1073/pnas.90.14.6676; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEE HJ, 1993, J IMMUNOL, V151, P6135; LEE JS, 1989, SOMAT CELL MOLEC GEN, V15, P143, DOI 10.1007/BF01535075; MACDONALD D, 1990, BRIT J HAEMATOL, V76, P168, DOI 10.1111/j.1365-2141.1990.tb07867.x; MATHEW RC, 1992, J IMMUNOL, V148, P3572; MATSUDA I, 1994, BIOCHEM BIOPH RES CO, V199, P439, DOI 10.1006/bbrc.1994.1248; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P51732; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NISHIDA J, 1991, INT IMMUNOL, V3, P245, DOI 10.1093/intimm/3.3.245; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TANABE T, 1987, J BIOL CHEM, V262, P16580; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VANLEEUWEN BH, 1989, BLOOD, V73, P1142; WATANABE S, 1994, INT IMMUNOL, V6, P523, DOI 10.1093/intimm/6.4.523	41	28	28	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	2	S			594	604		10.1016/0091-6749(94)90135-X	http://dx.doi.org/10.1016/0091-6749(94)90135-X			11	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PH235	8083467				2022-12-18	WOS:A1994PH23500004
J	TOVEY, ER; WOOLCOCK, AJ				TOVEY, ER; WOOLCOCK, AJ			DIRECT EXPOSURE OF CARPETS TO SUNLIGHT CAN KILL ALL MITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							DUST MITES; ALLERGENS				TOVEY, ER (corresponding author), UNIV SYDNEY, DEPT MED, D06, SYDNEY, NSW 2006, AUSTRALIA.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; BISCHOFF ERC, 1992, EXP APPL ACAROL, V16, P1, DOI 10.1007/BF01201489; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; KINNAIRD C H, 1974, Acarologia (Paris), V16, P340; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0	5	28	29	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1072	1074		10.1016/S0091-6749(94)70058-3	http://dx.doi.org/10.1016/S0091-6749(94)70058-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006313				2022-12-18	WOS:A1994NT17200018
J	DYKEWICZ, MS; KIM, HW; ORFAN, N; YOO, TJ; LIEBERMAN, P				DYKEWICZ, MS; KIM, HW; ORFAN, N; YOO, TJ; LIEBERMAN, P			IMMUNOLOGICAL ANALYSIS OF ANAPHYLAXIS TO PROTAMINE COMPONENT IN NEUTRAL PROTAMINE HAGEDORN HUMAN INSULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INSULIN; DIABETES; PROTAMINE; IMMEDIATE-TYPE REACTIONS; ANAPHYLAXIS	RECOMBINANT DNA INSULIN; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; CARDIAC-CATHETERIZATION; INTRAVENOUS PROTAMINE; ADVERSE REACTIONS; NPH INSULIN; ALLERGY; SULFATE; HEPARIN	We report the clinical and immunologic analysis of two patients with diabetes who had anaphylaxis to neutral protamine Hagedom (NPH) human insulin in the absence of allergy to regular insulin. A 36-year-old woman without a recent history of local insulin reactions or interruption of insulin therapy experienced anaphylaxis within 15 minutes of her usual morning dose of subcutaneously administered NPH human insulin. A 62-year-old man with a history of generalized reactions to NPH human insulin and of anaphylaxis to intravenously administered protamine had generalized urticaria after injection of NPH human insulin. Both patients subsequently tolerated Lente human insulin. Skin test results in both patients were negative to regular and Lente insulin preparations but positive to NPH insulin and to protamine at concentrations tested. In vitro assays demonstrated that both patients had markedly elevated serum levels of IgE and IgG to protamine, but not to regular human insulin, and that their IgE antibodies to protamine recognized protamine antigenic determinants in NPH human insulin. We conclude that the anaphylactic reactions to NPH insulin in our patients were mediated by IgE to protamine, which should be a pathogenetic consideration in the evaluation of immediate-type reactions to protamine-containing insulins.	UNIV TENNESSEE,CTR HLTH SCI,ALLERGY & IMMUNOL SECT,MEMPHIS,TN 38163; NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,CHICAGO,IL 60611	University of Tennessee System; University of Tennessee Health Science Center; Northwestern University	DYKEWICZ, MS (corresponding author), ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,ST LOUIS,MO 63104, USA.							ALTMAN JJ, 1983, LANCET, V2, P524; ARKINS JA, 1962, J ALLERGY, V33, P69, DOI 10.1016/0021-8707(62)90065-5; BEST N, 1984, BRIT J ANAESTH, V56, P339, DOI 10.1093/bja/56.4.339; BEST N, 1983, BRIT J ANAESTH, V55, P1149, DOI 10.1093/bja/55.11.1149; BRUNI B, 1986, DIABETES CARE, V9, P552, DOI 10.2337/diacare.9.5.552b; CAPLAN SN, 1976, NEW ENGL J MED, V295, P172; CHUNG F, 1984, CAN ANAESTH SOC J, V31, P314, DOI 10.1007/BF03007897; DEGGES RD, 1987, AM J SURG, V154, P696, DOI 10.1016/0002-9610(87)90247-9; DOOLAN L, 1981, ANAESTH INTENS CARE, V9, P147, DOI 10.1177/0310057X8100900209; FISER WP, 1985, J THORAC CARDIOV SUR, V89, P63; GARCIAORTEGA P, 1984, BRIT MED J, V288, P1271, DOI 10.1136/bmj.288.6426.1271; GOTTSCHLICH GM, 1988, J ALLERGY CLIN IMMUN, V81, P238, DOI 10.1016/0091-6749(88)90514-3; GOTTSCHLICH GM, 1988, ANN ALLERGY, V61, P277; GRAMMER L, 1986, CLIN REV ALLERG, V4, P189; GRAMMER LC, 1985, J LAB CLIN MED, V105, P108; GRAMMER LC, 1984, JAMA-J AM MED ASSOC, V251, P1459, DOI 10.1001/jama.251.11.1459; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V71, P250, DOI 10.1016/0091-6749(83)90107-0; GRANT J A, 1984, Journal of Allergy and Clinical Immunology, V73, P180; GREENBERGER PA, 1989, AM J MED SCI, V298, P104, DOI 10.1097/00000441-198908000-00006; HOBBHAHN J, 1988, ANESTH ANALG, V67, P253; KELLER R, 1968, INT ARCH ALLER A IMM, V34, P139, DOI 10.1159/000230104; KIRKLIN JK, 1986, ANN THORAC SURG, V41, P193, DOI 10.1016/S0003-4975(10)62668-9; KNAPE JTA, 1981, ANESTHESIOLOGY, V55, P324, DOI 10.1097/00000542-198109000-00025; KOLLNER A, 1991, DEUT MED WOCHENSCHR, V116, P1234, DOI 10.1055/s-2008-1063741; KUMAR D, 1977, J CLIN ENDOCR METAB, V45, P1159, DOI 10.1210/jcem-45-6-1159; LAKIN JD, 1977, J ALLERGY CLIN IMMUN, V61, P102; LIEBERMAN P, 1984, JAMA-J AM MED ASSOC, V215, P1106; LOWENSTEIN E, 1988, American Review of Respiratory Disease, V137, P245; MATTSON JR, 1975, ARCH INTERN MED, V135, P818, DOI 10.1001/archinte.135.6.818; MCINTYRE RW, 1986, AM J CARDIOL, V58, P857, DOI 10.1016/0002-9149(86)90371-1; MOREL DR, 1987, ANESTHESIOLOGY, V66, P597, DOI 10.1097/00000542-198705000-00002; MOREL DR, 1988, CIRC RES, V62, P905, DOI 10.1161/01.RES.62.5.905; RADEGRAN K, 1971, EUR SURG RES, V3, P139, DOI 10.1159/000127560; RENT R, 1975, J IMMUNOL, V114, P120; SANCHEZ MB, 1982, LANCET, V1, P1243; SHARATH MD, 1985, J THORAC CARDIOV SUR, V90, P86; SKIDGEL RA, 1988, FASEB J, V2, pA1382; SMALL P, 1984, ANN ALLERGY, V53, P39; STEFANISZYN HJ, 1984, J THORAC CARDIOV SUR, V87, P678; STEWART WJ, 1984, CIRCULATION, V70, P788, DOI 10.1161/01.CIR.70.5.788; TOBIN MC, 1986, MOL IMMUNOL, V23, P245, DOI 10.1016/0161-5890(86)90050-7; VINCENT GM, 1991, CATHETER CARDIO DIAG, V23, P164, DOI 10.1002/ccd.1810230303; VONTZ FK, 1982, AM SURGEON, V48, P549; WEILER JM, 1990, J ALLERGY CLIN IMMUN, V85, P713, DOI 10.1016/0091-6749(90)90189-B; WEILER JM, 1985, J ALLERGY CLIN IMMUN, V75, P297, DOI 10.1016/0091-6749(85)90061-2; WEISS ME, 1991, CLIN REV ALLERG, V9, P339; WEISS ME, 1990, CLIN EXP ALLERGY, V20, P713, DOI 10.1111/j.1365-2222.1990.tb02713.x; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402; WILES PG, 1983, BRIT MED J, V287, P531, DOI 10.1136/bmj.287.6391.531; 1983, J ALLERGY CLIN IMMUN, V72, P515	50	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1994	93	1	1				117	125		10.1016/0091-6749(94)90240-2	http://dx.doi.org/10.1016/0091-6749(94)90240-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MT781	8308177	Bronze			2022-12-18	WOS:A1994MT78100014
J	GERSTMAN, BB; BOSCO, LA; TOMITA, DK				GERSTMAN, BB; BOSCO, LA; TOMITA, DK			TRENDS IN THE PREVALENCE OF ASTHMA HOSPITALIZATION IN THE 5-YEAR-OLD TO 14-YEAR-OLD MICHIGAN MEDICAID POPULATION, 1980 TO 1986	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; MEDICAL ASSISTANCE; TITLE-19; EPIDEMIOLOGIC METHODS	CHILDHOOD ASTHMA; UNITED-STATES; CHILDREN; MORTALITY	Background: Despite advances in therapy, morbidity and mortality rates as a result of pediatric asthma appear to have increased during the past decade. Epidemiologic evidence suggests that these increases disproportionately affected black children and the urban poor. Methods: With use of data from the Medicaid Management Information System, we estimated the prevalence of asthma hospitalization in the 5- to 14-year-old Michigan Medicaid population for the period 1980 to 1986. Results: Large increases were seen between 1980 and 1984, with leveling off or a slight decline thereafter. In 5- to 9-year-old children, the prevalence of asthma hospitalization increased from 2.3 per 1000 persons in 1980 to 4.5 per 1000 in 1984. Ten- to 14-year-old children demonstrated an increase of 2.2 per 1000 in 1980 to 3.2 per 1000 in 1984. Comparable trends occurred in all strata defined by age, race, residency, and gender. However, the largest increases were noted in urban black children, in which the rate more than doubled from 3.2 per 1000 in 1980 to 7.1 per 1000 in 1984. The adjusted relative risk for asthma hospitalization associated with being male was 1.6 (95% CI: 1.5, 1.7), with being black was 2.2 (95% CI: 2.1, 2.4), and with living in an urban county was 1.1 (95% CI: 1.04, 1.4). Conclusions: Within this relatively homogeneous low socioeconomic population, black race remained a strong predictor for asthma hospitalization, whereas urban residence was only minimally associated with this outcome.	CTR MED EFFECTIVENESS RES,AGCY HLTH CARE PROMOT & RES,ROCKVILLE,MD; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA	Amgen	GERSTMAN, BB (corresponding author), SAN JOSE STATE UNIV,DEPT HLTH SCI,SAN JOSE,CA 95192, USA.							ARMITAGE P, 1987, STATISTICAL METHODS; CAMBELL S, 1990, J FORENSIC SCI, V35, P356; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; GERGEN PJ, 1988, PEDIATRICS, V81, P1; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; JONES CP, 1991, AM J EPIDEMIOL, V134, P1079, DOI 10.1093/oxfordjournals.aje.a116011; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MITCHELL EA, 1989, EUR RESPIR J, V2, P470; MITCHELL RG, 1973, ARCH DIS CHILD, V48, P467, DOI 10.1136/adc.48.6.467; MULLALLY DI, 1984, ANN ALLERGY, V53, P15; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; Rothman K, 1986, MODERN EPIDEMIOLOGY; SLY RM, 1986, ANN ALLERGY, V56, P207; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STROM BL, 1985, CLIN PHARMACOL THER, V38, P359, DOI 10.1038/clpt.1985.188; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777	19	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					838	843		10.1016/0091-6749(93)90340-L	http://dx.doi.org/10.1016/0091-6749(93)90340-L			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473671	Bronze			2022-12-18	WOS:A1993KY25100003
J	AFFRIME, MB; LORBER, R; DANZIG, M; CUSS, F; BRANNAN, MD				AFFRIME, MB; LORBER, R; DANZIG, M; CUSS, F; BRANNAN, MD			3 MONTH EVALUATION OF ELECTROCARDIOGRAPHIC EFFECTS OF LORATADINE IN HUMANS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				259	259						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100473
J	SHEPHERD, GM; BURTON, DA				SHEPHERD, GM; BURTON, DA			ADMINISTRATION OF CEPHALOSPORIN ANTIBIOTICS TO PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	2				262	262						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK431					2022-12-18	WOS:A1993KK43100485
J	SLATER, JE				SLATER, JE			LATEX ALLERGY - WHAT DO WE KNOW	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											SLATER, JE (corresponding author), CHILDRENS NATL MED CTR,DEPT ALLERGY & IMMUNOL,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.							CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; HARRINGTON RA, 1987, DRUG INTEL CLIN PHAR, V21, P721, DOI 10.1177/106002808702100909; JONES RT, 1992, J ALLERGY CLIN IMMUN, V89, P225; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; LOZYNSKY OA, 1986, ANN ALLERGY, V56, P62; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; SWANSON MC, 1992, J ALLERGY CLIN IMMUN, V89, P227; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; YOUNG MC, 1992, J ALLERGY CLIN IMMUN, V89, P226	9	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				279	281		10.1016/S0091-6749(05)80003-X	http://dx.doi.org/10.1016/S0091-6749(05)80003-X			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527311				2022-12-18	WOS:A1992JP52000001
J	WEMPE, JB; TAMMELING, EP; POSTMA, DS; AUFFARTH, B; TEENGS, JP; KOETER, GH				WEMPE, JB; TAMMELING, EP; POSTMA, DS; AUFFARTH, B; TEENGS, JP; KOETER, GH			EFFECTS OF BUDESONIDE AND BAMBUTEROL ON CIRCADIAN VARIATION OF AIRWAY RESPONSIVENESS AND NOCTURNAL SYMPTOMS OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; NOCTURNAL ASTHMA; CORTICOSTEROIDS; BETA-AGONISTS; AIRWAY HYPERRESPONSIVENESS	ALLERGEN-INDUCED ASTHMA; BRONCHIAL RESPONSIVENESS; INHALED HISTAMINE; LUNG-FUNCTION; RELEASE TERBUTALINE; SUSTAINED-RELEASE; FLOW-RATE; CORTICOSTEROIDS; HYPERREACTIVITY; BRONCHODILATOR	Effects of the inhaled corticosteroid budesonide and the oral beta-agonist bambuterol on the nocturnal worsening of asthma were studied in patients with allergic asthma with a circadian peak expiratory flow variation greater-than-or-equal-to 15% (group 1, n = 8) and <15% (group 2, n = 9). Airflow limitation and airway responsiveness to histamine were measured during 24 hours after 4 weeks of treatment with (A) 0.4 mg budesonide at 8 AM and 8 PM, (B) 20 mg bambuterol at 8 PM, and (C) placebo, in a randomized, crossover design. Patients in group 1 had worse nocturnal symptom scores and a greater airway responsiveness than patients in group 2; in addition, patients in group 1 had a larger increase in responsiveness during the night (1.1 versus 0.6 doubling concentrations [DC]). Both budesonide and bambuterol improved responsiveness more at night than during daytime, thus decreasing circadian variation: at 4 AM, increases in PC20 were 2.0 DC after budesonide and 0.8 DC after bambuterol, compared with placebo. Bambuterol reduced circadian variation in FEV1, but in contrast to budesonide, did not improve 24-hour mean levels of FEV1 and PC20. Both drugs beneficially influenced nocturnal symptoms; the effects of budesonide were stronger than those of bambuterol. Our findings demonstrate that budesonide and bambuterol reduce nocturnal airway responsiveness and asthma symptoms and suggest a relationship between the degree of airway responsiveness and the presence of nocturnal symptoms of asthma.	UNIV GRONINGEN HOSP,DEPT PULMONOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen								AALDEREN WMC, 1989, THORAX, V44, P803; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BARNES PJ, 1984, BRIT MED J, V288, P1397, DOI 10.1136/bmj.288.6428.1397; BHAGAT RG, 1985, AM REV RESPIR DIS, V131, P902; BRAND PLP, 1991, AM REV RESPIR DIS, V143, P916, DOI 10.1164/ajrccm/143.5_Pt_1.916; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1984, CLIN ALLERGY, V14, P61, DOI 10.1111/j.1365-2222.1984.tb02191.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DAHL R, 1989, J ALLERGY CLIN IMMUN, V83, P811, DOI 10.1016/0091-6749(89)90019-5; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; DALONZO GE, 1990, AM REV RESPIR DIS, V142, P84, DOI 10.1164/ajrccm/142.1.84; DAVIES RJ, 1976, AM REV RESPIR DIS, V114, P1011; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; FAIRFAX AJ, 1980, THORAX, V35, P526, DOI 10.1136/thx.35.7.526; GERVAIS P, 1977, J ALLERGY CLIN IMMUN, V59, P207, DOI 10.1016/0091-6749(77)90151-8; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; KENNEDY BM, 1987, CHROMATOGRAPHIA, V24, P895, DOI 10.1007/BF02688606; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LORENTZSON S, 1990, THORAX, V45, P733, DOI 10.1136/thx.45.10.733; MAESEN FPV, 1990, CHEST, V98, P866, DOI 10.1378/chest.98.4.866; MANNING PJ, 1987, J APPL PHYSIOL, V63, P1572, DOI 10.1152/jappl.1987.63.4.1572; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; MOHIUDDIN AA, 1990, AM REV RESPIR DIS, V142, P1153, DOI 10.1164/ajrccm/142.5.1153; MORRISON JFJ, 1989, BRIT J CLIN PHARMACO, V28, P545, DOI 10.1111/j.1365-2125.1989.tb03540.x; MORRISON JFJ, 1990, BMJ, V301, P4773; NEYENS HJ, 1983, EUR RESPIR J, V64, P591; PERSSON G, 1988, EUR RESPIR J, V1, P223; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POLOSA R, 1990, J ALLERGY CLIN IMMUN, V86, P265, DOI 10.1016/S0091-6749(05)80075-2; POSTMA DS, 1986, J ALLERGY CLIN IMMUN, V77, P471, DOI 10.1016/0091-6749(86)90182-X; QUANJER PH, 1983, B EUR PHYSIOPATHO S5, V19, P93; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SANDSTROM T, 1988, RESPIRATION, V53, P31, DOI 10.1159/000195393; SOUTAR CA, 1975, THORAX, V30, P436, DOI 10.1136/thx.30.4.436; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8	42	28	28	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				349	357		10.1016/S0091-6749(05)80014-4	http://dx.doi.org/10.1016/S0091-6749(05)80014-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1356117				2022-12-18	WOS:A1992JP52000012
J	WALLUKAT, G; WOLLENBERGER, A				WALLUKAT, G; WOLLENBERGER, A			AUTOANTIBODIES TO BETA-2-ADRENERGIC RECEPTORS WITH ANTIADRENERGIC ACTIVITY FROM PATIENTS WITH ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; BETA-2-ADRENERGIC RECEPTORS; SERUM GAMMA-GLOBULINS; CULTURED HEART CELLS; CLENBUTEROL	BETA-ADRENERGIC RECEPTORS; BRONCHIAL-ASTHMA; GENE; ADRENOCEPTOR	The serum gamma-globulin fraction from patients with allergic bronchial asthma (8/8), in contrast to the fraction from nonatopic control subjects (10/10), was found to inhibit the positive chronotropic action of the beta-2-selective adrenergic agonist, clenbuterol, on pyruvate- or lactate-treated cultured neonatal rat heart myocytes. No inhibition was exerted on the positive chronotropic response to prenalterol, which acted via beta-1-adrenergic receptors. The inhibitory effect of the asthmatic gamma-globulins was concentration dependent. It could nearly be abolished by immunoprecipitation with antihuman gamma-globulin and antihuman IgG, but not with antihuman IgM. This finding means that the inhibitory immunoglobulins of the patients with asthma were chiefly autoantibodies of the IgG isotype, capable of cross-reacting with chronotropic beta-2-adrenergic receptors on the cultured rat cardiomyocytes. These findings provide support for the notion that autoimmunity plays a role in the impairment of beta-adrenergic responsiveness in patients with allergic bronchial asthma.			WALLUKAT, G (corresponding author), INST CARDIOVASC RES,DIV CELLULAR & MOLEC CARDIOL,ROBERT ROSSLE STR 10,W-1115 BERLIN,GERMANY.							ALLEN JM, 1988, EMBO J, V7, P133, DOI 10.1002/j.1460-2075.1988.tb02792.x; ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BASRAN GS, 1981, THORAX, V36, P712; BLECHER M, 1984, J ALLERGY CLIN IMMUN, V74, P246, DOI 10.1016/0091-6749(84)90253-7; COHEN ML, 1982, N-S ARCH PHARMACOL, V320, P145, DOI 10.1007/BF00506314; CONOLLY ME, 1976, J CLIN INVEST, V58, P1307, DOI 10.1172/JCI108586; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOHLMAN HG, 1987, J BIOL CHEM, V242, P1482; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; ETAICHE M, 1985, CAN J PHYSL PHARM, V63, P1221; FRASER CM, 1981, NEW ENGL J MED, V305, P1165, DOI 10.1056/NEJM198111123052001; FRIESEN HG, 1982, CIBA F S, V90, P248; HALLE W, 1970, AM J CARDIOL, V25, P292, DOI 10.1016/S0002-9149(70)80006-6; HARRISON LC, 1982, CIBA F SYMP, V90, P248; INSEL PA, 1990, FASEB J, V4, P2732, DOI 10.1096/fasebj.4.10.2197153; KARLINER JS, 1985, BIOCHEM BIOPH RES CO, V128, P376, DOI 10.1016/0006-291X(85)91689-4; KAUMANN AJ, 1982, N-S ARCH PHARMACOL, V320, P119, DOI 10.1007/BF00506312; LAU YH, 1980, CIRC RES, V47, P41, DOI 10.1161/01.RES.47.1.41; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MAGNUSSON Y, 1989, CLIN EXP IMMUNOL, V78, P42; MCLIMANS WF, 1968, BIOTECHNOL BIOENG, V10, P725, DOI 10.1002/bit.260100603; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; POTTER PC, 1987, FED PROC, V6, P1379; ROITT IM, 1982, CIBA F S, V90, P248; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; Szentivanyi A, 1979, Triangle, V18, P109; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; VENTER JC, 1980, SCIENCE, V207, P1361, DOI 10.1126/science.6153472; WALLUKAT G, 1991, MOL CELL BIOCHEM, V102, P35; WALLUKAT G, 1988, 14TH INT C BIOCH, P164; Wallukat G., 1987, INVOLVEMENT BETA2 AD; WEIR DM, 1967, EXPT IMMUNOLOGY, P3; WILLIAMS RS, 1983, J CARDIOVASC PHARM, V5, P266, DOI 10.1097/00005344-198303000-00017	34	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					581	587		10.1016/0091-6749(91)90151-D	http://dx.doi.org/10.1016/0091-6749(91)90151-D			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1655856				2022-12-18	WOS:A1991GL04900006
J	ROBERTS, RL; ANK, BJ; STIEHM, ER				ROBERTS, RL; ANK, BJ; STIEHM, ER			HUMAN EOSINOPHILS ARE MORE TOXIC THAN NEUTROPHILS IN ANTIBODY-INDEPENDENT KILLING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PERIPHERAL-BLOOD GRANULOCYTES; CHRONIC GRANULOMATOUS-DISEASE; MAJOR BASIC-PROTEIN; CELL CYTO-TOXICITY; HYPEREOSINOPHILIC SYNDROME; FUNCTIONAL-PROPERTIES; SURVIVAL; INVITRO; SYSTEM; PURIFICATION	Eosinophils (EOSs) are implicated in damaging host tissues in diseases such as asthma and eosinophilic gastroenteritis. In the present study, we assessed the cytotoxicity of human EOSs from peripheral blood of patients with eosinophilia and from peritoneal fluid of patients undergoing continuous peritoneal dialysis and compared them to normal neutrophils. Cytotoxicity was measured by the release of chromium-51 from cultured tumor cells and chicken erythrocytes. Both EOSs and neutrophils were separated on discontinuous Percoll gradients with > 95% purity. The granulocytes were activated by preincubation in an ice bath with phorbol myristate acetate and washed before incubation with the target cells. The EOSs lysed significantly more tumor cells (K562, Raji, and CEM lines) in an 18-hour assay than did neutrophils, and no significant difference was found between the peritoneal and blood EOSs. The EOSs were also much more efficient than neutrophils in lysing chicken erythrocytes when they were activated by granulocyte-macrophage colony-stimulating factor instead of phorbol myristate acetate. Cytolysis by EOSs is mediated by both oxidative and nonoxidative mechanisms, as indicated by experiments with cells from patients with chronic granulomatous disease. Thus, EOSs are much more cytotoxic than neutrophils and potentially much more damaging to patients with eosinophilia.			ROBERTS, RL (corresponding author), UNIV CALIF LOS ANGELES,MED CTR,SCH MED,DEPT PEDIAT,DIV IMMUNOL ALLERGY,LOS ANGELES,CA 90024, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R22HD009800, R01HD009800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015332] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15332] Funding Source: Medline; NICHD NIH HHS [HD-09800] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACKERMAN SJ, 1982, PHAGOCYTIC CELLS ADV, P269; CHIN TW, 1986, CELL IMMUNOL, V103, P646; CLARK RA, 1981, J IMMUNOL, V126, P1295; COOK RM, 1987, INT ARCH ALLER A IMM, V83, P428, DOI 10.1159/000234380; DOR PJ, 1984, AM REV RESPIR DIS, V130, P1072; ELHAG A, 1987, J IMMUNOL, V139, P2406; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; FLAUM MA, 1981, BLOOD, V58, P1012; GRAZIANO RF, 1989, J IMMUNOL, V142, P230; HALLGREN R, 1987, AM REV RESPIR DIS, V135, P639; JONA JZ, 1976, AM J DIS CHILD, V130, P1136, DOI 10.1001/archpedi.1976.02120110098015; JONG EC, 1980, J IMMUNOL, V124, P1949; KATZ AJ, 1984, J ALLERGY CLIN IMMUN, V74, P72, DOI 10.1016/0091-6749(84)90090-3; KAY H D, 1986, Natural Immunity and Cell Growth Regulation, V5, P1; KAY HD, 1983, J IMMUNOL, V130, P475; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; PARRILLO JE, 1978, BLOOD, V51, P457; PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283, DOI 10.1002/jlb.41.4.283; PETRIE HT, 1985, J IMMUNOL, V134, P230; ROBERTS RL, 1984, J IMMUNOL, V132, P2000; ROBERTS RL, 1990, J IMMUNOL METHODS, V126, P205, DOI 10.1016/0022-1759(90)90152-L; ROBERTS RL, 1985, BLOOD, V65, P433; ROBERTS RL, 1989, AM J DIS CHILD, V143, P944, DOI 10.1001/archpedi.1989.02150200104027; ROBERTS RL, 1986, PEDIATR RES, V20, P378, DOI 10.1203/00006450-198604000-00024; ROBERTS RL, 1989, J LEUKOCYTE BIOL, V46, P299; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SEDGWICK JB, 1988, J ALLERGY CLIN IMMUN, V81, P876, DOI 10.1016/0091-6749(88)90945-1; SLAVIN RG, 1983, ALLERGY PRINCIPLES P, P1067; TAUBER AI, 1979, INFLAMMATION, V3, P261, DOI 10.1007/BF00914183; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; WELLER PF, 1980, AM J PATHOL, V100, P793; WOOD ML, 1984, CLIN EXP DERMATOL, V9, P139, DOI 10.1111/j.1365-2230.1984.tb00774.x; YAZDANBAKHSH M, 1986, INFECT IMMUN, V53, P192, DOI 10.1128/IAI.53.1.192-198.1986	36	28	28	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1105	1115		10.1016/0091-6749(91)92156-U	http://dx.doi.org/10.1016/0091-6749(91)92156-U			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045615	Bronze			2022-12-18	WOS:A1991FR06600010
J	LAM, S; ALMAJED, S; CHAN, H; TSE, K; LERICHE, JC; CHANYEUNG, M				LAM, S; ALMAJED, S; CHAN, H; TSE, K; LERICHE, JC; CHANYEUNG, M			DIFFERENCES IN MEDIATOR RELEASE BETWEEN ALLERGIC RHINITIS AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							NONSPECIFIC BRONCHIAL REACTIVITY; INHALED HISTAMINE; RESPONSIVENESS; RELEASABILITY; PARENCHYMA; EPITHELIUM; CHALLENGE; AIRWAYS; TRACHEA; LAVAGE	To determine why patients with allergic rhinitis alone differ in their airway response to inhaled allergen compared to patients with allergic asthma, bronchial lavage was performed in 10 subjects with allergic asthma and in five subjects with allergic rhinitis, before and after inhalation challenge with antigen to produce an immediate asthmatic reaction. Before antigen challenge, the subjects with asthma had higher absolute neutrophil counts in the lavage fluid. After antigen challenge, the subjects with asthma released significant amounts of bronchoconstrictive mediators, such as histamine and thromboxane B2 into the lavage fluid, whereas subjects with rhinitis alone did not. There was also a significant increase in prostaglandin E2 in the subjects with asthma after antigen challenge. Nonimmunologic bronchoconstriction with methacholine inhalation challenge in six other subjects with asthma did not demonstrate an increase in any of the lavage fluid mediator levels that were measured. A positive correlation was found between methacholine provocative concentration causing a 20% drop in FEV1 and the concentration of prostaglandin E2 in the lavage fluid before challenge. The significance of this observation has yet to be determined. The results suggest that subjects with allergic asthma differ from subjects with rhinitis alone in their capacity to release more mediators into the airways on antigen challenge. It is not known whether this increase in mediators is due to increase in the number of mast cells in the airways or due to increase in mediator releasability from the mast cells of subjects with asthma.	UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DEPT MED,DIV RESP,VANCOUVER V5Z 1M9,BC,CANADA	University of British Columbia								ALTOUNYAN REC, 1970, SODIUM CROMOGLYCATE, P47; BARNES PJ, 1985, BRIT J PHARMACOL, V86, P685, DOI 10.1111/j.1476-5381.1985.tb08946.x; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; CAMPAGNE JG, 1969, SCAND J RESPIR DIS, V50, P76; CASOLARO V, 1989, AM REV RESPIR DIS, V139, P1375, DOI 10.1164/ajrccm/139.6.1375; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FEINBERG SM, 1952, J ALLERGY, V23, P387, DOI 10.1016/0021-8707(52)90001-4; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; GRODZINSKA L, 1975, J PHARM PHARMACOL, V27, P88, DOI 10.1111/j.2042-7158.1975.tb09414.x; GUERZON GM, 1979, AM REV RESPIR DIS, V119, P59; HOLGATE ST, 1986, EUR J RESPIR DIS S, V15, P34; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KREKNIET J, 1973, RESPIRATION, V30, P345; LAM S, 1985, CHEST, V88, P856, DOI 10.1378/chest.88.6.856; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NATHAN RA, 1979, J ALLERGY CLIN IMMUN, V63, P150; PETERS SP, 1985, INT ARCH ALLER A IMM, V76, P344, DOI 10.1159/000233719; POPA VT, 1979, J ALLERGY CLIN IMMUN, V63, P141; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; SCHULMAN ES, 1982, J APPL PHYSIOL, V53, P589, DOI 10.1152/jappl.1982.53.3.589; SMITH JM, 1965, AM REV RESPIR DIS, V92, P16; SMITH JM, 1983, ALLERGY PRINCIPLES P, V2, P771; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; TUNG R, 1982, J IMMUNOL, V128, P2067; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; ZUIDEMA P, 1969, RESPIRATION, VS 26, P141, DOI 10.1159/000192648	37	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					842	849		10.1016/0091-6749(91)90131-7	http://dx.doi.org/10.1016/0091-6749(91)90131-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	2013679				2022-12-18	WOS:A1991FG05900014
J	SEIDEL, WF; COHEN, S; BLIWISE, NG; DEMENT, WC				SEIDEL, WF; COHEN, S; BLIWISE, NG; DEMENT, WC			DIRECT MEASUREMENT OF DAYTIME SLEEPINESS AFTER ADMINISTRATION OF CETIRIZINE AND HYDROXYZINE WITH A STANDARDIZED ELECTROENCEPHALOGRAPHIC ASSESSMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB			LATENCY TEST; OBJECTIVE MEASURES; CHRONIC INSOMNIA; PERFORMANCE; ANTIHISTAMINES; QUANTIFICATION; NARCOLEPSY; NIGHTTIME; BUSPIRONE; ALERTNESS	Alertness is a vital function, and medications that do not impair this vital function are clinically desirable in terms of safety. In a comparative study to measure daytime alertness objectively, 60 men and women in good health were assigned to receive either cetirizine, 5 mg. 10 mg, or 20 mg, hydroxyzine, 25 mg, or placebo in a randomized, double-blind, parallel-group design. Subjects slept in the laboratory for 2 consecutive nights to facilitate adaptation. During the second night, the subjects' sleep patterns were recorded by electroencephalogram (EEG), electrooculogram, and chin electromyogram. After the second night, subjects were awakened at 7:30 AM and given a single dose of the assigned treatment. Multiple Sleep Latency Tests (standardized 20-minute opportunites to fall asleep in bed while EEG and eye movements are recorded) were given every 2 hours. Subjects who received cetirizine did not differ from control subjects given placebo in any measure of daytime alertness. Subjects who received hydroxyzine were significantly more sedated than were control subjects given placebo for about 4 hours after treatment. The data from this study provide evidence that cetirizine does not differ from placebo with respect to alertness. The usefulness of the specific and sensitive standardized electroencephalogram, compared with alternative assessments of daytime alertness, is discussed.	STANFORD UNIV,MED CTR,SCH MED,SLEEP RES CTR,STANFORD,CA 94305	Stanford University				Seidel, Wesley/0000-0002-4799-7843	PHS HHS [05804] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIRA SA, 1985, SLEEP, V8, P325, DOI 10.1093/sleep/8.4.325; BILLIARD M, 1987, SLEEP, V10, P27, DOI 10.1093/sleep/10.suppl_1.27; BLIWISE D, 1984, AM J PSYCHIAT, V141, P191; BONNET MH, 1988, NEUROPSYCHOPHARMACOL, V1, P225, DOI 10.1016/0893-133X(88)90021-8; BORBELY AA, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1696; BROWMAN CP, 1989, CLIN ELECTROENCEPHAL, V20, P45, DOI 10.1177/155005948902000110; Carskadon M. A., 1977, SLEEP RES, V6, P200; CARSKADON MA, 1987, NEUROSCI BIOBEHAV R, V11, P307, DOI 10.1016/S0149-7634(87)80016-7; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; CIRIGNOTTA F, 1988, PHARMACOL BIOCHEM BE, V29, P807, DOI 10.1016/0091-3057(88)90212-2; CLODORE M, 1986, CHRONOBIOL INT, V3, P255, DOI 10.3109/07420528609079543; COLEMAN RM, 1985, ANN ALLERGY, V55, P232; DEMENT WC, 1986, AVIAT SPACE ENVIR MD, V57, pB14; DEROECK J, 1989, ACTA PSYCHIAT SCAND, V79, P129; DOROW R, 1987, BRAIN RES BULL, V19, P319, DOI 10.1016/0361-9230(87)90100-6; GUILLEMINAULT C, 1982, EUR J PEDIATR, V139, P165, DOI 10.1007/BF01377349; HINDMARCH I, 1980, BRIT J CLIN PHARMACO, V10, P189, DOI 10.1111/j.1365-2125.1980.tb01745.x; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; JOHNSON LC, 1982, PSYCHOPHARMACOLOGY, V76, P101, DOI 10.1007/BF00435262; Kales A, 1968, MANUAL STANDARDIZED; LEVINE B, 1987, SLEEP, V10, P590; LEVINE B, 1988, SLEEP, V11, P39; MATTMANN P, 1982, ARZNEIMITTELFORSCH, V32-1, P461; MCNAIR DM, 1970, MANUAL PROFILE MOOD; NICHOLSON AN, 1986, EUR J CLIN PHARMACOL, V30, P27, DOI 10.1007/BF00614191; REYNOLDS CF, 1982, ELECTROEN CLIN NEURO, V53, P443, DOI 10.1016/0013-4694(82)90009-8; RICHARDSON GS, 1978, ELECTROEN CLIN NEURO, V45, P621, DOI 10.1016/0013-4694(78)90162-1; ROEHRS T, 1983, SLEEP, V6, P319, DOI 10.1093/sleep/6.4.319; ROTH T, 1987, J ALLERGY CLIN IMMUN, V80, P94, DOI 10.1016/S0091-6749(87)80197-5; SASAKI M, 1986, AVIAT SPACE ENVIR MD, V57, pB29; SCHNEIDERHELMER.D, 1983, EUR NEUROL, V23, P353; SEIDEL WF, 1984, SCIENCE, V224, P1262, DOI 10.1126/science.6729454; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SEIDEL WF, 1985, PSYCHOPHARMACOLOGY, V87, P371, DOI 10.1007/BF00432724; SEIDEL WF, 1984, SLEEP, V3, P320; SEIDEL WF, 1987, SLEEP RES, V16, P140; SIMONS FER, 1989, OCT S ADV ANT THER N; STEPANSKI E, 1988, SLEEP, V11, P54, DOI 10.1093/sleep/11.1.54; SUGERMAN JL, 1989, SLEEP, V12, P106, DOI 10.1093/sleep/12.2.106; WEGMANN HM, 1986, AVIAT SPACE ENVIR MD, V57, pB53; ZORICK F, 1983, B EUR PHYSIOPATH RES, V19, P600; ZWYGHUIZENDOORENBOS A, 1988, SLEEP, V11, P562, DOI 10.1093/sleep/11.6.562; ZWYGHUIZENDOORENBOS A, 1988, NEUROPSYCHOPHARMACOL, V1, P279	43	28	28	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			1029	1033		10.1016/S0091-6749(05)80249-0	http://dx.doi.org/10.1016/S0091-6749(05)80249-0			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	2148177				2022-12-18	WOS:A1990ER13100008
J	REISS, WG; SLAUGHTER, RL; LUDWIG, EA; MIDDLETON, E; JUSKO, WJ				REISS, WG; SLAUGHTER, RL; LUDWIG, EA; MIDDLETON, E; JUSKO, WJ			STEROID DOSE SPARING - PHARMACODYNAMIC RESPONSES TO SINGLE VERSUS DIVIDED DOSES OF METHYLPREDNISOLONE IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,SCH PHARM,DEPT PHARMACEUT,HOCHSTETTER 565,BUFFALO,NY 14260; BUFFALO GEN HOSP,DEPT PHARM,BUFFALO,NY 14203; BUFFALO GEN HOSP,SCH MED,BUFFALO,NY 14203; SUNY BUFFALO,SCH MICROBIOL IMMUNOL,BUFFALO,NY 14260; SUNY BUFFALO,SCH PHARM,DEPT PHARM & MED,BUFFALO,NY 14260; BUFFALO GEN HOSP,DEPT MED,BUFFALO,NY 14203	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center; Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Buffalo General Medical Center			Jusko, William J/G-4885-2015		PHS HHS [24211] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BRITTON MG, 1976, BRIT MED J, V2, P73, DOI 10.1136/bmj.2.6027.73; BROOKS SM, 1972, NEW ENGL J MED, V286, P1125, DOI 10.1056/NEJM197205252862103; CERESA F, 1969, J CLIN ENDOCR METAB, V29, P1074, DOI 10.1210/jcem-29-8-1074; DUNLAP NE, 1984, CLIN CHEST MED, V5, P669; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; EBLING WF, 1984, J CHROMATOGR, V305, P271, DOI 10.1016/S0378-4347(00)83342-3; EITCHES RW, 1985, AM J DIS CHILD, V139, P264, DOI 10.1001/archpedi.1985.02140050058022; ELLULMICALLEF R, 1975, THORAX, V30, P312, DOI 10.1136/thx.30.3.312; GAMBERTOGLIO JG, 1980, J CLIN ENDOCR METAB, V51, P561, DOI 10.1210/jcem-51-3-561; GLYNN AM, 1986, CLIN PHARMACOL THER, V39, P654, DOI 10.1038/clpt.1986.114; HARFI H, 1983, ARCH INTERN MED, V143, P1328; HASKELL RJ, 1983, ARCH INTERN MED, V143, P1324, DOI 10.1001/archinte.143.7.1324; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; JONSSON S, 1988, CHEST, V94, P723, DOI 10.1378/chest.94.4.723; JUSKO WJ, 1990, J CLIN PHARMACOL, V30, P303, DOI 10.1002/j.1552-4604.1990.tb03598.x; JUSKO WJ, 1975, J CLIN ENDOCR METAB, V40, P278, DOI 10.1210/jcem-40-2-278; KANDROTAS RJ, 1987, CLINPHARM THER, V42, P466; KONG AN, 1989, CLIN PHARMACOL THER, V46, P616, DOI 10.1038/clpt.1989.196; KOZOWER M, 1974, J CLIN ENDOCR METAB, V38, P407, DOI 10.1210/jcem-38-3-407; LAMPL KL, 1985, AM REV RESPIR DIS, V132, P1015; LEONARD EJ, 1987, J ALLERGY CLIN IMMUN, V79, P775, DOI 10.1016/0091-6749(87)90210-7; NICHOLS AI, 1989, J PHARMACOKINET BIOP, V17, P209, DOI 10.1007/BF01059029; NICHOLS AI, 1989, PHARMACEUT RES, V6, P198; NICHOLS T, 1965, J CLIN ENDOCR METAB, V25, P343, DOI 10.1210/jcem-25-3-343; PETEREIT LB, 1977, CLIN PHARMACOL THER, V22, P912; REINBERG A, 1983, J ALLERGY CLIN IMMUN, V71, P425, DOI 10.1016/0091-6749(83)90073-8; REINBERG A, 1974, CHRONOBIOLOGIA, V1, P333; Rohdewald P., 1985, AGENTS ACTIONS, V17, P290; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; WALD JA, 1986, J ALLERGY CLIN IMMUN, V78, P36, DOI 10.1016/0091-6749(86)90112-0; 1988, SOLUMEDROL METHYLPRE	36	28	29	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1990	85	6					1058	1066		10.1016/0091-6749(90)90051-5	http://dx.doi.org/10.1016/0091-6749(90)90051-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DK509	2191992				2022-12-18	WOS:A1990DK50900012
J	HEDLIN, G; SILBER, G; NACLERIO, R; PROUD, D; EGGLESTON, P; ADKINSON, NF				HEDLIN, G; SILBER, G; NACLERIO, R; PROUD, D; EGGLESTON, P; ADKINSON, NF			ATTENUATION OF ALLERGEN SENSITIVITY EARLY IN THE COURSE OF RAGWEED IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205	Johns Hopkins University	HEDLIN, G (corresponding author), KAROLINSKA HOSP,HUDDINGE UNIV HOSP,DEPT PEDIAT,B57,S-14186 HUDDINGE,SWEDEN.				NIAID NIH HHS [AI 21703] Funding Source: Medline; NINDS NIH HHS [NS 22488, NS 00811] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022488, K07NS000811] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; DANTZLER BS, 1980, ANN ALLERGY, V45, P213; FOUCARD T, 1978, CLIN ALLERGY, V8, P249, DOI 10.1111/j.1365-2222.1978.tb03221.x; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; HAMILTON RG, 1980, J IMMUNOL, V124, P2966; HEDLIN G, 1986, J ALLERGY CLIN IMMUN, V77, P488, DOI 10.1016/0091-6749(86)90184-3; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; KJELLMAN NIM, 1980, ALLERGY, V35, P323, DOI 10.1111/j.1398-9995.1980.tb01774.x; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MENDOZA GR, 1982, INT ARCH ALLER A IMM, V69, P282, DOI 10.1159/000233185; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V65, P87, DOI 10.1016/0091-6749(80)90191-8; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P255; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3	27	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					390	399		10.1016/0091-6749(89)90426-0	http://dx.doi.org/10.1016/0091-6749(89)90426-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2476472				2022-12-18	WOS:A1989AR19900019
J	YOSHIZAWA, I; NOMA, T; KAWANO, Y; YATA, J				YOSHIZAWA, I; NOMA, T; KAWANO, Y; YATA, J			ALLERGEN-SPECIFIC INDUCTION OF INTERLEUKIN-2 (IL-2) RESPONSIVENESS IN LYMPHOCYTES FROM CHILDREN WITH ASTHMA .1. ANTIGEN-SPECIFICITY AND INITIAL EVENTS OF THE INDUCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SAITAMA MED SCH,DEPT PEDIAT,38 MOROHONGO,MORIYAMA,SAITAMA 35004,JAPAN; NATL DEF MED COLL,CENT RES LAB,TOKOROZAWA,SAITAMA 359,JAPAN; NATL DEF MED COLL,DEPT PEDIAT,TOKOROZAWA,SAITAMA 359,JAPAN; TOKYO MED & DENT UNIV,DEPT PEDIAT,TOKYO 113,JAPAN	Saitama Medical University; National Defense Medical College - Japan; National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU)								BLACK PL, 1980, J ALLERGY CLIN IMMUN, V66, P394, DOI 10.1016/0091-6749(80)90119-0; BONNARD GD, 1979, J IMMUNOL, V123, P2704; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; BUCKLEY RH, 1977, J ALLERGY CLIN IMMUN, V59, P70, DOI 10.1016/0091-6749(77)90180-4; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GILLIS S, 1978, J IMMUNOL, V120, P2127; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; HOCHMAN PS, 1984, J EXP MED, V160, P1925, DOI 10.1084/jem.160.6.1925; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; MATSUSHITA S, 1987, J IMMUNOL, V138, P109; MINAMI M, 1980, J IMMUNOL, V124, P1314; MIYAMOTO T, 1974, J ALLERGY CLIN IMMUN, V53, P9, DOI 10.1016/0091-6749(74)90094-3; NOMA T, 1985, EUR J IMMUNOL, V15, P833, DOI 10.1002/eji.1830150817; NOMA T, IN PRESS ANN ALLERGY; NOMA T, 1987, JPN J ALLERGOL, V36, P75; PAWLY LJ, 1982, J IMMUNOL METHODS, V50, P173; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROMAGNANI S, 1973, Clinical Allergy, V3, P51, DOI 10.1111/j.1365-2222.1973.tb01309.x; RUSCETTI FW, 1977, J IMMUNOL, V119, P131; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; Smith K A, 1979, Ann N Y Acad Sci, V332, P423, DOI 10.1111/j.1749-6632.1979.tb47136.x; SMITH KA, 1980, IMMUNOL REV, V51, P337, DOI 10.1111/j.1600-065X.1980.tb00327.x; THORSBY E, 1982, IMMUNOL REV, V66, P39, DOI 10.1111/j.1600-065X.1982.tb00433.x; YAMAMURA K, 1985, NATURE, V316, P67, DOI 10.1038/316067a0	26	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					246	255		10.1016/0091-6749(89)90332-1	http://dx.doi.org/10.1016/0091-6749(89)90332-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2474592				2022-12-18	WOS:A1989AL83600017
J	SCHROECKENSTEIN, DC; BUSH, RK; CHERVINSKY, P; BUSSE, WW				SCHROECKENSTEIN, DC; BUSH, RK; CHERVINSKY, P; BUSSE, WW			12-HOUR BRONCHODILATION IN ASTHMA WITH A SINGLE AEROSOL DOSE OF THE ANTICHOLINERGIC COMPOUND GLYCOPYRROLATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,SCH MED,MADISON,WI 53706; WILLIAM S MIDDLETON MEM VET ADM HOSP,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital								ALTOUNYAN R. E. C., 1964, THORAX, V19, P406, DOI 10.1136/thx.19.5.406; Cochran WG, 1957, EXPT DESIGNS; FRITH PA, 1982, AUST NZ J MED, V12, P686; GAL TJ, 1984, AM REV RESPIR DIS, V129, P871, DOI 10.1164/arrd.1984.129.5.871; GAL TJ, 1981, ANESTH ANALG, V60, P85; GROSS NJ, 1984, AM REV RESPIR DIS, V129, P856, DOI 10.1164/arrd.1984.129.5.856; JOLOBE OMP, 1981, BRIT J DIS CHEST, V75, P413, DOI 10.1016/0007-0971(81)90032-2; LIN MT, 1978, ANN ALLERGY, V40, P326; MCFADDEN ER, 1981, J ALLERGY CLIN IMMUN, V68, P91, DOI 10.1016/0091-6749(81)90164-0; MIRAKHUR RK, 1980, J ROY SOC MED, V73, P727, DOI 10.1177/014107688007301008; PARTRIDGE MR, 1981, THORAX, V36, P530, DOI 10.1136/thx.36.7.530; RAMMAMURTHY S, 1972, CAN ANAESTH SOC J, V19, P399; SUN DCH, 1962, ANN NY ACAD SCI, V99, P153, DOI 10.1111/j.1749-6632.1962.tb45298.x; WALKER FB, 1987, CHEST, V91, P49, DOI 10.1378/chest.91.1.49; WYANT GM, 1974, CAN ANAESTH SOC J, V21, P230, DOI 10.1007/BF03013116	15	28	31	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					115	119		10.1016/0091-6749(88)90060-7	http://dx.doi.org/10.1016/0091-6749(88)90060-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392363				2022-12-18	WOS:A1988P400400019
J	MAGNUSSEN, H; REUSS, G; JORRES, R				MAGNUSSEN, H; REUSS, G; JORRES, R			METHYLXANTHINES INHIBIT EXERCISE-INDUCED BRONCHOCONSTRICTION AT LOW SERUM THEOPHYLLINE CONCENTRATION AND IN A DOSE-DEPENDENT FASHION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MAGNUSSEN, H (corresponding author), KRANKENHAUS GROSSHANSDORF, ZENTRUM PNEUMOL & THORAXCHIRURG, LVA FREIE & HANSESTADT HAMBURG, D-2070 GROSSHANSDORF, FED REP GER.							DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; ELIAS JA, 1981, AM REV RESPIR DIS, V123, P550; ELLIS EF, 1984, J ALLERGY CLIN IMMUN, V73, P690, DOI 10.1016/0091-6749(84)90307-5; KLEIN JJ, 1983, AM REV RESPIR DIS, V127, P413, DOI 10.1164/arrd.1983.127.4.413; KUGLER D, 1982, PRAX KLIN PNEUMOL, V36, P27; MAGNUSSEN H, 1986, CHEST, V90, P722, DOI 10.1378/chest.90.5.722; MAGNUSSEN H, 1987, AM REV RESPIR DIS, V136, P1163, DOI 10.1164/ajrccm/136.5.1163; POLLOCK J, 1977, PEDIATRICS, V60, P840; SCHEIDTMACKES M, 1984, AKTUELLE PROBLEME TH, P54; SIEGEL S, 1956, NONPARAMETRIC STAT, P75; WEINBERGER M, 1984, J ALLERGY CLIN IMMUN, V73, P525, DOI 10.1016/0091-6749(84)90505-0	11	28	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					518	525		10.1016/0091-6749(88)90190-X	http://dx.doi.org/10.1016/0091-6749(88)90190-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181					2022-12-18	WOS:A1988M618100006
J	STEINBERG, DR; BERNSTEIN, DI; GALLAGHER, JS; ARLIAN, L; BERNSTEIN, IL				STEINBERG, DR; BERNSTEIN, DI; GALLAGHER, JS; ARLIAN, L; BERNSTEIN, IL			COCKROACH SENSITIZATION IN LABORATORY WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,ML 563,231 BETHESDA AVE,CINCINNATI,OH 45267; WRIGHT STATE UNIV,DEPT BIOL SCI & PHYSIOL,DAYTON,OH 45435	University System of Ohio; University of Cincinnati; University System of Ohio; Wright State University Dayton								BERNSTEIN IL, 1975, J ALLERGY CLIN IMMUN, V56, P323; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BURGE PS, 1980, CLIN ALLERGY, V10, P355, DOI 10.1111/j.1365-2222.1980.tb02119.x; CHANG JL, 1984, MT SINAI J MED, V51, P197; FRANKLAND AW, 1965, BRIT J IND MED, V22, P157; FRASER BN, 1979, S AFR MED J, V55, P637; HULETT AC, 1979, ANN ALLERGY, V42, P160; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1985, CLIN REV ALLERG, V3, P363, DOI 10.1007/BF02993001; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WIDE L, 1967, LANCET, V2, P1105	14	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					586	590		10.1016/0091-6749(87)90012-1	http://dx.doi.org/10.1016/0091-6749(87)90012-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3668123	Bronze			2022-12-18	WOS:A1987K522400012
J	BURROWS, B				BURROWS, B			THE NATURAL-HISTORY OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BURROWS, B (corresponding author), UNIV ARIZONA,COLL MED,DIV RESP SCI,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.				NHLBI NIH HHS [HL-14136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTER CE, 1976, AM REV RESPIR DIS, V113, P305; BLACK PL, 1976, BRONCHIAL ASTHMA MEC, P53; BRADFORD J, 1952, Am Pract Dig Treat, V3, P349; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1983, CHEST, V84, P657, DOI 10.1378/chest.84.6.657; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; BURROWS B, 1980, AM REV RESPIR DIS, V122, P709, DOI 10.1164/arrd.1980.122.5.709; BURROWS B, 1975, AM REV RESPIR DIS, V112, P365; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; BURROWS B, 1984, CHEST S, V85, pS12; DERRICK EH, 1971, MED J AUSTRALIA, V1, P1317, DOI 10.5694/j.1326-5377.1971.tb88132.x; DODGE R, 1986, AM REV RESPIR DIS, V133, P981; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Fletcher CM, 1976, NATURAL HIST CHRONIC; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LEBOWITZ MD, 1984, J ALLERGY CLIN IMMUN, V73, P259, DOI 10.1016/S0091-6749(84)80017-2; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; OGILVIE A. G., 1962, THORAX, V17, P183, DOI 10.1136/thx.17.3.183; Orie NGM, 1961, BRONCHITIS INT S; POSTMA DS, 1979, AM REV RESPIR DIS, V119, P357; POSTMA DS, 1985, EUR J RESPIR DIS, V67, P56; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; RYSSING E, 1959, Acta Paediatr, V48, P255; SHACHTER EN, 1984, CHEST, V85, P623; SPEIZER FE, 1976, BRONCHIAL ASTHMA MEC, P43; TABONA M, 1984, CHEST, V85, P782, DOI 10.1378/chest.85.6.782; TAYLOR RG, 1985, THORAX, V40, P9, DOI 10.1136/thx.40.1.9; VANDELENDE R, 1969, CRITICAL ANAL 3 FIEL, V1, P140; VOLLMER WM, 1985, AM REV RESPIR DIS, V132, P1186; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	34	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			373	377		10.1016/0091-6749(87)90052-2	http://dx.doi.org/10.1016/0091-6749(87)90052-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624687				2022-12-18	WOS:A1987K103700004
J	MULLER, U; RABSON, AR; BISCHOF, M; LOMNITZER, R; DREBORG, S; LANNER, A				MULLER, U; RABSON, AR; BISCHOF, M; LOMNITZER, R; DREBORG, S; LANNER, A			A DOUBLE-BLIND-STUDY COMPARING MONOMETHOXY POLYETHYLENE GLYCOL-MODIFIED HONEYBEE VENOM AND UNMODIFIED HONEYBEE VENOM FOR IMMUNOTHERAPY .1. CLINICAL-RESULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WITWATERSRAND,S AFRICAN INST MED RES,DEPT IMMUNOL,JOHANNESBURG 2001,SOUTH AFRICA; PHARMACIA DIAGNOST AB,DEPT CLIN RES,UPPSALA,SWEDEN	University of Witwatersrand; Pfizer; Pharmacia Corporation	MULLER, U (corresponding author), ZIEGLERSPITAL,DIV MED,BOX 2600,CH-3001 BERN,SWITZERLAND.							AHLSTEDT S, 1983, INT ARCH ALLER A IMM, V71, P228, DOI 10.1159/000233395; AKERBLOM E, 1982, 11TH P ANN M INT C A, P153; BAURLE G, 1983, DTSCH MED WOCHENSCHR, V36, P1351; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; CLAYTON WF, 1983, CLIN ALLERGY, V13, P123, DOI 10.1111/j.1365-2222.1983.tb02579.x; CRAFT DF, 1983, PED CLIN N AM, V30, P873; DREBORG S, UNPUB J ALLERGY CLIN; Finney D, 1978, STATISTICAL METHOD B, P69; GILLMAN SA, 1980, ANN ALLERGY, V45, P351; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; HOFFMAN DR, 1981, ANN ALLERGY, V46, P17; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LANNER A, UNPUB DOUBLE BLIND S, V2; LEE WY, 1978, INT ARCH ALLER A IMM, V56, P159, DOI 10.1159/000232019; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1982, INT ARCH ALLER A IMM, V68, P312; NATAF P, 1984, CLIN ALLERGY, V14, P269, DOI 10.1111/j.1365-2222.1984.tb02206.x; NORDVALL SL, 1986, ALLERGY, V41, P89, DOI 10.1111/j.1398-9995.1986.tb00283.x; OHMAN S, 1986, ALLERGY, V41, P81, DOI 10.1111/j.1398-9995.1986.tb00282.x; PATTERSON R, 1985, J ALLERGY CLIN IMMUN, V75, P382, DOI 10.1016/0091-6749(85)90076-4; PEPPE BC, 1983, J ALLERGY CLIN IMMUN, V71, P120, DOI 10.1016/0091-6749(83)90249-X; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P735; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; URBANEK R, 1978, DEUT MED WOCHENSCHR, V103, P1656, DOI 10.1055/s-0028-1129317; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; WIE SI, 1981, INT ARCH ALLER A IMM, V64, P84, DOI 10.1159/000232678; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	30	28	30	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				252	261		10.1016/0091-6749(87)90027-3	http://dx.doi.org/10.1016/0091-6749(87)90027-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3624680				2022-12-18	WOS:A1987K103600003
J	TEE, RD; GORDON, DJ; TAYLOR, AJN				TEE, RD; GORDON, DJ; TAYLOR, AJN			CROSS-REACTIVITY BETWEEN ANTIGENS OF FUNGAL EXTRACTS STUDIED BY RAST INHIBITION AND IMMUNOBLOT TECHNIQUE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											TEE, RD (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT OCCUPAT MED,FULHAM RD,LONDON SW3 6HP,ENGLAND.							AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P437, DOI 10.1016/0091-6749(82)90006-9; AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; GRAVESEN S, 1983, FOLIA ALLERGOL IM S4, V30, P128; HOFFMAN DR, 1979, J ALLERGY CLIN IMMUN, V63, P213; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; KARR RM, 1981, J ALLERGY CLIN IMMUN, V67, P194, DOI 10.1016/0091-6749(81)90061-0; KIM SJ, 1979, AM REV RESPIR DIS, V120, P1297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SB, 1983, CLIN CHEST MED, V4, P23; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIJAY HM, 1979, INT ARCH ALLER A IMM, V60, P227; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	14	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1987	79	4					627	633		10.1016/S0091-6749(87)80159-8	http://dx.doi.org/10.1016/S0091-6749(87)80159-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G9720	3549841				2022-12-18	WOS:A1987G972000012
J	HALSEY, AB; MARTIN, ME; RUFF, ME; JACOBS, FO; JACOBS, RL				HALSEY, AB; MARTIN, ME; RUFF, ME; JACOBS, FO; JACOBS, RL			SUNFLOWER OIL IS NOT ALLERGENIC TO SUNFLOWER SEED SENSITIVE PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HALSEY, AB (corresponding author), WILFORD HALL USAF MED CTR,ALLERGY & IMMUNOL STN,LACKLAND AFB,TX 78236, USA.							BUSH RK, 1985, J ALLERGY CLIN IMMUN, V76, P242, DOI 10.1016/0091-6749(85)90709-2; MALISH D, 1981, J ALLERGY CLIN IMMUN, V67, P35, DOI 10.1016/0091-6749(81)90042-7; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; NORDLEE JA, 1981, J ALLERGY CLIN IMMUN, V68, P376, DOI 10.1016/0091-6749(81)90136-6; NORMAN P, 1983, ALLERGY PRINCIPLES P, P298; NOYES JH, 1979, J ALLERGY CLIN IMMUN, V63, P242, DOI 10.1016/0091-6749(79)90107-6; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; 1984, NIH842442 AM AC ALL, P5	8	28	29	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				408	410		10.1016/0091-6749(86)90025-4	http://dx.doi.org/10.1016/0091-6749(86)90025-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	3760399				2022-12-18	WOS:A1986E114800006
J	HELM, RM; BUCKLEY, RH; ADKINSON, NF; SQUILLACE, DL; GLEICH, GJ; YUNGINGER, JW				HELM, RM; BUCKLEY, RH; ADKINSON, NF; SQUILLACE, DL; GLEICH, GJ; YUNGINGER, JW			VARIABILITY OF IGE PROTEIN MEASUREMENT IN CELL-CULTURE SUPERNATANTS - RESULTS FROM A MULTICENTER COLLABORATIVE STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,406 GUGGENHEIM BLDG,ROCHESTER,MN 55905; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,DEPT INTERNAL MED,ROCHESTER,MN 55901; DUKE UNIV,MED CTR,DIV PEDIAT ALLERGY & IMMUNOL,DURHAM,NC 27710; JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,BALTIMORE,MD 21239; MAYO MED SCH,DEPT IMMUNOL,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic; Duke University; Johns Hopkins University; Mayo Clinic			Buckley, Rebecca/AAB-1578-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI012675] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-12675] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; CHEN PP, 1984, J IMMUNOL, V133, P1909; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; EISENBREY AB, 1983, J IMMUNOL METHODS, V58, P365; FISER PM, 1979, J IMMUNOL, V123, P1788; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HASSNER A, 1983, J IMMUNOL, V130, P1567; HEMADY Z, 1983, J ALLERGY CLIN IMMUN, V71, P324, DOI 10.1016/0091-6749(83)90087-8; MAGNUSSON CGM, 1981, CLIN ALLERGY, V11, P453, DOI 10.1111/j.1365-2222.1981.tb01619.x; MAGNUSSON CGM, 1982, J ALLERGY CLIN IMMUN, V70, P326, DOI 10.1016/0091-6749(82)90021-5; MAGNUSSON CGM, 1985, J ALLERGY CLIN IMMUN, V75, P513, DOI 10.1016/S0091-6749(85)80026-9; Masson P L, 1981, Methods Enzymol, V74 Pt C, P106; OHTA K, 1983, J ALLERGY CLIN IMMUN, V71, P212, DOI 10.1016/0091-6749(83)90102-1; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P579; SAMPSON HA, 1981, J IMMUNOL, V127, P829; SARFATI M, 1984, IMMUNOLOGY, V53, P783; SARYAN JA, 1983, J IMMUNOL, V130, P242; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SPIEGELBERG HL, 1983, J IMMUNOL, V131, P3001; TJIO AH, 1979, J IMMUNOL, V122, P2131; ZURAW BL, 1981, J IMMUNOL, V127, P1169	22	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1986	77	6					880	889		10.1016/0091-6749(86)90387-8	http://dx.doi.org/10.1016/0091-6749(86)90387-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C8694	3711555				2022-12-18	WOS:A1986C869400014
J	TEE, RD; GORDON, DJ; LACEY, J; NUNN, AJ; BROWN, M; TAYLOR, AJN				TEE, RD; GORDON, DJ; LACEY, J; NUNN, AJ; BROWN, M; TAYLOR, AJN			OCCUPATIONAL ALLERGY TO THE COMMON HOUSEFLY (MUSCA-DOMESTICA) - USE OF IMMUNOLOGICAL RESPONSE TO IDENTIFY ATMOSPHERIC ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,DEPT OCCUPAT MED,FULHAM RD,LONDON SW3 6HP,ENGLAND; ROTHAMSTED EXPTL STN,DEPT PLANT PATHOL,HARPENDEN AL5 2JQ,HERTS,ENGLAND; BROMPTON HOSP,MRC,TB & CHEST DIS UNIT,LONDON SW3 6HP,ENGLAND; CIVIL SERV MED ADVISORY SERV,LONDON,ENGLAND	Royal Brompton Hospital; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Royal Brompton Hospital				Nunn, Andrew/0000-0002-9158-4595				AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BUISSERET P, 1978, LANCET, V1, P668; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; DJORDJEVIC S, 1971, Srpski Arkhiv za Tselokupno Lekarstvo, V99, P335; EDWARDS RG, 1983, LAB ANIM, V17, P235, DOI 10.1258/002367783781070696; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; FRANKLAND AW, 1981, IMMUNOLOGICAL CLIN A, P373; IWAMA A, 1974, ACTA SCH MED U GIFU, V22, P156; JAMIESON HC, 1938, J ALLERGY, V9, P273; LOZANO AP, 1965, BRONCHIAL ASTHMA, P99; REED CE, 1982, J ALLERGY CLIN IMMUN, V70, P38, DOI 10.1016/0091-6749(82)90199-3; SHIVPURI DN, 1971, ANN ALLERGY, V29, P588; SPUZIC V, 1969, GLAS SRPSKA AKAD NAU, V21, P107; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; Wirtz R.A., 1980, Bulletin of the Entomological Society of America, V26, P356	16	28	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					826	831		10.1016/0091-6749(85)90756-0	http://dx.doi.org/10.1016/0091-6749(85)90756-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	4067132				2022-12-18	WOS:A1985AWX9300012
J	FABBRI, LM; AIZAWA, H; OBYRNE, PM; BETHEL, RA; WALTERS, EH; HOLTZMAN, MJ; NADEL, JA				FABBRI, LM; AIZAWA, H; OBYRNE, PM; BETHEL, RA; WALTERS, EH; HOLTZMAN, MJ; NADEL, JA			AN ANTI-INFLAMMATORY DRUG (BW755C) INHIBITS AIRWAY HYPERRESPONSIVENESS INDUCED BY OZONE IN DOGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			WALTERS, Eugene/AAL-2264-2021; Fabbri, Leonardo M/I-4055-2012	Fabbri, Leonardo M/0000-0001-8894-1689; O'Byrne, Paul/0000-0003-0979-281X	NHLBI NIH HHS [HL-07159, HL-00797, HL-24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136, K08HL000797] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUM T, 1971, AM J PHYSIOL, V221, P1470, DOI 10.1152/ajplegacy.1971.221.5.1470; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; FABBRI LM, 1983, AM REV RESPIR DIS, V127, P244; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; HIGGS GA, 1980, EUR J PHARMACOL, V66, P81, DOI 10.1016/0014-2999(80)90297-6; HIGGS GA, 1979, BIOCHEM PHARMACOL, V28, P1959, DOI 10.1016/0006-2952(79)90651-8; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; HOLTZMAN MJ, 1983, J APPL PHYSIOL, V55, P1232, DOI 10.1152/jappl.1983.55.4.1232; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; ITO Y, 1981, BRIT J PHARMACOL, V73, P563, DOI 10.1111/j.1476-5381.1981.tb10456.x; KORDANSKY D, 1978, ANN INTERN MED, V88, P508, DOI 10.7326/0003-4819-88-4-508; LEE LY, 1980, J APPL PHYSIOL, V48, P163, DOI 10.1152/jappl.1980.48.1.163; LEE LY, 1979, J APPL PHYSIOL, V46, P1108, DOI 10.1152/jappl.1979.46.6.1108; LEE LY, 1977, J APPL PHYSIOL, V43, P626, DOI 10.1152/jappl.1977.43.4.626; MORLEY J, 1982, BRONCHIAL HYPERREACT, P219; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OBYRNE PM, PROSTAGLANDINS; RADMARK O, 1980, FEBS LETT, V110, P213, DOI 10.1016/0014-5793(80)80075-5; RANDALL RW, 1980, AGENTS ACTIONS, V10, P553, DOI 10.1007/BF02024164; ROTTOLI P, 1983, MED RESPIRATORIA OGG, P87; SANERKIN NG, 1965, J PATHOL BACTERIOL, V89, P535, DOI 10.1002/path.1700890211; SHIMASAKI H, 1976, BIOCHEM BIOPH RES CO, V68, P1256, DOI 10.1016/0006-291X(76)90332-6; VANSELOW NA, 1967, ANN INTERN MED, V66, P568, DOI 10.7326/0003-4819-66-3-568; WALTERS EH, 1984, J APPL PHYSIOL, V57, P129, DOI 10.1152/jappl.1984.57.1.129; WALTERS EH, 1981, THORAX, V36, P571, DOI 10.1136/thx.36.8.571	28	28	28	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					162	166		10.1016/0091-6749(85)90695-5	http://dx.doi.org/10.1016/0091-6749(85)90695-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE88	3926851				2022-12-18	WOS:A1985APE8800007
J	HARM, DL; KOTSES, H; CREER, TL				HARM, DL; KOTSES, H; CREER, TL			IMPROVING THE ABILITY OF PEAK EXPIRATORY FLOW-RATES TO PREDICT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OHIO UNIV,DEPT PSYCHOL,PORTER HALL,ATHENS,OH 45701	University System of Ohio; Ohio University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002972] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL2972, HL27402] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANNER AS, 1976, JAMA-J AM MED ASSOC, V235, P1337, DOI 10.1001/jama.235.13.1337; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; CREER TL, 1980, J RESPIR MED, V24; FISHI MA, 1981, NEW ENGL J MED, V305, P783; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; TAPLIN PS, 1978, J ASTHMA RES, V16, P15, DOI 10.3109/02770907809106608	6	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	5					688	694		10.1016/0091-6749(85)90672-4	http://dx.doi.org/10.1016/0091-6749(85)90672-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AUU34	4056253				2022-12-18	WOS:A1985AUU3400006
J	INOUYE, T; TARLO, S; BRODER, I; COREY, P; DAVIES, G; LEZNOFF, A; MINTZ, S; THOMAS, P				INOUYE, T; TARLO, S; BRODER, I; COREY, P; DAVIES, G; LEZNOFF, A; MINTZ, S; THOMAS, P			SEVERITY OF ASTHMA IN SKIN-TEST NEGATIVE AND SKIN-TEST POSITIVE PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GAGE RES INST,DEPT MED,223 COLL ST,TORONTO M5T 1R4,ONTARIO,CANADA; UNIV TORONTO,DEPT EPIDEMIOL & BIOSTAT,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto				Tarlo, Susan/0000-0002-4746-5310				GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HANNEUSE Y, 1978, CLIN ALLERGY, V8, P165, DOI 10.1111/j.1365-2222.1978.tb00461.x; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; OGLIVIE AG, 1962, THORAX, V17, P183; PEARSON R S B, 1958, Acta Allergol, V12, P277; PEARSON RSB, 1968, P ROY SOC MED, V61, P467, DOI 10.1177/003591576806100524; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; SCHOENBERG JB, 1978, RESP PHYSIOL, V33, P367, DOI 10.1016/0034-5687(78)90063-4; SIBBALD B, 1980, CLIN ALLERGY, V10, P313, DOI 10.1111/j.1365-2222.1980.tb02113.x; Turner-Warwick M, 1971, Br J Dis Chest, V65, P1, DOI 10.1016/0007-0971(71)90001-5; UNGER L, 1935, J ALLERGY, V7, P364	11	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					313	319		10.1016/0091-6749(85)90063-6	http://dx.doi.org/10.1016/0091-6749(85)90063-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3968339				2022-12-18	WOS:A1985ABZ0500013
J	KUNOS, G; KUNOS, I; HIRATA, F; ISHAC, EJN				KUNOS, G; KUNOS, I; HIRATA, F; ISHAC, EJN			ADRENERGIC-RECEPTORS - POSSIBLE MECHANISM OF INVERSE REGULATION OF ALPHA-RECEPTOR AND BETA-RECEPTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCGILL UNIV,DEPT PHARMACOL & MED,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,DEPT PAEDIAT,MONTREAL H3G 1Y6,QUEBEC,CANADA; NIMH,CELL BIOL LAB,BETHESDA,MD 20205	McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; ARNAUD A, 1982, EUR J RESPIR DIS, V63, P126; Axelrod J, 1975, Recent Prog Horm Res, V31, P1; BARNES PJ, 1980, NATURE, V285, P569, DOI 10.1038/285569a0; CHAN TM, 1979, J BIOL CHEM, V254, P2428; CHANG HY, 1982, J PHARMACOL EXP THER, V221, P784; CORWIN EJ, 1982, AM J PHYSIOL, V243, pF23, DOI 10.1152/ajprenal.1982.243.1.F23; DAVIES AO, 1984, ANNU REV PHYSIOL, V46, P119; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; FRASER CM, 1980, BIOCHEM BIOPH RES CO, V94, P390, DOI 10.1016/S0006-291X(80)80233-6; HARKER C T, 1984, Physiologist, V27, P243; HIRATA F, 1981, J BIOL CHEM, V256, P7730; ITOH H, 1984, J BIOL CHEM, V259, P5464; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; KAUMANN AJ, 1972, N-S ARCH PHARMAKOL, V273, P134, DOI 10.1007/BF00508086; KRZANOWSKI JJ, 1983, J ALLERGY CLIN IMMUN, V72, P433, DOI 10.1016/0091-6749(83)90578-X; KUNOS G, 1978, ANNU REV PHARMACOL, V18, P291, DOI 10.1146/annurev.pa.18.040178.001451; KUNOS G, 1968, NATURE, V217, P1077, DOI 10.1038/2171077a0; KUNOS G, 1980, TRENDS PHARMACOL SCI, V1, P282, DOI 10.1016/0165-6147(80)90023-1; KUNOS G, 1984, P NATL ACAD SCI-BIOL, V81, P6178, DOI 10.1073/pnas.81.19.6178; KUNOS G, 1980, BRIT J PHARMACOL, V71, P371, DOI 10.1111/j.1476-5381.1980.tb10950.x; KUNOS G, 1981, ADRENOCEPTORS CATECH, V1, P297; KUNOS G, 1985, ADRENERGIC RECEPTORS; KUNOS G, 1985, J CARDIOVASC PHAR S6, V7, P87; KUPFER LE, 1984, FED PROC, V43, P871; MALBON CC, 1978, J BIOL CHEM, V253, P8820; MALBON CC, 1980, J BIOL CHEM, V255, P8692; NAKAMURA T, 1984, J BIOCHEM-TOKYO, V96, P127, DOI 10.1093/oxfordjournals.jbchem.a134804; NICKERSON M, 1977, FED PROC, V36, P2580; NOGUCHI A, 1983, ENDOCRINOLOGY, V113, P672, DOI 10.1210/endo-113-2-672; OKAJIMA F, 1982, ARCH BIOCHEM BIOPHYS, V213, P658, DOI 10.1016/0003-9861(82)90596-3; PARKER CW, 1973, J CLIN INVEST, V52, P1342, DOI 10.1172/JCI107306; PREIKSAITIS HG, 1979, LIFE SCI, V24, P35, DOI 10.1016/0024-3205(79)90277-7; PREIKSAITIS HG, 1982, J BIOL CHEM, V257, P4321; REED CE, 1974, J ALLERGY CLIN IMMUN, V53, P34, DOI 10.1016/0091-6749(74)90097-9; Szentivanyi A, 1979, Triangle, V18, P109; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; TIRRI R, 1984, COMP BIOCHEM PHYS C, V77, P301, DOI 10.1016/0742-8413(84)90017-3; WOLFE BB, 1976, P NATL ACAD SCI USA, V73, P1343, DOI 10.1073/pnas.73.4.1343	39	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					346	351		10.1016/0091-6749(85)90652-9	http://dx.doi.org/10.1016/0091-6749(85)90652-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2991359				2022-12-18	WOS:A1985APE8900016
J	WALLS, AF; LONGBOTTOM, JL				WALLS, AF; LONGBOTTOM, JL			COMPARISON OF RAT FUR, URINE, SALIVA, AND OTHER RAT ALLERGEN EXTRACTS BY SKIN TESTING, RAST, AND RAST INHIBITION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,INST CARDIOTHORAC,LONDON SW3 6HP,ENGLAND	Royal Brompton Hospital								ANDERSON MC, 1981, J IMMUNOL, V127, P972; ARMITAGE P, 1971, STATISTICAL METHODS, P281; BALDO BA, 1982, PROG ALLERGY, V30, P1; BARNETT SA, 1963, STUDY BEHAVIOR PRINC; BEESON MF, 1983, CLIN ALLERGY, V13, P433, DOI 10.1111/j.1365-2222.1983.tb02619.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coca AF, 1922, J IMMUNOL, V7, P163; COCKCROFT A, 1981, LANCET, V1, P827; DAVIES GE, 1983, J IMMUNOASSAY, V4, P113, DOI 10.1080/15321818308057004; DAVIES GE, 1981, INT ARCH ALLER A IMM, V64, P302, DOI 10.1159/000232707; EDWARDS RG, 1983, LAB ANIM, V17, P235, DOI 10.1258/002367783781070696; ELRAB MOG, 1980, J ALLERGY CLIN IMMUN, V66, P190; GILDAY F J, 1956, Del Med J, V28, P110; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GREEN CJ, 1979, ANIM ANAESTH, P155; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; GUERIN B, 1981, ANN ALLERGY, V46, P127; Hunter W. M., 1967, HDB EXPT IMMUNOLOGY, P608; KLIGMAN AM, 1963, ADV BIOL SKIN, P110; LECAQUE D, 1982, CELL TISSUE RES, V226, P621; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LONGBOTTOM JL, 1981, CLIN ALLERGY, V12, P426; LONGBOTTOM JL, 1980, ADV ALLERGOLOGY APPL, P483; LONGBOTTOM JL, 1983, 11 P INT C ALL CLIN, P525; LUTSKY II, 1975, ANN ALLERGY, V35, P201; MAGRE F, 1981, EXPERIENTIA, V37, P1336; MARZULLI FRANCIS N., 1957, JOUR AMER VET MED ASSOC, V131, P80; NEWMANTAYLOR A, 1977, LANCET, V2, P847; NEWMANTAYLOR AJ, 1981, THORAX, V36, P229; OHMAN JL, 1975, J ALLERGY CLIN IMMUN, V55, P16, DOI 10.1016/S0091-6749(75)80004-2; Pepys J., 1975, , Clinical aspects of immunology., P877; PHILIPS JJ, 1977, J I ANIMAL TECHNOL, V28, P109; RAJKA G, 1961, ACTA ALLERGOL, V16, P168, DOI 10.1111/j.1398-9995.1961.tb02891.x; RUDOLPH R, 1983, 11 P INT C ALL CLIN, P437; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SCHWARTZ B, 1981, ALLERGY S1, V37; SIEGEL S, 1956, NONPARAMETRIC STAT, P202; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V6, P435; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; Spain W. C., 1942, JOUR ALLERGY, V13, P563, DOI 10.1016/S0021-8707(42)90069-8; SREEBNY LM, 1969, ARCH ORAL BIOL, V14, P397, DOI 10.1016/0003-9969(69)90094-6; TAYLOR G, 1976, NATURE, V260, P280, DOI 10.1038/260280a0; TEASDALE EL, 1983, BRIT MED J, V286, P1480, DOI 10.1136/bmj.286.6376.1480; TOH YC, 1982, ENDOKRINOLOGIE, V79, P7; TUFT L, 1967, AM J MED SCI, V253, P19, DOI 10.1097/00000441-196701000-00005; VIANDER M, 1983, INT ARCH ALLER A IMM, V71, P252, DOI 10.1159/000233399; WAHN U, 1980, J ALLERGY CLIN IMMUN, V65, P413, DOI 10.1016/0091-6749(80)90233-X; WALLS AF, 1983, ALLERGY, V38, P419, DOI 10.1111/j.1398-9995.1983.tb05085.x; WALLS AF, 1983, ALLERGY, V38, P501, DOI 10.1111/j.1398-9995.1983.tb02359.x; WALLS AF, 1984, THESIS U LONDON; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X	52	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					242	251		10.1016/0091-6749(85)90053-3	http://dx.doi.org/10.1016/0091-6749(85)90053-3			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	3968335				2022-12-18	WOS:A1985ABZ0500003
J	BERNSTEIN, DI; GALLAGHER, JS; GRAD, M; BERNSTEIN, IL				BERNSTEIN, DI; GALLAGHER, JS; GRAD, M; BERNSTEIN, IL			LOCAL OCULAR ANAPHYLAXIS TO PAPAIN ENZYME CONTAINED IN A CONTACT-LENS CLEANSING SOLUTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267, USA.							BAUR X, 1979, CLIN ALLERGY, V9, P75, DOI 10.1111/j.1365-2222.1979.tb01525.x; BAUR X, 1982, CLIN ALLERGY, V12, P9, DOI 10.1111/j.1365-2222.1982.tb03121.x; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V50, P235, DOI 10.1016/0091-6749(72)90017-6; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; GUMBY P, 1983, JAMA, V249, P1115; KAPSALIS AA, 1978, CLIN EXP IMMUNOL, V33, P150; MANSFIELD LE, 1983, J ALLERGY CLIN IMMUN, V71, P371, DOI 10.1016/0091-6749(83)90064-7; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V63, P98, DOI 10.1016/0091-6749(79)90198-2; WIDE L, 1967, LANCET, V2, P1105	9	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					258	260		10.1016/0091-6749(84)90255-0	http://dx.doi.org/10.1016/0091-6749(84)90255-0			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TJ808	6470359				2022-12-18	WOS:A1984TJ80800007
J	HOOK, WA; POWERS, K; SIRAGANIAN, RP				HOOK, WA; POWERS, K; SIRAGANIAN, RP			SKIN-TESTS AND BLOOD LEUKOCYTE HISTAMINE-RELEASE OF PATIENTS WITH ALLERGIES TO LABORATORY-ANIMALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIDR,INTRAMURAL RES PROGRAM,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	HOOK, WA (corresponding author), NIDR,MICROBIOL & IMMUNOL LAB,CLIN IMMUNOL SECT,BLDG 10,ROOM 1A28,BETHESDA,MD 20205, USA.							COCKCROFT A, 1981, LANCET, V1, P827; LEVY DA, 1975, INT ARCH ALLER A IMM, V49, P219, DOI 10.1159/000231399; LINCOLN TA, 1974, J OCCUP ENVIRON MED, V16, P465; LUTSKY II, 1975, ANN ALLERGY, V35, P201; NIE NH, 1975, STATISTICAL PACKAGE; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V63, P435, DOI 10.1016/0091-6749(79)90219-7; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; TAYLOR AN, 1977, LANCET, V2, P847; TAYLOR G, 1976, NATURE, V260, P280, DOI 10.1038/260280a0; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; WAHN U, 1981, MOL IMMUNOL, V18, P19, DOI 10.1016/0161-5890(81)90044-4; WAHN U, 1980, J IMMUNOL, V125, P2544	16	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					457	465		10.1016/0091-6749(84)90355-5	http://dx.doi.org/10.1016/0091-6749(84)90355-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6200526				2022-12-18	WOS:A1984SM08900006
J	LEHRER, SB; BARBANDI, F; TAYLOR, JP; SALVAGGIO, JE				LEHRER, SB; BARBANDI, F; TAYLOR, JP; SALVAGGIO, JE			TOBACCO-SMOKE SENSITIVITY - IS THERE AN IMMUNOLOGICAL BASIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70112	Tulane University					NIAID NIH HHS [AI 13401] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER CG, 1979, AM J PATHOL, V96, P249; BECKER CG, 1977, J EXP MED, V146, P457, DOI 10.1084/jem.146.2.457; BECKER CG, 1981, BLOOD, V58, P861; BECKER CG, 1976, P NATL ACAD SCI USA, V73, P1712, DOI 10.1073/pnas.73.5.1712; BICK RL, 1981, THROMB HAEMOSTASIS, V46, P231; BLUE JA, 1970, ANN ALLERGY, V28, P110; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1020; GLEICH GJ, 1979, AM REV RESPIR DIS, V120, P995; HARKAVY J, 1968, ANN ALLERGY, V26, P447; HARRIS MC, 1964, SENSITIVITY CHEST DI, P93; KELLER NF, 1976, J ALLERGY CLIN IMMUN, V57, P278; LEHRER SB, 1980, INT ARCH ALLER A IMM, V62, P16, DOI 10.1159/000232479; LEHRER SB, 1978, J ALLERGY CLIN IMMUN, V62, P368, DOI 10.1016/0091-6749(78)90138-0; MCDOUGALL JC, 1976, J ALLERGY CLIN IMMUN, V57, P237; MCFADDEN ER, 1969, PSYCHOSOM MED, V31, P134, DOI 10.1097/00006842-196903000-00007; SALVAGGIO JE, 1964, J ALLERGY, V35, P62, DOI 10.1016/0021-8707(64)90050-4; SAVEL H, 1970, ARCH ENVIRON HEALTH, V21, P146, DOI 10.1080/00039896.1970.10667212; SHEPHARD RJ, 1979, ENVIRON RES, V20, P392, DOI 10.1016/0013-9351(79)90015-X; SPEER F, 1968, ARCH ENVIRON HEALTH, V16, P443, DOI 10.1080/00039896.1968.10665084; TAYLOR G, 1974, ENV TOBACCO SMOKE EF, P50; ZUSSMAN BM, 1974, J ASTHMA RES, V11, P159, DOI 10.3109/02770907409100294	21	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					240	245		10.1016/S0091-6749(84)80014-7	http://dx.doi.org/10.1016/S0091-6749(84)80014-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6699306				2022-12-18	WOS:A1984SF02000004
J	PIERSON, WE; COVERT, DS; KOENIG, JQ				PIERSON, WE; COVERT, DS; KOENIG, JQ			AIR-POLLUTANTS, BRONCHIAL HYPERREACTIVITY, AND EXERCISE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,SCH MED,DEPT ENVIRONM HLTH,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	PIERSON, WE (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195, USA.				NIEHS NIH HHS [R01 ES 02366] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002366] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVOL EL, 1983, JAPCA J AIR WASTE MA, V33, P1055, DOI 10.1080/00022470.1983.10465691; BETHEL RA, 1983, AM REV RESPIR DIS, V128, P987; BOUSHEY HA, 1982, J ALLERGY CLIN IMMUN, V69, P335, DOI 10.1016/0091-6749(82)90142-7; BUCZKO GB, 1984, AM REV RESPIR DIS, V129, P12; DELUCIA AJ, 1977, J APPL PHYSIOL, V43, P75, DOI 10.1152/jappl.1977.43.1.75; DIMEO MJ, 1981, AM REV RESPIR DIS, V124, P245; FRANK NR, 1962, J APPL PHYSIOL, V17, P252, DOI 10.1152/jappl.1962.17.2.252; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HACKNEY JD, 1976, ENVIRON HEALTH PERSP, V18, P141, DOI 10.2307/3428696; HAZUCHA M, 1973, ARCH ENVIRON HEALTH, V27, P183, DOI 10.1080/00039896.1973.10666349; HORVATH SM, 1981, AM REV RESPIR DIS, V123, P496; ILLING JW, 1980, J TOXICOL ENV HEALTH, V6, P843, DOI 10.1080/15287398009529902; KOENIG JQ, 1982, J ALLERGY CLIN IMMUN, V69, P339, DOI 10.1016/0091-6749(82)90143-9; KOENIG JQ, 1983, J TOXICOL ENV HEALTH, V11, P129, DOI 10.1080/15287398309530327; KOENIG JQ, 1980, ENVIRON RES, V22, P145, DOI 10.1016/0013-9351(80)90126-7; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; LINN WS, 1980, AM REV RESPIR DIS, V121, P243; MCCAFFERTY WB, 1979, AIR POLLUTION ATHLET, P160; MCDONNELL WF, 1983, J APPL PHYSIOL, V54, P1345, DOI 10.1152/jappl.1983.54.5.1345; SAVIN WM, 1979, J APPL PHYSIOL, V46, P309, DOI 10.1152/jappl.1979.46.2.309; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SPEIZER FE, 1966, ARCH ENVIRON HEALTH, V12, P725, DOI 10.1080/00039896.1966.10664471; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204	25	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					717	721		10.1016/0091-6749(84)90313-0	http://dx.doi.org/10.1016/0091-6749(84)90313-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6715735				2022-12-18	WOS:A1984SS04600020
J	NYHOLM, L; LOWENSTEIN, H; YUNGINGER, JW				NYHOLM, L; LOWENSTEIN, H; YUNGINGER, JW			IMMUNOCHEMICAL PARTIAL IDENTITY BETWEEN 2 INDEPENDENTLY IDENTIFIED AND ISOLATED MAJOR ALLERGENS FROM ALTERNARIA-ALTERNATA (ALT-L AND AG-1)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COPENHAGEN,PROT LAB,DK-2200 COPENHAGEN N,DENMARK; MAYO MED SCH,DEPT PEDIAT,ROCHESTER,MN 55901; MAYO MED SCH,DEPT INTERNAL MED ALLERGY,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901	University of Copenhagen; Mayo Clinic; Mayo Clinic; Mayo Clinic					NIAID NIH HHS [AI-16791] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016791] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P437, DOI 10.1016/0091-6749(82)90006-9; AUKRUST L, 1982, Allergy (Copenhagen), V37, P36; AXELSEN NH, 1973, SCAND J IMMUNOL   S1, V2, P1; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P20, DOI 10.1016/0091-6749(80)90172-4; HARBOE N, 1973, SCAND J IMMUNOL S1, V2, P61; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; LIND P, 1982, Allergy (Copenhagen), V37, P39; LOWENSTEIN H, 1977, INT ARCH ALLER A IMM, V55, P1, DOI 10.1159/000231900; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWENSTEIN H, 1975, SCAND J IMMUNOL S3, V4, P59; LOWENSTEIN H, 1980, ADV ALLERGOLOGY APPL, P573; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NYHOLM L, 1982, Allergy (Copenhagen), V37, P40; NYHOLM L, UNPUB ISOLATION PART; Yunginger J. W., 1980, MANUAL CLIN IMMUNOLO, P778; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	16	28	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	5					461	467		10.1016/0091-6749(83)90462-1	http://dx.doi.org/10.1016/0091-6749(83)90462-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QQ742	6404974				2022-12-18	WOS:A1983QQ74200005
J	PICHICHERO, ME; INSEL, RA				PICHICHERO, ME; INSEL, RA			MUCOSAL ANTIBODY-RESPONSE TO PARENTERAL VACCINATION WITH HEMOPHILUS-INFLUENZAE TYPE-B CAPSULE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PICHICHERO, ME (corresponding author), UNIV ROCHESTER, MED CTR, SCH MED & DENT, DEPT PEDIAT, ROCHESTER, NY 14642 USA.		Pichichero, Michael E/AID-7886-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017217, T32AI007169] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 72523, AI 07169, AI 17217] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander Hattie E., 1944, YALE JOUR BIOL AND MED, V16, P425; ANDERSON P, 1977, INFECT IMMUN, V15, P472, DOI 10.1128/IAI.15.2.472-477.1977; ANDERSON P, 1978, J IMMUNOL, V120, P866; ANDERSON P, 1972, J CLIN INVEST, V51, P39, DOI 10.1172/JCI106794; ENGVALL E, 1972, J IMMUNOL, V109, P129; FUHRMAN JA, 1981, J EXP MED, V153, P534, DOI 10.1084/jem.153.3.534; Ganguly R, 1980, Prog Allergy, V27, P1; HOHMANN A, 1979, INFECT IMMUN, V25, P27, DOI 10.1128/IAI.25.1.27-33.1979; LANGE S, 1980, INFECT IMMUN, V28, P17, DOI 10.1128/IAI.28.1.17-23.1980; LANGE S, 1978, ACTA PATH MICRO IM C, V86, P145; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; MICHAELS RH, 1975, PEDIATR RES, V9, P513, DOI 10.1203/00006450-197505000-00010; NEWMAN RB, 1970, J LAB CLIN MED, V76, P107; PELTOLA H, 1977, PEDIATRICS, V60, P730; PICHICHERO ME, 1981, J CLIN INVEST, V67, P1482, DOI 10.1172/JCI110178; PICHICHERO ME, 1980, J INFECT DIS, V142, P694, DOI 10.1093/infdis/142.5.694; PICHICHERO ME, 1982, J INFECT DIS, V146, P243, DOI 10.1093/infdis/146.2.243; PIERCE NF, 1980, J IMMUNOL, V124, P307; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; POWELL KR, 1977, J INFECT DIS, V136, P109, DOI 10.1093/infdis/136.1.109; RICHMAN LK, 1981, J IMMUNOL, V126, P2079; ROBBINS JB, 1973, PEDIATR RES, V7, P103, DOI 10.1203/00006450-197303000-00001; SCHAEFER ME, 1977, J DENT RES, V56, P728, DOI 10.1177/00220345770560070401; SCHLIEP G, 1978, J CLIN CHEM CLIN BIO, V16, P631; SCHNEERSON R, 1971, J IMMUNOL, V107, P1081; STEINSTREILEIN J, 1980, INFECT IMMUN, V30, P391; SVENNERHOLM AM, 1980, INFECT IMMUN, V30, P337; SVENNERHOLM AM, 1981, J INFECT DIS, V143, P707, DOI 10.1093/infdis/143.5.707; SVENNERHOLM AM, 1980, INFECT IMMUN, V30, P427; SVENNERHOLM AM, 1977, SCAND J IMMUNOL, V6, P1345; TOMASI TB, 1980, J ALLERGY CLIN IMMUN, V65, P12, DOI 10.1016/0091-6749(80)90171-2; Turk D, 1967, HAEMOPHILUS INFLUENZ; WEISZCARRINGTON P, 1979, J IMMUNOL, V123, P1705	33	28	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					481	486		10.1016/0091-6749(83)90585-7	http://dx.doi.org/10.1016/0091-6749(83)90585-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6605372				2022-12-18	WOS:A1983RR91600009
J	RICKETTI, AJ; GREENBERGER, PA; PRUZANSKY, JJ; PATTERSON, R				RICKETTI, AJ; GREENBERGER, PA; PRUZANSKY, JJ; PATTERSON, R			HYPERREACTIVITY OF MEDIATOR-RELEASING CELLS FROM PATIENTS WITH ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS AS EVIDENCED BY BASOPHIL HISTAMINE-RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTON AH, 1969, J PHARMACOL EXP THER, V166, P285; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GRAMMER L, 1981, INT ARCH ALLER A IMM, V66, P179, DOI 10.1159/000232817; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; NOBLE WE, 1963, J GEN MICROBIOL, V52, P397; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1974, INT ARCH ALLER A IMM, V46, P150, DOI 10.1159/000231119; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; PEPYS J, 1969, MONOGR ALERGY, V14; RADIN RC, CLIN ALLERGY; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SAAVEDRADELGADO AMP, 1980, J ALLERGY CLIN IMMUN, V66, P464, DOI 10.1016/0091-6749(80)90007-X; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87	17	28	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					386	392		10.1016/0091-6749(83)90504-3	http://dx.doi.org/10.1016/0091-6749(83)90504-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6194196	Bronze			2022-12-18	WOS:A1983RN33000009
J	VAIDA, GA; GOLDMAN, MA; BLOCH, KJ				VAIDA, GA; GOLDMAN, MA; BLOCH, KJ			TESTING FOR HEPATITIS-B VIRUS IN PATIENTS WITH CHRONIC URTICARIA AND ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, MED SERV, ALLERGY UNIT, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	VAIDA, GA (corresponding author), MASSACHUSETTS GEN HOSP, MED SERV, CLIN IMMUNOL UNIT, BOSTON, MA 02114 USA.							ALPERT E, 1971, NEW ENGL J MED, V285, P185, DOI 10.1056/NEJM197107222850401; ALTER HJ, 1982, JAMA-J AM MED ASSOC, V247, P2272, DOI 10.1001/jama.247.16.2272; BYWATERS EG, 1971, ANN RHEUM DIS, V30, P121, DOI 10.1136/ard.30.2.121; CALNAN CD, 1964, BMJ-BRIT MED J, V2, P649, DOI 10.1136/bmj.2.5410.649; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; COLLINS AB, 1983, CLIN IMMUNOL IMMUNOP, V26, P137, DOI 10.1016/0090-1229(83)90182-4; CUPPS TR, 1982, JAMA-J AM MED ASSOC, V247, P1994, DOI 10.1001/jama.247.14.1994; DENES AE, 1978, JAMA-J AM MED ASSOC, V239, P210, DOI 10.1001/jama.239.3.210; DIENSTAG JL, 1978, ANN INTERN MED, V89, P34, DOI 10.7326/0003-4819-89-1-34; DIENSTAG JL, 1982, AM J EPIDEMIOL, V115, P26, DOI 10.1093/oxfordjournals.aje.a113277; DOLIN R, 1982, NEW ENGL J MED, V306, P657; ELLIS FR, 1981, TRANSFUSION, V21, P623; FEINMAN SV, 1975, CAN MED ASSOC J, V112, P43; FINEMAN SM, 1980, SOUTHERN MED J, V73, P915, DOI 10.1097/00007611-198007000-00026; GOCKE DJ, 1975, AM J MED SCI, V270, P49, DOI 10.1097/00000441-197507000-00007; GOWER RG, 1978, J ALLERGY CLIN IMMUN, V62, P222, DOI 10.1016/0091-6749(78)90211-7; GREEN GR, 1965, ANN ALLERGY, V23, P30; HERNANDEZASENSIO M, 1979, J IMMUNOL, V122, P1601; JACOBSON KW, 1980, JAMA-J AM MED ASSOC, V243, P1644, DOI 10.1001/jama.243.16.1644; KOHLER PF, 1981, N ENGL SOC ALLERGY P, V2, P136; LEWIS TL, 1973, NEW ENGL J MED, V289, P645, DOI 10.1056/NEJM197309272891301; LINNEMANN CC, 1977, AM J CLIN PATHOL, V67, P257; LJUNGGREN B, 1971, ACTA DERM-VENEREOL, V51, P295; LOCKSHIN NA, 1972, ARCH DERMATOL, V105, P570, DOI 10.1001/archderm.105.4.570; MAHONEY JP, 1978, SOUTHERN MED J, V71, P624, DOI 10.1097/00007611-197806000-00006; MILLER DA, 1968, AM J MED, V44, P68, DOI 10.1016/0002-9343(68)90238-6; NOMURA A, 1982, JAMA-J AM MED ASSOC, V247, P2247, DOI 10.1001/jama.247.16.2247; PATTISON CP, 1975, AM J EPIDEMIOL, V101, P59, DOI 10.1093/oxfordjournals.aje.a112071; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P436, DOI 10.1016/0091-6749(80)90237-7; POPP JW, 1981, ARCH INTERN MED, V141, P623, DOI 10.1001/archinte.141.5.623; SHELDON JM, 1954, J ALLERGY, V25, P525, DOI 10.1016/S0021-8707(54)90034-9; SHUMAKER JB, 1974, ARCH INTERN MED, V133, P483, DOI 10.1001/archinte.133.3.483; SMITH JL, 1976, J INFECT DIS, V133, P705, DOI 10.1093/infdis/133.6.705; THOMPSON JS, 1968, ANN INTERN MED, V69, P361, DOI 10.7326/0003-4819-69-2-361; THORNE EG, 1972, CUTIS, V10, P705; WEISS TD, 1978, AM J MED, V64, P269, DOI 10.1016/0002-9343(78)90055-4; WROBEL DM, 1973, CAN MED ASSOC J, V108, P570; WRUBLE LD, 1977, SOUTHERN MED J, V70, P1075, DOI 10.1097/00007611-197709000-00020; [No title captured]	39	28	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					193	198		10.1016/0091-6749(83)90529-8	http://dx.doi.org/10.1016/0091-6749(83)90529-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6886256				2022-12-18	WOS:A1983RD95900014
J	CHEN, SE; BERNSTEIN, IL				CHEN, SE; BERNSTEIN, IL			THE GUINEA-PIG MODEL OF DIISOCYANATE SENSITIZATION .1. IMMUNOLOGICAL STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NIOSH CDC HHS [OH 733-01] Funding Source: Medline	NIOSH CDC HHS		AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; BRUCKNER HC, 1968, ARCH ENVIRON HEALTH, V16, P619, DOI 10.1080/00039896.1968.10665117; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; BUTCHER BT, 1976, J ALLERGY CLIN IMMUN, V58, P89, DOI 10.1016/0091-6749(76)90110-X; CHARLES J, 1976, THORAX, V31, P127, DOI 10.1136/thx.31.2.127; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P223, DOI 10.1016/0091-6749(77)90134-8; EMMETT EA, 1976, J OCCUP ENVIRON MED, V18, P802, DOI 10.1097/00043764-197612000-00006; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; HAMILTON A, 1974, IND TOXICOLOGY, P331; KABE J, 1971, Japanese Journal of Allergology, V20, P444; KAROL MH, 1980, TOXICOL APPL PHARM, V53, P260, DOI 10.1016/0041-008X(80)90425-1; KAROL MH, 1979, TOXICOL APPL PHARM, V51, P73, DOI 10.1016/0041-008X(79)90009-7; KAROL MH, 1980, AM REV RESPIR DIS, V122, P965; KAROL MH, 1980, CLIN ALLERGY, V10, P101, DOI 10.1111/j.1365-2222.1980.tb02086.x; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P546, DOI 10.1080/0002889778507807; KONDRATEV GG, 1971, T LENINGRAD SANIT GI, V93, P154; MUNN A., 1965, ANN OCCUP HYG, V8, P163; MUNOZ J, 1971, METHODS IMMUNOLOGY I, V3, P146; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; OVARY Z, 1976, INT ARCH ALLER A IMM, V51, P416, DOI 10.1159/000231616; SANDRIDGE RL, 1978, LABORATORY METHODS; SCHEEL L D, 1964, Am Ind Hyg Assoc J, V25, P179, DOI 10.1080/00028896409342574; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; TSE CST, 1979, AM REV RESPIR DIS, V120, P829; WILLIAMSON K. S., 1964, Transactions of the Association of Industrial Medical Officers, V14, P81	28	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	5					383	392		10.1016/0091-6749(82)90029-X	http://dx.doi.org/10.1016/0091-6749(82)90029-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PQ105	6290554	Bronze			2022-12-18	WOS:A1982PQ10500011
J	KOENIG, JQ; PIERSON, WE; HORIKE, M; FRANK, R				KOENIG, JQ; PIERSON, WE; HORIKE, M; FRANK, R			BRONCHOCONSTRICTOR RESPONSES TO SULFUR-DIOXIDE OR SULFUR-DIOXIDE PLUS SODIUM-CHLORIDE DROPLETS IN ALLERGIC, NON-ASTHMATIC ADOLESCENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KOENIG, JQ (corresponding author), UNIV WASHINGTON,DEPT ENVIRONM HLTH,SEATTLE,WA 98195, USA.				NIEHS NIH HHS [5 P01 ES 01478] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CHARLSON RJ, 1978, ATMOS ENVIRON, V12, P39, DOI 10.1016/0004-6981(78)90187-7; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; COVERT DS, 1979, CHARACTER ORIGINS SM; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; FISH JE, 1978, RESPIRATION, V36, P57, DOI 10.1159/000193927; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; GREEN M, 1974, J APPL PHYSIOL, V37, P793, DOI 10.1152/jappl.1974.37.6.793; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; KOENIG JQ, 1980, ENVIRON RES, V22, P145, DOI 10.1016/0013-9351(80)90126-7; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; KOENIG JQ, ARCH ENV HLTH; MCJILTON CE, 1976, AM REV RESPIR DIS, V113, P163; NADEL JA, 1961, J APPL PHYSIOL, V16, P717, DOI 10.1152/jappl.1961.16.4.717; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SNEDECOR GW, 1966, STATISTICAL METHODS	17	28	28	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					339	344		10.1016/0091-6749(82)90143-9	http://dx.doi.org/10.1016/0091-6749(82)90143-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	7069069				2022-12-18	WOS:A1982NL28000002
J	OERTEL, H; KALINER, M				OERTEL, H; KALINER, M			THE BIOLOGIC ACTIVITY OF MAST-CELL GRANULES IN RAT SKIN - EFFECTS OF ADRENOCORTICOSTEROIDS ON LATE-PHASE INFLAMMATORY RESPONSES INDUCED BY MAST-CELL GRANULES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,ROOM 11N250,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								ALLISON F, 1955, J EXP MED, V102, P669, DOI 10.1084/jem.102.6.669; ASBOEHAN.G, 1969, BRIT J DERMATOL, VS 81, P2, DOI 10.1111/j.1365-2133.1969.tb12838.x; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BARNES CD, 1973, DRUG DOSAGE LABORATO, P278; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DUNSKY EH, 1977, J ALLERGY CLIN IMMUN, V59, P142, DOI 10.1016/0091-6749(77)90216-0; FLOMAN Y, 1976, PROSTAGLANDINS, V12, P403, DOI 10.1016/0090-6980(76)90021-6; GLATT M, 1977, AGENTS ACTIONS, V7, P321, DOI 10.1007/BF01969563; GREEN GR, 1967, J ALLERGY, V40, P224, DOI 10.1016/0021-8707(67)90085-8; GRYGLEWSKI RJ, 1975, PROSTAGLANDINS, V10, P343, DOI 10.1016/S0090-6980(75)80087-6; HENDERSON WR, 1979, J IMMUNOL, V122, P1322; KIM CJ, 1965, J ALLERGY, V36, P353, DOI 10.1016/0021-8707(65)90042-0; KLINE B. S., 1932, JOUR ALLERGY, V3, P531, DOI 10.1016/S0021-8707(32)90148-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; Menkin V, 1940, AM J PHYSIOL, V129, P0691, DOI 10.1152/ajplegacy.1940.129.3.691; MIDDLETON E, 1975, NEW DIRECTIONS ASTHM, P433; OERTEL H, 1980, FED PROC, V39, P905; PEPYS J, 1977, AM REV RESPIR DIS, V116, P573, DOI 10.1164/arrd.1977.116.4.573; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; RAPHAEL GD, 1978, EXP CELL RES, V115, P428, DOI 10.1016/0014-4827(78)90300-2; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SHEA C, 1978, ANN CLIN LAB SCI, V8, P30; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; TANNENBAUM S, 1980, J IMMUNOL, V125, P325; TOLONE G, 1979, BRIT J EXP PATHOL, V60, P269; WARD PA, 1966, J EXP MED, V124, P209, DOI 10.1084/jem.124.2.209; ZWEIMAN B, 1976, J ALLERGY CLIN IMMUN, V58, P657, DOI 10.1016/0091-6749(76)90177-9	36	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					238	245		10.1016/0091-6749(81)90190-1	http://dx.doi.org/10.1016/0091-6749(81)90190-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	6267116				2022-12-18	WOS:A1981MG54400012
J	PATTERSON, R; PRUZANSKY, JJ; HARRIS, KE				PATTERSON, R; PRUZANSKY, JJ; HARRIS, KE			AN AGENT THAT RELEASES BASOPHIL AND MAST-CELL HISTAMINE BUT BLOCKS CYCLOOXYGENASE AND LIPOXYGENASE METABOLISM OF ARACHIDONIC-ACID INHIBITS IMMUNOGLOBULIN E-MEDIATED ASTHMA IN RHESUS-MONKEYS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PATTERSON, R (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611, USA.				NIAID NIH HHS [AI 11759] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DOUGLAS WW, 1970, PHARMACOLOGICAL BASI, P643; EVERITT BJ, 1979, PHARMACOLOGIST, V21, P153; HIGGS GA, 1978, 7TH P INT C PHARM, P334; HOGARTHS.RS, 1967, IMMUNOLOGY, V13, P535; HYMAN AL, 1978, AM REV RESPIR DIS, V117, P111; KELLY JF, 1974, J LAB CLIN MED, V83, P738; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER MM, 1976, J LAB CLIN MED, V88, P995; PATTERSON R, 1978, J CLIN INVEST, V62, P519, DOI 10.1172/JCI109155; PATTERSON R, 1980, J ALLERGY CLIN IMMUN, V65, P269, DOI 10.1016/0091-6749(80)90154-2; PATTERSON R, 1976, J CLIN INVEST, V57, P586, DOI 10.1172/JCI108314; PATTERSON R, 1969, J LAB CLIN MED, V73, P924; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V62, P371, DOI 10.1016/0091-6749(78)90139-2; PATTERSON R, 1978, J LAB CLIN MED, V92, P283; PATTERSON R, 1981, J ALLERGY CLIN IMMUN, V67, P146, DOI 10.1016/0091-6749(81)90010-5; PATTERSON R, 1979, J CLIN INVEST, V64, P49, DOI 10.1172/JCI109462; PATTERSON R, 1981, T ASSOC AM PHYSICIAN, V93, P317; PRUZANSKY JJ, 1970, INT ARCH ALLER A IMM, V38, P522, DOI 10.1159/000230305; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SNEDECOR GW, 1978, STATISTICAL METHODS, P215	20	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					444	449		10.1016/0091-6749(81)90097-X	http://dx.doi.org/10.1016/0091-6749(81)90097-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	6179973				2022-12-18	WOS:A1981LU06800005
J	SHAFIEE, A; YUNGINGER, JW; GLEICH, GJ				SHAFIEE, A; YUNGINGER, JW; GLEICH, GJ			ISOLATION AND CHARACTERIZATION OF RUSSIAN THISTLE (SALSOLA-PESTIFER POLLEN ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, ROCHESTER, MN 55901 USA; MAYO MED SCH, DEPT PEDIAT, ALLERG DIS RES LAB, ROCHESTER, MN 55901 USA; MAYO MED SCH, DEPT MED, ROCHESTER, MN 55901 USA; UNIV TEHRAN, COLL PHARM, Tehran, IRAN; MAYO MED SCH, DEPT IMMUNOL, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Tehran; Mayo Clinic					NIAID NIH HHS [AI 11482, AI 42546] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADOLPHSON C, 1978, J ALLERGY CLIN IMMUN, V62, P197, DOI 10.1016/0091-6749(78)90208-7; AWDEH ZL, 1968, NATURE, V219, P66, DOI 10.1038/219066a0; Bennich H, 1971, Adv Immunol, V13, P1; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DAVIS BJ, 1968, METHODS IMMUNOLOGY I, V2, P38; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; JOHNSON P, 1965, EUR POLYM J, V1, P63; KABAT EA, 1967, EXPERIMENTAL IMMUNOC, P476; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; MARSH DG, 1975, ANTIGENS, V3, P271; NEWMARK FM, 1978, ANN ALLERGY, V40, P18; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PAULL BR, 1977, J ALLERGY CLIN IMMUN, V59, P334, DOI 10.1016/0091-6749(77)90056-2; RADOLA BJ, 1973, ANN NY ACAD SCI, V209, P127, DOI 10.1111/j.1749-6632.1973.tb47523.x; SHAFIEE A, 1976, ANN ALLERGY, V37, P133; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; VARGA JM, 1972, J ALLERGY CLIN IMMUN, V49, P274, DOI 10.1016/0091-6749(72)90095-4; WIDE L, 1967, LANCET, V2, P1105	21	28	30	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					472	481		10.1016/0091-6749(81)90101-9	http://dx.doi.org/10.1016/0091-6749(81)90101-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	7346531				2022-12-18	WOS:A1981LU06800009
J	INCAUDO, G; SCHATZ, M; YAMAMOTO, F; MELLON, M; CREPEA, S; JOHNSON, JD				INCAUDO, G; SCHATZ, M; YAMAMOTO, F; MELLON, M; CREPEA, S; JOHNSON, JD			INTRANASAL FLUNISOLIDE IN THE TREATMENT OF PERENNIAL RHINITIS - CORRELATION WITH IMMUNOLOGICAL PARAMETERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAISER PERMANENTE MED CTR,DEPT ALLERGY,MED GRP,7060 CLAIREMONT MESA DR,SAN DIEGO,CA 92111; USN,REG MED CTR,DEPT PEDIAT,ALLERGY CLIN,SAN DIEGO,CA 92134; USN,REG MED CTR,DEPT INTERNAL MED,SAN DIEGO,CA 92134; SYNTEX RES CORP,PALO ALTO,CA 94304; USN,REG MED CTR,CTR CLIN INVEST,SAN DIEGO,CA 92134	Kaiser Permanente; United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; Syntex Corporation; United States Department of Defense; United States Navy								AARON TH, 1965, ANN ALLERGY, V23, P100; BLOOM FL, 1977, ANN ALLERGY, V38, P408; BROSTOFF J, 1969, J ALLERGY, V44, P77, DOI 10.1016/0021-8707(69)90003-3; BROWN H M, 1974, Clinical Allergy, V4, P331, DOI 10.1111/j.1365-2222.1974.tb01394.x; BROWN HM, 1972, BRIT MED J, V1, P585, DOI 10.1136/bmj.1.5800.585; CZARNY D, 1968, LANCET, V2, P188; GIBSON GJ, 1974, BRIT MED J, V4, P503, DOI 10.1136/bmj.4.5943.503; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GODFREY MP, 1957, LANCET, V1, P757; HANSEN IB, 1974, ACTA ALLERGOL, V29, P281, DOI 10.1111/j.1398-9995.1974.tb01655.x; HORAN JD, 1978, CAN MED ASSOC J, V119, P334; ISHIZAKA K, 1970, J ALLERGY, V46, P197, DOI 10.1016/0021-8707(70)90023-7; KAMMERMEYER JK, 1977, J ALLERGY CLIN IMMUN, V59, P287, DOI 10.1016/0091-6749(77)90049-5; LOFKVIST T, 1976, ACTA ALLERGOL, V31, P227, DOI 10.1111/j.1398-9995.1976.tb01683.x; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; NAKAJIMA S, 1975, CLIN EXP IMMUNOL, V21, P306; PENNYPACKER CS, 1954, J ALLERGY, V25, P513, DOI 10.1016/S0021-8707(54)90032-5; RUFF F, 1975, POSTGRAD MED J, V51, P54; SCHULZ JI, 1978, CLIN ALLERGY, V8, P313, DOI 10.1111/j.1365-2222.1978.tb00466.x; SMITH JM, 1975, BRIT MED J, V2, P255, DOI 10.1136/bmj.2.5965.255; SPITZ E, 1972, J ALLERGY CLIN IMMUN, V49, P337, DOI 10.1016/0091-6749(72)90132-7; TARLO SM, 1977, J ALLERGY CLIN IMMUN, V59, P232, DOI 10.1016/0091-6749(77)90155-5; TURKELTAUB PC, 1976, J ALLERGY CLIN IMMUN, V58, P597, DOI 10.1016/0091-6749(76)90206-2; VINER AS, 1976, CLIN ALLERGY, V6, P251, DOI 10.1111/j.1365-2222.1976.tb01904.x; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	25	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	1					41	49		10.1016/0091-6749(80)90175-X	http://dx.doi.org/10.1016/0091-6749(80)90175-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB459	7350203				2022-12-18	WOS:A1980JB45900007
J	KINO, T				KINO, T			ALLERGY TO INSECTS IN JAPAN .2. REAGINIC SENSITIVITY TO SILKWORM MOTH IN PATIENTS WITH BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KINO, T (corresponding author), KYOTO UNIV, CHEST DIS RES INST, SAKYO KU, KYOTO 606, JAPAN.							ARBESMAN CE, 1977, INT ARCH ALLER A IMM, V53, P310, DOI 10.1159/000231767; BALYEAT RAY M., 1932, JOUR ALLERGY, V3, P227, DOI 10.1016/S0021-8707(32)90338-4; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; FIGLEY KD, 1940, J ALLERGY, V11, P376; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; KINO T, 1978, J ALLERGY CLIN IMMUN, V61, P10, DOI 10.1016/0091-6749(78)90467-0; KINO T, 1978, JAP J ALLERGOL, V27, P31; LANGLOIS C, 1963, J ALLERGY, V34, P385, DOI 10.1016/0021-8707(63)90001-7; PARLATO SALVATORE J., 1932, JOUR ALLERGY, V3, P459, DOI 10.1016/S0021-8707(32)90181-6; Parlato SJ, 1932, J ALLERGY, V3, P125	10	28	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					131	138		10.1016/0091-6749(79)90047-2	http://dx.doi.org/10.1016/0091-6749(79)90047-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	572384				2022-12-18	WOS:A1979HG42600007
J	LIEBERMAN, P; SIEGLE, RL				LIEBERMAN, P; SIEGLE, RL			COMPLEMENT ACTIVATION FOLLOWING INTRAVENOUS CONTRAST MATERIAL ADMINISTRATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE,CTR HLTH SCI,DEPT MED,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT DIAGNOST RADIOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center								ARROYAVE CM, 1977, CLIN EXP IMMUNOL, V29, P89; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; LANG JH, 1976, INVEST RADIOL, V11, P303, DOI 10.1097/00004424-197607000-00007; LASSER EC, 1977, RADIOLOGY, V125, P1; LASSER EC, 1976, RADIOLOGY, V119, P91, DOI 10.1148/119.1.91; MANCINI G, 1964, PROTIDES BIOLOGICAL, P370; Mayer M.M., 1961, EXPT IMMUNOCHEMISTRY, P133; OCHSNER SF, 1971, SOUTHERN MED J, V64, P907, DOI 10.1097/00007611-197108000-00002; Pendergrass EP, 1942, AM J ROENTGENOL RADI, V48, P741; RING J, 1978, J ALLERGY CLIN IMMUN, V61, P145, DOI 10.1016/0091-6749(78)90296-8; SCHUR PH, 1977, AM J CLIN PATHOL, V68, P647; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; SIEGLE RL, 1976, INVEST RADIOL, V11, P98, DOI 10.1097/00004424-197603000-00004; SIMON RA, 1978, J ALLERGY CLIN IMMUN, V61, P145, DOI 10.1016/0091-6749(78)90295-6; TILL G, 1977, P FED AM SOC EXP BIO, V36, P1264; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974	16	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	1					13	17		10.1016/0091-6749(79)90076-9	http://dx.doi.org/10.1016/0091-6749(79)90076-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HC424	447947				2022-12-18	WOS:A1979HC42400004
J	PAULI, G; BESSOT, JC; HIRTH, C; THIERRY, R				PAULI, G; BESSOT, JC; HIRTH, C; THIERRY, R			DISSOCIATION OF HOUSE DUST ALLERGIES - COMPARISON BETWEEN SKIN-TESTS, INHALATION TESTS, SPECIFIC LGE AND BASOPHIL HISTAMINE-RELEASE MEASUREMENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR HOSP UNIV STRASBOURG,BACTERIOL IMMUNOL LAB,F-67005 STRASBOURG,FRANCE	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	PAULI, G (corresponding author), CTR HOSP UNIV STRASBOURG,FAC MED,PNEUMOPHTISIOL CLIN,F-67005 STRASBOURG,FRANCE.							Aalberse R C, 1975, Dev Biol Stand, V29, P197; ARAUJOFONTAINE A, 1974, THESIS; BESSOT JC, 1976, B ACT THERAP, V66, P1935; BOATNER CHARLOTTE H., 1940, SCIENCE, V91, P389, DOI 10.1126/science.91.2364.389; JOHANSSON SGO, 1975, ADV DIAGNOSIS ALLERG; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P117, DOI 10.1016/0091-6749(72)90007-3; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MAUNSELL K, 1968, LANCET, V1, P1267; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MCALLEN MK, 1970, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.5708.501; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; PAULI G, 1977, CLIN ALLERGY, V7, P337, DOI 10.1111/j.1365-2222.1977.tb01461.x; PAULI G, 1973, REV FR MAL RESP, V5, P711; RIMINGTON C, 1947, BRIT J EXP PATHOL, V28, P309; STENIUS B, 1969, LANCET, V2, P455; Sutherland C, 1942, Br Med J, V2, P280; VIRCHOW C, 1976, CLIN ALLERGY, V6, P147, DOI 10.1111/j.1365-2222.1976.tb01892.x; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; VOORHORST R, 1975, ALLERGY, V74; WEEKE B, 1975, INT ARCH ALLER A IMM, V49, P74, DOI 10.1159/000231378	20	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	4					245	252		10.1016/0091-6749(79)90108-8	http://dx.doi.org/10.1016/0091-6749(79)90108-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GR842	85649	Bronze			2022-12-18	WOS:A1979GR84200004
J	SHEFFER, AL; FEARON, DT; AUSTEN, KF				SHEFFER, AL; FEARON, DT; AUSTEN, KF			CLINICAL AND BIOCHEMICAL EFFECTS OF IMPEDED ANDROGEN (OXYMETHOLONE) THERAPY OF HEREDITARY ANGIOEDEMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SHEFFER, AL (corresponding author), ROBERT B BRIGHAM HOSP,DEPT MED,BOSTON,MA 02120, USA.								0	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					275	280		10.1016/0091-6749(79)90144-1	http://dx.doi.org/10.1016/0091-6749(79)90144-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479480				2022-12-18	WOS:A1979HQ46900008
J	MIKLICH, DR; RENNE, CM; CREER, TL; ALEXANDER, AB; CHAI, H; DAVIS, MH; HOFFMAN, A; DANKERBROWN, P				MIKLICH, DR; RENNE, CM; CREER, TL; ALEXANDER, AB; CHAI, H; DAVIS, MH; HOFFMAN, A; DANKERBROWN, P			CLINICAL UTILITY OF BEHAVIOR-THERAPY AS AN ADJUNCTIVE TREATMENT FOR ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL ASTHMA CTR, DIV BEHAV SCI, DENVER, CO 80204 USA									AITKEN R C B, 1972, P375; ALEXANDER AB, 1972, PSYCHOSOM MED, V34, P388, DOI 10.1097/00006842-197209000-00002; ALEXANDER AB, 1972, J PSYCHOSOM RES, V16, P405, DOI 10.1016/0022-3999(72)90065-7; BALLARD M, 1973, THESIS U LONDON; BANDURA A, 1969, PRINCIPLES BEHAVIOR, P424; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; CHAI H, 1973, AM J DIS CHILD, V125, P757, DOI 10.1001/archpedi.1973.04160050095021; CHAI H, 1975, ADV ASTHMA ALLERGY, V2, P1; COOPER AJ, 1964, BEHAV RES THER, V1, P351; DAVIS MH, 1973, J PSYCHOSOM RES, V17, P121, DOI 10.1016/0022-3999(73)90012-3; FREEMAN GL, 1964, AM J DIS CHILD, V107, P560, DOI 10.1001/archpedi.1964.02080060562002; HINSHAW HC, 1969, DIS CHEST, P332; HOEKELMAN RA, 1974, PEDIATR CLIN N AM, V21, P5; JOHNSTON.DE, 1968, AM J DIS CHILD, V115, P213, DOI 10.1001/archpedi.1968.02100010215010; KANFER FH, 1970, LEARNING F BEHAVIOR, P133; KAZDIN AE, 1976, PSYCHOL BULL, V83, P729, DOI 10.1037/0033-2909.83.5.729; Kimble GA., 1961, HILGARD MARQUIS COND; KNAPP PH, COMMUNICATION; KOTSES H, 1976, J PSYCHOSOM RES, V20, P453, DOI 10.1016/0022-3999(76)90009-X; MOORE N, 1965, J PSYCHOSOM RES, V9, P257, DOI 10.1016/0022-3999(65)90051-6; POLGAR G, 1971, PULMONARY FUNCTION T, P67; PURCELL K, 1969, PSYCHOSOM MED, V31, P144, DOI 10.1097/00006842-196903000-00008; RIMM DC, 1974, BEHAV THERAPY TECHNI, P43; SCHERR MS, 1975, ANN ALLERGY, V35, P289; SERGEANT HG, 1969, LANCET, V2, P1321; STILSON DW, 1966, PROBABILITY STATISTI, P35; WALTON D, 1960, BEHAVIOUR THERAPY NE, P188; Wolpe J., 1958, PSYCHOTHERAPY RECIPR; WOODWORTH RS, 1954, EXPT PSYCHOLOGY, P733; YORKSTON NJ, 1974, J PSYCHOSOM RES, V18, P371, DOI 10.1016/0022-3999(74)90058-0	30	28	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	5					285	294		10.1016/0091-6749(77)90107-5	http://dx.doi.org/10.1016/0091-6749(77)90107-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA243	915145	Bronze			2022-12-18	WOS:A1977EA24300003
J	HIRSCH, SR; KALBFLEISCH, JH				HIRSCH, SR; KALBFLEISCH, JH			CIRCULATING BASOPHILS IN NORMAL SUBJECTS AND IN SUBJECTS WITH HAY-FEVER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM CTR,RES SERV,WOOD,WI 53193; MED COLL WISCONSIN,BIOSTATISTICS UNIT,MILWAUKEE,WI 53233; MED COLL WISCONSIN,DEPT MED,ALLERGY SECT,MILWAUKEE,WI 53233	Medical College of Wisconsin; Medical College of Wisconsin								HIRSCH SR, 1974, J ALLERGY CLIN IMMUN, V53, P303, DOI 10.1016/0091-6749(74)90110-9; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; KIMURA I, 1975, Clinical Allergy, V5, P95, DOI 10.1111/j.1365-2222.1975.tb01840.x; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; MAY C D, 1973, Clinical Allergy, V3, P319, DOI 10.1111/j.1365-2222.1973.tb01340.x; PATTERSON R, 1972, ALLERGIC DISEASES DI, P161; SHELLEY WB, 1965, JAMA-J AM MED ASSOC, V192, P108; TODD JC, 1948, CLINICAL DIAGNOSIS L, P220	8	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	6					676	682		10.1016/0091-6749(76)90179-2	http://dx.doi.org/10.1016/0091-6749(76)90179-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP077	993482				2022-12-18	WOS:A1976CP07700006
J	GLEICH, GJ; JONES, RT				GLEICH, GJ; JONES, RT			MEASUREMENT OF IGE ANTIBODIES BY RADIOALLERGOSORBENT TEST .2. ANALYSES OF QUANTITATIVE RELATIONSHIPS IN TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT MED,ALLERGIC DIS RES LAB,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT MICROBIOL,ROCHESTER,MN; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN; MAYO CLIN & MAYO FDN,MED SCH,ROCHESTER,MN	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; GLEICH GJ, 1974, 8TH ALL P INT C, P44; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MIDGLEY A R JR, 1969, Acta Endocrinologica Supplementum, V142, P163; PORATH J, 1972, NATURE-NEW BIOL, V238, P261, DOI 10.1038/newbio238261a0; SUNDBERG L, COMMUNICATION; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294; ZEISS CR, 1973, J IMMUNOL, V110, P414	13	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	5					346	357		10.1016/0091-6749(75)90006-8	http://dx.doi.org/10.1016/0091-6749(75)90006-8			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AB754	1120853	Bronze			2022-12-18	WOS:A1975AB75400006
J	LEFCOE, NM; TOOGOOD, JH; JONES, TR				LEFCOE, NM; TOOGOOD, JH; JONES, TR			INVITRO PHARMACOLOGIC STUDIES OF BRONCHODILATOR COMPOUNDS - INTERACTIONS AND MECHANISMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	2					94	94						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V5498					2022-12-18	WOS:A1975V549800063
J	BERNSTEI.IL; SAFFERMA.R				BERNSTEI.IL; SAFFERMA.R			CLINICAL SENSITIVITY TO GREEN-ALGAE DEMONSTRATED BY NASAL CHALLENGE AND IN VITRO TESTS OF IMMEDIATE HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT INTERN MED,DIV IMMUNOL,CINCINNATI,OH 45229; ENVIRONM PROTECTION AGCY,NATL ENVIRONM RES CTR,CINCINNATI,OH 45229	University of Cincinnati; United States Environmental Protection Agency								BENNINGHOFF WE, 1971, USIBP1 U MICH AER PR; BERNSTEIN IL, 1970, NATURE, V227, P851, DOI 10.1038/227851a0; BERNSTEIN IL, 1966, J ALLERGY, V38, P166, DOI 10.1016/0021-8707(66)90039-6; BERNSTEIN IL, 1970, EXCERPTA MEDICA  211, P5; BERRENS L, 1961, INT ARCH ALLER A IMM, V19, P341, DOI 10.1159/000229224; BLANCHARD DC, 1970, SCIENCE, V170, P626, DOI 10.1126/science.170.3958.626; BROWN RM, 1964, SCIENCE, V143, P583, DOI 10.1126/science.143.3606.583; CRANE R, 1970, 23 ANN C ENG MED BIO; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; PERELMUTTER L, 1969, LANCET, V1, P1269; SCHLICHTING HE, 1964, LLOYD, V27, P64; SMITH KM, 1966, VIROLOGY, V28, P580, DOI 10.1016/0042-6822(66)90243-1; Sokal Robert R., 1969, BIOMETRY; Van Overeem MA, 1937, RECUEIL TRAVAUX BOT, V34, P388; WOODCOCK AH, 1955, BURSTING BUBBLES AIR, P1189	15	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	1					22	28		10.1016/0091-6749(73)90004-3	http://dx.doi.org/10.1016/0091-6749(73)90004-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	O5651	4118409				2022-12-18	WOS:A1973O565100003
J	BLUMENTHAL, MN; SCHOENWETTER, WF; MACDONALD, FM; MCHUGH, RB				BLUMENTHAL, MN; SCHOENWETTER, WF; MACDONALD, FM; MCHUGH, RB			CROMOLYN IN EXTRINSIC AND INTRINSIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MINNESOTA, MED SCH, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, DEPT BIOMETRY, MINNEAPOLIS, MN 55455 USA; VET ADM HOSP, MINNEAPOLIS, MN 55417 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System								ALTOUNYA.RE, 1969, RESPIRATION, VS 26, P131, DOI 10.1159/000192647; ANDERSON SD, 1972, AM REV RESPIR DIS, V106, P30, DOI 10.1164/arrd.1972.106.1.30; ASSEM ESK, 1970, INT ARCH ALLER A IMM, V38, P68, DOI 10.1159/000230260; ASTIN TW, 1971, BRITISH J CLINICAL B, V25, P459; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V50, P235, DOI 10.1016/0091-6749(72)90017-6; BURGHER LW, 1971, CHEST, V60, P210, DOI 10.1378/chest.60.3.210; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; CHEN JL, 1969, J ALLERGY, V43, P89, DOI 10.1016/0021-8707(69)90129-4; CLARKE PS, 1971, BRIT MED J, V1, P317, DOI 10.1136/bmj.1.5744.317; Cox J S, 1970, Adv Drug Res, V5, P115; COX J S G, 1971, British Journal of Diseases of the Chest, V65, P189, DOI 10.1016/0007-0971(71)90028-3; DAVIES SE, 1968, BRIT MED J, V3, P593, DOI 10.1136/bmj.3.5618.593; EGGLESTON PA, 1972, J ALLERGY CLIN IMMUN, V50, P57, DOI 10.1016/0091-6749(72)90079-6; ELGEFORS B, 1970, ACTA ALLERGOL, V25, P374, DOI 10.1111/j.1398-9995.1970.tb01274.x; FEDERER WT, 1955, EXPERIMENTAL DESIGNT, pCH14; FOX ZR, 1972, CAN MED ASSOC J, V106, P975; IRANI FA, 1972, AM REV RESPIR DIS, V106, P179, DOI 10.1164/arrd.1972.106.2.179; KERR JW, 1970, BMJ-BRIT MED J, V2, P139, DOI 10.1136/bmj.2.5702.139; KIDNER PH, 1968, LANCET, V2, P655; LOPEZ M, 1969, J ALLERGY, V44, P118, DOI 10.1016/0021-8707(69)90008-2; MOLK L, 1972, ANN ALLERGY, V30, P321; MORRISONSMITH J, 1968, BRIT MED J, V2, P340; MUNROFORD R, 1971, ANN ALLERGY, V29, P8; ORANGE RP, 1971, INT ARCH ALLER A IMM, V41, P79, DOI 10.1159/000230490; PATEL K R, 1971, Clinical Allergy, V1, P199, DOI 10.1111/j.1365-2222.1971.tb03019.x; PEPYS J, 1968, LANCET, V2, P134; POPPIUS H, 1970, BRIT MED J, V4, P337, DOI 10.1136/bmj.4.5731.337; READ J, 1969, MED J AUSTRALIA, V1, P566, DOI 10.5694/j.1326-5377.1969.tb92293.x; ROBERTSON DG, 1969, BMJ-BRIT MED J, V1, P552, DOI 10.1136/bmj.1.5643.552; SIMONSSON BG, 1972, THORAX, V27, P169, DOI 10.1136/thx.27.2.169; SLY RM, 1971, ANN ALLERGY, V29, P362; TAYLOR B, 1972, NZ MED J, V74, P374; WARD FG, 1969, BRIT MED J, V3, P176, DOI 10.1136/bmj.3.5663.176-d; WILLIAMS EJ, 1949, AUST J SCI RES SER A, V2, P149, DOI 10.1071/CH9490149	34	28	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	2					105	114		10.1016/0091-6749(73)90082-1	http://dx.doi.org/10.1016/0091-6749(73)90082-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q4190	4198879	Bronze			2022-12-18	WOS:A1973Q419000005
J	GALANT, SP; MAIBACH, HI				GALANT, SP; MAIBACH, HI			REPRODUCIBILITY OF ALLERGY EPICUTANEOUS TEST TECHNIQUES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF,DEPT PEDIAT,ORANGE,CA 92668									ALEXANDER HL, 1930, J ALLERGY, V2, P23; BECKER EL, 1948, J ALLERGY, V19, P317, DOI 10.1016/0021-8707(48)90112-9; BLACKLEY C, 1873, EXPERIMENTAL RESEARC; BRONSKY EA, 1969, PEDIATR CLIN N AM, V16, P85; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; Fineman AH, 1926, J IMMUNOL, V11, P465; GALANT S, 1972, ANN ALLERGY, V30, P53; GOTTLIEB PHILIP M., 1960, ANN ALLERGY, V18, P949; JOUBERT L, 1969, CLIN PHARMACOL THER, V10, P250; KAUFMAN HS, 1966, ANN ALLERGY, V24, P26; LINBLAD JH, 1961, J ALLERGY, V32, P392; MAIBACH HI, 1963, ARCH DERMATOL, V87, P743, DOI 10.1001/archderm.1963.01590180071015; PABST MR, 1940, NEW ORL MED SURG J, V93, P142; SHELDON JM, 1967, MANUAL CLINICAL ALLE; Snedecor G.W., 1980, STAT METHODS, V7; SQUIRE JR, 1950, CLIN SCI, V9, P127; STANWORT.DR, 1965, IMMUNOLOGY, V8, P323; VANARSDEL PP, 1957, J ALLERGY, V28, P251, DOI 10.1016/0021-8707(57)90130-2	18	28	28	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	51	4					245	250		10.1016/0091-6749(73)90144-9	http://dx.doi.org/10.1016/0091-6749(73)90144-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P3010	4689141				2022-12-18	WOS:A1973P301000007
J	ZWEIMAN, B; SLAVIN, RG; AARON, TH; FEINBERG, RJ; FALLIERS, CJ				ZWEIMAN, B; SLAVIN, RG; AARON, TH; FEINBERG, RJ; FALLIERS, CJ			EFFECTS OF AIR-POLLUTION ON ASTHMA - REVIEW	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ABBE M, 1967, B TOKYO MED DENT U, V14, P415; AMDUR M O, 1957, Am Ind Hyg Assoc Q, V18, P149; AMDUR MO, 1969, J AIR POLLUT CONTROL, V19, P639; [Anonymous], AIR POLLUTION; AYRES SM, 1970, CLIN PHARMACOL THER, V11, P337; BATES DV, 1972, AM REV RESPIR DIS, V105, P1; CARNOW BW, 1969, ARCH ENVIRON HEALTH, V18, P768, DOI 10.1080/00039896.1969.10665485; CHIARAMONTE LT, 1970, NEW YORK STATE J MED, V70, P394; CHO YW, 1968, ARCH ENVIRON HEALTH, V16, P651, DOI 10.1080/00039896.1968.10665123; Clayton J W Jr, 1969, J Air Pollut Control Assoc, V19, P644; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; EGBERT O E, 1948, Acta Allergol, V1, P224; FERRIS BG, 1966, NEW ENGL J MED, V275, P1413, DOI 10.1056/NEJM196612222752505; FONTANA VJ, 1966, NEW YORK STATE J MED, V66, P2913; FONTANA VJ, 1969, J ALLERGY, V43, P16, DOI 10.1016/0021-8707(69)90016-1; FRANK NR, 1962, J APPL PHYSIOL, V17, P252, DOI 10.1152/jappl.1962.17.2.252; FRY J, 1962, LANCET, V2, P1326; GIRSH LS, 1967, J ALLERGY, V39, P347, DOI 10.1016/0021-8707(67)90047-0; GLASSER M, 1967, ARCH ENVIRON HEALTH, V15, P684, DOI 10.1080/00039896.1967.10664987; GOLDSMIT.JR, 1969, ARCH ENVIRON HEALTH, V18, P516, DOI 10.1080/00039896.1969.10665446; GOLDSMITH J, 1970, DEVELOPMENT AIR QUAL, P1; GREENBURG L, 1964, ARCH ENVIRON HEALTH, V8, P642, DOI 10.1080/00039896.1964.10663734; GROSS P, 1965, MED THORAC, V22, P376; LAVE LB, 1970, SCIENCE, V169, P723, DOI 10.1126/science.169.3947.723; LEWIS R, 1962, PUBLIC HEALTH REP, V77, P947, DOI 10.2307/4591673; LOWRY T, 1956, U MINN MED B, V27, P234; MOTLEY HL, 1959, JAMA-J AM MED ASSOC, V171, P1469, DOI 10.1001/jama.1959.03010290027008; NADEL JA, 1968, ARCH ENVIRON HEALTH, V16, P651; PAPETTI RA, 1971, ENDEAVOUR, V30, P107, DOI 10.1016/0160-9327(71)90035-4; PHELPS HW, 1965, ARCH ENVIRON HEALTH, V10, P143, DOI 10.1080/00039896.1965.10663972; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SCHOETTLIN CE, 1961, PUBLIC HEALTH REP, V76, P545, DOI 10.2307/4591201; SMITH SO, UNPUBLISHED DATA; SPEIZER F E, 1969, Journal of the Air Pollution Control Association, V19, P647; SPEIZER WS, 1970, ARCH ENVIRON HEALTH, V21, P635; SPEIZER WS, 1966, ARCH ENVIRON HEALTH, V13, P753; SPOTNITZ M, 1965, AM REV RESPIR DIS, V92, P371; SULTZ HA, 1970, AM J PUBLIC HEALTH N, V60, P891, DOI 10.2105/AJPH.60.5.891; Thomas H V, 1967, J Air Pollut Control Assoc, V17, P33; THOMAS HV, 1969, J APPL PHYSIOL, V26, P793, DOI 10.1152/jappl.1969.26.6.793; WEILL H, 1964, JAMA-J AM MED ASSOC, V190, P811; WINKELSTEIN W, 1967, ARCH ENVIRON HEALTH, V14, P162, DOI 10.1080/00039896.1967.10664708; YOUNG WA, 1964, J APPL PHYSIOL, V19, P765, DOI 10.1152/jappl.1964.19.4.765; ZEIDBERG LD, 1961, AM REV RESPIR DIS, V84, P498; 1954, 95 PUBL HEALTH REL S; 1964, 1103USPHS PUBL HE SE, P362; 1969, AIR QUALITY CRITERIA; 1962, 978 PUBL HEALTH SERV; 1949, 306 PUBL HEALTH B	49	28	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	5					305	&		10.1016/0091-6749(72)90029-2	http://dx.doi.org/10.1016/0091-6749(72)90029-2			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	N9856	4561801	Bronze			2022-12-18	WOS:A1972N985600006
J	Bruusgaard-Mouritsen, MA; Jensen, BM; Poulsen, LK; Johansen, JD; Garvey, LH				Bruusgaard-Mouritsen, Maria Anna; Jensen, Bettina Margrethe; Poulsen, Lars K.; Johansen, Jeanne Duus; Garvey, Lene Heise			Optimizing investigation of suspected allergy to polyethylene glycols	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug allergy; anaphylaxis; polyethylene glycol; PEG; macrogol; skin prick test; basophil histamine release; COVID-19 vaccine	HISTAMINE-RELEASE; ANAPHYLAXIS; HYPERSENSITIVITY; IGE; CHLORHEXIDINE; SENSITIZATION; ETHYLENE	Background: Polyethylene glycols (PEGs) are polymers of varying molecular weight (MW) used widely as excipients in drugs and other products, including the mRNA vaccines against coronavirus disease 2019. Allergy to PEGs is rare. Skin testing and graded challenge carries a high risk of inducing systemic reactions. Objective: We evaluated skin prick test (SPT) results and in vitro reactivity over time to different MW PEGs and assessed cross-sensitization patterns in PEG allergy. Methods: Ten patients with previously diagnosed PEG allergy underwent SPT twice with PEGs 26 months apart. Lower MW (PEG 300, 3000, 6000) were tested, followed by PEG 20,000, in stepwise, increasing concentrations. Cross-sensitization to polysorbate 80 and poloxamer 407 was assessed. SPT was performed in 16 healthy controls. In vitro basophil histamine release (HR) test and passive sensitization HR test were performed in patients and controls. Results: Patients previously testing positive on SPT to PEG 3000 and/or 6000 also tested positive to PEG 20,000. Patients with a longer interval since diagnosis tested negative to lower MW PEGs and positive mainly to higher concentrations of PEG 20,000. Three patients developed systemic urticaria during SPT. Eight patients showed cross-sensitization to poloxamer 407 and 3 to polysorbate 80. All controls tested negative. In vitro tests showed limited usefulness. Conclusions: Skin test reactivity to PEG can decrease over time, but titrated SPT with increasing concentrations of PEG 20,000 can be diagnostic when lower MW PEGs test negative. To avoid systemic reactions, stepwise SPT is mandatory. (J Allergy Clin Immunol 2022;149:168-75.)	[Bruusgaard-Mouritsen, Maria Anna; Johansen, Jeanne Duus] Copenhagen Univ Hosp Gentofte, Natl Allergy Res Ctr, Copenhagen, Denmark; [Bruusgaard-Mouritsen, Maria Anna; Jensen, Bettina Margrethe; Poulsen, Lars K.; Johansen, Jeanne Duus; Garvey, Lene Heise] Copenhagen Univ Hosp Gentofte, Allergy Clin, Copenhagen, Denmark; [Garvey, Lene Heise] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen	Garvey, LH (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Allergy Clin, Gentofte Hosp Vej 8,1st Floor, DK-2900 Hellerup, Denmark.	lene.heise.garvey@regionh.dk	Johansen, Jeanne/AAM-6382-2021	Johansen, Jeanne/0000-0002-3537-8463; Bruusgaard-Mouritsen, Maria/0000-0003-4259-5711	Danish Environmental Protection Agency; Kongelig Hofbundtmager Aage Bangs Fond	Danish Environmental Protection Agency; Kongelig Hofbundtmager Aage Bangs Fond	This work was supported by grants from the Danish Environmental Protection Agency to the National Allergy Research Centre and Kongelig Hofbundtmager Aage Bangs Fond.	Girones MA, 2008, ALLERGOL IMMUNOPATH, V36, P110, DOI 10.1157/13120396; Badiu I, 2015, J INVEST ALLERG CLIN, V25, P368; Blanca M, 1996, CLIN EXP ALLERGY, V26, P335; Bommarito L, 2011, ANN ALLERG ASTHMA IM, V107, P542, DOI 10.1016/j.anai.2011.08.008; Bordere A, 2012, CONTACT DERMATITIS, V67, P376, DOI 10.1111/j.1600-0536.2012.02104.x; Brandt N, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-016-0138-3; Bruusgaard-Mouritsen MA, 2021, CLIN EXP ALLERGY, V51, P463, DOI 10.1111/cea.13822; Calogiuri G., 2016, CLIN IMMUNOL ENDOCR, V4, P9; Dewachter P, 2005, ALLERGY, V60, P705, DOI 10.1111/j.1398-9995.2005.00783.x; Dumortier G, 2006, PHARM RES-DORDR, V23, P2709, DOI 10.1007/s11095-006-9104-4; Garvey LH, 2021, BRIT J ANAESTH, V126, pE106, DOI 10.1016/j.bja.2020.12.020; Garvey LH, 2007, J ALLERGY CLIN IMMUN, V120, P409, DOI 10.1016/j.jaci.2007.04.029; Larsen LF, 2018, ALLERGY, V73, P137, DOI 10.1111/all.13243; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; Opstrup MS, 2016, CLIN EXP ALLERGY, V46, P1090, DOI 10.1111/cea.12743; Opstrup MS, 2014, ALLERGY, V69, P1390, DOI 10.1111/all.12466; Opstrup MS, 2010, J INVEST ALLERG CLIN, V20, P269; Oyarzabal N., 2017, CASE REP CLIN MED, V06, P143; Povoski SP, 2013, EXPERT REV MOL DIAGN, V13, P315, DOI [10.1586/erm.13.19, 10.1586/ERM.13.19]; Sellaturay P, 2021, J ALLER CL IMM-PRACT, V9, P670, DOI 10.1016/j.jaip.2020.09.029; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Wenande E, 2016, CLIN EXP ALLERGY, V46, P907, DOI 10.1111/cea.12760; Wenande E, 2015, A A CASE REP, V4, P61, DOI 10.1213/XAA.0000000000000126; Wenande EC, 2013, J ALLERGY CLIN IMMUN, V131, P1425, DOI 10.1016/j.jaci.2012.09.037; Yamasuji Y, 2013, CONTACT DERMATITIS, V69, P183, DOI 10.1111/cod.12084; Zhou ZH, 2021, J ALLER CL IMM-PRACT, V9, P1731, DOI 10.1016/j.jaip.2020.11.011	26	27	28	9	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2022	149	1					168	+		10.1016/j.jaci.2021.05.020	http://dx.doi.org/10.1016/j.jaci.2021.05.020			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YJ5AM	34052265				2022-12-18	WOS:000744544500026
J	Klingler, AI; Stevens, WW; Tan, BK; Peters, AT; Poposki, JA; Grammer, LC; Welch, KC; Smith, SS; Conley, DB; Kern, RC; Schleimer, RP; Kato, A				Klingler, Aiko I.; Stevens, Whitney W.; Tan, Bruce K.; Peters, Anju T.; Poposki, Julie A.; Grammer, Leslie C.; Welch, Kevin C.; Smith, Stephanie S.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.; Kato, Atsushi			Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis without nasal polyps; endotype; transcriptome; biomarker	GENE-EXPRESSION PROFILES; CELLS; TRANSCRIPTOME; MICROARRAY; DIVERSITY	Background: Chronic rhinosinusitis (CRS) without nasal polyps (CRSsNP) is a common disease that is characterized by multiple inflammatory endotypes. However, the molecular mechanisms in CRSsNP are poorly understood compared with those of polypoid CRS. Objective: Our aim was to identify mechanisms and biomarkers associated with inflammatory endotypes underpinning CRSsNP. Methods: Ethmoid tissues and nasal lavage fluids (NLFs) were obtained from control patients and patients with CRS. The gene expression profiles were determined by microarray analysis and quantitative RT-PCR, and expression of proteins was measured by ELISA and Luminex analysis. Results: Microarray found that compared with their levels of expression in control tissue, the levels of expression of 126, 241, and 545 genes were more than 3-fold and significantly elevated in CRSsNP with type 1 (T1) endotype, type 2 (T2) endotype, and type 3 (T3) endotype, respectively. Selected identified genes were confirmed by RT-PCR. Gene set enrichment analysis suggested that T1 CRSsNP was associated with IFN-gamma signaling and antiviral immunity controlled by T cells (T(H)1 and CD8(+)), natural killer cells, and antigen-presenting cells; T2 CRSsNP was associated with STAT6 signaling and IgE-mediated activation controlled by eosinophils, mast cells, T(H)2 cells, group 2 innate lymphoid cells, and antigen-presenting cells; and T3 CRSsNP was associated with IL-17 signaling, acute inflammatory response, complement-mediated inflammation, and infection controlled by neutrophils, T(H)17 cells, B cells, and antigen-presenting cells. The results suggest that T1 (CXCL9 and CXCL10), T2 (eosinophilic proteins and CCL26), and T3 (CSF3) endotypic biomarkers in NLF may be able to distinguish tissue endotypes in CRSsNP. Conclusions. Inflammatory endotypes in CRSsNP were controlled by different molecular mechanisms. NLF biomarker assays may allow for more precise and personalized medical treatments in CRS.	[Klingler, Aiko I.; Stevens, Whitney W.; Peters, Anju T.; Poposki, Julie A.; Grammer, Leslie C.; Kern, Robert C.; Schleimer, Robert P.; Kato, Atsushi] Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA; [Tan, Bruce K.; Welch, Kevin C.; Smith, Stephanie S.; Conley, David B.; Kern, Robert C.; Kato, Atsushi] Northwestern Univ, Feinberg Sch Med, Dept Otolaryngol, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Kato, A (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy & Immunol, 240 E Huron St,Room M304, Chicago, IL 60611 USA.	a-kato@northwestern.edu			National Institutes of Health [R01 AI104733, R01 AI137174, R37 HL068546, U19 AI106683, P01 AI145818]; Ernest S. Bazley Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Foundation	Supported in part by National Institutes of Health grants R01 AI104733, R01 AI137174, R37 HL068546, U19 AI106683, and P01 AI145818 and by a grant from the Ernest S. Bazley Foundation.	Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Atri C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061801; Bagchi S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01616; Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2; Brown CC, 2019, CELL, V179, P846, DOI 10.1016/j.cell.2019.09.035; Chen K, 2017, GENE, V614, P8, DOI 10.1016/j.gene.2017.01.016; Chow KT, 2018, ANNU REV IMMUNOL, V36, P667, DOI 10.1146/annurev-immunol-042617-053309; Esnault S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067560; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Grassi L, 2018, CELL REP, V24, P2784, DOI 10.1016/j.celrep.2018.08.018; Hancock REW, 2016, NAT REV IMMUNOL, V16, P321, DOI 10.1038/nri.2016.29; Hoggard M, 2018, INT FORUM ALLERGY RH, V8, P394, DOI 10.1002/alr.22074; Hurgin V, 2007, P NATL ACAD SCI USA, V104, P5044, DOI 10.1073/pnas.0611608104; Imoto Y, 2019, J ALLERGY CLIN IMMUN, V144, P1566, DOI 10.1016/j.jaci.2019.08.040; Jain S, 2011, J PHARM BIOALLIED SC, V3, P118, DOI 10.4103/0975-7406.76489; Jeffe JS, 2013, LARYNGOSCOPE, V123, P2104, DOI 10.1002/lary.24016; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Kato Y, 2018, AM J RESP CELL MOL, V59, P448, DOI 10.1165/rcmb.2017-0325OC; Mahdavinia M, 2014, J ALLERGY CLIN IMMUN, V133, P1759, DOI 10.1016/j.jaci.2013.12.1092; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Okada N, 2018, INT FORUM ALLERGY RH, V8, P592, DOI 10.1002/alr.22083; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS3, DOI 10.1002/alr.21694; Payne SC, 2008, AM J RHINOL, V22, P568, DOI 10.2500/ajr.2008.22.3233; Peterson S, 2012, J ALLERGY CLIN IMMUN, V129, P119, DOI 10.1016/j.jaci.2011.08.021; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Poposki JA, 2015, CLIN EXP ALLERGY, V45, P384, DOI 10.1111/cea.12471; Poposki JA, 2017, IMMUN INFLAMM DIS, V5, P233, DOI 10.1002/iid3.161; Poposki JA, 2011, J ALLERGY CLIN IMMUN, V128, P73, DOI 10.1016/j.jaci.2011.03.017; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226; Rostkowska-Nadolska B, 2011, AURIS NASUS LARYNX, V38, P58, DOI 10.1016/j.anl.2010.05.002; Saito H, 2006, NAT PROTOC, V1, P2178, DOI 10.1038/nprot.2006.344; Seshadri S, 2013, J ALLERGY CLIN IMMUN, V132, P1227, DOI 10.1016/j.jaci.2013.05.042; Simoni Y, 2018, IMMUNOLOGY, V153, P297, DOI 10.1111/imm.12862; Singhania A, 2018, AM J RESP CELL MOL, V58, P261, DOI 10.1165/rcmb.2017-0162OC; Smith KA, 2015, LARYNGOSCOPE, V125, P1547, DOI 10.1002/lary.25180; Stevens WW, 2019, J ALLER CL IMM-PRACT, V7, P2812, DOI 10.1016/j.jaip.2019.05.009; Takabayashi T, 2013, AM J RESP CRIT CARE, V187, P49, DOI 10.1164/rccm.201207-1292OC; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Tan BK, 2017, J ALLERGY CLIN IMMUN, V139, P699, DOI 10.1016/j.jaci.2016.06.063; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Toyama S, 2017, ALLERGOL INT, V66, P463, DOI 10.1016/j.alit.2017.01.001; Turner JH, 2018, J ALLERGY CLIN IMMUN, V141, P1895, DOI 10.1016/j.jaci.2018.02.002; Tyler MA, 2017, J ALLERGY CLIN IMMUN, V139, P1061, DOI 10.1016/j.jaci.2016.09.048; Van Roey GA, 2017, J ALLERGY CLIN IMMUN, V140, P89, DOI 10.1016/j.jaci.2016.11.015; Wang WQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26604; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Yoo F, 2019, INT FORUM ALLERGY RH, V9, P1151, DOI 10.1002/alr.22391	49	27	29	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1306	1317		10.1016/j.jaci.2020.11.037	http://dx.doi.org/10.1016/j.jaci.2020.11.037		APR 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	33326802	Green Accepted			2022-12-18	WOS:000637368900020
J	Rosas-Salazar, C; Kimura, KS; Shilts, MH; Strickland, BA; Freeman, MH; Wessinger, BC; Gupta, V; Brown, HM; Rajagopala, SV; Turner, JH; Das, SR				Rosas-Salazar, Christian; Kimura, Kyle S.; Shilts, Meghan H.; Strickland, Britton A.; Freeman, Michael H.; Wessinger, Bronson C.; Gupta, Veerain; Brown, Hunter M.; Rajagopala, Seesandra V.; Turner, Justin H.; Das, Suman R.			SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						16S rRNA sequencing; coronavirus; COVID-19; microbiome; nasal; nasopharynx; respiratory; SARS-CoV-2	SYNCYTIAL VIRUS; SEQUENCE DATA; SEVERITY; TRANSCRIPTOME; COVID-19	Background: Little is known about the relationships between severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), the respiratory virus responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, and the upper respiratory tract (URT) microbiome. Objective: We sought to compare the URT microbiome between SARS-CoV-2-infected and -uninfected adults and to examine the association of SARS-CoV-2 viral load with the URT microbiome during COVID-19. Methods: We characterized the URT microbiome using 16S ribosomal RNA sequencing in 59 adults (38 with confirmed, symptomatic, mild to moderate COVID-19 and 21 asymptomatic, uninfected controls). In those with COVID-19, we measured SARS-CoV-2 viral load using quantitative reverse transcription PCR. We then examined the association of SARS-CoV-2 infection status and its viral load with the a-diversity, 13-diversity, and abundance of bacterial taxa of the URT microbiome. Our main models were all adjusted for age and sex. Results: The observed species index was significantly higher in SARS-CoV-2-infected than in -uninfected adults (beta linear regression coefficient = 7.53; 95% CI, 0.17-14.89; P = .045). In differential abundance testing, 9 amplicon sequence variants were significantly different in both of our comparisons, with Peptoniphilus lacrimalis, Campylobacter hominis, Prevotella 9 copri, and an Anaerococcus unclassified amplicon sequence variant being more abundant in those with SARS-CoV-2 infection and in those with high viral load during COVID-19, whereas Corynebacterium unclassified, Staphylococcus haemolyticus, Prevotella disiens, and 2 Corynebacterium_1 unclassified amplicon sequence variants were more abundant in those without SARS-CoV-2 infection and in those with low viral load during COVID-19. Conclusions: Our findings suggest complex associations between SARS-CoV-2 and the URT microbiome in adults. Future studies are needed to examine how these viral-bacterial interactions can impact the clinical progression, severity, and recovery of COVID-19.	[Rosas-Salazar, Christian] Vanderbilt Univ, Med Ctr, Div Allergy Immunol & Pulm Med, Dept Pediat, Nashville, TN 37235 USA; [Kimura, Kyle S.; Freeman, Michael H.; Turner, Justin H.; Das, Suman R.] Vanderbilt Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 1215 21st Ave South,Med Ctr East,Ste 7209, Nashville, TN 37235 USA; [Shilts, Meghan H.; Strickland, Britton A.; Brown, Hunter M.; Rajagopala, Seesandra V.; Das, Suman R.] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, 1161 21st Ave South,Med Ctr North,Ste A2200, Nashville, TN 37232 USA; [Strickland, Britton A.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Wessinger, Bronson C.; Gupta, Veerain] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Turner, JH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 1215 21st Ave South,Med Ctr East,Ste 7209, Nashville, TN 37235 USA.; Das, SR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, 1161 21st Ave South,Med Ctr North,Ste A2200, Nashville, TN 37232 USA.	justin.h.turner@vumc.org; suman.r.das@vumc.org	Rosas-Salazar, Christian/AAC-8571-2021	Rosas-Salazar, Christian/0000-0001-6644-5780; Brown, Hunter/0000-0002-2398-6031; Das, Suman/0000-0003-2496-9724	National Institute of Allergy and Infectious Diseases [R21AI142321, R21AI154016, R21AI149262]; National Heart, Lung, and Blood Institute [K23HL148638, R01HL146401]; Vanderbilt Technologies for Advanced Genomics Core (National Institutes of Health) [UL1RR024975, P30CA68485, P30EY08126, G20RR030956]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Vanderbilt Technologies for Advanced Genomics Core (National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by funds from the National Institute of Allergy and Infectious Diseases (under award nos. R21AI142321, R21AI154016, and R21AI149262); the National Heart, Lung, and Blood Institute (under award nos. K23HL148638 and R01HL146401); and the Vanderbilt Technologies for Advanced Genomics Core (grant support from the National Institutes of Health under award nos. UL1RR024975, P30CA68485, P30EY08126, and G20RR030956). The contents are solely the responsibility of the authors and do not necessarily represent official views of the funding agencies.	Anderson MJ, 2001, AUSTRAL ECOL, V26, P32, DOI 10.1046/j.1442-9993.2001.01070.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Davis NM, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0605-2; De Maio F, 2020, BIOL PROCED ONLINE, V22, DOI 10.1186/s12575-020-00131-7; E11. R Development Core Team, 2006, R LANG ENV STAT COMP; E2. World Health Organization, 2020, CLIN MAN COVID 19 IN; Ederveen THA, 2018, MICROBIOME, V6, DOI 10.1186/s40168-017-0395-y; Fan J, 2020, J INFECTION, V81, pE64, DOI 10.1016/j.jinf.2020.06.047; Gu S, 2020, CLIN INFECT DIS, V5; Hiremath G, 2019, CLIN TRANSL GASTROEN, V10, DOI 10.14309/ctg.0000000000000039; Jari Oksanen G.B., 2020, R PACKAGE VERSION; Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266; Kimura KS, 2020, INT FORUM ALLERGY RH, V10, P1325, DOI 10.1002/alr.22703; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046; Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Man WH, 2017, NAT REV MICROBIOL, V15, P259, DOI 10.1038/nrmicro.2017.14; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Pujadas E, 2020, LANCET RESP MED, V8, pE70, DOI 10.1016/S2213-2600(20)30354-4; Rosas-Salazar C, 2018, J ALLERGY CLIN IMMUN, V142, P1447, DOI 10.1016/j.jaci.2017.10.049; Rosas-Salazar C, 2016, J INFECT DIS, V214, P1924, DOI 10.1093/infdis/jiw456; Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203; Shilts MH, 2021, J ALLERGY CLIN IMMUN, V147, P1097, DOI 10.1016/j.jaci.2020.06.023; Singh K, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00066; Sonawane AR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50217-w; World Health Organization, 2020, CLIN MAN COVID 19; Younes M, 2019, EFSA J, V17, DOI 10.2903/j.efsa.2019.5674; Zhang HC, 2021, CLIN INFECT DIS, V73, P376, DOI 10.1093/cid/ciaa663	32	27	27	3	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1226	+		10.1016/j.jaci.2021.02.001	http://dx.doi.org/10.1016/j.jaci.2021.02.001		APR 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	33577896	Green Published, Bronze			2022-12-18	WOS:000637368900016
J	Delemarre, T; Holtappels, G; De Ruyck, N; Zhang, N; Nauwynck, H; Bachert, C; Gevaert, E				Delemarre, Tim; Holtappels, Gabriele; De Ruyck, Natalie; Zhang, Nan; Nauwynck, Hans; Bachert, Claus; Gevaert, Elien			A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CRSsNP; CRSwNP; type 2 inflammation; neutrophils; NETosis; IL-17; Charcot-Leyden crystals		Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is generally associated with severe type 2 immune reactions in the white population. However, recent findings suggest an additional role for neutrophils in severe type 2 inflammation. Objective: This study aimed to characterize the neutrophilic inflammation in CRSwNP and its relation to eosinophilic inflammation in severe type 2 immune reactions. Methods: The presence and activation of neutrophils and eosinophils was analyzed in CRS without NP and CRSwNP by measuring cell and activation markers via immunohistochemistry, immunofluorescence, Luminex assay, ELISA, UniCAP, fluorescence-activated cell sorting, and PCR. Differential neutrophil migration was assessed via Boyden-chamber assay and neutrophil survival was analyzed via flow cytometry. Results: Both CRS without NP and CRSwNP displayed variable degrees of eosinophilic and neutrophilic inflammation, with a profound neutrophilic infiltration and activation in type 2 CRSwNP, associated with eosinophil extracellular traps cell death and Charcot-Leyden crystals, but independent of IL-17. Neutrophil extracellular traps cell death in CRSwNP was associated with bacterial colonization, however, neutrophils were less prone to undergo neutrophil extracellular traps cell death in the tissue of patients with severe type 2 CRSwNP. Neutrophils did not show increased migration nor survival in the CRSwNP environment in vitro. Conclusions: This study demonstrated a severe neutrophilic inflammation associated with severe eosinophilic type 2 inflammatory CRSwNP, the role of which needs further study.	[Delemarre, Tim; Holtappels, Gabriele; De Ruyck, Natalie; Zhang, Nan; Bachert, Claus; Gevaert, Elien] Univ Ghent, Fac Med, Upper Airways Res Lab, Ghent, Belgium; [Nauwynck, Hans] Univ Ghent, Fac Vet Med, Lab Virol, Ghent, Belgium; [Nauwynck, Hans] Univ Ghent, Ghent, Belgium; [Bachert, Claus] Karolinska Inst, Dept Clin Sci Intervent & Technol, Div Ear Nose & Throat Dis, Stockholm, Sweden	Ghent University; Ghent University; Ghent University; Karolinska Institutet	Bachert, C (corresponding author), Univ Ghent, UZ Ghent, Dept Head & Skin, Upper Airways Res Lab, C Heymanslaan 10, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be	Bachert, Claus/J-8825-2012	Delemarre, Tim/0000-0001-5901-1618; Nauwynck, Hans/0000-0001-5470-0713	Fonds Wetenschappelijk Onderzoek (FWO) [FWO/DPO/108]; FWO Flanders [1515516N, EOS GOG2318N]; Interuniversity Attraction Poles Grant [P7/30]; Sanofi [A17/TT/1942, A19/TT/0828]	Fonds Wetenschappelijk Onderzoek (FWO)(FWO); FWO Flanders(FWO); Interuniversity Attraction Poles Grant; Sanofi	E.G. was supported by a post-doctoral research fellowship from the Fonds Wetenschappelijk Onderzoek (FWO) (FWO/DPO/108). C.B. and E.G. were supported by grants from FWO Flanders (1515516N, EOS GOG2318N), the Interuniversity Attraction Poles Grant P7/30, and Sanofi (A17/TT/1942, A19/TT/0828).	Ahern S, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55040095; Arebro J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43568; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Bachert C, 2018, J ALLERGY CLIN IMMUN, V141, P1543, DOI 10.1016/j.jaci.2018.03.004; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Calus L, 2019, CLIN TRANSL ALLERGY, V9, DOI 10.1186/s13601-019-0269-4; Chalermwatanachai T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136068; Clancy DM, 2017, FEBS J, V284, P1712, DOI 10.1111/febs.14075; Cope EK, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0266-6; de Loos DD, 2019, J ALLERGY CLIN IMMUN, V143, P1207, DOI 10.1016/j.jaci.2018.12.986; de Oliveira S, 2016, NAT REV IMMUNOL, V16, P378, DOI 10.1038/nri.2016.49; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Delemarre T, 2020, J ALLERGY CLIN IMMUN, V146, P337, DOI 10.1016/j.jaci.2020.04.040; Derycke L, 2012, J CYST FIBROS, V11, P193, DOI 10.1016/j.jcf.2011.11.007; Farrera C, 2013, J IMMUNOL, V191, P2647, DOI 10.4049/jimmunol.1300436; Gevaert E, 2020, J ALLERGY CLIN IMMUN, V145, P427, DOI 10.1016/j.jaci.2019.08.027; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Gray RD, 2018, THORAX, V73, P134, DOI 10.1136/thoraxjnl-2017-210134; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Huvenne W, 2010, ALLERGY, V65, P1013, DOI 10.1111/j.1398-9995.2009.02313.x; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Keeter WC, 2018, J IMMUNOL, V200; Khan A, 2019, RHINOLOGY, V57, P32, DOI 10.4193/Rhin17.255; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Martinelli S, 2004, J BIOL CHEM, V279, P44123, DOI 10.1074/jbc.M405883200; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Pauwels B, 2015, EXPERT REV CLIN IMMU, V11, P349, DOI 10.1586/1744666X.2015.1010517; Persson EK, 2019, SCIENCE, V364, P751, DOI 10.1126/science.aaw4295; Polzehl D, 2006, ALLERGY, V61, P1275, DOI 10.1111/j.1398-9995.2006.01132.x; Ray A, 2017, TRENDS IMMUNOL, V38, P942, DOI 10.1016/j.it.2017.07.003; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shi LL, 2013, ALLERGY, V68, P101, DOI 10.1111/all.12064; Silvestre-Roig C, 2016, BLOOD, V127, P2173, DOI 10.1182/blood-2016-01-688887; Soler ZM, 2010, OTOLARYNG HEAD NECK, V142, P64, DOI 10.1016/j.otohns.2009.10.005; Storisteanu DML, 2017, AM J RESP CELL MOL, V56, P423, DOI 10.1165/rcmb.2016-0193PS; Teufelberger AR, 2018, J ALLERGY CLIN IMMUN, V141, P549, DOI 10.1016/j.jaci.2017.05.004; Thammavongsa V, 2013, SCIENCE, V342, P863, DOI 10.1126/science.1242255; Tokunaga T, 2015, ALLERGY, V70, P995, DOI 10.1111/all.12644; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Toussaint M, 2017, NAT MED, V23, P681, DOI 10.1038/nm.4332; Ueki S, 2018, BLOOD, V132, P2183, DOI 10.1182/blood-2018-04-842260; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Van Zele T, 2014, AM J RHINOL ALLERGY, V28, P192, DOI 10.2500/ajra.2014.28.4033; Wang X, 2014, INFLAMMATION, V37, P871, DOI 10.1007/s10753-013-9807-8; Warnatsch A, 2017, IMMUNITY, V46, P421, DOI 10.1016/j.immuni.2017.02.013; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Zhang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093754	49	27	29	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					179	+		10.1016/j.jaci.2020.08.036	http://dx.doi.org/10.1016/j.jaci.2020.08.036		JAN 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32949587				2022-12-18	WOS:000613645900022
J	Sakihara, T; Otsuji, K; Arakaki, Y; Hamada, K; Sugiura, S; Ito, K				Sakihara, Tetsuhiro; Otsuji, Kenta; Arakaki, Yohei; Hamada, Kazuya; Sugiura, Shiro; Ito, Komei			Randomized trial of early infant formula introduction to prevent cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; milk allergy; early introduction; prevention; cow's milk; randomized controlled trial; birth cohort; infant formula; cow's milk formula; soy formula		Background: Previous research has produced conflicting evidence on the preventive effects of early introduction of cow's milk protein on cow's milk allergy (CMA). Objective: Through a randomized controlled trial, we sought to determine whether the early introduction of cow's milk formula (CMF) could serve as an effective strategy in the primary prevention of CMA in a general population. Methods: We recruited newborns from 4 hospitals in Okinawa, Japan. Participants were randomly allocated to ingest at least10 mL of CMF daily (ingestion group) or avoid CMF (avoidance group) between 1 and 2 months of age. In the avoidance group breast-feeding was supplemented with soy formula as needed. Oral food challenge was performed at 6 months of age to assess CMA development. Continuous breast-feeding was recommended for both groups until 6 months of age Results: We identified 504 infants for randomization into the 2 groups. In all, the parents of 12 participants declined to receive the intervention, and the study sample comprised 491 participants (242 in the ingestion group and 249 in the avoidance group) for a modified intention-to-treat analysis. There were 2 CMA cases (0.8 %) among the 242 members of the ingestion group and 17 CMA cases (6.8 %) among the 249 participants in the avoidance group (risk ratio = 0.12; 95% CI = 0.01-0.50; P < .001). The risk difference was 6.0% (95% CI = 2.7-9.3). Approximately 70% of the participants in both groups were still being breast-fed at 6 months of age. Conclusions: Daily ingestion of CMF between 1 and 2 months of age prevents CMA development. This strategy does not compete with breast-feeding.	[Sakihara, Tetsuhiro] Heartlife Hosp, Dept Pediat, Nakagusuku, Okinawa, Japan; [Otsuji, Kenta] Okinawa Kyodo Hosp, Dept Pediat, Naha, Okinawa, Japan; [Arakaki, Yohei] Naha City Hosp, Dept Pediat, Naha, Okinawa, Japan; [Hamada, Kazuya] Univ Ryukyus, Grad Sch Med, Dept Child Hlth & Welf Pediat, Nishihara, Okinawa, Japan; [Sugiura, Shiro; Ito, Komei] Aichi Childrens Hlth & Med Ctr, Dept Allergy, Obu, Aichi, Japan	University of the Ryukyus	Sakihara, T (corresponding author), Heartlife Hosp, 208 Iju, Nakagami, Okinawa 9012492, Japan.	odekorin2000@yahoo.co.jp		Sakihara, Tetsuhiro/0000-0001-8002-5993				Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; de Silva D, 2020, PEDIAT ALLERG IMM-UK, V31, P813, DOI 10.1111/pai.13273; Ebisawa M, 2017, ALLERGOL INT, V66, P248, DOI 10.1016/j.alit.2017.02.001; Elizur A, 2012, J PEDIATR-US, V161, P482, DOI 10.1016/j.jpeds.2012.02.028; Feehley T, 2019, NAT MED, V25, P448, DOI 10.1038/s41591-018-0324-z; Fiocchi A, 2010, PEDIAT ALLERG IMM-UK, V21, P1, DOI [10.1111/j.1399-3038.2010.01068.x, 10.1097/WOX.0b013e3181defeb9]; Ierodiakonou D, 2016, JAMA-J AM MED ASSOC, V316, P1181, DOI 10.1001/jama.2016.12623; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Lowe AJ, 2011, J ALLERGY CLIN IMMUN, V128, P360, DOI 10.1016/j.jaci.2010.05.006; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Peters RL, 2019, J ALLER CL IMM-PRACT, V7, P462, DOI 10.1016/j.jaip.2018.08.038; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Sakihara T, 2016, ASIA PAC ALLERGY, V6, P207, DOI 10.5415/apallergy.2016.6.4.207; Santos A, 2010, PEDIAT ALLERG IMM-UK, V21, P1127, DOI 10.1111/j.1399-3038.2010.01040.x; Schoemaker AA, 2015, ALLERGY, V70, P963, DOI 10.1111/all.12630; The Okinawa Society of Child Health, 2018, REP HLTH CHECK INF T; Urashima M, 2019, JAMA PEDIATR, V173, P1137, DOI 10.1001/jamapediatrics.2019.3544; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060	20	27	28	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					224	+		10.1016/j.jaci.2020.08.021	http://dx.doi.org/10.1016/j.jaci.2020.08.021		JAN 2021	17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32890574	Bronze			2022-12-18	WOS:000613645900026
J	Freyer, CW; Porter, DL				Freyer, Craig W.; Porter, David L.			Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chimeric antigen receptor; cytokine release syndrome; immune effector cell-associated neurotoxicity syndrome; tocilizumab; tisagenlecleucel; axicabtagene ciloleucel	ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL; TOCILIZUMAB; BIOMARKERS; MANAGEMENT; CHILDREN; SURVIVAL; ADULTS	Chimeric antigen receptor T cells are a new and exciting immunotherapeutic approach to managing cancer, with impressive efficacy but potentially life-threatening inflammatory toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Patients with severe CRS may develop capillary leak syndrome and disseminated intravascular coagulation, with a cytokine signature similar to that of macrophage activation syndrome/hemophagocytic lymphohistiocytosis. Moderate-to-severe CRS is managed with the IL-6 receptor antagonist tocilizumab with or without corticosteroids, with questions remaining regarding the optimal management of nonresponders. ICANS is an inflammatory neurotoxicity typically occurring after CRS and characterized by impaired blood-brain barrier integrity. Symptoms of encephalopathy range from mild confusion and aphasia to somnolence, obtundation, and in some cases seizures and cerebral edema. ICANS is currently managed with corticosteroids; however, the optimal dose and duration remain to be determined. Little information is available to guide the management of patients with steroid-refractory ICANS. Numerous cytokine-targeted therapies have been proposed to manage these inflammatory toxicities, but few clinical data are available. Management of inflammatory toxicities of chimeric antigen receptor T cells often requires multidisciplinary management and intensive care, during which allergists and immunologists may encounter patients with these unique toxicities.	[Freyer, Craig W.] Hosp Univ Penn, Dept Pharm, 3400 Spruce St, Philadelphia, PA 19104 USA; [Porter, David L.] Hosp Univ Penn, Div Cellular Therapy & Stem Cell Transplant, Philadelphia, PA 19104 USA; [Porter, David L.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Freyer, CW (corresponding author), Hosp Univ Penn, Dept Pharm, 3400 Spruce St, Philadelphia, PA 19104 USA.	Craig.Freyer@pennmedicine.upenn.edu						Ahmed A, 2019, LANCET HAEMATOL, V6, pE630, DOI 10.1016/S2352-3026(19)30156-5; Ahmed N, 2020, BIOL BLOOD MARROW TR, V26, pS275; Alvi RM, 2019, J AM COLL CARDIOL, V74, P3099, DOI 10.1016/j.jacc.2019.10.038; [Anonymous], 2019, ACTEMRA PRESCRIBING; [Anonymous], 2019, **NON-TRADITIONAL**; [Anonymous], 2019, KYMRIAH; Brudno JN, 2020, NAT MED, V26, P270, DOI 10.1038/s41591-019-0737-3; Buechner J, 2017, BLOOD, V130, P1276; Cox MJ, 2020, BIOL BLOOD MARROW TR, V26, pS60; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; DeAngelo DJ, 2017, J IMMUNOTHER CANCER, V5; Fesnak AD, 2016, NAT REV CANCER, V16, P566, DOI 10.1038/nrc.2016.97; Fitzgerald JC, 2017, CRIT CARE MED, V45, pE124, DOI 10.1097/CCM.0000000000002053; Frey Noelle, 2019, Biol Blood Marrow Transplant, V25, pe123, DOI 10.1016/j.bbmt.2018.12.756; Frey NV, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.01892; Frey NV, 2016, AM J HEMATOL, V91, P146, DOI 10.1002/ajh.24238; Fried S, 2019, BONE MARROW TRANSPL, V54, P1643, DOI 10.1038/s41409-019-0487-3; Gardner RA, 2019, BLOOD, V134, P2149, DOI 10.1182/blood.2019001463; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; Gill S, 2016, BLOOD REV, V30, P157, DOI 10.1016/j.blre.2015.10.003; Gofshteyn JS, 2018, ANN NEUROL, V84, P537, DOI 10.1002/ana.25315; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Hay KA, 2018, BRIT J HAEMATOL, V183, P364, DOI 10.1111/bjh.15644; Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141; Hill JA, 2018, BLOOD, V131, P121, DOI 10.1182/blood-2017-07-793760; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Jiang HW, 2019, ANN HEMATOL, V98, P1721, DOI 10.1007/s00277-019-03685-z; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Karschnia P, 2019, BLOOD, V133, P2212, DOI 10.1182/blood-2018-12-893396; Kenderian SS, 2017, BIOL BLOOD MARROW TR, V23, P235, DOI 10.1016/j.bbmt.2016.09.002; Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Liu SY, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123051; Locke FL, 2017, BLOOD, V130; Loren AW, 2008, BONE MARROW TRANSPL, V41, P483, DOI 10.1038/sj.bmt.1705898; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Mestermann K, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5907; Myers RM, 2020, BIOL BLOOD MARROW TR, V26, pS39; National Comprehensive Cancer Network, MANAGEMENT IMMUNOTHE; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, DOI 10.1038/nrclinonc.2018.20; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Nguyen K, 2008, LEUKEMIA, V22, P2142, DOI 10.1038/leu.2008.251; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Park JH, 2020, BIOL BLOOD MARROW TR, V26, pS269; Park JH, 2018, CLIN INFECT DIS, V67, P533, DOI 10.1093/cid/ciy152; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Porter D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0571-y; Porter DL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5415; Ruark J, 2020, BIOL BLOOD MARROW TR, V26, P34, DOI 10.1016/j.bbmt.2019.09.037; Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Singh N, 2017, CYTOTHERAPY, V19, P867, DOI 10.1016/j.jcyt.2017.04.001; Sterner RM, 2019, BLOOD, V133, P697, DOI 10.1182/blood-2018-10-881722; Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040; Topp MS, 2020, BIOL BLOOD MARROW TR, V26, pS101; Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309; US Department of Health and Human Services, COMMON TERMINOLOGY C; Weber EW, 2019, BLOOD ADV, V3, P711, DOI 10.1182/bloodadvances.2018028720; Witzens-Harig M, 2014, ANN HEMATOL, V93, P1717, DOI 10.1007/s00277-014-2103-3; Zugmaier G, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.64	65	27	29	5	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2020	146	5					940	948		10.1016/j.jaci.2020.07.025	http://dx.doi.org/10.1016/j.jaci.2020.07.025			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OP5VH	32771558	Bronze			2022-12-18	WOS:000588153700030
J	Hemmings, O; Du Toit, G; Radulovic, S; Lack, G; Santos, AF				Hemmings, Oliver; Du Toit, George; Radulovic, Suzana; Lack, Gideon; Santos, Alexandra F.			Ara h 2 is the dominant peanut allergen despite similarities with Ara h 6	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ara h 2; Ara h 6; specific IgE; mast cell activation test; ImmunoCAP inhibition; peanut allergy; cross-reactivity	ORAL IMMUNOTHERAPY; IGE; CHILDREN; ACTIVATION; BASOPHIL; SENSITIZATION; PREVALENCE; PREDICTORS; REACTIVITY; TOLERANCE	Background: Arachis hypogaea 2 (Ara h 2)-specific IgE is to date the best serologic marker to diagnose peanut allergy. Ara h 6 shares approximately 60% sequence identity and multiple epitopes with Ara h 2. Objective: Our aim was to assess the diagnostic utility and relative importance of Ara h 2 and Ara h 6 in peanut allergy. Methods: A cohort 100 of children was studied. The cohort included chidren who had peanut allergy, children who were sensitized to but tolerant of peanut, and children who were neither sensitized nor allergic to peanut. Levels of specific IgE to peanut and individual allergens were quantified by using ImmunoCAP. ImmunoCAP inhibition experiments and mast cell activation tests in response to both Ara h 2 and Ara h 6 were performed. Statistical analyses were done using SPSS version 14 and Prism version 7 software. Results: Ara h 2-specific IgE and Ara h 6-specific IgE showed the greatest diagnostic accuracy for peanut allergy when compared with specific IgE to peanut and other peanut allergens. Most patients with peanut allergy were sensitized to both Ara h 2 and Ara h 6. Ara h 2 reduced Ara h 2-specific IgE binding more than Ara h 6 did (P < .001), whereas Ara h 6-specific IgE binding was inhibited to a similar degree by Ara h 2 and Ara h 6 (P = .432). In the mast cell activation test, Ara h 2 induced significantly greater maximal reactivity (P = .001) and a lower half maximal effective concentration (P = .002) than did Ara h 6 when testing cosensitized individuals. Conclusions: Ara h 2-specific IgE and Ara h 6-specific IgE provide the greatest accuracy to diagnose peanut allergy. Ara h 2 is the dominant conglutin in peanut allergy in the United Kingdom, despite a degree of cross-reactivity with Ara h 6.	[Hemmings, Oliver; Du Toit, George; Radulovic, Suzana; Lack, Gideon; Santos, Alexandra F.] Kings Coll London, Dept Women & Childrens Hlth Pediat Allergy, Sch Life Course Sci, Fac Life Sci & Med, London, England; [Hemmings, Oliver; Du Toit, George; Radulovic, Suzana; Lack, Gideon; Santos, Alexandra F.] Kings Coll London, Peter Gorer Dept Immunobiol, Sch Immunol & Microbial Sci, Fac Life Sci & Med, London, England; [Hemmings, Oliver; Lack, Gideon; Santos, Alexandra F.] Asthma UK Ctr Allerg Mech Asthma, London, England; [Du Toit, George; Radulovic, Suzana; Lack, Gideon; Santos, Alexandra F.] Guys & St Thomas Hosp, Evelina London Childrens Hosp, Childrens Allergy Serv, London, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Santos, AF (corresponding author), St Thomas Hosp, Dept Paediat Allergy, 2nd Floor,South Wing, London SE1 7EH, England.	alexandra.santos@kcl.ac.uk		Hemmings, Oliver/0000-0001-7452-2723; Santos, Alexandra/0000-0002-7805-1436	Medical Research Council (Medical Research Council Clinician Scientist Fellowship) [MR/M008517/1]; Asthma UK [AUK-BC-2015-01]; Department of Health via the National Institute for Health Research Comprehensive Biomedical Research Centre Award; King's College London; King's College Hospital NHS Foundation Trust; MRC [G0902018, MR/M008517/1] Funding Source: UKRI	Medical Research Council (Medical Research Council Clinician Scientist Fellowship); Asthma UK; Department of Health via the National Institute for Health Research Comprehensive Biomedical Research Centre Award; King's College London; King's College Hospital NHS Foundation Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Medical Research Council (Medical Research Council Clinician Scientist Fellowship MR/M008517/1), Asthma UK (grant AUK-BC-2015-01), and the Department of Health via the National Institute for Health Research Comprehensive Biomedical Research Centre Award to Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.	Amoah AS, 2013, J ALLERGY CLIN IMMUN, V132, P639, DOI 10.1016/j.jaci.2013.04.023; Ben-Shoshan M, 2010, J ALLERGY CLIN IMMUN, V125, P1327, DOI 10.1016/j.jaci.2010.03.015; Bernard H, 2015, J ALLERGY CLIN IMMUN, V135, P1267, DOI 10.1016/j.jaci.2014.10.025; Blanc F, 2009, CLIN EXP ALLERGY, V39, P1277, DOI 10.1111/j.1365-2222.2009.03294.x; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Burk CM, 2016, CLIN EXP ALLERGY, V46, P347, DOI 10.1111/cea.12635; Chen X, 2016, CLIN EXP ALLERGY, V46, P1120, DOI 10.1111/cea.12764; Chen XN, 2013, INT ARCH ALLERGY IMM, V160, P251, DOI 10.1159/000341642; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hazebrouck S, 2019, CLIN EXP ALLERGY, V49, P1107, DOI 10.1111/cea.13432; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Klemans RJB, 2013, CLIN EXP ALLERGY, V43, P967, DOI 10.1111/cea.12136; Klemans RJB, 2013, J ALLER CL IMM-PRACT, V1, P632, DOI 10.1016/j.jaip.2013.07.014; Koid AE, 2014, J AGR FOOD CHEM, V62, P206, DOI 10.1021/jf4022509; Koppelman SJ, 2005, CLIN EXP ALLERGY, V35, P490, DOI 10.1111/j.1365-2222.2005.02204.x; Koppelman SJ, 2016, FOOD CHEM TOXICOL, V91, P82, DOI 10.1016/j.fct.2016.02.016; Kukkonen AK, 2015, ALLERGY, V70, P1239, DOI 10.1111/all.12671; Kulis M, 2012, CLIN EXP ALLERGY, V42, P326, DOI 10.1111/j.1365-2222.2011.03934.x; Lehmann K, 2006, BIOCHEM J, V395, P463, DOI 10.1042/BJ20051728; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Porterfield HS, 2009, CLIN EXP ALLERGY, V39, P1099, DOI 10.1111/j.1365-2222.2009.03273.x; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Santos AF, 2020, ALLERGY, V75, P2309, DOI 10.1111/all.14301; Santos AF, 2018, J ALLERGY CLIN IMMUN, V142, P689, DOI 10.1016/j.jaci.2018.03.011; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Santos AF, 2014, J ALLERGY CLIN IMMUN, V134, P645, DOI 10.1016/j.jaci.2014.04.039; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Uotila R, 2019, PEDIAT ALLERG IMM-UK, V30, P248, DOI 10.1111/pai.13012; Uotila R, 2017, J ALLERGY CLIN IMMUN, V139, P1393, DOI 10.1016/j.jaci.2016.09.054; van der Valk JPM, 2016, EUR J PEDIATR, V175, P1227, DOI 10.1007/s00431-016-2733-7; van Erp FC, 2017, J ALLERGY CLIN IMMUN, V139, P358, DOI 10.1016/j.jaci.2016.06.041; Vickery BP, 2017, J ALLERGY CLIN IMMUN, V139, P173, DOI 10.1016/j.jaci.2016.05.027; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048	37	27	27	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2020	146	3					621	+		10.1016/j.jaci.2020.03.026	http://dx.doi.org/10.1016/j.jaci.2020.03.026			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NO0HS	32298698	Green Published, hybrid			2022-12-18	WOS:000569168900015
J	Howarth, P; Chupp, G; Nelsen, LM; Bradford, ES; Bratton, DJ; Smith, SG; Albers, FC; Brusselle, G; Bachert, C				Howarth, Peter; Chupp, Geoffrey; Nelsen, Linda M.; Bradford, Eric S.; Bratton, Daniel J.; Smith, Steven G.; Albers, Frank C.; Brusselle, Guy; Bachert, Claus			Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Howarth, Peter] Global Specialty & Primary Care, Global Med, Brentford, Middx, England; [Chupp, Geoffrey] Yale Sch Med, Yale Ctr Asthma & Airways Dis YCAAD, New Haven, CT USA; [Nelsen, Linda M.] GSK, Value Evidence & Outcomes, Collegeville, PA USA; [Bradford, Eric S.; Smith, Steven G.] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA; [Bratton, Daniel J.] GSK, Clin Stat, Uxbridge, Middx, England; [Albers, Frank C.] GSK, Resp Med Franchise, Res Triangle Pk, NC USA; [Brusselle, Guy] Univ Hosp Ghent, Dept Resp Med, Ghent, Belgium; [Bachert, Claus] Univ Hosp Ghent, Upper Airways Res Lab, Ghent, Belgium; [Albers, Frank C.] Avillion US Inc, Med Dept, Northbrook, IL USA	Yale University; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Howarth, P (corresponding author), Global Specialty & Primary Care, Global Med, Brentford, Middx, England.	peter.h.howarth@gsk.com	Nelsen, Linda/GZL-1004-2022; Smith, Steven/HDM-9496-2022; Bachert, Claus/J-8825-2012	Brusselle, Guy/0000-0001-7021-8505; Howarth, Peter/0000-0003-0619-7927	GlaxoSmithKline (GSK) [208115, MEA115588/NCT01691521, 200862/NCT02281318]	GlaxoSmithKline (GSK)(GlaxoSmithKline)	This post hoc meta-analysis (GSK ID 208115) and the parent studies (MENSA, GSK ID MEA115588/NCT01691521; MUSCA, GSK ID 200862/NCT02281318) were funded by GlaxoSmithKline (GSK).	Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Bleecker ER, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00936-2018; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290	8	27	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1713	+		10.1016/j.jaci.2020.02.002	http://dx.doi.org/10.1016/j.jaci.2020.02.002			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32084443	Bronze			2022-12-18	WOS:000539157800034
J	Satia, I; Watson, R; Scime, T; Dockry, RJ; Sen, S; Ford, JW; Mitchell, PD; Fowler, SJ; Gauvreau, GM; O'Byrne, PM; Smith, JA				Satia, Imran; Watson, Richard; Scime, Tara; Dockry, Rachel J.; Sen, Shilpi; Ford, James W.; Mitchell, Patrick D.; Fowler, Stephen J.; Gauvreau, Gail M.; O'Byrne, Paul M.; Smith, Jaclyn A.			Allergen challenge increases capsaicin-evoked cough responses in patients with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergen; capsaicin; cough; transient receptor potential vanilloid type 1	NERVE GROWTH-FACTOR; INHALED CORTICOSTEROIDS; NEUROTROPHIC FACTOR; CLUSTER-ANALYSIS; AIRWAY; ADULTS; BRONCHOCONSTRICTION; BRONCHOPROVOCATION; INFLAMMATION; SENSITIVITY	Background: Cough is a common and troublesome symptom in asthmatic patients, but little is known about the neuronal pathways that trigger cough. The mechanisms by which airway inflammation, airway hyperresponsiveness, and variable airflow obstruction cause cough are unclear. Objective: We sought to investigate the effects of allergen exposure on cough reflex sensitivity. Methods: We performed a 9-visit, randomized, single-blind, placebo-controlled, 2-way crossover study comparing cough responses to inhaled capsaicin in patients with mild atopic asthma after allergen challenge compared with diluent control. Full-dose capsaicin challenge was performed at screening to determine the capsaicin dose inducing a half-maximal response, which was subsequently administered at 30 minutes and 24 hours after inhaled allergen/diluent challenge. Spontaneous coughing was measured for 24 hours after allergen/diluent. Methacholine challenge and sputum induction were performed before and after allergen/diluent challenge. Results: Twelve steroid-naive subjects completed the study (6 female subjects; mean age, 34.8 years). Allergen inhalation caused both an early (mean +/- SD, 38.2% +/- 13.0%) and late (mean +/- SD, 23.7% +/- 13.2%) decrease in FEV1 and an increase in sputum eosinophil counts 24 hours later (after diluent: median, 1.9% left perpendicularinterquartile range, 0.8% to 5.8%right perpendicular; after allergen: median, 14.9% [interquartile range, 8.9% to 37.3%]; P =.005). There was also an increase in capsaicin-evoked coughs after allergen exposure compared with diluent at both 30 minutes (geometric mean coughs, 21.9 [95% CI, 16.5-29.20] vs 12.1 [95% CI, 8.3-17.7]; P <.001) and 24 hours (geometric mean coughs, 16.1 [95% CI, 11.3-23.0] vs 9.8 [95% CI, 6.1-15.8]; P =.001). Allergen exposure was also associated with an increase in spontaneous coughs over 24 hours. Conclusion: Allergen-induced bronchoconstriction and airway eosinophilia result in increased cough reflex sensitivity to capsaicin associated with an increase in 24-hour spontaneous coughing.	[Satia, Imran; Watson, Richard; Scime, Tara; Gauvreau, Gail M.; O'Byrne, Paul M.] McMaster Univ, Div Respirol, Dept Med, Hamilton, ON, Canada; [Satia, Imran; Dockry, Rachel J.; Sen, Shilpi; Ford, James W.; Fowler, Stephen J.; O'Byrne, Paul M.; Smith, Jaclyn A.] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Satia, Imran; Dockry, Rachel J.; Sen, Shilpi; Ford, James W.; Fowler, Stephen J.; O'Byrne, Paul M.; Smith, Jaclyn A.] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England; [Dockry, Rachel J.; Sen, Shilpi; Ford, James W.; Fowler, Stephen J.; Smith, Jaclyn A.] Univ Manchester, NHS Fdn Trust, Manchester, Lancs, England; [Mitchell, Patrick D.] Univ Calgary, Dept Med, Calgary, AB, Canada	McMaster University; University of Manchester; University of Manchester; Oxford University Hospitals NHS Foundation Trust; University of Manchester; University of Calgary	Smith, JA (corresponding author), Univ Manchester, Univ Hosp South Manchester, Educ & Res Ctr, Div Infect Immun & Resp Med, Level 2, Manchester M23 9LT, Lancs, England.	jacky.smith@manchester.ac.ak	Satia, Imran/ABA-2872-2020	Satia, Imran/0000-0003-4206-6000; Fowler, Stephen/0000-0002-4524-1663; Mitchell, Patrick/0000-0001-5705-9618; Smith, Jaclyn/0000-0001-8837-4928; Dockry, Rachel/0000-0002-0908-3362; O'Byrne, Paul/0000-0003-0979-281X	British Medical Association James Trust Award; European Respiratory Society/European Union Marie Curie Award; MRC [MR/K015141/1] Funding Source: UKRI	British Medical Association James Trust Award; European Respiratory Society/European Union Marie Curie Award; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by the British Medical Association James Trust Award. I.S. is funded by a fellowship from the European Respiratory Society/European Union Marie Curie Award.	Bleecker ER, 2016, LANCET, V388, P2115, DOI 10.1016/S0140-6736(16)31324-1; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Cockcroft DW, 2007, CAN RESPIR J, V14, P414, DOI 10.1155/2007/753450; Cockcroft DW, 2005, ALLERGY, V60, P56, DOI 10.1111/j.1398-9995.2004.00612.x; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Di Franco A, 2001, PULM PHARMACOL THER, V14, P35, DOI 10.1006/pupt.2000.0264; Diamant Z, 2013, J ALLERGY CLIN IMMUN, V132, P1045, DOI 10.1016/j.jaci.2013.08.023; Gauvreau GM, 2015, EUR RESPIR J, V46, DOI [10.1183/13993003.congress-2015.PA5091, 10.1183/13993003.00536-2015]; Gonzalez EJ, 2016, J PHYSIOL-LONDON, V594, P3575, DOI 10.1113/JP272148; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hilton ECY, 2013, J ALLERGY CLIN IMMUN, V132, P847, DOI 10.1016/j.jaci.2013.04.042; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; Lieu TM, 2012, AM J PHYSIOL-LUNG C, V302, pL941, DOI 10.1152/ajplung.00366.2011; Maher SA, 2015, EUR RESPIR J, V45, P1108, DOI 10.1183/09031936.00061614; Maher SA, 2009, AM J RESP CRIT CARE, V180, P923, DOI 10.1164/rccm.200903-0388OC; Manfreda J, 2001, CAN MED ASSOC J, V164, P995; Marsden PA, 2016, CHEST, V149, P1460, DOI 10.1016/j.chest.2016.02.676; Mincheva R, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-79; Minoguchi H, 2003, THORAX, V58, P19, DOI 10.1136/thorax.58.1.19; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Osman LM, 2001, THORAX, V56, P138, DOI 10.1136/thorax.56.2.138; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Raemdonck K, 2012, THORAX, V67, P19, DOI 10.1136/thoraxjnl-2011-200365; Satia I, 2017, THORAX, V72, P1144, DOI 10.1136/thoraxjnl-2016-209625; Satia I, 2017, J ALLERGY CLIN IMMUN, V139, P771, DOI 10.1016/j.jaci.2016.04.045; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002, DOI 10.1164/ajrccm.158.6.9803023; Watanabe T, 2015, AM J RESP CELL MOL, V53, P844, DOI 10.1165/rcmb.2015-0015OC; Weigand LA, 2012, J PHYSIOL-LONDON, V590, P4109, DOI 10.1113/jphysiol.2012.233460; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5	33	27	27	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2019	144	3					788	+		10.1016/j.jaci.2018.11.050	http://dx.doi.org/10.1016/j.jaci.2018.11.050			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IW8CV	30660644	Bronze, Green Submitted			2022-12-18	WOS:000485222300023
J	Lupinek, C; Hochwallner, H; Johansson, C; Mie, A; Rigler, E; Scheynius, A; Alm, J; Valenta, R				Lupinek, Christian; Hochwallner, Heidrun; Johansson, Catharina; Mie, Axel; Rigler, Eva; Scheynius, Annika; Alm, Johan; Valenta, Rudolf			Maternal allergen-specific IgG might protect the child against allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen; allergen-specific IgG; birth cohort; breast milk; cord blood; maternal IgG; microarrayed allergens; recombinant allergen; sensitization	POLLEN ALLERGEN; BLOCKING ANTIBODIES; RESPIRATORY ALLERGY; PREDICTIVE-VALUE; CELL EPITOPE; LIFE-STYLE; IMMUNOTHERAPY; IMMUNIZATION; MECHANISMS; MICROARRAY	Background: Analysis of allergen-specific IgE responses in birth cohorts with microarrayed allergens has provided detailed information regarding the evolution of specific IgE responses in children. High-resolution data regarding early development of allergen-specific IgG are needed. Objective: We sought to analyze IgG reactivity to microarrayed allergens in mothers during pregnancy, in cord blood samples, in breast milk, and in infants in the first years of life with the aim to investigate whether maternal allergen-specific IgG can protect against IgE sensitization in the offspring. Methods: Plasma samples from mothers during the third trimester, cord blood, breast milk collected 2 months after delivery, and plasma samples from children at 6, 12, and 60 months of age were analyzed for IgG reactivity to 164 microarrayed allergens (ImmunoCAP ISAC technology) in 99 families of the Swedish birth cohort Assessment of Lifestyle and Allergic Disease During Infancy (ALADDIN). IgE sensitizations to microarrayed allergens were determined at 5 years of age in the children. Results: Allergen-specific IgG reactivity profiles in mothers, cord blood, and breast milk were highly correlated. Maternal allergen-specific IgG persisted in some children at 6 months. Children's allergen-specific IgG production occurred at 6 months and reflected allergen exposure. Children who were IgE sensitized against an allergen at 5 years of age had significantly higher allergen-specific IgG levels than nonsensitized children. For all 164 tested allergens, children from mothers with increased (>30 ISAC standardized units) specific plasma IgG levels against an allergen had no IgE sensitizations against that allergen at 5 years of age. Conclusion: This is the first detailed analysis of the molecular IgG recognition profile in mothers and their children in early life. High allergen-specific IgG reactivity in the mother's plasma and breast milk and in cord blood seemed to protect against allergic sensitization at 5 years of age.	[Lupinek, Christian; Hochwallner, Heidrun; Rigler, Eva; Valenta, Rudolf] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria; [Johansson, Catharina; Mie, Axel; Scheynius, Annika; Alm, Johan] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden; [Scheynius, Annika; Alm, Johan] Karolinska Inst, Sodersjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden; [Valenta, Rudolf] FMBA Russia, NRC Inst Immunol, Moscow, Russia; [Valenta, Rudolf] Sechenov First Moscow State Med Univ, Dept Clin Immunol & Allergy, Lab Immunopathol, Moscow, Russia	Medical University of Vienna; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; NRC Institute of Immunology FMBA of Russia; Sechenov First Moscow State Medical University	Valenta, R (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Rudolf.valenta@meduniwien.ac.at	Lupinek, Christian/I-3311-2019	Lupinek, Christian/0000-0002-8612-8245; Valenta, Rudolf/0000-0001-5944-3365; Mie, Axel/0000-0001-8053-3541	Austrian Science Fund (FWF) [F4605, P25921-B21]; Swedish Medical Research Council; Centre for Allergy Research Karolinska Institutet; Stockholm County Council; Karolinska Institutet; Karolinska University Hospital, Phadia AB; Swedish Asthma and Allergy Research Association; Swedish Research Council for Working Life and Social Research; Cancer and Allergy Fund; "Mjolkdroppen'' Society; Ekhaga Foundation; "Frimurare Barnhuset'' in Stockholm Foundation; Hesselman Foundation, Sweden; Megagrant of the Government of the Russian Federation [14.W03.31.0024]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Centre for Allergy Research Karolinska Institutet(Karolinska Institutet); Stockholm County Council(Stockholm County Council); Karolinska Institutet(Karolinska Institutet); Karolinska University Hospital, Phadia AB(Karolinska Institutet); Swedish Asthma and Allergy Research Association; Swedish Research Council for Working Life and Social Research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Cancer and Allergy Fund; "Mjolkdroppen'' Society; Ekhaga Foundation; "Frimurare Barnhuset'' in Stockholm Foundation; Hesselman Foundation, Sweden; Megagrant of the Government of the Russian Federation	Supported by research grants from the Austrian Science Fund (FWF) projects F4605 and P25921-B21, the Swedish Medical Research Council, the Centre for Allergy Research Karolinska Institutet, the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institutet and the Karolinska University Hospital, Phadia AB, the Swedish Asthma and Allergy Research Association, the Swedish Research Council for Working Life and Social Research, the Cancer and Allergy Fund, the "Mjolkdroppen'' Society, the Ekhaga Foundation, the "Frimurare Barnhuset'' in Stockholm Foundation, and the Hesselman Foundation, Sweden. R.V. is recipient of a Megagrant of the Government of the Russian Federation (grant no. 14.W03.31.0024) and is foreign adjunct Professor for Allergy at the Karolinska Institutet, Stockholm, Sweden.	ANSARI AA, 1989, HUM IMMUNOL, V25, P59, DOI 10.1016/0198-8859(89)90070-0; Anto JM, 2017, J ALLERGY CLIN IMMUN, V139, P388, DOI 10.1016/j.jaci.2016.12.940; Asarnoj A, 2016, J ALLERGY CLIN IMMUN, V137, P813, DOI 10.1016/j.jaci.2015.09.052; Burton OT, 2018, J ALLERGY CLIN IMMUN, V141, P189, DOI 10.1016/j.jaci.2017.03.045; Chiu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102809; Cornelius C, 2016, EBIOMEDICINE, V11, P58, DOI 10.1016/j.ebiom.2016.07.023; Curin M, 2014, J ALLERGY CLIN IMMUN, V133, P918, DOI 10.1016/j.jaci.2013.10.058; Demoly P, 2003, DRUGS, V63, P1813, DOI 10.2165/00003495-200363170-00004; Fagerstedt S, 2016, J ALLERGY CLIN IMMUN, V137, P1253, DOI 10.1016/j.jaci.2015.11.009; Fedenko E, 2016, PEDIAT ALLERG IMM-UK, V27, P645, DOI 10.1111/pai.12572; Flicker S, 2013, IMMUNOBIOLOGY, V218, P884, DOI 10.1016/j.imbio.2012.10.008; Flicker S, 2009, J ALLERGY CLIN IMMUN, V124, P1358, DOI 10.1016/j.jaci.2009.09.024; Freidl R, 2017, J ALLERGY CLIN IMMUN, V139, P1897, DOI 10.1016/j.jaci.2016.10.018; GLOVSKY MM, 1991, ANN ALLERGY, V67, P21; Hales BJ, 2006, J ALLERGY CLIN IMMUN, V118, P361, DOI 10.1016/j.jaci.2006.04.001; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Hochwallner H, 2014, J ALLERGY CLIN IMMUN, V134, P1213, DOI 10.1016/j.jaci.2014.08.041; Huang X, 2018, ALLERGY, V73, P421, DOI 10.1111/all.13269; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Linhart B, 2014, CLIN EXP ALLERGY, V44, P278, DOI 10.1111/cea.12216; Lupinek Christian, 2016, Curr Treat Options Allergy, V3, P189; Lupinek C, 2014, METHODS, V66, P106, DOI 10.1016/j.ymeth.2013.10.008; Lupinek C, 2012, J ALLERGY CLIN IMMUN, V130, P1418, DOI 10.1016/j.jaci.2012.06.028; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; Matricardi PM, 2016, PEDIAT ALLERG IMM-UK, V27, P1, DOI 10.1111/pai.12563; Neunkirchner A, 2018, EBIOMEDICINE, V31, P66, DOI 10.1016/j.ebiom.2018.04.001; Niederberger V, 2018, J ALLERGY CLIN IMMUN, V142, P497, DOI 10.1016/j.jaci.2017.09.052; PEARSON DJ, 1977, CLIN ALLERGY, V7, P29, DOI 10.1111/j.1365-2222.1977.tb01421.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Posa D, 2017, J ALLERGY CLIN IMMUN, V139, P541, DOI 10.1016/j.jaci.2016.08.014; Resch Y, 2015, J ALLERGY CLIN IMMUN, V136, P1083, DOI 10.1016/j.jaci.2015.03.024; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Siroux V, 2017, J ALLERGY CLIN IMMUN, V139, P643, DOI 10.1016/j.jaci.2016.05.023; Skrindo I, 2015, PEDIAT ALLERG IMM-UK, V26, P239, DOI 10.1111/pai.12366; Stenius F, 2011, ALLERGY, V66, P1330, DOI 10.1111/j.1398-9995.2011.02662.x; Thomas WR, 2011, J ALLERGY CLIN IMMUN, V127, P855, DOI 10.1016/j.jaci.2010.12.1084; Uthoff H, 2003, J IMMUNOL, V171, P3485, DOI 10.4049/jimmunol.171.7.3485; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x; Valenta R, 2018, ADV IMMUNOL, V138, P195, DOI 10.1016/bs.ai.2018.03.002; Valenta R, 2017, IMMUNOL LETT, V189, P19, DOI 10.1016/j.imlet.2017.04.015; Valenta R, 2016, J ALLERGY CLIN IMMUN, V137, P351, DOI 10.1016/j.jaci.2015.12.1299; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; Victor JR, 2003, J ALLERGY CLIN IMMUN, V111, P269, DOI 10.1067/mai.2003.39; Westman M, 2017, SEMIN IMMUNOL, V30, P61, DOI 10.1016/j.smim.2017.07.005; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Wickman M, 2017, EBIOMEDICINE, V26, P91, DOI 10.1016/j.ebiom.2017.11.009; Wollmann E, 2015, J ALLERGY CLIN IMMUN, V136, P806, DOI 10.1016/j.jaci.2015.02.034; Zieglmayer P, 2016, EBIOMEDICINE, V11, P43, DOI 10.1016/j.ebiom.2016.08.022	52	27	28	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2019	144	2					536	548		10.1016/j.jaci.2018.11.051	http://dx.doi.org/10.1016/j.jaci.2018.11.051			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IN6LC	30685457	Green Accepted, hybrid			2022-12-18	WOS:000478789300021
J	D'Costa, S; Ayyadurai, S; Gibson, AJ; Mackey, E; Rajput, M; Sommerville, LJ; Wilson, N; Li, YH; Kubat, E; Kumar, A; Subramanian, H; Bhargava, A; Moeser, AJ				D'Costa, Susan; Ayyadurai, Saravanan; Gibson, Amelia J.; Mackey, Emily; Rajput, Mrigendra; Sommerville, Laura J.; Wilson, Neco; Li, Yihang; Kubat, Eric; Kumar, Ananth; Subramanian, Hariharan; Bhargava, Aditi; Moeser, Adam J.			Mast cell corticotropin-releasing factor subtype 2 suppresses mast cell degranulation and limits the severity of anaphylaxis and stress-induced intestinal permeability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; corticotropin-releasing factor receptor; stress; anaphylaxis; allergy; intestinal permeability	BARRIER FUNCTION; COLONIC-MUCOSA; UP-REGULATION; HORMONE; EXPRESSION; RECEPTOR; INFLAMMATION; RESPONSES; UROCORTIN; GROWTH	Background: Psychological stress and heightened mast cell (MC) activation are linked with important immunologic disorders, including allergy, anaphylaxis, asthma, and functional bowel diseases, but the mechanisms remain poorly defined. We have previously demonstrated that activation of the corticotropin-releasing factor (CRF) system potentiates MC degranulation responses during IgE-mediated anaphylaxis and psychological stress through corticotropin-releasing factor receptor subtype 1 (CRF1) expressed on MCs. Objective: In this study we investigated the role of corticotropin-releasing factor receptor subtype 2 (CRF2) as a modulator of stress-induced MC degranulation and associated disease pathophysiology. Methods: In vitro MC degranulation assays were performed with bone marrow-derived mast cells (BMMCs) derived from wildtype (WT) and CRF2-deficient (CRF2-/-) mice and RBL-2H3 MCs transfected with CRF(2)(-)overexpressing plasmid or CRF2 small interfering RNA. In vivo MC responses and associated pathophysiology in IgE-mediated passive systemic anaphylaxis and acute psychological restraint stress were measured in WT, CRF2-/-, and MC-deficient Kit(W-sh/W-sh) knock-in mice. Results: Compared with WT mice, CRF2-/- mice exhibited greater serum histamine levels and exacerbated IgE-mediated anaphylaxis and colonic permeability. In addition, CRF2-/- mice exhibited increased serum histamine levels and colonic permeability after acute restraint stress. Experiments with BMMCs and RBL-2H3 MCs demonstrated that CRF2 expressed on MCs suppresses store-operated Ca2+ entry signaling and MC degranulation induced by diverse MC stimuli. Experiments with MC-deficient Kit W-sh/W-sh mice systemically engrafted with WT and CRF2-/- BMMCs demonstrated the functional importance of MC CRF2 in modulating stress-induced pathophysiology. Conclusions: MC CRF2 is a negative global modulator of stimuli-induced MC degranulation and limits the severity of IgE-mediated anaphylaxis and stress-related disease pathogenesis.	[Ayyadurai, Saravanan; Mackey, Emily; Rajput, Mrigendra; Wilson, Neco; Li, Yihang; Moeser, Adam J.] Michigan State Univ, Dept Large Anim Clin Sci, Gastrointestinal Stress Biol Lab, Coll Vet Med, E Lansing, MI 48824 USA; [Kumar, Ananth; Subramanian, Hariharan; Moeser, Adam J.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [D'Costa, Susan] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27515 USA; [Gibson, Amelia J.] KeraFast, Boston, MA USA; [Mackey, Emily] North Carolina State Univ, Comparat Biomed Sci Program, Raleigh, NC USA; [Sommerville, Laura J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA; [Kubat, Eric; Bhargava, Aditi] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA; [Bhargava, Aditi] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA	Michigan State University; Michigan State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University; Duke University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Moeser, AJ (corresponding author), Michigan State Univ, Dept Large Anim Clin Sci, Gastrointestinal Stress Biol Lab, Neurosci Program,Physiol, E Lansing, MI 48824 USA.	moeserad@cvm.msu.edu	Subramanian, Hariharan/AHC-5755-2022	Rajput, mrigendra/0000-0002-0762-4188; Moeser, Adam/0000-0003-3068-627X	US National Institutes of Health [R01 HD072968, R21 AI140413, K08/R03 DK097462, R01 DK080787, F30 OD025354]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD072968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI140413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK084313, R03DK097462] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by US National Institutes of Health grants R01 HD072968 (to A.J.M.), R21 AI140413 (to A.J.M.), K08/R03 DK097462 (to A.J.M.), R01 DK080787 (to A.B.), and F30 OD025354 (to E.M.). A.J.M. is the Matilda R. Wilson Endowed Chair of Large Animal Clinical Sciences at Michigan State University, College of Veterinary Medicine. Astressin 2B was a kind gift of Dr Jean Rivier, Sentia Medical Sciences, Salk Institute for Biological Studies.	Alysandratos KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048934; Andrae DA, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-208; ARGENZIO RA, 1990, AM J VET RES, V51, P747; Asadi S, 2012, J INVEST DERMATOL, V132, P324, DOI 10.1038/jid.2011.334; Ayyadurai S, 2017, J LEUKOCYTE BIOL, V102, P1299, DOI 10.1189/jlb.2HI0317-088RR; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Balseiro-Gomez S, 2015, J IMMUNOL, V195, P2046, DOI 10.4049/jimmunol.1500253; Barbara G, 2004, GASTROENTEROLOGY, V126, P693, DOI 10.1053/j.gastro.2003.11.055; BERGMAN RK, 1965, J IMMUNOL, V95, P1; Boyer PE, 2015, BRIT J NUTR, V113, P783, DOI 10.1017/S000711451400422X; Cao J, 2006, MOL PHARMACOL, V69, P998, DOI 10.1124/mol.105.019539; Cao J, 2005, J IMMUNOL, V174, P7665, DOI 10.4049/jimmunol.174.12.7665; Chatzaki E, 2013, WORLD J GASTROENTERO, V19, P1416, DOI 10.3748/wjg.v19.i9.1416; Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106; Dedkova E N, 2000, Membr Cell Biol, V13, P357; FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105; Heffner KL, 2014, ANN ALLERG ASTHMA IM, V113, P13, DOI 10.1016/j.anai.2014.03.008; Holowka D, 2016, BIOCHEM SOC T, V44, P505, DOI 10.1042/BST20150273; Kashem SW, 2011, EUR J PHARMACOL, V668, P299, DOI 10.1016/j.ejphar.2011.06.027; Kempuraj D, 2004, ENDOCRINOLOGY, V145, P43, DOI 10.1210/en.2003-0805; Kishimoto T, 2000, NAT GENET, V24, P415, DOI 10.1038/74271; Klooker TK, 2010, GUT, V59, P1213, DOI 10.1136/gut.2010.213108; la Fleur SE, 2005, P NATL ACAD SCI USA, V102, P7647, DOI 10.1073/pnas.0408531102; Lennon EM, 2013, INFLAMM BOWEL DIS, V19, P712, DOI 10.1097/MIB.0b013e3182802a4e; Li YH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171617; Liu YX, 2014, ENDOCR-RELAT CANCER, V21, P639, DOI 10.1530/ERC-14-0239; Mackey E, 2016, BIOL SEX DIFFER, V7, DOI 10.1186/s13293-016-0113-7; Mahajan S, 2014, PEPTIDES, V54, P58, DOI 10.1016/j.peptides.2014.01.007; Moeser AJ, 2007, AM J PHYSIOL-GASTR L, V293, pG413, DOI 10.1152/ajpgi.00304.2006; Papadopoulou NG, 2005, J MOL ENDOCRINOL, V35, pR1, DOI 10.1677/jme.1.01833; Priftis KN, 2009, ALLERGY, V64, P18, DOI 10.1111/j.1398-9995.2008.01948.x; Re M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011489; Santos J, 1999, AM J PHYSIOL-GASTR L, V277, pG391, DOI 10.1152/ajpgi.1999.277.2.G391; Santos J, 2000, AM J PHYSIOL-GASTR L, V278, pG847, DOI 10.1152/ajpgi.2000.278.6.G847; Savard M, 2008, J CELL PHYSIOL, V216, P234, DOI 10.1002/jcp.21398; Smith F, 2010, AM J PHYSIOL-GASTR L, V298, pG352, DOI 10.1152/ajpgi.00081.2009; Soderholm JD, 2002, GASTROENTEROLOGY, V123, P1099, DOI 10.1053/gast.2002.36019; Suzuki R, 2010, J LEUKOCYTE BIOL, V88, P863, DOI 10.1189/jlb.0510253; Theoharides TC, 2009, CLIN EXP DERMATOL, V34, pE163, DOI 10.1111/j.1365-2230.2008.03043.x; Vaniotis G, 2011, AM J PHYSIOL-HEART C, V301, pH1754, DOI 10.1152/ajpheart.00657.2011; Wallon C, 2008, GUT, V57, P50, DOI 10.1136/gut.2006.117549; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; Yang B, 2013, SCAND J IMMUNOL, V78, P35, DOI 10.1111/sji.12062; Yuan PQ, 2016, AM J PHYSIOL-GASTR L, V310, pG387, DOI 10.1152/ajpgi.00337.2015; Yuan PQ, 2012, PEPTIDES, V38, P62, DOI 10.1016/j.peptides.2012.07.028	45	27	28	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1865	+		10.1016/j.jaci.2018.08.053	http://dx.doi.org/10.1016/j.jaci.2018.08.053			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30439403	Green Accepted, Bronze, Green Submitted			2022-12-18	WOS:000466784600022
J	Glesner, J; Filep, S; Vailes, LD; Wunschmann, S; Chapman, MD; Birrueta, G; Frazier, A; Jeong, KY; Schal, C; Bacharier, L; Beigelman, A; Busse, P; Schulten, V; Sette, A; Sci, B; Pomes, A				Glesner, Jill; Filep, Stephanie; Vailes, Lisa D.; Wunschmann, Sabina; Chapman, Martin D.; Birrueta, Giovanni; Frazier, April; Jeong, Kyoung Yong; Schal, Coby; Bacharier, Leonard; Beigelman, Avraham; Busse, Paula; Schulten, Veronique; Sette, Alessandro; Sci, Biol; Pomes, Anna			Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cockroach allergy; non-standardized extracts; cockroach allergen components; immunotherapy; diagnosis	GLUTATHIONE-S-TRANSFERASE; BLATTELLA-GERMANICA; BINDING PROTEINS; EXPOSURE; IDENTIFICATION; COMPONENTS; INDUCTION; CLONING; BLA-G-2	Background: Cockroach allergens are an important cause of IgE-mediated sensitization in inner-city asthmatic patients. However, cockroach extracts used for diagnosis and immunotherapy are not standardized. Objective: We sought to determine the allergen content of nonstandardized German cockroach extracts and the levels of sensitization to an expanded set of cockroach allergens as determinants of in vitro extract potency for IgE reactivity. Methods: Twelve German cockroach extracts were compared for allergen content and potency of IgE reactivity. Bla g 1, Bla g 2, and Bla g 5 were measured by using immunoassays. IgE antibody levels to 8 purified recombinant allergens from groups 1, 2, 4, 5, 6, 7, 9, and 11 were measured by using ImmunoCAP. IgE antibody binding inhibition assays were performed to assess extract in vitro potencies (concentration inhibiting 30% of the total IgE antibody-binding inhibition) relative to an arbitrarily selected reference extract in 5 patients with cockroach allergy. Results: Allergen levels were highly variable. Three new major allergens (groups 6, 9, and 11), were identified among highly cockroach-sensitized subjects (CAP class > 3). Sensitization profiles were unique per subject without immunodominant allergens. The sum of IgE to 8 allergen components showed a good correlation with cockroach-specific IgE levels (r = 0.88, P<.001). In vitro potencies varied among different extracts per subject and among subjects for each extract. Conclusions: The in vitro potency of German cockroach extracts for IgE reactivity depends on allergen content and allergen-specific IgE titers of patients with cockroach allergy. These factors are relevant for selection of potent extracts to be used for immunotherapy and for the design and interpretation of data from immunotherapy trials.	[Glesner, Jill; Filep, Stephanie; Vailes, Lisa D.; Wunschmann, Sabina; Chapman, Martin D.; Pomes, Anna] Indoor Biotechnol, 700 Harris St, Charlottesville, VA 22903 USA; [Birrueta, Giovanni; Frazier, April; Schulten, Veronique; Sette, Alessandro; Sci, Biol] La Jolla Inst Allergy & Immunol, La Jolla, CA USA; [Jeong, Kyoung Yong] Yonsei Univ, Coll Med, Dept Internal Med, Inst Allergy, Seoul, South Korea; [Schal, Coby] North Carolina State Univ, Dept Entomol & Plant Pathol, Raleigh, NC 27695 USA; [Bacharier, Leonard; Beigelman, Avraham] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Busse, Paula] Icahn Sch Med Mt Sinai, Div Clin Immunol, New York, NY 10029 USA; [Sette, Alessandro; Sci, Biol] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	INDOOR Biotechnologies; La Jolla Institute for Immunology; Yonsei University; Yonsei University Health System; University of North Carolina; North Carolina State University; Washington University (WUSTL); Icahn School of Medicine at Mount Sinai; University of California System; University of California San Diego	Pomes, A (corresponding author), Indoor Biotechnol, 700 Harris St, Charlottesville, VA 22903 USA.	apomes@inbio.com	Sette, Alessandro/AFO-8916-2022; Schal, Coby/A-8717-2010; Pomés, Anna/H-7010-2019; Jeong, Kyoung Yong/B-4032-2015	Schal, Coby/0000-0001-7195-6358; Pomés, Anna/0000-0002-8729-1829; Jeong, Kyoung Yong/0000-0001-9887-1426; Chapman, Martin/0000-0002-0845-3632; Filep, Stephanie/0000-0003-2135-5161; Bacharier, Leonard/0000-0003-0432-2704	National Institute of Allergy and Infectious Diseases/National Institutes of Health [R01AI077653, U19 AI135731, U19 AI100275, UM1 AI114271]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI114271, R01AI077653, U19AI135731, U19AI100275] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Research in this publication was supported by the National Institute of Allergy and Infectious Diseases/National Institutes of Health under Award Number R01AI077653 (to A.P. and M.D.C.), U19 AI135731 and U19 AI100275 (to A.S.), and UM1 AI114271 (Inner-City Asthma Consortium). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; Chuang JG, 2010, PROTEOMICS, V10, P3854, DOI 10.1002/pmic.201000348; Fan Y, 2005, INSECT MOL BIOL, V14, P45, DOI 10.1111/j.1365-2583.2004.00530.x; Fang Y, 2015, ALLERGY, V70, P1674, DOI 10.1111/all.12766; Gore JC, 2004, J MED ENTOMOL, V41, P953, DOI 10.1603/0022-2585-41.5.953; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Hindley J, 2006, J ALLERGY CLIN IMMUN, V117, P1389, DOI 10.1016/j.jaci.2006.02.017; Jeong KY, 2003, ALLERGY, V58, P1059, DOI 10.1034/j.1398-9995.2003.00167.x; Jeong KY, 2013, INT ARCH ALLERGY IMM, V161, P315, DOI 10.1159/000347034; Kitzmuller C, 2018, J ALLERGY CLIN IMMUN, V141, P293, DOI 10.1016/j.jaci.2017.02.044; Mueller GA, 2015, J ALLERGY CLIN IMMUN, V136, P1369, DOI 10.1016/j.jaci.2015.03.015; Mueller GA, 2013, J ALLERGY CLIN IMMUN, V132, P1420, DOI 10.1016/j.jaci.2013.06.014; Patterson ML, 2002, CLIN EXP ALLERGY, V32, P721, DOI 10.1046/j.1365-2222.2002.01397.x; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391, DOI 10.1164/ajrccm.165.3.2104027; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Schulten VM, 2018, J ALLERGY CLIN IMMUN, V141, pAB199, DOI 10.1016/j.jaci.2017.12.630; Slater JE, 2007, CLIN EXP ALLERGY, V37, P1033, DOI 10.1111/j.1365-2222.2007.02751.x; Wood RA, 2014, J ALLERGY CLIN IMMUN, V133, P846, DOI 10.1016/j.jaci.2013.08.047; Yun YY, 2001, ANN ALLERG ASTHMA IM, V86, P551, DOI 10.1016/S1081-1206(10)62904-3	26	27	27	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1474	+		10.1016/j.jaci.2018.07.036	http://dx.doi.org/10.1016/j.jaci.2018.07.036			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30170124	Green Accepted			2022-12-18	WOS:000463348900023
J	MacGlashan, D				MacGlashan, Donald			Autoantibodies to IgE and Fc epsilon RI and the natural variability of spleen tyrosine kinase expression in basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human; basophil; allergy; Fc receptors	HISTAMINE-RELEASE; SYK EXPRESSION; MAST-CELLS; DESENSITIZATION; ACTIVATION; RECEPTORS; URTICARIA; EFFICACY; ALLERGEN	Background: Secretion from human basophils and mast cells requires spleen tyrosine kinase (SYK) activity, but SYK expression is highly variable in the general population, and this variability predicts the magnitude of IgE-mediated secretion. One known mechanism of modulating SYK expression in human basophils is aggregation of FceRI. Objective: This study examines the possibility that functional autoantibodies are present in a wide variety of subjects and, in particular, subjects whose basophils poorly express SYK. It also tests whether any found antibodies could modulate SYK expression in maturing basophils and whether interaction with FcgRIIb/CD32b modulates the effect. Methods: An experimental algorithm for classifying the nature of histamine release induced by serum from 3 classes of subjects was developed. Results: The frequency of functional autoantibodies that produce characteristics concordant with FceRI-mediated secretion was zero in 34 subjects without chronic spontaneous urticaria (CSU). In patients with CSU, the frequency was lower than expected, approximately 7%. For the 5 of 68 unique sera from patients with CSU tested that contained anti-FceRI or anti-IgE antibodies, these antibodies were found to induce downregulation of SYK in both peripheral blood basophils and basophils developed from CD34(+) progenitors. Blocking interaction of these antibodies with CD32b did not alter their ability to downregulate SYK expression. Conclusions: This study establishes that functional autoantibodies to IgE/FceRI do not provide a good explanation for the variability in SYK expression in basophils in the general population. They do show that if antibodies with these characteristics are present, they are capable of modulating SYK expression in developing basophils.	[MacGlashan, Donald] Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University	MacGlashan, D (corresponding author), Johns Hopkins Univ, Dept Med, Asthma & Allergy Ctr, Unit Off 3, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	dmacglas@jhmi.edu			National Institutes of Health [AI100952, AI116658]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI100952, U01AI100952, R01AI116658] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants AI100952 and AI116658.	Adkinson NF, 1980, MEASUREMENT TOTAL SE; Baker R, 2008, ANN ALLERG ASTHMA IM, V100, P244, DOI 10.1016/S1081-1206(10)60449-8; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Chan YC, 2014, J ALLERGY CLIN IMMUN, V134, P1394, DOI 10.1016/j.jaci.2014.06.029; Eckman JA, 2008, J INVEST DERMATOL, V128, P1956, DOI 10.1038/jid.2008.55; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; GILBERT HS, 1975, BLOOD, V46, P279; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; Ishmael SS, 2010, J LEUKOCYTE BIOL, V87, P291, DOI 10.1189/jlb.0509336; Kepley CL, 1999, J ALLERGY CLIN IMMUN, V104, P279, DOI 10.1016/S0091-6749(99)70367-2; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; Lavens-Phillips SE, 2000, AM J RESP CELL MOL, V23, P566, DOI 10.1165/ajrcmb.23.4.4123; LICHTENSTEIN LM, 1992, J IMMUNOL, V148, P3929; MacGlashan D, 2000, BIOCHEM PHARMACOL, V60, P1717, DOI 10.1016/S0006-2952(00)00490-1; MACGLASHAN D, 1989, J CELL BIOL, V109, P123, DOI 10.1083/jcb.109.1.123; MacGlashan D, 2004, J ALLERGY CLIN IMMUN, V114, P1317, DOI 10.1016/j.jaci.2004.08.037; MacGlashan D, 2014, CLIN EXP ALLERGY, V44, P713, DOI 10.1111/cea.12155; MacGlashan D, 2012, CLIN EXP ALLERGY, V42, P1060, DOI 10.1111/j.1365-2222.2012.04013.x; MacGlashan D, 2008, J ALLERGY CLIN IMMUN, V121, P1500, DOI 10.1016/j.jaci.2008.04.019; MacGlashan D, 2016, J ALLERGY CLIN IMMUN, V137, P1256, DOI 10.1016/j.jaci.2015.10.043; MacGlashan D, 2011, INT IMMUNOPHARMACOL, V11, P475, DOI 10.1016/j.intimp.2010.12.018; MacGlashan DW, 2008, J IMMUNOL, V180, P4208, DOI 10.4049/jimmunol.180.6.4208; MacGlashan DW, 2007, J LEUKOCYTE BIOL, V82, P1003, DOI 10.1189/jlb.0207103; MacGlashan DW, 2007, J ALLERGY CLIN IMMUN, V119, P626, DOI 10.1016/j.jaci.2006.09.040; MacGlashan DW, 2017, J ALLERGY CLIN IMMUN, V139, P1680, DOI 10.1016/j.jaci.2016.12.965; MacGlashan DW, 2012, J ALLERGY CLIN IMMUN, V130, P1130, DOI 10.1016/j.jaci.2012.05.038; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Puan KJ, 2017, ALLERGY, V72, P373, DOI 10.1111/all.12952; Rauber MM, 2017, ALLERGY, V72, P1904, DOI 10.1111/all.13215; Schroeder JT, 2013, J ALLERGY CLIN IMMUN, V132, P1428, DOI 10.1016/j.jaci.2013.08.033; Shade KTC, 2015, J EXP MED, V212, P457, DOI 10.1084/jem.20142182; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Soundararajan S, 2005, J ALLERGY CLIN IMMUN, V115, P815, DOI 10.1016/j.jaci.2004.12.1120; Vilarino N, 2005, J IMMUNOL METHODS, V296, P11, DOI 10.1016/j.jim.2004.10.009; WARNER JA, 1987, J IMMUNOL, V139, P161	36	27	28	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					1100	+		10.1016/j.jaci.2018.05.019	http://dx.doi.org/10.1016/j.jaci.2018.05.019			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	29859965	Bronze, Green Accepted			2022-12-18	WOS:000460272900030
J	Szefler, SJ; Cloutier, MM; Villarreal, M; Hollenbach, JP; Gleason, M; Haas-Howard, C; Vinick, C; Calatroni, A; Cicutto, L; White, M; Williams, S; McGinn, M; Langton, C; Shocks, D; Mitchell, H; Stempel, DA				Szefler, Stanley J.; Cloutier, Michelle M.; Villarreal, Miguel; Hollenbach, Jessica P.; Gleason, Melanie; Haas-Howard, Christy; Vinick, Carol; Calatroni, Agustin; Cicutto, Lisa; White, Marty; Williams, Shann; McGinn, Meghan; Langton, Christine; Shocks, Donna; Mitchell, Herman; Stempel, David A.			Building Bridges for Asthma Care: Reducing school absence for inner-city children with health disparities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						African American; asthma; case management; care coordination; children; disease management; Hispanic; partnerships; school	PERFORMANCE; VALIDATION; EXACERBATIONS; ACHIEVEMENT; PROGRAM; ACCESS	Background: Children with asthma are at increased risk for experiencing health and educational disparities because of increased school absence. School nurses are well positioned to support asthma management and improve school attendance. Objective: We sought to implement and assess the effect of the Building Bridges for Asthma Care Program on improving school attendance and measures of asthma control. Methods: Children with asthma (age, 5-14 years) in the Denver Public School System (n = 240) and the Hartford Public School System (n = 223) were enrolled in the Building Bridges Program during the 2013-2014 and 2014-2015 school years and followed until the end of the second school year. The primary outcome was school absence, with secondary outcomes, including asthma control, measured based on Childhood Asthma Control Test or the Asthma Control Test scores and rescue inhaler use. Results: Participants experienced a 22% absolute decrease in school absenteeism, the number of children with an Asthma Control Test/Childhood Asthma Control Test score of less than the control threshold of 20 decreased from 42.7% to 28.8%, and bronchodilator use greater than 2 times per week decreased from 35.8% to 22.9% (all changes were significant, P < .01). Conclusions: Children enrolled in the Building Bridges for Asthma Care Program experienced reduced school absence and improved asthma control.	[Szefler, Stanley J.] Univ Colorado, Sch Med, Pediat Asthma Res Program, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Childrens Hosp Colorado, Breathing Inst, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Sect Pediat Pulm & Sleep Med, Aurora, CO USA; [Cloutier, Michelle M.] UCONN Hlth, Pediat & Med, Hartford, CT USA; [Cloutier, Michelle M.; Hollenbach, Jessica P.] Connecticut Childrens Med Ctr, Asthma Ctr, Hartford, CT USA; [Villarreal, Miguel; Calatroni, Agustin; Williams, Shann; McGinn, Meghan; Mitchell, Herman] Rho, Chapel Hill, NC USA; [Hollenbach, Jessica P.] Univ Connecticut, Sch Med, Dept Pediat, Hartford, CT 06112 USA; [Gleason, Melanie] Univ Colorado, Sch Med, Childrens Hosp Colorado, Bldg Bridges Asthma Program, Aurora, CO USA; [Gleason, Melanie] Univ Colorado, Sch Med, Sect Pediat Pulm Med, Dept Pediat, Aurora, CO USA; [Haas-Howard, Christy; Shocks, Donna] Denver Publ Sch, Nursing & Student Hlth Serv, Denver, CO USA; [Haas-Howard, Christy] Colorado Dept Educ, Asthma Grant Program, Denver, CO USA; [Vinick, Carol; Langton, Christine] Asthma Ctr, Hartford, CT USA; [Vinick, Carol; Langton, Christine] Connecticut Childrens Med Ctr, Hartford, CT USA; [Cicutto, Lisa] Univ Colorado Denver AMC, Community Outreach & Res, Natl Jewish Hlth, Denver, CO USA; [Cicutto, Lisa] Univ Colorado Denver AMC, Clin Sci Program, Denver, CO USA; [White, Marty] Childrens Hosp Colorado, Denver Publ Sch, Denver, CO USA; [Stempel, David A.] Propeller Hlth, San Francisco, CA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Connecticut Children's Medical Center; Rho; University of Connecticut; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Connecticut Children's Medical Center; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado	Szefler, SJ (corresponding author), Childrens Hosp Colorado, Breathing Inst, 13123 E 16th Ave,B395, Denver, CO 80045 USA.; Szefler, SJ (corresponding author), Dept Pediat, Sect Pediat Pulm & Sleep Med, 13123 E 16th Ave,B395, Denver, CO 80045 USA.	Stanley.Szefler@childrenscolorado.org		Szefler, Stanley/0000-0002-6911-3199; Langton, Christine/0000-0001-8649-8863	GlaxoSmithKline [FLV116794]; Caring for Colorado Foundation; McCormick Foundation; National Heart, Lung, and Blood Institute (NHLBI) AsthmaNet [U10 HL098075]; Colorado CTSA Grant from the National Institutes of Health (NIH)/National Center for Research Resources [UL1 RR025780]; NIH/National Center for Advancing Translational Sciences [UL1 TR000154]; State of Connecticut Department of Public Health; Community Health Network of Connecticut; NHLBI [1U34 HL130665-01, 1U34 HL130665-0]; University of Colorado School of Medicine through GlaxoSmithKline [FLV116794]; Colorado Department of Public Health and Environment grants [15 FLA 65765, 16 FHLA 76546, 17FHLA87312]; Kaiser Permanente; Colorado Department of Public Health and Environment; Colorado CTSA grant from the NIH/NCRR [UL1 TR001082]; Kaiser Permanente Foundation; Jessie Ball Du Pont Fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Caring for Colorado Foundation; McCormick Foundation; National Heart, Lung, and Blood Institute (NHLBI) AsthmaNet; Colorado CTSA Grant from the National Institutes of Health (NIH)/National Center for Research Resources; NIH/National Center for Advancing Translational Sciences; State of Connecticut Department of Public Health; Community Health Network of Connecticut; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); University of Colorado School of Medicine through GlaxoSmithKline; Colorado Department of Public Health and Environment grants; Kaiser Permanente; Colorado Department of Public Health and Environment; Colorado CTSA grant from the NIH/NCRR; Kaiser Permanente Foundation; Jessie Ball Du Pont Fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by GlaxoSmithKline study no. FLV116794. S.J.S. is supported by the Colorado Department of Public Health and Environment grants 15 FLA 65765, 16 FHLA 76546 and 17FHLA87312; the Caring for Colorado Foundation; the McCormick Foundation; and GlaxoSmithKline grant FLV116794. S.J.S. is also supported by National Heart, Lung, and Blood Institute (NHLBI) AsthmaNet U10 HL098075 and supported in part by Colorado CTSA Grant UL1 RR025780 from the National Institutes of Health (NIH)/National Center for Research Resources and UL1 TR000154 from the NIH/National Center for Advancing Translational Sciences. M.M.C. is supported by the State of Connecticut Department of Public Health, Community Health Network of Connecticut, and NHLBI 1U34 HL130665-01 and by the University of Colorado School of Medicine funded through GlaxoSmithKline FLV116794. M.V. is supported by the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. J.P.H. is supported by the State of Connecticut Department of Public Health, Community Health Network of Connecticut, NHLBI grant 1U34 HL130665-0, and the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. M.G. is supported by the Colorado Department of Public Health and Environment grants 15 FLA 65765, 16 FHLA 76546, and 17FHLA87312; the Caring for Colorado Foundation; the McCormick Foundation; and GlaxoSmithKline grant FLV116794. C.H.-H. is supported by Colorado Department of Public Health and Environment grants 15 FLA 65765, 16 FHLA 76546, and 17FHLA87312 and Kaiser Permanente and the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. C.V. is supported by NHLBI grant 1U34 HL130665-01 and supported the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. A.C. is supported by the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. L.C. is supported by the Colorado Department of Public Health and Environment, Colorado CTSA grant UL1 TR001082 from the NIH/NCRR, the Kaiser Permanente Foundation, the Jessie Ball Du Pont Fund, and the McCormick Foundation. M.W. is supported by Colorado Department of Public Health and Environment grants 15 FLA 65765, 16 FHLA 76546, and 17FHLA87312, the Caring for Colorado Foundation, the McCormick Foundation, and the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. S.W. is supported by the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. M.M. is supported by the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. C.L. is supported by the State of Connecticut Department of Public Health, the Community Health Network of Connecticut, and NHLBI grant 1U34 HL130665-01 and by the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794. H.M. is supported by the University of Colorado School of Medicine funded through GlaxoSmithKline grant FLV116794.	Akinbami Lara J, 2012, NCHS Data Brief, P1; [Anonymous], 2016, PREVENTING MISSED OP; Basch CE, 2011, J SCHOOL HEALTH, V81, P591, DOI 10.1111/j.1746-1561.2011.00631.x; Cicutto L, 2005, CHEST, V128, P1928, DOI 10.1378/chest.128.4.1928; Cicutto Lisa, 2016, NASN Sch Nurse, V31, P112, DOI 10.1177/1942602X15619996; Cicutto L, 2014, J CONTIN EDUC HEALTH, V34, P205, DOI 10.1002/chp.21254; Cicutto L, 2014, J ALLERGY CLIN IMMUN, V134, P1223, DOI 10.1016/j.jaci.2014.10.004; Cicutto L, 2013, J SCHOOL HEALTH, V83, P876, DOI 10.1111/josh.12106; Cloutier MM, 2011, PEDIATRICS, V127, P11, DOI 10.1542/peds.2010-1943; Crain EF, 1998, ARCH PEDIAT ADOL MED, V152, P333; Daniel LC, 2012, ANN ALLERG ASTHMA IM, V109, P41, DOI 10.1016/j.anai.2012.05.015; Diette GB, 2000, ARCH PEDIAT ADOL MED, V154, P923, DOI 10.1001/archpedi.154.9.923; Gerald LB, 2004, PEDIATRICS, V114, pE459, DOI 10.1542/peds.2004-0455; Gerald LB, 2006, J SCHOOL HEALTH, V76, P291, DOI 10.1111/j.1746-1561.2006.00114.x; Halterman JS, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2017.4938; Halterman JS, 2011, ARCH PEDIAT ADOL MED, V165, P262, DOI 10.1001/archpediatrics.2011.1; Halterman JS, 2001, AMBUL PEDIATR, V1, P201, DOI 10.1367/1539-4409(2001)001<0201:SRAUCW>2.0.CO;2; Ho D.E., 2011, J STAT SOFTW, V42, P1, DOI [10.18637/jss.v042.i08, DOI 10.18637/JSS.V042.I08]; Hoch HE, 2017, J ALLERGY CLIN IMMUN, V140, P1130, DOI 10.1016/j.jaci.2017.01.026; Holmes BW, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2016-0852; Lemanske RF, 2016, J ALLERGY CLIN IMMUN, V138, P711, DOI 10.1016/j.jaci.2016.06.015; Liberty KA, 2010, CHEST, V138, P1349, DOI 10.1378/chest.10-0543; Liptzin DR, 2016, J ALLER CL IMM-PRACT, V4, P972, DOI 10.1016/j.jaip.2016.04.016; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Maughan ED, 2016, AM EDUC, P19; Meng YY, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110312; Mizan SS, 2011, J ASTHMA, V48, P228, DOI 10.3109/02770903.2011.555038; Moonie S, 2008, J SCHOOL HEALTH, V78, P140, DOI 10.1111/j.1746-1561.2007.00276.x; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; R Development Core Team, 2021, LANG ENV STAT COMP; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Shapiro AD, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e105; Snieder HM, 2017, J SCHOOL HEALTH, V87, P941, DOI 10.1111/josh.12565; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; U.S. Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute, 2014, NON TRADITIONAL REF; US Environmental Protection Agency, 2012, PRES TASK FORC ENV H; Vargas PA, 2006, J SCHOOL HEALTH, V76, P223, DOI 10.1111/j.1746-1561.2006.00101.x; Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1	40	27	27	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2019	143	2					746	+		10.1016/j.jaci.2018.05.041	http://dx.doi.org/10.1016/j.jaci.2018.05.041			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	HK2DJ	30055181	Bronze			2022-12-18	WOS:000457718700033
J	Zhai, GT; Wang, H; Li, JX; Cao, PP; Jiang, WX; Song, J; Yao, Y; Wang, ZC; Wang, ZZ; Wang, MC; Liao, B; Feng, QM; Lu, X; Wang, H; Gao, PS; Liu, Z				Zhai, Guan-Ting; Wang, Hai; Li, Jing-Xian; Cao, Ping-Ping; Jiang, Wen-Xiu; Song, Jia; Yao, Yin; Wang, Zhi-Chao; Wang, Zhe-Zheng; Wang, Meng-Chen; Liao, Bo; Feng, Qi-Miao; Lu, Xiang; Wang, Heng; Gao, Peisong; Liu, Zheng			IgD-activated mast cells induce IgE synthesis in B cells in nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cell; chronic rhinosinusitis; eosinophil; IgD; IgE; mast cell; nasal polyps	CHRONIC RHINOSINUSITIS; HUMAN-IMMUNOGLOBULINS; EXPRESSION; MEMBRANE; STRATEGY; ALLERGEN; SWITCH; GENE; LPS	Background: Although upregulated expression of local IgD has been reported in patients with chronic rhinosinusitis (CRS), its function is unclear. Objective: We sought to explore the expression and function of soluble IgD in patients with CRS, particularly CRS with nasal polyps. Methods: IgD levels in sinonasal mucosa were analyzed by using RT-PCR and ELISA. Numbers and phenotypes of IgD(+) cells were studied by means of immunohistochemistry, immunofluorescence, and flow cytometry. HMC-1 cells, a human mast cell line, and mast cells purified from eosinophilic polyps were cultured alone or with naive B cells purified from peripheral blood. The antigen specificity of nasal IgD was investigated by using ELISA. Results: The mRNA expression of immunoglobulin heavy constant delta gene, numbers of IgD(+) cells, and protein levels of secretory IgD in sinonasal mucosa were increased in patients with CRS with or without nasal polyps compared with control subjects. Numbers of IgD(+) plasmablasts were increased in both eosinophilic and noneosinophilic polyps, whereas numbers of IgD(+) mast cells were only increased in eosinophilic polyps. Cross-linking IgD induced serum preincubated HMC-1 cells and polyp mast cells to produce B-cell activating factor, IL-21, IL-4, and IL-13 and to promote IgM, IgG, IgA, and IgE production from B cells. In eosinophilic polyps expression of those B cell-stimulating factors in mast cells and close contact between mast cells and B cells were found. Moreover, positive correlations of total IgD levels with total IgE levels and eosinophilia and upregulation of specific IgD against house dust mites were discovered in eosinophilic polyps. Conclusion: IgD-activated mast cells can facilitate IgE production and eosinophilic inflammation in patients with CRS with nasal polyps.	[Zhai, Guan-Ting; Wang, Hai; Li, Jing-Xian; Cao, Ping-Ping; Jiang, Wen-Xiu; Song, Jia; Yao, Yin; Wang, Zhi-Chao; Wang, Zhe-Zheng; Wang, Meng-Chen; Liao, Bo; Feng, Qi-Miao; Lu, Xiang; Wang, Heng; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China; [Gao, Peisong] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Baltimore, MD USA	Huazhong University of Science & Technology; Johns Hopkins University	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Otolaryngol Head & Neck Surg, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.	zhengliuent@hotmail.com		Yin, Yao/0000-0002-5833-5263	National Natural Science Foundation of China (NSFC) [81630024, 81570899, 81325006, 81400449, 81700893, 81670911]; Hubei Province Natural Science Foundation [2017CFA016]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Hubei Province Natural Science Foundation(Natural Science Foundation of Hubei Province)	Supported by National Natural Science Foundation of China (NSFC) grants 81630024, 81570899, and 81325006 (to Z.L.), 81400449 (to P.-P.C.), 81700893 (to B.L.), and 81670911 (to X.L.) and a Hubei Province Natural Science Foundation grant 2017CFA016 (to Z.L.).	Arpin C, 1998, J EXP MED, V187, P1169, DOI 10.1084/jem.187.8.1169; Baba S, 2014, CLIN EXP ALLERGY, V44, P701, DOI 10.1111/cea.12287; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P621, DOI 10.1016/j.jaip.2016.05.004; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Beaven MA, 2009, EUR J IMMUNOL, V39, P11, DOI 10.1002/eji.200838899; Bengten E, 2002, J IMMUNOL, V169, P2488, DOI 10.4049/jimmunol.169.5.2488; Boase S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-210; Cao PP, 2014, CLIN EXP ALLERGY, V44, P690, DOI 10.1111/cea.12304; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chen K, 2010, IMMUNOL REV, V237, P160, DOI 10.1111/j.1600-065X.2010.00929.x; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Cornec D, 2017, J AUTOIMMUN, V84, P122, DOI 10.1016/j.jaut.2017.08.006; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; FOKKENS WJ, 2012, RHINOL S, V50, P1; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Hulse KE, 2015, CLIN EXP ALLERGY, V45, P328, DOI 10.1111/cea.12472; Kato A, 2013, J ALLERGY CLIN IMMUN, V131, P933, DOI 10.1016/j.jaci.2013.02.023; Min JY, 2017, J ALLERGY CLIN IMMUN, V140, P1562, DOI 10.1016/j.jaci.2017.05.032; MONROE JG, 1983, EUR J IMMUNOL, V13, P208, DOI 10.1002/eji.1830130306; OKADA S, 1991, BLOOD, V78, P1706; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PENG Z, 1991, ALLERGY, V46, P436, DOI 10.1111/j.1398-9995.1991.tb04359.x; Perfetto SP, 2006, J IMMUNOL METHODS, V313, P199, DOI 10.1016/j.jim.2006.04.007; Preud'homme JL, 2000, MOL IMMUNOL, V37, P871, DOI 10.1016/S0161-5890(01)00006-2; ROWE DS, 1965, J EXP MED, V121, P171, DOI 10.1084/jem.121.1.171; ROWE DS, 1965, J EXP MED, V121, P185, DOI 10.1084/jem.121.1.185; Sokoya M, 2017, ANN ALLERG ASTHMA IM, V119, P317, DOI 10.1016/j.anai.2017.07.024; Song J, 2018, J ALLERGY CLIN IMMUN, V141, P927, DOI 10.1016/j.jaci.2017.10.014; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Van Zele T, 2014, AM J RHINOL ALLERGY, V28, P192, DOI 10.2500/ajra.2014.28.4033; Vanaja SK, 2016, CELL, V165, P1106, DOI 10.1016/j.cell.2016.04.015; Wang H, 2018, J ALLERGY CLIN IMMUN, V141, P586, DOI 10.1016/j.jaci.2017.06.013; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wang Y, 2016, ALLERGY, V71, P1612, DOI 10.1111/all.12963; ZHANG M, 1994, SCAND J IMMUNOL, V40, P502, DOI 10.1111/j.1365-3083.1994.tb03496.x; Zhang N, 2011, ALLERGY, V66, P141, DOI 10.1111/j.1398-9995.2010.02448.x; Zhang YN, 2016, J ALLERGY CLIN IMMUN, V137, P462, DOI 10.1016/j.jaci.2015.07.025	41	27	27	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1489	+		10.1016/j.jaci.2018.07.025	http://dx.doi.org/10.1016/j.jaci.2018.07.025			34	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	30102935	Bronze			2022-12-18	WOS:000449429800012
J	Szefler, SJ				Szefler, Stanley J.			Asthma across the lifespan: Time for a paradigm shift	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma exacerbation; asthma guidelines; Composite Asthma Severity Index; Seasonal Asthma Exacerbation Prediction Index; trajectories of lung growth	CHILDHOOD ASTHMA; LUNG-FUNCTION; SOCIAL DETERMINANTS; CHILDREN; OUTCOMES; MANAGEMENT; HEALTH; EXACERBATIONS; FLUTICASONE; MONTELUKAST	We have a unique opportunity to significantly reduce the worldwide burden of asthma in children and affect respiratory outcomes in adults. However, this will require a paradigm shift that is directed at altering the natural history of asthma, reducing asthma exacerbations, and preventing long-term adverse outcomes of childhood asthma. Attention should continue to be directed toward minimizing risk, as well as impairment, with a goal to achieve optimal control. Based on several National Institutes of Health studies conducted over the last 10 years, we now have the tools necessary to accomplish this goal. The tools include assessment of lung function over time or defining trajectories of lung growth, the Composite Asthma Severity Index score, a panel of useful biomarkers, the Seasonal Asthma Exacerbation Prediction Index score, and rapidly advancing technology that includes adherence monitoring. Future guideline revisions should consider incorporating recommendations to follow spirometry over time and defining trajectories of lung growth to assess risk for reduced lung growth and early decline, asthma burden by using biomarkers to select and monitor therapy, assessment of social determinants of health, evaluation of risk for seasonal exacerbations, and consideration of electronic adherence monitoring for difficult to -manage asthma. Guidelines should continue to include a core dedicated to the diagnosis and treatment of intermittent and mild and moderate persistent asthma and include additional sections dedicated to the management of severe asthma.	[Szefler, Stanley J.] Childrens Hosp Colorado, Breathing Inst, Aurora, CO USA; [Szefler, Stanley J.] Childrens Hosp Colorado, Pulm Med Sect, Aurora, CO USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Aurora, CO USA	Children's Hospital Colorado; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Szefler, SJ (corresponding author), Childrens Hosp Colorado, Sect Pulm Med, Breathing Inst, 13123 E 16th Ave,Box B395, Aurora, CO 80045 USA.	Stanley.Szefler@childrenscolorado.org		Szefler, Stanley/0000-0002-6911-3199	National Institutes of Health; National Heart, Lung, and Blood Institute; GlaxoSmithKline; Colorado Cancer, Cardiovascular, and Pulmonary Disease Program	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); GlaxoSmithKline(GlaxoSmithKline); Colorado Cancer, Cardiovascular, and Pulmonary Disease Program	S. J. Szefler has consulted for Aerocrine, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Genentech, Novartis, Roche, and Teva and has received research support from the National Institutes of Health; the National Heart, Lung, and Blood Institute; GlaxoSmithKline; and the Colorado Cancer, Cardiovascular, and Pulmonary Disease Program. He is also a former member of the Global Initiative for Asthma Scientific Committee and the National Asthma Education and Prevention Program Expert Panel 3.	Anderson WC, 2017, J ALLERGY CLIN IMMUN, V140, P671, DOI 10.1016/j.jaci.2017.06.015; Anderson WC, 2015, J ALLERGY CLIN IMMUN, V136, P848, DOI 10.1016/j.jaci.2015.07.007; Anise A, 2016, J ALLERGY CLIN IMMUN, V138, P1503, DOI 10.1016/j.jaci.2016.10.003; Asthma G.I.F, 2017, GLOB STRAT ASTHM MAN; Berry CE, 2016, AM J RESP CRIT CARE, V194, P607, DOI 10.1164/rccm.201604-0753OC; Fitzpatrick AM, 2016, J ALLERGY CLIN IMMUN, V138, P1608, DOI 10.1016/j.jaci.2016.09.028; Foster JM, 2014, J ALLERGY CLIN IMMUN, V134, P1260, DOI 10.1016/j.jaci.2014.05.041; Garg A, 2007, PEDIATRICS, V120, P547, DOI 10.1542/peds.2007-0398; Gold DR, 2017, J ALLERGY CLIN IMMUN, V140, P933, DOI 10.1016/j.jaci.2017.04.024; Halterman JS, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2017.4938; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Hoch HE, 2017, J ALLERGY CLIN IMMUN, V140, P1130, DOI 10.1016/j.jaci.2017.01.026; Kercsmar CM, 2017, JAMA PEDIATR, V171, P1072, DOI 10.1001/jamapediatrics.2017.2600; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, P112, DOI 10.1016/j.jaci.2011.10.030; Krouse RZ, 2017, J ALLERGY CLIN IMMUN, V139, P1052, DOI 10.1016/j.jaci.2016.08.041; Lemanske RF, 2016, J ALLERGY CLIN IMMUN, V138, P711, DOI 10.1016/j.jaci.2016.06.015; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Liptzin DR, 2016, J ALLER CL IMM-PRACT, V4, P972, DOI 10.1016/j.jaip.2016.04.016; Malka J, 2014, J ALLERGY CLIN IMMUN, V134, P483, DOI 10.1016/j.jaci.2014.03.039; McGeachie MJ, 2016, NEW ENGL J MED, V374, P1842, DOI 10.1056/NEJMoa1513737; Merchant RK, 2016, J ALLER CL IMM-PRACT, V4, P455, DOI 10.1016/j.jaip.2015.11.022; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Heart Lung and Blood Advisory Council Asthma Expert Working Group., 2014, DRAFT NEEDS ASS REP; National Institute for Health and Care Excellence, ASTHM DIAGN MON CHRO; Nkrumah-Elie Y, 2018, FUTURE DIRECTIONS PE, P151; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Reddel HK, 2015, J ALLERGY CLIN IMMUN, V136, P546, DOI 10.1016/j.jaci.2015.06.043; Sanchis J, 2016, CHEST, V150, P394, DOI 10.1016/j.chest.2016.03.041; Schulz A, 2004, HEALTH EDUC BEHAV, V31, P455, DOI 10.1177/1090198104265598; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Spahn JD, 2016, J ALLERGY CLIN IMMUN, V138, P1296, DOI 10.1016/j.jaci.2016.09.002; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler SJ, 2018, PERSONALIZING ASTHMA; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P3, DOI 10.1016/j.jaci.2013.10.018; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Tagiyeva N, 2016, AM J RESP CRIT CARE, V193, P23, DOI 10.1164/rccm.201505-0870OC; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008; Teach SJ, 2015, J ALLERGY CLIN IMMUN, V135, P1465, DOI 10.1016/j.jaci.2014.12.1942; von Mutius E, 2012, NEW ENGL J MED, V366, P827, DOI 10.1056/NEJMra1102783; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN, V129, P694, DOI 10.1016/j.jaci.2011.12.962; Williams DR, 2009, PEDIATRICS, V123, pS174, DOI 10.1542/peds.2008-2233H; Woods ER, 2016, MMWR-MORBID MORTAL W, V65, P11, DOI 10.15585/mmwr.su6501a4; Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	47	27	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					773	780		10.1016/j.jaci.2018.03.010	http://dx.doi.org/10.1016/j.jaci.2018.03.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29627424	Bronze			2022-12-18	WOS:000443726500007
J	van Anrooij, B; Elberink, JNGO; Span, LFR; de Monchy, JGR; Rosati, S; Mulder, AB; Kluin-Nelemans, JC				van Anrooij, Bjorn; Elberink, Joanne N. G. Oude; Span, Lambert F. R.; de Monchy, Jan G. R.; Rosati, Stefano; Mulder, Andre B.; Kluin-Nelemans, Johanna C.			Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ACTIVATED RECEPTOR 2; AIRWAY EPITHELIAL-CELLS; DIET-INDUCED OBESITY; INSULIN-RECEPTOR; PHOSPHORYLATION; EXPRESSION; RELEASE; SUBSTRATE-1; INHIBITION; PAR-2		[van Anrooij, Bjorn; Elberink, Joanne N. G. Oude; de Monchy, Jan G. R.] Univ Groningen, Univ Med Ctr Groningen, Dept Allergol, Groningen, Netherlands; [van Anrooij, Bjorn; Span, Lambert F. R.; Kluin-Nelemans, Johanna C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands; [Rosati, Stefano] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Mulder, Andre B.] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	van Anrooij, B (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Allergol, Groningen, Netherlands.; van Anrooij, B (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands.	b.van.anrooij@umcg.nl			Novartis	Novartis(Novartis)	Supported by a research grant and free use of drug from Novartis.	Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753; Andre DM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17558-w; Asokananthan N, 2002, J IMMUNOL, V168, P3577, DOI 10.4049/jimmunol.168.7.3577; Badeanlou L, 2011, NAT MED, V17, P1490, DOI 10.1038/nm.2461; BORISH L, 1992, J IMMUNOL, V149, P3078; Buteau J, 2006, DIABETES, V55, P1190, DOI 10.2337/db05-0825; Crilly A, 2012, ANN RHEUM DIS, V71, P1049, DOI 10.1136/annrheumdis-2011-200703; Danahay H, 2002, AM J PHYSIOL-LUNG C, V282, pL226, DOI 10.1152/ajplung.00311.2001; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Gotlib J, 2016, NEW ENGL J MED, V374, P2530, DOI 10.1056/NEJMoa1513098; Heide R, 2009, CLIN EXP DERMATOL, V34, P462, DOI 10.1111/j.1365-2230.2008.03005.x; Horny H-P., 2017, WHO CLASSIFICATION T, P61; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Hyun E, 2011, CRIT REV IMMUNOL, V31, P307, DOI 10.1615/CritRevImmunol.v31.i4.30; Hyun E, 2010, J IMMUNOL, V184, P2702, DOI 10.4049/jimmunol.0902171; Jairaman A, 2015, J IMMUNOL, V195, P2122, DOI 10.4049/jimmunol.1500396; Knight V, 2012, HEPATOLOGY, V55, P879, DOI 10.1002/hep.24784; Kouzaki H, 2013, AM J RESP CELL MOL, V49, P741, DOI 10.1165/rcmb.2012-0304OC; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kwapiszewska G, 2012, CIRC RES, V110, P1179, DOI 10.1161/CIRCRESAHA.111.257568; Lee CS, 2013, EUR RESPIR J, V41, P1147, DOI 10.1183/09031936.00050612; Lee HY, 2004, BIOCHEM PHARMACOL, V68, P1119, DOI 10.1016/j.bcp.2004.05.033; Li MM, 2015, MOL MED REP, V12, P6227, DOI 10.3892/mmr.2015.4179; Lim JX, 2013, FASEB J, V27, P4757, DOI 10.1096/fj.13-232702; Loffredo LF, 2017, ALLERGY, V72, P1988, DOI 10.1111/all.13222; Lohman RJ, 2012, J PHARMACOL EXP THER, V340, P256, DOI 10.1124/jpet.111.187062; Lortholary O, 2017, LANCET, V389, P612, DOI 10.1016/S0140-6736(16)31403-9; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; McArdle Maeve A, 2013, Front Endocrinol (Lausanne), V4, P52, DOI 10.3389/fendo.2013.00052; Molina SA, 2017, AM J PHYSIOL-LUNG C, V312, P1688, DOI 10.1152/ajplung.00364.2016; Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714; Neveu WA, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-28; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Palikhe NS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144500; Seront E, 2013, BRIT J CANCER, V109, P1586, DOI 10.1038/bjc.2013.505; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115; Tiwari S, 2007, J AM SOC NEPHROL, V18, P2661, DOI 10.1681/ASN.2006121410; Valent P, 2017, ANN ONCOL, V28, P2367, DOI 10.1093/annonc/mdx290; Valent P, 2017, CANCER RES, V77, P1261, DOI 10.1158/0008-5472.CAN-16-2234; van Anrooij B, 2016, ALLERGY, V71, P1585, DOI 10.1111/all.12920; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; Wei LP, 2014, CELL SIGNAL, V26, P1476, DOI 10.1016/j.cellsig.2014.03.008; Werner ED, 2004, J BIOL CHEM, V279, P35298, DOI 10.1074/jbc.M405203200; Wygrecka M, 2011, AM J RESP CRIT CARE, V183, P1703, DOI 10.1164/rccm.201009-1479OC; Xue ML, 2012, ARTHRITIS RHEUM-US, V64, P88, DOI 10.1002/art.33323	50	27	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					1006	+		10.1016/j.jaci.2018.06.003	http://dx.doi.org/10.1016/j.jaci.2018.06.003			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29890238	Bronze			2022-12-18	WOS:000443726500040
J	Ueharaguchi, Y; Honda, T; Kusuba, N; Hanakawa, S; Adachi, A; Sawada, Y; Otsuka, A; Kitoh, A; Dainichi, T; Egawa, G; Nakashima, C; Nakajima, S; Murata, T; Ono, S; Arita, M; Narumiya, S; Miyachi, Y; Kabashima, K				Ueharaguchi, Yuri; Honda, Tetsuya; Kusuba, Nobuhiro; Hanakawa, Sho; Adachi, Akimasa; Sawada, Yu; Otsuka, Atsushi; Kitoh, Akihiko; Dainichi, Teruki; Egawa, Gyohei; Nakashima, Chisa; Nakajima, Saeko; Murata, Teruasa; Ono, Sachiko; Arita, Makoto; Narumiya, Shuh; Miyachi, Yoshiki; Kabashima, Kenji			Thromboxane A(2) facilitates IL-17A production from V gamma 4(+) gamma delta T cells and promotes psoriatic dermatitis in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INFLAMMATION		[Ueharaguchi, Yuri; Honda, Tetsuya; Kusuba, Nobuhiro; Hanakawa, Sho; Adachi, Akimasa; Sawada, Yu; Otsuka, Atsushi; Kitoh, Akihiko; Dainichi, Teruki; Egawa, Gyohei; Nakashima, Chisa; Nakajima, Saeko; Murata, Teruasa; Ono, Sachiko; Miyachi, Yoshiki; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; [Honda, Tetsuya; Arita, Makoto] Kyoto Univ, Grad Sch Med, Dept Innovat, Ctr Immunoregulat Technol & Drugs, Kyoto, Japan; [Arita, Makoto] RIKEN Ctr Integrat Med Sci, Lab Metabol, Yokohama, Kanagawa, Japan; [Arita, Makoto] Keio Univ, Grad Sch Pharmaceut Sci, Div Physiol Chem & Metab, Tokyo, Japan; [Narumiya, Shuh] Kyoto Univ, Grad Sch Med, Dept Drug Discovery Med, Kyoto, Japan; [Kabashima, Kenji] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore; [Kabashima, Kenji] ASTAR, Inst Med Biol, Singapore, Singapore	Kyoto University; Kyoto University; RIKEN; Keio University; Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Honda, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan.; Honda, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Innovat, Ctr Immunoregulat Technol & Drugs, Kyoto, Japan.	hontetsu@kuhp.kyoto-u.ac.jp; kaba@kuhp.kyoto-u.ac.jp	Hanakawa, Sho/GSO-1564-2022; Dainichi, Teruki/AAL-5400-2020; Nakajima, Saeko/AAB-1577-2021	Hanakawa, Sho/0000-0002-0665-9602; Dainichi, Teruki/0000-0002-9497-0029; Egawa, Gyohei/0000-0002-6101-4719; Otsuka, Atsushi/0000-0001-7365-947X; Arita, Makoto/0000-0001-9902-0463; Nakajima, Saeko/0000-0003-0831-1447	Ministry of Education, Culture, Sports, Science and Technology of Japan; Astellas Pharma Inc in the Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program; Japan Society for the Promotion of Science KAKENHI [JP15K09766, JP15H05096, 263395]; Japan Science, and Japan Agency for Medical Research and Development (AMED) [16ek0410011h0003, 16he0902003h0002, JP17ek0410040];  [15H05790];  [15H1155];  [15K15417];  [JP15H05897];  [15H05898];  [15H04648]; Grants-in-Aid for Scientific Research [15H05897] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Astellas Pharma Inc in the Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program; Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Science, and Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); ; ; ; ; ; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by grants from Special Coordination Funds by the Ministry of Education, Culture, Sports, Science and Technology of Japan and Astellas Pharma Inc in the Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program (T.H.), Japan Society for the Promotion of Science KAKENHI (grant nos. JP15K09766, JP15H05096 [T.H.], and 263395 [K.K.]), Grants-in-Aid for Scientific Research (grant nos. 15H05790, 15H1155, 15K15417 [K.K.], JP15H05897, 15H05898, and 15H04648 [M.A]), Japan Science, and Japan Agency for Medical Research and Development (AMED) (grant nos. 16ek0410011h0003 and 16he0902003h0002 [K.K.], and JP17ek0410040 [S.N.]).	Ardigo M, 2013, SKIN RES TECHNOL, V19, P417, DOI 10.1111/srt.12062; Arita M, 2012, J BIOCHEM, V152, P313, DOI 10.1093/jb/mvs092; Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001; Ikai K, 1999, J DERMATOL SCI, V21, P135, DOI 10.1016/S0923-1811(99)00042-0; Juniper EF, 2000, CLIN EXP ALLERGY, V30, P132; Kabashima K, 2003, NAT IMMUNOL, V4, P694, DOI 10.1038/ni943; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Spertini F, 2016, J ALLERGY CLIN IMMUN, V138, P162, DOI 10.1016/j.jaci.2016.02.044; Sumaria N, 2011, J EXP MED, V208, P505, DOI 10.1084/jem.20101824; van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999	11	27	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					680	683		10.1016/j.jaci.2018.01.054	http://dx.doi.org/10.1016/j.jaci.2018.01.054			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29678752	Bronze			2022-12-18	WOS:000440664400037
J	Lee-Sarwar, K; Kelly, RS; Lasky-Su, J; Moody, DB; Mola, AR; Cheng, TY; Comstock, LE; Zeiger, RS; O'Connor, GT; Sandel, MT; Bacharier, LB; Beigelman, A; Laranjo, N; Gold, DR; Bunyavanich, S; Savage, JH; Weiss, ST; Brennan, PJ; Litonjua, AA				Lee-Sarwar, Kathleen; Kelly, Rachel S.; Lasky-Su, Jessica; Moody, D. Branch; Mola, Alex R.; Cheng, Tan-Yun; Comstock, Laurie E.; Zeiger, Robert S.; O'Connor, George T.; Sandel, Megan T.; Bacharier, Leonard B.; Beigelman, Avraham; Laranjo, Nancy; Gold, Diane R.; Bunyavanich, Supinda; Savage, Jessica H.; Weiss, Scott T.; Brennan, Patrick J.; Litonjua, Augusto A.			Intestinal microbial-derived sphingolipids are inversely associated with childhood food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							KILLER T-CELLS; VITAMIN-D; ACTIVATION; VARIANTS; PROTEIN; ASTHMA		[Lee-Sarwar, Kathleen; Moody, D. Branch; Mola, Alex R.; Cheng, Tan-Yun; Savage, Jessica H.; Brennan, Patrick J.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA; [Kelly, Rachel S.; Lasky-Su, Jessica; Laranjo, Nancy; Gold, Diane R.; Weiss, Scott T.; Litonjua, Augusto A.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Comstock, Laurie E.] Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA; [Comstock, Laurie E.] Harvard Med Sch, Boston, MA USA; [Zeiger, Robert S.] Kaiser Permanente Southern Calif, San Diego, CA USA; [O'Connor, George T.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; [O'Connor, George T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Sandel, Megan T.] Boston Med Ctr, Dept Pediat, Boston, MA USA; [Bacharier, Leonard B.; Beigelman, Avraham] Washington Univ, Sch Med, Dept Pediat, Div Pediat Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Bacharier, Leonard B.; Beigelman, Avraham] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Gold, Diane R.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Pediat Allergy Immunol, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kaiser Permanente; Boston University; Boston University; Boston Medical Center; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Harvard University; Harvard T.H. Chan School of Public Health; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Lee-Sarwar, K (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.	klee-sarwar@partners.org; augusto_litonjua@urmc.rochester.edu	kelly, rachel/H-4505-2017	kelly, rachel/0000-0003-3023-1822; Bacharier, Leonard/0000-0003-0432-2704; Zeiger, Robert/0000-0001-5788-5063	National Heart, Lung, and Blood Institute [U01HL091528]; National Institutes of Health (NIH) [R01HL108818, 5T32AI007306-30]; NIH [AI102945, R01AR048632]; Goodfellow family; Violin family; Karol family; Brigham and Women's Hospital Innovation Evergreen Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007427, R01HL091528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI102945, T32AI007306, R01AI118833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048632] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [UH3OD023268] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Goodfellow family; Violin family; Karol family; Brigham and Women's Hospital Innovation Evergreen Fund; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The Vitamin D Antenatal Asthma Reduction Trial was funded by the National Heart, Lung, and Blood Institute (grant no. U01HL091528). Additional funding came from the National Institutes of Health (NIH) (grant nos. R01HL108818 and 5T32AI007306-30). P.J.B. was supported by the NIH (grant no. AI102945) and generous support from the Goodfellow, Violin, and Karol families. P.J.B. and L.E.C. were supported by the Brigham and Women's Hospital Innovation Evergreen Fund. T.-Y.C. and D.B.M. were supported by the NIH (grant no. R01AR048632).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Brennan PJ, 2017, P NATL ACAD SCI USA, V114, P8348, DOI 10.1073/pnas.1705882114; Brennan PJ, 2014, P NATL ACAD SCI USA, V111, P13433, DOI 10.1073/pnas.1415357111; Brennan PJ, 2011, NAT IMMUNOL, V12, P1202, DOI 10.1038/ni.2143; Bridgewater Br E. A. M, 2014, METABOLOMICS, P04, DOI [DOI 10.4172/2153-0769.1000132, 10.4172/2153-0769.1000132]; Brown LCW, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001610; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; KATO M, 1995, ANAEROBE, V1, P135, DOI 10.1006/anae.1995.1009; Kawai S, 2002, J IMMUNOL METHODS, V260, P195, DOI 10.1016/S0022-1759(01)00549-X; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Ling ZX, 2014, APPL ENVIRON MICROB, V80, P2546, DOI 10.1128/AEM.00003-14; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; McHardy IH, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-17; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Methe BA, 2012, NATURE, V486, P215, DOI 10.1038/nature11209; Muindi K, 2010, P NATL ACAD SCI USA, V107, P3052, DOI 10.1073/pnas.0915056107; PANTOSTI A, 1991, INFECT IMMUN, V59, P2075, DOI 10.1128/IAI.59.6.2075-2082.1991; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Savage JH, 2018, ALLERGY, V73, P145, DOI 10.1111/all.13232; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Sordillo JE, 2017, J ALLERGY CLIN IMMUN, V139, P482, DOI 10.1016/j.jaci.2016.08.045; Tingley D, 2014, J STAT SOFTW, V59; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Yu W, 2016, NAT REV IMMUNOL, V16, P751, DOI 10.1038/nri.2016.111; Zitomersky NL, 2011, INFECT IMMUN, V79, P2012, DOI 10.1128/IAI.01348-10	30	27	27	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					335	+		10.1016/j.jaci.2018.04.016	http://dx.doi.org/10.1016/j.jaci.2018.04.016			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29729303	Green Accepted, Bronze			2022-12-18	WOS:000437837500048
J	Yao, Y; Chen, CL; Wang, N; Wang, ZC; Ma, J; Zhu, RF; Xu, XY; Zhou, PC; Yu, D; Liu, Z				Yao, Yin; Chen, Cai-Ling; Wang, Nan; Wang, Zhi-Chao; Ma, Jin; Zhu, Rong-Fei; Xu, Xiao-Yan; Zhou, Peng-Cheng; Yu, Di; Liu, Zheng			Correlation of allergen-specific T follicular helper cell counts with specific IgE levels and efficacy of allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							REGULATORY B-CELLS		[Yao, Yin; Chen, Cai-Ling; Wang, Nan; Wang, Zhi-Chao; Ma, Jin; Liu, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Zhu, Rong-Fei] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Allergy, Wuhan, Hubei, Peoples R China; [Xu, Xiao-Yan] China Resources & Wisco Gen Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China; [Zhou, Peng-Cheng; Yu, Di] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, ACT, Australia	Huazhong University of Science & Technology; Huazhong University of Science & Technology; China Resources Group; Australian National University; John Curtin School of Medical Research	Liu, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Hubei, Peoples R China.	zhengliuent@hotmail.com	Zhou, Pengcheng/AAQ-1320-2020; Yu, Di/C-2163-2009; Zhu, Rongfei/AAC-5570-2022; Zhou, Pengcheng/GRR-4171-2022	Zhou, Pengcheng/0000-0002-7736-2902; Yu, Di/0000-0003-1721-8922; Zhu, Rongfei/0000-0003-2103-3381; Zhou, Pengcheng/0000-0002-7736-2902; Yin, Yao/0000-0002-5833-5263	National Natural Science Foundation of China (NSFC) [81325006, 81570899, 81630024, 81429003]; Hubei Province Natural Science Foundation [2017CFA016]; Australian National Health and Medical Research Council (NHMRC) fellowship [GNT1085509]; National Basic Research Program of China 973 Program [2014CB541903]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Hubei Province Natural Science Foundation(Natural Science Foundation of Hubei Province); Australian National Health and Medical Research Council (NHMRC) fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Basic Research Program of China 973 Program(National Basic Research Program of China)	Supported by National Natural Science Foundation of China (NSFC) grants 81325006, 81570899, and 81630024 (to Z.L.) and 81429003 (to D.Y.), Hubei Province Natural Science Foundation grant 2017CFA016 (to Z.L.), the Australian National Health and Medical Research Council (NHMRC) fellowship GNT1085509 (to D.Y.), and the National Basic Research Program of China 973 Program 2014CB541903 (to D.Y.).	Chiang C, 2015, NAT METHODS, V12, P966, DOI [10.1038/NMETH.3505, 10.1038/nmeth.3505]; Chiang SCC, 2013, BLOOD, V121, P1345, DOI 10.1182/blood-2012-07-442558; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Jordakieva G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02321-y; Karnekura R, 2015, CLIN IMMUNOL, V158, P204, DOI 10.1016/j.clim.2015.02.016; Kim AS, 2016, J ALLERGY CLIN IMMUN, V138, P1192, DOI 10.1016/j.jaci.2016.03.017; Kubo M, 2017, ALLERGOL INT, V66, P377, DOI 10.1016/j.alit.2017.04.006; Meeths M, 2011, BLOOD, V118, P5783, DOI 10.1182/blood-2011-07-369090; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Sahoo A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8997; Schulten V, 2018, J ALLERGY CLIN IMMUN, V141, P775, DOI 10.1016/j.jaci.2017.04.032; Shamji MH, 2017, ALLERGY, V72, P1156, DOI 10.1111/all.13138; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Zhang YN, 2016, J ALLERGY CLIN IMMUN, V137, P462, DOI 10.1016/j.jaci.2015.07.025	14	27	31	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					321	324		10.1016/j.jaci.2018.03.008	http://dx.doi.org/10.1016/j.jaci.2018.03.008			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29626573	Green Accepted, Bronze			2022-12-18	WOS:000437837500043
J	Lenders, M; Schmitz, B; Brand, SM; Foell, D; Brand, E				Lenders, Malte; Schmitz, Boris; Brand, Stefan-Martin; Foell, Dirk; Brand, Eva			Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ENZYME REPLACEMENT THERAPY; SIGNAL INHIBITORY RECEPTOR; INNATE		[Lenders, Malte; Brand, Eva] Univ Hosp Muenster, Dept Nephrol Hypertens & Rheumatol, Internal Med D, Munster, Germany; [Schmitz, Boris; Brand, Stefan-Martin] Univ Hosp Muenster, Inst Sports Med, Mol Genet Cardiovasc Dis, Munster, Germany; [Foell, Dirk] Univ Hosp Muenster, Dept Pediat Rheumatol & Immunol, Munster, Germany	University of Munster; University of Munster; University of Munster	Brand, E (corresponding author), Univ Hosp Muenster, Dept Nephrol Hypertens & Rheumatol, Internal Med D, Munster, Germany.	Eva.Brand@ukmuenster.de	Schmitz, Boris/M-3205-2019	Schmitz, Boris/0000-0001-7041-7424; Lenders, Malte/0000-0001-8409-2886	Genzyme GmbH; Shire	Genzyme GmbH(Sanofi-AventisGenzyme Corporation); Shire	M.L. received speaker honoraria from Genzyme and Shire. E.B. received speaker honoraria from Amicus Therapeutics, Genzyme, and Shire. S.-M.B. received speaker honoraria from Shire. B.S. and D.F. have nothing to declare. Parts of this study were funded by Genzyme GmbH and Shire. The funding companies had no role in the design and conduction of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript. The researchers were independent of the funding source.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; de Wit J, 2011, BLOOD, V118, P6107, DOI 10.1182/blood-2011-05-352682; Drewniak A, 2013, BLOOD, V121, P2385, DOI 10.1182/blood-2012-08-450551; Hollak CEM, 2008, MOL GENET METAB, V95, P239, DOI 10.1016/j.ymgme.2008.08.006; Lenders M, 2017, J INTERN MED, V282, P241, DOI 10.1111/joim.12647; Lenders M, 2016, J AM SOC NEPHROL, V27, P256, DOI 10.1681/ASN.2014121226; Linthorst GE, 2004, KIDNEY INT, V66, P1589, DOI 10.1111/j.1523-1755.2004.00924.x; Mauhin W, 2015, JIMD REP, V22, P1, DOI 10.1007/8904_2014_371; Schiffmann R, 2015, J INHERIT METAB DIS, V38, P1129, DOI 10.1007/s10545-015-9845-5; Smid BE, 2013, MOL GENET METAB, V108, P132, DOI 10.1016/j.ymgme.2012.12.005; Steevels TAM, 2013, EUR J IMMUNOL, V43, P1297, DOI 10.1002/eji.201242916; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strasser D, 2012, IMMUNITY, V36, P32, DOI 10.1016/j.immuni.2011.11.015; Van Avondt K, 2016, J IMMUNOL, V196, P3686, DOI 10.4049/jimmunol.1501650; van de Vosse E, 2011, ANN HEMATOL, V90, P151, DOI 10.1007/s00277-010-1056-4; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Zhao XW, 2013, BLOOD, V122, P109, DOI 10.1182/blood-2013-03-494039	17	27	28	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2289	2292		10.1016/j.jaci.2017.12.1001	http://dx.doi.org/10.1016/j.jaci.2017.12.1001			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29421273	Bronze			2022-12-18	WOS:000434701600038
J	Na, H; Lim, H; Choi, G; Kim, BK; Kim, SH; Chang, YS; Nurieva, R; Dong, C; Chang, SH; Chung, Y				Na, Hyeongjin; Lim, Hoyong; Choi, Garam; Kim, Byung-Keun; Kim, Sae-Hoon; Chang, Yoon-Seok; Nurieva, Roza; Dong, Chen; Chang, Seon Hee; Chung, Yeonseok			Concomitant suppression of T(H)2 and T(H)17 cell responses in allergic asthma by targeting retinoic acid receptor-related orphan receptor gamma t	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; T(H)17 cell; T(H)2 cell; retinoic acid receptor-related orphan receptor gamma t; B-cell lymphoma 6	MONOCLONAL-ANTIBODY; HELPER-CELLS; TH17 CELLS; IFN-GAMMA; IN-VIVO; DIFFERENTIATION; INFLAMMATION; TH2; EXPRESSION; INNATE	Background: Allergic asthma is a heterogeneous chronic inflammatory disease of the airways with a massive infiltration of eosinophils or neutrophils mediated by allergen-specific T(H)2 and T(H)17 cells, respectively. Therefore successful treatment of allergic asthma will require suppression of both T(H)2 and T(H)17 cells. Objective: We sought to investigate the role of the T(H)17 cell pathway in regulating T(H)2 cell responses in allergic asthma. Methods: Allergic asthma was induced by intranasal challenge with proteinase allergens in C57BL/6, Il17a 2/2 Il17f 2/2, and retinoic acid receptor-related orphan receptor gt (RORgt) gfp/gfp mice. A pharmacologic RORgt inhibitor was used to evaluate its preventive and therapeutic effects in allergic asthma. Characteristics of allergic airway inflammation were analyzed by using flow cytometry, histology, quantitative real-time PCR, and ELISA. Mixed bone marrow chimeric mice, fate mapping analysis, short hairpin RNA transduction, and in vitro T-cell differentiation were used for mechanistic studies. Results: Mice deficient in IL-17A and IL-17F, as well as RORgt, exhibited a significant reduction not only in T(H)17 cell responses but also in T(H)2 cell responses in an animal model of allergic asthma. Similarly, mice treated with an RORgt inhibitor had significantly diminished T(H)17 and T(H)2 cell responses, leading to reduced neutrophil and eosinophil numbers in the airway. RORgt-deficient T cells were intrinsically defective in differentiating into T(H)2 cells and expressed increased levels of B-cell lymphoma 6 (Bcl6). Bcl6 knockdown resulted in a remarkable restoration of T(H)2 cell differentiation in RORgtdeficient T cells. Blockade of RORgt also significantly hampered the differentiation of human T(H)2 and T(H)17 cells from naive CD4 1 T cells. Conclusion: RORgt in T cells is required for optimal T(H)2 cell differentiation by suppressing Bcl6 expression; this finding suggests that targeting RORgt might be a promising approach for the treatment of allergic asthma by concomitantly suppressing T(H)17 and T(H)2 cell responses in the airway.	[Na, Hyeongjin; Lim, Hoyong; Choi, Garam; Chung, Yeonseok] Seoul Natl Univ, Lab Immune Regulat, Inst Pharmaceut Sci, Seoul, South Korea; [Na, Hyeongjin; Choi, Garam; Chung, Yeonseok] Seoul Natl Univ, Plus Program BK21, Coll Pharm, Seoul, South Korea; [Kim, Byung-Keun; Kim, Sae-Hoon; Chang, Yoon-Seok] Seoul Natl Univ, Coll Med, Div Allergy & Clin Immunol, Dept Internal Med,Seoul Natl Univ Bundang Hosp, Seongnam, South Korea; [Nurieva, Roza; Chang, Seon Hee] MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Dong, Chen] Tsinghua Univ, Inst Immunol, Beijing, Peoples R China; [Dong, Chen] Tsinghua Univ, Sch Med, Beijing, Peoples R China	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; University of Texas System; UTMD Anderson Cancer Center; Tsinghua University; Tsinghua University	Chang, SH (corresponding author), MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.; Chung, Y (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea.	shchang@mdanderson.org; yeonseok@snu.ac.kr	dong, chen/B-3181-2009; Chang, Seon Hee/AAQ-9521-2020; Chang, Yoon-Seok/J-5628-2012	dong, chen/0000-0002-0084-9130; Chang, Seon Hee/0000-0002-9389-508X; Chang, Yoon-Seok/0000-0003-3157-0447; Chung, Yeonseok/0000-0001-5780-4841; Kim, Byung-Keun/0000-0001-5147-6306	National Research Foundation of Korea [2017R1A2B3007392]; Korean Health Technology R&D Project, Ministry of Health Welfare [HI14C2282]; Cancer Prevention and Research Institute of Texas [RP130078]; Department of Defense [W81XWH-16-1-0100]; NRF - Ministry of Education of Korea [2015H1A2A1030805]; NATIONAL CANCER INSTITUTE [R03CA219760] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI125269, R03AI120027, R21AI120012] Funding Source: NIH RePORTER	National Research Foundation of Korea(National Research Foundation of Korea); Korean Health Technology R&D Project, Ministry of Health Welfare; Cancer Prevention and Research Institute of Texas; Department of Defense(United States Department of Defense); NRF - Ministry of Education of Korea; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by research grants 2017R1A2B3007392 (to Y.C.) from the National Research Foundation of Korea and HI14C2282 (to Y.C.) from the Korean Health Technology R&D Project, Ministry of Health & Welfare; the Cancer Prevention and Research Institute of Texas (RP130078; to S.H.C.); and the Department of Defense (W81XWH-16-1-0100; to S.H.C.). H.N. is a recipient of the Global Ph.D. Fellowship Program through NRF (2015H1A2A1030805) funded by the Ministry of Education of Korea.	Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Bellini A, 2012, MUCOSAL IMMUNOL, V5, P140, DOI 10.1038/mi.2011.60; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Chung KF, 2015, LANCET, V386, P1086, DOI 10.1016/S0140-6736(15)00157-9; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Corry David B, 2002, Am J Respir Med, V1, P185; Cosmi L, 2011, ALLERGY, V66, P989, DOI 10.1111/j.1398-9995.2011.02576.x; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Huang JL, 2017, J IMMUNOL, V198, P669, DOI 10.4049/jimmunol.1600977; Ichiyama K, 2016, IMMUNITY, V44, P1284, DOI 10.1016/j.immuni.2016.05.015; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jin W, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.58; Johansson C, 2004, INT ARCH ALLERGY IMM, V135, P93, DOI 10.1159/000080651; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kumar N, 2012, ACS CHEM BIOL, V7, P672, DOI 10.1021/cb200496y; Kusam S, 2003, J IMMUNOL, V170, P2435, DOI 10.4049/jimmunol.170.5.2435; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leppkes M, 2009, GASTROENTEROLOGY, V136, P257, DOI 10.1053/j.gastro.2008.10.018; Lim H, 2015, INT IMMUNOPHARMACOL, V28, P846, DOI 10.1016/j.intimp.2015.03.051; Lim H, 2013, IMMUNOL LETT, V156, P140, DOI 10.1016/j.imlet.2013.10.003; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Liu XD, 2016, CELL REP, V14, P1735, DOI 10.1016/j.celrep.2016.01.038; Migueres M, 2014, CLIN TRANSL ALLERGY, V4, DOI 10.1186/2045-7022-4-16; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Newcomb DC, 2013, CURR OPIN IMMUNOL, V25, P755, DOI 10.1016/j.coi.2013.08.002; Newcomb DC, 2009, J IMMUNOL, V182, P5317, DOI 10.4049/jimmunol.0803868; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Oriss TB, 1997, J IMMUNOL, V158, P3666; Park SH, 2014, PULM CIRC, V4, P654, DOI 10.1086/678511; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Roussel L, 2010, J IMMUNOL, V184, P4531, DOI 10.4049/jimmunol.0903162; Scheerens H, 2014, CLIN EXP ALLERGY, V44, P38, DOI 10.1111/cea.12220; Silvestri M, 1999, ANN ALLERG ASTHMA IM, V83, P335, DOI 10.1016/S1081-1206(10)62674-9; Stritesky GL, 2011, IMMUNITY, V34, P39, DOI 10.1016/j.immuni.2010.12.013; van Hamburg JP, 2008, EUR J IMMUNOL, V38, P2573, DOI 10.1002/eji.200737840; von Vietinghoff S, 2009, J IMMUNOL, V183, P865, DOI 10.4049/jimmunol.0804080; Xu T, 2011, J BIOL CHEM, V286, P22707, DOI 10.1074/jbc.C111.250407; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Yeh WI, 2014, J NEUROIMMUNOL, V267, P20, DOI 10.1016/j.jneuroim.2013.12.001; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002; Yu S, 2014, J ALLERGY CLIN IMMUN, V133, P943, DOI 10.1016/j.jaci.2014.02.015; Zhu JF, 2006, CELL RES, V16, P3, DOI 10.1038/sj.cr.7310002	53	27	30	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2061	+		10.1016/j.jaci.2017.07.050	http://dx.doi.org/10.1016/j.jaci.2017.07.050			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	28943467	Bronze, Green Accepted			2022-12-18	WOS:000434701600013
J	Mummy, DG; Kruger, SJ; Zha, W; Sorkness, RL; Jarjour, NN; Schiebler, ML; Denlinger, LC; Evans, MD; Fain, SB				Mummy, David G.; Kruger, Stanley J.; Zha, Wei; Sorkness, Ronald L.; Jarjour, Nizar N.; Schiebler, Mark L.; Denlinger, Loren C.; Evans, Michael D.; Fain, Sean B.			Ventilation defect percent in helium-3 magnetic resonance imaging as a biomarker of severe outcomes in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LUNG		[Mummy, David G.; Fain, Sean B.] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA; [Kruger, Stanley J.; Zha, Wei; Fain, Sean B.] Univ Wisconsin, Dept Med Phys, 1530 Med Sci Ctr, Madison, WI 53706 USA; [Sorkness, Ronald L.] Univ Wisconsin, Dept Pharm, Madison, WI USA; [Sorkness, Ronald L.; Jarjour, Nizar N.; Denlinger, Loren C.] Univ Wisconsin, Dept Allergy Pulm & Crit Care Med, Madison, WI USA; [Sorkness, Ronald L.] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Schiebler, Mark L.; Fain, Sean B.] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA; [Evans, Michael D.] Univ Wisconsin, Biostat & Med Informat, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fain, SB (corresponding author), Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA.; Fain, SB (corresponding author), Univ Wisconsin, Dept Med Phys, 1530 Med Sci Ctr, Madison, WI 53706 USA.; Fain, SB (corresponding author), Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA.	sfain@wisc.edu	Schiebler, Mark/V-5201-2019; Mummy, David/L-8167-2019; Fain, Sean/K-4260-2016	Evans, Michael/0000-0001-7449-3993; Mummy, David/0000-0001-7885-109X; Kruger, Stanley/0000-0001-8929-2596; Fain, Sean/0000-0001-5461-0646; schiebler, mark/0000-0002-9120-5428	NCATS NIH HHS [UL1 TR000427, UL1 TR002373] Funding Source: Medline; NHLBI NIH HHS [R01 HL080412, R01 HL069116, U10 HL109168] Funding Source: Medline; NIH HHS [S10 OD016394] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427, UL1TR002373] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109168, R01HL069116, R01HL080412] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD016394] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Fain SB, 2008, ACAD RADIOL, V15, P753, DOI 10.1016/j.acra.2007.10.019; Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451; Kirby M, 2015, RADIOLOGY, V277, P872, DOI 10.1148/radiol.2015150037; Kirby M, 2014, RADIOLOGY, V273, P887, DOI 10.1148/radiol.14140161; Kirby M, 2011, ACAD RADIOL, V18, P1006, DOI 10.1016/j.acra.2011.03.005; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Niles DJ, 2013, RADIOLOGY, V266, P618, DOI 10.1148/radiol.12111973; Ridgeway G, 2017, GBM GEN BOOSTED REGR; Woodhouse N, 2005, J MAGN RESON IMAGING, V21, P365, DOI 10.1002/jmri.20290	9	27	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1140	+		10.1016/j.jaci.2017.10.016	http://dx.doi.org/10.1016/j.jaci.2017.10.016			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29129582	Green Accepted, Bronze			2022-12-18	WOS:000426974800040
J	Ogasawara, N; Poposki, JA; Klingler, AI; Tan, BK; Weibman, AR; Hulse, KE; Stevens, WW; Peters, AT; Grammer, LC; Schleimer, RP; Welch, KC; Smith, SS; Conley, DB; Raviv, JR; Soroosh, P; Akbari, O; Himi, T; Kern, RC; Kato, A				Ogasawara, Noriko; Poposki, Julie A.; Klingler, Aiko I.; Tan, Bruce K.; Weibman, Ava R.; Hulse, Kathryn E.; Stevens, Whitney W.; Peters, Anju T.; Grammer, Leslie C.; Schleimer, Robert P.; Welch, Kevin C.; Smith, Stephanie S.; Conley, David B.; Raviv, Joseph R.; Soroosh, Pejman; Akbari, Omid; Himi, Tetsuo; Kern, Robert C.; Kato, Atsushi			IL-10, TGF-beta, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ATOPIC-DERMATITIS; IMMUNE-RESPONSE; ECZEMA; CRTH2		[Ogasawara, Noriko; Poposki, Julie A.; Klingler, Aiko I.; Hulse, Kathryn E.; Stevens, Whitney W.; Peters, Anju T.; Grammer, Leslie C.; Schleimer, Robert P.; Kern, Robert C.; Kato, Atsushi] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA; [Tan, Bruce K.; Weibman, Ava R.; Schleimer, Robert P.; Welch, Kevin C.; Smith, Stephanie S.; Conley, David B.; Kern, Robert C.; Kato, Atsushi] Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA; [Raviv, Joseph R.] Univ Chicago, Pritzker Sch Med, NorthShore Univ Hlth Syst, Div Otolaryngol Head & Neck Surg, Evanston, IL USA; [Soroosh, Pejman] Janssen Res & Dev, San Diego, CA USA; [Akbari, Omid] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA USA; [Himi, Tetsuo] Sapporo Med Univ, Sch Med, Dept Otolaryngol, Sapporo, Hokkaido, Japan	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; NorthShore University Health System; University of Chicago; University of Southern California; Sapporo Medical University	Kato, A (corresponding author), Northwestern Univ, Dept Med, Feinberg Sch Med, Div Allergy & Immunol, Chicago, IL 60611 USA.; Kato, A (corresponding author), Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA.	a-kato@northwestern.edu	Ogasawara, Noriko/K-6453-2019; Soroosh, Pejman/AAD-8386-2021; Smith, Stephanie Shintani/AAY-4854-2020; Ogasawara, Noriko/ABE-5531-2021	Ogasawara, Noriko/0000-0002-6014-3607; Smith, Stephanie Shintani/0000-0002-0605-3993; Kato, Atsushi/0000-0001-9144-3138	NCI NIH HHS [P30 CA060553] Funding Source: Medline; NHLBI NIH HHS [R37 HL068546, R01 HL068546] Funding Source: Medline; NIAID NIH HHS [P01 AI106683, R01 AI137174, U19 AI106683, R01 AI104733] Funding Source: Medline; NIDDK NIH HHS [P30 DK048522] Funding Source: Medline; NIEHS NIH HHS [R01 ES025786, P30 ES007048] Funding Source: Medline; NIH HHS [S10 OD011996] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068546, R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI137174, P01AI106683, U19AI106683, R01AI104733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007048, R01ES025786] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD011996] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bartemes KR, 2014, J ALLERGY CLIN IMMUN, V134, P671, DOI 10.1016/j.jaci.2014.06.024; Brunner PM, 2017, J INVEST DERMATOL, V137, P18, DOI 10.1016/j.jid.2016.08.022; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Ge XH, 2010, J VIROL, V84, P3312, DOI 10.1128/JVI.02226-09; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Jia Y, 2016, AM J RESP CELL MOL, V55, P675, DOI 10.1165/rcmb.2016-0099OC; Kondo T, 2009, J IMMUNOL, V182, P1794, DOI 10.4049/jimmunol.0801347; Kouser Lubna, 2017, Curr Treat Options Allergy, V4, P43, DOI 10.1007/s40521-017-0117-5; Laing KJ, 2010, J CLIN IMMUNOL, V30, P703, DOI 10.1007/s10875-010-9441-2; Liu S, 2017, J ALLERGY CLIN IMMUN; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Morgan TK, 2015, J LOW GENIT TRACT DI, V19, P345, DOI 10.1097/LGT.0000000000000147; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Olsen JR, 2016, BRIT J GEN PRACT, V66, pE53, DOI 10.3399/bjgp15X688093; Oran AE, 2004, J VIROL, V78, P4376, DOI 10.1128/JVI.78.8.4376-4380.2004; Poposki JA, 2017, IMMUN INFLAMM DIS, V5, P233, DOI 10.1002/iid3.161; Rigas D, 2017, J ALLERGY CLIN IMMUN, V139, P1468, DOI 10.1016/j.jaci.2016.08.034; Roesner LM, 2015, J INVEST DERMATOL, V135, P2324, DOI 10.1038/jid.2015.162; van Velzen M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003547; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Wolfl M, 2008, CYTOM PART A, V73A, P1043, DOI 10.1002/cyto.a.20594; Wollenberg A, 2012, CHEM IMMUNOL ALLERGY, V96, P89, DOI 10.1159/000331892; Zhang X, 2008, CLIN VACCINE IMMUNOL, V15, P1436, DOI 10.1128/CVI.00123-08	23	27	29	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					1147	+		10.1016/j.jaci.2017.09.025	http://dx.doi.org/10.1016/j.jaci.2017.09.025			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29074458	Green Accepted, Bronze			2022-12-18	WOS:000426974800043
J	Bogaert, DJ; Kuehn, HS; Bonroy, C; Calvo, KR; Dehoorne, J; Vanlander, AV; De Bruyne, M; Cytlak, U; Bigley, V; De Baets, F; De Baere, E; Rosenzweig, SD; Haerynck, F; Dullaers, M				Bogaert, Delfien J.; Kuehn, Hye Sun; Bonroy, Carolien; Calvo, Katherine R.; Dehoorne, Joke; Vanlander, Arnaud V.; De Bruyne, Marieke; Cytlak, Urszula; Bigley, Venetia; De Baets, Frans; De Baere, Elfride; Rosenzweig, Sergio D.; Haerynck, Filomeen; Dullaers, Melissa			A novel IKAROS haploinsufficiency kindred with unexpectedly late and variable B-cell maturation defects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HEMATOPOIESIS		[Bogaert, Delfien J.; De Bruyne, Marieke; Haerynck, Filomeen; Dullaers, Melissa] Univ Ghent, Dept Pulm Med, Clin Immunol Res Lab, Ghent, Belgium; [Bogaert, Delfien J.; De Bruyne, Marieke; De Baets, Frans; Haerynck, Filomeen; Dullaers, Melissa] Univ Ghent, Dept Pediat, Div Pediat Immunol & Pulmonol, Ghent, Belgium; [Bogaert, Delfien J.; Bonroy, Carolien; De Bruyne, Marieke; De Baets, Frans; De Baere, Elfride; Haerynck, Filomeen; Dullaers, Melissa] Univ Ghent, Jeffrey Modell Diag & Res Ctr, Ctr Primary Immunodeficiency, Ghent, Belgium; [Bonroy, Carolien] Univ Ghent, Dept Lab Med, Ghent, Belgium; [Dehoorne, Joke] Univ Ghent, Dept Pediat, Div Pediat Nephrol & Rheumatol, Ghent, Belgium; [Vanlander, Arnaud V.] Univ Ghent, Dept Pediat, Div Pediat Neurol & Metab, Ghent, Belgium; [Bogaert, Delfien J.; De Bruyne, Marieke] Univ Ghent, Ctr Med Genet, Ghent, Belgium; Ghent Univ Hosp, Ghent, Belgium; [Bogaert, Delfien J.; Dullaers, Melissa] VIB Inflammat Res Ctr, Lab Immunoregulat, Ghent, Belgium; [Kuehn, Hye Sun; Rosenzweig, Sergio D.] NIH, Serv Immunol, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA; [Calvo, Katherine R.] NIH, Hematol Sect, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA; [Cytlak, Urszula; Bigley, Venetia] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Cytlak, Urszula; Bigley, Venetia] Newcastle Tyne Hosp NHS Fdn Trust, Northern Ctr Bone Marrow Transplantat, Newcastle Upon Tyne, Tyne & Wear, England; [Dullaers, Melissa] Univ Ghent, Dept Internal Med, Ghent, Belgium	Ghent University; Ghent University; Ghent University; Ghent University; Ghent University; Ghent University; Ghent University; Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Ghent University	Dullaers, M (corresponding author), Univ Ghent, Dept Pulm Med, Clin Immunol Res Lab, Ghent, Belgium.; Dullaers, M (corresponding author), Univ Ghent, Dept Pediat, Div Pediat Immunol & Pulmonol, Ghent, Belgium.; Dullaers, M (corresponding author), Univ Ghent, Jeffrey Modell Diag & Res Ctr, Ctr Primary Immunodeficiency, Ghent, Belgium.; Dullaers, M (corresponding author), VIB Inflammat Res Ctr, Lab Immunoregulat, Ghent, Belgium.; Dullaers, M (corresponding author), Univ Ghent, Dept Internal Med, Ghent, Belgium.	Melissa.Dullaers@ugent.be	Cytlak, Urszula/Y-2382-2019; Haerynck, Filomeen/AAD-6761-2020; Bogaert, Delfien/AAF-5977-2021; De Baere, Elfride/E-7405-2017; dehoorne, jo/C-6745-2018; Bigley, Venetia/AAU-9738-2020	Cytlak, Urszula/0000-0002-2536-6012; De Baere, Elfride/0000-0002-5609-6895; dehoorne, jo/0000-0003-4759-0717; Bigley, Venetia/0000-0002-3017-2474; /0000-0002-4268-5461; Calvo, Katherine/0000-0002-0771-4191; De Bruyne, Marieke/0000-0001-6636-5537; Haerynck, Filomeen/0000-0001-9161-7361; Bonroy, Carolien/0000-0002-9170-4200	Ghent University Hospital Spearhead Initiative for Immunology Research; National Institutes of Health Clinical Center intramural research program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001122] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL010304, ZIACL090025] Funding Source: NIH RePORTER	Ghent University Hospital Spearhead Initiative for Immunology Research; National Institutes of Health Clinical Center intramural research program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	Supported by the Ghent University Hospital Spearhead Initiative for Immunology Research and the National Institutes of Health Clinical Center intramural research program.	Bogaert DJA, 2016, J MED GENET, V53, P575, DOI 10.1136/jmedgenet-2015-103690; Goldman FD, 2012, PEDIATR BLOOD CANCER, V58, P591, DOI 10.1002/pbc.23160; Hoshino A, 2017, J ALLERGY CLIN IMMUN, V140, P223, DOI 10.1016/j.jaci.2016.09.029; John LB, 2011, MOL IMMUNOL, V48, P1272, DOI 10.1016/j.molimm.2011.03.006; Kakinuma S, 2007, ONCOGENE, V26, P2945, DOI 10.1038/sj.onc.1210100; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Schjerven H, 2013, NAT IMMUNOL, V14, P1073, DOI 10.1038/ni.2707; Sellars Maclean, 2011, World J Biol Chem, V2, P132, DOI 10.4331/wjbc.v2.i6.132; Spinner MA, 2014, BLOOD, V123, P809, DOI 10.1182/blood-2013-07-515528	9	27	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					432	+		10.1016/j.jaci.2017.08.019	http://dx.doi.org/10.1016/j.jaci.2017.08.019			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28927821	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000419312200056
J	Sullivan, A; Wang, EY; Farrell, J; Whitaker, P; Faulkner, L; Peckham, D; Park, BK; Naisbitt, DJ				Sullivan, Andrew; Wang, Eryi; Farrell, John; Whitaker, Paul; Faulkner, Lee; Peckham, Daniel; Park, B. Kevin; Naisbitt, Dean J.			beta-Lactam hypersensitivity involves expansion of circulating and skin-resident T(H)22 cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human; T cells; drug hypersensitivity	INDUCED LIVER-INJURY; MEMORY T-CELLS; DRUG HYPERSENSITIVITY; CYSTIC-FIBROSIS; CYTOTOXIC T; DISEASES; CHEMICALS; NAIVE; TH22; PIPERACILLIN	Background: beta-Lactam hypersensitivity has been classified according to the phenotype and function of drug-specific T cells. However, new T-cell subsets have not been considered. Objective: The objective of this study was to use piperacillin as a model of beta-lactam hypersensitivity to study the nature of the drug-specific T-cell response induced in the blood and skin of hypersensitive patients and healthy volunteers. Methods: Drug-specific T cells were cloned from blood and inflamed skin, and cellular phenotype and function were explored. Naive T cells from healthy volunteers were primed to piperacillin, cloned, and subjected to the similar analyses. Results: PBMC and T-cell clones (n = 570, 84% CD4(+)) from blood of piperacillin-hypersensitive patients proliferated and secreted T(H)1/T(H)2 cytokines alongside IL-22 after drug stimulation. IL-17A secretion was not detected. Drug-specific clones from inflamed skin (n = 96, 83% CD4(+)) secreted a similar profile of cytokines but displayed greater cytolytic activity, secreting perforin, granzyme B, and Fas ligand when activated. Blood- and skin-derived clones expressed high levels of skin-homing chemokine receptors and migrated in the presence of the ligands CCL17 and CCL27. Piperacillin-primed naive T cells from healthy volunteers also secreted IFN-gamma, IL-13, IL-22, and cytolytic molecules. Aryl hydrocarbon receptor blockade prevented differentiation of the naive T cells into antigen-specific IL-22 secreting cells. Conclusion: Together, our results reveal that circulating and skin-resident, antigen-specific, IL-22 secreting T cells are detectable in patients with beta-lactam hypersensitivity. Furthermore, differentiation of naive T cells into antigen specific T(H)22 cells is dependent on aryl hydrocarbon receptor signaling.	[Sullivan, Andrew; Wang, Eryi; Farrell, John; Faulkner, Lee; Park, B. Kevin; Naisbitt, Dean J.] Univ Liverpool, MRC Ctr Drug Safety Sci, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England; [Whitaker, Paul; Peckham, Daniel] St James Hosp, Reg Adult Cyst Fibrosis Unit, Leeds, W Yorkshire, England	University of Liverpool; Saint James's University Hospital	Naisbitt, DJ (corresponding author), Univ Liverpool, Pharmacol, Ashton St, Liverpool L69 3GE, Merseyside, England.	dnes@liv.ac.uk	wang, eryi/GWU-5333-2022	Peckham, Daniel/0000-0001-7723-1868; Naisbitt, Dean/0000-0003-4107-7832	Cystic Fibrosis Trust [PJ533]; Centre for Drug Safety Science - MRC [G0700654]; Medical Research Council [MR/L006758/1, G0700654] Funding Source: researchfish; MRC [MR/L006758/1, G0700654] Funding Source: UKRI	Cystic Fibrosis Trust; Centre for Drug Safety Science - MRC; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a grant from the Cystic Fibrosis Trust (PJ533). Central funds were obtained from the Centre for Drug Safety Science supported by the MRC (G0700654).	Baba N, 2012, HUM IMMUNOL, V73, P795, DOI 10.1016/j.humimm.2012.05.002; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Cavani A, 2012, CHEM IMMUNOL ALLERGY, V96, P39, DOI 10.1159/000331870; Chen YC, 2015, ALLERGY, V70, P568, DOI 10.1111/all.12602; Daly AK, 2014, CURR DRUG METAB, V15, P196, DOI 10.2174/138920021502140327180733; Dietz L, 2010, TOXICOL SCI, V117, P336, DOI 10.1093/toxsci/kfq209; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; El-Ghaiesh S, 2012, J PHARMACOL EXP THER, V341, P597, DOI 10.1124/jpet.111.190900; Eyerich K, 2015, ALLERGO J, V24, P17, DOI 10.1007/s15007-015-0750-x; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Faulkner L, 2016, TOXICOL SCI, V154, P416, DOI 10.1093/toxsci/kfw177; Fujita H, 2013, J DERMATOL SCI, V72, P3, DOI 10.1016/j.jdermsci.2013.04.028; Gaide O, 2015, NAT MED, V21, P647, DOI 10.1038/nm.3860; Geiger R, 2009, J EXP MED, V206, P1525, DOI 10.1084/jem.20090504; Hofmann MA, 2016, CURR OPIN ALLERGY CL, V16, P451, DOI 10.1097/ACI.0000000000000310; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Kagami S, 2010, J INVEST DERMATOL, V130, P1373, DOI 10.1038/jid.2009.399; Kakinuma T, 2003, BRIT J DERMATOL, V148, P203, DOI 10.1046/j.1365-2133.2003.05066.x; Kim SH, 2015, HEPATOLOGY, V62, P887, DOI 10.1002/hep.27912; Martin SF, 2010, CELL MOL LIFE SCI, V67, P4171, DOI 10.1007/s00018-010-0495-3; Mirshafiey A, 2015, INT J DERMATOL, V54, P880, DOI 10.1111/ijd.12883; Monshi MM, 2013, HEPATOLOGY, V57, P727, DOI 10.1002/hep.26077; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Phillips EJ, 2011, J ALLERGY CLIN IMMUN, V127, pS60, DOI 10.1016/j.jaci.2010.11.046; Picard D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001116; Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x; Pichler WJ, 2003, ANN INTERN MED, V139, P683, DOI 10.7326/0003-4819-139-8-200310210-00012; Pirmohamed M, 2015, J ALLERGY CLIN IMMUN, V136, P236, DOI 10.1016/j.jaci.2015.06.022; Posadas SJ, 2002, J ALLERGY CLIN IMMUN, V109, P155, DOI 10.1067/mai.2002.120563; Rozieres A, 2009, ALLERGY, V64, P534, DOI 10.1111/j.1398-9995.2008.01674.x; Sabat R, 2014, NAT REV DRUG DISCOV, V13, P21, DOI 10.1038/nrd4176; Spanou Z, 2006, J AM SOC NEPHROL, V17, P2919, DOI 10.1681/ASN.2006050418; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Watanabe R, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010302; Whitaker P, 2012, CURR OPIN ALLERGY CL, V12, P369, DOI 10.1097/ACI.0b013e328355b849; Whitaker P, 2011, J IMMUNOL, V187, P200, DOI 10.4049/jimmunol.1100647; Wuillemin N, 2014, AM J PATHOL, V184, P1677, DOI 10.1016/j.ajpath.2014.02.018; Yaseen FS, 2015, J ALLERGY CLIN IMMUN, V136, P474, DOI 10.1016/j.jaci.2015.02.036; Yawalkar N, 2000, J ALLERGY CLIN IMMUN, V106, P1171, DOI 10.1067/mai.2000.110922; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241; Zawodniak A, 2010, ALLERGY, V65, P376, DOI 10.1111/j.1398-9995.2009.02180.x	42	27	28	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					235	+		10.1016/j.jaci.2017.01.020	http://dx.doi.org/10.1016/j.jaci.2017.01.020			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28219704	Green Accepted, Bronze			2022-12-18	WOS:000419312200029
J	Hirota, T; Nakayama, T; Sato, S; Yanagida, N; Matsui, T; Sugiura, S; Takaoka, Y; Hizawa, N; Fujieda, S; Miyatake, A; Sasaki, T; Amagai, M; Doi, S; Ito, K; Ebisawa, M; Tamari, M				Hirota, Tomomitsu; Nakayama, Tsuguhisa; Sato, Sakura; Yanagida, Noriyuki; Matsui, Teruaki; Sugiura, Shiro; Takaoka, Yuri; Hizawa, Nobuyuki; Fujieda, Shigeharu; Miyatake, Akihiko; Sasaki, Takashi; Amagai, Masayuki; Doi, Satoru; Ito, Komei; Ebisawa, Motohiro; Tamari, Mayumi			Association study of childhood food allergy with genome-wide association studies-discovered loci of atopic dermatitis and eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OF-FUNCTION MUTATIONS; RISK-FACTORS		[Hirota, Tomomitsu; Nakayama, Tsuguhisa; Tamari, Mayumi] RIKEN, Inst Phys & Chem Res, Lab Resp & Allerg Dis, Ctr Integrat Med Sci, Wako, Saitama, Japan; [Sato, Sakura; Yanagida, Noriyuki; Ebisawa, Motohiro] Natl Hosp Org, Sagamihara Natl Hosp, Natl Clin Res Ctr, Sagamihara, Kanagawa, Japan; [Matsui, Teruaki; Sugiura, Shiro; Ito, Komei] Aichi Childrens Hlth & Med Ctr, Dept Allergy, Obu, Aichi, Japan; [Takaoka, Yuri; Doi, Satoru] Osaka Prefectural Med Ctr Resp & Allerg Dis, Osaka, Japan; [Hizawa, Nobuyuki] Univ Tsukuba, Div Resp Med, Inst Clin Med, Tsukuba, Ibaraki, Japan; [Fujieda, Shigeharu] Univ Fukui, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Fukui, Japan; [Miyatake, Akihiko] Miyatake Asthma Clin, Osaka, Japan; [Sasaki, Takashi; Amagai, Masayuki] Keio Univ, Dept Dermatol, Sch Med, Tokyo, Japan; [Tamari, Mayumi] Jikei Univ, Sch Med, Res Ctr Med Sci, Tokyo, Japan	RIKEN; Osaka Prefectural Medical Center Respiratory & Allergic Diseases; University of Tsukuba; University of Fukui; Keio University; Jikei University	Tamari, M (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Resp & Allerg Dis, Ctr Integrat Med Sci, Wako, Saitama, Japan.	mayumitamari@jikei.ac.jp	Tamari, Mayumi/N-5378-2015; Sasaki, Takashi/AAD-1461-2019; Amagai, Masayuki/K-5325-2013; Nakayama, Tsuguhisa/AAE-9730-2021; æ, ç æ ç/U-4186-2019; Yanagida, Noriyuki/ABF-3471-2021	Amagai, Masayuki/0000-0003-3314-7052; æ, ç æ ç/0000-0002-3660-1823; Yanagida, Noriyuki/0000-0001-9643-744X; Sasaki, Takashi/0000-0002-6275-046X; sugiura, shiro/0000-0003-1048-2704; Ebisawa, Motohiro/0000-0003-4117-558X	Ministry of Education, Culture, Sports, Science and Technology; Japan Agency for Medical Research and Development (AMED) [15649725]; Ministry of Health, Labour and Welfare of Japan	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology and the Japan Agency for Medical Research and Development (AMED; grant no. 15649725), and by the Health and Labor Science Research Grants of the Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare of Japan.	Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Parkes M, 2013, NAT REV GENET, V14, P661, DOI 10.1038/nrg3502; Portelli MA, 2015, CLIN EXP ALLERGY, V45, P21, DOI 10.1111/cea.12327; Rothenberg ME, 2015, GASTROENTEROLOGY, V148, P1143, DOI 10.1053/j.gastro.2015.02.002; Sasaki T, 2014, J DERMATOL SCI, V76, P10, DOI 10.1016/j.jdermsci.2014.06.004; Schoos AMM, 2016, J ALLERGY CLIN IMMUN, V137, P844, DOI 10.1016/j.jaci.2015.10.004; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X	9	27	27	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1713	+		10.1016/j.jaci.2017.05.034	http://dx.doi.org/10.1016/j.jaci.2017.05.034			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28629743	Bronze			2022-12-18	WOS:000417206000030
J	Johansson, EK; Bergstrom, A; Kull, I; Lind, T; Soderhall, C; van Hage, M; Wickman, M; Ballardini, N; Wahlgren, CF				Johansson, Emma Kristin; Bergstrom, Anna; Kull, Inger; Lind, Tomas; Soderhall, Cilla; van Hage, Marianne; Wickman, Magnus; Ballardini, Natalia; Wahlgren, Carl-Fredrik			IgE sensitization in relation to preschool eczema and filaggrin mutation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergens; atopic dermatitis; birth cohort; filaggrin; food allergy; IgE; peanut; population; sensitization; skin barrier	OF-FUNCTION MUTATIONS; LONGITUDINAL BIRTH COHORT; ATOPIC-DERMATITIS; PEANUT ALLERGY; FOOD ALLERGY; RISK-FACTORS; DISEASE; CHILDHOOD; CHILDREN; ASTHMA	Background: Eczema (atopic dermatitis) is associated with an increased risk of having IgE antibodies. IgE sensitization can occur through an impaired skin barrier. Filaggrin gene (FLG) mutation is associated with eczema and possibly also with IgE sensitization. Objective: We sought to explore the longitudinal relation between preschool eczema (PSE), FLG mutation, or both and IgE sensitization in childhood. Methods: A total of 3201 children from the BAMSE (Children Allergy Milieu Stockholm Epidemiology) birth cohort recruited from the general population were included. Regular parental questionnaires identified children with eczema. Blood samples were collected at 4, 8, and 16 years of age for analysis of specific IgE. FLG mutation analysis was performed on 1890 of the children. Results: PSE was associated with IgE sensitization to both food allergens and aeroallergens up to age 16 years (overall adjusted odds ratio, 2.30; 95% CI, 2.00-2.66). This association was even stronger among children with persistent PSE. FLG mutation was associated with IgE sensitization to peanut at age 4 years (adjusted odds ratio, 1.88; 95% CI, 1.03-3.44) but not to other allergens up to age 16 years. FLG mutation and PSE were not effect modifiers for the association between IgE sensitization and PSE or FLG mutation, respectively. Sensitized children with PSE were characterized by means of polysensitization, but no other specific IgE sensitization patterns were found. Conclusions: PSE is associated with IgE sensitization to both food allergens and aeroallergens up to 16 years of age. FLG mutation is associated with IgE sensitization to peanut but not to other allergens. Sensitized children with preceding PSE are more often polysensitized.	[Johansson, Emma Kristin; Wahlgren, Carl-Fredrik] Karolinska Inst, Dermatol & Venereol Unit, Dept Med Solna, Stockholm, Sweden; [Johansson, Emma Kristin] Soder Sjukhuset, Dermatol & Venereal Clin, Sjukhusbacken 10, SE-11883 Stockholm, Sweden; [Kull, Inger] Soder Sjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden; [Kull, Inger; Wickman, Magnus; Ballardini, Natalia] Soder Sjukhuset, Sachs Children & Youth Hosp, Stockholm, Sweden; [Bergstrom, Anna; Wickman, Magnus; Ballardini, Natalia] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Soderhall, Cilla] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Soderhall, Cilla] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Lind, Tomas] Stockholm Cty Council, Dept Occupat & Environm Med, Stockholm, Sweden; [Lind, Tomas] Karolinska Inst, Inst Environm Med, Environm Epidemiol Unit, Stockholm, Sweden; [van Hage, Marianne] Karolinska Inst, Dept Med Solna, Immunol & Allergy Unit, Stockholm, Sweden; [van Hage, Marianne] Karolinska Univ Hosp, Stockholm, Sweden; [Ballardini, Natalia] Kings Coll London, St Johns Inst Dermatol, London, England; [Wahlgren, Carl-Fredrik] Karolinska Univ Hosp Solna, Dept Dermatol, Stockholm, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; Sodersjukhuset Hospital; Sodersjukhuset Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Stockholm County Council; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of London; King's College London; Karolinska Institutet; Karolinska University Hospital	Johansson, EK (corresponding author), Soder Sjukhuset, Dermatol & Venereal Clin, Sjukhusbacken 10, SE-11883 Stockholm, Sweden.	emma.k.johansson@sll.se	Johansson, Emma K/AAD-7193-2022; Johansson, Emma/AAY-3468-2021; van Hage, Marianne/A-9678-2017	Johansson, Emma K/0000-0002-3318-3910; van Hage, Marianne/0000-0003-3091-1596; Ballardini, Natalia/0000-0001-6759-346X	Swedish Asthma and Allergy Association Research Foundation; Welander-Finsen Foundation; Karolinska Institutet; Swedish Research Council; Stockholm County Council; Stockholm County Council (ALF project); Swedish Research Council for Working Life and Social Welfare; European Commission's Seventh Framework 29 Program MeDALL [261357]; Hesselman's Research Foundation	Swedish Asthma and Allergy Association Research Foundation; Welander-Finsen Foundation; Karolinska Institutet(Karolinska Institutet); Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm County Council(Stockholm County Council); Stockholm County Council (ALF project)(Stockholm County Council); Swedish Research Council for Working Life and Social Welfare; European Commission's Seventh Framework 29 Program MeDALL; Hesselman's Research Foundation	Supported by the Swedish Asthma and Allergy Association Research Foundation, the Welander-Finsen Foundation, Karolinska Institutet, the Swedish Research Council, the Stockholm County Council, the Stockholm County Council (ALF project), the Swedish Research Council for Working Life and Social Welfare, the European Commission's Seventh Framework 29 Program MeDALL (grant agreement 261357), and the Hesselman's Research Foundation. Thermo Fisher Scientific kindly provided the reagents for the study.	Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Ballardini N, 2016, ALLERGY, V71, P342, DOI 10.1111/all.12798; Bertelsen RJ, 2014, CLIN EXP ALLERGY, V44, P142, DOI 10.1111/cea.12231; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Bohme M, 2012, J ALLERGY CLIN IMMUN, V129, P1153, DOI 10.1016/j.jaci.2011.11.032; Bousquet J, 2016, ALLERGY, V71, P1513, DOI 10.1111/all.12880; Bousquet J, 2015, ALLERGY, V70, P1062, DOI 10.1111/all.12637; Brough HA, 2015, J ALLERGY CLIN IMMUN, V135, P164, DOI 10.1016/j.jaci.2014.10.007; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Calinski T., 1974, COMMUN STAT-THEOR M, V3, P1, DOI [DOI 10.1080/03610927408827101, 10.1080/03610927408827101]; Dharmage SC, 2014, ALLERGY, V69, P17, DOI 10.1111/all.12268; Dotterud LK, 1997, CLIN EXP ALLERGY, V27, P252, DOI 10.1111/j.1365-2222.1997.tb00703.x; Flohr C, 2014, ALLERGY, V69, P3, DOI 10.1111/all.12270; Flohr C, 2014, J INVEST DERMATOL, V134, P345, DOI 10.1038/jid.2013.298; Gabet S, 2016, INT J HYG ENVIR HEAL, V219, P792, DOI 10.1016/j.ijheh.2016.09.001; Heeringa SG, 2017, APPL SURVEY DATA ANA, VSecond, DOI DOI 10.1201/9781315153278; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Johansson EK, 2017, PEDIAT ALLERG IMM-UK, V28, P44, DOI 10.1111/pai.12657; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Ronmark E, 2003, PEDIAT ALLERG IMM-UK, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Tan HTT, 2012, J ALLERGY CLIN IMMUN, V130, P1211, DOI 10.1016/j.jaci.2012.07.022; Thyssen JP, 2015, J ALLERGY CLIN IMMUN, V135, P1375, DOI 10.1016/j.jaci.2015.01.001; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; van der Hulst AE, 2007, J ALLERGY CLIN IMMUN, V120, P565, DOI 10.1016/j.jaci.2007.05.042; Venkataraman D, 2014, J ALLERGY CLIN IMMUN, V134, P876, DOI 10.1016/j.jaci.2014.07.033; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043	33	27	28	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1572	+		10.1016/j.jaci.2017.04.008	http://dx.doi.org/10.1016/j.jaci.2017.04.008			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28456621	Bronze			2022-12-18	WOS:000417206000011
J	Jonstam, K; Westman, M; Holtappels, G; Holweg, CTJ; Bachert, C				Jonstam, Karin; Westman, Marit; Holtappels, Gabriele; Holweg, Cecile T. J.; Bachert, Claus			Serum periostin, IgE, and SE-IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; LEBRIKIZUMAB; INFLAMMATION; EXPRESSION		[Jonstam, Karin; Westman, Marit; Bachert, Claus] Karolinska Inst, Div ENT Dis, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Jonstam, Karin; Westman, Marit; Bachert, Claus] Karolinska Univ Hosp, Dept Ear Nose & Throat Dis, Stockholm, Sweden; [Westman, Marit] Karolinska Inst, Dept Med Solna, Stockholm, Sweden; [Holtappels, Gabriele; Bachert, Claus] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Holweg, Cecile T. J.] Genentech Inc, OMNI Biomarker Dev, San Francisco, CA 94080 USA	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Ghent University; Roche Holding; Genentech	Jonstam, K (corresponding author), Karolinska Inst, Div ENT Dis, Dept Clin Sci Intervent & Technol, Stockholm, Sweden.; Jonstam, K (corresponding author), Karolinska Univ Hosp, Dept Ear Nose & Throat Dis, Stockholm, Sweden.	Karin.jonstam@sll.se	Jonstam, Karin/M-6266-2019; Bachert, Claus/J-8825-2012					Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Hanania NA, 2016, LANCET RESP MED, V4, P781, DOI 10.1016/S2213-2600(16)30265-X; Hanania NA, 2015, THORAX, V70, P748, DOI 10.1136/thoraxjnl-2014-206719; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Milonski J, 2015, EUR ARCH OTO-RHINO-L, V272, P3715, DOI 10.1007/s00405-014-3481-9; Palme S, 2017, CLIN BIOCHEM, V50, P139, DOI 10.1016/j.clinbiochem.2016.10.002; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Wang M, 2015, J ALLERGY CLIN IMMUN, V136, P1700, DOI 10.1016/j.jaci.2015.09.005	9	27	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1705	+		10.1016/j.jaci.2017.07.031	http://dx.doi.org/10.1016/j.jaci.2017.07.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28870464				2022-12-18	WOS:000417206000027
J	Grabiec, AM; Denny, N; Doherty, JA; Happonen, KE; Hankinson, J; Connolly, E; Fife, ME; Fujimori, T; Fujino, N; Goenka, A; Holden, S; Tavernier, G; Shah, R; Cook, PC; MacDonald, AS; Niven, RM; Dahlback, B; Fowler, SJ; Simpson, A; Hussell, T				Grabiec, Aleksander M.; Denny, Nicholas; Doherty, John A.; Happonen, Kaisa E.; Hankinson, Jenny; Connolly, Emma; Fife, Mark E.; Fujimori, Toshifumi; Fujino, Naoya; Goenka, Anu; Holden, Susan; Tavernier, Gael; Shah, Rajesh; Cook, Peter C.; MacDonald, Andrew S.; Niven, Robert M.; Dahlback, Bjorn; Fowler, Stephen J.; Simpson, Angela; Hussell, Tracy			Diminished airway macrophage expression of the Axl receptor tyrosine kinase is associated with defective efferocytosis in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							APOPTOTIC CELL CLEARANCE; LUNG; PHAGOCYTOSIS; INFLAMMATION		[Grabiec, Aleksander M.; Denny, Nicholas; Doherty, John A.; Connolly, Emma; Fife, Mark E.; Fujimori, Toshifumi; Fujino, Naoya; Goenka, Anu; Cook, Peter C.; MacDonald, Andrew S.; Hussell, Tracy] Univ Manchester, Manchester Collaborat Ctr Inflammat Res, Manchester, Lancs, England; [Grabiec, Aleksander M.] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Microbiol, Krakow, Poland; [Happonen, Kaisa E.; Dahlback, Bjorn] Lund Univ, Div Clin Chem, Dept Translat Med, Malmo, Sweden; [Hankinson, Jenny; Holden, Susan; Tavernier, Gael; Niven, Robert M.; Fowler, Stephen J.; Simpson, Angela] Univ Manchester, Manchester Acad Hlth Sci Ctr, Div Infect Immun & Resp Med, Manchester, Lancs, England; [Shah, Rajesh] Univ Hosp South Manchester, Dept Thorac Surg, Manchester, Lancs, England	University of Manchester; Jagiellonian University; Lund University; University of Manchester; Wythenshawe Hospital NHS Foundation Trust	Hussell, T (corresponding author), Univ Manchester, Manchester Collaborat Ctr Inflammat Res, Manchester, Lancs, England.	tracy.hussell@manchester.ac.uk	Cook, Peter/E-6731-2015; Goenka, Anu/M-6700-2019; Grabiec, Aleksander M/O-4746-2014	Cook, Peter/0000-0002-5208-4985; Goenka, Anu/0000-0002-8152-2155; Grabiec, Aleksander M/0000-0001-9472-850X	Manchester Allergy, Respiratory and Thoracic Surgery Biobank; North West Lung Centre Charity; AstraZeneca; GlaxoSmithKline; Swedish Research Council; Swedish Heart-Lung Foundation; National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester National Health Service (NHS) Foundation Trust; MRC [MC_PC_15072, MR/N001427/1, G0802752] Funding Source: UKRI; Academy of Medical Sciences (AMS) [SBF002\\1076] Funding Source: researchfish; Medical Research Council [MR/N001427/1, MC_PC_15072, G0802752] Funding Source: researchfish	Manchester Allergy, Respiratory and Thoracic Surgery Biobank; North West Lung Centre Charity; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester National Health Service (NHS) Foundation Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We acknowledge the Manchester Allergy, Respiratory and Thoracic Surgery Biobank and the North West Lung Centre Charity for supporting this project. In addition, we thank the study participants for their contribution.; This research was supported by a precompetitive, open innovation award to the Manchester Collaborative Centre for Inflammation Research by AstraZeneca and GlaxoSmithKline. K.E.H. and B.D. were supported by the Swedish Research Council and the Swedish Heart-Lung Foundation. This report is independent research supported by the National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester National Health Service (NHS) Foundation Trust. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health.	[Anonymous], 2008, THORAX, V63, piv1; Baharom F, 2016, J IMMUNOL, V196, P4498, DOI 10.4049/jimmunol.1600071; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Desch AN, 2016, AM J RESP CRIT CARE, V193, P614, DOI 10.1164/rccm.201507-1376OC; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Ekman C, 2010, J THROMB HAEMOST, V8, P838, DOI 10.1111/j.1538-7836.2010.03752.x; Fernandez-Boyanapalli R, 2013, J ALLERGY CLIN IMMUN, V131, P1041, DOI 10.1016/j.jaci.2012.09.028; Fujimori T, 2015, MUCOSAL IMMUNOL, V8, P1021, DOI 10.1038/mi.2014.129; Grabiec AM, 2016, SEMIN IMMUNOPATHOL, V38, P409, DOI 10.1007/s00281-016-0555-3; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-035OC; Kent LM, 2010, INT IMMUNOPHARMACOL, V10, P57, DOI 10.1016/j.intimp.2009.09.021; Ko CP, 2014, MOL MED REP, V9, P1400, DOI 10.3892/mmr.2014.1933; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Schmid ET, 2016, ELIFE, V5, DOI 10.7554/eLife.12414; Simpson JL, 2013, CLIN EXP ALLERGY, V43, P29, DOI 10.1111/j.1365-2222.2012.04075.x	15	27	27	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2017	140	4					1144	+		10.1016/j.jaci.2017.03.024	http://dx.doi.org/10.1016/j.jaci.2017.03.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FI7JL		hybrid, Green Published			2022-12-18	WOS:000412172900026
J	Takahashi, T; Kato, A; Berdnikovs, S; Stevens, WW; Suh, LA; Norton, JE; Carter, RG; Harris, KE; Peters, AT; Hulse, KE; Grammer, LC; Welch, KC; Shintani-Smith, S; Tan, BK; Conley, DB; Kern, RC; Bochner, BS; Schleimer, RP				Takahashi, Toru; Kato, Atsushi; Berdnikovs, Sergejs; Stevens, Whitney W.; Suh, Lydia A.; Norton, James E.; Carter, Roderick G.; Harris, Kathleen E.; Peters, Anju T.; Hulse, Kathryn E.; Grammer, Leslie C.; Welch, Kevin C.; Shintani-Smith, Stephanie; Tan, Bruce K.; Conley, David B.; Kern, Robert C.; Bochner, Bruce S.; Schleimer, Robert P.			Microparticles in nasal lavage fluids in chronic rhinosinusitis: Potential biomarkers for diagnosis of aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microparticles; epithelial injury; eosinophil activation; apoptosis; mast cell activation; basophil activation; CD137; CD69; chronic rhinosinusitis; aspirin-exacerbated respiratory disease	CIRCULATING ENDOTHELIAL MICROPARTICLES; INNATE LYMPHOID-CELLS; MAST-CELLS; ACTIVATION MARKERS; BLOOD EOSINOPHILS; EFFECTOR-CELLS; FLOW-CYTOMETRY; UP-REGULATION; IN-VITRO; EXPRESSION	Background: Microparticles (MPs) are submicron-sized shed membrane vesicles released from activated or injured cells and are detectable by flow cytometry. MP levels have been used as biomarkers to evaluate cell injury or activation in patients with pathological conditions. Objective: We sought to compare MP types and levels in nasal lavage fluids (NLFs) from controls and patients with chronic rhinosinusitis without nasal polyps (CRSsNP), chronic rhinosinusitis with nasal polyps (CRSwNP), and aspirin-exacerbated respiratory disease (AERD). Methods: We collected NLFs from patients with CRSsNP (n=33), CRSwNP (n=45), and AERD (n=31) and control (n=24) subjects. Standardized flow cytometry methods were used to characterize the following MP types: endothelial MPs, epithelial MPs (epithelial cell adhesion molecule [EpCAM](+) MPs, E-cadherin(+) MPs), platelet MPs (CD31(+) CD41(+) MPs), eosinophil MPs (EGF-like module-containing mucin-like hormone receptor-like 1[EMR1](+) MPs), mast cell MPs (high-affinity IgE receptor [FceRI](+) c-kit(+) MPs), and basophil MPs (CD203c(+) c-kit(2) MPs). Basophil activation was evaluated by the mean fluorescence intensity of CD203c on basophil MPs. Results: Activated mast cell MPs (CD137(+) FceRI(+) c-kit(+) MPs) were significantly increased in NLFs of controls compared with NLFs of patients with CRSsNP (2.3-fold; P < .02), CRSwNP (2.3-fold; P < .03), and AERD (7.4-fold; P < .0001). Platelet MPs (3.5-fold; P < .01) and basophil MPs (2.5-fold; P < .05) were increased only in patients with AERD. Mean fluorescence intensity of CD203c on MPs was increased in patients with CRSwNP (P < .002) and AERD (P < .0001), but not in patients with CRSsNP. EpCAM(+) MPs in patients with CRSwNP were no different from control (P = .91) and lower than those in patients with CRSsNP (P < .02) and AERD (P < .002). Conclusions: Based on released MPs, mast cells, platelets, and basophils were more highly activated in patients with AERD than in patients with CRS. Epithelial injury was lower in patients with CRSwNP than in patients with CRSsNP and AERD. MP analysis may help identify phenotypes of CRS, and in distinguishing AERD from CRSwNP.	[Takahashi, Toru; Kato, Atsushi; Berdnikovs, Sergejs; Stevens, Whitney W.; Suh, Lydia A.; Norton, James E.; Carter, Roderick G.; Harris, Kathleen E.; Peters, Anju T.; Hulse, Kathryn E.; Grammer, Leslie C.; Kern, Robert C.; Bochner, Bruce S.; Schleimer, Robert P.] Northwestern Univ, Dept Med, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60611 USA; [Kato, Atsushi; Welch, Kevin C.; Shintani-Smith, Stephanie; Tan, Bruce K.; Conley, David B.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Schleimer, RP (corresponding author), Northwestern Univ, Div Allergy Immunol, Feinberg Sch Med, 240 E Huron,Rm M305, Chicago, IL 60611 USA.	rpschleimer@northwestern.edu	Smith, Stephanie Shintani/AAY-4854-2020	Smith, Stephanie Shintani/0000-0002-0605-3993; Kato, Atsushi/0000-0001-9144-3138; Takahashi, Toru/0000-0002-4648-4587	Chronic Rhinosinusitis Integrative Studies Program from the National Institutes of Health [R37HL068546, U19AI106683]; Ernest S. Bazley Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001424] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI106683] Funding Source: NIH RePORTER	Chronic Rhinosinusitis Integrative Studies Program from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ernest S. Bazley Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported in part by the Chronic Rhinosinusitis Integrative Studies Program from the National Institutes of Health (grant nos. R37HL068546 and U19AI106683), and by the Ernest S. Bazley Foundation.	Amabile N, 2005, J AM SOC NEPHROL, V16, P3381, DOI 10.1681/ASN.2005050535; Amabile N, 2008, AM J RESP CRIT CARE, V177, P1268, DOI 10.1164/rccm.200710-1458OC; Amabile N, 2014, EUR HEART J, V35, P2972, DOI 10.1093/eurheartj/ehu153; Amabile N, 2009, J HEART LUNG TRANSPL, V28, P1081, DOI 10.1016/j.healun.2009.06.005; Bachelet I, 2007, TRENDS IMMUNOL, V28, P360, DOI 10.1016/j.it.2007.06.007; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Barry MC, 2010, IRISH J MED SCI, V179, P35, DOI 10.1007/s11845-009-0282-z; Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639; Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928; Boumiza Radhia, 2005, Clin Mol Allergy, V3, P9, DOI 10.1186/1476-7961-3-9; Buzas EI, 2014, NAT REV RHEUMATOL, V10, P356, DOI 10.1038/nrrheum.2014.19; Cocucci E, 2015, TRENDS CELL BIOL, V25, P364, DOI 10.1016/j.tcb.2015.01.004; Duarte D, 2013, ALLERGY, V68, P1073, DOI 10.1111/all.12190; Dursun AB, 2008, ANN ALLERG ASTHMA IM, V100, P420, DOI 10.1016/S1081-1206(10)60465-6; Goubran HA, 2015, TRANSFUS APHER SCI, V52, P12, DOI 10.1016/j.transci.2014.12.015; Hamann J, 2007, EUR J IMMUNOL, V37, P2797, DOI 10.1002/eji.200737553; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; Heller F, 2008, MUCOSAL IMMUNOL, V1, pS58, DOI 10.1038/mi.2008.46; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Hupin C, 2014, ALLERGY, V69, P1540, DOI 10.1111/all.12503; Italiano JE, 2010, CURR OPIN HEMATOL, V17, P578, DOI 10.1097/MOH.0b013e32833e77ee; Jimenez JJ, 2003, THROMB RES, V109, P175, DOI 10.1016/S0049-3848(03)00064-1; Julius P, 1999, EUR RESPIR J, V13, P1253, DOI 10.1034/j.1399-3003.1999.13f07.x; Lackner P, 2010, STROKE, V41, P2353, DOI 10.1161/STROKEAHA.110.584995; Laidlaw TM, 2016, NEW ENGL J MED, V374, P484, DOI 10.1056/NEJMcibr1514013; Laidlaw TM, 2015, J ALLERGY CLIN IMMUN, V135, P1407, DOI 10.1016/j.jaci.2015.02.005; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; Legrand F, 2014, J ALLERGY CLIN IMMUN, V133, P1439, DOI 10.1016/j.jaci.2013.11.041; Liu T, 2015, J IMMUNOL, V195, P3537, DOI 10.4049/jimmunol.1500905; Mahdavinia M, 2014, J ALLERGY CLIN IMMUN, V133, P1759, DOI 10.1016/j.jaci.2013.12.1092; Martin S, 2000, INT ARCH ALLERGY IMM, V123, P249, DOI 10.1159/000024451; Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P214, DOI 10.1513/pats.200504-031AC; Matsumoto K, 1998, AM J RESP CELL MOL, V18, P860, DOI 10.1165/ajrcmb.18.6.3159; Mazzeo C, 2015, J ALLERGY CLIN IMMUN, V135, P1603, DOI 10.1016/j.jaci.2014.11.026; Meng J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082373; Mitsui C, 2016, J ALLERGY CLIN IMMUN, V137, P400, DOI 10.1016/j.jaci.2015.05.041; Nishimoto H, 2005, BLOOD, V106, P4241, DOI 10.1182/blood-2005-04-1358; Nopp A, 2000, ALLERGY, V55, P148, DOI 10.1034/j.1398-9995.2000.00363.x; Nozaki T, 2009, J AM COLL CARDIOL, V54, P601, DOI 10.1016/j.jacc.2009.05.022; Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002; Ono E, 2010, J ALLERGY CLIN IMMUN, V125, P483, DOI 10.1016/j.jaci.2009.10.074; Payne SC, 2011, LARYNGOSCOPE, V121, P2262, DOI 10.1002/lary.21969; Pignatti P, 2002, ALLERGY, V57, P411, DOI 10.1034/j.1398-9995.2002.23454.x; Pirro M, 2006, ARTERIOSCL THROM VAS, V26, P2530, DOI 10.1161/01.ATV.0000243941.72375.15; Poncelet P, 2015, TRANSFUS APHER SCI, V53, P110, DOI 10.1016/j.transci.2015.10.008; Pospichalova V, 2015, J EXTRACELL VESICLES, V4, P25530; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Schleimer RP, 2012, EOSINOPHILS HLTH DIS, P78; Schnell U, 2013, BBA-BIOMEMBRANES, V1828, P1989, DOI 10.1016/j.bbamem.2013.04.018; Shah MD, 2008, PLATELETS, V19, P365, DOI 10.1080/09537100802054107; Soyka MB, 2012, J ALLERGY CLIN IMMUN, V130, P1087, DOI 10.1016/j.jaci.2012.05.052; Szczeklik A, 2000, THORAX, V55, pS42, DOI 10.1136/thorax.55.suppl_2.S42; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Takahashi T, 2014, INT J CHRONIC OBSTR, V9, P303, DOI 10.2147/COPD.S38931; Takahashi T, 2013, EXP LUNG RES, V39, P155, DOI 10.3109/01902148.2013.784932; Takahashi T, 2012, THORAX, V67, P1067, DOI 10.1136/thoraxjnl-2011-201395; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Walsh GM, 2003, J ENDOCRINOL, V178, P37, DOI 10.1677/joe.0.1780037; Welker P, 2000, J INVEST DERMATOL, V114, P44, DOI 10.1046/j.1523-1747.2000.00827.x; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	65	27	28	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					720	729		10.1016/j.jaci.2017.01.022	http://dx.doi.org/10.1016/j.jaci.2017.01.022			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28238741	Bronze, Green Accepted			2022-12-18	WOS:000409241500011
J	Van Roey, GA; Vanison, CC; Wu, J; Huang, JH; Suh, LA; Carter, RG; Norton, JE; Shintani-Smith, S; Conley, DB; Welch, KC; Peters, AT; Grammer, LC; Harris, KE; Hulse, KE; Kato, A; Stevens, WW; Kern, RC; Schleimer, RP; Tan, BK				Van Roey, Griet A.; Vanison, Christopher C.; Wu, Jeffanie; Huang, Julia H.; Suh, Lydia A.; Carter, Roderick G.; Norton, James E.; Shintani-Smith, Stephanie; Conley, David B.; Welch, Kevin C.; Peters, Anju T.; Grammer, Leslie C.; Harris, Kathleen E.; Hulse, Kathryn E.; Kato, Atsushi; Stevens, Whitney W.; Kern, Robert C.; Schleimer, Robert P.; Tan, Bruce K.			Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; complement; basement membrane; antibodies; classical complement pathway	SYSTEMIC-LUPUS-ERYTHEMATOSUS; TO-MESENCHYMAL TRANSITION; MAST-CELLS; SINONASAL TISSUE; EPITHELIAL-CELLS; INVIVO CLEARANCE; ALLERGIC-ASTHMA; ONCOSTATIN-M; C3A; POLYPS	Background: Complement plays a major role in inflammatory diseases, but its involvement and mechanisms of activation in patients with chronic rhinosinusitis (CRS) are not known. Objectives: After earlier studies discovering autoantibodies in patients with CRS, we sought to investigate the nature, extent, and location of complement activation in nasal tissue of patients with CRS. Specifically, we were interested in whether antibodymediated activation through the classical pathway was a major mechanism for complement activation in patients with CRS. Methods: Nasal tissue was obtained from patients with CRS and control subjects. Tissue homogenates were analyzed for complement activation products (ELISA-C5b-9, C4d, activated C1, and C5a) and major complement-fixing antibodies (Luminex). Tissue sections were stained for C5b-9, C4d, and laminin. Antibodies were purified with protein A/G columns from nasal polyps (NP), matching patient serum, and control serum and assayed for basement membrane binding by means of ELISA. Results: C5b-9 levels were significantly increased in NP tissue compared with uncinate tissue (UT) of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and those with chronic rhinosinusitis without nasal polyps (CRSsNP; P < .01). Similarly, C4d levels were increased in NPs compared with UT of patients with CRSwNP, patients with CRSsNP, and control subjects (P < .05). Activated C1 levels were also increased in NP tissue compared with UT of patients with CRSsNP and control subjects (P < .05) and correlated with levels of C5a (P < .01), local immunoglobulins (especially IgM, P < .0001), and antidouble-stranded DNA IgG (P < .05). Immunofluorescence showed that C5b-9 and C4d deposition occurred linearly along the epithelial basement membrane. NP tissue extracts had significantly more anti-basement membrane antibodies than sera from patients with CRSwNP and control subjects (P < .0001). Conclusion: Levels of C5b-9, C4d, and activated C1 were significantly increased locally in NP tissue. C5b-9 and C4d were almost universally deposited linearly along the basement membrane of NP tissue. Furthermore, activated C1 levels were best correlated with local immunoglobulin and C5a levels. Together, these data suggest that the classical pathway plays a major role in complement activation in patients with CRS.	[Van Roey, Griet A.; Vanison, Christopher C.; Wu, Jeffanie; Huang, Julia H.; Shintani-Smith, Stephanie; Conley, David B.; Welch, Kevin C.; Kato, Atsushi; Kern, Robert C.; Schleimer, Robert P.; Tan, Bruce K.] Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, 676 North St Clair,Suite 1325, Chicago, IL 60611 USA; [Suh, Lydia A.; Carter, Roderick G.; Norton, James E.; Peters, Anju T.; Grammer, Leslie C.; Harris, Kathleen E.; Hulse, Kathryn E.; Kato, Atsushi; Stevens, Whitney W.; Kern, Robert C.; Schleimer, Robert P.] Northwestern Univ, Div Allergy & Immunol, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University	Tan, BK (corresponding author), Northwestern Univ, Dept Otolaryngol, Feinberg Sch Med, 676 North St Clair,Suite 1325, Chicago, IL 60611 USA.	b-tan@northwestern.edu	Smith, Stephanie Shintani/AAY-4854-2020	Smith, Stephanie Shintani/0000-0002-0605-3993; Kato, Atsushi/0000-0001-9144-3138	National Institutes of Health (NIH) [K23DC012067]; Chronic Rhinosinusitis Integrative Studies Program (CRISP) [U19 AI106683, R37 HL078860, R01 HL068546, R01 AI072570, R01 AI104733]; Triological Society/American College of Surgeons; Ernest S. Bazley Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055884] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001424] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068546, R37HL068546, R01HL078860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI106683, U19AI106683, R01AI104733, R01AI072570] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K23DC012067] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chronic Rhinosinusitis Integrative Studies Program (CRISP); Triological Society/American College of Surgeons; Ernest S. Bazley Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	Supported by National Institutes of Health (NIH) grant K23DC012067 (to B.K.T.); Chronic Rhinosinusitis Integrative Studies Program (CRISP) grants U19 AI106683 (to B.K.T., R.C.K., K.E.H., A.K., and R.P.S.), R37 HL078860, R01 HL068546, R01 AI072570, and R01 AI104733 (to R.P.S.); the Triological Society/American College of Surgeons (to B.K.T.); and the Ernest S. Bazley Foundation.	ADLER S, 1986, J CLIN INVEST, V77, P762, DOI 10.1172/JCI112372; [Anonymous], 2004, TECHNICAL RESOURCE B; Banks CA, 2014, OTOLARYNG HEAD NECK, V151, P215, DOI 10.1177/0194599814528672; Chan LS, 1999, ARCH DERMATOL, V135, P569, DOI 10.1001/archderm.135.5.569; Cherukuri A, 2001, J IMMUNOL, V167, P163, DOI 10.4049/jimmunol.167.1.163; CHRISTIANRITTER KK, 1994, AM J PATHOL, V144, P171; De Schryver E, 2016, J ALLERGY CLIN IMMUN, V138, P893, DOI 10.1016/j.jaci.2016.03.040; DiScipio RG, 2007, INT IMMUNOPHARMACOL, V7, P1909, DOI 10.1016/j.intimp.2007.07.006; Dykewicz MS, 2010, J ALLERGY CLIN IMMUN, V125, pS103, DOI 10.1016/j.jaci.2009.12.989; ELLATI SG, 1994, J INVEST DERMATOL, V102, P803, DOI 10.1111/1523-1747.ep12378589; ELSNER J, 1994, EUR J IMMUNOL, V24, P518, DOI 10.1002/eji.1830240304; ELSNER J, 1994, BLOOD, V83, P3324; Ference EH, 2015, INT FORUM ALLERGY RH, V5, P929, DOI 10.1002/alr.21556; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fosbrink M, 2006, J BIOL CHEM, V281, P19009, DOI 10.1074/jbc.M602055200; Fure H, 1997, SCAND J IMMUNOL, V46, P553, DOI 10.1046/j.1365-3083.1997.d01-168.x; Gevaert P, 2013, ALLERGY, V68, P55, DOI 10.1111/all.12054; Giles BM, 2013, IMMUNOL RES, V55, P10, DOI 10.1007/s12026-012-8345-z; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, P1075, DOI 10.1016/j.jaci.2013.01.043; Hulse KE, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Jane-wit D, 2013, CIRCULATION, V128, P2504, DOI 10.1161/CIRCULATIONAHA.113.002972; Janeway Jr CA, 2001, IMMUNOLOBIOLOGY IMMU; Jeffe JS, 2013, LARYNGOSCOPE, V123, P2104, DOI 10.1002/lary.24016; JORDON RE, 1975, J INVEST DERMATOL, V65, P162, DOI 10.1111/1523-1747.ep12598113; Jozsi M., ANTICOMPLEMENT AUTOA, DOI [10.5772/23516, DOI 10.5772/23516]; Kastl SP, 2008, ARTERIOSCL THROM VAS, V28, P498, DOI 10.1161/ATVBAHA.107.160580; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Kato A, 2008, J ALLERGY CLIN IMMUN, V121, P1385, DOI 10.1016/j.jaci.2008.03.002; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Kern RC, 2008, AM J RHINOL, V22, P549, DOI 10.2500/ajr.2008.22.3228; KRETZSCHMAR T, 1993, EUR J IMMUNOL, V23, P558, DOI 10.1002/eji.1830230239; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lane AP, 2006, AM J RHINOL, V20, P117, DOI 10.1177/194589240602000122; Lessey E, 2008, IMMUNOL RES, V41, P223, DOI 10.1007/s12026-008-8028-y; Mathern DR, 2015, CLIN J AM SOC NEPHRO, V10, P1636, DOI 10.2215/CJN.06230614; Meltzer EO, 2004, J ALLERGY CLIN IMMUN, V114, pS133, DOI 10.1016/j.jaci.2004.09.011; Meltzer EO, 2004, OTOLARYNG HEAD NECK, V131, pS1, DOI 10.1016/j.otohns.2004.09.067; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; MOONEY E, 1992, ARCH DERMATOL, V128, P58, DOI 10.1001/archderm.128.1.58; MURAKAMI Y, 1993, IMMUNOLOGY, V79, P633; Murata Kazunori, 2009, Transplant Rev (Orlando), V23, P139, DOI 10.1016/j.trre.2009.02.005; Orjuela A, 2015, AM J NEPHROL, V41, P241, DOI 10.1159/000381965; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Pothoven KL, 2015, J ALLERGY CLIN IMMUN, V136, P737, DOI 10.1016/j.jaci.2015.01.043; Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487; ROTHMAN BL, 1990, J IMMUNOL, V145, P592; Schlosser RJ, 2010, AM J RHINOL ALLERGY, V24, P21, DOI 10.2500/ajra.2010.24.3399; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Shin HW, 2012, AM J RESP CRIT CARE, V185, P944, DOI 10.1164/rccm.201109-1706OC; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Takafuji S, 1996, ALLERGY, V51, P563; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Tan BK, 2010, CURR OPIN OTOLARYNGO, V18, P21, DOI 10.1097/MOO.0b013e3283350053; Tang ZY, 2009, J AM SOC NEPHROL, V20, P593, DOI 10.1681/ASN.2008040434; TORBOHM I, 1990, KIDNEY INT, V37, P1098, DOI 10.1038/ki.1990.91; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Van Zele T, 2009, LARYNGOSCOPE, V119, P1753, DOI 10.1002/lary.20484; vanBruggen MCJ, 1997, EUR J IMMUNOL, V27, P1564, DOI 10.1002/eji.1830270636; Varsano S, 2000, THORAX, V55, P364, DOI 10.1136/thorax.55.5.364; WEBSTER RO, 1982, J CLIN INVEST, V70, P1177, DOI 10.1172/JCI110716; WEETMAN AP, 1989, CLIN EXP IMMUNOL, V77, P25; WEISDORF DJ, 1981, J LAB CLIN MED, V98, P823; Woolhiser MR, 2004, CLIN IMMUNOL, V110, P172, DOI 10.1016/j.clim.2003.11.007; Zhang X, 2010, EXPERT REV CLIN IMMU, V6, P269, DOI 10.1586/ECI.09.84; Zhen QL, 2005, J CLIN INVEST, V115, P3428, DOI 10.1172/JCI23587	68	27	27	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					89	+		10.1016/j.jaci.2016.11.015	http://dx.doi.org/10.1016/j.jaci.2016.11.015			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27979430	Green Accepted, Bronze			2022-12-18	WOS:000404542000009
J	Kim, DW; Kulka, M; Jo, A; Eun, KM; Arizmendi, N; Tancowny, BP; Hong, SN; Lee, JP; Jin, HR; Lockey, RF; Kim, DK; Cho, SH				Kim, Dae Woo; Kulka, Marianna; Jo, Ara; Eun, Kyoung Mi; Arizmendi, Narcy; Tancowny, Brian P.; Hong, Seung-No; Lee, Jung Pyo; Jin, Hong Ryul; Lockey, Richard F.; Kim, Dong-Kyu; Cho, Seong H.			Cross-talk between human mast cells and epithelial cells by IgE-mediated periostin production in eosinophilic nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							THYMIC STROMAL LYMPHOPOIETIN; KAPPA-B; ASSOCIATION; INFLAMMATION; EXPRESSION; PROMOTES; ASTHMA		[Kim, Dae Woo; Eun, Kyoung Mi; Hong, Seung-No; Jin, Hong Ryul] Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Boramae Med Ctr, Seoul, South Korea; [Kim, Dae Woo; Jo, Ara; Lockey, Richard F.; Cho, Seong H.] Univ S Florida, Morsani Coll Med, Div Allergy Immunol, Dept Internal Med, Tampa, FL USA; [Kulka, Marianna; Arizmendi, Narcy; Tancowny, Brian P.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada; [Kulka, Marianna; Arizmendi, Narcy; Tancowny, Brian P.] Natl Res Council Canada, Natl Inst Nanotechnol, Edmonton, AB, Canada; [Lee, Jung Pyo] Seoul Natl Univ, Coll Med, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea; [Kim, Dong-Kyu] Hallym Univ, Coll Med, Chuncheon Sacred Heart Hosp, Dept Otorhinolaryngol Head & Neck Surg, Chunchon, South Korea; [Kim, Dong-Kyu] Hallym Univ, Coll Med, Nano Bioregenerat Med Inst, Chunchon, South Korea	Seoul National University (SNU); Seoul National University Hospital; State University System of Florida; University of South Florida; University of Alberta; National Research Council Canada; Seoul National University (SNU); Seoul National University Hospital; Hallym University; Hallym University	Kim, DK (corresponding author), Hallym Univ, Coll Med, Chuncheon Sacred Heart Hosp, Dept Otorhinolaryngol Head & Neck Surg, Chunchon, South Korea.; Kim, DK (corresponding author), Hallym Univ, Coll Med, Nano Bioregenerat Med Inst, Chunchon, South Korea.	doctordk@naver.com; scho2@health.usf.edu		Jo, Ara/0000-0002-2781-8529; Kim, Dong-Kyu/0000-0003-4917-0177; Hong, Seung-No/0000-0002-5759-9929	Canadian Institutes for Health Research; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2015R1C1A1A01054573]; National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI110731] Funding Source: NIH RePORTER	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	M. Kulka receives grant support from the Canadian Institutes for Health Research. D.-K. Kim receives grant support from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2015R1C1A1A01054573). S.H. Cho receives grant support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Kanemitsu Y, 2013, J ALLERGY CLIN IMMUN, V132, P305, DOI 10.1016/j.jaci.2013.04.050; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; Kim MA, 2014, ANN ALLERG ASTHMA IM, V113, P314, DOI 10.1016/j.anai.2014.06.014; Laury AM, 2014, INT FORUM ALLERGY RH, V4, P716, DOI 10.1002/alr.21367; Lee HC, 2012, J ALLERGY CLIN IMMUN, V130, P1187, DOI 10.1016/j.jaci.2012.07.031; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Wang M, 2015, J ALLERGY CLIN IMMUN, V136, P1700, DOI 10.1016/j.jaci.2015.09.005	10	27	27	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2017	139	5					1692	+		10.1016/j.jaci.2016.09.026	http://dx.doi.org/10.1016/j.jaci.2016.09.026			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ET7HI	27771323	Green Accepted, Bronze			2022-12-18	WOS:000400465300035
J	Tyler, MA; Russell, CB; Smith, DE; Rottman, JB; Dietz, CJP; Hu, XG; Citardi, MJ; Fakhri, S; Assassi, S; Luong, A				Tyler, Matthew A.; Russell, Chris B.; Smith, Dirk E.; Rottman, James B.; Dietz, Caroline J. Padro; Hu, Xuguang; Citardi, Martin J.; Fakhri, Samer; Assassi, Shervin; Luong, Amber			Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SERUM SKIN-TEST; NASAL POLYPS; CHRONIC URTICARIA; ASTHMA; ENTEROTOXINS; MUCOSA; CELLS; IGE		[Tyler, Matthew A.; Dietz, Caroline J. Padro; Citardi, Martin J.; Fakhri, Samer; Luong, Amber] Univ Texas McGovern Med Sch, Dept Otorhinolaryngol Head & Neck Surg, Houston, TX 77030 USA; [Tyler, Matthew A.; Dietz, Caroline J. Padro; Citardi, Martin J.; Fakhri, Samer; Luong, Amber] Texas Sinus Inst, Houston, TX 77004 USA; [Russell, Chris B.; Hu, Xuguang] Amgen Inc, Dept Med Sci, Seattle, WA USA; [Smith, Dirk E.] Amgen Inc, Dept Inflammat Res, Seattle, WA USA; [Rottman, James B.] Amgen Inc, Dept Pathol, Cambridge, MA USA; [Dietz, Caroline J. Padro; Luong, Amber] Univ Texas McGovern Med Sch, Ctr Immunol & Autoimmune Dis, Inst Mol Med, Houston, TX USA; [Fakhri, Samer] Amer Univ Beirut, Dept Otolaryngol Head & Neck Surg, Beirut, Lebanon; [Assassi, Shervin] Univ Texas McGovern Med Sch, Div Rheumatol, Houston, TX USA	Amgen; Amgen; Amgen; American University of Beirut	Luong, A (corresponding author), Univ Texas McGovern Med Sch, Dept Otorhinolaryngol Head & Neck Surg, Houston, TX 77030 USA.; Luong, A (corresponding author), Texas Sinus Inst, Houston, TX 77004 USA.	amber.u.luong@uth.tmc.edu		Russell, Chris/0000-0002-0240-1815	Amgen; Center for Clinical and Translational Sciences; National Institutes of Health Clinical and Translational Award - National Center for Advancing Translational Science [UL1 TR000371, KL2 TR000370]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000371, KL2TR000370] Funding Source: NIH RePORTER	Amgen(Amgen); Center for Clinical and Translational Sciences; National Institutes of Health Clinical and Translational Award - National Center for Advancing Translational Science; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The cost of the microarray processing was partially supported by Amgen. A.L. is supported by the Center for Clinical and Translational Sciences, which is funded by National Institutes of Health Clinical and Translational Award UL1 TR000371 and KL2 TR000370 from the National Center for Advancing Translational Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Science or the National Institutes of Health.	Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Baba S, 2014, LARYNGOSCOPE, V124, pE115, DOI 10.1002/lary.24462; Bachert C, 2012, J ALLERGY CLIN IMMUN, V130, P376, DOI 10.1016/j.jaci.2012.05.012; Bachert C, 2010, J ALLERGY CLIN IMMUN, V126, P962, DOI 10.1016/j.jaci.2010.07.007; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; De Schryver E, 2015, ALLERGY ASTHMA IMMUN, V7, P321, DOI 10.4168/aair.2015.7.4.321; Endo Y, 2015, IMMUNITY, V42, P294, DOI 10.1016/j.immuni.2015.01.016; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fritz SB, 2003, J ALLERGY CLIN IMMUN, V112, P1057, DOI 10.1016/j.jaci.2003.09.042; Gauthier M, 2015, AM J RESP CRIT CARE, V192, P660, DOI 10.1164/rccm.201504-0763PP; Jian W, 2009, AM J OTOLARYNG, V30, P24, DOI 10.1016/j.amjoto.2008.01.003; Kato A, 2015, ALLERGOL INT, V64, P121, DOI 10.1016/j.alit.2014.12.006; Konstantinou GN, 2009, ALLERGY, V64, P1256, DOI 10.1111/j.1398-9995.2009.02132.x; Plager DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011450; Platzer MH, 2005, ALLERGY, V60, P1152, DOI 10.1111/j.1398-9995.2005.00841.x; Shaw JL, 2013, AM J RESP CRIT CARE, V188, P432, DOI 10.1164/rccm.201212-2227OC; Shaw JL, 2012, INT FORUM ALLERGY RH, V2, P233, DOI 10.1002/alr.21021; Staubach P, 2006, DERMATOLOGY, V212, P150, DOI 10.1159/000090656; Strohner P, 2012, CLIN CHEM LAB MED, V50, P1263, DOI 10.1515/cclm-2011-0644; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Wang M, 2015, J ALLERGY CLIN IMMUN, V136, P1700, DOI 10.1016/j.jaci.2015.09.005	21	27	28	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					1061	+		10.1016/j.jaci.2016.09.048	http://dx.doi.org/10.1016/j.jaci.2016.09.048			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27871878	Green Accepted, Bronze			2022-12-18	WOS:000397295800048
J	Baiz, N; Macchiaverni, P; Tulic, MK; Rekima, A; Annesi-Maesano, I; Verhasselt, V				Baiz, Nour; Macchiaverni, Patricia; Tulic, Meri K.; Rekima, Akila; Annesi-Maesano, Isabella; Verhasselt, Valerie		EDEN Mother-Child Cohort Study Grp	Early oral exposure to house dust mite allergen through breast milk: A potential risk factor for allergic sensitization and respiratory allergies in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY; ASTHMA; CHILDHOOD		[Baiz, Nour; Annesi-Maesano, Isabella] UPMC Univ Paris 06, Sorbonne Univ, INSERM,Med Sch St Antoine, IPLESP UMRS 1136,Epidemiol Allerg & Resp Dis Dept, Paris, France; [Macchiaverni, Patricia] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil; [Tulic, Meri K.; Rekima, Akila; Verhasselt, Valerie] Univ Nice Sophia Antipolis, TIM, EA 6302, Nice, France; [Tulic, Meri K.; Verhasselt, Valerie] Worldwide Univ Network, Int Inflammat in FLAME Network, Perth, WA, Australia	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universidade de Sao Paulo; UDICE-French Research Universities; Universite Cote d'Azur	Verhasselt, V (corresponding author), Univ Nice Sophia Antipolis, TIM, EA 6302, Nice, France.; Verhasselt, V (corresponding author), Worldwide Univ Network, Int Inflammat in FLAME Network, Perth, WA, Australia.	verhasseltvalerie@gmail.com	de Lauzon-Guillain, Blandine/P-4659-2016; Annesi-Maesano, Isabella/D-9173-2016; Heude, Barbara/G-3095-2016; Rekima, Akila/AAE-7782-2021; Macchiaverni, Patricia/K-8507-2018; Lepeule, Johanna/N-2579-2013; Verhasselt, Valerie/AAO-2373-2020; FRITEL, Xavier/K-8566-2012; Charles, Marie Aline/F-8567-2017; Tulic, Meri K/ABB-5138-2020; Tulic, Meri/P-6613-2016; Bernard, Jonathan/T-7064-2017; Charles, Marie Aline/S-1866-2019; Saurel-Cubizolles, Marie-Josephe/D-1571-2014	de Lauzon-Guillain, Blandine/0000-0001-5887-8842; Annesi-Maesano, Isabella/0000-0002-6340-9300; Heude, Barbara/0000-0002-1565-1629; Rekima, Akila/0000-0003-2323-6334; Macchiaverni, Patricia/0000-0002-1897-9013; Lepeule, Johanna/0000-0001-8907-197X; FRITEL, Xavier/0000-0002-4987-8127; Charles, Marie Aline/0000-0003-4025-4390; Tulic, Meri K/0000-0002-2661-2369; Tulic, Meri/0000-0002-2661-2369; Bernard, Jonathan/0000-0002-6418-983X; Charles, Marie Aline/0000-0003-4025-4390; Saurel-Cubizolles, Marie-Josephe/0000-0002-2210-974X; Germa, Alice/0000-0002-0505-4986; verhasselt, valerie/0000-0002-5732-9048; HANKARD, Regis/0000-0001-8450-5839; BAIZ, Nour/0000-0001-6165-3935	Fonds de Dotation "Recherche en Sante Respiratoire''; Societe Francaise d'Allergologie (SFA); Universite de Nice Sophia-Antipolis; Fondation Princesse Grace; French Ministry of Research: Instituts Federatifs de Recherche Program; INSERM Nutrition Research Program; French Ministry of Health: Perinatality Program; French National Institute for Population Health Surveillance (INVS); Paris-Sud University; French National Institute for Health Education (INPES); Nestle; Mutuelle Generale de l'Education Nationale (MGEN); French speaking association for the study of diabetes and metabolism (Alfediam); Sao Paulo Research Foundation (Fundacao de amparo a pesquisa do estado de Sao Paulo) [2012/51290-6]; European Union	Fonds de Dotation "Recherche en Sante Respiratoire''; Societe Francaise d'Allergologie (SFA); Universite de Nice Sophia-Antipolis; Fondation Princesse Grace; French Ministry of Research: Instituts Federatifs de Recherche Program; INSERM Nutrition Research Program(Institut National de la Sante et de la Recherche Medicale (Inserm)); French Ministry of Health: Perinatality Program; French National Institute for Population Health Surveillance (INVS); Paris-Sud University; French National Institute for Health Education (INPES)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Nestle(Nestle SA); Mutuelle Generale de l'Education Nationale (MGEN); French speaking association for the study of diabetes and metabolism (Alfediam); Sao Paulo Research Foundation (Fundacao de amparo a pesquisa do estado de Sao Paulo); European Union(European Commission)	The following organizations funded this study: Fonds de Dotation "Recherche en Sante Respiratoire,'' Societe Francaise d'Allergologie (SFA), Universite de Nice Sophia-Antipolis, Fondation Princesse Grace, French Ministry of Research: Instituts Federatifs de Recherche Program, INSERM Nutrition Research Program, French Ministry of Health: Perinatality Program, French National Institute for Population Health Surveillance (INVS), Paris-Sud University, French National Institute for Health Education (INPES), Nestle, Mutuelle Generale de l'Education Nationale (MGEN), French speaking association for the study of diabetes and metabolism (Alfediam), Sao Paulo Research Foundation (Fundacao de amparo a pesquisa do estado de Sao Paulo grant no. 2012/51290-6), and European Union-funded MedAll project. The funding sources had no role in data collection, analysis of data, interpretation of results, or writing of this manuscript.	ABBOTT J, 1981, CLIN ALLERGY, V11, P589, DOI 10.1111/j.1365-2222.1981.tb02179.x; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baiz N, 2014, J ALLERGY CLIN IMMUN, V133, P147, DOI 10.1016/j.jaci.2013.05.017; Custovic A, 2015, CLIN EXP ALLERGY, V45, P54, DOI 10.1111/cea.12450; Elizur A, 2016, CURR OPIN ALLERGY CL, V16, P157, DOI 10.1097/ACI.0000000000000243; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Grimshaw KEC, 2013, PEDIATRICS, V132, pE1529, DOI 10.1542/peds.2012-3692; Hasselaar E., 2006, HLTH IS BEDROOM INDO, P185; Heude B, 2016, INT J EPIDEMIOL, V45, P353, DOI 10.1093/ije/dyv151; Macchiaverni P, 2014, ALLERGY, V69, P395, DOI 10.1111/all.12332; Macchiaverni P, 2011, SCAND J IMMUNOL, V74, P619, DOI 10.1111/j.1365-3083.2011.02615.x; Macchiaverni P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139064; Palmer DJ, 2008, CLIN EXP ALLERGY, V38, P1186, DOI 10.1111/j.1365-2222.2008.03014.x; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Rocchi S, 2015, SCI TOTAL ENVIRON, V505, P1026, DOI 10.1016/j.scitotenv.2014.10.086; Tobias KRC, 2004, INT ARCH ALLERGY IMM, V133, P365, DOI 10.1159/000077356; UCHIKOSHI S, 1982, Tokai Journal of Experimental and Clinical Medicine, V7, P233; van den Bemt L, 2006, CLIN EXP ALLERGY, V36, P233, DOI 10.1111/j.1365-2222.2006.02427.x; Verhasselt V, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0139; Verhasselt V, 2010, CURR OPIN IMMUNOL, V22, P623, DOI 10.1016/j.coi.2010.08.008; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1	23	27	27	4	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2017	139	1					369	+		10.1016/j.jaci.2016.07.021	http://dx.doi.org/10.1016/j.jaci.2016.07.021			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EK5WM	27566456	Bronze			2022-12-18	WOS:000393996800043
J	London, NR; Tharakan, A; Rule, AM; Lane, AP; Biswal, S; Ramanathan, M				London, Nyall R., Jr.; Tharakan, Anuj; Rule, Ana M.; Lane, Andrew P.; Biswal, Shyam; Ramanathan, Murugappan, Jr.			Air pollutant-mediated disruption of sinonasal epithelial cell barrier function is reversed by activation of the Nrf2 pathway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[London, Nyall R., Jr.; Tharakan, Anuj; Lane, Andrew P.; Ramanathan, Murugappan, Jr.] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Rule, Ana M.; Biswal, Shyam] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Ramanathan, M (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.	mramana3@jhmi.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES020859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Cho DY, 2014, INT FORUM ALLERGY RH, V4, P966, DOI 10.1002/alr.21413; Fan X, 2013, AM J PHYSIOL-LUNG C, V305, P1267, DOI 10.1152/ajplung.00288.2012; Kim KH, 2015, ENVIRON INT, V74, P136, DOI 10.1016/j.envint.2014.10.005; Li N, 2009, ENVIRON HEALTH PERSP, V117, P1116, DOI 10.1289/ehp.0800319; Rule AM, 2010, J ENVIRON MONITOR, V12, P1807, DOI 10.1039/c0em00034e; Schleimer Robert P, 2009, Proc Am Thorac Soc, V6, P288, DOI 10.1513/pats.200808-088RM; Shintani Y, 2015, ALLERGOL INT, V64, pS54, DOI 10.1016/j.alit.2015.06.004; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Sussan TE, 2015, AM J PHYSIOL-LUNG C, V309, pL27, DOI 10.1152/ajplung.00398.2014	9	27	27	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1736	+		10.1016/j.jaci.2016.06.027	http://dx.doi.org/10.1016/j.jaci.2016.06.027			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27576127	Bronze			2022-12-18	WOS:000390019300039
J	Garn, H; Bahn, S; Baune, BT; Binder, EB; Bisgaard, H; Chatila, TA; Chavakis, T; Culmsee, C; Dannlowski, U; Gay, S; Gern, J; Haahtela, T; Kircher, T; Muller-Ladner, U; Neurath, MF; Preissner, KT; Reinhardt, C; Rook, G; Russell, S; Schmeck, B; Stappenbeck, T; Steinhoff, U; van Os, J; Weiss, S; Zemlin, M; Renz, H				Garn, Holger; Bahn, Sabine; Baune, Bernhard T.; Binder, Elisabeth B.; Bisgaard, Hans; Chatila, Talal A.; Chavakis, Triantafyllos; Culmsee, Carsten; Dannlowski, Udo; Gay, Steffen; Gern, James; Haahtela, Tari; Kircher, Tilo; Mueller-Ladner, Ulf; Neurath, Markus F.; Preissner, Klaus T.; Reinhardt, Christoph; Rook, Graham; Russell, Shannon; Schmeck, Bernd; Stappenbeck, Thaddeus; Steinhoff, Ulrich; van Os, Jim; Weiss, Scott; Zemlin, Michael; Renz, Harald			Current concepts in chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic inflammation; immune dysregulation; metabolism; environment; epigenetics; stress; biodiversity	EARLY-LIFE; VITAMIN-D; EXTRACELLULAR RNA; SCHIZOPHRENIA-PATIENTS; INTESTINAL MICROBIOTA; RHEUMATOID-ARTHRITIS; ALLERGIC DISEASE; GUT MICROBIOTA; ANTIBIOTIC USE; ASTHMA	Recent research indicates that chronic inflammatory diseases, including allergies and autoimmune and neuropsychiatric diseases, share common pathways of cellular and molecular dysregulation. It was the aim of the International von-Behring-Rontgen Symposium (October 16-18, 2014, in Marburg, Germany) to discuss recent developments in this field. These include a concept of biodiversity; the contribution of urbanization, lifestyle factors, and nutrition (eg, vitamin D); and new mechanisms of metabolic and immune dysregulation, such as extracellular and intracellular RNAs and cellular and mitochondrial stress. Epigenetic mechanisms contribute further to altered gene expression and therefore to the development of chronic inflammation. These novel findings provide the foundation for further development of preventive and therapeutic strategies.	[Garn, Holger] Univ Marburg, Inst Lab Med & Pathobiochem, Mol Diagnost, D-35032 Marburg, Germany; [Culmsee, Carsten] Univ Marburg, Inst Pharmacol & Clin Pharm, D-35032 Marburg, Germany; [Steinhoff, Ulrich] Univ Marburg, Inst Med Microbiol, D-35032 Marburg, Germany; [Zemlin, Michael] Univ Marburg, Childrens Hosp, D-35032 Marburg, Germany; [Bahn, Sabine] Univ Cambridge, Ctr Neuropsychiat Res, Cambridge CB2 1TN, England; [Baune, Bernhard T.] Univ Adelaide, Discipline Psychiat, Adelaide, SA 5005, Australia; [Binder, Elisabeth B.] Max Planck Inst Psychiat, Dept Translat Res Psychiat, Munich, Germany; [Bisgaard, Hans] Univ Copenhagen, Fac Hlth Sci, COPSAC, DK-1168 Copenhagen, Denmark; [Chatila, Talal A.] Harvard Univ, Boston Childrens Hosp, Cambridge, MA 02138 USA; [Chavakis, Triantafyllos] Tech Univ Dresden, Clin Pathobiochem, Dresden, Germany; [Dannlowski, Udo] Univ Munster, Dept Psychiat, Munster, Germany; [Gay, Steffen] Univ Zurich Hosp, Ctr Expt Rheumatol, Zurich, Switzerland; [Gern, James] Ctr Clin Sci, Div Allergy & Immunol, Madison, WI USA; [Haahtela, Tari] Univ Helsinki Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Kircher, Tilo] Univ Marburg, Dept Psychiat & Psychotherapy, D-35032 Marburg, Germany; [Mueller-Ladner, Ulf] Univ Giessen, Fac Med, Clin Rheumatol & Clin Immunol, Giessen, Germany; [Neurath, Markus F.] Univ Giessen, Fac Med, Dept Biochem, Giessen, Germany; [Preissner, Klaus T.] Univ Erlangen Nurnberg, Med Clin Gastroenterol, Pneumonol, Endocrinol, Erlangen, Germany; [Reinhardt, Christoph] Univ Med Ctr Mainz, CTH, Mainz, Germany; [Rook, Graham] UCL, Ctr Clin Microbiol, London WC1E 6BT, England; [Russell, Shannon] Univ British Columbia, Michael Smith Labs, Vancouver, BC V5Z 1M9, Canada; [Schmeck, Bernd] Univ Giessen, Inst Lung Res, Giessen, Germany; [Schmeck, Bernd] Univ Marburg, Marburg Lung Ctr, D-35032 Marburg, Germany; [Schmeck, Bernd] Univ Marburg, German Ctr Lung Res DZL, D-35032 Marburg, Germany; [Schmeck, Bernd] Univ Med Ctr Giessen, Dept Med Pulm & Crit Care Med, Marburg, Germany; [Stappenbeck, Thaddeus] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63130 USA; [van Os, Jim] Maastricht Univ, Dept Psychiat & Psychol, NL-6200 MD Maastricht, Netherlands; [Weiss, Scott] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; University of Cambridge; University of Adelaide; Max Planck Society; University of Copenhagen; Harvard University; Boston Children's Hospital; Technische Universitat Dresden; University of Munster; University of Zurich; University Zurich Hospital; University of Helsinki; Helsinki University Central Hospital; Philipps University Marburg; Justus Liebig University Giessen; Justus Liebig University Giessen; University of Erlangen Nuremberg; Johannes Gutenberg University of Mainz; University of London; University College London; University of British Columbia; Justus Liebig University Giessen; Philipps University Marburg; Philipps University Marburg; Washington University (WUSTL); Maastricht University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Renz, H (corresponding author), Univ Marburg, Inst Lab Med, Baldinger Str, D-35043 Marburg, Germany.	harald.renz@uk-gm.de	van Os, Jim/C-2113-2014; Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; Bisgaard, Hans/N-4761-2016; Kircher, Tilo/AAT-6480-2020; Zemlin, Michael/AAB-5746-2020; van Os, Jim/V-8884-2019; Culmsee, Carsten/ABC-3120-2021; Chavakis, Triantafyllos/ABE-8845-2020	Bisgaard, Hans/0000-0003-4131-7592; Kircher, Tilo/0000-0002-2514-2625; Zemlin, Michael/0000-0001-9528-7419; van Os, Jim/0000-0002-7245-1586; Culmsee, Carsten/0000-0002-5121-5015; Dannlowski, Udo/0000-0002-0623-3759; Garn, Holger/0000-0002-5178-4023; Schmeck, Bernd/0000-0002-2767-3606; Steinhoff, Ulrich/0000-0003-2141-7756; Chatila, Talal/0000-0001-7439-2762	von-Behring-Rontgen-Foundation; LOEWE Excellence Centre UGMLC (Universities of Giessen & Marburg Lung Centre); Deutsches Zentrum fur Lungenforschung (DZL); Deutsche Forschungsgemeinschaft DFG [KI 588/14-1, DA 1151/5-1, AFI 11802, RE 737/23-1, RE 3450/3-1, RE 3450/5-1, SFB1021, FOR 2107]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER	von-Behring-Rontgen-Foundation; LOEWE Excellence Centre UGMLC (Universities of Giessen & Marburg Lung Centre); Deutsches Zentrum fur Lungenforschung (DZL); Deutsche Forschungsgemeinschaft DFG(German Research Foundation (DFG)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the von-Behring-Rontgen-Foundation, LOEWE Excellence Centre UGMLC (Universities of Giessen & Marburg Lung Centre), the Deutsches Zentrum fur Lungenforschung (DZL), and the Deutsche Forschungsgemeinschaft DFG FOR 2107 (grants. KI 588/14-1, DA 1151/5-1, AFI 11802, RE 737/23-1, RE 3450/3-1, RE 3450/5-1) and SFB1021.	Andersen CJ, 2016, ADV NUTR, V7, P66, DOI 10.3945/an.115.010207; Arloth J, 2015, NEURON, V86, P1189, DOI 10.1016/j.neuron.2015.05.034; Baumgart DC, 2012, LANCET, V380, P1590, DOI 10.1016/S0140-6736(12)60026-9; Baune BT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-125; Baune BT, 2012, BIOL PSYCHIAT, V72, P655, DOI 10.1016/j.biopsych.2012.04.002; Bisgaard H, 2014, CLIN EXP ALLERGY, V44, P475, DOI 10.1111/cea.12291; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Brandao I, 2015, GUT MICROBES, V6, P202, DOI 10.1080/19490976.2015.1034417; Cabrera-Fuentes HA, 2014, THROMB HAEMOSTASIS, V112, P1110, DOI 10.1160/TH14-08-0703; Choi EY, 2008, SCIENCE, V322, P1101, DOI 10.1126/science.1165218; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Cosselman KE, 2015, NAT REV CARDIOL, V12, P627, DOI 10.1038/nrcardio.2015.152; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; Danese S, 2011, NEW ENGL J MED, V365, P1713, DOI 10.1056/NEJMra1102942; de Witte L, 2014, SCHIZOPHR RES, V154, P23, DOI 10.1016/j.schres.2014.02.005; Dolga AM, 2013, J BIOL CHEM, V288, P10792, DOI 10.1074/jbc.M113.453522; Dolga AM, 2012, GLIA, V60, P2050, DOI 10.1002/glia.22419; Ege MJ, 2012, ALLERGY, V67, P1565, DOI 10.1111/all.12028; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ehling A, 2006, J IMMUNOL, V176, P4468, DOI 10.4049/jimmunol.176.7.4468; Eskan MA, 2012, NAT IMMUNOL, V13, P465, DOI 10.1038/ni.2260; Eyre HA, 2015, JAMA PSYCHIAT, V72, P511, DOI 10.1001/jamapsychiatry.2014.3128; Fischer S, 2014, CELL TISSUE RES, V355, P635, DOI 10.1007/s00441-014-1850-8; Frommer KW, 2012, ANN RHEUM DIS, V71, P1724, DOI 10.1136/annrheumdis-2011-200924; Fyhrquist N, 2014, J ALLERGY CLIN IMMUN, V134, P1301, DOI 10.1016/j.jaci.2014.07.059; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Haahtela T, 2013, WORLD ALLERGY ORGAN, V6, DOI 10.1186/1939-4551-6-3; Hagner S, 2013, ALLERGY, V68, P322, DOI 10.1111/all.12094; Hajishengallis G, 2013, TRENDS IMMUNOL, V34, P1, DOI 10.1016/j.it.2012.08.003; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Heijtza RD, 2011, P NATL ACAD SCI USA, V108, P3047, DOI 10.1073/pnas.1010529108; Hergenreider E, 2012, NAT CELL BIOL, V14, P249, DOI 10.1038/ncb2441; Herold S, 2011, AM J RESP CRIT CARE, V183, P1380, DOI 10.1164/rccm.201009-1431OC; Hormann N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113080; Karlsson FH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2266; Karouzakis E, 2014, J IMMUNOL, V193, P4945, DOI 10.4049/jimmunol.1400066; Kelly FJ, 2015, ANN NY ACAD SCI, V1340, P84, DOI 10.1111/nyas.12720; Koeth RA, 2013, NAT MED, V19, P576, DOI 10.1038/nm.3145; Landshamer S, 2008, CELL DEATH DIFFER, V15, P1553, DOI 10.1038/cdd.2008.78; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Lynch SV, 2014, J ALLERGY CLIN IMMUN, V134, P593, DOI 10.1016/j.jaci.2014.04.018; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; McFall-Ngai M, 2013, P NATL ACAD SCI USA, V110, P3229, DOI 10.1073/pnas.1218525110; Mirzakhani H, 2015, CLIN EXP ALLERGY, V45, P114, DOI 10.1111/cea.12430; Mitroulis I, 2014, THROMB HAEMOSTASIS, V111, P1004, DOI 10.1160/TH13-09-0794; Muller-Ladner U, 2009, NAT REV RHEUMATOL, V5, P659, DOI 10.1038/nrrheum.2009.232; Myin-Germeys I, 2009, PSYCHOL MED, V39, P1533, DOI 10.1017/S0033291708004947; Neidhart M, 2014, ARTHRITIS RHEUMATOL, V66, P1723, DOI 10.1002/art.38574; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Pabst O, 2012, MUCOSAL IMMUNOL, V5, P232, DOI 10.1038/mi.2012.4; Pace TWW, 2006, AM J PSYCHIAT, V163, P1630, DOI 10.1176/appi.ajp.163.9.1630; Perez MK, 2014, IMMUNOL ALLERGY CLIN, V34, P777, DOI 10.1016/j.iac.2014.07.002; Raison CL, 2010, ARCH GEN PSYCHIAT, V67, P1211, DOI 10.1001/archgenpsychiatry.2010.161; Reinhardt C, 2012, NATURE, V483, P627, DOI 10.1038/nature10893; Renz H, 2012, NAT REV IMMUNOL, V12, P9, DOI 10.1038/nri3112; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rogosch T, 2012, J IMMUNOL, V189, P5449, DOI 10.4049/jimmunol.1103347; Rolando M, 2013, CELL HOST MICROBE, V13, P395, DOI 10.1016/j.chom.2013.03.004; Rook GA, 2013, P NATL ACAD SCI USA, V110, P18360, DOI 10.1073/pnas.1313731110; Rook Graham A. W., 2013, Evolution Medicine and Public Health, P46, DOI 10.1093/emph/eot004; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Ruokolainen L, 2015, ALLERGY, V70, P195, DOI 10.1111/all.12545; Russell SL, 2015, J ALLERGY CLIN IMMUN, V135, P100, DOI 10.1016/j.jaci.2014.06.027; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schaffler A, 2006, ENDOCR REV, V27, P449, DOI 10.1210/er.2005-0022; Schwarz E, 2012, MOL PSYCHIATR, V17, P494, DOI 10.1038/mp.2011.42; Schwarz E, 2014, SCHIZOPHRENIA BULL, V40, P787, DOI 10.1093/schbul/sbt105; Sevelsted A, 2015, PEDIATRICS, V135, pE92, DOI 10.1542/peds.2014-0596; Severance E.G., 2014, SCHIZOPHR RES; Simsekyilmaz S, 2014, CIRCULATION, V129, P598, DOI 10.1161/CIRCULATIONAHA.113.002562; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Smoller JW, 2013, LANCET, V381, P1371, DOI 10.1016/S0140-6736(12)62129-1; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Stensballe LG, 2013, J PEDIATR-US, V162, P832, DOI 10.1016/j.jpeds.2012.09.049; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sun LL, 2015, CELL HOST MICROBE, V17, P85, DOI 10.1016/j.chom.2014.11.004; Thiering E, 2015, TRENDS ENDOCRIN MET, V26, P384, DOI 10.1016/j.tem.2015.05.002; Tomasik J, 2014, SCHIZOPHR RES; van Os J, 2010, NATURE, V468, P203, DOI 10.1038/nature09563; Verdile G, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/105828; Verhulst SL, 2008, J ASTHMA, V45, P828, DOI 10.1080/02770900802339734; Virgin HW, 2014, CELL, V157, P142, DOI 10.1016/j.cell.2014.02.032; von Hertzen L, 2011, EMBO REP, V12, P1089, DOI 10.1038/embor.2011.195; Weiss ST, 2011, J ALLERGY CLIN IMMUN, V127, P1128, DOI 10.1016/j.jaci.2011.02.025; Zemlin M, 2007, J IMMUNOL, V178, P1180, DOI 10.4049/jimmunol.178.2.1180	91	27	28	0	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					47	56		10.1016/j.jaci.2016.02.046	http://dx.doi.org/10.1016/j.jaci.2016.02.046			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	27373325	Bronze, Green Published			2022-12-18	WOS:000379659100005
J	Gagliardo, R; Gras, D; La Grutta, S; Chanez, P; Di Sano, C; Albano, GD; Vachier, I; Montalbano, AM; Anzalone, G; Bonanno, A; Riccobono, L; Gjomarkaj, M; Profita, M				Gagliardo, Rosalia; Gras, Delphine; La Grutta, Stefania; Chanez, Pascal; Di Sano, Caterina; Albano, Giusy D.; Vachier, Isabelle; Montalbano, Angela M.; Anzalone, Giulia; Bonanno, Anna; Riccobono, Loredana; Gjomarkaj, Mark; Profita, Mirella			Airway lipoxin A(4)/formyl peptide receptor 2-lipoxin receptor levels in pediatric patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; inflammation/resolution; induced sputum; lipoxin A(4); formyl peptide receptor 2-lipoxin receptor; glucocorticosteroids	GLUCOCORTICOID-RECEPTOR; ACUTE-INFLAMMATION; A(4); RESOLUTION; INDUCTION; CHILDREN; MEDIATOR; ANALOGS; PHOSPHORYLATION; BIOSYNTHESIS	Background: Lipoxins are biologically active eicosanoids with anti-inflammatory properties. Lipoxin A(4) (LXA(4)) signaling blocks asthmatic responses in human and experimental model systems. There is evidence that patients with respiratory diseases, including severe asthma (SA), display defective generation of lipoxin signals despite glucocorticoid therapy. Objective: We investigated airway levels of formyl peptide receptor 2-lipoxin receptor (FPR2/ALXR), LXA(4), and its counterregulatory compound, leukotriene B-4 (LTB4), in patients with childhood asthma. We addressed the potential interplay of the LXA(4-)FPR2/ALXR axis and glucocorticoids in the resolution of inflammation. Methods: We examined LXA(4) and LTB4 concentrations in induced sputum supernatants from children with intermittent asthma (IA), children with SA, and healthy control (HC) children. In addition, we investigated FPR2/ALXR expression in induced sputum cells obtained from the study groups. Finally, we evaluated in vitro the molecular interaction between LXA(4) and glucocorticoid receptor-based mechanisms. Results: We found that children with SA have decreased LXA(4) concentrations in induced sputum supernatants in comparison with children with IA. In contrast to decreases in LXA(4) concentrations, LTB4 concentrations were increased in children with asthma independent of severity. LXA(4) concentrations negatively correlated with LTB4 concentrations and with exacerbation numbers in children with SA. FPR2/ALXR expression was reduced in induced sputum cells of children with SA compared with that seen in HC subjects and children with IA. Finally, we describe in vitro the existence of crosstalk between LXA(4) and glucocorticoid receptor at the cytosolic level mediated by G protein-coupled FPR2/ALXR in peripheral blood granulocytes isolated from HC subjects, children with IA, and children with SA. Conclusion: Our findings provide evidence for defective LXA(4) generation and FPR2/ALXR expression that, associated with increased LTB4, might be involved in a reduction in the ability of inhaled corticosteroids to impair control of airway inflammation in children with SA.	[Gagliardo, Rosalia; La Grutta, Stefania; Di Sano, Caterina; Albano, Giusy D.; Montalbano, Angela M.; Anzalone, Giulia; Bonanno, Anna; Riccobono, Loredana; Gjomarkaj, Mark; Profita, Mirella] Italian Natl Res Council, Inst Biomed & Mol Immunol, Unit Immunopathol & Pharmacol Resp Syst, Palermo, Italy; [Gras, Delphine; Chanez, Pascal] Aix Marseille Univ, AP HM, Dept Malad Resp, Marseille, France; [Vachier, Isabelle] Med Bio Med, Montpellier, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Gagliardo, R (corresponding author), CNR, Ist Biomed & Immunol Mol, Via U La Malfa 153, I-90146 Palermo, Italy.	gagliardo@ibim.cnr.it	Gagliardo, Rosalia/AAX-7244-2020; Gras, Delphine/AAP-7248-2020; Gras, Delphine/A-7062-2017; Bonanno, Anna/AAV-9474-2020; Profita, Mirella/AFU-7423-2022; Profita, Mirella/D-8957-2018; Abano, Giusy Daniela/AAY-3896-2020; Profita, Mirella/AAY-3165-2020; bonanno, anna/F-7613-2015; Montalbano, Angela Marina/AAY-3905-2020; La Grutta, Stefania/N-3615-2014; DI SANO, CATERINA/AAX-7536-2020; Vachier, Isabelle/AAV-5731-2020; Riccobono, Loredana/F-7950-2015	Gras, Delphine/0000-0002-6630-2955; Profita, Mirella/0000-0002-7821-8283; Abano, Giusy Daniela/0000-0001-6944-4118; bonanno, anna/0000-0003-3448-283X; Montalbano, Angela Marina/0000-0001-5950-4834; La Grutta, Stefania/0000-0001-8026-0715; Vachier, Isabelle/0000-0003-2730-5165; Riccobono, Loredana/0000-0002-0012-3591; chanez, pascal/0000-0003-4059-0917	Italian National Research Council (CNR); European Union Framework Programme for Research, GA2LEN project, Global Allergy and Asthma European Network [FOOD-CT-2004-506378]	Italian National Research Council (CNR)(Consiglio Nazionale delle Ricerche (CNR)); European Union Framework Programme for Research, GA2LEN project, Global Allergy and Asthma European Network	Supported by the Italian National Research Council (CNR) and the European Union Framework Programme for Research, contract no. FOOD-CT-2004-506378, GA<SUP>2</SUP>LEN project, Global Allergy and Asthma European Network.	Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; Ariel A, 2003, J IMMUNOL, V170, P6266, DOI 10.4049/jimmunol.170.12.6266; Back M, 2014, BRIT J PHARMACOL, V171, P3551, DOI 10.1111/bph.12665; Bae YS, 2003, J IMMUNOL, V171, P6807, DOI 10.4049/jimmunol.171.12.6807; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bonnans C, 2002, AM J RESP CRIT CARE, V165, P1531, DOI 10.1164/rccm.200201-053OC; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Chen WW, 2008, MOL ENDOCRINOL, V22, P1754, DOI 10.1210/me.2007-0219; Chinthamani S, 2012, AM J PHYSIOL-CELL PH, V302, pC968, DOI 10.1152/ajpcell.00259.2011; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; DREBORG S, 1993, ALLERGY, V48, P473, DOI 10.1111/j.1398-9995.1993.tb01102.x; Efthimiadis A, 2002, EUR RESPIR J, V20, p19S, DOI 10.1183/09031936.02.00001902; Eid N, 2002, PEDIATRICS, V109, P217, DOI 10.1542/peds.109.2.217; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033; Gagliardo R, 2013, INT J IMMUNOPATH PH, V26, P725, DOI 10.1177/039463201302600316; Gagliardo R, 2009, PEDIAT ALLERG IMM-UK, V20, P780, DOI 10.1111/j.1399-3038.2009.00945.x; Gewirtz AT, 2002, J IMMUNOL, V168, P5260, DOI 10.4049/jimmunol.168.10.5260; Gungor HE, 2014, INT ARCH ALLERGY IMM, V163, P193, DOI 10.1159/000358490; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; HAGG E, 1987, CLIN ENDOCRINOL, V26, P221, DOI 10.1111/j.1365-2265.1987.tb00780.x; Hashimoto A, 2007, BIOMED PHARMACOTHER, V61, P81, DOI 10.1016/j.biopha.2006.06.023; Haworth O, 2007, EUR RESPIR J, V30, P980, DOI 10.1183/09031936.00005807; Henson PM, 2005, NAT IMMUNOL, V6, P1179, DOI 10.1038/ni1205-1179; Jones PD, 2001, AM J RESP CRIT CARE, V164, P1146, DOI 10.1164/ajrccm.164.7.2103015; La Grutta S, 2003, AM J RESP CRIT CARE, V167, P1490, DOI 10.1164/rccm.200206-549OC; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Maderna P, 2009, BRIT J PHARMACOL, V158, P947, DOI 10.1111/j.1476-5381.2009.00386.x; Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; O'Byrne PM, 1999, AM J RESP CRIT CARE, V159, pS41; Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Planaguma A, 2008, AM J RESP CRIT CARE, V178, P574, DOI 10.1164/rccm.200801-061OC; Ramon S, 2014, EUR J IMMUNOL, V44, P357, DOI 10.1002/eji.201343316; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Sawmynaden P, 2006, BIOCHEM BIOPH RES CO, V349, P1351, DOI 10.1016/j.bbrc.2006.08.179; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2005, PROSTAG OTH LIPID M, V77, P4, DOI 10.1016/j.prostaglandins.2004.09.016; Serhan CN, 2002, PROSTAG OTH LIPID M, V68-9, P433, DOI 10.1016/S0090-6980(02)00047-3; Starosta V, 2008, J IMMUNOL, V181, P8688, DOI 10.4049/jimmunol.181.12.8688; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Wiegers GJ, 1998, TRENDS PHARMACOL SCI, V19, P317, DOI 10.1016/S0165-6147(98)01229-2; Wu SH, 2010, PEDIATR PULM, V45, P333, DOI 10.1002/ppul.21186	49	27	29	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1796	1806		10.1016/j.jaci.2015.11.045	http://dx.doi.org/10.1016/j.jaci.2015.11.045			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26971688				2022-12-18	WOS:000377527200021
J	Colley, T; Mercado, N; Kunori, Y; Brightling, C; Bhavsar, PK; Barnes, PJ; Ito, K				Colley, Thomas; Mercado, Nicolas; Kunori, Yuichi; Brightling, Christopher; Bhavsar, Pankaj K.; Barnes, Peter J.; Ito, Kazuhiro			Defective sirtuin-1 increases IL-4 expression through acetylation of GATA-3 in patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MYD88; SIRT1; DEACETYLASE; IRAK4		[Colley, Thomas; Mercado, Nicolas; Kunori, Yuichi; Bhavsar, Pankaj K.; Barnes, Peter J.; Ito, Kazuhiro] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London, England; [Brightling, Christopher] Univ Leicester, Glenfield Hosp, Resp Med, Leicester, Leics, England	Imperial College London; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Ito, K (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London, England.	k.ito@imperial.ac.uk	Ito, Kazuhiro/AAF-5994-2019	Barnes, Peter/0000-0002-5122-4018; brightling, chris/0000-0002-9345-4903; mercado, nicolas/0000-0002-8728-0994	National Institute for Health Research [NF-SI-0611-10148] Funding Source: researchfish; Asthma UK [06/010] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK		Alsina L, 2014, NAT IMMUNOL, V15, P1134, DOI 10.1038/ni.3028; Barnes PJ, 2011, BREATHE, V7, P229, DOI 10.1183/20734735.026410; Caito S, 2010, FASEB J, V24, P3145, DOI 10.1096/fj.09-151308; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Nakamaru Y, 2009, FASEB J, V23, P2810, DOI 10.1096/fj.08-125468; Sahiner UM, 2011, WORLD ALLERGY ORGAN, V4, P151, DOI 10.1097/WOX.0b013e318232389e; Saunders CJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004041; Schatorje EJH, 2012, SCAND J IMMUNOL, V75, P436, DOI 10.1111/j.1365-3083.2012.02671.x; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Yamamoto T, 2014, MOL IMMUNOL, V58, P66, DOI 10.1016/j.molimm.2013.11.008; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	13	27	27	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1595	1597		10.1016/j.jaci.2015.10.013	http://dx.doi.org/10.1016/j.jaci.2015.10.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26627546	Green Submitted, Bronze			2022-12-18	WOS:000376180200038
J	Carpio, C; Villasante, C; Galera, R; Romero, D; de Cos, A; Hernanz, A; Garcia-Rio, F				Carpio, Carlos; Villasante, Carlos; Galera, Raul; Romero, David; de Cos, Ana; Hernanz, Angel; Garcia-Rio, Francisco			Systemic inflammation and higher perception of dyspnea mimicking asthma in obese subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Obesity; dyspnea; asthma; inflammation	BODY-MASS INDEX; INTERLEUKIN-1 RECEPTOR; MESSENGER-RNA; RISK; CYTOKINES; HYPERNOCICEPTION; STANDARDIZATION; OVERDIAGNOSIS; HYPERALGESIA; ASSOCIATION	Background: There are a variable number of obese subjects with self-reported diagnosis of asthma but without current or previous evidence of airflow limitation, bronchial reversibility, or airway hyperresponsiveness (misdiagnosed asthma). However, the mechanisms of asthma-like symptoms in obesity remain unclear. Objectives: We sought to evaluate the perception of dyspnea during bronchial challenge and exercise testing in obese patients with asthma and misdiagnosed asthma compared with obese control subjects to identify the mechanisms of asthma-like symptoms in obesity. Methods: In a cross-sectional study we included obese subjects with asthma (n = 25), misdiagnosed asthma (n = 23), and no asthma or respiratory symptoms (n = 27). Spirometry, lung volumes, exhaled nitric oxide levels, and systemic biomarker levels were measured. Dyspnea scores during adenosine bronchial challenge and incremental exercise testing were obtained. Results: During bronchial challenge, patients with asthma or misdiagnosed asthma reached a higher Borg-FEV1 slope than control subjects. Moreover, maximum dyspnea and the Borg-oxygen uptake (V'O-2) slope were significantly greater during exercise in subjects with asthma or misdiagnosed asthma than in control subjects. The maximum dyspnea achieved during bronchial challenge correlated with IL-1 beta levels, whereas peak respiratory frequency, ventilatory equivalent for CO2, and IL-6 and IL-1 beta levels were independent predictors of the Borg-V'O-2 slope during exercise (r(2) = 0.853, P < .001). Conclusions: A false diagnosis of asthma (misdiagnosed asthma) in obese subjects is attributable to an increased perception of dyspnea, which, during exercise, is mainly associated with systemic inflammation and excessive ventilation for metabolic demands.	[Carpio, Carlos; Villasante, Carlos; Galera, Raul; Romero, David; Garcia-Rio, Francisco] Hosp Univ La Paz, Serv Neumol, Paseo Castellana 261, Madrid 28034, Spain; [Hernanz, Angel] Hosp Univ La Paz, Serv Bioquim, Madrid 28034, Spain; [de Cos, Ana] IdiPAZ, Serv Endocrinol & Nutr, Unidad Obesidad, Madrid, Spain; [Carpio, Carlos; Villasante, Carlos; Galera, Raul; Romero, David; Garcia-Rio, Francisco] CIBER Enfermedades Resp CIBERES, Madrid, Spain; [Garcia-Rio, Francisco] Univ Autonoma Madrid, E-28049 Madrid, Spain	Hospital Universitario La Paz; Hospital Universitario La Paz; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Autonomous University of Madrid	Garcia-Rio, F (corresponding author), Hosp Univ La Paz, Serv Neumol, Paseo Castellana 261, Madrid 28034, Spain.	fgr01m@gmail.com	Garcia-Rio, Francisco/AAC-9981-2020	Garcia-Rio, Francisco/0000-0002-7227-2238; Carpio, Carlos/0000-0003-4090-4306				Aaron SD, 2008, CAN MED ASSOC J, V179, P1121, DOI 10.1503/cmaj.081332; Aleksandrova NP, 2015, RESP PHYSIOL NEUROBI, V209, P85, DOI 10.1016/j.resp.2014.12.006; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; ATS, 2003, AM J RESP CRIT CARE, V167, P211, DOI 10.1164/rccm.167.2.211; Bahadori Katayoun, 2009, BMC Pulm Med, V9, P24, DOI 10.1186/1471-2466-9-24; Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; Barranco P, 2011, J INVEST ALLERG CLIN, V21, P540; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beuther DA, 2005, J ALLERGY CLIN IMMUN, V115, P1100, DOI 10.1016/j.jaci.2004.12.1141; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BRADY LS, 1994, J NEUROSCI, V14, P4951; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Clark AK, 2010, J NEUROSCI, V30, P573, DOI 10.1523/JNEUROSCI.3295-09.2010; Cunha TM, 2008, EUR J PAIN, V12, P1059, DOI 10.1016/j.ejpain.2008.02.003; Cunha TM, 2005, P NATL ACAD SCI USA, V102, P1755, DOI 10.1073/pnas.0409225102; De Jongh RF, 2003, ANESTH ANALG, V96, P1096, DOI 10.1213/01.ANE.0000055362.56604.78; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; De Meer G, 2001, THORAX, V56, P362, DOI 10.1136/thorax.56.5.362; ERICSSON A, 1995, J COMP NEUROL, V361, P681, DOI 10.1002/cne.903610410; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Global Initiative for Asthma, 2006, GLOB STRAT ASTHM MAN; Graff GR, 1999, ARCH PHYSIOL BIOCHEM, V107, P97, DOI 10.1076/apab.107.2.97.4344; JONES NL, 1985, AM REV RESPIR DIS, V131, P700; Jones P., 1996, RESP SENSATION, P311; Lee EJ, 2009, J ASTHMA, V46, P339, DOI 10.1080/02770900802660931; MAHLER DA, 1991, AM REV RESPIR DIS, V144, P39, DOI 10.1164/ajrccm/144.1.39; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Ofir D, 2007, J APPL PHYSIOL, V102, P2217, DOI 10.1152/japplphysiol.00898.2006; Pakhale S, 2010, CHEST, V137, P1316, DOI 10.1378/chest.09-2491; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Racionero M, 1997, ARCH BRONCONEUMOL, V33, P109; Reeve AJ, 2000, EUR J PAIN-LONDON, V4, P247, DOI 10.1053/eujp.2000.0177; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Scott S, 2012, CHEST, V141, P616, DOI 10.1378/chest.11-0948; Shim YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061022; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; Spielberger C.D., 1970, STAI MANUAL; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Taylor B, 2008, THORAX, V63, P14, DOI 10.1136/thx.2007.082784; van Huisstede A, 2013, RESP MED, V107, P1356, DOI 10.1016/j.rmed.2013.05.007; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; Wegner A, 2014, BRAIN BEHAV IMMUN, V41, P46, DOI 10.1016/j.bbi.2014.05.001; WHO, 2015, OB OV; YABUUCHI K, 1994, MOL BRAIN RES, V27, P27, DOI 10.1016/0169-328X(94)90180-5	52	27	27	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2016	137	3					718	+		10.1016/j.jaci.2015.11.010	http://dx.doi.org/10.1016/j.jaci.2015.11.010			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DG2LB	26768410	Bronze			2022-12-18	WOS:000371897500013
J	Renand, A; Archila, LD; McGinty, J; Wambre, E; Robinson, D; Hales, BJ; Thomas, WR; Kwok, WW				Renand, Amedee; Archila, Luis D.; McGinty, John; Wambre, Erik; Robinson, David; Hales, Belinda J.; Thomas, Wayne R.; Kwok, William W.			Chronic cat allergen exposure induces a T(H)2 cell-dependent IgG(4) response related to low sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cat allergy; Fel d 1; Fel d 4; T(H)2 cells; allergen tolerance; asthma; class II tetramer; CD154; IgG4; allergen exposure	FEL D 1; MODIFIED TH2 RESPONSE; POLLEN IMMUNOTHERAPY; IMMUNOGLOBULIN G4; IMMUNE TOLERANCE; B-CELLS; IGE; INDUCTION; SWITCH; DIFFERENTIATION	Background: In human subjects, allergen tolerance has been observed after high-dose allergen exposure or after completed allergen immunotherapy, which is related to the accumulation of anti-inflammatory IgG(4). However, the specific T-cell response that leads to IgG(4) induction during chronic allergen exposure remains poorly understood. Objective: We sought to evaluate the relationship between cat allergen-specific T-cell frequency, cat allergen-specific IgE and IgG(4) titers, and clinical status in adults with cat allergy with and without cat ownership and the cellular mechanism by which IgG(4) is produced. Methods: Fel d 1-, Fel d 4-, Fel d 7-, and Fel d 8-specific T-cell responses were characterized by CD154 expression after antigen stimulation. Results: In allergic subjects without cat ownership, the frequency of cat allergen (Fel d 1 and Fel d 4)-specific T(H)2 (sT(H)2) cells correlates with higher IgE levels and is linked to asthma. Paradoxically, we observed that subjects with cat allergy and chronic cat exposure maintain a high frequency of sT(H)2 cells, which correlates with higher IgG(4) levels and low sensitization. B cells from allergic, but not nonallergic subjects, are able to produce IgG(4) after cognate interactions with sT(H)2 clones and Fel d 1 peptide or the Fel d 1 recombinant protein. Conclusion: These experiments suggest that (1) allergen-experienced B cells with the capacity to produce IgG(4) are present in allergic subjects and (2) cat allergen exposure induces an IgG(4) response in a T(H)2 cell-dependent manner. Thus IgG(4) accumulation could be mediated by chronic activation of the T(H)2 response, which in turn drives desensitization.	[Renand, Amedee; Archila, Luis D.; McGinty, John; Wambre, Erik; Kwok, William W.] Virginia Mason, Benaroya Res Inst, Seattle, WA USA; [Robinson, David] Virginia Mason Med Ctr, Asthma & Allergy Dept, Seattle, WA 98101 USA; [Kwok, William W.] Univ Washington, Dept Med, Seattle, WA USA; [Hales, Belinda J.; Thomas, Wayne R.] Univ Western Australia, Telethon Kids Inst, Subiaco, WA, Australia	Benaroya Research Institute; Virginia Mason Medical Center; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Telethon Kids Institute; University of Western Australia	Kwok, WW (corresponding author), Benaroya Res Inst, 1201 9th Ave, Seattle, WA 98101 USA.	bkwok@benaroyaresearch.org	Renand, Amedee/A-9884-2018	Renand, Amedee/0000-0003-2265-549X	National Institutes of Health [HHSN272200700046C]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health contract HHSN272200700046C.	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; Adjobimey T, 2010, ANN TROP MED PARASIT, V104, P455, DOI 10.1179/136485910X12786389891407; Akdis CA, 2014, J CLIN INVEST, V124, P4678, DOI 10.1172/JCI78891; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Bacher P, 2013, J IMMUNOL, V190, P3967, DOI 10.4049/jimmunol.1202221; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Bublin M, 2014, J ALLERGY CLIN IMMUN, V134, P521, DOI 10.1016/j.jaci.2014.04.015; Burnett M, 2013, J ALLER CL IMM-PRACT, V1, P350, DOI 10.1016/j.jaip.2013.03.011; Cerutti A, 1998, J IMMUNOL, V160, P2145; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Erwin EA, 2014, ANN ALLERG ASTHMA IM, V112, P545, DOI 10.1016/j.anai.2014.03.007; Figueiredo CA, 2010, INFECT IMMUN, V78, P3160, DOI 10.1128/IAI.01228-09; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; Goodnow CC, 2010, NAT IMMUNOL, V11, P681, DOI 10.1038/ni.1900; Gronlund H, 2010, INT ARCH ALLERGY IMM, V151, P265, DOI 10.1159/000250435; Hales BJ, 2013, J ALLER CL IMM-PRACT, V1, P656, DOI 10.1016/j.jaip.2013.08.008; Hales BJ, 2013, J ALLERGY CLIN IMMUN, V1, pe1; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jones Meinir G., 2008, V138, P247, DOI 10.1007/978-1-59745-366-0_20; Kolfschoten MV, 2007, SCIENCE, V317, P1554, DOI 10.1126/science.1144603; Kwok WW, 2010, J ALLERGY CLIN IMMUN, V125, P1407, DOI 10.1016/j.jaci.2010.03.037; McHeyzer-Williams M, 2012, NAT REV IMMUNOL, V12, P24, DOI 10.1038/nri3128; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Mobs C, 2012, J ALLERGY CLIN IMMUN, V130, P1108, DOI 10.1016/j.jaci.2012.07.056; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Oryszczyn MP, 2009, CLIN EXP ALLERGY, V39, P1515, DOI 10.1111/j.1365-2222.2009.03288.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Pone EJ, 2012, FRONT BIOSCI-LANDMRK, V17, P2594, DOI 10.2741/4073; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Renand A, 2014, J ALLERGY CLIN IMMUN, V134, P1456, DOI 10.1016/j.jaci.2014.07.048; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; Smith W, 2011, INT ARCH ALLERGY IMM, V156, P159, DOI 10.1159/000322879; Uermosi C, 2014, ALLERGY, V69, P338, DOI 10.1111/all.12327; Varga EM, 2013, J ALLERGY CLIN IMMUN, V131, P1419, DOI 10.1016/j.jaci.2012.08.037; Vinuesa CG, 2013, NAT IMMUNOL, V14, P119, DOI 10.1038/ni.2511; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Wambre E, 2014, J ALLERGY CLIN IMMUN, V133, P872, DOI 10.1016/j.jaci.2013.10.054; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Xu ZM, 2012, NAT REV IMMUNOL, V12, P517, DOI 10.1038/nri3216; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	47	27	28	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1627	U302		10.1016/j.jaci.2015.07.031	http://dx.doi.org/10.1016/j.jaci.2015.07.031			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26371841	Green Accepted			2022-12-18	WOS:000366044300025
J	Schaarschmidt, H; Ellinghaus, D; Rodriguez, E; Kretschmer, A; Baurecht, H; Lipinski, S; Meyer-Hoffert, U; Harder, J; Lieb, W; Novak, N; Foelster-Holst, R; Esparza-Gordillo, J; Marenholz, I; Ruschendorf, F; Hubner, N; Reischl, E; Waldenberger, M; Gieger, C; Illig, T; Kabesch, M; Zhang, XJ; Xiao, FL; Lee, YA; Franke, A; Weidinger, S				Schaarschmidt, Heidi; Ellinghaus, David; Rodriguez, Elke; Kretschmer, Anja; Baurecht, Hansjoerg; Lipinski, Simone; Meyer-Hoffert, Ulf; Harder, Juergen; Lieb, Wolfgang; Novak, Natalija; Foelster-Holst, Regina; Esparza-Gordillo, Jorge; Marenholz, Ingo; Ruschendorf, Franz; Hubner, Norbert; Reischl, Eva; Waldenberger, Melanie; Gieger, Christian; Illig, Thomas; Kabesch, Michael; Zhang, Xue-Jun; Xiao, Feng-Li; Lee, Young-Ae; Franke, Andre; Weidinger, Stephan			A genome-wide association study reveals 2 new susceptibility loci for atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POPULATION; VARIANT		[Schaarschmidt, Heidi; Ellinghaus, David; Lipinski, Simone; Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Lieb, Wolfgang] Univ Kiel, Inst Epidemiol, Kiel, Germany; [Lieb, Wolfgang] Univ Kiel, Biobank PopGen, Kiel, Germany; [Rodriguez, Elke; Kretschmer, Anja; Baurecht, Hansjoerg; Meyer-Hoffert, Ulf; Harder, Juergen; Foelster-Holst, Regina; Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergol, Kiel, Germany; [Kretschmer, Anja; Reischl, Eva; Waldenberger, Melanie; Gieger, Christian] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany; [Kretschmer, Anja; Reischl, Eva; Waldenberger, Melanie; Gieger, Christian] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, Neuherberg, Germany; [Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, Bonn, Germany; [Esparza-Gordillo, Jorge; Marenholz, Ingo; Ruschendorf, Franz; Hubner, Norbert; Lee, Young-Ae] Max Delbruck Ctr MDC Mol Med, Berlin, Germany; [Esparza-Gordillo, Jorge; Marenholz, Ingo; Lee, Young-Ae] Univ Med Berlin, Pediat Allergy Expt & Clin Res Ctr, Berlin, Germany; [Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany; [Kabesch, Michael] KUNO Univ Childrens Hosp Regensburg, Dept Pediat Pneumol & Allergy, Regensburg, Germany; [Zhang, Xue-Jun; Xiao, Feng-Li] Anhui Med Univ, Hosp 1, Inst Dermatol, Hefei, Peoples R China	University of Kiel; University of Kiel; University of Kiel; University of Kiel; Schleswig Holstein University Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Bonn; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School; Anhui Medical University	Schaarschmidt, H (corresponding author), Univ Kiel, Inst Clin Mol Biol, Kiel, Germany.	sweidinger@dermatology.uni-kiel.de	Waldenberger, Melanie/B-5355-2014; Ellinghaus, David/G-4467-2012; Ellinghaus, David/ABC-3610-2020; Meyer-Hoffert, Ulf/F-4623-2012; Lieb, Wolfgang/AAC-7650-2022; Weidinger, Stephan/C-8461-2011; Lipinski, Simone/L-9818-2017; Franke, Andre/B-2151-2010; Kabesch, Michael/AAB-5701-2020; Kabesch, Michael/GZM-1583-2022; Reischl, Eva/B-9311-2013; Baurecht, Hansjorg/C-4035-2013	Waldenberger, Melanie/0000-0003-0583-5093; Ellinghaus, David/0000-0002-4332-6110; Meyer-Hoffert, Ulf/0000-0003-2305-1428; Weidinger, Stephan/0000-0003-3944-252X; Lipinski, Simone/0000-0002-9322-7372; Franke, Andre/0000-0003-1530-5811; Reischl, Eva/0000-0003-4055-8060; Gieger, Christian/0000-0001-6986-9554; Rodriguez, Elke/0000-0003-3692-3950; Baurecht, Hansjorg/0000-0002-9265-5594; Harder, Jurgen/0000-0002-4075-4603				Ellinghaus D, 2013, NAT GENET, V45, P808, DOI 10.1038/ng.2642; Esparza-Gordillo J, 2013, J ALLERGY CLIN IMMUN, V132, P371, DOI 10.1016/j.jaci.2013.01.057; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Nica AC, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002003; Ottolenghi C, 2002, GENOMICS, V79, P333, DOI 10.1006/geno.2002.6711; Pacholsky D, 2004, J CELL SCI, V117, P5257, DOI 10.1242/jcs.01406; Panigrahi AK, 2012, BIOCHEM J, V442, P661, DOI 10.1042/BJ20111745; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166	12	27	29	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					802	+		10.1016/j.jaci.2015.01.047	http://dx.doi.org/10.1016/j.jaci.2015.01.047			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25865352				2022-12-18	WOS:000360913300035
J	Nagarkar, DR; Ramirez-Carrozzi, V; Choy, DF; Lee, K; Soriano, R; Jia, GQ; Abbas, AR; Modrusan, Z; Pappu, R; Arron, JR				Nagarkar, Deepti R.; Ramirez-Carrozzi, Vladimir; Choy, David F.; Lee, Kevin; Soriano, Robert; Jia, Guiquan; Abbas, Alexander R.; Modrusan, Zora; Pappu, Rajita; Arron, Joseph R.			IL-13 mediates IL-33-dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMA; INFLAMMATION; IL-33		[Nagarkar, Deepti R.; Ramirez-Carrozzi, Vladimir; Choy, David F.; Lee, Kevin; Soriano, Robert; Jia, Guiquan; Abbas, Alexander R.; Modrusan, Zora; Pappu, Rajita; Arron, Joseph R.] Genentech Inc, San Francisco, CA 94080 USA	Roche Holding; Genentech	Nagarkar, DR (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.	arron.joseph@gene.com		Choy, David/0000-0003-1351-6113; Arron, Joseph/0000-0001-7677-9979				Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P63; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Deckers J, 2013, TRENDS IMMUNOL, V34, P540, DOI 10.1016/j.it.2013.08.004; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104	10	27	27	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					202	205		10.1016/j.jaci.2015.01.036	http://dx.doi.org/10.1016/j.jaci.2015.01.036			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25784274	Bronze			2022-12-18	WOS:000357542200027
J	Park, MA; Solensky, R; Khan, DA; Castells, MC; Macy, EM; Lang, DM				Park, Miguel A.; Solensky, Roland; Khan, David A.; Castells, Mariana C.; Macy, Eric M.; Lang, David M.			Patients with positive skin test results to penicillin should not undergo penicillin or amoxicillin challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY; HYPERSENSITIVITY; VANCOMYCIN; REGISTER; HISTORY; COHORT; HEALTH		[Park, Miguel A.; Solensky, Roland] Amer Acad Allergy Asthma & Immunol, Adverse React Drugs Biol & Latex Comm, Milwaukee, WI 53202 USA; [Khan, David A.] Amer Acad Allergy Asthma & Immunol, Food Allergy Anaphylaxis Dermatol & Drug Allergy, Milwaukee, WI USA; [Castells, Mariana C.] Amer Acad Allergy Asthma & Immunol, Board Directors, Milwaukee, WI USA; [Lang, David M.] Amer Acad Allergy Asthma & Immunol, Practice & Policy Div, Milwaukee, WI USA; [Macy, Eric M.] Univ Calif San Diego, San Diego Med Ctr, So Calif Permanente Med Grp, Dept Allergy, San Diego, CA 92103 USA	Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of California System; University of California San Diego	Park, MA (corresponding author), Amer Acad Allergy Asthma & Immunol, Adverse React Drugs Biol & Latex Comm, Milwaukee, WI 53202 USA.	park.miguel@mayo.edu		Macy, Eric/0000-0002-5857-9444				Bousquet PJ, 2008, CLIN EXP ALLERGY, V38, P185, DOI 10.1111/j.1365-2222.2007.02867.x; Carstensen B, 2011, SCAND J PUBLIC HEALT, V39, P58, DOI 10.1177/1403494811404278; Cieslak PR, 1999, INFECT CONT HOSP EP, V20, P557, DOI 10.1086/501669; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; Kwan T, 1999, CLIN INVEST MED, V22, P256; Legere HJ, 2009, J CYST FIBROS, V8, P418, DOI 10.1016/j.jcf.2009.08.002; Lynge E, 2011, SCAND J PUBLIC HEALT, V39, P30, DOI 10.1177/1403494811401482; Macy E, 2002, ALLERGY, V57, P1151, DOI 10.1034/j.1398-9995.2002.23700.x; Macy E, 2014, J ALLERGY CLIN IMMUN, V133, P790, DOI 10.1016/j.jaci.2013.09.021; Macy E, 2013, J ALLER CL IMM-PRACT, V1, P258, DOI 10.1016/j.jaip.2013.02.002; Macy Eric, 2009, Perm J, V13, P12; Park MA, 2011, INT ARCH ALLERGY IMM, V154, P57, DOI 10.1159/000319209; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Solensky R, 2000, ANN ALLERG ASTHMA IM, V84, P329, DOI 10.1016/S1081-1206(10)62782-2; Solensky R, 2013, J ALLER CL IMM-PRACT, V1, P264, DOI 10.1016/j.jaip.2013.03.010; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986	19	27	27	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					816	817		10.1016/j.jaci.2014.08.045	http://dx.doi.org/10.1016/j.jaci.2014.08.045			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25441646	Bronze			2022-12-18	WOS:000351065000031
J	George, M; Topaz, M; Rand, C; Sommers, MS; Glanz, K; Pantalon, MV; Mao, JJ; Shea, JA				George, Maureen; Topaz, Maxim; Rand, Cynthia; Sommers, Marilyn (Lynn) Sawyer; Glanz, Karen; Pantalon, Michael V.; Mao, Jun J.; Shea, Judy A.			Inhaled corticosteroid beliefs, complementary and alternative medicine, and uncontrolled asthma in urban minority adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; self-management; instrument development; beliefs; complementary and alternative medicine; inhaled corticosteroids; adherence; black; minority; urban; mixed methods; patient-provider communication	AFRICAN-AMERICAN ADULTS; MEDICATION ADHERENCE; SELF-MANAGEMENT; LOW-INCOME; HERBAL REMEDIES; HEALTH LITERACY; OLDER-ADULTS; FOCUS GROUPS; PATIENT; COMMUNICATION	Background: Many factors contribute to uncontrolled asthma; negative inhaled corticosteroid (ICS) beliefs and complementary and alternative medicine (CAM) endorsement are 2 that are more prevalent in black compared with white adults. Objectives: This mixed-methods study (1) developed and psychometrically tested a brief self-administered tool with low literacy demands to identify negative ICS beliefs and CAM endorsement and (2) evaluated the clinical utility of the tool as a communication prompt in primary care. Methods: Comprehensive literature reviews and content experts identified candidate items for our instrument that were distributed to 304 subjects for psychometric testing. In the second phase content analysis of 33 audio-recorded primary care visits provided a preliminary evaluation of the instrument's clinical utility. Results: Psychometric testing of the instrument identified 17 items representing ICS beliefs (alpha = .59) and CAM endorsement (alpha = .68). Test-retest analysis demonstrated a high level of reliability (intraclass correlation coefficient = 0.77 for CAM items and 0.79 for ICS items). We found high rates of CAM endorsement (93%), negative ICS beliefs (68%), and uncontrolled asthma (69%). CAM endorsement was significantly associated with uncontrolled asthma (P = .04). Qualitative data analysis provided preliminary evidence for the instrument's clinical utility in that knowledge of ICS beliefs and CAM endorsement prompted providers to initiate discussions with patients. Conclusion: Negative ICS beliefs and CAM endorsement were common and associated with uncontrolled asthma. A brief self-administered instrument that identifies beliefs and behaviors that likely undermine ICS adherence might be a leveraging tool to change the content of communications during clinic visits.	[George, Maureen; Topaz, Maxim; Sommers, Marilyn (Lynn) Sawyer; Glanz, Karen] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; [George, Maureen; Sommers, Marilyn (Lynn) Sawyer] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA; [Sommers, Marilyn (Lynn) Sawyer] Univ Penn, Sch Nursing, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA; [George, Maureen; Glanz, Karen] Univ Penn, Ctr Hlth Behav Res, Philadelphia, PA 19104 USA; [Topaz, Maxim] Univ Haifa, IL-31999 Haifa, Israel; [Rand, Cynthia] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Mao, Jun J.; Shea, Judy A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Pantalon, Michael V.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Pantalon, Michael V.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Haifa; Johns Hopkins University; University of Pennsylvania; Pennsylvania Medicine; Yale University; Yale University	George, M (corresponding author), Univ Penn, Sch Nursing, Dept Family & Community Hlth, 418 Curie Blvd, Philadelphia, PA 19104 USA.	mgeorge@nursing.upenn.edu	Topaz, Maxim/AAQ-7121-2021	Topaz, Maxim/0000-0002-2358-9837; George, Maureen/0000-0001-9234-7842	National Center for Complementary and Alternative Medicine (National Institute of Health) [1K23AT003907]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [K23AT003907] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine (National Institute of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by the National Center for Complementary and Alternative Medicine (National Institute of Health; 1K23AT003907).	Adams RJ, 2003, J ALLERGY CLIN IMMUN, V112, P445, DOI 10.1067/mai.2003.1625; Adler SR, 1999, J FAM PRACTICE, V48, P453; Ahmedani BK, 2013, ANN ALLERG ASTHMA IM, V110, P75, DOI 10.1016/j.anai.2012.11.006; [Anonymous], 2011, IBM SPSS STAT WINDOW; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Baptist AP, 2010, QUAL HEALTH RES, V20, P117, DOI 10.1177/1049732309355288; Barnes Patricia M, 2004, Adv Data, P1; Battersby M, 2010, JT COMM J QUAL PATIE, V36, P561, DOI 10.1016/S1553-7250(10)36084-3; Bender BG, 2005, IMMUNOL ALLERGY CLIN, V25, P107, DOI 10.1016/j.iac.2004.09.005; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Boulet LP, 2012, CLIN CHEST MED, V33, P405, DOI 10.1016/j.ccm.2012.06.002; Butz A, 2010, J ASTHMA, V47, P478, DOI 10.3109/02770901003692793; Colland VT, 2004, PATIENT EDUC COUNS, V55, P416, DOI 10.1016/j.pec.2003.04.010; Collins KS, 2002, FINDINGS COMMONWEALT; Conn KM, 2007, PEDIATRICS, V120, pE521, DOI 10.1542/peds.2006-3023; Cosmetic Ingredient Review Expert, 2001, INT J TOXICOL, V20, P61; Eakin MN, 2012, ANN ALLERG ASTHMA IM, V109, P90, DOI 10.1016/j.anai.2012.06.009; Eisenberg DM, 2001, ANN INTERN MED, V135, P344, DOI 10.7326/0003-4819-135-5-200109040-00011; Eiser AR, 2007, ACAD MED, V82, P176, DOI 10.1097/ACM.0b013e31802d92ea; Federman AD, 2013, PATIENT EDUC COUNS, V92, P273, DOI 10.1016/j.pec.2013.02.013; George M, 2003, J ALLERGY CLIN IMMUN, V111, P967, DOI 10.1067/mai.2003.1459; George M, 2006, J GEN INTERN MED, V21, P1317, DOI 10.1111/j.1525-1497.2006.00624.x; George M, 2013, APPL NURS RES, V26, P139, DOI 10.1016/j.apnr.2012.11.005; George M, 2013, NURS CLIN N AM, V48, P53, DOI 10.1016/j.cnur.2012.11.002; George M, 2009, J ASTHMA, V46, P618, DOI 10.1080/02770900903029788; Horne R, 2006, CHEST, V130, p65S, DOI 10.1378/chest.130.1_suppl.65S; Horne R, 2010, CHRONIC ILLN, V6, P243, DOI 10.1177/1742395310369018; Howell L, 2006, J AM BOARD FAM MED, V19, P566, DOI 10.3122/jabfm.19.6.566; Institute of Medicine, 2003, UNEQUAL TREATMENT CO; Jackson J.E., 2005, ENCY BIOSTATISTICS, V2nd; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Kuo Grace M, 2004, BMC Complement Altern Med, V4, P18, DOI 10.1186/1472-6882-4-18; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lanski SL, 2003, PEDIATRICS, V111, P981, DOI 10.1542/peds.111.5.981; LaPointe NMA, 2011, AM HEART J, V161, P855, DOI 10.1016/j.ahj.2011.02.009; Le TT, 2008, J ASTHMA, V45, P33, DOI 10.1080/02770900701815552; McKenzie LB, 2010, PEDIATRICS, V126, P509, DOI 10.1542/peds.2009-3392; McQuaid EL, 2014, ACAD PEDIATR, V14, P192, DOI 10.1016/j.acap.2013.09.006; Morton RW, 2014, ARCH DIS CHILD; *NAT CTR COMPL ALT, WHAT IS COMPL ALT ME; Ponieman D, 2009, ANN ALLERG ASTHMA IM, V103, P38, DOI 10.1016/S1081-1206(10)60141-X; Robinson A, 2004, COMPLEMENT THER MED, V12, P90, DOI 10.1016/j.ctim.2004.09.006; Roy A, 2010, ANN ALLERG ASTHMA IM, V104, P132, DOI 10.1016/j.anai.2009.11.024; Satterfield JM, 2009, MILBANK Q, V87, P368, DOI 10.1111/j.1468-0009.2009.00561.x; Schoenthaler AM, 2012, DIABETES EDUCATOR, V38, P397, DOI 10.1177/0145721712440333; Sleath B, 2012, PEDIATRICS, V130, P627, DOI 10.1542/peds.2012-0913; Tasaki K, 2002, PSYCHO-ONCOL, V11, P212, DOI 10.1002/pon.552; Urbano FL, 2008, J MANAGE CARE PHARM, V14, P41, DOI 10.18553/jmcp.2008.14.1.41; Wells K, 2008, AM J RESP CRIT CARE, V178, P1194, DOI 10.1164/rccm.200808-1233OC; Wilson SR, 2010, AM J RESP CRIT CARE, V181, P566, DOI 10.1164/rccm.200906-0907OC	50	27	27	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1252	1259		10.1016/j.jaci.2014.07.044	http://dx.doi.org/10.1016/j.jaci.2014.07.044			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	AW1UG	25218286	Green Accepted			2022-12-18	WOS:000346075400005
J	Kharya, G; Nademi, Z; Leahy, TR; Dunn, J; Barge, D; Schulz, A; Cant, A; Gennery, A; Slatter, M				Kharya, Gaurav; Nademi, Zohreh; Leahy, T. Ronan; Dunn, Janice; Barge, Dawn; Schulz, Ansgar; Cant, Andrew; Gennery, Andrew; Slatter, Mary			Haploidentical T-cell alpha beta receptor and CD19-depleted stem cell transplant for Wiskott-Aldrich syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DEPLETION		[Kharya, Gaurav; Nademi, Zohreh; Leahy, T. Ronan; Cant, Andrew; Gennery, Andrew; Slatter, Mary] Royal Victoria Infirm, Dept Paediat Immunol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Nademi, Zohreh; Cant, Andrew; Gennery, Andrew; Slatter, Mary] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Dunn, Janice] Royal Victoria Infirm, Cellular Therapies Facil, Haematol Transplant Lab, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Barge, Dawn] Royal Victoria Infirm, Reg Immunol Lab, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Schulz, Ansgar] Univ Med Ctr, Dept Pediat & Adolescent Med, Ulm, Germany	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Ulm University	Kharya, G (corresponding author), Royal Victoria Infirm, Dept Paediat Immunol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	mary.slatter@nuth.nhs.uk	Leahy, Ronan/AAL-5008-2021; Kharya, Gaurav/AAW-1450-2020	Leahy, Ronan/0000-0001-6419-9328; Kharya, Gaurav/0000-0003-2181-1825				Friedrich W, 2009, IMMUNOL RES, V44, P18, DOI 10.1007/s12026-008-8063-8; Gennery AR, 2010, J ALLERGY CLIN IMMUN, V126, P602, DOI 10.1016/j.jaci.2010.06.015; Locatelli F, 2013, IMMUNOL LETT, V155, P21, DOI 10.1016/j.imlet.2013.09.027; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182/blood-2010-11-319376; Oevermann L, 2012, ANN NY ACAD SCI, V1266, P161, DOI 10.1111/j.1749-6632.2012.06606.x; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Pai SY, 2010, IMMUNOL ALLERGY CLIN, V30, P179, DOI 10.1016/j.iac.2010.02.001; Schumm M, 2013, CYTOTHERAPY, V15, P1253, DOI 10.1016/j.jcyt.2013.05.014; Willcox CR, 2012, NAT IMMUNOL, V13, P872, DOI 10.1038/ni.2394	9	27	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1199	1201		10.1016/j.jaci.2014.04.041	http://dx.doi.org/10.1016/j.jaci.2014.04.041			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24985403				2022-12-18	WOS:000344938900030
J	la Marca, G; Canessa, C; Giocaliere, E; Romano, F; Malvagia, S; Funghini, S; Moriondo, M; Valleriani, C; Lippi, F; Ombrone, D; Della Bona, ML; Speckmann, C; Borte, S; Brodszki, N; Gennery, AR; Weinacht, K; Celmeli, F; Pagel, J; de Martino, M; Guerrini, R; Wittkowski, H; Santisteban, I; Bali, P; Ikinciogullari, A; Hershfield, M; Notarangelo, LD; Resti, M; Azzari, C				la Marca, Giancarlo; Canessa, Clementina; Giocaliere, Elisa; Romano, Francesca; Malvagia, Sabrina; Funghini, Silvia; Moriondo, Maria; Valleriani, Claudia; Lippi, Francesca; Ombrone, Daniela; Della Bona, Maria Luisa; Speckmann, Carsten; Borte, Stephan; Brodszki, Nicholas; Gennery, Andrew R.; Weinacht, Katja; Celmeli, Fatih; Pagel, Julia; de Martino, Maurizio; Guerrini, Renzo; Wittkowski, Helmut; Santisteban, Ines; Bali, Pawan; Ikinciogullari, Aydan; Hershfield, Michael; Notarangelo, Luigi D.; Resti, Massimo; Azzari, Chiara			Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Purine nucleoside phosphorylase; severe combined immunodeficiency; newborn screening; tandem mass spectrometry; late-onset; delayed-onset; purine nucleoside phosphorylase-combined immunodeficiency; T-cell receptor excision circle; inherited disorder	ADENOSINE-DEAMINASE DEFICIENCY; MUTATIONS; PATIENT	Background: Purine nucleoside phosphorylase (PNP) deficiency is a rare form of autosomal recessive combined primary immunodeficiency caused by a enzyme defect leading to the accumulation of inosine, 2'-deoxy-inosine (dIno), guanosine, and 2'-deoxy-guanosine (dGuo) in all cells, especially lymphocytes. Treatments are available and curative for PNP deficiency, but their efficacy depends on the early approach. PNP-combined immunodeficiency complies with the criteria for inclusion in a newborn screening program. Objective: This study evaluate whether mass spectrometry can identify metabolite abnormalities in dried blood spots (DBSs) from affected patients, with the final goal of individuating the disease at birth during routine newborn screening. Methods: DBS samples from 9 patients with genetically confirmed PNP-combined immunodeficiency, 10,000 DBS samples from healthy newborns, and 240 DBSs from healthy donors of different age ranges were examined. Inosine, dIno, guanosine, and dGuo were tested by using tandem mass spectrometry (TMS). T-cell receptor excision circle (TREC) and kappa-deleting recombination excision circle (KREC) levels were evaluated by using quantitative RT-PCR only for the 2 patients (patients 8 and 9) whose neonatal DBSs were available. Results: Mean levels of guanosine, inosine, dGuo, and dIno were 4.4, 133.3, 3.6, and 3.8 mu mol/L, respectively, in affected patients. No indeterminate or false-positive results were found. In patient 8 TREC levels were borderline and KREC levels were abnormal; in patient 9 TRECs were undetectable, whereas KREC levels were normal. Conclusion: TMS is a valid method for diagnosis of PNP deficiency on DBSs of affected patients at a negligible cost. TMS identifies newborns with PNP deficiency, whereas TREC or KREC measurement alone can fail.	[la Marca, Giancarlo; Giocaliere, Elisa; Malvagia, Sabrina; Funghini, Silvia; Ombrone, Daniela; Della Bona, Maria Luisa; Guerrini, Renzo] Meyer Childrens Hosp, Paediat Neurol Unit & Labs, Dept Neurosci, Newborn Screening Biochem & Pharmacol Lab, Florence, Italy; [la Marca, Giancarlo; Giocaliere, Elisa; Malvagia, Sabrina; Funghini, Silvia; Ombrone, Daniela; Della Bona, Maria Luisa] Univ Florence, Dept Neurosci, I-50121 Florence, Italy; [Canessa, Clementina; Romano, Francesca; Moriondo, Maria; Valleriani, Claudia; Lippi, Francesca; de Martino, Maurizio; Resti, Massimo; Azzari, Chiara] Meyer Childrens Univ Hosp, Florence, Italy; [Canessa, Clementina; Romano, Francesca; Moriondo, Maria; Valleriani, Claudia; Lippi, Francesca; de Martino, Maurizio; Resti, Massimo; Azzari, Chiara] Univ Florence, Dept Hlth Sci, I-50121 Florence, Italy; [Speckmann, Carsten] Immundefizienz Univ Freiburg, Ctr Chron, Zentrum Kinderheilkunde & Jugendmed, Freiburg, Germany; [Borte, Stephan] Karolinska Univ Hosp Huddinge, Dept Lab Med, Div Clin Immunol & Transfus Med, Stockholm, Sweden; [Borte, Stephan] Univ Leipzig, Translat Ctr Regenerat Med TRM, D-04109 Leipzig, Germany; [Brodszki, Nicholas] Skane Univ Hosp, Childrens Hosp Lund, Dept Allergy & Immunol, Lund, Sweden; [Gennery, Andrew R.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Weinacht, Katja] Childrens Hosp, Div Hematol & Oncol, Boston, MA 02115 USA; [Weinacht, Katja] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Celmeli, Fatih] Antalya Educ & Res Hosp, Antalya, Turkey; [Pagel, Julia] Univ Klinikum Schleswig Holstein, D-23538 Lubeck, Germany; [Pagel, Julia] Univ Childrens Hosp Muenster, Dept Gen Pediat, Munster, Germany; [Wittkowski, Helmut] Univ Childrens Hosp Muenster, Munster, Germany; [Santisteban, Ines; Bali, Pawan; Hershfield, Michael] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Ikinciogullari, Aydan] Ankara Univ, Sch Med, Dept Pediat Immunol & Allergy, TR-06100 Ankara, Turkey; [Notarangelo, Luigi D.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA	University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Florence; Karolinska Institutet; Karolinska University Hospital; Leipzig University; Lund University; Skane University Hospital; Newcastle University - UK; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Antalya Training & Research Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Munster; University of Munster; Duke University; Ankara University; Harvard University; Boston Children's Hospital	Azzari, C (corresponding author), Univ Florence, Meyer Childrens Univ Hosp, Dept Hlth Sci, Viale Pieraccini 24, I-50139 Florence, Italy.	chiara.azzari@unifi.it	Malvagia, Sabrina/K-3580-2018; Notarangelo, Luigi D/F-9718-2016; Çelmeli, Fatih/HGC-5173-2022; Resti, Massimo/AAB-8756-2019; Azzari, Chiara/AAB-8584-2019; la Marca, Giancarlo/A-2853-2013; İkinciogullari, Aydan/AAQ-3841-2020; Moriondo, Maria/AAB-7883-2019; Lippi, francesca/AAB-8952-2019	Malvagia, Sabrina/0000-0002-3968-0264; Notarangelo, Luigi D/0000-0002-8335-0262; Resti, Massimo/0000-0001-6350-1361; Azzari, Chiara/0000-0001-7236-1655; İkinciogullari, Aydan/0000-0003-1145-0843; Moriondo, Maria/0000-0001-9653-8371; Lippi, francesca/0000-0003-2533-1802; la marca, giancarlo/0000-0003-3319-7260; Guerrini, Renzo/0000-0002-7272-7079; Speckmann, Carsten/0000-0002-6217-1556	Famiglia Cassigoli; University of Florence; Meyer Children's University Hospital; Tuscany (Italy) region; Sigma-Tau Pharmaceuticals; Orphan Europe	Famiglia Cassigoli; University of Florence; Meyer Children's University Hospital; Tuscany (Italy) region; Sigma-Tau Pharmaceuticals; Orphan Europe	Supported in part by a donation from Famiglia Cassigoli (to C. A.) and a grant from the University of Florence (to C. A. and G. l. M.), Meyer Children's University Hospital (to M. R.), and the Tuscany (Italy) region (to C. A., G. l. M., and M. R.). Sigma-Tau Pharmaceuticals provided grant support to M.H. and I.S. Orphan Europe provided grant support to E.G. and F.R.	Al-Saud B, 2009, CLIN BIOCHEM, V42, P1725, DOI 10.1016/j.clinbiochem.2009.08.017; Arredondo-Vega FX, 2002, BLOOD, V99, P1005, DOI 10.1182/blood.V99.3.1005; ARREDONDOVEGA FX, 1990, J CLIN INVEST, V86, P444, DOI 10.1172/JCI114730; AUST MR, 1992, AM J HUM GENET, V51, P763; Azzari C, 2011, J ALLERGY CLIN IMMUN, V127, P1394, DOI 10.1016/j.jaci.2011.03.040; Borte S, 2012, BLOOD, V119, P2552, DOI 10.1182/blood-2011-08-371021; Dalal I, 2001, CLIN GENET, V59, P430, DOI 10.1034/j.1399-0004.2001.590608.x; Grunebaum E, 2004, NUCLEOS NUCLEOT NUCL, V23, P1411, DOI 10.1081/NCN-200027647; Health Resources and Services Administration, 2010, RES 20 M JAN 22 2010; Hershfield M., 2004, IMMUNOLOGIC DISORDER, P480; Hershfield MS., 2001, METABOLIC MOL BASES, V8th, P2585; Kwan A, 2013, J ALLERGY CLIN IMMUN, V132, P140, DOI 10.1016/j.jaci.2013.04.024; la Marca G, 2008, J INHERIT METAB DIS, V31, pS395, DOI 10.1007/s10545-008-0965-z; la Marca G, 2013, J ALLERGY CLIN IMMUN, V131, P1604, DOI 10.1016/j.jaci.2012.08.054; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; Markert ML, 1997, HUM MUTAT, V9, P118, DOI 10.1002/(SICI)1098-1004(1997)9:2<118::AID-HUMU3>3.0.CO;2-5; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Puck JM, 2011, CURR OPIN PEDIATR, V23, P667, DOI 10.1097/MOP.0b013e32834cb9b0; Somech R, 2013, IMMUNOL RES, V56, P150, DOI 10.1007/s12026-012-8380-9; Speckmann C, 2012, J ALLERGY CLIN IMMUN, V130, P991, DOI 10.1016/j.jaci.2012.04.004	20	27	28	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					155	+		10.1016/j.jaci.2014.01.040	http://dx.doi.org/10.1016/j.jaci.2014.01.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24767876	Green Submitted			2022-12-18	WOS:000338930300020
J	Hatchwell, L; Girkin, J; Dun, MD; Morten, M; Verrills, N; Toop, HD; Morris, JC; Johnston, SL; Foster, PS; Collison, A; Mattes, J				Hatchwell, Luke; Girkin, Jason; Dun, Matthew D.; Morten, Matthew; Verrills, Nicole; Toop, Hamish D.; Morris, Jonathan C.; Johnston, Sebastian L.; Foster, Paul S.; Collison, Adam; Mattes, Joerg			Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Long-acting beta(2)-agonist; salmeterol; formoterol; salbutamol; asthma; allergy; rhinovirus; exacerbation; chemokine; dexamethasone; (S)-2-amino-4-(4-[heptyloxy]phenyl)-2-methylbutan-1-ol; protein phosphatase 2A; nuclear factor kappa B	NF-KAPPA-B; DENDRITIC CELLS; FLUTICASONE PROPIONATE; ASTHMA EXACERBATIONS; TISSUE EOSINOPHILIA; T(H)2 CELLS; INFLAMMATION; THERAPY; EOTAXIN; MODEL	Background: beta-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning mechanisms remain poorly understood. Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been described in vitro. Objective: We sought to elucidate the molecular mechanisms by which beta-agonists exert anti-inflammatory effects in allergen-driven and rhinovirus 1B-exacerbated allergic airways disease (AAD). Methods: Mice were sensitized and then challenged with house dust mite to induce AAD while receiving treatment with salmeterol, formoterol, or salbutamol. Mice were also infected with rhinovirus 1B to exacerbate lung inflammation and therapeutically administered salmeterol, dexamethasone, or the PP2A-activating drug (S)-2-amino-4-(4-[heptyloxy]phenyl)-2methylbutan-1-ol (AAL[S]). Results: Systemic or intranasal administration of salmeterol protected against the development of allergen-and rhinovirus-induced airway hyperreactivity and decreased eosinophil recruitment to the lungs as effectively as dexamethasone. Formoterol and salbutamol also showed anti-inflammatory properties. Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor kappa B subunits in the lungs. The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference. Conversely, increasing PP2A activity with AAL(S) abolished rhinovirus-induced airway hyperreactivity, eosinophil influx, and CCL11, CCL20, and CXCL2 expression. Salmeterol also directly activated immunoprecipitated PP2A in vitro isolated from human airway epithelial cells. Conclusions: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits.	[Hatchwell, Luke; Girkin, Jason; Morten, Matthew; Collison, Adam; Mattes, Joerg] Univ Newcastle, Expt & Translat Resp Med Grp, Newcastle, NSW 2300, Australia; [Hatchwell, Luke; Girkin, Jason; Morten, Matthew; Foster, Paul S.; Collison, Adam; Mattes, Joerg] Univ Newcastle, Prior Res Ctr Asthma & Resp Dis, Newcastle, NSW 2300, Australia; Hunter Med Res Inst, Newcastle, NSW, Australia; [Dun, Matthew D.; Verrills, Nicole] Univ Newcastle, Sch Biomed Sci & Pharm, Dept Med Biochem, Newcastle, NSW 2300, Australia; [Dun, Matthew D.; Verrills, Nicole] Hunter Med Res Inst, Canc Res Program, Newcastle, NSW, Australia; [Dun, Matthew D.; Verrills, Nicole] Hunter Canc Res Alliance, Newcastle, NSW, Australia; [Toop, Hamish D.; Morris, Jonathan C.] Univ New S Wales, Sch Chem, Sydney, NSW, Australia; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Airway Dis Infect Sect, Natl Heart & Lung Inst, Med Res Council, London SW7 2AZ, England; [Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, London SW7 2AZ, England; [Mattes, Joerg] Newcastle Childrens Hosp, Paediat Resp & Sleep Med Unit, Newcastle, NSW, Australia	University of Newcastle; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of New South Wales Sydney; Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Imperial College London; University of London; King's College London	Mattes, J (corresponding author), Newcastle Childrens Hosp, Hunter Med Res Inst, Expt & Translat Resp Med Grp, Lookout Rd, New Lambton, NSW 2305, Australia.	Joerg.Mattes@newcastle.edu.au	Dun, Matthew D./I-3399-2012; Johnston, Sebastian Lennox/I-2423-2012; Toop, Hamish/AAV-8207-2020; Foster, Paul/G-5057-2013; MATTES, JOERG/M-5179-2019; Morris, Jonathan C/A-9923-2008; Collison, Adam/G-7718-2013	Johnston, Sebastian Lennox/0000-0003-3009-9200; Morris, Jonathan C/0000-0002-5109-9069; Verrills, Nicole/0000-0002-7894-0137; Toop, Hamish/0000-0003-4637-4764; Girkin, Jason/0000-0002-0739-1070; Collison, Adam/0000-0002-3074-3046; , Paul/0000-0002-0827-8299; Dun, Matthew/0000-0002-9063-5370	National Health Medical Research Council (NHMRC) [G1000314]; NH&MRC Health Professional Research Fellowship [G0186769]; Chair from Asthma UK [CH1155]; MRC Centre Grant [G1000758]; ERC FP7 Advanced Grant [233015]; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish	National Health Medical Research Council (NHMRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)National Health and Medical Research Council (NHMRC) of Australia); NH&MRC Health Professional Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Chair from Asthma UK; MRC Centre Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ERC FP7 Advanced Grant; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the National Health Medical Research Council (NH & MRC; G1000314 to J.M. and N.V.) and an NH&MRC Health Professional Research Fellowship (G0186769 to J.M.). S.L.J. was supported by a Chair from Asthma UK (CH1155). This work was supported in part by MRC Centre Grant G1000758 and ERC FP7 Advanced Grant 233015 (to S.L.J.).	Barnes PJ, 2012, J ALLERGY CLIN IMMUN, V129, P48, DOI 10.1016/j.jaci.2011.11.006; Barnes PJ, 2010, TRENDS PHARMACOL SCI, V31, P335, DOI 10.1016/j.tips.2010.04.009; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Crispin JC, 2012, J IMMUNOL, V188, P3567, DOI 10.4049/jimmunol.1200143; Currie GP, 2005, RESP MED, V99, P683, DOI 10.1016/j.rmed.2004.11.008; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; Don AS, 2007, J BIOL CHEM, V282, P15833, DOI 10.1074/jbc.M609124200; Dunn JJ, 2004, J CLIN MICROBIOL, V42, P79, DOI 10.1128/JCM.42.1.79-82.2004; Edwards MR, 2006, PULM PHARMACOL THER, V19, P320, DOI 10.1016/j.pupt.2005.09.005; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; FARR BM, 1990, J INFECT DIS, V162, P1173, DOI 10.1093/infdis/162.5.1173; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7; Herbert C, 2008, CLIN EXP ALLERGY, V38, P847, DOI 10.1111/j.1365-2222.2008.02950.x; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Hu ZL, 2012, CELL MOL IMMUNOL, V9, P267, DOI 10.1038/cmi.2011.56; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Janssens V, 2012, CURR MOL MED, V12, P268, DOI 10.2174/156652412799218930; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kanoh S, 2011, CLIN EXP ALLERGY, V41, P1747, DOI 10.1111/j.1365-2222.2011.03852.x; Kay AB, 2005, TRENDS MOL MED, V11, P148, DOI 10.1016/j.molmed.2005.02.002; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kobayashi Y, 2012, PULM PHARMACOL THER, V25, P201, DOI 10.1016/j.pupt.2012.02.005; Kobayashi Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027627; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lloyd C, 2002, IMMUNOLOGY, V105, P144, DOI 10.1046/j.1365-2567.2002.01344.x; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Miskolci V, 2003, ARCH BIOCHEM BIOPHYS, V417, P44, DOI 10.1016/S0003-9861(03)00336-9; Nagarkar DR, 2009, J IMMUNOL, V183, P6698, DOI 10.4049/jimmunol.0900298; Palmqvist M, 1997, EUR RESPIR J, V10, P2484, DOI 10.1183/09031936.97.10112489; Puhakka T, 1998, J ALLERGY CLIN IMMUN, V101, P726, DOI 10.1016/S0091-6749(98)70301-X; Rachelefsky Gary S, 2009, Clin Cornerstone, V9, P9; Riesenfeld EP, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-22; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Schneider D, 2013, AM J PHYSIOL-LUNG C, V304, pL162, DOI 10.1152/ajplung.00182.2012; Singam R, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-32; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Wallace AM, 2012, TOXICOL SCI, V126, P589, DOI 10.1093/toxsci/kfr351; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wills-Karp M, 2004, CURR ALLERGY ASTHM R, V4, P123	47	27	27	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1720	1727		10.1016/j.jaci.2013.11.014	http://dx.doi.org/10.1016/j.jaci.2013.11.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24388637				2022-12-18	WOS:000336672500026
J	Nanzer, AM; Chambers, ES; Ryanna, K; Freeman, AT; Colligan, G; Richards, DF; Timms, PM; Martineau, AR; Griffiths, CJ; Corrigan, CJ; Hawrylowicz, CM				Nanzer, Alexandra M.; Chambers, Emma S.; Ryanna, Kimuli; Freeman, Anna T.; Colligan, Grainne; Richards, David F.; Timms, Peter M.; Martineau, Adrian R.; Griffiths, Christopher J.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.			The effects of calcitriol treatment in glucocorticoid-resistant asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VITAMIN-D		[Nanzer, Alexandra M.; Chambers, Emma S.; Ryanna, Kimuli; Freeman, Anna T.; Richards, David F.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.] Kings Coll London, MRC, London WC2R 2LS, England; [Nanzer, Alexandra M.; Chambers, Emma S.; Ryanna, Kimuli; Freeman, Anna T.; Richards, David F.; Corrigan, Christopher J.; Hawrylowicz, Catherine M.] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London WC2R 2LS, England; [Nanzer, Alexandra M.; Colligan, Grainne; Martineau, Adrian R.; Griffiths, Christopher J.] Univ London, Ctr Primary Care & Publ Hlth, Blizard Inst, London, England; [Timms, Peter M.] Homerton Univ NHS Fdn Trust, London, England	University of London; King's College London; University of London; King's College London; University of London	Nanzer, AM (corresponding author), Kings Coll London, MRC, London WC2R 2LS, England.	catherine.hawrylowicz@kcl.ac.uk	Martineau, Adrian R/A-3083-2010; Chambers, Emma/AAI-3521-2021; Hawrylowicz, Catherine/Q-8483-2017	Chambers, Emma/0000-0003-0990-8835; Hawrylowicz, Catherine/0000-0002-2337-7463; Timms, Peter/0000-0002-1682-0025; Corrigan, Chris/0000-0002-0706-6534	Medical Research Council [G1000758] Funding Source: Medline; Medical Research Council [G1000758B] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, AUK-IG-2014-296, 08/019, AUK-AC-2012-01, MRC-AsthmaUKCentre] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK		Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Gupta A, 2011, AM J RESP CRIT CARE, V184, P1342, DOI 10.1164/rccm.201107-1239OC; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Holick Michael F, 2011, J Clin Endocrinol Metab, V96, P1; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Janssen E, 2014, CLIN IMMUNOL, V150, P220, DOI 10.1016/j.clim.2013.12.006; Majak P, 2011, J ALLERGY CLIN IMMUN, V127, P1294, DOI 10.1016/j.jaci.2010.12.016; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	11	27	29	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1755	1757		10.1016/j.jaci.2014.03.015	http://dx.doi.org/10.1016/j.jaci.2014.03.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24786237				2022-12-18	WOS:000336672500031
J	Curin, M; Swoboda, I; Wollmann, E; Lupinek, C; Spitzauer, S; van Hage, M; Valenta, R				Curin, Mirela; Swoboda, Ines; Wollmann, Eva; Lupinek, Christian; Spitzauer, Susanne; van Hage, Marianne; Valenta, Rudolf			Microarrayed dog, cat, and horse allergens show weak correlation between allergen-specific IgE and IgG responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SYMPTOMS		[Curin, Mirela; Swoboda, Ines; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Vienna, Austria; [Curin, Mirela; Swoboda, Ines; Wollmann, Eva; Lupinek, Christian; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol, Vienna, Austria; [Spitzauer, Susanne] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [van Hage, Marianne] Karolinska Inst, Dept Med Solna, Clin Immunol & Allergy Unit, Stockholm, Sweden; [van Hage, Marianne] St Gorans Univ Hosp, S-11281 Stockholm, Sweden	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Karolinska Institutet; Saint Goran's Hospital	Curin, M (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Vienna, Austria.	Rudolf.valenta@meduniwien.ac.at	van Hage, Marianne/A-9678-2017; Lupinek, Christian/I-3311-2019	van Hage, Marianne/0000-0003-3091-1596; Lupinek, Christian/0000-0002-8612-8245; Swoboda, Ines/0000-0002-9164-1721; Rigler, Eva/0000-0002-3596-3937; Valenta, Rudolf/0000-0001-5944-3365; Curin, Mirela/0000-0003-2575-4127	Austrian Science Fund FWF [F 4605] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bousquet J, 2013, INT ARCH ALLERGY IMM, V161, P1, DOI 10.1159/000343018; Jarvis D, 2007, J ALLERGY CLIN IMMUN, V119, P697, DOI 10.1016/j.jaci.2006.10.042; Lupinek C, 2013, METHODS         1022, DOI [10.1016/j.ymeth.2013.10.008, DOI 10.1016/J.YMETH.2013.10.008.[]; Matsui EC, 2005, CLIN EXP ALLERGY, V35, P1347, DOI 10.1111/j.1365-2222.2005.02331.x; Nilsson OB, 2012, ALLERGY, V67, P751, DOI 10.1111/j.1398-9995.2012.02826.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4	6	27	27	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					918	921		10.1016/j.jaci.2013.10.058	http://dx.doi.org/10.1016/j.jaci.2013.10.058			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24406070	Green Published, hybrid			2022-12-18	WOS:000332397600048
J	Focke-Tejkl, M; Campana, R; Reininger, R; Lupinek, C; Blatt, K; Valent, P; Pavkov-Keller, T; Keller, W; Valenta, R				Focke-Tejkl, Margarete; Campana, Raffaela; Reininger, Renate; Lupinek, Christian; Blatt, Katharina; Valent, Peter; Pavkov-Keller, Tea; Keller, Walter; Valenta, Rudolf			Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; grass pollen allergen; peptides; epitopes	STRUCTURAL-CHARACTERIZATION; IMMUNOTHERAPY; EPITOPES; PROTEIN; PEPTIDE; ANTIBODY; VACCINE; BINDING; CRYSTALLIZATION; DISRUPTION	Background: The major timothy grass pollen allergen Phl p 5 belongs to the most potent allergens involved in hay fever and asthma. Objective: This study characterized immune-dominant IgE- and T-cell-recognition sites of Phl p 5. Methods: Seven peptides, P1 to P7 with a length of 31 to 38 amino acids that spanned the Phl p 5 sequence, were synthesized, characterized by circular dichroism spectroscopy, and tested for IgE reactivity, basophil activation, and T-cell reactivity. Carrier-bound peptides were studied for their ability to induce IgG antibodies in rabbits which recognize Phl p 5 or cross-reactive allergens from different grass species. Peptide-specific antibodies were tested for the capability to inhibit IgE reactivity to Phl p 5 and allergen-induced basophil activation of patients with allergy. Results: The peptides exhibited no secondary structure and showed no IgE reactivity or relevant allergenic activity, indicating that Phl p 5 IgE epitopes are conformational. Except for P3, peptide-specific IgG antibodies blocked IgE binding to Phl p 5 of patients with allergy and cross-reacted with temperate grasses. IgE inhibition experiments and molecular modeling identified several clustered conformational IgE epitopes on the N- as well as C-terminal domain of Phl p 5. P4, which stimulated the strongest T-cell and cytokine responses in patients, was not part of the major IgE-reactive regions. Conclusion: Our study shows an interesting dissociation of the major IgE- and T-cell-reactive domains in Phl p 5 which provides a basis for the development of novel forms of immunotherapy that selectively target IgE or T-cell responses.	[Focke-Tejkl, Margarete; Reininger, Renate; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, A-1090 Vienna, Austria; [Focke-Tejkl, Margarete; Campana, Raffaela; Lupinek, Christian; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol, A-1090 Vienna, Austria; [Blatt, Katharina; Valent, Peter] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria; [Pavkov-Keller, Tea; Keller, Walter] Graz Univ, Inst Mol Biosci, Graz, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; University of Graz	Valenta, R (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Div Immunopathol,Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Test, Test/Y-7921-2019; Valent, Peter/B-8533-2016; Lupinek, Christian/I-3311-2019; Gamperl, Susi/V-2715-2019; Test, PV/U-9451-2019; Keller, Walter/AAW-1501-2021; Pavkov-Keller, Tea/K-9234-2015	Valent, Peter/0000-0003-0456-5095; Lupinek, Christian/0000-0002-8612-8245; Gamperl, Susi/0000-0003-0456-5095; Keller, Walter/0000-0002-2261-958X; Pavkov-Keller, Tea/0000-0001-7871-6680; Valenta, Rudolf/0000-0001-5944-3365; Campana, Raffaela/0000-0001-9309-9908	Christian Doppler Research Association; Biomay AG, Vienna, Austria; Austrian Science Fund (FWF) [F4604, F4605, F4611]	Christian Doppler Research Association; Biomay AG, Vienna, Austria; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by the Christian Doppler Research Association, by a research grant from Biomay AG, Vienna, Austria, and by projects F4604, F4605, F4611 of the Austrian Science Fund (FWF).	ARNON R, 1992, FASEB J, V6, P3265, DOI 10.1096/fasebj.6.14.1385242; Blackley CH., 1873, EXPT RES CAUSES NATU; Blaher B, 1996, J ALLERGY CLIN IMMUN, V98, P124, DOI 10.1016/S0091-6749(96)70234-8; Bufe A, 1996, J BIOL CHEM, V271, P27193, DOI 10.1074/jbc.271.44.27193; Calderon M, 2012, ALLERGY, V67, P462, DOI 10.1111/j.1398-9995.2012.02785.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Focke-Tejkl M, 2012, CURR OPIN ALLERGY CL, V12, P555, DOI 10.1097/ACI.0b013e328357ca53; Gieras A, 2011, J IMMUNOL, V186, P5333, DOI 10.4049/jimmunol.1000804; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Jahn-Schmid B, 2002, J IMMUNOL, V169, P6005, DOI 10.4049/jimmunol.169.10.6005; KAY A, 2008, ALLERGY ALLERGIC DIS; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Larche M, 2011, CURR TOP MICROBIOL, V352, P107, DOI 10.1007/82_2011_131; Maglio O, 2002, PROTEIN ENG, V15, P635, DOI 10.1093/protein/15.8.635; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Mothes-Luksch N, 2008, J IMMUNOL, V181, P4864, DOI 10.4049/jimmunol.181.7.4864; Muller WD, 1998, CLIN EXP ALLERGY, V28, P1538; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niemi M, 2008, ACTA CRYSTALLOGR F, V64, P25, DOI 10.1107/S174430910706160X; Niespodziana K, 2011, J ALLERGY CLIN IMMUN, V127, P1562, DOI 10.1016/j.jaci.2011.02.004; Noon L, 1911, LANCET, V1, P1572; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; Padavattan S, 2009, J IMMUNOL, V182, P2141, DOI 10.4049/jimmunol.0803018; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; Singh MB, 2003, IMMUNOL CELL BIOL, V81, P86, DOI 10.1046/j.0818-9641.2002.01144.x; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; Stoecklinger A, 2012, INT ARCH ALLERGY IMM, V158, P326, DOI 10.1159/000333551; Suphioglu C, 1998, MOL IMMUNOL, V35, P293, DOI 10.1016/S0161-5890(98)00050-9; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759; Thomas WR, 2011, J ALLERGY CLIN IMMUN, V127, P855, DOI 10.1016/j.jaci.2010.12.1084; Twaroch TE, 2011, J ALLERGY CLIN IMMUN, V128, P178, DOI 10.1016/j.jaci.2011.03.011; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Vrtala S, 1999, J IMMUNOL, V163, P5489; Westritschnig K, 2004, J IMMUNOL, V172, P5684, DOI 10.4049/jimmunol.172.9.5684; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029; ZHANG L, 1992, MOL IMMUNOL, V29, P1383, DOI 10.1016/0161-5890(92)90175-W	52	27	27	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					836	+		10.1016/j.jaci.2013.08.038	http://dx.doi.org/10.1016/j.jaci.2013.08.038			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EK	24182774	Green Accepted			2022-12-18	WOS:000332397600028
J	Gelb, AF; Yamamoto, A; Mauad, T; Kollin, J; Schein, MJ; Nadel, JA				Gelb, Arthur F.; Yamamoto, Alfred; Mauad, Thais; Kollin, Jozef; Schein, Mark J.; Nadel, Jay A.			Unsuspected mild emphysema in nonsmoking patients with chronic asthma with persistent airway obstruction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ELASTIC RECOIL; FATAL ASTHMA; DISTAL LUNG		[Gelb, Arthur F.] Lakewood Reg Med Ctr, Dept Med, Div Pulm, Lakewood, CA 90805 USA; [Gelb, Arthur F.] Univ Calif Los Angeles, Med Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA; [Yamamoto, Alfred; Kollin, Jozef] LRMC, Dept Pathol, Lakewood, CA USA; [Mauad, Thais] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil; [Schein, Mark J.] LRMC, Dept Radiol, Lakewood, CA USA; [Nadel, Jay A.] Univ Calif San Francisco, Med Ctr, Cardiovasc Res Inst, San Francisco, CA USA; [Nadel, Jay A.] Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA USA; [Nadel, Jay A.] Univ Calif San Francisco, Med Ctr, Dept Physiol, San Francisco, CA USA; [Nadel, Jay A.] Univ Calif San Francisco, Med Ctr, Dept Radiol, San Francisco, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Universidade de Sao Paulo; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gelb, AF (corresponding author), Lakewood Reg Med Ctr, Dept Med, Div Pulm, Lakewood, CA 90805 USA.	afgelb1@gmail.com	Mauad, Thais/G-1254-2012	Mauad, Thais/0000-0002-3354-1466				Burgel PR, 2008, EUR RESPIR J, V32, P1068, DOI 10.1183/09031936.00172007; COLEBATCH HJ, 1973, J APPL PHYSIOL, V34, P143, DOI 10.1152/jappl.1973.34.2.143; Dolhnikoff M, 2009, J ALLERGY CLIN IMMUN, V123, P1090, DOI 10.1016/j.jaci.2009.02.032; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778, DOI 10.1164/ajrccm.162.5.2001037; GOLD WM, 1967, J APPL PHYSIOL, V23, P433, DOI 10.1152/jappl.1967.23.4.433; Kraft M, 2006, CHEST, V130, P1726, DOI 10.1378/chest.130.6.1726; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; MCCARTHY DS, 1980, THORAX, V35, P298, DOI 10.1136/thx.35.4.298; MCFADDEN ER, 1969, J APPL PHYSIOL, V27, P452, DOI 10.1152/jappl.1969.27.4.452; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x; WOOLCOCK AJ, 1968, AM REV RESPIR DIS, V98, P788	12	27	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					263	265		10.1016/j.jaci.2013.09.045	http://dx.doi.org/10.1016/j.jaci.2013.09.045			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24290280	Green Published			2022-12-18	WOS:000329105700037
J	Nakano, T; Inoue, Y; Shimojo, N; Yamaide, F; Morita, Y; Arima, T; Tomiita, M; Kohno, Y				Nakano, Taiji; Inoue, Yuzaburo; Shimojo, Naoki; Yamaide, Fumiya; Morita, Yoshinori; Arima, Takayasu; Tomiita, Minako; Kohno, Yoichi			Lower levels of hsa-mir-15a, which decreases VEGFA, in the CD4(+) T cells of pediatric patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ENDOTHELIAL GROWTH-FACTOR; BRONCHIAL-ASTHMA; INDUCED SPUTUM; ANGIOGENESIS; MICRORNA-15A; CHILDREN		[Nakano, Taiji; Inoue, Yuzaburo; Shimojo, Naoki; Yamaide, Fumiya; Morita, Yoshinori; Arima, Takayasu; Kohno, Yoichi] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Tomiita, Minako] Chiba Childrens Hosp, Dept Allergy & Rheumatol, Chiba, Japan	Chiba University; Chiba Children's Hospital	Nakano, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan.	yuzaburo@chiba-u.jp	YAMAIDE, FUMIYA/H-9500-2019; Yamaide, Fumiya/GLU-2426-2022; Inoue, Yuzaburo/E-3262-2019	Inoue, Yuzaburo/0000-0001-5904-687X; YAMAIDE, FUMIYA/0000-0002-2916-9710; Nakano, Taiji/0000-0001-7499-1204				Asai K, 2003, CLIN EXP ALLERGY, V33, P595, DOI 10.1046/j.1365-2222.2003.01576.x; Lorenzi JCC, 2012, INT J NEUROSCI, V122, P466, DOI 10.3109/00207454.2012.678444; Dejean E, 2011, LEUKEMIA, V25, P1882, DOI 10.1038/leu.2011.168; Detoraki A, 2010, ALLERGY, V65, P946, DOI 10.1111/j.1398-9995.2010.02372.x; Global Initiative for Asthma (GINA), 2012, GLOB STRAT ASTHM MAN; Hossny E, 2009, PEDIAT ALLERG IMM-UK, V20, P89, DOI 10.1111/j.1399-3038.2008.00730.x; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Marek N, 2010, CLIN IMMUNOL, V137, P261, DOI 10.1016/j.clim.2010.07.007; Sun CY, 2013, CARCINOGENESIS, V34, P426, DOI 10.1093/carcin/bgs333; Yin KJ, 2012, J BIOL CHEM, V287, P27055, DOI 10.1074/jbc.M112.364414; Yoo Y, 2010, ANN ALLERG ASTHMA IM, V104, P36, DOI 10.1016/j.anai.2009.11.012; Yuan Y, 2012, MOL IMMUNOL, V52, P61, DOI 10.1016/j.molimm.2012.04.007	13	27	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1224	1227		10.1016/j.jaci.2013.06.041	http://dx.doi.org/10.1016/j.jaci.2013.06.041			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23954351				2022-12-18	WOS:000326235600029
J	Swoboda, I; Balic, N; Klug, C; Focke, M; Weber, M; Spitzauer, S; Neubauer, A; Quirce, S; Douladiris, N; Papadopoulos, NG; Valenta, R				Swoboda, Ines; Balic, Nadja; Klug, Christoph; Focke, Margit; Weber, Milena; Spitzauer, Susanne; Neubauer, Angela; Quirce, Santiago; Douladiris, Nikolaos; Papadopoulos, Nikolaos G.; Valenta, Rudolf			A general strategy for the generation of hypoallergenic molecules for the immunotherapy of fish allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PARVALBUMIN; ADULTS		[Swoboda, Ines; Focke, Margit; Weber, Milena; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol & Allergy Res,Ctr Pathophysiol, Vienna, Austria; [Swoboda, Ines; Klug, Christoph] Univ Appl Sci, Campus Vienna Bioctr, Mol Biotechnol Sect, Vienna, Austria; [Balic, Nadja; Spitzauer, Susanne] Med Univ Vienna, Clin Inst Med & Chem Lab Diagnost, Vienna, Austria; [Neubauer, Angela] Biomay AG, Vienna, Austria; [Quirce, Santiago] Hosp La Paz Hlth Res Inst IdiPAZ, Dept Allergy, Madrid, Spain; [Douladiris, Nikolaos; Papadopoulos, Nikolaos G.] Univ Athens, Dept Pediat 2, GR-10679 Athens, Greece	Medical University of Vienna; Vienna Biocenter (VBC); Medical University of Vienna; National & Kapodistrian University of Athens	Swoboda, I (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol & Allergy Res,Ctr Pathophysiol, Vienna, Austria.	ines.swoboda@meduniwien.ac.at	Papadopoulos, Nikolaos/ABE-1774-2021; N.G., Papadopoulos/L-8670-2013; s, q/AAD-7171-2020	Papadopoulos, Nikolaos/0000-0002-4448-3468; N.G., Papadopoulos/0000-0002-4448-3468; Swoboda, Ines/0000-0002-9164-1721; Valenta, Rudolf/0000-0001-5944-3365; Papadopoulos, Nikolaos/0000-0002-2508-3872				Asero R, 2009, INT ARCH ALLERGY IMM, V150, P271, DOI 10.1159/000222679; Kuehn A, 2011, ALLERGY, V66, P299, DOI 10.1111/j.1398-9995.2010.02463.x; Swoboda I, 2002, J IMMUNOL, V168, P4576, DOI 10.4049/jimmunol.168.9.4576; Swoboda I, 2007, J IMMUNOL, V178, P6290, DOI 10.4049/jimmunol.178.10.6290; Valenta R, 2011, J ALLERGY CLIN IMMUN, V127, P860, DOI 10.1016/j.jaci.2011.02.016; Van Do T, 2005, J ALLERGY CLIN IMMUN, V116, P1314, DOI 10.1016/j.jaci.2005.07.033; Vazquez-Cortes S, 2012, ANN ALLERG ASTHMA IM, V108, P62, DOI 10.1016/j.anai.2011.10.006; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011	8	27	27	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					979	981		10.1016/j.jaci.2013.04.027	http://dx.doi.org/10.1016/j.jaci.2013.04.027			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23763969				2022-12-18	WOS:000325096500029
J	Zafred, D; Nandy, A; Pump, L; Kahlert, H; Keller, W				Zafred, Domen; Nandy, Andreas; Pump, Linda; Kahlert, Helga; Keller, Walter			Crystal structure and immunologic characterization of the major grass pollen allergen Phl p 4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Grass pollen allergy; recombinant allergen; Phl p 4; Sec c 4; cross-reactive carbohydrate determinant; basophil release assay; dehydrogenase; bicovalently attached flavin adenine dinucleotide	IGE ANTIBODIES; TIMOTHY; PROTEIN; PRATENSE; ALIGNMENT; BINDING; SURFACE; OXIDOREDUCTASE; IMMUNOTHERAPY; ORGANIZATION	Background: Phl p 4 is a major pollen allergen but exhibits lower allergenicity than other major allergens. The natural protein is glycosylated and shows cross-reactivity with related and structurally unrelated allergens. Objective: We sought to determine the high-resolution crystal structure of Phl p 4 and to evaluate the immunologic properties of the recombinant allergen in comparison with natural Phl p 4. Methods: Different isoallergens of Phl p 4 were expressed, and the nonglycosylated mutant was crystallized. The specific role of protein and carbohydrate epitopes for allergenicity was studied by using IgE inhibition and basophil release assays. Results: The 3-dimensional structure was determined by using x-ray crystallography at a resolution of 1.9 angstrom. The allergen is a glucose dehydrogenase with a bicovalently attached flavin adenine dinucleotide. Glycosylated and nonglycosylated recombinant Phl p 4 showed identical inhibition of IgE binding, but compared with natural Phl p 4, all recombinant isoforms displayed a reduced IgE-binding inhibition. However, the recombinant protein exhibited an approximately 10-fold higher potency in basophil release assays than the natural protein. Conclusion: The crystal structure reveals the compact globular nature of the protein, and the observed binding pocket implies the size of the natural substrate. Plant-derived cross-reactive carbohydrate determinants (CCDs) appear to reduce the allergenicity of the natural allergen, whereas the Pichia pastoris-derived glycosylation does not. Our results imply yet undescribed mechanism of how CCDs dampen the immune response, leading to a novel understanding of the role of CCDs.	[Zafred, Domen; Keller, Walter] Graz Univ, IMB, A-8010 Graz, Austria; [Nandy, Andreas; Pump, Linda; Kahlert, Helga] Allergopharma Joachim Ganzer KG, Div Res & Dev, Reinbek, Germany	University of Graz; Allergopharma	Keller, W (corresponding author), Graz Univ, IMB, Humboldtstr 50-3, A-8010 Graz, Austria.	walter.keller@uni-graz.at	Keller, Walter/AAW-1501-2021; Zafred, Domen/Q-6244-2018	Keller, Walter/0000-0002-2261-958X; Zafred, Domen/0000-0002-2029-4902	Austrian National Science Fund (FWF) through the SFB projects [F1805, F4604]; Austrian Science Foundation (FDF)	Austrian National Science Fund (FWF) through the SFB projects(Austrian Science Fund (FWF)); Austrian Science Foundation (FDF)	Supported by the Austrian National Science Fund (FWF) through the SFB projects F1805 and F4604.; D. Zafred and W. Keller have received grants from the Austrian Science Foundation (FDF). The rest of the authors declare that they have no relevant conflicts of interest.	Alexeev I, 2007, P NATL ACAD SCI USA, V104, P6170, DOI 10.1073/pnas.0700579104; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Carlson JC, 2011, NAT CHEM, V3, P628, DOI [10.1038/NCHEM.1087, 10.1038/nchem.1087]; Chapman MD, 2008, J ALLERGY CLIN IMMUN, V122, P882, DOI 10.1016/j.jaci.2008.07.030; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Cromwell O, 2011, J ALLERGY CLIN IMMUN, V127, P865, DOI 10.1016/j.jaci.2011.01.047; Cunane LM, 2000, J MOL BIOL, V295, P357, DOI 10.1006/jmbi.1999.3290; D'Arcy A, 2003, ACTA CRYSTALLOGR D, V59, P396, DOI 10.1107/S0907444902022011; Dall'Antonia F, 2011, J ALLERGY CLIN IMMUN, V128, P872, DOI 10.1016/j.jaci.2011.07.007; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeWitt AM, 2006, CLIN EXP ALLERGY, V36, P77, DOI 10.1111/j.1365-2222.2006.02399.x; EKRAMODDOULLAH AKM, 1983, MOL IMMUNOL, V20, P465, DOI 10.1016/0161-5890(83)90027-5; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evrard GX, 2007, ACTA CRYSTALLOGR D, V63, P108, DOI 10.1107/S0907444906023389; FAHLBUSCH B, 1993, CLIN EXP ALLERGY, V23, P51, DOI 10.1111/j.1365-2222.1993.tb02484.x; Fahlbusch B, 1998, CLIN EXP ALLERGY, V28, P799; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; HAAVIK S, 1985, INT ARCH ALLER A IMM, V78, P260, DOI 10.1159/000233896; Hallberg BM, 2004, J MOL BIOL, V341, P781, DOI 10.1016/j.jmb.2004.06.033; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hu YC, 2000, AUST J PLANT PHYSIOL, V27, P363, DOI 10.1071/PP99147; Huang CH, 2005, J BIOL CHEM, V280, P38831, DOI 10.1074/jbc.M506078200; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kahlert H, 2003, CLIN EXP ALLERGY, V33, P1266, DOI 10.1046/j.1365-2222.2003.01756.x; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Leferink NGH, 2008, ARCH BIOCHEM BIOPHYS, V474, P292, DOI 10.1016/j.abb.2008.01.027; Liu YC, 2011, NAT CHEM BIOL, V7, P304, DOI 10.1038/nchembio.556; Mari A, 2008, ALLERGY, V63, P891, DOI 10.1111/j.1398-9995.2008.01703.x; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nandy A, 2005, BIOCHEM BIOPH RES CO, V337, P563, DOI 10.1016/j.bbrc.2005.09.087; Noinaj N, 2011, J BIOL CHEM, V286, P23533, DOI 10.1074/jbc.M111.247833; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rajashankar K, 2002, ACTA CRYSTALLOGR D, V58, P1175, DOI 10.1107/S0907444902007254; Razzera G, 2010, STRUCTURE, V18, P1011, DOI 10.1016/j.str.2010.05.012; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schrodinger LLC, 2010, PYMOL MOL GRAPH SYST; Shakib F, 2008, TRENDS IMMUNOL, V29, P633, DOI 10.1016/j.it.2008.08.007; Stumvoll S, 2002, BIOL CHEM, V383, P1383, DOI 10.1515/BC.2002.157; Suck R, 2000, CLIN EXP ALLERGY, V30, P1395, DOI 10.1046/j.1365-2222.2000.00886.x; Tripodi S, 2012, J ALLERGY CLIN IMMUN, V129, P834, DOI 10.1016/j.jaci.2011.10.045; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; Wald M, 2007, CLIN EXP ALLERGY, V37, P441, DOI 10.1111/j.1365-2222.2007.02669.x; Wallner S, 2012, FLAVOPROTEINS, V1, P1; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Wilkins MR, 1999, METH MOL B, V112, P531; Winkler A, 2008, NAT CHEM BIOL, V4, P739, DOI 10.1038/nchembio.123; Zwart PH, 2004, ACTA CRYSTALLOGR D, V60, P2230, DOI 10.1107/S0907444904012995	59	27	27	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					696	+		10.1016/j.jaci.2013.03.021	http://dx.doi.org/10.1016/j.jaci.2013.03.021			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23683465				2022-12-18	WOS:000323612000022
J	Iwata, S; Yamaoka, K; Niiro, H; Nakano, K; Wang, SP; Akashi, K; Tanaka, Y				Iwata, Shigeru; Yamaoka, Kunihiro; Niiro, Hiroaki; Nakano, Kazuhisa; Wang, Sheau-Pey; Akashi, Koichi; Tanaka, Yoshiya			Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Syk; Toll-like receptor 9; TNF receptor-associated factor 6; B cells	IMMUNE-RESPONSES; DENDRITIC CELLS; HUMAN NAIVE; MEMORY; SYK; LUPUS; INHIBITOR; MECHANISM; ROLES; CD40	Background: B cells are activated by combined signals through the B-cell receptor (BCR) and CD40. However, the underlying mechanisms by which BCR signals synergize with Toll-like receptor (TLR) signaling in human B cells remain unclear. Objective: We sought to elucidate a role of spleen tyrosine kinase (Syk), a key molecule of BCR signaling, in TLR-mediated activation of human B cells. Methods: Human naive and memory B cells were stimulated with combinations of anti-BCR, soluble CD40 ligand, and CpG. Effects of the Syk inhibitors on several B-cell functions and expression of TLR9, TNF receptor-associated factors (TRAFs), and phospho-nuclear factor kappa B in B cells were assessed. Results: Activation of BCR synergized with CD40- and TLR9-mediated signals in driving robust proliferation, cell-cycle progression, expression of costimulatory molecules, cytokine production, and immunoglobulin production of human B-cell subsets, especially memory B cells. However, the Syk inhibitors remarkably abrogated these B-cell functions. Notably, after stimulation through all 3 receptors, B-cell subsets induced marked expression of TLR9, TRAF6, and phospho-nuclear factor kB, which was again significantly abrogated by the Syk inhibitors. Conclusion: Syk-mediated BCR signaling is a prerequisite for optimal induction of TLR9 and TRAF6, allowing efficient propagation of TLR9-mediated signaling in memory B cells. These results also underscore the role of Syk in aberrant B-cell activation in patients with autoimmune diseases. (J Allergy Clin Immunol 2012; 129: 1594-601.)	[Tanaka, Yoshiya] Univ Occupat & Environm Hlth, Dept Internal Med 1, Sch Med, Kitakyushu, Fukuoka 8078555, Japan; [Niiro, Hiroaki; Akashi, Koichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka 812, Japan	University of Occupational & Environmental Health - Japan; Kyushu University	Tanaka, Y (corresponding author), Univ Occupat & Environm Hlth, Dept Internal Med 1, Sch Med, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	tanaka@med.uoeh-u.ac.jp			Ministry of Health, Labor and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan; University of Occupational and Environmental Health, Japan	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); University of Occupational and Environmental Health, Japan(University of Occupational & Environmental Health - Japan)	Supported in part by a Research Grant-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan; the Ministry of Education, Culture, Sports, Science and Technology of Japan; and the University of Occupational and Environmental Health, Japan.	An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Bahjat FR, 2008, ARTHRITIS RHEUM-US, V58, P1433, DOI 10.1002/art.23428; Beaven MA, 1996, CURR OPIN IMMUNOL, V8, P766, DOI 10.1016/S0952-7915(96)80002-1; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Bernasconi NL, 2003, BLOOD, V101, P4500, DOI 10.1182/blood-2002-11-3569; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Christensen SR, 2006, IMMUNITY, V25, P417, DOI 10.1016/j.immuni.2006.07.013; Deng GM, 2010, ARTHRITIS RHEUM-US, V62, P2086, DOI 10.1002/art.27452; Graham JP, 2010, IMMUNOL REV, V237, P226, DOI 10.1111/j.1600-065X.2010.00932.x; Guo QW, 2010, MOL IMMUNOL, V47, P1783, DOI 10.1016/j.molimm.2010.02.017; Iwata S, 2011, J RHEUMATOL, V38, P633, DOI 10.3899/jrheum.100729; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; Kindler V, 1997, J IMMUNOL, V159, P2085; Kobayashi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004736; Krieg AM, 2002, NAT IMMUNOL, V3, P423, DOI 10.1038/ni0502-423; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug Anne, 2008, V183, P129; Kulathu Y, 2009, IMMUNOL REV, V232, P286, DOI 10.1111/j.1600-065X.2009.00837.x; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lin YC, 2010, MOL IMMUNOL, V47, P1569, DOI 10.1016/j.molimm.2010.01.008; Liossis SNC, 1996, J CLIN INVEST, V98, P2549, DOI 10.1172/JCI119073; Maruyama M, 2000, NATURE, V407, P636, DOI 10.1038/35036600; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Podolanczuk A, 2009, BLOOD, V113, P3154, DOI 10.1182/blood-2008-07-166439; Rowland SL, 2007, J IMMUNOL, V179, P4645, DOI 10.4049/jimmunol.179.7.4645; Ruprecht CR, 2006, EUR J IMMUNOL, V36, P810, DOI 10.1002/eji.200535744; Sakurai D, 2007, EUR J IMMUNOL, V37, P110, DOI 10.1002/eji.200636623; Sanjuan MA, 2006, J CELL BIOL, V172, P1057, DOI 10.1083/jcb.200508058; Tabrizi SJ, 2009, J IMMUNOL, V182, P1490, DOI 10.4049/jimmunol.182.3.1490; Tangye SG, 2003, J IMMUNOL, V170, P686, DOI 10.4049/jimmunol.170.2.686; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6; Weinblatt ME, 2010, NEW ENGL J MED, V363, P1303, DOI 10.1056/NEJMoa1000500; Wong WSF, 2004, BBA-PROTEINS PROTEOM, V1697, P53, DOI 10.1016/j.bbapap.2003.11.013; Xie P, 2008, CYTOKINE GROWTH F R, V19, P199, DOI 10.1016/j.cytogfr.2008.04.002	35	27	28	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1594	+		10.1016/j.jaci.2012.03.014	http://dx.doi.org/10.1016/j.jaci.2012.03.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22541243				2022-12-18	WOS:000304764600021
J	O'Brian, AL; Lemanske, RF; Evans, MD; Gangnon, RE; Gern, JE; Jackson, DJ				O'Brian, Amy L.; Lemanske, Robert F., Jr.; Evans, Michael D.; Gangnon, Ronald E.; Gern, James E.; Jackson, Daniel J.			Recurrent severe exacerbations in early life and reduced lung function at school age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA		[O'Brian, Amy L.; Lemanske, Robert F., Jr.; Gern, James E.; Jackson, Daniel J.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53715 USA; [Lemanske, Robert F., Jr.; Gern, James E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Evans, Michael D.; Gangnon, Ronald E.] Univ Wisconsin, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	O'Brian, AL (corresponding author), Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI 53715 USA.	djj@medicine.wisc.edu		Gangnon, Ronald/0000-0003-2587-6714; Evans, Michael/0000-0001-7449-3993	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD061879] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831, R01HL061879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061879] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR003186, 1UL1RR025011, UL1 RR025011, UL1 RR025011-01, M01RR03186] Funding Source: Medline; NHLBI NIH HHS [P01 HL70831, R01 HL61879, P01 HL070831, R01 HL061879-02, P01 HL070831-01] Funding Source: Medline; NICHD NIH HHS [R01 HD061879] Funding Source: Medline; NIMH NIH HHS [R01 MH061879] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Eigen H, 2001, AM J RESP CRIT CARE, V163, P619, DOI 10.1164/ajrccm.163.3.2002054; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2010, CURR OPIN ALLERGY CL, V10, P133, DOI 10.1097/ACI.0b013e3283352f7c; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363	9	27	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1162	1164		10.1016/j.jaci.2011.11.046	http://dx.doi.org/10.1016/j.jaci.2011.11.046			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22236729	Green Accepted			2022-12-18	WOS:000302144600040
J	Gershon, A; Guan, J; Victor, JC; Wang, CN; To, T				Gershon, Andrea; Guan, Jun; Victor, J. Charles; Wang, Chengning; To, Teresa			The course of asthma activity: A population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; health services use; remission; natural history	NATURAL-HISTORY; CHILDHOOD ASTHMA; DIAGNOSED ASTHMA; REMISSION; CHILDREN; RELAPSE; NO	Background: Unlike most chronic diseases, which tend to progress over time, asthma is known to persist, possibly resolve, and/or present with any combination of remissions and relapses. As a result, its course has been difficult to characterize and its prognosis difficult to predict. Objective: To quantify the proportion of individuals with asthma who have active disease and, of those, the proportion who experience significant gaps in their asthma activity; and to determine factors associated with asthma activity. Methods: Universal population health administrative databases were used to identify all individuals with asthma living in Ontario, Canada, in 1993 and follow them for 15 years. Active asthma was indicated by 1 or more physician claims for asthma. Results: Of 613,394 individuals with asthma in 1993, 504,851 (82.3%) had active disease in subsequent years. Of those who had complete follow-up, 74.6% experienced a gap of 2 or more years in their asthma activity. Previous asthma claims, older and younger age, and a codiagnosis of chronic obstructive pulmonary disease correlated with greater asthma activity. Conclusion: Over 15 years, most individuals with asthma in Ontario, Canada, had active disease that was interspersed by periods of inactivity when they did not require medical attention and were likely in remission. These analyses offer insight into the natural course of asthma activity that may help improve the ability to predict an individual's course of disease. (J Allergy Clin Immunol 2012; 129: 679-86.)	[Gershon, Andrea; Guan, Jun; Victor, J. Charles; To, Teresa] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; [Gershon, Andrea] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Gershon, Andrea; Wang, Chengning; To, Teresa] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Gershon, Andrea; Victor, J. Charles; To, Teresa] Univ Toronto, Toronto, ON, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Gershon, A (corresponding author), Inst Clin Evaluat Sci, G1 06,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	andrea.gershon@ices.on.ca	Victor, J Charles/F-8765-2011	Victor, J Charles/0000-0003-1720-9356	Ontario Ministry of Health; University of Toronto, Toronto, Ontario, Canada; Government of Ontario; Institute for Clinical Evaluative Sciences (ICES); Ontario Ministry of Health and Long-Term Care	Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); University of Toronto, Toronto, Ontario, Canada(University of Toronto); Government of Ontario; Institute for Clinical Evaluative Sciences (ICES)(University of Toronto); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario)	A. G. is supported by an Ontario Ministry of Health Career Scientist Award. T. T. is supported by the Dales Award in Medical Research from the University of Toronto, Toronto, Ontario, Canada. Funding for this project was made available through the Government of Ontario who had no role in study design, collection, analysis, interpretation of data, writing of the report, or in the decision to submit the report for publication. This study was also supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred.	Aaron SD, 2008, CAN MED ASSOC J, V179, P1121, DOI 10.1503/cmaj.081332; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Ekerljung L, 2008, RESP MED, V102, P1730, DOI 10.1016/j.rmed.2008.07.011; Gershon AS, 2009, AM J RESP CRIT CARE, V179; Gershon AS, 2009, COPD, V6, P388, DOI 10.1080/15412550903140865; Gershon AS, 2009, CAN RESPIR J, V16, P183, DOI 10.1155/2009/963098; Holm M, 2007, EUR RESPIR J, V30, P62, DOI 10.1183/09031936.00121705; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Murray CS, 2008, CURR OPIN ALLERGY CL, V8, P77, DOI 10.1097/ACI.0b013e3282f41769; Plessis V, 2002, DEFINITIONS RURAL; Quinn K, 2006, AM J PUBLIC HEALTH, V96, P1599, DOI 10.2105/AJPH.2005.071514; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Statistics Canada, 2004, PCCF VERS 4D US GUID; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Stupka E, 2009, AM J MED, V122, P6, DOI 10.1016/j.amjmed.2008.09.022; Subbarao P, 2009, CAN MED ASSOC J, V181, pE181, DOI 10.1503/cmaj.080612; To T, 2006, PEDIAT ALLERG IMM-UK, V17, P69, DOI 10.1111/j.1399-3038.2005.00346.x; TO T, 2004, AM J RESP CRIT CARE, V169, pA383; To T, 2007, ARCH PEDIAT ADOL MED, V161, P1197, DOI 10.1001/archpedi.161.12.1197; To T, 2010, AM J RESP CRIT CARE, V181, P337, DOI 10.1164/rccm.200907-1035OC; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246; Warke TJ, 2002, EUR RESPIR J, V19, P284, DOI 10.1183/09031936.02.00882002	26	27	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					679	686		10.1016/j.jaci.2011.11.014	http://dx.doi.org/10.1016/j.jaci.2011.11.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22178637	Bronze			2022-12-18	WOS:000301189300011
J	Martin, H; Reuter, S; Dehzad, N; Heinz, A; Bellinghausen, I; Saloga, J; Haasler, I; Korn, S; Jonuleit, H; Buhl, R; Becker, C; Taube, C				Martin, Helen; Reuter, Sebastian; Dehzad, Nina; Heinz, Anke; Bellinghausen, Iris; Saloga, Joachim; Haasler, Ina; Korn, Stephanie; Jonuleit, Helmut; Buhl, Roland; Becker, Christian; Taube, Christian			CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Humanized animal model; AHR; pulmonary inflammation; regulatory T cells	BLOOD MONONUCLEAR-CELLS; HUMAN PERIPHERAL-BLOOD; MEDIATED SUPPRESSION; IMMUNE-RESPONSES; LYMPHOID-TISSUES; SCID MICE; IN-VIVO; IGE; INFLAMMATION; ASTHMA	Background: Based on their potency to control allergic diseases, regulatory T (Treg) cells represent a promising target for novel strategies to interfere with allergic airway inflammation. We have previously demonstrated that stimulation of the CD4 molecule on human Treg cells activates their suppressive activity in vitro and in vivo. Objective: We sought to determine the effect of CD4-mediated Treg-cell activation on pulmonary inflammation in a humanized mouse model of allergic airway inflammation. Methods: PBMCs obtained from donors allergic to birch pollen or from healthy donors were injected into NOD-severe combined immunodeficiency gamma c(-/-) mice, followed by allergen airway challenges and analysis of airway responsiveness and inflammation. For Treg-cell activation, mice were treated with the CD4-binding, lck-activating recombinant HIV-1 surface protein gp120 after sensitization prior to allergen challenge. Control experiments with CD25-depleted PBMCs were performed to evaluate the role of Treg cells. Results: PBMCs from allergic donors but not from healthy donors induced airway inflammation and airway hyperresponsiveness. Treatment with gp120 prior to allergen challenge abrogated airway hyperresponsiveness and reduced the inflammatory immune response. In contrast, treatment had no effect on inflammation and airway hyperresponsiveness in mice that received CD25-depleted PBMCs, demonstrating Treg-cell dependency of disease prevention. Conclusion: Allergic airway inflammation can be prevented by stimulation of human Treg cells by CD4. These results suggest a clinical potential of Treg-cell activation by high-affinity CD4 ligands in allergic diseases. (J Allergy Clin Immunol 2012;129:521-8.)	[Taube, Christian] Leiden Univ, Dept Pulmonol, Med Ctr, NL-2300 RC Leiden, Netherlands; [Martin, Helen; Reuter, Sebastian; Dehzad, Nina; Heinz, Anke; Haasler, Ina; Korn, Stephanie; Buhl, Roland; Taube, Christian] Johannes Gutenberg Univ Mainz, Dept Med 3, Univ Med Ctr, Mainz, Germany; [Bellinghausen, Iris; Saloga, Joachim; Jonuleit, Helmut; Becker, Christian] Johannes Gutenberg Univ Mainz, Dept Dermatol, Univ Med Ctr, Mainz, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Taube, C (corresponding author), Leiden Univ, Dept Pulmonol, Med Ctr, Albinusdreef 2,POB 9600, NL-2300 RC Leiden, Netherlands.	c.taube@lumc.nl	Reuter, Sebastian/L-1804-2013; Becker, Christian/F-5384-2010; Jonuleit, Helmut/D-8059-2011; Becker, Christian/GLS-0862-2022; Becker, Christian/AAD-4549-2020	Becker, Christian/0000-0002-1716-7208; Jonuleit, Helmut/0000-0002-5672-9365; Becker, Christian/0000-0002-1716-7208; Becker, Christian/0000-0002-1716-7208; Reuter, Sebastian/0000-0002-1784-0124	Deutsche Forschungsgemeinschaft (DFG) [Ta275/41, Ta275/5-1, BE-3685/1-1]; Forschungs Zentrum Immunologie (FZI) Mainz	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Forschungs Zentrum Immunologie (FZI) Mainz	This study was funded by Deutsche Forschungsgemeinschaft (DFG) (grants Ta275/41 and Ta275/5-1 to C.T. and BE-3685/1-1 to C.B.) and Forschungs Zentrum Immunologie (FZI) Mainz to C.T.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Allan SE, 2007, INT IMMUNOL, V19, P345, DOI 10.1093/intimm/dxm014; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Becker C, 2007, EUR J IMMUNOL, V37, P1217, DOI 10.1002/eji.200636480; Becker C, 2009, BLOOD, V114, P1263, DOI 10.1182/blood-2009-02-206730; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Bopp T, 2009, J IMMUNOL, V182, P4017, DOI 10.4049/jimmunol.0803310; Boudousquie C, 2009, CLIN EXP ALLERGY, V39, P1415, DOI 10.1111/j.1365-2222.2009.03314.x; CHIANG BL, 1995, J ALLERGY CLIN IMMUN, V95, P69, DOI 10.1016/S0091-6749(95)70154-0; GAGNON R, 1995, J ALLERGY CLIN IMMUN, V95, P1268, DOI 10.1016/S0091-6749(95)70085-4; Herz U, 1998, J INVEST DERMATOL, V110, P224, DOI 10.1046/j.1523-1747.1998.00119.x; Herz U, 2004, CLIN EXP ALLERGY, V34, P478, DOI 10.1111/j.1365-2222.2004.01887.x; HIVROZ C, 1993, EUR J IMMUNOL, V23, P600, DOI 10.1002/eji.1830230303; Hoffmann P, 2009, EUR J IMMUNOL, V39, P1088, DOI 10.1002/eji.200838904; Ji JX, 2009, INT IMMUNOL, V21, P283, DOI 10.1093/intimm/dxn146; Jiang Q, 2008, BLOOD, V112, P2858, DOI 10.1182/blood-2008-03-145946; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kearley J, 2008, J ALLERGY CLIN IMMUN, V122, P617, DOI 10.1016/j.jaci.2008.05.048; King M, 2008, CLIN IMMUNOL, V126, P303, DOI 10.1016/j.clim.2007.11.001; Kinter A, 2007, P NATL ACAD SCI USA, V104, P3390, DOI 10.1073/pnas.0611423104; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lin YL, 2008, ALLERGY, V63, P67, DOI 10.1111/j.1398-9995.2007.01526.x; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Miyara M, 2009, J ALLERGY CLIN IMMUN, V123, P749, DOI 10.1016/j.jaci.2009.03.001; Nilsson J, 2006, BLOOD, V108, P3808, DOI 10.1182/blood-2006-05-021576; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; Reuter S, 2008, EUR RESPIR J, V31, P773, DOI 10.1183/09031936.00058907; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Sonar SS, 2010, J CLIN INVEST, V120, P2767, DOI 10.1172/JCI39543; Steinsvik TE, 1999, SCAND J IMMUNOL, V49, P67; Thunberg S, 2007, CLIN EXP ALLERGY, V37, P1127, DOI 10.1111/j.1365-2222.2007.02739.x; Tiemessen MM, 2002, J ALLERGY CLIN IMMUN, V110, P934, DOI 10.1067/mai.2002.128856	33	27	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					521	U376		10.1016/j.jaci.2011.09.038	http://dx.doi.org/10.1016/j.jaci.2011.09.038			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22078574	Bronze			2022-12-18	WOS:000299951700032
J	Keet, CA; Wood, RA; Matsui, EC				Keet, Corinne A.; Wood, Robert A.; Matsui, Elizabeth C.			Personal and parental nativity as risk factors for food sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; food sensitization; immigration; nativity; child; hay fever; asthma; eczema; aeroallergen	FOREIGN-BORN; ATOPIC SENSITIZATION; ASTHMA PREVALENCE; UNITED-STATES; IGE LEVELS; CHILDREN; ALLERGY; CHILDHOOD; BIRTH; ASSOCIATIONS	Background: Immigrants to developed countries have low rates of aeroallergen sensitization and asthma, but less is known about both food allergy and the role of parental immigration status. Objective: We sought to evaluate the relationship between personal and parental nativity and the risk of food sensitization. Methods: Three thousand five hundred fifty subjects less than 21 years old from the Nation Health and Examination Survey 2005-2006 were included. Odds ratios (ORs) were generated by using logistic regression, which adjusted for race/ethnicity, sex, age, and household income and accounted for the complex survey design. Nativity was classified as US-born or foreign-born, and the age of immigration was estimated. Head-of-household nativity was used as a proxy for parental nativity. Food sensitization was defined as at least 1 specific IgE level of 0.35 kU/L or greater to milk, egg, or peanut. Aeroallergen-specific sensitizations and the presence of asthma, allergic rhinitis, or eczema were also assessed. Results: Compared with those born outside the United States (US), US-born children and adolescents had higher odds of sensitization to any food (OR, 2.05; 95% CI, 1.49-2.83; P < .001). Among the foreign-born group, those who arrived before 2 years of age had higher odds of food sensitization than those who arrived later (OR, 2.68; 95% CI, 1.19-6.08; P = .02). Within the US-born group, in contrast, children of immigrants were at the highest risk (OR, 1.53; 95% CI, 1.05-2.24; P = .02). Conclusion: Although foreign-born children and adolescents are at lower risk of food sensitization compared with those born in the US, among those born in the US, the children of immigrants are at the highest risk. (J Allergy Clin Immunol 2012; 129: 169-75.)	[Keet, Corinne A.; Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21218 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Div Allergy & Clin Immunol, Dept Med, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Keet, CA (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21202 USA.	ckeet1@jhmi.edu		Keet, Corinne/0000-0002-6585-239X; Matsui, Elizabeth/0000-0001-8134-5593	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [1KL2RR025006-01]; National Institutes of Health; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025006] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The study described was made possible by grant no. 1KL2RR025006-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on the NCRR is available at http://www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.; C. A. Keet and E. C. Matsui receive research support from the National Institutes of Health. R. A. Wood has consultant arrangements with the Asthma and Allergy Foundation of America, receives research support from the National Institutes of Health, and is on the Medical Advisory Board for the Food Allergy and Anaphylaxis Network.	Acevedo-Garcia D, 2007, SOC SCI MED, V65, P2503, DOI 10.1016/j.socscimed.2007.06.033; [Anonymous], 2011, WHO FACT SHEET INT W; ASSEYR AF, 1994, J INVEST ALLERG CLIN, V4, P192; Barnes Kathleen C, 2007, Proc Am Thorac Soc, V4, P58, DOI 10.1513/pats.200607-146JG; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Brugge D, 2008, J ASTHMA, V45, P785, DOI 10.1080/02770900802179957; Brugge D, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-13; Cataldo F, 2006, PEDIAT ALLERG IMM-UK, V17, P364, DOI 10.1111/j.1399-3038.2006.00421.x; Djuardi Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007711; Dumanovsky T, 2007, J ASTHMA, V44, P297, DOI 10.1080/02770900701344140; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Eldeirawi K, 2005, J ALLERGY CLIN IMMUN, V116, P42, DOI 10.1016/j.jaci.2005.03.041; Eldeirawi K, 2009, J ASTHMA, V46, P796, DOI 10.3109/02770900903114572; Eldeirawi KM, 2006, J ASTHMA, V43, P279, DOI 10.1080/0277090060022869; Figueiredo CA, 2010, INFECT IMMUN, V78, P3160, DOI 10.1128/IAI.01228-09; Friberg IM, 2010, TRENDS PARASITOL, V26, P540, DOI 10.1016/j.pt.2010.06.010; Fumagalli M, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-264; Fumagalli M, 2009, J EXP MED, V206, P1395, DOI 10.1084/jem.20082779; Gruber C, 2002, PEDIAT ALLERG IMM-UK, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Hewitson JP, 2009, MOL BIOCHEM PARASIT, V167, P1, DOI 10.1016/j.molbiopara.2009.04.008; Hjern A, 1999, ACTA PAEDIATR, V88, P1107, DOI 10.1080/08035259950168171; Holguin F, 2005, AM J RESP CRIT CARE, V171, P103, DOI 10.1164/rccm.200402-143OC; Hong X, 2011, J ALLERGY CLIN IMMUN, V128, pe2; Hong XM, 2011, J ALLERGY CLIN IMMUN, V128, P374, DOI 10.1016/j.jaci.2011.05.007; Hopkin J, 2009, PARASITE IMMUNOL, V31, P267, DOI 10.1111/j.1365-3024.2009.01104.x; Keet CA, 2011, J ALLERGY CLIN IMMUN, V128, P414, DOI 10.1016/j.jaci.2011.06.011; Kouriba B, 2005, J IMMUNOL, V174, P6274, DOI 10.4049/jimmunol.174.10.6274; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Maizels RM, 2008, J BIOL, V8, P62; Mendoza Fernando S, 2009, Pediatrics, V124 Suppl 3, pS187, DOI 10.1542/peds.2009-1100F; Migliore E, 2007, ALLERGY, V62, P293, DOI 10.1111/j.1398-9995.2007.01238.x; Moller M, 2007, HUM MOL GENET, V16, P1828, DOI 10.1093/hmg/ddm131; Mosnaim GS, 2007, J ALLERGY CLIN IMMUN, V120, P1160, DOI 10.1016/j.jaci.2007.08.040; Netuveli G, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-120; Niggemann B, 2011, ALLERGY, V66, P980, DOI 10.1111/j.1398-9995.2011.02561.x; Peisong G, 2004, GENES IMMUN, V5, P58, DOI 10.1038/sj.gene.6364030; Pereg D, 2008, ALLERGY, V63, P1040, DOI 10.1111/j.1398-9995.2008.01661.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Rottem M, 2005, INT ARCH ALLERGY IMM, V136, P198, DOI 10.1159/000083894; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sternthal MJ, 2011, J ALLERGY CLIN IMMUN, V128, P337, DOI 10.1016/j.jaci.2011.05.008; Subramanian SV, 2009, AM J PUBLIC HEALTH, V99, P690, DOI 10.2105/AJPH.2007.128843; Svendsen ER, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-55; Thornton CA, 2010, CURR ALLERGY ASTHM R, V10, P444, DOI 10.1007/s11882-010-0148-5; U.S. Census Bureau, 2010, AM FAM LIV ARR 2010; Ventura MT, 2004, ALLERGY, V59, P632, DOI 10.1111/j.1398-9995.2004.00448.x; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014	52	27	28	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					169	U244		10.1016/j.jaci.2011.10.002	http://dx.doi.org/10.1016/j.jaci.2011.10.002			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22075329	Green Accepted			2022-12-18	WOS:000298634000022
J	Oh, SH; Park, CO; Wu, WH; Kim, JY; Jin, S; Byamba, D; Bae, BG; Noh, S; Lim, BJ; Noh, JY; Lee, KH				Oh, Sang Ho; Park, Chang Ook; Wu, Wen Hao; Kim, Ji Young; Jin, Shan; Byamba, Dashlkhumbe; Bae, Byung Gi; Noh, Seongmin; Lim, Beom Jin; Noh, Ji Yeon; Lee, Kwang Hoon			Corticotropin-releasing hormone downregulates IL-10 production by adaptive forkhead box protein 3-negative regulatory T cells in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Corticotropin-releasing hormone; stress; atopic dermatitis; IL-10; forkhead box protein 3; regulatory T cell	BLOOD MONONUCLEAR-CELLS; RECEPTOR 1; STRESS-RESPONSE; MAST-CELLS; EXPRESSION; ANXIETY; CYTOKINE; SKIN; BEHAVIOR; DISEASE	Background: Corticotropin-releasing hormone (CRH) is the central regulating hormone of the hypothalamic-pituitary-adrenal axis. CRH also has diverse functional effects in the periphery and is related to the aggravation of several cutaneous diseases; however, the effect of CRH on T cells in patients with atopic dermatitis (AD) has not been well evaluated. Objective: We investigated whether CRH directly affects peripheral T(H)1, T(H)2, and regulatory T (Treg) cells in patients with AD. Methods: We assessed whether T cells express the CRH receptor protein and mRNA by using flow cytometry, Western blotting, immunofluorescence, immunohistochemistry, and RT-PCR. We evaluated cytokine expression using ELISA after treating the T cells extracted from patients with AD and healthy control subjects (HCs) with CRH. Flow cytometry was then used to evaluate any direct effects of CRH on TH1, TH2, and Treg cells from patients with AD and HCs. Results: T cells from patients with AD expressed significantly lower CRH receptor 1/2 mRNA levels than T cells from HCs. T cells from HCs reacted with different IL-4 and IFN-gamma secretions to CRH treatment, whereas T cells from patients with AD did not. IL-10 production was significantly decreased in the supernatants from both the HCs and patients with AD after CRH treatment. CRH upregulated IL-4 production by TH2 cells and downregulated IFN-g production by TH1 cells in HCs. CRH also suppressed the production of IL-10 by forkhead box protein 3-negative Treg cells in both groups, but the difference was only significant in patients with AD. Conclusions: CRH-mediated suppression of IL-10 secretion from Treg cells might explain stress-related exacerbations in patients with AD. (J Allergy Clin Immunol 2012; 129: 151-9.)	[Oh, Sang Ho; Park, Chang Ook; Wu, Wen Hao; Kim, Ji Young; Jin, Shan; Byamba, Dashlkhumbe; Bae, Byung Gi; Noh, Seongmin; Noh, Ji Yeon; Lee, Kwang Hoon] Yonsei Univ, Coll Med, Res Inst, Dept Dermatol & Cutaneous Biol, Seoul 120752, South Korea; [Lim, Beom Jin] Yonsei Univ, Coll Med, Dept Pathol, Seoul 120752, South Korea; [Jin, Shan; Byamba, Dashlkhumbe; Lim, Beom Jin; Noh, Ji Yeon; Lee, Kwang Hoon] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lee, KH (corresponding author), Yonsei Univ, Coll Med, Res Inst, Dept Dermatol & Cutaneous Biol, 134 Shinchon Dong, Seoul 120752, South Korea.	kwanglee@yuhs.ac		Park, Chang Ook/0000-0003-3856-1201; Oh, Sang Ho/0000-0002-4477-1400; Noh, ji yeon/0000-0002-4158-9443; Lim, Beom Jin/0000-0003-2856-0133	Ministry for Health, Welfare & Family Affairs, Republic of Korea [A080892, A101348]	Ministry for Health, Welfare & Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	Supported by grants of the Korean Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A080892 and A101348).	Agarwal SK, 2001, J INTERF CYTOK RES, V21, P147, DOI 10.1089/107999001750133159; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; ANGIONI S, 1993, LIFE SCI, V53, P1735, DOI 10.1016/0024-3205(93)90160-5; Arck PC, 2006, J INVEST DERMATOL, V126, P1697, DOI 10.1038/sj.jid.5700104; Arndt J, 2008, CURR ALLERGY ASTHM R, V8, P312, DOI 10.1007/s11882-008-0050-6; Bae BG, 2011, ACTA DERM VENEREOL; Baker C, 2003, J NEUROENDOCRINOL, V15, P1070, DOI 10.1046/j.1365-2826.2003.01099.x; Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; Bauer ME, 2008, NEUROIMMUNOMODULAT, V15, P241, DOI 10.1159/000156467; Belloni B, 2008, CURR OPIN ALLERGY CL, V8, P423, DOI 10.1097/ACI.0b013e32830fb8fd; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Brandt C, 2009, ALLERGY, V64, P1588, DOI 10.1111/j.1398-9995.2009.02054.x; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen ZB, 2005, P NATL ACAD SCI USA, V102, P14735, DOI 10.1073/pnas.0507014102; Choi EH, 2005, J INVEST DERMATOL, V124, P587, DOI 10.1111/j.0022-202X.2005.23589.x; Choi JM, 2010, P NATL ACAD SCI USA, V107, P18575, DOI 10.1073/pnas.1000400107; Freier E, 2010, PSYCHONEUROENDOCRINO, V35, P663, DOI 10.1016/j.psyneuen.2009.10.005; Fujio K, 2010, ADV IMMUNOL, V105, P99, DOI 10.1016/S0065-2776(10)05004-2; Haczku A, 2010, J ALLERGY CLIN IMMUN, V125, P550, DOI 10.1016/j.jaci.2009.11.005; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hashizume H, 2005, BRIT J DERMATOL, V152, P1161, DOI 10.1111/j.1365-2133.2005.06449.x; Hashizume H, 2006, CURR OPIN ALLERGY CL, V6, P335, DOI 10.1097/01.all.0000244793.03239.40; Holsboer F, 2010, ANNU REV PSYCHOL, V61, P81, DOI 10.1146/annurev.psych.093008.100321; Kawana S, 2010, CLIN EXP DERMATOL, V35, P835, DOI 10.1111/j.1365-2230.2009.03771.x; Lee HJ, 2009, EXP DERMATOL, V18, P199, DOI 10.1111/j.1600-0625.2008.00781.x; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Magalhaes AC, 2010, NAT NEUROSCI, V13, P622, DOI 10.1038/nn.2529; McEwen BS, 2007, PHYSIOL REV, V87, P873, DOI 10.1152/physrev.00041.2006; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Muller MB, 2003, NAT NEUROSCI, V6, P1100, DOI 10.1038/nn1123; NEMEROFF CB, 1988, ARCH GEN PSYCHIAT, V45, P577; Oh SH, 2010, ACTA DERM-VENEREOL, V90, P582, DOI 10.2340/00015555-0933; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; OWENS MJ, 1991, PHARMACOL REV, V43, P425; Paus R, 2006, TRENDS IMMUNOL, V27, P32, DOI 10.1016/j.it.2005.10.002; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V107, P171, DOI 10.1067/mai.2001.111850; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V108, P455, DOI 10.1067/mai.2001.117800; SINGH VK, 1989, J NEUROIMMUNOL, V23, P257, DOI 10.1016/0165-5728(89)90058-1; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2001, FASEB J, V15, P1678, DOI 10.1096/fj.00-0850rev; Sommershof A, 2009, BRAIN BEHAV IMMUN, V23, P1117, DOI 10.1016/j.bbi.2009.07.003; Spielberger C, 1983, MANUAL STATE TRAIT A; Steckler T, 1999, BIOL PSYCHIAT, V46, P1480, DOI 10.1016/S0006-3223(99)00170-5; Tagen M, 2007, J INVEST DERMATOL, V127, P1789, DOI 10.1038/sj.jid.5700757; Theoharides TC, 2004, TRENDS PHARMACOL SCI, V25, P563, DOI 10.1016/j.tips.2004.09.007; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wu WH, 2010, J ALLERGY CLIN IMMUN, V126, P290, DOI 10.1016/j.jaci.2010.05.024; Xiang LB, 2011, NEUROIMMUNOMODULAT, V18, P1, DOI 10.1159/000311450; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zhou ZF, 2008, NATURE, V452, P997, DOI 10.1038/nature06858	61	27	28	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					151	U220		10.1016/j.jaci.2011.09.008	http://dx.doi.org/10.1016/j.jaci.2011.09.008			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	869XT	22000570				2022-12-18	WOS:000298634000019
J	Filipiak-Pittroff, B; Schnopp, C; Berdel, D; Naumann, A; Sedlmeier, S; Onken, A; Rodriguez, E; Folster-Holst, R; Baurecht, H; Ollert, M; Ring, J; Cramer, C; von Berg, A; Bauer, CP; Herbarth, O; Lehmann, I; Schaaf, B; Koletzko, S; Wichmann, HE; Heinrich, J; Weidinger, S				Filipiak-Pittroff, Birgit; Schnopp, Christina; Berdel, Dietrich; Naumann, Aline; Sedlmeier, Simon; Onken, Anna; Rodriguez, Elke; Foelster-Holst, Regina; Baurecht, Hansjoerg; Ollert, Markus; Ring, Johannes; Cramer, Claudia; von Berg, Andrea; Bauer, Carl Peter; Herbarth, Olf; Lehmann, Irina; Schaaf, Beate; Koletzko, Sibylle; Wichmann, Heinz-Erich; Heinrich, Joachim; Weidinger, Stephan		GINIplus Study Grp; LISAplus Study Grp	Predictive value of food sensitization and filaggrin mutations in children with eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eczema; atopic dermatitis; asthma; food sensitization; food allergy; filaggrin; prediction	INFANT NUTRITIONAL INTERVENTION; PROSPECTIVE BIRTH COHORT; ATOPIC-DERMATITIS; ALLERGIC SENSITIZATION; NATURAL COURSE; RISK-FACTORS; FOLLOW-UP; HENS EGG; ASTHMA; PREVALENCE	Background: It was reported that in infants with eczema and food sensitization, the presence of a filaggrin (FLG) null mutation predicts future asthma with a specificity and positive predictive value of 100%. Objectives: We sought to evaluate the predictive value of food sensitization and food allergy, FLG haploinsufficiency, and their combination in infants with early-onset eczema for persistent eczema and childhood asthma. Methods: The German Infant Nutritional Intervention (GINI) and Influence of Lifestyle-related Factors on the Immune System and the Development of Allergies in Childhood (LISA) birth cohorts, as well as a collection of 65 cases of early-onset eczema with and without food allergy were investigated. Results: The risk for asthma was significantly increased by food sensitization (positive diagnostic likelihood ratios [PLRs] of 1.9 [95% CI, 1.1-3.4] in the GINI cohort and 5.5 [95% CI, 2.8-10.8] in the LISA cohort) and the presence of an FLG mutation (PLRs of 2.9 [95% CI, 1.2-6.6] in the GINI cohort and 2.8 [95% CI, 1.0-7.9] in the LISA cohort) with a rather high specificity (79.1% and 92.9% in the GINI cohort and 89.0% and 91.7% in the LISA cohort, respectively) but low sensitivity (40.0% and 39.3% in the GINI cohort and 31.6% and 23.5% in the LISA cohort, respectively). Likewise, the risk for persistent eczema was increased. In the clinical cases neither food allergy nor FLG mutations had a significant effect. The combination of both parameters did not improve prediction and reached positive predictive values of 52.3% (GINI cohort), 66.9% (LISA cohort), and 30.6% (clinical cases), assuming an asthma prevalence in children with early eczema of 30%. Conclusion: Early food sensitization and the presence of an FLG mutation in infants with early eczema increase the risk for later asthma, but the combination of the 2 factors does not represent a clinically useful approach to reliably identify children at risk. (J Allergy Clin Immunol 2011;128:1235-41.)	[Filipiak-Pittroff, Birgit; Wichmann, Heinz-Erich; Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [Filipiak-Pittroff, Birgit; Berdel, Dietrich; von Berg, Andrea] Marien Hosp, Wesel, Germany; [Schnopp, Christina; Sedlmeier, Simon; Onken, Anna; Ollert, Markus; Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Baurecht, Hansjoerg] Tech Univ Munich, GSISH, Munich, Germany; [Bauer, Carl Peter] Tech Univ Munich, Dept Pediat, Munich, Germany; [Naumann, Aline] Univ Tubingen, Dept Med Biometry, Tubingen, Germany; [Rodriguez, Elke; Foelster-Holst, Regina; Baurecht, Hansjoerg; Weidinger, Stephan] Univ Kiel, Dept Dermatol Venereol & Allergy, Kiel, Germany; [Cramer, Claudia] Univ Dusseldorf, IUF Leibniz Res Inst Environm Med, D-40225 Dusseldorf, Germany; [Herbarth, Olf] Univ Leipzig, Fac Med Environm Med & Environm Hyg, Leipzig, Germany; [Lehmann, Irina] UFZ Helmholtz Ctr Environm Res, Dept Human Exposure Res & Epidemiol, Leipzig, Germany; [Koletzko, Sibylle] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; St. Marien Hospital; Technical University of Munich; Technical University of Munich; Technical University of Munich; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Kiel; Heinrich Heine University Dusseldorf; Leibniz Institut fur Umweltmedizinische Forschung (IUF); Leipzig University; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); University of Munich	Heinrich, J (corresponding author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany.	joachim.heinrich@helmholtz-muenchen.de	Heinrich, Joachim/N-1720-2013; Baurecht, Hansjoerg/C-4035-2013; Ring, Johannes/GLN-4341-2022; Weidinger, Stephan/C-8461-2011; Rodríguez, Elke/C-4259-2013; Wichmann, Heinz Erich/AAA-5695-2022	Heinrich, Joachim/0000-0002-9620-1629; Baurecht, Hansjoerg/0000-0002-9265-5594; Ring, Johannes/0000-0001-8236-3152; Weidinger, Stephan/0000-0003-3944-252X; Rodríguez, Elke/0000-0003-3692-3950; Lehmann, Irina/0000-0001-8875-5587; Ollert, Markus W./0000-0002-8055-0103	German Ministry of Education and Research (BMBF), National Genome Research Network [NGFN 01GS 0818]; Christiane Kuhne Center for Allergy Research and Education; Federal Ministry for Education, Science, Research and Technology [01 EE 9401-4, 01 EG 9705/2, 01EG9732]; Federal Ministry for Environment (IUF) [FKZ 20462296]; GSF National Research Centre for the Environment and Health; DFG [WE 2678/4-1]; ALK-Abello; Allergopharma; Almirall-Hermal; Astellas; Bavarian Nordic; Bencard; Biogen Idec; Galderma; GlaxoSmithKline-Stiefel; Leo; MSD; Novartis; Phadia; PLS Design; Procter Gamble; Sanofi Aventis; Stallergenes	German Ministry of Education and Research (BMBF), National Genome Research Network(Federal Ministry of Education & Research (BMBF)); Christiane Kuhne Center for Allergy Research and Education; Federal Ministry for Education, Science, Research and Technology; Federal Ministry for Environment (IUF); GSF National Research Centre for the Environment and Health; DFG(German Research Foundation (DFG)); ALK-Abello; Allergopharma; Almirall-Hermal(Almirall); Astellas(Astellas Pharmaceuticals); Bavarian Nordic; Bencard; Biogen Idec(Biogen); Galderma; GlaxoSmithKline-Stiefel; Leo(LEO Pharma); MSD; Novartis(Novartis); Phadia(Phadia); PLS Design; Procter Gamble(Procter & Gamble); Sanofi Aventis(Sanofi-Aventis); Stallergenes	Supported by a grant of the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN 01GS 0818) and the Christiane Kuhne Center for Allergy Research and Education (http://www.ck-care.ch/). The German Infant Nutritional Intervention study was supported for the first 3 years by grants of the Federal Ministry for Education, Science, Research and Technology (grant no. 01 EE 9401-4). The 6-year follow-up was partly funded by the Federal Ministry for Environment (IUF, FKZ 20462296) and by the GSF National Research Centre for the Environment and Health. The LISA birth cohort was funded by grants of the Federal Ministry for Education, Science, Research and Technology (grant no. 01 EG 9705/2 and 01EG9732) and the Federal Ministry for Environment (IUF, FKZ 20462296). S. W. is supported by a Heisenberg professorship of the DFG (WE 2678/4-1).; M. Ollert has received honoraria from Phadia. J. Ring has received research support from ALK-Abello, Allergopharma, Almirall-Hermal, Astellas, Bavarian Nordic, Bencard, Biogen Idec, Galderma, GlaxoSmithKline-Stiefel, Leo, MSD, Novartis, Phadia, PLS Design, Procter & Gamble, Sanofi Aventis, and Stallergenes. C. P. Bauer has received honoraria from MSD and Nestle. The rest of authors declare that they have no relevant conflicts of interest.	Ahrens B, 2010, ALLERGY, V65, P1554, DOI 10.1111/j.1398-9995.2010.02429.x; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Cramer C, 2010, J ALLERGY CLIN IMMUN, V125, P1254, DOI 10.1016/j.jaci.2010.03.036; Eller E, 2009, ALLERGY, V64, P1023, DOI 10.1111/j.1398-9995.2009.01952.x; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.018; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P536, DOI 10.1111/j.1365-2222.2007.02691.x; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Ricci G, 2006, J AM ACAD DERMATOL, V55, P765, DOI 10.1016/j.jaad.2006.04.064; Rochat MK, 2010, J ALLERGY CLIN IMMUN, V126, P1170, DOI 10.1016/j.jaci.2010.09.008; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Team RDC, 2009, R LANG ENV STAT COMP; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Werfel Thomas, 2009, J Dtsch Dermatol Ges, V7, P265, DOI 10.1111/j.1610-0387.2008.06901.x; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Wood RA, 2003, PEDIATRICS, V111, P1631; Zuberbier T, 2004, ALLERGY, V59, P338, DOI 10.1046/j.1398-9995.2003.00403.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	35	27	27	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1235	U573		10.1016/j.jaci.2011.09.014	http://dx.doi.org/10.1016/j.jaci.2011.09.014			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	22030464				2022-12-18	WOS:000298342700012
J	Renz, H; Autenrieth, IB; Brandtzaeg, P; Cookson, WO; Holgate, S; von Mutius, E; Valenta, R; Haller, D				Renz, Harald; Autenrieth, Ingo B.; Brandtzaeg, Per; Cookson, William O.; Holgate, Stephen; von Mutius, Erika; Valenta, Rudolf; Haller, Dirk			Gene-environment interaction in chronic disease: A European Science Foundation Forward Look	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Gene-environment; inflammation; immunology; chronic disease; Europe; lifestyle; genetic factors; interdisciplinary; policy; foresight	INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; CHILDHOOD ASTHMA; INTESTINAL INFLAMMATION; SUSCEPTIBILITY LOCI; HYGIENE HYPOTHESIS; EPIGENETIC CONTROL; ALLERGIC DISEASE; CROHNS-DISEASE; GUT MICROBIOME	Over the last half century, a dramatic increase in the incidence of chronic inflammatory diseases, such as asthma, allergy, and irritable bowel syndrome, has rightfully led to concern about how the modern lifestyle might inappropriately trigger innate physiologic defense mechanisms. Health care research in the Western world is faced with a significant challenge if it is to meet the needs of its populations in the decades ahead. The tools with which we hope to advance our understanding of the intrinsic and extrinsic mechanisms of chronic inflammatory diseases must therefore be adequately exploited and further developed to identify treatment and prevention strategies. There is an urgent need to prioritize resources and identify the most efficient scientific and societal initiatives to be adopted within this area. In this context national collaboration within Europe and beyond to establish state-of-the-art practices with an interdisciplinary perspective and promote an efficient exchange of best practices is essential. Such an approach likely represents the most efficient manner in which strategies for amelioration of the increase of chronic inflammatory diseases in the Western world can be achieved. The present report is based on a Forward Look initiative conducted by the European Medical Research Councils under the European Science Foundation. Experts from industry and academia, as well as relevant interest organizations, have been consulted in the process of conducting this initiative and have, based on this work, developed a set of final recommendations that target academic research, science funders, and policy makers. (J Allergy Clin Immunol 2011; 128: S27-49.)	[Renz, Harald] Univ Marburg, Inst Lab Med & Pathobiochem, D-35043 Marburg, Germany; [Autenrieth, Ingo B.] Univ Tubingen Hosp, Inst Med Microbiol & Hyg, Tubingen, Germany; [Brandtzaeg, Per] Univ Oslo, Ctr Immune Regulat, Lab Immunochem & Immunopathol, Oslo, Norway; [Brandtzaeg, Per] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Pathol, N-0027 Oslo, Norway; [Cookson, William O.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Holgate, Stephen] Univ Southampton, Dept Infect Inflammat & Immun, Southampton, Hants, England; [Holgate, Stephen] Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; [von Mutius, Erika] Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; [Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Haller, Dirk] Tech Univ Munich, ZIEL Res Ctr Nutr & Food Sci, D-8050 Freising Weihenstephan, Germany; [Haller, Dirk] Tech Univ Munich, CDD Ctr Diet & Dis, D-8050 Freising Weihenstephan, Germany	Philipps University Marburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Oslo; University of Oslo; National Hospital Norway; Imperial College London; University of Southampton; University of Southampton; University of Munich; Medical University of Vienna; Technical University of Munich; Technical University of Munich	Renz, H (corresponding author), Univ Marburg, Inst Lab Med & Pathobiochem, Baldingerstr, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de	Cookson, William/HHC-1790-2022	Haller, Dirk/0000-0002-6977-4085; Valenta, Rudolf/0000-0001-5944-3365; von Mutius, Erika/0000-0002-8893-4515	European Science Foundation; InfectoPharm; Airsonnett; Medical Research Council [G0801056B] Funding Source: researchfish	European Science Foundation(European Science Foundation (ESF)European Commission); InfectoPharm; Airsonnett; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This Forward Look was financed by the European Science Foundation.; GlaxoSmithKline, ALK-Abello, and Protectimmun; has received speaker's fees from InfectoPharm; has received research support from Airsonnett AB; is a member of the Expert Panel for the UK Research Excellence Framework; and is Associate Editor of the Journal of Allergy and Clinical Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	Abraham C, 2011, GASTROENTEROLOGY, V140, P1729, DOI 10.1053/j.gastro.2011.02.012; Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Bell JT, 2011, ANN HUM GENET, V75, P10, DOI 10.1111/j.1469-1809.2010.00629.x; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Brandtzaeg P, 2010, CURR OPIN GASTROEN, V26, P554, DOI 10.1097/MOG.0b013e32833dccf8; Brandtzaeg P, 2010, NAT REV GASTRO HEPAT, V7, P380, DOI 10.1038/nrgastro.2010.80; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P803, DOI 10.1016/j.jaci.2009.11.048; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Caluwaerts S, 2010, ORAL ONCOL, V46, P564, DOI 10.1016/j.oraloncology.2010.04.008; Chatenoud L, 2010, CLIN EXP IMMUNOL, V160, P106, DOI 10.1111/j.1365-2249.2010.04125.x; Corren J, 2011, N ENGL J MED; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Cryan JF, 2011, NEUROGASTROENT MOTIL, V23, P187, DOI 10.1111/j.1365-2982.2010.01664.x; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Fava F, 2011, WORLD J GASTROENTERO, V17, P557, DOI 10.3748/wjg.v17.i5.557; Fiorino G, 2010, CURR DRUG TARGETS, V11, P249, DOI 10.2174/138945010790309975; Fisher HR, 2011, ARCH DIS CHILD, V96, P259, DOI 10.1136/adc.2009.172460; Garrett WS, 2010, CELL, V140, P859, DOI 10.1016/j.cell.2010.01.023; Ghia JE, 2007, AM J PHYSIOL-GASTR L, V293, pG711, DOI 10.1152/ajpgi.00240.2007; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hall JA, 2011, IMMUNITY, V35, P13, DOI 10.1016/j.immuni.2011.07.002; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V125, pS81, DOI 10.1016/j.jaci.2009.10.071; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Johannsen H, 2009, CLIN EXP ALLERGY, V39, P1801, DOI 10.1111/j.1365-2222.2009.03368.x; Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213; Koletzko B, 2009, AM J CLIN NUTR, V89, P1836, DOI 10.3945/ajcn.2008.27091; Koplin J, 2008, PEDIAT ALLERG IMM-UK, V19, P682, DOI 10.1111/j.1399-3038.2008.00731.x; Kopp MV, 2009, CURR OPIN CLIN NUTR, V12, P298, DOI 10.1097/MCO.0b013e32832989a3; Kosaka Nobuyoshi, 2010, Silence, V1, P7, DOI 10.1186/1758-907X-1-7; MacDonald TT, 2011, GASTROENTEROLOGY, V140, P1768, DOI 10.1053/j.gastro.2011.02.047; McCarthy MI, 2010, NEW ENGL J MED, V363, P2339, DOI 10.1056/NEJMra0906948; McGovern DPB, 2010, NAT GENET, V42, P332, DOI 10.1038/ng.549; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Mills RE, 2011, NATURE, V470, P59, DOI 10.1038/nature09708; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; O'Rahilly S, 2009, NATURE, V462, P307, DOI 10.1038/nature08532; O'Regan GM, 2009, J ALLERGY CLIN IMMUN, V124, pR2, DOI 10.1016/j.jaci.2009.07.013; Pascual RM, 2010, CURR OPIN PHARMACOL, V10, P226, DOI 10.1016/j.coph.2010.05.013; Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655; Pinier M, 2010, AM J GASTROENTEROL, V105, P2551, DOI 10.1038/ajg.2010.372; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Renz H, 2011, NAT IMMUNOL, V12, P273, DOI 10.1038/ni0411-273; Rescigno M, 2008, CURR OPIN IMMUNOL, V20, P669, DOI 10.1016/j.coi.2008.09.007; Salminen S, 1998, BRIT J NUTR, V80, pS147, DOI 10.1079/BJN19980108; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Slack E, 2009, SCIENCE, V325, P617, DOI 10.1126/science.1172747; Smythies LE, 2010, J BIOL CHEM, V285, P19593, DOI 10.1074/jbc.M109.069955; Spor A, 2011, NAT REV MICROBIOL, V9, P279, DOI 10.1038/nrmicro2540; Steidler L, 2006, ANN NY ACAD SCI, V1072, P176, DOI 10.1196/annals.1326.031; Swamy M, 2010, NAT IMMUNOL, V11, P656, DOI 10.1038/ni.1905; Thornton CA, 2010, CURR ALLERGY ASTHM R, V10, P444, DOI 10.1007/s11882-010-0148-5; Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359; Todd JA, 2010, IMMUNITY, V32, P457, DOI 10.1016/j.immuni.2010.04.001; Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823; van der Wouden JC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002173.pub2; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wehkamp J, 2005, NAT CLIN PRACT GASTR, V2, P406, DOI 10.1038/ncpgasthep0265; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Willis-Owen SAG, 2009, CURR ALLERGY ASTHM R, V9, P3, DOI 10.1007/s11882-009-0001-x; Wilson CB, 2009, NAT REV IMMUNOL, V9, P91, DOI 10.1038/nri2487; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xavier RJ, 2008, NAT REV IMMUNOL, V8, P631, DOI 10.1038/nri2361; Ziegler AG, 2010, IMMUNITY, V32, P468, DOI 10.1016/j.immuni.2010.03.018	80	27	29	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6		S			S27	S49		10.1016/j.jaci.2011.09.039	http://dx.doi.org/10.1016/j.jaci.2011.09.039			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	857DV	22118218				2022-12-18	WOS:000297696700002
J	Gros, E; Petzold, S; Maintz, L; Bieber, T; Novak, N				Gros, Eva; Petzold, Susanne; Maintz, Laura; Bieber, Thomas; Novak, Natalija			Reduced IFN-gamma receptor expression and attenuated IFN-gamma response by dendritic cells in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Monocytes; dendritic cells; IFN-gamma; IFN-gamma receptor; signal transducer and activator of transcription 1; atopic dermatitis	FC-EPSILON-RI; INTERFERON REGULATORY FACTOR-1; T-CELL; INDOLEAMINE 2,3-DIOXYGENASE; GENE-EXPRESSION; IN-VIVO; TRYPTOPHAN DEGRADATION; HUMAN MONOCYTES; ECZEMA; IRF-1	Background: Atopic dermatitis (AD) is characterized by a predominance of T(H)2 immune reactions but weaker T(H)1 immune responses in acute skin lesions. Objectives: To evaluate whether enhanced T(H)2 immunity in patients with AD might impair T(H)1 immune responses by affecting the IFN-gamma responsiveness of antigen-presenting cells, we investigated IFN-gamma receptor and IL-4 receptor a chain expression, IFN-gamma signaling, and the expression of IFN-gamma-responsive mediators in dendritic cells (DCs) and their precursors from patients with AD compared with those from healthy subjects. Methods: Skin biopsy specimens were obtained and both monocytes and monocyte-derived dendritic cells (MoDCs) from patients with AD (n = 86) and control subjects (n = 84) were analyzed by means of flow cytometry, real-time PCR, ELISA, and HPLC. Results: We observed lower IFN-gamma receptor II expression combined with higher IL-4 receptor alpha chain expression on epidermal DCs, monocytes, and MoDCs from patients with AD. Induction of IFN-gamma-inducible factors, such as interferon regulatory factor 1, interferon-inducible protein 10, and indoleamine 2,3-dioxygenase, was attenuated in IFN-gamma-pulsed MoDCs from patients with AD. Weaker signal transducer and activator of transcription 1 activation mirrored by lower phosphorylated signal transducer and activator of transcription 1 levels in response to IFN-gamma stimulation could be observed in epidermal DCs, monocytes, and MoDCs from patients with AD. Conclusion: Impaired IFN-gamma signaling together with attenuated IFN-gamma responses in DCs and their precursor cells might contribute to the T(H)2 bias in patients with AD. (J Allergy Clin Immunol 2011;128:1015-21.)	[Gros, Eva; Petzold, Susanne; Maintz, Laura; Bieber, Thomas; Novak, Natalija] Univ Bonn, Dept Dermatol & Allergy, Med Center, D-53105 Bonn, Germany	University of Bonn	Novak, N (corresponding author), Univ Bonn, Dept Dermatol & Allergy, Med Center, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de	Jahreis, Susanne/AAA-9826-2020		Deutsche Forschungsgemeinschaft (DFG) [SFB704 TPA4, NO454/5-2]; University of Bonn; German Research Council	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); University of Bonn; German Research Council(German Research Foundation (DFG))	Supported by grants from the Deutsche Forschungsgemeinschaft (DFG SFB704 TPA4) and a BONFOR grant of the University of Bonn. S. P. was supported by a grant from the Maria von Linden-Programm for women in science of the University of Bonn. N.N. is supported by a Heisenberg-Professorship of the DFG NO454/5-2.; Disclosure of potential conflict of interest: N. Novak has received research support from the German Research Council. The rest of the authors have declared that they have no conflict of interest.	Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akkoc T, 2008, J ALLERGY CLIN IMMUN, V121, P652, DOI 10.1016/j.jaci.2007.12.1171; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bernabei P, 2001, J LEUKOCYTE BIOL, V70, P950; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Brown SJ, 2009, J INVEST DERMATOL, V129, P543, DOI 10.1038/jid.2008.413; Chan LS, 2001, J INVEST DERMATOL, V117, P977, DOI 10.1046/j.0022-202x.2001.01484.x; Chon SY, 1996, J BIOL CHEM, V271, P17247, DOI 10.1074/jbc.271.29.17247; Coccia EM, 2000, INT IMMUNOL, V12, P977, DOI 10.1093/intimm/12.7.977; Dickensheets HL, 1999, J LEUKOCYTE BIOL, V65, P307, DOI 10.1002/jlb.65.3.307; Elser B, 2002, IMMUNITY, V17, P703, DOI 10.1016/S1074-7613(02)00471-5; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 1999, ARCH DERMATOL, V135, P1551, DOI 10.1001/archderm.135.12.1551; Horr B, 2006, INT IMMUNOPHARMACOL, V6, P1577, DOI 10.1016/j.intimp.2006.06.005; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kraft S, 2002, J INVEST DERMATOL, V118, P830, DOI 10.1046/j.1523-1747.2002.01757.x; Krause CD, 2007, CYTOKINE GROWTH F R, V18, P473, DOI 10.1016/j.cytogfr.2007.06.009; Krutzik PO, 2003, CYTOM PART A, V55A, P61, DOI 10.1002/cyto.a.10072; LESTER MR, 1995, J IMMUNOL, V154, P6174; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Maintz L, 2007, EUR J DERMATOL, V17, P267, DOI 10.1684/ejd.2007.0200; Matsui E, 2000, CLIN EXP ALLERGY, V30, P1250, DOI 10.1046/j.1365-2222.2000.00931.x; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2002, J INVEST DERMATOL, V119, P870, DOI 10.1046/j.1523-1747.2002.00191.x; Novak N, 2002, J INVEST DERMATOL, V119, P842, DOI 10.1046/j.1523-1747.2002.00102.x; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Paludan SR, 1998, SCAND J IMMUNOL, V48, P459; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; Santegoets SJAM, 2008, J LEUKOCYTE BIOL, V84, P143, DOI 10.1189/jlb.1107750; Schedel M, 2008, AM J RESP CRIT CARE, V177, P613, DOI 10.1164/rccm.200703-373OC; Scheler M, 2007, AM J PATHOL, V171, P1936, DOI 10.2353/ajpath.2007.070281; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Silva NM, 2002, INFECT IMMUN, V70, P859, DOI 10.1128/IAI.70.2.859-868.2002; Simon D, 2009, ALLERGY, V64, P1681, DOI 10.1111/j.1398-9995.2009.02097.x; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; von Bubnoff D, 2002, J IMMUNOL, V169, P1810, DOI 10.4049/jimmunol.169.4.1810; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Xu H, 2008, IMMUNOL LETT, V121, P1, DOI 10.1016/j.imlet.2008.08.008	45	27	28	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1015	1021		10.1016/j.jaci.2011.05.043	http://dx.doi.org/10.1016/j.jaci.2011.05.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21774972				2022-12-18	WOS:000296578200014
J	Loisel, DA; Tan, Z; Tisler, CJ; Evans, MD; Gangnon, RE; Jackson, DJ; Gern, JE; Lemanske, RF; Ober, C				Loisel, Dagan A.; Tan, Zheng; Tisler, Christopher J.; Evans, Michael D.; Gangnon, Ronald E.; Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F.; Ober, Carole			IFNG genotype and sex interact to influence the risk of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IFN-gamma; asthma; children; sex differences; single nucleotide polymorphism; association study	REGULATORY FACTOR-1 POLYMORPHISMS; SINGLE-NUCLEOTIDE POLYMORPHISMS; INTERFERON-GAMMA; GENE POLYMORPHISMS; BETA(2)-ADRENOCEPTOR POLYMORPHISMS; RHINOVIRUS ILLNESSES; CYTOKINE RESPONSES; T-CELLS; ASSOCIATION; ATOPY	Background: Asthma is a complex disease characterized by sex-specific differences in incidence, prevalence, and severity, but little is known about the molecular basis of these sex-based differences. Objective: To investigate the genetic architecture of sex differences in asthma risk, we evaluated (1) associations between polymorphisms in the IFNG gene and childhood-onset asthma in combined and sex-specific samples and (2) interactions between polymorphisms and sex on asthma risk. Methods: Main and sex-interaction effects of IFNG genetic diversity on asthma risk and IFN-gamma levels were examined in a birth cohort of children at high risk for asthma and allergic diseases. Replication of the genetic association was assessed in an independent sample of asthma cases. Results: Significant genotype-sex interactions on asthma were observed for 2 IFNG single nucleotide polymorphisms, rs2069727 and rs2430561, which were in strong linkage disequilibrium with each other. In contrast, none of the 10 IFNG single nucleotide polymorphisms showed significant main effects on asthma. The observed genotype-sex interaction on asthma was characterized by nonadditivity; that is, heterozygous boys had the highest risk for asthma, and heterozygous girls had the lowest risk. The interaction effect was robust to other asthma risk factors but was limited to children who experienced wheezing illnesses with viral infections during the first 3 years of life. Genotype-sex interactions were also observed in the IFN-gamma response to LPS in the first year of life. Finally, the sex-interaction effect was replicated in an independent population of childhood asthma cases. Conclusions: These results provide insight into the genetic basis of sex differences in asthma and highlight the potential importance of interactions among sex, genotype, and environmental factors in asthma pathogenesis. (J Allergy Clin Immunol 2011;128:524-31.)	[Loisel, Dagan A.] Univ Chicago, Dept Human Genet, CLSC, Chicago, IL 60637 USA; [Ober, Carole] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; [Tisler, Christopher J.; Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53706 USA; [Evans, Michael D.; Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53706 USA; [Gangnon, Ronald E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53706 USA; [Lemanske, Robert F.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA	University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Loisel, DA (corresponding author), Univ Chicago, Dept Human Genet, CLSC, Room 431F,920 E 58th St, Chicago, IL 60637 USA.	dloisel@bsd.uchicago.edu		Evans, Michael/0000-0001-7449-3993; Ober, Carole/0000-0003-4626-9809; Gangnon, Ronald/0000-0003-2587-6714	National Institutes of Health [R01 HL61879, P01 HL70831, M01 RR03186, R01 HL085197, M01 RR00055, F32 HL095268, T32 HL007605]; Pharmaxis; American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline; AstraZeneca; Merck; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD061879] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, M01RR003186, M01RR000055] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085197, P01HL070831, R01HL061879, F32HL095268, T32HL007605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061879] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pharmaxis; American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Merck(Merck & Company); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Supported by National Institutes of Health grants R01 HL61879, P01 HL70831, M01 RR03186, R01 HL085197, and M01 RR00055. D. A. L. was supported by National Institutes of Health grants F32 HL095268 and T32 HL007605.; Disclosure of potential conflict of interest: D. J. Jackson has received research support from Pharmaxis, the National Institutes of Health, and the American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline. J. E. Gern is on the scientific advisory board of and holds stock options for 3V Biosciences; has consulted and holds stock options for EraGen Biosciences; has consulted for Synairgen, Boehringer Inhgelheim, Pulmatrix, GlaxoSmithKline, and Biota; and has received research support from AstraZeneca and Merck. R. F. Lemanske, Jr, is a speaker for Merck, Doembecher Children's Hospital, Washington University, the Medicus Group, the Park Nicolet Institute, the ACAAI, the LA Allergy Society, the Michigan Allergy/Asthma Society, the Medical College of Wisconsin, the Fund for Medical Research and Education (Detroit), the Children's Hospital of Minnesota, the Toronto Allergy Society, the AAAAI, Beaumont Hospital, the University of Illinois, the Canadian Society of Allergy and Clinical Immunology, New York Presbyterian, the Med Media Educational Group, Onpointe Medical Communication, the Medical University of South Carolina, Health Matters Communication, Bishop McCann, Donohue Purohit Miller, the Center for Health Care Education, the University of California San Francisco, the American Thoracic Society, the University of Iowa, Indiana University, the American Lung Association of the Upper Midwest, Vanderbilt University, and Rochester Children's Hospital; is a consultant and speaker for AstraZeneca; is a consultant for Map Pharmaceuticals, Gray Consulting, Smith Research, the Merck Childhood Asthma Network, Novartis, Quintiles/Innovax, RC Horowitz & Co, International Meetings and Science, Scienomics, Scientific Therapeutics, Gray Consulting, and Cognimed Inc; is an author of Up-to-Date; and is a textbook Editor for Elsevier. C. Ober receives research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Comings DE, 2000, MOL GENET METAB, V71, P19, DOI 10.1006/mgme.2000.3015; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488; Dillie KTS, 2008, CLIN EXP ALLERGY, V38, P298, DOI 10.1111/j.1365-2222.2007.02891.x; Filigheddu F, 2004, PHARMACOGENOMICS J, V4, P154, DOI 10.1038/sj.tpj.6500247; FOX HS, 1991, J IMMUNOL, V146, P4362; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Gourdy P, 2005, BLOOD, V105, P2415, DOI 10.1182/blood-2004-07-2819; Guerra S, 2005, CHEST, V128, P609, DOI 10.1378/chest.128.2.609; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Haller G, 2009, J ALLERGY CLIN IMMUN, V124, P1204, DOI 10.1016/j.jaci.2009.09.013; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; Hong MG, 2008, HUM MOL GENET, V17, P2370, DOI 10.1093/hmg/ddn137; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Hutchings A, 2002, PEDIATR TRANSPLANT, V6, P69, DOI 10.1034/j.1399-3046.2002.1o444.x; Matos GI, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-33; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2009, J ALLERGY CLIN IMMUN, V124, P949, DOI 10.1016/j.jaci.2009.07.024; Karjalainen J, 2002, J ALLERGY CLIN IMMUN, V109, P514, DOI 10.1067/mai.2002.121948; Kulig M, 1999, J PEDIATR-US, V134, P453, DOI 10.1016/S0022-3476(99)70203-9; Kumar A, 2008, GENES IMMUN, V9, P294, DOI 10.1038/gene.2008.17; Kynyk JA, 2011, CURR OPIN PULM MED, V17, P6, DOI 10.1097/MCP.0b013e3283410038; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413, DOI 10.1164/ajrccm.156.5.9701060; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Li YF, 2007, RESP MED, V101, P1977, DOI 10.1016/j.rmed.2007.04.006; Lopez-Maderuelo D, 2003, AM J RESP CRIT CARE, V167, P970, DOI 10.1164/rccm.200205-438BC; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Nakao F, 2001, J ALLERGY CLIN IMMUN, V107, P499, DOI 10.1067/mai.2001.113051; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Ober C, 2011, TRENDS GENET, V27, P107, DOI 10.1016/j.tig.2010.12.004; Pravica V, 2000, HUM IMMUNOL, V61, P863, DOI 10.1016/S0198-8859(00)00167-1; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Santillan AA, 2003, J ALLERGY CLIN IMMUN, V112, P1095, DOI 10.1016/j.jaci.2003.09.029; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Seibold MA, 2008, HUM MOL GENET, V17, P2681, DOI 10.1093/hmg/ddn168; Shao CC, 2004, J HUM GENET, V49, P115, DOI 10.1007/s10038-003-0118-z; SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Tso HW, 2005, GENES IMMUN, V6, P358, DOI 10.1038/sj.gene.6364189; Uekert SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1375, DOI 10.1016/j.jaci.2006.09.008; Vandenbroeck K, 2003, TRENDS PHARMACOL SCI, V24, P284, DOI 10.1016/S0165-6147(03)00131-7; Vink NM, 2010, J ALLERGY CLIN IMMUN, V126, P498, DOI 10.1016/j.jaci.2010.06.018; Vollmer-Conna U, 2008, CLIN INFECT DIS, V47, P1418, DOI 10.1086/592967; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; Wang TN, 2006, CLIN EXP ALLERGY, V36, P1147, DOI 10.1111/j.1365-2222.2006.02551.x; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104; Yao WG, 2010, J ALLERGY CLIN IMMUN, V126, P483, DOI 10.1016/j.jaci.2010.06.028	56	27	29	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					524	531		10.1016/j.jaci.2011.06.016	http://dx.doi.org/10.1016/j.jaci.2011.06.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21798578	Green Accepted			2022-12-18	WOS:000294283400010
J	Ozcan, E; Rauter, I; Garibyan, L; Dillon, SR; Geha, RS				Ozcan, Esra; Rauter, Ingrid; Garibyan, Lilit; Dillon, Stacey R.; Geha, Raif S.			Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Toll-like receptor 9; CD40; transmembrane activator and calcium-modulating cyclophilin ligand interactor; class-switch recombination; plasma cell; immunoglobulin; B cells	COMMON VARIABLE IMMUNODEFICIENCY; FAMILY-MEMBERS BAFF; DENDRITIC CELLS; T-BET; EXPRESSION; TACI; APRIL; MICE; TLR9; DEFICIENT	Background: B cells receive activating signals from T cells through CD40, from microbial DNA through Toll-like receptor (TLR) 9, and from dendritic cells through transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI). TLR9 and CD40 ligation augment TACI-driven B-cell activation, but only the mechanism of synergy between CD40 and TACI has been explored. Synergy between CD40 and TLR9 in B-cell activation is controversial. Objective: We sought to examine the mechanisms by which TLR9 modulates CD40-and TACI-mediated activation of B cells and to determine whether all 3 receptors synergize to activate B cells. Methods: Naive murine B cells and human PBMCs were stimulated with combinations of anti-CD40, CpG, and a proliferation inducing ligand in the presence of IL-4. Proliferation was measured by means of tritiated thymidine incorporation. Immunoglobulin production was measured by means of ELISA. Class-switch recombination (CSR) was examined by measuring mRNA for germline transcripts, activation-induced cytidine deaminase (AICDA), and mature immunoglobulin transcripts. Plasma cell differentiation was examined by using syndecan-1/CD138 staining and mRNA expression of B lymphocyte-induced maturation protein 1 (Blimp-1). Results: TLR9 synergized with CD40 and TACI in driving CSR and inducing IgG(1) and IgE secretion by naive murine B cells and synergized with TACI in driving B-cell proliferation and plasma cell differentiation. All 3 receptors synergized together in driving murine B-cell proliferation, CSR, plasma cell differentiation, and IgG(1) and IgE secretion. TLR9 synergized with CD40 and TACI in driving IgG secretion in IL-4-stimulated human B cells. Conclusion: Signals from TLR9, TACI, and CD40 are integrated to promote B-cell activation and differentiation. (J Allergy Clin Immunol 2011;128:601-9.)	[Ozcan, Esra; Rauter, Ingrid; Garibyan, Lilit; Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Ozcan, Esra; Rauter, Ingrid; Garibyan, Lilit; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Dillon, Stacey R.] Zymogenet Inc, Seattle, WA 98105 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Zymogenet Inc.	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 1 Blackfan Circle, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu	Garibyan, Lilit/AAR-1638-2020		March of Dimes [6-FY07-285]; National Institutes of Health [AI-031541]; ZymoGenetics (BMS); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI031541, U19AI031541, R01AI031136, U01AI031541] Funding Source: NIH RePORTER	March of Dimes(March of Dimes); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ZymoGenetics (BMS); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by March of Dimes grant no. 6-FY07-285 and National Institutes of Health grant AI-031541.; Disclosure of potential conflict of interest: S. R. Dillon is employed by and has received research support from ZymoGenetics (BMS). The rest of the authors have declared that they have no conflict of interest.	Acosta-Rodriguez EV, 2007, EUR J IMMUNOL, V37, P990, DOI 10.1002/eji.200636698; Badr G, 2008, BLOOD, V111, P2744, DOI 10.1182/blood-2007-03-081232; Bauer S, 2009, ADV EXP MED BIOL, V653, P15; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; Brugnoni D, 1996, PEDIATR ALLERGY IMMU, V7, P176, DOI 10.1111/j.1399-3038.1996.tb00129.x; Brummel R, 2005, J IMMUNOL, V174, P2429, DOI 10.4049/jimmunol.174.4.2429; Buhtoiarov IN, 2006, J IMMUNOL, V176, P309, DOI 10.4049/jimmunol.176.1.309; Carpenter EL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-93; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; Castigli E, 2007, J ALLERGY CLIN IMMUN, V120, P885, DOI 10.1016/j.jaci.2007.06.012; Cunningham-Rundles C, 2006, J IMMUNOL, V176, P1978, DOI 10.4049/jimmunol.176.3.1978; Dedeoglu F, 2004, INT IMMUNOL, V16, P395, DOI 10.1093/intimm/dxh042; Diehl SA, 2008, J IMMUNOL, V180, P4805, DOI 10.4049/jimmunol.180.7.4805; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; Ferrari S, 2001, P NATL ACAD SCI USA, V98, P12614, DOI 10.1073/pnas.221456898; Fuhler GM, 2010, EXP CELL RES, V316, P1816, DOI 10.1016/j.yexcr.2010.03.013; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; FULEIHAN R, 1993, CURR OPIN IMMUNOL, V5, P963, DOI 10.1016/0952-7915(93)90113-7; Gantner F, 2003, EUR J IMMUNOL, V33, P1576, DOI 10.1002/eji.200323444; Hasbold J, 1998, EUR J IMMUNOL, V28, P1040, DOI 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0; He B, 2004, J IMMUNOL, V173, P4479, DOI 10.4049/jimmunol.173.7.4479; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Jiang W, 2007, EUR J IMMUNOL, V37, P2205, DOI 10.1002/eji.200636984; Kanswal S, 2008, J IMMUNOL, V181, P976, DOI 10.4049/jimmunol.181.2.976; Katsenelson N, 2007, EUR J IMMUNOL, V37, P1785, DOI 10.1002/eji.200636800; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kortylewski M, 2009, CANCER RES, V69, P2497, DOI 10.1158/0008-5472.CAN-08-3031; Lee JJ, 2009, BLOOD, V114, P2254, DOI 10.1182/blood-2008-11-189720; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Liu NS, 2003, NAT IMMUNOL, V4, P687, DOI 10.1038/ni941; Mackay F, 2003, CYTOKINE GROWTH F R, V14, P311, DOI 10.1016/S1359-6101(03)00023-6; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Ozcan E, 2009, J ALLERGY CLIN IMMUN, V123, P1277, DOI 10.1016/j.jaci.2009.03.019; Peng SL, 2003, NAT IMMUNOL, V4, P1041, DOI 10.1038/ni1103-1041a; ROTHMAN P, 1990, INT IMMUNOL, V2, P621, DOI 10.1093/intimm/2.7.621; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Sousa CR, 2003, PATHOL BIOL, V51, P67, DOI 10.1016/S0369-8114(03)00099-3; Taubenheim N, 2005, J IMMUNOL, V175, P5498, DOI 10.4049/jimmunol.175.8.5498; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Vinuesa CG, 2010, IMMUNOL REV, V237, P72, DOI 10.1111/j.1600-065X.2010.00937.x; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Xu SL, 2001, MOL CELL BIOL, V21, P4067, DOI 10.1128/MCB.21.12.4067-4074.2001; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790; Yu JE, 2009, J ALLERGY CLIN IMMUN, V124, P349, DOI 10.1016/j.jaci.2009.05.019; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	52	27	27	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					601	U252		10.1016/j.jaci.2011.04.052	http://dx.doi.org/10.1016/j.jaci.2011.04.052			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21741080	Green Accepted			2022-12-18	WOS:000294283400020
J	Schroer, KT; Gibson, AM; Sivaprasad, U; Bass, SA; Ericksen, MB; Wills-Karp, M; LeCras, T; Fitzpatrick, AM; Brown, LAS; Stringer, KF; Hershey, GKK				Schroer, Kathy T.; Gibson, Aaron M.; Sivaprasad, Umasundari; Bass, Stacey A.; Ericksen, Mark B.; Wills-Karp, Marsha; LeCras, Tim; Fitzpatrick, Anne M.; Brown, Lou Ann S.; Stringer, Keith F.; Hershey, Gurjit K. Khurana			Downregulation of glutathione S-transferase pi in asthma contributes to enhanced oxidative stress	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Glutathione S-transferase pi; asthma; oxidative stress; redox homeostasis; gene	CYSTEINE/CYSTINE REDOX STATE; GENE-EXPRESSION; TRANSCRIPTION FACTOR; ALLERGIC RESPONSES; REAL-TIME; LUNG; NRF2; P1; CHILDHOOD; MICE	Background: Glutathione S-transferase pi (GSTPi) is the predominant redox regulator in the lung. Although evidence implicates an important role for GSTPi in asthma, the mechanism for this has remained elusive. Objectives: We sought to determine how GSTPi is regulated in asthma and to elucidate its role in maintaining redox homeostasis. Methods: We elucidated the regulation of GSTPi in children with asthma and used murine models of asthma to determine the role of GSTPi in redox homeostasis. Results: Our findings demonstrate that GSTPi transcript levels are markedly downregulated in allergen-and IL-13-treated murine models of asthma through signal transducer and activator of transcription 6-dependent and independent pathways. Nuclear factor erythroid 2-related factor 2 was also downregulated in these models. The decrease in GSTPi expression was associated with decreased total glutathione S-transferase activity in the lungs of mice. Examination of cystine intermediates uncovered a functional role for GSTPi in regulating cysteine oxidation, whereby GSTPi-deficient mice exhibited increased oxidative stress (increase in percentage cystine) compared with wild-type mice after allergen challenge. GSTPi expression was similarly downregulated in children with asthma. Conclusions: These data collectively suggest that downregulation of GSTPi after allergen challenge might contribute to the asthma phenotype because of disruption of redox homeostasis and increased oxidative stress. Furthermore, GSTPi might be an important therapeutic target for asthma, and evaluation of GSTPi expression might prove beneficial in identifying patients who would benefit from therapy targeting this pathway. (J Allergy Clin Immunol 2011;128:539-48.)	[Schroer, Kathy T.; Gibson, Aaron M.; Sivaprasad, Umasundari; Bass, Stacey A.; Ericksen, Mark B.; Wills-Karp, Marsha; LeCras, Tim; Stringer, Keith F.; Hershey, Gurjit K. Khurana] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Dept Pediat, Cincinnati, OH 45221 USA; [Fitzpatrick, Anne M.; Brown, Lou Ann S.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Emory University	Hershey, GKK (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Dept Pediat, Cincinnati, OH 45221 USA.	Gurjit.Khurana.Hershey@cchmc.org		Le Cras, Timothy/0000-0001-8538-2703; Fitzpatrick, Anne/0000-0002-2933-5926	National Institutes of Health [U19A170235]; American Heart Association; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant U19A170235 (G. K. K. H.).; Disclosure of potential conflict of interest: T. LeCras receives research support from the National Institutes of Health (NIH) and the American Heart Association. A. M. Fitzpatrick receives research support from the NIH; the National Heart, Lung, and Blood Institute; and the National Institute of Nursing Research. G. K. K. Hershey receives research support from the NIH. The rest of the authors have declared that they have no conflict of interest.	Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Bauer M, 2006, CELL TISSUE RES, V324, P423, DOI 10.1007/s00441-005-0150-8; Bloom Barbara, 2006, Vital Health Stat 10, P1; Chen WG, 2009, J IMMUNOL, V183, P7870, DOI 10.4049/jimmunol.0901028; Conklin DJ, 2009, AM J PHYSIOL-HEART C, V296, pH1586, DOI 10.1152/ajpheart.00867.2008; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Diaz-Sanchez D, 2005, AM J PHYSIOL-LUNG C, V289, pL722, DOI 10.1152/ajplung.00217.2005; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Guajardo JR, 2005, J ALLERGY CLIN IMMUN, V115, P243, DOI 10.1016/j.jaci.2004.10.032; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Ikeda H, 2002, BIOCHEM J, V364, P563, DOI 10.1042/BJ20011756; Iyer SS, 2009, AM J RESP CELL MOL, V40, P90, DOI 10.1165/rcmb.2007-0447OC; Iyer SS, 2009, AM J PHYSIOL-LUNG C, V296, pL37, DOI 10.1152/ajplung.90401.2008; Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865; Jussila J, 2001, TOXICOL APPL PHARM, V171, P61, DOI 10.1006/taap.2000.9116; KANO T, 1987, CANCER RES, V47, P5626; Knight TR, 2007, TOXICOL SCI, V100, P513, DOI 10.1093/toxsci/kfm233; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Larsson ML, 2001, CHEST, V120, P711, DOI 10.1378/chest.120.3.711; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Lowry MH, 2008, AM J RESP CELL MOL, V38, P509, DOI 10.1165/rcmb.2007-0128OC; Malaviya R, 2002, J IMMUNOL, V168, P421, DOI 10.4049/jimmunol.168.1.421; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Michel S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013894; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; OWEN S, 1991, NEW ENGL J MED, V325, P586; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rasmi Y, 2006, CLIN BIOCHEM, V39, P997, DOI 10.1016/j.clinbiochem.2006.06.010; Ruiz-Laguna J, 2006, ENVIRON SCI TECHNOL, V40, P3646, DOI 10.1021/es060056e; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schroer KT, 2009, J PEDIATR-US, V154, P401, DOI 10.1016/j.jpeds.2008.08.040; Schroer KT, 2009, J PEDIAT, V154, pe1; Sharma P, 2008, IMMUNITY, V29, P551, DOI 10.1016/j.immuni.2008.07.019; Tabata Y, 2006, J IMMUNOL, V177, P7905, DOI 10.4049/jimmunol.177.11.7905; Tamer L, 2004, RESPIROLOGY, V9, P493, DOI 10.1111/j.1440-1843.2004.00657.x; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161, DOI 10.1164/ajrccm/146.5_Pt_1.1161; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; Walters DM, 2002, AM J RESP CELL MOL, V27, P413, DOI 10.1165/rcmb.4844; Watanabe T, 2009, MUTAT RES-GEN TOX EN, V673, P9, DOI 10.1016/j.mrgentox.2008.11.004; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yeh MY, 2008, RESP MED, V102, P248, DOI 10.1016/j.rmed.2007.09.005; Zhou J, 2008, AM J RESP CRIT CARE, V178, P1202, DOI 10.1164/rccm.200801-178OC; Zimmermann N, 2005, AM J RESP CELL MOL, V32, P428, DOI 10.1165/rcmb.2004-0269OC	53	27	27	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					539	548		10.1016/j.jaci.2011.04.018	http://dx.doi.org/10.1016/j.jaci.2011.04.018			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21570714	Green Accepted			2022-12-18	WOS:000294283400012
J	Maarof, G; Krzysiek, R; Decline, JL; Cohen, J; Habes, D; Jacquemin, E				Maarof, Ghyath; Krzysiek, Roman; Decline, Jean-Luc; Cohen, Joseph; Habes, Dalila; Jacquemin, Emmanuel			Management of post-liver transplant-associated IgE-mediated food allergy in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TACROLIMUS		[Maarof, Ghyath; Krzysiek, Roman] Univ Paris 11, Hop Antoine Beclere, INSERM, U996,Serv Microbiol Immunol Biol, Clamart, France; [Maarof, Ghyath; Krzysiek, Roman] CHU Antoine Beclere, AP HP, Clamart, France; [Maarof, Ghyath] Univ Tishreen, Fac Med, Latakia, Syria; [Decline, Jean-Luc; Cohen, Joseph; Habes, Dalila; Jacquemin, Emmanuel] Univ Paris 11, Serv Hepatol Pediat, CHU Bicetre, AP HP, Le Kremlin Bicetre, France; [Decline, Jean-Luc; Cohen, Joseph; Habes, Dalila; Jacquemin, Emmanuel] Univ Paris 11, Ctr Reference Natl Atresie Voies Biliaires, CHU Bicetre, AP HP, Le Kremlin Bicetre, France; [Jacquemin, Emmanuel] Univ Paris 11, INSERM, U757, F-91405 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Maarof, G (corresponding author), Univ Paris 11, Hop Antoine Beclere, INSERM, U996,Serv Microbiol Immunol Biol, Clamart, France.	emmanuel.jacquemin@bct.aphp.fr	jacquemin, emmanuel/J-8673-2013					de Herve MGD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011784; Gabe SM, 1998, GASTROENTEROLOGY, V115, P67, DOI 10.1016/S0016-5085(98)70366-X; Granot E, 2006, PEDIATR TRANSPLANT, V10, P690, DOI 10.1111/j.1399-3046.2006.00542.x; Kelly D, 2004, LANCET, V364, P1054, DOI 10.1016/S0140-6736(04)17060-8; Legendre C, 1997, NEW ENGL J MED, V337, P822, DOI 10.1056/NEJM199709183371204; Lykavieris P, 2003, TRANSPLANTATION, V75, P152, DOI 10.1097/00007890-200301150-00027; Neu J, 2007, NUTR REV, V65, P282, DOI [10.1301/nr.2007.jun.282-285, 10.1111/j.1753-4887.2007.tb00305.x]; Ozbek OY, 2009, PEDIATR ALLERGY IMMU, V20, P741, DOI 10.1111/j.1399-3038.2009.00867.x; Sugiyama M, 2004, SCAND J RHEUMATOL, V33, P108, DOI 10.1080/03009740310004351; Tsuda M, 2010, IMMUNOL LETT, V132, P45, DOI 10.1016/j.imlet.2010.05.007; Wang Z, 2009, INT IMMUNOPHARMACOL, V9, P564, DOI 10.1016/j.intimp.2009.01.029	11	27	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1296	1298		10.1016/j.jaci.2010.12.1094	http://dx.doi.org/10.1016/j.jaci.2010.12.1094			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21310473				2022-12-18	WOS:000290018600027
J	Vereda, A; Sirvent, S; Villalba, M; Rodriguez, R; Cuesta-Herranz, J; Palomares, O				Vereda, Andrea; Sirvent, Sofia; Villalba, Mayte; Rodriguez, Rosalia; Cuesta-Herranz, Javier; Palomares, Oscar			Improvement of mustard (Sinapis alba) allergy diagnosis and management by linking clinical features and component-resolved approaches	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECOMBINANT PRODUCTION; PROTEIN; CLONING; SEEDS		[Vereda, Andrea; Cuesta-Herranz, Javier] Univ Complutense Madrid, Serv Alergia, Fdn Jimenez Diaz, Madrid, Spain; [Sirvent, Sofia; Villalba, Mayte; Rodriguez, Rosalia; Palomares, Oscar] Univ Complutense Madrid, Fac Quim, Dept Bioquim & Biol Mol, Madrid, Spain	Complutense University of Madrid; Complutense University of Madrid	Vereda, A (corresponding author), Univ Complutense Madrid, Serv Alergia, Fdn Jimenez Diaz, Madrid, Spain.	oscar.palomares@quim.ucm.es	Palomares, Oscar/ABG-5229-2020; Villalba, Mayte/K-5365-2014; Sirvent, Sofia/L-4339-2014; RODRIGUEZ, ROSALIA/K-4993-2014; Villalba, María Teresa/AAW-1067-2020	RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Villalba, María Teresa/0000-0002-0042-9953; Palomares, Oscar/0000-0003-4516-0369				Bublin M, 2010, J ALLERGY CLIN IMMUN, V125, P687, DOI 10.1016/j.jaci.2009.10.017; Caballero T, 2002, ANN ALLERG ASTHMA IM, V89, P166, DOI 10.1016/S1081-1206(10)61933-3; Palacin A, 2006, J ALLERGY CLIN IMMUN, V117, P1423, DOI 10.1016/j.jaci.2006.01.026; Palomares O, 2005, INT ARCH ALLERGY IMM, V137, P18, DOI 10.1159/000084609; Palomares O, 2008, NEW ENGL J MED, V358, P1306, DOI 10.1056/NEJMc0707778; Palomares O, 2007, J ALLERGY CLIN IMMUN, V119, P1189, DOI 10.1016/j.jaci.2007.01.027; Rance F, 2000, ALLERGY, V55, P496, DOI 10.1034/j.1398-9995.2000.00383.x; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sirvent S, 2009, CLIN EXP ALLERGY, V39, P1929, DOI 10.1111/j.1365-2222.2009.03382.x	9	27	27	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1304	1307		10.1016/j.jaci.2011.01.020	http://dx.doi.org/10.1016/j.jaci.2011.01.020			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21349575				2022-12-18	WOS:000290018600031
J	Wan, YZI; Strachan, DP; Evans, DM; Henderson, J; McKeever, T; Holloway, JW; Hall, IP; Sayers, I				Wan, Yize I.; Strachan, David P.; Evans, David M.; Henderson, John; McKeever, Tricia; Holloway, John W.; Hall, Ian P.; Sayers, Ian			A genome-wide association study to identify genetic determinants of atopy in subjects from the United Kingdom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; specific IgE; skin prick test; genome-wide association study; British 1958 Birth Cohort	CHROMOSOME 13Q14; BIRTH COHORT; IGE LEVELS; ASTHMA; CHILDHOOD; VARIANTS; LOCUS; POLYMORPHISMS; SENSITIZATION; LINKAGE	Background: A genetic component in the development of atopy has been identified. However, numerous heritability models have been proposed with inconsistent replication of susceptibility loci and genes. Objective: We sought to use a genome-wide association study approach to examine genetic susceptibility to atopy, which was defined as increased specific IgE levels, positive skin prick test (SPT) responses, or both, within a large discovery cohort and 3 additional white populations. Methods: Single nucleotide polymorphisms (SNPs) across the genome were tested for association with increased specific IgE levels (>= 0.35 kU(A)/L) in the British 1958 Birth Cohort (1083 cases and 2770 control subjects; Illumina 550K Array) to 1 or more allergens, including house dust mite (Der p 1), mixed grass, or cat fur. Independent replication of identified loci (P <= .05) was assessed in 3 case-control cohorts from the United Kingdom (n = 3225). Combined analyses of data for top signals across cohorts were conducted for atopic phenotypes: increased specific IgE levels (1378 cases and 3151 control subjects) and positive SPT responses (1058 cases and 2167 control subjects). Results: A single SNP on chromosome 13q14 met genome-wide significance (P = 2.15 x 10(-9)), and a further 6 loci (4.50 x 10(-7) <= P <= 5.00 x 10(-5)) showed weaker evidence for association with increased specific IgE levels in the British 1958 Birth Cohort. However, no SNPs studied showed consistent association with atopy defined by increased specific IgE levels, positive SPT responses, or both in all study cohorts. Conclusions: Seven putative atopy loci were identified using a genome-wide association study approach but showed limited replication across several white populations. This study suggests that large-scale analyses with results from multiple populations will be needed to reliably identify key genetic factors underlying atopy predisposition. (J Allergy Clin Immunol 2011;127:223-31.)	[Wan, Yize I.; Hall, Ian P.; Sayers, Ian] Univ Nottingham Hosp, Div Therapeut & Mol Med, Nottingham Resp Biomed Res Unit, Nottingham NG7 2UH, England; [Strachan, David P.] St Georges Med Sch, Div Community Hlth Sci, London, England; [Evans, David M.] Univ Bristol, Dept Social Med, Bristol, Avon, England; [Henderson, John] Univ Bristol, Dept Community Based Med, Bristol, Avon, England; [McKeever, Tricia] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Holloway, John W.] Univ Southampton, Sch Med, Div Human Genet, Southampton, Hants, England; [Holloway, John W.] Univ Southampton, Sch Med, Div Infect Inflammat & Immun, Southampton, Hants, England	University of Nottingham; St Georges University London; University of Bristol; University of Bristol; University of Nottingham; University of Southampton; University of Southampton	Wan, YZI (corresponding author), Univ Nottingham Hosp, Div Therapeut & Mol Med, Nottingham Resp Biomed Res Unit, Nottingham NG7 2UH, England.	msxyw@nottingham.ac.uk	Holloway, John W/B-5424-2009; Evans, David M/H-6325-2013	Holloway, John W/0000-0001-9998-0464; Evans, David M/0000-0003-0663-4621; Hall, Ian/0000-0001-9933-3216; Sayers, Ian/0000-0001-5601-5410	Medical Research Council [G0000934]; Wellcome Trust [068545/Z/02, 079895]; Juvenile Diabetes Research Foundation International; National Institute for Health Research Cambridge Biomedical Research Centre; Asthma UK; British Lung Foundation; Asthma, Allergy, and Inflammation Research (AAIR); Medical Research Council (UK);  [U01 DK062418]; Medical Research Council [G0600705, G0800582, G1001799, G9815508] Funding Source: researchfish; Asthma UK [05/055] Funding Source: researchfish; MRC [G1001799, G0600705, G0800582, G0000934] Funding Source: UKRI; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK062418] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Asthma UK; British Lung Foundation; Asthma, Allergy, and Inflammation Research (AAIR); Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection, funded by Medical Research Council grant G0000934 and Wellcome Trust grant 068545/Z/02 (http://www.b58cgene.sgul.ac.uk/). This analysis uses genotype data deposited by the Wellcome Trust Sanger Institute and by the Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research, University of Cambridge, which is funded by the Juvenile Diabetes Research Foundation International, the Wellcome Trust, and the National Institute for Health Research Cambridge Biomedical Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award (079895). The British 1958 Birth Cohort genotypes deposited by DIL were generated by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Allergy and Infectious Diseases (NIAID), the National Human Genome Research Institute (NHGRI), the National Institute of Child Health and Human Development (NICHD), and the Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children Cohort. The Nottingham Gedling cohort collection was funded by Asthma UK and the British Lung Foundation. The Southampton cohort is supported by Asthma, Allergy, and Inflammation Research (AAIR).; J. Henderson receives research support from the Medical Research Council (UK). I. P. Hall receives research support from Asthma UK. The rest of the authors have declared that they have no conflict of interest.	Anderson GG, 2002, EUR J HUM GENET, V10, P266, DOI 10.1038/sj.ejhg.5200801; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chen JJ, 2006, J INVEST DERMATOL, V126, P300, DOI 10.1038/sj.jid.5700103; Ciullo M, 2006, HUM MOL GENET, V15, P1735, DOI 10.1093/hmg/ddl097; Coca AF, 1923, J IMMUNOL, V8, P163; Cooke RA, 1916, J IMMUNOL, V1, P201; Denham S, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-38; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Fukai H, 2004, PHARMACOGENETICS, V14, P683, DOI 10.1097/00008571-200410000-00006; Gauderman W, 2009, QUANTO 1 1 COMPUTER; Gusareva ES, 2009, IMMUNOGENETICS, V61, P15, DOI 10.1007/s00251-008-0343-x; Hall IP, 2006, LANCET, V368, P771, DOI 10.1016/S0140-6736(06)69287-8; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Jackola DR, 2002, MOL IMMUNOL, V39, P367, DOI 10.1016/S0161-5890(02)00108-6; Jang N, 2005, GENES IMMUN, V6, P262, DOI 10.1038/sj.gene.6364169; Lesueur F, 2007, J INVEST DERMATOL, V127, P1403, DOI 10.1038/sj.jid.5700749; Li Y, 2006, AM J HUM GENET S, VS79, P2290; Maier LM, 2006, J ALLERGY CLIN IMMUN, V117, P1306, DOI 10.1016/j.jaci.2005.12.1354; McKeever TM, 2002, AM J RESP CRIT CARE, V165, P1299, DOI 10.1164/rccm.2109030; MEYERS DA, 1995, CLIN EXP ALLERGY, V25, P113, DOI 10.1111/j.1365-2222.1995.tb00437.x; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Perkin MR, 2006, PEDIAT ALLERG IMM-UK, V17, P118, DOI 10.1111/j.1399-3038.2005.00364.x; Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Sanak Marek, 2007, Allergol Int, V56, P397, DOI 10.2332/allergolint.R-07-145; Sayers I, 2003, THORAX, V58, P417, DOI 10.1136/thorax.58.5.417; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Strachan DR, 2001, J ALLERGY CLIN IMMUN, V108, P901, DOI 10.1067/mai.2001.119408; Timpson NJ, 2009, HUM MOL GENET, V18, P1510, DOI 10.1093/hmg/ddp052; Tremblay K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002907; Ueno H, 2003, NAT IMMUNOL, V4, P457, DOI 10.1038/ni916; Valacer DJ, 2000, DRUGS, V59, P1, DOI 10.2165/00003495-200059001-00001; Valacer DJ, 2000, DRUGS, V59, P1; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wills-Karp M, 2004, NAT REV GENET, V5, P376, DOI 10.1038/nrg1326; Wright AF, 1999, NAT GENET, V23, P397, DOI 10.1038/70501	40	27	27	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					223	U358		10.1016/j.jaci.2010.10.006	http://dx.doi.org/10.1016/j.jaci.2010.10.006			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21094521				2022-12-18	WOS:000285917300032
J	Hong, XM; Tsai, HJ; Liu, X; Arguelles, L; Kumar, R; Wang, GY; Kuptsova-Clarkson, N; Pearson, C; Ortiz, K; Bonzagni, A; Apollon, S; Fu, LL; Pongracic, JA; Schleimer, R; Holt, PG; Bauchner, H; Wang, XB				Hong, Xiumei; Tsai, Hui-Ju; Liu, Xin; Arguelles, Lester; Kumar, Rajesh; Wang, Guoying; Kuptsova-Clarkson, Nataliya; Pearson, Colleen; Ortiz, Kathryn; Bonzagni, Anthony; Apollon, Stephanie; Fu, Lingling; Pongracic, Jacqueline A.; Schleimer, Robert; Holt, Patrick G.; Bauchner, Howard; Wang, Xiaobin			Does genetic regulation of IgE begin in utero? Evidence from T(H)1/T(H)2 gene polymorphisms and cord blood total IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Genetic association; candidate gene; cord blood IgE; gene-gene interaction	SERUM IMMUNOGLOBULIN-E; GERMAN MULTICENTER ATOPY; ENVIRONMENTAL ALLERGENS; SIGNAL-TRANSDUCTION; INHALANT ALLERGENS; ASSOCIATION; ASTHMA; SENSITIZATION; VARIANTS; CHILDREN	Background: Elucidation of early life factors is critical to understand the development of allergic diseases, especially those manifesting in early life such as food allergies and atopic dermatitis. Cord blood IgE (CBIgE) is a recognized risk factor for the subsequent development of allergic diseases. In contrast with numerous genetic studies of total serum IgE in children and adults, limited genetic studies on CBIgE have been conducted. Objective: To test the associations between functional or tagging single nucleotide polymorphisms (SNPs) in genes involved in the T(H)1/T(H)2 pathway and CBIgE in a large US inner-city birth cohort. Methods: CBIgE, measured by Phadia ImmnunoCAP, was analyzed as a continuous and a binary variable. The association of each SNP with the 2 outcomes was tested using tobit and logistic regression models, respectively, with adjustment for pertinent covariates, ancestral proportion, and multiple testing. Ethnic heterogeneity and gene-gene interactions were also explored. Results: Three SNPs (rs1800925, rs2069743, and rs1295686) in the IL13 gene were significantly associated with CBIgE concentration (P <= 6 x 10(-4), FDR-corrected P < .05). These SNPs jointly influenced CBIgE in a dose-response manner (P for trend = 9 x 10(-8)). Significant associations also were observed for SNPs in the IL-13 receptor alpha 1 (rs5956080) and signal transducer and activator of transcription 6 (rs11172106) genes. Ethnicity-specific genetic effects were observed for SNPs in the IL5 and GATA3 genes. Several gene-gene interactions (including IL13-IL4 receptor and IL13-signal transducer and activator of transcription 6 interactions) were detected in relation to CBIgE. Conclusion: Our data demonstrated that multiple SNPs were individually and jointly associated with CBIgE, with evidence of gene-gene interactions and ethnic heterogeneity. These findings suggest that genetic regulation of IgE may begin in utero. (J Allergy Clin Immunol 2010;126:1059-67.)	[Wang, Xiaobin] Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60614 USA; [Hong, Xiumei; Tsai, Hui-Ju; Liu, Xin; Arguelles, Lester; Wang, Guoying; Kuptsova-Clarkson, Nataliya; Wang, Xiaobin] Childrens Mem Hosp, Childrens Mem Res Ctr, Chicago, IL 60614 USA; [Kumar, Rajesh; Pongracic, Jacqueline A.] Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Tsai, Hui-Ju] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan; [Pearson, Colleen; Ortiz, Kathryn; Bonzagni, Anthony; Apollon, Stephanie; Fu, Lingling; Bauchner, Howard] Boston Univ, Sch Med, Dept Pediat, Chicago, IL USA; [Pearson, Colleen; Ortiz, Kathryn; Bonzagni, Anthony; Apollon, Stephanie; Fu, Lingling] Boston Med Ctr, Chicago, IL USA; [Schleimer, Robert] Northwestern Univ, Div Allergy Immunol, Feinberg Sch Med, Chicago, IL 60614 USA; [Holt, Patrick G.] Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA, Australia	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; National Health Research Institutes - Taiwan; Boston University; Northwestern University; Feinberg School of Medicine; Telethon Kids Institute; University of Western Australia	Wang, XB (corresponding author), Northwestern Univ, Childrens Mem Hosp, Feinberg Sch Med, Mary Ann & J Milburn Smith Child Hlth Res Program, 2300 Childrens Plaza,Box 157, Chicago, IL 60614 USA.	xbwang@childrensmemorial.org	Tsai, Hui-Ju/E-3937-2010; Wang, Guoying/F-8908-2011; Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935; Bauchner, Howard/0000-0002-8368-9805; Kumar, Rajesh/0000-0002-1962-7108	March of Dimes [20-FY02-56]; NIEHS [R21 ES011666]; NICHD [R01 HD041702]; Food Allergy Initiative; NIAID [R21AI079872, R21AI087888]; NHLBI [K23HL093023]; National Institutes of Health/Clinical and Translational Science Awards Program, Northwestern University [KL2RR025740]; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Food Allergy Project; National Institutes of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD041702] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741, KL2RR025740] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL093023] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072570, R21AI079872, R21AI087888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES011666] Funding Source: NIH RePORTER	March of Dimes(March of Dimes); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Food Allergy Initiative; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health/Clinical and Translational Science Awards Program, Northwestern University(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Food Allergy Project; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The parent study is supported in part by the March of Dimes PERI grants (PI: X.W., 20-FY02-56), NIEHS (PI: X.W., R21 ES011666), and NICHD (PI: X.W., R01 HD041702). The follow-up study is supported in part by the Food Allergy Initiative and NIAID (PI: X.W., R21AI079872). R.K. is supported by the NHLBI (K23HL093023). X.L. has been supported by a career development award from the National Institutes of Health/Clinical and Translational Science Awards Program, Northwestern University (KL2RR025740). X.L. also is supported by an NIAID grant (R21AI087888).; R. Kumar has received research support from the National Heart, Lung, and Blood Institute. J. A. Pongracic has received research support from the National Institute of Allergy and Infectious Diseases and the Food Allergy Project. R. Schleimer has received research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Battle NC, 2007, AM J RESP CRIT CARE, V175, P881, DOI 10.1164/rccm.200607-992OC; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERGMANN RL, 1995, ALLERGY, V50, P65, DOI 10.1111/j.1398-9995.1995.tb02484.x; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Chan IHS, 2006, J ALLERGY CLIN IMMUN, V117, P127, DOI 10.1016/j.jaci.2005.09.031; Chang JC, 2004, PEDIAT ALLERG IMM-UK, V15, P506, DOI 10.1111/j.1399-3038.2004.00161.x; Chen CM, 2009, ALLERGY, V64, P1327, DOI 10.1111/j.1398-9995.2009.02005.x; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Holt PG, 2008, J ALLERGY CLIN IMMUN, V122, P717, DOI 10.1016/j.jaci.2008.08.019; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; Jacobsen HP, 2001, J ALLERGY CLIN IMMUN, V107, P659; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lee PH, 2009, BIOINFORMATICS, V25, P1048, DOI 10.1093/bioinformatics/btp103; Liu X, 2004, J ALLERGY CLIN IMMUN, V113, P489, DOI 10.1016/j.jaci.2003.12.037; Liu X, 2003, J ALLERGY CLIN IMMUN, V112, P382, DOI 10.1067/mai.2003.1635; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Murata T, 1998, INT IMMUNOL, V10, P1103, DOI 10.1093/intimm/10.8.1103; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Price AL, 2007, AM J HUM GENET, V80, P1024, DOI 10.1086/518313; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Roy B, 2002, J LEUKOCYTE BIOL, V72, P580; Sadeghnejad A, 2004, THORAX, V59, P936, DOI 10.1136/thx.2004.024224; Sadeghnejad A, 2007, PEDIAT ALLERG IMM-UK, V18, P288, DOI 10.1111/j.1399-3038.2006.00524.x; Vercelli D, 2002, CURR OPIN ALLERGY CL, V2, P389, DOI 10.1097/00130832-200210000-00004; Wang XB, 2002, JAMA-J AM MED ASSOC, V287, P195, DOI 10.1001/jama.287.2.195; Wen HJ, 2006, PEDIAT ALLERG IMM-UK, V17, P489, DOI 10.1111/j.1399-3038.2006.00461.x; Yang KD, 2007, CLIN EXP ALLERGY, V37, P680, DOI 10.1111/j.1365-2222.2007.02698.x; Yang KD, 2010, ALLERGY, V65, P731, DOI 10.1111/j.1398-9995.2009.02260.x; Zheng G, 2007, GENET EPIDEMIOL, V31, P834, DOI 10.1002/gepi.20244	41	27	29	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1059	U251		10.1016/j.jaci.2010.08.029	http://dx.doi.org/10.1016/j.jaci.2010.08.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	21050946	Green Accepted			2022-12-18	WOS:000283727100024
J	Ginde, AA; Sutherland, ER				Ginde, Adit A.; Sutherland, E. Rand			Vitamin D in asthma: Panacea or true promise?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Asthma; prevention; treatment; vitamin D	PREGNANCY; CHILDREN		[Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA; [Sutherland, E. Rand] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA; [Sutherland, E. Rand] Natl Jewish Hlth, Dept Med, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Jewish Health	Sutherland, ER (corresponding author), 1400 Jackson St,J-201, Denver, CO 80206 USA.	sutherlande@njhealth.org						Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; CAMARGO CA, 2008, AM J RESP CRIT CAR S, V177, pA993; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	15	27	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					59	60		10.1016/j.jaci.2010.05.030	http://dx.doi.org/10.1016/j.jaci.2010.05.030			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20620566				2022-12-18	WOS:000280061800011
J	Sokolowska, M; Stefanska, J; Wodz-Naskiewicz, K; Cieslak, M; Pawliczak, R				Sokolowska, Milena; Stefanska, Joanna; Wodz-Naskiewicz, Karolina; Cieslak, Malgorzata; Pawliczak, Rafal			Cytosolic phospholipase A(2) group IVA is overexpressed in patients with persistent asthma and regulated by the promoter microsatellites	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENE; EXPRESSION; ALPHA		[Sokolowska, Milena; Stefanska, Joanna; Wodz-Naskiewicz, Karolina; Pawliczak, Rafal] Med Univ Lodz, Fac Biomed Sci & Postgrad Training, Dept Immunopathol, Chair Allergol Immunol & Dermatol, Lodz, Poland; [Cieslak, Malgorzata] Med Univ Lodz, Fac Med, Dept Immunol Rheumatol & Allergy, Lodz, Poland	Medical University Lodz; Medical University Lodz	Sokolowska, M (corresponding author), Med Univ Lodz, Fac Biomed Sci & Postgrad Training, Dept Immunopathol, Chair Allergol Immunol & Dermatol, Lodz, Poland.	rafal.pawliczak@csk.umed.lodz.pl	Pawliczak, Rafal Tomasz/S-9649-2016; Pawliczak, Rafa/S-2021-2019; Wieczfinska, Joanna/S-9723-2016; Stefańska, Joanna/M-5042-2018	Pawliczak, Rafa/0000-0001-6784-453X; Stefańska, Joanna/0000-0003-0272-8831; Wieczfinska, Joanna/0000-0002-8830-1507; Sokolowska, Milena/0000-0001-9710-6685				Adler DH, 2008, J CLIN INVEST, V118, P2121, DOI 10.1172/JCI30473; Bayele HK, 2007, BLOOD, V110, P3039, DOI 10.1182/blood-2006-12-063289; Choi IW, 2005, J ALLERGY CLIN IMMUN, V116, P537, DOI 10.1016/j.jaci.2005.05.034; Dolan-O'Keefe M, 2000, AM J PHYSIOL-LUNG C, V278, pL649, DOI 10.1152/ajplung.2000.278.4.L649; *GLOB IN ASTHM GIN, 2008, GLOB STRAT ASTHM MAN; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Nakasaki K, 2000, J MAT CYCLES WASTE M, V2, P31; Pawliczak R, 2004, J BIOL CHEM, V279, P48550, DOI 10.1074/jbc.M408926200; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Sokolowska M, 2007, CLIN EXP IMMUNOL, V150, P124, DOI 10.1111/j.1365-2249.2007.03459.x; Uhlemann AC, 2004, J INFECT DIS, V189, P2227, DOI 10.1086/421242; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; 2000, AM J RESPIR CARE MED, V162, P2341	14	27	27	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1393	1395		10.1016/j.jaci.2010.02.016	http://dx.doi.org/10.1016/j.jaci.2010.02.016			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20392485	Bronze			2022-12-18	WOS:000278831000032
J	Waibel, KH; Gomez, R				Waibel, Kirk H.; Gomez, Robert			Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EGG ALLERGY; VACCINATION		[Waibel, Kirk H.] Brooke Army Med Ctr, Dept Med, Allergy Immunol Serv, Ft Sam Houston, TX 78234 USA; [Gomez, Robert] Wilford Hall USAF Med Ctr, Allergy Immunol Clin, Dept Med, Lackland AFB, TX USA	San Antonio Military Medical Center; United States Department of Defense; United States Army; United States Department of Defense; United States Air Force	Waibel, KH (corresponding author), Brooke Army Med Ctr, Dept Med, Allergy Immunol Serv, Ft Sam Houston, TX 78234 USA.	kirk.waibel@amedd.army.mil						Esposito S, 2008, VACCINE, V26, P4664, DOI 10.1016/j.vaccine.2008.06.095; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Kelso JM, 2009, ANN ALLERG ASTHMA IM, V103, pS1, DOI 10.1016/S1081-1206(10)60350-X; KLETZ MR, 1990, ANN ALLERGY, V64, P527; *MEDIMMUNE LLC, 2009, SCI PROD MON MEDIMMU; Nasser S, 2009, CLIN EXP ALLERGY, V39, P1288, DOI 10.1111/j.1365-2222.2009.03331.x; PICKERING LK, 2009, RED BOOK 2009 REPORT, P400; Saltzman RW, 2009, J ALLERGY CLIN IMMUN, V123, pS175, DOI 10.1016/j.jaci.2008.12.659; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372	9	27	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					749	751		10.1016/j.jaci.2009.12.015	http://dx.doi.org/10.1016/j.jaci.2009.12.015			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20060576	Bronze			2022-12-18	WOS:000275883200037
J	Camargo, CA; Rachelefsky, G; Schatz, M				Camargo, Carlos A., Jr.; Rachelefsky, Gary; Schatz, Michael			Managing asthma exacerbations in the emergency department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma exacerbation; emergency department; Expert Panel Report 3; acute asthma; respiratory failure	INTRAVENOUS MAGNESIUM-SULFATE; RANDOMIZED CONTROLLED-TRIAL; PULSE OXIMETRY; SEVERITY SCORE; CHILDREN; ALBUTEROL; ADMISSION; HYDROCORTISONE; METAANALYSIS; TERBUTALINE		[Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA 02114 USA; [Rachelefsky, Gary] Univ Calif Los Angeles, David Geffen Sch Med, Execut Care Ctr Asthma Allergy & Resp Dis, Los Angeles, CA 90095 USA; [Schatz, Michael] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Kaiser Permanente	Camargo, CA (corresponding author), Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA 02114 USA.		Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654				Bryson D, 2006, PREHOSP EMERG CARE, V10, P418, DOI 10.1080/10903120600884814; Camargo CA, 2003, AM J RESP CRIT CARE, V167, P528, DOI 10.1164/rccm.200208-802OC; Camargo Jr CA, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001115, 10.1002/14651858.CD001115]; Cham G W M, 2002, Eur J Emerg Med, V9, P225, DOI 10.1097/00063110-200209000-00004; Cheuk DKL, 2005, ARCH DIS CHILD, V90, P74, DOI 10.1136/adc.2004.050005; Chey T, 1999, J CLIN EPIDEMIOL, V52, P1157, DOI 10.1016/S0895-4356(99)00111-0; CONNETT GJ, 1993, PEDIATR PULM, V15, P345, DOI 10.1002/ppul.1950150606; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; EDMONDS ML, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002308; GEELHOED GC, 1994, ANN EMERG MED, V23, P1236, DOI 10.1016/S0196-0644(94)70347-7; Gorelick MH, 2004, PEDIATR EMERG CARE, V20, P22, DOI 10.1097/01.pec.0000106239.72265.16; Gorelick MH, 2004, ACAD EMERG MED, V11, P10, DOI 10.1197/S106-6563(03)00579-7; HARRISON BDW, 1986, LANCET, V1, P181; Hess DR, 1999, CHEST, V115, P184, DOI 10.1378/chest.115.1.184; Karpel JP, 1997, CHEST, V112, P348, DOI 10.1378/chest.112.2.348; Karras DJ, 2000, ACAD EMERG MED, V7, P327, DOI 10.1111/j.1553-2712.2000.tb02231.x; Keahey L, 2002, ANN EMERG MED, V40, P300, DOI 10.1067/mem.2002.126813; Kelly AM, 2004, RESP MED, V98, P777, DOI 10.1016/j.rmed.2004.01.008; Kelly Anne-Maree, 2002, Emerg Med (Fremantle), V14, P142, DOI 10.1046/j.1442-2026.2002.00308.x; Keogh KA, 2001, J PEDIATR-US, V139, P273, DOI 10.1067/mpd.2001.116282; Kim IK, 2005, PEDIATRICS, V116, P1127, DOI 10.1542/peds.2004-2136; Lahn M, 2004, CHEST, V126, P362, DOI 10.1378/chest.126.2.362; Lee DL, 2005, ACAD EMERG MED, V12, P820, DOI 10.1197/j.aem.2005.04.020; McCarren M, 2000, ACAD EMERG MED, V7, P28, DOI 10.1111/j.1553-2712.2000.tb01887.x; McFadden ER, 2003, AM J RESP CRIT CARE, V168, P740, DOI 10.1164/rccm.200208-902SO; MENITOVE SM, 1983, AM J MED, V74, P898, DOI 10.1016/0002-9343(83)91082-3; Plotnick LH, 2000, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000060, 10.1002/14651858.CD000060]; Ram FSF, 2005, COCHRANE DB SYST REV, DOI [10.1002/146514858.CD004360.pub2, 10.1002/14651858.CD004360.pub3, 10.1002/14651858.CD003137.pub2]; RATTO D, 1988, JAMA-J AM MED ASSOC, V260, P527, DOI 10.1001/jama.260.4.527; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Rodrigo C, 1998, CHEST, V113, P593, DOI 10.1378/chest.113.3.593; RODRIGO G, 1993, CHEST, V104, P1325, DOI 10.1378/chest.104.5.1325; Rodrigo G, 1998, CHEST, V114, P1016, DOI 10.1378/chest.114.4.1016; Rodrigo GJ, 2005, THORAX, V60, P740, DOI 10.1136/thx.2005.040444; Rodrigo GJ, 2005, AM J RESP CRIT CARE, V171, P1231, DOI 10.1164/rccm.200410-1415OC; Rowe B H, 2001, Respir Care, V46, P1380; Rowe BH, 2000, ANN EMERG MED, V36, P181, DOI 10.1067/mem.2000.105659; Rowe BH, 2006, J ALLERGY CLIN IMMUN, V117, P53, DOI 10.1016/j.jaci.2005.09.033; Rowe BH, 2004, RESP MED, V98, P275, DOI 10.1016/j.rmed.2003.11.016; Schuckman H, 1998, ANN EMERG MED, V31, P333, DOI 10.1016/S0196-0644(98)70343-9; SLY RM, 1977, J ALLERGY CLIN IMMUN, V59, P128, DOI 10.1016/0091-6749(77)90214-7; SMITH PR, 1977, CHEST, V71, P129, DOI 10.1378/chest.71.2.129; Smith SR, 2002, ACAD EMERG MED, V9, P99, DOI 10.1197/aemj.9.2.99; Sole D, 1999, J ASTHMA, V36, P327, DOI 10.3109/02770909909068225; Strauss L, 1997, AM J RESP CRIT CARE, V155, P454, DOI 10.1164/ajrccm.155.2.9032178; TRAVERS A, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002988; TUXEN DV, 1994, AM J RESP CRIT CARE, V150, P870, DOI 10.1164/ajrccm.150.3.8087364; *US DEP HHS, 3 US DEP HHS NAT I H; Wright RO, 1997, ACAD EMERG MED, V4, P114, DOI 10.1111/j.1553-2712.1997.tb03716.x	49	27	27	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2		S			S5	S14		10.1016/j.jaci.2009.05.010	http://dx.doi.org/10.1016/j.jaci.2009.05.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CE	19647135				2022-12-18	WOS:000268860500002
J	Watanabe, S; Yamasaki, A; Hashimoto, K; Shigeoka, Y; Chikumi, H; Hasegawa, Y; Sumikawa, T; Takata, M; Okazaki, R; Watanabe, M; Yokogawa, T; Yamamura, M; Hayabuchi, T; Gerthoffer, WT; Halayko, AJ; Shimizu, E				Watanabe, Satoko; Yamasaki, Akira; Hashimoto, Kiyoshi; Shigeoka, Yasushi; Chikumi, Hiroki; Hasegawa, Yasuyuki; Sumikawa, Takashi; Takata, Miyako; Okazaki, Ryota; Watanabe, Masanari; Yokogawa, Tsuyoshi; Yamamura, Miki; Hayabuchi, Tatsuya; Gerthoffer, William T.; Halayko, Andrew J.; Shimizu, Eiji			Expression of functional leukotriene B-4 receptors on human airway smooth muscle cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway remodeling; airway smooth muscle cells; LTB4; BLT	PROTEIN-COUPLED RECEPTOR; ASTHMA; PROLIFERATION; PHENOTYPE; LAMININ; GROWTH; MAPK; LTB4	Background: Leukotriene B-4 (LTB4) increases in induced sputum and exhaled breath condensate in people with asthma. Furthermore, the T(H)2-type immune response and airway hyperresponsiveness induced by ovalbumin sensitization is markedly suppressed in LTB4 receptor (BLT) 1 null mice. These studies suggest that LTB4 may contribute to asthma pathophysiology. However, the direct effects of LTB4 on human airway smooth muscle (ASM) have not been studied. ObjectivesWe sought to determine the expression of LTB4 receptors on human ASM and its functional role in mediating responses of human ASM cells, and the effect of LTB4 on these cells. Methods: Immunohistochemistry, RT-PCR, Western blotting, and flow cytometry were used to determine the expression of LTB4 receptors. To determine the effect of LTB4 on human ASM cells, cell proliferation was assessed by counting cells, and chemokinesis was assessed by gold particle phagokinesis assay. Results: We confirmed expression of both BLT1 and BLT2 in human ASM cells in bronchial tissue and in cell culture. LTB4 markedly induced cyclin D1 expression, proliferation, and chemokinesis of human ASM cells. LTB4 also induced phosphorylation of both p42/p44 mitogen-activated protein kinase (MAPK) and downstream PI3 kinase effector, Akt1. However, we observed no induction of c-Jun N-terminal kinase or p38 MAPK. Notably, LTB4-induced migration and proliferation of ASM cells were inhibited by the BLT1 specific antagonist, U75302, and by inhibitors of p42/p44 MAPK phosphorylation (U1026), and PI3 kinase (LY294002). Conclusions: These observations are the first to suggest a role for a LTB4-BLT1 signaling axis in ASM responses that may contribute to the pathogenesis of airway remodeling in asthma. (J Allergy Clin Immunol 2009;124:59-65.)	[Watanabe, Satoko; Yamasaki, Akira; Hashimoto, Kiyoshi; Shigeoka, Yasushi; Chikumi, Hiroki; Hasegawa, Yasuyuki; Sumikawa, Takashi; Takata, Miyako; Okazaki, Ryota; Watanabe, Masanari; Yokogawa, Tsuyoshi; Yamamura, Miki; Hayabuchi, Tatsuya; Shimizu, Eiji] Tottori Univ, Div Med Oncol & Mol Respirol, Dept Multidisciplinary Internal Med, Fac Med, Yonago, Tottori 6838503, Japan; [Gerthoffer, William T.] Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Winnipeg, MB, Canada; [Halayko, Andrew J.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada	Tottori University; University of South Alabama; University of Manitoba; University of Manitoba	Yamasaki, A (corresponding author), Tottori Univ, Div Med Oncol & Mol Respirol, Dept Multidisciplinary Internal Med, Fac Med, 86 Nishi Machi, Yonago, Tottori 6838503, Japan.	yamasaki@med.tottori-u.ac.jp		Halayko, Andrew/0000-0002-7865-4552; Gerthoffer, William/0000-0001-5154-4962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077726] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL077726] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; Back M, 2005, P NATL ACAD SCI USA, V102, P17501, DOI 10.1073/pnas.0505845102; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; EBINA M, 1990, AM REV RESPIR DIS, V141, P1322, DOI 10.1164/ajrccm/141.5_Pt_1.1322; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Goncharova EA, 2003, AM J RESP CELL MOL, V29, P19, DOI 10.1165/rcmb.2002-0254OC; Gosens R, 2006, AM J PHYSIOL-LUNG C, V291, pL523, DOI 10.1152/ajplung.00013.2006; Gosens R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-73; Halayko AJ, 2006, CURR DRUG TARGETS, V7, P525, DOI 10.2174/138945006776818728; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Knox AJ, 2000, CLIN EXP ALLERGY, V30, P606; Kostikas K, 2005, CHEST, V127, P1553, DOI 10.1378/chest.127.5.1553; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V276, pL246, DOI 10.1152/ajplung.1999.276.2.L246; Lazaar AL, 2005, J ALLERGY CLIN IMMUN, V116, P488, DOI 10.1016/j.jaci.2005.06.030; Madison JM, 2003, AM J RESP CELL MOL, V29, P8, DOI 10.1165/rcmb.F272; Masuda K, 2003, J BIOL CHEM, V278, P24552, DOI 10.1074/jbc.M302801200; Murata K, 1999, CLIN EXP METASTAS, V17, P525, DOI 10.1023/A:1006626529536; Naureckas ET, 1999, AM J RESP CRIT CARE, V160, P2062, DOI 10.1164/ajrccm.160.6.9903131; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; Oliver Brian G, 2006, Allergol Int, V55, P215, DOI 10.2332/allergolint.55.215; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Parameswaran K, 2002, AM J RESP CRIT CARE, V166, P738, DOI 10.1164/rccm.200204-291OC; Qiu H, 2006, P NATL ACAD SCI USA, V103, P6913, DOI 10.1073/pnas.0602208103; Rahman MS, 2006, J IMMUNOL, V177, P4064, DOI 10.4049/jimmunol.177.6.4064; Shigeoka Y, 2004, J CANCER RES CLIN, V130, P146, DOI 10.1007/s00432-003-0520-0; SHINDO K, 1995, EUR RESPIR J, V8, P605; Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217; Tong WG, 2005, BIOCHEM BIOPH RES CO, V335, P949, DOI 10.1016/j.bbrc.2005.07.166; Tran T, 2007, AM J RESP CELL MOL, V37, P668, DOI 10.1165/rcmb.2007-0165OC; Tran T, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-117; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zaitsu M, 1998, J ASTHMA, V35, P445, DOI 10.3109/02770909809048953	43	27	29	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2009	124	1					59	65		10.1016/j.jaci.2009.03.024	http://dx.doi.org/10.1016/j.jaci.2009.03.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	469OR	19477492	Green Accepted			2022-12-18	WOS:000267909700006
J	Walgraffe, D; Matteotti, C; el Bakkoury, M; Garcia, L; Marchand, C; Bullens, D; Vandenbranden, M; Jacquet, A				Walgraffe, David; Matteotti, Christel; el Bakkoury, Mohamed; Garcia, Lida; Marchand, Celine; Bullens, Dominique; Vandenbranden, Michel; Jacquet, Alain			A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Der p 1; recombinant hypoallergen; aggregates; prophylactic vaccinations	HOUSE-DUST MITE; CYSTEINE PROTEASE ACTIVITY; HIGH-LEVEL EXPRESSION; AIRWAY INFLAMMATION; PROTEOLYTIC ACTIVITY; MAJOR ALLERGEN; DERMATOPHAGOIDES-PTERONYSSINUS; RECOMBINANT PRO-DER-P-1; IMMUNE-RESPONSES; IMMUNOGLOBULIN-E	Background: Recombinant hypoallergens that display reduced allergenicity but retain T-cell reactivity represent promising candidates to improve the safety and efficacy of allergen-specific vaccines or immunotherapy. Objective: The current study reports the immunologic characterization of a hypoallergenic variant of the major mite allergen Der p 1. Methods: The recombinant proform of Der p 1 (ProDer p 1) was expressed in Escherichia coli (ProDer p 1 coli), purified and characterized at the level of its secondary structure, and IgE and T-cell reactivities. Moreover, the prophylactic potential of ProDer p 1 coli vaccinations was evaluated in a murine Der p 1 sensitization model. Results: After purification and refolding, ProDer p 1 coli remained aggregated with a higher beta-sheet content and altered Der p 1 conformational epitopes compared with the correctly folded monomeric ProDer p 1 produced in Chinese hamster ovary cells. Both ProDer p 1 forms were able to retain the Der p 1-specific T-cell reactivity but direct ELISA, competitive inhibition, and rat basophil leukemia assays clearly showed that ProDer p 1 coli displays a very weak IgE reactivity. Mice vaccinations with aggregated ProDer p 1 adjuvanted with alum induced a T(H)1-biased immune response that prevented the subsequent allergic response after Der p 1 sensitization and airway challenge with aerosolized mite extracts. Furthermore, ProDer p 1 coli treatment inhibited the development of airway eosinophilia and airway hyperresponsiveness to inhaled methacholine. Conclusion: Aggregated forms of Der p 1 could represent hypoallergens suitable for the prevention of mite allergy. (J Allergy Clin Immunol 2009;123:1150-6.)	[Walgraffe, David; Matteotti, Christel; el Bakkoury, Mohamed; Garcia, Lida; Marchand, Celine; Jacquet, Alain] Univ Libre Bruxelles, Lab Allergol Expt, Inst Biol & Med Mol, B-6041 Charleroi, Belgium; [Bullens, Dominique] Catholic Univ Louvain, Dept Expt Med, Div Clin Immunol, B-3000 Louvain, Belgium; [Bullens, Dominique] Catholic Univ Louvain, Div Pediat, Dept Woman & Child, B-3000 Louvain, Belgium; [Vandenbranden, Michel] Univ Libre Bruxelles, Lab Struct & Fonct Membranes Biol, Brussels, Belgium	Universite Libre de Bruxelles; Universite Catholique Louvain; Universite Catholique Louvain; Universite Libre de Bruxelles	Jacquet, A (corresponding author), Univ Libre Bruxelles, Lab Allergol Expt, Inst Biol & Med Mol, Rue Prof Jeener & Brachet 12, B-6041 Charleroi, Belgium.	alainjacquet@ulb.ac.be	Bullens, Dominique M A/T-6211-2017; Jacquet, Alain/T-8611-2019; Jacquet, Alain/GQI-0546-2022	Bullens, Dominique M A/0000-0002-4595-9579; Jacquet, Alain/0000-0002-0980-9741; Jacquet, Alain/0000-0002-0980-9741	GlaxoSmithKline Biologicals; Region Wallonne	GlaxoSmithKline Biologicals(GlaxoSmithKline); Region Wallonne	Supported in part by GlaxoSmithKline Biologicals and the Region Wallonne (Direction generale des Technologies, de la Recherche et de l'Energic).	Akdis CA, 2000, INT ARCH ALLERGY IMM, V121, P261, DOI 10.1159/000024352; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Chevigne A, 2007, J MOL BIOL, V374, P170, DOI 10.1016/j.jmb.2007.08.025; CHUA KY, 1992, J ALLERGY CLIN IMMUN, V89, P95, DOI 10.1016/S0091-6749(05)80045-4; de Halleux S, 2006, J ALLERGY CLIN IMMUN, V117, P571, DOI 10.1016/j.jaci.2005.11.032; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4&lt;1211::AID-IMMU1211&gt;3.0.CO;2-R; Gieni RS, 1996, IMMUNOLOGY, V87, P119; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Jacquet A, 2000, CLIN EXP ALLERGY, V30, P677, DOI 10.1046/j.1365-2222.2000.00823.x; Jacquet A, 2002, CLIN EXP ALLERGY, V32, P1048, DOI 10.1046/j.1365-2222.2002.01437.x; King C, 1998, J IMMUNOL, V161, P3645; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; Lund L, 2007, CLIN EXP ALLERGY, V37, P564, DOI 10.1111/j.1365-2222.2007.02687.x; Maezawa Y, 2004, CLIN EXP IMMUNOL, V135, P12, DOI 10.1111/j.1365-2249.2004.02337.x; Magi M, 2004, J ALLERGY CLIN IMMUN, V114, P545, DOI 10.1016/j.jaci.2004.04.014; Massaer M, 2001, INT ARCH ALLERGY IMM, V125, P32, DOI 10.1159/000053794; Mayr SI, 2002, J IMMUNOL, V169, P2061, DOI 10.4049/jimmunol.169.4.2061; Meno K, 2005, J IMMUNOL, V175, P3835, DOI 10.4049/jimmunol.175.6.3835; Nakajima H, 2007, INT ARCH ALLERGY IMM, V142, P265, DOI 10.1159/000097357; Niederberger V, 2006, EXPERT REV VACCINES, V5, P103, DOI 10.1586/14760584.5.1.103; Puxeddu I, 2005, J ALLERGY CLIN IMMUN, V116, P531, DOI 10.1016/j.jaci.2005.06.007; Quarcoo D, 2004, J ALLERGY CLIN IMMUN, V114, P288, DOI 10.1016/j.jaci.2004.03.055; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Schulz O, 1998, J CLIN PATHOL-MOL PA, V51, P222, DOI 10.1136/mp.51.4.222; SCOBIE G, 1994, BIOCHEM SOC T, V22, pS448, DOI 10.1042/bst022448s; Shakib F, 2000, CLIN EXP ALLERGY, V30, P751, DOI 10.1046/j.1365-2222.2000.00865.x; Takahashi K, 2000, INT ARCH ALLERGY IMM, V122, P108, DOI 10.1159/000024366; Takai T, 2005, J ALLERGY CLIN IMMUN, V115, P555, DOI 10.1016/j.jaci.2004.11.024; Takai T, 2002, FEBS LETT, V531, P265, DOI 10.1016/S0014-5793(02)03534-2; van Oort E, 2002, EUR J BIOCHEM, V269, P671, DOI 10.1046/j.0014-2956.2001.02700.x; VANSTOKKUM IHM, 1995, BIOCHEMISTRY-US, V34, P10508, DOI 10.1021/bi00033a024; Vigano C, 2004, BIOPOLYMERS, V74, P19, DOI 10.1002/bip.20035; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x	39	27	33	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1150	1156		10.1016/j.jaci.2008.11.038	http://dx.doi.org/10.1016/j.jaci.2008.11.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19152967				2022-12-18	WOS:000266309400025
J	Matangkasombut, P; Pichavant, M; Yasumi, T; Hendricks, C; Savage, PB; Dekruyff, RH; Umetsu, DT				Matangkasombut, Ponpan; Pichavant, Muriel; Yasumi, Takahiro; Hendricks, Carrie; Savage, Paul B.; Dekruyff, Rosemarie H.; Umetsu, Dale T.			Direct activation of natural killer T cells induces airway hyperreactivity in nonhuman primates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							NKT CELLS; ASTHMA; MODEL		[Matangkasombut, Ponpan; Pichavant, Muriel; Yasumi, Takahiro; Dekruyff, Rosemarie H.; Umetsu, Dale T.] Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Matangkasombut, Ponpan] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Hendricks, Carrie] Charles River Labs, Worcester, MA USA; [Savage, Paul B.] Brigham Young Univ, Dept Chem, Provo, UT 84602 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Brigham Young University	Matangkasombut, P (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02115 USA.	Dale.Umetsu@childrens.harvard.edu	Savage, Paul B/HGB-3414-2022; Savage, Paul B/E-1448-2011; Pichavant, Muriel/B-9036-2018	Savage, Paul B/0000-0002-4642-6109; Savage, Paul B/0000-0002-4642-6109; Pichavant, Muriel/0000-0002-1315-4397; Yasumi, Takahiro/0000-0003-3257-5071	NCRR NIH HHS [M01 RR000070, M01 RR000070-35A10280] Funding Source: Medline; NHLBI NIH HHS [R01 HL062348, HL63248, R01 HL062348-09] Funding Source: Medline; NIAID NIH HHS [AI26322, R01 AI026322-17, R01 AI026322] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026322] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Coffman RL, 2005, J EXP MED, V201, P1875, DOI 10.1084/jem.20050901; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Meyer EH, 2008, ANNU REV MED, V59, P281, DOI 10.1146/annurev.med.59.061506.154139; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691	10	27	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1287	1289		10.1016/j.jaci.2008.02.006	http://dx.doi.org/10.1016/j.jaci.2008.02.006			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18355909	Green Accepted			2022-12-18	WOS:000255961700032
J	Cousins, DJ; McDonald, J; Lee, TH				Cousins, David J.; McDonald, Joanne; Lee, Tak H.			Therapeutic approaches for control of transcription factors in allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						transcription factors; asthma; atopic dermatitis; signal transducer and activator of transcription 6; GAT43; T(H)2; nuclear factor of activated T cells; nuclear factor kappa B; glucocorticoid receptor	NF-KAPPA-B; CYTOKINE GENE-EXPRESSION; COLONY-STIMULATING FACTOR; GLUCOCORTICOID-RECEPTOR; AIRWAY INFLAMMATION; T-CELL; ATOPIC-DERMATITIS; SIGNALING PATHWAYS; PULMONARY INFLAMMATION; FUNCTIONAL ANTAGONISM	The inflammatory response observed in allergic disease involves multiple cell types but is orchestrated in part by the T(H)2 cytokines IL-4, IL-5, and IL-13. In recent years, the transcription factors that control the expression and function of these cytokines have been elucidated, including signal transducer and activator of transcription 6, GATA3, nuclear factor of activated T cells, and nuclear factor kappa B. These molecules are attractive targets for therapeutic intervention because they regulate the expression of numerous effector molecules and functions simultaneously. For instance, the immunosuppressive agents glucocorticoids and cyclosporin A both function by repressing the activity of transcription factors through a variety of mechanisms. In this review we examine the role of each transcription factor in allergic disease and discuss approaches that have been taken to therapeutically interfere with transcription factor function in allergic disease.	[Cousins, David J.] Kings Coll London, Guys Hosp, UK Ctr Allerg Mech Asthma, MRC Asthma, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Cousins, DJ (corresponding author), Kings Coll London, Guys Hosp, UK Ctr Allerg Mech Asthma, MRC Asthma, 5th Floor Thomas Guy House, London SE1 9RT, England.	david.cousins@kcl.ac.uk	Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059; Cousins, David/0000-0003-3821-9596	Medical Research Council [G9536930] Funding Source: Medline; MRC [G9536930] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adcock Ian M, 2004, Proc Am Thorac Soc, V1, P247, DOI 10.1513/pats.200402-001MS; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; Bechstein WO, 2000, TRANSPL INT, V13, P313, DOI 10.1007/s001470050708; Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; Bureau F, 2000, J IMMUNOL, V165, P5822, DOI 10.4049/jimmunol.165.10.5822; Chapoval SP, 2007, J IMMUNOL, V179, P7030, DOI 10.4049/jimmunol.179.10.7030; Chivers JE, 2006, MOL PHARMACOL, V70, P2084, DOI 10.1124/mol.106.025841; Choi IW, 2004, INT IMMUNOPHARMACOL, V4, P1817, DOI 10.1016/j.intimp.2004.07.030; Corrigan Chris J, 2002, Am J Respir Med, V1, P47; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Desmet C, 2004, J IMMUNOL, V173, P5766, DOI 10.4049/jimmunol.173.9.5766; Donovan CE, 1999, J IMMUNOL, V163, P6827; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408-1006OC; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Fonacier L, 2005, J ALLERGY CLIN IMMUN, V115, P1249, DOI 10.1016/j.jaci.2005.04.006; Gagliardo R, 2003, AM J RESP CRIT CARE, V168, P1190, DOI 10.1164/rccm.200205-479OC; Gilmour J, 2007, J ALLERGY CLIN IMMUN, V120, P56, DOI 10.1016/j.jaci.2007.03.033; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Henderson WR, 2002, J IMMUNOL, V169, P5294, DOI 10.4049/jimmunol.169.9.5294; Hersperger R, 2004, J MED CHEM, V47, P4950, DOI 10.1021/jm031101l; Hill S, 1999, AM J RESP CELL MOL, V21, P728, DOI 10.1165/ajrcmb.21.6.3709; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Hoshino A, 2004, INT IMMUNOL, V16, P1497, DOI 10.1093/intimm/dxh151; Huang TJ, 2001, BRIT J PHARMACOL, V134, P1029, DOI 10.1038/sj.bjp.0704344; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Jee YK, 2005, J BIOL CHEM, V280, P23243, DOI 10.1074/jbc.M503659200; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Khan LN, 2000, AM J RESP CRIT CARE, V162, P1377, DOI 10.1164/ajrccm.162.4.9911117; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee CC, 2008, MOL THER, V16, P60, DOI 10.1038/sj.mt.6300309; Lee GR, 2004, INT IMMUNOL, V16, P1155, DOI 10.1093/intimm/dxh117; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lowenberg M, 2006, EMBO REP, V7, P1023, DOI 10.1038/sj.embor.7400775; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Maneechotesuwan K, 2007, J IMMUNOL, V178, P2491, DOI 10.4049/jimmunol.178.4.2491; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; McCusker CT, 2007, J IMMUNOL, V179, P2556, DOI 10.4049/jimmunol.179.4.2556; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Mizuno H, 1997, BRAIN RES, V746, P256, DOI 10.1016/S0006-8993(96)01259-0; Mowen KA, 2004, IMMUNOL REV, V202, P203, DOI 10.1111/j.0105-2896.2004.00209.x; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Nakamura Y, 2000, J ALLERGY CLIN IMMUN, V105, P1146, DOI 10.1067/mai.2000.107045; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; Ngoc LP, 2005, CURR OPIN ALLERGY CL, V5, P161, DOI 10.1097/01.all.0000162309.97480.45; Noguchi H, 2004, NAT MED, V10, P305, DOI 10.1038/nm994; Nyce J, 2002, CURR OPIN ALLERGY CL, V2, P533, DOI 10.1097/00130832-200212000-00009; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; Olyaei A J, 2001, Curr Opin Crit Care, V7, P384, DOI 10.1097/00075198-200112000-00003; Pai SY, 2004, P NATL ACAD SCI USA, V101, P1993, DOI 10.1073/pnas.0308697100; Peng Q, 2004, AM J RESP CRIT CARE, V169, P596, DOI 10.1164/rccm.200307-888OC; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Ponticelli C, 2004, TRANSPLANT P, V36, p557S, DOI 10.1016/j.transproceed.2003.12.046; Poynter ME, 2002, AM J PATHOL, V160, P1325, DOI 10.1016/S0002-9440(10)62559-X; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Rippmann JF, 2005, FEBS LETT, V579, P173, DOI 10.1016/j.febslet.2004.11.071; Roehrl MHA, 2004, P NATL ACAD SCI USA, V101, P7554, DOI 10.1073/pnas.0401835101; Santangelo S, 2002, J IMMUNOL, V169, P1893, DOI 10.4049/jimmunol.169.4.1893; Schacke H, 2004, P NATL ACAD SCI USA, V101, P227, DOI 10.1073/pnas.0300372101; Schaecke H, 2007, MOL CELL ENDOCRINOL, V275, P109, DOI 10.1016/j.mce.2007.05.014; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shiina T, 2004, J BIOL CHEM, V279, P55493, DOI 10.1074/jbc.M409770200; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Skapenko A, 2004, J EXP MED, V199, P423, DOI 10.1084/jem.20031323; Smith PJ, 2001, J IMMUNOL, V167, P2502, DOI 10.4049/jimmunol.167.5.2502; Smoak K, 2006, MOL CELL BIOL, V26, P9126, DOI 10.1128/MCB.00679-06; STAUMONTSALLE D, 2008, J ALLERGY CLIN  0213; Stolzenberger S, 2001, EUR J BIOCHEM, V268, P4809, DOI 10.1046/j.1432-1327.2001.02417.x; Sundrud MS, 2003, J IMMUNOL, V171, P3542, DOI 10.4049/jimmunol.171.7.3542; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Venkatesh N, 2004, P NATL ACAD SCI USA, V101, P8969, DOI 10.1073/pnas.0402803101; Ward JE, 2007, PPAR RES, V2007, DOI 10.1155/2007/14983; Weih F, 1997, J IMMUNOL, V158, P5211; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; WYNN TA, 2000, ANON REV IMMUNOL, V21, P425; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamashita N, 2006, AM J PHYSIOL-LUNG C, V290, pL1045, DOI 10.1152/ajplung.00195.2005; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Yokozeki H, 2000, J EXP MED, V191, P995, DOI 10.1084/jem.191.6.995; Yokozeki H, 2004, GENE THER, V11, P1753, DOI 10.1038/sj.gt.3302341; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	101	27	30	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					803	809		10.1016/j.jaci.2008.02.008	http://dx.doi.org/10.1016/j.jaci.2008.02.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18395546				2022-12-18	WOS:000254884000001
J	Rachelefsky, G; Hogarth, DK				Rachelefsky, Gary; Hogarth, D. Kyle			Issues in the diagnosis of alpha(1)-antitrypsin deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alpha(1)-antitrypsin deficiency; augmentation therapy; genetic testing; diagnosis	OBSTRUCTIVE PULMONARY-DISEASE; ALPHA-1-ANTITRYPSIN DEFICIENCY; LUNG-FUNCTION; ALPHA(1)-PROTEASE INHIBITOR; RESPIRATORY SYMPTOMS; FOLLOW-UP; ADOLESCENTS; INDIVIDUALS; PREVENTION; EMPHYSEMA	alpha(1)-Antitrypsin deficiency is a relatively common genetic disease that is underrecognized and underdiagnosed. Early diagnosis in the asymptomatic patient helps modify lifestyle choices to reduce the risk of emphysema. In 2003, the American Thoracic Society and the European Respiratory Society issued guidelines to improve standards in diagnosing alpha(1)-antitrypsin deficiency. This review highlights key recommendations for diagnosis of alpha(1)-antitrypsin deficiency, including the different types of diagnostic tests recommended in the guidelines. Options for patient treatment will be discussed.	[Rachelefsky, Gary] Univ Calif Los Angeles, Med Ctr, Execut Care Ctr Asthma Allergy & Resp Dis, Los Angeles, CA 90095 USA; [Hogarth, D. Kyle] Univ Chicago, Sect Pulm & Crit Care, Dept Med, Chicago, IL 60637 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Chicago	Rachelefsky, G (corresponding author), Univ Calif Los Angeles, Med Ctr, Execut Care Ctr Asthma Allergy & Resp Dis, 200 UCLA Med Plaza,Suite 140-17, Los Angeles, CA 90095 USA.	grachelefsky@mednet.ucla.edu						*ALPH 1 FDN, 2007, WHAT ALPH 1 ANT DEF; *ALPH ANT DEF REG, 1999, AM J RESP CRIT CARE, V158, P49; *ALPH FDN, 2007, HEALTHC PROV GUID AL; Amer Thoracic Soc European Respir, 2003, AM J RESP CRIT CARE, V168, P818, DOI 10.1164/rccm.168.7.818; [Anonymous], 1997, B WORLD HEALTH ORGAN, V75, P397; BALS R, 2007, AM J RESP MED, V101, P1708; Bernspang E, 2007, RESP MED, V101, P1971, DOI 10.1016/j.rmed.2007.04.003; Brantly M, 2006, CLIN CHEM, V52, P2180, DOI 10.1373/clinchem.2006.078907; BRANTLY ML, 1991, CHEST, V100, P703, DOI 10.1378/chest.100.3.703; Campos MA, 2005, CHEST, V128, P1179, DOI 10.1378/chest.128.3.1179; Carpenter MJ, 2007, ANN BEHAV MED, V33, P22, DOI 10.1207/s15324796abm3301_3; CRYSTAL RG, 1985, J CLIN INVEST, V85, P343; Dahl M, 2002, ANN INTERN MED, V136, P270, DOI 10.7326/0003-4819-136-4-200202190-00006; de Serres FJ, 2002, CHEST, V122, P1818, DOI 10.1378/chest.122.5.1818; de Serres Frederick J, 2006, COPD, V3, P133, DOI 10.1080/15412550600829257; DeMeo DL, 2007, THORAX, V62, P806, DOI 10.1136/thx.2006.075846; Dirksen A, 1999, AM J RESP CRIT CARE, V160, P1468, DOI 10.1164/ajrccm.160.5.9901055; DIRKSEN A, 2007, ATS ANN M MAY 18 23; GITTER AC, 2007, ATS ANN M MAY 18 23; HOGARTH DK, 2007, AM COLL CHEST PHYS M; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; Louie SG, 2005, ANN PHARMACOTHER, V39, P1861, DOI 10.1345/aph.1E061; McElvaney NG, 1997, CHEST, V111, P394, DOI 10.1378/chest.111.2.394; Needham M, 2004, THORAX, V59, P441, DOI 10.1136/thx.2003.006510; Norman MR, 1997, ANN CLIN BIOCHEM, V34, P230, DOI 10.1177/000456329703400303; Parr DG, 2006, THORAX, V61, P485, DOI 10.1136/thx.2005.054890; Piitulainen E, 1998, ACTA PAEDIATR, V87, P1120; Piitulainen E, 1999, EUR RESPIR J, V13, P247, DOI 10.1183/09031936.99.13224799; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Seersholm N, 1997, EUR RESPIR J, V10, P2260, DOI 10.1183/09031936.97.10102260; Senn O, 2005, EUR RESPIR J, V26, P909, DOI 10.1183/09031936.05.00021605; Snyder MR, 2006, CLIN CHEM, V52, P2236, DOI 10.1373/clinchem.2006.072991; Stocks James M, 2006, COPD, V3, P17, DOI 10.1080/15412550500493220; Stoller JK, 2007, ANN THORAC SURG, V83, P241, DOI 10.1016/j.athoracsur.2006.07.080; Stoller JK, 2005, LANCET, V365, P2225, DOI 10.1016/S0140-6736(05)66781-5; STOLLER JK, 1994, CLEV CLIN J MED, V61, P461, DOI 10.3949/ccjm.61.6.461; Strange C, 2006, ARCH PEDIAT ADOL MED, V160, P531, DOI 10.1001/archpedi.160.5.531; Strange C, 2006, RESPIRATION, V73, P185, DOI 10.1159/000088061; Sveger T, 1998, PEDIATR RES, V44, P939, DOI 10.1203/00006450-199812000-00019; SVEGER T, 1994, ACTA PAEDIATR, V83, P1170; Sveger T, 1997, ACTA PAEDIATR, V86, P37, DOI 10.1111/j.1651-2227.1997.tb08828.x; Sveger T, 1999, ACTA PAEDIATR, V88, P315, DOI 10.1080/08035259950170097; Thelin T, 1996, ACTA PAEDIATR, V85, P1207; Trulock EP, 2006, J HEART LUNG TRANSPL, V25, P880, DOI 10.1016/j.healun.2006.06.001; WALL M, 1990, J PEDIATR-US, V116, P248, DOI 10.1016/S0022-3476(05)82882-3; Wencker M, 2001, CHEST, V119, P737, DOI 10.1378/chest.119.3.737; 2005, ADV FOR JUN 24 26 LA	47	27	30	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					833	838		10.1016/j.jaci.2007.12.1183	http://dx.doi.org/10.1016/j.jaci.2007.12.1183			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18313128				2022-12-18	WOS:000254884000004
J	Venemalm, L; Degerbeck, F; Smith, W				Venemalm, Lennart; Degerbeck, Fredrik; Smith, William			IgE-mediated reaction to mepivacaine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LOCAL-ANESTHETICS; ADVERSE-REACTIONS; EXPERIENCE; HISTORY		[Venemalm, Lennart] Phadia AB, Uppsala, Sweden; [Smith, William] Royal Adelaide Hosp, Dept Allergy & Clin Immunol, Adelaide, SA 5000, Australia; [Degerbeck, Fredrik] Malarinvest AB, Uppsala, Sweden	Thermo Fisher Scientific; Phadia; Royal Adelaide Hospital	Venemalm, L (corresponding author), Phadia AB, Uppsala, Sweden.	lennart.venemalm@phadia.com		Smith, William/0000-0001-9640-1172; Smith, William/0000-0002-4610-998X				Baluga Juan Carlos, 2003, Rev Alerg Mex, V50, P176; Berkun Y, 2003, ANN ALLERG ASTHMA IM, V91, P342, DOI 10.1016/S1081-1206(10)61680-8; CHANDLER MJ, 1987, J ALLERGY CLIN IMMUN, V79, P883, DOI 10.1016/0091-6749(87)90236-3; CuestaHerranz J, 1997, J ALLERGY CLIN IMMUN, V99, P427, DOI 10.1016/S0091-6749(97)70064-2; DESHAZO RD, 1979, J ALLERGY CLIN IMMUN, V63, P387, DOI 10.1016/0091-6749(79)90211-2; Gall H, 1996, J ALLERGY CLIN IMMUN, V97, P933, DOI 10.1016/S0091-6749(96)80067-4; Gonzalez-Delgado P, 2006, J INVEST ALLERG CLIN, V16, P311; NNOORMALIN A, 2005, TROP BIOMED, V22, P179; Prieto A, 2005, ALLERGY, V60, P261, DOI 10.1111/j.1398-9995.2005.00648.x	9	27	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1058	1059		10.1016/j.jaci.2007.12.1154	http://dx.doi.org/10.1016/j.jaci.2007.12.1154			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18234312				2022-12-18	WOS:000254884000039
J	Lively, TN; Kossen, K; Balhorn, A; Koya, T; Zinnen, S; Takeda, K; Lucas, JJ; Polisky, B; Richards, IM; Gelfand, EW				Lively, Tricia N.; Kossen, Karl; Balhorn, Annette; Koya, Toshiyuki; Zinnen, Shawn; Takeda, Katsuyuki; Lucas, Joseph J.; Polisky, Barry; Richards, Ivan M.; Gelfand, Erwin W.			Effect of chemically modified IL-13 short interfering RNA on development	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						siRNA; IL-13; AHR; eosinophilia	AIRWAY HYPERRESPONSIVENESS; MAST-CELLS; MODIFIED SIRNAS; MOUSE MODEL; IN-VIVO; INTERLEUKIN-13; INFLAMMATION; ASTHMA; HYPERREACTIVITY; INHIBITION	Background: RNA interference is an endogenous cellular mechanism in which short interfering RNAs (siRNAs) direct the sequence specific degradation of a target mRNA. siRNAs can be synthesized with chemical modifications to increase stability and reduce double-stranded RNA-induced immune responses without affecting their ability to elicit degradation of target mRNA. Objectives: This study examined the use of chemically modified siRNAs in a mouse model of allergen-induced airway hyperresponsiveness. Methods: Chemically modified siRNAs were designed and screened in a cell-based reporter assay. The most potent siRNAs were then screened in bone marrow-derived mast cells to demonstrate efficacy in primary cells. Results: A candidate siRNA was formulated and administered to sensitized mice just before airway challenge with allergen. Administration of the siRNA was shown to reduce airway resistance significantly in sensitized and challenged mice by 60%, whereas a control siRNA had no effect. Conclusion: These data demonstrate the effectiveness of introducing targeted siRNAs to prevent induction of allergen-induced airway dysfunction and suggest potential therapeutic applications.	[Lively, Tricia N.; Balhorn, Annette; Koya, Toshiyuki; Takeda, Katsuyuki; Lucas, Joseph J.; Gelfand, Erwin W.] Natl Jewish Ctr Immunol & Resp Med, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; [Kossen, Karl; Zinnen, Shawn; Polisky, Barry; Richards, Ivan M.] Sirna Therapeut, Boulder, CO USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Ctr Immunol & Resp Med, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org			NHLBI NIH HHS [HL-61005, P01 HL036577, HL-36577, R01 HL061005] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL061005] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Bragonzi A, 1999, GENE THER, V6, P1995, DOI 10.1038/sj.gt.3301039; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408; Ge Q, 2004, P NATL ACAD SCI USA, V101, P8676, DOI 10.1073/pnas.0402486101; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HARTSOUGH KC, 2006, P AM THOR SOC, V3, pA584; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280; Li GM, 2005, CELL IMMUNOL, V238, P10, DOI 10.1016/j.cellimm.2005.12.001; Matsuyama W, 2006, J IMMUNOL, V176, P1928, DOI 10.4049/jimmunol.176.3.1928; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TAKEDA K, 2005, ALLERGOL INT, V54, P263; Taube C, 2004, J IMMUNOL, V172, P6398, DOI 10.4049/jimmunol.172.10.6398; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Tomkinson A, 2002, J ALLERGY CLIN IMMUN, V109, P810, DOI 10.1067/mai.2002.123531; Tompkins SM, 2004, P NATL ACAD SCI USA, V101, P8682, DOI 10.1073/pnas.0402630101; Townley RG, 2003, CLIN REV ALLERG IMMU, V24, P85, DOI 10.1385/CRIAI:24:1:85; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; Yang M, 2001, AM J RESP CELL MOL, V25, P522, DOI 10.1165/ajrcmb.25.4.4620; Zhang WD, 2005, NAT MED, V11, P56, DOI 10.1038/nm1174; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	35	27	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					88	94		10.1016/j.jaci.2007.08.029	http://dx.doi.org/10.1016/j.jaci.2007.08.029			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17936889	Green Published, Bronze			2022-12-18	WOS:000252372000013
J	Gonzalez-Rioja, R; Ibarrola, I; Arilla, MC; Ferrer, A; Mir, A; Andreu, C; Martinez, A; Asturias, JA				Gonzalez-Rioja, Roberto; Ibarrola, Ignacio; Arilla, M. Carmen; Ferrer, Angel; Mir, Amparo; Andreu, Carmen; Martinez, Alberto; Asturias, Juan A.			Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hybrid proteins; IgE epitope; Parietaria pollen allergy; recombinant hypoallergens; T-cell epitope	MAJOR ALLERGEN; GRASS-POLLEN; RECOMBINANT ALLERGENS; CDNA CLONING; RESPONSES; PAR-J-1; VACCINATION; EPITOPES; IMMUNOGENICITY; IDENTIFICATION	Background: Despite the use of conventional allergen-specific immunotherapy in clinical practice, more defined, efficient, and safer allergy vaccines are required. Objective: The aim of the study was to obtain hypoallergenic molecules by deleting B-cell epitopes, which could potentially be applied to Parietaria judaica pollen allergy treatment. Methods: Three hybrid molecules (Q1, Q2, and Q3) derived from fragments of the 2 major P judaica pollen allergens, Par j 1 and Par j 2, were engineered by means of PCR. Hybrid structures were compared with their natural components by means of circular dichroism, and their biologic activities were compared by using T-cell proliferation assays. Their IgE-binding activity was determined with Western blotting, skin prick tests, and enzyme allergosorbent and ELISA inhibition tests. Results: The hybrid proteins, especially Q2 and Q3, revealed significantly reduced IgE reactivity compared with the natural allergens, as well as with the whole P judaica extract. Furthermore, in vivo skin prick tests showed that the hybrid proteins had a significantly lower potency to induce cutaneous reactions than the whole P judaica extract. Two (Q1 and Q2) of the 3 hybrid proteins induced a comparable T-cell proliferation response as that produced by the whole extract and natural allergens. Conclusion: Considering its reduced anaphylactogenic potential, together with its conserved T-cell reactivity, the engineered Q2 protein could be used in safe and shortened schedules of allergen-specific immunotherapy against P judaica pollen allergy.Clinical implications: Recombinant hybrid Q2 is able to induce T-cell proliferation, thus evidencing a potential therapeutic effect. Its reduced IgE-binding capacity envisages an excellent safety profile.	Dept Res & Dev, E-48008 Bilbao, Spain; Hosp Vega Baja Orihhuela, Serv Alergia, Alicante, Spain; Univ Valencia, Gandia & Cent Res Univ, Francisco Borja Hosp, Allergy Serv, Valencia, Spain	University of Valencia	Asturias, JA (corresponding author), Dept Res & Dev, Alameda Urquijo 27, E-48008 Bilbao, Spain.	juan.asturias@bial.com		Asturias, Juan/0000-0001-9570-522X; Ferrer, Angel/0000-0001-6567-053X				Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Akdis CA, 2000, INT ARCH ALLERGY IMM, V121, P261, DOI 10.1159/000024352; Akdis CA, 2000, ALLERGY, V55, P522, DOI 10.1034/j.1398-9995.2000.00120.x; Arilla MC, 2006, CLIN EXP ALLERGY, V36, P87, DOI 10.1111/j.1365-2222.2006.02406.x; Asturias JA, 2004, J INVEST ALLERG CLIN, V14, P43; Asturias JA, 2003, CLIN EXP ALLERGY, V33, P978, DOI 10.1046/j.1365-2222.2003.01707.x; Asturias JA, 2003, CLIN EXP ALLERGY, V33, P518, DOI 10.1046/j.1365-2222.2003.01631.x; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bonura A, 2007, INT ARCH ALLERGY IMM, V142, P274, DOI 10.1159/000097358; Bonura A, 2001, INT ARCH ALLERGY IMM, V126, P32, DOI 10.1159/000049492; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Colombo P, 1998, ALLERGY, V53, P917, DOI 10.1111/j.1398-9995.1998.tb03791.x; Colombo P, 2003, INT ARCH ALLERGY IMM, V130, P173, DOI 10.1159/000069520; Colombo P, 1998, J IMMUNOL, V160, P2780; Cortes L, 2006, J ALLERGY CLIN IMMUN, V118, P878, DOI 10.1016/j.jaci.2006.05.029; COSTA MA, 1994, FEBS LETT, V341, P182, DOI 10.1016/0014-5793(94)80453-2; Costa MA, 2000, ALLERGY, V55, P246, DOI 10.1034/j.1398-9995.2000.00265.x; Cromwell O, 2006, IMMUNOL ALLERGY CLIN, V26, P261, DOI 10.1016/j.iac.2006.02.001; De Palma R, 1999, J IMMUNOL, V162, P1982; Duro G, 1996, FEBS LETT, V399, P295, DOI 10.1016/S0014-5793(96)01328-2; Ferreira Fatima, 2006, Inflammation & Allergy Drug Targets, V5, P5, DOI 10.2174/187152806775269295; Georgiou G, 1996, CURR OPIN BIOTECH, V7, P190, DOI 10.1016/S0958-1669(96)80012-7; Gonzalez-Rioja R, 2007, CLIN EXP ALLERGY, V37, P243, DOI 10.1111/j.1365-2222.2007.02643.x; Ibarrola I, 2004, CLIN EXP ALLERGY, V34, P303, DOI 10.1111/j.1365-2222.2004.01859.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; King TP, 2001, J IMMUNOL, V166, P6057, DOI 10.4049/jimmunol.166.10.6057; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.11.041; Linhart B, 2005, CURR OPIN IMMUNOL, V17, P646, DOI 10.1016/j.coi.2005.09.010; Linhart B, 2005, J ALLERGY CLIN IMMUN, V115, P1010, DOI 10.1016/j.jaci.2004.12.1142; Linhart B, 2004, INT ARCH ALLERGY IMM, V134, P324, DOI 10.1159/000079535; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Schramm G, 1999, J IMMUNOL, V162, P2406; Stumvoll S, 2003, J ALLERGY CLIN IMMUN, V111, P974, DOI 10.1067/mai.2003.1376; TRAPANI A, 2006, 25 C VIENN AUSTR JUN, P15; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; Valenta R, 2004, METHODS, V32, P207, DOI 10.1016/j.ymeth.2003.08.001; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Westritschnig K, 2003, CURR OPIN ALLERGY CL, V3, P495, DOI 10.1097/01.all.0000104454.09202.1b	42	27	32	3	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					602	609		10.1016/j.jaci.2007.04.039	http://dx.doi.org/10.1016/j.jaci.2007.04.039			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17561242	Bronze			2022-12-18	WOS:000249505400019
J	Jartti, T; Burmeister, KA; Seroogy, CM; Jennens-Clough, MLA; Tisler, CJ; Salazar, LP; DaSilva, DF; Evans, MD; Vrtis, RF; Wallace, PK; Ruiz-Perez, B; Gangnon, RE; Lemanske, RF; Gern, JE				Jartti, Tuomas; Burmeister, Kristjan A.; Seroogy, Christine M.; Jennens-Clough, Martha L. A.; Tisler, Christopher J.; Salazar, Lisa P.; DaSilva, Douglas F.; Evans, Michael D.; Vrtis, Rose F.; Wallace, Paul K.; Ruiz-Perez, Begona; Gangnon, Ronald E.; Lemanske, Robert F., Jr.; Gern, James E.			Association between CD4(+)CD25(high) T cells and atopy in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						regulatory CD4(+)CD25(+) T cell; activated T cell; seasonality; atopy; pollen sensitization; cytokine; wheezing; atopic dermatitis; sex; child	RESPONSE PATTERNS; PERIPHERAL-BLOOD; REGULATORY CELLS; ASTHMA; SUPPRESSION; EXPRESSION; FOXP3; CHILDHOOD; INDUCTION; IMMUNOTHERAPY	Background: There is evidence that CD4(+)CD25(high) T-regulatory cells are important for establishing tolerance to allergens, but information in children is limited. Objective: To test the hypothesis that greater numbers and function of CD4(+)CD25(high) T cells are associated with a reduced risk of childhood allergies and wheezing. Methods: A cohort of 151 six-year-old children from atopic families was analyzed for peripheral blood CD4(+)CD25(high) and CD4(+)CD25(int) T cells by flow cytometry and for clinical and immunologic correlates of atopy. The associations between these variables were assessed by regression analysis. Results: Factors positively associated with % CD4(+)CD25(high)/ CD4 T cells were male sex, number of positive allergen-specific IgE tests, total IgE, season, and 1-month average total pollen count preceding blood draw. The percentage of CD4(+)CD25(high)/ total CD4 T cells did not correlate with induced cytokine production, and correlated negatively with suppressive capacity of CD4(+)CD25(+) T cells (r = -0.45; P = .034). The percentage of CD4(+)CD25(int)/CD4 T cells was 54% higher in pollen-sensitized children compared with nonsensitized children in spring (P = .023 for interaction), and correlated positively with IL-5, IL-10, and IL-13 (P <= .001 for all). Conclusion: Our findings suggest that blood CD4(+)CD25(high) cells are a mixture of activated and regulatory T cells, and that these cells could be seasonally regulated by environmental factors such as pollen exposure. Clinical implications: Seasonal increases in CD4CD25(high) expression in children with allergy may represent systemic immune activation caused by pollen exposures.	Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Roswell Pk Canc Inst, Dept Flow Cytometry, Buffalo, NY 14263 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Roswell Park Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Gern, JE (corresponding author), K4-918 CSC,600 Highland Ave, Madison, WI 53792 USA.	Gern@medicine.wisc.edu	Wallace, PK/ABB-7704-2022	Wallace, PK/0000-0001-7823-9917; Evans, Michael/0000-0001-7449-3993; Gangnon, Ronald/0000-0003-2587-6714	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR003186] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080072, P01HL070831] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR03186] Funding Source: Medline; NHLBI NIH HHS [R01 HL080072, P01 HL70831] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, P99, DOI 10.1067/mai.2001.112119; Baecher-Allan C, 2005, CLIN IMMUNOL, V115, P10, DOI 10.1016/j.clim.2005.02.018; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; GemouEngesaeth V, 1997, PEDIATRICS, V99, P695, DOI 10.1542/peds.99.5.695; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Mantel PY, 2006, J IMMUNOL, V176, P3593, DOI 10.4049/jimmunol.176.6.3593; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1016/S0091-6749(03)01868-2; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Shi HZ, 2004, CLIN IMMUNOL, V113, P172, DOI 10.1016/j.clim.2004.06.009; Smith EG., 1984, SAMPLING IDENTIFYING; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q; Uekert SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1375, DOI 10.1016/j.jaci.2006.09.008; Valencia X, 2006, BLOOD, V108, P253, DOI 10.1182/blood-2005-11-4567; van Oosterhout AJM, 2005, EUR RESPIR J, V26, P918, DOI 10.1183/09031936.05.00011205; Vukmanovic-Stejic M, 2005, BRIT J DERMATOL, V153, P750, DOI 10.1111/j.1365-2133.2005.06675.x; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441	27	27	28	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					177	183		10.1016/j.jaci.2007.03.008	http://dx.doi.org/10.1016/j.jaci.2007.03.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17433828				2022-12-18	WOS:000248066400026
J	Reefer, AJ; Satinover, SM; Wilson, BB; Woodfolk, JA				Reefer, Amanda J.; Satinover, Shama M.; Wilson, Barbara B.; Woodfolk, Judith A.			The relevance of microbial allergens to the IgE antibody repertoire in atopic and nonatopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; bacterial allergens; fungal allergens; IgE antibodies; atopy; chemokines; thymus and activation-regulated chemokine; macrophage inflammatory protein 3 alpha; inhalant allergens; food allergens	ACTIVATION-REGULATED CHEMOKINE; DUST-MITE ALLERGENS; EUROPEAN TASK-FORCE; DENDRITIC CELLS; SEBORRHEIC DERMATITIS; CONSENSUS REPORT; IMMUNE-RESPONSE; SERUM THYMUS; SCORAD INDEX; T-CELLS	Background: A propensity to microbial skin infections has been reported in atopic ("high IgE") and nonatopic ("low IgE") forms of eczema. However, the relationship between antimicrobial IgE antibodies and nonatopic disease is unclear. Objective: We examined the relevance of microbial allergens to the allergen-specific IgE antibody repertoire in patients with atopic dermatitis. Methods: Patients with IgE levels of less than 150 IU/mL were stratified according to sensitivity (n = 22) or no sensitivity (n = 27) to 11 common food allergens and aeroallergens. The prevalence and titers of antimicrobial IgE antibodies were compared with those of patients (n = 36) with increased total IgE levels (> 150 IU/mL). Skin-derived serum chemokines were also analyzed. Results: Patients with low IgE levels showed decreased disease severity, increased age of onset, a striking female predominance, and a distinct distribution of skin lesions. High titer IgE antibodies (sum of 8 bacterial and fungal allergens 29.8 +/- 32.6 IU/mL) and multisensitization specific for microbial allergens was characteristic of patients with high IgE levels, with an overall 84% positivity; however, antimicrobial IgE antibodies comprised 3% or less of allergen-specific IgE antibodies. By contrast, antimicrobial IgE antibodies were detected in only 20% of patients with low IgE, and titers were negligible, irrespective of sensitization to common allergens. These patients were monosensitized, and exclusive microbial sensitivity was uncommon (10%). Patients with low IgE with no sensitivity to common allergens had lower levels of serum macrophage inflammatory protein 3 alpha compared with their sensitized counterparts. Conclusion: Antimicrobial IgE antibodies are uncommon in patients with atopic dermatitis with low IgE levels. Clinical implications: Hypersensitivity to microbial allergens is an unlikely trigger for eczematous eruptions in patients with low IgE levels.	Univ Virginia Hlth Syst, Div Allergy, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Dermatol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Woodfolk, JA (corresponding author), Univ Virginia Hlth Syst, Div Allergy, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu						Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Casagrande BF, 2006, J INVEST DERMATOL, V126, P2414, DOI 10.1038/sj.jid.5700431; Fabrizi G, 1999, EUR J DERMATOL, V9, P380; Falk MHS, 2005, ACTA DERM-VENEREOL, V85, P17, DOI 10.1080/00015550410022276; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hirahara K, 2006, J IMMUNOL, V177, P4488, DOI 10.4049/jimmunol.177.7.4488; Howell MD, 2006, CLIN IMMUNOL, V121, P332, DOI 10.1016/j.clim.2006.08.008; Jackola DR, 2004, HUM IMMUNOL, V65, P20, DOI 10.1016/j.humimm.2003.10.012; Jahnz-Rozyk K, 2005, ALLERGY, V60, P685, DOI 10.1111/j.1398-9995.2005.00774.x; KAGI MK, 1994, INT ARCH ALLERGY IMM, V103, P332, DOI 10.1159/000236651; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Keller M, 2005, J IMMUNOL, V175, P7678, DOI 10.4049/jimmunol.175.11.7678; KIEFFER M, 1990, J AM ACAD DERMATOL, V22, P739, DOI 10.1016/0190-9622(90)70100-V; Kim BE, 2007, J ALLERGY CLIN IMMUN, V119, P457, DOI 10.1016/j.jaci.2006.10.005; Kim TY, 1999, CLIN EXP DERMATOL, V24, P226, DOI 10.1046/j.1365-2230.1999.00460.x; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; Nakayama T, 2001, INT IMMUNOL, V13, P95, DOI 10.1093/intimm/13.1.95; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P215, DOI 10.1067/mai.2003.1590; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2002, J INVEST DERMATOL, V119, P870, DOI 10.1046/j.1523-1747.2002.00191.x; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Oppel T, 2000, BRIT J DERMATOL, V143, P1193, DOI 10.1046/j.1365-2133.2000.03887.x; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Reefer AJ, 2007, J ALLERGY CLIN IMMUN, V119, pS238, DOI 10.1016/j.jaci.2006.12.605; Ricci G, 2000, BRIT J DERMATOL, V143, P379, DOI 10.1046/j.1365-2133.2000.03666.x; Ring J, 2001, J AM ACAD DERMATOL, V45, pS49, DOI 10.1067/mjd.2001.117015.24; Salt BH, 2007, J ALLERGY CLIN IMMUN, V119, P508, DOI 10.1016/j.jaci.2006.11.006; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Schafer T, 2000, BRIT J DERMATOL, V143, P992, DOI 10.1046/j.1365-2133.2000.03832.x; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Zheng XY, 2003, J DERMATOL, V30, P26	41	27	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					156	163		10.1016/j.jaci.2007.03.042	http://dx.doi.org/10.1016/j.jaci.2007.03.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17507082	Bronze			2022-12-18	WOS:000248066400023
J	Kinnunen, T; Jutila, K; Kwok, WW; Rytoknen-Nissinen, M; Immonen, A; Saarelainen, S; Narvanen, A; Taivainen, A; Virtanen, T				Kinnunen, Tuure; Jutila, Kalle; Kwok, William W.; Rytoknen-Nissinen, Marja; Immonen, Anu; Saarelainen, Soili; Narvanen, Ale; Taivainen, Antti; Virtanen, Tuomas			Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; altered peptide ligand; Bos d 2; lipocalin allergen; peptide immunotherapy; T cells; T-cell receptorss; T(H)1/T(H)2	T-CELL EPITOPE; MULTIPLE-SCLEROSIS; IMMUNE DEVIATION; INDUCTION; MODULATION; ACTIVATION; RESPONSES; CLONES; ANERGY; ENCEPHALOMYELITIS	Background: Peptide immunotherapy is a promising alternative for treating allergic diseases. One way to enhance the efficacy of peptide immunotherapy is to use altered peptide ligands (APLs) that contain amino acid substitutions compared with the natural peptide. Objective: To evaluate the potential of an APL of the immunodominant epitope of lipocalin allergen Bos d 2 for peptide immunotherapy. Methods: Peripheral blood CD4(+) T-cell responses of 8 HLA-DR-4-positive subjects to the natural ligand of Bus d 2 (p127-142) or to an APL (pN135D) were analyzed by MHC class If tetramer staining after in vitro expansion with the peptides. Long-term T-cell lines (TCLs) were induced with the peptides, and the cytokine production, cross-reactivity, and T-cell receptor V beta subtype expression of the TCLs were analyzed. Results: CD4(+) T cells specific for both p127-142 and pN135D were readily detected in peripheral blood after a single in vitro stimulation. Whereas the TCLs induced with p127-142 were T(H)2/T(H)0-deviated, those induced with pN135D were T(H)1/T(H)0-deviated and highly cross-reactive with p127-142. Moreover, the pN135D-induced TCLs appeared to use a broader repertoire of T-cell receptor V beta subtypes than those induced with p127-142. Conclusion: An APL of an immunodominant allergen epitope was able to induce a novel T(H)1-deviated T-cell population cross-reactive with the natural epitope in vitro. This cell population could have a therapeutic immunomodulatory function in vivo through bystander suppression. Clinical implications: These results support the idea that altered peptide ligands may be used to enhance the efficacy of peptide immunotherapy.	Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Pulm Dis, SF-70210 Kuopio, Finland; Virginia Mason, Benaroya Res Inst, Seattle, WA USA	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Benaroya Research Institute; Virginia Mason Medical Center	Kinnunen, T (corresponding author), Univ Kuopio, Dept Clin Microbiol, POB 1627, FIN-70211 Kuopio, Finland.	ttkinnun@hytti.uku.fi	Kinnunen, Tuure/D-4898-2011; Narvanen, Ale/A-6002-2009	Kinnunen, Tuure/0000-0003-1595-5371; Rytkonen-Nissinen, Marja/0000-0002-2014-8315				Alleva DG, 2002, DIABETES, V51, P2126, DOI 10.2337/diabetes.51.7.2126; Ausubel LJ, 1999, CELL IMMUNOL, V193, P99, DOI 10.1006/cimm.1998.1447; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FRANCO A, 1994, EUR J IMMUNOL, V24, P940, DOI 10.1002/eji.1830240424; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Janssen EM, 2000, J IMMUNOL, V164, P580, DOI 10.4049/jimmunol.164.2.580; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kinnunen T, 2005, INT IMMUNOL, V17, P1573, DOI 10.1093/intimm/dxh332; Kinnunen T, 2003, EUR J IMMUNOL, V33, P1717, DOI 10.1002/eji.200322952; Kinnunen T, 2005, CLIN EXP ALLERGY, V35, P797, DOI 10.1111/j.1365-2222.2005.02247.x; Larche M, 2001, IMMUNOLOGY, V104, P377, DOI 10.1046/j.1365-2567.2001.01293.x; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734, DOI 10.4049/jimmunol.167.3.1734; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Ponsaerts P, 2002, J IMMUNOL, V169, P1669, DOI 10.4049/jimmunol.169.4.1669; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Ria F., 2001, Current Molecular Medicine (Hilversum), V1, P297, DOI 10.2174/1566524013363690; Santambrogio L, 1998, J NEUROIMMUNOL, V81, P1, DOI 10.1016/S0165-5728(97)00138-0; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; Turvy DN, 1998, J IMMUNOL METHODS, V212, P9, DOI 10.1016/S0022-1759(97)00206-8; Vergelli M, 1996, EUR J IMMUNOL, V26, P2624, DOI 10.1002/eji.1830261113; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Verhoef A, 2000, J IMMUNOL, V164, P6034, DOI 10.4049/jimmunol.164.11.6034; Wilton SD, 1997, BIOTECHNIQUES, V22, P642, DOI 10.2144/97224bm14; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0; YAMAMOTO K, 1992, INT IMMUNOL, V4, P1219, DOI 10.1093/intimm/4.11.1219; Yoshida K, 2002, BLOOD, V99, P2499, DOI 10.1182/blood.V99.7.2499; Zeiler T, 1999, J IMMUNOL, V162, P1415	40	27	43	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					965	972		10.1016/j.jaci.2007.01.011	http://dx.doi.org/10.1016/j.jaci.2007.01.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17335888				2022-12-18	WOS:000245729500028
J	Lee, KS; Kim, SR; Park, HS; Park, SJ; Min, KH; Lee, KY; Jin, SM; Lee, YC				Lee, Kyung Sun; Kim, So Ri; Park, Hee Sun; Park, Seoung Ju; Min, Kyung Hoon; Lee, Ka Young; Jin, Sun Mi; Lee, Yong Chul			Cysteinyl leukotriene upregulates IL-11 expression in allergic airway disease of mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cysteinyl leukotrienes; IL-11; airway; inflammation; remodeling	FACTOR-KAPPA-B; GROWTH-FACTOR; TISSUE INHIBITOR; GENE-EXPRESSION; INTERLEUKIN-11; CYTOKINE; ASTHMA; INFLAMMATION; CELLS; ACTIVATION	Background: Chronic airway inflammation and airway remodeling are important features of bronchial asthma. IL-11 is one of the important mediators involved in the process of airway inflammation and remodeling. Cysteinyl leukotrienes (cysLTs) play roles in recruitment of inflammatory cells, airway smooth muscle contraction, vascular leakage, increased mucus secretion, decreased mucociliary clearance, and airway fibrosis. Objective: An aim of the present study was to determine the effect of the cysLTs on the regulation of IL-11 expression. Methods: We used a C57BL/6 mouse model of allergic airway disease and murine tracheal epithelial cells to examine the effects of cysLTs on the regulation of IL-11 expression. Results: Our present study with an ovalbumin-induced murine model of allergic airway disease revealed that levels of leukotriene C-4 (LTC4) in bronchoalveolar lavage fluids were increased and that administration of montelukast or pranlukast reduced the increased levels of LTC4; the increased expression of IL-11 protein and mRNA in lung tissues; airway inflammation, bronchial hyperresponsiveness; the increased levels of TGF-beta 1, IL-4, and IL-13 in bronchoalveolar lavage fluids and lung tissues; and airway fibrosis. In addition, LTC4 stimulates epithelial cells to produce IL-11. Our results also showed that cysLT type I receptor antagonists downregulated the activity of a transcription factor, nuclear factor kappa B, and BAY 11-7085 substantially reduced the increased levels of IL-11 after ovalbumin inhalation. Conclusion: These results suggest that cysLTs regulate the IL-11 expression in allergic airway disease. Clinical implications: These findings provide one of the molecular mechanisms for the effects of cysLTs on airway inflammation and fibrosis in allergic airway diseases.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Airway Remodeling Lab, Jeonju 561180, South Korea	Jeonbuk National University	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, Airway Remodeling Lab, San 2-20,Geumam Dong, Jeonju 561180, South Korea.	leeyc@chonbuk.ac.kr	Park, Seoungju/D-4444-2014; Kim, So Ri/AAS-1630-2021	Kim, So Ri/0000-0002-6074-9158; Park, Hee Sun/0000-0002-9730-8524				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bamba S, 2003, AM J PHYSIOL-GASTR L, V285, pG529, DOI 10.1152/ajpgi.00050.2003; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Busse WW, 1998, AM J RESP CRIT CARE, V157, pS210, DOI 10.1164/ajrccm.157.6.mar-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cobellis G, 1999, J NEUROENDOCRINOL, V11, P725; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DU XX, 1994, BLOOD, V83, P33; DU XX, 1994, BLOOD, V83, P2023; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; ELIAS JA, 1994, J BIOL CHEM, V269, P22261; ELIAS JA, 1995, ENDOCRINOLOGY, V136, P489, DOI 10.1210/en.136.2.489; ELIAS JA, 1994, J IMMUNOL, V152, P2421; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Kawano T, 2003, J ALLERGY CLIN IMMUN, V112, P369, DOI 10.1067/mai.2003.1636; Komura E, 2005, CANCER RES, V65, P3281, DOI 10.1158/0008-5472.CAN-04-2339; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Lee KS, 2004, J ALLERGY CLIN IMMUN, V114, P1093, DOI 10.1016/j.jaci.2004.07.039; Lynch KR, 1999, NATURE, V399, P789; MAIER R, 1993, J BIOL CHEM, V268, P21527; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; Minshall E, 2000, J ALLERGY CLIN IMMUN, V105, P232, DOI 10.1016/S0091-6749(00)90070-8; NEBEN S, 1993, STEM CELLS, V11, P156; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Redington AE, 1997, THORAX, V52, P310, DOI 10.1136/thx.52.4.310; ROEB E, 1993, HEPATOLOGY, V18, P1437, DOI 10.1016/0270-9139(93)90236-G; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Yang G, 2004, J CLIN INVEST, V114, P669, DOI 10.1172/JCI200419300; YANG L, 1994, J BIOL CHEM, V269, P32732; Yang L, 1996, MOL CELL BIOL, V16, P3300; YANG L, 1995, BLOOD, V86, P2526, DOI 10.1182/blood.V86.7.2526.bloodjournal8672526; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337; ZHENG T, 1994, J IMMUNOL, V153, P4742; Zhu Z, 2001, AM J RESP CRIT CARE, V164, pS67, DOI 10.1164/ajrccm.164.supplement_2.2106070	46	27	37	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					141	149		10.1016/j.jaci.2006.09.001	http://dx.doi.org/10.1016/j.jaci.2006.09.001			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208595				2022-12-18	WOS:000243622200020
J	Sicherer, SH; Bock, SA				Sicherer, Scott H.; Bock, S. Allan			An expanding evidence base provides food for thought to avoid indigestion in managing difficult dilemmas in food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						food allergy; diagnostic testing; oral food challenge	PEANUT ALLERGY; SKIN-TEST; CHILDREN; ANAPHYLAXIS; MANAGEMENT; ANTIGEN; PROTEIN; MODEL; SENSITIZATION; CHALLENGES		Mt Sinai Sch Med, Elliot & roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Dept Pediat, New York, NY USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA	Icahn School of Medicine at Mount Sinai; National Jewish Health	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu						Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Baker SS, 2000, PEDIATRICS, V106, P346; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; CHAPMAN JA, 2006, IN PRESS ANN ALLERGY; DAVID TJ, 1984, ARCH DIS CHILD, V59, P983, DOI 10.1136/adc.59.10.983; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V114, P377, DOI 10.1016/j.jaci.2004.03.040; Hauswirth DW, 2005, J ALLERGY CLIN IMMUN, V115, P632, DOI 10.1016/j.jaci.2004.10.034; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Omata N, 2005, J ALLERGY CLIN IMMUN, V115, P822, DOI 10.1016/j.jaci.2004.12.1121; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Reininger R, 2003, INT ARCH ALLERGY IMM, V130, P275, DOI 10.1159/000070214; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roberts G, 2002, ALLERGY, V57, P713, DOI 10.1034/j.1398-9995.2002.03366.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P1146, DOI 10.1016/j.jaci.2004.07.034; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353	32	27	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1419	1422		10.1016/j.jaci.2006.01.051	http://dx.doi.org/10.1016/j.jaci.2006.01.051			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751007				2022-12-18	WOS:000238332300033
J	Seidel-Guyenot, W; Perschon, S; Dechant, N; Alt, R; Knop, J; Steinbrink, K				Seidel-Guyenot, Wolfgang; Perschon, Sylwia; Dechant, Natascha; Alt, Ruth; Knop, Jurgen; Steinbrink, Kerstin			Low zone tolerance induced by systemic application of allergens inhibits T(C)1-mediated skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						tolerance; contact allergens; contact hypersensitivity; regulatory T cells; haptens; occupational disease	REGULATORY T-CELLS; ORAL TOLERANCE; CONTACT SENSITIVITY; AUTOIMMUNE ENCEPHALOMYELITIS; ULTRAVIOLET-RADIATION; INDUCTION; MICE; SUPPRESSION; NICKEL; HYPERSENSITIVITY	Background: The induction of tolerance may be a promising target of strategies aimed at preventing harmful allergic diseases. Low zone tolerance (LZT), induced by epicutaneous application of low doses of contact allergens, inhibits the development of T(C)1-mediated contact hypersensitivity (CHS). Objective: We evaluated the effect of systemic (oral, intravenous) administration of low amounts of haptens; on specific immune reactions and tolerance induction. Methods: By using the mouse model of LZT, we analyzed immune reactions in vivo (skin inflammation) and T-cell responses in vitro after oral, intravenous, or epicutaneous application of low amounts of the contact allergen 2,4,6-trinitro-1-chlorobenzene (TNCB). Results: Subimmunogenic doses of TNCB applied orally and intravenously induced a significant tolerance reaction in vivo comparable to epicutaneously tolerized mice, indicating that LZT is a systemically mediated tolerance reaction. In vitro analysis in all models of LZT revealed the generation of IL-10 secreting, regulatory CD4(+) T cells that were absolutely required for the development of hapten-specific CD8(+) T(C)2 cells. Adoptive transfer experiments identified CD8(+) T(C)2 cells as effector T cells of LZT inhibiting the development of CHS-promoting T(C)1 cells and consequently the manifestation of CHS. These suppressor CD8(+) T(C)2 cells were found as well in skin-draining as in mesenteric lymph nodes and in the spleen of tolerized animals independent of the route of tolerization. Conclusion: These data indicate that systemic uptake and presentation of small amounts of haptens (eg, contact allergens, drugs, metals) induce the development of LZT and thus prevent inappropriate activation of the immune system and protect from allergic diseases. Clinical implications: These findings will be of particular importance because tolerance induction by protocols applying subimmunogenic, low amounts of haptens may be used as tools for immunotherapy in allergic and autoimmune diseases.	Univ Mainz, Dept Dermatol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Steinbrink, K (corresponding author), Univ Mainz, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany.	steinbrink@hautklinik.klinik.uni-mainz.de						Cavani A, 2003, J IMMUNOL, V171, P5760, DOI 10.4049/jimmunol.171.11.5760; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Chen YH, 1996, P NATL ACAD SCI USA, V93, P388, DOI 10.1073/pnas.93.1.388; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; CLAMAN HN, 1976, J IMMUNOL, V116, P704; Desvignes C, 2000, J IMMUNOL, V164, P2515, DOI 10.4049/jimmunol.164.5.2515; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; EISEN HN, 1952, J EXP MED, V95, P473, DOI 10.1084/jem.95.5.473; ELMETS CA, 1983, J EXP MED, V158, P781, DOI 10.1084/jem.158.3.781; FAIRCHILD RL, 1986, J IMMUNOL, V137, P2125; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Fujihashi K, 2001, P NATL ACAD SCI USA, V98, P3310, DOI 10.1073/pnas.061412598; FURUE M, 1985, J INVEST DERMATOL, V85, P139, DOI 10.1111/1523-1747.ep12276557; Garside P, 2001, SEMIN IMMUNOL, V13, P177, DOI 10.1006/smim.2001.0310; Gautam S C, 1989, Reg Immunol, V2, P33; GAUTAM SC, 1985, J IMMUNOL, V135, P2975; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; Lushniak BD, 2003, INT ARCH OCC ENV HEA, V76, P325, DOI 10.1007/s00420-002-0417-2; Maurer M, 2003, J CLIN INVEST, V112, P432, DOI 10.1172/JCI200318106; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; NAKANO Y, 1981, IMMUNOLOGY, V42, P111; Roelofs-Haarhuis K, 2004, J IMMUNOL, V173, P1043, DOI 10.4049/jimmunol.173.2.1043; Roelofs-Haarhuis K, 2003, J IMMUNOL, V171, P2863, DOI 10.4049/jimmunol.171.6.2863; Schwarz A, 2004, J IMMUNOL, V172, P1036, DOI 10.4049/jimmunol.172.2.1036; Seidel-Guyenot W, 2004, EUR J IMMUNOL, V34, P3082, DOI 10.1002/eji.200425402; Steinbrink K, 1996, J INVEST DERMATOL, V107, P243, DOI 10.1111/1523-1747.ep12329721; Steinbrink K, 1996, J EXP MED, V183, P759, DOI 10.1084/jem.183.3.759; Wu HY, 2003, IMMUNOL RES, V28, P265, DOI 10.1385/IR:28:3:265; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001	30	27	30	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1170	1177		10.1016/j.jaci.2006.01.014	http://dx.doi.org/10.1016/j.jaci.2006.01.014			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675348				2022-12-18	WOS:000237436300032
J	Davis, BE; Todd, DC; Cockcroft, DW				Davis, BE; Todd, DC; Cockcroft, DW			Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antihistamine; leukotriene antagonist; allergen inhalation	LEUKOTRIENE RECEPTOR ANTAGONIST; INDUCED AIRWAY RESPONSES; INDUCED BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS; ORAL CETIRIZINE; HISTAMINE; BECLOMETHASONE; HYPERRESPONSIVENESS; METHACHOLINE; MANAGEMENT	Background: The early asthmatic response (EAR) to inhaled allergen results from IgE-mediated release of multiple mast-cell mediators, including leukotrienes and histamine, both of which cause bronchoconstriction. Combination therapy directed at blocking the effects of both mediators might protect against the EAR better than either therapy alone. Objective; We sought to evaluate the effect of desloratadine and montelukast, administered alone and in combination, on the EAR to inhaled allergen. Methods: Ten adults with mild-to-moderate atopic asthma participated in a randomized, 4-way crossover study design comparing placebo, 5 mg of desloratadine, 10 mg of montelukast, and the combination administered at 26 hours and 2 hours before each allergen challenge conducted at least 7 days apart. The primary end point was the concentration of allergen that resulted in a 20% decrease in FEVI (PC20). Results: The geometric mean allergen PC20 (mean log +/- SEM) for combination therapy, montelukast, desloratadine, and placebo was 697 U/mL (2.8433 +/- 0.3253), 338 U/mL (2.5295 +/- 0.2979), 123 U/mL (2.0883 +/- 0.2102), and 104 U/mL (2.0166 +/- 0.2553), respectively (n = 9; P < .00001, ANOVA). Montelukast increased the allergen PC20 4.8-fold, and combination therapy increased the allergen PC20 8.9-fold. The effect of the combination was greater than that with montelukast alone (P < .02). Desloratadine treatment was no different than placebo. Conclusions: The early response to inhaled allergen was unchanged after desloratadine therapy and partially inhibited with montelukast therapy. The combination of desloratadine and montelukast provided superior efficacy to either blocker administered alone. Investigations into the possible mechanisms of the enhanced inhibition are necessary.	Univ Saskatchewan, Div Resp Med, Royal Univ Hosp, Dept Med, Saskatoon, SK S7N 0W8, Canada	University of Saskatchewan	Cockcroft, DW (corresponding author), Univ Saskatchewan, Div Resp Med, Ellis Hall,Rm 551,5th Floor, Saskatoon, SK S7N 0W8, Canada.	cockcroft@sask.usask.ca						Bentley AM, 1996, CLIN EXP ALLERGY, V26, P909, DOI 10.1111/j.1365-2222.1996.tb00626.x; BJORCK T, 1993, PULM PHARMACOL, V6, P87, DOI 10.1006/pulp.1993.1012; Blake KV, 1999, ANN PHARMACOTHER, V33, P1299, DOI 10.1345/aph.18430; COCKCROFT DW, 1992, ANN ALLERGY, V68, P245; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1993, J ALLERGY CLIN IMMUN, V91, P1163, DOI 10.1016/0091-6749(93)90319-B; DAHLEN SE, 1991, ADV PROSTAG THROMB L, V21, P461; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; GONG H, 1990, J ALLERGY CLIN IMMUN, V85, P632, DOI 10.1016/0091-6749(90)90104-C; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Murdoch D, 2003, DRUGS, V63, P2051, DOI 10.2165/00003495-200363190-00010; Palmqvist M, 2005, ALLERGY, V60, P65, DOI 10.1111/j.1398-9995.2005.00633.x; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RAFFERTY P, 1990, BRIT J CLIN PHARMACO, V30, P229, DOI 10.1111/j.1365-2125.1990.tb03769.x; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Ruck LM, 2001, LIFE SCI, V68, P2825, DOI 10.1016/S0024-3205(01)01064-5; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TOWN GI, 1990, J ALLERGY CLIN IMMUN, V86, P886, DOI 10.1016/S0091-6749(05)80151-4	24	27	30	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					768	772		10.1016/j.jaci.2005.06.014	http://dx.doi.org/10.1016/j.jaci.2005.06.014			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210049				2022-12-18	WOS:000235686600009
J	Gold, DR; Acevedo-Garcia, D				Gold, DR; Acevedo-Garcia, D			Immigration to the United States and acculturation as risk factors for asthma and allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; allergy; children; immigration; migration; acculturation; Mexican American; Hispanic; Latino	PUERTO-RICAN; MEXICO-CITY; ATOPY; CHILDREN; RESPONSIVENESS; CALIFORNIA; HISPANICS; MORTALITY; ADULTS; BIRTH		Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Gold, DR (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	diane.gold@channing.harvard.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010922] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES10922] Funding Source: Medline; NCEH CDC HHS [R01 A1/EHS 35786] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCEH CDC HHS		Bermudez OI, 2000, J AM DIET ASSOC, V100, P665, DOI 10.1016/S0002-8223(00)00195-4; Borja-Aburto VH, 1998, ENVIRON HEALTH PERSP, V106, P849, DOI 10.2307/3434129; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Cagney KA, 2004, J GEN INTERN MED, V19, P229, DOI 10.1111/j.1525-1497.2004.30359.x; Eldeirawi K, 2005, J ALLERGY CLIN IMMUN, V116, P42, DOI 10.1016/j.jaci.2005.03.041; Finch BK, 2000, J HEALTH SOC BEHAV, V41, P295, DOI 10.2307/2676322; Hjern A, 1999, ACTA PAEDIATR, V88, P1107, DOI 10.1080/08035259950168171; Holguin F, 2005, AM J RESP CRIT CARE, V171, P103, DOI 10.1164/rccm.200402-143OC; Holguin F, 2003, EPIDEMIOLOGY, V14, P521, DOI 10.1097/01.ede.0000081999.15060.ae; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504, DOI 10.1164/ajrccm.161.2.9906025; Kalyoncu AF, 2002, EUR RESPIR J, V19, P980, DOI 10.1183/09031936.02.00305302; Krebs NF, 2003, PEDIATRICS, V112, P424, DOI 10.1542/peds.112.2.424; LEUNG R, 1994, AUST NZ J MED, V24, P255, DOI 10.1111/j.1445-5994.1994.tb02168.x; LEUNG RC, 1994, MED J AUSTRALIA, V161, P418, DOI 10.5694/j.1326-5377.1994.tb127522.x; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Norman B.A., 2004, ENCY HLTH BEHAV; Ortega AN, 2000, J NERV MENT DIS, V188, P728, DOI 10.1097/00005053-200011000-00002; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; ROBERTS B, CTR MIGRATION DEV WO; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Unger JB, 2000, HEALTH PSYCHOL, V19, P403, DOI 10.1037//0278-6133.19.5.403; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032	23	27	27	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					38	41		10.1016/j.jaci.2005.04.033	http://dx.doi.org/10.1016/j.jaci.2005.04.033			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990770				2022-12-18	WOS:000235686300005
J	Konno, S; Golden, DBK; Schroeder, J; Hamilton, RG; Lichtenstein, LM; Huang, SK				Konno, S; Golden, DBK; Schroeder, J; Hamilton, RG; Lichtenstein, LM; Huang, SK			Increased expression of osteopontin is associated with long-term bee venom immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						venom immunotherapy; gene chip microarray; clustering; osteopontin; biomarker	CYTOKINE; CELLS; PATIENT; MICE	Background: Venom allergen immunotherapy (VIT) is proven to be highly effective for insect allergy, but the mechanisms and the biomarkers associated with clinical efficacy remain elusive. Objective: The aim of this study was to identify candidate biomarkers associated with successful VIT. Methods: Gene chip array and clustering analyses of PBMCs from subjects with or without VIT were performed. Results: From gene chip array and clustering analyses, an increased expression of osteopontin was found in patients who completed 5 to 6 years of VIT and discontinued therapy for 3 to 6 years (completed treatment group) compared with the untreated group. A significantly higher level of serum osteopontin was found in the completed treatment group compared with the untreated group (n = 16 in each group; P < .001). Conclusion: The upregulation of osteopontin after VIT suggests a role of osteopontin as a candidate biomarker for VIT.	Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	skhuang@jhmi.edu	Konno, Satoshi/G-1669-2012; Huang, Shau-Ku/F-5509-2010		NIAID NIH HHS [AI-52468] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052468] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; CANTOR H, 1995, ANN NY ACAD SCI, V760, P143, DOI 10.1111/j.1749-6632.1995.tb44626.x; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chehimi J, 2001, CLIN IMMUNOL, V100, P49, DOI 10.1006/clim.2001.5039; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298, DOI 10.1016/S0091-6749(98)70239-8; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; Golden DBK, 2000, IMMUNOL ALLERGY CLIN, V20, P553, DOI 10.1016/S0889-8561(05)70166-1; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V87, P134, DOI 10.1016/S1081-1206(10)62207-7; Jansson M, 2002, J IMMUNOL, V168, P2096, DOI 10.4049/jimmunol.168.5.2096; Koguchi Y, 2002, INFECT IMMUN, V70, P1042, DOI 10.1128/IAI.70.3.1042-1048.2002; Li XF, 2003, J INTERF CYTOK RES, V23, P259, DOI 10.1089/107999003321829971; Mazzali M, 2002, QJM-INT J MED, V95, P3, DOI 10.1093/qjmed/95.1.3; MIYAZAKI Y, 1995, ANN NY ACAD SCI, V21, P334; O'Regan AW, 2000, J LEUKOCYTE BIOL, V68, P495; Portnoy J M, 1999, J Allergy Clin Immunol, V103, P963, DOI 10.1016/S0091-6749(99)70450-1; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Tuck AB, 1999, ONCOGENE, V18, P4237, DOI 10.1038/sj.onc.1202799; Uede T, 1997, MICROBIOL IMMUNOL, V41, P641, DOI 10.1111/j.1348-0421.1997.tb01906.x; WILSON AB, 1994, ALLERGY, V49, P272, DOI 10.1111/j.1398-9995.1994.tb02660.x; Yamamoto N, 2003, J CLIN INVEST, V112, P181, DOI 10.1172/JCI200317778; Yu XQ, 1999, AM J PATHOL, V154, P833, DOI 10.1016/S0002-9440(10)65330-8; Yumoto K, 2002, P NATL ACAD SCI USA, V99, P4556, DOI 10.1073/pnas.052523599	23	27	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1063	1067		10.1016/j.jaci.2005.01.055	http://dx.doi.org/10.1016/j.jaci.2005.01.055			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867867				2022-12-18	WOS:000229055100025
J	Hauber, HP; Daigneault, P; Frenkiel, S; Lavigne, F; Hung, HL; Levitt, RC; Hamid, G				Hauber, HP; Daigneault, P; Frenkiel, S; Lavigne, F; Hung, HL; Levitt, RC; Hamid, G			Niflumic acid and MSI-2216 reduce TNF-alpha-induced mucin expression in human airway mucosa	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway; explant model; hCLCA1; inhibition; laser capture microdissection; MSI-2216; MUC5AC; mucin; niflumic acid; TNF-alpha	TUMOR-NECROSIS-FACTOR; CHLORIDE CHANNEL HCLCA1; MUC5AC	Background: Human chloride channel, calcium-activated I (hCLCA1) has been shown to induce mucin (MUC) gene expression and mucus production in bronchial epithelial cells. Objective: To investigate whether blocking hCLCA1 decreases mucus production. Methods: Expression of hCLCA1 and mucus was stimulated with TNF-alpha in human upper airway mucosal explant tissue. MUC5AC mRNA and mucus protein expression was blocked by inhibiting hCLCA1 by using channel blockers (niflumic acid [NFA] and MSI-2216) without and with TNF-alpha stimulation. Expression of MUC5AC, hCLCA1, and COX-2 mRNA was quantified by using real-time PCR. Mucus protein was assessed by periodic acid Schiff staining. Laser capture microdissection was performed to quantify hCLCA1 and MUC5AC mRNA expression in epithelial cells derived from mucosal explant tissue. Results: TNF-alpha significantly increased MUC5AC and hCLCA1 mRNA as well as mucus and hCLCA1 protein expression in the mucosal explant tissue (P < .05). Inhibition of hCLCA1 with NFA or MSI-2216 showed a significant dose-dependent reduction of mucus production for both blockers in the mucosal explant tissue (P < .05). MUC5AC mRNA was also decreased by both blockers in the whole mucosal tissue and in laser-captured mucosa epithelial cells. Conclusions: Unstimulated and TNF-alpha-induced mucin expression could be decreased by NFA and MSI-2216. Inhibiting hCLCA1 may be a potential new approach to reduce mucus overproduction.	Res Ctr Borstel, Dept Med, D-23845 Borstel, Germany; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; Univ Montreal, Hop Notre Dame de Bon Secours, Montreal, PQ, Canada; Plymouth Meeting, Genaera Corp, Plymouth, Devon, England	Forschungszentrum Borstel; McGill University; Universite de Montreal	Hauber, HP (corresponding author), Res Ctr Borstel, Dept Med, Pk Allee 35, D-23845 Borstel, Germany.	hphauber@fz-borstel.de		Daigneault, Patrick/0000-0003-0959-9956				ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; Barnett J, 1994, BIOCHIM BIOPHYS ACTA, V324, P26; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; DANDURAND RJ, 1994, AM J RESP CRIT CARE, V149, P1499, DOI 10.1164/ajrccm.149.6.8004305; GIAID A, 1993, LANCET, V341, P1550; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Hauber HP, 2003, LARYNGOSCOPE, V113, P1037, DOI 10.1097/00005537-200306000-00022; Hovenberg HW, 1996, GLYCOCONJUGATE J, V13, P839, DOI 10.1007/BF00702348; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kim YD, 2002, MOL PHARMACOL, V62, P1112, DOI 10.1124/mol.62.5.1112; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Minshall E, 1997, CAN J PHYSIOL PHARM, V75, P911, DOI 10.1139/cjpp-75-7-911; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; PFEFFER KD, 1993, AM J RESP CELL MOL, V9, P511, DOI 10.1165/ajrcmb/9.5.511; Senior RM, 1998, FISHMANS PULMONARY D, P659; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; WAGNER JG, 2003, AM J RESP CRIT CARE, V167, pA466; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Zhou YH, 2002, NOVART FDN SYMP, V248, P150	22	27	34	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					266	271		10.1016/j.jaci.2004.09.039	http://dx.doi.org/10.1016/j.jaci.2004.09.039			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696080				2022-12-18	WOS:000227043600009
J	Higashi, N; Mita, H; Taniguchi, M; Turikisawa, N; Higashi, A; Ozawa, Y; Tohma, S; Arimura, K; Akiyama, K				Higashi, N; Mita, H; Taniguchi, M; Turikisawa, N; Higashi, A; Ozawa, Y; Tohma, S; Arimura, K; Akiyama, K			Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Churg-Strouss syndrome; vasculitides; 3-bromotyrosine; 3-chlorotyrosine; leukotriene E-4	CHURG-STRAUSS-SYNDROME; RHEUMATOLOGY 1990 CRITERIA; HUMAN EOSINOPHIL PEROXIDASE; ASPIRIN-INDUCED ASTHMA; BROMINATING OXIDANTS; MOLECULAR-CLONING; HUMAN-NEUTROPHILS; HUMAN PLASMA; 3-CHLOROTYROSINE; MYELOPEROXIDASE	Background: Vasculitides are classified on the basis of the type of cell involved, namely, eosinophilic vasculitides such as Churg-Strauss syndrome (CSS) and noneosinophilic vasculitides. However, knowledge on inflammatory mediators and oxidative tissue damage associated with vasculitides is insufficient. Objective: We measured the urinary concentrations of inflammatory mediators and tyrosine derivatives to assess biomarkers; associated with the pathophysiology of vasculitides. Methods: Urine was collected from 9 patients with CSS during acute exacerbation and during clinical remission, 24 patients with rheumatoid arthritis in stable condition, and 8 patients with vasculitis diseases (VDs) during acute exacerbation. Leukotriene E-4 (LTE4), 9alpha,11beta prostaglandin F-2, and eosinophil-derived neurotoxin (EDN) concentrations were determined by enzyme immunoassay. 3-Bromotyrosine (BrY) and 3-chlorotyrosine (CIY) concentrations were determined by gas chromatography-mass spectrometry. Results: The urinary LTE4, EDIN, BrY, and CIY concentrations were significantly higher in the patients with CSS during acute exacerbation than in healthy control subjects and, except for urinary CIY concentration, significantly decreased during clinical remission. The urinary EDN and BrY concentrations were significantly higher in patients with CSS during acute exacerbation than in patients with VD during acute exacerbation. Only urinary LTE4 concentration was significantly different between the patients with rheumatoid arthritis in stable condition and the patients with VD during acute exacerbation. Conclusion: Oxidative tissue damage caused by eosinophil peroxidase is a pathophysiological characteristic of eosinophil-associated diseases such as CSS. Urinary LTE4 concentration may reflect a pathophysiological event involved in eosinophilic and noneosinophific vasculitides. Cysteinyl-leukotriene pathways are potential therapeutic targets for small-vessel vasculitides.	Natl Sagamihara Hosp, Clin Res Ctr, Kanagawa, Japan; Kagoshima Univ, Sch Med, Dept Internal Med 3, Kagoshima 890, Japan	Kagoshima University	Higashi, N (corresponding author), Natl Inst Environm Med, Karolinska Inst, Scheeles Vag 1,POB 287, SE-17177 Stockholm, Sweden.	Noritaka.Higashi@imm.ki.se						Aldridge RE, 2002, FREE RADICAL BIO MED, V33, P847, DOI 10.1016/S0891-5849(02)00976-0; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; COOPER JAD, 1986, AM REV RESPIR DIS, V133, P321; Evereklioglu C, 2003, NEPHROLOGY, V8, P231, DOI 10.1046/j.1440-1797.2003.00180.x; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Frost MT, 2000, BIOCHEM J, V345, P453, DOI 10.1042/0264-6021:3450453; Gaut JP, 2002, ANAL BIOCHEM, V300, P252, DOI 10.1006/abio.2001.5469; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Higashi N, 2004, J ALLERGY CLIN IMMUN, V113, P277, DOI 10.1016/j.jaci.2003.10.068; Higashi N, 2002, CLIN EXP ALLERGY, V32, P1484, DOI 10.1046/j.1365-2745.2002.01507.x; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; JENNETTE JC, 1989, AM J PATHOL, V135, P921; JONG EC, 1980, J IMMUNOL, V124, P1378; KLEBANOFF SJ, 1983, CIBA F SYMP, V99, P92; Kumlin M, 1997, ALLERGY, V52, P124, DOI 10.1111/j.1398-9995.1997.tb00966.x; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Mani AR, 2003, BIOCHEM J, V374, P521, DOI 10.1042/BJ20030670; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; Mastalerz L, 2004, J ALLERGY CLIN IMMUN, V113, P771, DOI 10.1016/j.jaci.2003.12.323; MAYATEPEK E, 1995, ARCH DIS CHILD, V72, P526, DOI 10.1136/adc.72.6.526; Mita H, 2004, CLIN EXP ALLERGY, V34, P931, DOI 10.1111/j.1365-2222.2004.01968.x; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; Sampson A. P., 2001, Clinical and Experimental Allergy Reviews, V1, P170, DOI 10.1046/j.1472-9725.2001.00034.x; Sato E, 2001, J RHEUMATOL, V28, P502; Savige J, 1999, AM J CLIN PATHOL, V111, P507; Schmitt WH, 1998, ARTHRITIS RHEUM, V41, P445, DOI 10.1002/1529-0131(199803)41:3<445::AID-ART10>3.3.CO;2-V; Sjostrom M, 2001, EUR J BIOCHEM, V268, P2578, DOI 10.1046/j.1432-1327.2001.02142.x; SUNDY JS, 1995, RHEUM DIS CLIN N AM, V21, P861; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Szczeklik A, 2002, J ALLERGY CLIN IMMUN, V109, P572, DOI 10.1067/mai.2002.121700; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; Tsurikisawa N, 2004, ANN ALLERG ASTHMA IM, V92, P80, DOI 10.1016/S1081-1206(10)61714-0; VANDERWOUDE FJ, 1985, LANCET, V1, P425; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Weller Peter F., 2001, Journal of Allergy and Clinical Immunology, V108, P175, DOI 10.1067/mai.2001.117176; WELLER PF, 1994, CURR OPIN IMMUNOL, V6, P85, DOI 10.1016/0952-7915(94)90038-8; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l	51	27	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1353	1358		10.1016/j.jaci.2004.09.027	http://dx.doi.org/10.1016/j.jaci.2004.09.027			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577834				2022-12-18	WOS:000225577400015
J	Taramarcaz, P; Grissell, TV; Borgas, T; Gibson, PG				Taramarcaz, P; Grissell, TV; Borgas, T; Gibson, PG			Transient postviral vocal cord dysfunction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXTRATHORACIC AIRWAY DYSFUNCTION; ASTHMA; CHILDREN; COUGH		John Hunter Hosp, Dept Resp & Sleep Med, Hunter Med Res Inst, Newcastle, NSW 2310, Australia	Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle	Taramarcaz, P (corresponding author), John Hunter Hosp, Dept Resp & Sleep Med, Hunter Med Res Inst, Locked Bag 1,HRMC,Lookout Rd,New Lambton Heights, Newcastle, NSW 2310, Australia.		gibson, peter/G-6194-2014	gibson, peter/0000-0001-5865-489X				Bahrainwala A H, 2001, Curr Opin Pulm Med, V7, P8, DOI 10.1097/00063198-200101000-00002; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; Carney IK, 1997, AM J RESP CRIT CARE, V156, P211, DOI 10.1164/ajrccm.156.1.9605044; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Rolla G, 1998, J ALLERGY CLIN IMMUN, V102, P204, DOI 10.1016/S0091-6749(98)70087-9; Teran LM, 1997, AM J RESP CRIT CARE, V155, P1362, DOI 10.1164/ajrccm.155.4.9105080; van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098; Wood RP, 1996, J ALLERGY CLIN IMMUN, V98, P481, DOI 10.1016/S0091-6749(96)70079-9	10	27	27	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1471	1472		10.1016/j.jaci.2004.08.038	http://dx.doi.org/10.1016/j.jaci.2004.08.038			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577854				2022-12-18	WOS:000225577400033
J	Asensio, T; Crespo, JF; Sanchez-Monge, R; Lopez-Torrejon, G; Somoza, ML; Rodriguez, J; Salcedo, G				Asensio, T; Crespo, JF; Sanchez-Monge, R; Lopez-Torrejon, G; Somoza, ML; Rodriguez, J; Salcedo, G			Novel plant pathogenesis-related protein family involved in food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; melon; plant pathogenesis-related protein; allergen characterization	FRUIT; SUBTILISIN; CUCUMISIN; IGE	Background: Members belonging to 9 different families of plant pathogenesis-related (PR) proteins have been identified as pollen and food allergens. However, no PR-I protein, a family widely distributed throughout the plant kingdom, has been involved so far in allergic reactions. On the other hand, melon ranges among the most relevant fruits causing food allergy in some countries, but the majority of its allergens remain still unidentified. Objective: We sought to identify melon allergens related to plant PR proteins. Methods: A serum pool or individual sera from 17 patients with allergy to melon confirmed by means of double-blind, placebo-controlled food challenge were used to detect IgE binding proteins of extracts from melon pulp and juice. Cue m 3 was isolated from melon juice by reverse-phase HPLC and characterized by means of N-terminal amino acid sequencing of internal peptides, matrixassisted laser desorption/ionization mass spectrometry analysis, direct and inhibition ELISA assays, and skin prick tests. Results: Cue m 3 was a minor component of the melon juice, with a molecular weight of 16,097 d and a blocked N-terminus. N-terminal amino acid sequences of 3 different peptides derived from endo-Lys C digestion (overall 41 residues) showed more than 60% of sequence identity with PR-1 proteins from grape and cucumber. Cue m 3 bound IgE from 12 of 17 sera from patients allergic to melon and inhibited approximately 40 % and 70 % of the IgE binding to melon pulp and juice extracts, respectively. Positive skin prick test responses to purified Cue m 3 were found in 2 of 14 allergic patients. Conclusion: A new melon allergen belonging to the PR-1 protein family has been isolated and characterized. It is the first evidence of the involvement of this plant protein family in food allergy.	Univ Politecn Madrid, Dept Biotechnol, Unidad Bioquim, ETS Ingn Agronomos, Madrid 28040, Spain; Hosp Rio Ortega, Secc Alergia, Valladolid, Spain; Hosp Univ Doce Octubre, Serv Alergia, Madrid, Spain	Universidad Politecnica de Madrid; Hospital Universitario 12 de Octubre	Salcedo, G (corresponding author), Univ Politecn Madrid, Dept Biotechnol, Unidad Bioquim, ETS Ingn Agronomos, Ciudad Univ, Madrid 28040, Spain.	gsalcedo@bit.etsia.upm.es		Lopez-Torrejon, Gema/0000-0003-2588-4378; Somoza, Maria Luisa/0000-0002-0141-8914				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Cuesta-Herranz J, 2003, CLIN EXP ALLERGY, V33, P827, DOI 10.1046/j.1365-2222.2003.01680.x; Cuesta-Herranz J, 2000, CLIN EXP ALLERGY, V30, P1411, DOI 10.1046/j.1365-2222.2000.00868.x; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V111, P628, DOI 10.1067/mai.2003.75; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ORTIZ JCG, 1995, ALLERGY, V50, P269, DOI 10.1111/j.1398-9995.1995.tb01145.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P968, DOI 10.1067/mai.2000.110467; Rodriguez J, 2002, CURR OPIN ALLERGY CL, V2, P233, DOI 10.1097/00130832-200206000-00013; Rodriguez-Perez R, 2003, J ALLERGY CLIN IMMUN, V111, P634, DOI 10.1067/mai.2003.74; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7; YAMAGATA H, 1994, J BIOL CHEM, V269, P32725	16	27	31	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					896	899		10.1016/j.jaci.2004.06.014	http://dx.doi.org/10.1016/j.jaci.2004.06.014			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	861SO	15480331				2022-12-18	WOS:000224439100025
J	Asero, R; Mistrello, G; Roncarolo, D; Amato, S				Asero, R; Mistrello, G; Roncarolo, D; Amato, S			Walnut-induced anaphylaxis with cross-reactivity to hazelnut and Brazil nut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							TREE NUT; FOOD; IDENTIFICATION; ALLERGY; PEANUT		Clin San Carlo, Ambulatorio Allergol, Paderno Dugnano, MI, Italy; Lofarma SpA, Milan, Italy		Asero, R (corresponding author), Clin San Carlo, Ambulatorio Allergol, Paderno Dugnano, MI, Italy.		Amato, Sandra/AAH-4430-2021	Amato, Sandra/0000-0002-3277-0662				Asero R, 2003, J ALLERGY CLIN IMMUN, V112, P427, DOI 10.1067/mai.2003.1611; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P517, DOI 10.1067/mai.2002.127434; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V103, P1180, DOI 10.1016/S0091-6749(99)70196-X; Teuber SS, 2003, CURR ALLERGY ASTHM R, V3, P54, DOI 10.1007/s11882-003-0013-x	10	27	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					358	360		10.1016/j.jaci.2003.11.019	http://dx.doi.org/10.1016/j.jaci.2003.11.019			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767457				2022-12-18	WOS:000188885700030
J	Shirai, T; Magara, KK; Motohashi, S; Yamashita, M; Kimura, M; Suwazomo, Y; Nogawa, K; Kuriyama, T; Taniguchi, M; Nakayama, T				Shirai, T; Magara, KK; Motohashi, S; Yamashita, M; Kimura, M; Suwazomo, Y; Nogawa, K; Kuriyama, T; Taniguchi, M; Nakayama, T			T(H)1-biased immunity induced by exposure to Antarctic winter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1/T(H)2 cells; cytokines; allergy; inflammation	PITUITARY-ADRENAL AXIS; T-CELLS; COLD-EXPOSURE; NKT CELLS; STRESS; ACTIVATION; CYTOKINES; EXERCISE; HUMANS; INTERLEUKIN-6	Background: Certain immune functions are known to be impaired in human beings exposed to Antarctic winter; in particular, decreased amounts of serum proinflammatory cytokines, such as TNF-alpha and IL-1, were noted. It is not known, however, whether this exposure has any effect on T-cell-mediated acquired immune functions. Objectives: This study aims to investigate whether exposure to Antarctic winter has any effect on T cell-dependent immune functions. Methods: We assessed changes in various immunologic indicators. including serum levels of various cytokines, peripheral blood Valpha24Vbeta11 natural killer T cell numbers, and T(H)1/T(H)2 ratios of 40 Japanese personnel exposed to an Antarctic winter. Also, a 2-month inland traverse was executed during the isolation, and the effect on the above indicators was assessed. Results: All subjects were healthy during the Antarctic isolation. The levels of serum TNF-alpha, IL-1Ra, IL-6, and IL-1beta were dramatically reduced and remained at low levels throughout the isolation. The decrease in the levels of TNF-alpha and IL-1Ra was more pronounced during the inland traverse than during the rest of the isolation. The percentage of Valpha24Vbeta11 natural killer T cells was significantly increased at the midpoint of the isolation. Most interestingly, T(H)1/T(H)2 ratio was increased significantly, and this T(H)1 bias was most prominent at the late point of the isolation. Conclusions: Exposure to an Antarctic winter appeared to induce T(H)1-skewed immunity in human beings. (J Allergy Clin Immunol 2003;111:1353-60.).	Chiba Univ, Grad Sch Med, Dept Med Immunol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Respirol, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Med Immunol, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Occupat & Environm Med, Chiba 2608670, Japan; Japan Sci & Technol Corp, PRESTO Project, Chiba, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Immune Regulat, Chiba, Japan	Chiba University; Chiba University; Chiba University; Chiba University; Japan Science & Technology Agency (JST); RIKEN	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Med Immunol, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007				AARSTAD HJ, 1983, SCAND J IMMUNOL, V18, P461, DOI 10.1111/j.1365-3083.1983.tb00878.x; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Brenner IKM, 1999, J APPL PHYSIOL, V87, P699, DOI 10.1152/jappl.1999.87.2.699; Cui JQ, 1999, J EXP MED, V190, P783, DOI 10.1084/jem.190.6.783; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; Dugue B, 2000, CLIN PHYSIOL, V20, P114; Elenkov IJ, 1999, TRENDS ENDOCRIN MET, V10, P359, DOI 10.1016/S1043-2760(99)00188-5; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; Farrace S, 1999, PHYSIOL BEHAV, V66, P613, DOI 10.1016/S0031-9384(98)00341-2; Gaillard RC, 2000, ANN NY ACAD SCI, V917, P647; Goade DE, 2001, PHOTOCHEM PHOTOBIOL, V74, P108, DOI 10.1562/0031-8655(2001)074<0108:ULIRIA>2.0.CO;2; HARBUZ MS, 1992, J ENDOCRINOL, V134, P327, DOI 10.1677/joe.0.1340327; Hartmann G, 2000, CYTOKINE, V12, P246, DOI 10.1006/cyto.1999.0533; Jansky L, 1996, EUR J APPL PHYSIOL O, V72, P445, DOI 10.1007/BF00242274; JIANG CG, 1990, BRAIN BEHAV IMMUN, V4, P278, DOI 10.1016/0889-1591(90)90032-L; JURANKOVA E, 1995, MOL CHEM NEUROPATHOL, V25, P213, DOI 10.1007/BF02960914; Kawano T, 1999, CANCER RES, V59, P5102; Klausen T, 1997, EUR J APPL PHYSIOL, V76, P480, DOI 10.1007/s004210050278; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; LACKOVIC V, 1988, J INTERFERON RES, V8, P393, DOI 10.1089/jir.1988.8.393; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; Lugg D, 1999, ACTA ASTRONAUT, V44, P693, DOI 10.1016/S0094-5765(99)00068-5; Mazzeo RS, 2001, J APPL PHYSIOL, V91, P2143; Mehta SK, 2000, J MED VIROL, V61, P235, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;235::AID-JMV10&gt;3.0.CO;2-4; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MULLER HK, 1995, PATHOLOGY, V27, P186; Oya H, 2000, CLIN EXP IMMUNOL, V121, P384, DOI 10.1046/j.1365-2249.2000.01310.x; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; REGNIER JA, 1981, AM J VET RES, V42, P294; Rhind SG, 2001, AM J PHYSIOL-REG I, V281, pR66; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Shearer WT, 2002, J ALLERGY CLIN IMMUN, V109, P854, DOI 10.1067/mai.2002.123873; Shephard RJ, 1998, CAN J PHYSIOL PHARM, V76, P539, DOI 10.1139/y98-046; Shephard RJ, 1998, CAN J PHYSIOL PHARM, V76, P828, DOI 10.1139/cjpp-76-9-828; Shimizu T, 2000, SCAND J IMMUNOL, V51, P285; SHU JY, 1993, DEV COMP IMMUNOL, V17, P357, DOI 10.1016/0145-305X(93)90007-D; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Taniguchi M, 2000, SEMIN IMMUNOL, V12, P543, DOI 10.1006/smim.2000.0270; Tingate TR, 1997, IMMUNOL CELL BIOL, V75, P275, DOI 10.1038/icb.1997.42; Tringali G, 2000, NEUROIMMUNOMODULAT, V7, P177, DOI 10.1159/000026436; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024	46	27	28	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1353	1360		10.1067/mai.2003.1504	http://dx.doi.org/10.1067/mai.2003.1504			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789239				2022-12-18	WOS:000183424700027
J	Adachi, T; Stafford, S; Kayaba, H; Chihara, J; Alam, R				Adachi, T; Stafford, S; Kayaba, H; Chihara, J; Alam, R			Myosin light chain kinase mediates eosinophil chemotaxis in a mitogen-activated protein kinase-dependent manner	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemotaxis; eosinophil; eotaxin; mitogen-activated protein kinase; myosin light chain kinase	CELL MOTILITY; PHOSPHORYLATION	Background: Eosinophil migration in the tissue is one characteristic feature of allergic diseases. The CC chemokine eotaxin plays a pivotal role in local accumulation of eosinophils. Myosin light chain kinase (MLCK) is known to regulate cytoskeletal rearrangement and cell motility by means of phosphorylation of myosin light chain (MLC). Objective: We have previously shown that mitogen-activated protein (MAP) kinases are important for eosinophil migration. In the present study we hypothesized that MLCK is downstream of MAP kinases, thereby linking the MAP kinase pathway to the activation of cytoskeletal components required for eosinophil chemotaxis. Methods: Blood eosinophils were purified by using Percoll and anti-CD16 antibody-coated magnetic beads. We investigated the phosphorylation of MLCK and MLC by using the phosphorous 32-orthophosphates-labeled eosinophils. The kinase activity of MLCK was determined by measuring the phosphotransferase activity for the MLCK-specific peptide substrate. The chemotaxis assay was performed in a 48-well Boyden microchamber. Results: The phosphotransferase activity of MLCK for a substrate peptide was enhanced in eotaxin-stimulated eosinophils. We also found that eotaxin induced phosphorylation of MLCK in vivo in phosphorous 32-orthophosphate-labeled eosinophils. PD98059 (MAP/extracellular signal-regulated kinase inhibitor) or SB202190 (p38 MAP kinase inhibitor) abrogated the eotaxin-induced phosphorylation of MLCK. The phosphorylation of MLC was upregulated by eotaxin. Eosinophil chemotaxis was inhibited by means of pretreatment of the MLCK inhibitor ML-7. Conclusion: These results suggest that eotaxin regulates MLCK through both extracellular signal-regulated kinase 1 and p38 MAP kinase. MLCK activation is a critical step in the cytoskeletal rearrangements leading to eosinophil migration.	Akita Univ, Sch Med, Dept Clin Lab & Med, Akita 0108543, Japan; Univ Texas, Med Branch, Div Allergy & Immunol, Dept Internal Med, Galveston, TX 77550 USA	Akita University; University of Texas System; University of Texas Medical Branch Galveston	Adachi, T (corresponding author), Akita Univ, Sch Med, Dept Clin Lab & Med, 1-1-1 Hondo, Akita 0108543, Japan.				NIAID NIH HHS [P01 AI46004, R01 AI50179] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046004, R01AI050179] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi T, 2001, J IMMUNOL, V167, P4609, DOI 10.4049/jimmunol.167.8.4609; Blue EK, 2002, AM J PHYSIOL-CELL PH, V282, pC451, DOI 10.1152/ajpcell.00333.2001; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412; Morrison DL, 1996, BIOCHEM CELL BIOL, V74, P549, DOI 10.1139/o96-459; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; Walker JW, 1998, P NATL ACAD SCI USA, V95, P1568, DOI 10.1073/pnas.95.4.1568	10	27	30	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					113	116		10.1067/mai.2003.27	http://dx.doi.org/10.1067/mai.2003.27			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532105				2022-12-18	WOS:000180465500017
J	Fiocchi, A; Bouygue, GR; Restani, P; Gaiaschi, A; Terracciano, L; Martelli, A				Fiocchi, A; Bouygue, GR; Restani, P; Gaiaschi, A; Terracciano, L; Martelli, A			Anaphylaxis to rice by inhalation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD; IDENTIFICATION; ALLERGENS; EXERCISE		Univ Milan, Melloni Child & Maternal Med Hosp, Milan, Italy; Univ Milan, Dept Pharmacol Sci, Toxicol Lab, Milan, Italy	University of Milan; University of Milan	Fiocchi, A (corresponding author), Univ Milan, Melloni Child & Maternal Med Hosp, Milan, Italy.		Terracciano, Luigi M./AAB-5335-2022	Terracciano, Luigi M./0000-0002-9393-9660; Fiocchi, Alessandro/0000-0002-2549-0523				Bahna SL, 2001, ANN ALLERG ASTHMA IM, V86, P414, DOI 10.1016/S1081-1206(10)62487-8; Caffarelli C, 1997, ALLERGY ASTHMA PROC, V18, P245, DOI 10.2500/108854197778594007; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; FIOCCHI A, 1995, J AM COLL NUTR, V14, P245; Fiocchi A, 1997, J ALLERGY CLIN IMMUN, V100, P424, DOI 10.1016/S0091-6749(97)70258-6; Ikezawa Z, 1992, Acta Derm Venereol Suppl (Stockh), V176, P108; NISHIO T, 1993, THEOR APPL GENET, V86, P317, DOI 10.1007/BF00222095; Sander I, 2001, J ALLERGY CLIN IMMUN, V107, P907, DOI 10.1067/mai.2001.113761; Wuthrich B, 2002, ALLERGY, V57, P263, DOI 10.1034/j.1398-9995.2002.1n3550.x; Zapletal A, 1987, LUNG FUNCTION CHILDR	10	27	28	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					193	195		10.1067/mai.2003.12	http://dx.doi.org/10.1067/mai.2003.12			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532119				2022-12-18	WOS:000180465500031
J	Vailes, LD; Sun, AW; Ichikawa, K; Wu, ZN; Sulahian, TH; Chapman, MD; Guyre, PM				Vailes, LD; Sun, AW; Ichikawa, K; Wu, ZN; Sulahian, TH; Chapman, MD; Guyre, PM			High-level expression of immunoreactive recombinant cat allergen (Fel d 1): Targeting to antigen-presenting cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cat allergen; antigen-presenting cells; asthma; in vitro diagnostics; immunotherapy	FEL-D-I; FC-GAMMA-RI; AFFINITY IGG RECEPTOR; MONOCLONAL-ANTIBODIES; SEQUENCE-ANALYSIS; MAJOR ALLERGEN; BINDING; CHILDREN; ASTHMA; SENSITIZATION	Background: Cat allergen Fel d 1 is a heterodimer encoded by 2 separate genes that has been difficult to produce as a fully immunoreactive molecule. Objective: We sought to engineer recombinant (r) Fel d 1 with IgE and IgG antibody binding comparable with that of the natural allergen that could be targeted to antigen-presenting cells. Methods: The rFel d 1 chains were coexpressed in baculovirus, either linked to the anti-CD64 antibody H22 (rFel d 1 H22(+)) or alone (rFel d 1 H22(-)). Binding of expressed allergens to mouse and human antibodies was compared with that of natural (n) Fel d 1 by means of enzyme immunoassay and antigen-binding and inhibition RIAs. Binding of rFel d 1 H22(+) to the CD64 receptor on leukocyte subpopulations and on the THP-1 cell line was analyzed by means of flow cytometry. Results: The baculovirus-expressed allergens migrated with molecular weights of 49 kd (rFel d I H22(+)) and 22 kd (rFel d 1 H22(-)). The rFel d 1 inhibited IgG antibody binding to nFel by greater than 95% and showed identical dose-dependent inhibition curves. There was an excellent quantitative correlation between IgE and IgG antibody binding to rFel d 1 and nFel d 1 in sera from patients with cat allergy (IgE: n = 258, r > 0.72, P < .001). The rFel d 1 H22(+) bound to monocytes but not to lymphocytes or neutrophils, and binding of rFel d 1 H22(+) to THP-1 cells was inhibited by a soluble CD64 fusion protein. Conclusions: Recombinant Fell d 1 chains have been successfully coexpressed as mature proteins with comparable immunoreactivities to nFel d 1. The rFel d 1 can be targeted to antigen-presenting cells through CD64. These constructs will facilitate structural studies of Fell d 1 and the development of improved allergy diagnostics and therapeutics.	INDOOR Biotechnol Inc, Charlottesville, VA 22903 USA; Dartmouth Coll Sch Med, Dept Physiol, Lebanon, NH USA; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 305, Japan; Univ Virginia, Asthma & Allerg Dis Ctr, Dept Med, Charlottesville, VA USA; Dartmouth Coll Sch Med, Dept Pharmacol, Lebanon, NH USA	INDOOR Biotechnologies; Dartmouth College; University of Tsukuba; University of Virginia; Dartmouth College	Vailes, LD (corresponding author), INDOOR Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.			Chapman, Martin/0000-0002-0845-3632	NIAID NIH HHS [AI 32557, AI 34607, AI-40686] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040686, U01AI034607, U19AI034607, R01AI032557] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; Best EA, 2000, PROTEIN EXPRES PURIF, V20, P462, DOI 10.1006/prep.2000.1327; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chapman MD, 2001, J ALLERGY CLIN IMMUN, V107, pS414, DOI 10.1067/mai.2001.113672; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; Fanger NA, 1997, J IMMUNOL, V158, P3090; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; Ichikawa K, 2001, CLIN EXP ALLERGY, V31, P1279, DOI 10.1046/j.1365-2222.2001.01169.x; Keler T, 1997, CANCER RES, V57, P4008; Keler T, 2000, J IMMUNOL, V165, P6738, DOI 10.4049/jimmunol.165.12.6738; Kraft D, 1999, INT ARCH ALLERGY IMM, V118, P171, DOI 10.1159/000024058; Larche M, 2001, INT ARCH ALLERGY IMM, V124, P272, DOI 10.1159/000053730; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; MORGANELLI PM, 1988, J IMMUNOL, V140, P2296; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; OHMAN JL, 1974, J IMMUNOL, V113, P1668; Okayama Y, 2000, J IMMUNOL, V164, P4332, DOI 10.4049/jimmunol.164.8.4332; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; ROGERS BL, 1993, MOL IMMUNOL, V30, P559, DOI 10.1016/0161-5890(93)90030-F; SLUNT JB, 1995, J ALLERGY CLIN IMMUN, V95, P1221, DOI 10.1016/S0091-6749(95)70079-X; Smith AM, 2001, J ALLERGY CLIN IMMUN, V107, P977, DOI 10.1067/mai.2001.115629; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; Vailes LD, 2001, J ALLERGY CLIN IMMUN, V107, pS219; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; van Vugt MJ, 1999, BLOOD, V94, P808, DOI 10.1182/blood.V94.2.808.414k31_808_817; vanRee R, 1997, ALLERGY, V52, P795; Wallace PK, 2001, J IMMUNOL METHODS, V248, P183, DOI 10.1016/S0022-1759(00)00351-3	39	27	31	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					757	762		10.1067/mai.2002.129035	http://dx.doi.org/10.1067/mai.2002.129035			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417885				2022-12-18	WOS:000179082500011
J	Goldmann, DA				Goldmann, DA			Blood-borne pathogens and nosocomial infections	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		blood-borne infection; nosocomial infection; occupational health; hepatitis B virus; hepatitis C virus; HIV	HEALTH-CARE WORKERS; HEPATITIS-C VIRUS; GLOVE PERFORATION; HIV TRANSMISSION; OCCUPATIONAL EXPOSURES; NEEDLESTICK INJURIES; SELF-PROTECTION; UNITED-STATES; B-VIRUS; CONTACT	Guidelines to prevent the transmission of blood-borne infections have evolved rapidly since the recognition that "serum hepatitis" could be transmitted to health care personnel via percutaneous exposure to blood. The HIV epidemic focused renewed attention on the problem of protecting health care personnel, culminating in "standard precautions" for patient care, which emphasized the use of gloves for all contact with blood and body fluids. This focus on protection of the health care worker sometimes obscures the other important functions of gloves: protection of patients from microorganisms on the hands of providers and prevention of patient-to-patient transmission of nosocomial pathogens. The risk of infection after percutaneous exposure to the 3 major blood-borne viruses-hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV varies greatly. The risk for a nonimmune individual exposed to HBV may be >30% if the source is Hb(e)Ag-positive. The average infection rate for HCV is 1.8%. For HIV, the average risk is 0.3%, but is higher with deep injury, when there is visible blood on the device, when a needle has been in an artery or vein, or when the source patient is in the terminal phase of HIV. Prompt administration of anti-HIV therapy reduces risk by about 80%. Mucous membrane and cutaneous exposures carry less risk. Recent efforts to reduce needlestick injuries in hospitals have reduced the risk to health care providers. Surgeons and other health care professionals who are infected with HIV or HCV pose a very small risk to their patients, although a number of outbreaks have been traced to surgeons who are HBV carriers; most have been HbeAg-positive.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Infect Control Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Goldmann, DA (corresponding author), Div Infect Dis, 300 Longwood Ave, Boston, MA 02115 USA.	Don.Goldmann@tch.harvard.edu						Alter M J, 1997, Clin Liver Dis, V1, P559, DOI 10.1016/S1089-3261(05)70321-4; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BELL DM, 1995, SURG CLIN N AM, V75, P1189; Beltrami EM, 2000, CLIN MICROBIOL REV, V13, P385, DOI 10.1128/CMR.13.3.385-407.2000; BENNETT B, 1991, OBSTET GYNECOL, V78, P1019; BRADLEY DW, 1991, SEMIN LIVER DIS, V11, P128, DOI 10.1055/s-2008-1040431; BROUGH SJ, 1988, BRIT J SURG, V75, P317, DOI 10.1002/bjs.1800750408; BYRNE EB, 1966, J AMER MED ASSOC, V195, P362, DOI 10.1001/jama.195.5.362; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; *CDC, 1988, MMWR-MORBID MORTAL W, V37, P377; *CDC, 1990, MMWR-MORBID MORTAL W, V39, P489; *CDCP, 1985, MMWR-MORBID MORTAL W, V34, P681; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P21; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P285; CHAPMAN S, 1993, AM J OBSTET GYNECOL, V168, P1354, DOI 10.1016/S0002-9378(11)90764-9; CHIARELLO IA, 2000, DOUGLAS BENNETTS PRI, P3052; COHEN MS, 1992, J DERMATOL SURG ONC, V18, P873, DOI 10.1111/j.1524-4725.1992.tb02919.x; COHN GM, 1990, AM J OBSTET GYNECOL, V162, P715, DOI 10.1016/0002-9378(90)90992-G; COLE RP, 1989, BRIT J PLAST SURG, V42, P481, DOI 10.1016/0007-1226(89)90019-2; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DAVIES GL, 1995, GASTROENTEROLOGY, P2082; *DEP LAB, 1991, FED REGISTER, V56, P64175; *DEP LAB OCC SAF H, 1989, FED REGISTER, V54, P23042; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; DODDS RDA, 1990, BRIT J SURG, V77, P219, DOI 10.1002/bjs.1800770228; DOEBBELING BN, 1988, ANN INTERN MED, V109, P394, DOI 10.7326/0003-4819-109-5-394; DOYLE PM, 1992, BRIT J OBSTET GYNAEC, V99, P83, DOI 10.1111/j.1471-0528.1992.tb14402.x; Duckworth G J, 1999, Commun Dis Public Health, V2, P188; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; Folin AC, 1997, INFECT CONT HOSP EP, V18, P244; GANI JS, 1990, AUST NZ J SURG, V60, P171, DOI 10.1111/ans.1990.60.3.171; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; Garner Julia S., 1996, Infection Control and Hospital Epidemiology, V17, P53; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GIBAS A, 1993, AM J EPIDEMIOL, V9, P442; GREEN SE, 1992, ANN ROY COLL SURG, V74, P306; HAIDUVEN DJ, 1992, INFECT CONT HOSP EP, V13, P265, DOI 10.2307/30145501; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Houston F, 2000, LANCET, V356, P999, DOI 10.1016/S0140-6736(00)02719-7; Ippolito G, 1998, JAMA-J AM MED ASSOC, V280, P28, DOI 10.1001/jama.280.1.28; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; Jensen SL, 1997, EUR J SURG, V163, P163; KRISTENSEN MS, 1992, INFECT CONT HOSP EP, V13, P719; KUH C, 1950, JAMA-J AM MED ASSOC, V143, P631, DOI 10.1001/jama.1950.02910420019006; LEIBOWITZ S, 1949, JAMA-J AM MED ASSOC, V140, P1331, DOI 10.1001/jama.1949.82900520001006; LYNCH P, 1987, ANN INTERN MED, V107, P243, DOI 10.7326/0003-4819-107-2-243; Mahoney FJ, 1997, ARCH INTERN MED, V157, P2601, DOI 10.1001/archinte.157.22.2601; MATTA H, 1988, BRIT MED J, V297, P597, DOI 10.1136/bmj.297.6648.597; MCLEOD GG, 1989, J BONE JOINT SURG BR, V71, P489, DOI 10.1302/0301-620X.71B3.2722946; MCQUILLAN GM, 1997, VIRAL HEPATITIS LIVE, P267; Mendelson MH, 1998, INFECT CONT HOSP EP, V19, P401; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; *NAT COMM DIS CTR, 1970, PHS PUBL, V2054; PANILIO AL, 1992, AM J OBSTET GYNECOL, V167, P703; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; POLISH LB, 1993, AM J INFECT CONTROL, V21, P196, DOI 10.1016/0196-6553(93)90031-X; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; PURO V, 1995, AM J INFECT CONTROL, V23, P273, DOI 10.1016/0196-6553(95)90056-X; QUEBBEMAN EJ, 1991, ANN SURG, V214, P614, DOI 10.1097/00000658-199111000-00012; ROBERT L, 1994, INFECT CONT HOSP EP, V15, P349; ROBERT LM, 1995, ANN INTERN MED, V122, P653, DOI 10.7326/0003-4819-122-9-199505010-00002; ROGERS AS, 1993, JAMA-J AM MED ASSOC, V269, P1795, DOI 10.1001/jama.269.14.1795; ROSE DA, 1994, INFECT CONT HOSP EP, V15, P349; Ross RS, 2000, NEW ENGL J MED, V343, P1851, DOI 10.1056/NEJM200012213432505; SANTORI M, 1993, SCAND J INFECT DIS, V25, P270; SCHWIMMER A, 1994, J AM DENT ASSOC, V125, P196, DOI 10.14219/jada.archive.1994.0276; SERRANO CW, 1991, OBSTET GYNECOL, V77, P525; Tokars J I, 1994, ASAIO J, V40, P1020, DOI 10.1097/00002480-199410000-00021; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; TRUMBULL ML, 1951, JAMA-J AM MED ASSOC, V145, P965, DOI 10.1001/jama.1951.02920310021005; VONREYN CF, 1993, JAMA-J AM MED ASSOC, V269, P1807, DOI 10.1001/jama.269.14.1807; WERNER BG, 1982, ANN INTERN MED, V97, P367, DOI 10.7326/0003-4819-97-3-367; WEST DJ, 1984, AM J MED SCI, V287, P26, DOI 10.1097/00000441-198403000-00006; WHITE MC, 1993, AM J INFECT CONTROL, V21, P243, DOI 10.1016/0196-6553(93)90416-2; WONG ES, 1991, JAMA-J AM MED ASSOC, V265, P1123, DOI 10.1001/jama.265.9.1123; 1996, LANCET, V348, P492	80	27	28	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S21	S26		10.1067/mai.2002.125337	http://dx.doi.org/10.1067/mai.2002.125337			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170239				2022-12-18	WOS:000177572200004
J	Phipatanakul, W; Nowak-Wegrzyn, A; Eggleston, PA; Van Natta, M; Kesavan, J; Schuberth, K; Wood, RA				Phipatanakul, W; Nowak-Wegrzyn, A; Eggleston, PA; Van Natta, M; Kesavan, J; Schuberth, K; Wood, RA			The efficacy of montelukast in the treatment of cat allergen-induced asthma in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						montelukast; acoustic rhinometry; cat challenge; cat allergen; pediatric asthma	LEUKOTRIENE-RECEPTOR ANTAGONIST; EXERCISE-INDUCED BRONCHOCONSTRICTION; 14-YEAR-OLD CHILDREN; ACOUSTIC RHINOMETRY; DOUBLE-BLIND; RESPONSES; EXPOSURE; RHINITIS; TRIAL; SENSITIZATION	Background: Montelukast is a leukotriene antagonist approved for the treatment of childhood asthma in children age 2 years and older. There are limited studies on its effects on allergic asthma in children. Objective: We sought to evaluate montelukast's effects on upper and lower airway responses to intense cat allergen exposure. Methods: In a double-blind, placebo-controlled, cross-over trial 18 subjects aged 6 to 14 years with cat-induced asthma were randomly assigned to receive 1 week each of either montelukast or placebo, followed by a 1-hour cat challenge in an environmental exposure unit. Upper and lower respiratory tract symptoms were rated, and spirometry and acoustic rhinometry were performed. Challenges were stopped early if the subject became too uncomfortable or had a greater than 50% decrease in FEV1. Results: Overall changes in FEV1 were significantly different with montelukast treatment and remained significant after adjusting for allergen level (P = .02; adjusted P = .01). Lower respiratory tract symptom scores were significantly reduced with montelukast versus placebo (P = .007) but lost significance after adjusting for allergen level (P = .16). Challenge length was significantly longer with montelukast versus placebo (P < .001) and remained significant after adjusting for allergen level (P = .019). Montelukast did not significantly affect upper respiratory responses, as measured by means of symptom scores (P = .43) and changes in acoustic rhinometry (P = .078). Conclusions: Montelukast was significantly more effective than placebo in attenuating lower respiratory responses and extending challenge length when cat-sensitive children with mild persistent asthma were exposed to high levels of cat allergen.	Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Div Allergy & Immunol, Boston, MA 02115 USA; Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Div Biostat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Div Environm Hlth Engn, Baltimore, MD 21205 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Phipatanakul, W (corresponding author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Immunol, Fegan 6,300 Longwood Ave, Boston, MA 02115 USA.			Nowak-Wegrzyn, Anna/0000-0002-0960-9854	NIAID NIH HHS [AI07007] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P211, DOI 10.1016/S1081-1206(10)62228-4; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; FINDLAY SR, 1992, J ALLERGY CLIN IMMUN, V89, P1040, DOI 10.1016/0091-6749(92)90227-S; HILBERG O, 1989, J APPL PHYSIOL, V66, P295, DOI 10.1152/jappl.1989.66.1.295; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; NIEMEIJER NR, 1992, ALLERGY, V47, P431, DOI 10.1111/j.1398-9995.1992.tb02084.x; Noonan MJ, 1998, EUR RESPIR J, V11, P1232, DOI 10.1183/09031936.98.11061232; Phipatanakul W, 1998, J ALLERGY CLIN IMMUN, V102, P896, DOI 10.1016/S0091-6749(98)70325-2; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V105, P704, DOI 10.1067/mai.2000.105123; Pullerits T, 1999, AM J RESP CRIT CARE, V159, P1814, DOI 10.1164/ajrccm.159.6.9810016; REISS TF, 1998, ARCH INTERN MED, V11, P1232; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x	21	27	29	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					794	799		10.1067/mai.2002.123530	http://dx.doi.org/10.1067/mai.2002.123530			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994702				2022-12-18	WOS:000175687800008
J	Altschul, AS; Scherrer, DL; Munoz-Furlong, A; Sicherer, SH				Altschul, AS; Scherrer, DL; Munoz-Furlong, A; Sicherer, SH			Manufacturing and labeling issues for commercial products: Relevance to food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Mt Sinai Sch Med, Jaffe Food Allergy Inst, Dept Pediat Allergy, New York, NY USA; Food Allergy & Anaphylaxis Network, Fairfax, VA USA	Icahn School of Medicine at Mount Sinai	Altschul, AS (corresponding author), Mt Sinai Sch Med, Jaffe Food Allergy Inst, Dept Pediat Allergy, New York, NY USA.							Niemann LM, 2000, J ALLERGY CLIN IMMUN, V105, pS188, DOI 10.1016/S0091-6749(00)90993-X; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; *USFDA CTR FOOD SA, 2001, OFF SCI AN SUPP	3	27	30	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					468	468						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	476FK	11544472	Bronze			2022-12-18	WOS:000171215400024
J	Primeau, MN; Adkinson, NF; Hamilton, RG				Primeau, MN; Adkinson, NF; Hamilton, RG			Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						natural rubber; latex allergy; pharmaceutical vial closures; skin testing	PREVALENCE; IGE; SENSITIZATION; POPULATION; ANTIBODIES	Background: The release of allergenic proteins from natural rubber vial closures (stoppers) into aqueous pharmaceuticals may induce allergic reactions In individuals with latex allergy (LA) receiving medications from such vials. Objective: The goal of this study was to determine whether solutions stored in vials containing natural rubber closures release allergenic proteins detectable by skin testing of subjects with LA. Methods: Five pharmaceutical vial closures (2 natural rubber and 3 synthetic) were coded, inserted onto vials containing phenol-saline-human serum albumin, and stored in an inverted position before use. Twelve volunteers with and 11 volunteers without LA underwent skin testing with solutions from each of the 5 vials, either those not punctured (OP) or those punctured 40 times with a 21-gauge needle 12 to ZA hours before testing (40P), Results: All intradermal skin test responses in the group without LA were negative. Two and 5 of the 12 subjects with LA had positive intradermal skin reactions to OP and 40P solutions, respectively, from vials containing rubber closures. Two subjects with LA had inexplicable, positive, nonreproducible intradermal skin test reactions to solutions from vials containing bromobutyl but not vials with isoprene synthetic closures. In vitro inhibition analysis detected 6 to 7 AU/g latex allergen in extracts of cut natural rubber containing closures but not in extracts of synthetic closures. Conclusion: Natural rubber vial closures released allergenic latex proteins into the tested solutions in direct contact during storage in sufficient quantities to elicit positive intradermal skin reactions in some individuals with LA. These data support a recommendation to eliminate natural rubber from closures of pharmaceutical vials.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA	Johns Hopkins University	Hamilton, RG (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI-08270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; Bernardini R, 1998, J ALLERGY CLIN IMMUN, V101, P621, DOI 10.1016/S0091-6749(98)70169-1; *FOOD DRUG ADM, 1991, 911 FDA MDA; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; HAMILTON RG, 1996, CLIN IMMUNOLOGY PRIN, P2169; JONES JM, 1996, UROLOGY, V4, P898; Kaczmarek RG, 1996, ANN ALLERG ASTHMA IM, V76, P51, DOI 10.1016/S1081-1206(10)63406-0; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; Kurup VP, 2000, CLIN EXP ALLERGY, V30, P359; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Liss GM, 1999, AM J IND MED, V35, P196, DOI 10.1002/(SICI)1097-0274(199902)35:2<196::AID-AJIM12>3.0.CO;2-Y; NORMAN PS, 1997, MANUAL CLIN LAB IMMU, P875; Saxon A, 2000, ANN ALLERG ASTHMA IM, V84, P199, DOI 10.1016/S1081-1206(10)62756-1; Thomsen DJ, 2000, AM J HEALTH-SYST PH, V57, P44, DOI 10.1093/ajhp/57.1.44; TOWSE A, 1995, DIABETES CARE, V18, P1195, DOI 10.2337/diacare.18.8.1195; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; VASSALLO SA, 1995, ANESTH ANALG, V80, P1057, DOI 10.1097/00000539-199505000-00039; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342; YUNGINGER JW, 1994, J ALLERGY CLIN IMMUN, V93, P836, DOI 10.1016/0091-6749(94)90374-3; 1999, LATEX ALLERGY NEWS, V6, P1; 1996, PHARMACOPEIAL FORUM, V22, P2886	21	27	30	3	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					958	962		10.1067/mai.2001.115630	http://dx.doi.org/10.1067/mai.2001.115630			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398071	Bronze			2022-12-18	WOS:000169454800003
J	Takeuchi, K; Kishioka, C; Ishinaga, H; Sakakura, Y; Majima, Y				Takeuchi, K; Kishioka, C; Ishinaga, H; Sakakura, Y; Majima, Y			Histamine alters gene expression in cultured human nasal epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine receptors; mRNA; allergic rhinitis; reverse transcription-polymerase chain reaction; nasal mucosa; ZO-1; IL-8	TUMOR-NECROSIS-FACTOR; RECEPTOR MESSENGER-RNA; TIGHT-JUNCTION; ENDOTHELIAL-CELLS; FACTOR-ALPHA; ALLERGIC RHINITIS; ZONULA-OCCLUDENS; RELEASE; MUCOSA; ZO-1	Background: Airway epithelial cells produce cytokines and participate in the regulation of mucosal immunity. Although nasal epithelial cells express histamine receptors, it is not exactly known how nasal epithelial cells respond to histamine. Objective: The objective of this study was to examine whether histamine can alter the expression of the 4 genes encoding H-1 receptor, IL-8, TNF-alpha and ZO-1 tight-junction protein in cultured nasal epithelial cells. Methods: We added histamine or vehicle to cultured human nasal epithelial cells and extracted RNA from them 4 hours later. After DNase treatment, mRNAs of beta -actin, H-1 receptor, IL-8, TNF-alpha, and ZO-1 tight-junction protein were amplified by using RT-PCR. Results: Histamine significantly upregulated IL-8 mRNA expression and significantly downregulated ZO-1 mRNA expression. The latter effect was blocked by pretreatment with mepyramine, an H-1 receptor antagonist. Conclusion: The reduction of ZO-1 mRNA by histamine may cause increased permeability of the mucosa during allergic reactions in the nose.	Mie Univ, Sch Med, Dept Otorhinolaryngol, Tsu, Mie 514, Japan; Kaisei Hosp, Dept Otorhinolaryngol, Mie, Japan	Mie University	Majima, Y (corresponding author), Mie Univ, Sch Med, Dept Otorhinolaryngol, 2-174 Edobashi, Tsu, Mie 514, Japan.							Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410, DOI 10.1016/S0091-6749(98)70256-8; Arima M, 1999, AM J RESP CELL MOL, V21, P684, DOI 10.1165/ajrcmb.21.6.3671; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; BACKER MD, 1993, BIOCHEM BIOPH RES CO, V197, P1601; BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; Bissonnette EY, 1996, AM J RESP CELL MOL, V14, P620, DOI 10.1165/ajrcmb.14.6.8652190; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DOUGLASS JA, 1994, AM J RESP CRIT CARE, V150, P1108, DOI 10.1164/ajrccm.150.4.7921444; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; Gardner TW, 1996, BIOCHEM J, V320, P717, DOI 10.1042/bj3200717; GRUBER BL, 1994, IMMUNOLOGY INFLAMMAT, P337; HILL SJ, 1990, PHARMACOL REV, V42, P45; Hirata N, 1999, J ALLERGY CLIN IMMUN, V103, P944, DOI 10.1016/S0091-6749(99)70443-4; Iriyoshi N, 1996, CLIN EXP ALLERGY, V26, P379, DOI 10.1111/j.1365-2222.1996.tb00553.x; JEANNIN P, 1994, BLOOD, V84, P2229; KAWAGUCHI S, 1995, ANN OTO RHINOL LARYN, V104, P394, DOI 10.1177/000348949510400510; KleinJan A, 1999, J ALLERGY CLIN IMMUN, V103, P441, DOI 10.1016/S0091-6749(99)70469-0; KRAUSE D, 1991, NEUROSCI LETT, V128, P301, DOI 10.1016/0304-3940(91)90284-Z; McCarthy KM, 1996, J CELL SCI, V109, P2287; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; Nakasaki T, 1999, PROSTAG OTH LIPID M, V58, P29, DOI 10.1016/S0090-6980(99)00021-0; NEDWIN GE, 1985, J IMMUNOL, V135, P2492; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; ROTROSEN D, 1986, J CELL BIOL, V103, P2379, DOI 10.1083/jcb.103.6.2379; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Usui S, 2000, ANN OTO RHINOL LARYN, V109, P271, DOI 10.1177/000348940010900307; VANNIER E, 1991, J EXP MED, V174, P281, DOI 10.1084/jem.174.1.281; WENIG BM, 1993, ATLAS HEAD NECK PATH, P7; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WU R, 1985, AM REV RESPIR DIS, V132, P311; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281	39	27	35	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					310	314		10.1067/mai.2001.112127	http://dx.doi.org/10.1067/mai.2001.112127			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174198				2022-12-18	WOS:000167071400018
J	Kurtz, KM; Hamilton, RG; Schaefer, JA; Adkinson, NF				Kurtz, KM; Hamilton, RG; Schaefer, JA; Adkinson, NF			A hooded exposure chamber method for semiquantitative latex aeroallergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; aeroallergen challenge; occupational allergy; occupational asthma	OCCUPATIONAL ASTHMA; AMMONIATED LATEX; RUBBER; ALLERGY; PREVALENCE; DIAGNOSIS; IGE	Background: Allergen challenges are useful in adjudicating discordant clinical histories and skin test responses, serologic test responses, or both, as well as in determining the degree of allergic reactivity. Latex allergen challenges have been developed but have limitations that reduce their usefulness. Objective: We sought to develop a novel hooded exposure chamber (HEC) system to allow safe, sensitive, and semiquantitative evaluation of respiratory latex allergy. Methods: The HEC system uses an impinger to produce a particle cloud of cornstarch isolated from powdered latex gloves, The particles are air driven into a face shield and hood to simultaneously challenge the subject's conjunctiva, nose, and lungs during 3 minutes of normal tidal breathing. A cloud of respirable latex allergen-associated cornstarch particles (LACs) is consistently produced in the HEC during challenges. Twenty-three subjects with latex: allergy (history and positive skin test response, positive serologic test response, or both) and 3 atopic control subjects not allergic to latex (history and negative skin test response, negative serologic test response, or both) were sequentially exposed to air, control cornstarch, and then progressive 2-fold increments of LACs in a single-masked fashion. A positive challenge result was defined as (1) a peak expiratory flow rate decline of 15% or greater from baseline; (2) a peak expiratory now rate decline of 10% or greater and an increase of either the rhinoconjunctivitis or chest symptom score scale of 3 or more points from baseline; or (3) an increase of either the rhinoconjunctivitis or chest symptom score scale of 6 or more points from baseline. Results: Twenty-two of the 23 subjects with latex allergy reached threshold criteria for a positive challenge at LAC titers of 1:8 or greater, giving a sensitivity of 0.96. Challenge endpoints were moderately corrected with skin test sensitivity (r(s) = -0.55, P = .01) but not with RAST reactivity. None of the 3 control subjects responded to LACs at the 1:8 dilution. No patient or control subject responded to the air or control cornstarch control exposures. All responses were confined to mild symptoms of allergic rhinoconjunctivitis, asthma, or both that either resolved spontaneously or were easily reversed with inhaled albuterol. No subject experienced a systemic or late-phase reaction. Conclusion: The HEC procedure is a safe, sensitive, and specific method for masked semiquantitative latex aeroallergen challenges that mimic occupational latex exposure to powdered latex gloves.	Johns Hopkins Asthma & Allergy Ctr, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA; Johns Hopkins Univ, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Adkinson, NF (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Dept Med, Div Clin Immunol & Allergy, 5501 Hopkins Bayview Circle,Room 2A62, Baltimore, MD 21224 USA.				NIAID NIH HHS [AI31867, AI43654] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031867, R01AI043654, U01AI031867] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUR X, 1990, LANCET, V335, P912, DOI 10.1016/0140-6736(90)90508-3; BEAUDOUIN E, 1990, REV FR ALLERGOL, V30, P157, DOI 10.1016/S0335-7457(05)80230-8; BEEZHOLD D, 1992, ARCH SURG-CHICAGO, V127, P1354; BER DJ, 1993, J ALLERGY CLIN IMMUN, V91, P271; Brown RH, 1998, ANESTHESIOLOGY, V89, P292, DOI 10.1097/00000542-199808000-00004; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; BRUGNAMI G, 1995, J ALLERGY CLIN IMMUN, V96, P457, DOI 10.1016/S0091-6749(95)70287-3; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; Hamilton R. G., 1997, MANUAL CLIN LAB IMMU, P881; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; HAMILTON RG, 1994, J LAB CLIN MED, V123, P594; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Hamilton RG, 1996, J ALLERGY CLIN IMMUN, V98, P872, DOI 10.1016/S0091-6749(96)80003-0; Hamilton RG, 1997, ANN ALLERG ASTHMA IM, V79, P266, DOI 10.1016/S1081-1206(10)63013-X; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P618, DOI 10.1016/S0091-6749(99)70333-7; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; MARCOS C, 1991, ANN ALLERGY, V67, P319; MEEROPOL E, 1990, NEW ENGL J MED, V323, P1072; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; PAGANO M, 1993, PRINCIPLES BIOSTATIS, P369; PIPKORN U, 1987, ALLERGY, V42, P496, DOI 10.1111/j.1398-9995.1987.tb00371.x; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; Primeau MN, 2000, J ALLERGY CLIN IMMUN, V105, pS245, DOI 10.1016/S0091-6749(00)91153-9; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; TOMAZIC VJ, 1994, J ALLERGY CLIN IMMUN, V93, P751, DOI 10.1016/0091-6749(94)90255-0; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887	34	27	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					178	184		10.1067/mai.2001.112125	http://dx.doi.org/10.1067/mai.2001.112125			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	394PW	11150009				2022-12-18	WOS:000166533300029
J	Annett, RD; Aylward, EH; Lapidus, J; Bender, BG; DuHamel, T				Annett, RD; Aylward, EH; Lapidus, J; Bender, BG; DuHamel, T		Childhood Asthma Management Progra	Neurocognitive functioning in children with mild and moderate asthma in the Childhood Asthma Management Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood Asthma Management Program; asthma severity; neurocognitive functioning	BECLOMETHASONE DIPROPIONATE; SCHOOL PERFORMANCE; THEOPHYLLINE; GROWTH; ASSOCIATION	Background: The Childhood Asthma Management Program (CAMP) is a multicenter double-blind, randomized, placebo-controlled, clinical trial of two anti-inflammatory agents and placebo in children with mild and moderate asthma. Objective: The interrelationship between asthma severity and neurocognitive functioning among 1041 children (age range, 5-12 years) enrolled in the CAMP trial was examined. Methods: Asthma severity was established at baseline with a clinical history of asthma symptomatology and measures of lung function (spirometry and methacholine challenge). Diary cards were used in a screening to record nighttime awakenings and doctor contacts caused by asthma symptoms, symptom severity, and number of puffs from a rescue inhaler, All children received a comprehensive neurocognitive assessment at the end of the 28-day screening period (before randomization), including measures of intelligence, attention, memory, and academic achievement. Results: Significant differences were found between children with mild and moderate asthma on lung function and symptom outcome variables (log(e)FEV(1)PC(20),Delta FEV1 percent predicted, change in peak flow percent predicted, nighttime awakenings caused by asthma, average symptom severity score, and average daily number of puffs from a rescue inhaler) but not on neurocognitive variables. Multiple regression analyses revealed that asthma outcomes could not be predicted by neurocognitive variables despite controlling for socioeconomic status. The prevalence of neurocognitive dysfunction, as indicated by the use of psychostimulant medication, was found to be consistent with that found in the existing literature. Conclusion: Mild and moderate asthma symptoms are not related to neurocognitive functioning in the children enrolled in CAMP, Mean performance on neurocognitive variables was found to be similar to that of national normative data.	Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Albuquerque, NM 87131 USA; Univ Washington, Seattle, WA 98195 USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; ABCD Inc, Seattle, WA USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Washington; University of Washington Seattle; Oregon Health & Science University; National Jewish Health	Annett, RD (corresponding author), Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Albuquerque, NM 87131 USA.				NHLBI NIH HHS [N01-HR-16044, N01-HR-16045, NHLBI-HR-90-13] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR016045, N01HR016044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS W, 1990, MANUAL WIDE RANGE AS; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ANNETT RD, 1994, NEUROPSYCHOL REV, V4, P91, DOI 10.1007/BF01874830; APTER AJ, 1994, J ALLERGY CLIN IMMUN, V94, P732, DOI 10.1016/0091-6749(94)90181-3; BENDER BG, 1988, J AM ACAD CHILD PSY, V27, P720, DOI 10.1097/00004583-198811000-00010; BENDER BG, 1991, ANN ALLERGY, V66, P41; BIEDERMAN J, 1994, J AM ACAD CHILD PSY, V33, P842, DOI 10.1097/00004583-199407000-00010; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Childhood Asthma Management Program, 1994, CHILDH ASTHM MAN PRO; COULTAS DB, 1988, AM REV RESPIR DIS, V135, P1386; DeFries JC, 1991, READING BRAIN BIOL B; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; DUNLEAVY RA, 1981, J CONSULT CLIN PSYCH, V49, P137, DOI 10.1037/0022-006X.49.1.137; FREUDENBERG N, 1980, J SCHOOL HEALTH, V50, P522, DOI 10.1111/j.1746-1561.1980.tb02079.x; Gordon M., 1987, TECHNICAL GUIDE GORD; GUTSTADT LB, 1989, AM J DIS CHILD, V143, P471, DOI 10.1001/archpedi.1989.02150160101020; HALFON N, 1993, PEDIATRICS, V91, P56; Kiess H. O., 1996, STAT CONCEPTS BEHAV; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LINDGREN S, 1992, NEW ENGL J MED, V327, P926, DOI 10.1056/NEJM199209243271305; LUDWICK SK, 1986, J PEDIATR-US, V109, P446, DOI 10.1016/S0022-3476(86)80115-9; Lupien SJ, 1997, BRAIN RES REV, V24, P1, DOI 10.1016/S0165-0173(97)00004-0; MORRISON DC, 1988, J LEARN DISABIL, V21, P124, DOI 10.1177/002221948802100211; MRAZEK DA, 1992, ANN ALLERGY, V69, P285; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, V2nd; PERRIN JM, 1994, PEDIATR ANN, V23, P676, DOI 10.3928/0090-4481-19941201-08; PURCELL K, 1969, PSYCHOSOM MED, V31, P144, DOI 10.1097/00006842-196903000-00008; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; Safer DJ, 1996, PEDIATRICS, V98, P1084; SATTLER JH, 1991, ASSESSMENT CHILDREN; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; SUESS WM, 1981, J CONSULT CLIN PSYCH, V49, P135, DOI 10.1037/0022-006X.49.1.135; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; WABER DP, 1984, CHILD DEV, V55, P1878, DOI 10.1111/j.1467-8624.1984.tb00429.x; Wechsler D., 1989, MANUAL WECHSLER PRES; Wechsler D., 1991, MANUAL WECHSLER INTE; WOODCOCK RW, 1990, TEST ACHIEVEMENT STA	37	27	28	1	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					717	724		10.1067/mai.2000.105226	http://dx.doi.org/10.1067/mai.2000.105226			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	306PB	10756221				2022-12-18	WOS:000086604100009
J	Razmovski, V; O'Meara, TJ; Taylor, DJM; Tovey, ER				Razmovski, V; O'Meara, TJ; Taylor, DJM; Tovey, ER			A new method for simultaneous immunodetection and morphologic identification of individual sources of pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aeroallergen; airborne pollen; Lol pl; Lol p 5; paucimicronic; mAb antibodies; Hirst spore trap	GRASS-POLLEN; AIRBORNE PARTICLES; PVDF MEMBRANES; AEROALLERGENS; ASTHMA; AIR; QUANTIFICATION; ANTIGENS; ANTIBODY; SMALLER	Background: Exposure to outdoor allergens has commonly been estimated by collecting airborne particles with a Hirst-type spore trap and then using morphologic criteria to identify the intact pollen grains and fungal spores that are recognized as allergen sources. Several antibody-based blotting or fixation methods have also been developed that enable the counting of amorphous airborne particles carrying allergen, but none of these methods allow the ready association of the released allergen with the morphologically identifiable particle of origin. A method has been developed that uses pressure-sensitive adhesive tape to sample the airborne particles and then allows the immunoidentification of the specific particles that are the allergen sources. Objective: Our purpose was to visualize and immunostain the particles carrying pollen allergen that are collected with a volumetric spore trap. Methods: A Burkard sampler was used to collect airborne particles onto pressure-sensitive adhesive tapes. The particles were permanently fixed between the tape and a protein-binding membrane when the tape was laminated with the membrane. Allergens that elute from the particles onto the membrane were detected with a range of antibodies. Both the particle and associated immunostained allergen were viewed through the transparent tape for final microscopic identification. Results: Polyclonal and monoclonal antibodies and IgE from allergic patients stained allergens in the periphery of particles collected on the tapes. Individual pollen grains and paucimicronic particles were seen with halos of immunostained allergen surrounding them. When IgE was used, the density of immunostaining in the halo surrounding Lolium perenne pollen grains was found to be proportional to the level of Lolium-specific IgE. The method is highly sensitive and can be used to detect different airborne particles that carry allergen. Both the particle and the immunostaining can be subjected to a range of simple measurement techniques. Conclusion: Individual particles carrying allergens and antigens were visualized. These particles included intact pollen grains, paucimicronic particles, and fungal spores.	Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia	University of Sydney	Tovey, ER (corresponding author), Univ Sydney, Inst Resp Med, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				Acevedo F, 1998, ALLERGY, V53, P594, DOI 10.1111/j.1398-9995.1998.tb03935.x; AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; Ekebom A, 1996, GRANA, V35, P113, DOI 10.1080/00173139609429481; EMBERLIN J, 1995, CLIN EXP ALLERGY, V25, P202, DOI 10.1111/j.1365-2222.1995.tb01029.x; Emberlin J, 1995, CLIN EXP ALLERGY, V25, P33, DOI 10.1111/j.1365-2222.1995.tb00040.x; FERNANDEZCALDAS E, 1989, GRANA, V28, P205, DOI 10.1080/00173138909427432; Lovborg U, 1999, CLIN EXP ALLERGY, V29, P973; Lovborg U, 1998, INT ARCH ALLERGY IMM, V117, P220, DOI 10.1159/000024014; MARK D, 1986, ANN OCCUP HYG, V30, P89, DOI 10.1093/annhyg/30.1.89; O'Meara TJ, 1998, LANCET, V351, P1488, DOI 10.1016/S0140-6736(05)78870-X; Razmovski V, 1998, GRANA, V37, P305, DOI 10.1080/00173139809362683; REED CE, 1986, J ALLERGY CLIN IMMUN, V78, P1028, DOI 10.1016/0091-6749(86)90298-8; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; SCHUMACHER MJ, 1988, J ALLERGY CLIN IMMUN, V82, P608, DOI 10.1016/0091-6749(88)90972-4; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STEWART GA, 1985, MED J AUSTRALIA, V143, P426, DOI 10.5694/j.1326-5377.1985.tb123117.x; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; Takahashi Y, 1995, GRANA, V34, P357, DOI 10.1080/00173139509429071; TAKAHASHI Y, 1993, ALLERGY, V48, P94, DOI 10.1111/j.1398-9995.1993.tb00692.x; TAKAHASHI Y, 1993, GRANA, V32, P302, DOI 10.1080/00173139309429993; Tarlton JF, 1996, J IMMUNOL METHODS, V191, P65, DOI 10.1016/0022-1759(96)00003-8; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; YliPanula E, 1997, ALLERGY, V52, P541, DOI 10.1111/j.1398-9995.1997.tb02597.x	26	27	28	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					725	731		10.1067/mai.2000.105222	http://dx.doi.org/10.1067/mai.2000.105222			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756222	Bronze			2022-12-18	WOS:000086604100010
J	Gupta, R; Singh, BP; Sridhara, S; Gaur, SN; Chaudhary, VK; Arora, N				Gupta, R; Singh, BP; Sridhara, S; Gaur, SN; Chaudhary, VK; Arora, N			Allergens of Curvularia lunata during cultivation in different media	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; Curvularia lunata; fungus; standardization; characterization; extract; source material	ASPERGILLUS-FUMIGATUS; CANDIDA-ALBICANS; BRONCHOPULMONARY ASPERGILLOSIS; CLADOSPORIUM-HERBARUM; FUNGAL ALLERGENS; ALTERNARIA; EXTRACTS; STANDARDIZATION; IDENTIFICATION; PREVALENCE	Background: Despite enormous efforts toward the standardization of fungal extracts, only a few extracts have been characterized that are relevant for the diagnosis and immunotherapy of allergy-associated disorders. Objective: The goal of this study was to determine the optimum growth condition of Curvularia lunata, an important fungal allergen for quality raw material, and to analyze the C lunata extract for IgE- and IgG-binding proteins. Methods: C lunata was grown in synthetic (Czapeck Dox medium), semisynthetic (Sabouraud's broth [SB]), and natural media (potato dextrose [PD]) for different periods of time. The extracts were probed for allergenic and antigenic activity, with pooled patient sera and polyclonal antibodies raised against C lunata by means of ELISAs, immunoblots (in vitro), and intradermal tests (in vivo). Results: The growth of C lunata was better in semisynthetic media (ie, SB) compared with other types of media. Dry weight and protein content was maximum in the 7-day culture of SE. ELISA with pooled sera from C lunata-sensitive patients exhibited that cultures grown in SE for 11 to 13 days and PD plus 1.0% agar for 5 days were the most potent. Intradermal tests with 11- to 13-day SB culture extract showed maximum skin reactivity in allergy patients. Immunoblots with patient sera showed 10 to 14 IgE-binding proteins in 5- to 15-day SE cultures. Analysis of 5- to 15-day SE extract with rabbit sera showed 10 to 16 IgG-binding proteins. Conclusions: The extract from 11- to 13-day SE cultures were most biologically potent (intradermal tests) and showed high antigenic and allergenic reactivity (ELISA and immunoblot). The addition of yeast extract did not affect the dry weight and protein content of the C lunata extract. Furthermore, addition of agar in PD medium increases the dry weight and protein content of the fungal mat. Synthetic media was not suitable for mass cultivation of C lunata.	Ctr Biochem Technol, Allergy & Immunol Sect, Delhi 110007, India; Univ Delhi, Vallabhbhai Patel Chest Inst, Delhi 110007, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); University of Delhi	Arora, N (corresponding author), Ctr Biochem Technol, Allergy & Immunol Sect, Room 509,Univ Delhi Campus,Mall Rd,Near Jubilee H, Delhi 110007, India.				NATIONAL EYE INSTITUTE [R01EY006400] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY006400] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Agarwal MK, 1974, ADV POLLEN SPORE RES, V1, P78; AUKRUST L, 1978, ALLERGY, V33, P24, DOI 10.1111/j.1398-9995.1978.tb01503.x; AUKRUST L, 1979, INT ARCH ALLER A IMM, V60, P68, DOI 10.1159/000232324; BANERJEE B, 1990, ASIAN PAC J ALLERGY, V8, P13; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; CAROL E, 1986, J ALLERGY CLIN IMMUN, V77, P842; Corey JP, 1997, OTOLARYNG HEAD NECK, V117, P516, DOI 10.1016/S0194-5998(97)70024-X; Corsico R, 1998, ANN ALLERG ASTHMA IM, V80, P71, DOI 10.1016/S1081-1206(10)62943-2; DHILLON M, 1991, ANN ALLERGY, V66, P385; DIXIT AB, 1992, J ALLERGY CLIN IMMUN, V90, P11, DOI 10.1016/S0091-6749(06)80006-0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Elliott MW, 1997, CLIN EXP ALLERGY, V27, P55, DOI 10.1111/j.1365-2222.1997.tb01827.x; Esch RE, 1997, METHODS, V13, P2, DOI 10.1006/meth.1997.0491; EVERARDO AM, 1995, MYCOPATHOLOGIA, V131, P75; Galant S, 1998, ANN ALLERG ASTHMA IM, V81, P203, DOI 10.1016/S1081-1206(10)62813-X; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; KAUFFMAN HF, 1985, INT ARCH ALLER A IMM, V76, P168, DOI 10.1159/000233685; KLEINETEBBE J, 1993, CLIN EXP ALLERGY, V23, P211, DOI 10.1111/j.1365-2222.1993.tb00884.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE FR, 1991, AUST NZ J MED, V21, P871, DOI 10.1111/j.1445-5994.1991.tb01410.x; LEHRER SB, 1990, ALLERGY PROC, V11, P197, DOI 10.2500/108854190778879846; LONGBOTTOM JL, 1983, CLIN EXP IMMUNOL, V53, P354; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZ J, 1985, ALLERGOL IMMUNOPATH, V13, P501; NAGENDRA PKV, 1998, INDIAN J ALLERGY APP, V12, P5; PARIS S, 1990, INT ARCH ALLER A IMM, V92, P1, DOI 10.1159/000235216; Pumhirun P, 1997, ASIAN PAC J ALLERGY, V15, P183; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SAVOLAINEN J, 1989, INT ARCH ALLER A IMM, V90, P61, DOI 10.1159/000235001; Savolainen J, 1998, ALLERGY, V53, P359, DOI 10.1111/j.1398-9995.1998.tb03906.x; SAVOLAINEN J, 1995, CLIN EXP ALLERGY, V25, P357, DOI 10.1111/j.1365-2222.1995.tb01054.x; SHAFIEE A, 1978, ANN ALLERGY, V40, P220; SINGH B P, 1981, Proceedings of the Indian National Science Academy Part B Biological Sciences, V47, P78; SINGH BP, 1992, BIOCHEM INT, V27, P477; SINGH BP, 1987, ANN ALLERGY, V59, P229; TRAVIS WD, 1991, HUM PATHOL, V22, P240; VANDERHEIDE S, 1985, ALLERGY, V40, P586; VERMA J, 1994, INT ARCH ALLERGY IMM, V104, P175, DOI 10.1159/000236727; VIJAY HM, 1985, INT ARCH ALLER A IMM, V78, P37, DOI 10.1159/000233860; Voller A., 1976, AM SOC MICROBIOL, V17, P506	40	27	27	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				857	862		10.1016/S0091-6749(99)70299-X	http://dx.doi.org/10.1016/S0091-6749(99)70299-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518833				2022-12-18	WOS:000083281200020
J	Bernstein, JA; Bernstein, DI; Stauder, T; Lummus, Z; Bernstein, IL				Bernstein, JA; Bernstein, DI; Stauder, T; Lummus, Z; Bernstein, IL			A cross-sectional survey of sensitization to Aspergillus oryzae-derived lactase in pharmaceutical workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lactase; Aspergillus oryzae; sensitization; cross-sectional survey; occupational; respiratory symptoms; pharmaceutical industry; risk factors atopy	OCCUPATIONAL ASTHMA; PROCESSING WORKERS; ALPHA-AMYLASE; EXPOSURE; RESPONSES; INDUSTRY; ENZYMES	Background: The presence of IgE-mediated occupational respiratory sensitization to microbial enzymes has been wed documented in a variety of industries. Aspergillus oryzae-derived lactase is used as a dietary aid for patients with lactose intolerance. Objective: In 1993, a cross-sectional survey of 94 pharmaceutical workers exposed to lactase for a mean duration of 23 months and 24 nonexposed recently hired employees was initiated to identify lactase-sensitized workers and potential risk factors that could be used in making recommendations for preventing future cases of lactase sensitization. Methods: The survey included a physician-administered questionnaire, skin prick testing to lactase enzyme and a panel of common aeroallergens, and spirometry. Results: Twenty-seven of 94 lactase-exposed workers (29%) had positive skin test responses to lactase. These workers were 9 times more likely to have upper or lower respiratory symptoms compared with workers with negative skin test responses. Atopic workers were 4 times more likely to have lactase skin sensitivity than nonatopic workers. However, atopy was not a risk factor for the development of upper and/or lower respiratory symptoms. Lactase skin reactivity was not observed in the 24 nonexposed employees. Conclusion: This cross-sectional survey revealed that atopic workers were more likely to have lactase sensitization and that lactase-sensitized workers were more likely to have upper and/or lower respiratory symptoms, but atopy was not a risk factor for upper or lower respiratory symptoms. In spite of these findings, the company allowed only nonatopic, nonlactase-sensitized workers to continue working in high Lactase-exposure areas with careful symptom monitoring and use of protective clothing. Although this strategy was successful in total prevention of new cases of occupational respiratory disease after 5 years, the results of this cross-sectional survey do not support exclusion of atopic workers from working with industrial enzymes.	Univ Cincinnati, Coll Med, Dept Med, Div Immunol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Bernstein, JA (corresponding author), Univ Cincinnati, Coll Med, Dept Med, Div Immunol, 231 Bethesda Ave,563, Cincinnati, OH 45267 USA.			Bernstein, Jonathan/0000-0002-3476-1196				BAUR X, 1988, RESPIRATION, V54, P70, DOI 10.1159/000195503; BERNSTEIN DI, 1994, J ALLERGY CLIN IMMUN, V94, P498, DOI 10.1016/0091-6749(94)90206-2; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; BERNSTEIN DI, 1987, J ALLERGY CLIN IMMUN, V80, P791, DOI 10.1016/S0091-6749(87)80267-1; BERNSTEIN DI, 1985, J ALLERGY CLIN IMMUN, V76, P458, DOI 10.1016/0091-6749(85)90727-4; BERNSTEIN DI, 1992, ASTHMA WORKPLACE, P373; BERNSTEIN JA, 1993, CHEST, V103, P532, DOI 10.1378/chest.103.2.532; BRISMAN J, 1991, BRIT J IND MED, V48, P604; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V73, P574, DOI 10.1016/0091-6749(84)90513-X; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; LISS GM, 1984, J ALLERGY CLIN IMMUN, V73, P348, DOI 10.1016/0091-6749(84)90407-X; LOSADA E, 1986, J ALLERGY CLIN IMMUN, V77, P635, DOI 10.1016/0091-6749(86)90358-1; LOSADA E, 1992, J ALLERGY CLIN IMMUN, V89, P118, DOI 10.1016/S0091-6749(05)80048-X; Muir DCF, 1997, AM J IND MED, V31, P570, DOI 10.1002/(SICI)1097-0274(199705)31:5<570::AID-AJIM11>3.0.CO;2-W; OTT K, 1998, ANN ALLERG ASTHMA IM, V81, P64; QUIRCE S, 1992, J ALLERGY CLIN IMMUN, V90, P970, DOI 10.1016/0091-6749(92)90470-M; SANDERS SW, 1992, CLIN PHARMACY, V11, P533; SMITH AB, 1990, CHEST, V98, P398, DOI 10.1378/chest.98.2.398; VENABLES KM, 1988, BRIT J IND MED, V45, P667	20	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1153	1157		10.1016/S0091-6749(99)70192-2	http://dx.doi.org/10.1016/S0091-6749(99)70192-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359899				2022-12-18	WOS:000080929500026
J	Eigenmann, PA; Tropia, L; Hauser, C				Eigenmann, PA; Tropia, L; Hauser, C			The mucosal adhesion receptor alpha 4 beta 7 integrin is selectively increased in lymphocytes stimulated with lactoglobulin in children allergic to cow's milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food hypersensitivity; cow's milk; atopic dermatitis; lymphocyte homing; integrins; L-selectin; suppressor T lymphocytes; human	ATOPIC-DERMATITIS PATIENTS; HOMING RECEPTOR; FOOD CHALLENGES; PEANUT ALLERGY; IN-SITU; CELLS; EXPANSION; RESPONSES; ROTAVIRUS; MOLECULE	Background: It has been shown in mice that the integrin alpha 4 beta 7 directs the migration of memory T cells into the gut-associated lymphoid tissue. However, little is known about T-cell homing mechanisms in children with food allergies. Objective: We investigated the expression of this and other integrins in children with different manifestations of cow's milk allergy (urticaria, atopic dermatitis, and wheezing). Methods: PBMCs were stimulated with beta-lactoglobulin, 1 of the major allergenic proteins in cow's milk, and tetanus toxoid, Integrin expression was studied by flow cytometric analysis after 1 week of culture. Results: We found significantly higher expression of the alpha 4 beta 7 integrin in cells from patients compared with control subjects with no allergies (P = .005) when beta-lactoglobulin was used to stimulate the cells. alpha 4 beta 7 integrin was also expressed at significantly higher levels in beta-lactoglobulin-stimulated cells than in tetanus toroid-stimulated cells (P = .005). The alpha E beta 7 and the alpha 4 beta 1 integrins were not upregulated by allergen stimulation. Most alpha 4 beta 7 integrin-expressing cells were identified as CD4(+) T cells. Conclusion: These results show that alpha 4 beta 7 integrin expression after stimulation with beta-lactoglobulin correlates with the presumptive site of cow's milk sensitization (ie, the gut-associated lymphoid tissue but not with the site of symptoms of cow's milk allergy).	Univ Geneva, Sch Med, Dept Pediat, CH-1211 Geneva, Switzerland; Univ Geneva, Sch Med, Dept Med, Div Immunol & Allergy, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Eigenmann, PA (corresponding author), Univ Hosp Geneva, Allergy Unit, 24 Rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.		Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; DORION BJ, 1995, PEDIATR ALLERGY IMMU, V6, P95, DOI 10.1111/j.1399-3038.1995.tb00266.x; Eigenmann PA, 1996, PEDIATR ALLERGY IMMU, V7, P12, DOI 10.1111/j.1399-3038.1996.tb00100.x; EIGENMANN PA, 1995, J ALLERGY CLIN IMMUN, V96, P549, DOI 10.1016/S0091-6749(95)70300-4; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HAMANN A, 1994, J IMMUNOL, V152, P3282; Hauer AC, 1997, PEDIATR RES, V42, P629, DOI 10.1203/00006450-199711000-00014; HAUSER C, IN PRESS CELL ADHESI; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; Lobb RR, 1996, ANN NY ACAD SCI, V796, P113, DOI 10.1111/j.1749-6632.1996.tb32573.x; Rott LS, 1997, J CLIN INVEST, V100, P1204, DOI 10.1172/JCI119633; Sampson H A, 1995, Allergy, V50, P46; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SHINODA S, 1993, CLIN EXP ALLERGY, V23, P689, DOI 10.1111/j.1365-2222.1993.tb01795.x; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207, DOI 10.1016/S0091-6749(98)70410-5; Williams MB, 1998, J IMMUNOL, V161, P4227	25	27	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				931	936		10.1016/S0091-6749(99)70441-0	http://dx.doi.org/10.1016/S0091-6749(99)70441-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329831	Bronze			2022-12-18	WOS:000080470200032
J	Rickard, KA; Stempel, DA				Rickard, KA; Stempel, DA			Asthma survey demonstrates that the goals of the NHLBI have not been acomplished.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract									Virginia Mason Clin, Seattle, WA 98101 USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	Virginia Mason Medical Center; GlaxoSmithKline									0	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	2	S		655	S171	S171						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	165FC					2022-12-18	WOS:000078509000658
J	Koh, YY; Lee, MH; Kim, CK; Min, YG; Kim, YK; Min, KU; Kim, YY				Koh, YY; Lee, MH; Kim, CK; Min, YG; Kim, YK; Min, KU; Kim, YY			A familial predisposition in bronchial hyperresponsiveness among patients with allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; bronchial hyperresponsiveness; bronchial responsiveness index; familial predisposition	GENETIC-FACTORS; INHALATION CHALLENGE; ASTHMA; RESPONSIVENESS; METHACHOLINE; REACTIVITY; HISTAMINE; HYPERREACTIVITY; CHILDREN; PARENTS	Background: Nonasthmatic subjects with allergic rhinitis often have bronchial hyperresponsiveness (BHR). The mechanisms responsible for ERR in asthma include genetic predisposition and airway inflammation, but the causes of BHR in allergic rhinitis are poorly understood. Objective: The aim of this study was to investigate whether there is a familial prediposition in allergic rhinitis-associated BHR. Methods: One hundred fifteen children with allergic rhinitis (probands) and their family members underwent methacholine bronchial challenge and skin prick tests with airborne allergens. The probands were divided into 2 groups: BHR(+) (methacholine PC20 <18 mg/mL determined by the dosimeter method; n = 42) and BHR(-) (n = 73). Results: The overall prevalence of BHR was higher in family members of BHR(+) probands than in those of BHR(-) probands (23.3% [27 of 116] vs 10.5% [21 of 200], P < .01). In mothers, this difference was marked (21.4% vs 8.2%, P < .05); a similar trend was observed in fathers (16.7% vs 6.8%) and siblings (34.4% vs 18.5%), although the differences did not reach significance (.05 < P < .1). The bronchial responsiveness index (BR index), a continuous variable derived from the results of methacholine challenge, was significantly higher among family members of the BHR(+) group than those of the BHR(-) group. Furthermore, even when only family members without BHR were considered, the BR index was significantly higher among those (n = 89) of the BHR(+) group than those (n = 179) of the BHR(-) group. There was no difference in atopic status as assessed by the prevalence of atopy (or atopy index) between family members of the BHR(+) group and the BHR(-) group. Conclusion: Our results indicated that there is a significant familial predisposition for BHR among patients with allergic rhinitis. Further studies are needed to elucidate whether genetic factors play a role in allergic rhinitis-associated BHR.	Seoul Natl Univ Hosp, Dept Pediat, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Dept Otolaryngol, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Seoul National University Hospital	Kim, YY (corresponding author), Seoul Natl Univ, Childrens Hosp, Dept Pediat, 28 Yongon Dong, Seoul 110744, South Korea.		Min, Kyung-Up/J-5468-2012; Koh, Young Yull/J-5368-2012; Koh, Young Yull/D-6059-2012					AUBIER M, 1992, AM REV RESPIR DIS, V146, P122, DOI 10.1164/ajrccm/146.1.122; BLEECKER ER, 1997, GENETICS ALLERGY AST, P307; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66, DOI 10.1136/adc.62.1.66; COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CROCKCROFT DW, 1984, ANN ALLERGY, V53, P26; DREBORG S, 1989, ALLERGY S10, V44, P52; EGGLESTON PA, 1988, J ALLERGY CLIN IMMUN, V81, P1036, DOI 10.1016/0091-6749(88)90176-5; Evans R., 1993, ALLERGY PRINCIPLES P, P1109; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58, DOI 10.1016/S0091-6749(97)70195-7; GURWITZ D, 1981, J PEDIATR-US, V98, P551, DOI 10.1016/S0022-3476(81)80758-5; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HOPP RJ, 1988, ANN ALLERGY, V61, P184; Kim JM, 1984, TUBERCUL RESP DIS, V31, P1; KIM WK, 1995, J KOREAN SOC ALLERGO, V15, P304; KIM YK, 1998, IN PRESS J KOREAN SO; KONIG P, 1974, J ALLERGY CLIN IMMUN, V54, P280, DOI 10.1016/0091-6749(74)90014-1; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LONGO G, 1987, AM J DIS CHILD, V141, P331, DOI 10.1001/archpedi.1987.04460030109037; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, pS35, DOI 10.1164/ajrccm/136.4_Pt_2.S35; PAIK YH, 1991, J KOREAN MED ASSOC, V34, P69; PAUWELS R, 1985, EUR J RESPIR DIS, V66, P98; PAUWELS R, 1997, ALLERGY ALLERGIC DIS, P682; PIFFERI M, 1994, CHEST, V105, P706, DOI 10.1378/chest.105.3.706; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; PRIETO L, 1994, THORAX, V49, P711, DOI 10.1136/thx.49.7.711; PRIETO L, 1994, ANN ALLERGY, V72, P534; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SMITH L, 1995, ANN ALLERG ASTHMA IM, V74, P454; STEVENS WJ, 1980, EUR J RESPIR DIS, V61, P203; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; VERDIANI P, 1990, J ALLERGY CLIN IMMUN, V86, P576, DOI 10.1016/S0091-6749(05)80215-5; YOON KA, 1993, J KOREAN PEDIATR ASS, V36, P25	43	27	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				921	926		10.1016/S0091-6749(98)70329-X	http://dx.doi.org/10.1016/S0091-6749(98)70329-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847432				2022-12-18	WOS:000077690700009
J	Sawyer, G; Kemp, T; Shaw, R; Patchett, K; Siebers, R; Lewis, S; Beasley, R; Crane, J; Fitzharris, P				Sawyer, G; Kemp, T; Shaw, R; Patchett, K; Siebers, R; Lewis, S; Beasley, R; Crane, J; Fitzharris, P			Biologic pollution in infant bedding in New Zealand: High allergen exposure during a vulnerable period	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Der p 1; Fel d 1; house dust mite; cat; allergens; bedding; infants; New Zealand	HOUSE-DUST MITE; DER-P-I; CHILDHOOD ASTHMA; RISK FACTOR; INHALANT ALLERGENS; INDOOR ALLERGENS; SENSITIZATION; IGE; CHILDREN; ANTIBODIES	Background: High exposure to house dust mite and cat allergens in early life predisposes to allergic sensitization and to the development and persistence of asthma, Prevalence and severity of asthma are high in New Zealand, Objective: The objective of this study was to determine the concentrations of Der p 1 and Fel d 1 in infant bedding in Wellington, New Zealand, Methods: Infants were visited at home at a mean age of 11 weeks and again at 15 months. The concentration (mu g/g fine dust) and content (mu g/m(2)) of Der p 1 (154 infants) and Fel d 1 (75 infants) were measured in dust samples taken from each infant's bed. Results: At 11 weeks, geometric: mean (95% confidence intervals) Der p 1 levels were 18.3 mu g/g (13.8 to 24.1) and 3.51 mu g/m(2) (2.4 to 5.2). By 15 months, Der p 1 had risen significantly to 44.0 mu g/g (35.0 to 55.3) and 49.0 mu g/m(2) (36.0 to 66.8), Bedding that included a sheepskin mas used by a third of the infants and contained higher concentrations (mu g/g) and content (mu g/m(2)) of Der p 1 than beds without sheepskins, Cat ownership nas the major determinant of Fel d 1 levels, with 48% of infants living with cats. At the first, visit, the mean concentration of Fel d 1 in bedding was 44.6 mu g/g (23.5 to 84.9) for houses with cats and 3.0 mu g/g (2.1 to 1.3) for those without cats, remaining essentially unchanged at the second visit. When expressed as micrograms pet square meter, there was a significant increase between visits, from 8.1 (3.9 to 16.6) to 39.6 (19.9 to 78.5) in the cat-inclusive households. Conclusions: Extremely high levels of house dust mite allergen have been found in these infants' environments, which, together with the high levels of cat allergen in almost half who kept eats, are likely to be a major determinant of asthma prevalence and severity in New Zealand.	Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, Wellington S, New Zealand	University of Otago	Fitzharris, P (corresponding author), Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, POB 7343, Wellington S, New Zealand.		Siebers, Robert/A-4102-2009	Siebers, Robert/0000-0002-6359-3144; Beasley, Richard/0000-0003-0337-406X				ABBOTT J, 1981, CLIN ALLERGY, V11, P589, DOI 10.1111/j.1365-2222.1981.tb02179.x; Burney P, 1996, EUR RESPIR J, V9, P687; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; DELACOURT C, 1994, ALLERGY, V49, P843, DOI 10.1111/j.1398-9995.1994.tb00785.x; FLANNERY EM, 1994, AUST NZ J MED, V24, P687, DOI 10.1111/j.1445-5994.1994.tb01784.x; GELBER LE, 1993, AM REV RESPIR DIS, V147, P575; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; HOLT PG, 1988, IMMUNOLOGY, V63, P591; INGHAM PE, 1976, MED J AUSTRALIA, V1, P302, DOI 10.5694/j.1326-5377.1976.tb140629.x; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; MULVEY PM, 1973, MED J AUSTRALIA, V1, P11; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Siebers R., 1997, Journal of Allergy and Clinical Immunology, V99, pS392; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOVEY ER, 1975, MED J AUSTRALIA, V2, P770, DOI 10.5694/j.1326-5377.1975.tb106278.x; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; vanStrien RT, 1995, CLIN EXP ALLERGY, V25, P1184, DOI 10.1111/j.1365-2222.1995.tb03042.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner AM, 1996, PEDIAT ALLERG IMM-UK, V7, P61, DOI 10.1111/j.1399-3038.1996.tb00108.x; Wickens K, 1997, CLIN EXP ALLERGY, V27, P1077, DOI 10.1111/j.1365-2222.1997.tb01260.x; Wickman M, 1996, ALLERGY, V51, P511, DOI 10.1111/j.1398-9995.1996.tb04658.x	34	27	28	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					765	770		10.1016/S0091-6749(98)70016-8	http://dx.doi.org/10.1016/S0091-6749(98)70016-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819293				2022-12-18	WOS:000077033400010
J	Joshi, P; Kakakios, A; Jayasekera, J; Isaacs, D				Joshi, P; Kakakios, A; Jayasekera, J; Isaacs, D			A comparison of IL-2 levels in nasopharyngeal and endotracheal aspirates of babies with respiratory syncytial viral bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokine; nasopharynx; respiratory syncytial virus; IL-2	T-CELLS; ATOPIC ASTHMA; NASAL LAVAGE; IN-VIVO; CYTOKINES; HYPERRESPONSIVENESS; RHINOVIRUS; CHILDREN	Background: Cytokines such as IL-2 are thought to be important in the pathogenesis of respiratory tract inflammation, Cytokine levels in nasopharyngeal aspirates (NPAs) have been used as a measure of respiratory inflammation in children with viral infections, hut it is unclear whether they reflect levels in the lower respiratory tract, Objective: We sought to assess the correlation between IL-2 levels in the nasopharyngeal and endotracheal secretions of children intubated with respiratory syncytial virus (RSV)-positive bronchiolitis. Methods: NPA and endotracheal aspirates were collected concurrently from intubated infants with RSV-positive bronchiolitis, IL-2 levels were assayed by ELISA, and the results were compared according to collection site. Results: Nine paired specimens were collected. IL-2 levels ranged from 31 pg/mL to 8040 pg/mL. No significant difference was found in the geometric mean IL-2 values from the 2 collection sites, The intraclass correlation coefficient between NPA IL-2 levels and endotracheal aspirate IL-2 levels was 0.83, Conclusion: IL-2 levels in NPAs are comparable with those in the lower respiratory tracts of infants with RSV-positive bronchiolitis, NPA cytokine levels provide a simple and useful means of assessing respiratory tract inflammation.	Royal Alexandra Hosp Children, Dept Immunol & Infect Dis, Parramatta, NSW 2124, Australia		Isaacs, D (corresponding author), Royal Alexandra Hosp Children, Dept Immunol & Infect Dis, POB 3515, Parramatta, NSW 2124, Australia.							ARMITAGE P, 1997, STAT METHODS MED RES, P272; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; ENGVALL E, 1972, J IMMUNOL, V109, P129; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; NOAH TL, 1995, AM J RESP CRIT CARE, V152, P1290, DOI 10.1164/ajrccm.152.4.7551384; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434; Wimalasundera SS, 1997, J INFECT DIS, V176, P755, DOI 10.1086/514101	10	27	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				618	620		10.1016/S0091-6749(98)70278-7	http://dx.doi.org/10.1016/S0091-6749(98)70278-7			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802370				2022-12-18	WOS:000076600400012
J	Tang, LL; Benjaponpitak, S; DeKruyff, RH; Umetsu, DT				Tang, LL; Benjaponpitak, S; DeKruyff, RH; Umetsu, DT			Reduced prevalence of allergic disease in patients with multiple sclerosis is associated with enhanced IL-12 production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; autoimmune disease; IL-12; multiple sclerosis	CD4(+) T-CELLS; IN-VITRO; INTERLEUKIN-12; CYTOKINE; LYMPHOCYTES; ASTHMA; ENCEPHALOMYELITIS; SUSCEPTIBILITY; CHROMOSOME-5; EXPRESSION	Background: We previously showed that the prevalence of allergic disease is decreased in patients with multiple sclerosis (MS); however, the mechanisms that explain this finding have not previously been defined. Objectives: We have demonstrated that protection of patients with MS from allergic disease may be caused by the production in monocytes from these patients of elevated quantities of IL-12 compared with that observed in monocytes from individuals with allergies. Methods: Purified monocytes from peripheral blood of subjects with or without allergies and from individuals with MS were directly stimulated with Staphylococcus aureus Cowan strain I in the absence of T cells. IL-12 was quantitated by a sensitive reverse transcription, competitive PCR. esults: IL-12 production was 5-fold greater in monocytes from patients with MS (n = 11) than that from individuals with allergies (n = 10) (for subjects with MS, 1.90 +/- 0.18 vs 1.24 +/- 0.19 log(10) fmol/mu L for individuals with allergies) (P =.02), Although the production of IL-12 in monocytes from patients with MS was slightly higher than that from subjects without allergies, this difference was not statistically significant. Conclusions: lL-12 production in individuals with MS is much greater than in individuals with allergies, Because IL-12 induces T-H1 cytokine synthesis and reduces the production of T-H2 cytokines, which amplify and prolong allergic inflammation, these studies suggest that enhanced IL-12 production may protect individuals with MS from the development of allergy but may predispose such individuals toward autoimmune inflammation in the central nervous system.	Stanford Univ, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA	Stanford University	Umetsu, DT (corresponding author), Stanford Univ, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024571, R01AI026322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020610] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI24571, R01-AI26322] Funding Source: Medline; NIAMS NIH HHS [P60-AR20610] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balashov KE, 1997, P NATL ACAD SCI USA, V94, P599, DOI 10.1073/pnas.94.2.599; Blotta MH, 1997, J IMMUNOL, V158, P5589; COMPSTON D, 1986, MULTIPLE SCLEROSIS B, P56; DeKruyff RH, 1997, J IMMUNOL, V158, P359; Drulovic J, 1997, J NEUROL SCI, V147, P145, DOI 10.1016/S0022-510X(96)05320-8; Gieni RS, 1996, INT IMMUNOL, V8, P1511, DOI 10.1093/intimm/8.10.1511; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713; Karpuj MV, 1997, NEUROGENETICS, V1, P21, DOI 10.1007/s100480050003; Kim TS, 1997, J IMMUNOL, V158, P4137; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Leonard JP, 1997, CRIT REV IMMUNOL, V17, P545; LINDEGARD B, 1985, ACTA NEUROL SCAND, V71, P267; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MARSHALL JD, 1995, J IMMUNOL, V155, P111; McRae BL, 1997, EUR J IMMUNOL, V27, P2650, DOI 10.1002/eji.1830271026; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Navikas V, 1996, J NEUROSCI RES, V45, P322, DOI 10.1002/(SICI)1097-4547(19960815)45:4<322::AID-JNR1>3.0.CO;2-B; Neukirch F, 1997, J ALLERGY CLIN IMMUN, V99, P270; Nicoletti F, 1996, J NEUROIMMUNOL, V70, P87, DOI 10.1016/S0165-5728(96)00101-4; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SALTINE S, 1997, NAT MED, V3, P1394; SANTAMBROGIO L, 1995, J NEUROIMMUNOL, V58, P211, DOI 10.1016/0165-5728(95)00022-T; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Shaw MK, 1997, J EXP MED, V185, P1711, DOI 10.1084/jem.185.9.1711; SIEBURTH D, 1992, GENOMICS, V14, P59, DOI 10.1016/S0888-7543(05)80283-6; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; WEINER HL, 1983, ARCH NEUROL-CHICAGO, V40, P704, DOI 10.1001/archneur.1983.04050100044018; WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985	34	27	29	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					428	435		10.1016/S0091-6749(98)70131-9	http://dx.doi.org/10.1016/S0091-6749(98)70131-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768584				2022-12-18	WOS:000076212800016
J	Etzioni, A; Gershoni-Baruch, R; Pollack, S; Shehadeh, N				Etzioni, A; Gershoni-Baruch, R; Pollack, S; Shehadeh, N			Leukocyte adhesion deficiency type II: Long-term follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							E-SELECTIN-DEFICIENT; LYMPHOCYTE; MICE		Technion Israel Inst Technol, B Rappaport Sch Med, Rambam Med Ctr, Dept Pediat & Clin Immunol, Haifa, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Etzioni, A (corresponding author), Rambam Med Ctr, Dept Pediat, IL-31095 Haifa, Israel.							ANDERSON DC, 1996, METAEBOLIC MOL BASES, P3955; Etzioni A, 1996, PEDIATR RES, V39, P191, DOI 10.1203/00006450-199602000-00001; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Kuijpers TW, 1997, INT IMMUNOL, V9, P607, DOI 10.1093/intimm/9.4.607; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; MOLY P, 1996, CELL, V86, P643; Munoz FM, 1997, J CLIN INVEST, V100, P2099, DOI 10.1172/JCI119744; PRICE TH, 1994, BLOOD, V84, P1635; Salmi M, 1997, ADV IMMUNOL, V64, P139, DOI 10.1016/S0065-2776(08)60889-5; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9	10	27	28	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					323	324		10.1016/S0091-6749(98)70104-6	http://dx.doi.org/10.1016/S0091-6749(98)70104-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723680	Bronze			2022-12-18	WOS:000075537100029
J	van der Veen, MJ; Lopuhaa, CE; Aalberse, RC; Jansen, HM; van der Zee, JS				van der Veen, MJ; Lopuhaa, CE; Aalberse, RC; Jansen, HM; van der Zee, JS			Bronchial allergen challenge with isolated major allergens of Dermatophagoides pteronyssinus: The role of patient characteristics in the early asthmatic response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; bronchial provocation test; early asthmatic response; IgE; skin test	COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; INHALATION CHALLENGE; MITE ALLERGENS; SKIN-TESTS; EOSINOPHILS; REACTIVITY; ENDOTOXIN; EXTRACTS	Background: The use of allergen extracts will hamper studies into quantitative aspects of allergic responses because the precise amount of relevant allergen for each patient is unknown. Objective: We applied isolated IgE-binding components (major allergens) in the technique of bronchial allergen challenge to determine the role of patient characteristics in the early asthmatic response (EAR), Methods: In 30 patients with mild-to-moderate asthma, the EAR was investigated after inhalation of an isolated major allergen of Dermatophagoides pteronyssinus (i.e., Der p 1 [n = 16] or Der p 2 [n = 14]), The degree of early-phase bronchial responsiveness to allergen (the cumulated dose of allergen causing a 20% fall in FEV1 [PD(20)allergen]) was related to the degree of nonspecific bronchial responsiveness (the concentration of histamine causing a 20% fall in FEV1 [PC(20)histamine]) and the level of specific IgE or allergen thresholds as found in skin tests and basophil histamine release assays. Results: Twenty-seven patients with an immediate response during allergen and histamine challenges (Delta FEV1, greater than or equal to 20%) were analyzed. In these patients, a strong correlation was found between PD(20)allergen and PC(20)histamine (r = 0.81, p < 0.001), Weak correlations were found between PD(20)allergen and the level of specific IgE (r = -0.36, p = 0.07) or allergen thresholds as found in skin tests (skin prick test, r = 0.36 and p = 0.07; intracutaneous test, r = 0.49 and p = 0.01) or basophil histamine release assays (r = 0.37, p = 0.08). Moreover, no significant contribution of these indices of IgE-mediated hypersensitivity to the prediction of PD(20)allergen by multilinear regression models with PC(20)histamine was found. Conclusion: In asthmatic patients allergic to house dust mites the degree of nonspecific bronchial hyperresponsiveness is the main determinant of early-phase bronchial responsiveness to allergen, In these patients the degree of allergic sensitivity does not contribute to the prediction of the EAR after allergen inhalation.	Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1100 DE Amsterdam, Netherlands; Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Allergy, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	van der Zee, JS (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, F4-208,POB 22700, NL-1100 DE Amsterdam, Netherlands.		van der Zee, Jaring/AAQ-6669-2021; van der Zee, Jaring/HGU-9235-2022; van der Zee, Jaring S/M-8462-2013	van der Zee, Jaring S/0000-0002-8698-6039				BEL EH, 1987, AM REV RESPIR DIS, V136, P979, DOI 10.1164/ajrccm/136.4.979; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; DREBORG S, 1992, ALLERGY, V47, P418, DOI 10.1111/j.1398-9995.1992.tb02082.x; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471, DOI 10.1164/ajrccm.149.6.8004300; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; Muller U, 1997, CLIN EXP ALLERGY, V27, P915, DOI 10.1111/j.1365-2222.1997.tb01233.x; NGUYEN KL, 1990, J ALLERGY CLIN IMMUN, V85, P1020, DOI 10.1016/0091-6749(90)90046-7; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POOLE S, 1989, J BIOL STAND, V17, P161, DOI 10.1016/0092-1157(89)90006-1; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Robuschi M, 1997, AM J RESP CRIT CARE, V155, P1461, DOI 10.1164/ajrccm.155.4.9105094; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Sicherer SH, 1997, J ALLERGY CLIN IMMUN, V99, P798, DOI 10.1016/S0091-6749(97)80014-0; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TIFFENEAU R., 1959, ACTA ALLERGOL, V14, P416, DOI 10.1111/j.1398-9995.1959.tb02857.x; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; WAHL R, 1989, INT ARCH ALLER A IMM, V90, P224, DOI 10.1159/000235029; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6; Witteman AM, 1996, INT ARCH ALLERGY IMM, V109, P369, DOI 10.1159/000237265; WOOLLEY KL, 1995, AM J RESP CRIT CARE, V151, P1915, DOI 10.1164/ajrccm.151.6.7767540; YASUEDA H, 1994, CLIN EXP ALLERGY, V24, P1030, DOI 10.1111/j.1365-2222.1994.tb02739.x; Yasueda H, 1996, CLIN EXP ALLERGY, V26, P171, DOI 10.1111/j.1365-2222.1996.tb00076.x; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	30	27	28	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					24	31		10.1016/S0091-6749(98)70051-X	http://dx.doi.org/10.1016/S0091-6749(98)70051-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679844				2022-12-18	WOS:000074909500006
J	Romano, A; Quaratino, D; Venuti, A; Venemalm, L; Mayorga, C; Blanca, M				Romano, A; Quaratino, D; Venuti, A; Venemalm, L; Mayorga, C; Blanca, M			Selective type-1 hypersensitivity to cefuroxime	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UCSC, Dept Internal Med & Geriatr, Allergy Unit, Rome, Italy; Pharmacia & Upjohn Inc, Uppsala, Sweden; Carlos Haya Hosp, Res Unit Allerg Dis, Malaga, Spain; IRCS Oasi Maria SS, Troina, Italy	Catholic University of the Sacred Heart; Pfizer; Pharmacia Corporation; Hospital Carlos Haya; IRCCS Oasi Maria SS	Romano, A (corresponding author), Ambulatorio Allergol, Complesso Integrato Columbus,Via Pineta Sacchetti, I-00168 Rome, Italy.		Mayorga, Lina/FBO-7730-2022; Mayorga, Cristobalina/D-7167-2018; Romano, Antonino/D-3102-2017	Mayorga, Cristobalina/0000-0001-8852-8077; Romano, Antonino/0000-0001-9742-9898				BRAVO CM, 1995, ALLERGY, V50, P359, DOI 10.1111/j.1398-9995.1995.tb01160.x; NAGAKURA N, 1990, INT ARCH ALLER A IMM, V93, P126, DOI 10.1159/000235291; PEPYS J, 1994, ANAESTHESIA, V49, P470, DOI 10.1111/j.1365-2044.1994.tb03515.x; VANARSDEL PP, 1991, JAMA-J AM MED ASSOC, V265, P2254, DOI 10.1001/jama.265.17.2254; YARBROUGH JA, 1989, ANN ALLERGY, V63, P235	5	27	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	1				564	565		10.1016/S0091-6749(98)70368-9	http://dx.doi.org/10.1016/S0091-6749(98)70368-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZH469	9564816	Bronze			2022-12-18	WOS:000073113500026
J	Asero, R; Mistrello, G; Roncarolo, D; Antoniotti, PL; Falagiani, P				Asero, R; Mistrello, G; Roncarolo, D; Antoniotti, PL; Falagiani, P			A case of garlic allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Osped Caduti Bollatesi, Dept Allergol, I-20021 Milan, Italy; Lab Farmaceut Lofarma, Milan, Italy		Asero, R (corresponding author), Osped Caduti Bollatesi, Dept Allergol, Via Piave 20, I-20021 Milan, Italy.							BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BURGESS JF, 1952, CAN MED ASSOC J, V66, P275; Delaney T A, 1996, Australas J Dermatol, V37, P109, DOI 10.1111/j.1440-0960.1996.tb01019.x; EY PL, 1978, BIOCHEMISTRY-US, V15, P429; LYBARGER JA, 1982, J ALLERGY CLIN IMMUN, V69, P448, DOI 10.1016/0091-6749(82)90120-8; PASTORELLO EA, 1989, J ALLERGY CLIN IMMUN, V84, P475, DOI 10.1016/0091-6749(89)90360-6; SINHA SM, 1977, ARCH DERMATOL, V113, P776, DOI 10.1001/archderm.113.6.776	7	27	27	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					427	428		10.1016/S0091-6749(98)70261-1	http://dx.doi.org/10.1016/S0091-6749(98)70261-1			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525465				2022-12-18	WOS:000072593900026
J	Mori, A; Kaminuma, O; Suko, M; Mikami, T; Nishizaki, Y; Ohmura, T; Hoshino, A; Asakura, Y; Miyazawa, K; Ando, T; Okumura, Y; Yamamoto, K; Okudaira, H				Mori, A; Kaminuma, O; Suko, M; Mikami, T; Nishizaki, Y; Ohmura, T; Hoshino, A; Asakura, Y; Miyazawa, K; Ando, T; Okumura, Y; Yamamoto, K; Okudaira, H			Cellular and molecular mechanisms of IL-5 synthesis in atopic diseases: A study with allergen-specific human helper T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on New Trends in Immunopharmacology	JUL 06, 1996	TOKYO, JAPAN	Novartis Pharma KK, Tokyo, Japan		IL-5; T cell; atopic disease; bronchial asthma	MESSENGER-RNA EXPRESSION; HUMAN INTERLEUKIN-5 GENE; BRONCHOALVEOLAR LAVAGE; CYCLOSPORINE-A; BRONCHIAL BIOPSIES; LYMPHOCYTES-T; ASTHMA; CYTOKINE; EOSINOPHILS; RECEPTOR	Background: Cytokines produced by helper T cells are intimately involved in chronic allergic diseases associated with eosinophilic inflammation, Objective: We investigated the production of IL-5, a potent growth factor and chemotactic factor for eosinophils, by CD4(+) T lymphocytes in patients with asthma. Methods: Allergen-specific T cell clones and T cell hybridomas were established from the peripheral blood lymphocytes of patients with asthma, and the responses to various stimuli,were determined. Results: After nonspecific stimulation, IL-5 production by CD4(+) T cells from both atopic and nonatopic subjects with asthma was significantly enhanced compared with that by cells from healthy controls. Peripheral blood mononuclear cells from atopic asthma patients both proliferated and produced IL-5 after incubation with mite allergen, suggesting that mite-specific helper T cells were involved in the eosinophilic inflammation of atopic asthma. A human IL-5 promoter:enhancer luciferase gene construct transfected into IL-5-producing T cell clones,vas clearly transcribed after stimulation, indicating that the 515 base pair IL-5 gene segment upstream of the coding region was sufficient to respond to activating signals in human helper T cells. The same gene segment,cas not transcribed in IL-5-nonproducing T cell clones, suggesting that human T cell IL-5 synthesis is regulated at the transcriptional level. Experiments with T cell hybridomas confirmed these findings and suggested that a unique transcription factor may be essential for human IL-5 gene transcription. Conclusion: Enhanced IL-5 production by helper T cells seems to cause the eosinophilic inflammation of both atopic and nonatopic asthma. Elucidation of IL-5-specific regulatory mechanisms may facilitate the development of novel treatments for allergic diseases associated with eosinophilic inflammation.	Univ Tokyo, Fac Med, Dept Med & Phys Therapy, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Okudaira, H (corresponding author), Univ Tokyo, Fac Med, Dept Med & Phys Therapy, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Yamamoto, Kazuhiko/N-5096-2015					ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DANIELLE RP, 1988, IMMUNOLOGY IMMUNOLOG, P503; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22, DOI 10.1164/ajrccm/145.2_Pt_2.S22; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KRISHNASWAMY G, 1993, AM J RESP CELL MOL, V9, P279, DOI 10.1165/ajrcmb/9.3.279; MORI A, 1995, INT ARCH ALLERGY IMM, V107, P366, DOI 10.1159/000237036; Mori A, 1996, J IMMUNOL, V156, P2400; MORI A, 1995, INT IMMUNOL, V7, P449, DOI 10.1093/intimm/7.3.449; MORI A, 1994, ENV DERMATOL, V1, P42; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; Okudaira H, 1997, INT ARCH ALLERGY IMM, V113, P331, DOI 10.1159/000237592; OKUDAIRA H, 1994, ACI NEWS, V6, P19; RIEGEL JS, 1992, CHEM IMMUNOL, V51, P266; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHEFFER AL, 1992, CLIN EXP ALLERGY S1, V22, P1; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TANABE T, 1987, J BIOL CHEM, V262, P16580; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757	36	27	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	2	S			S56	S64		10.1016/S0091-6749(97)70006-X	http://dx.doi.org/10.1016/S0091-6749(97)70006-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	YR026	9440546				2022-12-18	WOS:000071449600006
J	Peng, ZK; Arthur, G; Rector, ES; KierekJaszczuk, D; Simons, FER; Becker, AB				Peng, ZK; Arthur, G; Rector, ES; KierekJaszczuk, D; Simons, FER; Becker, AB			Heterogeneity of polyclonal IgE characterized by differential charge, affinity to protein A, and antigenicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; heterogeneity; cross-reactivity; dog; immunoglobulin	HISTAMINE-RELEASING FACTORS; MONOCLONAL-ANTIBODIES; STAPHYLOCOCCUS-AUREUS; ALTERNATIVE RNA; BINDING; IMMUNOGLOBULIN; RECOGNITION; ISOFORMS; DOGS	Functional and physical heterogeneity of polyclonal IgE has been reported. Extremely low serum concentrations of IgE have limited the study of these important differences. We have purified polyclonal dog IgE and developed polyclonal and monoclonal (mAb C2) anti-dog IgE antibodies. In this study chromatofocusing of dog IgE revealed two biologically active IgE fractions: IgE1 eluted at pH 5.0, and IgE2 eluted at pH 4.7. The two IgE subforms (IgEs) exhibited typical IgE characteristics: positive in the 48-hour passive cutaneous anaphylaxis response, heat-labile, identical molecular weight, and reactive to polyclonal anti-dog IgE. However, the two IgEs were found to be significantly heterogeneous. IgE1 bound to protein A and did not react with mAb C2 in ELISA and isoelectric focusing-immunoblotting, whereas IgE2 did not bind to protein A and reacted with mAb C2. Further, in sodium dodecylsulfate-polyacrylamide gel electrophoresis and immunoblotting, IgE2, but not IgE1, reacted with seven well-defined mAb anti-human IgE antibodies and an mAb anti-mouse IgE antibody, even though both IgE1 and IgE2 reacted with polyclonal anti-human and anti-mouse IgE. Neuraminidase or endoglycosidase treatment did not abolish the differential antigenicity and charge of IgE1 and IgE2, although the antigenicity of IgE2 was significantly reduced after incubation with endoglycosidase. These data suggest that carbohydrate moieties are not involved in the observed differences in antigenicity and charge and that the two IgE molecules represent distinct isotypes. In studies with seven purified IgE fractions obtained from different ragweed-allergic dogs, the distribution of ragweed IgE2 varied 200-fold, whereas ragweed total IgE levels varied only fourfold. This raises the possibility of a relationship between different IgEs and the allergic response.	UNIV MANITOBA,DEPT PEDIAT,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,DEPT CHILD HLTH,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,DEPT IMMUNOL,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3T 2N2,CANADA	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba								ASSEM ESK, 1981, CLIN ALLERGY, V11, P367, DOI 10.1111/j.1365-2222.1981.tb01607.x; BECKER AB, 1989, J APPL PHYSIOL, V66, P2691, DOI 10.1152/jappl.1989.66.6.2691; BERGSTRAND H, 1986, ALLERGY, V41, P11, DOI 10.1111/j.1398-9995.1986.tb00269.x; CONROY MC, 1979, INT ARCH ALLER A IMM, V60, P106, DOI 10.1159/000232329; DEBOER DJ, 1993, VET IMMUNOL IMMUNOP, V37, P183, DOI 10.1016/0165-2427(93)90193-8; FORSGREN A, 1966, J IMMUNOL, V97, P822; GODFREY RC, 1978, IMMUNOLOGY, V35, P581; HOOK WA, 1991, MOL IMMUNOL, V28, P631, DOI 10.1016/0161-5890(91)90132-4; INGANAS M, 1980, SCAND J IMMUNOL, V12, P23, DOI 10.1111/j.1365-3083.1980.tb00037.x; ISHIZAKA T, 1988, ALLERGY PRINCIPLES P, P79; JOHANSSON SGO, 1978, IMMUNOL REV, V41, P248, DOI 10.1111/j.1600-065X.1978.tb01467.x; KleineTebbe J, 1996, J ALLERGY CLIN IMMUN, V98, P181, DOI 10.1016/S0091-6749(96)70241-5; KRONVALL G, 1969, J IMMUNOL, V103, P828; LICHTENSTEIN LM, 1988, J ALLERGY CLIN IMMUN, V81, P814, DOI 10.1016/0091-6749(88)90936-0; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MACDONALD SM, 1990, SPRINGER SEMIN IMMUN, V12, P415; MACDONALD SM, 1991, CLIN EXP ALLERGY, V21, P133, DOI 10.1111/j.1365-2222.1991.tb00815.x; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; PENG Z, 1993, AM J VET RES, V54, P239; PENG ZK, 1994, INT ARCH ALLERGY IMM, V104, P204, DOI 10.1159/000236731; Peng ZK, 1996, INT ARCH ALLERGY IMM, V110, P149, DOI 10.1159/000237279; PENG ZK, 1993, INT ARCH ALLERGY IMM, V102, P176, DOI 10.1159/000236569; POPA V, 1985, INT ARCH ALLER A IMM, V77, P349, DOI 10.1159/000233843; RECTOR E, 1985, IMMUNOLOGY, V55, P481; ROBERTSON MW, 1991, J IMMUNOL, V147, P3024; SAINTREMY JMR, 1983, J IMMUNOL, V130, P1341; SAITO M, 1979, J BIOL CHEM, V254, P7845; SALTVEDT E, 1976, SCAND J IMMUNOL, V5, P1103; SAXON A, 1995, INT ARCH ALLERGY IMM, V107, P45, DOI 10.1159/000236926; WILLEMSE A, 1985, CLIN EXP IMMUNOL, V59, P351; ZAVAZAL V, 1985, FOLIA MICROBIOL, V30, P237, DOI 10.1007/BF02923516; ZHANG K, 1994, J BIOL CHEM, V269, P456	32	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					87	95		10.1016/S0091-6749(97)70199-4	http://dx.doi.org/10.1016/S0091-6749(97)70199-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257792				2022-12-18	WOS:A1997XP42800014
J	Weinstein, AG; McKee, L; Stapleford, J; Faust, D				Weinstein, AG; McKee, L; Stapleford, J; Faust, D			An economic evaluation of short-term inpatient rehabilitation for children with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pediatric asthma rehabilitation; economic evaluation; drug compliance; inhaled corticosteroids; family therapy	CHILDHOOD ASTHMA; HOSPITALIZATION; IMPACT; PROGRAM; HEALTH	Background: The cost of asthma care in the United States in 1990 has been estimated to be 6.2 billion dollars. the greatest proportion is due to hospital care. Objective: We report changes in estimated medical charges of 59 children with severe asthma 1 year before inpatient rehabilitation and over a 4-year follow-up period. Methods: Asthma resource use (e.g., hospital, physician, medication) was identified before and after inpatient rehabilitation. Estimated charges were assigned. this was done retrospectively for the 1-year period before rehabilitation, prospectively during rehabilitation, and over a 4-year followup period. Patients served as their own controls. there was no control group. Results: When median asthma resource use 1 year before rehabilitation was compared with that during the first, second, third, and fourth years of follow-up, there was a reduction in median hospitalization and median emergency care. compared with mean total medical charges the year before rehabilitation, reductions in mean total medical charges were 56.7% at the completion of the first year (excluding charges for rehabilitation), 70.5% at second year, 74.6% at third year, and 77.5% at fourth year. Over the 4-year postrehabilitation period, the discounted cumulative net savings was $29,605. the discounted cumulative net savings surpassed the mean rehabilitation charge during the early months of the fourth year of the postrehabilitation period. Conclusion: Inpatient rehabilitation was significantly associated with a reduction in estimated total medical charges over a 4-year follow-up period.	THOMAS JEFFERSON UNIV,DEPT INFORMAT SYST,PHILADELPHIA,PA 19107; EASTERN COLL,DEPT BUSINESS,ST DAVIDS,PA; LOUISIANA STATE UNIV,SCH MED,CHILDRENS HOSP,DEPT PSYCHOL,NEW ORLEANS,LA	Jefferson University; Children's Hospital of New Orleans; Louisiana State University System	Weinstein, AG (corresponding author), JEFFERSON MED COLL,ALFRED I DUPONT INST,DIV CLIN IMMUNOL & ALLERGY,POB 269,WILMINGTON,DE 19899, USA.							*ASTHM REH SUBC, 1993, AM AC ALL IMM ANN M; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CREER TL, 1987, J ALLERGY CLIN IMMUN, V80, P500, DOI 10.1016/0091-6749(87)90086-8; EVANS R, 1987, CHEST S, V91, P655; HALFON N, 1993, PEDIATRICS, V91, P56; LEWIS CE, 1984, PEDIATRICS, V74, P478; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; *NAT ASTHM ED PROG, 1991, 913042 NAT HEART LUN; *NAT HEART LUNG BL, 1984, 852362 NIH; *NAT HEART LUNG BL, 1984, 852635 NIH NAT HEART; *NAT HEART LUNG BL, 1984, 852364 NIH; *NAT HEART LUNG BL, 1984, 852363 NIH; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; *RHON POUL ROR, 1992, NATL DIS THER IND; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; STRUNK RC, 1989, J ALLERGY CLIN IMMUN, V83, P477, DOI 10.1016/0091-6749(89)90137-1; TAYLOR WR, 1992, PEDIATRICS, V90, P657; WEINSTEIN A, 1993, J ALLERGY CLIN IMMUN, V91, P269; Weinstein A G, 1991, Del Med J, V63, P291; WEINSTEIN AG, 1992, J ALLERGY CLIN IMMUN, V90, P66, DOI 10.1016/S0091-6749(06)80012-6; WEINSTEIN AG, 1987, ANN ALLERGY, V59, P256; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1688; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777	26	27	28	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					264	273		10.1016/S0091-6749(96)70149-5	http://dx.doi.org/10.1016/S0091-6749(96)70149-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757202	Bronze			2022-12-18	WOS:A1996VC99500004
J	Ottervanger, JP; Phaff, RAS; Vermeulen, EGJ; Stricker, BHC				Ottervanger, JP; Phaff, RAS; Vermeulen, EGJ; Stricker, BHC			Anaphylaxis to omeprazole	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NETHERLANDS CTR MONITORING ADVERSE DRUG REACT,NL-2280 HK RIJSWIJK,NETHERLANDS; DIAGNOST CTR DE VALKENIER,ROTTERDAM,NETHERLANDS; ZUIDERZIEKENHUIS HOSP,DEPT SURG,ROTTERDAM,NETHERLANDS									CLISSOLD SP, 1986, DRUGS, V32, P15, DOI 10.2165/00003495-198632010-00002; HAENEY MR, 1992, BRIT MED J, V305, P870, DOI 10.1136/bmj.305.6858.870-c; MEDING B, 1986, CONTACT DERMATITIS, V15, P36, DOI 10.1111/j.1600-0536.1986.tb01259.x; SOLVELL L, 1989, CAN J GASTROENTEROL, V3, pA91; VANDERKLAUW MM, 1993, BRIT J CLIN PHARMACO, V35, P400	5	27	27	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1413	1414		10.1016/S0091-6749(96)70212-9	http://dx.doi.org/10.1016/S0091-6749(96)70212-9			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648040				2022-12-18	WOS:A1996VD60700032
J	Stanaland, BE; FernandezCaldas, E; Jacinto, CM; Trudeau, WL; Lockey, RF				Stanaland, BE; FernandezCaldas, E; Jacinto, CM; Trudeau, WL; Lockey, RF			Positive nasal challenge responses to Blomia tropicalis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blomia tropicalis; Dermatophagoides pteronyssinus; D-farinae; mite allergens; house dust; allergic rhinitis; asthma; cross-reactivity	MITE ALLERGY; DUST MITES; SENSITIZATION; INDIVIDUALS	Background: Blomia tropicalis, a dust mite commonly found in subtropical and tropical environments, is the fourth most common mite in the United States. Thirty-eight percent of 167 consecutive subjects evaluated for allergic respiratory symptoms in the Tampa Bay area had positive skin test responses to B. tropicalis. Methods: Nasal challenges were performed in 19 subjects with allergic rhinitis; 12 had positive skin test responses to B. tropicalis (group I), and seven had negative skin test responses to B. tropicalis but positive skin test responses to Dermatophagoides pteronyssinus and D. farinae (group II). Subjects were challenged with a normal saline control solution and increasing concentrations of a 1 mg/ml in-house extract of B. tropicalis (1:125,000 vol/ vol, 1:25,000 vol/vol, 1:5000 vol/vol, 1:1000 vol/vol, and 1:200 vol/vol). Inspiratory nasal airway resistance (was measured every 5 minutes for 15 minutes by posterior rhinomanometry at 50 Pa after each nasal challenge. Results: Nasal challenge response was considered positive and stopped when the mean inspiratory nasal airway resistance was greater than twice the mean inspiratory nasal airway resistance after the normal saline challenge. Ten of 12 (83%) subjects in group I and none of seven (0%) subjects in group II had positive nasal challenge responses to B. tropicalis (p = 0.0024). Conclusion: B. tropicalis is allergenic and should be considered as a cause of allergic rhinitis when evaluating a patient who lives in an area where it is endemic.	JAMES A HALEY VET HOSP,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,DIV ALLERGY & IMMUNOL,TAMPA,FL	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida								ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; FERNANDEZCALDAS E, 1993, J INVEST ALLERG CLIN, V3, P245; FernandezCaldas E, 1995, PROG ALLER CLIN IMM, V3, P317; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; HURTADO I, 1987, ANN ALLERGY, V59, P128; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; NETO J, 1980, REV BRAS ALERG IMUNO, V2, P140; PUERTA L, 1993, J INVEST ALLERG CLIN, V3, P198; STANALAND BE, 1994, J ALLERGY CLIN IMMUN, V94, P452, DOI 10.1016/0091-6749(94)90200-3; TOGIAS AG, 1995, ASTHMA RHINITIS, P1009; [No title captured]	15	27	29	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1996	97	5					1045	1049		10.1016/S0091-6749(96)70256-7	http://dx.doi.org/10.1016/S0091-6749(96)70256-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UL261	8626980				2022-12-18	WOS:A1996UL26100003
J	Verberne, AAPH; Hop, WCJ; Creyghton, FBM; vanRooij, RWG; vandenBerg, M; deJongste, JC; Kerrebijn, KF				Verberne, AAPH; Hop, WCJ; Creyghton, FBM; vanRooij, RWG; vandenBerg, M; deJongste, JC; Kerrebijn, KF			Airway responsiveness after a single dose of salmeterol and during four months of treatment in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						salmeterol; salbutamol; airway responsiveness; asthma; children	BRONCHIAL RESPONSIVENESS; INHALED SALMETEROL; INDUCED BRONCHOCONSTRICTION; MODERATE ASTHMA; AGONIST; SALBUTAMOL; ALBUTEROL; BRONCHODILATOR; FORMULATIONS; HISTAMINE	Background: Inhalation of a single dose of the long-acting beta(2)-adrenoceptor agonist salmeterol protects against methacholine-induced airway obstruction and other bronchoconstricting stimuli for at least 12 hours. Hypothetically, twice daily dosing of salmeterol may result in continuous protection. Objective: This study was designed to investigate the protective effect of a single dose of salmeterol and of continuous twice daily treatment on airway responsiveness to methacholine. Methods: In a double-blind, parallel study, salmeterol 50 mu g twice daily was compared with salbutamol 200 mu g twice daily. Thirty children with mild asthma, who had little or no bronchial obstruction and were hyperresponsive to methacholine (PD20 less than or equal to 150 mu g) were allocated to receive either salmeterol of salbutamol. Airway responsiveness was measured before study entry, 12 hours after a single dose of drug was given, and monthly during 4 months of daily treatment. Measurements were always performed at the same time of the day, 12 hours after the last dose of medication was administered. Results: No significant differences in FEV(1) were found between treatments at any time point. PD20 significantly increased after the first dose of salmeterol was given (geometric mean, 100 mu g). Geometric mean PD20 values were significantly better during salmeterol treatment than during salmeterol treatment, 52 and 25 mu g, respectively (p = 0.0005). Conclusion: The protection provided by salmeterol during maintenance treatment was less than that provided after the first dose (p < 0.001). However, protection did not diminish during the 4-month treatment period and remained significant compared with paseline (p = 0.003).	ERASMUS UNIV ROTTERDAM, SUBDIV PEDIAT RESP MED, DEPT PEDIAT, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT EPIDEMIOL & BIOSTAT, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam	Verberne, AAPH (corresponding author), SOPHIA CHILDRENS UNIV HOSP, SUBDIV PEDIAT RESP MED, DEPT PEDIAT, DR MOLEWATERPLEIN 60, 3015 GJ ROTTERDAM, NETHERLANDS.							ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; [Anonymous], 1993, THORAX, V48, pS1; Ariens E.J., 1987, BRONCHIAL HYPERRESPO, P7; BEACH JR, 1993, PULM PHARMACOL, V6, P155, DOI 10.1006/pulp.1993.1020; BIRNIE D, 1990, THORAX, V45, P199, DOI 10.1136/thx.45.3.199; BOOTH H, 1993, THORAX, V48, P1121, DOI 10.1136/thx.48.11.1121; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; DEBAETS FM, 1990, AM REV RESPIR DIS, V142, P581, DOI 10.1164/ajrccm/142.3.581; DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; DUIVERMAN EJ, 1987, PEDIATR PULM, V3, P38, DOI 10.1002/ppul.1950030111; GONGORA HC, 1991, AM REV RESPIR DIS, V144, P626, DOI 10.1164/ajrccm/144.3_Pt_1.626; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; LUNDBACK B, 1993, THORAX, V48, P148, DOI 10.1136/thx.48.2.148; MACONOCHIE JG, 1994, BRIT J CLIN PHARMACO, V37, P199, DOI 10.1111/j.1365-2125.1994.tb04261.x; MALO JL, 1992, J ALLERGY CLIN IMMUN, V89, P567, DOI 10.1016/0091-6749(92)90324-U; NEIJENS HJ, 1979, J ALLERGY CLIN IMMUN, V64, P507, DOI 10.1016/0091-6749(79)90060-5; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; ROBERTS J A, 1992, American Review of Respiratory Disease, V145, pA418; ROBERTS JA, 1992, THORAX, V47; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCHLUCHTER MD, 1990, BMDP STATISTICAL SOF, V2, P1207; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SVEDMYR N, 1990, AM REV RESPIR DIS, V141, pS31; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; VANAMSTERDAM RGM, 1990, AM REV RESPIR DIS, V142, P1124, DOI 10.1164/ajrccm/142.5.1124; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426, DOI 10.1136/bmj.303.6815.1426; VATHENEN AS, 1988, LANCET, V1, P554; VERBERNE AAPH, 1993, J ALLERGY CLIN IMMUN, V91, P127, DOI 10.1016/0091-6749(93)90305-Y; VERBERNE AAPH, 1993, LIFE SCI, V52, P2181, DOI 10.1016/0024-3205(93)90732-I; WAHEDNA I, 1993, AM REV RESPIR DIS, V148, P707, DOI 10.1164/ajrccm/148.3.707; Zapletal A, 1987, PROGR RESPIRATION RE, P114	35	27	28	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					938	946		10.1016/S0091-6749(96)80068-6	http://dx.doi.org/10.1016/S0091-6749(96)80068-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655889	Green Published			2022-12-18	WOS:A1996UG08600008
J	Kobayashi, I; Sakiyama, Y; Tame, A; Kobayashi, K; Matsumoto, S				Kobayashi, I; Sakiyama, Y; Tame, A; Kobayashi, K; Matsumoto, S			IgE and IgG(4) antibodies from patients with mite allergy recognize different epitopes of Dermatophagoides pteronyssinus group II antigen (Der p 2)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dermatophagoides pteronyssinus; Der p 2; fusion protein; IgE; IgG(4); epitope mapping; Western blot analysis	HUMAN B-CELLS; DER-F-II; SEQUENCE-ANALYSIS; BRONCHIAL-ASTHMA; ESCHERICHIA-COLI; EXPRESSION; BINDING; PEPTIDES; CHILDREN; CLONING	Background: Der p 2, composed of 129 amino acids, is one of the major allergens of Dermatophagoides pteronyssinus. Several groups reported epitope mapping of IgE antibody but not of IgG or IgG subclass antibodies in Der p 2. Objective: The purpose of this study was to compare the epitopes recognized by Der p 2-specific IgE antibodies with those recognized by IgG(4) antibodies. Methods: Recombinant fusion proteins containing a full-length peptide or overlapping five fragments of Der p 2 were prepared and analyzed for their reactivity with IgE and IgG subclass antibodies in sera from patients with mite allergy by means of Western blot procedure. Results: IgE antibodies in 12 of 13 sera tested bound to full-length Der p 2 (1-129). In 11 of these 12 sera, IgE antibodies bound to one or more of fragments 41-80, 64-105, or 81-129 but not to those of 1-40 or 20-63. Of the 11 sera in which the IgE antibodies to the fragments were detected, only four contained detectable levels of IgG(4) antibodies reactive to the fragments. The binding of the IgG(4) antibodies against the fragments were rather wide and differed from those of IgE antibodies. Conclusion: Results revealed that there are differences in epitope recognition between IgE and IgG(4) antibodies; IgE antibodies recognize restricted parts of Der p 2 antigen compared with IgG(4).			Kobayashi, I (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT PEDIAT,KITA KU,NORTH 15,WEST 7,SAPPORO,HOKKAIDO 060,JAPAN.		Kobayashi, Ichiro/G-8638-2012					CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GREENE WK, 1991, J IMMUNOL, V147, P3768; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; KOLBE L, 1994, INT ARCH ALLERGY IMM, V103, P214, DOI 10.1159/000236630; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN KL, 1991, ANN ALLERGY, V67, P63; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; MILLS FC, 1992, J IMMUNOL, V149, P1075; NOSSAL GJV, 1992, CELL, V66, P1; OSHIKA E, 1993, PEDIATR RES, V33, P209, DOI 10.1203/00006450-199302000-00025; OSHIKA E, 1992, ANN ALLERGY, V69, P427; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHAPIRA SK, 1991, P NATL ACAD SCI USA, V88, P7528, DOI 10.1073/pnas.88.17.7528; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; VANMILLIGEN FJ, 1994, INT ARCH ALLERGY IMM, V103, P274, DOI 10.1159/000236639; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; VANTHOF W, 1993, INT ARCH ALLERGY IMM, V101, P437, DOI 10.1159/000236488; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402, DOI 10.1159/000234724; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757	28	27	29	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					638	645		10.1016/S0091-6749(96)70309-3	http://dx.doi.org/10.1016/S0091-6749(96)70309-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621849				2022-12-18	WOS:A1996TW08700009
J	Brannan, MD; Seiberling, M; Cutler, DL; Cuss, FM; Affrime, MB				Brannan, MD; Seiberling, M; Cutler, DL; Cuss, FM; Affrime, MB			Lack of systemic activity with intranasal mometasone furoate.	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	3				62	62						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TV536					2022-12-18	WOS:A1996TV53600062
J	WOOD, CC; FIREMAN, P; GROSSMAN, J; WECKER, M; MACGREGOR, T				WOOD, CC; FIREMAN, P; GROSSMAN, J; WECKER, M; MACGREGOR, T			PRODUCT CHARACTERISTICS AND PHARMACOKINETICS OF INTRANASAL IPRATROPIUM BROMIDE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IPRATROPIUM; NASAL SPRAY; PHARMACOKINETICS; RHINITIS; COMMON COLD	SYSTEMIC ABSORPTION; EXCRETION	The in vivo absorption potential of ipratropium bromide nasal spray was evaluated in studies involving healthy volunteers (0.03%, 0.06%, and 0.12% dosage strengths) and patients with perennial rhinitis (0.03% and 0.06%) and the common cold (0.06%). The dose used was two sprays per nostril, corresponding to a total dose of 84 mu g, 168 mu g, and 336 mu g for the three dosage strengths. These studies indicate that 10% or less of active drug is absorbed systemically after nasal administration based on the amount of unchanged drug excreted in urine in a 24-hour interval. In most instances, the plasma drug concentrations were undetectable. In none of these studies did plasma ipratropium concentrations reach a level where systemic anticholinergic effects are known to occur.	BOEHRINGER INGELHEIM PHARMACEUT INC,PITTSBURGH,PA; BOEHRINGER INGELHEIM PHARMACEUT INC,TUCSON,AZ	Boehringer Ingelheim; Boehringer Ingelheim	WOOD, CC (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,POB 368,RIDGEFIELD,CT 06877, USA.							ADLUNG J, 1976, ARZNEIMITTEL-FORSCH, V26, P1005; BAUER R, 1976, ARZNEIMITTEL-FORSCH, V26, P974; ENSING K, 1989, EUR J CLIN PHARMACOL, V36, P189, DOI 10.1007/BF00609193; ENSING K, 1988, J PHARMACEUT BIOMED, V6, P433, DOI 10.1016/0731-7085(88)80010-4; ENSINGER HA, 1987, EUR J CLIN PHARMACOL, V33, P459, DOI 10.1007/BF00544235; EUGELL DW, 1986, AM J MED S5A, V81, P18; GROSS NJ, 1988, NEW ENGL J MED, V319, P486; GROSSMAN J, 1992, J ALLERGY CLIN IMMUN, V89, P183; MACGREGOR TR, 1992, J ALLERGY CLIN IMMUN, V89, P182; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V7, P457	10	27	27	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1111	1116		10.1016/S0091-6749(95)70214-8	http://dx.doi.org/10.1016/S0091-6749(95)70214-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7751527				2022-12-18	WOS:A1995QY91800006
J	CHANEZ, P; VIGNOLA, AM; PAULEUGENE, N; DUGAS, B; GODARD, P; MICHEL, FB; BOUSQUET, J				CHANEZ, P; VIGNOLA, AM; PAULEUGENE, N; DUGAS, B; GODARD, P; MICHEL, FB; BOUSQUET, J			MODULATION BY INTERLEUKIN-4 OF CYTOKINE RELEASE FROM MONONUCLEAR PHAGOCYTES IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MONOCYTES; ALVEOLAR MACROPHAGES; ASTHMA; IL-1; TNF-ALPHA; IL-6; IL-4	TUMOR-NECROSIS-FACTOR; HUMAN ALVEOLAR MACROPHAGES; ARACHIDONIC-ACID METABOLISM; SUPEROXIDE ANION PRODUCTION; FACTOR-ALPHA; BRONCHIAL-ASTHMA; BLOOD MONOCYTES; ALLERGIC ASTHMATICS; INTERFERON-GAMMA; IMMUNOGLOBULIN-E	Background: Interleukin (IL)-4 is involved in IgE upregulation and downregulates cytokine release by mononuclear phagocytes. Mononuclear cells release greater amounts of IL-1, tumor necrosis factor-alpha, and IL-6 in patients with asthma than in control subjects, but the effect of IL-4 on cells from patients with asthma is unknown. The effects of IL-4 on the release of IL-1, tumor necrosis factor-alpha, and IL-6 by monocytes and alveolar macrophages were compared in 19 patients with asthma and 18 control subjects. Methods: The release of IL-1, tumor necrosis factor-alpha, and IL-6 from unstimulated and lipopolysaccharide stimulated monocytes and alveolar macrophages was measured by ELISA. The effect of 30 U of IL-4 on the release of these cytokines was studied. Results: Lipopolysaccharide-stimulated monocytes released significantly fewer cytokines in patients with asthma than in control subjects. IL-4 significantly inhibited cytokine release by monocytes of both groups. Unstimulated alveolar macrophages from patients with asthma released more cytokines than those of control subjects. Lipopolysaccharide induced a significantly greater increase in cytokine release in alveolar macrophages of control subjects n comparison with asthmatic subjects. IL-4 abolished the release of cytokines in alveolar macrophages from control subjects and had a minimal inhibitory effect on alveolar macrophages from patients with asthma. Conclusions: Alveolar macrophages from patients with asthma are hyperreactive but less prone to lipopolysaccharide stimulation and IL-4-downregulation than those from normal subjects.	CNR,IST FISIOPATOL RESP,PALERMO,ITALY; CTR HOSP REG & UNIV MONTPELLIER,MALAD RESP CLIN,MONTPELLIER,FRANCE; CTR HOSP REG & UNIV MONTPELLIER,INSERM,CJF 9210,MONTPELLIER,FRANCE	Consiglio Nazionale delle Ricerche (CNR); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ARNOUX B, 1987, B EUR PHYSIOPATH RES, V23, P119; BALTER MS, 1988, AM REV RESPIR DIS, V138, P1134, DOI 10.1164/ajrccm/138.5.1134; BHASKARAN G, 1992, J LEUKOCYTE BIOL, V52, P218, DOI 10.1002/jlb.52.2.218; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; CHANEZ P, 1991, AM REV RESPIR DIS, V144, P923, DOI 10.1164/ajrccm/144.4.923; CHANEZ P, 1993, ALLERGY, V48, P576, DOI 10.1111/j.1398-9995.1993.tb00751.x; CHANEZ P, 1993, J ALLERGY CLIN IMMUN, V92, P869, DOI 10.1016/0091-6749(93)90065-N; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; DAMON M, 1987, PROSTAG OTH LIPID M, V34, P291, DOI 10.1016/0090-6980(87)90251-6; DEROCHEMONTEIX BG, 1993, AM J RESPIR CELL MOL, V8, P160; ELIAS JA, 1987, J LEUKOCYTE BIOL, V42, P114, DOI 10.1002/jlb.42.2.114; ESSNER R, 1989, J IMMUNOL, V142, P3857; FERRO TJ, 1987, AM REV RESPIR DIS, V135, P682; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; GOSSET P, 1988, AM REV RESPIR DIS, V138, P40, DOI 10.1164/ajrccm/138.1.40; HART PH, 1989, P NATL ACAD SCI USA, V84, P3803; HASKILL S, 1988, J IMMUNOL, V140, P1690; HOWELL CJ, 1989, AM REV RESPIR DIS, V140, P1340, DOI 10.1164/ajrccm/140.5.1340; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JOSEPH M, 1980, CLIN EXP IMMUNOL, V40, P416; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KOTLOFF RM, 1990, AM J RESP CELL MOL, V3, P497, DOI 10.1165/ajrcmb/3.5.497; KOUZAN S, 1988, AM REV RESPIR DIS, V137, P38, DOI 10.1164/ajrccm/137.1.38; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; LE JM, 1987, LAB INVEST, V56, P234; LE JM, 1989, LAB INVEST, V61, P588; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P2061; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; PUERINGER RJ, 1992, J APPL PHYSIOL, V73, P781, DOI 10.1152/jappl.1992.73.2.781; PUJOL JL, 1990, INT ARCH ALLER A IMM, V91, P207, DOI 10.1159/000235117; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; RANKIN JA, 1989, J ALLERGY CLIN IMMUN, V83, P722, DOI 10.1016/0091-6749(89)90005-5; RIEDY MC, 1992, J LEUKOCYTE BIOL, V52, P125, DOI 10.1002/jlb.52.1.125; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SANCEAU J, 1991, J IMMUNOL, V147, P2630; TEVELDE AA, 1988, J IMMUNOL, V140, P1548; THORPE R, 1992, BLOOD REV, V6, P133, DOI 10.1016/0268-960X(92)90025-L; URBAN JL, 1986, P NATL ACAD SCI USA, V83, P5233, DOI 10.1073/pnas.83.14.5233; VANHAL PTW, 1991, J IMMUNOL, V147, P2630; WEWERS MD, 1989, J IMMUNOL, V143, P1635; WITSELL AL, 1992, P NATL ACAD SCI USA, V89, P4754, DOI 10.1073/pnas.89.10.4754; WONG HL, 1992, J IMMUNOL, V148, P2119; YANAGAWA H, 1991, MICROBIOL IMMUNOL, V35, P879, DOI 10.1111/j.1348-0421.1991.tb02028.x; 1987, AM REV RESPIR DIS, V136, P224	51	27	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				997	1005		10.1016/0091-6749(94)90118-X	http://dx.doi.org/10.1016/0091-6749(94)90118-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798548				2022-12-18	WOS:A1994PY23000008
J	VIRCHOW, JC; OEHLING, A; BOER, L; HANSEL, TT; WERNER, P; MATTHYS, H; BLASER, K; WALKER, C				VIRCHOW, JC; OEHLING, A; BOER, L; HANSEL, TT; WERNER, P; MATTHYS, H; BLASER, K; WALKER, C			PULMONARY-FUNCTION, ACTIVATED T-CELLS, PERIPHERAL-BLOOD EOSINOPHILIA, AND SERUM ACTIVITY FOR EOSINOPHIL SURVIVAL IN-VITRO - A LONGITUDINAL-STUDY IN BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; T-CELL ACTIVATION EOSINOPHILS; FEV(1); LONGITUDINAL CORRELATION	COLONY-STIMULATING FACTOR; INTERLEUKIN-5; EXPRESSION; SEVERITY; BIOPSIES; COUNTS	A close correlation among the number of activated, peripheral blood T helper cells, eosinophilia, and airflow obstruction has been reported in patients with asthma. To test these cross-sectional data we performed a prospective, longitudinal study investigating the relationships among T-cell activation in peripheral blood, eosinophilia, forced expiratory volume in 1 second (FEV(1)) and serum activity toward eosinophil survival in 20 individuals with asthma over a period of 21 days after admission to a clinic located 1560 m above sea level. During the study, maintenance treatment with inhaled beta(2)-agonists and theophylline was unchanged. Five patients had also been faking inhaled corticosteroids, and this was also not changed during the study period According to the changes in pulmonary function observed at the end of the study patients were divided into three groups: twelve patients whose pulmonary function improved by more than 10% from baseline (group I), four patients whose pulmonary function deteriorated by more than 10% from baseline necessitating therapeutic intervention (group II), and four patients with no change in FEV(1) (<10% from baseline) (group III). Activation of T cells as determined by interleukin-2 receptor expression, number of eosinophils, and serum activity toward eosinophil survival in vitro declined in group I; whereas FEV(1) increased. The decrease in FEV(1) in group II was associated with an increase in interleukin-2 receptor-positive T cells, number of eosinophils, and serum activity. In group III FEV(1) interleukin-2 receptor expression on T cells, the number of peripheral blood eosinophils, and the measured serum activity for eosinophil survival in vitro did not change significantly from baseline. With the exception of FEV(1) and eosinophil numbers, which came close to reaching statistically significant correlations with the measured serum activity for eosinophils, the percent changes from baseline to the end of the study of all other parameters were closely correlated with correlation coefficients between 0.76 and 0.54. We conclude that a close correlation does exist between changes in T-cell activation, numbers of eosinophils, serum activity toward eosinophil survival in vitro, and the degree of airflow obstruction in patients with asthma, observed longitudinally, suggesting that these parameters are interrelated.	HOCHGEBIRGSKLIN DAVOS, DAVOS, SWITZERLAND; SWISS INST ALLERGY & ASTHMA RES, CH-7270 DAVOS, SWITZERLAND	Swiss Institute of Allergy & Asthma Research	VIRCHOW, JC (corresponding author), UNIV HOSP FREIBURG, DEPT PNEUMOL, HUGSTETTERSTR 55, D-79106 FREIBURG, GERMANY.							AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Gollash H., 1889, FORTSCHR MED, V7, P361; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HENRIKSEN JM, 1986, ALLERGY, V41, P499, DOI 10.1111/j.1398-9995.1986.tb00335.x; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; Menz G, 1987, Experientia Suppl, V51, P197; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PLATTSMILLS TAE, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P367; RAGHAVACHAR A, 1987, J IMMUNOL, V139, P3753; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; RUHLE KH, 1976, PNEUMONOLOGIE, V153, P223, DOI 10.1007/BF02095889; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SILBERSTEIN DS, 1987, IMMUNOL TODAY, V8, P380, DOI 10.1016/0167-5699(87)90214-3; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; VIRCHOW JC, 1992, AM REV RESPIR DIS, V146, P604, DOI 10.1164/ajrccm/146.3.604; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109	30	27	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2					240	249		10.1016/0091-6749(94)90046-9	http://dx.doi.org/10.1016/0091-6749(94)90046-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC926	8064076				2022-12-18	WOS:A1994PC92600015
J	BORISH, L; DISHUCK, J; COX, L; MASCALI, JJ; WILLIAMS, J; ROSENWASSER, LJ				BORISH, L; DISHUCK, J; COX, L; MASCALI, JJ; WILLIAMS, J; ROSENWASSER, LJ			SEZARY-SYNDROME WITH ELEVATED SERUM IGE AND HYPEREOSINOPHILIA - ROLE OF DYSREGULATED CYTOKINE PRODUCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIES; SEZARY SYNDROME; IGE; EOSINOPHILIA; INTERLEUKIN-4; INTERLEUKIN-5; LOW-AFFINITY IGE RECEPTORS (FC-EPSILON-RII)	T-CELL CLONES; ADHESION MOLECULE-1 ICAM-1; COLONY-STIMULATING FACTOR; HUMAN B-CELLS; INTERFERON-GAMMA; FUNCTIONAL-PROPERTIES; HUMAN INTERLEUKIN-5; EOSINOPHIL FUNCTION; HUMAN-LYMPHOCYTES; GENE-EXPRESSION	A 62-year-old man presented with a 4-year history of a pruritic erythematous rash. Initial workup was not diagnostic, and the rash was refractory to standard treatment. A complete blood cell count demonstrated a white cell count of 9100 cells/mul with 61% polymorphonuclear neutrophils, 16% eosinophils, and 17% lymphocytes. A serum protein electrophoresis revealed an M spike identified as IgGkappa. His IgE level was 11,900 IU/mL A bone marrow biopsy specimen demonstrated ''atypical plasma cells'' but was not diagnostic for myeloma. Peripheral blood smear was remarkable for highly convoluted lymphoid cells diagnostic for Sezary T cells. Consistent with this diagnosis, 89% of his peripheral blood CD2+ cells expressed CD4. The eosinophilia, elevated IgE level, and monoclonal gammopathy led to further investigations. Circulating adherent monocytes were 96% positive for presumed low-affinity IgE receptor expression as shown by surface IgE binding. In a 9-day lymphocyte coculture, the patient's T lymphocytes induced IgE production in vitro (1.25 ng/ml) by a normal donor's cultured B cells. A healthy donor's T cells failed to induce IgE production (0 ng/ml) in a similar culture system. In situ hybridization with an Sulfur-35-labeled cDNA probe revealed interleukin-4 mRNA expression by 84% and interleukin-2 mRNA expression by 62% of nonadherent peripheral blood mononuclear cells. Interleukin-5 mRNA was shown by reverse transcription and the polymerase chain reaction. These studies demonstrate a subject with Sezary T cell leukemia with hypereosinophilia and elevated IgE due to presumed enhanced interleukin-4 and interleukin-5 production by the Sezary T cells.	UNIV COLORADO,HLTH SCI CTR,NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Cox, Linda/AAP-1697-2021	Cox, Linda/0000-0002-5258-6870	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI024848, R01AI025173] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25173, AI24848] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMS JT, 1991, J IMMUNOL, V146, P1455; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; BENVENISTE J, 1983, J CLIN INVEST, V71, P221; BORISH L, 1990, International Journal of Immunopathology and Pharmacology, V3, P1; BRENNER CA, 1989, BIOTECHNIQUES, V7, P1096; BRODER S, 1976, J CLIN INVEST, V58, P1297, DOI 10.1172/JCI108585; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DEKRUYFF RH, 1989, J EXP MED, V170, P1477, DOI 10.1084/jem.170.5.1477; DELPOZO V, 1990, J IMMUNOL, V144, P3117; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DISHUCK J, 1991, Journal of Allergy and Clinical Immunology, V87, P206, DOI 10.1016/0091-6749(91)91550-D; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GRIFFITHS CEM, 1989, BRIT J DERMATOL, V120, P1, DOI 10.1111/j.1365-2133.1989.tb07759.x; HAYNES BF, 1981, NEW ENGL J MED, V304, P1319, DOI 10.1056/NEJM198105283042202; KATONA IM, 1988, J IMMUNOL, V140, P3206; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, pA213; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MELEWICZ FM, 1982, CLIN EXP IMMUNOL, V49, P364; MELEWICZ FM, 1980, J IMMUNOL, V125, P1026; MICHAEL JG, 1979, INT ARCH ALLER A IMM, V58, P474; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy GF, 1988, ADV PATHOL, V1, P131; NICKOLOFF BJ, 1989, JAMA-J AM MED ASSOC, V261, P2217, DOI 10.1001/jama.261.15.2217; NICKOLOFF BJ, 1988, ARCH DERMATOL, V124, P1835, DOI 10.1001/archderm.124.12.1835; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; ROMAGNANI S, 1990, IMMUNOL TODAY, V11, P316, DOI 10.1016/S0167-5699(10)80004-0; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; SANDERSON CJ, 1986, P NATL ACAD SCI USA, V83, P437, DOI 10.1073/pnas.83.2.437; SPIEGELBERG HL, 1980, CLIN IMMUNOL IMMUNOP, V15, P424, DOI 10.1016/0090-1229(80)90054-9; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; VOWELS BR, 1991, J INVEST DERMATOL, V96, pA609; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WIESELTHIER JS, 1990, J AM ACAD DERMATOL, V22, P381, DOI 10.1016/0190-9622(90)70054-L; WILLIAMS J, 1991, J ALLERGY CLIN IMMUN, V87, pA245; WOOD GS, 1986, J AM ACAD DERMATOL, V14, P1006, DOI 10.1016/S0190-9622(86)70124-2; WOOD GS, 1982, BLOOD, V59, P876; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; YOSHIDA T, 1975, J IMMUNOL, V114, P915	54	27	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				123	131		10.1016/0091-6749(93)90046-I	http://dx.doi.org/10.1016/0091-6749(93)90046-I			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335848				2022-12-18	WOS:A1993LQ35300018
J	PORTNOY, J; PACHECO, F; BALLAM, Y; BARNES, C				PORTNOY, J; PACHECO, F; BALLAM, Y; BARNES, C			THE EFFECT OF TIME AND EXTRACTION BUFFERS ON RESIDUAL PROTEIN AND ALLERGEN CONTENT OF EXTRACTS DERIVED FROM 4 STRAINS OF ALTERNARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALTERNARIA; EXTRACTS; IMMUNOBLOTTING; 2-DIMENSIONAL ELECTROPHORESIS; ELISA INHIBITION; MOLD ALLERGY	POLLEN	Background: A series of studies was performed to identify optimal elution conditions for production of desired Alternaria allergens with simultaneous reduction of undesired ones. Methods: Proteins and allergens from four strains of Alternaria extracted for differing time intervals and in different buffers were analyzed by one- and two-dimensional electrophoresis, as well as by immunoglobulin E enzyme-linked immunosorbent assay inhibition and immunoblotting. Results: The amount of protein and carbohydrate released varied with each time interval but was consistent between buffers. Extracts from longer time intervals tended to contain more carbohydrate. Electrophoresis of the four strains demonstrated many similar proteins; however, the concentrations of these proteins showed considerable interstrain difference. Comparison of extraction times for single strains by immunoblotting showed that certain allergens are preferentially released during specific time intervals. Some allergens were seen to be most prevalent in a 24-hour extract, whereas others were most prevalent in a 1-hour extract. Two-dimensional electrophoresis resolved bands into discrete spots. The major shared elements of the four strains could be easily identified. The appearance and disappearance of in&vidual protein elements with time was seen. Conclusions: Elution conditions have a significant impact on quantities of specific glycoproteins contained in extracts of Alternaria and must be controlled and optimized when such extracts are produced for allergen purification.			PORTNOY, J (corresponding author), CHILDRENS MERCY HOSP,ALLERGY IMMUNOL SECT,KANSAS CITY,MO 64108, USA.				NIAID NIH HHS [R29 AI27476-01A1] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P432, DOI 10.1016/0091-6749(82)90005-7; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ESCH RE, 1989, ADV BIOSCI, V74, P3; HELM RM, 1987, INT ARCH ALLER A IMM, V82, P178, DOI 10.1159/000234184; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; KARLSSONBORGA A, 1989, ANN ALLERGY, V63, P521; KARR RM, 1981, J ALLERGY CLIN IMMUN, V67, P194, DOI 10.1016/0091-6749(81)90061-0; KING TP, 1981, ARCH BIOCHEM BIOPHYS, V212, P127, DOI 10.1016/0003-9861(81)90351-9; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSEN E, 1991, J IMMUNOL, V147, P205; PARIS S, 1990, J ALLERGY CLIN IMMUN, V85, P941, DOI 10.1016/0091-6749(90)90081-E; PORTNOY J, 1990, ANN ALLERGY, V65, P109; STERINGER I, 1987, INT ARCH ALLER A IMM, V84, P190, DOI 10.1159/000234422; VIJAY HM, 1985, INT ARCH ALLER A IMM, V78, P37, DOI 10.1159/000233860; VIJAY HM, 1984, INT ARCH ALLER A IMM, V74, P256, DOI 10.1159/000233554; WAHL R, 1989, ANN ALLERGY, V63, P527; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	21	27	27	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1993	91	4					930	938		10.1016/0091-6749(93)90351-F	http://dx.doi.org/10.1016/0091-6749(93)90351-F			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KY251	8473682				2022-12-18	WOS:A1993KY25100014
J	CARR, A; PENNY, R; COOPER, DA				CARR, A; PENNY, R; COOPER, DA			ALLERGY AND DESENSITIZATION TO ZIDOVUDINE IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME (AIDS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							SULFADIAZINE DESENSITIZATION		UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW,AUSTRALIA	University of New South Wales Sydney; Kirby Institute	CARR, A (corresponding author), ST VINCENTS HOSP,CTR IMMUNOL,SYDNEY,NSW 2010,AUSTRALIA.							BELL ET, 1985, LANCET, V1, P163; FINEGOLD I, 1986, J ALLERGY CLIN IMMUN, V78, P905, DOI 10.1016/0091-6749(86)90238-1; JACOBSON MA, 1989, J ACQ IMMUN DEF SYND, V2, P382; LEE MH, 1990, 6 INT C AIDS, P2026; MCKINLEY GF, 1990, LANCET, V335, P384; MEYRIER A, 1975, BMJ, V2, P458; TENANTFLOWERS M, 1991, AIDS, V5, P311, DOI 10.1097/00002030-199103000-00011	7	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1993	91	2					683	685		10.1016/0091-6749(93)90276-L	http://dx.doi.org/10.1016/0091-6749(93)90276-L			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KN548	8436782				2022-12-18	WOS:A1993KN54800018
J	GOLDSTEIN, MF; DVORIN, DJ; DUNSKY, EH; LESSER, RW; HEUMAN, PJ; LOOSE, JH				GOLDSTEIN, MF; DVORIN, DJ; DUNSKY, EH; LESSER, RW; HEUMAN, PJ; LOOSE, JH			ALLERGIC RHIZOMUCOR SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion							NEWLY RECOGNIZED FORM; PARA-NASAL SINUS; ASPERGILLUS SINUSITIS; FUNGAL SINUSITIS; BRONCHOPULMONARY ASPERGILLOSIS; CURVULARIA-LUNATA; DRECHSLERA-HAWAIIENSIS; BIPOLARIS; PHAEOHYPHOMYCOSIS; DIAGNOSIS		HAHNEMANN UNIV,SCH MED,SERV ALLERGY & IMMUNOL,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,SCH MED,DEPT MED,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,SCH MED,DEPT OTOLARYNGOL,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,SCH MED,DEPT CLIN MICROBIOL,PHILADELPHIA,PA 19102; HAHNEMANN UNIV,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19102	Drexel University; Drexel University; Drexel University; Drexel University; Drexel University; Drexel University								ADAM RD, 1986, MEDICINE, V65, P203, DOI 10.1097/00005792-198607000-00001; ALDOORY Y, 1984, MOULD ALLERGY, V2, P34; ALLPHIN AL, 1991, LARYNGOSCOPE, V101, P815, DOI 10.1288/00005537-199108000-00003; ANTOINE GA, 1989, OTOLARYNG HEAD NECK, V100, P158; BENATAR SR, 1980, THORAX, V35, P515, DOI 10.1136/thx.35.7.515; BERGSTROM L, 1970, ANN OTO RHINOL LARYN, V79, P70, DOI 10.1177/000348947007900107; BERRY AJ, 1984, PEDIATR INFECT DIS J, V3, P150, DOI 10.1097/00006454-198403000-00018; BITNER A F, 1991, Journal of Allergy and Clinical Immunology, V87, P143, DOI 10.1016/0091-6749(91)91303-B; BLITZER A, 1980, LARYNGOSCOPE, V90, P635, DOI 10.1288/00005537-198004000-00010; BLODI FC, 1969, AM J OPHTHALMOL, V67, P698, DOI 10.1016/S0002-9394(69)90994-5; BORTYNSK JM, 1990, OTOLARYNGOL HEAD NEC, V103, P32; BRUMMUND W, 1986, JAMA-J AM MED ASSOC, V256, P3249; CASTELLI JB, 1978, OTOLARYNG HEAD NECK, V86, P696, DOI 10.1177/019459987808600505; DEJUAN E, 1983, AM J OPHTHALMOL, V96, P299, DOI 10.1016/S0002-9394(14)77818-3; DUNLOP IS, 1988, BRIT J OPHTHALMOL, V72, P127, DOI 10.1136/bjo.72.2.127; ENCE BK, 1990, AM J RHINOL, V4, P169; FRENKEL I, 1987, PEDIATR INFECT DIS J, V7, P1130; FRIEDMAN GC, 1991, AM J CLIN PATHOL, V96, P368, DOI 10.1093/ajcp/96.3.368; GOLDSTEIN MF, 1985, J ALLERGY CLIN IMMUN, V76, P515, DOI 10.1016/0091-6749(85)90737-7; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; GOURLEY DS, 1989, INSIGHTS ALLERGY, P4; GRAMMER LC, 1986, INT ARCH ALLER A IMM, V79, P246, DOI 10.1159/000233980; GREENBERGER PA, 1988, ALLERGY PRINCIPLES P, P1219; GROOTE CA, 1970, ARCHIV OTOLARYNGOL, V92, P288; HALWIG JM, 1985, AM REV RESPIR DIS, V132, P186; HARPSTER WH, 1985, OTOLARYNG HEAD NECK, V93, P683; HENDERSON LT, 1988, SOUTHERN MED J, V81, P846, DOI 10.1097/00007611-198807000-00010; HENDRICK DJ, 1982, AM REV RESPIR DIS, V126, P935; HOLLAND C L, 1991, Journal of Allergy and Clinical Immunology, V87, P144, DOI 10.1016/0091-6749(91)91305-D; HUTCHESON PS, 1991, J ALLERGY CLIN IMMUN, V88, P390, DOI 10.1016/0091-6749(91)90102-T; IRWIN RS, 1973, AM REV RESPIR DIS, V108, P955; JACKSON IT, 1987, PLAST RECONSTR SURG, V79, P804, DOI 10.1097/00006534-198705000-00022; Jahrsdoerfer R A, 1979, Am J Otolaryngol, V1, P6, DOI 10.1016/S0196-0709(79)80003-4; JAY WM, 1988, AM J OPHTHALMOL, V105, P366, DOI 10.1016/0002-9394(88)90299-1; JONATHAN D, 1989, J LARYNGOL OTOL, V103, P1181, DOI 10.1017/S0022215100111296; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KATZENSTEIN ALA, 1983, AM J SURG PATHOL, V7, P439, DOI 10.1097/00000478-198307000-00006; LAMB D, 1982, J PATHOL, V137, P56; LEGENT F, 1980, J FR OTORHINOLARYNG, V29, P39; MACMILLAN RH, 1987, HUM PATHOL, V18, P960, DOI 10.1016/S0046-8177(87)80276-9; MANNING SC, 1989, LARYNGOSCOPE, V99, P681; MANNING SC, 1991, ARCH OTOLARYNGOL, V117, P174; MCALEER R, 1981, THORAX, V36, P338, DOI 10.1136/thx.36.5.338; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; MCGINNIS MR, 1986, J CLIN MICROBIOL, V24, P250, DOI 10.1128/JCM.24.2.250-259.1986; MILLAR JW, 1981, THORAX, V36, P710; MULLBACHER A, 1984, P NATL ACAD SCI-BIOL, V81, P3835, DOI 10.1073/pnas.81.12.3835; NISHIOKA G, 1987, ARCH OTOLARYNGOL, V113, P665; PADHYE AA, 1986, J CLIN MICROBIOL, V24, P245, DOI 10.1128/JCM.24.2.245-249.1986; PHILIP G, 1989, HISTOPATHOLOGY, V14, P222, DOI 10.1111/j.1365-2559.1989.tb02135.x; Plaignaud M, 1791, J CHIR, V1, P111; REED CE, 1985, J ALLERGY CLIN IMMUN, V76, P773, DOI 10.1016/0091-6749(85)90746-8; ROBSON JMB, 1989, AUST NZ J MED, V19, P351, DOI 10.1111/j.1445-5994.1989.tb00278.x; ROLSTON KVI, 1985, REV INFECT DIS, V7, P525; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SAFIRSTEIN BH, 1976, CHEST, V70, P788, DOI 10.1378/chest.70.6.788; SCHEER L, 1992, ANN ALLERGY, V68, P1185; SHAH A, 1990, ANN ALLERGY, V64, P507; SHAH A, 1990, RESP MED, V84, P249, DOI 10.1016/S0954-6111(08)80044-3; SHER TH, 1988, J ALLERGY CLIN IMMUN, V81, P844, DOI 10.1016/0091-6749(88)90940-2; SINGH J, 1977, J OTOLARYNGOL, V6, P37; SOBOL SM, 1984, LARYNGOSCOPE, V94, P620; STAMMBERGER H, 1985, ANN OTO RHINOL LARYN, V94, P1; Stevens M H, 1981, Am J Otolaryngol, V2, P348, DOI 10.1016/S0196-0709(81)80045-2; WASHBURN RG, 1988, MEDICINE, V67, P231, DOI 10.1097/00005792-198807000-00004; WAXMAN JE, 1987, LARYNGOSCOPE, V97, P261; YOUNG CN, 1978, J LARYNGOL OTOL, V92, P137, DOI 10.1017/S0022215100085145; ZIESKE LA, 1991, OTOLARYNG HEAD NECK, V105, P567, DOI 10.1177/019459989110500408; ZINREICH SJ, 1988, RADIOLOGY, V169, P439, DOI 10.1148/radiology.169.2.3174990	70	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				394	404		10.1016/S0091-6749(05)80020-X	http://dx.doi.org/10.1016/S0091-6749(05)80020-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527322				2022-12-18	WOS:A1992JP52000018
J	SILTON, RP; FERNANDEZCALDAS, E; TRUDEAU, WL; SWANSON, MC; LOCKEY, RF				SILTON, RP; FERNANDEZCALDAS, E; TRUDEAU, WL; SWANSON, MC; LOCKEY, RF			PREVALENCE OF SPECIFIC IGE TO THE STORAGE MITE, ALEUROGLYPHUS-OVATUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALEUROGLYPHUS-OVATUS; DERMATOPHAGOIDES-PTERONYSSINUS; STORAGE MITES; HOUSE DUST MITES; CROSS-REACTIVITY; SKIN TESTS; ASTHMA; ALLERGIC RHINITIS; IMMUNOBLOTS	HOUSE DUST MITE; ALLERGENIC CROSS-REACTIVITY; DERMATOPHAGOIDES-PTERONYSSINUS; LEPIDOGLYPHUS-DESTRUCTOR; TYROPHAGUS-PUTRESCENTIAE; FARMING POPULATION; ENVIRONMENTS; RHINITIS; FARMERS	Aleuroglyphus ovatus (Ao) is a storage mite that has a worldwide distribution and has been found in stored bran, wheat, chicken meal, and dried fish products. Ao was isolated from a chicken meal sample, cultured on whole wheat flour at 75% relative humidity, and 1 gm of pure Ao bodies were extracted, 1:20 wt/vol, in 0.2 mol/L of ammonium bicarbonate. Der p I, major allergen of Dermatophagoides pteronyssinus (Dp), or Der f I, major allergen to Dermatophagoides farinae (Df), was not detected in extracts of Ao. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed 25 bands (6 to 110 kd), and thin-layer isoelectric focusing revealed 19 bands (isoelectric point, 3.5 to 9.3). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis immunoblots with six different sera identified nine IgE binding bands (16 to 100 kd). Thin-layer isoelectric focusing immunoblots identified 16 IgE binding bands (isoelectric point, 4.5 to 9.3). An aliquot of the Ao extract was diluted in bicarbonate buffer (pH 9.2) and adsorbed to plastic microtiter plates. RAST to Ao and Dp were performed with sera of 163 atopic individuals (88 with allergic rhinitis and 75 with allergic asthma with or without allergic rhinitis). All individuals had appropriately positive skin tests that correlated with a history of exacerbation secondary to allergen exposure. RAST results to Dp and Ao were analyzed by regression analysis (r = 0.64; p = 0.0001). Fifty-five individuals were RAST positive to Dp alone, 32 to Ao and Dp, and three to Ao alone; 73 individuals were negative to Ao and Dp. RAST inhibition demonstrated moderate cross-reactivity between Ao and Dp.	UNIV S FLORIDA,COLL MED,TAMPA,FL 33612	State University System of Florida; University of South Florida								ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P166, DOI 10.1016/0091-6749(84)90281-1; CARBALLO L, 1991, J ALLERGY CLIN IMMUN, V87, P189; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; FERNANDEZ-CALDAS E, 1991, Journal of Allergy and Clinical Immunology, V87, P322, DOI 10.1016/0091-6749(91)92013-Q; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; FERNANDEZCALDAS E, 1990, J ALLERGY CLIN IMMUN, V85, P183; GRIFFIN P, 1989, J ALLERGY CLIN IMMUN, V84, P108, DOI 10.1016/0091-6749(89)90184-X; Hsin K. l., 1964, Acta Entomologica Sinica, V13, P428; HUGHES AM, 1976, MIN AGR FISH FOOD TE, V9; INGRAM CG, 1979, LANCET, V2, P1330; JEFFREY IG, 1976, J STORED PROD RES, V12, P149, DOI 10.1016/0022-474X(76)90003-5; JOHANSSON E, 1988, INT ARCH ALLER A IMM, V85, P8, DOI 10.1159/000234468; KORSGAARD J, 1979, ALLERGY, V34, P225, DOI 10.1111/j.1398-9995.1979.tb01703.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCZYNSKA CM, 1990, CLIN EXP ALLERGY, V20, P403, DOI 10.1111/j.1365-2222.1990.tb02801.x; MIYAMOTO T, 1969, J ALLERGY, V44, P228, DOI 10.1016/0021-8707(69)90089-6; PRIMENTAL D, 1960, ANN ENTOMOL SOC AM, V53, P549; REVSBECH P, 1987, ALLERGY, V42, P423, DOI 10.1111/j.1398-9995.1987.tb00357.x; SINHA RN, 1966, J ECON ENTOMOL, V59, P227; STENIUS B, 1972, SCAND J RESPIR DIS, V53, P338; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; TERHO EO, 1982, ALLERGY, V37, P15, DOI 10.1111/j.1398-9995.1982.tb04112.x; TERHO EO, 1985, ALLERGY, V40, P23, DOI 10.1111/j.1398-9995.1985.tb04150.x; TRUDEAU W, 1991, J ALLERGY CLIN IMMUN, V85, P238; VANHAGEHAMSTEN M, 1989, J ALLERGY CLIN IMMUN, V83, P581, DOI 10.1016/0091-6749(89)90069-9; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WRAITH DG, 1979, CLIN ALLERGY, V9, P545, DOI 10.1111/j.1365-2222.1979.tb00478.x	33	27	29	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					595	603		10.1016/0091-6749(91)90153-F	http://dx.doi.org/10.1016/0091-6749(91)90153-F			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1918725				2022-12-18	WOS:A1991GL04900008
J	SIMONS, FER				SIMONS, FER			RECENT ADVANCES IN H1-RECEPTOR ANTAGONIST TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	CONF ON ADVANCEMENTS IN ANTIALLERGIC THERAPY : BEYOND CONVENTIONAL ANTIHISTAMINES	OCT 12-15, 1989	NAPLES, FL	PFIZER LAB			PHARMACODYNAMIC PROPERTIES; THERAPEUTIC EFFICACY; TERFENADINE; LORATADINE; CETIRIZINE; HISTAMINE; ASTEMIZOLE; SKIN	The second-generation H-1-receptor antagonists terfenadine, astemizole, loratadine, and cetirizine are important first-line drugs for the relief of symptoms in patients with allergic rhinoconjunctivitis or chronic urticaria and may eventually supplant the potentially sedating first-generation H-1-receptor antagonists in the treatment of these disorders. Terfenadine, astemizole, loratadine, and cetirizine produce an incidence of central nervous system and anticholinergic adverse effects similar to that produced by placebo. Our ability to use H-1-receptor antagonists optimally has been greatly enhanced by recent pharmacokinetic and pharmacodynamic studies of these medications.	UNIV MANITOBA,DEPT PEDIAT & CHILD HLTH,ALLERGY & CLIN IMMUNOL SECT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba								CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; HEYKANTS J, 1986, DRUG DEVELOP RES, V8, P71, DOI 10.1002/ddr.430080109; KASSEM N, 1988, ANN ALLERGY, V60, P505; MALO JL, 1990, J ALLERGY CLIN IMMUN, V85, P729, DOI 10.1016/0091-6749(90)90191-6; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; RIHOUX JP, 1985, ANN ALLERGY, V55, P392; SHALL L, 1988, BRIT J DERMATOL, V119, P525, DOI 10.1111/j.1365-2133.1988.tb03257.x; SIMONS FER, 1989, J ALLERGY CLIN IMMUN, V84, P845, DOI 10.1016/0091-6749(89)90377-1; SIMONS FER, 1989, ANN ALLERGY, V63, P266; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V82, P1068; SORKIN EM, 1985, DRUGS, V29, P34, DOI 10.2165/00003495-198529010-00002; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8	13	27	27	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	2	S			995	999						5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER131	1979802				2022-12-18	WOS:A1990ER13100001
J	SCHULLER, DE; SELCOW, JE; JOOS, TH; HANNAWAY, PJ; HIRSCH, SR; SCHWARTZ, HJ; FILLEY, WV; FINK, JN				SCHULLER, DE; SELCOW, JE; JOOS, TH; HANNAWAY, PJ; HIRSCH, SR; SCHWARTZ, HJ; FILLEY, WV; FINK, JN			A MULTICENTER TRIAL OF NEDOCROMIL SODIUM, 1-PERCENT NASAL SOLUTION, COMPARED WITH CROMOLYN SODIUM AND PLACEBO IN RAGWEED SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV SUBURBAN HLTH CTR,CLEVELAND,OH; OKLAHOMA ALLERGY CLIN,OKLAHOMA CITY,OK; MED COLL WISCONSIN,MILWAUKEE,WI 53226	Medical College of Wisconsin	SCHULLER, DE (corresponding author), GEISINGER MED CTR,DEPT PEDIAT ALLERGY IMMUNOL & PULM MED,N ACAD DR,DANVILLE,PA 17822, USA.							BEAUVAIS F, 1989, DRUGS, V37, P4, DOI 10.2165/00003495-198900371-00003; BELLIONI P, 1988, Rhinology (Utrecht), V26, P281; BERMAN BA, 1988, J ALLERGY CLIN IMMUN, V81, P980, DOI 10.1016/0091-6749(88)90165-0; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CHANDRA RK, 1982, ANN ALLERGY, V49, P131; CHURCH MK, 1982, CLIN ALLERGY, V12, P223, DOI 10.1111/j.1365-2222.1982.tb02522.x; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CORRADO OJ, 1987, J ALLERGY CLIN IMMUN, V80, P218, DOI 10.1016/0091-6749(87)90132-1; EADY RP, 1985, BRIT J PHARMACOL, V85, P323, DOI 10.1111/j.1476-5381.1985.tb08864.x; HANDELMAN NI, 1977, J ALLERGY CLIN IMMUN, V59, P237, DOI 10.1016/0091-6749(77)90156-7; HASTIE R, 1979, LAB INVEST, V40, P554; HIRSCH SR, 1977, ANN ALLERGY, V39, P66; KOCH GG, 1982, BIOMETRICS, V38, P563, DOI 10.2307/2530041; KONNO A, 1987, J ALLERGY CLIN IMMUN, V79, P620, DOI 10.1016/S0091-6749(87)80158-6; KONNO A, 1981, ARCH OTO-RHINO-LARYN, V232, P253, DOI 10.1007/BF00457450; LIU C-M, 1988, Rhinology (Utrecht), V26, P167; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; PELIKAN Z, 1988, J ALLERGY CLIN IMMUN, V82, P1103, DOI 10.1016/0091-6749(88)90150-9; RUHNO J, 1988, J ALLERGY CLIN IMMUN, V18, P570; Schwartz H J, 1986, Ear Nose Throat J, V65, P449; SCHWARTZ HJ, 1987, J ALLERGY CLIN IMMUN, V79, P186; SCHWARTZ LB, 1987, AM REV RESPIR DIS, V135, P1186; SIPILA P, 1987, CLIN OTOLARYNGOL, V12, P365, DOI 10.1111/j.1365-2273.1987.tb00218.x; VOLOVITZ B, 1988, J ALLERGY CLIN IMMUN, V82, P414, DOI 10.1016/0091-6749(88)90000-0; WELSH PW, 1977, J ALLERGY CLIN IMMUN, V60, P104, DOI 10.1016/0091-6749(77)90034-3	29	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				554	561		10.1016/S0091-6749(05)80212-X	http://dx.doi.org/10.1016/S0091-6749(05)80212-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2172349				2022-12-18	WOS:A1990EG45400016
J	SCHWARZ, YA; KIVITY, S; ILFELD, DN; SCHLESINGER, M; GREIF, J; TOPILSKY, M; GARTY, MS				SCHWARZ, YA; KIVITY, S; ILFELD, DN; SCHLESINGER, M; GREIF, J; TOPILSKY, M; GARTY, MS			A CLINICAL AND IMMUNOLOGICAL STUDY OF COLCHICINE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BEILINSON MED CTR, CLIN PHARMACOL UNIT, IL-49100 PETAH TIQWA, ISRAEL; TEL AVIV MED CTR & SCH MED, INST PULM & ALLERG DIS, TEL AVIV, ISRAEL; BARZILAI GOVT HOSP, ALLERGY & IMMUNOL UNIT, ASHQELON, ISRAEL	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University; Barzilai Medical Center								ALVARELLOS A, 1986, J RHEUMATOL, V13, P804; CALLEN JP, 1985, J AM ACAD DERMATOL, V13, P193, DOI 10.1016/S0190-9622(85)70158-2; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; HARPER TB, 1980, CLIN ALLERGY, V10, P555, DOI 10.1111/j.1365-2222.1980.tb02137.x; HUNNINGHAKE GW, 1987, AM REV RESPIR DIS, V135, P66; HWANG KC, 1985, CLIN ALLERGY, V15, P67, DOI 10.1111/j.1365-2222.1985.tb02257.x; ILFELD D, 1984, CLIN EXP IMMUNOL, V57, P438; ILFELD D, 1982, CLIN EXP IMMUNOL, V50, P99; ILFELD D, 1985, CLIN EXP IMMUNOL, V61, P360; ILFELD DN, 1986, CLIN ALLERGY, V16, P407, DOI 10.1111/j.1365-2222.1986.tb01975.x; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KERSHENOBICH D, 1984, CLIN RES, V32, pA490; KERSHENOBICH D, 1988, NEW ENGL J MED, V318, P1709, DOI 10.1056/NEJM198806303182602; KUNCL RW, 1987, NEW ENGL J MED, V316, P1562, DOI 10.1056/NEJM198706183162502; PETERS RS, 1983, WESTERN J MED, V138, P43; PETERS SP, 1987, AM REV RESPIR DIS, V135, pS42; REIBMAN J, 1986, J IMMUNOL, V136, P1027; RIVLIN J, 1981, CLIN ALLERGY, V11, P353, DOI 10.1111/j.1365-2222.1981.tb01605.x; ROLAPLESZCZYNSKI M, 1981, INT ARCH ALLER A IMM, V64, P361, DOI 10.1159/000232717; RUDOLPH SA, 1977, P NATL ACAD SCI USA, V74, P3404, DOI 10.1073/pnas.74.8.3404; SCHLESINGER M, 1983, CLIN EXP IMMUNOL, V54, P73; SEIDEMAN P, 1987, J RHEUMATOL, V14, P777; SPILBERG I, 1979, J CLIN INVEST, V64, P775, DOI 10.1172/JCI109523; SUGIO K, 1987, LIFE SCI, V40, P35, DOI 10.1016/0024-3205(87)90249-9	26	27	28	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					578	582		10.1016/0091-6749(90)90096-M	http://dx.doi.org/10.1016/0091-6749(90)90096-M			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2138186				2022-12-18	WOS:A1990CU66800007
J	RAES, M; MULDER, P; KERREBIJN, KF				RAES, M; MULDER, P; KERREBIJN, KF			LONG-TERM EFFECT OF IPRATROPIUM BROMIDE AND FENOTEROL ON THE BRONCHIAL HYPERRESPONSIVENESS TO HISTAMINE IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ERASMUS UNIV,SOPHIA CHILDRENS HOSP,DEPT PAEDIAT,DIV PULM MED,GORDELWEG 160,3038 GE ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT MED STAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam								BRITTON J, 1986, THORAX, V41, P128, DOI 10.1136/thx.41.2.128; BRITTON J, 1988, THORAX, V43, P300, DOI 10.1136/thx.43.4.300; DANIEL EE, 1986, RESP PHYSIOL, V63, P109, DOI 10.1016/0034-5687(86)90034-4; DUIVERMAN EJ, 1987, PEDIATR PULM, V3, P38, DOI 10.1002/ppul.1950030111; DUIVERMAN EJ, 1986, B EUR PHYSIOPATH RES, V22, P27; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KERREBIJN KF, 1986, B EUR PHYSIOPATHOL S, V22, P7; LOWHAGEN O, 1987, BRONCHIAL HYPERRESPO, P387; MACKLEM PT, 1985, CHEST, V87, P1585; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; NEWCOMB R, 1985, AM REV RESPIR DIS, V132, P12; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P87; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; RAMSDALE EH, 1985, THORAX, V40, P422, DOI 10.1136/thx.40.6.422; SALOME CM, 1983, THORAX, V38, P854, DOI 10.1136/thx.38.11.854; SLY PD, 1987, THORAX, V42, P357, DOI 10.1136/thx.42.5.357; VATHENEN AS, 1988, LANCET, V1, P554; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; YANTA MA, 1981, J APPL PHYSIOL, V50, P869, DOI 10.1152/jappl.1981.50.4.869; Zapletal A, 1976, Cesk Pediatr, V31, P532	22	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				874	879		10.1016/0091-6749(89)90382-5	http://dx.doi.org/10.1016/0091-6749(89)90382-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2532229				2022-12-18	WOS:A1989CG29300003
J	CRANE, J; ODONNELL, TV; PRIOR, IA; WAITE, DA				CRANE, J; ODONNELL, TV; PRIOR, IA; WAITE, DA			THE RELATIONSHIPS BETWEEN ATOPY, BRONCHIAL HYPERRESPONSIVENESS, AND A FAMILY HISTORY OF ASTHMA - A CROSS-SECTIONAL STUDY OF MIGRANT TOKELAUAN CHILDREN IN NEW-ZEALAND	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CRANE, J (corresponding author), WELLINGTON SCH MED,DEPT MED,POB 7343,WELLINGTON,NEW ZEALAND.							BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BREWSTER DR, 1980, NZ MED J, V89, P339; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; CHANYEUNG MN, 1982, AM J MED, V82, P411; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66, DOI 10.1136/adc.62.1.66; COCKCROFT DW, 1988, J ALLERGY CLIN IMMUN, V81, P111, DOI 10.1016/0091-6749(88)90229-1; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GREGG I, 1983, ASTHMA, P160; HOLGATE ST, 1987, CLIN SCI, V73, P561, DOI 10.1042/cs0730561; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; MURANAKA M, 1975, J ALLERGY CLIN IMMUN, V56, P429; PRIOR IAM, 1974, INT J EPIDEMIOL, V3, P225, DOI 10.1093/ije/3.3.225; SIBBALD B, 1980, THORAX, V35, P67; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; WOOLCOCK AJ, 1988, AUST NZ J MED, V18, pA188; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	21	27	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				768	772		10.1016/0091-6749(89)90307-2	http://dx.doi.org/10.1016/0091-6749(89)90307-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2809026				2022-12-18	WOS:A1989CA31400016
J	GOSWAMI, SK; OHASHI, M; STATHAS, P; MAROM, ZM				GOSWAMI, SK; OHASHI, M; STATHAS, P; MAROM, ZM			PLATELET-ACTIVATING FACTOR STIMULATES SECRETION OF RESPIRATORY GLYCOCONJUGATE FROM HUMAN AIRWAYS IN CULTURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CUNY MT SINAI SCH MED, DEPT MED,DIV PULM,ANNENBERG 24-30,BOX 1232, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ADLER KB, 1987, EXP LUNG RES, V13, P25, DOI 10.3109/01902148709064307; ADLER KB, 1986, IN VITRO MODELS RESP, P27; AMADOR E, 1963, CLIN CHEM, V9, P391; ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BENVENISTE J, 1974, NATURE, P249; CHIGNARD M, 1979, NATURE, V279, P799, DOI 10.1038/279799a0; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; FLEISCH JH, 1985, J PHARMACOL EXP THER, V233, P148; GOSWAMI SK, 1985, BIOCHIM BIOPHYS ACTA, V834, P263, DOI 10.1016/0005-2760(85)90164-X; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; KALINER M, 1986, AM REV RESPIR DIS, V134, P612; KEAL EE, 1975, NEW DIRECTIONS ASTHM, P223; LOTNER GZ, 1980, J IMMUNOL, V124, P676; LUNDGREN JD, 1988, AM REV RESPIR DIS, V137, P353, DOI 10.1164/ajrccm/137.2.353; LYNCH JM, 1979, J IMMUNOL, V123, P1219; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MAROM Z, 1984, PROSTAGLANDINS, V28, P79, DOI 10.1016/0090-6980(84)90115-1; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MAROM Z, 1984, AM REV RESPIR DIS, V129, P62; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; PINCKARD RN, 1979, J IMMUNOL, V123, P1847; RUBIN A E, 1987, American Review of Respiratory Disease, V135, pA158; SHELHAMER JH, 1984, EXP LUNG RES, V7, P149, DOI 10.3109/01902148409069675; SHELHAMER JH, 1980, J CLIN INVEST, V66, P1400, DOI 10.1172/JCI109993; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; SNYDER CE, 1984, IN VITRO CELL DEV B, V20, P95, DOI 10.1007/BF02626649; STIMLER NP, 1983, AM J PATHOL, V113, P75; STIMLER NP, 1981, AM J PATHOL, V105, P64; TAPPEL AL, 1962, METHOD ENZYMOL, V5, P539, DOI 10.1016/S0076-6879(62)05272-6; Vargaftig B B, 1981, Ann N Y Acad Sci, V370, P119, DOI 10.1111/j.1749-6632.1981.tb29727.x; VARGAFTIG BB, 1983, TRENDS PHARMACOL SCI, V4, P341, DOI 10.1016/0165-6147(83)90433-9; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X	33	27	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				726	734		10.1016/0091-6749(89)90301-1	http://dx.doi.org/10.1016/0091-6749(89)90301-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2478607	Bronze			2022-12-18	WOS:A1989CA31400010
J	SMITH, AB; CASTELLAN, RM; LEWIS, D; MATTE, T				SMITH, AB; CASTELLAN, RM; LEWIS, D; MATTE, T			GUIDELINES FOR THE EPIDEMIOLOGIC ASSESSMENT OF OCCUPATIONAL ASTHMA - REPORT OF THE SUBCOMMITTEE ON THE EPIDEMIOLOGIC ASSESSMENT OF OCCUPATIONAL ASTHMA, OCCUPATIONAL-LUNG-DISEASE-COMMITTEE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIOSH, ATLANTA, GA USA; EASTERN VIRGINIA MED SCH, DEPT FAMILY & COMMUNITY MED, NORFOLK, VA 23501 USA; NIOSH, MORGANTOWN, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Eastern Virginia Medical School; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	SMITH, AB (corresponding author), EASTERN VIRGINIA MED SCH, NOAA, NORFOLK, VA 23501 USA.		Smith, Adam/GPS-8322-2022					AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; AGRUP G, 1986, BRIT J IND MED, V43, P192; [Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; BANKS DE, 1986, CHEST, V89, P389, DOI 10.1378/chest.89.3.389; BARDY JD, 1987, AM REV RESPIR DIS, V135, P1033; BOEHLECKE BA, 1981, CHEST, V79, pS114; BROOKS SM, 1982, J ALLERGY CLIN IMMUN, V70, P56, DOI 10.1016/0091-6749(82)90202-0; BROOKS SM, 1985, BRONCHIAL ASTHMA, P461; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; BURGE PS, 1987, BRIT J DIS CHEST, V81, P105; BURGE PS, 1979, THORAX, V34, P300, DOI 10.1136/thx.34.3.300; BURGE PS, 1979, CLIN ALLERGY, V9, P185, DOI 10.1111/j.1365-2222.1979.tb01540.x; BURGESS WA, 1981, RECOGNITION HLTH HAZ, P1; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; BUTCHER BT, 1986, J ALLERGY CLIN IMMUN, V78, P547, DOI 10.1016/0091-6749(86)90068-0; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CHANYEUNG M, 1986, AM REV RESPIR DIS, V133, P666; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; COCHRANE GM, 1977, THORAX, V32, P171, DOI 10.1136/thx.32.2.171; COOKSON JB, 1987, CHEST, V91, pS97, DOI 10.1378/chest.91.6.97S; DALES RE, 1987, AM REV RESPIR DIS, V135, P817, DOI 10.1164/arrd.1987.135.4.817; DAVIES GE, 1983, J IMMUNOASSAY, V4, P113, DOI 10.1080/15321818308057004; DAVIES RJ, 1984, SEMIN RESPIR MED, V5, P229, DOI 10.1055/s-2007-1011457; EDWARDS RG, 1983, LAB ANIM, V17, P235, DOI 10.1258/002367783781070696; EICHENHORN MS, 1982, CHEST, V82, P306, DOI 10.1378/chest.82.3.306; EISEN EA, 1987, STATE ART REV, V2, P213; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; FAIRBAIRN A S, 1959, Br J Prev Soc Med, V13, P175; FEINSTEIN AR, 1978, CLIN PHARMACOL THER, V23, P81; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FIGLEY KD, 1928, JAMA-J AM MED ASSOC, P90; GARDNER RM, 1981, OCCUPATIONAL LUNG DI, P61; GHIO AJ, 1986, AM REV RESPIR DIS, V133, pA155; GLINDMEYER HW, 1987, AM REV RESPIR DIS, V136, P449, DOI 10.1164/ajrccm/136.2.449; GRAMMER LC, 1987, J OCCUP ENVIRON MED, V29, P806; HANKINSON JL, 1986, J OCCUP ENVIRON MED, V28, P1081, DOI 10.1097/00043764-198610000-00032; HANKINSON JL, 1986, J OCCUP ENVIRON MED, V28, P1222; HARBER P, 1985, J OCCUP ENVIRON MED, V27, P651; HARGREAVE FE, 1983, SEMIN RESPIR MED, V4, P224, DOI 10.1055/s-2007-1012487; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; HELSING KJ, 1976, INT J EPIDEMIOL, V5, P125, DOI 10.1093/ije/5.2.125; HENDRICK DJ, 1983, ANN ALLERGY, V51, P179; HENDRICK DJ, 1986, AM REV RESPIR DIS, V133, P600; HETZEL MR, 1981, THORAX, V36, P481, DOI 10.1136/thx.36.7.481; Horvath EJ, 1981, MANUAL SPIROMETRY OC; Hosey A., 1973, IND ENV ITS EVALUATI, P95; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; LANGMUIR AD, 1963, NEW ENGL J MED, V268, P182, DOI 10.1056/NEJM196301242680405; LONDON MA, 1986, 843711729 NAT I OCC; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; LOVE RG, 1980, BRIT J IND MED, V37, P63; MALO JL, 1988, THORAX, V43, P371, DOI 10.1136/thx.43.5.371; McKERROW C B, 1958, Br J Ind Med, V15, P75; MIETTINEN OS, 1985, J CHRON DIS, V38, P543, DOI 10.1016/0021-9681(85)90039-6; NEWMAN J M, 1984, Journal of Nutrition for the Elderly, V4, P3, DOI 10.1300/J052v04n02_02; OBRIEN D, 1987, ECTB15603 NAT I OCC; PENNOCK BE, 1981, CHEST, V80, P97, DOI 10.1378/chest.80.1.97; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PRATTER MR, 1983, CHEST, V84, P42, DOI 10.1378/chest.84.1.42; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, V32; ROZAS CJ, 1982, ARCH INTERN MED, V142, P1287, DOI 10.1001/archinte.142.7.1287; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; RUTSTEIN DD, 1983, AM J PUBLIC HEALTH, V73, P1054, DOI 10.2105/AJPH.73.9.1054; SALVAGGIO JE, 1986, DHHS NIOSH86102 PUBL, P461; SAMET JM, 1978, AM J EPIDEMIOL, V108, P435, DOI 10.1093/oxfordjournals.aje.a112642; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SEGUIN P, 1987, J OCCUP ENVIRON MED, V29, P340; SHIM CS, 1980, AM J MED, V68, P11, DOI 10.1016/0002-9343(80)90155-2; SMITH AB, 1987, AM J IND MED, V12, P205, DOI 10.1002/ajim.4700120209; SMITH AB, 1980, J OCCUP ENVIRON MED, V22, P327, DOI 10.1097/00043764-198005000-00005; SOULE RD, 1973, IND ENV EVALUATION C, P711; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; SWANSON MC, 1984, AM REV RESPIR DIS, V129, P844, DOI 10.1164/arrd.1984.129.5.844; TASHKIN DP, 1979, ENVIRON RES, V20, P403, DOI 10.1016/0013-9351(79)90016-1; TOPPING MD, 1985, BRIT J IND MED, V42, P312; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; VENABLES KM, 1985, BRIT J IND MED, V42, P517; VIRTANEN T, 1986, INT ARCH ALLER A IMM, V81, P253, DOI 10.1159/000234143; WEISS ST, 1984, AM REV RESPIR DIS, V129, P898; WOOLCOCK AJ, 1987, CHEST, V91, pS89, DOI 10.1378/chest.91.6.89S; 1985, FED REG         1213, V50, P51120; 1988, LANCET, V1, P26; 1960, BRIT MED J, V1, P1665	83	27	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	2	S			794	805		10.1016/0091-6749(89)90342-4	http://dx.doi.org/10.1016/0091-6749(89)90342-4			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CC527	2681333	Bronze			2022-12-18	WOS:A1989CC52700002
J	BUSSEL, JB				BUSSEL, JB			MODULATION OF FC RECEPTOR CLEARANCE AND ANTIPLATELET ANTIBODIES AS A CONSEQUENCE OF INTRAVENOUS IMMUNE GLOBULIN INFUSION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BUSSEL, JB (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,DEPT PEDIAT & MED,525 E 68TH ST,ROOM N-740,NEW YORK,NY 10021, USA.							BURDACH SEG, 1986, J PEDIATR-US, V109, P770, DOI 10.1016/S0022-3476(86)80691-6; BUSSEL J, 1988, J PEDIATR-US, V112, P298, DOI 10.1016/S0022-3476(88)80074-X; BUSSEL J, 1986, J CLIN IMMUNOL, V6, P50, DOI 10.1007/BF00915364; BUSSEL J, 1988, BLOOD, V72, pA262; BUSSEL JB, 1988, TRANSFUSION, V28, P38, DOI 10.1046/j.1537-2995.1988.28188127949.x; BUSSEL JB, 1988, NEW ENGL J MED, V319, P1374, DOI 10.1056/NEJM198811243192103; BUSSEL JB, 1983, BLOOD, V62, P480; BUSSEL JB, 1988, BLOOD, V72, P121; CLARKSON SB, 1986, NEW ENGL J MED, V314, P1236, DOI 10.1056/NEJM198605083141907; ENGLEHARD D, 1986, J PEDIATR, V108, P77; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; HOLLENBERG JP, 1988, J PEDIATR-US, V112, P530, DOI 10.1016/S0022-3476(88)80163-X; IMBACH P, 1983, LANCET, V2, P577; KIMBERLY RP, 1984, J IMMUNOL, V132, P745; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; MUELLERECKHARDT C, IN PRESS BLUT; NUGENT D, 1986, BLOOD S, V70, P356; SALAMA A, 1983, LANCET, V2, P193; STAHL CP, 1986, BLOOD, V67, P421; STOHL W, 1986, CLIN IMMUNOL IMMUNOP, V41, P273, DOI 10.1016/0090-1229(86)90111-X; SULTAN Y, 1984, LANCET, V2, P765; TOVO PA, 1984, J PEDIATR, V105, P667	22	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			566	578		10.1016/0091-6749(89)90193-0	http://dx.doi.org/10.1016/0091-6749(89)90193-0			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2677093				2022-12-18	WOS:A1989AZ39800002
J	LEUNG, DYM				LEUNG, DYM			IMMUNOMODULATION BY INTRAVENOUS IMMUNE GLOBULIN IN KAWASAKI DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	LEUNG, DYM (corresponding author), CHILDRENS HOSP MED CTR,DIV ALLERGY,ENDERS 8,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022058] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37260] Funding Source: Medline; NIAID NIH HHS [AI22058] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; FUJIWARA H, 1978, PEDIATRICS, V61, P100; FURUSHO K, 1984, LANCET, V2, P1055; GROENEWEGEN G, 1985, TRANSPLANTATION, V40, P21, DOI 10.1097/00007890-198507000-00005; GROENEWEGEN G, 1985, NATURE, V316, P361, DOI 10.1038/316361a0; HICKS RV, 1986, PEDIATR CLIN N AM, V33, P1151; KATO H, 1982, AM J CARDIOL, V49, P1748; KAWADA K, 1987, EXP HEMATOL, V15, P133; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; KISHIMOTO T, 1987, J CLIN IMMUNOL, V7, P343, DOI 10.1007/BF00917012; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; LEUNG DYM, 1982, CLIN IMMUNOL IMMUNOP, V23, P100, DOI 10.1016/0090-1229(82)90075-7; LEUNG DYM, 1986, J CLIN INVEST, V77, P1428, DOI 10.1172/JCI112454; LEUNG DYM, 1986, J EXP MED, V164, P1958, DOI 10.1084/jem.164.6.1958; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; POBER JS, 1986, J IMMUNOL, V137, P1893; POBER JS, 1983, NATURE, V301, P437; ROWLEY AH, 1988, PEDIATR INFECT DIS J, V7, P633; SULTAN Y, 1984, LANCET, V2, P765; SUZUKI A, 1985, Heart and Vessels, V1, P94, DOI 10.1007/BF02066356; YANAGAWA H, 1987, PEDIATRICS, V80, P58; [No title captured]	24	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1989	84	4	2	S			588	594		10.1016/0091-6749(89)90195-4	http://dx.doi.org/10.1016/0091-6749(89)90195-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZ398	2677095				2022-12-18	WOS:A1989AZ39800004
J	RACKHAM, A; BROWN, CA; CHANDRA, RK; HO, P; HOOGERWERF, PE; KENNEDY, RJ; KNIGHT, A; LANGER, H; MILNE, J; MOOTE, DW; NICKERSON, GH; ROSEN, L; STEPHENSON, H; BROADHEAD, M; LALONDE, Y; STPIERRE, JP				RACKHAM, A; BROWN, CA; CHANDRA, RK; HO, P; HOOGERWERF, PE; KENNEDY, RJ; KNIGHT, A; LANGER, H; MILNE, J; MOOTE, DW; NICKERSON, GH; ROSEN, L; STEPHENSON, H; BROADHEAD, M; LALONDE, Y; STPIERRE, JP			A CANADIAN MULTICENTER STUDY WITH ZADITEN (KETOTIFEN) IN THE TREATMENT OF BRONCHIAL-ASTHMA IN CHILDREN AGED 5 TO 17 YEARS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SANDOZ CANADA INC,CLIN RES DEPT,MED AFFAIRS,385 BOUCHARD BLVD,DORVAL H9R 4P5,QUEBEC,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,KENTVILLE,NS,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,ST JOHNS,NEWFOUNDLAND,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,TORONTO,ONTARIO,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,ABBOTTSFORD,BC,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,CALGARY,ALBERTA,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,DON MILLS,ONTARIO,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,LONDON,ONTARIO,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,BRIDGEWATER,NS,CANADA; SANDOZ CANADA INC,CLIN RES DEPT,DOWNSVIEW,ONTARIO,CANADA	Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz; Novartis; Sandoz								ADACHI M, 1984, PHARMATHERAPEUTICA, V4, P36; AOKI S, 1988, BRIT J PHARMACOL, V93, pP54; ARNOUX B, 1988, AM REV RESPIR DIS, V137, P855, DOI 10.1164/ajrccm/137.4.855; BERNSTEIN IL, 1986, J ALLERGY CLIN IMMUN, V78, P491, DOI 10.1016/0091-6749(86)90094-1; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; CRAPS L, 1980, ACTA THERAP, V6, P213; CRAPS LP, 1985, BRONCHIAL ASTHMA MEC, P734; DALNEGRO RW, 1986, INT J CLIN PHARM TH, V24, P100; DOROW P, 1986, EUR J RESPIR DIS, V69, pA54; EISER N, 1984, DEV ANTIASTHMA DRUGS, P121; GIRARD JP, 1977, ACTA ALLERGOL, V32, P27; GOLDSTEIN RS, 1978, DRUGS, V16, P256, DOI 10.2165/00003495-197816030-00007; GRAFFLONNEVIG V, 1985, J ALLERGY CLIN IMMUN, V76, P59, DOI 10.1016/0091-6749(85)90805-X; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; HENDY MS, 1986, RESPIRATION, V49, P296, DOI 10.1159/000194894; KELLY P, 1982, RES CLIN FORUMS, V4, P35; LOFTUS BG, 1987, J ALLERGY CLIN IMMUN, V79, P350, DOI 10.1016/0091-6749(87)90154-0; MARTIN U, 1978, ARZNEIMITTELFORSCH, V28-1, P770; Martin U, 1981, PHARM BIOCH PROPERTI, V3, P424; MAZZONI L, 1985, BRIT J PHARMACOL, V86, P571; MCCLAY WP, 1984, BRIT MED J, V288, P911; MORLEY J, 1984, LANCET, V2, P1142; MULHERN B, 1982, IRISH MED J, V75, P25; MUSSAFFI H, 1986, J ALLERGY CLIN IMMUN, V77, P48, DOI 10.1016/0091-6749(86)90321-0; NEIJENS HJ, 1988, IMMUNOL ALLERGY PRAC, V10, P17; OSTERBALLE O, 1979, ALLERGY, V34, P125, DOI 10.1111/j.1398-9995.1979.tb01373.x; PLATTSMILLS TAE, 1982, LANCET, V2, P675; REISER J, 1985, LANCET, V1, P206; SALMON MA, 1982, RES CLIN FORUMS, V4, P45; STRATTON D, 1984, BRIT J DIS CHEST, V78, P163, DOI 10.1016/0007-0971(84)90117-7; TAMURA G, 1986, CLIN ALLERGY, V16, P535, DOI 10.1111/j.1365-2222.1986.tb01992.x; TAYLOR B, 1979, CLIN ALLERGY, V9, P241, DOI 10.1111/j.1365-2222.1979.tb01549.x; WELLS A, 1979, CLIN ALLERGY, V9, P237, DOI 10.1111/j.1365-2222.1979.tb01548.x	33	27	27	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1989	84	3					286	296		10.1016/0091-6749(89)90410-7	http://dx.doi.org/10.1016/0091-6749(89)90410-7			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AR199	2674262				2022-12-18	WOS:A1989AR19900003
J	LEMAO, J; PAULI, G; TEKAIA, F; HOYET, C; BISCHOFF, E; DAVID, B				LEMAO, J; PAULI, G; TEKAIA, F; HOYET, C; BISCHOFF, E; DAVID, B			GUANINE CONTENT AND DERMATOPHAGOIDES-PTERONYSSINUS ALLERGENS IN HOUSE DUST SAMPLES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST PASTEUR,UNITE IMMUNOALLERGIE,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE; GESELL HAUSBIOL FORSCH,MAINZ,FED REP GER; UNIV STRASBOURG 1,FAC MED,F-67070 STRASBOURG,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Tekaia, Fredj/H-4553-2012					ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; BAKER WE, 1952, DIGESTIVE SYSTEM INT, P27; BISCHOFF E, 1985, ALLERGOLOGIE, V8, P97; BISCHOFF E, 1984, ALLERGOLOGIE, V11, P446; BISCHOFF E, 1985, ALLERGOL, V8, P35; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; DANDEU JP, 1987, J ALLERGY CLIN IMMUN, V79, P132; Finney D, 1978, STATISTICAL METHOD B, P69; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; KEILIN J, 1959, BIOL REV, V34, P265, DOI 10.1111/j.1469-185X.1959.tb01308.x; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; KROLL J, 1972, PROTIDS BIOL FLUID, P529; LEMAO J, 1980, J ALLERGY CLIN IMMUN, V65, P381, DOI 10.1016/0091-6749(80)90217-1; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; MAUNSELL K, 1968, LANCET, V1, P1267; PAULI G, 1986, REV FR ALLERGOL, V26, P163, DOI 10.1016/S0335-7457(86)80027-2; PAULI G, 1972, REV FR ALLERGOL, V12, P141, DOI 10.1016/S0035-2845(72)80014-3; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; Shapiro R, 1968, Prog Nucleic Acid Res Mol Biol, V8, P73; STEWART GA, 1986, J ALLERGY CLIN IMMUN, V77, P14, DOI 10.1016/0091-6749(86)90316-7; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; TOVEY E, 1979, CLIN ALLERGY, V9, P253, DOI 10.1111/j.1365-2222.1979.tb01551.x; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; VANBRONSWIJK JE, 1971, ANN ENTOMOL SOC AM, V64, P789, DOI 10.1093/aesa/64.4.789; VANBRONSWIJK JEMH, 1986, J MED ENTOMOL, V23, P217, DOI 10.1093/jmedent/23.2.217; VANBRONSWIJK JEMH, 1986, EXP APPL ACAROL, V2, P231, DOI 10.1007/BF01193955; Voorhorst R., 1964, Allergie Asthma, V10, P329; WEEKE B, 1973, MANUAL QUANTITATIVE, P47; Yman L, 1975, Dev Biol Stand, V29, P151	34	27	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					926	933						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2715551	Bronze			2022-12-18	WOS:A1989U716100013
J	MULLINS, RJ; OLSON, LG; SUTHERLAND, DC				MULLINS, RJ; OLSON, LG; SUTHERLAND, DC			NASAL HISTAMINE CHALLENGES IN SYMPTOMATIC ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL NEWCASTLE HOSP,HUNTER IMMUNOL UNIT,PACIFIC ST,NEWCASTLE,NSW 2300,AUSTRALIA; UNIV NEWCASTLE,FAC MED,NEWCASTLE,NSW 2308,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,DEPT IMMUNOL,CAMPERDOWN,NSW 2050,AUSTRALIA	University of Newcastle; University of Sydney			Mullins, Raymond James/H-8013-2019	Mullins, Raymond James/0000-0002-0267-1591				BORUM P, 1983, EUR J RESPIR DIS, V64, P65; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; ECCLES R, 1983, EUR J RESPIR DIS, V64, P150; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V58, P563, DOI 10.1016/0091-6749(76)90202-5; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2	5	27	26	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					955	959		10.1016/0091-6749(89)90111-5	http://dx.doi.org/10.1016/0091-6749(89)90111-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2715553				2022-12-18	WOS:A1989U716100017
J	BOUSQUET, J; RIVORY, JP; MAHEUT, M; MICHEL, FB; MION, C				BOUSQUET, J; RIVORY, JP; MAHEUT, M; MICHEL, FB; MION, C			DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NICERGOLINE IN THE TREATMENT OF PRURITUS IN PATIENTS RECEIVING MAINTENANCE HEMODIALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU MONTPELLIER,CTR HEMODIALYSE LANGUEDOC MEDITERRANEEN,F-34059 MONTPELLIER,FRANCE; CHU MONTPELLIER,CTR HEMODIALYSE VITTEL,F-34059 MONTPELLIER,FRANCE; CHU MONTPELLIER,NEPHROL CLIN,F-34059 MONTPELLIER,FRANCE	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	BOUSQUET, J (corresponding author), CHU MONTPELLIER,MALADIES RESP CLIN,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					BHAT K, 1984, ANN ALLERGY, V52, P282; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V81, P605; DEKROES S, 1983, DERMATOLOGICA, V166, P199, DOI 10.1159/000249867; DOLOVICH J, 1984, ARTIF ORGANS, V8, P334, DOI 10.1111/j.1525-1594.1984.tb04301.x; GILCHREST BA, 1982, ARCH DERMATOL, V118, P154, DOI 10.1001/archderm.118.3.154; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V74, P544, DOI 10.1016/0091-6749(84)90392-0; HUCHET AM, 1981, J CARDIOVASC PHARM, V3, P677, DOI 10.1097/00005344-198107000-00003; LIEVRE M, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1227; MARSHALL CP, 1985, J ALLERGY CLIN IMMUN, V75, P563, DOI 10.1016/0091-6749(85)90030-2; MAURICE F, 1986, J ALLERGY CLIN IMMUN, V77, P594, DOI 10.1016/0091-6749(86)90351-9; MONERETVAUTRIN DA, 1980, MED HYG, V38, P119; MURPHY JE, 1982, DIALYSIS TRANSPLANT, V11, P480; NICHOLLS A, 1986, BRIT MED J, V292, P1221, DOI 10.1136/bmj.292.6530.1221; NIELSEN T, 1980, DAN MED BULL, V27, P269; PATTERSON R, 1986, INT ARCH ALLER A IMM, V79, P53, DOI 10.1159/000233942; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; TAPIA L, 1979, INT J DERMATOL, V18, P217	18	27	30	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					825	828		10.1016/0091-6749(89)90021-3	http://dx.doi.org/10.1016/0091-6749(89)90021-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2708742				2022-12-18	WOS:A1989U342000018
J	ZWOLLO, P; ANSARI, AA; MARSH, DG				ZWOLLO, P; ANSARI, AA; MARSH, DG			ASSOCIATION OF CLASS-II DNA RESTRICTION FRAGMENTS WITH RESPONSIVENESS TO AMBROSIA-ARTEMISIIFOLIA (SHORT RAGWEED) POLLEN ALLERGEN AMB-A-V IN RAGWEED-ALLERGIC PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239	Johns Hopkins University					NIAID NIH HHS [AI-20059, AI-19727] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019727, R55AI019727, R01AI020059] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON G, 1987, J BIOL CHEM, V262, P8748; ARNHEIM N, 1985, P NATL ACAD SCI USA, V82, P6970, DOI 10.1073/pnas.82.20.6970; BIAS WB, 1981, HUM IMMUNOL, V2, P155, DOI 10.1016/0198-8859(81)90062-8; BLUMENTHAL M, 1985, J ALLERGY CLIN IMMUN, V75, P155, DOI 10.1016/0091-6749(85)90338-0; CAIRNS JS, 1985, NATURE, V317, P166, DOI 10.1038/317166a0; CANN HM, 1983, P NATL ACAD SCI-BIOL, V80, P1665, DOI 10.1073/pnas.80.6.1665; COHEN D, 1984, P NATL ACAD SCI-BIOL, V81, P1774, DOI 10.1073/pnas.81.6.1774; COHEN N, 1986, IMMUNOGENETICS, V23, P84, DOI 10.1007/BF00377966; FIGUEROA F, 1986, IMMUNOL TODAY, V7, P78, DOI 10.1016/0167-5699(86)90089-7; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; GOODFRIEND L, 1985, MOL IMMUNOL, V22, P899, DOI 10.1016/0161-5890(85)90076-8; GREGERSEN PK, 1986, P NATL ACAD SCI USA, V83, P2642, DOI 10.1073/pnas.83.8.2642; HEBERKATZ E, 1983, J MOL CELL IMMUNOL, V1, P3; INOKO H, 1986, IMMUNOGENETICS, V23, P126, DOI 10.1007/BF00377973; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; LEE BSM, 1987, IMMUNOGENETICS, V26, P85; LEE BSM, 1987, P NATL ACAD SCI USA, V84, P4591, DOI 10.1073/pnas.84.13.4591; LIU CP, 1988, J IMMUNOL, V140, P3631; MARCADET A, 1985, IMMUNOGENETICS, V22, P679, DOI 10.1007/BF00430317; MARCADET A, 1985, IMMUNOGENETICS, V22, P93, DOI 10.1007/BF00430598; MARSH DG, 1987, FASEB J, V46, P1047; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MARSH DG, 1976, NOBEL S, V33, P23; NEPOM GT, 1984, HUM IMMUNOL, V10, P143, DOI 10.1016/0198-8859(84)90035-1; ROEBBER M, 1985, J IMMUNOL, V134, P3062; ROEBBER M, 1982, J IMMUNOL, V129, P120; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STETLER D, 1985, P NATL ACAD SCI USA, V82, P8100, DOI 10.1073/pnas.82.23.8100; TERMIJTELEN A, 1982, IMMUNOL REV, V66, P79, DOI 10.1111/j.1600-065X.1982.tb00435.x; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; TROWSDALE J, 1985, IMMUNOL REV, P85; VANROOD JJ, 1976, NATURE, V262, P795, DOI 10.1038/262795a0; WU S, 1987, J IMMUNOL, V138, P2953; WU SK, 1986, NATURE, V324, P676, DOI 10.1038/324676a0	36	27	27	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					45	54		10.1016/0091-6749(89)90476-4	http://dx.doi.org/10.1016/0091-6749(89)90476-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2563269				2022-12-18	WOS:A1989T041900007
J	GRAMMER, LC; EGGUM, P; SILVERSTEIN, M; SHAUGHNESSY, MA; LIOTTA, JL; PATTERSON, R				GRAMMER, LC; EGGUM, P; SILVERSTEIN, M; SHAUGHNESSY, MA; LIOTTA, JL; PATTERSON, R			PROSPECTIVE IMMUNOLOGICAL AND CLINICAL-STUDY OF A POPULATION EXPOSED TO HEXAMETHYLENE DIISOCYANATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,OCCUPAT MED SECT,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611; NAVISTAR INT CORP,CHICAGO,IL; UNITED AUTOMOBILE WORKERS,INT UNION,DETROIT,MI	Northwestern University; Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11043] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BOXER MB, 1987, J ALLERGY CLIN IMMUN, V80, P147, DOI 10.1016/0091-6749(87)90123-0; BRUGSCH HG, 1963, NEW ENGL J MED, V268, P353, DOI 10.1056/NEJM196302142680705; GRAMMER LC, 1985, J LAB CLIN MED, V105, P108; MARKHAM TN, 1967, JOM-J OCCUP MED, V9, P471; MCGRATH KG, 1984, J OCCUP ENVIRON MED, V26, P671; PATTERSON R, 1987, INT ARCH ALLER A IMM, V84, P93, DOI 10.1159/000234404; PATTERSON R, 1986, INT ARCH ALLER A IMM, V79, P53, DOI 10.1159/000233942; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WOODBURY JW, 1956, IND MED, V24, P540; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; 1985, MMWR S, V34, P145; 1973, OCCUPATIONAL EXPOSUR	17	27	27	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					627	633		10.1016/0091-6749(88)90975-X	http://dx.doi.org/10.1016/0091-6749(88)90975-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171003				2022-12-18	WOS:A1988Q639900015
J	PEARSON, DJ				PEARSON, DJ			PSYCHOLOGIC AND SOMATIC INTERRELATIONSHIPS IN ALLERGY AND PSEUDOALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANCHESTER,DEPT MED,MANCHESTER M13 9PL,LANCS,ENGLAND	University of Manchester								BLACKWOOD FW, 1982, SCOTT MED J, V27, P175; BRENNER B, 1979, PSYCHOL MED, V9, P737, DOI 10.1017/S003329170003405X; BURNS BH, 1972, BRIT J PSYCHIAT, V121, P405, DOI 10.1192/bjp.121.4.405; CAHOON RL, 1972, ERGONOMICS, V15, P157, DOI 10.1080/00140137208924420; DAVID TJ, 1985, J ROY SOC MED, V78, P21; DEKKER E, 1957, J PSYCHOSOM RES, V2, P97, DOI 10.1016/0022-3999(57)90015-6; DEKKER E, 1956, J PSYCHOSOM RES, V1, P58, DOI 10.1016/0022-3999(56)90035-6; DENISON DM, 1966, AEROSPACE MED, V37, P1010; DIAZ MA, 1979, AM J PSYCHIAT, V136, P1217; DUBO S, 1961, J PEDIATR-US, V59, P402, DOI 10.1016/S0022-3476(61)80296-5; EGGER J, 1985, LANCET, V1, P540; ELKINS RN, 1981, AM J PSYCHIAT, V138, P178; ELLIS EF, 1985, J ALLERGY CLIN IMMUN, V76, P297, DOI 10.1016/0091-6749(85)90645-1; ERNSTING J, 1978, AVIAT SPACE ENVIR MD, V49, P495; ESCOBAR JI, 1982, JAMA-J AM MED ASSOC, V247, P1859, DOI 10.1001/jama.247.13.1859; FINN R, 1978, LANCET, V1, P426; FRY L, 1964, BR MED J, V51, P1145; FURUKAWA CT, 1984, LANCET, V1, P621; FURUKAWA CT, IN PRESS J ALLERGY C; GLUCKMAN L, 1974, NEW ZEAL MED J, V80, P411; GODFREY S, 1973, J PSYCHOSOM RES, V17, P293, DOI 10.1016/0022-3999(73)90106-2; GRAHAM DT, 1950, J ALLERGY, V21, P478, DOI 10.1016/0021-8707(50)90095-5; GRAHAM PJ, 1967, BRIT J PREV SOC MED, V21, P78; GREDEN JF, 1974, AM J PSYCHIAT, V131, P1089; Haldane J.S., 1935, RESPIRATION; HARPER AM, 1965, J NEUROL NEUROSUR PS, V28, P449, DOI 10.1136/jnnp.28.5.449; HERBERT M, 1965, J PSYCHOSOM RES, V8, P353, DOI 10.1016/0022-3999(65)90076-0; HERRIDGE CF, 1968, BRIT MED J, V2, P160, DOI 10.1136/bmj.2.5598.160; HORTON DJ, 1978, AM REV RESPIR DIS, V117, P1029; JUSTESEN DR, 1970, SCIENCE, V170, P864, DOI 10.1126/science.170.3960.864; KALINER M, 1982, ANN INTERN MED, V96, P349, DOI 10.7326/0003-4819-96-3-349; Kennedy F, 1926, ARCH NEURO PSYCHIATR, V15, P28, DOI 10.1001/archneurpsyc.1926.02200190031002; KHANNA PB, 1986, BRIT MED J, V292, P1430; KING DS, 1981, BIOL PSYCHIAT, V16, P3; KOENIG JQ, 1982, J ALLERGY CLIN IMMUN, V69, P339, DOI 10.1016/0091-6749(82)90143-9; LEIGHTON KM, 1982, BRIT MED J, V284, P789, DOI 10.1136/bmj.284.6318.789-a; LOBITZ WC, 1953, AMA ARCH DERM SYPH, V67, P575, DOI 10.1001/archderm.1953.01540060037006; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; MAGARIAN GJ, 1982, MEDICINE, V61, P219, DOI 10.1097/00005792-198207000-00002; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MCFADDEN ER, 1969, PSYCHOSOM MED, V31, P134, DOI 10.1097/00006842-196903000-00007; MCFADDEN ER, 1971, NY STATE J MED, V71, P2161; MCNICHOL KN, 1973, BRIT MED J, V4, P16, DOI 10.1136/bmj.4.5883.16; MURPHY MB, 1980, BRIT MED J, V281, P1322, DOI 10.1136/bmj.281.6251.1322; NEUHAUS EC, 1958, PSYCHOSOM MED, V20, P181, DOI 10.1097/00006842-195805000-00003; OSWALD NC, 1970, BMJ-BRIT MED J, V2, P14, DOI 10.1136/bmj.2.5700.14; OTTENBERG P, 1958, PSYCHOSOM MED, V20, P395, DOI 10.1097/00006842-195809000-00007; PARDEE I, 1938, J NERV MENT DIS, V88, P88; PEARSON DJ, 1983, LANCET, V1, P1259; PEARSON DJ, 1985, PAR PSEUDOALLERGIC R, V4, P59; RANDOLPH TG, 1976, CLIN ECOLOGY, P9; RIX KJB, 1984, BRIT J PSYCHIAT, V145, P121, DOI 10.1192/bjp.145.2.121; ROXANAS MG, 1977, MED J AUSTRALIA, V2, P639, DOI 10.5694/j.1326-5377.1977.tb107691.x; SANKEY RJ, 1984, BRIT MED J, V288, P1369, DOI 10.1136/bmj.288.6427.1369; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SILVER W, 1971, PEDIATRICS, V47, P635; SIMON P, 1978, PSYCHOL MED, V8, P335, DOI 10.1017/S0033291700014392; SNOW SS, 1980, BRIT J PSYCHIAT, V136, P297, DOI 10.1192/bjp.136.3.297; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; STAFFIERI D, 1952, Ann Allergy, V10, P38; SWANSON JM, 1980, SCIENCE, V207, P1485, DOI 10.1126/science.7361102; TARNOWMORDI WO, 1984, BRIT MED J, V289, P1113, DOI 10.1136/bmj.289.6452.1113-a; TRIPP JH, 1979, BRIT MED J, V2, P707, DOI 10.1136/bmj.2.6192.707; TUNE GS, 1964, PERCEPT MOTOR SKILL, V19, P551, DOI 10.2466/pms.1964.19.2.551; VAUGHAN WT, 1931, J ALLERGY, V2, P125; WARNER JO, 1984, ARCH DIS CHILD, V59, P151, DOI 10.1136/adc.59.2.151; WEISS B, 1980, SCIENCE, V207, P1487, DOI 10.1126/science.7361103; WEISS JH, 1966, J PSYCHOSOM RES, V10, P267, DOI 10.1016/0022-3999(66)90094-8; WHORWELL PJ, 1986, GUT, V27, P37, DOI 10.1136/gut.27.1.37; ZEALLEY AK, 1971, P ROY SOC MED, V64, P825, DOI 10.1177/003591577106400810; 1981, J ALLERGY CLIN IMMUN, V67, P333	72	27	29	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1988	81	2					351	360		10.1016/0091-6749(88)90900-1	http://dx.doi.org/10.1016/0091-6749(88)90900-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	M0993	3276762	Bronze			2022-12-18	WOS:A1988M099300001
J	VANZIELEGHEM, MA; JUNIPER, EF				VANZIELEGHEM, MA; JUNIPER, EF			A COMPARISON OF BUDESONIDE AND BECLOMETHASONE DIPROPIONATE NASAL AEROSOLS IN RAGWEED-INDUCED RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST JOSEPHS HOSP, DEPT MED, FIRESTONE REG CHEST & ALLERGY CLIN, 50 CHARLTON AVE E, HAMILTON L8N 4A6, ONTARIO, CANADA; ASTRA PHARMACEUT CANADA LTD, INVEST CLIN RES GRP, MISSISSAUGA, ONTARIO, CANADA; MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McGill University; McMaster University; McMaster University								BAGGOTT PJ, 1984, AM REV RESPIR DIS, V129, pA76; BJORKANDER J, 1982, EUR J RESPIR DIS, V63, P108; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BRATTSAND R, 1982, EUR J RESPIR DIS, V63, P62; BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; CHATTERJEE J, 1974, CAN MED ASSOC J, V110, P659; CZARNY D, 1968, LANCET, V2, P188; HOLOPAINEN E, 1977, ACTA ALLERGOL, V32, P263, DOI 10.1111/j.1398-9995.1977.tb01358.x; JOHANSSON SA, 1982, EUR J RESPIR DIS, V63, P74; JUNIPER EF, 1985, J ALLERGY CLIN IMMUN, V75, P578, DOI 10.1016/0091-6749(85)90033-8; JUNIPER EF, 1981, CLIN ALLERGY, V11, P61, DOI 10.1111/j.1365-2222.1981.tb01567.x; MYGIND N, 1978, ACTA OTO-LARYNGOL, V85, P437; NORUSIS MJ, 1985, SPSSX ADV STATISTICS, P195; OKUDA M, 1980, CLIN OTOLARYNGOL, V5, P315, DOI 10.1111/j.1365-2273.1980.tb00897.x; PIPKORN U, 1982, EUR J RESPIR DIS, V63, P211; PIPKORN U, 1984, ANN ALLERGY, V52, P183; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V82, P260, DOI 10.3109/00016487609120899; STEENSEN H, 1981, ALLERGY, V36, P245, DOI 10.1111/j.1398-9995.1981.tb01570.x; WARLAND A, 1981, ALLERGY, V36, P425, DOI 10.1111/j.1398-9995.1981.tb01849.x	20	27	29	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					887	892		10.1016/0091-6749(87)90237-5	http://dx.doi.org/10.1016/0091-6749(87)90237-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3584744				2022-12-18	WOS:A1987H904400009
J	LANG, DM; HOPP, RJ; BEWTRA, AK; NAIR, NM; WATT, GD; TOWNLEY, RG				LANG, DM; HOPP, RJ; BEWTRA, AK; NAIR, NM; WATT, GD; TOWNLEY, RG			DISTRIBUTION OF METHACHOLINE INHALATION CHALLENGE RESPONSES IN A SELECTED ADULT-POPULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV, SCH MED, CTR ALLERG DIS, 2500 CALIF, OMAHA, NE 68178 USA	Creighton University			Hopp, Russell/K-4578-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001508] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL01508-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOUS J, 1984, AM REV RESPIR DIS, V129, P216; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GREGG I, 1977, ASTHMA, P227; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HOPP RJ, 1986, AM REV RESPIR DIS, V134, P994, DOI 10.1164/arrd.1986.134.5.994; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V74, P154, DOI 10.1016/0091-6749(84)90279-3; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LONGO G, 1983, LANCET, V2, P792; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; RYO UY, 1976, JAMA-J AM MED ASSOC, V236, P927; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; TOWNLEY RG, 1983, PROVOCATIVE CHALLENG, P177; 1971, 1ST P HNLBI EP WORKS	20	27	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					533	540		10.1016/0091-6749(87)90372-1	http://dx.doi.org/10.1016/0091-6749(87)90372-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3546467				2022-12-18	WOS:A1987G479500017
J	LOFTUS, BG; PRICE, JF				LOFTUS, BG; PRICE, JF			LONG-TERM, PLACEBO-CONTROLLED TRIAL OF KETOTIFEN IN THE MANAGEMENT OF PRESCHOOL-CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KINGS COLL,SCH MED & DENT,DEPT CHILD HLTH,LONDON SE5 8RX,ENGLAND	University of London; King's College London	LOFTUS, BG (corresponding author), KINGS COLL,SCH MED & DENT,DEPT THORAC MED,DENMARK HILL,LONDON SE5 8RX,ENGLAND.							BURANAKUL B, 1974, AM J DIS CHILD, V128, P343, DOI 10.1001/archpedi.1974.02110280073009; BURNS RBP, 1983, J ASTHMA, V20, P105, DOI 10.3109/02770908309077073; GRAFFLONNEVIG V, 1980, ALLERGY, V35, P341, DOI 10.1111/j.1398-9995.1980.tb01776.x; GROGGINS RC, 1981, ARCH DIS CHILD, V56, P304, DOI 10.1136/adc.56.4.304; HAMBLETON G, 1982, RES CLIN FORUMS, V4, P31; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; HOLGATE ST, 1985, BRIT MED J, V291, P92, DOI 10.1136/bmj.291.6488.92; KELLY P, 1982, RES CLIN FORUMS, V4, P35; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; LOFTUS BG, 1985, CLIN ALLERGY, V15, P465, DOI 10.1111/j.1365-2222.1985.tb02296.x; MCKENZIE SA, 1979, ARCH DIS CHILD, V54, P581, DOI 10.1136/adc.54.8.581; REISER J, 1985, LANCET, V1, P206; SALMON MA, 1982, RES CLIN FORUMS, V4, P45; SILVERMAN M, 1972, BMJ-BRIT MED J, V3, P378, DOI 10.1136/bmj.3.5823.378; STRATTON D, 1984, BR J DIS CHEST, V78, P164; TAYLOR B, 1979, CLIN ALLERGY, V9, P241, DOI 10.1111/j.1365-2222.1979.tb01549.x; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1982, RES CLIN FORUMS, V4, P85	18	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1987	79	2					350	355		10.1016/0091-6749(87)90154-0	http://dx.doi.org/10.1016/0091-6749(87)90154-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G1791	3546465	Bronze			2022-12-18	WOS:A1987G179100009
J	TESSIER, P; CARTIER, A; LARCHEVEQUE, J; GHEZZO, H; MARTIN, RR; MALO, JL				TESSIER, P; CARTIER, A; LARCHEVEQUE, J; GHEZZO, H; MARTIN, RR; MALO, JL			WITHIN-DAY AND BETWEEN-DAY REPRODUCIBILITY OF ISOCAPNIC COLD AIR CHALLENGES IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA	Universite de Montreal								[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BARYISHAY E, 1983, AM REV RESPIR DIS, V127, P572, DOI 10.1164/arrd.1983.127.5.572; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1980, J ALLERGY CLIN IMMUN, V66, P458, DOI 10.1016/0091-6749(80)90006-8; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HEATON RW, 1983, THORAX, V38, P506, DOI 10.1136/thx.38.7.506; HEATON RW, 1984, CHEST, V86, P810, DOI 10.1378/chest.86.6.810; LEMIRE I, 1984, J ALLERGY CLIN IMMUN, V73, P234, DOI 10.1016/S0091-6749(84)80013-5; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; NEIJENS HJ, 1982, B EUR PHYSIOPATH RES, V18, P427; OBYRNE PM, 1982, THORAX, V37, P913, DOI 10.1136/thx.37.12.913; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; OREHEK J, 1976, B EUR PHYSIOPATH RES, V12, P565; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; Sokal R.R., 1981, BIOMETRY, V2nd ed.; WEISS JW, 1983, J ALLERGY CLIN IMMUN, V72, P140, DOI 10.1016/0091-6749(83)90521-3; WEISS ST, 1984, AM REV RESPIR DIS, V129, P898	25	27	27	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1986	78	3	1				379	387		10.1016/0091-6749(86)90021-7	http://dx.doi.org/10.1016/0091-6749(86)90021-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E1148	3760397				2022-12-18	WOS:A1986E114800002
J	STROBER, W				STROBER, W			GLUTEN-SENSITIVE ENTEROPATHY - A NONALLERGIC IMMUNE HYPERSENSITIVITY OF THE GASTROINTESTINAL-TRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											STROBER, W (corresponding author), NIAID, CLIN INVEST LAB, MUCOSAL IMMUN SECT, BETHESDA, MD 20205 USA.							ALARCONSEGOVIA D, 1964, AM J MED, V36, P485, DOI 10.1016/0002-9343(64)90098-1; ALP MH, 1971, LANCET, V2, P682; AMBINDER JM, 1982, CLIN IMMUNOL IMMUNOP, V23, P269, DOI 10.1016/0090-1229(82)90113-1; ASHKENAZI A, 1980, PEDIATR RES, V14, P776, DOI 10.1203/00006450-198005000-00013; BAER AN, 1980, GASTROENTEROLOGY, V79, P754; BAHNA SL, 1980, ANN ALLERGY, V44, P146; BAKER PG, 1976, Q J MED, V45, P603; BAKLIEN K, 1974, LANCET, V2, P1087; BENSON GD, 1964, MEDICINE, V43, P1; BETUEL H, 1980, TISSUE ANTIGENS, V15, P231; COOPER BT, 1978, BRIT MED J, V1, P537, DOI 10.1136/bmj.1.6112.537; COOPER BT, 1982, DIGESTION, V23, P89, DOI 10.1159/000198692; CROWE JP, 1980, DIGESTION, V20, P95, DOI 10.1159/000198424; DEMARCHI M, 1983, GUT, V24, P706, DOI 10.1136/gut.24.8.706; DOHERTY M, 1981, LANCET, V1, P517; ETERMAN KP, 1978, CLIN EXP IMMUNOL, V31, P92; FALCHUK ZM, 1974, J CLIN INVEST, V53, P487, DOI 10.1172/JCI107582; FALCHUK ZM, 1974, GUT, V15, P947, DOI 10.1136/gut.15.12.947; FALCHUK ZM, 1972, J CLIN INVEST, V51, P1602, DOI 10.1172/JCI106958; FERGUSON A, 1971, GUT, V12, P988, DOI 10.1136/gut.12.12.988; FERGUSON A, 1972, BMJ-BRIT MED J, V1, P75, DOI 10.1136/bmj.1.5792.75; FERGUSON A, 1975, LANCET, V1, P895; FERGUSON A, 1976, ACTA PAEDIATR SCAND, V65, P541, DOI 10.1111/j.1651-2227.1976.tb04929.x; FLORES AF, 1982, GASTROENTEROLOGY, V82, P1058; HALL RP, 1981, CLIN EXP IMMUNOL, V45, P234; HALL RP, 1980, CLIN EXP IMMUNOL, V40, P431; HEKKENS WTH, 1977, PERSPECTIVES COELIAC, P75; HOBBS JR, 1969, LANCET, V2, P649; HOBBS JR, 1968, LANCET, V1, P217; HOLMES GKT, 1974, GUT, V15, P278, DOI 10.1136/gut.15.4.278; JOS J, 1979, SCAND J IMMUNOL, V9, P441, DOI 10.1111/j.1365-3083.1979.tb03066.x; JOS J, 1974, COELIAC DISEASE, P91; KAGNOFF MF, 1982, NATURE, V296, P158, DOI 10.1038/296158a0; KAGNOFF MF, 1984, J EXP MED, V160, P1544, DOI 10.1084/jem.160.5.1544; KASARDA DD, 1977, PERSPECTIVES COELIAC, P55; KASARDA DD, 1981, FOOD NUTRITION EVOLU, P201; KATZ AJ, 1978, GASTROENTEROLOGY, V75, P695; KATZ SI, 1980, ANN INTERN MED, V93, P857, DOI 10.7326/0003-4819-93-6-857; KAVAI M, 1977, ACTA PAEDIATR HUNG, V18, P235; KENRICK KG, 1970, GUT, V11, P635, DOI 10.1136/gut.11.8.635; KEUNING JJ, 1976, LANCET, V1, P506; KLAEVEMAN HL, 1975, GASTROENTEROLOGY, V68, P572; KUMAR PJ, 1973, GUT, V14, P280, DOI 10.1136/gut.14.4.280; LANCASTERSMITH M, 1976, J CLIN PATHOL, V29, P592, DOI 10.1136/jcp.29.7.592; LANCASTERSMITH M, 1975, BRIT J DERMATOL, V92, P37, DOI 10.1111/j.1365-2133.1975.tb03030.x; LANCASTERSMITH M, 1977, GUT, V18, P887, DOI 10.1136/gut.18.11.887; LAWLEY TJ, 1980, J INVEST DERMATOL, V74, P9, DOI 10.1111/1523-1747.ep12514565; LOEB PM, 1971, J CLIN INVEST, V50, P559, DOI 10.1172/JCI106525; MANN JG, 1970, AM J MED, V48, P357, DOI 10.1016/0002-9343(70)90066-5; MARSH MN, 1984, GASTROENTEROLOGY, V86, P1174; MCCRAE WM, 1975, LANCET, V1, P187; MEARIN ML, 1985, CLIN GENET, V27, P45; MEARIN ML, 1983, GUT, V24, P532, DOI 10.1136/gut.24.6.532; MORGANROTH J, 1972, AM J DIG DIS, V17, P205, DOI 10.1007/BF02232292; NEPOM GT, 1984, J EXP MED, V159, P394, DOI 10.1084/jem.159.2.394; PADYKULA HA, 1961, GASTROENTEROLOGY, V40, P735; PENA AS, 1978, GASTROENTEROLOGY, V75, P230; SCOTT BB, 1977, J PATHOL, V121, P219, DOI 10.1002/path.1711210405; SCOTT H, 1980, SCAND J GASTROENTERO, V15, P81, DOI 10.3109/00365528009181436; SHINER M, 1974, COELIAC DISEASE, P121; SHINER M, 1972, LANCET, P77; SIMPSON FG, 1983, SCAND J GASTROENTERO, V18, P749, DOI 10.3109/00365528309182090; STERN M, 1979, EUR J PEDIATR, V130, P165, DOI 10.1007/BF00455262; STOCKBRUGGER R, 1978, ACTA DERM-VENEREOL, V58, P343; STOKES PL, 1976, Q J MED, V45, P567; STROBER W, 1975, ANN INTERN MED, V83, P242, DOI 10.7326/0003-4819-83-2-242; TOMKIN GH, 1971, LANCET, V2, P124; UNSWORTH DJ, 1981, CLIN EXP IMMUNOL, V46, P286; WALDMANN TA, 1967, NEW ENGL J MED, V276, P761, DOI 10.1056/NEJM196704062761401; WEISS JB, 1983, J CLIN INVEST, V72, P96, DOI 10.1172/JCI110988	70	27	27	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			202	211		10.1016/0091-6749(86)90013-8	http://dx.doi.org/10.1016/0091-6749(86)90013-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3013966				2022-12-18	WOS:A1986D299700013
J	GOLDEN, DBK; SCHWARTZ, HJ				GOLDEN, DBK; SCHWARTZ, HJ			GUIDELINES FOR VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		DVORIN D, 1984, Journal of Allergy and Clinical Immunology, V73, P188; GOLDEN D B K, 1982, Journal of Allergy and Clinical Immunology, V69, P124; GOLDEN D B K, 1984, Journal of Allergy and Clinical Immunology, V73, P189; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P482, DOI 10.1016/0091-6749(81)90102-0; GOLDEN DBK, 1981, JAMA-J AM MED ASSOC, V246, P2460, DOI 10.1001/jama.246.21.2460; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P735; SANTRACH PJ, 1980, ANN ALLERGY, V45, P130; SCHWARTZ HJ, 1981, J ALLERGY CLIN IMMUN, V67, P81, DOI 10.1016/0091-6749(81)90051-8; SOBOTKA AK, 1978, J IMMUNOL, V121, P2477; STUCKEY M, 1982, LANCET, V2, P41	14	27	27	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1986	77	5					727	728		10.1016/0091-6749(86)90418-5	http://dx.doi.org/10.1016/0091-6749(86)90418-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	C3903	3700897				2022-12-18	WOS:A1986C390300016
